Identification O 0
of O 0
APC2 O 0
, O 0
a O 0
homologue O 0
of O 0
the O 0
adenomatous B-Disease 1
polyposis I-Disease 1
coli I-Disease 1
tumour I-Disease 1
suppressor O 0
. O 0

The O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( I-Disease 0
APC I-Disease 1
) I-Disease 0
tumour I-Disease 1
- O 0
suppressor O 0
protein O 0
controls O 0
the O 0
Wnt O 0
signalling O 0
pathway O 0
by O 0
forming O 0
a O 0
complex O 0
with O 0
glycogen O 0
synthase O 0
kinase O 0
3beta O 0
( O 0
GSK O 0
- O 0
3beta O 0
) O 0
, O 0
axin O 0
/ O 0
conductin O 0
and O 0
betacatenin O 0
. O 0

Complex O 0
formation O 0
induces O 0
the O 0
rapid O 0
degradation O 0
of O 0
betacatenin O 0
. O 0

In O 0
colon B-Disease 1
carcinoma I-Disease 1
cells O 0
, O 0
loss O 0
of O 0
APC O 1
leads O 0
to O 0
the O 0
accumulation O 0
of O 0
betacatenin O 0
in O 0
the O 0
nucleus O 0
, O 0
where O 0
it O 0
binds O 0
to O 0
and O 0
activates O 0
the O 0
Tcf O 0
- O 0
4 O 0
transcription O 0
factor O 0
( O 0
reviewed O 0
in O 0
[ O 0
1 O 0
] O 0
[ O 0
2 O 0
] O 0
) O 0
. O 0

Here O 0
, O 0
we O 0
report O 0
the O 0
identification O 0
and O 0
genomic O 0
structure O 0
of O 0
APC O 1
homologues O 0
. O 0

Mammalian O 0
APC2 O 0
, O 0
which O 0
closely O 0
resembles O 0
APC O 1
in O 0
overall O 0
domain O 0
structure O 0
, O 0
was O 0
functionally O 0
analyzed O 0
and O 0
shown O 0
to O 0
contain O 0
two O 0
SAMP O 0
domains O 0
, O 0
both O 0
of O 0
which O 0
are O 0
required O 0
for O 0
binding O 0
to O 0
conductin O 0
. O 0

Like O 0
APC O 1
, O 0
APC2 O 0
regulates O 0
the O 0
formation O 0
of O 0
active O 0
betacatenin O 0
- O 0
Tcf O 0
complexes O 0
, O 0
as O 0
demonstrated O 0
using O 0
transient O 0
transcriptional O 0
activation O 0
assays O 0
in O 0
APC O 1
- O 0
/ O 0
- O 0
colon B-Disease 1
carcinoma I-Disease 1
cells O 0
. O 0

Human O 0
APC2 O 0
maps O 0
to O 0
chromosome O 0
19p13 O 0
. O 0

3 O 0
. O 0

APC O 1
and O 0
APC2 O 0
may O 0
therefore O 0
have O 0
comparable O 0
functions O 0
in O 0
development O 0
and O 0
cancer B-Disease 1
. O 0

A O 0
common O 0
MSH2 O 0
mutation O 0
in O 0
English O 0
and O 0
North O 0
American O 0
HNPCC B-Disease 1
families O 0
: O 0
origin O 0
, O 0
phenotypic O 0
expression O 0
, O 0
and O 0
sex O 0
specific O 0
differences O 0
in O 0
colorectal B-Disease 1
cancer I-Disease 1
. O 0

The O 0
frequency O 0
, O 0
origin O 0
, O 0
and O 0
phenotypic O 0
expression O 0
of O 0
a O 0
germline O 0
MSH2 O 0
gene O 0
mutation O 0
previously O 0
identified O 0
in O 0
seven O 0
kindreds O 0
with O 0
hereditary B-Disease 1
non I-Disease 1
- I-Disease 1
polyposis I-Disease 1
cancer I-Disease 1
syndrome I-Disease 1
( O 0
HNPCC B-Disease 1
) O 0
was O 0
investigated O 0
. O 0

The O 0
mutation O 0
( O 0
A O 0
- O 0
- O 0
> O 0
T O 0
at O 0
nt943 O 0
+ O 0
3 O 0
) O 0
disrupts O 0
the O 0
3 O 0
splice O 0
site O 0
of O 0
exon O 0
5 O 0
leading O 0
to O 0
the O 0
deletion O 0
of O 0
this O 0
exon O 0
from O 0
MSH2 O 0
mRNA O 0
and O 0
represents O 0
the O 0
only O 0
frequent O 0
MSH2 O 0
mutation O 0
so O 0
far O 0
reported O 0
. O 0

Although O 0
this O 0
mutation O 0
was O 0
initially O 0
detected O 0
in O 0
four O 0
of O 0
33 O 0
colorectal B-Disease 1
cancer I-Disease 1
families O 0
analysed O 0
from O 0
eastern O 0
England O 0
, O 0
more O 0
extensive O 0
analysis O 0
has O 0
reduced O 0
the O 0
frequency O 0
to O 0
four O 0
of O 0
52 O 0
( O 0
8 O 0
% O 0
) O 0
English O 0
HNPCC B-Disease 1
kindreds O 0
analysed O 0
. O 0

In O 0
contrast O 0
, O 0
the O 0
MSH2 O 0
mutation O 0
was O 0
identified O 0
in O 0
10 O 0
of O 0
20 O 0
( O 0
50 O 0
% O 0
) O 0
separately O 0
identified O 0
colorectal B-Disease 0
families O 0
from O 0
Newfoundland O 0
. O 0

To O 0
investigate O 0
the O 0
origin O 0
of O 0
this O 0
mutation O 0
in O 0
colorectal B-Disease 1
cancer I-Disease 1
families O 0
from O 0
England O 0
( O 0
n O 0
= O 0
4 O 0
) O 0
, O 0
Newfoundland O 0
( O 0
n O 0
= O 0
10 O 0
) O 0
, O 0
and O 0
the O 0
United O 0
States O 0
( O 0
n O 0
= O 0
3 O 0
) O 0
, O 0
haplotype O 0
analysis O 0
using O 0
microsatellite O 0
markers O 0
linked O 0
to O 0
MSH2 O 0
was O 0
performed O 0
. O 0

Within O 0
the O 0
English O 0
and O 0
US O 0
families O 0
there O 0
was O 0
little O 0
evidence O 0
for O 0
a O 0
recent O 0
common O 0
origin O 0
of O 0
the O 0
MSH2 O 0
splice O 0
site O 0
mutation O 0
in O 0
most O 0
families O 0
. O 0

In O 0
contrast O 0
, O 0
a O 0
common O 0
haplotype O 0
was O 0
identified O 0
at O 0
the O 0
two O 0
flanking O 0
markers O 0
( O 0
CA5 O 0
and O 0
D2S288 O 0
) O 0
in O 0
eight O 0
of O 0
the O 0
Newfoundland O 0
families O 0
. O 0

These O 0
findings O 0
suggested O 0
a O 0
founder O 0
effect O 0
within O 0
Newfoundland O 0
similar O 0
to O 0
that O 0
reported O 0
by O 0
others O 0
for O 0
two O 0
MLH1 O 0
mutations O 0
in O 0
Finnish O 0
HNPCC B-Disease 1
families O 0
. O 0

We O 0
calculated O 0
age O 0
related O 0
risks O 0
of O 0
all O 0
, O 0
colorectal B-Disease 0
, I-Disease 0
endometrial I-Disease 0
, I-Disease 0
and I-Disease 0
ovarian I-Disease 1
cancers I-Disease 1
in O 0
nt943 O 0
+ O 0
3 O 0
A O 0
- O 0
- O 0
> O 0
T O 0
MSH2 O 0
mutation O 0
carriers O 0
( O 0
n O 0
= O 0
76 O 0
) O 0
for O 0
all O 0
patients O 0
and O 0
for O 0
men O 0
and O 0
women O 0
separately O 0
. O 0

For O 0
both O 0
sexes O 0
combined O 0
, O 0
the O 0
penetrances O 0
at O 0
age O 0
60 O 0
years O 0
for O 0
all O 0
cancers B-Disease 0
and O 0
for O 0
colorectal B-Disease 1
cancer I-Disease 1
were O 0
0 O 0
. O 0

86 O 0
and O 0
0 O 0
. O 0

57 O 0
, O 0
respectively O 0
. O 0

The O 0
risk O 0
of O 0
colorectal B-Disease 1
cancer I-Disease 1
was O 0
significantly O 0
higher O 0
( O 0
p O 0
< O 0
0 O 0
. O 0
01 O 0
) O 0
in O 0
males O 0
than O 0
females O 0
( O 0
0 O 0
. O 0
63 O 0
v O 0
0 O 0
. O 0
30 O 0
and O 0
0 O 0
. O 0
84 O 0
v O 0
0 O 0
. O 0
44 O 0
at O 0
ages O 0
50 O 0
and O 0
60 O 0
years O 0
, O 0
respectively O 0
) O 0
. O 0

For O 0
females O 0
there O 0
was O 0
a O 0
high O 0
risk O 0
of O 0
endometrial B-Disease 1
cancer I-Disease 1
( O 0
0 O 0
. O 0
5 O 0
at O 0
age O 0
60 O 0
years O 0
) O 0
and O 0
premenopausal B-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
( O 0
0 O 0
. O 0
2 O 0
at O 0
50 O 0
years O 0
) O 0
. O 0

These O 0
intersex O 0
differences O 0
in O 0
colorectal B-Disease 1
cancer I-Disease 1
risks O 0
have O 0
implications O 0
for O 0
screening O 0
programmes O 0
and O 0
for O 0
attempts O 0
to O 0
identify O 0
colorectal B-Disease 1
cancer I-Disease 1
susceptibility O 0
modifiers O 0
. O 0

Age O 0
of O 0
onset O 0
in O 0
Huntington B-Disease 1
disease I-Disease 1
: O 0
sex O 0
specific O 0
influence O 0
of O 0
apolipoprotein O 0
E O 0
genotype O 0
and O 0
normal O 0
CAG O 0
repeat O 0
length O 0
. O 0

Age O 0
of O 0
onset O 0
( O 0
AO O 0
) O 0
of O 0
Huntington B-Disease 1
disease I-Disease 1
( O 0
HD B-Disease 1
) O 0
is O 0
known O 0
to O 0
be O 0
correlated O 0
with O 0
the O 0
length O 0
of O 0
an O 0
expanded O 0
CAG O 0
repeat O 0
in O 0
the O 0
HD B-Disease 1
gene O 0
. O 0

Apolipoprotein O 0
E O 0
( O 0
APOE O 0
) O 0
genotype O 0
, O 0
in O 0
turn O 0
, O 0
is O 0
known O 0
to O 0
influence O 0
AO O 0
in O 0
Alzheimer B-Disease 1
disease I-Disease 1
, O 0
rendering O 0
the O 0
APOE O 0
gene O 0
a O 0
likely O 0
candidate O 0
to O 0
affect O 0
AO O 0
in O 0
other O 0
neurological B-Disease 0
diseases I-Disease 0
too O 0
. O 0

We O 0
therefore O 0
determined O 0
APOE O 0
genotype O 0
and O 0
normal O 0
CAG O 0
repeat O 0
length O 0
in O 0
the O 0
HD B-Disease 1
gene O 0
for O 0
138 O 0
HD B-Disease 1
patients O 0
who O 0
were O 0
previously O 0
analysed O 0
with O 0
respect O 0
to O 0
CAG O 0
repeat O 0
length O 0
. O 0

Genotyping O 0
for O 0
APOE O 0
was O 0
performed O 0
blind O 0
to O 0
clinical O 0
information O 0
. O 0

In O 0
addition O 0
to O 0
highlighting O 0
the O 0
effect O 0
of O 0
the O 0
normal O 0
repeat O 0
length O 0
upon O 0
AO O 0
in O 0
maternally O 0
inherited O 0
HD B-Disease 1
and O 0
in O 0
male O 0
patients O 0
, O 0
we O 0
show O 0
that O 0
the O 0
APOE O 0
epsilon2epsilon3 O 0
genotype O 0
is O 0
associated O 0
with O 0
significantly O 0
earlier O 0
AO O 0
in O 0
males O 0
than O 0
in O 0
females O 0
. O 0

Such O 0
a O 0
sex O 0
difference O 0
in O 0
AO O 0
was O 0
not O 0
apparent O 0
for O 0
any O 0
of O 0
the O 0
other O 0
APOE O 0
genotypes O 0
. O 0

Our O 0
findings O 0
suggest O 0
that O 0
subtle O 0
differences O 0
in O 0
the O 0
course O 0
of O 0
the O 0
neurodegeneration B-Disease 1
in O 0
HD B-Disease 1
may O 0
allow O 0
interacting O 0
genes O 0
to O 0
exert O 0
gender O 0
specific O 0
effects O 0
upon O 0
AO O 0
. O 0

Familial B-Disease 1
deficiency I-Disease 1
of I-Disease 1
the I-Disease 1
seventh I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
associated O 0
with O 0
recurrent O 0
bacteremic B-Disease 0
infections I-Disease 0
due I-Disease 0
to I-Disease 0
Neisseria I-Disease 0
. O 0

The O 0
serum O 0
of O 0
a O 0
29 O 0
- O 0
year O 0
old O 0
woman O 0
with O 0
a O 0
recent O 0
episode O 0
of O 0
disseminated B-Disease 0
gonococcal I-Disease 1
infection I-Disease 1
and O 0
a O 0
history O 0
of O 0
meningococcal B-Disease 0
meningitis I-Disease 1
and O 0
arthritis B-Disease 0
as O 0
a O 0
child O 0
was O 0
found O 0
to O 0
lack O 0
serum O 0
hemolytic O 0
complement O 0
activity O 0
. O 0

The O 0
seventh O 0
component O 0
of O 0
complement O 0
( O 0
C7 O 0
) O 0
was O 0
not O 0
detected O 0
by O 0
functional O 0
or O 0
immunochemical O 0
assays O 0
, O 0
whereas O 0
other O 0
components O 0
were O 0
normal O 0
by O 0
hemolytic O 0
and O 0
immunochemical O 0
assessment O 0
. O 0

Her O 0
fresh O 0
serum O 0
lacked O 0
complement O 0
- O 0
mediated O 0
bactericidal O 0
activity O 0
against O 0
Neisseria O 0
gonorrhoeae O 0
, O 0
but O 0
the O 0
addition O 0
of O 0
fresh O 0
normal O 0
serum O 0
or O 0
purified O 0
C7 O 0
restored O 0
bactericidal O 0
activity O 0
as O 0
well O 0
as O 0
hemolytic O 0
activity O 0
. O 0

The O 0
absence B-Disease 0
of I-Disease 0
functional I-Disease 0
C7 I-Disease 0
activity O 0
could O 0
not O 0
be O 0
accounted O 0
for O 0
on O 0
the O 0
basis O 0
of O 0
an O 0
inhibitor O 0
. O 0

Opsonization O 0
and O 0
generation O 0
of O 0
chemotactic O 0
activity O 0
functioned O 0
normally O 0
. O 0

Complete B-Disease 0
absence I-Disease 0
of I-Disease 0
C7 I-Disease 0
was O 0
also O 0
found O 0
in O 0
one O 0
sibling O 0
who O 0
had O 0
the O 0
clinical O 0
syndrome O 0
of O 0
meningococcal B-Disease 0
meningitis I-Disease 1
and O 0
arthritis B-Disease 0
as O 0
a O 0
child O 0
and O 0
in O 0
this O 0
siblings O 0
clinically O 0
well O 0
eight O 0
- O 0
year O 0
- O 0
old O 0
son O 0
. O 0

HLA O 0
histocompatibility O 0
typing O 0
of O 0
the O 0
family O 0
members O 0
did O 0
not O 0
demonstrate O 0
evidence O 0
for O 0
genetic O 0
linkage O 0
of O 0
C7 B-Disease 0
deficiency I-Disease 0
with O 0
the O 0
major O 0
histocompatibility O 0
loci O 0
. O 0

This O 0
report O 0
represents O 0
the O 0
first O 0
cases O 0
of O 0
C7 B-Disease 0
deficiency I-Disease 0
associated O 0
with O 0
infectious O 0
complications O 0
and O 0
suggests O 0
that O 0
bactericidal O 0
activity O 0
may O 0
be O 0
important O 0
in O 0
host O 0
defense O 0
against O 0
bacteremic B-Disease 0
neisseria I-Disease 0
infections I-Disease 0
. O 0

Increased O 0
incidence O 0
of O 0
cancer B-Disease 1
in O 0
patients O 0
with O 0
cartilage B-Disease 1
- I-Disease 1
hair I-Disease 1
hypoplasia I-Disease 1
. O 0

OBJECTIVE O 0
Previous O 0
reports O 0
have O 0
suggested O 0
an O 0
increased O 0
risk O 0
of O 0
cancer B-Disease 1
among O 0
patients O 0
with O 0
cartilage B-Disease 1
- I-Disease 1
hair I-Disease 1
hypoplasia I-Disease 1
( O 0
CHH B-Disease 0
) O 0
. O 0

This O 0
study O 0
was O 0
carried O 0
out O 0
to O 0
further O 0
evaluate O 0
this O 0
risk O 0
among O 0
patients O 0
with O 0
CHH B-Disease 0
and O 0
their O 0
first O 0
- O 0
degree O 0
relatives O 0
. O 0

STUDY O 0
DESIGN O 0
One O 0
hundred O 0
twenty O 0
- O 0
two O 0
patients O 0
with O 0
CHH B-Disease 0
were O 0
identified O 0
through O 0
2 O 0
countrywide O 0
epidemiologic O 0
surveys O 0
in O 0
1974 O 0
and O 0
in O 0
1986 O 0
. O 0

Their O 0
parents O 0
and O 0
nonaffected O 0
siblings O 0
were O 0
identified O 0
through O 0
the O 0
Population O 0
Register O 0
Center O 0
. O 0

This O 0
cohort O 0
underwent O 0
follow O 0
- O 0
up O 0
for O 0
cancer B-Disease 1
incidence O 0
through O 0
the O 0
Finnish O 0
Cancer O 1
Registry O 0
to O 0
the O 0
end O 0
of O 0
1995 O 0
. O 0

RESULTS O 0
A O 0
statistically O 0
significant O 0
excess O 0
risk O 0
of O 0
cancer B-Disease 1
was O 0
seen O 0
among O 0
the O 0
patients O 0
with O 0
CHH B-Disease 0
( O 0
standardized O 0
incidence O 0
ratio O 0
6 O 0
. O 0
9 O 0
, O 0
95 O 0
% O 0
confidence O 0
interval O 0
2 O 0
. O 0
3 O 0
to O 0
16 O 0
) O 0
, O 0
which O 0
was O 0
mainly O 0
attributable O 0
to O 0
non B-Disease 0
- I-Disease 0
Hodgkins I-Disease 0
lymphoma I-Disease 1
( O 0
standardized O 0
incidence O 0
ratio O 0
90 O 0
, O 0
95 O 0
% O 0
confidence O 0
interval O 0
18 O 0
to O 0
264 O 0
) O 0
. O 0

In O 0
addition O 0
, O 0
a O 0
significant O 0
excess O 0
risk O 0
of O 0
basal B-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
was O 0
seen O 0
( O 0
standardized O 0
incidence O 0
ratio O 0
35 O 0
, O 0
95 O 0
% O 0
confidence O 0
interval O 0
7 O 0
. O 0
2 O 0
to O 0
102 O 0
) O 0
. O 0

The O 0
cancer B-Disease 1
incidence O 0
among O 0
the O 0
siblings O 0
or O 0
the O 0
parents O 0
did O 0
not O 0
differ O 0
from O 0
the O 0
average O 0
cancer B-Disease 1
incidence O 0
in O 0
the O 0
Finnish O 0
population O 0
. O 0

CONCLUSIONS O 0
This O 0
study O 0
confirms O 0
an O 0
increased O 0
risk O 0
of O 0
cancer B-Disease 1
, O 0
especially O 0
non B-Disease 0
- I-Disease 0
Hodgkins I-Disease 0
lymphoma I-Disease 1
, O 0
probably O 0
attributable O 0
to O 0
defective O 0
immunity O 0
, O 0
among O 0
patients O 0
with O 0
CHH B-Disease 0
. O 0

Genotype O 0
and O 0
phenotype O 0
in O 0
patients O 0
with O 0
dihydropyrimidine B-Disease 0
dehydrogenase I-Disease 0
deficiency I-Disease 0
. O 0

Dihydropyrimidine B-Disease 1
dehydrogenase I-Disease 1
( I-Disease 1
DPD I-Disease 1
) I-Disease 1
deficiency I-Disease 1
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
disease I-Disease 1
characterised O 0
by O 0
thymine O 0
- O 0
uraciluria O 0
in O 0
homozygous O 0
deficient O 0
patients O 0
and O 0
has O 0
been O 0
associated O 0
with O 0
a O 0
variable O 0
clinical O 0
phenotype O 0
. O 0

In O 0
order O 0
to O 0
understand O 0
the O 0
genetic O 0
and O 0
phenotypic O 0
basis O 0
for O 0
DPD B-Disease 1
deficiency I-Disease 0
, O 0
we O 0
have O 0
reviewed O 0
17 O 0
families O 0
presenting O 0
22 O 0
patients O 0
with O 0
complete O 0
deficiency B-Disease 1
of I-Disease 1
DPD I-Disease 1
. O 0

In O 0
this O 0
group O 0
of O 0
patients O 0
, O 0
7 O 0
different O 0
mutations O 0
have O 0
been O 0
identified O 0
, O 0
including O 0
2 O 0
deletions O 0
[ O 0
295 O 0
- O 0
298delTCAT O 0
, O 0
1897delC O 0
] O 0
, O 0
1 O 0
splice O 0
- O 0
site O 0
mutation O 0
[ O 0
IVS14 O 0
+ O 0
1G O 0
> O 0
A O 0
) O 0
] O 0
and O 0
4 O 0
missense O 0
mutations O 0
( O 0
85T O 0
> O 0
C O 0
, O 0
703C O 0
> O 0
T O 0
, O 0
2658G O 0
> O 0
A O 0
, O 0
2983G O 0
> O 0
T O 0
) O 0
. O 0

Analysis O 0
of O 0
the O 0
prevalence O 0
of O 0
the O 0
various O 0
mutations O 0
among O 0
DPD B-Disease 1
patients O 0
has O 0
shown O 0
that O 0
the O 0
G O 0
- O 0
- O 0
> O 0
A O 0
point O 0
mutation O 0
in O 0
the O 0
invariant O 0
splice O 0
donor O 0
site O 0
is O 0
by O 0
far O 0
the O 0
most O 0
common O 0
( O 0
52 O 0
% O 0
) O 0
, O 0
whereas O 0
the O 0
other O 0
six O 0
mutations O 0
are O 0
less O 0
frequently O 0
observed O 0
. O 0

A O 0
large O 0
phenotypic O 0
variability O 0
has O 0
been O 0
observed O 0
, O 0
with O 0
convulsive B-Disease 0
disorders I-Disease 0
, O 0
motor B-Disease 1
retardation I-Disease 1
and O 0
mental B-Disease 1
retardation I-Disease 1
being O 0
the O 0
most O 0
abundant O 0
manifestations O 0
. O 0

A O 0
clear O 0
correlation O 0
between O 0
the O 0
genotype O 0
and O 0
phenotype O 0
has O 0
not O 0
been O 0
established O 0
. O 0

An O 0
altered O 0
beta O 0
- O 0
alanine O 0
, O 0
uracil O 0
and O 0
thymine O 0
homeostasis O 0
might O 0
underlie O 0
the O 0
various O 0
clinical B-Disease 0
abnormalities I-Disease 0
encountered O 0
in O 0
patients O 0
with O 0
DPD B-Disease 1
deficiency I-Disease 0
. O 0

Fibroblast O 0
growth O 0
factor O 0
homologous O 0
factor O 0
2 O 0
( O 0
FHF2 O 0
) O 0
: O 0
gene O 0
structure O 0
, O 0
expression O 0
and O 0
mapping O 0
to O 0
the O 0
Borjeson B-Disease 0
- I-Disease 0
Forssman I-Disease 0
- I-Disease 0
Lehmann I-Disease 0
syndrome I-Disease 0
region O 0
in O 0
Xq26 O 0
delineated O 0
by O 0
a O 0
duplication O 0
breakpoint O 0
in O 0
a O 0
BFLS B-Disease 0
- O 0
like O 0
patient O 0
. O 0

Borjeson B-Disease 0
- I-Disease 0
Forssman I-Disease 0
- I-Disease 0
Lehmann I-Disease 0
syndrome I-Disease 0
( O 0
BFLS B-Disease 0
) O 0
is O 0
a O 0
syndromal O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
mental I-Disease 1
retardation I-Disease 1
, O 0
which O 0
maps O 0
by O 0
linkage O 0
to O 0
the O 0
q26 O 0
region O 0
of O 0
the O 0
human O 0
X O 0
chromosome O 0
. O 0

We O 0
have O 0
identified O 0
a O 0
male O 0
patient O 0
with O 0
BFLS B-Disease 0
- O 0
like O 0
features O 0
and O 0
a O 0
duplication O 0
, O 0
46 O 0
, O 0
Y O 0
, O 0
dup O 0
( O 0
X O 0
) O 0
( O 0
q26q28 O 0
) O 0
, O 0
inherited O 0
from O 0
his O 0
phenotypically O 0
normal O 0
mother O 0
. O 0

Fluorescence O 0
in O 0
situ O 0
hybridisation O 0
using O 0
yeast O 0
artificial O 0
chromosome O 0
clones O 0
from O 0
Xq26 O 0
localised O 0
the O 0
duplication O 0
breakpoint O 0
to O 0
an O 0
approximately O 0
400 O 0
- O 0
kb O 0
interval O 0
in O 0
the O 0
Xq26 O 0
. O 0

3 O 0
region O 0
between O 0
DXS155 O 0
and O 0
DXS294 O 0
/ O 0
DXS730 O 0
. O 0

Database O 0
searches O 0
and O 0
analysis O 0
of O 0
available O 0
genomic O 0
DNA O 0
sequence O 0
from O 0
the O 0
region O 0
revealed O 0
the O 0
presence O 0
of O 0
the O 0
fibroblast O 0
growth O 0
factor O 0
homologous O 0
factor O 0
gene O 0
, O 0
FHF2 O 0
, O 0
within O 0
the O 0
duplication O 0
breakpoint O 0
interval O 0
. O 0

The O 0
gene O 0
structure O 0
of O 0
FHF2 O 0
was O 0
determined O 0
and O 0
two O 0
new O 0
exons O 0
were O 0
identified O 0
, O 0
including O 0
a O 0
new O 0
5 O 0
end O 0
exon O 0
, O 0
1B O 0
. O 0

FHF2 O 0
is O 0
a O 0
large O 0
gene O 0
extending O 0
over O 0
approximately O 0
200 O 0
kb O 0
in O 0
Xq26 O 0
. O 0

3 O 0
and O 0
is O 0
composed O 0
of O 0
at O 0
least O 0
seven O 0
exons O 0
. O 0

It O 0
shows O 0
tissue O 0
- O 0
specific O 0
alternative O 0
splicing O 0
and O 0
alternative O 0
transcription O 0
starts O 0
. O 0

Northern O 0
blot O 0
hybridisation O 0
showed O 0
highest O 0
expression O 0
in O 0
brain O 0
and O 0
skeletal O 0
muscle O 0
. O 0

The O 0
FHF2 O 0
gene O 0
localisation O 0
and O 0
tissue O 0
- O 0
specific O 0
expression O 0
pattern O 0
suggest O 0
it O 0
to O 0
be O 0
a O 0
candidate O 0
gene O 0
for O 0
familial O 0
cases O 0
of O 0
the O 0
BFLS B-Disease 0
syndrome I-Disease 0
and O 0
other O 0
syndromal O 0
and O 0
non O 0
- O 0
specific O 0
forms O 0
of O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
mental I-Disease 1
retardation I-Disease 1
mapping O 0
to O 0
the O 0
region O 0
. O 0

Germline O 0
E O 0
- O 0
cadherin O 0
gene O 0
( O 0
CDH1 O 0
) O 0
mutations O 0
predispose O 0
to O 0
familial B-Disease 0
gastric I-Disease 0
cancer I-Disease 1
and O 0
colorectal B-Disease 1
cancer I-Disease 1
. O 0

Inherited O 0
mutations O 0
in O 0
the O 0
E O 0
- O 0
cadherin O 0
gene O 0
( O 0
CDH1 O 0
) O 0
were O 0
described O 0
recently O 0
in O 0
three O 0
Maori O 0
kindreds O 0
with O 0
familial B-Disease 0
gastric I-Disease 0
cancer I-Disease 1
. O 0

Familial B-Disease 1
gastric I-Disease 1
cancer I-Disease 1
is O 0
genetically O 0
heterogeneous O 0
and O 0
it O 0
is O 0
not O 0
clear O 0
what O 0
proportion O 0
of O 0
gastric B-Disease 0
cancer I-Disease 1
susceptibility O 0
in O 0
non O 0
- O 0
Maori O 0
populations O 0
is O 0
due O 0
to O 0
germline O 0
CDH1 O 0
mutations O 0
. O 0

Therefore O 0
, O 0
we O 0
screened O 0
eight O 0
familial B-Disease 0
gastric I-Disease 0
cancer I-Disease 1
kindreds O 0
of O 0
British O 0
and O 0
Irish O 0
origin O 0
for O 0
germline O 0
CDH1 O 0
mutations O 0
, O 0
by O 0
SSCP O 0
analysis O 0
of O 0
all O 0
16 O 0
exons O 0
and O 0
flanking O 0
sequences O 0
. O 0

Each O 0
family O 0
contained O 0
( O 0
i O 0
) O 0
two O 0
cases O 0
of O 0
gastric B-Disease 0
cancer I-Disease 1
in O 0
first O 0
degree O 0
relatives O 0
with O 0
one O 0
affected O 0
before O 0
age O 0
50 O 0
years O 0
; O 0
or O 0
( O 0
ii O 0
) O 0
three O 0
or O 0
more O 0
cases O 0
of O 0
gastric B-Disease 0
cancer I-Disease 1
. O 0

Novel O 0
germline O 0
CDH1 O 0
mutations O 0
( O 0
a O 0
nonsense O 0
and O 0
a O 0
splice O 0
site O 0
) O 0
were O 0
detected O 0
in O 0
two O 0
families O 0
( O 0
25 O 0
% O 0
) O 0
. O 0

Both O 0
mutations O 0
were O 0
predicted O 0
to O 0
truncate O 0
the O 0
E O 0
- O 0
cadherin O 0
protein O 0
in O 0
the O 0
signal O 0
peptide O 0
domain O 0
. O 0

In O 0
one O 0
family O 0
there O 0
was O 0
evidence O 0
of O 0
non O 0
- O 0
penetrance O 0
and O 0
susceptibility O 0
to O 0
both O 0
gastric B-Disease 0
and I-Disease 0
colorectal I-Disease 1
cancer I-Disease 1
; O 0
thus O 0
, O 0
in O 0
addition O 0
to O 0
six O 0
cases O 0
of O 0
gastric B-Disease 0
cancer I-Disease 1
, O 0
a O 0
CDH1 O 0
mutation O 0
carrier O 0
developed O 0
colorectal B-Disease 1
cancer I-Disease 1
at O 0
age O 0
30 O 0
years O 0
. O 0

We O 0
have O 0
confirmed O 0
that O 0
germline O 0
mutations O 0
in O 0
the O 0
CDH1 O 0
gene O 0
cause O 0
familial B-Disease 0
gastric I-Disease 0
cancer I-Disease 1
in O 0
non O 0
- O 0
Maori O 0
populations O 0
. O 0

However O 0
, O 0
only O 0
a O 0
minority O 0
of O 0
familial O 0
gastric B-Disease 0
cancers I-Disease 0
can O 0
be O 0
accounted O 0
for O 0
by O 0
CDH1 O 0
mutations O 0
. O 0

Loss O 0
of O 0
E O 0
- O 0
cadherin O 0
function O 0
has O 0
been O 0
implicated O 0
in O 0
the O 0
pathogenesis O 0
of O 0
sporadic O 0
colorectal B-Disease 0
and I-Disease 0
other I-Disease 0
cancers I-Disease 0
, O 0
and O 0
our O 0
findings O 0
provide O 0
evidence O 0
that O 0
germline O 0
CDH1 O 0
mutations O 0
predispose O 0
to O 0
early O 0
onset O 0
colorectal B-Disease 1
cancer I-Disease 1
. O 0

Thus O 0
, O 0
CDH1 O 0
should O 0
be O 0
investigated O 0
as O 0
a O 0
cause O 0
of O 0
inherited O 0
susceptibility O 0
to O 0
both O 0
gastric B-Disease 0
and I-Disease 0
colorectal I-Disease 0
cancers I-Disease 0
. O 0

A O 0
zinc O 0
finger O 0
truncation O 0
of O 0
murine O 0
WT1 O 0
results O 0
in O 0
the O 0
characteristic O 0
urogenital B-Disease 0
abnormalities I-Disease 0
of O 0
Denys B-Disease 1
- I-Disease 1
Drash I-Disease 1
syndrome I-Disease 1
. O 0

The O 0
Wilms B-Disease 1
tumor I-Disease 1
- O 0
suppressor O 0
gene O 0
, O 0
WT1 O 0
, O 0
plays O 0
a O 0
key O 0
role O 0
in O 0
urogenital O 0
development O 0
, O 0
and O 0
WT1 B-Disease 0
dysfunction I-Disease 0
is O 0
implicated O 0
in O 0
both O 0
neoplastic B-Disease 0
( O 0
Wilms B-Disease 1
tumor I-Disease 1
, O 0
mesothelioma B-Disease 0
, O 0
leukemias B-Disease 1
, O 0
and O 0
breast B-Disease 0
cancer I-Disease 1
) O 0
and O 0
nonneoplastic B-Disease 1
( O 0
glomerulosclerosis B-Disease 0
) O 0
disease O 0
. O 0

The O 0
analysis O 0
of O 0
diseases O 0
linked O 0
specifically O 0
with O 0
WT1 O 0
mutations O 0
, O 0
such O 0
as O 0
Denys B-Disease 1
- I-Disease 1
Drash I-Disease 1
syndrome I-Disease 1
( O 0
DDS B-Disease 1
) O 0
, O 0
can O 0
provide O 0
valuable O 0
insight O 0
concerning O 0
the O 0
role O 0
of O 0
WT1 O 0
in O 0
development O 0
and O 0
disease O 0
. O 0

DDS B-Disease 1
is O 0
a O 0
rare O 0
childhood O 0
disease O 0
characterized O 0
by O 0
a O 0
nephropathy B-Disease 1
involving O 0
mesangial B-Disease 1
sclerosis I-Disease 1
, O 0
XY O 0
pseudohermaphroditism B-Disease 0
, O 0
and O 0
/ O 0
or O 0
Wilms B-Disease 1
tumor I-Disease 1
( O 0
WT B-Disease 0
) O 0
. O 0

DDS B-Disease 1
patients O 0
are O 0
constitutionally O 0
heterozygous O 0
for O 0
exonic O 0
point O 0
mutations O 0
in O 0
WT1 O 0
, O 0
which O 0
include O 0
mutations O 0
predicted O 0
to O 0
truncate O 0
the O 0
protein O 0
within O 0
the O 0
C O 0
- O 0
terminal O 0
zinc O 0
finger O 0
( O 0
ZF O 0
) O 0
region O 0
. O 0

We O 0
report O 0
that O 0
heterozygosity O 0
for O 0
a O 0
targeted O 0
murine O 0
Wt1 O 0
allele O 0
, O 0
Wt1 O 0
( O 0
tmT396 O 0
) O 0
, O 0
which O 0
truncates O 0
ZF3 O 0
at O 0
codon O 0
396 O 0
, O 0
induces O 0
mesangial B-Disease 1
sclerosis I-Disease 1
characteristic O 0
of O 0
DDS B-Disease 1
in O 0
adult O 0
heterozygous O 0
and O 0
chimeric O 0
mice O 0
. O 0

Male B-Disease 1
genital I-Disease 1
defects I-Disease 1
also O 0
were O 0
evident O 0
and O 0
there O 0
was O 0
a O 0
single O 0
case O 0
of O 0
Wilms B-Disease 1
tumor I-Disease 1
in O 0
which O 0
the O 0
transcript O 0
of O 0
the O 0
nontargeted O 0
allele O 0
showed O 0
an O 0
exon O 0
9 O 0
skipping O 0
event O 0
, O 0
implying O 0
a O 0
causal O 0
link O 0
between O 0
Wt1 B-Disease 1
dysfunction I-Disease 1
and O 0
Wilms B-Disease 1
tumorigenesis I-Disease 1
in O 0
mice O 0
. O 0

However O 0
, O 0
the O 0
mutant O 0
WT1 O 0
( O 0
tmT396 O 0
) O 0
protein O 0
accounted O 0
for O 0
only O 0
5 O 0
% O 0
of O 0
WT1 O 0
in O 0
both O 0
heterozygous O 0
embryonic O 0
stem O 0
cells O 0
and O 0
the O 0
WT B-Disease 0
. O 0

This O 0
has O 0
implications O 0
regarding O 0
the O 0
mechanism O 0
by O 0
which O 0
the O 0
mutant O 0
allele O 0
exerts O 0
its O 0
effect O 0
. O 0

Mechanism O 0
of O 0
increased O 0
iron O 0
absorption O 0
in O 0
murine O 0
model O 0
of O 0
hereditary B-Disease 0
hemochromatosis I-Disease 1
: O 0
increased O 0
duodenal O 0
expression O 0
of O 0
the O 0
iron O 0
transporter O 0
DMT1 O 0
. O 0

Hereditary B-Disease 1
hemochromatosis I-Disease 1
( O 0
HH B-Disease 0
) O 0
is O 0
a O 0
common O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
characterized O 0
by O 0
tissue O 0
iron O 0
deposition O 0
secondary O 0
to O 0
excessive O 0
dietary O 0
iron O 0
absorption O 0
. O 0

We O 0
recently O 0
reported O 0
that O 0
HFE O 0
, O 0
the O 0
protein O 0
defective O 0
in O 0
HH B-Disease 0
, O 0
was O 0
physically O 0
associated O 0
with O 0
the O 0
transferrin O 0
receptor O 0
( O 0
TfR O 0
) O 0
in O 0
duodenal O 0
crypt O 0
cells O 0
and O 0
proposed O 0
that O 0
mutations O 0
in O 0
HFE O 0
attenuate O 0
the O 0
uptake O 0
of O 0
transferrin O 0
- O 0
bound O 0
iron O 0
from O 0
plasma O 0
by O 0
duodenal O 0
crypt O 0
cells O 0
, O 0
leading O 0
to O 0
up O 0
- O 0
regulation O 0
of O 0
transporters O 0
for O 0
dietary O 0
iron O 0
. O 0

Here O 0
, O 0
we O 0
tested O 0
the O 0
hypothesis O 0
that O 0
HFE O 0
- O 0
/ O 0
- O 0
mice O 0
have O 0
increased O 0
duodenal O 0
expression O 0
of O 0
the O 0
divalent O 0
metal O 0
transporter O 0
( O 0
DMT1 O 0
) O 0
. O 0

By O 0
4 O 0
weeks O 0
of O 0
age O 0
, O 0
the O 0
HFE O 0
- O 0
/ O 0
- O 0
mice O 0
demonstrated O 0
iron O 0
loading O 0
when O 0
compared O 0
with O 0
HFE O 0
+ O 0
/ O 0
+ O 0
littermates O 0
, O 0
with O 0
elevated O 0
transferrin O 0
saturations O 0
( O 0
68 O 0
. O 0
4 O 0
% O 0
vs O 0
. O 0
49 O 0
. O 0
8 O 0
% O 0
) O 0
and O 0
elevated O 0
liver O 0
iron O 0
concentrations O 0
( O 0
985 O 0
micrograms O 0
vs O 0
. O 0
381 O 0
micrograms O 0
) O 0
. O 0

By O 0
using O 0
Northern O 0
blot O 0
analyses O 0
, O 0
we O 0
quantitated O 0
duodenal O 0
expression O 0
of O 0
both O 0
classes O 0
of O 0
DMT1 O 0
transcripts O 0
one O 0
containing O 0
an O 0
iron O 0
responsive O 0
element O 0
( O 0
IRE O 0
) O 0
, O 0
called O 0
DMT1 O 0
( O 0
IRE O 0
) O 0
, O 0
and O 0
one O 0
containing O 0
no O 0
IRE O 0
, O 0
called O 0
DMT1 O 0
( O 0
non O 0
- O 0
IRE O 0
) O 0
. O 0

The O 0
positive O 0
control O 0
for O 0
DMT1 O 0
up O 0
- O 0
regulation O 0
was O 0
a O 0
murine O 0
model O 0
of O 0
dietary B-Disease 1
iron I-Disease 1
deficiency I-Disease 1
that O 0
demonstrated O 0
greatly O 0
increased O 0
levels O 0
of O 0
duodenal O 0
DMT1 O 0
( O 0
IRE O 0
) O 0
mRNA O 0
. O 0

HFE O 0
- O 0
/ O 0
- O 0
mice O 0
also O 0
demonstrated O 0
an O 0
increase O 0
in O 0
duodenal O 0
DMT1 O 0
( O 0
IRE O 0
) O 0
mRNA O 0
( O 0
average O 0
7 O 0
. O 0
7 O 0
- O 0
fold O 0
) O 0
, O 0
despite O 0
their O 0
elevated O 0
transferrin O 0
saturation O 0
and O 0
hepatic O 0
iron O 0
content O 0
. O 0

Duodenal O 0
expression O 0
of O 0
DMT1 O 0
( O 0
non O 0
- O 0
IRE O 0
) O 0
was O 0
not O 0
increased O 0
, O 0
nor O 0
was O 0
hepatic O 0
expression O 0
of O 0
DMT1 O 0
increased O 0
. O 0

These O 0
data O 0
support O 0
the O 0
model O 0
for O 0
HH O 0
in O 0
which O 0
HFE O 0
mutations O 0
lead O 0
to O 0
inappropriately O 0
low O 0
crypt O 0
cell O 0
iron O 0
, O 0
with O 0
resultant O 0
stabilization O 0
of O 0
DMT1 O 0
( O 0
IRE O 0
) O 0
mRNA O 0
, O 0
up O 0
- O 0
regulation O 0
of O 0
DMT1 O 0
, O 0
and O 0
increased O 0
absorption O 0
of O 0
dietary O 0
iron O 0
. O 0

Neurophysiologic O 0
follow O 0
- O 0
up O 0
of O 0
long O 0
- O 0
term O 0
dietary O 0
treatment O 0
in O 0
adult O 0
- O 0
onset O 0
adrenoleukodystrophy B-Disease 1
. O 0

OBJECTIVE O 0
To O 0
monitor O 0
the O 0
effects O 0
of O 0
dietary O 0
treatment O 0
in O 0
adult O 0
- O 0
onset O 0
adrenoleukodystrophy B-Disease 1
( O 0
ALD B-Disease 0
) O 0
by O 0
means O 0
of O 0
somatosensory O 0
evoked O 0
potentials O 0
( O 0
SEPs O 0
) O 0
and O 0
motor O 0
evoked O 0
potentials O 0
( O 0
MEPs O 0
) O 0
. O 0

BACKGROUND O 0
SEPs O 0
and O 0
MEPs O 0
have O 0
proved O 0
useful O 0
in O 0
revealing O 0
signs O 0
of O 0
progressively O 0
severe O 0
, O 0
central O 0
dying B-Disease 0
- I-Disease 0
back I-Disease 0
axonopathy I-Disease 0
in O 0
early O 0
stages O 0
of O 0
adult O 0
- O 0
onset O 0
ALD B-Disease 0
. O 0

METHODS O 0
Eight O 0
patients O 0
with O 0
adult O 0
- O 0
onset O 0
ALD B-Disease 0
underwent O 0
clinical O 0
examination O 0
, O 0
brain O 0
and O 0
spine O 0
MRI O 0
, O 0
and O 0
SEP O 0
and O 0
MEP O 0
studies O 0
before O 0
and O 0
after O 0
3 O 0
years O 0
of O 0
Lorenzos O 0
oil O 0
dietary O 0
therapy O 0
. O 0

RESULTS O 0
Before O 0
treatment O 0
, O 0
brain O 0
MRI O 0
was O 0
normal O 0
in O 0
five O 0
patients O 0
. O 0

Three O 0
of O 0
these O 0
patients O 0
had O 0
pure O 0
spinal B-Disease 0
SEP I-Disease 0
abnormalities I-Disease 0
and O 0
in O 0
the O 0
remaining O 0
two O 0
patients O 0
SEPs O 0
showed O 0
signs O 0
of O 0
involvement O 0
of O 0
both O 0
the O 0
spinal O 0
and O 0
cerebral O 0
somatosensory O 0
tracts O 0
. O 0

After O 0
treatment O 0
, O 0
the O 0
three O 0
patients O 0
with O 0
pure O 0
spinal B-Disease 1
abnormalities I-Disease 1
showed O 0
clinical O 0
and O 0
neurophysiologic O 0
worsening O 0
, O 0
whereas O 0
the O 0
two O 0
patients O 0
with O 0
a O 0
more O 0
advanced O 0
stage O 0
of O 0
disease O 0
( O 0
exhibited O 0
by O 0
SEPs O 0
) O 0
showed O 0
substantially O 0
unchanged O 0
clinical O 0
and O 0
neurophysiologic O 0
features O 0
. O 0

The O 0
patients O 0
with O 0
abnormal O 0
brain O 0
MRI O 0
at O 0
the O 0
onset O 0
of O 0
treatment O 0
showed O 0
clinical O 0
and O 0
neurophysiologic O 0
worsening O 0
. O 0

CONCLUSIONS O 0
Lorenzos O 0
oil O 0
therapy O 0
had O 0
no O 0
effect O 0
on O 0
patients O 0
with O 0
evidence O 0
of O 0
inflammatory B-Disease 1
brain I-Disease 1
lesions I-Disease 1
. O 0

Moreover O 0
, O 0
in O 0
patients O 0
without O 0
clear O 0
signs O 0
of O 0
inflammatory O 0
damage O 0
, O 0
this O 0
treatment O 0
does O 0
not O 0
modify O 0
significantly O 0
the O 0
natural O 0
course O 0
of O 0
the O 0
disease O 0
. O 0

However O 0
, O 0
because O 0
effective O 0
treatments O 0
should O 0
begin O 0
before O 0
the O 0
onset O 0
of O 0
severe O 0
neurologic O 0
symptoms O 0
, O 0
SEPs O 0
and O 0
MEPs O 0
should O 0
be O 0
considered O 0
to O 0
evaluate O 0
the O 0
effectiveness O 0
of O 0
other O 0
experimental O 0
treatments O 0
in O 0
the O 0
patient O 0
with O 0
a O 0
negative O 0
brain O 0
MRI O 0
. O 0

GCH1 O 0
mutation O 0
in O 0
a O 0
patient O 0
with O 0
adult O 0
- O 0
onset O 0
oromandibular B-Disease 1
dystonia I-Disease 1
. O 0

The O 0
authors O 0
report O 0
a O 0
mutation O 0
in O 0
exon O 0
5 O 0
of O 0
GCH1 O 0
in O 0
a O 0
patient O 0
with O 0
adult O 0
- O 0
onset O 0
oromandibular B-Disease 1
dystonia I-Disease 1
and O 0
no O 0
obvious O 0
family O 0
history O 0
of O 0
dystonia B-Disease 0
. O 0

The O 0
patient O 0
responded O 0
positively O 0
to O 0
treatment O 0
with O 0
L O 0
- O 0
dopa O 0
. O 0

These O 0
findings O 0
demonstrate O 0
that O 0
GCH1 O 0
mutations O 0
must O 0
be O 0
considered O 0
even O 0
in O 0
patients O 0
with O 0
dystonic B-Disease 0
symptoms O 0
not O 0
typical O 0
of O 0
dopa B-Disease 1
- I-Disease 1
responsive I-Disease 1
dystonia I-Disease 1
. O 0

Germline O 0
mutations O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
in O 0
Korean O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
patients O 0
. O 0

We O 0
extensively O 0
analyzed O 0
genomic O 0
DNA O 0
and O 0
messenger O 0
RNA O 0
( O 0
mRNA O 0
) O 0
from O 0
62 O 0
unrelated O 0
Korean O 0
patients O 0
with O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
( O 0
FAP B-Disease 0
) O 0
for O 0
identification O 0
of O 0
germline O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( O 0
APC B-Disease 1
) O 0
gene O 0
mutations O 0
. O 0

We O 0
adopted O 0
both O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphism O 0
( O 0
SSCP O 0
) O 0
analysis O 0
and O 0
a O 0
method O 0
of O 0
analysis O 0
involving O 0
the O 0
reverse O 0
transcription O 0
- O 0
polymerase O 0
chain O 0
reaction O 0
( O 0
RT O 0
- O 0
PCR O 0
) O 0
followed O 0
by O 0
a O 0
protein O 0
truncation O 0
test O 0
( O 0
PTT O 0
) O 0
. O 0

DNA O 0
sequencing O 0
confirmed O 0
all O 0
alterations O 0
represented O 0
by O 0
aberrant O 0
bands O 0
. O 0

Germline O 0
mutations O 0
were O 0
identified O 0
in O 0
38 O 0
patients O 0
( O 0
61 O 0
% O 0
) O 0
. O 0

Nineteen O 0
of O 0
the O 0
detected O 0
mutations O 0
were O 0
presumed O 0
to O 0
be O 0
novel O 0
, O 0
thus O 0
emphasizing O 0
the O 0
heterogeneity O 0
of O 0
the O 0
mutational O 0
spectrum O 0
in O 0
Korean O 0
FAP B-Disease 0
patients O 0
. O 0

In O 0
the O 0
initial O 0
48 O 0
patients O 0
, O 0
SSCP O 0
analysis O 0
was O 0
followed O 0
by O 0
PTT O 0
for O 0
those O 0
patients O 0
for O 0
whom O 0
no O 0
detectable O 0
mutations O 0
were O 0
found O 0
by O 0
SSCP O 0
. O 0

Using O 0
this O 0
combined O 0
approach O 0
, O 0
we O 0
identified O 0
germline O 0
APC B-Disease 1
gene O 0
mutations O 0
in O 0
29 O 0
of O 0
the O 0
48 O 0
FAP B-Disease 0
patients O 0
( O 0
60 O 0
% O 0
) O 0
, O 0
including O 0
6 O 0
patients O 0
in O 0
whom O 0
SSCP O 0
analysis O 0
failed O 0
to O 0
distinguish O 0
the O 0
mutant O 0
allele O 0
. O 0

In O 0
the O 0
14 O 0
later O 0
patients O 0
, O 0
we O 0
identified O 0
truncating O 0
mutations O 0
in O 0
9 O 0
patients O 0
( O 0
64 O 0
% O 0
) O 0
using O 0
PTT O 0
only O 0
. O 0

Our O 0
results O 0
confirm O 0
that O 0
the O 0
mutation O 0
detection O 0
rate O 0
with O 0
PTT O 0
was O 0
superior O 0
to O 0
that O 0
with O 0
SSCP O 0
, O 0
and O 0
suggest O 0
that O 0
PTT O 0
would O 0
be O 0
a O 0
more O 0
practical O 0
screening O 0
method O 0
to O 0
detect O 0
germline O 0
mutations O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
in O 0
FAP B-Disease 0
patients O 0
. O 0

Molecular O 0
epidemiology O 0
of O 0
C9 B-Disease 1
deficiency I-Disease 1
heterozygotes O 0
with O 0
an O 0
Arg95Stop O 0
mutation O 0
of O 0
the O 0
C9 O 0
gene O 0
in O 0
Japan O 0
. O 0

Deficiency B-Disease 1
of I-Disease 1
the I-Disease 1
ninth I-Disease 1
component I-Disease 1
of I-Disease 1
human I-Disease 1
complement I-Disease 1
( O 0
C9 O 0
) O 0
is O 0
the O 0
most O 0
common O 0
complement B-Disease 1
deficiency I-Disease 1
in O 0
Japan O 0
, O 0
with O 0
an O 0
incidence O 0
of O 0
approximately O 0
one O 0
homozygote O 0
in O 0
1000 O 0
, O 0
but O 0
is O 0
very O 0
rare O 0
in O 0
other O 0
countries O 0
. O 0

Genetic O 0
analyses O 0
of O 0
Japanese O 0
C9 B-Disease 1
deficiency I-Disease 1
have O 0
shown O 0
that O 0
a O 0
C O 0
- O 0
to O 0
- O 0
T O 0
transition O 0
leading O 0
to O 0
TGA O 0
stop O 0
codon O 0
for O 0
Arg95 O 0
in O 0
exon O 0
4 O 0
of O 0
the O 0
C9 O 0
gene O 0
( O 0
Arg95Stop O 0
) O 0
is O 0
common O 0
in O 0
Japanese O 0
C9 B-Disease 1
deficiency I-Disease 1
. O 0

To O 0
determine O 0
the O 0
prevalence O 0
of O 0
heterozygous O 0
carriers O 0
of O 0
the O 0
Arg95Stop O 0
mutation O 0
in O 0
a O 0
Japanese O 0
population O 0
, O 0
we O 0
collected O 0
DNA O 0
samples O 0
from O 0
300 O 0
individuals O 0
in O 0
two O 0
of O 0
the O 0
four O 0
main O 0
islands O 0
of O 0
Japan O 0
. O 0

Heterozygote O 0
detection O 0
was O 0
performed O 0
with O 0
an O 0
allele O 0
- O 0
specific O 0
polymerase O 0
chain O 0
reaction O 0
( O 0
PCR O 0
) O 0
system O 0
designed O 0
to O 0
detect O 0
exclusively O 0
only O 0
one O 0
of O 0
the O 0
normal O 0
and O 0
mutant O 0
alleles O 0
, O 0
followed O 0
by O 0
confirmation O 0
with O 0
PCR O 0
/ O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphism O 0
( O 0
SSCP O 0
) O 0
analysis O 0
and O 0
direct O 0
sequencing O 0
. O 0

Twenty O 0
individuals O 0
were O 0
heterozygous O 0
for O 0
the O 0
Arg95Stop O 0
mutation O 0
. O 0

None O 0
was O 0
homozygous O 0
. O 0

The O 0
prevalence O 0
of O 0
carriers O 0
of O 0
the O 0
Arg95Stop O 0
mutation O 0
was O 0
6 O 0
. O 0

7 O 0
% O 0
( O 0
20 O 0
/ O 0
300 O 0
) O 0
. O 0

An O 0
estimated O 0
frequency O 0
( O 0
0 O 0
. O 0
12 O 0
% O 0
) O 0
of O 0
complete O 0
C9 B-Disease 1
deficiency I-Disease 1
due O 0
to O 0
homozygous O 0
Arg95Stop O 0
mutation O 0
was O 0
consistent O 0
with O 0
frequencies O 0
determined O 0
by O 0
serological O 0
studies O 0

The O 0
hereditary B-Disease 0
hemochromatosis I-Disease 1
protein O 0
, O 0
HFE O 0
, O 0
specifically O 0
regulates O 0
transferrin O 0
- O 0
mediated O 0
iron O 0
uptake O 0
in O 0
HeLa O 0
cells O 0
. O 0

HFE O 0
is O 0
the O 0
protein O 0
product O 0
of O 0
the O 0
gene O 0
mutated O 0
in O 0
the O 0
autosomal B-Disease 1
recessive I-Disease 1
disease I-Disease 1
hereditary B-Disease 0
hemochromatosis I-Disease 1
( O 0
Feder O 0
, O 0
J O 0
. O 0

N O 0
. O 0
, O 0
Gnirke O 0
, O 0
A O 0
. O 0
, O 0
Thomas O 0
, O 0
W O 0
. O 0
, O 0
Tsuchihashi O 0
, O 0
Z O 0
. O 0
, O 0
Ruddy O 0
, O 0
D O 0
. O 0

A O 0
. O 0
, O 0
Basava O 0
, O 0
A O 0
. O 0
, O 0
Dormishian O 0
, O 0
F O 0
. O 0
, O 0
Domingo O 0
, O 0
R O 0
. O 0

J O 0
. O 0
, O 0
Ellis O 0
, O 0
M O 0
. O 0

C O 0
. O 0
, O 0
Fullan O 0
, O 0
A O 0
. O 0
, O 0
Hinton O 0
, O 0
L O 0
. O 0

M O 0
. O 0
, O 0
Jones O 0
, O 0
N O 0
. O 0

L O 0
. O 0
, O 0
Kimmel O 0
, O 0
B O 0
. O 0

E O 0
. O 0
, O 0
Kronmal O 0
, O 0
G O 0
. O 0

S O 0
. O 0
, O 0
Lauer O 0
, O 0
P O 0
. O 0
, O 0
Lee O 0
, O 0
V O 0
. O 0

K O 0
. O 0
, O 0
Loeb O 0
, O 0
D O 0
. O 0

B O 0
. O 0
, O 0
Mapa O 0
, O 0
F O 0
. O 0

A O 0
. O 0
, O 0
McClelland O 0
, O 0
E O 0
. O 0
, O 0
Meyer O 0
, O 0
N O 0
. O 0

C O 0
. O 0
, O 0
Mintier O 0
, O 0
G O 0
. O 0

A O 0
. O 0
, O 0
Moeller O 0
, O 0
N O 0
. O 0
, O 0
Moore O 0
, O 0
T O 0
. O 0
, O 0
Morikang O 0
, O 0
E O 0
. O 0
, O 0
Prasss O 0
, O 0
C O 0
. O 0

E O 0
. O 0
, O 0
Quintana O 0
, O 0
L O 0
. O 0
, O 0
Starnes O 0
, O 0
S O 0
. O 0

M O 0
. O 0
, O 0
Schatzman O 0
, O 0
R O 0
. O 0

C O 0
. O 0
, O 0
Brunke O 0
, O 0
K O 0
. O 0

J O 0
. O 0
, O 0
Drayna O 0
, O 0
D O 0
. O 0

T O 0
. O 0
, O 0
Risch O 0
, O 0
N O 0
. O 0

J O 0
. O 0
, O 0
Bacon O 0
, O 0
B O 0
. O 0

R O 0
. O 0
, O 0
and O 0
Wolff O 0
, O 0
R O 0
. O 0

R O 0
. O 0

( O 0
1996 O 0
) O 0
Nat O 0
. O 0

Genet O 0
. O 0

13 O 0
, O 0
399 O 0
- O 0
408 O 0
) O 0
. O 0

At O 0
the O 0
cell O 0
surface O 0
, O 0
HFE O 0
complexes O 0
with O 0
transferrin O 0
receptor O 0
( O 0
TfR O 0
) O 0
, O 0
increasing O 0
the O 0
dissociation O 0
constant O 0
of O 0
transferrin O 0
( O 0
Tf O 0
) O 0
for O 0
its O 0
receptor O 0
10 O 0
- O 0
fold O 0
( O 0
Gross O 0
, O 0
C O 0
. O 0

N O 0
. O 0
, O 0
Irrinki O 0
, O 0
A O 0
. O 0
, O 0
Feder O 0
, O 0
J O 0
. O 0
N O 0
. O 0
, O 0
and O 0
Enns O 0
, O 0
C O 0
. O 0
A O 0
. O 0
( O 0
1998 O 0
) O 0
J O 0
. O 0
Biol O 0
. O 0
Chem O 0
. O 0
273 O 0
, O 0
22068 O 0
- O 0
22074 O 0
; O 0
Feder O 0
, O 0
J O 0
. O 0
N O 0
. O 0
, O 0
Penny O 0
, O 0
D O 0
. O 0
M O 0
. O 0
, O 0
Irrinki O 0
, O 0
A O 0
. O 0
, O 0
Lee O 0
, O 0
V O 0
. O 0
K O 0
. O 0
, O 0
Lebron O 0
, O 0
J O 0
. O 0
A O 0
. O 0
, O 0
Watson O 0
, O 0
N O 0
. O 0
, O 0
Tsuchihashi O 0
, O 0
Z O 0
. O 0
, O 0
Sigal O 0
, O 0
E O 0
. O 0
, O 0
Bjorkman O 0
, O 0
P O 0
. O 0
J O 0
. O 0
, O 0
and O 0
Schatzman O 0
, O 0
R O 0
. O 0
C O 0
. O 0
( O 0
1998 O 0
) O 0
Proc O 0
. O 0
Natl O 0
. O 0

Acad O 0
. O 0

Sci O 0
. O 0

U O 0
S O 0
A O 0
95 O 0
, O 0
1472 O 0
- O 0
1477 O 0
) O 0
. O 0

HFE O 0
does O 0
not O 0
remain O 0
at O 0
the O 0
cell O 0
surface O 0
, O 0
but O 0
traffics O 0
with O 0
TfR O 0
to O 0
Tf O 0
- O 0
positive O 0
internal O 0
compartments O 0
( O 0
Gross O 0
et O 0
al O 0
. O 0
, O 0
1998 O 0
) O 0
. O 0

Using O 0
a O 0
HeLa O 0
cell O 0
line O 0
in O 0
which O 0
the O 0
expression O 0
of O 0
HFE O 0
is O 0
controlled O 0
by O 0
tetracycline O 0
, O 0
we O 0
show O 0
that O 0
the O 0
expression O 0
of O 0
HFE O 0
reduces O 0
55Fe O 0
uptake O 0
from O 0
Tf O 0
by O 0
33 O 0
% O 0
but O 0
does O 0
not O 0
affect O 0
the O 0
endocytic O 0
or O 0
exocytic O 0
rates O 0
of O 0
TfR O 0
cycling O 0
. O 0

Therefore O 0
, O 0
HFE O 0
appears O 0
to O 0
reduce O 0
cellular O 0
acquisition O 0
of O 0
iron O 0
from O 0
Tf O 0
within O 0
endocytic O 0
compartments O 0
. O 0

HFE O 0
specifically O 0
reduces O 0
iron O 0
uptake O 0
from O 0
Tf O 0
, O 0
as O 0
non O 0
- O 0
Tf O 0
- O 0
mediated O 0
iron O 0
uptake O 0
from O 0
Fe O 0
- O 0
nitrilotriacetic O 0
acid O 0
is O 0
not O 0
altered O 0
. O 0

These O 0
results O 0
explain O 0
the O 0
decreased O 0
ferritin O 0
levels O 0
seen O 0
in O 0
our O 0
HeLa O 0
cell O 0
system O 0
and O 0
demonstrate O 0
the O 0
specific O 0
control O 0
of O 0
HFE O 0
over O 0
the O 0
Tf O 0
- O 0
mediated O 0
pathway O 0
of O 0
iron O 0
uptake O 0
. O 0

These O 0
results O 0
also O 0
have O 0
implications O 0
for O 0
the O 0
understanding O 0
of O 0
cellular O 0
iron O 0
homeostasis O 0
in O 0
organs O 0
such O 0
as O 0
the O 0
liver O 0
, O 0
pancreas O 0
, O 0
heart O 0
, O 0
and O 0
spleen O 0
that O 0
are O 0
iron O 0
loaded O 0
in O 0
hereditary B-Disease 1
hemochromatotic I-Disease 1
individuals O 0
lacking O 0
functional O 0
HFE O 0
. O 0

Mutation O 0
and O 0
haplotype O 0
studies O 0
of O 0
familial B-Disease 0
Mediterranean I-Disease 0
fever I-Disease 0
reveal O 0
new O 0
ancestral O 0
relationships O 0
and O 0
evidence O 0
for O 0
a O 0
high O 0
carrier O 0
frequency O 0
with O 0
reduced O 0
penetrance O 0
in O 0
the O 0
Ashkenazi O 0
Jewish O 0
population O 0
. O 0

Familial B-Disease 1
Mediterranean I-Disease 1
fever I-Disease 1
( O 0
FMF B-Disease 0
) O 0
is O 0
a O 0
recessive B-Disease 0
disorder I-Disease 0
characterized O 0
by O 0
episodes O 0
of O 0
fever O 0
with O 0
serositis B-Disease 1
or O 0
synovitis B-Disease 1
. O 0

The O 0
FMF B-Disease 0
gene O 0
( O 0
MEFV O 0
) O 0
was O 0
cloned O 0
recently O 0
, O 0
and O 0
four O 0
missense O 0
mutations O 0
were O 0
identified O 0
. O 0

Here O 0
we O 0
present O 0
data O 0
from O 0
non O 0
- O 0
Ashkenazi O 0
Jewish O 0
and O 0
Arab O 0
patients O 0
in O 0
whom O 0
we O 0
had O 0
not O 0
originally O 0
found O 0
mutations O 0
and O 0
from O 0
a O 0
new O 0
, O 0
more O 0
ethnically O 0
diverse O 0
panel O 0
. O 0

Among O 0
90 O 0
symptomatic O 0
mutation O 0
- O 0
positive O 0
individuals O 0
, O 0
11 O 0
mutations O 0
accounted O 0
for O 0
79 O 0
% O 0
of O 0
carrier O 0
chromosomes O 0
. O 0

Of O 0
the O 0
two O 0
mutations O 0
that O 0
are O 0
novel O 0
, O 0
one O 0
alters O 0
the O 0
same O 0
residue O 0
( O 0
680 O 0
) O 0
as O 0
a O 0
previously O 0
known O 0
mutation O 0
, O 0
and O 0
the O 0
other O 0
( O 0
P369S O 0
) O 0
is O 0
located O 0
in O 0
exon O 0
3 O 0
. O 0

Consistent O 0
with O 0
another O 0
recent O 0
report O 0
, O 0
the O 0
E148Q O 0
mutation O 0
was O 0
observed O 0
in O 0
patients O 0
of O 0
several O 0
ethnicities O 0
and O 0
on O 0
multiple O 0
microsatellite O 0
haplotypes O 0
, O 0
but O 0
haplotype O 0
data O 0
indicate O 0
an O 0
ancestral O 0
relationships O 0
between O 0
non O 0
- O 0
Jewish O 0
Italian O 0
and O 0
Ashkenazi O 0
Jewish O 0
patients O 0
with O 0
FMF B-Disease 0
and O 0
other O 0
affected O 0
populations O 0
. O 0

Among O 0
approximately O 0
200 O 0
anonymous O 0
Ashkenazi O 0
Jewish O 0
DNA O 0
samples O 0
, O 0
the O 0
MEFV O 0
carrier O 0
frequency O 0
was O 0
21 O 0
% O 0
, O 0
with O 0
E148Q O 0
the O 0
most O 0
common O 0
mutation O 0
. O 0

Several O 0
lines O 0
of O 0
evidence O 0
indicate O 0
reduced O 0
penetrance O 0
among O 0
Ashkenazi O 0
Jews O 0
, O 0
especially O 0
for O 0
E148Q O 0
, O 0
P369S O 0
, O 0
and O 0
K695R O 0
. O 0

Nevertheless O 0
, O 0
E148Q O 0
helps O 0
account O 0
for O 0
recessive O 0
inheritance O 0
in O 0
an O 0
Ashkenazi O 0
family O 0
previously O 0
reported O 0
as O 0
an O 0
unusual O 0
case O 0
of O 0
dominantly O 0
inherited O 0
FMF B-Disease 0
. O 0

The O 0
presence O 0
of O 0
three O 0
frequent O 0
MEFV O 0
mutations O 0
in O 0
multiple O 0
Mediterranean O 0
populations O 0
strongly O 0
suggests O 0
a O 0
heterozygote O 0
advantage O 0
in O 0
this O 0
geographic O 0
region O 0
. O 0

Autoimmune B-Disease 1
lymphoproliferative I-Disease 1
syndrome I-Disease 1
with O 0
defective O 0
Fas O 0
: O 0
genotype O 0
influences O 0
penetrance O 0
. O 0

Autoimmune B-Disease 1
lymphoproliferative I-Disease 1
syndrome I-Disease 1
( O 0
ALPS B-Disease 1
) O 0
is O 0
a O 0
disorder B-Disease 0
of I-Disease 0
lymphocyte I-Disease 0
homeostasis I-Disease 0
and I-Disease 0
immunological I-Disease 0
tolerance I-Disease 0
. O 0

Most O 0
patients O 0
have O 0
a O 0
heterozygous O 0
mutation O 0
in O 0
the O 0
APT1 O 0
gene O 0
, O 0
which O 0
encodes O 0
Fas O 0
( O 0
CD95 O 0
, O 0
APO O 0
- O 0
1 O 0
) O 0
, O 0
mediator O 0
of O 0
an O 0
apoptotic O 0
pathway O 0
crucial O 0
to O 0
lymphocyte O 0
homeostasis O 0
. O 0

Of O 0
17 O 0
unique O 0
APT1 O 0
mutations O 0
in O 0
unrelated O 0
ALPS B-Disease 1
probands O 0
, O 0
12 O 0
( O 0
71 O 0
% O 0
) O 0
occurred O 0
in O 0
exons O 0
7 O 0
- O 0
9 O 0
, O 0
which O 0
encode O 0
the O 0
intracellular O 0
portion O 0
of O 0
Fas O 0
. O 0

In O 0
vitro O 0
, O 0
activated O 0
lymphocytes O 0
from O 0
all O 0
17 O 0
patients O 0
showed O 0
apoptotic O 0
defects O 0
when O 0
exposed O 0
to O 0
an O 0
anti O 0
- O 0
Fas O 0
agonist O 0
monoclonal O 0
antibody O 0
. O 0

Similar O 0
defects O 0
were O 0
found O 0
in O 0
a O 0
Fas O 0
- O 0
negative O 0
cell O 0
line O 0
transfected O 0
with O 0
cDNAs O 0
bearing O 0
each O 0
of O 0
the O 0
mutations O 0
. O 0

In O 0
cotransfection O 0
experiments O 0
, O 0
Fas O 0
constructs O 0
with O 0
either O 0
intra O 0
- O 0
or O 0
extracellular O 0
mutations O 0
caused O 0
dominant O 0
inhibition O 0
of O 0
apoptosis O 0
mediated O 0
by O 0
wild O 0
- O 0
type O 0
Fas O 0
. O 0

Two O 0
missense O 0
Fas O 0
variants O 0
, O 0
not O 0
restricted O 0
to O 0
patients O 0
with O 0
ALPS B-Disease 1
, O 0
were O 0
identified O 0
. O 0

Variant O 0
A O 0
( O 0
- O 0
1 O 0
) O 0
T O 0
at O 0
the O 0
Fas O 0
signal O 0
- O 0
sequence O 0
cleavage O 0
site O 0
, O 0
which O 0
mediates O 0
apoptosis O 0
less O 0
well O 0
than O 0
wild O 0
- O 0
type O 0
Fas O 0
and O 0
is O 0
partially O 0
inhibitory O 0
, O 0
was O 0
present O 0
in O 0
13 O 0
% O 0
of O 0
African O 0
American O 0
alleles O 0
. O 0

Among O 0
the O 0
ALPS B-Disease 1
- O 0
associated O 0
Fas O 0
mutants O 0
, O 0
dominant O 0
inhibition O 0
of O 0
apoptosis O 0
was O 0
much O 0
more O 0
pronounced O 0
in O 0
mutants O 0
affecting O 0
the O 0
intracellular O 0
, O 0
versus O 0
extracellular O 0
, O 0
portion O 0
of O 0
the O 0
Fas O 0
receptor O 0
. O 0

Mutations O 0
causing O 0
disruption O 0
of O 0
the O 0
intracellular O 0
Fas O 0
death O 0
domain O 0
also O 0
showed O 0
a O 0
higher O 0
penetrance O 0
of O 0
ALPS B-Disease 1
phenotype O 0
features O 0
in O 0
mutation O 0
- O 0
bearing O 0
relatives O 0
. O 0

Significant O 0
ALPS B-Disease 1
- O 0
related O 0
morbidity O 0
occurred O 0
in O 0
44 O 0
% O 0
of O 0
relatives O 0
with O 0
intracellular O 0
mutations O 0
, O 0
versus O 0
0 O 0
% O 0
of O 0
relatives O 0
with O 0
extracellular O 0
mutations O 0
. O 0

Thus O 0
, O 0
the O 0
location O 0
of O 0
mutations O 0
within O 0
APT1 O 0
strongly O 0
influences O 0
the O 0
development O 0
and O 0
the O 0
severity O 0
of O 0
ALPS B-Disease 1
. O 0

Multicentric O 0
origin O 0
of O 0
hemochromatosis B-Disease 1
gene O 0
( O 0
HFE O 0
) O 0
mutations O 0
. O 0

Genetic B-Disease 0
hemochromatosis I-Disease 1
( O 0
GH B-Disease 1
) O 0
is O 0
believed O 0
to O 0
be O 0
a O 0
disease O 0
restricted O 0
to O 0
those O 0
of O 0
European O 0
ancestry O 0
. O 0

In O 0
northwestern O 0
Europe O 0
, O 0
> O 0
80 O 0
% O 0
of O 0
GH B-Disease 1
patients O 0
are O 0
homozygous O 0
for O 0
one O 0
mutation O 0
, O 0
the O 0
substitution O 0
of O 0
tyrosine O 0
for O 0
cysteine O 0
at O 0
position O 0
282 O 0
( O 0
C282Y O 0
) O 0
in O 0
the O 0
unprocessed O 0
protein O 0
. O 0

In O 0
a O 0
proportion O 0
of O 0
GH B-Disease 1
patients O 0
, O 0
two O 0
mutations O 0
are O 0
present O 0
, O 0
C282Y O 0
and O 0
H63D O 0
. O 0

The O 0
clinical O 0
significance O 0
of O 0
this O 0
second O 0
mutation O 0
is O 0
such O 0
that O 0
it O 0
appears O 0
to O 0
predispose O 0
1 O 0
% O 0
- O 0
2 O 0
% O 0
of O 0
compound O 0
heterozygotes O 0
to O 0
expression O 0
of O 0
the O 0
disease O 0
. O 0

The O 0
distribution O 0
of O 0
the O 0
two O 0
mutations O 0
differ O 0
, O 0
C282Y O 0
being O 0
limited O 0
to O 0
those O 0
of O 0
northwestern O 0
European O 0
ancestry O 0
and O 0
H63D O 0
being O 0
found O 0
at O 0
allele O 0
frequencies O 0
> O 0
5 O 0
% O 0
, O 0
in O 0
Europe O 0
, O 0
in O 0
countries O 0
bordering O 0
the O 0
Mediterranean O 0
, O 0
in O 0
the O 0
Middle O 0
East O 0
, O 0
and O 0
in O 0
the O 0
Indian O 0
subcontinent O 0
. O 0

The O 0
C282Y O 0
mutation O 0
occurs O 0
on O 0
a O 0
haplotype O 0
that O 0
extends O 0
< O 0
/ O 0
= O 0
6 O 0
Mb O 0
, O 0
suggesting O 0
that O 0
this O 0
mutation O 0
has O 0
arisen O 0
during O 0
the O 0
past O 0
2 O 0
, O 0
000 O 0
years O 0
. O 0

The O 0
H63D O 0
mutation O 0
is O 0
older O 0
and O 0
does O 0
not O 0
occur O 0
on O 0
such O 0
a O 0
large O 0
extended O 0
haplotype O 0
, O 0
the O 0
haplotype O 0
in O 0
this O 0
case O 0
extending O 0
< O 0
/ O 0
= O 0
700 O 0
kb O 0
. O 0

Here O 0
we O 0
report O 0
the O 0
finding O 0
of O 0
the O 0
H63D O 0
and O 0
C282Y O 0
mutations O 0
on O 0
new O 0
haplotypes O 0
. O 0

In O 0
Sri O 0
Lanka O 0
we O 0
have O 0
found O 0
H63D O 0
on O 0
three O 0
new O 0
haplotypes O 0
and O 0
have O 0
found O 0
C282Y O 0
on O 0
one O 0
new O 0
haplotype O 0
, O 0
demonstrating O 0
that O 0
these O 0
mutations O 0
have O 0
arisen O 0
independently O 0
on O 0
this O 0
island O 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
the O 0
HFE O 0
gene O 0
has O 0
been O 0
the O 0
subject O 0
of O 0
selection O 0
pressure O 0
. O 0

These O 0
selection O 0
pressures O 0
could O 0
be O 0
due O 0
to O 0
infectious B-Disease 0
diseases I-Disease 0
, O 0
environmental O 0
conditions O 0
, O 0
or O 0
other O 0
genetic B-Disease 1
disorders I-Disease 1
such O 0
as O 0
anemia B-Disease 0
. O 0

A O 0
retrospective O 0
anonymous O 0
pilot O 0
study O 0
in O 0
screening O 0
newborns O 0
for O 0
HFE O 0
mutations O 0
in O 0
Scandinavian O 0
populations O 0
. O 0

We O 0
have O 0
retrospectively O 0
analyzed O 0
837 O 0
random O 0
anonymized O 0
dried O 0
blood O 0
spot O 0
( O 0
DBS O 0
) O 0
samples O 0
from O 0
neonatal O 0
screening O 0
programs O 0
in O 0
Scandinavia O 0
for O 0
mutations O 0
in O 0
HFE O 0
, O 0
the O 0
candidate O 0
gene O 0
for O 0
hemochromatosis B-Disease 1
. O 0

We O 0
have O 0
found O 0
C282Y O 0
allele O 0
frequencies O 0
of O 0
2 O 0
. O 0

3 O 0
% O 0
( O 0
+ O 0
2 O 0
. O 0
0 O 0
% O 0
) O 0
( O 0
- O 0
1 O 0
. O 0
3 O 0
% O 0
) O 0
in O 0
Greenland O 0
, O 0
4 O 0
. O 0

5 O 0
% O 0
+ O 0
/ O 0
- O 0
1 O 0
. O 0

9 O 0
% O 0
in O 0
Iceland O 0
, O 0
5 O 0
. O 0

1 O 0
% O 0
+ O 0
/ O 0
- O 0
2 O 0
. O 0

3 O 0
% O 0
in O 0
the O 0
Faeroe O 0
Islands O 0
, O 0
and O 0
8 O 0
. O 0

2 O 0
% O 0
+ O 0
/ O 0
- O 0
2 O 0
. O 0

7 O 0
% O 0
in O 0
Denmark O 0
. O 0

The O 0
high O 0
prevalence O 0
of O 0
HFE O 0
mutations O 0
in O 0
Denmark O 0
suggests O 0
that O 0
population O 0
screening O 0
for O 0
the O 0
C282Y O 0
mutation O 0
could O 0
be O 0
highly O 0
advantageous O 0
in O 0
terms O 0
of O 0
preventive O 0
health O 0
care O 0
. O 0

Long O 0
- O 0
term O 0
follow O 0
- O 0
up O 0
evaluation O 0
of O 0
C282Y O 0
homozygotes O 0
and O 0
H63D O 0
/ O 0
C282Y O 0
compound O 0
heterozygotes O 0
will O 0
give O 0
an O 0
indication O 0
of O 0
the O 0
penetrance O 0
of O 0
the O 0
mutations O 0
. O 0

Identification O 0
of O 0
the O 0
mutation O 0
in O 0
the O 0
alkaptonuria B-Disease 0
mouse O 0
model O 0
. O 0

Alkaptonuria B-Disease 1
( O 0
aku B-Disease 1
) O 0
, O 0
an O 0
inborn B-Disease 1
error I-Disease 1
of I-Disease 1
metabolism I-Disease 1
caused O 0
by O 0
the O 0
loss O 0
of O 0
homogentisate O 0
1 O 0
, O 0
2 O 0
- O 0
dioxygenase O 0
( O 0
HGD O 0
) O 0
, O 0
has O 0
been O 0
described O 0
in O 0
a O 0
mouse O 0
model O 0
created O 0
by O 0
ethylnitrosourea O 0
mutagenesis O 0
but O 0
the O 0
mutation O 0
in O 0
these O 0
mice O 0
has O 0
not O 0
previously O 0
been O 0
identified O 0
. O 0

We O 0
used O 0
RT O 0
- O 0
PCR O 0
to O 0
amplify O 0
the O 0
Hgd O 0
cDNA O 0
from O 0
Hgd O 0
( O 0
aku O 1
) O 0
/ O 0
Hgd O 0
( O 0
aku O 1
) O 0
mice O 0
. O 0

Two O 0
products O 0
shorter O 0
than O 0
the O 0
wild O 0
- O 0
type O 0
product O 0
were O 0
amplified O 0
. O 0

Restriction O 0
mapping O 0
and O 0
DNA O 0
sequencing O 0
were O 0
then O 0
used O 0
to O 0
identify O 0
the O 0
Hgd O 0
( O 0
aku O 1
) O 0
mouse O 0
mutation O 0
, O 0
found O 0
to O 0
be O 0
a O 0
single O 0
base O 0
change O 0
in O 0
a O 0
splice O 0
donor O 0
consensus O 0
sequence O 0
, O 0
causing O 0
exon O 0
skipping O 0
and O 0
frame O 0
- O 0
shifted O 0
products O 0
. O 0

This O 0
base O 0
change O 0
allowed O 0
us O 0
to O 0
create O 0
a O 0
non O 0
- O 0
radioactive O 0
genotyping O 0
assay O 0
for O 0
this O 0
allele O 0
. O 0

Non B-Disease 1
- I-Disease 1
syndromic I-Disease 1
hearing I-Disease 1
loss I-Disease 1
associated O 0
with O 0
enlarged B-Disease 1
vestibular I-Disease 1
aqueduct I-Disease 1
is O 0
caused O 0
by O 0
PDS B-Disease 1
mutations O 0
. O 0

Enlarged B-Disease 1
vestibular I-Disease 1
aqueduct I-Disease 1
( O 0
EVA B-Disease 0
) O 0
, O 0
known O 0
as O 0
the O 0
most O 0
common O 0
form O 0
of O 0
inner B-Disease 1
ear I-Disease 1
abnormality I-Disease 1
, O 0
has O 0
recently O 0
been O 0
of O 0
particular O 0
genetic O 0
interest O 0
because O 0
this O 0
anomaly O 0
is O 0
inherited O 0
in O 0
a O 0
recessive O 0
manner O 0
. O 0

The O 0
locus O 0
for O 0
non B-Disease 0
- I-Disease 0
syndromic I-Disease 0
sensorineural I-Disease 0
hearing I-Disease 0
loss I-Disease 0
with O 0
EVA B-Disease 0
has O 0
been O 0
mapped O 0
to O 0
the O 0
same O 0
chromosomal O 0
region O 0
, O 0
7q31 O 0
, O 0
as O 0
the O 0
Pendred B-Disease 0
syndrome I-Disease 0
locus O 0
. O 0

In O 0
the O 0
present O 0
study O 0
, O 0
seven O 0
mutations O 0
in O 0
the O 0
PDS B-Disease 1
gene O 0
( O 0
PDS O 1
) O 0
, O 0
the O 0
gene O 0
responsible O 0
for O 0
Pendred B-Disease 0
syndrome I-Disease 0
, O 0
have O 0
been O 0
found O 0
in O 0
families O 0
of O 0
non B-Disease 0
- I-Disease 0
syndromic I-Disease 0
sensorineural I-Disease 0
hearing I-Disease 0
loss I-Disease 0
with O 0
EVA B-Disease 0
. O 0

One O 0
family O 0
is O 0
homozygous O 0
, O 0
three O 0
families O 0
are O 0
compound O 0
heterozygotes O 0
, O 0
and O 0
two O 0
families O 0
are O 0
heterozygous O 0
but O 0
with O 0
no O 0
other O 0
mutation O 0
detected O 0
. O 0

The O 0
present O 0
results O 0
provide O 0
evidence O 0
that O 0
mutations O 0
in O 0
PDS O 1
cause O 0
both O 0
syndromic B-Disease 0
and I-Disease 0
non I-Disease 0
- I-Disease 0
syndromic I-Disease 0
hearing I-Disease 0
loss I-Disease 0
. O 0
. O 0

Mutational O 0
analysis O 0
and O 0
genotype O 0
- O 0
phenotype O 0
correlation O 0
of O 0
29 O 0
unrelated O 0
Japanese O 0
patients O 0
with O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
. O 0

BACKGROUND O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
( O 0
ALD B-Disease 0
) O 0
is O 0
an O 0
inherited B-Disease 0
disease I-Disease 0
characterized O 0
by O 0
progressive O 0
neurologic B-Disease 0
dysfunction I-Disease 0
, O 0
occasionally O 0
associated O 0
with O 0
adrenal B-Disease 0
insufficiency I-Disease 0
. O 0

The O 0
classic O 0
form O 0
of O 0
ALD B-Disease 0
usually O 0
has O 0
onset O 0
in O 0
childhood O 0
( O 0
childhood B-Disease 0
cerebral I-Disease 1
ALD I-Disease 1
) O 0
, O 0
with O 0
rapid O 0
neurologic B-Disease 0
deterioration I-Disease 0
leading O 0
to O 0
a O 0
vegetative O 0
state O 0
. O 0

Adult O 0
- O 0
onset O 0
cerebral B-Disease 1
ALD I-Disease 1
also O 0
presents O 0
with O 0
rapidly O 0
progressive O 0
neurologic B-Disease 0
dysfunction I-Disease 0
. O 0

Milder O 0
phenotypes O 0
such O 0
as O 0
adrenomyeloneuropathy B-Disease 1
and O 0
Addison B-Disease 1
disease I-Disease 1
only O 1
also O 0
have O 0
been O 0
recognized O 0
. O 0

Despite O 0
discovery O 0
of O 0
the O 0
causative O 0
gene O 0
, O 0
a O 0
molecular O 0
basis O 0
for O 0
the O 0
diverse O 0
clinical O 0
presentations O 0
remains O 0
to O 0
be O 0
elucidated O 0
. O 0

OBJECTIVES O 0
To O 0
conduct O 0
mutational O 0
analyses O 0
in O 0
29 O 0
Japanese O 0
patients O 0
with O 0
ALD B-Disease 0
from O 0
29 O 0
unrelated O 0
families O 0
, O 0
to O 0
obtain O 0
knowledge O 0
of O 0
the O 0
spectrum O 0
of O 0
mutations O 0
in O 0
this O 0
gene O 0
, O 0
and O 0
to O 0
study O 0
genotype O 0
- O 0
phenotype O 0
correlations O 0
in O 0
Japanese O 0
patients O 0
. O 0

METHODS O 0
The O 0
29 O 0
patients O 0
comprised O 0
13 O 0
patients O 0
with O 0
childhood B-Disease 0
cerebral I-Disease 1
ALD I-Disease 1
, O 0
11 O 0
patients O 0
with O 0
adult O 0
- O 0
onset O 0
cerebral B-Disease 1
ALD I-Disease 1
, O 0
and O 0
5 O 0
patients O 0
with O 0
adrenomyeloneuropathy B-Disease 1
. O 0

We O 0
conducted O 0
detailed O 0
mutational O 0
analyses O 0
of O 0
29 O 0
unrelated O 0
Japanese O 0
patients O 0
with O 0
ALD B-Disease 0
by O 0
genomic O 0
Southern O 0
blot O 0
analysis O 0
and O 0
direct O 0
nucleotide O 0
sequence O 0
analysis O 0
of O 0
reverse O 0
transcriptase O 0
- O 0
polymerase O 0
chain O 0
reaction O 0
products O 0
derived O 0
from O 0
total O 0
RNA O 0
that O 0
was O 0
extracted O 0
from O 0
cultured O 0
skin O 0
fibroblasts O 0
, O 0
lymphoblastoid O 0
cells O 0
, O 0
or O 0
peripheral O 0
blood O 0
leukocytes O 0
. O 0

RESULTS O 0
Three O 0
patients O 0
with O 0
adult O 0
- O 0
onset O 0
cerebral B-Disease 1
ALD I-Disease 1
were O 0
identified O 0
as O 0
having O 0
large O 0
genomic O 0
rearrangements O 0
. O 0

The O 0
remaining O 0
26 O 0
patients O 0
were O 0
identified O 0
as O 0
having O 0
21 O 0
independent O 0
mutations O 0
, O 0
including O 0
12 O 0
novel O 0
mutations O 0
resulting O 0
in O 0
small O 0
nucleotide O 0
alterations O 0
in O 0
the O 0
ALD B-Disease 0
gene O 0
. O 0

Eighteen O 0
( O 0
69 O 0
% O 0
) O 0
of O 0
26 O 0
mutations O 0
were O 0
missense O 0
mutations O 0
. O 0

Most O 0
missense O 0
mutations O 0
involved O 0
amino O 0
acids O 0
conserved O 0
in O 0
homologous O 0
gene O 0
products O 0
, O 0
including O 0
PMP70 O 0
, O 0
mALDRP O 0
, O 0
and O 0
Pxa1p O 0
. O 0

The O 0
AG O 0
dinucleotide O 0
deletion O 0
at O 0
position O 0
1081 O 0
- O 0
1082 O 0
, O 0
which O 0
has O 0
been O 0
reported O 0
previously O 0
to O 0
be O 0
the O 0
most O 0
common O 0
mutation O 0
in O 0
white O 0
patients O 0
( O 0
12 O 0
% O 0
- O 0
17 O 0
% O 0
) O 0
, O 0
was O 0
also O 0
identified O 0
as O 0
the O 0
most O 0
common O 0
mutation O 0
in O 0
Japanese O 0
patients O 0
( O 0
12 O 0
% O 0
) O 0
. O 0

All O 0
phenotypes O 0
were O 0
associated O 0
with O 0
mutations O 0
resulting O 0
in O 0
protein O 0
truncation O 0
or O 0
subtle O 0
amino O 0
acid O 0
changes O 0
. O 0

There O 0
were O 0
no O 0
differences O 0
in O 0
phenotypic O 0
expressions O 0
between O 0
missense O 0
mutations O 0
involving O 0
conserved O 0
amino O 0
acids O 0
and O 0
those O 0
involving O 0
nonconserved O 0
amino O 0
acids O 0
. O 0

CONCLUSIONS O 0
There O 0
are O 0
no O 0
obvious O 0
correlations O 0
between O 0
the O 0
phenotypes O 0
of O 0
patients O 0
with O 0
ALD B-Disease 0
and O 0
their O 0
genotypes O 0
, O 0
suggesting O 0
that O 0
other O 0
genetic O 0
or O 0
environmental O 0
factors O 0
modify O 0
the O 0
phenotypic O 0
expressions O 0
of O 0
ALD B-Disease 0
. O 0
. O 0

A O 0
common O 0
human O 0
skin B-Disease 0
tumour I-Disease 1
is O 0
caused O 0
by O 0
activating O 0
mutations O 0
in O 0
beta O 0
- O 0
catenin O 0
. O 0

WNT O 0
signalling O 0
orchestrates O 0
a O 0
number O 0
of O 0
developmental O 0
programs O 0
. O 0

In O 0
response O 0
to O 0
this O 0
stimulus O 0
, O 0
cytoplasmic O 0
beta O 0
- O 0
catenin O 0
( O 0
encoded O 0
by O 0
CTNNB1 O 0
) O 0
is O 0
stabilized O 0
, O 0
enabling O 0
downstream O 0
transcriptional O 0
activation O 0
by O 0
members O 0
of O 0
the O 0
LEF O 0
/ O 0
TCF O 0
family O 0
. O 0

One O 0
of O 0
the O 0
target O 0
genes O 0
for O 0
beta O 0
- O 0
catenin O 0
/ O 0
TCF O 0
encodes O 0
c O 0
- O 0
MYC O 0
, O 0
explaining O 0
why O 0
constitutive O 0
activation O 0
of O 0
the O 0
WNT O 0
pathway O 0
can O 0
lead O 0
to O 0
cancer B-Disease 1
, O 0
particularly O 0
in O 0
the O 0
colon O 0
. O 0

Most O 0
colon B-Disease 0
cancers I-Disease 0
arise O 0
from O 0
mutations O 0
in O 0
the O 0
gene O 0
encoding O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( O 0
APC B-Disease 1
) O 0
, O 0
a O 0
protein O 0
required O 0
for O 0
ubiquitin O 0
- O 0
mediated O 0
degradation O 0
of O 0
beta O 0
- O 0
catenin O 0
, O 0
but O 0
a O 0
small O 0
percentage O 0
of O 0
colon B-Disease 1
and I-Disease 1
some I-Disease 1
other I-Disease 1
cancers I-Disease 1
harbour O 0
beta O 0
- O 0
catenin O 0
- O 0
stabilizing O 0
mutations O 0
. O 0

Recently O 0
, O 0
we O 0
discovered O 0
that O 0
transgenic O 0
mice O 0
expressing O 0
an O 0
activated O 0
beta O 0
- O 0
catenin O 0
are O 0
predisposed O 0
to O 0
developing O 0
skin B-Disease 1
tumours I-Disease 1
resembling O 0
pilomatricomas B-Disease 0
. O 0

Given O 0
that O 0
the O 0
skin O 0
of O 0
these O 0
adult O 0
mice O 0
also O 0
exhibits O 0
signs O 0
of O 0
de O 0
novo O 0
hair O 0
- O 0
follicle O 0
morphogenesis O 0
, O 0
we O 0
wondered O 0
whether O 0
human O 0
pilomatricomas B-Disease 0
might O 0
originate O 0
from O 0
hair O 0
matrix O 0
cells O 0
and O 0
whether O 0
they O 0
might O 0
possess O 0
beta O 0
- O 0
catenin O 0
- O 0
stabilizing O 0
mutations O 0
. O 0

Here O 0
, O 0
we O 0
explore O 0
the O 0
cell O 0
origin O 0
and O 0
aetiology O 0
of O 0
this O 0
common O 0
human O 0
skin B-Disease 0
tumour I-Disease 1
. O 0

We O 0
found O 0
nuclear O 0
LEF O 0
- O 0
1 O 0
in O 0
the O 0
dividing O 0
tumour B-Disease 1
cells O 0
, O 0
providing O 0
biochemical O 0
evidence O 0
that O 0
pilomatricomas B-Disease 0
are O 0
derived O 0
from O 0
hair O 0
matrix O 0
cells O 0
. O 0

At O 0
least O 0
75 O 0
% O 0
of O 0
these O 0
tumours B-Disease 1
possess O 0
mutations O 0
affecting O 0
the O 0
amino O 0
- O 0
terminal O 0
segment O 0
, O 0
normally O 0
involved O 0
in O 0
phosphorylation O 0
- O 0
dependent O 0
, O 0
ubiquitin O 0
- O 0
mediated O 0
degradation O 0
of O 0
the O 0
protein O 0
. O 0

This O 0
percentage O 0
of O 0
CTNNB1 O 0
mutations O 0
is O 0
greater O 0
than O 0
in O 0
all O 0
other O 0
human O 0
tumours B-Disease 1
examined O 0
thus O 0
far O 0
, O 0
and O 0
directly O 0
implicates O 0
beta O 0
- O 0
catenin O 0
/ O 0
LEF O 0
misregulation O 0
as O 0
the O 0
major O 0
cause O 0
of O 0
hair O 0
matrix O 0
cell O 0
tumorigenesis O 0
in O 0
humans O 0
. O 0
. O 0

The O 0
Pendred B-Disease 0
syndrome I-Disease 0
gene O 0
encodes O 0
a O 0
chloride O 0
- O 0
iodide O 0
transport O 0
protein O 0
. O 0

Pendred B-Disease 0
syndrome I-Disease 0
is O 0
the O 0
most O 0
common O 0
form O 0
of O 0
syndromic B-Disease 1
deafness I-Disease 1
and O 0
characterized O 0
by O 0
congenital O 0
sensorineural B-Disease 0
hearing I-Disease 0
loss I-Disease 0
and O 0
goitre B-Disease 0
. O 0

This O 0
disorder O 0
was O 0
mapped O 0
to O 0
chromosome O 0
7 O 0
and O 0
the O 0
gene O 0
causing O 0
Pendred B-Disease 0
syndrome I-Disease 0
( O 0
PDS B-Disease 1
) O 0
was O 0
subsequently O 0
identified O 0
by O 0
positional O 0
cloning O 0
. O 0

PDS O 1
encodes O 0
a O 0
putative O 0
transmembrane O 0
protein O 0
designated O 0
pendrin O 0
. O 0

Pendrin O 0
is O 0
closely O 0
related O 0
to O 0
a O 0
family O 0
of O 0
sulfate O 0
transport O 0
proteins O 0
that O 0
includes O 0
the O 0
rat O 0
sulfate O 0
- O 0
anion O 0
transporter O 0
( O 0
encoded O 0
by O 0
Sat O 0
- O 0
1 O 0
; O 0
29 O 0
% O 0
amino O 0
acid O 0
sequence O 0
identity O 0
) O 0
, O 0
the O 0
human O 0
diastrophic B-Disease 1
dysplasia I-Disease 1
sulfate O 0
transporter O 0
( O 0
encoded O 0
by O 0
DTD O 1
; O 0
32 O 0
% O 0
) O 0
and O 0
the O 0
human O 0
sulfate O 0
transporter O 0
downregulated O 0
in O 0
adenoma B-Disease 0
( O 0
encoded O 0
by O 0
DRA O 0
; O 0
45 O 0
% O 0
) O 0
. O 0

On O 0
the O 0
basis O 0
of O 0
this O 0
homology O 0
and O 0
the O 0
presence O 0
of O 0
a O 0
slightly O 0
modified O 0
sulfate O 0
- O 0
transporter O 0
signature O 0
sequence O 0
comprising O 0
its O 0
putative O 0
second O 0
transmembrane O 0
domain O 0
, O 0
pendrin O 0
has O 0
been O 0
proposed O 0
to O 0
function O 0
as O 0
a O 0
sulfate O 0
transporter O 0
. O 0

We O 0
were O 0
unable O 0
to O 0
detect O 0
evidence O 0
of O 0
sulfate O 0
transport O 0
following O 0
the O 0
expression O 0
of O 0
pendrin O 0
in O 0
Xenopus O 0
laevis O 0
oocytes O 0
by O 0
microinjection O 0
of O 0
PDS O 1
cRNA O 0
or O 0
in O 0
Sf9 O 0
cells O 0
following O 0
infection O 0
with O 0
PDS O 1
- O 0
recombinant O 0
baculovirus O 0
. O 0

The O 0
rates O 0
of O 0
transport O 0
for O 0
iodide O 0
and O 0
chloride O 0
were O 0
significantly O 0
increased O 0
following O 0
the O 0
expression O 0
of O 0
pendrin O 0
in O 0
both O 0
cell O 0
systems O 0
. O 0

Our O 0
results O 0
demonstrate O 0
that O 0
pendrin O 0
functions O 0
as O 0
a O 0
transporter O 0
of O 0
chloride O 0
and O 0
iodide O 0
, O 0
but O 0
not O 0
sulfate O 0
, O 0
and O 0
may O 0
provide O 0
insight O 0
into O 0
thyroid O 0
physiology O 0
and O 0
the O 0
pathophysiology O 0
of O 0
Pendred B-Disease 0
syndrome I-Disease 0
. O 0
. O 0

HFE O 0
mutations O 0
analysis O 0
in O 0
711 O 0
hemochromatosis B-Disease 1
probands O 0
: O 0
evidence O 0
for O 0
S65C O 0
implication O 0
in O 0
mild O 0
form O 0
of O 0
hemochromatosis B-Disease 1
. O 0

Hereditary B-Disease 1
hemochromatosis I-Disease 1
( O 0
HH B-Disease 0
) O 0
is O 0
a O 0
common O 0
autosomal B-Disease 1
recessive I-Disease 1
genetic I-Disease 1
disorder I-Disease 1
of O 0
iron O 0
metabolism O 0
. O 0

The O 0
HFE O 0
candidate O 0
gene O 0
encoding O 0
an O 0
HLA O 0
class O 0
I O 0
- O 0
like O 0
protein O 0
involved O 0
in O 0
HH B-Disease 0
was O 0
identified O 0
in O 0
1996 O 0
. O 0

Two O 0
missense O 0
mutations O 0
have O 0
been O 0
described O 0
C282Y O 0
, O 0
accounting O 0
for O 0
80 O 0
% O 0
to O 0
90 O 0
% O 0
of O 0
HH B-Disease 0
chromosomes O 0
, O 0
and O 0
H63D O 0
, O 0
which O 0
is O 0
associated O 0
with O 0
a O 0
milder O 0
form O 0
of O 0
the O 0
disease O 0
representing O 0
40 O 0
% O 0
to O 0
70 O 0
% O 0
of O 0
non O 0
- O 0
C282Y O 0
HH B-Disease 0
chromosomes O 0
. O 0

We O 0
report O 0
here O 0
on O 0
the O 0
analysis O 0
of O 0
C282Y O 0
, O 0
H63D O 0
, O 0
and O 0
the O 0
193A O 0
- O 0
- O 0
> O 0
T O 0
substitution O 0
leading O 0
to O 0
the O 0
S65C O 0
missense O 0
substitution O 0
in O 0
a O 0
large O 0
series O 0
of O 0
probands O 0
and O 0
controls O 0
. O 0

The O 0
results O 0
confirm O 0
that O 0
the O 0
C282Y O 0
substitution O 0
was O 0
the O 0
main O 0
mutation O 0
involved O 0
in O 0
hemochromatosis B-Disease 1
, O 0
accounting O 0
for O 0
85 O 0
% O 0
of O 0
carrier O 0
chromosomes O 0
, O 0
whereas O 0
the O 0
H63D O 0
substitution O 0
represented O 0
39 O 0
% O 0
of O 0
the O 0
HH B-Disease 0
chromosomes O 0
that O 0
did O 0
not O 0
carry O 0
the O 0
C282Y O 0
mutation O 0
. O 0

In O 0
addition O 0
, O 0
our O 0
screening O 0
showed O 0
that O 0
the O 0
S65C O 0
substitution O 0
was O 0
significantly O 0
enriched O 0
in O 0
probands O 0
with O 0
at O 0
least O 0
one O 0
chromosome O 0
without O 0
an O 0
assigned O 0
mutation O 0
. O 0

This O 0
substitution O 0
accounted O 0
for O 0
7 O 0
. O 0

8 O 0
% O 0
of O 0
HH B-Disease 0
chromosomes O 0
that O 0
were O 0
neither O 0
C282Y O 0
nor O 0
H63D O 0
. O 0

This O 0
enrichment O 0
of O 0
S65C O 0
among O 0
HH B-Disease 0
chromosomes O 0
suggests O 0
that O 0
the O 0
S65C O 0
substitution O 0
is O 0
associated O 0
with O 0
the O 0
mild O 0
form O 0
of O 0
hemochromatosis B-Disease 1
. O 0

Germline O 0
BRCA1 O 0
alterations O 0
in O 0
a O 0
population O 0
- O 0
based O 0
series O 0
of O 0
ovarian B-Disease 0
cancer I-Disease 1
cases O 0
. O 0

The O 0
objective O 0
of O 0
this O 0
study O 0
was O 0
to O 0
provide O 0
more O 0
accurate O 0
frequency O 0
estimates O 0
of O 0
breast B-Disease 0
cancer I-Disease 1
susceptibility O 0
gene O 0
1 O 0
( O 0
BRCA1 O 0
) O 0
germline O 0
alterations O 0
in O 0
the O 0
ovarian B-Disease 0
cancer I-Disease 1
population O 0
. O 0

To O 0
achieve O 0
this O 0
, O 0
we O 0
determined O 0
the O 0
prevalence O 0
of O 0
BRCA1 O 0
alterations O 0
in O 0
a O 0
population O 0
- O 0
based O 0
series O 0
of O 0
consecutive O 0
ovarian B-Disease 0
cancer I-Disease 1
cases O 0
. O 0

This O 0
is O 0
the O 0
first O 0
population O 0
- O 0
based O 0
ovarian B-Disease 0
cancer I-Disease 1
study O 0
reporting O 0
BRCA1 O 0
alterations O 0
derived O 0
from O 0
a O 0
comprehensive O 0
screen O 0
of O 0
the O 0
entire O 0
coding O 0
region O 0
. O 0

One O 0
hundred O 0
and O 0
seven O 0
ovarian B-Disease 0
cancer I-Disease 1
cases O 0
were O 0
analyzed O 0
for O 0
BRCA1 O 0
alterations O 0
using O 0
the O 0
RNase O 0
mismatch O 0
cleavage O 0
assay O 0
followed O 0
by O 0
direct O 0
sequencing O 0
. O 0

Two O 0
truncating O 0
mutations O 0
, O 0
962del4 O 0
and O 0
3600del11 O 0
, O 0
were O 0
identified O 0
. O 0

Both O 0
patients O 0
had O 0
a O 0
family O 0
history O 0
of O 0
breast B-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
. O 0

Several O 0
novel O 0
as O 0
well O 0
as O 0
previously O 0
reported O 0
uncharacterized O 0
variants O 0
were O 0
also O 0
identified O 0
, O 0
some O 0
of O 0
which O 0
were O 0
associated O 0
with O 0
a O 0
family O 0
history O 0
of O 0
cancer B-Disease 1
. O 0

The O 0
frequency O 0
distribution O 0
of O 0
common O 0
polymorphisms O 0
was O 0
determined O 0
in O 0
the O 0
91 O 0
Caucasian O 0
cancer B-Disease 1
cases O 0
in O 0
this O 0
series O 0
and O 0
24 O 0
sister O 0
controls O 0
using O 0
allele O 0
- O 0
specific O 0
amplification O 0
. O 0

The O 0
rare O 0
form O 0
of O 0
the O 0
Q356R O 0
polymorphism O 0
was O 0
significantly O 0
( O 0
P O 0
= O 0
0 O 0
. O 0
03 O 0
) O 0
associated O 0
with O 0
a O 0
family O 0
history O 0
of O 0
ovarian B-Disease 0
cancer I-Disease 1
, O 0
suggesting O 0
that O 0
this O 0
polymorphism O 0
may O 0
influence O 0
ovarian B-Disease 0
cancer I-Disease 1
risk O 0
. O 0

In O 0
summary O 0
, O 0
our O 0
data O 0
suggest O 0
a O 0
role O 0
for O 0
some O 0
uncharacterized O 0
variants O 0
and O 0
rare O 0
forms O 0
of O 0
polymorphisms O 0
in O 0
determining O 0
ovarian B-Disease 0
cancer I-Disease 1
risk O 0
, O 0
and O 0
highlight O 0
the O 0
necessity O 0
to O 0
screen O 0
for O 0
missense O 0
alterations O 0
as O 0
well O 0
as O 0
truncating O 0
mutations O 0
in O 0
this O 0
population O 0
. O 0

Adrenoleukodystrophy O 0
- O 0
related O 0
protein O 0
can O 0
compensate O 0
functionally O 0
for O 0
adrenoleukodystrophy B-Disease 1
protein I-Disease 1
deficiency I-Disease 1
( O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
) O 0
: O 0
implications O 0
for O 0
therapy O 0
. O 0

Inherited B-Disease 0
defects I-Disease 0
in O 0
the O 0
peroxisomal O 0
ATP O 0
- O 0
binding O 0
cassette O 0
( O 0
ABC O 0
) O 0
transporter O 0
adrenoleukodystrophy B-Disease 1
protein O 0
( O 0
ALDP O 0
) O 0
lead O 0
to O 0
the O 0
lethal O 0
peroxisomal B-Disease 1
disorder I-Disease 1
X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
( O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
) O 0
, O 0
for O 0
which O 0
no O 0
efficient O 0
treatment O 0
has O 0
been O 0
established O 0
so O 0
far O 0
. O 0

Three O 0
other O 0
peroxisomal O 0
ABC O 0
transporters O 0
currently O 0
are O 0
known O 0
adrenoleukodystrophy O 1
- O 0
related O 0
protein O 0
( O 0
ALDRP O 0
) O 0
, O 0
70 O 0
kDa O 0
peroxisomal O 0
membrane O 0
protein O 0
( O 0
PMP70 O 0
) O 0
and O 0
PMP70 O 0
- O 0
related O 0
protein O 0
. O 0

By O 0
using O 0
transient O 0
and O 0
stable O 0
overexpression O 0
of O 0
human O 0
cDNAs O 0
encoding O 0
ALDP O 0
and O 0
its O 0
closest O 0
relative O 0
ALDRP O 0
, O 0
we O 0
could O 0
restore O 0
the O 0
impaired O 0
peroxisomal O 0
beta O 0
- O 0
oxidation O 0
in O 0
fibroblasts O 0
of O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
patients O 0
. O 0

The O 0
pathognomonic O 0
accumulation O 0
of O 0
very O 0
long O 0
chain O 0
fatty O 0
acids O 0
could O 0
also O 0
be O 0
prevented O 0
by O 0
overexpression O 0
of O 0
ALDRP O 0
in O 0
immortalized O 0
X O 1
- O 1
ALD O 1
cells O 0
. O 0

Immunofluorescence O 0
analysis O 0
demonstrated O 0
that O 0
the O 0
functional O 0
replacement O 0
of O 0
ALDP O 0
by O 0
ALDRP O 0
was O 0
not O 0
due O 0
to O 0
stabilization O 0
of O 0
the O 0
mutated O 0
ALDP O 0
itself O 0
. O 0

Moreover O 0
, O 0
we O 0
were O 0
able O 0
to O 0
restore O 0
the O 0
peroxisomal O 0
beta O 0
- O 0
oxidation O 0
defect O 0
in O 0
the O 0
liver O 0
of O 0
ALDP O 0
- O 0
deficient O 0
mice O 0
by O 0
stimulation O 0
of O 0
ALDRP O 0
and O 0
PMP70 O 0
gene O 0
expression O 0
through O 0
a O 0
dietary O 0
treatment O 0
with O 0
the O 0
peroxisome O 0
proliferator O 0
fenofibrate O 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
a O 0
correction O 0
of O 0
the O 0
biochemical O 0
defect O 0
in O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
could O 0
be O 0
possible O 0
by O 0
drug O 0
- O 0
induced O 0
overexpression O 0
or O 0
ectopic O 0
expression O 0
of O 0
ALDRP O 0
. O 0
. O 0

Centrosome O 0
amplification O 0
and O 0
a O 0
defective O 0
G2 O 0
- O 0
M O 0
cell O 0
cycle O 0
checkpoint O 0
induce O 0
genetic O 0
instability O 0
in O 0
BRCA1 O 0
exon O 0
11 O 0
isoform O 0
- O 0
deficient O 0
cells O 0
. O 0

Germline O 0
mutations O 0
of O 0
the O 0
Brca1 O 0
tumor B-Disease 0
suppressor O 0
gene O 0
predispose O 0
women O 0
to O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 1
cancers I-Disease 1
. O 0

To O 0
study O 0
mechanisms O 0
underlying O 0
BRCA1 O 0
- O 0
related O 0
tumorigenesis O 0
, O 0
we O 0
derived O 0
mouse O 0
embryonic O 0
fibroblast O 0
cells O 0
carrying O 0
a O 0
targeted O 0
deletion O 0
of O 0
exon O 0
11 O 0
of O 0
the O 0
Brca1 O 0
gene O 0
. O 0

We O 0
show O 0
that O 0
the O 0
mutant O 0
cells O 0
maintain O 0
an O 0
intact O 0
G1 O 0
- O 0
S O 0
cell O 0
cycle O 0
checkpoint O 0
and O 0
proliferate O 0
poorly O 0
. O 0

However O 0
, O 0
a O 0
defective O 0
G2 O 0
- O 0
M O 0
checkpoint O 0
in O 0
these O 0
cells O 0
is O 0
accompanied O 0
by O 0
extensive O 0
chromosomal B-Disease 0
abnormalities I-Disease 0
. O 0

Mutant O 0
fibroblasts O 0
contain O 0
multiple O 0
, O 0
functional O 0
centrosomes O 0
, O 0
which O 0
lead O 0
to O 0
unequal O 0
chromosome O 0
segregation O 0
, O 0
abnormal O 0
nuclear O 0
division O 0
, O 0
and O 0
aneuploidy B-Disease 1
. O 0

These O 0
data O 0
uncover O 0
an O 0
essential O 0
role O 0
of O 0
BRCA1 O 0
in O 0
maintaining O 0
genetic O 0
stability O 0
through O 0
the O 0
regulation O 0
of O 0
centrosome O 0
duplication O 0
and O 0
the O 0
G2 O 0
- O 0
M O 0
checkpoint O 0
and O 0
provide O 0
a O 0
molecular O 0
basis O 0
for O 0
the O 0
role O 0
of O 0
BRCA1 O 0
in O 0
tumorigenesis O 0
. O 0
. O 0

Defective O 0
CD95 O 0
/ O 0
APO O 0
- O 0
1 O 0
/ O 0
Fas O 0
signal O 0
complex O 0
formation O 0
in O 0
the O 0
human O 0
autoimmune B-Disease 1
lymphoproliferative I-Disease 1
syndrome I-Disease 1
, I-Disease 0
type I-Disease 0
Ia I-Disease 0
. O 0

Heterozygous O 0
mutations O 0
in O 0
the O 0
CD95 O 0
( O 0
APO O 0
- O 0
1 O 0
/ O 0
Fas O 0
) O 0
receptor O 0
occur O 0
in O 0
most O 0
individuals O 0
with O 0
autoimmune B-Disease 1
lymphoproliferative I-Disease 1
syndrome I-Disease 1
( O 0
ALPS B-Disease 1
) O 0
and O 0
dominantly O 0
interfere O 0
with O 0
apoptosis O 0
by O 0
an O 0
unknown O 0
mechanism O 0
. O 0

We O 0
show O 0
that O 0
local O 0
or O 0
global O 0
alterations O 0
in O 0
the O 0
structure O 0
of O 0
the O 0
cytoplasmic O 0
death O 0
domain O 0
from O 0
nine O 0
independent O 0
ALPS B-Disease 1
CD95 O 0
death O 0
- O 0
domain O 0
mutations O 0
result O 0
in O 0
a O 0
failure O 0
to O 0
bind O 0
the O 0
FADD O 0
/ O 0
MORT1 O 0
signaling O 0
protein O 0
. O 0

Despite O 0
heterozygosity O 0
for O 0
the O 0
abnormal O 0
allele O 0
, O 0
lymphocytes O 0
from O 0
ALPS B-Disease 1
patients O 0
showed O 0
markedly O 0
decreased O 0
FADD O 0
association O 0
and O 0
a O 0
loss O 0
of O 0
caspase O 0
recruitment O 0
and O 0
activation O 0
after O 0
CD95 O 0
crosslinking O 0
. O 0

These O 0
data O 0
suggest O 0
that O 0
intracytoplasmic O 0
CD95 O 0
mutations O 0
in O 0
ALPS B-Disease 1
impair O 0
apoptosis O 0
chiefly O 0
by O 0
disrupting O 0
death O 0
- O 0
domain O 0
interactions O 0
with O 0
the O 0
signaling O 0
protein O 0
FADD O 0
/ O 0
MORT1 O 0
. O 0
. O 0

Analysis O 0
of O 0
alkaptonuria B-Disease 0
( O 0
AKU B-Disease 0
) O 0
mutations O 0
and O 0
polymorphisms O 0
reveals O 0
that O 0
the O 0
CCC O 0
sequence O 0
motif O 0
is O 0
a O 0
mutational O 0
hot O 0
spot O 0
in O 0
the O 0
homogentisate O 0
1 O 0
, O 0
2 O 0
dioxygenase O 0
gene O 0
( O 0
HGO O 0
) O 0
. O 0

We O 0
recently O 0
showed O 0
that O 0
alkaptonuria B-Disease 0
( O 0
AKU B-Disease 0
) O 0
is O 0
caused O 0
by O 0
loss O 0
- O 0
of O 0
- O 0
function O 0
mutations O 0
in O 0
the O 0
homogentisate O 0
1 O 0
, O 0
2 O 0
dioxygenase O 0
gene O 0
( O 0
HGO O 0
) O 0
. O 0

Herein O 0
we O 0
describe O 0
haplotype O 0
and O 0
mutational O 0
analyses O 0
of O 0
HGO O 0
in O 0
seven O 0
new O 0
AKU B-Disease 0
pedigrees O 0
. O 0

These O 0
analyses O 0
identified O 0
two O 0
novel O 0
single O 0
- O 0
nucleotide O 0
polymorphisms O 0
( O 0
INV4 O 0
+ O 0
31A O 0
- O 0
- O 0
> O 0
G O 0
and O 0
INV11 O 0
+ O 0
18A O 0
- O 0
- O 0
> O 0
G O 0
) O 0
and O 0
six O 0
novel O 0
AKU B-Disease 0
mutations O 0
( O 0
INV1 O 0
- O 0
1G O 0
- O 0
- O 0
> O 0
A O 0
, O 0
W60G O 0
, O 0
Y62C O 0
, O 0
A122D O 0
, O 0
P230T O 0
, O 0
and O 0
D291E O 0
) O 0
, O 0
which O 0
further O 0
illustrates O 0
the O 0
remarkable O 0
allelic O 0
heterogeneity O 0
found O 0
in O 0
AKU B-Disease 0
. O 0

Reexamination O 0
of O 0
all O 0
29 O 0
mutations O 0
and O 0
polymorphisms O 0
thus O 0
far O 0
described O 0
in O 0
HGO O 0
shows O 0
that O 0
these O 0
nucleotide O 0
changes O 0
are O 0
not O 0
randomly O 0
distributed O 0
; O 0
the O 0
CCC O 0
sequence O 0
motif O 0
and O 0
its O 0
inverted O 0
complement O 0
, O 0
GGG O 0
, O 0
are O 0
preferentially O 0
mutated O 0
. O 0

These O 0
analyses O 0
also O 0
demonstrated O 0
that O 0
the O 0
nucleotide O 0
substitutions O 0
in O 0
HGO O 0
do O 0
not O 0
involve O 0
CpG O 0
dinucleotides O 0
, O 0
which O 0
illustrates O 0
important O 0
differences O 0
between O 0
HGO O 0
and O 0
other O 0
genes O 0
for O 0
the O 0
occurrence O 0
of O 0
mutation O 0
at O 0
specific O 0
short O 0
- O 0
sequence O 0
motifs O 0
. O 0

Because O 0
the O 0
CCC O 0
sequence O 0
motifs O 0
comprise O 0
a O 0
significant O 0
proportion O 0
( O 0
34 O 0
. O 0
5 O 0
% O 0
) O 0
of O 0
all O 0
mutated O 0
bases O 0
that O 0
have O 0
been O 0
observed O 0
in O 0
HGO O 0
, O 0
we O 0
conclude O 0
that O 0
the O 0
CCC O 0
triplet O 0
is O 0
a O 0
mutational O 0
hot O 0
spot O 0
in O 0
HGO O 0
. O 0

Fabry B-Disease 1
disease I-Disease 1
: O 0
identification O 0
of O 0
novel O 0
alpha O 0
- O 0
galactosidase O 0
A O 0
mutations O 0
and O 0
molecular O 0
carrier O 0
detection O 0
by O 0
use O 0
of O 0
fluorescent O 0
chemical O 0
cleavage O 0
of O 0
mismatches O 0
. O 0

Fabry B-Disease 1
disease I-Disease 1
( O 0
FD B-Disease 0
) O 0
( O 0
angiokeratoma B-Disease 1
corporis I-Disease 0
diffusum I-Disease 0
) O 0
is O 0
an O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
inborn I-Disease 0
error I-Disease 0
of I-Disease 0
glycosphingolipid I-Disease 0
metabolism I-Disease 0
caused O 0
by O 0
defects O 0
in O 0
the O 0
lysosomal O 0
alpha O 0
- O 0
galactosidase O 0
A O 0
gene O 0
( O 0
GLA O 0
) O 0
. O 0

The O 0
enzymatic O 0
defect O 0
leads O 0
to O 0
the O 0
systemic O 0
accumulation O 0
of O 0
neutral O 0
glycosphingolipids O 0
with O 0
terminal O 0
alpha O 0
- O 0
galactosyl O 0
moieties O 0
. O 0

Clinically O 0
, O 0
affected O 0
hemizygous O 0
males O 0
have O 0
angiokeratoma B-Disease 1
, O 0
severe B-Disease 1
acroparesthesia I-Disease 1
, O 0
renal B-Disease 0
failure I-Disease 0
, O 0
and O 0
vasculopathy B-Disease 0
of I-Disease 0
the I-Disease 0
heart I-Disease 0
and I-Disease 0
brain I-Disease 0
. O 0

While O 0
demonstration O 0
of O 0
alpha B-Disease 1
- I-Disease 1
galactosidase I-Disease 1
deficiency I-Disease 1
in O 0
leukocytes O 0
is O 0
diagnostic O 0
in O 0
affected O 0
males O 0
, O 0
enzymatic O 0
detection O 0
of O 0
female O 0
carriers O 0
is O 0
often O 0
inconclusive O 0
, O 0
due O 0
to O 0
random O 0
X O 0
- O 0
chromosomal O 0
inactivation O 0
, O 0
underlining O 0
the O 0
need O 0
of O 0
molecular O 0
investigations O 0
for O 0
accurate O 0
genetic O 0
counseling O 0
. O 0

By O 0
use O 0
of O 0
chemical O 0
cleavage O 0
of O 0
mismatches O 0
adapted O 0
to O 0
fluorescence O 0
- O 0
based O 0
detection O 0
systems O 0
, O 0
we O 0
have O 0
characterized O 0
the O 0
mutations O 0
underlying O 0
alpha B-Disease 0
- I-Disease 0
Gal I-Disease 0
A I-Disease 0
deficiency I-Disease 0
in O 0
16 O 0
individuals O 0
from O 0
six O 0
unrelated O 0
families O 0
with O 0
FD B-Disease 0
. O 0

The O 0
mutational O 0
spectrum O 0
included O 0
five O 0
missense O 0
mutations O 0
( O 0
C202W O 0
, O 0
C223G O 0
, O 0
N224D O 0
, O 0
R301Q O 0
, O 0
and O 0
Q327K O 0
) O 0
and O 0
one O 0
splice O 0
- O 0
site O 0
mutation O 0
[ O 0
IVS3 O 0
G O 0
( O 0
- O 0
1 O 0
) O 0
- O 0
- O 0
> O 0
C O 0
] O 0
. O 0

Studies O 0
at O 0
the O 0
mRNA O 0
level O 0
showed O 0
that O 0
the O 0
latter O 0
led O 0
to O 0
altered O 0
pre O 0
- O 0
mRNA O 0
splicing O 0
with O 0
consequent O 0
alteration O 0
of O 0
the O 0
mRNA O 0
translational O 0
reading O 0
frame O 0
and O 0
generation O 0
of O 0
a O 0
premature O 0
termination O 0
codon O 0
of O 0
translation O 0
. O 0

By O 0
use O 0
of O 0
this O 0
strategy O 0
, O 0
carrier O 0
status O 0
was O 0
accurately O 0
assessed O 0
in O 0
all O 0
seven O 0
at O 0
- O 0
risk O 0
females O 0
tested O 0
, O 0
whereas O 0
enzymatic O 0
dosages O 0
failed O 0
to O 0
diagnose O 0
or O 0
exclude O 0
heterozygosity O 0
. O 0
. O 0

Prenatal O 0
diagnosis O 0
by O 0
FISH O 0
in O 0
a O 0
family O 0
with O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
caused O 0
by O 0
duplication O 0
of O 0
PLP O 0
gene O 0
. O 0

A O 0
diagnosis O 0
of O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
( O 0
MIM O 0
312080 O 0
) O 0
was O 0
made O 0
in O 0
a O 0
young O 0
boy O 0
. O 0

No O 0
mutation O 0
in O 0
the O 0
coding O 0
region O 0
of O 0
the O 0
proteolipid O 0
protein O 0
( O 0
PLP O 0
) O 0
gene O 0
had O 0
been O 0
found O 0
. O 0

The O 0
boys O 0
maternal O 0
aunt O 0
came O 0
for O 0
prenatal O 0
diagnosis O 0
when O 0
16 O 0
+ O 0
weeks O 0
pregnant O 0
and O 0
carrying O 0
a O 0
male O 0
fetus O 0
. O 0

Samples O 0
were O 0
tested O 0
for O 0
duplication O 0
of O 0
the O 0
PLP O 0
gene O 0
, O 0
by O 0
interphase O 0
FISH O 0
, O 0
in O 0
lymphocyte O 0
preparations O 0
from O 0
the O 0
proband O 0
, O 0
his O 0
aunt O 0
and O 0
an O 0
amniotic O 0
fluid O 0
cell O 0
preparation O 0
from O 0
the O 0
fetus O 0
. O 0

The O 0
proband O 0
was O 0
found O 0
to O 0
carry O 0
the O 0
duplication O 0
, O 0
thus O 0
confirming O 0
the O 0
diagnosis O 0
of O 0
Pelizaeus B-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
, O 0
but O 0
neither O 0
the O 0
aunt O 0
nor O 0
the O 0
fetus O 0
carried O 0
a O 0
duplication O 0
. O 0
. O 0

Dominant O 0
negative O 0
effect O 0
of O 0
the O 0
APC1309 O 0
mutation O 0
: O 0
a O 0
possible O 0
explanation O 0
for O 0
genotype O 0
- O 0
phenotype O 0
correlations O 0
in O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
. O 0

Inactivation O 0
of O 0
the O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( O 0
APC B-Disease 1
) O 0
gene O 0
product O 0
initiates O 0
colorectal O 0
tumorigenesis O 0
. O 0

Patients O 0
with O 0
familial B-Disease 1
APC I-Disease 1
( O 0
FAP B-Disease 0
) O 0
carry O 0
germ O 0
- O 0
line O 0
mutations O 0
in O 0
the O 0
APC B-Disease 1
gene O 0
and O 0
develop O 0
multiple O 0
colorectal B-Disease 1
adenomas I-Disease 1
and O 0
subsequent O 0
carcinomas B-Disease 0
early O 0
in O 0
life O 0
. O 0

The O 0
severity O 0
of O 0
the O 0
disease O 0
correlates O 0
with O 0
the O 0
position O 0
of O 0
the O 0
inherited O 0
APC B-Disease 1
mutation O 0
( O 0
genotype O 0
- O 0
phenotype O 0
correlation O 0
) O 0
. O 0

Together O 0
with O 0
the O 0
fact O 0
that O 0
both O 0
germ O 0
- O 0
line O 0
and O 0
sporadic O 0
APC B-Disease 1
mutations O 0
cluster O 0
in O 0
the O 0
central O 0
region O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
, O 0
this O 0
points O 0
to O 0
a O 0
dominant O 0
negative O 0
effect O 0
of O 0
certain O 0
APC B-Disease 1
mutants O 0
. O 0

Loss O 0
of O 0
APC B-Disease 1
function O 0
was O 0
recently O 0
shown O 0
to O 0
result O 0
in O 0
enhanced O 0
beta O 0
- O 0
catenin O 0
- O 0
/ O 0
Tcf O 0
- O 0
mediated O 0
transcription O 0
in O 0
colon O 0
epithelial O 0
cells O 0
. O 0

Here O 0
, O 0
we O 0
provide O 0
experimental O 0
evidence O 0
for O 0
a O 0
dominant O 0
negative O 0
effect O 0
of O 0
APC B-Disease 1
gene O 0
products O 0
associated O 0
with O 0
severe O 0
polyposis B-Disease 1
. O 0

Wild O 0
- O 0
type O 0
APC B-Disease 1
activity O 0
in O 0
beta O 0
- O 0
catenin O 0
- O 0
/ O 0
Tcf O 0
- O 0
mediated O 0
transcription O 0
was O 0
strongly O 0
inhibited O 0
by O 0
a O 0
mutant O 0
APC B-Disease 1
that O 0
is O 0
truncated O 0
at O 0
codon O 0
1309 O 0
. O 0

In O 0
contrast O 0
, O 0
mutant O 0
APC B-Disease 1
gene O 0
products O 0
that O 0
are O 0
associated O 0
with O 0
attenuated B-Disease 0
polyposis I-Disease 1
( O 0
codon O 0
386 O 0
or O 0
1465 O 0
) O 0
interfered O 0
only O 0
weakly O 0
with O 0
wild O 0
- O 0
type O 0
APC B-Disease 1
activity O 0
. O 0

These O 0
results O 0
suggest O 0
a O 0
molecular O 0
explanation O 0
for O 0
the O 0
genotype O 0
- O 0
phenotype O 0
correlation O 0
in O 0
FAP B-Disease 0
patients O 0
and O 0
support O 0
the O 0
idea O 0
that O 0
colorectal B-Disease 0
tumor I-Disease 0
growth O 0
might O 0
be O 0
, O 0
in O 0
part O 0
, O 0
driven O 0
by O 0
selection O 0
for O 0
a O 0
mutation O 0
in O 0
the O 0
mutation O 0
cluster O 0
region O 0
. O 0
. O 0

BRCA1 O 0
interacts O 0
with O 0
components O 0
of O 0
the O 0
histone O 0
deacetylase O 0
complex O 0
. O 0

Germ O 0
- O 0
line O 0
mutations O 0
in O 0
the O 0
BRCA1 O 0
tumor O 0
- O 0
suppressor O 0
gene O 0
are O 0
associated O 0
with O 0
an O 0
increased O 0
susceptibility O 0
to O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
. O 0

BRCA1 O 0
contains O 0
a O 0
carboxyl O 0
- O 0
terminal O 0
domain O 0
( O 0
BRCT O 0
) O 0
that O 0
is O 0
shared O 0
with O 0
several O 0
other O 0
proteins O 0
involved O 0
in O 0
maintaining O 0
genome O 0
integrity O 0
. O 0

In O 0
an O 0
effort O 0
to O 0
understand O 0
the O 0
function O 0
of O 0
BRCA1 O 0
, O 0
we O 0
sought O 0
to O 0
isolate O 0
proteins O 0
that O 0
interact O 0
with O 0
the O 0
BRCT O 0
domain O 0
. O 0

Purified O 0
BRCT O 0
polypeptide O 0
was O 0
used O 0
as O 0
a O 0
probe O 0
to O 0
screen O 0
a O 0
human O 0
placenta O 0
cDNA O 0
expression O 0
library O 0
by O 0
Far O 0
Western O 0
analysis O 0
. O 0

Here O 0
we O 0
report O 0
that O 0
BRCA1 O 0
interacts O 0
in O 0
vivo O 0
and O 0
in O 0
vitro O 0
with O 0
the O 0
Rb O 0
- O 0
binding O 0
proteins O 0
, O 0
RbAp46 O 0
and O 0
RbAp48 O 0
, O 0
as O 0
well O 0
as O 0
with O 0
Rb O 0
. O 0

Moreover O 0
, O 0
the O 0
BRCT O 0
domain O 0
associates O 0
with O 0
the O 0
histone O 0
deacetylases O 0
HDAC1 O 0
and O 0
HDAC2 O 0
. O 0

These O 0
results O 0
demonstrate O 0
that O 0
BRCA1 O 0
interacts O 0
with O 0
components O 0
of O 0
the O 0
histone O 0
deacetylase O 0
complex O 0
, O 0
and O 0
therefore O 0
may O 0
explain O 0
the O 0
involvement O 0
of O 0
BRCA1 O 0
in O 0
multiple O 0
processes O 0
such O 0
as O 0
transcription O 0
, O 0
DNA O 0
repair O 0
, O 0
and O 0
recombination O 0
. O 0
. O 0

Combined B-Disease 1
genetic I-Disease 1
deficiency I-Disease 1
of I-Disease 1
C6 I-Disease 1
and I-Disease 1
C7 I-Disease 1
in O 0
man O 0
. O 0

By O 0
routine O 0
screening O 0
of O 0
sera O 0
, O 0
a O 0
subject O 0
was O 0
discovered O 0
who O 0
showed O 0
a O 0
sub B-Disease 0
- I-Disease 0
total I-Disease 0
deficiency I-Disease 0
of I-Disease 0
C6 I-Disease 0
and I-Disease 0
C7 I-Disease 0
. O 0

No O 0
clinical O 0
disease O 0
was O 0
associated O 0
with O 0
this O 0
deficiency O 0
which O 0
was O 0
transmitted O 0
through O 0
the O 0
subjects O 0
family O 0
as O 0
a O 0
single O 0
genetic O 0
characteristic O 0
, O 0
the O 0
C6 B-Disease 1
deficiency I-Disease 1
being O 0
associated O 0
with O 0
a O 0
silent O 0
allele O 0
at O 0
the O 0
structural O 0
locus O 0
. O 0

The O 0
propositus O 0
was O 0
found O 0
to O 0
have O 0
low O 0
quantities O 0
of O 0
an O 0
abnormal O 0
C6 O 0
which O 0
was O 0
both O 0
antigenically O 0
deficient O 0
and O 0
smaller O 0
in O 0
size O 0
than O 0
normal O 0
C6 O 0
( O 0
110 O 0
, O 0
000 O 0
daltons O 0
compared O 0
with O 0
140 O 0
, O 0
000 O 0
daltons O 0
) O 0
and O 0
small O 0
quantities O 0
of O 0
apparently O 0
normal O 0
C7 O 0
. O 0

It O 0
is O 0
concluded O 0
that O 0
the O 0
most O 0
likely O 0
explanation O 0
for O 0
this O 0
defect O 0
is O 0
that O 0
the O 0
subject O 0
has O 0
a O 0
structural O 0
mutation O 0
in O 0
his O 0
C6 O 0
gene O 0
which O 0
produces O 0
hyopsynthesis O 0
not O 0
only O 0
of O 0
C6 O 0
but O 0
also O 0
of O 0
the O 0
closely O 0
linked O 0
gene O 0
for O 0
C7 O 0
. O 0

These O 0
findings O 0
suggest O 0
the O 0
possibility O 0
that O 0
C6 O 0
and O 0
C7 O 0
may O 0
function O 0
as O 0
a O 0
single O 0
genetic O 0
unit O 0
and O 0
that O 0
the O 0
primary O 0
transcript O 0
copied O 0
from O 0
the O 0
genome O 0
includes O 0
information O 0
for O 0
both O 0
proteins O 0
. O 0
. O 0

Changes O 0
at O 0
P183 O 0
of O 0
emerin O 0
weaken O 0
its O 0
protein O 0
- O 0
protein O 0
interactions O 0
resulting O 0
in O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
Emery I-Disease 0
- I-Disease 0
Dreifuss I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
. O 0

Emery B-Disease 0
- I-Disease 0
Dreifuss I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
EDMD B-Disease 0
) O 0
is O 0
an O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
recessive I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
characterized O 0
by O 0
early O 0
contractures B-Disease 1
of I-Disease 1
the I-Disease 1
elbows I-Disease 1
, I-Disease 1
Achilles I-Disease 1
tendons I-Disease 1
and I-Disease 1
spine I-Disease 1
, O 0
slowly O 0
progressive O 0
muscle B-Disease 1
wasting I-Disease 1
and O 0
weakness B-Disease 1
, O 0
and O 0
cardiomyopathy B-Disease 1
associated O 0
with O 0
cardiac B-Disease 1
conduction I-Disease 1
defects I-Disease 1
. O 0

The O 0
emerin O 0
gene O 0
has O 0
been O 0
mapped O 0
to O 0
Xq28 O 0
and O 0
encodes O 0
a O 0
34 O 0
- O 0
kDa O 0
serine O 0
- O 0
rich O 0
protein O 0
, O 0
emerin O 0
, O 0
which O 0
has O 0
been O 0
localized O 0
to O 0
the O 0
nuclear O 0
envelope O 0
in O 0
a O 0
wide O 0
variety O 0
of O 0
tissues O 0
, O 0
including O 0
skeletal O 0
and O 0
cardiac O 0
muscle O 0
. O 0

Mutations O 0
spanning O 0
the O 0
emerin O 0
gene O 0
have O 0
been O 0
identified O 0
in O 0
patients O 0
with O 0
EDMD B-Disease 0
. O 0

We O 0
present O 0
here O 0
the O 0
effect O 0
, O 0
on O 0
emerin O 0
protein O 0
expression O 0
, O 0
of O 0
two O 0
missense O 0
mutations O 0
identified O 0
in O 0
unrelated O 0
EDMD B-Disease 0
patients O 0
. O 0

These O 0
alterations O 0
predict O 0
the O 0
replacement O 0
of O 0
a O 0
proline O 0
residue O 0
at O 0
position O 0
183 O 0
with O 0
either O 0
a O 0
histidine O 0
or O 0
a O 0
threonine O 0
. O 0

Biochemical O 0
analysis O 0
has O 0
demonstrated O 0
that O 0
the O 0
mobility O 0
and O 0
expression O 0
levels O 0
of O 0
the O 0
mutant O 0
forms O 0
of O 0
emerin O 0
are O 0
indistinguishable O 0
from O 0
that O 0
of O 0
wild O 0
- O 0
type O 0
emerin O 0
, O 0
but O 0
that O 0
they O 0
have O 0
weakened O 0
interactions O 0
with O 0
nuclear O 0
lamina O 0
components O 0
. O 0

In O 0
comparison O 0
with O 0
the O 0
usual O 0
EDMD B-Disease 0
phenotype O 0
, O 0
patients O 0
with O 0
P183 O 0
missense O 0
mutations O 0
have O 0
a O 0
later O 0
age O 0
at O 0
onset O 0
of O 0
first O 0
symptoms O 0
, O 0
elbow B-Disease 1
contractures I-Disease 1
, O 0
ankle B-Disease 0
contractures I-Disease 0
, O 0
upper B-Disease 0
limb I-Disease 0
weakness I-Disease 1
and O 0
lower B-Disease 1
limb I-Disease 1
weakness I-Disease 1
, O 0
but O 0
there O 0
is O 0
no O 0
difference O 0
for O 0
the O 0
age O 0
at O 0
onset O 0
of O 0
cardiac B-Disease 0
involvement I-Disease 0
. O 0

This O 0
is O 0
the O 0
first O 0
report O 0
of O 0
protein O 0
studies O 0
on O 0
patients O 0
with O 0
missense O 0
mutations O 0
resulting O 0
in O 0
the O 0
clinical O 0
features O 0
of O 0
EDMD B-Disease 0
. O 0

These O 0
studies O 0
demonstrate O 0
the O 0
importance O 0
of O 0
proline O 0
183 O 0
for O 0
the O 0
proper O 0
structure O 0
/ O 0
function O 0
of O 0
emerin O 0
. O 0
. O 0

Microdeletions O 0
at O 0
chromosome O 0
bands O 0
1q32 O 0
- O 0
q41 O 0
as O 0
a O 0
cause O 0
of O 0
Van B-Disease 0
der I-Disease 0
Woude I-Disease 0
syndrome I-Disease 0
. O 0

Van B-Disease 0
der I-Disease 0
Woude I-Disease 0
syndrome I-Disease 0
( O 0
VWS B-Disease 0
) O 0
is O 0
an O 0
autosomal B-Disease 0
dominant I-Disease 0
disorder I-Disease 0
comprising O 0
cleft B-Disease 1
lip I-Disease 1
and O 0
/ O 0
or O 0
cleft B-Disease 0
palate I-Disease 0
and O 0
lip B-Disease 0
pits I-Disease 0
. O 0

We O 0
reported O 0
previously O 0
a O 0
family O 0
whose O 0
underlying O 0
mutation O 0
is O 0
a O 0
500 O 0
- O 0
800 O 0
kb O 0
deletion O 0
localized O 0
to O 0
chromosome O 0
bands O 0
1q32 O 0
- O 0
q41 O 0
[ O 0
Sander O 0
et O 0
al O 0
. O 0
, O 0
1994 O 0
Hum O 0
Mol O 0
Genet O 0
3 O 0
576 O 0
- O 0
578 O 0
] O 0
. O 0

Along O 0
with O 0
cleft B-Disease 1
lip I-Disease 1
/ I-Disease 1
palate I-Disease 1
and O 0
lip B-Disease 0
pits I-Disease 0
, O 0
affected O 0
relatives O 0
exhibit O 0
developmental B-Disease 0
delays I-Disease 0
, O 0
suggesting O 0
that O 0
the O 0
function O 0
of O 0
a O 0
gene O 0
nearby O 0
may O 0
also O 0
be O 0
disrupted O 0
. O 0

To O 0
further O 0
localize O 0
the O 0
VWS B-Disease 0
gene O 0
we O 0
searched O 0
for O 0
other O 0
deletions O 0
that O 0
cause O 0
VWS B-Disease 0
. O 0

An O 0
allele O 0
loss O 0
assay O 0
was O 0
performed O 0
using O 0
a O 0
novel O 0
highly O 0
polymorphic O 0
marker O 0
, O 0
D1S3753 O 0
. O 0

From O 0
a O 0
panel O 0
of O 0
37 O 0
unrelated O 0
individuals O 0
, O 0
we O 0
detected O 0
an O 0
allele O 0
loss O 0
in O 0
one O 0
family O 0
, O 0
indicating O 0
the O 0
presence O 0
of O 0
a O 0
deletion O 0
. O 0

In O 0
this O 0
family O 0
, O 0
the O 0
phenotype O 0
in O 0
three O 0
generations O 0
of O 0
affected O 0
individuals O 0
was O 0
confined O 0
to O 0
the O 0
cardinal O 0
signs O 0
of O 0
VWS B-Disease 0
. O 0

Surprisingly O 0
, O 0
mapping O 0
of O 0
the O 0
new O 0
deletion O 0
showed O 0
that O 0
it O 0
extended O 0
0 O 0
. O 0

2 O 0
- O 0
1 O 0
Mb O 0
beyond O 0
the O 0
proximal O 0
breakpoint O 0
for O 0
the O 0
deletion O 0
described O 0
previously O 0
. O 0

No O 0
deletions O 0
were O 0
detected O 0
in O 0
seven O 0
cases O 0
of O 0
popliteal B-Disease 1
pterygia I-Disease 1
syndrome I-Disease 1
, O 0
76 O 0
cases O 0
of O 0
mixed O 0
syndromic B-Disease 0
forms I-Disease 0
of I-Disease 0
cleft I-Disease 1
lip I-Disease 1
and I-Disease 0
palate I-Disease 0
, O 0
and O 0
178 O 0
cases O 0
of O 0
nonsyndromic B-Disease 0
cleft I-Disease 1
lip I-Disease 1
and I-Disease 0
palate I-Disease 0
. O 0

Splicing O 0
defects O 0
in O 0
the O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
gene O 0
, O 0
ATM O 0
: O 0
underlying O 0
mutations O 0
and O 0
consequences O 0
. O 0

Mutations O 0
resulting O 0
in O 0
defective O 0
splicing O 0
constitute O 0
a O 0
significant O 0
proportion O 0
( O 0
30 O 0
/ O 0
62 O 0
[ O 0
48 O 0
% O 0
] O 0
) O 0
of O 0
a O 0
new O 0
series O 0
of O 0
mutations O 0
in O 0
the O 0
ATM O 0
gene O 0
in O 0
patients O 0
with O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
( O 0
AT B-Disease 0
) O 0
that O 0
were O 0
detected O 0
by O 0
the O 0
protein O 0
- O 0
truncation O 0
assay O 0
followed O 0
by O 0
sequence O 0
analysis O 0
of O 0
genomic O 0
DNA O 0
. O 0

Fewer O 0
than O 0
half O 0
of O 0
the O 0
splicing O 0
mutations O 0
involved O 0
the O 0
canonical O 0
AG O 0
splice O 0
- O 0
acceptor O 0
site O 0
or O 0
GT O 0
splice O 0
- O 0
donor O 0
site O 0
. O 0

A O 0
higher O 0
percentage O 0
of O 0
mutations O 0
occurred O 0
at O 0
less O 0
stringently O 0
conserved O 0
sites O 0
, O 0
including O 0
silent O 0
mutations O 0
of O 0
the O 0
last O 0
nucleotide O 0
of O 0
exons O 0
, O 0
mutations O 0
in O 0
nucleotides O 0
other O 0
than O 0
the O 0
conserved O 0
AG O 0
and O 0
GT O 0
in O 0
the O 0
consensus O 0
splice O 0
sites O 0
, O 0
and O 0
creation O 0
of O 0
splice O 0
- O 0
acceptor O 0
or O 0
splice O 0
- O 0
donor O 0
sites O 0
in O 0
either O 0
introns O 0
or O 0
exons O 0
. O 0

These O 0
splicing O 0
mutations O 0
led O 0
to O 0
a O 0
variety O 0
of O 0
consequences O 0
, O 0
including O 0
exon O 0
skipping O 0
and O 0
, O 0
to O 0
a O 0
lesser O 0
degree O 0
, O 0
intron O 0
retention O 0
, O 0
activation O 0
of O 0
cryptic O 0
splice O 0
sites O 0
, O 0
or O 0
creation O 0
of O 0
new O 0
splice O 0
sites O 0
. O 0

In O 0
addition O 0
, O 0
5 O 0
of O 0
12 O 0
nonsense O 0
mutations O 0
and O 0
1 O 0
missense O 0
mutation O 0
were O 0
associated O 0
with O 0
deletion O 0
in O 0
the O 0
cDNA O 0
of O 0
the O 0
exons O 0
in O 0
which O 0
the O 0
mutations O 0
occurred O 0
. O 0

No O 0
ATM O 0
protein O 0
was O 0
detected O 0
by O 0
western O 0
blotting O 0
in O 0
any O 0
AT B-Disease 0
cell O 0
line O 0
in O 0
which O 0
splicing O 0
mutations O 0
were O 0
identified O 0
. O 0

Several O 0
cases O 0
of O 0
exon O 0
skipping O 0
in O 0
both O 0
normal O 0
controls O 0
and O 0
patients O 0
for O 0
whom O 0
no O 0
underlying O 0
defect O 0
could O 0
be O 0
found O 0
in O 0
genomic O 0
DNA O 0
were O 0
also O 0
observed O 0
, O 0
suggesting O 0
caution O 0
in O 0
the O 0
interpretation O 0
of O 0
exon O 0
deletions O 0
observed O 0
in O 0
ATM O 0
cDNA O 0
when O 0
there O 0
is O 0
no O 0
accompanying O 0
identification O 0
of O 0
genomic O 0
mutations O 0
. O 0
. O 0

Alpha O 0
- O 0
cardiac O 0
actin O 0
is O 0
a O 0
novel O 0
disease O 0
gene O 0
in O 0
familial B-Disease 1
hypertrophic I-Disease 1
cardiomyopathy I-Disease 1
. O 0

We O 0
identified O 0
the O 0
alpha O 0
- O 0
cardiac O 0
actin O 0
gene O 0
( O 0
ACTC O 0
) O 0
as O 0
a O 0
novel O 0
disease O 0
gene O 0
in O 0
a O 0
pedigree O 0
suffering O 0
from O 0
familial B-Disease 1
hypertrophic I-Disease 1
cardiomyopathy I-Disease 1
( O 0
FHC B-Disease 1
) O 0
. O 0

Linkage O 0
analyses O 0
excluded O 0
all O 0
the O 0
previously O 0
reported O 0
FHC B-Disease 1
loci O 0
as O 0
possible O 0
disease O 0
loci O 0
in O 0
the O 0
family O 0
studied O 0
, O 0
with O 0
lod O 0
scores O 0
varying O 0
between O 0
- O 0
2 O 0
. O 0

5 O 0
and O 0
- O 0
6 O 0
. O 0

0 O 0
0 O 0
. O 0

Further O 0
linkage O 0
analyses O 0
of O 0
plausible O 0
candidate O 0
genes O 0
highly O 0
expressed O 0
in O 0
the O 0
adult O 0
human O 0
heart O 0
identified O 0
ACTC O 0
as O 0
the O 0
most O 0
likely O 0
disease O 0
gene O 0
, O 0
showing O 0
a O 0
maximal O 0
lod O 0
score O 0
of O 0
3 O 0
. O 0

6 O 0
6 O 0
. O 0

Mutation O 0
analysis O 0
of O 0
ACTC O 0
revealed O 0
an O 0
Ala295Ser O 0
mutation O 0
in O 0
exon O 0
5 O 0
close O 0
to O 0
2 O 0
missense O 0
mutations O 0
recently O 0
described O 0
to O 0
cause O 0
the O 0
inherited O 0
form O 0
of O 0
idiopathic B-Disease 1
dilated I-Disease 1
cardiomyopathy I-Disease 1
( O 0
IDC B-Disease 0
) O 0
. O 0

Overgrowth B-Disease 0
of I-Disease 0
oral I-Disease 0
mucosa I-Disease 0
and I-Disease 0
facial I-Disease 0
skin I-Disease 0
, O 0
a O 0
novel O 0
feature O 0
of O 0
aspartylglucosaminuria B-Disease 0
. O 0

Aspartylglucosaminuria B-Disease 1
( O 0
AGU B-Disease 0
) O 0
is O 0
a O 0
lysosomal B-Disease 0
storage I-Disease 0
disorder I-Disease 0
caused O 0
by O 0
deficiency B-Disease 1
of I-Disease 1
aspartylglucosaminidase I-Disease 1
( O 0
AGA O 0
) O 0
. O 0

The O 0
main O 0
symptom O 0
is O 0
progressive O 0
mental B-Disease 1
retardation I-Disease 1
. O 0

A O 0
spectrum O 0
of O 0
different O 0
mutations O 0
has O 0
been O 0
reported O 0
in O 0
this O 0
disease O 0
, O 0
one O 0
missense O 0
mutation O 0
( O 0
Cys163Ser O 0
) O 0
being O 0
responsible O 0
for O 0
the O 0
majority O 0
of O 0
Finnish O 0
cases O 0
. O 0

We O 0
were O 0
able O 0
to O 0
examine O 0
66 O 0
Finnish O 0
AGU B-Disease 0
patients O 0
for O 0
changes O 0
in O 0
the O 0
oral O 0
mucosa O 0
and O 0
44 O 0
of O 0
these O 0
for O 0
changes O 0
in O 0
facial O 0
skin O 0
. O 0

Biopsy O 0
specimens O 0
of O 0
16 O 0
oral O 0
lesions O 0
, O 0
12 O 0
of O 0
them O 0
associated O 0
with O 0
the O 0
teeth O 0
, O 0
plus O 0
two O 0
facial B-Disease 0
lesions I-Disease 0
were O 0
studied O 0
histologically O 0
. O 0

Immunohistochemical O 0
staining O 0
for O 0
AGA O 0
was O 0
performed O 0
on O 0
15 O 0
oral O 0
specimens O 0
. O 0

Skin O 0
was O 0
seborrhoeic O 0
in O 0
adolescent O 0
and O 0
adult O 0
patients O 0
, O 0
with O 0
erythema B-Disease 0
of I-Disease 0
the I-Disease 0
facial I-Disease 0
skin I-Disease 0
already O 0
common O 0
in O 0
childhood O 0
. O 0

Of O 0
44 O 0
patients O 0
, O 0
nine O 0
( O 0
20 O 0
% O 0
) O 0
had O 0
facial B-Disease 0
angiofibromas I-Disease 0
, O 0
tumours B-Disease 1
primarily O 0
occurring O 0
in O 0
association O 0
with O 0
tuberous B-Disease 0
sclerosis I-Disease 0
. O 0

Oedemic B-Disease 0
buccal I-Disease 0
mucosa I-Disease 0
( O 0
leucoedema B-Disease 0
) O 0
and O 0
gingival B-Disease 0
overgrowths I-Disease 0
were O 0
more O 0
frequent O 0
in O 0
AGU B-Disease 0
patients O 0
than O 0
in O 0
controls O 0
( O 0
p O 0
< O 0
0 O 0
. O 0
001 O 0
) O 0
. O 0

Of O 0
16 O 0
oral B-Disease 0
mucosal I-Disease 0
lesions I-Disease 0
studied O 0
histologically O 0
, O 0
15 O 0
represented O 0
fibroepithelial B-Disease 1
or I-Disease 1
epithelial I-Disease 1
hyperplasias I-Disease 1
and O 0
were O 0
reactive O 0
in O 0
nature O 0
. O 0

Cytoplasmic O 0
vacuolisation O 0
was O 0
evident O 0
in O 0
four O 0
. O 0

Immunohistochemically O 0
, O 0
expression O 0
of O 0
AGA O 0
in O 0
AGU B-Disease 0
patients O 0
mucosal B-Disease 0
lesions I-Disease 0
did O 0
not O 0
differ O 0
from O 0
that O 0
seen O 0
in O 0
corresponding O 0
lesions O 0
of O 0
normal O 0
subjects O 0
. O 0

Thus O 0
, O 0
the O 0
high O 0
frequency O 0
of O 0
mucosal B-Disease 1
overgrowth I-Disease 1
in O 0
AGU B-Disease 0
patients O 0
does O 0
not O 0
appear O 0
to O 0
be O 0
directly O 0
associated O 0
with O 0
lysosomal O 0
storage O 0
or O 0
with O 0
alterations O 0
in O 0
the O 0
level O 0
of O 0
AGA O 0
expression O 0
. O 0

Characterization O 0
of O 0
a O 0
germline O 0
mosaicism O 0
in O 0
families O 0
with O 0
Lowe B-Disease 1
syndrome I-Disease 1
, O 0
and O 0
identification O 0
of O 0
seven O 0
novel O 0
mutations O 0
in O 0
the O 0
OCRL1 O 0
gene O 0
. O 0

The O 0
oculocerebrorenal B-Disease 1
syndrome I-Disease 1
of I-Disease 0
Lowe I-Disease 0
( O 0
OCRL B-Disease 1
) O 0
is O 0
an O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
disorder I-Disease 1
characterized O 0
by O 0
major O 0
abnormalities B-Disease 1
of I-Disease 1
eyes I-Disease 1
, I-Disease 1
nervous I-Disease 1
system I-Disease 1
, I-Disease 1
and I-Disease 1
kidneys I-Disease 1
. O 0

Mutations O 0
in O 0
the O 0
OCRL1 O 0
gene O 0
have O 0
been O 0
associated O 0
with O 0
the O 0
disease O 0
. O 0

OCRL1 O 0
encodes O 0
a O 0
phosphatidylinositol O 0
4 O 0
, O 0
5 O 0
- O 0
biphosphate O 0
( O 0
PtdIns O 0
[ O 0
4 O 0
, O 0
5 O 0
] O 0
P2 O 0
) O 0
5 O 0
- O 0
phosphatase O 0
. O 0

We O 0
have O 0
examined O 0
the O 0
OCRL1 O 0
gene O 0
in O 0
eight O 0
unrelated O 0
patients O 0
with O 0
OCRL B-Disease 1
and O 0
have O 0
found O 0
seven O 0
new O 0
mutations O 0
and O 0
one O 0
recurrent O 0
in O 0
- O 0
frame O 0
deletion O 0
. O 0

Among O 0
the O 0
new O 0
mutations O 0
, O 0
two O 0
nonsense O 0
mutations O 0
( O 0
R317X O 0
and O 0
E558X O 0
) O 0
and O 0
three O 0
other O 0
frameshift O 0
mutations O 0
caused O 0
premature O 0
termination O 0
of O 0
the O 0
protein O 0
. O 0

A O 0
missense O 0
mutation O 0
, O 0
R483G O 0
, O 0
was O 0
located O 0
in O 0
the O 0
highly O 0
conserved O 0
PtdIns O 0
( O 0
4 O 0
, O 0
5 O 0
) O 0
P2 O 0
5 O 0
- O 0
phosphatase O 0
domain O 0
. O 0

Finally O 0
, O 0
one O 0
frameshift O 0
mutation O 0
, O 0
2799delC O 0
, O 0
modifies O 0
the O 0
C O 0
- O 0
terminal O 0
part O 0
of O 0
OCRL1 O 0
, O 0
with O 0
an O 0
extension O 0
of O 0
six O 0
amino O 0
acids O 0
. O 0

Altogether O 0
, O 0
70 O 0
% O 0
of O 0
missense O 0
mutations O 0
are O 0
located O 0
in O 0
exon O 0
15 O 0
, O 0
and O 0
52 O 0
% O 0
of O 0
all O 0
mutations O 0
cluster O 0
in O 0
exons O 0
11 O 0
- O 0
15 O 0
. O 0

We O 0
also O 0
identified O 0
two O 0
new O 0
microsatellite O 0
markers O 0
for O 0
the O 0
OCRL1 O 0
locus O 0
, O 0
and O 0
we O 0
detected O 0
a O 0
germline O 0
mosaicism O 0
in O 0
one O 0
family O 0
. O 0

This O 0
observation O 0
has O 0
direct O 0
implications O 0
for O 0
genetic O 0
counseling O 0
of O 0
Lowe B-Disease 1
syndrome I-Disease 1
families O 0
. O 0
. O 0

MEFV O 0
- O 0
Gene O 0
analysis O 0
in O 0
armenian O 0
patients O 0
with O 0
Familial B-Disease 1
Mediterranean I-Disease 1
fever I-Disease 1
: O 0
diagnostic O 0
value O 0
and O 0
unfavorable O 0
renal O 0
prognosis O 0
of O 0
the O 0
M694V O 0
homozygous O 0
genotype O 0
- O 0
genetic O 0
and O 0
therapeutic O 0
implications O 0
. O 0

Familial B-Disease 1
Mediterranean I-Disease 1
fever I-Disease 1
( O 0
FMF B-Disease 0
) O 0
is O 0
a O 0
recessively B-Disease 1
inherited I-Disease 1
disorder I-Disease 1
that O 0
is O 0
common O 0
in O 0
patients O 0
of O 0
Armenian O 0
ancestry O 0
. O 0

To O 0
date O 0
, O 0
its O 0
diagnosis O 0
, O 0
which O 0
can O 0
be O 0
made O 0
only O 0
retrospectively O 0
, O 0
is O 0
one O 0
of O 0
exclusion O 0
, O 0
based O 0
entirely O 0
on O 0
nonspecific O 0
clinical O 0
signs O 0
that O 0
result O 0
from O 0
serosal B-Disease 0
inflammation I-Disease 0
and O 0
that O 0
may O 0
lead O 0
to O 0
unnecessary O 0
surgery O 0
. O 0

Renal B-Disease 0
amyloidosis I-Disease 0
, O 0
prevented O 0
by O 0
colchicine O 0
, O 0
is O 0
the O 0
most O 0
severe O 0
complication O 0
of O 0
FMF B-Disease 0
, O 0
a O 0
disorder O 0
associated O 0
with O 0
mutations O 0
in O 0
the O 0
MEFV O 0
gene O 0
. O 0

To O 0
evaluate O 0
the O 0
diagnostic O 0
and O 0
prognostic O 0
value O 0
of O 0
MEFV O 0
- O 0
gene O 0
analysis O 0
, O 0
we O 0
investigated O 0
90 O 0
Armenian O 0
FMF B-Disease 0
patients O 0
from O 0
77 O 0
unrelated O 0
families O 0
that O 0
were O 0
not O 0
selected O 0
through O 0
genetic O 0
- O 0
linkage O 0
analysis O 0
. O 0

Eight O 0
mutations O 0
, O 0
one O 0
of O 0
which O 0
( O 0
R408Q O 0
) O 0
is O 0
new O 0
, O 0
were O 0
found O 0
to O 0
account O 0
for O 0
93 O 0
% O 0
of O 0
the O 0
163 O 0
independent O 0
FMF B-Disease 0
alleles O 0
, O 0
with O 0
both O 0
FMF B-Disease 0
alleles O 0
identified O 0
in O 0
89 O 0
% O 0
of O 0
the O 0
patients O 0
. O 0

In O 0
several O 0
instances O 0
, O 0
family O 0
studies O 0
provided O 0
molecular O 0
evidence O 0
for O 0
pseudodominant O 0
transmission O 0
and O 0
incomplete O 0
penetrance O 0
of O 0
the O 0
disease O 0
phenotype O 0
. O 0

The O 0
M694V O 0
homozygous O 0
genotype O 0
was O 0
found O 0
to O 0
be O 0
associated O 0
with O 0
a O 0
higher O 0
prevalence O 0
of O 0
renal B-Disease 1
amyloidosis I-Disease 1
and O 0
arthritis B-Disease 0
, O 0
compared O 0
with O 0
other O 0
genotypes O 0
( O 0
P O 0
= O 0
. O 0
0002 O 0
and O 0
P O 0
= O 0
. O 0
006 O 0
, O 0
respectively O 0
) O 0
. O 0

The O 0
demonstration O 0
of O 0
both O 0
the O 0
diagnostic O 0
and O 0
prognostic O 0
value O 0
of O 0
MEFV O 0
analysis O 0
and O 0
particular O 0
modes O 0
of O 0
inheritance O 0
should O 0
lead O 0
to O 0
new O 0
ways O 0
for O 0
management O 0
of O 0
FMF O 0
- O 0
including O 0
genetic O 0
counseling O 0
and O 0
therapeutic O 0
decisions O 0
in O 0
affected O 0
families O 0
. O 0

Noninvasive O 0
test O 0
for O 0
fragile B-Disease 1
X I-Disease 1
syndrome I-Disease 1
, O 0
using O 0
hair O 0
root O 0
analysis O 0
. O 0

Identification O 0
of O 0
the O 0
FMR1 O 0
gene O 0
and O 0
the O 0
repeat O 0
- O 0
amplification O 0
mechanism O 0
causing O 0
fragile B-Disease 1
X I-Disease 1
syndrome I-Disease 1
led O 0
to O 0
development O 0
of O 0
reliable O 0
DNA O 0
- O 0
based O 0
diagnostic O 0
methods O 0
, O 0
including O 0
Southern O 0
blot O 0
hybridization O 0
and O 0
PCR O 0
. O 0

Both O 0
methods O 0
are O 0
performed O 0
on O 0
DNA O 0
isolated O 0
from O 0
peripheral O 0
blood O 0
cells O 0
and O 0
measure O 0
the O 0
repeat O 0
size O 0
in O 0
FMR1 O 0
. O 0

Using O 0
an O 0
immunocytochemical O 0
technique O 0
on O 0
blood O 0
smears O 0
, O 0
we O 0
recently O 0
developed O 0
a O 0
novel O 0
test O 0
for O 0
identification O 0
of O 0
patients O 0
with O 0
fragile B-Disease 1
X I-Disease 1
syndrome I-Disease 1
. O 0

This O 0
method O 0
, O 0
also O 0
called O 0
" O 0
antibody O 0
test O 0
, O 0
" O 0
uses O 0
monoclonal O 0
antibodies O 0
against O 0
the O 0
FMR1 O 0
gene O 0
product O 0
( O 0
FMRP O 0
) O 0
and O 0
is O 0
based O 0
on O 0
absence O 0
of O 0
FMRP O 0
in O 0
patients O 0
cells O 0
. O 0

Here O 0
we O 0
describe O 0
a O 0
new O 0
diagnostic O 0
test O 0
to O 0
identify O 0
male O 0
patients O 0
with O 0
fragile B-Disease 1
X I-Disease 1
syndrome I-Disease 1
, O 0
on O 0
the O 0
basis O 0
of O 0
lack O 0
of O 0
FMRP O 0
in O 0
their O 0
hair O 0
roots O 0
. O 0

Expression O 0
of O 0
FMRP O 0
in O 0
hair O 0
roots O 0
was O 0
studied O 0
by O 0
use O 0
of O 0
an O 0
FMRP O 0
- O 0
specific O 0
antibody O 0
test O 0
, O 0
and O 0
the O 0
percentage O 0
of O 0
FMRP O 0
- O 0
expressing O 0
hair O 0
roots O 0
in O 0
controls O 0
and O 0
in O 0
male O 0
fragile B-Disease 1
X I-Disease 1
patients O 0
was O 0
determined O 0
. O 0

Control O 0
individuals O 0
showed O 0
clear O 0
expression O 0
of O 0
FMRP O 0
in O 0
nearly O 0
every O 0
hair O 0
root O 0
, O 0
whereas O 0
male O 0
fragile B-Disease 1
X I-Disease 1
patients O 0
lacked O 0
expression O 0
of O 0
FMRP O 0
in O 0
almost O 0
all O 0
their O 0
hair O 0
roots O 0
. O 0

Mentally B-Disease 1
retarded I-Disease 1
female O 0
patients O 0
with O 0
a O 0
full O 0
mutation O 0
showed O 0
FMRP O 0
expression O 0
in O 0
only O 0
some O 0
of O 0
their O 0
hair O 0
roots O 0
( O 0
< O 0
55 O 0
% O 0
) O 0
, O 0
and O 0
no O 0
overlap O 0
with O 0
normal O 0
female O 0
controls O 0
was O 0
observed O 0
. O 0

The O 0
advantages O 0
of O 0
this O 0
test O 0
are O 0
( O 0
1 O 0
) O 0
plucking O 0
of O 0
hair O 0
follicles O 0
does O 0
no O 0
appreciable O 0
harm O 0
to O 0
the O 0
mentally B-Disease 1
retarded I-Disease 1
patient O 0
, O 0
( O 0
2 O 0
) O 0
hairs O 0
can O 0
be O 0
sent O 0
in O 0
a O 0
simple O 0
envelope O 0
to O 0
a O 0
diagnostic O 0
center O 0
, O 0
and O 0
( O 0
3 O 0
) O 0
the O 0
result O 0
of O 0
the O 0
test O 0
is O 0
available O 0
within O 0
5 O 0
h O 0
of O 0
plucking O 0
. O 0

In O 0
addition O 0
, O 0
this O 0
test O 0
enabled O 0
us O 0
to O 0
identify O 0
two O 0
fragile B-Disease 1
X I-Disease 1
patients O 0
who O 0
did O 0
not O 0
show O 0
the O 0
full O 0
mutation O 0
by O 0
analysis O 0
of O 0
DNA O 0
isolated O 0
from O 0
blood O 0
cells O 0
. O 0
. O 0

In O 0
Swedish O 0
families O 0
with O 0
hereditary B-Disease 1
prostate I-Disease 1
cancer I-Disease 1
, O 0
linkage O 0
to O 0
the O 0
HPC1 O 0
locus O 0
on O 0
chromosome O 0
1q24 O 0
- O 0
25 O 0
is O 0
restricted O 0
to O 0
families O 0
with O 0
early O 0
- O 0
onset O 0
prostate B-Disease 1
cancer I-Disease 1
. O 0

Prostate B-Disease 1
cancer I-Disease 1
clusters O 0
in O 0
some O 0
families O 0
, O 0
and O 0
an O 0
estimated O 0
5 O 0
% O 0
- O 0
10 O 0
% O 0
of O 0
all O 0
cases O 0
are O 0
estimated O 0
to O 0
result O 0
from O 0
inheritance O 0
of O 0
prostate O 1
cancer O 1
- O 0
susceptibility O 0
genes O 0
. O 0

We O 0
previously O 0
reported O 0
evidence O 0
of O 0
linkage O 0
to O 0
the O 0
1q24 O 0
- O 0
25 O 0
region O 0
( O 0
HPC1 O 0
) O 0
in O 0
91 O 0
North O 0
American O 0
and O 0
Swedish O 0
families O 0
each O 0
with O 0
multiple O 0
cases O 0
of O 0
prostate B-Disease 1
cancer I-Disease 1
( O 0
Smith O 0
et O 0
al O 0
. O 0
1996 O 0
) O 0
. O 0

In O 0
the O 0
present O 0
report O 0
we O 0
analyze O 0
40 O 0
( O 0
12 O 0
original O 0
and O 0
28 O 0
newly O 0
identified O 0
) O 0
Swedish O 0
families O 0
with O 0
hereditary B-Disease 1
prostate I-Disease 1
cancer I-Disease 1
( O 0
HPC B-Disease 0
) O 0
that O 0
, O 0
on O 0
the O 0
basis O 0
of O 0
40 O 0
markers O 0
spanning O 0
a O 0
25 O 0
- O 0
cM O 0
interval O 0
within O 0
1q24 O 0
- O 0
25 O 0
, O 0
have O 0
evidence O 0
of O 0
linkage O 0
. O 0

In O 0
the O 0
complete O 0
set O 0
of O 0
families O 0
, O 0
a O 0
maximum O 0
two O 0
- O 0
point O 0
LOD O 0
score O 0
of O 0
1 O 0
. O 0

10 O 0
was O 0
observed O 0
at O 0
D1S413 O 0
( O 0
at O 0
a O 0
recombination O 0
fraction O 0
[ O 0
theta O 0
] O 0
of O 0
. O 0
1 O 0
) O 0
, O 0
with O 0
a O 0
maximum O 0
NPL O 0
( O 0
nonparametric O 0
linkage O 0
) O 0
Z O 0
score O 0
of O 0
1 O 0
. O 0

64 O 0
at O 0
D1S202 O 0
( O 0
P O 0
= O 0
. O 0
05 O 0
) O 0
. O 0

The O 0
evidence O 0
of O 0
linkage O 0
to O 0
this O 0
region O 0
originated O 0
almost O 0
exclusively O 0
from O 0
the O 0
subset O 0
of O 0
12 O 0
early O 0
- O 0
onset O 0
( O 0
age O 0
< O 0
65 O 0
years O 0
) O 0
families O 0
, O 0
which O 0
yielded O 0
a O 0
maximum O 0
LOD O 0
score O 0
of O 0
2 O 0
. O 0

38 O 0
at O 0
D1S413 O 0
( O 0
straight O 0
theta O 0
= O 0
0 O 0
) O 0
and O 0
an O 0
NPL O 0
Z O 0
score O 0
of O 0
1 O 0
. O 0

95 O 0
at O 0
D1S422 O 0
( O 0
P O 0
= O 0
. O 0
03 O 0
) O 0
. O 0

Estimates O 0
from O 0
heterogeneity O 0
tests O 0
suggest O 0
that O 0
, O 0
within O 0
Sweden O 0
, O 0
as O 0
many O 0
as O 0
50 O 0
% O 0
of O 0
early O 0
- O 0
onset O 0
families O 0
had O 0
evidence O 0
of O 0
linkage O 0
to O 0
the O 0
HPC1 O 0
region O 0
. O 0

These O 0
results O 0
are O 0
consistent O 0
with O 0
the O 0
hypothesis O 0
of O 0
linkage O 0
to O 0
HPC1 O 0
in O 0
a O 0
subset O 0
of O 0
families O 0
with O 0
prostate B-Disease 1
cancer I-Disease 1
, O 0
particularly O 0
those O 0
with O 0
an O 0
early O 0
age O 0
at O 0
diagnosis O 0
. O 0

Molecular O 0
basis O 0
of O 0
feline O 0
beta B-Disease 0
- I-Disease 0
glucuronidase I-Disease 0
deficiency I-Disease 0
: O 0
an O 0
animal O 0
model O 0
of O 0
mucopolysaccharidosis B-Disease 1
VII I-Disease 1
. O 0

A O 0
family O 0
of O 0
domestic O 0
cats O 0
was O 0
found O 0
that O 0
exhibited O 0
clinical O 0
and O 0
biochemical O 0
abnormalities O 0
consistent O 0
with O 0
mucopolysaccharidosis B-Disease 1
VII I-Disease 1
, O 0
an O 0
autosomal B-Disease 0
recessive I-Disease 0
lysosomal I-Disease 0
storage I-Disease 0
disorder I-Disease 0
caused O 0
by O 0
beta B-Disease 0
- I-Disease 0
glucuronidase I-Disease 0
deficiency I-Disease 0
. O 0

beta O 0
- O 0
Glucuronidase O 0
activity O 0
was O 0
undetectable O 0
in O 0
affected O 0
cat O 0
fibroblasts O 0
and O 0
restored O 0
by O 0
retroviral O 0
gene O 0
transfer O 0
of O 0
rat O 0
beta O 0
- O 0
glucuronidase O 0
cDNA O 0
. O 0

beta O 0
- O 0
Glucuronidase O 0
mRNA O 0
was O 0
normal O 0
in O 0
affected O 0
cat O 0
testis O 0
by O 0
Northern O 0
blot O 0
analysis O 0
. O 0

Normal O 0
feline O 0
beta O 0
- O 0
glucuronidase O 0
cDNA O 0
was O 0
cloned O 0
and O 0
characterized O 0
, O 0
and O 0
amplified O 0
from O 0
affected O 0
cat O 0
fibroblasts O 0
by O 0
reverse O 0
transcription O 0
coupled O 0
polymerase O 0
chain O 0
reaction O 0
. O 0

There O 0
was O 0
a O 0
G O 0
- O 0
to O 0
- O 0
A O 0
transition O 0
in O 0
the O 0
affected O 0
cat O 0
cDNA O 0
that O 0
predicted O 0
an O 0
E351K O 0
substitution O 0
, O 0
destroyed O 0
a O 0
BssSI O 0
site O 0
, O 0
and O 0
eliminated O 0
GUSB O 0
enzymatic O 0
activity O 0
in O 0
expression O 0
studies O 0
. O 0

Multiple O 0
species O 0
comparison O 0
and O 0
the O 0
crystal O 0
structure O 0
of O 0
human O 0
beta O 0
- O 0
glucuronidase O 0
indicated O 0
that O 0
E351 O 0
is O 0
a O 0
highly O 0
conserved O 0
residue O 0
most O 0
likely O 0
essential O 0
in O 0
maintenance O 0
of O 0
the O 0
enzymes O 0
conformation O 0
. O 0

BssSI O 0
digestion O 0
of O 0
polymerase O 0
chain O 0
reaction O 0
products O 0
amplified O 0
from O 0
genomic O 0
DNA O 0
indicated O 0
that O 0
affected O 0
cats O 0
were O 0
homozygous O 0
and O 0
cats O 0
with O 0
half O 0
- O 0
normal O 0
beta O 0
- O 0
glucuronidase O 0
activity O 0
were O 0
heterozygous O 0
for O 0
the O 0
missense O 0
mutation O 0
. O 0

Carriers O 0
identified O 0
in O 0
this O 0
manner O 0
produced O 0
affected O 0
kittens O 0
in O 0
prospective O 0
breedings O 0
, O 0
and O 0
a O 0
feline O 0
MPS B-Disease 1
VII I-Disease 1
breeding O 0
colony O 0
has O 0
been O 0
established O 0
. O 0
. O 0

A O 0
common O 0
molecular O 0
basis O 0
for O 0
rearrangement B-Disease 0
disorders I-Disease 0
on O 0
chromosome O 0
22q11 O 0
. O 0

The O 0
chromosome O 0
22q11 O 0
region O 0
is O 0
susceptible O 0
to O 0
rearrangements O 0
that O 0
are O 0
associated O 0
with O 0
congenital B-Disease 1
anomaly I-Disease 1
disorders I-Disease 1
and O 0
malignant B-Disease 1
tumors I-Disease 1
. O 0

Three O 0
congenital B-Disease 1
anomaly I-Disease 1
disorders I-Disease 1
, O 0
cat B-Disease 0
- I-Disease 0
eye I-Disease 0
syndrome I-Disease 0
, O 0
der B-Disease 0
( I-Disease 0
) I-Disease 0
syndrome I-Disease 0
and O 0
velo B-Disease 0
- I-Disease 0
cardio I-Disease 0
- I-Disease 0
facial I-Disease 0
syndrome I-Disease 0
/ O 0
DiGeorge B-Disease 1
syndrome I-Disease 1
( O 0
VCFS B-Disease 0
/ O 0
DGS B-Disease 0
) O 0
are O 0
associated O 0
with O 0
tetrasomy O 0
, O 0
trisomy O 0
or O 0
monosomy O 0
, O 0
respectively O 0
, O 0
for O 0
part O 0
of O 0
chromosome O 0
22q11 O 0
. O 0

VCFS B-Disease 0
/ O 0
DGS B-Disease 0
is O 0
the O 0
most O 0
common O 0
syndrome O 0
associated O 0
with O 0
22q11 O 0
rearrangements O 0
. O 0

In O 0
order O 0
to O 0
determine O 0
whether O 0
there O 0
are O 0
particular O 0
regions O 0
on O 0
22q11 O 0
that O 0
are O 0
prone O 0
to O 0
rearrangements O 0
, O 0
the O 0
deletion O 0
end O 0
- O 0
points O 0
in O 0
a O 0
large O 0
number O 0
of O 0
VCFS B-Disease 0
/ O 0
DGS B-Disease 0
patients O 0
were O 0
defined O 0
by O 0
haplotype O 0
analysis O 0
. O 0

Most O 0
VCFS B-Disease 0
/ O 0
DGS B-Disease 0
patients O 0
have O 0
a O 0
similar O 0
3 O 0
Mb O 0
deletion O 0
, O 0
some O 0
have O 0
a O 0
nested O 0
distal O 0
deletion O 0
breakpoint O 0
resulting O 0
in O 0
a O 0
1 O 0
. O 0

5 O 0
Mb O 0
deletion O 0
and O 0
a O 0
few O 0
rare O 0
patients O 0
have O 0
unique O 0
deletions O 0
or O 0
translocations O 0
. O 0

The O 0
high O 0
prevalence O 0
of O 0
the O 0
disorder O 0
in O 0
the O 0
population O 0
and O 0
the O 0
fact O 0
that O 0
most O 0
cases O 0
occur O 0
sporadically O 0
suggest O 0
that O 0
sequences O 0
at O 0
or O 0
near O 0
the O 0
breakpoints O 0
confer O 0
susceptibility O 0
to O 0
chromosome O 0
rearrangements O 0
. O 0

To O 0
investigate O 0
this O 0
hypothesis O 0
, O 0
we O 0
developed O 0
hamster O 0
- O 0
human O 0
somatic O 0
hybrid O 0
cell O 0
lines O 0
from O 0
VCFS B-Disease 0
/ O 0
DGS B-Disease 0
patients O 0
with O 0
all O 0
three O 0
classes O 0
of O 0
deletions O 0
and O 0
we O 0
now O 0
show O 0
that O 0
the O 0
breakpoints O 0
occur O 0
within O 0
similar O 0
low O 0
copy O 0
repeats O 0
, O 0
termed O 0
LCR22s O 0
. O 0

To O 0
support O 0
this O 0
idea O 0
further O 0
, O 0
we O 0
identified O 0
a O 0
family O 0
that O 0
carries O 0
an O 0
interstitial O 0
duplication O 0
of O 0
the O 0
same O 0
3 O 0
Mb O 0
region O 0
that O 0
is O 0
deleted O 0
in O 0
VCFS B-Disease 0
/ O 0
DGS B-Disease 0
patients O 0
. O 0

We O 0
present O 0
models O 0
to O 0
explain O 0
how O 0
the O 0
LCR22s O 0
can O 0
mediate O 0
different O 0
homologous O 0
recombination O 0
events O 0
, O 0
thereby O 0
generating O 0
a O 0
number O 0
of O 0
rearrangements O 0
that O 0
are O 0
associated O 0
with O 0
congenital B-Disease 1
anomaly I-Disease 1
disorders I-Disease 1
. O 0

We O 0
identified O 0
five O 0
additional O 0
copies O 0
of O 0
the O 0
LCR22 O 0
on O 0
22q11 O 0
that O 0
may O 0
mediate O 0
other O 0
rearrangements O 0
leading O 0
to O 0
disease O 0
. O 0

Functional O 0
consequences O 0
of O 0
mutations O 0
in O 0
the O 0
early O 0
growth O 0
response O 0
2 O 0
gene O 0
( O 0
EGR2 O 0
) O 0
correlate O 0
with O 0
severity O 0
of O 0
human O 0
myelinopathies B-Disease 1
. O 0

The O 0
early O 0
growth O 0
response O 0
2 O 0
gene O 0
( O 0
EGR2 O 0
) O 0
is O 0
a O 0
Cys2His2zinc O 0
finger O 0
transcription O 0
factor O 0
which O 0
is O 0
thought O 0
to O 0
play O 0
a O 0
role O 0
in O 0
the O 0
regulation O 0
of O 0
peripheral O 0
nervous O 0
system O 0
myelination O 0
. O 0

This O 0
idea O 0
is O 0
based O 0
partly O 0
on O 0
the O 0
phenotype O 0
of O 0
homozygous O 0
Krox20 O 0
( O 0
Egr2 O 0
) O 0
knockout O 0
mice O 0
, O 0
which O 0
display O 0
hypomyelination B-Disease 1
of I-Disease 0
the I-Disease 0
PNS I-Disease 0
and O 0
a O 0
block O 0
of O 0
Schwann O 0
cells O 0
at O 0
an O 0
early O 0
stage O 0
of O 0
differentiation O 0
. O 0

Mutations O 0
in O 0
the O 0
human O 0
EGR2 O 0
gene O 0
have O 0
recently O 0
been O 0
associated O 0
with O 0
the O 0
inherited B-Disease 0
peripheral I-Disease 0
neuropathies I-Disease 0
Charcot B-Disease 0
- I-Disease 0
Marie I-Disease 0
- I-Disease 0
Tooth I-Disease 0
type I-Disease 0
1 I-Disease 0
, O 0
Dejerine B-Disease 1
- I-Disease 1
Sottas I-Disease 1
syndrome I-Disease 1
and O 0
congenital B-Disease 0
hypomyelinating I-Disease 0
neuropathy I-Disease 0
. O 0

Three O 0
of O 0
the O 0
four O 0
EGR2 O 0
mutations O 0
are O 0
dominant O 0
and O 0
occur O 0
within O 0
the O 0
zinc O 0
finger O 0
DNA O 0
- O 0
binding O 0
domain O 0
. O 0

The O 0
fourth O 0
mutation O 0
is O 0
recessive O 0
and O 0
affects O 0
the O 0
inhibitory O 0
domain O 0
( O 0
R1 O 0
) O 0
that O 0
binds O 0
the O 0
NAB O 0
transcriptional O 0
co O 0
- O 0
repressors O 0
. O 0

A O 0
combination O 0
of O 0
DNA O 0
- O 0
binding O 0
assays O 0
and O 0
transcriptional O 0
analysis O 0
was O 0
used O 0
to O 0
determine O 0
the O 0
functional O 0
consequences O 0
of O 0
these O 0
mutations O 0
. O 0

The O 0
zinc O 0
finger O 0
mutations O 0
affect O 0
DNA O 0
binding O 0
and O 0
the O 0
amount O 0
of O 0
residual O 0
binding O 0
directly O 0
correlates O 0
with O 0
disease O 0
severity O 0
. O 0

The O 0
R1 O 0
domain O 0
mutation O 0
prevents O 0
interaction O 0
of O 0
EGR2 O 0
with O 0
the O 0
NAB O 0
co O 0
- O 0
repressors O 0
and O 0
thereby O 0
increases O 0
transcriptional O 0
activity O 0
. O 0

These O 0
data O 0
provide O 0
insight O 0
into O 0
the O 0
possible O 0
disease O 0
mechanisms O 0
underlying O 0
EGR2 O 0
mutations O 0
and O 0
the O 0
reason O 0
for O 0
varying O 0
severity O 0
and O 0
differences O 0
in O 0
inheritance O 0
patterns O 0
. O 0
. O 0

Autosomal B-Disease 0
recessive I-Disease 0
familial I-Disease 0
neurohypophyseal I-Disease 0
diabetes I-Disease 1
insipidus I-Disease 1
with O 0
continued O 0
secretion O 0
of O 0
mutant O 0
weakly O 0
active O 0
vasopressin O 0
. O 0

Familial B-Disease 0
neurohypophyseal I-Disease 0
diabetes I-Disease 1
insipidus I-Disease 1
is O 0
an O 0
autosomal B-Disease 0
dominant I-Disease 0
disorder I-Disease 0
characterized O 0
by O 0
post O 0
- O 0
natal O 0
development O 0
of O 0
arginine B-Disease 1
vasopressin I-Disease 1
( I-Disease 1
AVP I-Disease 1
) I-Disease 1
deficiency I-Disease 1
due O 0
to O 0
mutations O 0
in O 0
the O 0
AVP O 0
gene O 0
. O 0

All O 0
published O 0
mutations O 0
affect O 0
the O 0
signal O 0
peptide O 0
or O 0
the O 0
neurophysin O 0
- O 0
II O 0
carrier O 0
protein O 0
and O 0
are O 0
presumed O 0
to O 0
interfere O 0
with O 0
processing O 0
of O 0
the O 0
preprohormone O 0
, O 0
leading O 0
to O 0
neuronal B-Disease 1
damage I-Disease 1
. O 0

We O 0
studied O 0
an O 0
unusual O 0
Palestinian O 0
family O 0
consisting O 0
of O 0
asymptomatic O 0
first O 0
cousin O 0
parents O 0
and O 0
three O 0
children O 0
affected O 0
with O 0
neurohypophyseal B-Disease 0
diabetes I-Disease 1
insipidus I-Disease 1
, O 0
suggesting O 0
autosomal O 0
recessive O 0
inheritance O 0
. O 0

All O 0
three O 0
affected O 0
children O 0
were O 0
homozygous O 0
and O 0
the O 0
parents O 0
heterozygous O 0
for O 0
a O 0
single O 0
novel O 0
mutation O 0
( O 0
C301 O 0
- O 0
> O 0
T O 0
) O 0
in O 0
exon O 0
1 O 0
, O 0
replacing O 0
Pro7 O 0
of O 0
mature O 0
AVP O 0
with O 0
Leu O 0
( O 0
Leu O 0
- O 0
AVP O 0
) O 0
. O 0

Leu O 0
- O 0
AVP O 0
was O 0
a O 0
weak O 0
agonist O 0
with O 0
approximately O 0
30 O 0
- O 0
fold O 0
reduced O 0
binding O 0
to O 0
the O 0
human O 0
V2 O 0
receptor O 0
. O 0

Measured O 0
by O 0
radioimmunoassay O 0
with O 0
a O 0
synthetic O 0
Leu O 0
- O 0
AVP O 0
standard O 0
, O 0
serum O 0
Leu O 0
- O 0
AVP O 0
levels O 0
were O 0
elevated O 0
in O 0
all O 0
three O 0
children O 0
and O 0
further O 0
increased O 0
during O 0
water O 0
deprivation O 0
to O 0
as O 0
high O 0
as O 0
30 O 0
times O 0
normal O 0
. O 0

The O 0
youngest O 0
child O 0
( O 0
2 O 0
years O 0
old O 0
) O 0
was O 0
only O 0
mildly O 0
affected O 0
but O 0
had O 0
Leu O 0
- O 0
AVP O 0
levels O 0
similar O 0
to O 0
her O 0
severely O 0
affected O 0
8 O 0
- O 0
year O 0
- O 0
old O 0
brother O 0
, O 0
suggesting O 0
that O 0
unknown O 0
mechanisms O 0
may O 0
partially O 0
compensate O 0
for O 0
a O 0
deficiency B-Disease 1
of I-Disease 1
active I-Disease 1
AVP I-Disease 1
in O 0
very O 0
young O 0
children O 0
. O 0
. O 0

X O 0
inactivation O 0
and O 0
somatic O 0
cell O 0
selection O 0
rescue O 0
female O 0
mice O 0
carrying O 0
a O 0
Piga O 0
- O 0
null O 0
mutation O 0
. O 0

A O 0
somatic O 0
mutation O 0
in O 0
the O 0
X O 0
linked O 0
PIGA O 0
gene O 0
is O 0
responsible O 0
for O 0
the O 0
deficiency B-Disease 1
of I-Disease 1
glycosyl I-Disease 1
phosphatidylinositol I-Disease 1
( I-Disease 1
GPI I-Disease 1
) I-Disease 1
- I-Disease 1
anchored I-Disease 1
proteins I-Disease 1
on O 0
blood O 0
cells O 0
from O 0
patients O 0
with O 0
paroxysmal B-Disease 1
nocturnal I-Disease 1
hemoglobinuria I-Disease 1
. O 0

No O 0
inherited O 0
form O 0
of O 0
GPI B-Disease 0
- I-Disease 0
anchor I-Disease 0
deficiency I-Disease 0
has O 0
been O 0
described O 0
. O 0

Because O 0
conventional O 0
Piga O 0
gene O 0
knockout O 0
is O 0
associated O 0
with O 0
high O 0
embryonic B-Disease 0
lethality I-Disease 0
in O 0
chimeric O 0
mice O 0
, O 0
we O 0
used O 0
the O 0
Cre O 0
/ O 0
loxP O 0
system O 0
. O 0

We O 0
generated O 0
mice O 0
in O 0
which O 0
two O 0
loxP O 0
sites O 0
flank O 0
part O 0
of O 0
Piga O 0
exon O 0
2 O 0
. O 0

After O 0
crossbreeding O 0
with O 0
female O 0
mice O 0
of O 0
the O 0
EIIa O 0
- O 0
cre O 0
strain O 0
, O 0
the O 0
floxed O 0
allele O 0
undergoes O 0
Cre O 0
- O 0
mediated O 0
recombination O 0
with O 0
high O 0
efficiency O 0
during O 0
early O 0
embryonic O 0
development O 0
. O 0

Because O 0
of O 0
X O 0
chromosome O 0
inactivation O 0
, O 0
female O 0
offspring O 0
are O 0
mosaic O 0
for O 0
cells O 0
that O 0
express O 0
or O 0
lack O 0
GPI O 0
- O 0
linked O 0
proteins O 0
. O 0

Analysis O 0
of O 0
mosaic O 0
mice O 0
showed O 0
that O 0
in O 0
heart O 0
, O 0
lung O 0
, O 0
kidney O 0
, O 0
brain O 0
, O 0
and O 0
liver O 0
, O 0
mainly O 0
wild O 0
- O 0
type O 0
Piga O 0
is O 0
active O 0
, O 0
suggesting O 0
that O 0
these O 0
tissues O 0
require O 0
GPI O 0
- O 0
linked O 0
proteins O 0
. O 0

The O 0
salient O 0
exceptions O 0
were O 0
spleen O 0
, O 0
thymus O 0
, O 0
and O 0
red O 0
blood O 0
cells O 0
, O 0
which O 0
had O 0
almost O 0
equal O 0
numbers O 0
of O 0
cells O 0
expressing O 0
the O 0
wild O 0
- O 0
type O 0
or O 0
the O 0
recombined O 0
allele O 0
, O 0
implying O 0
that O 0
GPI O 0
- O 0
linked O 0
proteins O 0
are O 0
not O 0
essential O 0
for O 0
the O 0
derivation O 0
of O 0
these O 0
tissues O 0
. O 0

PIGA O 0
( O 0
- O 0
) O 0
cells O 0
had O 0
no O 0
growth O 0
advantage O 0
, O 0
suggesting O 0
that O 0
other O 0
factors O 0
are O 0
needed O 0
for O 0
their O 0
clonal O 0
dominance O 0
in O 0
patients O 0
with O 0
paroxysmal B-Disease 1
nocturnal I-Disease 1
hemoglobinuria I-Disease 1
. O 0
. O 0

The O 0
C282Y O 0
mutation O 0
causing O 0
hereditary B-Disease 0
hemochromatosis I-Disease 1
does O 0
not O 0
produce O 0
a O 0
null O 0
allele O 0
. O 0

Targeted O 0
mutagenesis O 0
was O 0
used O 0
to O 0
produce O 0
two O 0
mutations O 0
in O 0
the O 0
murine O 0
hemochromatosis B-Disease 1
gene O 0
( O 0
Hfe O 0
) O 0
locus O 0
. O 0

The O 0
first O 0
mutation O 0
deletes O 0
a O 0
large O 0
portion O 0
of O 0
the O 0
coding O 0
sequence O 0
, O 0
generating O 0
a O 0
null O 0
allele O 0
. O 0

The O 0
second O 0
mutation O 0
introduces O 0
a O 0
missense O 0
mutation O 0
( O 0
C282Y O 0
) O 0
into O 0
the O 0
Hfe O 0
locus O 0
, O 0
but O 0
otherwise O 0
leaves O 0
the O 0
gene O 0
intact O 0
. O 0

This O 0
mutation O 0
is O 0
identical O 0
to O 0
the O 0
disease O 0
- O 0
causing O 0
mutation O 0
in O 0
patients O 0
with O 0
hereditary B-Disease 0
hemochromatosis I-Disease 1
. O 0

Mice O 0
carrying O 0
each O 0
of O 0
the O 0
two O 0
mutations O 0
were O 0
bred O 0
and O 0
analyzed O 0
. O 0

Homozygosity O 0
for O 0
either O 0
mutation O 0
results O 0
in O 0
postnatal O 0
iron O 0
loading O 0
. O 0

The O 0
effects O 0
of O 0
the O 0
null O 0
mutation O 0
are O 0
more O 0
severe O 0
than O 0
the O 0
effects O 0
of O 0
the O 0
C282Y O 0
mutation O 0
. O 0

Mice O 0
heterozygous O 0
for O 0
either O 0
mutation O 0
accumulate O 0
more O 0
iron O 0
than O 0
normal O 0
controls O 0
. O 0

Interestingly O 0
, O 0
although O 0
liver O 0
iron O 0
stores O 0
are O 0
greatly O 0
increased O 0
, O 0
splenic O 0
iron O 0
is O 0
decreased O 0
. O 0

We O 0
conclude O 0
that O 0
the O 0
C282Y O 0
mutation O 0
does O 0
not O 0
result O 0
in O 0
a O 0
null O 0
allele O 0
. O 0
. O 0

Genotype O 0
- O 0
phenotype O 0
analysis O 0
in O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
Emery I-Disease 0
- I-Disease 0
Dreifuss I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
and O 0
identification O 0
of O 0
a O 0
missense O 0
mutation O 0
associated O 0
with O 0
a O 0
milder O 0
phenotype O 0
. O 0

Direct O 0
sequencing O 0
of O 0
the O 0
emerin O 0
gene O 0
in O 0
22 O 0
families O 0
with O 0
Emery B-Disease 0
- I-Disease 0
Dreifuss I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
EMD B-Disease 1
) O 0
revealed O 0
mutations O 0
in O 0
21 O 0
( O 0
95 O 0
% O 0
) O 0
, O 0
confirming O 0
that O 0
emerin O 0
mutations O 0
can O 0
be O 0
identified O 0
in O 0
the O 0
majority O 0
of O 0
families O 0
with O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
EMD I-Disease 1
. O 0

Most O 0
emerin O 0
mutations O 0
result O 0
in O 0
absence O 0
of O 0
the O 0
protein O 0
. O 0

In O 0
this O 0
study O 0
three O 0
mutations O 0
( O 0
a O 0
missense O 0
mutation O 0
Pro183Thr O 0
and O 0
two O 0
in O 0
- O 0
frame O 0
deletions O 0
removing O 0
residues O 0
95 O 0
- O 0
99 O 0
and O 0
236 O 0
- O 0
241 O 0
, O 0
respectively O 0
) O 0
were O 0
unusual O 0
in O 0
being O 0
associated O 0
with O 0
expression O 0
of O 0
mutant O 0
protein O 0
. O 0

The O 0
phenotype O 0
in O 0
these O 0
families O 0
was O 0
compared O 0
in O 0
detail O 0
with O 0
the O 0
clinical O 0
features O 0
in O 0
cases O 0
with O 0
typical O 0
null O 0
mutations O 0
. O 0

For O 0
the O 0
in O 0
- O 0
frame O 0
deletions O 0
there O 0
were O 0
no O 0
significant O 0
differences O 0
. O 0

In O 0
the O 0
family O 0
with O 0
the O 0
missense O 0
mutation O 0
the O 0
phenotype O 0
was O 0
milder O 0
. O 0

Age O 0
at O 0
onset O 0
was O 0
later O 0
for O 0
first O 0
symptoms O 0
and O 0
for O 0
development O 0
of O 0
ankle B-Disease 0
contractures I-Disease 0
and O 0
muscle B-Disease 1
weakness I-Disease 1
. O 0

These O 0
findings O 0
have O 0
diagnostic O 0
implications O 0
as O 0
well O 0
as O 0
pointing O 0
to O 0
functionally O 0
important O 0
regions O 0
of O 0
the O 0
emerin O 0
protein O 0
. O 0
. O 0

Severe O 0
clinical O 0
expression O 0
in O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
Emery I-Disease 0
- I-Disease 0
Dreifuss I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
. O 0

X B-Disease 0
- I-Disease 0
linked I-Disease 0
Emery I-Disease 0
- I-Disease 0
Dreifuss I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
EDMD B-Disease 0
) O 0
is O 0
a O 0
relatively O 0
rare O 0
benign B-Disease 1
neuromuscular I-Disease 1
disorder I-Disease 1
which O 0
can O 0
vary O 0
remarkably O 0
in O 0
onset O 0
, O 0
course O 0
and O 0
severity O 0
. O 0

In O 0
the O 0
present O 0
study O 0
, O 0
a O 0
TCTAC O 0
deletion O 0
spanning O 0
the O 0
nucleotides O 0
631 O 0
- O 0
635 O 0
of O 0
the O 0
emerin O 0
gene O 0
caused O 0
an O 0
unusually O 0
severe O 0
disease O 0
phenotype O 0
including O 0
loss B-Disease 0
of I-Disease 0
ambulation I-Disease 0
and O 0
severe O 0
muscle B-Disease 1
wasting I-Disease 1
in O 0
two O 0
affected O 0
brothers O 0
. O 0

The O 0
same O 0
mutation O 0
has O 0
been O 0
reported O 0
previously O 0
in O 0
an O 0
unrelated O 0
family O 0
showing O 0
a O 0
significantly O 0
milder O 0
phenotype O 0
. O 0

The O 0
interfamilial O 0
heterogeneity O 0
in O 0
distribution O 0
and O 0
in O 0
severity O 0
of O 0
the O 0
features O 0
in O 0
the O 0
two O 0
families O 0
point O 0
to O 0
environmental O 0
or O 0
genetic O 0
modification O 0
as O 0
the O 0
cause O 0
of O 0
clinical O 0
variability O 0
in O 0
Emery B-Disease 0
- I-Disease 0
Dreifuss I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
. O 0
. O 0

Common O 0
mutations O 0
in O 0
BRCA1 O 0
and O 0
BRCA2 O 0
do O 0
not O 0
contribute O 0
to O 0
early O 0
prostate B-Disease 1
cancer I-Disease 1
in O 0
Jewish O 0
men O 0
. O 0

BACKGROUND O 0
Families O 0
with O 0
a O 0
high O 0
incidence O 0
of O 0
hereditary B-Disease 1
breast I-Disease 1
cancer I-Disease 1
, O 0
and O 0
subsequently O 0
shown O 0
to O 0
have O 0
terminating O 0
mutations O 0
in O 0
BRCA1 O 0
or O 0
BRCA2 O 0
, O 0
appear O 0
to O 0
have O 0
a O 0
higher O 0
incidence O 0
of O 0
prostate B-Disease 1
cancer I-Disease 1
among O 0
male O 0
relatives O 0
. O 0

We O 0
aimed O 0
to O 0
determine O 0
whether O 0
the O 0
common O 0
germline O 0
mutations O 0
of O 0
BRCA1 O 0
or O 0
BRCA2 O 0
in O 0
Ashkenazi O 0
Jewish O 0
men O 0
predisposed O 0
them O 0
to O 0
prostate B-Disease 1
cancer I-Disease 1
. O 0

METHODS O 0
We O 0
examined O 0
genomic O 0
DNA O 0
from O 0
83 O 0
( O 0
for O 0
BRCA1 O 0
185delAG O 0
) O 0
or O 0
82 O 0
( O 0
for O 0
BRCA2 O 0
6174delT O 0
) O 0
Ashkenazi O 0
Jewish O 0
prostate B-Disease 1
cancer I-Disease 1
patients O 0
, O 0
most O 0
of O 0
whom O 0
were O 0
treated O 0
at O 0
a O 0
relatively O 0
young O 0
age O 0
, O 0
for O 0
the O 0
most O 0
common O 0
germline O 0
mutation O 0
in O 0
each O 0
gene O 0
seen O 0
in O 0
the O 0
Ashkenazi O 0
population O 0
. O 0

RESULTS O 0
Our O 0
study O 0
should O 0
have O 0
been O 0
able O 0
to O 0
detect O 0
a O 0
4 O 0
- O 0
5 O 0
- O 0
fold O 0
increase O 0
in O 0
the O 0
risk O 0
of O 0
prostate B-Disease 1
cancer I-Disease 1
due O 0
to O 0
mutation O 0
of O 0
BRCA1 O 0
or O 0
BRCA2 O 0
. O 0

However O 0
, O 0
only O 0
one O 0
( O 0
1 O 0
. O 0
15 O 0
% O 0
; O 0
95 O 0
% O 0
confidence O 0
interval O 0
, O 0
0 O 0
- O 0
3 O 0
. O 0
6 O 0
% O 0
) O 0
of O 0
the O 0
patients O 0
was O 0
heterozygous O 0
for O 0
the O 0
BRCA1 O 0
mutant O 0
allele O 0
, O 0
and O 0
only O 0
two O 0
were O 0
heterozygous O 0
for O 0
the O 0
BRCA2 O 0
mutation O 0
( O 0
2 O 0
. O 0
4 O 0
% O 0
; O 0
95 O 0
% O 0
confidence O 0
interval O 0
, O 0
0 O 0
- O 0
6 O 0
. O 0
2 O 0
% O 0
) O 0
. O 0

CONCLUSIONS O 0
The O 0
incidence O 0
of O 0
each O 0
of O 0
the O 0
germline O 0
mutations O 0
in O 0
these O 0
prostate B-Disease 1
cancer I-Disease 1
patients O 0
closely O 0
matched O 0
their O 0
incidence O 0
( O 0
about O 0
1 O 0
% O 0
) O 0
in O 0
the O 0
general O 0
Ashkenazi O 0
Jewish O 0
population O 0
. O 0

This O 0
suggests O 0
that O 0
unlike O 0
cases O 0
of O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 1
cancers I-Disease 1
, O 0
mutations O 0
in O 0
BRCA1 O 0
or O 0
BRCA2 O 0
do O 0
not O 0
significantly O 0
predispose O 0
men O 0
to O 0
prostate B-Disease 1
cancer I-Disease 1

Beta O 0
- O 0
catenin O 0
accumulation O 0
and O 0
mutation O 0
of O 0
the O 0
CTNNB1 O 0
gene O 0
in O 0
hepatoblastoma B-Disease 0
. O 0

Hepatoblastoma B-Disease 0
is O 0
a O 0
rare O 0
malignant B-Disease 1
tumor I-Disease 1
of I-Disease 1
the I-Disease 1
liver I-Disease 1
that O 0
occurs O 0
in O 0
children O 0
at O 0
an O 0
average O 0
age O 0
of O 0
2 O 0
to O 0
3 O 0
years O 0
. O 0

Epidemiologic O 0
studies O 0
have O 0
shown O 0
an O 0
increased O 0
frequency O 0
of O 0
this O 0
tumor B-Disease 0
type O 0
in O 0
families O 0
affected O 0
by O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
. O 0

In O 0
addition O 0
to O 0
the O 0
epidemiologic O 0
data O 0
, O 0
molecular O 0
genetic O 0
studies O 0
suggest O 0
that O 0
inactivation O 0
of O 0
the O 0
APC B-Disease 1
tumor I-Disease 1
suppressor O 0
may O 0
be O 0
involved O 0
in O 0
hepatoblastoma B-Disease 0
tumorigenesis O 0
. O 0

A O 0
major O 0
function O 0
of O 0
APC O 1
is O 0
the O 0
downregulation O 0
of O 0
beta O 0
- O 0
catenin O 0
, O 0
a O 0
transcription O 0
- O 0
activating O 0
protein O 0
with O 0
oncogenic O 0
potential O 0
. O 0

In O 0
an O 0
ongoing O 0
immunohistochemical O 0
study O 0
of O 0
beta O 0
- O 0
catenin O 0
expression O 0
in O 0
sporadic O 0
cases O 0
of O 0
tumor B-Disease 0
types O 0
that O 0
are O 0
associated O 0
with O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
, O 0
we O 0
observed O 0
increased O 0
beta O 0
- O 0
catenin O 0
levels O 0
in O 0
the O 0
cytoplasm O 0
and O 0
in O 0
the O 0
nuclei O 0
of O 0
three O 0
investigated O 0
hepatoblastomas B-Disease 0
. O 0

Sequencing O 0
of O 0
exon O 0
3 O 0
of O 0
the O 0
beta O 0
- O 0
catenin O 0
gene O 0
( O 0
CTNNB1 O 0
) O 0
revealed O 0
an O 0
activating O 0
mutation O 0
in O 0
one O 0
of O 0
the O 0
tumor B-Disease 0
samples O 0
. O 0

Our O 0
data O 0
indicate O 0
for O 0
the O 0
first O 0
time O 0
that O 0
beta O 0
- O 0
catenin O 0
accumulation O 0
may O 0
play O 0
a O 0
role O 0
in O 0
the O 0
development O 0
of O 0
hepatoblastoma B-Disease 0
and O 0
that O 0
activating O 0
mutations O 0
of O 0
the O 0
beta O 0
- O 0
catenin O 0
gene O 0
may O 0
substitute O 0
biallelic O 0
APC O 1
inactivation O 0
in O 0
this O 0
tumor B-Disease 0
type O 0
. O 0

Genes O 0
Chromosomes O 0
Cancer O 1
25 O 0
399 O 0
- O 0
402 O 0
, O 0
1999 O 0
. O 0
. O 0

Decrease O 0
in O 0
GTP O 0
cyclohydrolase O 0
I O 0
gene O 0
expression O 0
caused O 0
by O 0
inactivation O 0
of O 0
one O 0
allele O 0
in O 0
hereditary B-Disease 1
progressive I-Disease 1
dystonia I-Disease 1
with O 0
marked O 0
diurnal O 0
fluctuation O 0
. O 0

Hereditary B-Disease 0
progressive I-Disease 0
dystonia I-Disease 0
with O 0
marked O 0
diurnal O 0
fluctuation O 0
( O 0
HPD B-Disease 1
; O 0
dopa B-Disease 1
- I-Disease 1
responsive I-Disease 1
dystonia I-Disease 1
, O 0
DRD B-Disease 0
) O 0
have O 0
been O 0
recently O 0
found O 0
to O 0
be O 0
caused O 0
by O 0
a O 0
genetic B-Disease 1
defect I-Disease 1
in O 0
the O 0
GTP O 0
cyclohydrolase O 0
I O 0
( O 0
GCH1 O 0
) O 0
gene O 0
. O 0

In O 0
this O 0
study O 0
, O 0
we O 0
quantified O 0
the O 0
mRNA O 0
level O 0
of O 0
GCH1 O 0
in O 0
phytohemagglutinin O 0
( O 0
PHA O 0
) O 0
- O 0
stimulated O 0
mononuclear O 0
blood O 0
cells O 0
from O 0
one O 0
Japanese O 0
family O 0
that O 0
do O 0
not O 0
have O 0
a O 0
mutation O 0
in O 0
the O 0
coding O 0
region O 0
or O 0
splice O 0
junctions O 0
of O 0
the O 0
gene O 0
. O 0

The O 0
results O 0
showed O 0
that O 0
the O 0
amounts O 0
of O 0
the O 0
GCH1 O 0
mRNA O 0
were O 0
decreased O 0
to O 0
about O 0
40 O 0
% O 0
of O 0
the O 0
normal O 0
level O 0
in O 0
both O 0
patients O 0
and O 0
carriers O 0
. O 0

In O 0
addition O 0
, O 0
we O 0
found O 0
that O 0
the O 0
GCH1 O 0
mRNA O 0
was O 0
transcribed O 0
from O 0
only O 0
one O 0
allele O 0
, O 0
indicating O 0
that O 0
the O 0
other O 0
allele O 0
was O 0
in O 0
an O 0
inactive O 0
state O 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
some O 0
novel O 0
mutations O 0
should O 0
exist O 0
on O 0
one O 0
of O 0
the O 0
alleles O 0
in O 0
some O 0
unknown O 0
region O 0
of O 0
the O 0
GCH1 O 0
gene O 0
, O 0
and O 0
may O 0
decrease O 0
the O 0
GCH1 O 0
mRNA O 0
causing O 0
the O 0
HPD B-Disease 1
/ O 0
DRD B-Disease 0
symptoms O 0
. O 0
. O 0

Sulfate O 0
transport O 0
is O 0
not O 0
impaired O 0
in O 0
pendred B-Disease 0
syndrome I-Disease 0
thyrocytes O 0
. O 0

Pendred B-Disease 0
syndrome I-Disease 0
is O 0
the O 0
most O 0
common O 0
form O 0
of O 0
syndromic B-Disease 1
deafness I-Disease 1
, O 0
characterized O 0
by O 0
dyshormonogenic B-Disease 0
goiter I-Disease 1
associated O 0
with O 0
sensory B-Disease 1
- I-Disease 1
neural I-Disease 1
deafness I-Disease 1
. O 0

The O 0
gene O 0
responsible O 0
for O 0
the O 0
disease O 0
( O 0
PDS B-Disease 1
) O 0
has O 0
been O 0
cloned O 0
, O 0
but O 0
its O 0
function O 0
is O 0
as O 0
yet O 0
unknown O 0
and O 0
the O 0
connection O 0
between O 0
thyroid B-Disease 0
goiter I-Disease 1
and O 0
sensory B-Disease 1
- I-Disease 1
neural I-Disease 1
deafness I-Disease 1
remains O 0
an O 0
enigma O 0
. O 0

PDS O 1
codes O 0
for O 0
a O 0
novel O 0
protein O 0
, O 0
pendrin O 0
, O 0
which O 0
is O 0
closely O 0
related O 0
to O 0
a O 0
number O 0
of O 0
sufate O 0
transporters O 0
. O 0

Mechanisms O 0
by O 0
which O 0
abnormal O 0
sulfate O 0
transport O 0
could O 0
deleteriously O 0
affect O 0
iodide O 0
organification O 0
have O 0
been O 0
proposed O 0
. O 0

We O 0
tested O 0
sulfate O 0
transport O 0
in O 0
thyrocytes O 0
obtained O 0
from O 0
Pendred B-Disease 0
syndrome I-Disease 0
patients O 0
and O 0
found O 0
that O 0
it O 0
was O 0
not O 0
defective O 0
. O 0

This O 0
suggests O 0
that O 0
pendrin O 0
in O 0
fact O 0
may O 0
not O 0
be O 0
a O 0
sulfate O 0
transporter O 0
, O 0
and O 0
emphasizes O 0
the O 0
importance O 0
of O 0
functional O 0
studies O 0
on O 0
this O 0
novel O 0
protein O 0
. O 0
. O 0

Small O 0
deletions O 0
in O 0
the O 0
type O 0
II O 0
collagen O 0
triple O 0
helix O 0
produce O 0
kniest B-Disease 0
dysplasia I-Disease 0
. O 0

Kniest B-Disease 0
dysplasia I-Disease 0
is O 0
a O 0
moderately O 0
severe O 0
type B-Disease 1
II I-Disease 1
collagenopathy I-Disease 1
, O 0
characterized O 0
by O 0
short O 0
trunk O 0
and O 0
limbs O 0
, O 0
kyphoscoliosis B-Disease 1
, O 0
midface B-Disease 1
hypoplasia I-Disease 1
, O 0
severe O 0
myopia B-Disease 0
, O 0
and O 0
hearing B-Disease 0
loss I-Disease 0
. O 0

Mutations O 0
in O 0
the O 0
gene O 0
that O 0
encodes O 0
type O 0
II O 0
collagen O 0
( O 0
COL2A1 O 0
) O 0
, O 0
the O 0
predominant O 0
protein O 0
of O 0
cartilage O 0
, O 0
have O 0
been O 0
identified O 0
in O 0
a O 0
number O 0
of O 0
individuals O 0
with O 0
Kniest B-Disease 0
dysplasia I-Disease 0
. O 0

All O 0
but O 0
two O 0
of O 0
these O 0
previously O 0
described O 0
mutations O 0
cause O 0
in O 0
- O 0
frame O 0
deletions O 0
in O 0
type O 0
II O 0
collagen O 0
, O 0
either O 0
by O 0
small O 0
deletions O 0
in O 0
the O 0
gene O 0
or O 0
splice O 0
site O 0
alterations O 0
. O 0

Furthermore O 0
, O 0
all O 0
but O 0
one O 0
of O 0
these O 0
mutations O 0
is O 0
located O 0
between O 0
exons O 0
12 O 0
and O 0
24 O 0
in O 0
the O 0
COL2A1 O 0
gene O 0
. O 0

We O 0
used O 0
heteroduplex O 0
analysis O 0
to O 0
identify O 0
sequence O 0
anomalies O 0
in O 0
five O 0
individuals O 0
with O 0
Kniest B-Disease 0
dysplasia I-Disease 0
. O 0

Sequencing O 0
of O 0
the O 0
index O 0
patients O 0
genomic O 0
DNA O 0
identified O 0
four O 0
new O 0
dominant O 0
mutations O 0
in O 0
COL2A1 O 0
that O 0
result O 0
in O 0
Kniest B-Disease 0
dysplasia I-Disease 0
a O 0
21 O 0
- O 0
bp O 0
deletion O 0
in O 0
exon O 0
16 O 0
, O 0
an O 0
18 O 0
- O 0
bp O 0
deletion O 0
in O 0
exon O 0
19 O 0
, O 0
and O 0
4 O 0
- O 0
bp O 0
deletions O 0
in O 0
the O 0
splice O 0
donor O 0
sites O 0
of O 0
introns O 0
14 O 0
and O 0
20 O 0
. O 0

A O 0
previously O 0
described O 0
28 O 0
- O 0
bp O 0
deletion O 0
at O 0
the O 0
COL2A1 O 0
exon O 0
12 O 0
- O 0
intron O 0
12 O 0
junction O 0
, O 0
deleting O 0
the O 0
splice O 0
donor O 0
site O 0
, O 0
was O 0
identified O 0
in O 0
the O 0
fifth O 0
case O 0
. O 0

The O 0
latter O 0
three O 0
mutations O 0
are O 0
predicted O 0
to O 0
result O 0
in O 0
exon O 0
skipping O 0
in O 0
the O 0
mRNA O 0
encoded O 0
from O 0
the O 0
mutant O 0
allele O 0
. O 0

These O 0
data O 0
suggest O 0
that O 0
Kniest B-Disease 0
dysplasia I-Disease 0
results O 0
from O 0
shorter O 0
type O 0
II O 0
collagen O 0
monomers O 0
, O 0
and O 0
support O 0
the O 0
hypothesis O 0
that O 0
alteration O 0
of O 0
a O 0
specific O 0
COL2A1 O 0
domain O 0
, O 0
which O 0
may O 0
span O 0
from O 0
exons O 0
12 O 0
to O 0
24 O 0
, O 0
leads O 0
to O 0
the O 0
Kniest B-Disease 0
dysplasia I-Disease 0
phenotype O 0
. O 0
. O 0

Classical B-Disease 0
galactosemia I-Disease 0
and O 0
mutations O 0
at O 0
the O 0
galactose O 0
- O 0
1 O 0
- O 0
phosphate O 0
uridyl O 0
transferase O 0
( O 0
GALT O 0
) O 0
gene O 0
. O 0

Classical B-Disease 0
galactosemia I-Disease 0
is O 0
caused O 0
by O 0
a O 0
deficiency O 0
in O 0
activity O 0
of O 0
the O 0
enzyme O 0
galactose O 0
- O 0
1 O 0
- O 0
phosphate O 0
uridyl O 0
transferase O 0
( O 0
GALT O 0
) O 0
, O 0
which O 0
, O 0
in O 0
turn O 0
, O 0
is O 0
caused O 0
by O 0
mutations O 0
at O 0
the O 0
GALT O 0
gene O 0
. O 0

The O 0
disorder O 0
exhibits O 0
considerable O 0
allelic O 0
heterogeneity O 0
and O 0
, O 0
at O 0
the O 0
end O 0
of O 0
1998 O 0
, O 0
more O 0
than O 0
150 O 0
different O 0
base O 0
changes O 0
were O 0
recorded O 0
in O 0
24 O 0
different O 0
populations O 0
and O 0
ethnic O 0
groups O 0
in O 0
15 O 0
countries O 0
worldwide O 0
. O 0

The O 0
mutations O 0
most O 0
frequently O 0
cited O 0
are O 0
Q188R O 0
, O 0
K285N O 0
, O 0
S135L O 0
, O 0
and O 0
N314D O 0
. O 0

Q188R O 0
is O 0
the O 0
most O 0
common O 0
mutation O 0
in O 0
European O 0
populations O 0
or O 0
in O 0
those O 0
predominantly O 0
of O 0
European O 0
descent O 0
. O 0

Overall O 0
, O 0
it O 0
accounts O 0
for O 0
60 O 0
- O 0
70 O 0
% O 0
of O 0
mutant O 0
chromosomes O 0
, O 0
but O 0
there O 0
are O 0
significant O 0
differences O 0
in O 0
its O 0
relative O 0
frequency O 0
in O 0
individual O 0
populations O 0
. O 0

Individuals O 0
homoallelic O 0
for O 0
Q188R O 0
tend O 0
to O 0
have O 0
a O 0
severe O 0
phenotype O 0
and O 0
this O 0
is O 0
in O 0
keeping O 0
with O 0
the O 0
virtually O 0
complete O 0
loss O 0
of O 0
enzyme O 0
activity O 0
observed O 0
in O 0
in O 0
vitro O 0
expression O 0
systems O 0
. O 0

Globally O 0
, O 0
K285N O 0
is O 0
rarer O 0
, O 0
but O 0
in O 0
many O 0
European O 0
populations O 0
it O 0
can O 0
be O 0
found O 0
on O 0
25 O 0
- O 0
40 O 0
% O 0
of O 0
mutant O 0
chromosomes O 0
. O 0

It O 0
is O 0
invariably O 0
associated O 0
with O 0
a O 0
severe O 0
phenotype O 0
. O 0

S135L O 0
is O 0
found O 0
almost O 0
exclusively O 0
in O 0
African O 0
Americans O 0
. O 0

In O 0
vitro O 0
expression O 0
results O 0
are O 0
discrepant O 0
, O 0
but O 0
some O 0
individuals O 0
carrying O 0
S135L O 0
appear O 0
to O 0
exhibit O 0
GALT O 0
activity O 0
in O 0
some O 0
tissues O 0
. O 0

Duarte O 0
1 O 0
( O 0
or O 0
Los O 0
Angeles O 0
) O 0
and O 0
Duarte O 0
2 O 0
( O 0
or O 0
Duarte O 0
) O 0
variants O 0
carry O 0
the O 0
same O 0
amino O 0
acid O 0
substitution O 0
, O 0
N314D O 0
, O 0
even O 0
though O 0
D1 O 0
is O 0
associated O 0
with O 0
increased O 0
erythrocyte O 0
GALT O 0
activity O 0
and O 0
D2 O 0
with O 0
reduced O 0
activity O 0
. O 0

N314D O 0
is O 0
in O 0
linkage O 0
disequilibrium O 0
with O 0
other O 0
base O 0
changes O 0
that O 0
differ O 0
on O 0
the O 0
D1 O 0
and O 0
D2 O 0
alleles O 0
. O 0

N314D O 0
does O 0
not O 0
impair O 0
GALT O 0
activity O 0
in O 0
in O 0
vitro O 0
expression O 0
systems O 0
. O 0

However O 0
, O 0
there O 0
are O 0
differences O 0
in O 0
the O 0
abundance O 0
of O 0
GALT O 0
protein O 0
in O 0
lymphoblastoid O 0
cells O 0
lines O 0
from O 0
D2 O 0
and O 0
D1 O 0
individuals O 0
. O 0

It O 0
is O 0
unclear O 0
whether O 0
the O 0
specific O 0
molecular O 0
changes O 0
that O 0
distinguish O 0
the O 0
D1 O 0
and O 0
D2 O 0
alleles O 0
account O 0
for O 0
the O 0
different O 0
activities O 0
. O 0

The O 0
considerable O 0
genetic O 0
heterogeneity O 0
documented O 0
to O 0
date O 0
undoubtedly O 0
contributes O 0
to O 0
the O 0
phenotypic O 0
heterogeneity O 0
that O 0
is O 0
observed O 0
in O 0
galactosemia B-Disease 0
. O 0

The O 0
additional O 0
effects O 0
of O 0
nonallelic O 0
variation O 0
and O 0
other O 0
constitutional O 0
factors O 0
on O 0
phenotypic O 0
variability O 0
remain O 0
to O 0
be O 0
elucidated O 0
. O 0
. O 0

Mutations O 0
of O 0
the O 0
VHL B-Disease 1
gene O 0
in O 0
sporadic B-Disease 0
renal I-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
: O 0
definition O 0
of O 0
a O 0
risk O 0
factor O 0
for O 0
VHL B-Disease 1
patients O 0
to O 0
develop O 0
an O 0
RCC B-Disease 1
. O 0

To O 0
investigate O 0
the O 0
nature O 0
of O 0
somatic O 0
von B-Disease 0
Hippel I-Disease 0
- I-Disease 0
Lindau I-Disease 0
( O 0
VHL B-Disease 1
) O 0
mutations O 0
, O 0
we O 0
analyzed O 0
173 O 0
primary O 0
sporadic O 0
human O 0
renal B-Disease 0
cell I-Disease 0
carcinomas I-Disease 0
for O 0
mutations O 0
of O 0
the O 0
VHL B-Disease 1
tumor I-Disease 1
suppressor O 0
gene O 0
, O 0
using O 0
polymerase O 0
chain O 0
reaction O 0
( O 0
PCR O 0
) O 0
and O 0
single O 0
- O 0
strand O 0
conformational O 0
polymorphism O 0
analysis O 0
( O 0
SSCP O 0
) O 0
of O 0
DNA O 0
. O 0

We O 0
detected O 0
abnormal O 0
SSCP O 0
pattern O 0
in O 0
73 O 0
samples O 0
. O 0

After O 0
sequencing O 0
, O 0
we O 0
identified O 0
microdeletions O 0
in O 0
58 O 0
% O 0
of O 0
cases O 0
, O 0
microinsertions O 0
in O 0
17 O 0
% O 0
, O 0
nonsense O 0
mutations O 0
in O 0
8 O 0
% O 0
, O 0
and O 0
missense O 0
mutations O 0
in O 0
17 O 0
% O 0
. O 0

Among O 0
these O 0
mutations O 0
, O 0
50 O 0
% O 0
correspond O 0
to O 0
new O 0
mutations O 0
. O 0

VHL B-Disease 1
mutations O 0
were O 0
found O 0
only O 0
in O 0
the O 0
nonpapillary B-Disease 0
renal I-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
( O 0
RCC B-Disease 1
) O 0
subtype O 0
, O 0
as O 0
previously O 0
reported O 0
. O 0

To O 0
compare O 0
somatic O 0
and O 0
germline O 0
mutations O 0
, O 0
we O 0
used O 0
the O 0
VHL B-Disease 1
database O 0
, O 0
which O 0
includes O 0
507 O 0
mutations O 0
. O 0

The O 0
study O 0
of O 0
mutational O 0
events O 0
revealed O 0
a O 0
significant O 0
difference O 0
between O 0
somatic O 0
and O 0
germline O 0
mutations O 0
with O 0
mutations O 0
leading O 0
to O 0
truncated O 0
proteins O 0
observed O 0
in O 0
78 O 0
% O 0
of O 0
somatic O 0
mutations O 0
vs O 0
only O 0
37 O 0
% O 0
in O 0
germline O 0
mutations O 0
( O 0
P O 0
< O 0
0 O 0
. O 0
001 O 0
) O 0
. O 0

We O 0
postulated O 0
that O 0
a O 0
specific O 0
pattern O 0
of O 0
VHL B-Disease 1
mutations O 0
is O 0
associated O 0
with O 0
sporadic B-Disease 0
RCC I-Disease 1
. O 0

This O 0
pattern O 0
corresponds O 0
to O 0
mutations O 0
leading O 0
mainly O 0
to O 0
truncated O 0
proteins O 0
with O 0
few O 0
specific O 0
missense O 0
mutations O 0
. O 0

We O 0
then O 0
analyzed O 0
the O 0
occurrence O 0
of O 0
RCC B-Disease 1
in O 0
VHL B-Disease 1
families O 0
, O 0
based O 0
on O 0
the O 0
nature O 0
of O 0
mutations O 0
. O 0

We O 0
observed O 0
RCC B-Disease 1
in O 0
at O 0
least O 0
one O 0
member O 0
of O 0
the O 0
VHL B-Disease 1
families O 0
in O 0
77 O 0
% O 0
of O 0
cases O 0
with O 0
mutations O 0
leading O 0
to O 0
truncated O 0
proteins O 0
versus O 0
55 O 0
% O 0
in O 0
cases O 0
with O 0
missense O 0
mutations O 0
( O 0
P O 0
< O 0
0 O 0
. O 0
05 O 0
) O 0
. O 0

Thus O 0
, O 0
mutations O 0
resulting O 0
in O 0
truncated O 0
proteins O 0
may O 0
lead O 0
to O 0
a O 0
higher O 0
risk O 0
of O 0
RCC B-Disease 1
in O 0
VHL B-Disease 1
patients O 0

Defective O 0
CTLA O 0
- O 0
4 O 0
cycling O 0
pathway O 0
in O 0
Chediak B-Disease 1
- I-Disease 1
Higashi I-Disease 1
syndrome I-Disease 1
: O 0
a O 0
possible O 0
mechanism O 0
for O 0
deregulation O 0
of O 0
T O 0
lymphocyte O 0
activation O 0
. O 0

Cytotoxic O 0
T O 0
lymphocyte O 0
- O 0
associated O 0
antigen O 0
4 O 0
( O 0
CTLA O 0
- O 0
4 O 0
, O 0
also O 0
known O 0
as O 0
CD152 O 0
) O 0
has O 0
been O 0
shown O 0
to O 0
play O 0
a O 0
major O 0
role O 0
in O 0
the O 0
regulation O 0
of O 0
T O 0
cell O 0
activation O 0
. O 0

Its O 0
membrane O 0
expression O 0
is O 0
highly O 0
regulated O 0
by O 0
endocytosis O 0
and O 0
trafficking O 0
through O 0
the O 0
secretory O 0
lysosome O 0
pathway O 0
. O 0

Chediak B-Disease 1
- I-Disease 1
Higashi I-Disease 1
syndrome I-Disease 1
( O 0
CHS B-Disease 1
) O 0
is O 0
an O 0
inherited B-Disease 0
disorder I-Disease 0
caused O 0
by O 0
mutations O 0
in O 0
the O 0
lysosomal O 0
trafficking O 0
regulator O 0
gene O 0
, O 0
LYST O 0
. O 0

It O 0
results O 0
in O 0
defective O 0
membrane O 0
targeting O 0
of O 0
the O 0
proteins O 0
present O 0
in O 0
secretory O 0
lysosomes O 0
, O 0
and O 0
it O 0
is O 0
associated O 0
with O 0
a O 0
variety O 0
of O 0
features O 0
, O 0
including O 0
a O 0
lymphoproliferative B-Disease 1
syndrome I-Disease 1
with O 0
hemophagocytosis B-Disease 0
. O 0

The O 0
murine O 0
equivalent O 0
of O 0
CHS B-Disease 1
, O 0
beige O 0
mice O 0
, O 0
present O 0
similar O 0
characteristics O 0
but O 0
do O 0
not O 0
develop O 0
the O 0
lymphoproliferative B-Disease 1
syndrome I-Disease 1
. O 0

We O 0
show O 0
herein O 0
that O 0
CTLA O 0
- O 0
4 O 0
is O 0
present O 0
in O 0
enlarged O 0
, O 0
abnormal O 0
vesicles O 0
in O 0
CHS B-Disease 1
T O 0
cells O 0
and O 0
is O 0
not O 0
properly O 0
expressed O 0
at O 0
the O 0
cell O 0
surface O 0
after O 0
T O 0
cell O 0
activation O 0
, O 0
whereas O 0
its O 0
surface O 0
expression O 0
is O 0
not O 0
impaired O 0
. O 0

It O 0
is O 0
therefore O 0
proposed O 0
that O 0
the O 0
defective O 0
surface O 0
expression O 0
of O 0
CTLA O 0
- O 0
4 O 0
by O 0
CHS B-Disease 1
T O 0
cells O 0
is O 0
involved O 0
in O 0
the O 0
generation O 0
of O 0
lymphoproliferative B-Disease 0
disease I-Disease 0
. O 0

This O 0
observation O 0
may O 0
provide O 0
insight O 0
into O 0
the O 0
role O 0
of O 0
CTLA O 0
- O 0
4 O 0
in O 0
humans O 0
. O 0
. O 0

Proteolipoprotein O 0
gene O 0
analysis O 0
in O 0
82 O 0
patients O 0
with O 0
sporadic O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
Disease I-Disease 1
: O 0
duplications O 0
, O 0
the O 0
major O 0
cause O 0
of O 0
the O 0
disease O 0
, O 0
originate O 0
more O 0
frequently O 0
in O 0
male O 0
germ O 0
cells O 0
, O 0
but O 0
point O 0
mutations O 0
do O 0
not O 0
. O 0

The O 0
Clinical O 0
European O 0
Network O 0
on O 0
Brain B-Disease 0
Dysmyelinating I-Disease 0
Disease I-Disease 0
. O 0

Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
Disease I-Disease 1
( O 0
PMD B-Disease 1
) O 0
is O 0
an O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
developmental I-Disease 0
defect I-Disease 0
of I-Disease 0
myelination I-Disease 0
affecting O 0
the O 0
central O 0
nervous O 0
system O 0
and O 0
segregating O 0
with O 0
the O 0
proteolipoprotein O 0
( O 0
PLP O 0
) O 0
locus O 0
. O 0

Investigating O 0
82 O 0
strictly O 0
selected O 0
sporadic O 0
cases O 0
of O 0
PMD B-Disease 1
, O 0
we O 0
found O 0
PLP O 0
mutations O 0
in O 0
77 O 0
% O 0
; O 0
complete O 0
PLP O 0
- O 0
gene O 0
duplications O 0
were O 0
the O 0
most O 0
frequent O 0
abnormality O 0
( O 0
62 O 0
% O 0
) O 0
, O 0
whereas O 0
point O 0
mutations O 0
in O 0
coding O 0
or O 0
splice O 0
- O 0
site O 0
regions O 0
of O 0
the O 0
gene O 0
were O 0
involved O 0
less O 0
frequently O 0
( O 0
38 O 0
% O 0
) O 0
. O 0

We O 0
analyzed O 0
the O 0
maternal O 0
status O 0
of O 0
56 O 0
cases O 0
to O 0
determine O 0
the O 0
origin O 0
of O 0
both O 0
types O 0
of O 0
PLP O 0
mutation O 0
, O 0
since O 0
this O 0
is O 0
relevant O 0
to O 0
genetic O 0
counseling O 0
. O 0

In O 0
the O 0
22 O 0
point O 0
mutations O 0
, O 0
68 O 0
% O 0
of O 0
mothers O 0
were O 0
heterozygous O 0
for O 0
the O 0
mutation O 0
, O 0
a O 0
value O 0
identical O 0
to O 0
the O 0
two O 0
- O 0
thirds O 0
of O 0
carrier O 0
mothers O 0
that O 0
would O 0
be O 0
expected O 0
if O 0
there O 0
were O 0
an O 0
equal O 0
mutation O 0
rate O 0
in O 0
male O 0
and O 0
female O 0
germ O 0
cells O 0
. O 0

In O 0
sharp O 0
contrast O 0
, O 0
among O 0
the O 0
34 O 0
duplicated O 0
cases O 0
, O 0
91 O 0
% O 0
of O 0
mothers O 0
were O 0
carriers O 0
, O 0
a O 0
value O 0
significantly O 0
( O 0
chi2 O 0
= O 0
9 O 0
. O 0
20 O 0
, O 0
P O 0
< O 0
. O 0
01 O 0
) O 0
in O 0
favor O 0
of O 0
a O 0
male O 0
bias O 0
, O 0
with O 0
an O 0
estimation O 0
of O 0
the O 0
male O 0
/ O 0
female O 0
mutation O 0
frequency O 0
( O 0
k O 0
) O 0
of O 0
9 O 0
. O 0

3 O 0
3 O 0
. O 0

Moreover O 0
, O 0
we O 0
observed O 0
the O 0
occurrence O 0
of O 0
de O 0
novo O 0
mutations O 0
between O 0
parental O 0
and O 0
grandparental O 0
generations O 0
in O 0
17 O 0
three O 0
- O 0
generation O 0
families O 0
, O 0
which O 0
allowed O 0
a O 0
direct O 0
estimation O 0
of O 0
the O 0
k O 0
value O 0
( O 0
k O 0
= O 0
11 O 0
) O 0
. O 0

Again O 0
, O 0
a O 0
significant O 0
male O 0
mutation O 0
imbalance O 0
was O 0
observed O 0
only O 0
for O 0
the O 0
duplications O 0
. O 0

Chromosome O 0
breakage O 0
in O 0
the O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
and I-Disease 0
Angelman I-Disease 0
syndromes I-Disease 0
involves O 0
recombination O 0
between O 0
large O 0
, O 0
transcribed O 0
repeats O 0
at O 0
proximal O 0
and O 0
distal O 0
breakpoints O 0
. O 0

Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
and O 0
Angelman B-Disease 1
syndrome I-Disease 1
( O 0
AS B-Disease 0
) O 0
are O 0
distinct O 0
neurobehavioral B-Disease 1
disorders I-Disease 1
that O 0
most O 0
often O 0
arise O 0
from O 0
a O 0
4 O 0
- O 0
Mb O 0
deletion O 0
of O 0
chromosome O 0
15q11 O 0
- O 0
q13 O 0
during O 0
paternal O 0
or O 0
maternal O 0
gametogenesis O 0
, O 0
respectively O 0
. O 0

At O 0
a O 0
de O 0
novo O 0
frequency O 0
of O 0
approximately O 0
. O 0

67 O 0
- O 0
1 O 0
/ O 0
10 O 0
, O 0
000 O 0
births O 0
, O 0
these O 0
deletions O 0
represent O 0
a O 0
common O 0
structural O 0
chromosome O 0
change O 0
in O 0
the O 0
human O 0
genome O 0
. O 0

To O 0
elucidate O 0
the O 0
mechanism O 0
underlying O 0
these O 0
events O 0
, O 0
we O 0
characterized O 0
the O 0
regions O 0
that O 0
contain O 0
two O 0
proximal O 0
breakpoint O 0
clusters O 0
and O 0
a O 0
distal O 0
cluster O 0
. O 0

Novel O 0
DNA O 0
sequences O 0
potentially O 0
associated O 0
with O 0
the O 0
breakpoints O 0
were O 0
positionally O 0
cloned O 0
from O 0
YACs O 0
within O 0
or O 0
near O 0
these O 0
regions O 0
. O 0

Analyses O 0
of O 0
rodent O 0
- O 0
human O 0
somatic O 0
- O 0
cell O 0
hybrids O 0
, O 0
YAC O 0
contigs O 0
, O 0
and O 0
FISH O 0
of O 0
normal O 0
or O 0
rearranged O 0
chromosomes O 0
15 O 0
identified O 0
duplicated O 0
sequences O 0
( O 0
the O 0
END O 0
repeats O 0
) O 0
at O 0
or O 0
near O 0
the O 0
breakpoints O 0
. O 0

The O 0
END O 0
- O 0
repeat O 0
units O 0
are O 0
derived O 0
from O 0
large O 0
genomic O 0
duplications O 0
of O 0
a O 0
novel O 0
gene O 0
( O 0
HERC2 O 0
) O 0
, O 0
many O 0
copies O 0
of O 0
which O 0
are O 0
transcriptionally O 0
active O 0
in O 0
germline O 0
tissues O 0
. O 0

One O 0
of O 0
five O 0
PWS B-Disease 0
/ O 0
AS B-Disease 0
patients O 0
analyzed O 0
to O 0
date O 0
has O 0
an O 0
identifiable O 0
, O 0
rearranged O 0
HERC2 O 0
transcript O 0
derived O 0
from O 0
the O 0
deletion O 0
event O 0
. O 0

We O 0
postulate O 0
that O 0
the O 0
END O 0
repeats O 0
flanking O 0
15q11 O 0
- O 0
q13 O 0
mediate O 0
homologous O 0
recombination O 0
resulting O 0
in O 0
deletion O 0
. O 0

Furthermore O 0
, O 0
we O 0
propose O 0
that O 0
active O 0
transcription O 0
of O 0
these O 0
repeats O 0
in O 0
male O 0
and O 0
female O 0
germ O 0
cells O 0
may O 0
facilitate O 0
the O 0
homologous O 0
recombination O 0
process O 0
. O 0

Linkage O 0
analysis O 0
in O 0
a O 0
large O 0
Brazilian O 0
family O 0
with O 0
van B-Disease 1
der I-Disease 1
Woude I-Disease 1
syndrome I-Disease 1
suggests O 0
the O 0
existence O 0
of O 0
a O 0
susceptibility O 0
locus O 0
for O 0
cleft B-Disease 0
palate I-Disease 0
at O 0
17p11 O 0
. O 0
2 O 0
- O 0
11 O 0
. O 0
1 O 0
. O 0

van B-Disease 1
der I-Disease 1
Woude I-Disease 1
syndrome I-Disease 1
( O 0
VWS B-Disease 0
) O 0
, O 0
which O 0
has O 0
been O 0
mapped O 0
to O 0
1q32 O 0
- O 0
41 O 0
, O 0
is O 0
characterized O 0
by O 0
pits B-Disease 0
and I-Disease 0
/ I-Disease 0
or I-Disease 0
sinuses I-Disease 0
of I-Disease 0
the I-Disease 0
lower I-Disease 0
lip I-Disease 0
, O 0
cleft B-Disease 1
lip I-Disease 1
/ I-Disease 1
palate I-Disease 1
( O 0
CL B-Disease 0
/ I-Disease 0
P I-Disease 0
) O 0
, O 0
cleft B-Disease 0
palate I-Disease 0
( O 0
CP B-Disease 0
) O 0
, O 0
bifid B-Disease 0
uvula I-Disease 0
, O 0
and O 0
hypodontia B-Disease 1
( O 0
H B-Disease 1
) O 0
. O 0

The O 0
expression O 0
of O 0
VWS B-Disease 0
, O 0
which O 0
has O 0
incomplete O 0
penetrance O 0
, O 0
is O 0
highly O 0
variable O 0
. O 0

Both O 0
the O 0
occurrence O 0
of O 0
CL B-Disease 0
/ I-Disease 0
P I-Disease 0
and O 0
CP B-Disease 0
within O 0
the O 0
same O 0
genealogy O 0
and O 0
a O 0
recurrence O 0
risk O 0
< O 0
40 O 0
% O 0
for O 0
CP B-Disease 0
among O 0
descendants O 0
with O 0
VWS B-Disease 0
have O 0
suggested O 0
that O 0
the O 0
development O 0
of O 0
clefts B-Disease 0
in O 0
this O 0
syndrome O 0
is O 0
influenced O 0
by O 0
modifying O 0
genes O 0
at O 0
other O 0
loci O 0
. O 0

To O 0
test O 0
this O 0
hypothesis O 0
, O 0
we O 0
have O 0
conducted O 0
linkage O 0
analysis O 0
in O 0
a O 0
large O 0
Brazilian O 0
kindred O 0
with O 0
VWS B-Disease 0
, O 0
considering O 0
as O 0
affected O 0
the O 0
individuals O 0
with O 0
CP B-Disease 0
, O 0
regardless O 0
of O 0
whether O 0
it O 0
is O 0
associated O 0
with O 0
other O 0
clinical O 0
signs O 0
of O 0
VWS B-Disease 0
. O 0

Our O 0
results O 0
suggest O 0
that O 0
a O 0
gene O 0
at O 0
17p11 O 0
. O 0

2 O 0
- O 0
11 O 0
2 O 0
- O 0
11 O 0
. O 0

1 O 0
, O 0
together O 0
with O 0
the O 0
VWS B-Disease 0
gene O 0
at O 0
1p32 O 0
- O 0
41 O 0
, O 0
enhances O 0
the O 0
probability O 0
of O 0
CP B-Disease 0
in O 0
an O 0
individual O 0
carrying O 0
the O 0
two O 0
at O 0
- O 0
risk O 0
genes O 0
. O 0

If O 0
this O 0
hypothesis O 0
is O 0
confirmed O 0
in O 0
other O 0
VWS B-Disease 0
pedigrees O 0
, O 0
it O 0
will O 0
represent O 0
one O 0
of O 0
the O 0
first O 0
examples O 0
of O 0
a O 0
gene O 0
, O 0
mapped O 0
through O 0
linkage O 0
analysis O 0
, O 0
which O 0
modifies O 0
the O 0
expression O 0
of O 0
a O 0
major O 0
gene O 0
. O 0

New O 0
mutations O 0
, O 0
polymorphisms O 0
, O 0
and O 0
rare O 0
variants O 0
in O 0
the O 0
ATM O 0
gene O 0
detected O 0
by O 0
a O 0
novel O 0
SSCP O 0
strategy O 0
. O 0

The O 0
gene O 0
for O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
, O 0
ATM O 0
, O 0
spans O 0
about O 0
150 O 0
kb O 0
of O 0
genomic O 0
DNA O 0
. O 0

ATM O 0
mutations O 0
are O 0
found O 0
along O 0
the O 0
entire O 0
gene O 0
, O 0
with O 0
no O 0
evidence O 0
of O 0
a O 0
mutational O 0
hot O 0
spot O 0
. O 0

Using O 0
DNA O 0
as O 0
the O 0
starting O 0
material O 0
, O 0
we O 0
screened O 0
the O 0
ATM O 0
gene O 0
in O 0
92 O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
patients O 0
, O 0
using O 0
an O 0
optimized O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphism O 0
( O 0
SSCP O 0
) O 0
technique O 0
that O 0
detected O 0
all O 0
previously O 0
known O 0
mutations O 0
in O 0
the O 0
polymerase O 0
chain O 0
reaction O 0
( O 0
PCR O 0
) O 0
segments O 0
being O 0
analyzed O 0
. O 0

To O 0
expedite O 0
screening O 0
, O 0
we O 0
sequentially O 0
loaded O 0
the O 0
SSCP O 0
gels O 0
with O 0
three O 0
different O 0
sets O 0
of O 0
PCR O 0
products O 0
that O 0
were O 0
pretested O 0
to O 0
avoid O 0
overlapping O 0
patterns O 0
. O 0

Many O 0
of O 0
the O 0
DNA O 0
changes O 0
we O 0
detected O 0
were O 0
intragenic O 0
polymorphisms O 0
. O 0

Of O 0
an O 0
expected O 0
177 O 0
unknown O 0
mutations O 0
, O 0
we O 0
detected O 0
approximately O 0
70 O 0
% O 0
, O 0
mostly O 0
protein O 0
truncating O 0
mutations O 0
( O 0
that O 0
would O 0
have O 0
been O 0
detectable O 0
by O 0
protein O 0
truncation O 0
testing O 0
if O 0
RNA O 0
starting O 0
material O 0
had O 0
been O 0
available O 0
) O 0
. O 0

Mutations O 0
have O 0
now O 0
been O 0
defined O 0
for O 0
every O 0
exon O 0
of O 0
the O 0
ATM O 0
gene O 0
. O 0

Herein O 0
, O 0
we O 0
present O 0
35 O 0
new O 0
mutations O 0
and O 0
34 O 0
new O 0
intragenic O 0
polymorphisms O 0
or O 0
rare O 0
variants O 0
within O 0
the O 0
ATM O 0
gene O 0
. O 0

This O 0
is O 0
the O 0
most O 0
comprehensive O 0
compilation O 0
of O 0
ATM O 0
polymorphisms O 0
assembled O 0
to O 0
date O 0
. O 0

Defining O 0
polymorphic O 0
sites O 0
as O 0
well O 0
as O 0
mutations O 0
in O 0
the O 0
ATM O 0
gene O 0
will O 0
be O 0
of O 0
great O 0
importance O 0
in O 0
designing O 0
automated O 0
methods O 0
for O 0
detecting O 0
mutations O 0
. O 0
. O 0

A O 0
novel O 0
frameshift O 0
mutation O 0
in O 0
the O 0
McLeod B-Disease 0
syndrome I-Disease 0
gene O 0
in O 0
a O 0
Japanese O 0
family O 0
. O 0

We O 0
report O 0
a O 0
novel O 0
mutation O 0
in O 0
the O 0
XK O 0
gene O 0
( O 0
XK O 0
) O 0
in O 0
a O 0
Japanese O 0
patient O 0
with O 0
McLeod B-Disease 0
syndrome I-Disease 0
. O 0

A O 0
50 O 0
- O 0
year O 0
- O 0
old O 0
man O 0
showed O 0
progressive O 0
muscular B-Disease 0
atrophy I-Disease 0
, O 0
choreic B-Disease 1
movement I-Disease 1
, O 0
elevated O 0
level O 0
of O 0
serum O 0
creatinine O 0
kinase O 0
, O 0
and O 0
acanthocytosis B-Disease 1
. O 0

The O 0
expression O 0
level O 0
of O 0
all O 0
the O 0
Kell O 0
antigens O 0
in O 0
erythrocyte O 0
was O 0
decreased O 0
and O 0
molecular O 0
analysis O 0
revealed O 0
a O 0
single O 0
- O 0
base O 0
( O 0
T O 0
) O 0
deletion O 0
at O 0
the O 0
nucleotide O 0
position O 0
1095 O 0
in O 0
XK O 0
. O 0

This O 0
deletion O 0
caused O 0
a O 0
frameshift O 0
in O 0
translation O 0
, O 0
leading O 0
to O 0
a O 0
premature O 0
stop O 0
codon O 0
at O 0
the O 0
amino O 0
acid O 0
position O 0
408 O 0
. O 0

We O 0
conclude O 0
this O 0
single O 0
- O 0
base O 0
deletion O 0
causes O 0
defective O 0
Kx O 0
protein O 0
, O 0
which O 0
is O 0
responsible O 0
for O 0
the O 0
McLeod B-Disease 0
phenotype O 0
in O 0
this O 0
patient O 0
. O 0
. O 0

Association O 0
of O 0
BRCA1 O 0
with O 0
the O 0
hRad50 O 0
- O 0
hMre11 O 0
- O 0
p95 O 0
complex O 0
and O 0
the O 0
DNA O 0
damage O 0
response O 0
. O 0

BRCA1 O 0
encodes O 0
a O 0
tumor B-Disease 0
suppressor O 0
that O 0
is O 0
mutated O 0
in O 0
familial B-Disease 1
breast I-Disease 1
and I-Disease 1
ovarian I-Disease 1
cancers I-Disease 1
. O 0

Here O 0
, O 0
it O 0
is O 0
shown O 0
that O 0
BRCA1 O 0
interacts O 0
in O 0
vitro O 0
and O 0
in O 0
vivo O 0
with O 0
hRad50 O 0
, O 0
which O 0
forms O 0
a O 0
complex O 0
with O 0
hMre11 O 0
and O 0
p95 O 0
/ O 0
nibrin O 0
. O 0

Upon O 0
irradiation O 0
, O 0
BRCA1 O 0
was O 0
detected O 0
in O 0
discrete O 0
foci O 0
in O 0
the O 0
nucleus O 0
, O 0
which O 0
colocalize O 0
with O 0
hRad50 O 0
. O 0

Formation O 0
of O 0
irradiation O 0
- O 0
induced O 0
foci O 0
positive O 0
for O 0
BRCA1 O 0
, O 0
hRad50 O 0
, O 0
hMre11 O 0
, O 0
or O 0
p95 O 0
was O 0
dramatically O 0
reduced O 0
in O 0
HCC O 0
/ O 0
1937 O 0
breast B-Disease 0
cancer I-Disease 1
cells O 0
carrying O 0
a O 0
homozygous O 0
mutation O 0
in O 0
BRCA1 O 0
but O 0
was O 0
restored O 0
by O 0
transfection O 0
of O 0
wild O 0
- O 0
type O 0
BRCA1 O 0
. O 0

Ectopic O 0
expression O 0
of O 0
wild O 0
- O 0
type O 0
, O 0
but O 0
not O 0
mutated O 0
, O 0
BRCA1 O 0
in O 0
these O 0
cells O 0
rendered O 0
them O 0
less O 0
sensitive O 0
to O 0
the O 0
DNA O 0
damage O 0
agent O 0
, O 0
methyl O 0
methanesulfonate O 0
. O 0

These O 0
data O 0
suggest O 0
that O 0
BRCA1 O 0
is O 0
important O 0
for O 0
the O 0
cellular O 0
responses O 0
to O 0
DNA O 0
damage O 0
that O 0
are O 0
mediated O 0
by O 0
the O 0
hRad50 O 0
- O 0
hMre11 O 0
- O 0
p95 O 0
complex O 0
. O 0
. O 0

Relationship O 0
among O 0
genotype O 0
, O 0
biochemical O 0
phenotype O 0
, O 0
and O 0
cognitive O 0
performance O 0
in O 0
females O 0
with O 0
phenylalanine B-Disease 0
hydroxylase I-Disease 0
deficiency I-Disease 0
: O 0
report O 0
from O 0
the O 0
Maternal B-Disease 0
Phenylketonuria I-Disease 0
Collaborative O 0
Study O 0
. O 0

OBJECTIVE O 0
To O 0
examine O 0
the O 0
relationship O 0
of O 0
phenylalanine O 0
hydroxylase O 0
( O 0
PAH O 0
) O 0
genotypes O 0
to O 0
biochemical O 0
phenotype O 0
and O 0
cognitive O 0
development O 0
in O 0
maternal B-Disease 0
phenylketonuria I-Disease 0
( O 0
PKU B-Disease 0
) O 0
. O 0

METHODOLOGY O 0
PAH O 0
gene O 0
mutations O 0
were O 0
examined O 0
in O 0
222 O 0
hyperphenylalaninemic B-Disease 1
females O 0
enrolled O 0
in O 0
the O 0
Maternal B-Disease 1
PKU I-Disease 1
Collaborative O 0
Study O 0
( O 0
MPKUCS O 0
) O 0
. O 0

A O 0
total O 0
of O 0
84 O 0
different O 0
mutations O 0
were O 0
detected O 0
, O 0
and O 0
complete O 0
genotype O 0
was O 0
obtained O 0
in O 0
199 O 0
individuals O 0
. O 0

Based O 0
on O 0
previous O 0
knowledge O 0
about O 0
mutation O 0
- O 0
phenotype O 0
associations O 0
, O 0
78 O 0
of O 0
the O 0
mutations O 0
could O 0
be O 0
assigned O 0
to O 0
one O 0
of O 0
four O 0
classes O 0
of O 0
severity O 0
( O 0
severe O 0
PKU B-Disease 0
, O 0
moderate O 0
PKU B-Disease 0
, O 0
mild O 0
PKU B-Disease 0
, O 0
and O 0
mild B-Disease 0
hyperphenylalaninemia I-Disease 1
[ O 0
MHP B-Disease 0
] O 0
) O 0
. O 0

Then O 0
, O 0
189 O 0
MPKUCS O 0
subjects O 0
were O 0
grouped O 0
according O 0
to O 0
the O 0
various O 0
combinations O 0
of O 0
mutation O 0
classifications O 0
. O 0

The O 0
sample O 0
sizes O 0
were O 0
large O 0
enough O 0
for O 0
statistical O 0
testing O 0
in O 0
four O 0
groups O 0
with O 0
at O 0
least O 0
one O 0
mutation O 0
that O 0
completely O 0
abolishes O 0
enzyme O 0
activity O 0
. O 0

These O 0
patients O 0
are O 0
considered O 0
functionally O 0
hemizygous O 0
. O 0

RESULTS O 0
The O 0
biochemical O 0
phenotype O 0
predicted O 0
from O 0
the O 0
genotype O 0
in O 0
functionally O 0
hemizygous O 0
patients O 0
was O 0
related O 0
significantly O 0
to O 0
the O 0
assigned O 0
phenylalanine O 0
level O 0
. O 0

Cognitive O 0
performance O 0
( O 0
IQ O 0
) O 0
was O 0
also O 0
significantly O 0
related O 0
to O 0
genotype O 0
. O 0

The O 0
IQ O 0
of O 0
PAH B-Disease 0
- I-Disease 0
deficient I-Disease 0
mothers O 0
with O 0
a O 0
severe O 0
PKU B-Disease 0
mutation O 0
in O 0
combination O 0
with O 0
a O 0
MHP B-Disease 0
mutation O 0
or O 0
a O 0
mild O 0
PKU B-Disease 0
mutation O 0
was O 0
99 O 0
and O 0
96 O 0
, O 0
respectively O 0
, O 0
whereas O 0
the O 0
IQ O 0
of O 0
PKU B-Disease 0
mothers O 0
with O 0
two O 0
severe O 0
PKU B-Disease 0
mutations O 0
or O 0
with O 0
one O 0
severe O 0
and O 0
one O 0
moderate O 0
PKU B-Disease 0
mutation O 0
was O 0
83 O 0
and O 0
84 O 0
, O 0
respectively O 0
. O 0

Of O 0
the O 0
patients O 0
with O 0
PKU B-Disease 0
, O 0
92 O 0
% O 0
had O 0
been O 0
treated O 0
during O 0
childhood O 0
. O 0

Those O 0
who O 0
were O 0
untreated O 0
or O 0
treated O 0
late O 0
had O 0
lower O 0
than O 0
average O 0
IQ O 0
scores O 0
for O 0
their O 0
group O 0
of O 0
mutation O 0
combinations O 0
. O 0

Females O 0
with O 0
moderate O 0
or O 0
mild O 0
PKU B-Disease 0
who O 0
were O 0
treated O 0
early O 0
and O 0
treated O 0
for O 0
> O 0
6 O 0
years O 0
showed O 0
IQ O 0
scores O 0
10 O 0
points O 0
above O 0
average O 0
for O 0
their O 0
group O 0
. O 0

CONCLUSIONS O 0
The O 0
reproductive O 0
outcome O 0
in O 0
maternal B-Disease 0
phenylketonuria I-Disease 0
is O 0
dependent O 0
on O 0
prenatal O 0
metabolic O 0
control O 0
and O 0
postnatal O 0
environmental O 0
circumstances O 0
. O 0

Both O 0
factors O 0
depend O 0
on O 0
the O 0
intellectual O 0
resources O 0
of O 0
the O 0
mother O 0
with O 0
PKU B-Disease 0
. O 0

The O 0
significant O 0
relationship O 0
among O 0
genotype O 0
, O 0
biochemical O 0
phenotype O 0
, O 0
and O 0
cognitive O 0
performance O 0
observed O 0
in O 0
the O 0
present O 0
study O 0
is O 0
of O 0
importance O 0
for O 0
the O 0
development O 0
of O 0
an O 0
optimal O 0
strategy O 0
for O 0
future O 0
treatment O 0
of O 0
females O 0
with O 0
PKU B-Disease 0
who O 0
plan O 0
pregnancy O 0
. O 0
. O 0

Spinal B-Disease 0
xanthomatosis I-Disease 0
: O 0
a O 0
variant O 0
of O 0
cerebrotendinous B-Disease 1
xanthomatosis I-Disease 1
. O 0

We O 0
describe O 0
seven O 0
Dutch O 0
patients O 0
from O 0
six O 0
families O 0
with O 0
a O 0
slowly O 0
progressive O 0
, O 0
mainly O 0
spinal B-Disease 1
cord I-Disease 1
syndrome I-Disease 1
that O 0
remained O 0
for O 0
many O 0
years O 0
the O 0
sole O 0
expression O 0
of O 0
cerebrotendinous B-Disease 1
xanthomatosis I-Disease 1
( O 0
CTX B-Disease 0
) O 0
. O 0

MRI O 0
demonstrated O 0
white B-Disease 1
matter I-Disease 1
abnormalities I-Disease 1
in O 0
the O 0
lateral O 0
and O 0
dorsal O 0
columns O 0
of O 0
the O 0
spinal O 0
cord O 0
. O 0

Post O 0
- O 0
mortem O 0
examination O 0
of O 0
one O 0
of O 0
the O 0
patients O 0
showed O 0
extensive O 0
myelin O 0
loss O 0
in O 0
these O 0
columns O 0
. O 0

An O 0
array O 0
of O 0
genotypes O 0
was O 0
found O 0
in O 0
these O 0
patients O 0
. O 0

We O 0
conclude O 0
that O 0
spinal B-Disease 0
xanthomatosis I-Disease 0
is O 0
a O 0
clinical O 0
and O 0
radiological O 0
separate O 0
entity O 0
of O 0
CTX B-Disease 0
that O 0
should O 0
be O 0
included O 0
in O 0
the O 0
differential O 0
diagnosis O 0
of O 0
chronic B-Disease 0
myelopathy I-Disease 0
. O 0
. O 0

A O 0
transgene O 0
insertion O 0
creating O 0
a O 0
heritable O 0
chromosome O 0
deletion O 0
mouse O 0
model O 0
of O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
and I-Disease 1
angelman I-Disease 1
syndromes I-Disease 1
. O 0

Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
and O 0
Angelman B-Disease 1
syndrome I-Disease 1
( O 0
AS B-Disease 0
) O 0
result O 0
from O 0
the O 0
loss O 0
of O 0
function O 0
of O 0
imprinted O 0
genes O 0
in O 0
human O 0
chromosome O 0
15q11 O 0
- O 0
q13 O 0
. O 0

The O 0
central O 0
part O 0
of O 0
mouse O 0
chromosome O 0
7 O 0
is O 0
homologous O 0
to O 0
human O 0
15q11 O 0
- O 0
q13 O 0
, O 0
with O 0
conservation O 0
of O 0
both O 0
gene O 0
order O 0
and O 0
imprinted O 0
features O 0
. O 0

We O 0
report O 0
here O 0
the O 0
characterization O 0
of O 0
a O 0
transgene O 0
insertion O 0
( O 0
Epstein O 1
- O 1
Barr O 1
virus O 1
Latent O 0
Membrane O 0
Protein O 0
2A O 0
, O 0
LMP2A O 0
) O 0
into O 0
mouse O 0
chromosome O 0
7C O 0
, O 0
which O 0
has O 0
resulted O 0
in O 0
mouse O 0
models O 0
for O 0
PWS B-Disease 0
and O 0
AS B-Disease 0
dependent O 0
on O 0
the O 0
sex O 0
of O 0
the O 0
transmitting O 0
parent O 0
. O 0

Epigenotype O 0
( O 0
allelic O 0
expression O 0
and O 0
DNA O 0
methylation O 0
) O 0
and O 0
fluorescence O 0
in O 0
situ O 0
hybridization O 0
analyses O 0
indicate O 0
that O 0
the O 0
transgene O 0
- O 0
induced O 0
mutation O 0
has O 0
generated O 0
a O 0
complete O 0
deletion O 0
of O 0
the O 0
PWS B-Disease 0
/ O 0
AS B-Disease 0
- O 0
homologous O 0
region O 0
but O 0
has O 0
not O 0
deleted O 0
flanking O 0
loci O 0
. O 0

Because O 0
the O 0
intact O 0
chromosome O 0
7 O 0
, O 0
opposite O 0
the O 0
deleted O 0
homolog O 0
, O 0
maintains O 0
the O 0
correct O 0
imprint O 0
in O 0
somatic O 0
cells O 0
of O 0
PWS B-Disease 0
and O 0
AS B-Disease 0
mice O 0
and O 0
establishes O 0
the O 0
correct O 0
imprint O 0
in O 0
male O 0
and O 0
female O 0
germ O 0
cells O 0
of O 0
AS B-Disease 0
mice O 0
, O 0
homologous O 0
association O 0
and O 0
replication O 0
asynchrony O 0
are O 0
not O 0
part O 0
of O 0
the O 0
imprinting O 0
mechanism O 0
. O 0

This O 0
heritable O 0
- O 0
deletion O 0
mouse O 0
model O 0
will O 0
be O 0
particularly O 0
useful O 0
for O 0
the O 0
identification O 0
of O 0
the O 0
etiological O 0
genes O 0
and O 0
mechanisms O 0
, O 0
phenotypic O 0
basis O 0
, O 0
and O 0
investigation O 0
of O 0
therapeutic O 0
approaches O 0
for O 0
PWS B-Disease 0
. O 0
. O 0

Linkage O 0
analysis O 0
of O 0
5 O 0
novel O 0
van B-Disease 1
der I-Disease 1
Woude I-Disease 1
syndrome I-Disease 1
kindreds O 0
to O 0
1q32 O 0
- O 0
q41 O 0
markers O 0
further O 0
supports O 0
locus O 0
homogeneity O 0
of O 0
the O 0
disease O 0
trait O 0
. O 0

van B-Disease 1
der I-Disease 1
Woude I-Disease 1
syndrome I-Disease 1
( O 0
vWS B-Disease 1
, O 0
MIM O 0
119300 O 0
) O 0
is O 0
a O 0
rare O 0
autosomal B-Disease 1
dominant I-Disease 1
clefting I-Disease 1
condition I-Disease 1
with O 0
cardinal O 0
features O 0
of O 0
mucous B-Disease 1
cysts I-Disease 1
( O 0
lower B-Disease 0
- I-Disease 0
lip I-Disease 0
pits I-Disease 0
) O 0
and O 0
clefts B-Disease 1
to I-Disease 1
the I-Disease 1
lip I-Disease 1
and I-Disease 1
/ I-Disease 1
or I-Disease 1
palate I-Disease 1
. O 0

The O 0
vWS B-Disease 1
gene O 0
has O 0
been O 0
assigned O 0
to O 0
a O 0
locus O 0
in O 0
1q32 O 0
- O 0
q41 O 0
by O 0
linkage O 0
analysis O 0
and O 0
physical O 0
mapping O 0
. O 0

We O 0
have O 0
investigated O 0
5 O 0
novel O 0
vWS B-Disease 1
families O 0
through O 0
probands O 0
attended O 0
for O 0
cleft B-Disease 1
lip I-Disease 1
and I-Disease 0
/ I-Disease 0
or I-Disease 0
palate I-Disease 0
repair O 0
at O 0
the O 0
Department O 0
of O 0
Maxillofacial O 0
Surgery O 0
of O 0
Hopital O 0
Trousseau O 0
, O 0
Paris O 0
, O 0
in O 0
order O 0
to O 0
tentatively O 0
refine O 0
the O 0
genetic O 0
map O 0
of O 0
the O 0
vWS B-Disease 1
region O 0
in O 0
1q32 O 0
- O 0
q41 O 0
and O 0
possibly O 0
identify O 0
unlinked O 0
pedigrees O 0
. O 0

Linkage O 0
analysis O 0
was O 0
carried O 0
out O 0
to O 0
6 O 0
microsatellite O 0
markers O 0
( O 0
D1S249 O 0
, O 0
D1S425 O 0
, O 0
D1S491 O 0
, O 0
D1S205 O 0
, O 0
D1S414 O 0
, O 0
D1S425 O 0
) O 0
, O 0
yielding O 0
a O 0
maximum O 0
cumulative O 0
LOD O 0
score O 0
of O 0
Z O 0
= O 0
3 O 0
. O 0

27 O 0
at O 0
theta O 0
= O 0
0 O 0
. O 0

00 O 0
for O 0
D1S245 O 0
. O 0

The O 0
innermost O 0
four O 0
markers O 0
were O 0
found O 0
to O 0
be O 0
tightly O 0
linked O 0
to O 0
one O 0
another O 0
, O 0
with O 0
no O 0
evidence O 0
for O 0
recombination O 0
. O 0

Our O 0
results O 0
support O 0
linkage O 0
of O 0
vWS B-Disease 1
within O 0
a O 0
region O 0
of O 0
tightly O 0
linked O 0
markers O 0
and O 0
do O 0
not O 0
favour O 0
locus O 0
heterogeneity O 0
of O 0
the O 0
disease O 0
trait O 0
. O 0

Null O 0
mutation O 0
of O 0
the O 0
murine O 0
ATP7B O 0
( O 0
Wilson B-Disease 0
disease I-Disease 0
) O 0
gene O 0
results O 0
in O 0
intracellular B-Disease 0
copper I-Disease 0
accumulation I-Disease 0
and O 0
late B-Disease 0
- I-Disease 0
onset I-Disease 0
hepatic I-Disease 0
nodular I-Disease 0
transformation I-Disease 0
. O 0

The O 0
Atp7b O 0
protein O 0
is O 0
a O 0
copper O 0
- O 0
transporting O 0
ATPase O 0
expressed O 0
predominantly O 0
in O 0
the O 0
liver O 0
and O 0
to O 0
a O 0
lesser O 0
extent O 0
in O 0
most O 0
other O 0
tissues O 0
. O 0

Mutations O 0
in O 0
the O 0
ATP7B O 0
gene O 0
lead O 0
to O 0
Wilson B-Disease 0
disease I-Disease 0
, O 0
a O 0
copper B-Disease 1
toxicity I-Disease 1
disorder I-Disease 1
characterized O 0
by O 0
dramatic O 0
build O 0
- O 0
up O 0
of O 0
intracellular O 0
hepatic O 0
copper O 0
with O 0
subsequent O 0
hepatic B-Disease 0
and I-Disease 0
neuro I-Disease 0
- I-Disease 0
logical I-Disease 0
abnormalities I-Disease 0
. O 0

Using O 0
homologous O 0
recombination O 0
to O 0
disrupt O 0
the O 0
normal O 0
translation O 0
of O 0
ATP7B O 0
, O 0
we O 0
have O 0
generated O 0
a O 0
strain O 0
of O 0
mice O 0
that O 0
are O 0
homozygous O 0
mutants O 0
( O 0
null O 0
) O 0
for O 0
the O 0
Wilson B-Disease 0
disease I-Disease 0
gene O 0
. O 0

The O 0
ATP7B O 0
null O 0
mice O 0
display O 0
a O 0
gradual O 0
accumulation O 0
of O 0
hepatic O 0
copper O 0
that O 0
increases O 0
to O 0
a O 0
level O 0
60 O 0
- O 0
fold O 0
greater O 0
than O 0
normal O 0
by O 0
5 O 0
months O 0
of O 0
age O 0
. O 0

An O 0
increase O 0
in O 0
copper O 0
concentration O 0
was O 0
also O 0
observed O 0
in O 0
the O 0
kidney O 0
, O 0
brain O 0
, O 0
placenta O 0
and O 0
lactating O 0
mammary O 0
glands O 0
of O 0
homo O 0
- O 0
zygous O 0
mutants O 0
, O 0
although O 0
milk O 0
from O 0
the O 0
mutant O 0
glands O 0
was O 0
copper B-Disease 0
deficient I-Disease 0
. O 0

Morphological B-Disease 1
abnormalities I-Disease 1
resembling O 0
cirrhosis B-Disease 1
developed O 0
in O 0
the O 0
majority O 0
of O 0
the O 0
livers O 0
from O 0
homozygous O 0
mutants O 0
older O 0
than O 0
7 O 0
months O 0
of O 0
age O 0
. O 0

Progeny O 0
of O 0
the O 0
homozygous O 0
mutant O 0
females O 0
demonstrated O 0
neurological B-Disease 0
abnormalities I-Disease 0
and O 0
growth B-Disease 0
retardation I-Disease 0
characteristic O 0
of O 0
copper B-Disease 0
deficiency I-Disease 0
. O 0

Copper O 0
concentration O 0
in O 0
the O 0
livers O 0
of O 0
the O 0
newborn O 0
homozygous O 0
null O 0
mutants O 0
was O 0
decreased O 0
dramatically O 0
. O 0

In O 0
summary O 0
, O 0
inactivation O 0
of O 0
the O 0
murine O 0
ATP7B O 0
gene O 0
produces O 0
a O 0
form O 0
of O 0
cirrhotic B-Disease 1
liver I-Disease 1
disease I-Disease 1
that O 0
resembles O 0
Wilson B-Disease 0
disease I-Disease 0
in O 0
humans O 0
and O 0
the O 0
toxic O 0
milk O 0
phenotype O 0
in O 0
the O 0
mouse O 0
. O 0
. O 0

French O 0
Machado B-Disease 0
- I-Disease 0
Joseph I-Disease 0
disease I-Disease 0
patients O 0
do O 0
not O 0
exhibit O 0
gametic O 0
segregation O 0
distortion O 0
: O 0
a O 0
sperm O 0
typing O 0
analysis O 0
. O 0

Segregation O 0
distortion O 0
has O 0
been O 0
reported O 0
to O 0
occur O 0
in O 0
a O 0
number O 0
of O 0
the O 0
trinucleotide B-Disease 1
repeat I-Disease 1
disorders I-Disease 1
. O 0

On O 0
the O 0
basis O 0
of O 0
a O 0
sperm O 0
typing O 0
study O 0
performed O 0
in O 0
patients O 0
of O 0
Japanese O 0
descent O 0
with O 0
Machado B-Disease 0
- I-Disease 0
Joseph I-Disease 0
disease I-Disease 0
( O 0
MJD B-Disease 0
) O 0
, O 0
it O 0
was O 0
reported O 0
that O 0
disease O 0
alleles O 0
are O 0
preferentially O 0
transmitted O 0
during O 0
meiosis O 0
. O 0

We O 0
performed O 0
a O 0
sperm O 0
typing O 0
study O 0
of O 0
five O 0
MJD B-Disease 0
patients O 0
of O 0
French O 0
descent O 0
and O 0
analysis O 0
of O 0
the O 0
pooled O 0
data O 0
shows O 0
a O 0
ratio O 0
of O 0
mutant O 0
to O 0
normal O 0
alleles O 0
of O 0
379 O 0
436 O 0
( O 0
46 O 0
. O 0
5 O 0
53 O 0
. O 0
5 O 0
% O 0
) O 0
, O 0
which O 0
does O 0
not O 0
support O 0
meiotic O 0
segregation O 0
distortion O 0
. O 0

To O 0
confirm O 0
these O 0
results O 0
, O 0
sperm O 0
typing O 0
analysis O 0
was O 0
also O 0
performed O 0
using O 0
a O 0
polymorphic O 0
marker O 0
, O 0
D14S1050 O 0
, O 0
closely O 0
linked O 0
to O 0
the O 0
MJD1 O 0
gene O 0
. O 0

Among O 0
910 O 0
sperm O 0
analyzed O 0
, O 0
the O 0
allele O 0
linked O 0
to O 0
the O 0
disease O 0
chromosome O 0
was O 0
detected O 0
in O 0
50 O 0
. O 0

3 O 0
% O 0
of O 0
the O 0
samples O 0
and O 0
the O 0
allele O 0
linked O 0
to O 0
the O 0
normal O 0
chromosome O 0
was O 0
found O 0
in O 0
49 O 0
. O 0

6 O 0
% O 0
of O 0
the O 0
sperm O 0
. O 0

The O 0
difference O 0
in O 0
frequency O 0
of O 0
these O 0
two O 0
alleles O 0
is O 0
not O 0
significant O 0
( O 0
P O 0
= O 0
0 O 0
. O 0
8423 O 0
) O 0
. O 0

Likelihood O 0
- O 0
based O 0
analysis O 0
of O 0
segregation O 0
distortion O 0
in O 0
the O 0
single O 0
sperm O 0
data O 0
using O 0
the O 0
SPERMSEG O 0
program O 0
also O 0
showed O 0
no O 0
support O 0
for O 0
segregation O 0
distortion O 0
at O 0
the O 0
gamete O 0
level O 0
in O 0
this O 0
patient O 0
population O 0
. O 0

The O 0
previous O 0
report O 0
on O 0
the O 0
Japanese O 0
patients O 0
also O 0
suggested O 0
that O 0
disease O 0
allele O 0
stability O 0
may O 0
be O 0
influenced O 0
by O 0
a O 0
trans O 0
effect O 0
of O 0
an O 0
intragenic O 0
polymorphism O 0
( O 0
987 O 0
G O 0
/ O 0
C O 0
) O 0
in O 0
the O 0
wild O 0
- O 0
type O 0
allele O 0
. O 0

All O 0
of O 0
the O 0
French O 0
patients O 0
were O 0
heterozygous O 0
for O 0
this O 0
polymorphism O 0
. O 0

However O 0
, O 0
analysis O 0
of O 0
the O 0
variance O 0
in O 0
repeat O 0
number O 0
in O 0
sperm O 0
from O 0
the O 0
French O 0
MJD B-Disease 0
patients O 0
overlapped O 0
significantly O 0
with O 0
the O 0
variance O 0
in O 0
repeat O 0
number O 0
observed O 0
in O 0
the O 0
C O 0
/ O 0
C O 0
homozygous O 0
Japanese O 0
patients O 0
. O 0

Missense O 0
mutation O 0
in O 0
the O 0
alternative O 0
splice O 0
region O 0
of O 0
the O 0
PAX6 O 0
gene O 0
in O 0
eye B-Disease 0
anomalies I-Disease 0
. O 0

The O 0
PAX6 O 0
gene O 0
is O 0
involved O 0
in O 0
ocular O 0
morphogenesis O 0
, O 0
and O 0
PAX6 O 0
mutations O 0
have O 0
been O 0
detected O 0
in O 0
various O 0
types O 0
of O 0
ocular B-Disease 0
anomalies I-Disease 0
, O 0
including O 0
aniridia B-Disease 0
, O 0
Peters B-Disease 1
anomaly I-Disease 1
, O 0
corneal B-Disease 0
dystrophy I-Disease 0
, O 0
congenital B-Disease 1
cataract I-Disease 1
, O 0
and O 0
foveal B-Disease 0
hypoplasia I-Disease 0
. O 0

The O 0
gene O 0
encodes O 0
a O 0
transcriptional O 0
regulator O 0
that O 0
recognizes O 0
target O 0
genes O 0
through O 0
its O 0
paired O 0
- O 0
type O 0
DNA O 0
- O 0
binding O 0
domain O 0
. O 0

The O 0
paired O 0
domain O 0
is O 0
composed O 0
of O 0
two O 0
distinct O 0
DNA O 0
- O 0
binding O 0
subdomains O 0
, O 0
the O 0
N O 0
- O 0
terminal O 0
subdomain O 0
( O 0
NTS O 0
) O 0
and O 0
the O 0
C O 0
- O 0
terminal O 0
subdomain O 0
( O 0
CTS O 0
) O 0
, O 0
which O 0
bind O 0
respective O 0
consensus O 0
DNA O 0
sequences O 0
. O 0

The O 0
human O 0
PAX6 O 0
gene O 0
produces O 0
two O 0
alternative O 0
splice O 0
isoforms O 0
that O 0
have O 0
the O 0
distinct O 0
structure O 0
of O 0
the O 0
paired O 0
domain O 0
. O 0

The O 0
insertion O 0
, O 0
into O 0
the O 0
NTS O 0
, O 0
of O 0
14 O 0
additional O 0
amino O 0
acids O 0
encoded O 0
by O 0
exon O 0
5a O 0
abolishes O 0
the O 0
DNA O 0
- O 0
binding O 0
activity O 0
of O 0
the O 0
NTS O 0
and O 0
unmasks O 0
the O 0
DNA O 0
- O 0
binding O 0
ability O 0
of O 0
the O 0
CTS O 0
. O 0

Thus O 0
, O 0
exon O 0
5a O 0
appears O 0
to O 0
function O 0
as O 0
a O 0
molecular O 0
switch O 0
that O 0
specifies O 0
target O 0
genes O 0
. O 0

We O 0
ascertained O 0
a O 0
novel O 0
missense O 0
mutation O 0
in O 0
four O 0
pedigrees O 0
with O 0
Peters B-Disease 1
anomaly I-Disease 1
, O 0
congenital B-Disease 1
cataract I-Disease 1
, O 0
Axenfeldt B-Disease 1
anomaly I-Disease 1
, O 0
and O 0
/ O 0
or O 0
foveal B-Disease 0
hypoplasia I-Disease 0
, O 0
which O 0
, O 0
to O 0
our O 0
knowledge O 0
, O 0
is O 0
the O 0
first O 0
mutation O 0
identified O 0
in O 0
the O 0
splice O 0
- O 0
variant O 0
region O 0
. O 0

A O 0
T O 0
- O 0
- O 0
> O 0
A O 0
transition O 0
at O 0
the O 0
20th O 0
nucleotide O 0
position O 0
of O 0
exon O 0
5a O 0
results O 0
in O 0
a O 0
Val O 0
- O 0
- O 0
> O 0
Asp O 0
( O 0
GTC O 0
- O 0
- O 0
> O 0
GAC O 0
) O 0
substitution O 0
at O 0
the O 0
7th O 0
codon O 0
of O 0
the O 0
alternative O 0
splice O 0
region O 0
. O 0

Functional O 0
analyses O 0
demonstrated O 0
that O 0
the O 0
V54D O 0
mutation O 0
slightly O 0
increased O 0
NTS O 0
binding O 0
and O 0
decreased O 0
CTS O 0
transactivation O 0
activity O 0
to O 0
almost O 0
half O 0
. O 0
. O 0

Penetrances O 0
of O 0
BRCA1 O 0
1675delA O 0
and O 0
1135insA O 0
with O 0
respect O 0
to O 0
breast B-Disease 0
cancer I-Disease 1
and O 0
ovarian B-Disease 0
cancer I-Disease 1
. O 0

For O 0
genetic O 0
counseling O 0
and O 0
predictive O 0
testing O 0
in O 0
families O 0
with O 0
inherited B-Disease 0
breast I-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
, O 0
penetrances O 0
and O 0
expressions O 0
of O 0
the O 0
underlying O 0
mutations O 0
should O 0
be O 0
known O 0
. O 0

We O 0
have O 0
previously O 0
reported O 0
two O 0
BRCA1 O 0
founder O 0
mutations O 0
in O 0
the O 0
Norwegian O 0
population O 0
. O 0

Index O 0
cases O 0
for O 0
the O 0
present O 0
study O 0
were O 0
found O 0
two O 0
different O 0
ways O 0
through O 0
a O 0
series O 0
of O 0
consecutive O 0
ovarian B-Disease 1
cancers I-Disease 1
( O 0
n O 0
= O 0
16 O 0
) O 0
and O 0
through O 0
our O 0
family O 0
cancer B-Disease 1
clinic O 0
( O 0
n O 0
= O 0
14 O 0
) O 0
. O 0

Altogether O 0
, O 0
20 O 0
of O 0
the O 0
patients O 0
had O 0
BRCA1 O 0
1675delA O 0
, O 0
and O 0
10 O 0
had O 0
1135insA O 0
. O 0

Their O 0
relatives O 0
were O 0
described O 0
with O 0
respect O 0
to O 0
absence O 0
/ O 0
presence O 0
of O 0
breast B-Disease 1
and I-Disease 1
/ I-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
. O 0

Of O 0
133 O 0
living O 0
female O 0
relatives O 0
, O 0
83 O 0
( O 0
62 O 0
% O 0
) O 0
were O 0
tested O 0
for O 0
the O 0
presence O 0
of O 0
a O 0
mutation O 0
. O 0

No O 0
difference O 0
, O 0
in O 0
penetrance O 0
and O 0
expression O 0
, O 0
between O 0
the O 0
two O 0
mutations O 0
were O 0
found O 0
, O 0
whereas O 0
differences O 0
according O 0
to O 0
method O 0
of O 0
ascertainment O 0
were O 0
seen O 0
. O 0

The O 0
overall O 0
findings O 0
were O 0
that O 0
disease O 0
started O 0
to O 0
occur O 0
at O 0
age O 0
30 O 0
years O 0
and O 0
that O 0
by O 0
age O 0
50 O 0
years O 0
48 O 0
% O 0
of O 0
the O 0
mutation O 0
- O 0
carrying O 0
women O 0
had O 0
experienced O 0
breast B-Disease 1
and I-Disease 1
/ I-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
. O 0

More O 0
ovarian B-Disease 1
cancers I-Disease 1
than O 0
breast B-Disease 0
cancers I-Disease 0
were O 0
recorded O 0
. O 0

Both O 0
penetrance O 0
and O 0
expression O 0
( O 0
breast B-Disease 0
cancer I-Disease 1
vs O 0
. O 0
ovarian B-Disease 0
cancer I-Disease 1
) O 0
were O 0
different O 0
from O 0
those O 0
in O 0
reports O 0
of O 0
the O 0
Ashkenazi O 0
founder O 0
mutations O 0
. O 0

Whether O 0
the O 0
reported O 0
differences O 0
reflect O 0
true O 0
differences O 0
and O 0
/ O 0
or O 0
methodological O 0
problems O 0
is O 0
discussed O 0
. O 0

An O 0
observed O 0
excess O 0
of O 0
mutation O 0
carriers O 0
could O 0
not O 0
be O 0
accounted O 0
for O 0
by O 0
methodological O 0
problems O 0
; O 0
possible O 0
explanations O 0
were O 0
a O 0
" O 0
true O 0
" O 0
low O 0
penetrance O 0
or O 0
preferential O 0
segregation O 0
. O 0
. O 0

The O 0
dermatofibrosarcoma B-Disease 1
protuberans I-Disease 1
- O 0
associated O 0
collagen O 0
type O 0
Ialpha1 O 0
/ O 0
platelet O 0
- O 0
derived O 0
growth O 0
factor O 0
( O 0
PDGF O 0
) O 0
B O 0
- O 0
chain O 0
fusion O 0
gene O 0
generates O 0
a O 0
transforming O 0
protein O 0
that O 0
is O 0
processed O 0
to O 0
functional O 0
PDGF O 0
- O 0
BB O 0
. O 0

Dermatofibrosarcoma B-Disease 0
protuberans I-Disease 0
( O 0
DFSP B-Disease 0
) O 0
displays O 0
chromosomal O 0
rearrangements O 0
involving O 0
chromosome O 0
17 O 0
and O 0
22 O 0
, O 0
which O 0
fuse O 0
the O 0
collagen O 0
type O 0
Ialpha1 O 0
( O 0
COLIA1 O 0
) O 0
gene O 0
to O 0
the O 0
platelet O 0
- O 0
derived O 0
growth O 0
factor O 0
( O 0
PDGF O 0
) O 0
B O 0
- O 0
chain O 0
( O 0
PDGFB O 0
) O 0
gene O 0
. O 0

To O 0
characterize O 0
the O 0
functional O 0
and O 0
structural O 0
properties O 0
of O 0
the O 0
COLIA1 O 0
/ O 0
PDGFB O 0
fusion O 0
protein O 0
, O 0
we O 0
generated O 0
a O 0
stable O 0
NIH3T3 O 0
cell O 0
line O 0
that O 0
contained O 0
a O 0
tumor O 0
- O 0
derived O 0
chimeric O 0
gene O 0
resulting O 0
from O 0
a O 0
COIA1 O 0
intron O 0
7 O 0
- O 0
PDGFB O 0
intron O 0
1 O 0
fusion O 0
. O 0

Expression O 0
of O 0
the O 0
fusion O 0
protein O 0
led O 0
to O 0
morphological O 0
transformation O 0
and O 0
increased O 0
growth O 0
rate O 0
of O 0
these O 0
cells O 0
. O 0

The O 0
PDGF O 0
receptor O 0
kinase O 0
inhibitor O 0
CGP57148B O 0
reversed O 0
the O 0
transformed O 0
phenotype O 0
and O 0
reduced O 0
the O 0
growth O 0
rate O 0
of O 0
COLIA1 O 0
/ O 0
PDGFB O 0
- O 0
expressing O 0
cells O 0
but O 0
had O 0
no O 0
effects O 0
on O 0
control O 0
cells O 0
. O 0

The O 0
presence O 0
of O 0
dimeric O 0
COLIA1 O 0
/ O 0
PDGFB O 0
precursors O 0
was O 0
demonstrated O 0
through O 0
PDGFB O 0
immunoprecipitations O 0
of O 0
metabolically O 0
labeled O 0
cells O 0
and O 0
also O 0
by O 0
PDGFB O 0
immunoprecipitations O 0
followed O 0
by O 0
immunoblotting O 0
with O 0
COLIA1 O 0
antibodies O 0
. O 0

Pulse O 0
- O 0
chase O 0
studies O 0
demonstrated O 0
that O 0
the O 0
COLIA1 O 0
/ O 0
PDGFB O 0
precursor O 0
was O 0
processed O 0
to O 0
an O 0
end O 0
product O 0
that O 0
was O 0
indistinguishable O 0
from O 0
wild O 0
- O 0
type O 0
PDGF O 0
- O 0
BB O 0
. O 0

Finally O 0
, O 0
COLIA1 O 0
/ O 0
PDGFB O 0
- O 0
expressing O 0
cells O 0
generated O 0
tumors B-Disease 0
after O 0
s O 0
. O 0

c O 0
c O 0
. O 0
injection O 0
into O 0
nude O 0
mice O 0
, O 0
and O 0
tumor B-Disease 0
growth O 0
was O 0
reduced O 0
by O 0
treatment O 0
with O 0
CGP57148B O 0
. O 0

We O 0
conclude O 0
that O 0
the O 0
COLIA1 O 0
/ O 0
PDGFB O 0
fusion O 0
associated O 0
with O 0
DFSP B-Disease 0
contributes O 0
to O 0
tumor B-Disease 0
development O 0
through O 0
ectopic O 0
production O 0
of O 0
PDGF O 0
- O 0
BB O 0
and O 0
the O 0
formation O 0
of O 0
an O 0
autocrine O 0
loop O 0
. O 0

Our O 0
findings O 0
, O 0
thus O 0
, O 0
suggest O 0
that O 0
PDGF O 0
receptors O 0
could O 0
be O 0
a O 0
target O 0
for O 0
pharmacological O 0
treatment O 0
of O 0
DFSP B-Disease 0
and O 0
giant B-Disease 1
cell I-Disease 1
fibroblastoma I-Disease 1
, O 0
e O 0
. O 0
g O 0
. O 0
, O 0
through O 0
the O 0
use O 0
of O 0
PDGF O 0
receptor O 0
kinase O 0
inhibitors O 0
such O 0
as O 0
CGP57148B O 0
. O 0

Identification O 0
of O 0
a O 0
common O 0
PEX1 O 0
mutation O 0
in O 0
Zellweger B-Disease 1
syndrome I-Disease 1
. O 0

The O 0
Zellweger B-Disease 0
spectrum I-Disease 0
of I-Disease 0
disease I-Disease 0
, O 0
encompassing O 0
Zellweger B-Disease 1
syndrome I-Disease 1
and O 0
the O 0
progressively O 0
milder O 0
phenotypes O 0
of O 0
neonatal B-Disease 1
adrenoleukodystrophy I-Disease 1
and O 0
infantile B-Disease 0
Refsum I-Disease 0
disease I-Disease 0
, O 0
is O 0
due O 0
to O 0
a O 0
failure O 0
to O 0
form O 0
functional O 0
peroxisomes O 0
. O 0

Cell O 0
fusion O 0
complementation O 0
studies O 0
demonstrated O 0
that O 0
these O 0
diseases O 0
are O 0
genetically O 0
heterogeneous O 0
, O 0
with O 0
two O 0
- O 0
thirds O 0
of O 0
all O 0
patients O 0
lying O 0
within O 0
a O 0
single O 0
complementation O 0
group O 0
, O 0
CG1 O 0
. O 0

Molecular O 0
genetic O 0
and O 0
cell O 0
biology O 0
studies O 0
have O 0
shown O 0
that O 0
PEX1 O 0
is O 0
deficient O 0
in O 0
many O 0
CG1 O 0
patients O 0
. O 0

However O 0
, O 0
previous O 0
studies O 0
have O 0
focused O 0
on O 0
mildly O 0
affected O 0
patients O 0
and O 0
there O 0
is O 0
still O 0
no O 0
report O 0
of O 0
two O 0
mutant O 0
PEX1 O 0
alleles O 0
in O 0
any O 0
Zellweger B-Disease 1
syndrome I-Disease 1
patient O 0
. O 0

Furthermore O 0
, O 0
mutations O 0
in O 0
the O 0
PMP70 O 0
gene O 0
have O 0
also O 0
been O 0
identified O 0
in O 0
two O 0
Zellweger B-Disease 1
syndrome I-Disease 1
patients O 0
from O 0
CG1 O 0
, O 0
raising O 0
the O 0
possibility O 0
that O 0
CG1 O 0
patients O 0
may O 0
represent O 0
a O 0
mixture O 0
of O 0
PEX1 O 0
- O 0
deficient O 0
and O 0
PMP70 O 0
- O 0
deficient O 0
individuals O 0
. O 0

To O 0
address O 0
the O 0
molecular O 0
basis O 0
of O 0
disease O 0
in O 0
Zellweger B-Disease 1
syndrome I-Disease 1
patients O 0
from O 0
CG1 O 0
, O 0
we O 0
examined O 0
all O 0
24 O 0
PEX1 O 0
exons O 0
in O 0
four O 0
patients O 0
, O 0
including O 0
both O 0
patients O 0
that O 0
have O 0
mutations O 0
in O 0
PMP70 O 0
. O 0

PEX1 O 0
mutations O 0
were O 0
detected O 0
in O 0
all O 0
four O 0
patients O 0
, O 0
including O 0
a O 0
1 O 0
- O 0
bp O 0
insertion O 0
( O 0
c O 0
. O 0
2097insT O 0
) O 0
in O 0
exon O 0
13 O 0
that O 0
was O 0
present O 0
in O 0
three O 0
of O 0
the O 0
four O 0
patients O 0
. O 0

Subsequent O 0
studies O 0
demonstrated O 0
that O 0
this O 0
mutation O 0
is O 0
present O 0
in O 0
one O 0
- O 0
half O 0
of O 0
all O 0
CG1 O 0
patients O 0
and O 0
correlates O 0
with O 0
the O 0
Zellweger B-Disease 1
syndrome I-Disease 1
phenotype O 0
. O 0

As O 0
this O 0
mutation O 0
leads O 0
to O 0
a O 0
loss O 0
of O 0
protein O 0
function O 0
its O 0
frequency O 0
makes O 0
it O 0
the O 0
most O 0
common O 0
cause O 0
of O 0
Zellweger B-Disease 1
syndrome I-Disease 1
, O 0
helping O 0
to O 0
explain O 0
the O 0
high O 0
percentage O 0
of O 0
patients O 0
that O 0
belong O 0
to O 0
CG1 O 0
. O 0

Novel O 0
mutations O 0
in O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
protein O 0
gene O 0
and O 0
their O 0
effects O 0
on O 0
transcriptional O 0
, O 0
translational O 0
, O 0
and O 0
clinical O 0
phenotypes O 0
. O 0

Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
( O 0
WAS B-Disease 0
) O 0
is O 0
an O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
recessive I-Disease 1
immunodeficiency I-Disease 1
characterized O 0
by O 0
thrombocytopenia B-Disease 0
, O 0
eczema B-Disease 0
, O 0
and O 0
recurrent O 0
infections O 0
, O 0
and O 0
caused O 0
by O 0
mutations O 0
in O 0
the O 0
WAS B-Disease 0
protein O 0
( O 0
WASP O 0
) O 0
gene O 0
. O 0

WASP O 0
contains O 0
several O 0
functional O 0
domains O 0
through O 0
which O 0
it O 0
interacts O 0
with O 0
proteins O 0
involved O 0
in O 0
intracellular O 0
signaling O 0
and O 0
regulation O 0
of O 0
the O 0
actin O 0
cytoskeleton O 0
. O 0

In O 0
this O 0
report O 0
, O 0
17 O 0
WASP O 0
gene O 0
mutations O 0
were O 0
identified O 0
, O 0
12 O 0
of O 0
which O 0
are O 0
novel O 0
. O 0

DNA O 0
of O 0
affected O 0
males O 0
and O 0
obligate O 0
carriers O 0
was O 0
PCR O 0
amplified O 0
and O 0
analyzed O 0
by O 0
SSCA O 0
, O 0
heteroduplex O 0
analysis O 0
, O 0
and O 0
direct O 0
sequencing O 0
. O 0

The O 0
effects O 0
of O 0
the O 0
mutations O 0
at O 0
the O 0
mRNA O 0
and O 0
protein O 0
level O 0
were O 0
ascertained O 0
by O 0
RT O 0
- O 0
PCR O 0
and O 0
Western O 0
blot O 0
analyses O 0
. O 0

All O 0
missense O 0
mutations O 0
were O 0
located O 0
in O 0
exons O 0
1 O 0
- O 0
4 O 0
. O 0

Most O 0
of O 0
the O 0
nonsense O 0
, O 0
frameshift O 0
and O 0
splice O 0
site O 0
mutations O 0
were O 0
found O 0
in O 0
exons O 0
6 O 0
- O 0
11 O 0
. O 0

Mutations O 0
that O 0
alter O 0
splice O 0
sites O 0
led O 0
to O 0
the O 0
synthesis O 0
of O 0
several O 0
types O 0
of O 0
mRNAs O 0
, O 0
a O 0
fraction O 0
of O 0
which O 0
represented O 0
the O 0
normally O 0
spliced O 0
product O 0
. O 0

The O 0
presence O 0
of O 0
normally O 0
spliced O 0
transcripts O 0
was O 0
correlated O 0
with O 0
a O 0
milder O 0
phenotype O 0
. O 0

When O 0
one O 0
such O 0
case O 0
was O 0
studied O 0
by O 0
Western O 0
blotting O 0
, O 0
reduced O 0
amounts O 0
of O 0
normal O 0
- O 0
size O 0
WASP O 0
were O 0
present O 0
. O 0

In O 0
other O 0
cases O 0
as O 0
well O 0
, O 0
a O 0
correlation O 0
was O 0
found O 0
between O 0
the O 0
amount O 0
of O 0
normal O 0
or O 0
mutant O 0
WASP O 0
present O 0
and O 0
the O 0
phenotypes O 0
of O 0
the O 0
affected O 0
individuals O 0
. O 0

No O 0
protein O 0
was O 0
detected O 0
in O 0
two O 0
individuals O 0
with O 0
severe O 0
WAS B-Disease 0
. O 0

Reduced O 0
levels O 0
of O 0
a O 0
normal O 0
- O 0
size O 0
WASP O 0
with O 0
a O 0
missense O 0
mutation O 0
were O 0
seen O 0
in O 0
two O 0
individuals O 0
with O 0
XLT B-Disease 1
. O 0

It O 0
is O 0
concluded O 0
that O 0
mutation O 0
analysis O 0
at O 0
the O 0
DNA O 0
level O 0
is O 0
not O 0
sufficient O 0
for O 0
predicting O 0
clinical O 0
course O 0
. O 0

Studies O 0
at O 0
the O 0
transcript O 0
and O 0
protein O 0
level O 0
are O 0
needed O 0
for O 0
a O 0
better O 0
assessment O 0
. O 0
. O 0

Aminoglycoside O 0
antibiotics O 0
restore O 0
dystrophin O 0
function O 0
to O 0
skeletal O 0
muscles O 0
of O 0
mdx O 0
mice O 0
. O 0

Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
is O 0
caused O 0
by O 0
mutations O 0
in O 0
the O 0
dystrophin O 0
gene O 0
, O 0
leading O 0
to O 0
the O 0
absence O 0
of O 0
the O 0
dystrophin O 0
protein O 0
in O 0
striated O 0
muscle O 0
. O 0

A O 0
significant O 0
number O 0
of O 0
these O 0
mutations O 0
are O 0
premature O 0
stop O 0
codons O 0
. O 0

On O 0
the O 0
basis O 0
of O 0
the O 0
observation O 0
that O 0
aminoglycoside O 0
treatment O 0
can O 0
suppress O 0
stop O 0
codons O 0
in O 0
cultured O 0
cells O 0
, O 0
we O 0
tested O 0
the O 0
effect O 0
of O 0
gentamicin O 0
on O 0
cultured O 0
muscle O 0
cells O 0
from O 0
the O 0
mdx O 0
mouse O 0
- O 0
an O 0
animal O 0
model O 0
for O 0
DMD B-Disease 0
that O 0
possesses O 0
a O 0
premature O 0
stop O 0
codon O 0
in O 0
the O 0
dystrophin O 0
gene O 0
. O 0

Exposure O 0
of O 0
mdx O 0
myotubes O 0
to O 0
gentamicin O 0
led O 0
to O 0
the O 0
expression O 0
and O 0
localization O 0
of O 0
dystrophin O 0
to O 0
the O 0
cell O 0
membrane O 0
. O 0

We O 0
then O 0
evaluated O 0
the O 0
effects O 0
of O 0
differing O 0
dosages O 0
of O 0
gentamicin O 0
on O 0
expression O 0
and O 0
functional O 0
protection O 0
of O 0
the O 0
muscles O 0
of O 0
mdx O 0
mice O 0
. O 0

We O 0
identified O 0
a O 0
treatment O 0
regimen O 0
that O 0
resulted O 0
in O 0
the O 0
presence O 0
of O 0
dystrophin O 0
in O 0
the O 0
cell O 0
membrane O 0
in O 0
all O 0
striated O 0
muscles O 0
examined O 0
and O 0
that O 0
provided O 0
functional O 0
protection O 0
against O 0
muscular B-Disease 1
injury I-Disease 1
. O 0

To O 0
our O 0
knowledge O 0
, O 0
our O 0
results O 0
are O 0
the O 0
first O 0
to O 0
demonstrate O 0
that O 0
aminoglycosides O 0
can O 0
suppress O 0
stop O 0
codons O 0
not O 0
only O 0
in O 0
vitro O 0
but O 0
also O 0
in O 0
vivo O 0
. O 0

Furthermore O 0
, O 0
these O 0
results O 0
raise O 0
the O 0
possibility O 0
of O 0
a O 0
novel O 0
treatment O 0
regimen O 0
for O 0
muscular B-Disease 0
dystrophy I-Disease 0
and O 0
other O 0
diseases O 0
caused O 0
by O 0
premature O 0
stop O 0
codon O 0
mutations O 0
. O 0

This O 0
treatment O 0
could O 0
prove O 0
effective O 0
in O 0
up O 0
to O 0
15 O 0
% O 0
of O 0
patients O 0
with O 0
DMD B-Disease 0
. O 0
. O 0

Loss O 0
of O 0
the O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
gene O 0
product O 0
causes O 0
oxidative O 0
damage O 0
in O 0
target O 0
organs O 0
. O 0

Ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
( O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
) O 0
is O 0
characterized O 0
by O 0
a O 0
markedly O 0
increased O 0
sensitivity O 0
to O 0
ionizing O 0
radiation O 0
, O 0
increased O 0
incidence O 0
of O 0
cancer B-Disease 1
, O 0
and O 0
neurodegeneration B-Disease 1
, O 0
especially O 0
of O 0
the O 0
cerebellar O 0
Purkinje O 0
cells O 0
. O 0

Ionizing O 0
radiation O 0
oxidizes O 0
macromolecules O 0
and O 0
causes O 0
tissue O 0
damage O 0
through O 0
the O 0
generation O 0
of O 0
reactive O 0
oxygen O 0
species O 0
( O 0
ROS O 0
) O 0
. O 0

We O 0
therefore O 0
hypothesized O 0
that O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
is O 0
due O 0
to O 0
oxidative O 0
damage O 0
resulting O 0
from O 0
loss O 0
of O 0
function O 0
of O 0
the O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
gene O 0
product O 0
. O 0

To O 0
assess O 0
this O 0
hypothesis O 0
, O 0
we O 0
employed O 0
an O 0
animal O 0
model O 0
of O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
, O 0
the O 0
mouse O 0
with O 0
a O 0
disrupted O 0
Atm O 0
gene O 0
. O 0

We O 0
show O 0
that O 0
organs O 0
which O 0
develop O 0
pathologic O 0
changes O 0
in O 0
the O 0
Atm O 0
- O 0
deficient O 0
mice O 0
are O 0
targets O 0
of O 0
oxidative O 0
damage O 0
, O 0
and O 0
that O 0
cerebellar O 0
Purkinje O 0
cells O 0
are O 0
particularly O 0
affected O 0
. O 0

These O 0
observations O 0
provide O 0
a O 0
mechanistic O 0
basis O 0
for O 0
the O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
phenotype O 0
and O 0
lay O 0
a O 0
rational O 0
foundation O 0
for O 0
therapeutic O 0
intervention O 0
. O 0
. O 0

Recessively O 0
inherited O 0
multiple B-Disease 1
epiphyseal I-Disease 1
dysplasia I-Disease 1
with O 0
normal O 0
stature O 0
, O 0
club B-Disease 1
foot I-Disease 1
, O 0
and O 0
double B-Disease 0
layered I-Disease 0
patella I-Disease 0
caused O 0
by O 0
a O 0
DTDST O 0
mutation O 0
. O 0

We O 0
have O 0
observed O 0
over O 0
25 O 0
different O 0
mutations O 0
in O 0
the O 0
diastrophic B-Disease 1
dysplasia I-Disease 1
sulphate O 0
transporter O 0
gene O 0
( O 0
DTDST O 0
) O 0
in O 0
association O 0
with O 0
the O 0
recessive B-Disease 1
disorders I-Disease 1
achondrogenesis B-Disease 0
1B I-Disease 0
, O 0
atelosteogenesis B-Disease 1
2 I-Disease 1
, O 0
and O 0
diastrophic B-Disease 1
dysplasia I-Disease 1
. O 0

The O 0
c862t O 0
( O 0
R279W O 0
) O 0
transition O 0
is O 0
the O 0
most O 0
common O 0
mutation O 0
in O 0
non O 0
- O 0
Finnish O 0
patients O 0
, O 0
but O 0
in O 0
these O 0
disorders O 0
it O 0
is O 0
usually O 0
combined O 0
with O 0
other O 0
DTDST O 0
mutations O 0
. O 0

We O 0
had O 0
not O 0
seen O 0
a O 0
case O 0
of O 0
homozygosity O 0
for O 0
c862t O 0
( O 0
R279W O 0
) O 0
until O 0
we O 0
analysed O 0
DNA O 0
from O 0
a O 0
36 O 0
year O 0
old O 0
male O 0
with O 0
tall O 0
- O 0
normal O 0
stature O 0
( O 0
180 O 0
cm O 0
) O 0
who O 0
asked O 0
for O 0
genetic O 0
counselling O 0
for O 0
suspected O 0
multiple B-Disease 1
epiphyseal I-Disease 1
dysplasia I-Disease 1
. O 0

He O 0
was O 0
treated O 0
for O 0
club B-Disease 1
foot I-Disease 1
and O 0
hip B-Disease 1
dysplasia I-Disease 1
at O 0
birth O 0
. O 0

Skeletal O 0
changes O 0
consistent O 0
with O 0
multiple B-Disease 1
epiphyseal I-Disease 1
dysplasia I-Disease 1
, O 0
with O 0
the O 0
peculiar O 0
finding O 0
of O 0
a O 0
double B-Disease 0
layered I-Disease 0
patella I-Disease 0
, O 0
were O 0
recognised O 0
during O 0
childhood O 0
. O 0

Cleft B-Disease 0
palate I-Disease 0
, O 0
swelling B-Disease 0
of I-Disease 0
the I-Disease 0
ear I-Disease 0
pinna I-Disease 0
, O 0
and O 0
hitch B-Disease 0
hiker I-Disease 0
thumb I-Disease 0
were O 0
absent O 0
. O 0

He O 0
was O 0
found O 0
to O 0
be O 0
homozygous O 0
, O 0
and O 0
both O 0
healthy O 0
parents O 0
heterozygous O 0
, O 0
for O 0
the O 0
R279W O 0
mutation O 0
in O 0
DTDST O 0
, O 0
and O 0
his O 0
fibroblasts O 0
showed O 0
a O 0
sulphate O 0
incorporation O 0
defect O 0
typical O 0
of O 0
DTDST B-Disease 0
disorders I-Disease 0
. O 0

Counselling O 0
was O 0
given O 0
for O 0
a O 0
recessive B-Disease 0
disorder I-Disease 0
, O 0
thereby O 0
considerably O 0
reducing O 0
the O 0
probability O 0
of O 0
affected O 0
offspring O 0
. O 0

Multiple B-Disease 0
epiphyseal I-Disease 0
dysplasia I-Disease 0
is O 0
more O 0
frequently O 0
caused O 0
by O 0
dominant O 0
mutations O 0
in O 0
the O 0
COMP O 0
( O 0
EDM1 B-Disease 0
, O 0
McKusick O 0
132400 O 0
) O 0
and O 0
COL9A2 O 0
genes O 0
( O 0
EDM2 B-Disease 1
, O 0
McKusick O 0
600204 O 0
) O 0
. O 0

A O 0
few O 0
other O 0
patients O 0
and O 0
families O 0
with O 0
features O 0
similar O 0
to O 0
our O 0
proband O 0
have O 0
been O 0
described O 0
previously O 0
and O 0
considered O 0
to O 0
have O 0
autosomal O 0
recessive O 0
MED B-Disease 1
( O 0
EDM4 B-Disease 0
, O 0
McKusick O 0
226900 O 0
) O 0
. O 0

This O 0
observation O 0
confirms O 0
the O 0
existence O 0
of O 0
this O 0
entity O 0
and O 0
assigns O 0
it O 0
to O 0
the O 0
phenotypic O 0
spectrum O 0
associated O 0
with O 0
mutations O 0
at O 0
the O 0
DTDST O 0
locus O 0
. O 0
. O 0

Homozygosity O 0
for O 0
a O 0
novel O 0
DTDST O 0
mutation O 0
in O 0
a O 0
child O 0
with O 0
a O 0
' O 0
broad O 0
bone O 0
- O 0
platyspondylic O 0
' O 0
variant O 0
of O 0
diastrophic B-Disease 1
dysplasia I-Disease 1
. O 0

Atypical O 0
or O 0
variant O 0
forms O 0
of O 0
well O 0
- O 0
known O 0
chondrodysplasias B-Disease 0
may O 0
pose O 0
diagnostic O 0
problems O 0
. O 0

We O 0
report O 0
on O 0
a O 0
girl O 0
with O 0
clinical O 0
features O 0
suggesting O 0
diastrophic B-Disease 1
dysplasia I-Disease 1
but O 0
with O 0
unusual O 0
radiographic O 0
features O 0
including O 0
severe O 0
platyspondyly B-Disease 0
, O 0
wide O 0
metaphyses O 0
, O 0
and O 0
fibular O 0
overgrowth O 0
, O 0
which O 0
are O 0
partially O 0
reminiscent O 0
of O 0
metatropic B-Disease 0
dysplasia I-Disease 0
. O 0

The O 0
diagnosis O 0
was O 0
clarified O 0
by O 0
molecular O 0
analysis O 0
of O 0
the O 0
DTDST O 0
gene O 0
, O 0
which O 0
revealed O 0
homozygosity O 0
for O 0
a O 0
previously O 0
undescribed O 0
mutation O 0
leading O 0
to O 0
a O 0
Q454P O 0
substitution O 0
in O 0
the O 0
10th O 0
transmembrane O 0
domain O 0
of O 0
the O 0
DTDST O 0
sulfate O 0
transporter O 0
. O 0

Molecular O 0
analysis O 0
may O 0
be O 0
of O 0
particular O 0
value O 0
in O 0
such O 0
atypical O 0
cases O 0
. O 0
. O 0

The O 0
type O 0
of O 0
somatic O 0
mutation O 0
at O 0
APC O 1
in O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
is O 0
determined O 0
by O 0
the O 0
site O 0
of O 0
the O 0
germline O 0
mutation O 0
: O 0
a O 0
new O 0
facet O 0
to O 0
Knudson O 0
' O 0
s O 0
' O 0
two O 0
- O 0
hit O 0
' O 0
hypothesis O 0
. O 0

APC O 1
is O 0
often O 0
cited O 0
as O 0
a O 0
prime O 0
example O 0
of O 0
a O 0
tumor B-Disease 0
suppressor O 0
gene O 0
. O 0

Truncating O 0
germline O 0
and O 0
somatic O 0
mutations O 0
( O 0
or O 0
, O 0
infrequently O 0
, O 0
allelic O 0
loss O 0
) O 0
occur O 0
in O 0
tumors B-Disease 0
in O 0
FAP B-Disease 0
( O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
) O 0
. O 0

Most O 0
sporadic B-Disease 1
colorectal I-Disease 1
cancers I-Disease 1
also O 0
have O 0
two O 0
APC B-Disease 1
mutations O 0
. O 0

Clues O 0
from O 0
attenuated B-Disease 0
polyposis I-Disease 1
, O 0
missense O 0
germline O 0
variants O 0
with O 0
mild O 0
disease O 0
and O 0
the O 0
somatic O 0
mutation O 0
cluster O 0
region O 0
( O 0
codons O 0
1 O 0
, O 0
250 O 0
- O 0
1 O 0
, O 0
450 O 0
) O 0
indicate O 0
, O 0
however O 0
, O 0
that O 0
APC B-Disease 1
mutations O 0
might O 0
not O 0
result O 0
in O 0
simple O 0
loss O 0
of O 0
protein O 0
function O 0
. O 0

We O 0
have O 0
found O 0
that O 0
FAP B-Disease 0
patients O 0
with O 0
germline O 0
APC B-Disease 1
mutations O 0
within O 0
a O 0
small O 0
region O 0
( O 0
codons O 0
1 O 0
, O 0
194 O 0
- O 0
1 O 0
, O 0
392 O 0
at O 0
most O 0
) O 0
mainly O 0
show O 0
allelic O 0
loss O 0
in O 0
their O 0
colorectal B-Disease 1
adenomas I-Disease 1
, O 0
in O 0
contrast O 0
to O 0
other O 0
FAP B-Disease 0
patients O 0
, O 0
whose O 0
second O 0
hits O 0
tend O 0
to O 0
occur O 0
by O 0
truncating O 0
mutations O 0
in O 0
the O 0
mutation O 0
cluster O 0
region O 0
. O 0

Our O 0
results O 0
indicate O 0
that O 0
different O 0
APC B-Disease 1
mutations O 0
provide O 0
cells O 0
with O 0
different O 0
selective O 0
advantages O 0
, O 0
with O 0
mutations O 0
close O 0
to O 0
codon O 0
1 O 0
, O 0
300 O 0
providing O 0
the O 0
greatest O 0
advantage O 0
. O 0

Allelic O 0
loss O 0
is O 0
selected O 0
strongly O 0
in O 0
cells O 0
with O 0
one O 0
mutation O 0
near O 0
codon O 0
1 O 0
, O 0
300 O 0
. O 0

A O 0
different O 0
germline O 0
- O 0
somatic O 0
APC B-Disease 1
mutation O 0
association O 0
exists O 0
in O 0
FAP B-Disease 1
desmoids I-Disease 1
. O 0

APC O 1
is O 0
not O 0
, O 0
therefore O 0
, O 0
a O 0
classical O 0
tumor B-Disease 0
suppressor O 0
. O 0

Our O 0
findings O 0
also O 0
indicate O 0
a O 0
new O 0
mechanism O 0
for O 0
disease O 0
severity O 0
if O 0
a O 0
broader O 0
spectrum O 0
of O 0
mutations O 0
is O 0
selected O 0
in O 0
tumors B-Disease 0
, O 0
the O 0
somatic O 0
mutation O 0
rate O 0
is O 0
effectively O 0
higher O 0
and O 0
more O 0
tumors B-Disease 0
grow O 0
. O 0
. O 0

Mxi1 O 0
mutations O 0
in O 0
human O 0
neurofibrosarcomas B-Disease 1
. O 0

Mxi1 O 0
is O 0
thought O 0
to O 0
negatively O 0
regulate O 0
Myc O 0
function O 0
and O 0
may O 0
therefore O 0
be O 0
a O 0
potential O 0
tumor B-Disease 0
suppressor O 0
gene O 0
. O 0

Little O 0
effort O 0
has O 0
yet O 0
been O 0
made O 0
to O 0
find O 0
alterations O 0
involving O 0
this O 0
gene O 0
in O 0
human O 0
solid B-Disease 0
tumors I-Disease 0
. O 0

We O 0
screened O 0
31 O 0
human O 0
gastric B-Disease 0
cancers I-Disease 0
, O 0
7 O 0
esophageal B-Disease 0
cancers I-Disease 0
, O 0
85 O 0
bone B-Disease 1
and I-Disease 1
soft I-Disease 1
tissue I-Disease 1
tumors I-Disease 1
of O 0
various O 0
types O 0
, O 0
including O 0
4 O 0
neurofibrosarcomas B-Disease 1
. O 0

We O 0
also O 0
examined O 0
29 O 0
human O 0
tumor B-Disease 0
cell O 0
lines O 0
consisting O 0
of O 0
12 O 0
esophageal B-Disease 0
cancers I-Disease 0
, O 0
7 O 0
glioma B-Disease 0
/ O 0
glioblastomas B-Disease 1
and O 0
10 O 0
others O 0
for O 0
Mxi1 O 0
mutations O 0
in O 0
exons O 0
1 O 0
, O 0
2 O 0
, O 0
4 O 0
( O 0
HLH O 0
domain O 0
) O 0
, O 0
5 O 0
and O 0
6 O 0
. O 0

Polymerase O 0
chain O 0
reaction O 0
- O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphism O 0
( O 0
PCR O 0
- O 0
SSCP O 0
) O 0
and O 0
subsequent O 0
sequencing O 0
revealed O 0
three O 0
distinct O 0
polymorphisms O 0
in O 0
the O 0
intron O 0
- O 0
exon O 0
boundary O 0
upstream O 0
from O 0
exon O 0
6 O 0
. O 0

We O 0
discovered O 0
a O 0
missense O 0
mutation O 0
, O 0
GCA O 0
to O 0
GTA O 0
( O 0
Ala O 0
54 O 0
Val O 0
) O 0
, O 0
in O 0
exon O 0
2 O 0
in O 0
a O 0
neurofibrosarcoma B-Disease 0
patient O 0
( O 0
case O 0
1 O 0
) O 0
, O 0
two O 0
missense O 0
mutations O 0
, O 0
AAA O 0
to O 0
CAA O 0
( O 0
Lys O 0
118 O 0
Gln O 0
) O 0
and O 0
GAA O 0
to O 0
GGA O 0
( O 0
Glu O 0
154 O 0
Gly O 0
) O 0
in O 0
exon O 0
5 O 0
of O 0
another O 0
neurofibrosarcoma B-Disease 0
patient O 0
( O 0
case O 0
2 O 0
) O 0
, O 0
and O 0
3 O 0
amino O 0
acid O 0
substitutions O 0
, O 0
GTG O 0
to O 0
GCG O 0
( O 0
Val O 0
179 O 0
Ala O 0
) O 0
, O 0
GTT O 0
to O 0
GCT O 0
( O 0
Val O 0
181 O 0
Ala O 0
) O 0
and O 0
TTC O 0
to O 0
CTC O 0
( O 0
Phe O 0
186 O 0
Leu O 0
) O 0
, O 0
in O 0
a O 0
third O 0
neurofibrosarcoma B-Disease 0
patient O 0
( O 0
case O 0
3 O 0
) O 0
. O 0

In O 0
case O 0
3 O 0
, O 0
loss O 0
of O 0
heterozygosity O 0
was O 0
also O 0
demonstrated O 0
by O 0
informative O 0
( O 0
TTC O 0
) O 0
3 O 0
/ O 0
( O 0
TTC O 0
) O 0
2 O 0
polymorphism O 0
. O 0

Our O 0
data O 0
demonstrate O 0
that O 0
mutations O 0
occur O 0
in O 0
the O 0
Mxi1 O 0
gene O 0
in O 0
neurofibrosarcoma B-Disease 0
. O 0

Missense O 0
mutations O 0
in O 0
the O 0
functional O 0
domain O 0
of O 0
Mxi1 O 0
in O 0
these O 0
cases O 0
may O 0
be O 0
involved O 0
in O 0
the O 0
pathogenesis O 0
of O 0
neurofibrosarcoma B-Disease 0
. O 0
. O 0

A O 0
population O 0
- O 0
based O 0
study O 0
of O 0
the O 0
clinical O 0
expression O 0
of O 0
the O 0
hemochromatosis B-Disease 1
gene O 0
. O 0

BACKGROUND O 0
AND O 0
METHODS O 0
Hereditary B-Disease 1
hemochromatosis I-Disease 1
is O 0
associated O 0
with O 0
homozygosity O 0
for O 0
the O 0
C282Y O 0
mutation O 0
in O 0
the O 0
hemochromatosis B-Disease 1
( O 0
HFE O 0
) O 0
gene O 0
on O 0
chromosome O 0
6 O 0
, O 0
elevated O 0
serum O 0
transferrin O 0
saturation O 0
, O 0
and O 0
excess B-Disease 0
iron I-Disease 0
deposits I-Disease 0
throughout O 0
the O 0
body O 0
. O 0

To O 0
assess O 0
the O 0
prevalence O 0
and O 0
clinical O 0
expression O 0
of O 0
the O 0
HFE O 0
gene O 0
, O 0
we O 0
conducted O 0
a O 0
population O 0
- O 0
based O 0
study O 0
in O 0
Busselton O 0
, O 0
Australia O 0
. O 0

In O 0
1994 O 0
, O 0
we O 0
obtained O 0
blood O 0
samples O 0
for O 0
the O 0
determination O 0
of O 0
serum O 0
transferrin O 0
saturation O 0
and O 0
ferritin O 0
levels O 0
and O 0
the O 0
presence O 0
or O 0
absence O 0
of O 0
the O 0
C282Y O 0
mutation O 0
and O 0
the O 0
H63D O 0
mutation O 0
( O 0
which O 0
may O 0
contribute O 0
to O 0
increased O 0
hepatic O 0
iron O 0
levels O 0
) O 0
in O 0
3011 O 0
unrelated O 0
white O 0
adults O 0
. O 0

We O 0
evaluated O 0
all O 0
subjects O 0
who O 0
had O 0
persistently O 0
elevated O 0
transferrin O 0
- O 0
saturation O 0
values O 0
( O 0
45 O 0
percent O 0
or O 0
higher O 0
) O 0
or O 0
were O 0
homozygous O 0
for O 0
the O 0
C282Y O 0
mutation O 0
. O 0

We O 0
recommended O 0
liver O 0
biopsy O 0
for O 0
subjects O 0
with O 0
serum O 0
ferritin O 0
levels O 0
of O 0
300 O 0
ng O 0
per O 0
milliliter O 0
or O 0
higher O 0
. O 0

The O 0
subjects O 0
were O 0
followed O 0
for O 0
up O 0
to O 0
four O 0
years O 0
. O 0

RESULTS O 0
Sixteen O 0
of O 0
the O 0
subjects O 0
( O 0
0 O 0
. O 0
5 O 0
percent O 0
) O 0
were O 0
homozygous O 0
for O 0
the O 0
C282Y O 0
mutation O 0
, O 0
and O 0
424 O 0
( O 0
14 O 0
. O 0
1 O 0
percent O 0
) O 0
were O 0
heterozygous O 0
. O 0

The O 0
serum O 0
transferrin O 0
saturation O 0
was O 0
45 O 0
percent O 0
or O 0
higher O 0
in O 0
15 O 0
of O 0
the O 0
16 O 0
who O 0
were O 0
homozygous O 0
; O 0
in O 0
1 O 0
subject O 0
it O 0
was O 0
43 O 0
percent O 0
. O 0

Four O 0
of O 0
the O 0
homozygous O 0
subjects O 0
had O 0
previously O 0
been O 0
given O 0
a O 0
diagnosis O 0
of O 0
hemochromatosis B-Disease 1
, O 0
and O 0
12 O 0
had O 0
not O 0
. O 0

Seven O 0
of O 0
these O 0
12 O 0
patients O 0
had O 0
elevated O 0
serum O 0
ferritin O 0
levels O 0
in O 0
1994 O 0
; O 0
6 O 0
of O 0
the O 0
7 O 0
had O 0
further O 0
increases O 0
in O 0
1998 O 0
, O 0
and O 0
1 O 0
had O 0
a O 0
decrease O 0
, O 0
although O 0
the O 0
value O 0
remained O 0
elevated O 0
. O 0

The O 0
serum O 0
ferritin O 0
levels O 0
in O 0
the O 0
four O 0
other O 0
homozygous O 0
patients O 0
remained O 0
in O 0
the O 0
normal O 0
range O 0
. O 0

Eleven O 0
of O 0
the O 0
16 O 0
homozygous O 0
subjects O 0
underwent O 0
liver O 0
biopsy O 0
; O 0
3 O 0
had O 0
hepatic B-Disease 1
fibrosis I-Disease 1
, O 0
and O 0
1 O 0
, O 0
who O 0
had O 0
a O 0
history O 0
of O 0
excessive B-Disease 1
alcohol I-Disease 1
consumption I-Disease 1
, O 0
had O 0
cirrhosis B-Disease 1
and O 0
mild O 0
microvesicular B-Disease 0
steatosis I-Disease 0
. O 0

Eight O 0
of O 0
the O 0
16 O 0
homozygous O 0
subjects O 0
had O 0
clinical O 0
findings O 0
that O 0
were O 0
consistent O 0
with O 0
the O 0
presence O 0
of O 0
hereditary B-Disease 0
hemochromatosis I-Disease 1
, O 0
such O 0
as O 0
hepatomegaly B-Disease 1
, O 0
skin B-Disease 1
pigmentation I-Disease 1
, O 0
and O 0
arthritis B-Disease 0
. O 0

CONCLUSIONS O 0
In O 0
a O 0
population O 0
of O 0
white O 0
adults O 0
of O 0
northern O 0
European O 0
ancestry O 0
, O 0
0 O 0
. O 0

5 O 0
percent O 0
were O 0
homozygous O 0
for O 0
the O 0
C282Y O 0
mutation O 0
in O 0
the O 0
HFE O 0
gene O 0
. O 0

However O 0
, O 0
only O 0
half O 0
of O 0
those O 0
who O 0
were O 0
homozygous O 0
had O 0
clinical O 0
features O 0
of O 0
hemochromatosis B-Disease 1
, O 0
and O 0
one O 0
quarter O 0
had O 0
serum O 0
ferritin O 0
levels O 0
that O 0
remained O 0
normal O 0
over O 0
a O 0
four O 0
- O 0
year O 0
period O 0
. O 0

Large O 0
heterozygous O 0
deletion O 0
masquerading O 0
as O 0
homozygous O 0
missense O 0
mutation O 0
: O 0
a O 0
pitfall O 0
in O 0
diagnostic O 0
mutation O 0
analysis O 0
. O 0

The O 0
clinical O 0
use O 0
of O 0
molecular O 0
analyses O 0
in O 0
recessive B-Disease 1
disorders I-Disease 1
relies O 0
on O 0
the O 0
exact O 0
characterization O 0
of O 0
both O 0
mutant O 0
alleles O 0
in O 0
the O 0
affected O 0
patient O 0
. O 0

This O 0
can O 0
be O 0
problematic O 0
when O 0
only O 0
part O 0
of O 0
the O 0
gene O 0
is O 0
examined O 0
or O 0
when O 0
relevant O 0
DNA O 0
alterations O 0
are O 0
not O 0
recognized O 0
by O 0
standard O 0
methods O 0
. O 0

We O 0
present O 0
a O 0
child O 0
in O 0
whom O 0
phenylketonuria B-Disease 0
was O 0
apparently O 0
caused O 0
by O 0
homozygosity O 0
for O 0
the O 0
mutation O 0
E390G O 0
in O 0
exon O 0
11 O 0
of O 0
the O 0
phenylalanine O 0
hydroxylase O 0
( O 0
PAH O 0
) O 0
gene O 0
. O 0

However O 0
, O 0
the O 0
clinical O 0
severity O 0
of O 0
the O 0
disease O 0
was O 0
not O 0
quite O 0
as O 0
mild O 0
as O 0
expected O 0
, O 0
the O 0
mutation O 0
was O 0
not O 0
identified O 0
in O 0
the O 0
father O 0
despite O 0
confirmed O 0
paternity O 0
, O 0
and O 0
the O 0
paternal O 0
allele O 0
showed O 0
a O 0
highly O 0
unusual O 0
pattern O 0
of O 0
polymorphic O 0
markers O 0
in O 0
the O 0
PAH O 0
gene O 0
. O 0

Presence O 0
of O 0
a O 0
large O 0
deletion O 0
involving O 0
exons O 0
9 O 0
, O 0
10 O 0
and O 0
11 O 0
of O 0
the O 0
phenylalanine O 0
hydroxylase O 0
gene O 0
was O 0
confirmed O 0
by O 0
long O 0
- O 0
range O 0
PCR O 0
. O 0

Diagnostic O 0
DNA O 0
analyses O 0
should O 0
include O 0
a O 0
comprehensive O 0
examination O 0
of O 0
the O 0
whole O 0
relevant O 0
gene O 0
in O 0
the O 0
patient O 0
and O 0
confirmation O 0
of O 0
carrier O 0
status O 0
in O 0
both O 0
parents O 0
. O 0
. O 0

Early O 0
onset O 0
of O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
Emery I-Disease 0
- I-Disease 0
Dreifuss I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
in O 0
a O 0
boy O 0
with O 0
emerin O 0
gene O 0
deletion O 0
. O 0

A O 0
boy O 0
developed O 0
contractures B-Disease 0
of I-Disease 0
the I-Disease 0
Achilles I-Disease 0
tendons I-Disease 0
at O 0
3 O 0
years O 0
and O 0
of O 0
the O 0
postcervical O 0
muscles O 0
at O 0
7 O 0
years O 0
, O 0
although O 0
neither O 0
contractures B-Disease 0
of I-Disease 0
the I-Disease 0
elbows I-Disease 0
nor O 0
cardiac B-Disease 1
abnormality I-Disease 1
were O 0
recognized O 0
by O 0
the O 0
age O 0
of O 0
9 O 0
years O 0
. O 0

Muscle O 0
computed O 0
tomography O 0
scanning O 0
revealed O 0
changes O 0
characteristic O 0
of O 0
muscle O 0
involvement O 0
. O 0

Emerin O 0
was O 0
not O 0
detected O 0
in O 0
the O 0
biopsied O 0
muscle O 0
, O 0
and O 0
RT O 0
- O 0
PCR O 0
and O 0
PCR O 0
- O 0
based O 0
genomic O 0
DNA O 0
analyses O 0
of O 0
the O 0
emerin O 0
gene O 0
demonstrated O 0
no O 0
amplification O 0
product O 0
in O 0
the O 0
patient O 0
. O 0

These O 0
results O 0
confirmed O 0
the O 0
diagnosis O 0
of O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
Emery I-Disease 0
- I-Disease 0
Dreifuss I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
EDMD B-Disease 0
) O 0
, O 0
and O 0
reinforce O 0
the O 0
necessity O 0
of O 0
molecular O 0
genetic O 0
diagnosis O 0
of O 0
the O 0
membrane O 0
protein O 0
emerin O 0
in O 0
younger O 0
patients O 0
with O 0
possible O 0
EDMD B-Disease 0
before O 0
appearance O 0
of O 0
the O 0
typical O 0
symptoms O 0
, O 0
to O 0
avoid O 0
sudden B-Disease 0
cardiac I-Disease 0
death I-Disease 0
. O 0
. O 0

Duchenne B-Disease 0
/ I-Disease 0
Becker I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
: O 0
correlation O 0
of O 0
phenotype O 0
by O 0
electroretinography O 0
with O 0
sites O 0
of O 0
dystrophin O 0
mutations O 0
. O 0

The O 0
dark O 0
- O 0
adapted O 0
electroretinogram O 0
( O 0
ERG O 0
) O 0
of O 0
patients O 0
with O 0
Duchenne B-Disease 0
and I-Disease 0
Becker I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
( O 0
DMD B-Disease 0
/ O 0
BMD B-Disease 1
) O 0
shows O 0
a O 0
marked O 0
reduction O 0
in O 0
b O 0
- O 0
wave O 0
amplitude O 0
. O 0

Genotype O 0
- O 0
phenotype O 0
studies O 0
of O 0
mouse O 0
models O 0
for O 0
DMD B-Disease 0
show O 0
position O 0
- O 0
specific O 0
effects O 0
of O 0
the O 0
mutations O 0
upon O 0
the O 0
phenotype O 0
mice O 0
with O 0
5 O 0
defects O 0
of O 0
dystrophin O 0
have O 0
normal O 0
ERGs O 0
, O 0
those O 0
with O 0
defects O 0
in O 0
the O 0
central O 0
region O 0
have O 0
a O 0
normal O 0
b O 0
- O 0
wave O 0
amplitude O 0
associated O 0
with O 0
prolonged O 0
implicit O 0
times O 0
for O 0
both O 0
the O 0
b O 0
- O 0
wave O 0
and O 0
oscillatory O 0
potentials O 0
, O 0
and O 0
mice O 0
with O 0
3 O 0
defects O 0
have O 0
a O 0
phenotype O 0
similar O 0
to O 0
that O 0
seen O 0
in O 0
DMD B-Disease 0
/ O 0
BMD B-Disease 1
patients O 0
. O 0

The O 0
mouse O 0
studies O 0
suggest O 0
a O 0
key O 0
role O 0
for O 0
the O 0
carboxyl O 0
terminal O 0
dystrophin O 0
isoform O 0
, O 0
Dp260 O 0
, O 0
in O 0
retinal O 0
electrophysiology O 0
. O 0

We O 0
have O 0
undertaken O 0
a O 0
systematic O 0
evaluation O 0
of O 0
DMD B-Disease 0
/ O 0
BMD B-Disease 1
patients O 0
through O 0
clinical O 0
examination O 0
and O 0
review O 0
of O 0
the O 0
literature O 0
in O 0
order O 0
to O 0
determine O 0
whether O 0
the O 0
position O 0
- O 0
specific O 0
effects O 0
of O 0
mutations O 0
noted O 0
in O 0
the O 0
mouse O 0
are O 0
present O 0
in O 0
man O 0
. O 0

We O 0
have O 0
found O 0
that O 0
, O 0
in O 0
man O 0
, O 0
a O 0
wider O 0
variation O 0
of O 0
DMD B-Disease 1
defects I-Disease 1
correlate O 0
with O 0
reductions O 0
in O 0
the O 0
b O 0
- O 0
wave O 0
amplitude O 0
. O 0

Individuals O 0
with O 0
normal O 0
ERGs O 0
have O 0
mutations O 0
predominantly O 0
located O 0
5 O 0
of O 0
the O 0
transcript O 0
initiation O 0
site O 0
of O 0
Dp260 O 0
. O 0

Our O 0
results O 0
suggest O 0
that O 0
the O 0
most O 0
important O 0
determinant O 0
in O 0
the O 0
ERG O 0
b O 0
- O 0
wave O 0
phenotype O 0
is O 0
the O 0
mutation O 0
position O 0
, O 0
rather O 0
than O 0
muscle B-Disease 1
disease I-Disease 1
severity O 0
. O 0

Forty O 0
- O 0
six O 0
per O 0
cent O 0
of O 0
patients O 0
with O 0
mutations O 0
5 O 0
of O 0
the O 0
Dp260 O 0
transcript O 0
start O 0
site O 0
have O 0
abnormal O 0
ERGs O 0
, O 0
as O 0
opposed O 0
to O 0
94 O 0
% O 0
with O 0
more O 0
distal O 0
mutations O 0
. O 0

The O 0
human O 0
genotype O 0
- O 0
phenotype O 0
correlations O 0
are O 0
consistent O 0
with O 0
a O 0
role O 0
for O 0
Dp260 O 0
in O 0
normal O 0
retinal O 0
electrophysiology O 0
and O 0
may O 0
also O 0
reflect O 0
the O 0
expression O 0
of O 0
other O 0
C O 0
- O 0
terminal O 0
dystrophin O 0
isoforms O 0
and O 0
their O 0
contributions O 0
to O 0
retinal O 0
signal O 0
transmission O 0
. O 0
. O 0

Cis O 0
and O 0
trans O 0
effects O 0
of O 0
the O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
mutation O 0
in O 0
a O 0
cell O 0
culture O 0
model O 0
. O 0

The O 0
mutation O 0
causing O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
has O 0
been O 0
identified O 0
as O 0
a O 0
CTG O 0
expansion O 0
in O 0
the O 0
3 O 0
- O 0
untranslated O 0
region O 0
( O 0
3 O 0
- O 0
UTR O 0
) O 0
of O 0
the O 0
DM B-Disease 0
protein O 0
kinase O 0
gene O 0
( O 0
DMPK O 0
) O 0
, O 0
but O 0
the O 0
mechanism O 0
( O 0
s O 0
) O 0
of O 0
pathogenesis O 0
remain O 0
unknown O 0
. O 0

Studies O 0
using O 0
DM B-Disease 0
patient O 0
materials O 0
have O 0
often O 0
produced O 0
confusing O 0
results O 0
. O 0

Therefore O 0
, O 0
to O 0
study O 0
the O 0
effects O 0
of O 0
the O 0
DM B-Disease 0
mutation O 0
in O 0
a O 0
controlled O 0
environment O 0
, O 0
we O 0
have O 0
established O 0
a O 0
cell O 0
culture O 0
model O 0
system O 0
using O 0
C2C12 O 0
mouse O 0
myoblasts O 0
. O 0

By O 0
expressing O 0
chimeric O 0
reporter O 0
constructs O 0
containing O 0
a O 0
reporter O 0
gene O 0
fused O 0
to O 0
a O 0
human O 0
DMPK O 0
3 O 0
- O 0
UTR O 0
, O 0
we O 0
identified O 0
both O 0
cis O 0
and O 0
trans O 0
effects O 0
that O 0
are O 0
mediated O 0
by O 0
the O 0
DM B-Disease 0
mutation O 0
. O 0

Our O 0
data O 0
show O 0
that O 0
a O 0
mutant O 0
DMPK O 0
3 O 0
- O 0
UTR O 0
, O 0
with O 0
as O 0
few O 0
as O 0
57 O 0
CTGs O 0
, O 0
had O 0
a O 0
negative O 0
cis O 0
effect O 0
on O 0
protein O 0
expression O 0
and O 0
resulted O 0
in O 0
the O 0
aggregation O 0
of O 0
reporter O 0
transcripts O 0
into O 0
discrete O 0
nuclear O 0
foci O 0
. O 0

We O 0
determined O 0
by O 0
deletion O 0
analysis O 0
that O 0
an O 0
expanded O 0
( O 0
CTG O 0
) O 0
( O 0
n O 0
) O 0
tract O 0
alone O 0
was O 0
sufficient O 0
to O 0
mediate O 0
these O 0
cis O 0
effects O 0
. O 0

Furthermore O 0
, O 0
in O 0
contrast O 0
to O 0
the O 0
normal O 0
DMPK O 0
3 O 0
- O 0
UTR O 0
mRNA O 0
, O 0
a O 0
mutant O 0
DMPK O 0
3 O 0
- O 0
UTR O 0
mRNA O 0
with O 0
( O 0
CUG O 0
) O 0
( O 0
200 O 0
) O 0
selectively O 0
inhibited O 0
myogenic O 0
differentiation O 0
of O 0
C2C12 O 0
myoblasts O 0
. O 0

Genetic O 0
analysis O 0
and O 0
the O 0
Cre O 0
- O 0
loxP O 0
system O 0
were O 0
used O 0
to O 0
clearly O 0
demonstrate O 0
that O 0
the O 0
myoblast O 0
fusion O 0
defect O 0
could O 0
be O 0
rescued O 0
by O 0
eliminating O 0
the O 0
expression O 0
of O 0
the O 0
mutant O 0
DMPK O 0
3 O 0
- O 0
UTR O 0
transcript O 0
. O 0

Characterization O 0
of O 0
spontaneous O 0
deletion O 0
events O 0
mapped O 0
the O 0
inhibitory O 0
effect O 0
to O 0
the O 0
( O 0
CTG O 0
) O 0
( O 0
n O 0
) O 0
expansion O 0
and O 0
/ O 0
or O 0
the O 0
3 O 0
end O 0
of O 0
the O 0
DMPK O 0
3 O 0
- O 0
UTR O 0
. O 0

These O 0
results O 0
provide O 0
evidence O 0
that O 0
the O 0
DM B-Disease 0
mutation O 0
acts O 0
in O 0
cis O 0
to O 0
reduce O 0
protein O 0
production O 0
( O 0
consistent O 0
with O 0
DMPK B-Disease 0
haploinsufficiency I-Disease 0
) O 0
and O 0
in O 0
trans O 0
as O 0
a O 0
riboregulator O 0
to O 0
inhibit O 0
myogenesis O 0
. O 0
. O 0

Coats B-Disease 0
' I-Disease 0
disease I-Disease 0
of O 0
the O 0
retina O 0
( O 0
unilateral B-Disease 1
retinal I-Disease 1
telangiectasis I-Disease 1
) O 0
caused O 0
by O 0
somatic O 0
mutation O 0
in O 0
the O 0
NDP O 0
gene O 0
: O 0
a O 0
role O 0
for O 0
norrin O 0
in O 0
retinal O 0
angiogenesis O 0
. O 0

Coats B-Disease 1
disease I-Disease 1
is O 0
characterized O 0
by O 0
abnormal B-Disease 1
retinal I-Disease 1
vascular I-Disease 1
development I-Disease 1
( O 0
so O 0
- O 0
called O 0
retinal B-Disease 0
telangiectasis I-Disease 0
) O 0
which O 0
results O 0
in O 0
massive O 0
intraretinal B-Disease 1
and I-Disease 1
subretinal I-Disease 1
lipid I-Disease 1
accumulation I-Disease 1
( O 0
exudative B-Disease 1
retinal I-Disease 1
detachment I-Disease 1
) O 0
. O 0

The O 0
classical O 0
form O 0
of O 0
Coats B-Disease 1
disease I-Disease 1
is O 0
almost O 0
invariably O 0
isolated O 0
, O 0
unilateral O 0
and O 0
seen O 0
in O 0
males O 0
. O 0

A O 0
female O 0
with O 0
a O 0
unilateral O 0
variant O 0
of O 0
Coats B-Disease 1
disease I-Disease 1
gave O 0
birth O 0
to O 0
a O 0
son O 0
affected O 0
by O 0
Norrie B-Disease 1
disease I-Disease 1
. O 0

Both O 0
carried O 0
a O 0
missense O 0
mutation O 0
within O 0
the O 0
NDP O 0
gene O 0
on O 0
chromosome O 0
Xp11 O 0
. O 0

2 O 0
2 O 0
. O 0

Subsequently O 0
analysis O 0
of O 0
the O 0
retinas O 0
of O 0
nine O 0
enucleated O 0
eyes O 0
from O 0
males O 0
with O 0
Coats B-Disease 1
disease I-Disease 1
demonstrated O 0
in O 0
one O 0
a O 0
somatic O 0
mutation O 0
in O 0
the O 0
NDP O 0
gene O 0
which O 0
was O 0
not O 0
present O 0
within O 0
non O 0
- O 0
retinal O 0
tissue O 0
. O 0

We O 0
suggest O 0
that O 0
Coats B-Disease 0
telangiectasis I-Disease 0
is O 0
secondary O 0
to O 0
somatic O 0
mutation O 0
in O 0
the O 0
NDP O 0
gene O 0
which O 0
results O 0
in O 0
a O 0
deficiency B-Disease 1
of I-Disease 1
norrin I-Disease 1
( O 0
the O 0
protein O 0
product O 0
of O 0
the O 0
NDP O 0
gene O 0
) O 0
within O 0
the O 0
developing O 0
retina O 0
. O 0

This O 0
supports O 0
recent O 0
observations O 0
that O 0
the O 0
protein O 0
is O 0
critical O 0
for O 0
normal O 0
retinal O 0
vasculogenesis O 0
. O 0

Hereditary O 0
TP53 O 0
codon O 0
292 O 0
and O 0
somatic O 0
P16INK4A O 0
codon O 0
94 O 0
mutations O 0
in O 0
a O 0
Li B-Disease 1
- I-Disease 1
Fraumeni I-Disease 1
syndrome I-Disease 1
family O 0
. O 0

Li B-Disease 1
- I-Disease 1
Fraumeni I-Disease 1
syndrome I-Disease 1
is O 0
an O 0
autosomal B-Disease 0
dominant I-Disease 0
disorder I-Disease 0
that O 0
is O 0
characterized O 0
by O 0
various O 0
types O 0
of O 0
cancer B-Disease 1
in O 0
childhood O 0
and O 0
adult O 0
cases O 0
. O 0

Although O 0
hereditary O 0
TP53 O 0
mutation O 0
is O 0
very O 0
rare O 0
in O 0
different O 0
human O 0
cancers B-Disease 0
, O 0
it O 0
has O 0
been O 0
frequently O 0
reported O 0
in O 0
Li B-Disease 1
- I-Disease 1
Fraumeni I-Disease 1
syndrome I-Disease 1
. O 0

On O 0
the O 0
other O 0
hand O 0
, O 0
hereditary O 0
mutations O 0
of O 0
TP57KIP2 O 0
, O 0
P15INK4B O 0
, O 0
and O 0
P16INK4A O 0
, O 0
which O 0
affect O 0
the O 0
cell O 0
cycle O 0
similar O 0
to O 0
TP53 O 0
, O 0
were O 0
observed O 0
in O 0
some O 0
types O 0
of O 0
cancer B-Disease 1
. O 0

In O 0
a O 0
Turkish O 0
family O 0
with O 0
the O 0
diagnosis O 0
of O 0
Li B-Disease 1
- I-Disease 1
Fraumeni I-Disease 1
syndrome I-Disease 1
, O 0
we O 0
analyzed O 0
the O 0
mutation O 0
pattern O 0
of O 0
TP53 O 0
, O 0
P57KIP2 O 0
, O 0
P15INK4B O 0
, O 0
and O 0
P16INK4A O 0
in O 0
the O 0
peripheral O 0
blood O 0
, O 0
and O 0
loss O 0
of O 0
heterozygosity O 0
( O 0
homo O 0
/ O 0
hemizygous O 0
deletion O 0
) O 0
pattern O 0
of O 0
TP53 O 0
and O 0
P15INK4B O 0
/ O 0
P16INK4A O 0
in O 0
two O 0
tumor B-Disease 0
tissues O 0
. O 0

The O 0
propositus O 0
had O 0
a O 0
seminoma B-Disease 1
, O 0
his O 0
daughter O 0
a O 0
medulloblastoma B-Disease 1
, O 0
and O 0
one O 0
of O 0
his O 0
healthy O 0
cousins O 0
, O 0
a O 0
TP53 O 0
codon O 0
292 O 0
missense O 0
point O 0
mutation O 0
( O 0
AAA O 0
- O 0
- O 0
> O 0
ATA O 0
; O 0
Lys O 0
- O 0
- O 0
> O 0
Ile O 0
) O 0
in O 0
the O 0
peripheral O 0
blood O 0
cells O 0
. O 0

Tumor O 0
tissue O 0
obtained O 0
from O 0
the O 0
propositus O 0
with O 0
the O 0
seminoma B-Disease 1
revealed O 0
loss O 0
of O 0
heterozygosity O 0
in O 0
the O 0
TP53 O 0
gene O 0
. O 0

In O 0
the O 0
analyses O 0
of O 0
tumor B-Disease 0
tissues O 0
from O 0
the O 0
propositus O 0
and O 0
his O 0
daughter O 0
, O 0
a O 0
P16INK4A O 0
codon O 0
94 O 0
missense O 0
point O 0
mutation O 0
( O 0
GCG O 0
- O 0
- O 0
> O 0
GAG O 0
; O 0
Ala O 0
- O 0
- O 0
> O 0
Glu O 0
) O 0
was O 0
observed O 0
with O 0
the O 0
hereditary O 0
TP53 O 0
mutation O 0
. O 0

P16INK4A O 0
codon O 0
94 O 0
mutation O 0
observed O 0
in O 0
our O 0
family O 0
is O 0
a O 0
novel O 0
mutation O 0
in O 0
Li B-Disease 1
- I-Disease 1
Fraumeni I-Disease 1
syndrome I-Disease 1
. O 0

No O 0
other O 0
gene O 0
alteration O 0
in O 0
TP53 O 0
, O 0
P57KIP2 O 0
, O 0
P15INK4B O 0
, O 0
and O 0
P16INK4A O 0
was O 0
observed O 0
. O 0

Existence O 0
of O 0
the O 0
P16INK4A O 0
mutation O 0
and O 0
the O 0
hereditary O 0
TP53 O 0
mutation O 0
with O 0
or O 0
without O 0
loss O 0
of O 0
heterozygosity O 0
in O 0
the O 0
TP53 O 0
gene O 0
( O 0
seminoma B-Disease 1
/ O 0
medulloblastoma B-Disease 1
) O 0
may O 0
be O 0
evidence O 0
for O 0
a O 0
common O 0
mechanism O 0
involved O 0
in O 0
tumorogenesis B-Disease 1
. O 0

The O 0
gene O 0
alterations O 0
in O 0
TP53 O 0
and O 0
P16INK4A O 0
genes O 0
may O 0
be O 0
used O 0
as O 0
tumor B-Disease 0
markers O 0
in O 0
our O 0
family O 0
. O 0
. O 0

A O 0
novel O 0
mutation O 0
in O 0
the O 0
sodium O 0
/ O 0
iodide O 0
symporter O 0
gene O 0
in O 0
the O 0
largest O 0
family O 0
with O 0
iodide B-Disease 1
transport I-Disease 1
defect I-Disease 1
. O 0

We O 0
previously O 0
reported O 0
nine O 0
children O 0
with O 0
an O 0
autosomally O 0
recessive O 0
form O 0
of O 0
congenital B-Disease 0
hypothyroidism I-Disease 0
due O 0
to O 0
an O 0
iodide B-Disease 1
transport I-Disease 1
defect I-Disease 1
in O 0
a O 0
large O 0
Hutterite O 0
family O 0
with O 0
extensive O 0
consanguinity O 0
living O 0
in O 0
central O 0
Canada O 0
. O 0

Since O 0
the O 0
original O 0
report O 0
, O 0
we O 0
have O 0
diagnosed O 0
congenital B-Disease 0
hypothyroidism I-Disease 0
by O 0
newborn O 0
TSH O 0
screening O 0
in O 0
9 O 0
additional O 0
children O 0
from O 0
the O 0
family O 0
. O 0

We O 0
performed O 0
direct O 0
sequencing O 0
of O 0
the O 0
PCR O 0
products O 0
of O 0
each O 0
NIS O 0
( O 0
sodium O 0
/ O 0
iodide O 0
symporter O 0
) O 0
gene O 0
exon O 0
with O 0
flanking O 0
introns O 0
amplified O 0
from O 0
genomic O 0
DNA O 0
extracted O 0
from O 0
peripheral O 0
blood O 0
cells O 0
of O 0
the O 0
patients O 0
. O 0

We O 0
identified O 0
a O 0
novel O 0
NIS O 0
gene O 0
mutation O 0
, O 0
G395R O 0
( O 0
Gly395 O 0
- O 0
- O 0
> O 0
Arg O 0
; O 0
GGA O 0
- O 0
- O 0
> O 0
AGA O 0
) O 0
, O 0
in O 0
10 O 0
patients O 0
examined O 0
in O 0
the O 0
present O 0
study O 0
. O 0

All O 0
of O 0
the O 0
parents O 0
tested O 0
were O 0
heterozygous O 0
for O 0
the O 0
mutation O 0
, O 0
suggesting O 0
that O 0
the O 0
patients O 0
were O 0
homozygous O 0
. O 0

The O 0
mutation O 0
was O 0
located O 0
in O 0
the O 0
10th O 0
transmembrane O 0
helix O 0
. O 0

Expression O 0
experiments O 0
by O 0
transfection O 0
of O 0
the O 0
mutant O 0
NIS O 0
complimentary O 0
DNA O 0
into O 0
COS O 0
- O 0
7 O 0
cells O 0
showed O 0
no O 0
perchlorate O 0
- O 0
sensitive O 0
iodide O 0
uptake O 0
, O 0
confirming O 0
that O 0
the O 0
mutation O 0
is O 0
the O 0
direct O 0
cause O 0
of O 0
the O 0
iodide B-Disease 1
transport I-Disease 1
defect I-Disease 1
in O 0
these O 0
patients O 0
. O 0

A O 0
patient O 0
who O 0
showed O 0
an O 0
intermediate O 0
saliva O 0
/ O 0
serum O 0
technetium O 0
ratio O 0
( O 0
14 O 0
. O 0
0 O 0
; O 0
normal O 0
, O 0
> O 0
or O 0
= O 0
20 O 0
) O 0
and O 0
was O 0
considered O 0
to O 0
have O 0
a O 0
partial O 0
or O 0
less O 0
severe O 0
defect O 0
in O 0
the O 0
previous O 0
report O 0
( O 0
IX O 0
- O 0
24 O 0
) O 0
did O 0
not O 0
have O 0
a O 0
NIS O 0
gene O 0
mutation O 0
. O 0

It O 0
is O 0
now O 0
possible O 0
to O 0
use O 0
gene O 0
diagnostics O 0
of O 0
this O 0
unique O 0
NIS O 0
mutation O 0
to O 0
identify O 0
patients O 0
with O 0
congenital B-Disease 0
hypothyroidism I-Disease 0
due O 0
to O 0
an O 0
iodide B-Disease 1
transport I-Disease 1
defect I-Disease 1
in O 0
this O 0
family O 0
and O 0
to O 0
determine O 0
the O 0
carrier O 0
state O 0
of O 0
potential O 0
parents O 0
for O 0
genetic O 0
counseling O 0
and O 0
arranging O 0
rapid O 0
and O 0
early O 0
diagnosis O 0
of O 0
their O 0
infants O 0
. O 0

Molecular O 0
analysis O 0
in O 0
familial B-Disease 0
neurohypophyseal I-Disease 0
diabetes I-Disease 1
insipidus I-Disease 1
: O 0
early O 0
diagnosis O 0
of O 0
an O 0
asymptomatic O 0
carrier O 0
. O 0

Familial B-Disease 0
neurohypophyseal I-Disease 0
diabetes I-Disease 1
insipidus I-Disease 1
( O 0
FNDI B-Disease 1
) O 0
is O 0
an O 0
inherited O 1
deficiency B-Disease 1
of I-Disease 0
the I-Disease 0
hormone I-Disease 0
arginine I-Disease 0
vasopressin I-Disease 0
( O 0
AVP O 0
) O 0
and O 0
is O 0
transmitted O 0
as O 0
an O 0
autosomal O 0
dominant O 0
trait O 0
. O 0

In O 0
the O 0
present O 0
study O 0
we O 0
have O 0
analyzed O 0
the O 0
AVP O 0
- O 0
neurophysin O 0
II O 0
( O 0
AVP O 0
- O 0
NPII O 0
) O 0
gene O 0
in O 0
a O 0
Spanish O 0
kindred O 0
. O 0

Studies O 0
were O 0
performed O 0
on O 0
seven O 0
members O 0
( O 0
four O 0
clinically O 0
affected O 0
) O 0
of O 0
the O 0
family O 0
. O 0

Patients O 0
were O 0
diagnosed O 0
at O 0
the O 0
Hospital O 0
Universitario O 0
Gregorio O 0
Maranon O 0
( O 0
Madrid O 0
, O 0
Spain O 0
) O 0
. O 0

The O 0
entire O 0
coding O 0
region O 0
of O 0
the O 0
AVP O 0
- O 0
NPII O 0
gene O 0
of O 0
all O 0
family O 0
members O 0
was O 0
amplified O 0
by O 0
PCR O 0
and O 0
sequenced O 0
. O 0

All O 0
affected O 0
individuals O 0
presented O 0
a O 0
missense O 0
mutation O 0
( O 0
G1757 O 0
- O 0
- O 0
> O 0
A O 0
) O 0
that O 0
replaces O 0
glycine O 0
at O 0
position O 0
23 O 0
with O 0
arginine O 0
within O 0
the O 0
NPII O 0
domain O 0
. O 0

The O 0
substitution O 0
was O 0
confirmed O 0
by O 0
restriction O 0
endonuclease O 0
analysis O 0
and O 0
was O 0
present O 0
in O 0
heterozygosis O 0
. O 0

Additionally O 0
, O 0
one O 0
of O 0
the O 0
asymptomatic O 0
relatives O 0
( O 0
a O 0
girl O 0
8 O 0
months O 0
old O 0
at O 0
the O 0
time O 0
of O 0
study O 0
) O 0
was O 0
identified O 0
as O 0
carrier O 0
of O 0
the O 0
same O 0
mutation O 0
and O 0
developed O 0
the O 0
disease O 0
3 O 0
months O 0
later O 0
. O 0

The O 0
alteration O 0
found O 0
in O 0
the O 0
second O 0
exon O 0
of O 0
the O 0
gene O 0
in O 0
this O 0
family O 0
seems O 0
to O 0
be O 0
responsible O 0
for O 0
the O 0
disease O 0
, O 0
as O 0
all O 0
individuals O 0
harboring O 0
the O 0
mutation O 0
had O 0
been O 0
previously O 0
diagnosed O 0
or O 0
have O 0
eventually O 0
developed O 0
FNDI B-Disease 1
. O 0

Identification O 0
of O 0
the O 0
molecular O 0
defect O 0
underlying O 0
FNDI B-Disease 1
in O 0
affected O 0
families O 0
is O 0
a O 0
powerful O 0
tool O 0
for O 0
early O 0
asymptomatic O 0
diagnosis O 0
in O 0
infants O 0
. O 0
. O 0

Deficit O 0
of O 0
in O 0
vivo O 0
mitochondrial O 0
ATP O 0
production O 0
in O 0
patients O 0
with O 0
Friedreich B-Disease 1
ataxia I-Disease 1
. O 0

Friedreich B-Disease 1
ataxia I-Disease 1
( O 0
FRDA B-Disease 0
) O 0
, O 0
the O 0
most O 0
common O 0
of O 0
the O 0
inherited B-Disease 0
ataxias I-Disease 0
, O 0
is O 0
an O 0
autosomal B-Disease 0
recessive I-Disease 0
degenerative I-Disease 0
disorder I-Disease 0
, O 0
characterized O 0
clinically O 0
by O 0
onset O 0
before O 0
the O 0
age O 0
of O 0
25 O 0
of O 0
progressive B-Disease 1
gait I-Disease 1
and I-Disease 1
limb I-Disease 1
ataxia I-Disease 1
, O 0
absence B-Disease 0
of I-Disease 0
deep I-Disease 0
tendon I-Disease 0
reflexes I-Disease 0
, O 0
extensor B-Disease 0
plantar I-Disease 0
responses I-Disease 0
, O 0
and O 0
loss B-Disease 1
of I-Disease 1
position I-Disease 1
and I-Disease 1
vibration I-Disease 1
sense I-Disease 1
in O 0
the O 0
lower O 0
limbs O 0
. O 0

FRDA B-Disease 0
is O 0
caused O 0
by O 0
a O 0
GAA O 0
triplet O 0
expansion O 0
in O 0
the O 0
first O 0
intron O 0
of O 0
the O 0
FRDA B-Disease 0
gene O 0
on O 0
chromosome O 0
9q13 O 0
in O 0
97 O 0
% O 0
of O 0
patients O 0
. O 0

The O 0
FRDA B-Disease 0
gene O 0
encodes O 0
a O 0
widely O 0
expressed O 0
210 O 0
- O 0
aa O 0
protein O 0
, O 0
frataxin O 0
, O 0
which O 0
is O 0
located O 0
in O 0
mitochondria O 0
and O 0
is O 0
severely O 0
reduced O 0
in O 0
FRDA B-Disease 0
patients O 0
. O 0

Frataxin O 0
function O 0
is O 0
still O 0
unknown O 0
but O 0
the O 0
knockout O 0
of O 0
the O 0
yeast O 0
frataxin O 0
homologue O 0
gene O 0
( O 0
YFH1 O 0
) O 0
showed O 0
a O 0
severe O 0
defect O 0
of O 0
mitochondrial O 0
respiration O 0
and O 0
loss O 0
of O 0
mtDNA O 0
associated O 0
with O 0
elevated O 0
intramitochondrial O 0
iron O 0
. O 0

Here O 0
we O 0
report O 0
in O 0
vivo O 0
evidence O 0
of O 0
impaired O 0
mitochondrial O 0
respiration O 0
in O 0
skeletal O 0
muscle O 0
of O 0
FRDA B-Disease 0
patients O 0
. O 0

Using O 0
phosphorus O 0
magnetic O 0
resonance O 0
spectroscopy O 0
we O 0
demonstrated O 0
a O 0
maximum O 0
rate O 0
of O 0
muscle O 0
mitochondrial O 0
ATP O 0
production O 0
( O 0
V O 0
( O 0
max O 0
) O 0
) O 0
below O 0
the O 0
normal O 0
range O 0
in O 0
all O 0
12 O 0
FRDA B-Disease 0
patients O 0
and O 0
a O 0
strong O 0
negative O 0
correlation O 0
between O 0
mitochondrial O 0
V O 0
( O 0
max O 0
) O 0
and O 0
the O 0
number O 0
of O 0
GAA O 0
repeats O 0
in O 0
the O 0
smaller O 0
allele O 0
. O 0

Our O 0
results O 0
show O 0
that O 0
FRDA B-Disease 0
is O 0
a O 0
nuclear O 0
- O 0
encoded O 0
mitochondrial B-Disease 0
disorder I-Disease 0
affecting O 0
oxidative O 0
phosphorylation O 0
and O 0
give O 0
a O 0
rationale O 0
for O 0
treatments O 0
aimed O 0
to O 0
improve O 0
mitochondrial O 0
function O 0
in O 0
this O 0
condition O 0
. O 0
. O 0

Identification O 0
of O 0
a O 0
novel O 0
R21X O 0
mutation O 0
in O 0
the O 0
liver O 0
- O 0
type O 0
arginase O 0
gene O 0
( O 0
ARG1 O 0
) O 0
in O 0
four O 0
Portuguese O 0
patients O 0
with O 0
argininemia B-Disease 0
. O 0

Argininemia B-Disease 0
is O 0
a O 0
rare O 0
autossomal B-Disease 0
recessive I-Disease 0
disorder I-Disease 0
caused O 0
by O 0
deficiency B-Disease 0
in I-Disease 0
the I-Disease 0
cytosolic I-Disease 0
liver I-Disease 0
- I-Disease 0
type I-Disease 0
arginase I-Disease 0
enzyme I-Disease 0
( O 0
L O 0
- O 0
arginine O 0
urea O 0
- O 0
hydrolase O 0
; O 0
E O 0
. O 0
C O 0
. O 0
3 O 0
. O 0
5 O 0
. O 0
3 O 0
. O 0
1 O 0
) O 0
. O 0

In O 0
order O 0
to O 0
investigate O 0
the O 0
molecular O 0
basis O 0
for O 0
argininemia B-Disease 0
in O 0
four O 0
unrelated O 0
Portuguese O 0
patients O 0
( O 0
two O 0
from O 0
northern O 0
Portugal O 0
and O 0
two O 0
from O 0
Madeira O 0
Island O 0
) O 0
we O 0
performed O 0
a O 0
DNA O 0
sequence O 0
analysis O 0
of O 0
all O 0
the O 0
exons O 0
and O 0
exon O 0
/ O 0
intron O 0
boundaries O 0
of O 0
the O 0
liver O 0
- O 0
type O 0
arginase O 0
gene O 0
( O 0
ARG1 O 0
) O 0
. O 0

All O 0
patients O 0
were O 0
found O 0
to O 0
be O 0
homozygous O 0
for O 0
a O 0
newly O 0
identified O 0
C O 0
- O 0
> O 0
T O 0
transition O 0
in O 0
codon O 0
21 O 0
( O 0
exon O 0
2 O 0
) O 0
substituting O 0
arginine O 0
for O 0
a O 0
premature O 0
stop O 0
codon O 0
( O 0
R21X O 0
CGA O 0
to O 0
TGA O 0
) O 0
and O 0
generating O 0
a O 0
NlaIII O 0
restriction O 0
site O 0
. O 0

Restriction O 0
digestion O 0
following O 0
PCR O 0
amplification O 0
of O 0
ARG1 O 0
exon O 0
2 O 0
confirmed O 0
the O 0
presence O 0
of O 0
the O 0
mutation O 0
. O 0

Mutation O 0
of O 0
the O 0
sterol O 0
27 O 0
- O 0
hydroxylase O 0
gene O 0
( O 0
CYP27 O 0
) O 0
results O 0
in O 0
truncation O 0
of O 0
mRNA O 0
expressed O 0
in O 0
leucocytes O 0
in O 0
a O 0
Japanese O 0
family O 0
with O 0
cerebrotendinous B-Disease 1
xanthomatosis I-Disease 1
. O 0

OBJECTIVES O 0
A O 0
Japanese O 0
family O 0
with O 0
cerebrotendinous B-Disease 1
xanthomatosis I-Disease 1
( O 0
CTX B-Disease 0
) O 0
was O 0
investigated O 0
for O 0
a O 0
sequence O 0
alteration O 0
in O 0
the O 0
sterol O 0
27 O 0
- O 0
hydroxylase O 0
gene O 0
( O 0
CYP27 O 0
) O 0
. O 0

The O 0
expression O 0
of O 0
CYP27 O 0
has O 0
been O 0
mostly O 0
explored O 0
using O 0
cultured O 0
fibroblasts O 0
, O 0
prompting O 0
the O 0
examination O 0
of O 0
the O 0
transcripts O 0
from O 0
blood O 0
leucocytes O 0
as O 0
a O 0
simple O 0
and O 0
rapid O 0
technique O 0
. O 0

METHODS O 0
An O 0
alteration O 0
in O 0
CYP27 O 0
of O 0
the O 0
proband O 0
was O 0
searched O 0
for O 0
by O 0
polymerase O 0
chain O 0
reaction O 0
- O 0
single O 0
strand O 0
conformation O 0
polymorphism O 0
( O 0
PCR O 0
- O 0
SSCP O 0
) O 0
analysis O 0
and O 0
subsequent O 0
sequencing O 0
. O 0

Samples O 0
of O 0
RNA O 0
were O 0
subjected O 0
to O 0
reverse O 0
transcription O 0
PCR O 0
( O 0
RT O 0
- O 0
PCR O 0
) O 0
and O 0
the O 0
product O 0
of O 0
the O 0
proband O 0
was O 0
amplified O 0
with O 0
nested O 0
primers O 0
and O 0
sequenced O 0
. O 0

RESULTS O 0
A O 0
homozygous O 0
G O 0
to O 0
A O 0
transition O 0
at O 0
the O 0
5 O 0
end O 0
of O 0
intron O 0
7 O 0
was O 0
detected O 0
in O 0
the O 0
patient O 0
. O 0

In O 0
RT O 0
- O 0
PCR O 0
analysis O 0
, O 0
only O 0
a O 0
truncated O 0
transcript O 0
was O 0
detected O 0
in O 0
the O 0
patient O 0
, O 0
whereas O 0
both O 0
normal O 0
and O 0
truncated O 0
transcripts O 0
were O 0
detected O 0
in O 0
the O 0
siblings O 0
. O 0

The O 0
sequencing O 0
of O 0
the O 0
patients O 0
cDNA O 0
fragment O 0
disclosed O 0
a O 0
direct O 0
conjuction O 0
of O 0
exon O 0
6 O 0
and O 0
exon O 0
8 O 0
. O 0

CONCLUSION O 0
The O 0
mutation O 0
at O 0
splice O 0
donor O 0
site O 0
and O 0
the O 0
truncation O 0
of O 0
mRNA O 0
were O 0
identical O 0
with O 0
those O 0
of O 0
a O 0
recently O 0
reported O 0
Italian O 0
patient O 0
, O 0
although O 0
different O 0
in O 0
symptomatology O 0
. O 0

The O 0
application O 0
of O 0
blood O 0
leucocytes O 0
can O 0
be O 0
a O 0
simple O 0
technique O 0
on O 0
analysing O 0
a O 0
constructive O 0
abnormality B-Disease 0
of I-Disease 0
CYP27 I-Disease 0
mRNA O 0
. O 0
. O 0

Clinical O 0
and O 0
molecular O 0
genetic O 0
analysis O 0
of O 0
19 O 0
Wolfram B-Disease 1
syndrome I-Disease 1
kindreds O 0
demonstrating O 0
a O 0
wide O 0
spectrum O 0
of O 0
mutations O 0
in O 0
WFS1 O 0
. O 0

Wolfram B-Disease 1
syndrome I-Disease 1
is O 0
an O 0
autosomal B-Disease 0
recessive I-Disease 0
neurodegenerative I-Disease 0
disorder I-Disease 0
characterized O 0
by O 0
juvenile B-Disease 0
- I-Disease 0
onset I-Disease 0
diabetes I-Disease 0
mellitus I-Disease 0
and O 0
progressive O 0
optic B-Disease 1
atrophy I-Disease 1
. O 0

mtDNA O 0
deletions O 0
have O 0
been O 0
described O 0
, O 0
and O 0
a O 0
gene O 0
( O 0
WFS1 O 0
) O 0
recently O 0
has O 0
been O 0
identified O 0
, O 0
on O 0
chromosome O 0
4p16 O 0
, O 0
encoding O 0
a O 0
predicted O 0
890 O 0
amino O 0
acid O 0
transmembrane O 0
protein O 0
. O 0

Direct O 0
DNA O 0
sequencing O 0
was O 0
done O 0
to O 0
screen O 0
the O 0
entire O 0
coding O 0
region O 0
of O 0
the O 0
WFS1 O 0
gene O 0
in O 0
30 O 0
patients O 0
from O 0
19 O 0
British O 0
kindreds O 0
with O 0
Wolfram B-Disease 1
syndrome I-Disease 1
. O 0

DNA O 0
was O 0
also O 0
screened O 0
for O 0
structural O 0
rearrangements O 0
( O 0
deletions O 0
and O 0
duplications O 0
) O 0
and O 0
point O 0
mutations O 0
in O 0
mtDNA O 0
. O 0

No O 0
pathogenic O 0
mtDNA O 0
mutations O 0
were O 0
found O 0
in O 0
our O 0
cohort O 0
. O 0

We O 0
identified O 0
24 O 0
mutations O 0
in O 0
the O 0
WFS1 O 0
gene O 0
8 O 0
nonsense O 0
mutations O 0
, O 0
8 O 0
missense O 0
mutations O 0
, O 0
3 O 0
in O 0
- O 0
frame O 0
deletions O 0
, O 0
1 O 0
in O 0
- O 0
frame O 0
insertion O 0
, O 0
and O 0
4 O 0
frameshift O 0
mutations O 0
. O 0

Of O 0
these O 0
, O 0
23 O 0
were O 0
novel O 0
mutations O 0
, O 0
and O 0
most O 0
occurred O 0
in O 0
exon O 0
8 O 0
. O 0

The O 0
majority O 0
of O 0
patients O 0
were O 0
compound O 0
heterozygotes O 0
for O 0
two O 0
mutations O 0
, O 0
and O 0
there O 0
was O 0
no O 0
common O 0
founder O 0
mutation O 0
. O 0

The O 0
data O 0
were O 0
also O 0
analyzed O 0
for O 0
genotype O 0
- O 0
phenotype O 0
relationships O 0
. O 0

Although O 0
some O 0
interesting O 0
cases O 0
were O 0
noted O 0
, O 0
consideration O 0
of O 0
the O 0
small O 0
sample O 0
size O 0
and O 0
frequency O 0
of O 0
each O 0
mutation O 0
indicated O 0
no O 0
clear O 0
- O 0
cut O 0
correlations O 0
between O 0
any O 0
of O 0
the O 0
observed O 0
mutations O 0
and O 0
disease O 0
severity O 0
. O 0

There O 0
were O 0
no O 0
obvious O 0
mutation O 0
hot O 0
spots O 0
or O 0
clusters O 0
. O 0

Hence O 0
, O 0
molecular O 0
screening O 0
for O 0
Wolfram B-Disease 1
syndrome I-Disease 1
in O 0
affected O 0
families O 0
and O 0
for O 0
Wolfram B-Disease 1
syndrome I-Disease 1
- O 0
carrier O 0
status O 0
in O 0
subjects O 0
with O 0
psychiatric B-Disease 1
disorders I-Disease 1
or O 0
diabetes B-Disease 0
mellitus I-Disease 0
will O 0
require O 0
complete O 0
analysis O 0
of O 0
exon O 0
8 O 0
and O 0
upstream O 0
exons O 0
. O 0
. O 0

Late O 0
- O 0
onset O 0
familial B-Disease 0
Mediterranean I-Disease 0
fever I-Disease 0
( O 0
FMF B-Disease 0
) O 0
: O 0
a O 0
subset O 0
with O 0
distinct O 0
clinical O 0
, O 0
demographic O 0
, O 0
and O 0
molecular O 0
genetic O 0
characteristics O 0
. O 0

To O 0
determine O 0
the O 0
prevalence O 0
and O 0
characterize O 0
demographic O 0
, O 0
clinical O 0
, O 0
and O 0
genetic O 0
features O 0
of O 0
familial B-Disease 0
Mediterranean I-Disease 0
fever I-Disease 0
( O 0
FMF B-Disease 0
) O 0
of O 0
late O 0
onset O 0
, O 0
all O 0
patients O 0
experiencing O 0
their O 0
first O 0
FMF B-Disease 0
attack O 0
at O 0
age O 0
40 O 0
years O 0
or O 0
more O 0
were O 0
identified O 0
using O 0
the O 0
computerized O 0
registry O 0
of O 0
our O 0
FMF B-Disease 0
clinic O 0
, O 0
and O 0
then O 0
thoroughly O 0
interviewed O 0
and O 0
examined O 0
. O 0

The O 0
control O 0
group O 0
consisted O 0
of O 0
40 O 0
consecutive O 0
FMF B-Disease 0
patients O 0
, O 0
who O 0
arrived O 0
at O 0
the O 0
FMF B-Disease 0
clinic O 0
for O 0
their O 0
regular O 0
follow O 0
- O 0
up O 0
visit O 0
and O 0
were O 0
40 O 0
years O 0
of O 0
age O 0
or O 0
older O 0
at O 0
the O 0
time O 0
of O 0
the O 0
examination O 0
. O 0

The O 0
severity O 0
of O 0
the O 0
disease O 0
in O 0
patients O 0
and O 0
controls O 0
was O 0
determined O 0
using O 0
a O 0
modified O 0
score O 0
, O 0
developed O 0
previously O 0
. O 0

Mutational O 0
analysis O 0
in O 0
the O 0
FMF B-Disease 0
gene O 0
was O 0
performed O 0
using O 0
a O 0
commercial O 0
kit O 0
. O 0

Only O 0
20 O 0
of O 0
4000 O 0
( O 0
0 O 0
. O 0
5 O 0
% O 0
) O 0
patients O 0
had O 0
late O 0
- O 0
onset O 0
FMF B-Disease 0
. O 0

These O 0
patients O 0
were O 0
mostly O 0
men O 0
, O 0
of O 0
non O 0
- O 0
North O 0
African O 0
origin O 0
, O 0
P O 0
< O 0
0 O 0
. O 0

05 O 0
compared O 0
to O 0
controls O 0
. O 0

All O 0
had O 0
abdominal O 0
attacks O 0
and O 0
in O 0
most O 0
these O 0
were O 0
the O 0
only O 0
manifestation O 0
of O 0
their O 0
disease O 0
, O 0
P O 0
< O 0
0 O 0
. O 0

001 O 0
001 O 0
. O 0

None O 0
had O 0
chronic O 0
or O 0
prolonged O 0
manifestations O 0
of O 0
FMF B-Disease 0
, O 0
for O 0
example O 0
, O 0
amyloidosis B-Disease 0
, O 0
chronic B-Disease 0
arthritis I-Disease 0
, O 0
or O 0
protracted O 0
myalgia B-Disease 0
, O 0
P O 0
< O 0
0 O 0
. O 0

001 O 0
. O 0

The O 0
response O 0
to O 0
treatment O 0
was O 0
good O 0
despite O 0
using O 0
low O 0
colchicine O 0
dose O 0
, O 0
P O 0
< O 0
0 O 0
. O 0

05 O 0
. O 0

The O 0
overall O 0
severity O 0
score O 0
indicated O 0
a O 0
mild O 0
disease O 0
, O 0
P O 0
< O 0
0 O 0
. O 0

001 O 0
. O 0

Mutational O 0
analysis O 0
revealed O 0
absence O 0
of O 0
M694V O 0
homozygosity O 0
, O 0
P O 0
< O 0
0 O 0
. O 0

01 O 0
, O 0
compared O 0
to O 0
our O 0
regular O 0
FMF B-Disease 0
population O 0
. O 0

We O 0
conclude O 0
that O 0
the O 0
onset O 0
of O 0
FMF B-Disease 0
in O 0
a O 0
late O 0
age O 0
defines O 0
a O 0
milder O 0
form O 0
of O 0
disease O 0
with O 0
typical O 0
clinical O 0
, O 0
demographic O 0
, O 0
and O 0
molecular O 0
genetic O 0
characteristics O 0

A O 0
highly O 0
accurate O 0
, O 0
low O 0
cost O 0
test O 0
for O 0
BRCA1 O 0
mutations O 0
. O 0

The O 0
hereditary B-Disease 1
breast I-Disease 1
and I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
syndrome I-Disease 1
is O 0
associated O 0
with O 0
a O 0
high O 0
frequency O 0
of O 0
BRCA1 O 0
mutations O 0
. O 0

However O 0
, O 0
the O 0
widespread O 0
use O 0
of O 0
BRCA1 O 0
testing O 0
has O 0
been O 0
limited O 0
to O 0
date O 0
by O 0
three O 0
principal O 0
concerns O 0
the O 0
fear O 0
of O 0
loss O 0
of O 0
health O 0
and O 0
life O 0
insurance O 0
, O 0
the O 0
uncertain O 0
clinical O 0
value O 0
of O 0
a O 0
positive O 0
test O 0
result O 0
, O 0
and O 0
the O 0
current O 0
lack O 0
of O 0
an O 0
inexpensive O 0
and O 0
sensitive O 0
screening O 0
test O 0
for O 0
BRCA1 O 0
mutations O 0
. O 0

We O 0
have O 0
developed O 0
an O 0
inexpensive O 0
system O 0
for O 0
gene O 0
mutational O 0
scanning O 0
, O 0
based O 0
on O 0
a O 0
combination O 0
of O 0
extensive O 0
multiplex O 0
PCR O 0
amplification O 0
and O 0
two O 0
dimensional O 0
electrophoresis O 0
. O 0

The O 0
efficiency O 0
of O 0
this O 0
system O 0
, O 0
as O 0
a O 0
screening O 0
test O 0
for O 0
BRCA1 O 0
mutations O 0
, O 0
was O 0
evaluated O 0
in O 0
a O 0
panel O 0
of O 0
60 O 0
samples O 0
from O 0
high O 0
risk O 0
women O 0
, O 0
14 O 0
of O 0
which O 0
contained O 0
a O 0
previously O 0
identified O 0
mutation O 0
in O 0
BRCA1 O 0
. O 0

All O 0
14 O 0
mutations O 0
were O 0
identified O 0
, O 0
as O 0
well O 0
as O 0
an O 0
additional O 0
five O 0
that O 0
had O 0
previously O 0
escaped O 0
detection O 0
. O 0

In O 0
addition O 0
to O 0
the O 0
19 O 0
mutations O 0
, O 0
a O 0
total O 0
of O 0
15 O 0
different O 0
polymorphic O 0
variants O 0
were O 0
scored O 0
, O 0
most O 0
of O 0
which O 0
were O 0
recurring O 0
. O 0

All O 0
were O 0
confirmed O 0
by O 0
nucleotide O 0
sequencing O 0
. O 0

The O 0
cost O 0
of O 0
screening O 0
per O 0
sample O 0
was O 0
calculated O 0
to O 0
be O 0
approximately O 0
US O 0
$ O 0
70 O 0
for O 0
the O 0
manual O 0
technique O 0
used O 0
in O 0
this O 0
study O 0
, O 0
and O 0
may O 0
be O 0
reduced O 0
to O 0
approximately O 0
US O 0
$ O 0
10 O 0
with O 0
the O 0
introduction O 0
of O 0
commercially O 0
available O 0
PCR O 0
robotics O 0
and O 0
fluorescent O 0
imaging O 0
. O 0

Implementation O 0
of O 0
this O 0
method O 0
of O 0
mutation O 0
screening O 0
in O 0
the O 0
research O 0
and O 0
clinical O 0
setting O 0
should O 0
permit O 0
rapid O 0
accrual O 0
of O 0
quantitative O 0
data O 0
on O 0
genotype O 0
- O 0
phenotype O 0
associations O 0
for O 0
the O 0
evaluation O 0
of O 0
diagnostic O 0
testing O 0
. O 0
. O 0

Maternal B-Disease 0
uniparental I-Disease 0
disomy I-Disease 0
for I-Disease 0
chromosome I-Disease 0
14 I-Disease 0
in O 0
a O 0
boy O 0
with O 0
a O 0
normal O 0
karyotype O 0
. O 0

We O 0
report O 0
on O 0
a O 0
boy O 0
with O 0
a O 0
maternal B-Disease 0
uniparental I-Disease 0
disomy I-Disease 0
for I-Disease 0
chromosome I-Disease 0
14 I-Disease 0
( O 0
UPD B-Disease 0
( O 0
14 O 0
) O 0
) O 0
. O 0

At O 0
7 O 0
years O 0
of O 0
age O 0
he O 0
was O 0
referred O 0
to O 0
us O 0
by O 0
the O 0
paediatrician O 0
because O 0
of O 0
symptoms O 0
of O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
. O 0

He O 0
showed O 0
short B-Disease 0
stature I-Disease 0
, O 0
obesity B-Disease 0
, O 0
mild O 0
developmental B-Disease 1
delay I-Disease 1
, O 0
cryptorchidism B-Disease 0
, O 0
and O 0
some O 0
mild O 0
dysmorphic B-Disease 0
features I-Disease 0
. O 0

The O 0
history O 0
further O 0
indicated O 0
intrauterine B-Disease 0
growth I-Disease 0
retardation I-Disease 0
at O 0
the O 0
end O 0
of O 0
the O 0
pregnancy O 0
. O 0

His O 0
mother O 0
was O 0
44 O 0
years O 0
of O 0
age O 0
at O 0
the O 0
time O 0
of O 0
his O 0
birth O 0
. O 0

After O 0
birth O 0
he O 0
showed O 0
hypotonia B-Disease 0
with O 0
poor O 0
sucking O 0
, O 0
for O 0
which O 0
gavage O 0
feeding O 0
was O 0
needed O 0
. O 0

Motor O 0
development O 0
was O 0
delayed O 0
. O 0

After O 0
1 O 0
year O 0
he O 0
became O 0
obese B-Disease 1
despite O 0
a O 0
normal O 0
appetite O 0
. O 0

Recurrent O 0
middle B-Disease 0
ear I-Disease 0
infections I-Disease 0
, O 0
a O 0
high O 0
pain O 0
threshold O 0
, O 0
and O 0
a O 0
great O 0
skill O 0
with O 0
jigsaw O 0
puzzles O 0
were O 0
reported O 0
. O 0

There O 0
were O 0
no O 0
behavioural O 0
problems O 0
or O 0
sleep O 0
disturbance O 0
. O 0

Chromosomal O 0
analysis O 0
was O 0
normal O 0
( O 0
46 O 0
, O 0
XY O 0
) O 0
. O 0

DNA O 0
analysis O 0
for O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
showed O 0
no O 0
abnormalities O 0
. O 0

Two O 0
years O 0
later O 0
he O 0
was O 0
re O 0
- O 0
examined O 0
because O 0
we O 0
thought O 0
his O 0
features O 0
fitted O 0
the O 0
PWS B-Disease 0
- O 0
like O 0
phenotype O 0
associated O 0
with O 0
maternal O 0
UPD B-Disease 0
( O 0
14 O 0
) O 0
. O 0

At O 0
that O 0
time O 0
precocious O 0
puberty O 0
was O 0
evident O 0
. O 0

DNA O 0
analysis O 0
showed O 0
maternal B-Disease 1
heterodisomy I-Disease 1
for O 0
chromosome O 0
14 O 0
. O 0

In O 0
all O 0
the O 0
previously O 0
described O 0
11 O 0
cases O 0
with O 0
maternal O 0
UPD B-Disease 0
( O 0
14 O 0
) O 0
, O 0
a O 0
Robertsonian O 0
translocation O 0
involving O 0
chromosome O 0
14 O 0
was O 0
detected O 0
cytogenetically O 0
before O 0
DNA O 0
analysis O 0
. O 0

This O 0
is O 0
the O 0
first O 0
report O 0
of O 0
diagnosis O 0
of O 0
maternal O 0
UPD B-Disease 0
( O 0
14 O 0
) O 0
based O 0
on O 0
clinical O 0
features O 0
. O 0

This O 0
finding O 0
underlines O 0
the O 0
importance O 0
of O 0
DNA O 0
analysis O 0
for O 0
maternal O 0
UPD O 0
( O 0
14 O 0
) O 0
in O 0
patients O 0
with O 0
a O 0
similar O 0
PWS B-Disease 0
- O 0
like O 0
phenotype O 0
even O 0
without O 0
previous O 0
identification O 0
of O 0
a O 0
Robertsonian O 0
translocation O 0
involving O 0
chromosome O 0
14 O 0
. O 0
. O 0

Clinical O 0
and O 0
genetic O 0
study O 0
of O 0
Friedreich B-Disease 1
ataxia I-Disease 1
in O 0
an O 0
Australian O 0
population O 0
. O 0

Friedreich B-Disease 1
ataxia I-Disease 1
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
caused O 0
by O 0
mutations O 0
in O 0
the O 0
FRDA B-Disease 0
gene O 0
that O 0
encodes O 0
a O 0
210 O 0
- O 0
amino O 0
acid O 0
protein O 0
called O 0
frataxin O 0
. O 0

An O 0
expansion O 0
of O 0
a O 0
GAA O 0
trinucleotide O 0
repeat O 0
in O 0
intron O 0
1 O 0
of O 0
the O 0
gene O 0
is O 0
present O 0
in O 0
more O 0
than O 0
95 O 0
% O 0
of O 0
mutant O 0
alleles O 0
. O 0

Of O 0
the O 0
83 O 0
people O 0
we O 0
studied O 0
who O 0
have O 0
mutations O 0
in O 0
FRDA O 0
, O 0
78 O 0
are O 0
homozygous O 0
for O 0
an O 0
expanded O 0
GAA O 0
repeat O 0
; O 0
the O 0
other O 0
five O 0
patients O 0
have O 0
an O 0
expansion O 0
in O 0
one O 0
allele O 0
and O 0
a O 0
point O 0
mutation O 0
in O 0
the O 0
other O 0
. O 0

Here O 0
we O 0
present O 0
a O 0
detailed O 0
clinical O 0
and O 0
genetic O 0
study O 0
of O 0
a O 0
subset O 0
of O 0
51 O 0
patients O 0
homozygous O 0
for O 0
an O 0
expansion O 0
of O 0
the O 0
GAA O 0
repeat O 0
. O 0

We O 0
found O 0
a O 0
correlation O 0
between O 0
the O 0
size O 0
of O 0
the O 0
smaller O 0
of O 0
the O 0
two O 0
expanded O 0
alleles O 0
and O 0
age O 0
at O 0
onset O 0
, O 0
age O 0
into O 0
wheelchair O 0
, O 0
scoliosis B-Disease 1
, O 0
impaired O 0
vibration O 0
sense O 0
, O 0
and O 0
the O 0
presence O 0
of O 0
foot B-Disease 0
deformity I-Disease 0
. O 0

There O 0
was O 0
no O 0
significant O 0
correlation O 0
between O 0
the O 0
size O 0
of O 0
the O 0
smaller O 0
allele O 0
and O 0
cardiomyopathy B-Disease 1
, O 0
diabetes B-Disease 0
mellitus I-Disease 0
, O 0
loss B-Disease 0
of I-Disease 0
proprioception I-Disease 0
, O 0
or O 0
bladder B-Disease 0
symptoms I-Disease 0
. O 0

The O 0
larger O 0
allele O 0
size O 0
correlated O 0
with O 0
bladder B-Disease 0
symptoms I-Disease 0
and O 0
the O 0
presence O 0
of O 0
foot B-Disease 0
deformity I-Disease 0
. O 0

The O 0
duration O 0
of O 0
disease O 0
is O 0
correlated O 0
with O 0
wheelchair O 0
use O 0
and O 0
the O 0
presence O 0
of O 0
diabetes B-Disease 0
, O 0
scoliosis B-Disease 1
, O 0
bladder B-Disease 0
symptoms I-Disease 0
and O 0
impaired B-Disease 0
proprioception I-Disease 0
, O 0
and O 0
vibration O 0
sense O 0
but O 0
no O 0
other O 0
complications O 0
studied O 0
. O 0
. O 0

Novel O 0
mutations O 0
in O 0
XLRS1 O 0
causing O 0
retinoschisis B-Disease 0
, O 0
including O 0
first O 0
evidence O 0
of O 0
putative O 0
leader O 0
sequence O 0
change O 0
. O 0

Juvenile B-Disease 0
retinoschisis I-Disease 0
is O 0
an O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
recessive I-Disease 1
disease I-Disease 1
caused O 0
by O 0
mutations O 0
in O 0
the O 0
XLRS1 O 0
gene O 0
. O 0

We O 0
screened O 0
31 O 0
new O 0
unrelated O 0
patients O 0
and O 0
families O 0
for O 0
XLRS1 O 0
mutations O 0
in O 0
addition O 0
to O 0
previously O 0
reported O 0
mutations O 0
for O 0
60 O 0
of O 0
our O 0
families O 0
( O 0
Retinoschisis B-Disease 1
Consortium O 0
, O 0
Hum O 0
Mol O 0
Genet O 0
1998 O 0
; O 0
7 O 0
1185 O 0
- O 0
1192 O 0
) O 0
. O 0

Twenty O 0
- O 0
three O 0
different O 0
mutations O 0
including O 0
12 O 0
novel O 0
ones O 0
were O 0
identified O 0
in O 0
28 O 0
patients O 0
. O 0

Mutations O 0
identified O 0
in O 0
this O 0
study O 0
include O 0
19 O 0
missense O 0
mutations O 0
, O 0
two O 0
nonsense O 0
mutations O 0
, O 0
one O 0
intragenic O 0
deletion O 0
, O 0
four O 0
microdeletions O 0
, O 0
one O 0
insertion O 0
, O 0
and O 0
one O 0
intronic O 0
sequence O 0
substitution O 0
that O 0
is O 0
likely O 0
to O 0
result O 0
in O 0
a O 0
splice O 0
site O 0
defect O 0
. O 0

Two O 0
novel O 0
mutations O 0
, O 0
c O 0
. O 0

38T O 0
- O 0
- O 0
> O 0
C O 0
( O 0
L13P O 0
) O 0
and O 0
c O 0
. O 0

667T O 0
- O 0
- O 0
> O 0
C O 0
( O 0
C223R O 0
) O 0
, O 0
respectively O 0
, O 0
present O 0
the O 0
first O 0
genetic O 0
evidence O 0
for O 0
the O 0
functional O 0
significance O 0
of O 0
the O 0
putative O 0
leader O 0
peptide O 0
sequence O 0
and O 0
for O 0
the O 0
functional O 0
significance O 0
at O 0
the O 0
carboxyl O 0
terminal O 0
of O 0
the O 0
XLRS1 O 0
protein O 0
beyond O 0
the O 0
discoidin O 0
domain O 0
. O 0

Mutations O 0
in O 0
25 O 0
of O 0
the O 0
families O 0
were O 0
localized O 0
to O 0
exons O 0
4 O 0
- O 0
6 O 0
, O 0
emphasizing O 0
the O 0
critical O 0
functional O 0
significance O 0
of O 0
the O 0
discoidin O 0
domain O 0
of O 0
the O 0
XLRS1 O 0
protein O 0

Growth O 0
hormone O 0
treatment O 0
increases O 0
CO O 0
( O 0
2 O 0
) O 0
response O 0
, O 0
ventilation O 0
and O 0
central O 0
inspiratory O 0
drive O 0
in O 0
children O 0
with O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
. O 0

We O 0
studied O 0
whether O 0
the O 0
beneficial O 0
effects O 0
of O 0
growth O 0
hormone O 0
( O 0
GH O 1
) O 0
treatment O 0
on O 0
growth O 0
and O 0
body O 0
composition O 0
in O 0
PWS B-Disease 0
are O 0
accompanied O 0
by O 0
an O 0
improvement O 0
in O 0
respiratory O 0
function O 0
. O 0

We O 0
measured O 0
resting O 0
ventilation O 0
, O 0
airway O 0
occlusion O 0
pressure O 0
( O 0
P O 0
( O 0
0 O 0
. O 0
1 O 0
) O 0
) O 0
and O 0
ventilatory O 0
response O 0
to O 0
CO O 0
( O 0
2 O 0
) O 0
in O 0
nine O 0
children O 0
, O 0
aged O 0
7 O 0
- O 0
14 O 0
years O 0
, O 0
before O 0
and O 0
6 O 0
- O 0
9 O 0
months O 0
after O 0
the O 0
start O 0
of O 0
GH O 1
treatment O 0
. O 0

During O 0
GH O 1
treatment O 0
, O 0
resting O 0
ventilation O 0
increased O 0
by O 0
26 O 0
% O 0
, O 0
P O 0
( O 0
0 O 0
. O 0
1 O 0
) O 0
by O 0
72 O 0
% O 0
and O 0
the O 0
response O 0
to O 0
CO O 0
( O 0
2 O 0
) O 0
by O 0
65 O 0
% O 0
( O 0
P O 0
< O 0
0 O 0
. O 0
002 O 0
, O 0
< O 0
0 O 0
. O 0
04 O 0
and O 0
< O 0
0 O 0
. O 0
02 O 0
, O 0
respectively O 0
) O 0
. O 0

This O 0
observed O 0
increase O 0
in O 0
ventilatory O 0
output O 0
was O 0
not O 0
correlated O 0
to O 0
changes O 0
in O 0
body O 0
mass O 0
index O 0
. O 0

CONCLUSION O 0
Treatment O 0
of O 0
children O 0
with O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
seems O 0
to O 0
have O 0
a O 0
stimulatory O 0
effect O 0
on O 0
central O 0
respiratory O 0
structures O 0
. O 0

The O 0
observed O 0
increase O 0
in O 0
ventilation O 0
and O 0
inspiratory O 0
drive O 0
may O 0
contribute O 0
to O 0
the O 0
improved O 0
activity O 0
level O 0
reported O 0
by O 0
parents O 0
of O 0
PWS B-Disease 0
children O 0
during O 0
growth O 0
hormone O 0
therapy O 0

G130V O 0
, O 0
a O 0
common O 0
FRDA B-Disease 0
point O 0
mutation O 0
, O 0
appears O 0
to O 0
have O 0
arisen O 0
from O 0
a O 0
common O 0
founder O 0
. O 0

Friedreich B-Disease 1
ataxia I-Disease 1
( O 0
FRDA B-Disease 0
) O 0
is O 0
the O 0
most O 0
common O 0
inherited B-Disease 0
ataxia I-Disease 0
. O 0

About O 0
98 O 0
% O 0
of O 0
mutant O 0
alleles O 0
have O 0
an O 0
expansion O 0
of O 0
a O 0
GAA O 0
trinucleotide O 0
repeat O 0
in O 0
intron O 0
1 O 0
of O 0
the O 0
affected O 0
gene O 0
, O 0
FRDA O 0
. O 0

The O 0
other O 0
2 O 0
% O 0
are O 0
point O 0
mutations O 0
. O 0

Of O 0
the O 0
17 O 0
point O 0
mutations O 0
so O 0
far O 0
described O 0
, O 0
three O 0
appear O 0
to O 0
be O 0
more O 0
common O 0
. O 0

One O 0
of O 0
these O 0
is O 0
the O 0
G130V O 0
mutation O 0
in O 0
exon O 0
4 O 0
of O 0
FRDA O 0
. O 0

G130V O 0
, O 0
when O 0
present O 0
with O 0
an O 0
expanded O 0
GAA O 0
repeat O 0
on O 0
the O 0
other O 0
allele O 0
, O 0
is O 0
associated O 0
with O 0
an O 0
atypical O 0
FRDA B-Disease 0
phenotype O 0
. O 0

Haplotype O 0
analysis O 0
was O 0
undertaken O 0
on O 0
the O 0
four O 0
families O 0
who O 0
have O 0
been O 0
described O 0
with O 0
this O 0
mutation O 0
. O 0

The O 0
results O 0
suggest O 0
a O 0
common O 0
founder O 0
for O 0
this O 0
mutation O 0
. O 0

Although O 0
marked O 0
differences O 0
in O 0
extragenic O 0
marker O 0
haplotypes O 0
were O 0
seen O 0
in O 0
one O 0
family O 0
, O 0
similar O 0
intragenic O 0
haplotyping O 0
suggests O 0
the O 0
same O 0
mutation O 0
founder O 0
for O 0
this O 0
family O 0
with O 0
the O 0
differences O 0
explicable O 0
by O 0
two O 0
recombination O 0
events O 0
. O 0
. O 0

Synergistic O 0
effect O 0
of O 0
histone O 0
hyperacetylation O 0
and O 0
DNA O 0
demethylation O 0
in O 0
the O 0
reactivation O 0
of O 0
the O 0
FMR1 O 0
gene O 0
. O 0

Most O 0
fragile B-Disease 1
X I-Disease 1
syndrome I-Disease 1
patients O 0
have O 0
expansion O 0
of O 0
a O 0
( O 0
CGG O 0
) O 0
( O 0
n O 0
) O 0
sequence O 0
with O 0
> O 0
200 O 0
repeats O 0
( O 0
full O 0
mutation O 0
) O 0
in O 0
the O 0
FMR1 O 0
gene O 0
responsible O 0
for O 0
this O 0
condition O 0
. O 0

Hypermethylation O 0
of O 0
the O 0
expanded O 0
repeat O 0
and O 0
of O 0
the O 0
FMR1 O 0
promoter O 0
is O 0
almost O 0
always O 0
present O 0
and O 0
apparently O 0
suppresses O 0
transcription O 0
, O 0
resulting O 0
in O 0
absence O 0
of O 0
the O 0
FMR1 O 0
protein O 0
. O 0

We O 0
recently O 0
showed O 0
that O 0
transcriptional O 0
reactivation O 0
of O 0
FMR1 O 0
full O 0
mutations O 0
can O 0
be O 0
achieved O 0
by O 0
inducing O 0
DNA O 0
demethylation O 0
with O 0
5 O 0
- O 0
azadeoxycytidine O 0
( O 0
5 O 0
- O 0
azadC O 0
) O 0
. O 0

The O 0
level O 0
of O 0
histone O 0
acetylation O 0
is O 0
another O 0
important O 0
factor O 0
in O 0
regulating O 0
gene O 0
expression O 0
; O 0
therefore O 0
, O 0
we O 0
treated O 0
lymphoblastoid O 0
cell O 0
lines O 0
of O 0
non O 0
- O 0
mosaic O 0
full O 0
mutation O 0
patients O 0
with O 0
three O 0
drugs O 0
capable O 0
of O 0
inducing O 0
histone O 0
hyperacetylation O 0
. O 0

We O 0
observed O 0
a O 0
consistent O 0
, O 0
although O 0
modest O 0
, O 0
reactivation O 0
of O 0
the O 0
FMR1 O 0
gene O 0
with O 0
4 O 0
- O 0
phenylbutyrate O 0
, O 0
sodium O 0
butyrate O 0
and O 0
trichostatin O 0
A O 0
, O 0
as O 0
shown O 0
by O 0
RT O 0
- O 0
PCR O 0
. O 0

However O 0
, O 0
we O 0
report O 0
that O 0
combining O 0
these O 0
drugs O 0
with O 0
5 O 0
- O 0
azadC O 0
results O 0
in O 0
a O 0
2 O 0
- O 0
to O 0
5 O 0
- O 0
fold O 0
increase O 0
in O 0
FMR1 O 0
mRNA O 0
levels O 0
obtained O 0
with O 0
5 O 0
- O 0
azadC O 0
alone O 0
, O 0
thus O 0
showing O 0
a O 0
marked O 0
synergistic O 0
effect O 0
of O 0
histone O 0
hyperacetylation O 0
and O 0
DNA O 0
demethylation O 0
in O 0
the O 0
reactivation O 0
of O 0
FMR1 O 0
full O 0
mutations O 0
. O 0
. O 0

Constitutional O 0
von B-Disease 0
Hippel I-Disease 0
- I-Disease 0
Lindau I-Disease 0
( O 0
VHL B-Disease 1
) O 0
gene O 0
deletions O 0
detected O 0
in O 0
VHL B-Disease 1
families O 0
by O 0
fluorescence O 0
in O 0
situ O 0
hybridization O 0
. O 0

von B-Disease 0
Hippel I-Disease 0
- I-Disease 0
Lindau I-Disease 0
( I-Disease 0
VHL I-Disease 1
) I-Disease 0
disease I-Disease 0
is O 0
an O 0
autosomal B-Disease 0
dominantly I-Disease 0
inherited I-Disease 0
cancer I-Disease 1
syndrome I-Disease 0
predisposing O 0
to O 0
a O 0
variety O 0
of O 0
tumor B-Disease 0
types O 0
that O 0
include O 0
retinal O 0
hemangioblastomas B-Disease 1
, O 0
hemangioblastomas B-Disease 1
of O 0
the O 0
central O 0
nervous O 0
system O 0
, O 0
renal B-Disease 0
cell I-Disease 0
carcinomas I-Disease 0
, O 0
pancreatic B-Disease 0
cysts I-Disease 0
and I-Disease 0
tumors I-Disease 0
, O 0
pheochromocytomas B-Disease 1
, O 0
endolymphatic B-Disease 1
sac I-Disease 1
tumors I-Disease 1
, O 0
and O 0
epididymal B-Disease 0
cystadenomas I-Disease 0
[ O 0
W O 0
. O 0

M O 0
. O 0

Linehan O 0
et O 0
al O 0
. O 0
, O 0
J O 0
. O 0

Am O 0
. O 0
Med O 0
. O 0
Assoc O 0
. O 0
, O 0
273 O 0
564 O 0
- O 0
570 O 0
, O 0
1995 O 0
; O 0
E O 0
. O 0
A O 0
. O 0
Maher O 0
and O 0
W O 0
. O 0
G O 0
. O 0
Kaelin O 0
, O 0
Jr O 0
. O 0
, O 0
Medicine O 0
( O 0
Baltimore O 0
) O 0
, O 0
76 O 0
381 O 0
- O 0
391 O 0
, O 0
1997 O 0
; O 0
W O 0
. O 0
M O 0
. O 0
Linehan O 0
and O 0
R O 0
. O 0
D O 0
. O 0
Klausner O 0
, O 0
In O 0
B O 0
. O 0
Vogelstein O 0
and O 0
K O 0
. O 0
Kinzler O 0
( O 0
eds O 0
. O 0
) O 0
, O 0
The O 0
Genetic O 0
Basis O 0
of O 0
Human O 0
Cancer O 1
, O 0
pp O 0
. O 0

455 O 0
- O 0
473 O 0
, O 0
McGraw O 0
- O 0
Hill O 0
, O 0
1998 O 0
] O 0
. O 0

The O 0
VHL B-Disease 1
gene O 0
was O 0
localized O 0
to O 0
chromosome O 0
3p25 O 0
- O 0
26 O 0
and O 0
cloned O 0
[ O 0
F O 0
. O 0
Latif O 0
et O 0
al O 0
. O 0
, O 0
Science O 0
( O 0
Washington O 0
DC O 0
) O 0
, O 0
260 O 0
1317 O 0
- O 0
1320 O 0
, O 0
1993 O 0
] O 0
. O 0

Germline O 0
mutations O 0
in O 0
the O 0
VHL B-Disease 1
gene O 0
have O 0
been O 0
detected O 0
in O 0
the O 0
majority O 0
of O 0
VHL B-Disease 1
kindreds O 0
. O 0

The O 0
reported O 0
frequency O 0
of O 0
detection O 0
of O 0
VHL B-Disease 1
germline O 0
mutations O 0
has O 0
varied O 0
from O 0
39 O 0
to O 0
80 O 0
% O 0
( O 0
J O 0
. O 0
M O 0
. O 0
Whaley O 0
et O 0
al O 0
. O 0
, O 0
Am O 0
. O 0
J O 0
. O 0
Hum O 0
. O 0
Genet O 0
. O 0
, O 0
55 O 0
1092 O 0
- O 0
1102 O 0
, O 0
1994 O 0
; O 0
Clinical O 0
Research O 0
Group O 0
for O 0
Japan O 0
, O 0
Hum O 0
. O 0
Mol O 0
. O 0
Genet O 0
. O 0
, O 0
4 O 0
2233 O 0
- O 0
2237 O 0
, O 0
1995 O 0
; O 0
F O 0
. O 0
Chen O 0
et O 0
al O 0
. O 0
, O 0
Hum O 0
. O 0
Mutat O 0
. O 0
, O 0
5 O 0
66 O 0
- O 0
75 O 0
, O 0
1995 O 0
; O 0
E O 0
. O 0
R O 0
. O 0
Maher O 0
et O 0
al O 0
. O 0
, O 0
J O 0
. O 0
Med O 0
. O 0
Genet O 0
. O 0
, O 0
33 O 0
328 O 0
- O 0
332 O 0
, O 0
1996 O 0
; O 0
B O 0
. O 0
Zbar O 0
, O 0
Cancer O 1
Surv O 0
. O 0
, O 0
25 O 0
219 O 0
- O 0
232 O 0
, O 0
1995 O 0
) O 0
. O 0

Recently O 0
a O 0
quantitative O 0
Southern O 0
blotting O 0
procedure O 0
was O 0
found O 0
to O 0
improve O 0
this O 0
frequency O 0
( O 0
C O 0
. O 0
Stolle O 0
et O 0
al O 0
. O 0
, O 0
Hum O 0
. O 0
Mutat O 0
. O 0
, O 0
12 O 0
417 O 0
- O 0
423 O 0
, O 0
1998 O 0
) O 0
. O 0

In O 0
the O 0
present O 0
study O 0
, O 0
we O 0
report O 0
the O 0
use O 0
of O 0
fluorescence O 0
in O 0
situ O 0
hybridization O 0
( O 0
FISH O 0
) O 0
as O 0
a O 0
method O 0
to O 0
detect O 0
and O 0
characterize O 0
VHL B-Disease 1
germline O 0
deletions O 0
. O 0

We O 0
reexamined O 0
a O 0
group O 0
of O 0
VHL B-Disease 1
patients O 0
shown O 0
previously O 0
by O 0
single O 0
- O 0
strand O 0
conformation O 0
and O 0
sequencing O 0
analysis O 0
not O 0
to O 0
harbor O 0
point O 0
mutations O 0
in O 0
the O 0
VHL B-Disease 1
locus O 0
. O 0

We O 0
found O 0
constitutional O 0
deletions O 0
in O 0
29 O 0
of O 0
30 O 0
VHL B-Disease 1
patients O 0
in O 0
this O 0
group O 0
using O 0
cosmid O 0
and O 0
P1 O 0
probes O 0
that O 0
cover O 0
the O 0
VHL B-Disease 1
locus O 0
. O 0

We O 0
then O 0
tested O 0
six O 0
phenotypically O 0
normal O 0
offspring O 0
from O 0
four O 0
of O 0
these O 0
VHL B-Disease 1
families O 0
two O 0
were O 0
found O 0
to O 0
carry O 0
the O 0
deletion O 0
and O 0
the O 0
other O 0
four O 0
were O 0
deletion O 0
- O 0
free O 0
. O 0

In O 0
addition O 0
, O 0
germline O 0
mosaicism O 0
of O 0
the O 0
VHL B-Disease 1
gene O 0
was O 0
identified O 0
in O 0
one O 0
family O 0
. O 0

In O 0
sum O 0
, O 0
FISH O 0
was O 0
found O 0
to O 0
be O 0
a O 0
simple O 0
and O 0
reliable O 0
method O 0
to O 0
detect O 0
VHL B-Disease 1
germline O 0
deletions O 0
and O 0
practically O 0
useful O 0
in O 0
cases O 0
where O 0
other O 0
methods O 0
of O 0
screening O 0
have O 0
failed O 0
to O 0
detect O 0
a O 0
VHL B-Disease 1
gene I-Disease 1
abnormality I-Disease 1

Spectrum O 0
of O 0
hSNF5 O 0
/ O 0
INI1 O 0
somatic O 0
mutations O 0
in O 0
human O 0
cancer B-Disease 1
and O 0
genotype O 0
- O 0
phenotype O 0
correlations O 0
. O 0

The O 0
hSNF5 O 0
/ O 0
INI1 O 0
gene O 0
which O 0
encodes O 0
a O 0
member O 0
of O 0
the O 0
SWI O 0
/ O 0
SNF O 0
chromatin O 0
ATP O 0
- O 0
dependent O 0
remodeling O 0
complex O 0
, O 0
is O 0
a O 0
new O 0
tumor B-Disease 0
suppressor O 0
gene O 0
localized O 0
on O 0
chromosome O 0
22q11 O 0
. O 0

2 O 0
and O 0
recently O 0
shown O 0
to O 0
be O 0
mutated O 0
in O 0
malignant B-Disease 0
rhabdoid I-Disease 1
tumors I-Disease 1
. O 0

We O 0
have O 0
searched O 0
for O 0
hSNF5 O 0
/ O 0
INI1 O 0
mutations O 0
in O 0
229 O 0
tumors B-Disease 0
of O 0
various O 0
origins O 0
using O 0
a O 0
screening O 0
method O 0
based O 0
on O 0
denaturing O 0
high O 0
- O 0
performance O 0
liquid O 0
chromatography O 0
. O 0

A O 0
total O 0
of O 0
31 O 0
homozygous O 0
deletions O 0
and O 0
36 O 0
point O 0
alterations O 0
were O 0
identified O 0
. O 0

Point O 0
mutations O 0
were O 0
scattered O 0
along O 0
the O 0
coding O 0
sequence O 0
and O 0
included O 0
15 O 0
nonsense O 0
, O 0
15 O 0
frameshift O 0
, O 0
three O 0
splice O 0
site O 0
, O 0
two O 0
missense O 0
and O 0
one O 0
editing O 0
mutations O 0
. O 0

Mutations O 0
were O 0
retrieved O 0
in O 0
most O 0
rhabdoid B-Disease 1
tumors I-Disease 1
, O 0
whatever O 0
their O 0
sites O 0
of O 0
occurrence O 0
, O 0
indicating O 0
the O 0
common O 0
pathogenetic O 0
origin O 0
of O 0
these O 0
tumors B-Disease 0
. O 0

Recurrent O 0
hSNF5 O 0
/ O 0
INI1 O 0
alterations O 0
were O 0
also O 0
observed O 0
in O 0
choroid B-Disease 1
plexus I-Disease 1
carcinomas I-Disease 1
and O 0
in O 0
a O 0
subset O 0
of O 0
central O 0
primitive O 0
neuroectodermal B-Disease 0
tumors I-Disease 0
( O 0
cPNETs O 0
) O 0
and O 0
medulloblastomas B-Disease 0
. O 0

In O 0
contrast O 0
, O 0
hSNF5 O 0
/ O 0
INI1 O 0
point O 0
mutations O 0
were O 0
not O 0
detected O 0
in O 0
breast B-Disease 0
cancers I-Disease 0
, O 0
Wilms B-Disease 0
tumors I-Disease 0
, O 0
gliomas B-Disease 0
, O 0
ependymomas B-Disease 1
, O 0
sarcomas B-Disease 1
and O 0
other O 0
tumor B-Disease 0
types O 0
, O 0
even O 0
though O 0
most O 0
analyzed O 0
cases O 0
harbored O 0
loss O 0
of O 0
heterozygosity O 0
at O 0
22q11 O 0
. O 0

2 O 0
loci O 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
rhabdoid B-Disease 1
tumors I-Disease 1
, O 0
choroid B-Disease 1
plexus I-Disease 1
carcinomas I-Disease 1
and O 0
a O 0
subset O 0
of O 0
medulloblastomas B-Disease 0
and O 0
cPNETs O 0
share O 0
common O 0
pathways O 0
of O 0
oncogenesis O 0
related O 0
to O 0
hSNF5 O 0
/ O 0
INI1 O 0
alteration O 0
and O 0
that O 0
hSNF5 O 0
/ O 0
INI1 O 0
mutations O 0
define O 0
a O 0
genetically O 0
homogeneous O 0
family O 0
of O 0
highly O 0
aggressive O 0
cancers B-Disease 0
mainly O 0
occurring O 0
in O 0
young O 0
children O 0
and O 0
frequently O 0
, O 0
but O 0
not O 0
always O 0
, O 0
exhibiting O 0
a O 0
rhabdoid B-Disease 0
phenotype O 0

Ataxin O 0
- O 0
3 O 0
with O 0
an O 0
altered O 0
conformation O 0
that O 0
exposes O 0
the O 0
polyglutamine O 0
domain O 0
is O 0
associated O 0
with O 0
the O 0
nuclear O 0
matrix O 0
. O 0

Spinocerebellar B-Disease 0
ataxia I-Disease 0
type I-Disease 0
- I-Disease 0
3 I-Disease 0
or O 0
Machado B-Disease 0
- I-Disease 0
Joseph I-Disease 0
disease I-Disease 0
( O 0
SCA3 B-Disease 1
/ O 0
MJD B-Disease 0
) O 0
is O 0
a O 0
member O 0
of O 0
the O 0
CAG B-Disease 0
/ I-Disease 0
polyglutamine I-Disease 0
repeat I-Disease 0
disease I-Disease 0
family O 0
. O 0

In O 0
this O 0
family O 0
of O 0
disorders O 0
, O 0
a O 0
normally O 0
polymorphic O 0
CAG O 0
repeat O 0
becomes O 0
expanded O 0
, O 0
resulting O 0
in O 0
expression O 0
of O 0
an O 0
expanded O 0
polyglutamine O 0
domain O 0
in O 0
the O 0
disease O 0
gene O 0
product O 0
. O 0

Experimental O 0
models O 0
of O 0
polyglutamine B-Disease 1
disease I-Disease 1
implicate O 0
the O 0
nucleus O 0
in O 0
pathogenesis O 0
; O 0
however O 0
, O 0
the O 0
link O 0
between O 0
intranuclear O 0
expression O 0
of O 0
expanded O 0
polyglutamine O 0
and O 0
neuronal B-Disease 0
dysfunction I-Disease 0
remains O 0
unclear O 0
. O 0

Here O 0
we O 0
demonstrate O 0
that O 0
ataxin O 0
- O 0
3 O 0
, O 0
the O 0
disease O 0
protein O 0
in O 0
SCA3 B-Disease 1
/ O 0
MJD B-Disease 0
, O 0
adopts O 0
a O 0
unique O 0
conformation O 0
when O 0
expressed O 0
within O 0
the O 0
nucleus O 0
of O 0
transfected O 0
cells O 0
. O 0

The O 0
monoclonal O 0
antibody O 0
1C2 O 0
is O 0
known O 0
preferentially O 0
to O 0
bind O 0
expanded O 0
polyglutamine O 0
, O 0
but O 0
we O 0
find O 0
that O 0
it O 0
also O 0
binds O 0
a O 0
fragment O 0
of O 0
ataxin O 0
- O 0
3 O 0
containing O 0
a O 0
normal O 0
glutamine O 0
repeat O 0
. O 0

In O 0
addition O 0
, O 0
expression O 0
of O 0
ataxin O 0
- O 0
3 O 0
within O 0
the O 0
nucleus O 0
exposes O 0
the O 0
glutamine O 0
domain O 0
of O 0
the O 0
full O 0
- O 0
length O 0
non O 0
- O 0
pathological O 0
protein O 0
, O 0
allowing O 0
it O 0
to O 0
bind O 0
the O 0
monoclonal O 0
antibody O 0
1C2 O 0
. O 0

Fractionation O 0
and O 0
immunochemical O 0
experiments O 0
indicate O 0
that O 0
this O 0
novel O 0
conformation O 0
of O 0
intranuclear O 0
ataxin O 0
- O 0
3 O 0
is O 0
not O 0
due O 0
to O 0
proteolysis O 0
, O 0
suggesting O 0
instead O 0
that O 0
association O 0
with O 0
nuclear O 0
protein O 0
( O 0
s O 0
) O 0
alters O 0
the O 0
structure O 0
of O 0
full O 0
- O 0
length O 0
ataxin O 0
- O 0
3 O 0
which O 0
exposes O 0
the O 0
polyglutamine O 0
domain O 0
. O 0

This O 0
conformationally O 0
altered O 0
ataxin O 0
- O 0
3 O 0
is O 0
bound O 0
to O 0
the O 0
nuclear O 0
matrix O 0
. O 0

The O 0
pathological O 0
form O 0
of O 0
ataxin O 0
- O 0
3 O 0
with O 0
an O 0
expanded O 0
polyglutamine O 0
domain O 0
also O 0
associates O 0
with O 0
the O 0
nuclear O 0
matrix O 0
. O 0

These O 0
data O 0
suggest O 0
that O 0
an O 0
early O 0
event O 0
in O 0
the O 0
pathogenesis O 0
of O 0
SCA3 B-Disease 1
/ O 0
MJD B-Disease 0
may O 0
be O 0
an O 0
altered O 0
conformation O 0
of O 0
ataxin O 0
- O 0
3 O 0
within O 0
the O 0
nucleus O 0
that O 0
exposes O 0
the O 0
polyglutamine O 0
domain O 0
. O 0
. O 0

The O 0
human O 0
MAGEL2 O 0
gene O 0
and O 0
its O 0
mouse O 0
homologue O 0
are O 0
paternally O 0
expressed O 0
and O 0
mapped O 0
to O 0
the O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
region O 0
. O 0

Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
is O 0
a O 0
complex O 0
neurogenetic B-Disease 0
disorder I-Disease 0
. O 0

The O 0
phenotype O 0
is O 0
likely O 0
to O 0
be O 0
a O 0
contiguous B-Disease 1
gene I-Disease 1
syndrome I-Disease 1
involving O 0
genes O 0
which O 0
are O 0
paternally O 0
expressed O 0
only O 0
, O 0
located O 0
in O 0
the O 0
human O 0
15q11 O 0
- O 0
q13 O 0
region O 0
. O 0

Four O 0
mouse O 0
models O 0
of O 0
PWS B-Disease 0
have O 0
been O 0
reported O 0
but O 0
these O 0
do O 0
not O 0
definitively O 0
allow O 0
the O 0
delineation O 0
of O 0
the O 0
critical O 0
region O 0
and O 0
the O 0
associated O 0
genes O 0
involved O 0
in O 0
the O 0
aetiology O 0
of O 0
PWS B-Disease 0
. O 0

Moreover O 0
, O 0
targeted O 0
mutagenesis O 0
of O 0
mouse O 0
homologues O 0
of O 0
the O 0
human O 0
candidate O 0
PWS B-Disease 0
genes O 0
does O 0
not O 0
appear O 0
to O 0
result O 0
in O 0
any O 0
of O 0
the O 0
features O 0
of O 0
PWS B-Disease 0
. O 0

Therefore O 0
, O 0
the O 0
isolation O 0
of O 0
new O 0
genes O 0
in O 0
this O 0
region O 0
remains O 0
crucial O 0
for O 0
a O 0
better O 0
understanding O 0
of O 0
the O 0
molecular O 0
basis O 0
of O 0
PWS B-Disease 0
. O 0

In O 0
this O 0
manuscript O 0
, O 0
we O 0
report O 0
the O 0
characterization O 0
of O 0
MAGEL2 O 0
and O 0
its O 0
mouse O 0
homologue O 0
Magel2 O 0
. O 0

These O 0
are O 0
located O 0
in O 0
the O 0
human O 0
15q11 O 0
- O 0
q13 O 0
and O 0
mouse O 0
7C O 0
regions O 0
, O 0
in O 0
close O 0
proximity O 0
to O 0
NDN O 0
/ O 0
Ndn O 0
. O 0

By O 0
northern O 0
blot O 0
analysis O 0
we O 0
did O 0
not O 0
detect O 0
any O 0
expression O 0
of O 0
MAGEL2 O 0
/ O 0
Magel2 O 0
but O 0
by O 0
RT O 0
- O 0
PCR O 0
analysis O 0
, O 0
specific O 0
expression O 0
was O 0
detected O 0
in O 0
fetal O 0
and O 0
adult O 0
brain O 0
and O 0
in O 0
placenta O 0
. O 0

Both O 0
genes O 0
are O 0
intronless O 0
with O 0
tandem O 0
direct O 0
repeat O 0
sequences O 0
contained O 0
within O 0
a O 0
CpG O 0
island O 0
in O 0
the O 0
5 O 0
- O 0
untranscribed O 0
region O 0
. O 0

The O 0
transcripts O 0
encode O 0
putative O 0
proteins O 0
that O 0
are O 0
homologous O 0
to O 0
the O 0
MAGE O 0
proteins O 0
and O 0
NDN O 0
. O 0

Moreover O 0
, O 0
MAGEL2 O 0
/ O 0
Magel2 O 0
are O 0
expressed O 0
only O 0
from O 0
the O 0
paternal O 0
allele O 0
in O 0
brain O 0
, O 0
suggesting O 0
a O 0
potential O 0
role O 0
in O 0
the O 0
aetiology O 0
of O 0
PWS B-Disease 0
and O 0
its O 0
mouse O 0
model O 0
, O 0
respectively O 0
. O 0
. O 0

cDNA O 0
microarrays O 0
detect O 0
activation O 0
of O 0
a O 0
myogenic O 0
transcription O 0
program O 0
by O 0
the O 0
PAX3 O 0
- O 0
FKHR O 0
fusion O 0
oncogene O 0
. O 0

Alveolar B-Disease 0
rhabdomyosarcoma I-Disease 0
is O 0
an O 0
aggressive O 0
pediatric B-Disease 1
cancer I-Disease 1
of I-Disease 1
striated I-Disease 1
muscle I-Disease 1
characterized O 0
in O 0
60 O 0
% O 0
of O 0
cases O 0
by O 0
a O 0
t O 0
( O 0
2 O 0
; O 0
13 O 0
) O 0
( O 0
q35 O 0
; O 0
q14 O 0
) O 0
. O 0

This O 0
results O 0
in O 0
the O 0
fusion O 0
of O 0
PAX3 O 0
, O 0
a O 0
developmental O 0
transcription O 0
factor O 0
required O 0
for O 0
limb O 0
myogenesis O 0
, O 0
with O 0
FKHR O 0
, O 0
a O 0
member O 0
of O 0
the O 0
forkhead O 0
family O 0
of O 0
transcription O 0
factors O 0
. O 0

The O 0
resultant O 0
PAX3 O 0
- O 0
FKHR O 0
gene O 0
possesses O 0
transforming O 0
properties O 0
; O 0
however O 0
, O 0
the O 0
effects O 0
of O 0
this O 0
chimeric O 0
oncogene O 0
on O 0
gene O 0
expression O 0
are O 0
largely O 0
unknown O 0
. O 0

To O 0
investigate O 0
the O 0
actions O 0
of O 0
these O 0
transcription O 0
factors O 0
, O 0
both O 0
Pax3 O 0
and O 0
PAX3 O 0
- O 0
FKHR O 0
were O 0
introduced O 0
into O 0
NIH O 0
3T3 O 0
cells O 0
, O 0
and O 0
the O 0
resultant O 0
gene O 0
expression O 0
changes O 0
were O 0
analyzed O 0
with O 0
a O 0
murine O 0
cDNA O 0
microarray O 0
containing O 0
2 O 0
, O 0
225 O 0
elements O 0
. O 0

We O 0
found O 0
that O 0
PAX3 O 0
- O 0
FKHR O 0
but O 0
not O 0
PAX3 O 0
activated O 0
a O 0
myogenic O 0
transcription O 0
program O 0
including O 0
the O 0
induction O 0
of O 0
transcription O 0
factors O 0
MyoD O 0
, O 0
Myogenin O 0
, O 0
Six1 O 0
, O 0
and O 0
Slug O 0
as O 0
well O 0
as O 0
a O 0
battery O 0
of O 0
genes O 0
involved O 0
in O 0
several O 0
aspects O 0
of O 0
muscle O 0
function O 0
. O 0

Notable O 0
among O 0
this O 0
group O 0
were O 0
the O 0
growth O 0
factor O 0
gene O 0
Igf2 O 0
and O 0
its O 0
binding O 0
protein O 0
Igfbp5 O 0
. O 0

Relevance O 0
of O 0
this O 0
model O 0
was O 0
suggested O 0
by O 0
verification O 0
that O 0
three O 0
of O 0
these O 0
genes O 0
( O 0
IGFBP5 O 0
, O 0
HSIX1 O 0
, O 0
and O 0
Slug O 0
) O 0
were O 0
also O 0
expressed O 0
in O 0
alveolar B-Disease 1
rhabdomyosarcoma I-Disease 1
cell O 0
lines O 0
. O 0

This O 0
study O 0
utilizes O 0
cDNA O 0
microarrays O 0
to O 0
elucidate O 0
the O 0
pattern O 0
of O 0
gene O 0
expression O 0
induced O 0
by O 0
an O 0
oncogenic O 0
transcription O 0
factor O 0
and O 0
demonstrates O 0
the O 0
profound O 0
myogenic O 0
properties O 0
of O 0
PAX3 O 0
- O 0
FKHR O 0
in O 0
NIH O 0
3T3 O 0
cells O 0
. O 0
. O 0

Experimental O 0
hemochromatosis B-Disease 1
due O 0
to O 0
MHC O 0
class O 0
I O 0
HFE B-Disease 1
deficiency I-Disease 1
: O 0
immune O 0
status O 0
and O 0
iron O 0
metabolism O 0
. O 0

The O 0
puzzling O 0
linkage O 0
between O 0
genetic O 0
hemochromatosis B-Disease 1
and O 0
histocompatibility O 0
loci O 0
became O 0
even O 0
more O 0
so O 0
when O 0
the O 0
gene O 0
involved O 0
, O 0
HFE O 0
, O 0
was O 0
identified O 0
. O 0

Indeed O 0
, O 0
within O 0
the O 0
well O 0
defined O 0
, O 0
mainly O 0
peptide O 0
- O 0
binding O 0
, O 0
MHC O 0
class O 0
I O 0
family O 0
of O 0
molecules O 0
, O 0
HFE O 0
seems O 0
to O 0
perform O 0
an O 0
unusual O 0
yet O 0
essential O 0
function O 0
. O 0

As O 0
yet O 0
, O 0
our O 0
understanding O 0
of O 0
HFE O 0
function O 0
in O 0
iron O 0
homeostasis O 0
is O 0
only O 0
partial O 0
; O 0
an O 0
even O 0
more O 0
open O 0
question O 0
is O 0
its O 0
possible O 0
role O 0
in O 0
the O 0
immune O 0
system O 0
. O 0

To O 0
advance O 0
on O 0
both O 0
of O 0
these O 0
avenues O 0
, O 0
we O 0
report O 0
the O 0
deletion O 0
of O 0
HFE O 0
alpha1 O 0
and O 0
alpha2 O 0
putative O 0
ligand O 0
binding O 0
domains O 0
in O 0
vivo O 0
. O 0

HFE B-Disease 0
- I-Disease 0
deficient I-Disease 0
animals O 0
were O 0
analyzed O 0
for O 0
a O 0
comprehensive O 0
set O 0
of O 0
metabolic O 0
and O 0
immune O 0
parameters O 0
. O 0

Faithfully O 0
mimicking O 0
human O 0
hemochromatosis B-Disease 1
, O 0
mice O 0
homozygous O 0
for O 0
this O 0
deletion O 0
develop O 0
iron O 0
overload O 0
, O 0
characterized O 0
by O 0
a O 0
higher O 0
plasma O 0
iron O 0
content O 0
and O 0
a O 0
raised O 0
transferrin O 0
saturation O 0
as O 0
well O 0
as O 0
an O 0
elevated O 0
hepatic O 0
iron O 0
load O 0
. O 0

The O 0
primary O 0
defect O 0
could O 0
, O 0
indeed O 0
, O 0
be O 0
traced O 0
to O 0
an O 0
augmented O 0
duodenal O 0
iron O 0
absorption O 0
. O 0

In O 0
parallel O 0
, O 0
measurement O 0
of O 0
the O 0
gut O 0
mucosal O 0
iron O 0
content O 0
as O 0
well O 0
as O 0
iron O 0
regulatory O 0
proteins O 0
allows O 0
a O 0
more O 0
informed O 0
evaluation O 0
of O 0
various O 0
hypotheses O 0
regarding O 0
the O 0
precise O 0
role O 0
of O 0
HFE O 0
in O 0
iron O 0
homeostasis O 0
. O 0

Finally O 0
, O 0
an O 0
extensive O 0
phenotyping O 0
of O 0
primary O 0
and O 0
secondary O 0
lymphoid O 0
organs O 0
including O 0
the O 0
gut O 0
provides O 0
no O 0
compelling O 0
evidence O 0
for O 0
an O 0
obvious O 0
immune O 0
- O 0
linked O 0
function O 0
for O 0
HFE O 0
. O 0
. O 0

Somatic O 0
rearrangement O 0
of O 0
chromosome O 0
14 O 0
in O 0
human O 0
lymphocytes O 0
. O 0

Ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
is O 0
a O 0
rare O 0
genetic B-Disease 0
disorder I-Disease 0
associated O 0
with O 0
immune B-Disease 1
deficiency I-Disease 1
, O 0
chromosome B-Disease 0
instability I-Disease 0
, O 0
and O 0
a O 0
predisposition O 0
to O 0
lymphoid B-Disease 1
malignancy I-Disease 1
. O 0

We O 0
have O 0
detected O 0
chromosomally O 0
anomalous O 0
clones O 0
of O 0
lymphocytes O 0
in O 0
eight O 0
patients O 0
with O 0
this O 0
disorder O 0
. O 0

Chromosome O 0
banding O 0
disclosed O 0
that O 0
the O 0
clones O 0
are O 0
consistently O 0
marked O 0
by O 0
structural O 0
rearrangement O 0
of O 0
the O 0
long O 0
arm O 0
( O 0
q O 0
) O 0
of O 0
chromosome O 0
14 O 0
. O 0

A O 0
translocation O 0
involving O 0
14q O 0
was O 0
found O 0
in O 0
clones O 0
obtained O 0
from O 0
seven O 0
of O 0
the O 0
eight O 0
patients O 0
whereas O 0
a O 0
ring O 0
14 O 0
chromosome O 0
was O 0
found O 0
in O 0
a O 0
clone O 0
obtained O 0
from O 0
the O 0
other O 0
. O 0

These O 0
findings O 0
as O 0
well O 0
as O 0
data O 0
obtained O 0
by O 0
others O 0
for O 0
patients O 0
with O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
suggest O 0
that O 0
structural O 0
rearrangement O 0
of O 0
14q O 0
is O 0
the O 0
initial O 0
chromosomal O 0
change O 0
in O 0
lymphocyte O 0
clones O 0
of O 0
patients O 0
with O 0
this O 0
disorder O 0
. O 0

Chromosomes O 0
of O 0
lymphocytes O 0
from O 0
one O 0
of O 0
the O 0
patients O 0
were O 0
studied O 0
before O 0
and O 0
after O 0
the O 0
onset O 0
of O 0
chronic B-Disease 0
lymphocytic I-Disease 0
leukemia I-Disease 1
. O 0

Before O 0
leukemia B-Disease 1
was O 0
diagnosed O 0
, O 0
the O 0
patient O 0
had O 0
a O 0
lymphocyte O 0
clone O 0
with O 0
a O 0
14q O 0
translocation O 0
. O 0

This O 0
clone O 0
appears O 0
to O 0
have O 0
given O 0
rise O 0
to O 0
the O 0
leukemic B-Disease 1
cells O 0
. O 0

We O 0
hypothesize O 0
that O 0
structural O 0
rearrangement O 0
of O 0
14q O 0
is O 0
directly O 0
related O 0
to O 0
abnormal O 0
growth O 0
of O 0
lymphocytes O 0
and O 0
that O 0
it O 0
may O 0
be O 0
a O 0
step O 0
toward O 0
the O 0
development O 0
of O 0
lymphoid B-Disease 1
malignancies I-Disease 1
. O 0

Increasing O 0
evidence O 0
, O 0
provided O 0
by O 0
others O 0
, O 0
for O 0
the O 0
nonrandom O 0
involvement O 0
of O 0
14q O 0
in O 0
African O 0
- O 0
type O 0
Burkitts B-Disease 0
lymphoma I-Disease 1
and O 0
other O 0
lymphoid B-Disease 1
neoplasms I-Disease 1
further O 0
strengthens O 0
this O 0
hypothesis O 0
. O 0
. O 0

Exon O 0
9 O 0
mutations O 0
in O 0
the O 0
WT1 O 0
gene O 0
, O 0
without O 0
influencing O 0
KTS O 0
splice O 0
isoforms O 0
, O 0
are O 0
also O 0
responsible O 0
for O 0
Frasier B-Disease 0
syndrome I-Disease 0
. O 0

We O 0
report O 0
new O 0
mutations O 0
in O 0
exon O 0
9 O 0
of O 0
the O 0
WT1 O 0
gene O 0
that O 0
did O 0
not O 0
alter O 0
the O 0
ratio O 0
of O 0
+ O 0
/ O 0
- O 0
KTS O 0
splice O 0
isoforms O 0
in O 0
two O 0
unrelated O 0
patients O 0
with O 0
Frasier B-Disease 0
syndrome I-Disease 0
( O 0
FS B-Disease 0
) O 0
. O 0

The O 0
mutation O 0
of O 0
intron O 0
9 O 0
inducing O 0
defective O 0
alternative O 0
splicing O 0
was O 0
reported O 0
to O 0
be O 0
responsible O 0
for O 0
this O 0
syndrome O 0
. O 0

The O 0
mutations O 0
found O 0
in O 0
our O 0
cases O 0
occurred O 0
in O 0
the O 0
same O 0
exon O 0
of O 0
the O 0
WT1 O 0
gene O 0
as O 0
detected O 0
in O 0
Denys B-Disease 1
- I-Disease 1
Drash I-Disease 1
syndrome I-Disease 1
( O 0
DDS B-Disease 1
) O 0
and O 0
could O 0
not O 0
be O 0
explained O 0
by O 0
the O 0
previously O 0
proposed O 0
mechanism O 0
. O 0

The O 0
results O 0
suggest O 0
that O 0
the O 0
two O 0
syndromes O 0
originate O 0
from O 0
the O 0
same O 0
WT1 B-Disease 0
gene I-Disease 0
abnormality I-Disease 0
. O 0

From O 0
a O 0
molecular O 0
biological O 0
point O 0
of O 0
view O 0
, O 0
we O 0
concluded O 0
that O 0
the O 0
two O 0
diseases O 0
were O 0
not O 0
separable O 0
, O 0
and O 0
that O 0
FS B-Disease 0
should O 0
be O 0
included O 0
as O 0
an O 0
atypical O 0
form O 0
of O 0
DDS B-Disease 1
. O 0
. O 0

Splice O 0
- O 0
site O 0
mutation O 0
in O 0
the O 0
PDS B-Disease 1
gene O 0
may O 0
result O 0
in O 0
intrafamilial O 0
variability O 0
for O 0
deafness B-Disease 1
in O 0
Pendred B-Disease 0
syndrome I-Disease 0
. O 0

Pendred B-Disease 0
syndrome I-Disease 0
is O 0
a O 0
recessive B-Disease 1
inherited I-Disease 1
disorder I-Disease 1
that O 0
consists O 0
of O 0
developmental B-Disease 1
abnormalities I-Disease 1
of I-Disease 1
the I-Disease 1
cochlea I-Disease 1
, O 0
sensorineural B-Disease 0
hearing I-Disease 0
loss I-Disease 0
, O 0
and O 0
diffuse B-Disease 1
thyroid I-Disease 1
enlargement I-Disease 1
( O 0
goiter B-Disease 1
) O 0
. O 0

This O 0
disorder O 0
may O 0
account O 0
for O 0
up O 0
to O 0
10 O 0
% O 0
of O 0
cases O 0
of O 0
hereditary B-Disease 0
deafness I-Disease 1
. O 0

The O 0
disease O 0
gene O 0
( O 0
PDS B-Disease 1
) O 0
has O 0
been O 0
mapped O 0
to O 0
chromosome O 0
7q22 O 0
- O 0
q31 O 0
, O 0
and O 0
encodes O 0
a O 0
chloride O 0
- O 0
iodide O 0
transport O 0
protein O 0
. O 0

We O 0
performed O 0
mutation O 0
analysis O 0
of O 0
individual O 0
exons O 0
of O 0
the O 0
PDS B-Disease 1
gene O 0
in O 0
one O 0
Spanish O 0
family O 0
that O 0
shows O 0
intrafamilial O 0
variability O 0
of O 0
the O 0
deafness B-Disease 1
phenotype O 0
( O 0
two O 0
patients O 0
with O 0
profound O 0
and O 0
one O 0
with O 0
moderate O 0
- O 0
severe O 0
deafness B-Disease 1
) O 0
. O 0

We O 0
identified O 0
a O 0
new O 0
splice O 0
- O 0
site O 0
mutation O 0
affecting O 0
intron O 0
4 O 0
of O 0
the O 0
PDS B-Disease 1
gene O 0
, O 0
at O 0
nucleotide O 0
position O 0
639 O 0
+ O 0
7 O 0
. O 0

RNA O 0
analysis O 0
from O 0
lymphocytes O 0
of O 0
the O 0
affected O 0
patients O 0
showed O 0
that O 0
mutation O 0
639 O 0
+ O 0
7A O 0
- O 0
- O 0
> O 0
G O 0
generates O 0
a O 0
new O 0
donor O 0
splice O 0
site O 0
, O 0
leading O 0
to O 0
an O 0
mRNA O 0
with O 0
an O 0
insertion O 0
of O 0
six O 0
nucleotides O 0
from O 0
intron O 0
4 O 0
of O 0
PDS O 1
. O 0

Since O 0
the O 0
newly O 0
created O 0
donor O 0
splice O 0
site O 0
is O 0
likely O 0
to O 0
compete O 0
with O 0
the O 0
normal O 0
one O 0
, O 0
variations O 0
of O 0
the O 0
levels O 0
of O 0
normal O 0
and O 0
aberrant O 0
transcripts O 0
of O 0
the O 0
PDS B-Disease 1
gene O 0
in O 0
the O 0
cochlea O 0
may O 0
explain O 0
the O 0
variability O 0
in O 0
the O 0
deafness B-Disease 1
presentation O 0
. O 0
. O 0

The O 0
molecular O 0
basis O 0
of O 0
Sjogren B-Disease 1
- I-Disease 1
Larsson I-Disease 1
syndrome I-Disease 1
: O 0
mutation O 0
analysis O 0
of O 0
the O 0
fatty O 0
aldehyde O 0
dehydrogenase O 0
gene O 0
. O 0

Sjogren B-Disease 1
- I-Disease 1
Larsson I-Disease 1
syndrome I-Disease 1
( O 0
SLS B-Disease 0
) O 0
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
characterized O 0
by O 0
ichthyosis B-Disease 1
, O 0
mental B-Disease 1
retardation I-Disease 1
, O 0
spasticity B-Disease 0
, O 0
and O 0
deficient B-Disease 1
activity I-Disease 1
of I-Disease 1
fatty I-Disease 1
aldehyde I-Disease 1
dehydrogenase I-Disease 1
( O 0
FALDH O 0
) O 0
. O 0

To O 0
define O 0
the O 0
molecular O 0
defects O 0
causing O 0
SLS B-Disease 0
, O 0
we O 0
performed O 0
mutation O 0
analysis O 0
of O 0
the O 0
FALDH O 0
gene O 0
in O 0
probands O 0
from O 0
63 O 0
kindreds O 0
with O 0
SLS B-Disease 0
. O 0

Among O 0
these O 0
patients O 0
, O 0
49 O 0
different O 0
mutations O 0
- O 0
including O 0
10 O 0
deletions O 0
, O 0
2 O 0
insertions O 0
, O 0
22 O 0
amino O 0
acid O 0
substitutions O 0
, O 0
3 O 0
nonsense O 0
mutations O 0
, O 0
9 O 0
splice O 0
- O 0
site O 0
defects O 0
, O 0
and O 0
3 O 0
complex O 0
mutations O 0
- O 0
were O 0
found O 0
. O 0

All O 0
of O 0
the O 0
patients O 0
with O 0
SLS B-Disease 0
were O 0
found O 0
to O 0
carry O 0
mutations O 0
. O 0

Nineteen O 0
of O 0
the O 0
missense O 0
mutations O 0
resulted O 0
in O 0
a O 0
severe O 0
reduction O 0
of O 0
FALDH O 0
enzyme O 0
catalytic O 0
activity O 0
when O 0
expressed O 0
in O 0
mammalian O 0
cells O 0
, O 0
but O 0
one O 0
mutation O 0
( O 0
798G O 0
- O 0
- O 0
> O 0
C O 0
[ O 0
K266N O 0
] O 0
) O 0
seemed O 0
to O 0
have O 0
a O 0
greater O 0
effect O 0
on O 0
mRNA O 0
stability O 0
. O 0

The O 0
splice O 0
- O 0
site O 0
mutations O 0
led O 0
to O 0
exon O 0
skipping O 0
or O 0
utilization O 0
of O 0
cryptic O 0
acceptor O 0
- O 0
splice O 0
sites O 0
. O 0

Thirty O 0
- O 0
seven O 0
mutations O 0
were O 0
private O 0
, O 0
and O 0
12 O 0
mutations O 0
were O 0
seen O 0
in O 0
two O 0
or O 0
more O 0
probands O 0
of O 0
European O 0
or O 0
Middle O 0
Eastern O 0
descent O 0
. O 0

Four O 0
single O 0
- O 0
nucleotide O 0
polymorphisms O 0
( O 0
SNPs O 0
) O 0
were O 0
found O 0
in O 0
the O 0
FALDH O 0
gene O 0
. O 0

At O 0
least O 0
four O 0
of O 0
the O 0
common O 0
mutations O 0
( O 0
551C O 0
- O 0
- O 0
> O 0
T O 0
, O 0
682C O 0
- O 0
- O 0
> O 0
T O 0
, O 0
733G O 0
- O 0
- O 0
> O 0
A O 0
, O 0
and O 0
798 O 0
+ O 0
1delG O 0
) O 0
were O 0
associated O 0
with O 0
multiple O 0
SNP O 0
haplotypes O 0
, O 0
suggesting O 0
that O 0
these O 0
mutations O 0
originated O 0
independently O 0
on O 0
more O 0
than O 0
one O 0
occasion O 0
or O 0
were O 0
ancient O 0
SLS B-Disease 0
genes O 0
that O 0
had O 0
undergone O 0
intragenic O 0
recombination O 0
. O 0

Our O 0
results O 0
demonstrate O 0
that O 0
SLS B-Disease 0
is O 0
caused O 0
by O 0
a O 0
strikingly O 0
heterogeneous O 0
group O 0
of O 0
mutations O 0
in O 0
the O 0
FALDH O 0
gene O 0
and O 0
provide O 0
a O 0
framework O 0
for O 0
understanding O 0
the O 0
genetic O 0
basis O 0
of O 0
SLS B-Disease 0
and O 0
the O 0
development O 0
of O 0
DNA O 0
- O 0
based O 0
diagnostic O 0
tests O 0
. O 0
. O 0

Loss O 0
- O 0
of O 0
- O 0
function O 0
mutations O 0
in O 0
the O 0
cathepsin O 0
C O 0
gene O 0
result O 0
in O 0
periodontal B-Disease 0
disease I-Disease 0
and O 0
palmoplantar B-Disease 0
keratosis I-Disease 0
. O 0

Papillon B-Disease 0
- I-Disease 0
Lefevre I-Disease 0
syndrome I-Disease 0
, O 0
or O 0
keratosis B-Disease 0
palmoplantaris I-Disease 0
with O 0
periodontopathia B-Disease 0
( O 0
PLS B-Disease 0
, O 0
MIM O 0
245000 O 0
) O 0
, O 0
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
that O 0
is O 0
mainly O 0
ascertained O 0
by O 0
dentists O 0
because O 0
of O 0
the O 0
severe O 0
periodontitis B-Disease 1
that O 0
afflicts O 0
patients O 0
. O 0

Both O 0
the O 0
deciduous O 0
and O 0
permanent O 0
dentitions O 0
are O 0
affected O 0
, O 0
resulting O 0
in O 0
premature O 0
tooth B-Disease 1
loss I-Disease 1
. O 0

Palmoplantar B-Disease 1
keratosis I-Disease 1
, O 0
varying O 0
from O 0
mild O 0
psoriasiform O 0
scaly O 0
skin O 0
to O 0
overt O 0
hyperkeratosis B-Disease 0
, O 0
typically O 0
develops O 0
within O 0
the O 0
first O 0
three O 0
years O 0
of O 0
life O 0
. O 0

Keratosis B-Disease 1
also O 0
affects O 0
other O 0
sites O 0
such O 0
as O 0
elbows O 0
and O 0
knees O 0
. O 0

Most O 0
PLS B-Disease 0
patients O 0
display O 0
both O 0
periodontitis B-Disease 1
and O 0
hyperkeratosis B-Disease 0
. O 0

Some O 0
patients O 0
have O 0
only O 0
palmoplantar B-Disease 0
keratosis I-Disease 0
or O 0
periodontitis B-Disease 1
, O 0
and O 0
in O 0
rare O 0
individuals O 0
the O 0
periodontitis B-Disease 1
is O 0
mild O 0
and O 0
of O 0
late O 0
onset O 0
. O 0

The O 0
PLS O 0
locus O 0
has O 0
been O 0
mapped O 0
to O 0
chromosome O 0
11q14 O 0
- O 0
q21 O 0
( O 0
refs O 0
7 O 0
, O 0
8 O 0
, O 0
9 O 0
) O 0
. O 0

Using O 0
homozygosity O 0
mapping O 0
in O 0
eight O 0
small O 0
consanguineous O 0
families O 0
, O 0
we O 0
have O 0
narrowed O 0
the O 0
candidate O 0
region O 0
to O 0
a O 0
1 O 0
. O 0

2 O 0
- O 0
cM O 0
interval O 0
between O 0
D11S4082 O 0
and O 0
D11S931 O 0
. O 0

The O 0
gene O 0
( O 0
CTSC O 0
) O 0
encoding O 0
the O 0
lysosomal O 0
protease O 0
cathepsin O 0
C O 0
( O 0
or O 0
dipeptidyl O 0
aminopeptidase O 0
I O 0
) O 0
lies O 0
within O 0
this O 0
interval O 0
. O 0

We O 0
defined O 0
the O 0
genomic O 0
structure O 0
of O 0
CTSC O 0
and O 0
found O 0
mutations O 0
in O 0
all O 0
eight O 0
families O 0
. O 0

In O 0
two O 0
of O 0
these O 0
families O 0
we O 0
used O 0
a O 0
functional O 0
assay O 0
to O 0
demonstrate O 0
an O 0
almost O 0
total O 0
loss O 0
of O 0
cathepsin O 0
C O 0
activity O 0
in O 0
PLS B-Disease 0
patients O 0
and O 0
reduced O 0
activity O 0
in O 0
obligate O 0
carriers O 0
. O 0

Confirmation O 0
of O 0
linkage O 0
of O 0
Van B-Disease 0
der I-Disease 0
Woude I-Disease 0
syndrome I-Disease 0
to O 0
chromosome O 0
1q32 O 0
: O 0
evidence O 0
of O 0
association O 0
with O 0
STR O 0
alleles O 0
suggests O 0
possible O 0
unique O 0
origin O 0
of O 0
the O 0
disease O 0
mutation O 0
. O 0

Van B-Disease 0
der I-Disease 0
Woude I-Disease 0
syndrome I-Disease 0
( O 0
VWS B-Disease 0
) O 0
is O 0
an O 0
autosomal B-Disease 0
dominant I-Disease 0
craniofacial I-Disease 0
disorder I-Disease 0
with O 0
high O 0
penetrance O 0
and O 0
variable O 0
expression O 0
. O 0

Its O 0
clinical O 0
features O 0
are O 0
variably O 0
expressed O 0
, O 0
but O 0
include O 0
cleft B-Disease 1
lip I-Disease 1
and O 0
/ O 0
or O 0
cleft B-Disease 0
palate I-Disease 0
, O 0
lip B-Disease 0
pits I-Disease 0
and O 0
hypodontia B-Disease 1
. O 0

All O 0
VWS B-Disease 0
families O 0
studied O 0
to O 0
date O 0
map O 0
the O 0
disease O 0
gene O 0
to O 0
a O 0
< O 0
2 O 0
cM O 0
region O 0
of O 0
chromosome O 0
1q32 O 0
, O 0
with O 0
no O 0
evidence O 0
of O 0
locus O 0
heterogeneity O 0
. O 0

The O 0
aim O 0
of O 0
this O 0
study O 0
is O 0
to O 0
refine O 0
the O 0
localization O 0
of O 0
the O 0
VWS B-Disease 0
gene O 0
and O 0
to O 0
further O 0
assess O 0
possible O 0
heterogeneity O 0
. O 0

We O 0
analyzed O 0
four O 0
multiplex O 0
VWS B-Disease 0
families O 0
. O 0

All O 0
available O 0
members O 0
were O 0
clinically O 0
assessed O 0
and O 0
genotyped O 0
for O 0
19 O 0
short O 0
tandem O 0
repeat O 0
markers O 0
on O 0
chromosome O 0
1 O 0
in O 0
the O 0
VWS B-Disease 0
candidate O 0
gene O 0
region O 0
. O 0

We O 0
performed O 0
two O 0
- O 0
point O 0
and O 0
multipoint O 0
limit O 0
of O 0
detection O 0
( O 0
LOD O 0
) O 0
score O 0
analyses O 0
using O 0
a O 0
high O 0
penetrance O 0
autosomal O 0
dominant O 0
model O 0
. O 0

All O 0
families O 0
showed O 0
positive O 0
LOD O 0
scores O 0
without O 0
any O 0
recombination O 0
in O 0
the O 0
candidate O 0
region O 0
. O 0

The O 0
largest O 0
two O 0
- O 0
point O 0
LOD O 0
score O 0
was O 0
5 O 0
. O 0

87 O 0
87 O 0
. O 0

Our O 0
assay O 0
method O 0
for O 0
short O 0
tandem O 0
repeat O 0
( O 0
STR O 0
) O 0
markers O 0
provided O 0
highly O 0
accurate O 0
size O 0
estimation O 0
of O 0
marker O 0
allele O 0
fragment O 0
sizes O 0
, O 0
and O 0
therefore O 0
enabled O 0
us O 0
to O 0
determine O 0
the O 0
specific O 0
alleles O 0
segregating O 0
with O 0
the O 0
VWS B-Disease 0
gene O 0
in O 0
each O 0
of O 0
our O 0
four O 0
families O 0
. O 0

We O 0
observed O 0
a O 0
striking O 0
pattern O 0
of O 0
STR O 0
allele O 0
sharing O 0
at O 0
several O 0
closely O 0
linked O 0
loci O 0
among O 0
our O 0
four O 0
Caucasian O 0
VWS B-Disease 0
families O 0
recruited O 0
at O 0
three O 0
different O 0
locations O 0
in O 0
the O 0
US O 0
. O 0

These O 0
results O 0
suggest O 0
the O 0
possibility O 0
of O 0
a O 0
unique O 0
origin O 0
for O 0
a O 0
mutation O 0
responsible O 0
for O 0
many O 0
or O 0
most O 0
cases O 0
of O 0
VWS B-Disease 0
. O 0

A O 0
point O 0
mutation O 0
Thr O 0
( O 0
799 O 0
) O 0
Met O 0
on O 0
the O 0
alpha O 0
( O 0
2 O 0
) O 0
integrin O 0
leads O 0
to O 0
the O 0
formation O 0
of O 0
new O 0
human O 0
platelet O 0
alloantigen O 0
Sit O 0
( O 0
a O 0
) O 0
and O 0
affects O 0
collagen O 0
- O 0
induced O 0
aggregation O 0
. O 0

A O 0
new O 0
platelet O 0
- O 0
specific O 0
alloantigen O 0
, O 0
termed O 0
Sit O 0
( O 0
a O 0
) O 0
, O 0
was O 0
identified O 0
in O 0
a O 0
severe O 0
case O 0
of O 0
neonatal B-Disease 0
alloimmune I-Disease 0
thrombocytopenia I-Disease 0
. O 0

The O 0
Sit O 0
( O 0
a O 0
) O 0
alloantigen O 0
is O 0
of O 0
low O 0
frequency O 0
( O 0
1 O 0
/ O 0
400 O 0
) O 0
in O 0
the O 0
German O 0
population O 0
. O 0

Immunochemical O 0
studies O 0
demonstrated O 0
that O 0
the O 0
Sit O 0
( O 0
a O 0
) O 0
epitopes O 0
reside O 0
on O 0
platelet O 0
glycoprotein O 0
( O 0
GP O 0
) O 0
Ia O 0
. O 0

Nucleotide O 0
sequence O 0
analysis O 0
of O 0
GPIa O 0
cDNA O 0
derived O 0
from O 0
Sit O 0
( O 0
a O 0
) O 0
- O 0
positive O 0
platelets O 0
showed O 0
C O 0
( O 0
2531 O 0
) O 0
- O 0
- O 0
> O 0
T O 0
( O 0
2531 O 0
) O 0
point O 0
mutation O 0
, O 0
resulting O 0
in O 0
Thr O 0
( O 0
799 O 0
) O 0
Met O 0
dimorphism O 0
. O 0

Analysis O 0
of O 0
genomic O 0
DNA O 0
from O 0
22 O 0
Sit O 0
( O 0
a O 0
) O 0
- O 0
negative O 0
normal O 0
individuals O 0
showed O 0
that O 0
the O 0
Thr O 0
( O 0
799 O 0
) O 0
is O 0
encoded O 0
by O 0
ACG O 0
( O 0
2532 O 0
) O 0
( O 0
90 O 0
. O 0
9 O 0
% O 0
) O 0
or O 0
ACA O 0
( O 0
2532 O 0
) O 0
( O 0
9 O 0
. O 0
1 O 0
% O 0
) O 0
. O 0

To O 0
establish O 0
a O 0
DNA O 0
typing O 0
technique O 0
, O 0
we O 0
elucidated O 0
the O 0
organization O 0
of O 0
the O 0
GPIa O 0
gene O 0
adjacent O 0
to O 0
the O 0
polymorphic O 0
bases O 0
. O 0

The O 0
introns O 0
( O 0
421 O 0
bp O 0
and O 0
1 O 0
. O 0
2 O 0
kb O 0
) O 0
encompass O 0
a O 0
142 O 0
- O 0
bp O 0
exon O 0
with O 0
the O 0
2 O 0
polymorphic O 0
bases O 0
2531 O 0
and O 0
2532 O 0
. O 0

Polymerase O 0
chain O 0
reaction O 0
- O 0
restriction O 0
fragment O 0
length O 0
polymorphism O 0
analysis O 0
on O 0
DNA O 0
derived O 0
from O 0
100 O 0
donors O 0
using O 0
the O 0
restriction O 0
enzyme O 0
Mae O 0
III O 0
showed O 0
that O 0
the O 0
Met O 0
( O 0
799 O 0
) O 0
form O 0
of O 0
GPIa O 0
is O 0
restricted O 0
to O 0
Sit O 0
( O 0
a O 0
) O 0
( O 0
+ O 0
) O 0
phenotype O 0
. O 0

Analysis O 0
of O 0
stable O 0
Chinese O 0
hamster O 0
ovary O 0
transfectants O 0
expressing O 0
allele O 0
- O 0
specific O 0
recombinant O 0
forms O 0
of O 0
GPIa O 0
showed O 0
that O 0
anti O 0
- O 0
Sit O 0
( O 0
a O 0
) O 0
exclusively O 0
reacted O 0
with O 0
the O 0
Glu O 0
( O 0
505 O 0
) O 0
Met O 0
( O 0
799 O 0
) O 0
, O 0
but O 0
not O 0
with O 0
the O 0
Glu O 0
( O 0
505 O 0
) O 0
Thr O 0
( O 0
799 O 0
) O 0
and O 0
the O 0
Lys O 0
( O 0
505 O 0
) O 0
Thr O 0
( O 0
799 O 0
) O 0
isoforms O 0
. O 0

In O 0
contrast O 0
, O 0
anti O 0
- O 0
Br O 0
( O 0
a O 0
) O 0
( O 0
HPA O 0
- O 0
5b O 0
) O 0
only O 0
recognized O 0
the O 0
Lys O 0
( O 0
505 O 0
) O 0
Thr O 0
( O 0
799 O 0
) O 0
form O 0
, O 0
whereas O 0
anti O 0
- O 0
Br O 0
( O 0
b O 0
) O 0
( O 0
HPA O 0
- O 0
5a O 0
) O 0
reacted O 0
with O 0
both O 0
Glu O 0
( O 0
505 O 0
) O 0
Thr O 0
( O 0
799 O 0
) O 0
and O 0
Glu O 0
( O 0
505 O 0
) O 0
Met O 0
( O 0
799 O 0
) O 0
isoforms O 0
. O 0

These O 0
results O 0
demonstrated O 0
that O 0
the O 0
Met O 0
( O 0
799 O 0
) O 0
is O 0
responsible O 0
for O 0
formation O 0
of O 0
the O 0
Sit O 0
( O 0
a O 0
) O 0
alloantigenic O 0
determinants O 0
, O 0
whereas O 0
amino O 0
acid O 0
505 O 0
( O 0
Lys O 0
or O 0
Glu O 0
) O 0
specifically O 0
controls O 0
the O 0
expression O 0
of O 0
Br O 0
( O 0
a O 0
) O 0
and O 0
Br O 0
( O 0
b O 0
) O 0
epitopes O 0
, O 0
respectively O 0
. O 0

Platelet O 0
aggregation O 0
responses O 0
of O 0
Sit O 0
( O 0
a O 0
) O 0
( O 0
+ O 0
) O 0
individuals O 0
were O 0
diminished O 0
in O 0
response O 0
to O 0
collagen O 0
, O 0
indicating O 0
that O 0
the O 0
Thr O 0
( O 0
799 O 0
) O 0
Met O 0
mutation O 0
affects O 0
the O 0
function O 0
of O 0
the O 0
GPIa O 0
/ O 0
IIa O 0
complex O 0

Mutations O 0
of O 0
the O 0
cathepsin O 0
C O 0
gene O 0
are O 0
responsible O 0
for O 0
Papillon B-Disease 0
- I-Disease 0
Lefevre I-Disease 0
syndrome I-Disease 0
. O 0

Papillon B-Disease 0
- I-Disease 0
Lefevre I-Disease 0
syndrome I-Disease 0
( O 0
PLS B-Disease 0
) O 0
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
characterised O 0
by O 0
palmoplantar B-Disease 0
hyperkeratosis I-Disease 0
and O 0
severe O 0
early O 0
onset O 0
periodontitis B-Disease 1
that O 0
results O 0
in O 0
the O 0
premature O 0
loss O 0
of O 0
the O 0
primary O 0
and O 0
secondary O 0
dentitions O 0
. O 0

A O 0
major O 0
gene O 0
locus O 0
for O 0
PLS B-Disease 0
has O 0
been O 0
mapped O 0
to O 0
a O 0
2 O 0
. O 0

8 O 0
cM O 0
interval O 0
on O 0
chromosome O 0
11q14 O 0
. O 0

Correlation O 0
of O 0
physical O 0
and O 0
genetic O 0
maps O 0
of O 0
this O 0
interval O 0
indicate O 0
it O 0
includes O 0
at O 0
least O 0
40 O 0
ESTs O 0
and O 0
six O 0
known O 0
genes O 0
including O 0
the O 0
lysosomal O 0
protease O 0
cathepsin O 0
C O 0
gene O 0
( O 0
CTSC O 0
) O 0
. O 0

The O 0
CTSC O 0
message O 0
is O 0
expressed O 0
at O 0
high O 0
levels O 0
in O 0
a O 0
variety O 0
of O 0
immune O 0
cells O 0
including O 0
polymorphonuclear O 0
leucocytes O 0
, O 0
macrophages O 0
, O 0
and O 0
their O 0
precursors O 0
. O 0

By O 0
RT O 0
- O 0
PCR O 0
, O 0
we O 0
found O 0
CTSC O 0
is O 0
also O 0
expressed O 0
in O 0
epithelial O 0
regions O 0
commonly O 0
affected O 0
by O 0
PLS B-Disease 0
, O 0
including O 0
the O 0
palms O 0
, O 0
soles O 0
, O 0
knees O 0
, O 0
and O 0
oral O 0
keratinised O 0
gingiva O 0
. O 0

The O 0
4 O 0
. O 0

7 O 0
kb O 0
CTSC O 0
gene O 0
consists O 0
of O 0
two O 0
exons O 0
. O 0

Sequence O 0
analysis O 0
of O 0
CTSC O 0
from O 0
subjects O 0
affected O 0
with O 0
PLS B-Disease 0
from O 0
five O 0
consanguineous O 0
Turkish O 0
families O 0
identified O 0
four O 0
different O 0
mutations O 0
. O 0

An O 0
exon O 0
1 O 0
nonsense O 0
mutation O 0
( O 0
856C O 0
- O 0
- O 0
> O 0
T O 0
) O 0
introduces O 0
a O 0
premature O 0
stop O 0
codon O 0
at O 0
amino O 0
acid O 0
286 O 0
. O 0

Three O 0
exon O 0
2 O 0
mutations O 0
were O 0
identified O 0
, O 0
including O 0
a O 0
single O 0
nucleotide O 0
deletion O 0
( O 0
2692delA O 0
) O 0
of O 0
codon O 0
349 O 0
introducing O 0
a O 0
frameshift O 0
and O 0
premature O 0
termination O 0
codon O 0
, O 0
a O 0
2 O 0
bp O 0
deletion O 0
( O 0
2673 O 0
- O 0
2674delCT O 0
) O 0
that O 0
results O 0
in O 0
introduction O 0
of O 0
a O 0
stop O 0
codon O 0
at O 0
amino O 0
acid O 0
343 O 0
, O 0
and O 0
a O 0
G O 0
- O 0
- O 0
> O 0
A O 0
substitution O 0
in O 0
codon O 0
429 O 0
( O 0
2931G O 0
- O 0
- O 0
> O 0
A O 0
) O 0
introducing O 0
a O 0
premature O 0
termination O 0
codon O 0
. O 0

All O 0
PLS B-Disease 0
patients O 0
were O 0
homozygous O 0
for O 0
cathepsin O 0
C O 0
mutations O 0
inherited O 0
from O 0
a O 0
common O 0
ancestor O 0
. O 0

Parents O 0
and O 0
sibs O 0
heterozygous O 0
for O 0
cathepsin O 0
C O 0
mutations O 0
do O 0
not O 0
show O 0
either O 0
the O 0
palmoplantar B-Disease 0
hyperkeratosis I-Disease 0
or O 0
severe O 0
early O 0
onset O 0
periodontitis B-Disease 1
characteristic O 0
of O 0
PLS B-Disease 0
. O 0

A O 0
more O 0
complete O 0
understanding O 0
of O 0
the O 0
functional O 0
physiology O 0
of O 0
cathepsin O 0
C O 0
carries O 0
significant O 0
implications O 0
for O 0
understanding O 0
normal O 0
and O 0
abnormal O 0
skin O 0
development O 0
and O 0
periodontal B-Disease 0
disease I-Disease 0
susceptibility O 0

Mutational O 0
analysis O 0
of O 0
the O 0
HGO O 0
gene O 0
in O 0
Finnish O 0
alkaptonuria B-Disease 0
patients O 0
. O 0

Alkaptonuria B-Disease 1
( O 0
AKU B-Disease 0
) O 0
, O 0
the O 0
prototypic O 0
inborn B-Disease 1
error I-Disease 1
of I-Disease 1
metabolism I-Disease 1
, O 0
has O 0
recently O 0
been O 0
shown O 0
to O 0
be O 0
caused O 0
by O 0
loss O 0
of O 0
function O 0
mutations O 0
in O 0
the O 0
homogentisate O 0
- O 0
1 O 0
, O 0
2 O 0
- O 0
dioxygenase O 0
gene O 0
( O 0
HGO O 0
) O 0
. O 0

So O 0
far O 0
17 O 0
mutations O 0
have O 0
been O 0
characterised O 0
in O 0
AKU B-Disease 0
patients O 0
of O 0
different O 0
ethnic O 0
origin O 0
. O 0

We O 0
describe O 0
three O 0
novel O 0
mutations O 0
( O 0
R58fs O 0
, O 0
R330S O 0
, O 0
and O 0
H371R O 0
) O 0
and O 0
one O 0
common O 0
AKU B-Disease 0
mutation O 0
( O 0
M368V O 0
) O 0
, O 0
detected O 0
by O 0
mutational O 0
and O 0
polymorphism O 0
analysis O 0
of O 0
the O 0
HGO O 0
gene O 0
in O 0
five O 0
Finnish O 0
AKU B-Disease 0
pedigrees O 0
. O 0

The O 0
three O 0
novel O 0
AKU B-Disease 0
mutations O 0
are O 0
most O 0
likely O 0
specific O 0
for O 0
the O 0
Finnish O 0
population O 0
and O 0
have O 0
originated O 0
recently O 0
. O 0
. O 0

The O 0
identical O 0
5 O 0
' O 0
splice O 0
- O 0
site O 0
acceptor O 0
mutation O 0
in O 0
five O 0
attenuated B-Disease 0
APC I-Disease 1
families O 0
from O 0
Newfoundland O 0
demonstrates O 0
a O 0
founder O 0
effect O 0
. O 0

Inherited O 0
mutations O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
predispose O 0
carriers O 0
to O 0
multiple O 0
adenomatous B-Disease 1
polyps I-Disease 1
of I-Disease 1
the I-Disease 1
colon I-Disease 1
and I-Disease 1
rectum I-Disease 1
and O 0
to O 0
colorectal B-Disease 1
cancer I-Disease 1
. O 0

Mutations O 0
located O 0
at O 0
the O 0
extreme O 0
5 O 0
end O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
, O 0
however O 0
, O 0
are O 0
associated O 0
with O 0
a O 0
less O 0
severe O 0
disease O 0
known O 0
as O 0
attenuated B-Disease 0
adenomatous I-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( O 0
AAPC B-Disease 1
) O 0
. O 0

Many O 0
individuals O 0
with O 0
AAPC B-Disease 1
develop O 0
relatively O 0
few O 0
colorectal B-Disease 1
polyps I-Disease 1
but O 0
are O 0
still O 0
at O 0
high O 0
risk O 0
for O 0
colorectal B-Disease 1
cancer I-Disease 1
. O 0

We O 0
report O 0
here O 0
the O 0
identification O 0
of O 0
a O 0
5 O 0
APC B-Disease 1
germline O 0
mutation O 0
in O 0
five O 0
separately O 0
ascertained O 0
AAPC B-Disease 1
families O 0
from O 0
Newfoundland O 0
, O 0
Canada O 0
. O 0

This O 0
disease O 0
- O 0
causing O 0
mutation O 0
is O 0
a O 0
single O 0
basepair O 0
change O 0
( O 0
G O 0
to O 0
A O 0
) O 0
in O 0
the O 0
splice O 0
- O 0
acceptor O 0
region O 0
of O 0
APC B-Disease 1
intron O 0
3 O 0
that O 0
creates O 0
a O 0
mutant O 0
RNA O 0
without O 0
exon O 0
4 O 0
of O 0
APC O 1
. O 0

The O 0
observation O 0
of O 0
the O 0
same O 0
APC B-Disease 1
mutation O 0
in O 0
five O 0
families O 0
from O 0
the O 0
same O 0
geographic O 0
area O 0
demonstrates O 0
a O 0
founder O 0
effect O 0
. O 0

Furthermore O 0
, O 0
the O 0
identification O 0
of O 0
this O 0
germline O 0
mutation O 0
strengthens O 0
the O 0
correlation O 0
between O 0
the O 0
5 O 0
location O 0
of O 0
an O 0
APC B-Disease 1
disease O 0
- O 0
causing O 0
mutation O 0
and O 0
the O 0
attenuated B-Disease 0
polyposis I-Disease 1
phenotype O 0
. O 0
. O 0

Alstrom B-Disease 0
syndrome I-Disease 0
: O 0
further O 0
evidence O 0
for O 0
linkage O 0
to O 0
human O 0
chromosome O 0
2p13 O 0
. O 0

Alstrom B-Disease 0
syndrome I-Disease 0
is O 0
a O 0
rare O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
characterized O 0
by O 0
retinal B-Disease 0
degeneration I-Disease 0
, O 0
sensorineural B-Disease 0
hearing I-Disease 0
loss I-Disease 0
, O 0
early O 0
- O 0
onset O 0
obesity B-Disease 0
, O 0
and O 0
non B-Disease 1
- I-Disease 1
insulin I-Disease 1
- I-Disease 1
dependent I-Disease 1
diabetes I-Disease 1
mellitus I-Disease 1
. O 0

The O 0
gene O 0
for O 0
Alstrom B-Disease 0
syndrome I-Disease 0
( O 0
ALMS1 O 0
) O 0
has O 0
been O 0
previously O 0
localized O 0
to O 0
human O 0
chromosome O 0
2p13 O 0
by O 0
homozygosity O 0
mapping O 0
in O 0
two O 0
distinct O 0
isolated O 0
populations O 0
- O 0
French O 0
Acadian O 0
and O 0
North O 0
African O 0
. O 0

Pair O 0
- O 0
wise O 0
analyses O 0
resulted O 0
in O 0
maximum O 0
lod O 0
( O 0
logarithm O 0
of O 0
the O 0
odds O 0
ratio O 0
) O 0
scores O 0
of O 0
3 O 0
. O 0

84 O 0
and O 0
2 O 0
. O 0

9 O 0
, O 0
respectively O 0
. O 0

To O 0
confirm O 0
these O 0
findings O 0
, O 0
a O 0
large O 0
linkage O 0
study O 0
was O 0
performed O 0
in O 0
twelve O 0
additional O 0
families O 0
segregating O 0
for O 0
Alstrom B-Disease 0
syndrome I-Disease 0
. O 0

A O 0
maximum O 0
two O 0
- O 0
point O 0
lod O 0
score O 0
of O 0
7 O 0
. O 0

13 O 0
( O 0
theta O 0
= O 0
0 O 0
. O 0
00 O 0
) O 0
for O 0
marker O 0
D2S2110 O 0
and O 0
a O 0
maximum O 0
cumulative O 0
multipoint O 0
lod O 0
score O 0
of O 0
9 O 0
. O 0

16 O 0
for O 0
marker O 0
D2S2110 O 0
were O 0
observed O 0
, O 0
further O 0
supporting O 0
linkage O 0
to O 0
chromosome O 0
2p13 O 0
. O 0

No O 0
evidence O 0
of O 0
genetic O 0
heterogeneity O 0
was O 0
observed O 0
in O 0
these O 0
families O 0
. O 0

Meiotic O 0
recombination O 0
events O 0
have O 0
localized O 0
the O 0
critical O 0
region O 0
containing O 0
ALMS1 O 0
to O 0
a O 0
6 O 0
. O 0

1 O 0
- O 0
cM O 0
interval O 0
flanked O 0
by O 0
markers O 0
D2S327 O 0
and O 0
D2S286 O 0
. O 0

A O 0
fine O 0
resolution O 0
radiation O 0
hybrid O 0
map O 0
of O 0
31 O 0
genes O 0
and O 0
markers O 0
has O 0
been O 0
constructed O 0
. O 0

Pendred B-Disease 0
syndrome I-Disease 0
: O 0
phenotypic O 0
variability O 0
in O 0
two O 0
families O 0
carrying O 0
the O 0
same O 0
PDS B-Disease 1
missense O 0
mutation O 0
. O 0

Pendred B-Disease 0
syndrome I-Disease 0
comprises O 0
congenital B-Disease 0
sensorineural I-Disease 0
hearing I-Disease 0
loss I-Disease 0
, O 0
thyroid B-Disease 0
goiter I-Disease 1
, O 0
and O 0
positive O 0
perchlorate O 0
discharge O 0
test O 0
. O 0

Recently O 0
, O 0
this O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
was O 0
shown O 0
to O 0
be O 0
caused O 0
by O 0
mutations O 0
in O 0
the O 0
PDS B-Disease 1
gene O 0
, O 0
which O 0
encodes O 0
an O 0
anion O 0
transporter O 0
called O 0
pendrin O 0
. O 0

Molecular O 0
analysis O 0
of O 0
the O 0
PDS B-Disease 1
gene O 0
was O 0
performed O 0
in O 0
two O 0
consanguineous O 0
large O 0
families O 0
from O 0
Southern O 0
Tunisia O 0
comprising O 0
a O 0
total O 0
of O 0
23 O 0
individuals O 0
affected O 0
with O 0
profound O 0
congenital B-Disease 0
deafness I-Disease 1
; O 0
the O 0
same O 0
missense O 0
mutation O 0
, O 0
L445W O 0
, O 0
was O 0
identified O 0
in O 0
all O 0
affected O 0
individuals O 0
. O 0

A O 0
widened B-Disease 0
vestibular I-Disease 0
aqueduct I-Disease 0
was O 0
found O 0
in O 0
all O 0
patients O 0
who O 0
underwent O 0
computed O 0
tomography O 0
( O 0
CT O 0
) O 0
scan O 0
exploration O 0
of O 0
the O 0
inner O 0
ear O 0
. O 0

In O 0
contrast O 0
, O 0
goiter B-Disease 1
was O 0
present O 0
in O 0
only O 0
11 O 0
affected O 0
individuals O 0
, O 0
who O 0
interestingly O 0
had O 0
a O 0
normal O 0
result O 0
of O 0
the O 0
perchlorate O 0
discharge O 0
test O 0
whenever O 0
performed O 0
. O 0

The O 0
present O 0
results O 0
question O 0
the O 0
sensitivity O 0
of O 0
the O 0
perchlorate O 0
test O 0
for O 0
the O 0
diagnosis O 0
of O 0
Pendred B-Disease 0
syndrome I-Disease 0
and O 0
support O 0
the O 0
use O 0
of O 0
a O 0
molecular O 0
analysis O 0
of O 0
the O 0
PDS B-Disease 1
gene O 0
in O 0
the O 0
assessment O 0
of O 0
individuals O 0
with O 0
severe O 0
to O 0
profound O 0
congenital B-Disease 0
hearing I-Disease 0
loss I-Disease 0
associated O 0
with O 0
inner B-Disease 0
ear I-Disease 0
morphological I-Disease 0
anomaly I-Disease 0
even O 0
in O 0
the O 0
absence O 0
of O 0
a O 0
thyroid B-Disease 0
goiter I-Disease 1
. O 0
. O 0

Knobloch B-Disease 0
syndrome I-Disease 0
involving O 0
midline B-Disease 0
scalp I-Disease 0
defect I-Disease 0
of I-Disease 0
the I-Disease 0
frontal I-Disease 0
region I-Disease 0
. O 0

We O 0
report O 0
on O 0
a O 0
4 O 0
- O 0
year O 0
- O 0
old O 0
boy O 0
with O 0
Knobloch B-Disease 0
syndrome I-Disease 0
. O 0

He O 0
has O 0
vitreoretinal B-Disease 0
degeneration I-Disease 0
, O 0
high B-Disease 1
myopia I-Disease 1
, O 0
cataract B-Disease 0
, O 0
telecanthus B-Disease 0
, O 0
hypertelorism B-Disease 0
, O 0
and O 0
a O 0
high B-Disease 0
- I-Disease 0
arched I-Disease 0
palate I-Disease 0
. O 0

He O 0
also O 0
has O 0
a O 0
defect B-Disease 1
of I-Disease 1
the I-Disease 1
anterior I-Disease 1
midline I-Disease 1
scalp I-Disease 1
with O 0
involvement O 0
of O 0
the O 0
frontal O 0
bone O 0
as O 0
documented O 0
by O 0
a O 0
computed O 0
tomography O 0
( O 0
CT O 0
) O 0
scan O 0
. O 0

The O 0
brain O 0
was O 0
normal O 0
on O 0
CT O 0
scan O 0
and O 0
magnetic O 0
resonance O 0
imaging O 0
. O 0

We O 0
present O 0
a O 0
review O 0
of O 0
the O 0
23 O 0
published O 0
cases O 0
with O 0
this O 0
syndrome O 0
. O 0

Our O 0
patient O 0
illustrates O 0
the O 0
importance O 0
of O 0
investigating O 0
for O 0
underlying O 0
ocular O 0
and O 0
central O 0
nervous O 0
system O 0
pathology O 0
whenever O 0
midline B-Disease 0
scalp I-Disease 0
defects I-Disease 0
are O 0
present O 0
. O 0
. O 0

The O 0
DNA O 0
double O 0
- O 0
strand O 0
break O 0
repair O 0
gene O 0
hMRE11 O 0
is O 0
mutated O 0
in O 0
individuals O 0
with O 0
an O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
- I-Disease 0
like I-Disease 0
disorder I-Disease 0
. O 0

We O 0
show O 0
that O 0
hypomorphic O 0
mutations O 0
in O 0
hMRE11 O 0
, O 0
but O 0
not O 0
in O 0
ATM O 0
, O 0
are O 0
present O 0
in O 0
certain O 0
individuals O 0
with O 0
an O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
- I-Disease 0
like I-Disease 0
disorder I-Disease 0
( O 0
ATLD B-Disease 1
) O 0
. O 0

The O 0
cellular O 0
features O 0
resulting O 0
from O 0
these O 0
hMRE11 O 0
mutations O 0
are O 0
similar O 0
to O 0
those O 0
seen O 0
in O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
as O 0
well O 0
as O 0
NBS B-Disease 0
and O 0
include O 0
hypersensitivity B-Disease 1
to I-Disease 1
ionizing I-Disease 1
radiation I-Disease 1
, O 0
radioresistant O 0
DNA O 0
synthesis O 0
, O 0
and O 0
abrogation O 0
of O 0
ATM O 0
- O 0
dependent O 0
events O 0
, O 0
such O 0
as O 0
the O 0
activation O 0
of O 0
Jun O 0
kinase O 0
following O 0
exposure O 0
to O 0
gamma O 0
irradiation O 0
. O 0

Although O 0
the O 0
mutant O 0
hMre11 O 0
proteins O 0
retain O 0
some O 0
ability O 0
to O 0
interact O 0
with O 0
hRad50 O 0
and O 0
Nbs1 O 0
, O 0
formation O 0
of O 0
ionizing O 0
radiation O 0
- O 0
induced O 0
hMre11 O 0
and O 0
Nbs1 O 0
foci O 0
was O 0
absent O 0
in O 0
hMRE11 O 0
mutant O 0
cells O 0
. O 0

These O 0
data O 0
demonstrate O 0
that O 0
ATM O 0
and O 0
the O 0
hMre11 O 0
/ O 0
hRad50 O 0
/ O 0
Nbs1 O 0
protein O 0
complex O 0
act O 0
in O 0
the O 0
same O 0
DNA O 0
damage O 0
response O 0
pathway O 0
and O 0
link O 0
hMre11 O 0
to O 0
the O 0
complex O 0
pathology O 0
of O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
. O 0
. O 0

Mutations O 0
in O 0
TNFRSF11A O 0
, O 0
affecting O 0
the O 0
signal O 0
peptide O 0
of O 0
RANK O 0
, O 0
cause O 0
familial B-Disease 0
expansile I-Disease 0
osteolysis I-Disease 0
. O 0

Familial B-Disease 1
expansile I-Disease 1
osteolysis I-Disease 1
( O 0
FEO B-Disease 0
, O 0
MIM O 0
174810 O 0
) O 0
is O 0
a O 0
rare O 0
, O 0
autosomal B-Disease 0
dominant I-Disease 0
bone I-Disease 0
disorder I-Disease 0
characterized O 0
by O 0
focal O 0
areas O 0
of O 0
increased B-Disease 1
bone I-Disease 1
remodelling I-Disease 1
. O 0

The O 0
osteolytic B-Disease 0
lesions I-Disease 0
, O 0
which O 0
develop O 0
usually O 0
in O 0
the O 0
long O 0
bones O 0
during O 0
early O 0
adulthood O 0
, O 0
show O 0
increased O 0
osteoblast O 0
and O 0
osteoclast O 0
activity O 0
. O 0

Our O 0
previous O 0
linkage O 0
studies O 0
mapped O 0
the O 0
gene O 0
responsible O 0
for O 0
FEO B-Disease 0
to O 0
an O 0
interval O 0
of O 0
less O 0
than O 0
5 O 0
cM O 0
between O 0
D18S64 O 0
and O 0
D18S51 O 0
on O 0
chromosome O 0
18q21 O 0
. O 0

2 O 0
- O 0
21 O 0
2 O 0
- O 0
21 O 0
. O 0

3 O 0
in O 0
a O 0
large O 0
Northern O 0
Irish O 0
family O 0
. O 0

The O 0
gene O 0
encoding O 0
receptor O 0
activator O 0
of O 0
nuclear O 0
factor O 0
- O 0
kappa O 0
B O 0
( O 0
RANK O 0
; O 0
ref O 0
. O 0
5 O 0
) O 0
, O 0
TNFRSF11A O 0
, O 0
maps O 0
to O 0
this O 0
region O 0
. O 0

RANK O 0
is O 0
essential O 0
in O 0
osteoclast O 0
formation O 0
. O 0

We O 0
identified O 0
two O 0
heterozygous O 0
insertion O 0
mutations O 0
in O 0
exon O 0
1 O 0
of O 0
TNFRSF11A O 0
in O 0
affected O 0
members O 0
of O 0
four O 0
families O 0
with O 0
FEO B-Disease 0
or O 0
familial B-Disease 1
Paget I-Disease 1
disease I-Disease 1
of I-Disease 1
bone I-Disease 1
( O 0
PDB B-Disease 1
) O 0
. O 0

One O 0
was O 0
a O 0
duplication O 0
of O 0
18 O 0
bases O 0
and O 0
the O 0
other O 0
a O 0
duplication O 0
of O 0
27 O 0
bases O 0
, O 0
both O 0
of O 0
which O 0
affected O 0
the O 0
signal O 0
peptide O 0
region O 0
of O 0
the O 0
RANK O 0
molecule O 0
. O 0

Expression O 0
of O 0
recombinant O 0
forms O 0
of O 0
the O 0
mutant O 0
RANK O 0
proteins O 0
revealed O 0
perturbations O 0
in O 0
expression O 0
levels O 0
and O 0
lack O 0
of O 0
normal O 0
cleavage O 0
of O 0
the O 0
signal O 0
peptide O 0
. O 0

Both O 0
mutations O 0
caused O 0
an O 0
increase O 0
in O 0
RANK O 0
- O 0
mediated O 0
nuclear O 0
factor O 0
- O 0
kappaB O 0
( O 0
NF O 0
- O 0
kappaB O 0
) O 0
signalling O 0
in O 0
vitro O 0
, O 0
consistent O 0
with O 0
the O 0
presence O 0
of O 0
an O 0
activating O 0
mutation O 0
. O 0

Cardiac O 0
Na O 0
( O 0
+ O 0
) O 0
channel O 0
dysfunction O 0
in O 0
Brugada B-Disease 0
syndrome I-Disease 0
is O 0
aggravated O 0
by O 0
beta O 0
( O 0
1 O 0
) O 0
- O 0
subunit O 0
. O 0

BACKGROUND O 0
Mutations O 0
in O 0
the O 0
gene O 0
encoding O 0
the O 0
human O 0
cardiac O 0
Na O 0
( O 0
+ O 0
) O 0
channel O 0
alpha O 0
- O 0
subunit O 0
( O 0
hH1 O 0
) O 0
are O 0
responsible O 0
for O 0
chromosome O 0
3 O 0
- O 0
linked O 0
congenital B-Disease 1
long I-Disease 1
- I-Disease 1
QT I-Disease 1
syndrome I-Disease 1
( O 0
LQT3 B-Disease 0
) O 0
and O 0
idiopathic B-Disease 1
ventricular I-Disease 1
fibrillation I-Disease 1
( O 0
IVF B-Disease 0
) O 0
. O 0

An O 0
auxiliary O 0
beta O 0
( O 0
1 O 0
) O 0
- O 0
subunit O 0
, O 0
widely O 0
expressed O 0
in O 0
excitable O 0
tissues O 0
, O 0
shifts O 0
the O 0
voltage O 0
dependence O 0
of O 0
steady O 0
- O 0
state O 0
inactivation O 0
toward O 0
more O 0
negative O 0
potentials O 0
and O 0
restores O 0
normal O 0
gating O 0
kinetics O 0
of O 0
brain O 0
and O 0
skeletal O 0
muscle O 0
Na O 0
( O 0
+ O 0
) O 0
channels O 0
expressed O 0
in O 0
Xenopus O 0
oocytes O 0
but O 0
has O 0
little O 0
if O 0
any O 0
functional O 0
effect O 0
on O 0
the O 0
cardiac O 0
isoform O 0
. O 0

Here O 0
, O 0
we O 0
characterize O 0
the O 0
altered O 0
effects O 0
of O 0
a O 0
human O 0
beta O 0
( O 0
1 O 0
) O 0
- O 0
subunit O 0
( O 0
hbeta O 0
( O 0
1 O 0
) O 0
) O 0
on O 0
the O 0
heterologously O 0
expressed O 0
hH1 O 0
mutation O 0
( O 0
T1620M O 0
) O 0
previously O 0
associated O 0
with O 0
IVF B-Disease 0
. O 0

METHODS O 0
AND O 0
RESULTS O 0
When O 0
expressed O 0
alone O 0
in O 0
Xenopus O 0
oocytes O 0
, O 0
T1620M O 0
exhibited O 0
no O 0
persistent O 0
currents O 0
, O 0
in O 0
contrast O 0
to O 0
the O 0
LQT3 B-Disease 0
mutant O 0
channels O 0
, O 0
but O 0
the O 0
midpoint O 0
of O 0
steady O 0
- O 0
state O 0
inactivation O 0
( O 0
V O 0
( O 0
1 O 0
/ O 0
2 O 0
) O 0
) O 0
was O 0
significantly O 0
shifted O 0
toward O 0
more O 0
positive O 0
potentials O 0
than O 0
for O 0
wild O 0
- O 0
type O 0
hH1 O 0
. O 0

Coexpression O 0
of O 0
hbeta O 0
( O 0
1 O 0
) O 0
did O 0
not O 0
significantly O 0
alter O 0
current O 0
decay O 0
or O 0
recovery O 0
from O 0
inactivation O 0
of O 0
wild O 0
- O 0
type O 0
hH1 O 0
; O 0
however O 0
, O 0
it O 0
further O 0
shifted O 0
the O 0
V O 0
( O 0
1 O 0
/ O 0
2 O 0
) O 0
and O 0
accelerated O 0
the O 0
recovery O 0
from O 0
inactivation O 0
of O 0
T1620M O 0
. O 0

Oocyte O 0
macropatch O 0
analysis O 0
revealed O 0
that O 0
the O 0
activation O 0
kinetics O 0
of O 0
T1620M O 0
were O 0
normal O 0
. O 0

CONCLUSIONS O 0
It O 0
is O 0
suggested O 0
that O 0
coexpression O 0
of O 0
hbeta O 0
( O 0
1 O 0
) O 0
exposes O 0
a O 0
more O 0
severe O 0
functional O 0
defect O 0
that O 0
results O 0
in O 0
a O 0
greater O 0
overlap O 0
in O 0
the O 0
relationship O 0
between O 0
channel O 0
inactivation O 0
and O 0
activation O 0
( O 0
window O 0
current O 0
) O 0
in O 0
T1620M O 0
, O 0
which O 0
is O 0
proposed O 0
to O 0
be O 0
a O 0
potential O 0
pathophysiological O 0
mechanism O 0
of O 0
IVF B-Disease 0
in O 0
vivo O 0
. O 0

One O 0
possible O 0
explanation O 0
for O 0
our O 0
finding O 0
is O 0
an O 0
altered O 0
alpha O 0
- O 0
/ O 0
beta O 0
( O 0
1 O 0
) O 0
- O 0
subunit O 0
association O 0
in O 0
the O 0
mutant O 0
. O 0
. O 0

Meiotic O 0
segregation O 0
analysis O 0
of O 0
RB1 O 0
alleles O 0
in O 0
retinoblastoma B-Disease 1
pedigrees O 0
by O 0
use O 0
of O 0
single O 0
- O 0
sperm O 0
typing O 0
. O 0

In O 0
hereditary B-Disease 0
retinoblastoma I-Disease 1
, O 0
different O 0
epidemiological O 0
studies O 0
have O 0
indicated O 0
a O 0
preferential O 0
paternal O 0
transmission O 0
of O 0
mutant O 0
retinoblastoma B-Disease 1
alleles O 0
to O 0
offspring O 0
, O 0
suggesting O 0
the O 0
occurrence O 0
of O 0
a O 0
meiotic O 0
drive O 0
. O 0

To O 0
investigate O 0
this O 0
mechanism O 0
, O 0
we O 0
analyzed O 0
sperm O 0
samples O 0
from O 0
six O 0
individuals O 0
from O 0
five O 0
unrelated O 0
families O 0
affected O 0
with O 0
hereditary B-Disease 0
retinoblastoma I-Disease 1
. O 0

Single O 0
- O 0
sperm O 0
typing O 0
techniques O 0
were O 0
performed O 0
for O 0
each O 0
sample O 0
by O 0
study O 0
of O 0
two O 0
informative O 0
short O 0
tandem O 0
repeats O 0
located O 0
either O 0
in O 0
or O 0
close O 0
to O 0
the O 0
retinoblastoma B-Disease 1
gene O 0
( O 0
RB1 O 0
) O 0
. O 0

The O 0
segregation O 0
probability O 0
of O 0
mutant O 0
RB1 O 0
alleles O 0
in O 0
sperm O 0
samples O 0
was O 0
assessed O 0
by O 0
use O 0
of O 0
the O 0
SPERMSEG O 0
program O 0
, O 0
which O 0
includes O 0
experimental O 0
parameters O 0
, O 0
recombination O 0
fractions O 0
between O 0
the O 0
markers O 0
, O 0
and O 0
segregation O 0
parameters O 0
. O 0

A O 0
total O 0
of O 0
2 O 0
, O 0
952 O 0
single O 0
sperm O 0
from O 0
the O 0
six O 0
donors O 0
were O 0
analyzed O 0
. O 0

We O 0
detected O 0
a O 0
significant O 0
segregation O 0
distortion O 0
in O 0
the O 0
data O 0
as O 0
a O 0
whole O 0
( O 0
P O 0
= O 0
. O 0
0099 O 0
) O 0
and O 0
a O 0
significant O 0
heterogeneity O 0
in O 0
the O 0
segregation O 0
rate O 0
across O 0
donors O 0
( O 0
. O 0
0092 O 0
) O 0
. O 0

Further O 0
analysis O 0
shows O 0
that O 0
this O 0
result O 0
can O 0
be O 0
explained O 0
by O 0
segregation O 0
distortion O 0
in O 0
favor O 0
of O 0
the O 0
normal O 0
allele O 0
in O 0
one O 0
donor O 0
only O 0
and O 0
that O 0
it O 0
does O 0
not O 0
provide O 0
evidence O 0
of O 0
a O 0
significant O 0
segregation O 0
distortion O 0
in O 0
the O 0
other O 0
donors O 0
. O 0

The O 0
segregation O 0
distortion O 0
favoring O 0
the O 0
mutant O 0
RB1 O 0
allele O 0
does O 0
not O 0
seem O 0
to O 0
occur O 0
during O 0
spermatogenesis O 0
, O 0
and O 0
, O 0
thus O 0
, O 0
meiotic O 0
drive O 0
may O 0
result O 0
either O 0
from O 0
various O 0
mechanisms O 0
, O 0
including O 0
a O 0
fertilization O 0
advantage O 0
or O 0
a O 0
better O 0
mobility O 0
in O 0
sperm O 0
bearing O 0
a O 0
mutant O 0
RB1 O 0
gene O 0
, O 0
or O 0
from O 0
the O 0
existence O 0
of O 0
a O 0
defectively O 0
imprinted O 0
gene O 0
located O 0
on O 0
the O 0
human O 0
X O 0
chromosome O 0
. O 0

Friedreich B-Disease 1
ataxia I-Disease 1
: O 0
an O 0
overview O 0
. O 0

Friedreich B-Disease 1
ataxia I-Disease 1
, O 0
an O 0
autosomal B-Disease 0
recessive I-Disease 0
neurodegenerative I-Disease 0
disease I-Disease 0
, O 0
is O 0
the O 0
most O 0
common O 0
of O 0
the O 0
inherited B-Disease 0
ataxias I-Disease 0
. O 0

The O 0
recent O 0
discovery O 0
of O 0
the O 0
gene O 0
that O 0
is O 0
mutated O 0
in O 0
this O 0
condition O 0
, O 0
FRDA O 0
, O 0
has O 0
led O 0
to O 0
rapid O 0
advances O 0
in O 0
the O 0
understanding O 0
of O 0
the O 0
pathogenesis O 0
of O 0
Friedreich B-Disease 1
ataxia I-Disease 1
. O 0

About O 0
98 O 0
% O 0
of O 0
mutant O 0
alleles O 0
have O 0
an O 0
expansion O 0
of O 0
a O 0
GAA O 0
trinucleotide O 0
repeat O 0
in O 0
intron O 0
1 O 0
of O 0
the O 0
gene O 0
. O 0

This O 0
leads O 0
to O 0
reduced O 0
levels O 0
of O 0
the O 0
protein O 0
, O 0
frataxin O 0
. O 0

There O 0
is O 0
mounting O 0
evidence O 0
to O 0
suggest O 0
that O 0
Friedreich B-Disease 1
ataxia I-Disease 1
is O 0
the O 0
result O 0
of O 0
accumulation O 0
of O 0
iron O 0
in O 0
mitochondria O 0
leading O 0
to O 0
excess O 0
production O 0
of O 0
free O 0
radicals O 0
, O 0
which O 0
then O 0
results O 0
in O 0
cellular O 0
damage O 0
and O 0
death O 0
. O 0

Currently O 0
there O 0
is O 0
no O 0
known O 0
treatment O 0
that O 0
alters O 0
the O 0
natural O 0
course O 0
of O 0
the O 0
disease O 0
. O 0

The O 0
discovery O 0
of O 0
the O 0
FRDA B-Disease 0
gene O 0
and O 0
its O 0
possible O 0
function O 0
has O 0
raised O 0
hope O 0
that O 0
rational O 0
therapeutic O 0
strategies O 0
will O 0
be O 0
developed O 0
. O 0
. O 0

X B-Disease 1
- I-Disease 1
linked I-Disease 1
retinoschisis I-Disease 1
with O 0
point O 0
mutations O 0
in O 0
the O 0
XLRS1 O 0
gene O 0
. O 0

BACKGROUND O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
retinoschisis I-Disease 1
( O 0
XLRS B-Disease 1
) O 0
is O 0
a O 0
relatively O 0
rare O 0
vitreoretinal B-Disease 0
dystrophy I-Disease 0
that O 0
causes O 0
visual B-Disease 1
loss I-Disease 1
in O 0
young O 0
men O 0
. O 0

Recently O 0
, O 0
a O 0
gene O 0
responsible O 0
for O 0
this O 0
disease O 0
, O 0
designated O 0
XLRS1 O 0
, O 0
was O 0
identified O 0
, O 0
and O 0
several O 0
deleterious O 0
gene O 0
mutations O 0
were O 0
reported O 0
. O 0

OBJECTIVE O 0
To O 0
analyze O 0
Japanese O 0
patients O 0
clinically O 0
diagnosed O 0
as O 0
having O 0
XLRS B-Disease 1
formutational O 0
changes O 0
in O 0
the O 0
XLRS1 O 0
gene O 0
. O 0

METHODS O 0
Ten O 0
patients O 0
with O 0
XLRS B-Disease 1
underwent O 0
full O 0
ophthalmologic O 0
examination O 0
, O 0
including O 0
slitlamp O 0
biomicroscopy O 0
and O 0
dilated O 0
funduscopy O 0
. O 0

Genomic O 0
DNA O 0
was O 0
isolated O 0
from O 0
leukocytes O 0
, O 0
and O 0
all O 0
exons O 0
of O 0
the O 0
XLRS1 O 0
gene O 0
were O 0
amplified O 0
by O 0
polymerase O 0
chain O 0
reaction O 0
and O 0
analyzed O 0
using O 0
a O 0
direct O 0
sequencing O 0
method O 0
. O 0

RESULTS O 0
Point O 0
mutations O 0
in O 0
the O 0
XLRS1 O 0
gene O 0
were O 0
identified O 0
in O 0
all O 0
10 O 0
patients O 0
. O 0

The O 0
mutations O 0
were O 0
identical O 0
in O 0
each O 0
of O 0
2 O 0
pairs O 0
of O 0
brothers O 0
. O 0

Six O 0
of O 0
the O 0
point O 0
mutations O 0
represented O 0
missense O 0
mutations O 0
, O 0
1 O 0
was O 0
a O 0
nonsense O 0
mutation O 0
, O 0
and O 0
1 O 0
was O 0
a O 0
frameshift O 0
mutation O 0
. O 0

Five O 0
of O 0
the O 0
mutations O 0
are O 0
newly O 0
reported O 0
herein O 0
. O 0

CONCLUSIONS O 0
The O 0
discovery O 0
of O 0
new O 0
point O 0
mutations O 0
in O 0
this O 0
study O 0
increases O 0
the O 0
available O 0
information O 0
regarding O 0
the O 0
spectrum O 0
of O 0
genetic B-Disease 0
abnormalities I-Disease 0
and O 0
clinical O 0
manifestations O 0
of O 0
XLRS B-Disease 1
. O 0

However O 0
, O 0
the O 0
limited O 0
data O 0
failed O 0
to O 0
reveal O 0
a O 0
correlation O 0
between O 0
mutation O 0
and O 0
disease O 0
phenotype O 0
. O 0

CLINICAL O 0
RELEVANCE O 0
Identification O 0
of O 0
mutations O 0
in O 0
the O 0
XLRS1 O 0
gene O 0
and O 0
expanded O 0
information O 0
on O 0
clinical O 0
manifestations O 0
will O 0
facilitate O 0
early O 0
diagnosis O 0
, O 0
appropriate O 0
early O 0
therapy O 0
, O 0
and O 0
genetic O 0
counseling O 0
regarding O 0
the O 0
prognosis O 0
of O 0
XLRS B-Disease 1
. O 0
. O 0

Atm O 0
and O 0
Bax O 0
cooperate O 0
in O 0
ionizing O 0
radiation O 0
- O 0
induced O 0
apoptosis O 0
in O 0
the O 0
central O 0
nervous O 0
system O 0
. O 0

Ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
is O 0
a O 0
hereditary B-Disease 0
multisystemic I-Disease 0
disease I-Disease 0
resulting O 0
from O 0
mutations O 0
of O 0
ataxia B-Disease 0
telangiectasia I-Disease 0
, O 0
mutated O 0
( O 0
ATM O 0
) O 0
and O 0
is O 0
characterized O 0
by O 0
neurodegeneration B-Disease 1
, O 0
cancer B-Disease 1
, O 0
immune B-Disease 0
defects I-Disease 0
, O 0
and O 0
hypersensitivity B-Disease 1
to I-Disease 1
ionizing I-Disease 1
radiation I-Disease 1
. O 0

The O 0
molecular O 0
details O 0
of O 0
ATM O 0
function O 0
in O 0
the O 0
nervous O 0
system O 0
are O 0
unclear O 0
, O 0
although O 0
the O 0
neurological B-Disease 1
lesion I-Disease 1
in O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
becomes O 0
apparent O 0
early O 0
in O 0
life O 0
, O 0
suggesting O 0
a O 0
developmental O 0
origin O 0
. O 0

The O 0
central O 0
nervous O 0
system O 0
( O 0
CNS O 0
) O 0
of O 0
Atm O 0
- O 0
null O 0
mice O 0
shows O 0
a O 0
pronounced O 0
defect O 0
in O 0
apoptosis O 0
induced O 0
by O 0
genotoxic O 0
stress O 0
, O 0
suggesting O 0
ATM O 0
functions O 0
to O 0
eliminate O 0
neurons O 0
with O 0
excessive O 0
genomic O 0
damage O 0
. O 0

Here O 0
, O 0
we O 0
report O 0
that O 0
the O 0
death O 0
effector O 0
Bax O 0
is O 0
required O 0
for O 0
a O 0
large O 0
proportion O 0
of O 0
Atm O 0
- O 0
dependent O 0
apoptosis O 0
in O 0
the O 0
developing O 0
CNS O 0
after O 0
ionizing O 0
radiation O 0
( O 0
IR O 0
) O 0
. O 0

Although O 0
many O 0
of O 0
the O 0
same O 0
regions O 0
of O 0
the O 0
CNS O 0
in O 0
both O 0
Bax O 0
- O 0
/ O 0
- O 0
and O 0
Atm O 0
- O 0
/ O 0
- O 0
mice O 0
were O 0
radioresistant O 0
, O 0
mice O 0
nullizygous O 0
for O 0
both O 0
Bax O 0
and O 0
Atm O 0
showed O 0
additional O 0
reduction O 0
in O 0
IR O 0
- O 0
induced O 0
apoptosis O 0
in O 0
the O 0
CNS O 0
. O 0

Therefore O 0
, O 0
although O 0
the O 0
major O 0
IR O 0
- O 0
induced O 0
apoptotic O 0
pathway O 0
in O 0
the O 0
CNS O 0
requires O 0
Atm O 0
and O 0
Bax O 0
, O 0
a O 0
p53 O 0
- O 0
dependent O 0
collateral O 0
pathway O 0
exists O 0
that O 0
has O 0
both O 0
Atm O 0
- O 0
and O 0
Bax O 0
- O 0
independent O 0
branches O 0
. O 0

Further O 0
, O 0
Atm O 0
- O 0
and O 0
Bax O 0
- O 0
dependent O 0
apoptosis O 0
in O 0
the O 0
CNS O 0
also O 0
required O 0
caspase O 0
- O 0
3 O 0
activation O 0
. O 0

These O 0
data O 0
implicate O 0
Bax O 0
and O 0
caspase O 0
- O 0
3 O 0
as O 0
death O 0
effectors O 0
in O 0
neurodegenerative O 0
pathways O 0
. O 0
. O 0

Haim B-Disease 1
- I-Disease 1
Munk I-Disease 1
syndrome I-Disease 1
and O 0
Papillon B-Disease 0
- I-Disease 0
Lefevre I-Disease 0
syndrome I-Disease 0
are O 0
allelic O 0
mutations O 0
in O 0
cathepsin O 0
C O 0
. O 0

Of O 0
the O 0
many O 0
palmoplantar B-Disease 1
keratoderma I-Disease 1
( I-Disease 1
PPK I-Disease 1
) I-Disease 1
conditions I-Disease 1
, O 0
only O 0
Papillon B-Disease 0
- I-Disease 0
Lefevre I-Disease 0
syndrome I-Disease 0
( O 0
PLS B-Disease 0
) O 0
and O 0
Haim B-Disease 1
- I-Disease 1
Munk I-Disease 1
syndrome I-Disease 1
( O 0
HMS B-Disease 0
) O 0
are O 0
associated O 0
with O 0
premature O 0
periodontal O 0
destruction O 0
. O 0

Although O 0
both O 0
PLS B-Disease 0
and O 0
HMS B-Disease 0
share O 0
the O 0
cardinal O 0
features O 0
of O 0
PPK B-Disease 1
and O 0
severe O 0
periodontitis B-Disease 1
, O 0
a O 0
number O 0
of O 0
additional O 0
findings O 0
are O 0
reported O 0
in O 0
HMS B-Disease 0
including O 0
arachnodactyly B-Disease 1
, O 0
acro B-Disease 1
- I-Disease 1
osteolysis I-Disease 1
, O 0
atrophic B-Disease 1
changes I-Disease 1
of I-Disease 1
the I-Disease 1
nails I-Disease 1
, O 0
and O 0
a O 0
radiographic B-Disease 1
deformity I-Disease 1
of I-Disease 1
the I-Disease 1
fingers I-Disease 1
. O 0

While O 0
PLS B-Disease 0
cases O 0
have O 0
been O 0
identified O 0
throughout O 0
the O 0
world O 0
, O 0
HMS B-Disease 0
has O 0
only O 0
been O 0
described O 0
among O 0
descendants O 0
of O 0
a O 0
religious O 0
isolate O 0
originally O 0
from O 0
Cochin O 0
, O 0
India O 0
. O 0

Parental O 0
consanguinity O 0
is O 0
a O 0
characteristic O 0
of O 0
many O 0
cases O 0
of O 0
both O 0
conditions O 0
. O 0

Although O 0
autosomal O 0
recessive O 0
transmission O 0
of O 0
PLS B-Disease 0
is O 0
evident O 0
, O 0
a O 0
more O 0
" O 0
complex O 0
" O 0
autosomal O 0
recessive O 0
pattern O 0
of O 0
inheritance O 0
with O 0
phenotypic O 0
influences O 0
from O 0
a O 0
closely O 0
linked O 0
modifying O 0
locus O 0
has O 0
been O 0
hypothesised O 0
for O 0
HMS B-Disease 0
. O 0

Recently O 0
, O 0
mutations O 0
of O 0
the O 0
cathepsin O 0
C O 0
gene O 0
have O 0
been O 0
identified O 0
as O 0
the O 0
underlying O 0
genetic B-Disease 1
defect I-Disease 1
in O 0
PLS B-Disease 0
. O 0

To O 0
determine O 0
if O 0
a O 0
cathepsin O 0
C O 0
mutation O 0
is O 0
also O 0
responsible O 0
for O 0
HMS B-Disease 0
, O 0
we O 0
sequenced O 0
the O 0
gene O 0
in O 0
affected O 0
and O 0
unaffected O 0
subjects O 0
from O 0
the O 0
Cochin O 0
isolate O 0
in O 0
which O 0
both O 0
the O 0
PLS B-Disease 0
and O 0
HMS B-Disease 0
phenotypes O 0
appear O 0
. O 0

Here O 0
we O 0
report O 0
identification O 0
of O 0
a O 0
mutation O 0
of O 0
cathepsin O 0
C O 0
( O 0
exon O 0
6 O 0
, O 0
2127A O 0
- O 0
- O 0
> O 0
G O 0
) O 0
that O 0
changes O 0
a O 0
highly O 0
conserved O 0
amino O 0
acid O 0
in O 0
the O 0
cathepsin O 0
C O 0
peptide O 0
. O 0

This O 0
mutation O 0
segregates O 0
with O 0
HMS B-Disease 0
in O 0
four O 0
nuclear O 0
families O 0
. O 0

Additionally O 0
, O 0
the O 0
existence O 0
of O 0
a O 0
shared O 0
common O 0
haplotype O 0
for O 0
genetic O 0
loci O 0
flanking O 0
the O 0
cathepsin O 0
C O 0
gene O 0
suggests O 0
that O 0
affected O 0
subjects O 0
descended O 0
from O 0
the O 0
Cochin O 0
isolate O 0
are O 0
homozygous O 0
for O 0
a O 0
mutation O 0
inherited O 0
" O 0
identical O 0
by O 0
descent O 0
" O 0
from O 0
a O 0
common O 0
ancestor O 0
. O 0

This O 0
finding O 0
supports O 0
simple O 0
autosomal O 0
recessive O 0
inheritance O 0
for O 0
HMS B-Disease 0
in O 0
these O 0
families O 0
. O 0

We O 0
also O 0
report O 0
a O 0
mutation O 0
of O 0
the O 0
same O 0
exon O 0
6 O 0
CTSC O 0
codon O 0
( O 0
2126C O 0
- O 0
- O 0
> O 0
T O 0
) O 0
in O 0
a O 0
Turkish O 0
family O 0
with O 0
classical O 0
PLS B-Disease 0
. O 0

These O 0
findings O 0
provide O 0
evidence O 0
that O 0
PLS B-Disease 0
and O 0
HMS B-Disease 0
are O 0
allelic O 0
variants O 0
of O 0
cathepsin O 0
C O 0
gene O 0
mutations O 0
. O 0
. O 0

ATM O 0
- O 0
heterozygous O 0
germline O 0
mutations O 0
contribute O 0
to O 0
breast B-Disease 0
cancer I-Disease 1
- O 0
susceptibility O 0
. O 0

Approximately O 0
0 O 0
. O 0

5 O 0
% O 0
- O 0
1 O 0
% O 0
of O 0
the O 0
general O 0
population O 0
has O 0
been O 0
estimated O 0
to O 0
be O 0
heterozygous O 0
for O 0
a O 0
germline O 0
mutation O 0
in O 0
the O 0
ATM O 0
gene O 0
. O 0

Mutations O 0
in O 0
the O 0
ATM O 0
gene O 0
are O 0
responsible O 0
for O 0
the O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
( O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
) O 0
( O 0
MIM O 0
208900 O 0
) O 0
. O 0

The O 0
finding O 0
that O 0
ATM O 0
- O 0
heterozygotes O 0
have O 0
an O 0
increased O 0
relative O 0
risk O 0
for O 0
breast B-Disease 0
cancer I-Disease 1
was O 0
supported O 0
by O 0
some O 0
studies O 0
but O 0
not O 0
confirmed O 0
by O 0
others O 0
. O 0

In O 0
view O 0
of O 0
this O 0
discrepancy O 0
, O 0
we O 0
examined O 0
the O 0
frequency O 0
of O 0
ATM O 0
germline O 0
mutations O 0
in O 0
a O 0
selected O 0
group O 0
of O 0
Dutch O 0
patients O 0
with O 0
breast B-Disease 0
cancer I-Disease 1
. O 0

We O 0
have O 0
analyzed O 0
ATM O 0
germline O 0
mutations O 0
in O 0
normal O 0
blood O 0
lymphocytes O 0
, O 0
using O 0
the O 0
protein O 0
- O 0
truncation O 0
test O 0
followed O 0
by O 0
genomic O 0
- O 0
sequence O 0
analysis O 0
. O 0

A O 0
high O 0
percentage O 0
of O 0
ATM O 0
germline O 0
mutations O 0
was O 0
demonstrated O 0
among O 0
patients O 0
with O 0
sporadic B-Disease 0
breast I-Disease 0
cancer I-Disease 1
. O 0

The O 0
82 O 0
patients O 0
included O 0
in O 0
this O 0
study O 0
had O 0
developed O 0
breast B-Disease 0
cancer I-Disease 1
at O 0
age O 0
< O 0
45 O 0
and O 0
had O 0
survived O 0
> O 0
/ O 0
= O 0
5 O 0
years O 0
( O 0
mean O 0
15 O 0
years O 0
) O 0
, O 0
and O 0
in O 0
33 O 0
( O 0
40 O 0
% O 0
) O 0
of O 0
the O 0
patients O 0
a O 0
contralateral O 0
breast O 0
tumor O 0
had O 0
been O 0
diagnosed O 0
. O 0

Among O 0
these O 0
patients O 0
we O 0
identified O 0
seven O 0
( O 0
8 O 0
. O 0
5 O 0
% O 0
) O 0
ATM O 0
germline O 0
mutations O 0
, O 0
of O 0
which O 0
five O 0
are O 0
distinct O 0
. O 0

One O 0
splice O 0
- O 0
site O 0
mutation O 0
( O 0
IVS10 O 0
- O 0
6T O 0
- O 0
- O 0
> O 0
G O 0
) O 0
was O 0
detected O 0
three O 0
times O 0
in O 0
our O 0
series O 0
. O 0

Four O 0
heterozygous O 0
carriers O 0
were O 0
patients O 0
with O 0
bilateral O 0
breast O 0
cancer O 1
. O 0

Our O 0
results O 0
indicate O 0
that O 0
the O 0
mutations O 0
identified O 0
in O 0
this O 0
study O 0
are O 0
" O 0
A O 1
- O 1
T O 1
disease O 0
- O 0
causing O 0
" O 0
mutations O 0
that O 0
might O 0
be O 0
associated O 0
with O 0
an O 0
increased O 0
risk O 0
of O 0
breast O 0
cancer O 1
in O 0
heterozygotes O 0
. O 0

We O 0
conclude O 0
that O 0
ATM O 0
heterozygotes O 0
have O 0
an O 0
approximately O 0
ninefold O 0
- O 0
increased O 0
risk O 0
of O 0
developing O 0
a O 0
type O 0
of O 0
breast O 0
cancer O 1
characterized O 0
by O 0
frequent O 0
bilateral O 0
occurrence O 0
, O 0
early O 0
age O 0
at O 0
onset O 0
, O 0
and O 0
long O 0
- O 0
term O 0
survival O 0
. O 0

The O 0
specific O 0
characteristics O 0
of O 0
our O 0
population O 0
of O 0
patients O 0
may O 0
explain O 0
why O 0
such O 0
a O 0
high O 0
frequency O 0
was O 0
not O 0
found O 0
in O 0
other O 0
series O 0
. O 0

Human O 0
mutations O 0
in O 0
glucose O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
reflect O 0
evolutionary O 0
history O 0
. O 0

Glucose O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
is O 0
a O 0
cytosolic O 0
enzyme O 0
encoded O 0
by O 0
a O 0
housekeeping O 0
X O 0
- O 0
linked O 0
gene O 0
whose O 0
main O 0
function O 0
is O 0
to O 0
produce O 0
NADPH O 0
, O 0
a O 0
key O 0
electron O 0
donor O 0
in O 0
the O 0
defense O 0
against O 0
oxidizing O 0
agents O 0
and O 0
in O 0
reductive O 0
biosynthetic O 0
reactions O 0
. O 0

Inherited O 0
G6PD B-Disease 0
deficiency I-Disease 0
is O 0
associated O 0
with O 0
either O 0
episodic B-Disease 0
hemolytic I-Disease 1
anemia I-Disease 1
( O 0
triggered O 0
by O 0
fava O 0
beans O 0
or O 0
other O 0
agents O 0
) O 0
or O 0
life B-Disease 1
- I-Disease 1
long I-Disease 1
hemolytic I-Disease 1
anemia I-Disease 1
. O 0

We O 0
show O 0
here O 0
that O 0
an O 0
evolutionary O 0
analysis O 0
is O 0
a O 0
key O 0
to O 0
understanding O 0
the O 0
biology O 0
of O 0
a O 0
housekeeping O 0
gene O 0
. O 0

From O 0
the O 0
alignment O 0
of O 0
the O 0
amino O 0
acid O 0
( O 0
aa O 0
) O 0
sequence O 0
of O 0
52 O 0
glucose O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
species O 0
from O 0
42 O 0
different O 0
organisms O 0
, O 0
we O 0
found O 0
a O 0
striking O 0
correlation O 0
between O 0
the O 0
aa O 0
replacements O 0
that O 0
cause O 0
G6PD B-Disease 0
deficiency I-Disease 0
in O 0
humans O 0
and O 0
the O 0
sequence O 0
conservation O 0
of O 0
G6PD O 0
two O 0
- O 0
thirds O 0
of O 0
such O 0
replacements O 0
are O 0
in O 0
highly O 0
and O 0
moderately O 0
conserved O 0
( O 0
50 O 0
- O 0
99 O 0
% O 0
) O 0
aa O 0
; O 0
relatively O 0
few O 0
are O 0
in O 0
fully O 0
conserved O 0
aa O 0
( O 0
where O 0
they O 0
might O 0
be O 0
lethal O 0
) O 0
or O 0
in O 0
poorly O 0
conserved O 0
aa O 0
, O 0
where O 0
presumably O 0
they O 0
simply O 0
would O 0
not O 0
cause O 0
G6PD B-Disease 0
deficiency I-Disease 0
. O 0

This O 0
is O 0
consistent O 0
with O 0
the O 0
notion O 0
that O 0
all O 0
human O 0
mutants O 0
have O 0
residual O 0
enzyme O 0
activity O 0
and O 0
that O 0
null O 0
mutations O 0
are O 0
lethal O 0
at O 0
some O 0
stage O 0
of O 0
development O 0
. O 0

Comparing O 0
the O 0
distribution O 0
of O 0
mutations O 0
in O 0
a O 0
human O 0
housekeeping O 0
gene O 0
with O 0
evolutionary O 0
conservation O 0
is O 0
a O 0
useful O 0
tool O 0
for O 0
pinpointing O 0
amino O 0
acid O 0
residues O 0
important O 0
for O 0
the O 0
stability O 0
or O 0
the O 0
function O 0
of O 0
the O 0
corresponding O 0
protein O 0
. O 0

In O 0
view O 0
of O 0
the O 0
current O 0
explosive O 0
increase O 0
in O 0
full O 0
genome O 0
sequencing O 0
projects O 0
, O 0
this O 0
tool O 0
will O 0
become O 0
rapidly O 0
available O 0
for O 0
numerous O 0
other O 0
genes O 0
. O 0
. O 0

Constitutive O 0
and O 0
regulated O 0
modes O 0
of O 0
splicing O 0
produce O 0
six O 0
major O 0
myotonic B-Disease 1
dystrophy I-Disease 1
protein O 0
kinase O 0
( O 0
DMPK O 0
) O 0
isoforms O 0
with O 0
distinct O 0
properties O 0
. O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
is O 0
the O 0
most O 0
prevalent O 0
inherited B-Disease 1
neuromuscular I-Disease 1
disease I-Disease 1
in O 0
adults O 0
. O 0

The O 0
genetic B-Disease 1
defect I-Disease 1
is O 0
a O 0
CTG O 0
triplet O 0
repeat O 0
expansion O 0
in O 0
the O 0
3 O 0
- O 0
untranslated O 0
region O 0
of O 0
the O 0
myotonic B-Disease 1
dystrophy I-Disease 1
protein O 0
kinase O 0
( O 0
DMPK O 0
) O 0
gene O 0
, O 0
consisting O 0
of O 0
15 O 0
exons O 0
. O 0

Using O 0
a O 0
transgenic O 0
DMPK O 0
- O 0
overexpressor O 0
mouse O 0
model O 0
, O 0
we O 0
demonstrate O 0
here O 0
that O 0
the O 0
endogenous O 0
mouse O 0
DMPK O 0
gene O 0
and O 0
the O 0
human O 0
DMPK O 0
transgene O 0
produce O 0
six O 0
major O 0
alternatively O 0
spliced O 0
mRNAs O 0
which O 0
have O 0
almost O 0
identical O 0
cell O 0
type O 0
- O 0
dependent O 0
distribution O 0
frequencies O 0
and O 0
expression O 0
patterns O 0
. O 0

Use O 0
of O 0
a O 0
cryptic O 0
5 O 0
splice O 0
site O 0
in O 0
exon O 0
8 O 0
, O 0
which O 0
results O 0
in O 0
absence O 0
or O 0
presence O 0
of O 0
15 O 0
nucleotides O 0
specifying O 0
a O 0
VSGGG O 0
peptide O 0
motif O 0
, O 0
and O 0
/ O 0
or O 0
use O 0
of O 0
a O 0
cryptic O 0
3 O 0
splice O 0
site O 0
in O 0
exon O 0
14 O 0
, O 0
which O 0
leads O 0
to O 0
a O 0
frameshift O 0
in O 0
the O 0
mRNA O 0
reading O 0
frame O 0
, O 0
occur O 0
as O 0
independent O 0
stochastic O 0
events O 0
in O 0
all O 0
tissues O 0
examined O 0
. O 0

In O 0
contrast O 0
, O 0
the O 0
excision O 0
of O 0
exons O 0
13 O 0
/ O 0
14 O 0
that O 0
causes O 0
a O 0
frameshift O 0
and O 0
creates O 0
a O 0
C O 0
- O 0
terminally O 0
truncated O 0
protein O 0
is O 0
clearly O 0
cell O 0
type O 0
dependent O 0
and O 0
occurs O 0
predominantly O 0
in O 0
smooth O 0
muscle O 0
. O 0

We O 0
generated O 0
all O 0
six O 0
full O 0
- O 0
length O 0
mouse O 0
cDNAs O 0
that O 0
result O 0
from O 0
combinations O 0
of O 0
these O 0
three O 0
major O 0
splicing O 0
events O 0
and O 0
show O 0
that O 0
their O 0
transfection O 0
into O 0
cells O 0
in O 0
culture O 0
leads O 0
to O 0
production O 0
of O 0
four O 0
different O 0
approximately O 0
74 O 0
kDa O 0
full O 0
- O 0
length O 0
( O 0
heart O 0
- O 0
, O 0
skeletal O 0
muscle O 0
- O 0
or O 0
brain O 0
- O 0
specific O 0
) O 0
and O 0
two O 0
C O 0
- O 0
terminally O 0
truncated O 0
approximately O 0
68 O 0
kDa O 0
( O 0
smooth O 0
muscle O 0
- O 0
specific O 0
) O 0
isoforms O 0
. O 0

Information O 0
on O 0
DMPK O 0
mRNA O 0
and O 0
protein O 0
isoform O 0
expression O 0
patterns O 0
will O 0
be O 0
useful O 0
for O 0
recognizing O 0
differential O 0
effects O 0
of O 0
( O 0
CTG O 0
) O 0
( O 0
n O 0
) O 0
expansion O 0
in O 0
DM B-Disease 0
manifestation O 0
. O 0
. O 0

Genetic O 0
analysis O 0
, O 0
phenotypic O 0
diagnosis O 0
, O 0
and O 0
risk O 0
of O 0
venous B-Disease 1
thrombosis I-Disease 1
in O 0
families O 0
with O 0
inherited O 0
deficiencies B-Disease 0
of I-Disease 0
protein I-Disease 0
S I-Disease 0
. O 0

Protein B-Disease 0
S I-Disease 0
deficiency I-Disease 0
is O 0
a O 0
recognized O 0
risk O 0
factor O 0
for O 0
venous B-Disease 1
thrombosis I-Disease 1
. O 0

Of O 0
all O 0
the O 0
inherited O 0
thrombophilic B-Disease 0
conditions I-Disease 0
, O 0
it O 0
remains O 0
the O 0
most O 0
difficult O 0
to O 0
diagnose O 0
because O 0
of O 0
phenotypic O 0
variability O 0
, O 0
which O 0
can O 0
lead O 0
to O 0
inconclusive O 0
results O 0
. O 0

We O 0
have O 0
overcome O 0
this O 0
problem O 0
by O 0
studying O 0
a O 0
cohort O 0
of O 0
patients O 0
from O 0
a O 0
single O 0
center O 0
where O 0
the O 0
diagnosis O 0
was O 0
confirmed O 0
at O 0
the O 0
genetic O 0
level O 0
. O 0

Twenty O 0
- O 0
eight O 0
index O 0
patients O 0
with O 0
protein B-Disease 0
S I-Disease 0
deficiency I-Disease 0
and O 0
a O 0
PROS1 B-Disease 1
gene I-Disease 1
defect I-Disease 1
were O 0
studied O 0
, O 0
together O 0
with O 0
109 O 0
first O 0
- O 0
degree O 0
relatives O 0
. O 0

To O 0
avoid O 0
selection O 0
bias O 0
, O 0
we O 0
confined O 0
analysis O 0
of O 0
total O 0
and O 0
free O 0
protein O 0
S O 0
levels O 0
and O 0
thrombotic O 0
risk O 0
to O 0
the O 0
patients O 0
relatives O 0
. O 0

In O 0
this O 0
group O 0
of O 0
relatives O 0
, O 0
a O 0
low O 0
free O 0
protein O 0
S O 0
level O 0
was O 0
the O 0
most O 0
reliable O 0
predictor O 0
of O 0
a O 0
PROS1 B-Disease 1
gene I-Disease 1
defect I-Disease 1
( O 0
sensitivity O 0
97 O 0
. O 0
7 O 0
% O 0
, O 0
specificity O 0
100 O 0
% O 0
) O 0
. O 0

First O 0
- O 0
degree O 0
relatives O 0
with O 0
a O 0
PROS1 B-Disease 1
gene I-Disease 1
defect I-Disease 1
had O 0
a O 0
5 O 0
. O 0

0 O 0
- O 0
fold O 0
higher O 0
risk O 0
of O 0
thrombosis B-Disease 0
( O 0
95 O 0
% O 0
confidence O 0
interval O 0
, O 0
1 O 0
. O 0
5 O 0
- O 0
16 O 0
. O 0
8 O 0
) O 0
than O 0
those O 0
with O 0
a O 0
normal O 0
PROS1 O 0
gene O 0
and O 0
no O 0
other O 0
recognized O 0
thrombophilic B-Disease 1
defect I-Disease 1
. O 0

Although O 0
pregnancy O 0
/ O 0
puerperium O 0
and O 0
immobility O 0
/ O 0
trauma B-Disease 0
were O 0
important O 0
precipitating O 0
factors O 0
for O 0
thrombosis B-Disease 0
, O 0
almost O 0
half O 0
of O 0
the O 0
events O 0
were O 0
spontaneous O 0
. O 0

Relatives O 0
with O 0
splice O 0
- O 0
site O 0
or O 0
major O 0
structural O 0
defects B-Disease 0
in I-Disease 0
the I-Disease 0
PROS1 I-Disease 0
gene I-Disease 0
were O 0
more O 0
likely O 0
to O 0
have O 0
had O 0
a O 0
thrombotic O 0
event O 0
and O 0
had O 0
significantly O 0
lower O 0
total O 0
and O 0
free O 0
protein O 0
S O 0
levels O 0
than O 0
those O 0
relatives O 0
having O 0
missense O 0
mutations O 0
. O 0

We O 0
conclude O 0
that O 0
persons O 0
with O 0
PROS1 B-Disease 1
gene I-Disease 1
defects I-Disease 1
and O 0
protein B-Disease 0
S I-Disease 0
deficiency I-Disease 0
are O 0
at O 0
increased O 0
risk O 0
of O 0
thrombosis B-Disease 0
and O 0
that O 0
free O 0
protein O 0
S O 0
estimation O 0
offers O 0
the O 0
most O 0
reliable O 0
way O 0
of O 0
diagnosing O 0
the O 0
deficiency O 0
. O 0

( O 0
Blood O 0
. O 0
2000 O 0
; O 0
95 O 0
1935 O 0
- O 0
1941 O 0
) O 0
. O 0

Autoimmune B-Disease 1
lymphoproliferative I-Disease 1
syndrome I-Disease 1
( O 0
ALPS B-Disease 1
) O 0
in O 0
a O 0
child O 0
from O 0
consanguineous O 0
parents O 0
: O 0
a O 0
dominant O 0
or O 0
recessive O 0
disease O 0
? O 0

Autoimmune B-Disease 1
lymphoproliferative I-Disease 1
syndrome I-Disease 1
( O 0
ALPS B-Disease 1
) O 0
is O 0
characterized O 0
by O 0
autoimmune O 0
features O 0
and O 0
lymphoproliferations O 0
and O 0
is O 0
generally O 0
caused O 0
by O 0
defective O 0
Fas O 0
- O 0
mediated O 0
apoptosis O 0
. O 0

This O 0
report O 0
describes O 0
a O 0
child O 0
with O 0
clinical O 0
features O 0
of O 0
ALPS B-Disease 1
without O 0
detectable O 0
Fas O 0
expression O 0
on O 0
freshly O 0
isolated O 0
blood O 0
leukocytes O 0
. O 0

Detection O 0
of O 0
FAS O 0
transcripts O 0
via O 0
real O 0
- O 0
time O 0
quantitative O 0
PCR O 0
made O 0
a O 0
severe O 0
transcriptional O 0
defect O 0
unlikely O 0
. O 0

Sequencing O 0
of O 0
the O 0
FAS O 0
gene O 0
revealed O 0
a O 0
20 O 0
- O 0
nucleotide O 0
duplication O 0
in O 0
the O 0
last O 0
exon O 0
affecting O 0
the O 0
cytoplasmic O 0
signaling O 0
domain O 0
. O 0

The O 0
patient O 0
was O 0
homozygous O 0
for O 0
this O 0
mutation O 0
, O 0
whereas O 0
the O 0
consanguineous O 0
parents O 0
and O 0
the O 0
siblings O 0
were O 0
heterozygous O 0
. O 0

The O 0
patient O 0
reported O 0
here O 0
is O 0
a O 0
human O 0
homologue O 0
of O 0
the O 0
Fas O 0
- O 0
null O 0
mouse O 0
, O 0
inasmuch O 0
as O 0
she O 0
carries O 0
an O 0
autosomal O 0
homozygous O 0
mutation O 0
in O 0
the O 0
FAS O 0
gene O 0
and O 0
she O 0
shows O 0
the O 0
severe O 0
and O 0
accelerated O 0
ALPS B-Disease 1
phenotype O 0
. O 0

The O 0
heterozygous O 0
family O 0
members O 0
did O 0
not O 0
have O 0
the O 0
ALPS B-Disease 1
phenotype O 0
, O 0
indicating O 0
that O 0
the O 0
disease O 0
- O 0
causing O 0
FAS O 0
mutation O 0
in O 0
this O 0
family O 0
is O 0
autosomal O 0
recessive O 0
. O 0
. O 0

Identification O 0
of O 0
novel O 0
imprinted O 0
transcripts O 0
in O 0
the O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
and O 0
Angelman B-Disease 1
syndrome I-Disease 1
deletion O 0
region O 0
: O 0
further O 0
evidence O 0
for O 0
regional O 0
imprinting O 0
control O 0
. O 0

Deletions O 0
and O 0
other O 0
abnormalities O 0
of O 0
human O 0
chromosome O 0
15q11 O 0
- O 0
q13 O 0
are O 0
associated O 0
with O 0
two O 0
developmental O 0
disorders O 0
, O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
and O 0
Angelman B-Disease 1
syndrome I-Disease 1
( O 0
AS B-Disease 0
) O 0
. O 0

Loss O 0
of O 0
expression O 0
of O 0
imprinted O 0
, O 0
paternally O 0
expressed O 0
genes O 0
has O 0
been O 0
implicated O 0
in O 0
PWS B-Disease 0
. O 0

However O 0
, O 0
the O 0
number O 0
of O 0
imprinted O 0
genes O 0
that O 0
contribute O 0
to O 0
PWS B-Disease 0
, O 0
and O 0
the O 0
range O 0
over O 0
which O 0
the O 0
imprinting O 0
signal O 0
acts O 0
to O 0
silence O 0
one O 0
copy O 0
of O 0
the O 0
gene O 0
in O 0
a O 0
parent O 0
- O 0
of O 0
- O 0
origin O 0
- O 0
specific O 0
manner O 0
, O 0
are O 0
unknown O 0
. O 0

To O 0
identify O 0
additional O 0
imprinted O 0
genes O 0
that O 0
could O 0
contribute O 0
to O 0
the O 0
PWS B-Disease 0
phenotype O 0
and O 0
to O 0
understand O 0
the O 0
regional O 0
control O 0
of O 0
imprinting O 0
in O 0
15q11 O 0
- O 0
q13 O 0
, O 0
we O 0
have O 0
constructed O 0
an O 0
imprinted O 0
transcript O 0
map O 0
of O 0
the O 0
PWS O 0
- O 0
AS O 0
deletion O 0
interval O 0
. O 0

The O 0
imprinting O 0
status O 0
of O 0
22 O 0
expressed O 0
sequence O 0
tags O 0
derived O 0
from O 0
the O 0
radiation O 0
- O 0
hybrid O 0
human O 0
transcript O 0
maps O 0
or O 0
physical O 0
maps O 0
was O 0
determined O 0
in O 0
a O 0
reverse O 0
transcriptase O 0
- O 0
PCR O 0
assay O 0
and O 0
correlated O 0
with O 0
the O 0
position O 0
of O 0
the O 0
transcripts O 0
on O 0
the O 0
physical O 0
map O 0
. O 0

Seven O 0
new O 0
paternally O 0
expressed O 0
transcripts O 0
localize O 0
to O 0
an O 0
approximately O 0
1 O 0
. O 0

5 O 0
- O 0
Mb O 0
domain O 0
surrounding O 0
the O 0
SNRPN O 0
- O 0
associated O 0
imprinting O 0
center O 0
, O 0
which O 0
already O 0
includes O 0
four O 0
imprinted O 0
, O 0
paternally O 0
expressed O 0
genes O 0
. O 0

All O 0
other O 0
tested O 0
new O 0
transcripts O 0
in O 0
the O 0
deletion O 0
region O 0
were O 0
expressed O 0
from O 0
both O 0
alleles O 0
. O 0

A O 0
domain O 0
of O 0
exclusive O 0
paternal O 0
expression O 0
surrounding O 0
the O 0
imprinting O 0
center O 0
suggests O 0
strong O 0
regional O 0
control O 0
of O 0
the O 0
imprinting O 0
process O 0
. O 0

This O 0
study O 0
provides O 0
the O 0
means O 0
for O 0
further O 0
investigation O 0
of O 0
additional O 0
genes O 0
that O 0
cause O 0
or O 0
modify O 0
the O 0
phenotypes O 0
associated O 0
with O 0
rearrangements O 0
of O 0
15q11 O 0
- O 0
q13 O 0
. O 0

Combined O 0
analysis O 0
of O 0
hereditary B-Disease 1
prostate I-Disease 1
cancer I-Disease 1
linkage O 0
to O 0
1q24 O 0
- O 0
25 O 0
: O 0
results O 0
from O 0
772 O 0
hereditary B-Disease 1
prostate I-Disease 1
cancer I-Disease 1
families O 0
from O 0
the O 0
International O 0
Consortium O 0
for O 0
Prostate B-Disease 0
Cancer I-Disease 1
Genetics O 0
. O 0

A O 0
previous O 0
linkage O 0
study O 0
provided O 0
evidence O 0
for O 0
a O 0
prostate B-Disease 1
cancer I-Disease 1
- O 0
susceptibility O 0
locus O 0
at O 0
1q24 O 0
- O 0
25 O 0
. O 0

Subsequent O 0
reports O 0
in O 0
additional O 0
collections O 0
of O 0
families O 0
have O 0
yielded O 0
conflicting O 0
results O 0
. O 0

In O 0
addition O 0
, O 0
evidence O 0
for O 0
locus O 0
heterogeneity O 0
has O 0
been O 0
provided O 0
by O 0
the O 0
identification O 0
of O 0
other O 0
putative O 0
hereditary B-Disease 1
prostate I-Disease 1
cancer I-Disease 1
loci O 0
on O 0
Xq27 O 0
- O 0
28 O 0
, O 0
1q42 O 0
- O 0
43 O 0
, O 0
and O 0
1p36 O 0
. O 0

The O 0
present O 0
study O 0
describes O 0
a O 0
combined O 0
analysis O 0
for O 0
six O 0
markers O 0
in O 0
the O 0
1q24 O 0
- O 0
25 O 0
region O 0
in O 0
772 O 0
families O 0
affected O 0
by O 0
hereditary B-Disease 1
prostate I-Disease 1
cancer I-Disease 1
and O 0
ascertained O 0
by O 0
the O 0
members O 0
of O 0
the O 0
International O 0
Consortium O 0
for O 0
Prostate B-Disease 0
Cancer I-Disease 1
Genetics O 0
( O 0
ICPCG O 0
) O 0
from O 0
North O 0
America O 0
, O 0
Australia O 0
, O 0
Finland O 0
, O 0
Norway O 0
, O 0
Sweden O 0
, O 0
and O 0
the O 0
United O 0
Kingdom O 0
. O 0

Overall O 0
, O 0
there O 0
was O 0
some O 0
evidence O 0
for O 0
linkage O 0
, O 0
with O 0
a O 0
peak O 0
parametric O 0
multipoint O 0
LOD O 0
score O 0
assuming O 0
heterogeneity O 0
( O 0
HLOD O 0
) O 0
of O 0
1 O 0
. O 0

40 O 0
( O 0
P O 0
= O 0
. O 0
01 O 0
) O 0
at O 0
D1S212 O 0
. O 0

The O 0
estimated O 0
proportion O 0
of O 0
families O 0
( O 0
alpha O 0
) O 0
linked O 0
to O 0
the O 0
locus O 0
was O 0
. O 0

06 O 0
( O 0
1 O 0
- O 0
LOD O 0
support O 0
interval O 0
. O 0
01 O 0
- O 0
. O 0
12 O 0
) O 0
. O 0

This O 0
evidence O 0
was O 0
not O 0
observed O 0
by O 0
a O 0
nonparametric O 0
approach O 0
, O 0
presumably O 0
because O 0
of O 0
the O 0
extensive O 0
heterogeneity O 0
. O 0

Further O 0
parametric O 0
analysis O 0
revealed O 0
a O 0
significant O 0
effect O 0
of O 0
the O 0
presence O 0
of O 0
male O 0
- O 0
to O 0
- O 0
male O 0
disease O 0
transmission O 0
within O 0
the O 0
families O 0
. O 0

In O 0
the O 0
subset O 0
of O 0
491 O 0
such O 0
families O 0
, O 0
the O 0
peak O 0
HLOD O 0
was O 0
2 O 0
. O 0

In O 0
the O 0
subset O 0
of O 0
491 O 0
such O 0
families O 0
, O 0
the O 0
peak O 0
HLOD O 0
was O 0
2 O 0
. O 0

56 O 0
( O 0
P O 0
= O 0
. O 0
0006 O 0
) O 0
and O 0
alpha O 0
= O 0
. O 0

11 O 0
( O 0
1 O 0
- O 0
LOD O 0
support O 0
interval O 0
. O 0
04 O 0
- O 0
. O 0
19 O 0
) O 0
, O 0
compared O 0
with O 0
HLODs O 0
of O 0
0 O 0
in O 0
the O 0
remaining O 0
281 O 0
families O 0
. O 0

Within O 0
the O 0
families O 0
with O 0
male O 0
- O 0
to O 0
- O 0
male O 0
disease O 0
transmission O 0
, O 0
alpha O 0
increased O 0
with O 0
the O 0
early O 0
mean O 0
age O 0
at O 0
diagnosis O 0
( O 0
< O 0
65 O 0
years O 0
, O 0
alpha O 0
= O 0
. O 0
19 O 0
, O 0
with O 0
1 O 0
- O 0
LOD O 0
support O 0
interval O 0
. O 0
06 O 0
- O 0
. O 0
34 O 0
) O 0
and O 0
the O 0
number O 0
of O 0
affected O 0
family O 0
members O 0
( O 0
five O 0
or O 0
more O 0
family O 0
members O 0
, O 0
alpha O 0
= O 0
. O 0
15 O 0
, O 0
with O 0
1 O 0
- O 0
LOD O 0
support O 0
interval O 0
. O 0
04 O 0
- O 0
. O 0
28 O 0
) O 0
. O 0

The O 0
highest O 0
value O 0
of O 0
alpha O 0
was O 0
observed O 0
for O 0
the O 0
48 O 0
families O 0
that O 0
met O 0
all O 0
three O 0
criteria O 0
( O 0
peak O 0
HLOD O 0
= O 0
2 O 0
. O 0
25 O 0
, O 0
P O 0
= O 0
. O 0
001 O 0
, O 0
alpha O 0
= O 0
. O 0
29 O 0
, O 0
with O 0
1 O 0
- O 0
LOD O 0
support O 0
interval O 0
. O 0
08 O 0
- O 0
. O 0
53 O 0
) O 0
. O 0

These O 0
results O 0
support O 0
the O 0
finding O 0
of O 0
a O 0
prostate B-Disease 1
cancer I-Disease 1
- O 0
susceptibility O 0
gene O 0
linked O 0
to O 0
1q24 O 0
- O 0
25 O 0
, O 0
albeit O 0
in O 0
a O 0
defined O 0
subset O 0
of O 0
prostate B-Disease 1
cancer I-Disease 1
families O 0
. O 0

Although O 0
HPC1 O 0
accounts O 0
for O 0
only O 0
a O 0
small O 0
proportion O 0
of O 0
all O 0
families O 0
affected O 0
by O 0
hereditary B-Disease 1
prostate I-Disease 1
cancer I-Disease 1
, O 0
it O 0
appears O 0
to O 0
play O 0
a O 0
more O 0
prominent O 0
role O 0
in O 0
the O 0
subset O 0
of O 0
families O 0
with O 0
several O 0
members O 0
affected O 0
at O 0
an O 0
early O 0
age O 0
and O 0
with O 0
male O 0
- O 0
to O 0
- O 0
male O 0
disease O 0
transmission O 0
. O 0

A O 0
recurrent O 0
expansion O 0
of O 0
a O 0
maternal O 0
allele O 0
with O 0
36 O 0
CAG O 0
repeats O 0
causes O 0
Huntington B-Disease 1
disease I-Disease 1
in O 0
two O 0
sisters O 0
. O 0

Large O 0
intergenerational O 0
repeat O 0
expansions O 0
of O 0
the O 0
CAG O 0
trinucleotide O 0
repeat O 0
in O 0
the O 0
HD B-Disease 1
gene O 0
have O 0
been O 0
well O 0
documented O 0
for O 0
the O 0
male O 0
germline O 0
. O 0

We O 0
describe O 0
a O 0
recurrent O 0
large O 0
expansion O 0
of O 0
a O 0
maternal O 0
allele O 0
with O 0
36 O 0
CAG O 0
repeats O 0
( O 0
to O 0
66 O 0
and O 0
57 O 0
repeats O 0
, O 0
respectively O 0
, O 0
in O 0
two O 0
daughters O 0
) O 0
associated O 0
with O 0
onset O 0
of O 0
Huntington B-Disease 1
disease I-Disease 1
( O 0
HD B-Disease 1
) O 0
in O 0
the O 0
second O 0
and O 0
third O 0
decade O 0
in O 0
a O 0
family O 0
without O 0
history O 0
of O 0
HD B-Disease 1
. O 0

Our O 0
findings O 0
give O 0
evidence O 0
of O 0
a O 0
gonadal O 0
mosaicism O 0
in O 0
the O 0
unaffected O 0
mother O 0
. O 0

We O 0
hypothesize O 0
that O 0
large O 0
expansions O 0
also O 0
occur O 0
in O 0
the O 0
female O 0
germline O 0
and O 0
that O 0
a O 0
negative O 0
selection O 0
of O 0
oocytes O 0
with O 0
long O 0
repeats O 0
might O 0
explain O 0
the O 0
different O 0
instability O 0
behavior O 0
of O 0
the O 0
male O 0
and O 0
the O 0
female O 0
germlines O 0
. O 0
. O 0

Abnormal O 0
development O 0
of O 0
Purkinje O 0
cells O 0
and O 0
lymphocytes O 0
in O 0
Atm O 0
mutant O 0
mice O 0
. O 0

Motor B-Disease 1
incoordination I-Disease 1
, O 0
immune B-Disease 1
deficiencies I-Disease 1
, O 0
and O 0
an O 0
increased O 0
risk O 0
of O 0
cancer B-Disease 1
are O 0
the O 0
characteristic O 0
features O 0
of O 0
the O 0
hereditary B-Disease 0
disease I-Disease 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
( O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
) O 0
, O 0
which O 0
is O 0
caused O 0
by O 0
mutations O 0
in O 0
the O 0
ATM O 0
gene O 0
. O 0

Through O 0
gene O 0
targeting O 0
, O 0
we O 0
have O 0
generated O 0
a O 0
line O 0
of O 0
Atm O 0
mutant O 0
mice O 0
, O 0
Atm O 0
( O 0
y O 0
/ O 0
y O 0
) O 0
mice O 0
. O 0

In O 0
contrast O 0
to O 0
other O 0
Atm O 0
mutant O 0
mice O 0
, O 0
Atm O 0
( O 0
y O 0
/ O 0
y O 0
) O 0
mice O 0
show O 0
a O 0
lower O 0
incidence O 0
of O 0
thymic B-Disease 1
lymphoma I-Disease 1
and O 0
survive O 0
beyond O 0
a O 0
few O 0
months O 0
of O 0
age O 0
. O 0

Atm O 0
( O 0
y O 0
/ O 0
y O 0
) O 0
mice O 0
exhibit O 0
deficits O 0
in O 0
motor O 0
learning O 0
indicative O 0
of O 0
cerebellar B-Disease 0
dysfunction I-Disease 0
. O 0

Even O 0
though O 0
we O 0
found O 0
no O 0
gross O 0
cerebellar B-Disease 0
degeneration I-Disease 0
in O 0
older O 0
Atm O 0
( O 0
y O 0
/ O 0
y O 0
) O 0
animals O 0
, O 0
ectopic O 0
and O 0
abnormally O 0
differentiated O 0
Purkinje O 0
cells O 0
were O 0
apparent O 0
in O 0
mutant O 0
mice O 0
of O 0
all O 0
ages O 0
. O 0

These O 0
findings O 0
establish O 0
that O 0
some O 0
neuropathological B-Disease 0
abnormalities I-Disease 0
seen O 0
in O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
patients O 0
also O 0
are O 0
present O 0
in O 0
Atm O 0
mutant O 0
mice O 0
. O 0

In O 0
addition O 0
, O 0
we O 0
report O 0
a O 0
previously O 0
unrecognized O 0
effect O 0
of O 0
Atm B-Disease 1
deficiency I-Disease 1
on O 0
development O 0
or O 0
maintenance O 0
of O 0
CD4 O 0
( O 0
+ O 0
) O 0
8 O 0
( O 0
+ O 0
) O 0
thymocytes O 0
. O 0

We O 0
discuss O 0
these O 0
findings O 0
in O 0
the O 0
context O 0
of O 0
the O 0
hypothesis O 0
that O 0
abnormal O 0
development O 0
of O 0
Purkinje O 0
cells O 0
and O 0
lymphocytes O 0
contributes O 0
to O 0
the O 0
pathogenesis O 0
of O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
. O 0
. O 0

Novel O 0
mutations O 0
of O 0
the O 0
ATP7B O 0
gene O 0
in O 0
Japanese O 0
patients O 0
with O 0
Wilson B-Disease 0
disease I-Disease 0
. O 0

Wilson B-Disease 0
disease I-Disease 0
( O 0
WD B-Disease 1
) O 0
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
characterized O 0
by O 0
copper O 0
accumulation O 0
in O 0
the O 0
liver O 0
, O 0
brain O 0
, O 0
kidneys O 0
, O 0
and O 0
corneas O 0
, O 0
and O 0
culminating O 0
in O 0
copper O 0
toxication O 0
in O 0
these O 0
organs O 0
. O 0

In O 0
this O 0
study O 0
, O 0
we O 0
analyzed O 0
mutations O 0
of O 0
the O 0
responsible O 0
gene O 0
, O 0
ATP7B O 0
, O 0
in O 0
four O 0
Japanese O 0
patients O 0
with O 0
WD B-Disease 1
. O 0

By O 0
direct O 0
sequencing O 0
, O 0
we O 0
identified O 0
five O 0
mutations O 0
, O 0
of O 0
which O 0
two O 0
were O 0
novel O 0
, O 0
and O 0
16 O 0
polymorphisms O 0
, O 0
of O 0
which O 0
6 O 0
were O 0
novel O 0
. O 0

The O 0
mutations O 0
2871delC O 0
and O 0
2513delA O 0
shift O 0
the O 0
reading O 0
frame O 0
so O 0
that O 0
truncated O 0
abnormal O 0
protein O 0
is O 0
expected O 0
. O 0

In O 0
contrast O 0
to O 0
these O 0
mutations O 0
found O 0
in O 0
patients O 0
with O 0
hepatic O 0
- O 0
type O 0
of O 0
early O 0
onset O 0
, O 0
the O 0
mutations O 0
A874V O 0
, O 0
R778L O 0
, O 0
and O 0
3892delGTC O 0
were O 0
either O 0
missense O 0
mutations O 0
or O 0
in O 0
frame O 0
1 O 0
- O 0
amino O 0
acid O 0
deletion O 0
, O 0
and O 0
occurred O 0
in O 0
the O 0
patients O 0
with O 0
hepato O 0
- O 0
neurologic O 0
type O 0
of O 0
late O 0
onset O 0
. O 0

The O 0
mutations O 0
2871delC O 0
and O 0
R778L O 0
have O 0
been O 0
previously O 0
reported O 0
in O 0
a O 0
relatively O 0
large O 0
number O 0
of O 0
Japanese O 0
patients O 0
. O 0

In O 0
particular O 0
, O 0
R778L O 0
is O 0
known O 0
to O 0
be O 0
more O 0
prevalent O 0
in O 0
Asian O 0
countries O 0
than O 0
in O 0
other O 0
countries O 0
of O 0
the O 0
world O 0
. O 0

Our O 0
data O 0
are O 0
compatible O 0
with O 0
the O 0
hypothesis O 0
that O 0
the O 0
mutations O 0
tend O 0
to O 0
occur O 0
in O 0
a O 0
population O 0
- O 0
specific O 0
manner O 0
. O 0

Therefore O 0
, O 0
the O 0
accumulation O 0
of O 0
the O 0
types O 0
of O 0
mutations O 0
in O 0
Japanese O 0
patients O 0
with O 0
WD B-Disease 1
will O 0
facilitate O 0
the O 0
fast O 0
and O 0
effective O 0
genetic O 0
diagnosis O 0
of O 0
WD B-Disease 1
in O 0
Japanese O 0
patients O 0
. O 0
. O 0

Autoinhibition O 0
and O 0
activation O 0
mechanisms O 0
of O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
protein O 0
. O 0

The O 0
Rho O 0
- O 0
family O 0
GTPase O 0
, O 0
Cdc42 O 0
, O 0
can O 0
regulate O 0
the O 0
actin O 0
cytoskeleton O 0
through O 0
activation O 0
of O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
protein O 0
( O 0
WASP O 0
) O 0
family O 0
members O 0
. O 0

Activation O 0
relieves O 0
an O 0
autoinhibitory O 0
contact O 0
between O 0
the O 0
GTPase O 0
- O 0
binding O 0
domain O 0
and O 0
the O 0
carboxy O 0
- O 0
terminal O 0
region O 0
of O 0
WASP O 0
proteins O 0
. O 0

Here O 0
we O 0
report O 0
the O 0
autoinhibited O 0
structure O 0
of O 0
the O 0
GTPase O 0
- O 0
binding O 0
domain O 0
of O 0
WASP O 0
, O 0
which O 0
can O 0
be O 0
induced O 0
by O 0
the O 0
C O 0
- O 0
terminal O 0
region O 0
or O 0
by O 0
organic O 0
co O 0
- O 0
solvents O 0
. O 0

In O 0
the O 0
autoinhibited O 0
complex O 0
, O 0
intramolecular O 0
interactions O 0
with O 0
the O 0
GTPase O 0
- O 0
binding O 0
domain O 0
occlude O 0
residues O 0
of O 0
the O 0
C O 0
terminus O 0
that O 0
regulate O 0
the O 0
Arp2 O 0
/ O 0
3 O 0
actin O 0
- O 0
nucleating O 0
complex O 0
. O 0

Binding O 0
of O 0
Cdc42 O 0
to O 0
the O 0
GTPase O 0
- O 0
binding O 0
domain O 0
causes O 0
a O 0
dramatic O 0
conformational O 0
change O 0
, O 0
resulting O 0
in O 0
disruption O 0
of O 0
the O 0
hydrophobic O 0
core O 0
and O 0
release O 0
of O 0
the O 0
C O 0
terminus O 0
, O 0
enabling O 0
its O 0
interaction O 0
with O 0
the O 0
actin O 0
regulatory O 0
machinery O 0
. O 0

These O 0
data O 0
show O 0
that O 0
intrinsically O 0
unstructured O 0
peptides O 0
such O 0
as O 0
the O 0
GTPase O 0
- O 0
binding O 0
domain O 0
of O 0
WASP O 0
can O 0
be O 0
induced O 0
into O 0
distinct O 0
structural O 0
and O 0
functional O 0
states O 0
depending O 0
on O 0
context O 0
. O 0
. O 0

hCds1 O 0
- O 0
mediated O 0
phosphorylation O 0
of O 0
BRCA1 O 0
regulates O 0
the O 0
DNA O 0
damage O 0
response O 0
. O 0

Mutations O 0
in O 0
the O 0
BRCA1 O 0
( O 0
ref O 0
. O 0
1 O 0
) O 0
tumour B-Disease 1
suppressor O 0
gene O 0
are O 0
found O 0
in O 0
almost O 0
all O 0
of O 0
the O 0
families O 0
with O 0
inherited B-Disease 0
breast I-Disease 0
and I-Disease 0
ovarian I-Disease 1
cancers I-Disease 1
and O 0
about O 0
half O 0
of O 0
the O 0
families O 0
with O 0
only O 0
breast B-Disease 0
cancer I-Disease 1
. O 0

Although O 0
the O 0
biochemical O 0
function O 0
of O 0
BRCA1 O 0
is O 0
not O 0
well O 0
understood O 0
, O 0
it O 0
is O 0
important O 0
for O 0
DNA O 0
damage O 0
repair O 0
and O 0
cell O 0
- O 0
cycle O 0
checkpoint O 0
. O 0

BRCA1 O 0
exists O 0
in O 0
nuclear O 0
foci O 0
but O 0
is O 0
hyperphosphorylated O 0
and O 0
disperses O 0
after O 0
DNA O 0
damage O 0
. O 0

It O 0
is O 0
not O 0
known O 0
whether O 0
BRCA1 O 0
phosphorylation O 0
and O 0
dispersion O 0
and O 0
its O 0
function O 0
in O 0
DNA O 0
damage O 0
response O 0
are O 0
related O 0
. O 0

In O 0
yeast O 0
the O 0
DNA O 0
damage O 0
response O 0
and O 0
the O 0
replication O 0
- O 0
block O 0
checkpoint O 0
are O 0
mediated O 0
partly O 0
through O 0
the O 0
Cds1 O 0
kinase O 0
family O 0
. O 0

Here O 0
we O 0
report O 0
that O 0
the O 0
human O 0
Cds1 O 0
kinase O 0
( O 0
hCds1 O 0
/ O 0
Chk2 O 0
) O 0
regulates O 0
BRCA1 O 0
function O 0
after O 0
DNA O 0
damage O 0
by O 0
phosphorylating O 0
serine O 0
988 O 0
of O 0
BRCA1 O 0
. O 0

We O 0
show O 0
that O 0
hCds1 O 0
and O 0
BRCA1 O 0
interact O 0
and O 0
co O 0
- O 0
localize O 0
within O 0
discrete O 0
nuclear O 0
foci O 0
but O 0
separate O 0
after O 0
gamma O 0
irradiation O 0
. O 0

Phosphorylation O 0
of O 0
BRCA1 O 0
at O 0
serine O 0
988 O 0
is O 0
required O 0
for O 0
the O 0
release O 0
of O 0
BRCA1 O 0
from O 0
hCds1 O 0
. O 0

This O 0
phosphorylation O 0
is O 0
also O 0
important O 0
for O 0
the O 0
ability O 0
of O 0
BRCA1 O 0
to O 0
restore O 0
survival O 0
after O 0
DNA O 0
damage O 0
in O 0
the O 0
BRCA1 O 0
- O 0
mutated O 0
cell O 0
line O 0
HCC1937 O 0
. O 0
. O 0

Characterization O 0
of O 0
the O 0
rat O 0
spinocerebellar O 1
ataxia O 1
type O 1
3 O 1
gene O 0
. O 0

Machado B-Disease 0
- I-Disease 0
Joseph I-Disease 0
disease I-Disease 0
( O 0
MJD B-Disease 0
) O 0
belongs O 0
to O 0
a O 0
group O 0
of O 0
clinically O 0
and O 0
genetically O 0
heterogeneous O 0
neurodegenerative B-Disease 1
disorders I-Disease 1
characterized O 0
by O 0
progressive B-Disease 0
cerebellar I-Disease 0
ataxia I-Disease 0
. O 0

The O 0
disease O 0
- O 0
causing O 0
mutation O 0
has O 0
recently O 0
been O 0
identified O 0
as O 0
an O 0
unstable O 0
and O 0
expanded O 0
( O 0
CAG O 0
) O 0
n O 0
trinucleotide O 0
repeat O 0
in O 0
a O 0
novel O 0
gene O 0
of O 0
unknown O 0
function O 0
. O 0

In O 0
Caucasians O 0
, O 0
repeat O 0
expansions O 0
in O 0
the O 0
MJD1 O 0
gene O 0
have O 0
also O 0
been O 0
found O 0
in O 0
patients O 0
with O 0
the O 0
clinically O 0
distinct O 0
autosomal O 0
dominant O 0
spinocerebellar B-Disease 1
ataxia I-Disease 1
type I-Disease 1
3 I-Disease 1
( O 0
SCA3 B-Disease 1
) O 0
. O 0

In O 0
order O 0
to O 0
gain O 0
insight O 0
into O 0
the O 0
biology O 0
of O 0
the O 0
MJD1 O 0
/ O 0
SCA3 O 1
gene O 0
we O 0
cloned O 0
the O 0
rat O 0
homologue O 0
and O 0
studied O 0
its O 0
expression O 0
. O 0

The O 0
rat O 0
and O 0
human O 0
ataxin O 0
- O 0
3 O 0
genes O 0
are O 0
highly O 0
homologous O 0
with O 0
an O 0
overall O 0
sequence O 0
identity O 0
of O 0
approximately O 0
88 O 0
% O 0
. O 0

However O 0
, O 0
the O 0
C O 0
- O 0
terminal O 0
end O 0
of O 0
the O 0
putative O 0
protein O 0
differs O 0
strongly O 0
from O 0
the O 0
published O 0
human O 0
sequence O 0
. O 0

The O 0
( O 0
CAG O 0
) O 0
n O 0
block O 0
in O 0
the O 0
rat O 0
cDNA O 0
consists O 0
of O 0
just O 0
three O 0
interrupted O 0
units O 0
suggesting O 0
that O 0
a O 0
long O 0
polyglutamine O 0
stretch O 0
is O 0
not O 0
essential O 0
for O 0
the O 0
normal O 0
function O 0
of O 0
the O 0
ataxin O 0
- O 0
3 O 0
protein O 0
in O 0
rodents O 0
. O 0

The O 0
expression O 0
pattern O 0
of O 0
the O 0
SCA3 O 1
gene O 0
in O 0
various O 0
rat O 0
and O 0
human O 0
tissues O 0
was O 0
investigated O 0
by O 0
Northern O 0
blot O 0
analyses O 0
. O 0

The O 0
mature O 0
transcript O 0
is O 0
approximately O 0
6 O 0
kb O 0
in O 0
length O 0
. O 0

In O 0
rat O 0
testis O 0
, O 0
a O 0
smaller O 0
transcript O 0
of O 0
1 O 0
. O 0

3 O 0
kb O 0
was O 0
identified O 0
. O 0

Transcription O 0
of O 0
rsca3 O 0
was O 0
detected O 0
in O 0
most O 0
rat O 0
tissues O 0
including O 0
brain O 0
. O 0

Analyzing O 0
the O 0
expression O 0
level O 0
of O 0
the O 0
SCA3 O 1
gene O 0
in O 0
several O 0
human O 0
brain O 0
sections O 0
revealed O 0
no O 0
significant O 0
higher O 0
mRNA O 0
level O 0
in O 0
regions O 0
predominantly O 0
affected O 0
in O 0
MJD B-Disease 0
. O 0

Thus O 0
additional O 0
molecules O 0
and O 0
/ O 0
or O 0
regulatory O 0
events O 0
are O 0
necessary O 0
to O 0
explain O 0
the O 0
exclusive O 0
degeneration B-Disease 0
of I-Disease 0
certain I-Disease 0
brain I-Disease 0
areas I-Disease 0
. O 0

Emerin B-Disease 0
, I-Disease 0
deficiency I-Disease 0
of O 0
which O 0
causes O 0
Emery B-Disease 0
- I-Disease 0
Dreifuss I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
, O 0
is O 0
localized O 0
at O 0
the O 0
inner O 0
nuclear O 0
membrane O 0
. O 0

X B-Disease 0
- I-Disease 0
linked I-Disease 0
recessive I-Disease 0
Emery I-Disease 0
- I-Disease 0
Dreifuss I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
EDMD B-Disease 0
) O 0
is O 0
an O 0
inherited B-Disease 0
muscle I-Disease 0
disorder I-Disease 0
characterized O 0
by O 0
the O 0
clinical O 0
triad O 0
of O 0
progressive O 0
wasting B-Disease 1
of I-Disease 1
humero I-Disease 1
- I-Disease 1
peroneal I-Disease 1
muscles I-Disease 1
, O 0
early O 0
contractures B-Disease 0
of I-Disease 0
the I-Disease 0
elbows I-Disease 0
, I-Disease 0
Achilles I-Disease 0
tendons I-Disease 0
and I-Disease 0
postcervical I-Disease 0
muscles I-Disease 0
, O 0
and O 0
cardiac B-Disease 0
conduction I-Disease 0
block I-Disease 0
with O 0
a O 0
high O 0
risk O 0
of O 0
sudden B-Disease 1
death I-Disease 1
. O 0

The O 0
gene O 0
for O 0
EDMD B-Disease 0
on O 0
Xq28 O 0
encodes O 0
a O 0
novel O 0
protein O 0
named O 0
emerin O 0
that O 0
localizes O 0
at O 0
the O 0
nuclear O 0
membrane O 0
of O 0
skeletal O 0
, O 0
cardiac O 0
and O 0
smooth O 0
muscles O 0
and O 0
some O 0
other O 0
non O 0
- O 0
muscle O 0
tissues O 0
. O 0

To O 0
investigate O 0
a O 0
possible O 0
physiological O 0
role O 0
for O 0
emerin O 0
, O 0
we O 0
examined O 0
the O 0
ultrastructural O 0
localization O 0
of O 0
the O 0
protein O 0
in O 0
human O 0
skeletal O 0
muscle O 0
and O 0
HeLa O 0
cells O 0
, O 0
using O 0
ultrathin O 0
cryosections O 0
. O 0

We O 0
found O 0
that O 0
the O 0
immune O 0
- O 0
labeled O 0
colloidal O 0
gold O 0
particles O 0
were O 0
localized O 0
on O 0
the O 0
nucleoplasmic O 0
surface O 0
of O 0
the O 0
inner O 0
nuclear O 0
membrane O 0
, O 0
but O 0
not O 0
on O 0
the O 0
nuclear O 0
pore O 0
. O 0

Emerin O 0
stayed O 0
on O 0
the O 0
cytoplasmic O 0
surface O 0
of O 0
the O 0
nuclear O 0
lamina O 0
, O 0
even O 0
after O 0
detergent O 0
treatment O 0
that O 0
solubilizes O 0
membrane O 0
lipids O 0
and O 0
washes O 0
out O 0
membrane O 0
proteins O 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
emerin O 0
anchors O 0
at O 0
the O 0
inner O 0
nuclear O 0
membrane O 0
through O 0
the O 0
hydrophobic O 0
stretch O 0
, O 0
and O 0
protrudes O 0
from O 0
the O 0
hydrophilic O 0
region O 0
to O 0
the O 0
nucleoplasm O 0
where O 0
it O 0
interacts O 0
with O 0
the O 0
nuclear O 0
lamina O 0
. O 0

We O 0
speculate O 0
that O 0
emerin O 0
contributes O 0
to O 0
maintain O 0
the O 0
nuclear O 0
structure O 0
and O 0
stability O 0
, O 0
as O 0
well O 0
as O 0
nuclear O 0
functions O 0
, O 0
particularly O 0
in O 0
muscle O 0
tissues O 0
that O 0
have O 0
severe O 0
stress O 0
with O 0
rigorous O 0
contraction O 0
- O 0
relaxation O 0
movements O 0
and O 0
calcium O 0
flux O 0
. O 0
. O 0

Locus O 0
heterogeneity O 0
in O 0
Friedreich B-Disease 1
ataxia I-Disease 1
. O 0

Friedreich B-Disease 1
ataxia I-Disease 1
( O 0
FRDA B-Disease 0
) O 0
is O 0
the O 0
most O 0
common O 0
form O 0
of O 0
autosomal B-Disease 0
recessive I-Disease 0
ataxia I-Disease 0
. O 0

The O 0
disease O 0
locus O 0
was O 0
assigned O 0
to O 0
chromosome O 0
9 O 0
and O 0
the O 0
disease O 0
gene O 0
, O 0
STM7 O 0
/ O 0
X25 O 0
, O 0
has O 0
been O 0
isolated O 0
. O 0

To O 0
date O 0
most O 0
data O 0
suggest O 0
locus O 0
homogeneity O 0
in O 0
FRDA B-Disease 0
. O 0

We O 0
now O 0
provide O 0
strong O 0
evidence O 0
of O 0
a O 0
second O 0
FRDA B-Disease 0
locus O 0
. O 0

Studying O 0
two O 0
siblings O 0
with O 0
FRDA B-Disease 0
from O 0
two O 0
families O 0
we O 0
did O 0
not O 0
detect O 0
a O 0
mutation O 0
in O 0
STM7 O 0
/ O 0
X25 O 0
. O 0

Haplotype O 0
analysis O 0
of O 0
the O 0
STM7 O 0
/ O 0
X25 O 0
region O 0
of O 0
chromosome O 0
9 O 0
demonstrated O 0
that O 0
the O 0
relevant O 0
portion O 0
of O 0
chromosome O 0
9 O 0
differs O 0
in O 0
the O 0
patients O 0
. O 0

Although O 0
the O 0
patients O 0
studied O 0
had O 0
typical O 0
FRDA B-Disease 0
, O 0
one O 0
sibpair O 0
had O 0
the O 0
uncommon O 0
symptom O 0
of O 0
retained O 0
tendon O 0
reflexes O 0
. O 0

In O 0
order O 0
to O 0
investigate O 0
whether O 0
retained O 0
tendon O 0
reflexes O 0
are O 0
characteristic O 0
of O 0
FRDA B-Disease 0
caused O 0
by O 0
the O 0
second O 0
locus O 0
, O 0
FRDA2 O 0
, O 0
we O 0
studied O 0
an O 0
unrelated O 0
FRDA B-Disease 0
patient O 0
with O 0
retained O 0
tendon O 0
reflexes O 0
. O 0

The O 0
observation O 0
of O 0
typical O 0
mutations O 0
in O 0
STM7 O 0
/ O 0
X25 O 0
( O 0
GAA O 0
expansions O 0
) O 0
in O 0
this O 0
patient O 0
demonstrates O 0
that O 0
the O 0
two O 0
genetically O 0
different O 0
forms O 0
of O 0
FRDA B-Disease 0
cannot O 0
be O 0
distinguished O 0
clinically O 0
. O 0
. O 0

Glycerol O 0
as O 0
a O 0
correlate O 0
of O 0
impaired B-Disease 1
glucose I-Disease 1
tolerance I-Disease 1
: O 0
dissection O 0
of O 0
a O 0
complex O 0
system O 0
by O 0
use O 0
of O 0
a O 0
simple O 0
genetic O 0
trait O 0
. O 0

Glycerol O 0
kinase O 0
( O 0
GK O 0
) O 0
represents O 0
the O 0
primary O 0
entry O 0
of O 0
glycerol O 0
into O 0
glucose O 0
and O 0
triglyceride O 0
metabolism O 0
. O 0

Impaired B-Disease 1
glucose I-Disease 1
tolerance I-Disease 1
( O 0
IGT B-Disease 1
) O 0
and O 0
hypertriglyceridemia B-Disease 1
are O 0
associated O 0
with O 0
an O 0
increased O 0
risk O 0
of O 0
diabetes B-Disease 0
mellitus I-Disease 0
and O 0
cardiovascular B-Disease 0
disease I-Disease 0
. O 0

The O 0
relationship O 0
between O 0
glycerol O 0
and O 0
the O 0
risk O 0
of O 0
IGT B-Disease 1
, O 0
however O 0
, O 0
is O 0
poorly O 0
understood O 0
. O 0

We O 0
therefore O 0
undertook O 0
the O 0
study O 0
of O 0
fasting O 0
plasma O 0
glycerol O 0
levels O 0
in O 0
a O 0
cohort O 0
of O 0
1 O 0
, O 0
056 O 0
unrelated O 0
men O 0
and O 0
women O 0
of O 0
French O 0
- O 0
Canadian O 0
descent O 0
. O 0

Family O 0
screening O 0
in O 0
the O 0
initial O 0
cohort O 0
identified O 0
18 O 0
men O 0
from O 0
five O 0
families O 0
with O 0
severe O 0
hyperglycerolemia B-Disease 0
( O 0
values O 0
above O 0
2 O 0
. O 0
0 O 0
mmol O 0
/ O 0
liter O 0
) O 0
and O 0
demonstrated O 0
an O 0
X O 0
- O 0
linked O 0
pattern O 0
of O 0
inheritance O 0
. O 0

Linkage O 0
analysis O 0
of O 0
the O 0
data O 0
from O 0
12 O 0
microsatellite O 0
markers O 0
surrounding O 0
the O 0
Xp21 O 0
. O 0

3 O 0
GK O 0
gene O 0
resulted O 0
in O 0
a O 0
peak O 0
LOD O 0
score O 0
of O 0
3 O 0
. O 0

46 O 0
, O 0
centered O 0
around O 0
marker O 0
DXS8039 O 0
. O 0

In O 0
addition O 0
, O 0
since O 0
all O 0
of O 0
the O 0
families O 0
originated O 0
in O 0
a O 0
population O 0
with O 0
a O 0
proven O 0
founder O 0
effect O 0
- O 0
the O 0
Saguenay O 0
Lac O 0
- O 0
St O 0
. O 0

- O 0
Jean O 0
region O 0
of O 0
Quebec O 0
- O 0
a O 0
common O 0
disease O 0
haplotype O 0
was O 0
sought O 0
. O 0

Indeed O 0
, O 0
a O 0
six O 0
- O 0
marker O 0
haplotype O 0
extending O 0
over O 0
a O 0
region O 0
of O 0
5 O 0
. O 0

5 O 0
cM O 0
was O 0
observed O 0
in O 0
all O 0
families O 0
. O 0

Resequencing O 0
of O 0
the O 0
GK O 0
gene O 0
in O 0
family O 0
members O 0
led O 0
to O 0
the O 0
discovery O 0
of O 0
a O 0
N288D O 0
missense O 0
mutation O 0
in O 0
exon O 0
10 O 0
, O 0
which O 0
resulted O 0
in O 0
the O 0
substitution O 0
of O 0
a O 0
highly O 0
conserved O 0
asparagine O 0
residue O 0
by O 0
a O 0
negatively O 0
charged O 0
aspartic O 0
acid O 0
. O 0

Clinical O 0
and O 0
molecular O 0
genetics O 0
of O 0
primary B-Disease 1
dystonias I-Disease 1
. O 0

Primary B-Disease 1
dystonias I-Disease 1
are O 0
movement B-Disease 0
disorders I-Disease 0
with O 0
dystonia B-Disease 0
as O 0
a O 0
major O 0
symptom O 0
. O 0

They O 0
are O 0
frequently O 0
inherited O 0
as O 0
Mendelian O 0
traits O 0
. O 0

There O 0
are O 0
at O 0
least O 0
eight O 0
clinically O 0
distinct O 0
autosomal O 0
dominant O 0
and O 0
two O 0
X O 0
- O 0
linked O 0
recessive O 0
forms O 0
. O 0

In O 0
addition O 0
, O 0
pedigree O 0
analyses O 0
suggest O 0
the O 0
occurrence O 0
of O 0
an O 0
autosomal O 0
recessive O 0
variant O 0
. O 0

The O 0
clinical O 0
classification O 0
is O 0
increasingly O 0
being O 0
replaced O 0
by O 0
a O 0
genetic O 0
one O 0
. O 0

To O 0
date O 0
gene O 0
loci O 0
have O 0
been O 0
identified O 0
in O 0
at O 0
least O 0
six O 0
autosomal O 0
dominant O 0
forms O 0
, O 0
i O 0
. O 0
e O 0
. O 0
, O 0
in O 0
idiopathic B-Disease 1
torsion I-Disease 1
dystonia I-Disease 1
( O 0
9q34 O 0
) O 0
, O 0
focal B-Disease 0
dystonia I-Disease 0
( O 0
18p O 0
) O 0
, O 0
adult O 0
- O 0
onset O 0
idiopathic B-Disease 1
torsion I-Disease 1
dystonia I-Disease 1
of O 0
mixed O 0
type O 0
( O 0
8p21 O 0
- O 0
q22 O 0
) O 0
, O 0
dopa B-Disease 1
- I-Disease 1
responsive I-Disease 1
dystonia I-Disease 1
( O 0
14q22 O 0
. O 0
1 O 0
- O 0
q22 O 0
. O 0
2 O 0
) O 0
, O 0
and O 0
paroxysmal B-Disease 0
dystonic I-Disease 0
choreoathetosis I-Disease 0
( O 0
2q25 O 0
- O 0
q33 O 0
; O 0
1p21 O 0
- O 0
p13 O 0
. O 0
3 O 0
) O 0
. O 0

Gene O 0
loci O 0
in O 0
the O 0
X O 0
- O 0
linked O 0
recessive O 0
forms O 0
have O 0
been O 0
assigned O 0
to O 0
Xq13 O 0
. O 0

1 O 0
in O 0
the O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
dystonia I-Disease 1
parkinsonism I-Disease 1
syndrome I-Disease 1
and O 0
to O 0
Xq22 O 0
in O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
sensorineural I-Disease 0
deafness I-Disease 1
, O 0
dystonia B-Disease 0
, O 0
and O 0
mental B-Disease 1
retardation I-Disease 1
. O 0

The O 0
disease O 0
genes O 0
have O 0
been O 0
identified O 0
in O 0
two O 0
autosomal O 0
dominant O 0
forms O 0
and O 0
in O 0
one O 0
X O 0
- O 0
linked O 0
recessive O 0
form O 0
. O 0

Mutations O 0
in O 0
a O 0
gene O 0
coding O 0
for O 0
an O 0
ATP O 0
- O 0
binding O 0
protein O 0
were O 0
detected O 0
in O 0
idiopathic B-Disease 1
torsion I-Disease 1
dystonia I-Disease 1
( O 0
DYT1 O 0
) O 0
, O 0
and O 0
the O 0
GTP O 0
cyclohydrolase O 0
1 O 0
gene O 0
is O 0
mutated O 0
in O 0
dopa B-Disease 1
- I-Disease 1
responsive I-Disease 1
dystonia I-Disease 1
( O 0
DYT5 O 0
) O 0
. O 0

In O 0
sensorineural B-Disease 0
deafness I-Disease 1
, O 0
dystonia B-Disease 0
, O 0
and O 0
mental B-Disease 1
retardation I-Disease 1
, O 0
mutations O 0
were O 0
found O 0
in O 0
the O 0
gene O 0
DDP O 0
coding O 0
for O 0
a O 0
polypeptide O 0
of O 0
unknown O 0
function O 0
. O 0

This O 0
article O 0
reviews O 0
the O 0
clinical O 0
and O 0
molecular O 0
genetics O 0
of O 0
primary B-Disease 1
dystonias I-Disease 1
, O 0
critically O 0
discusses O 0
present O 0
findings O 0
, O 0
and O 0
proposes O 0
referring O 0
to O 0
the O 0
known O 0
forms O 0
, O 0
most O 0
of O 0
which O 0
can O 0
be O 0
distinguished O 0
by O 0
genetic O 0
criteria O 0
, O 0
as O 0
dystonias B-Disease 1
1 I-Disease 1
- I-Disease 1
12 I-Disease 1
. O 0

Determination O 0
of O 0
30 O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
mutations O 0
, O 0
including O 0
15 O 0
not O 0
previously O 0
described O 0
. O 0

X B-Disease 1
- I-Disease 1
linked I-Disease 1
Adrenoleukodystrophy I-Disease 1
( O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
) O 0
is O 0
the O 0
most O 0
frequent O 0
peroxisomal B-Disease 0
disease I-Disease 0
. O 0

It O 0
mainly O 0
involves O 0
the O 0
nervous O 0
system O 0
white O 0
matter O 0
, O 0
adrenal O 0
cortex O 0
and O 0
testes O 0
. O 0

Several O 0
distinct O 0
clinical O 0
phenotypes O 0
are O 0
known O 0
. O 0

The O 0
principal O 0
biochemical O 0
abnormality O 0
is O 0
the O 0
accumulation O 0
of O 0
saturated O 0
very O 0
- O 0
long O 0
- O 0
chain O 0
fatty O 0
acids O 0
( O 0
VLCFAs O 0
> O 0
C22 O 0
0 O 0
, O 0
mainly O 0
C26 O 0
0 O 0
) O 0
, O 0
which O 0
is O 0
due O 0
to O 0
impaired O 0
capacity O 0
for O 0
beta O 0
- O 0
oxidation O 0
in O 0
peroxisomes O 0
. O 0

Diagnosis O 0
is O 0
usually O 0
based O 0
on O 0
the O 0
VLCFA O 0
levels O 0
in O 0
plasma O 0
or O 0
cultured O 0
skin O 0
fibroblasts O 0
in O 0
both O 0
patients O 0
and O 0
carriers O 0
. O 0

In O 0
0 O 0
. O 0

1 O 0
% O 0
of O 0
affected O 0
males O 0
, O 0
however O 0
, O 0
the O 0
plasma O 0
C26 O 0
0 O 0
level O 0
is O 0
borderline O 0
normal O 0
, O 0
and O 0
15 O 0
% O 0
of O 0
obligate O 0
female O 0
carriers O 0
have O 0
normal O 0
results O 0
. O 0

Effective O 0
mutation O 0
detection O 0
in O 0
these O 0
families O 0
is O 0
therefore O 0
fundamental O 0
to O 0
unambiguously O 0
determine O 0
the O 0
genetic O 0
status O 0
of O 0
each O 0
individual O 0
at O 0
risk O 0
. O 0

Of O 0
particular O 0
concern O 0
are O 0
female O 0
members O 0
of O 0
kindreds O 0
segregating O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
mutations O 0
, O 0
because O 0
normal O 0
VLCFA O 0
levels O 0
do O 0
not O 0
guarantee O 0
lack O 0
of O 0
carrier O 0
status O 0
. O 0

We O 0
describe O 0
a O 0
fast O 0
method O 0
for O 0
detection O 0
of O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
mutations O 0
. O 0

The O 0
method O 0
is O 0
based O 0
on O 0
SSCP O 0
analysis O 0
of O 0
nested O 0
PCR O 0
fragments O 0
followed O 0
by O 0
sequence O 0
- O 0
determination O 0
reactions O 0
. O 0

Using O 0
this O 0
methodology O 0
we O 0
have O 0
found O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
mutations O 0
in O 0
30 O 0
kindreds O 0
, O 0
including O 0
15 O 0
not O 0
previously O 0
reported O 0
. O 0

beta O 0
- O 0
galactosidase O 0
gene O 0
mutations O 0
affecting O 0
the O 0
lysosomal O 0
enzyme O 0
and O 0
the O 0
elastin O 0
- O 0
binding O 0
protein O 0
in O 0
GM1 B-Disease 0
- I-Disease 0
gangliosidosis I-Disease 0
patients O 0
with O 0
cardiac B-Disease 0
involvement I-Disease 0
. O 0

GM1 B-Disease 0
- I-Disease 0
gangliosidosis I-Disease 0
is O 0
a O 0
lysosomal B-Disease 0
storage I-Disease 0
disorder I-Disease 0
caused O 0
by O 0
deficiency B-Disease 1
of I-Disease 1
acid I-Disease 1
beta I-Disease 1
- I-Disease 1
galactosidase I-Disease 1
( O 0
GLB1 O 0
) O 0
. O 0

We O 0
report O 0
five O 0
new O 0
beta O 0
- O 0
galactosidase O 0
gene O 0
mutations O 0
in O 0
nine O 0
Italian O 0
patients O 0
and O 0
one O 0
fetus O 0
, O 0
segregating O 0
in O 0
seven O 0
unrelated O 0
families O 0
. O 0

Six O 0
of O 0
the O 0
eight O 0
patients O 0
with O 0
the O 0
infantile O 0
, O 0
severe O 0
form O 0
of O 0
the O 0
disease O 0
presented O 0
cardiac B-Disease 0
involvement I-Disease 0
, O 0
a O 0
feature O 0
rarely O 0
associated O 0
with O 0
GM1 B-Disease 0
- I-Disease 0
gangliosidosis I-Disease 0
. O 0

Molecular O 0
analysis O 0
of O 0
the O 0
patients O 0
RNA O 0
and O 0
DNA O 0
identified O 0
two O 0
new O 0
RNA O 0
splicing O 0
defects O 0
, O 0
three O 0
new O 0
and O 0
three O 0
previously O 0
described O 0
amino O 0
acid O 0
substitutions O 0
. O 0

Interestingly O 0
, O 0
all O 0
patients O 0
with O 0
cardiac B-Disease 0
involvement I-Disease 0
were O 0
homozygous O 0
for O 0
one O 0
of O 0
these O 0
mutations O 0
R59H O 0
, O 0
Y591C O 0
, O 0
Y591N O 0
, O 0
or O 0
IVS14 O 0
- O 0
2A O 0
> O 0
G O 0
. O 0

In O 0
contrast O 0
, O 0
all O 0
other O 0
patients O 0
were O 0
compound O 0
heterozygous O 0
for O 0
one O 0
of O 0
the O 0
following O 0
mutations O 0
R201H O 0
, O 0
R482H O 0
, O 0
G579D O 0
, O 0
IVS8 O 0
+ O 0
2T O 0
> O 0
C O 0
. O 0

Although O 0
we O 0
could O 0
not O 0
directly O 0
correlate O 0
the O 0
presence O 0
of O 0
cardiac B-Disease 1
abnormalities I-Disease 1
with O 0
specific O 0
genetic B-Disease 1
lesions I-Disease 1
, O 0
the O 0
mutations O 0
identified O 0
in O 0
patients O 0
with O 0
cardiomyopathy B-Disease 1
fell O 0
in O 0
the O 0
GLB1 O 0
cDNA O 0
region O 0
common O 0
to O 0
the O 0
lysosomal O 0
enzyme O 0
and O 0
the O 0
Hbeta O 0
- O 0
Gal O 0
- O 0
related O 0
protein O 0
, O 0
also O 0
known O 0
as O 0
the O 0
elastin O 0
binding O 0
protein O 0
( O 0
EBP O 0
) O 0
. O 0

Consequently O 0
, O 0
both O 0
molecules O 0
are O 0
affected O 0
by O 0
the O 0
mutations O 0
, O 0
and O 0
they O 0
may O 0
contribute O 0
differently O 0
to O 0
the O 0
occurrence O 0
of O 0
specific O 0
clinical O 0
manifestations O 0
. O 0
. O 0

In O 0
vivo O 0
modulation O 0
of O 0
Hmgic O 0
reduces O 0
obesity B-Disease 0
. O 0

The O 0
HMGI O 0
family O 0
of O 0
proteins O 0
consists O 0
of O 0
three O 0
members O 0
, O 0
HMGIC O 0
, O 0
HMGI O 0
and O 0
HMGI O 0
( O 0
Y O 0
) O 0
, O 0
that O 0
function O 0
as O 0
architectural O 0
factors O 0
and O 0
are O 0
essential O 0
components O 0
of O 0
the O 0
enhancesome O 0
. O 0

HMGIC O 0
is O 0
predominantly O 0
expressed O 0
in O 0
proliferating O 0
, O 0
undifferentiated O 0
mesenchymal O 0
cells O 0
and O 0
is O 0
not O 0
detected O 0
in O 0
adult O 0
tissues O 0
. O 0

It O 0
is O 0
disrupted O 0
and O 0
misexpressed O 0
in O 0
a O 0
number O 0
of O 0
mesenchymal B-Disease 0
tumour I-Disease 1
cell O 0
types O 0
, O 0
including O 0
fat B-Disease 0
- I-Disease 0
cell I-Disease 0
tumours I-Disease 1
( O 0
lipomas B-Disease 0
) O 0
. O 0

In O 0
addition O 0
Hmgic O 0
- O 0
/ O 0
- O 0
mice O 0
have O 0
a O 0
deficiency O 0
in O 0
fat O 0
tissue O 0
. O 0

To O 0
study O 0
its O 0
role O 0
in O 0
adipogenesis O 0
and O 0
obesity B-Disease 0
, O 0
we O 0
examined O 0
Hmgic O 0
expression O 0
in O 0
the O 0
adipose O 0
tissue O 0
of O 0
adult O 0
, O 0
obese B-Disease 1
mice O 0
. O 0

Mice O 0
with O 0
a O 0
partial B-Disease 0
or I-Disease 0
complete I-Disease 0
deficiency I-Disease 0
of I-Disease 0
Hmgic I-Disease 0
resisted O 0
diet O 0
- O 0
induced O 0
obesity B-Disease 0
. O 0

Disruption O 0
of O 0
Hmgic O 0
caused O 0
a O 0
reduction O 0
in O 0
the O 0
obesity B-Disease 0
induced O 0
by O 0
leptin B-Disease 0
deficiency I-Disease 0
( O 0
Lepob O 0
/ O 0
Lepob O 0
) O 0
in O 0
a O 0
gene O 0
- O 0
dose O 0
- O 0
dependent O 0
manner O 0
. O 0

Our O 0
studies O 0
implicate O 0
a O 0
role O 0
for O 0
HMGIC O 0
in O 0
fat O 0
- O 0
cell O 0
proliferation O 0
, O 0
indicating O 0
that O 0
it O 0
may O 0
be O 0
an O 0
adipose O 0
- O 0
specific O 0
target O 0
for O 0
the O 0
treatment O 0
of O 0
obesity B-Disease 0
. O 0
. O 0

Molecular O 0
analysis O 0
of O 0
the O 0
genotype O 0
- O 0
phenotype O 0
relationship O 0
in O 0
factor B-Disease 0
X I-Disease 0
deficiency I-Disease 0
. O 0

Factor B-Disease 0
X I-Disease 0
deficiency I-Disease 0
is O 0
a O 0
rare O 0
haemorrhagic B-Disease 1
condition I-Disease 1
, O 0
normally O 0
inherited O 0
as O 0
an O 0
autosomal O 0
recessive O 0
trait O 0
, O 0
in O 0
which O 0
a O 0
variable O 0
clinical O 0
presentation O 0
correlates O 0
poorly O 0
with O 0
laboratory O 0
phenotype O 0
. O 0

The O 0
factor O 0
X O 0
( O 0
F10 O 0
) O 0
genes O 0
of O 0
14 O 0
unrelated O 0
individuals O 0
with O 0
factor B-Disease 0
X I-Disease 0
deficiency I-Disease 0
( O 0
12 O 0
familial O 0
and O 0
two O 0
sporadic O 0
cases O 0
) O 0
were O 0
sequenced O 0
yielding O 0
a O 0
total O 0
of O 0
13 O 0
novel O 0
mutations O 0
. O 0

Family O 0
studies O 0
were O 0
performed O 0
in O 0
order O 0
to O 0
distinguish O 0
the O 0
contributions O 0
of O 0
individual O 0
mutant O 0
F10 O 0
alleles O 0
to O 0
the O 0
clinical O 0
and O 0
laboratory O 0
phenotypes O 0
. O 0

Missense O 0
mutations O 0
were O 0
studied O 0
by O 0
means O 0
of O 0
molecular O 0
modelling O 0
, O 0
whereas O 0
single O 0
basepair O 0
substitutions O 0
in O 0
splice O 0
sites O 0
and O 0
the O 0
5 O 0
flanking O 0
region O 0
were O 0
examined O 0
by O 0
in O 0
vitro O 0
splicing O 0
assay O 0
and O 0
luciferase O 0
reporter O 0
gene O 0
assay O 0
respectively O 0
. O 0

The O 0
deletion O 0
allele O 0
of O 0
a O 0
novel O 0
hexanucleotide O 0
insertion O 0
/ O 0
deletion O 0
polymorphism O 0
in O 0
the O 0
F10 O 0
gene O 0
promoter O 0
region O 0
was O 0
shown O 0
by O 0
reporter O 0
gene O 0
assay O 0
, O 0
to O 0
reduce O 0
promoter O 0
activity O 0
by O 0
approximately O 0
20 O 0
% O 0
. O 0

One O 0
family O 0
manifesting O 0
an O 0
autosomal O 0
dominant O 0
pattern O 0
of O 0
inheritance O 0
possessed O 0
three O 0
clinically O 0
affected O 0
members O 0
who O 0
were O 0
heterozygous O 0
for O 0
a O 0
splice O 0
- O 0
site O 0
mutation O 0
that O 0
was O 0
predicted O 0
to O 0
lead O 0
to O 0
the O 0
production O 0
of O 0
a O 0
truncated O 0
protein O 0
product O 0
. O 0

A O 0
model O 0
which O 0
accounts O 0
for O 0
the O 0
dominant O 0
negative O 0
effect O 0
of O 0
this O 0
lesion O 0
is O 0
presented O 0
. O 0

Variation O 0
in O 0
the O 0
antigen O 0
level O 0
of O 0
heterozygous O 0
relatives O 0
of O 0
probands O 0
was O 0
found O 0
to O 0
be O 0
significantly O 0
higher O 0
between O 0
families O 0
than O 0
within O 0
families O 0
, O 0
consistent O 0
with O 0
the O 0
view O 0
that O 0
the O 0
nature O 0
of O 0
the O 0
F10 O 0
lesion O 0
( O 0
s O 0
) O 0
segregating O 0
in O 0
a O 0
given O 0
family O 0
is O 0
a O 0
prime O 0
determinant O 0
of O 0
the O 0
laboratory O 0
phenotype O 0
. O 0

By O 0
contrast O 0
, O 0
no O 0
such O 0
relationship O 0
could O 0
be O 0
discerned O 0
between O 0
laboratory O 0
phenotype O 0
and O 0
polymorphism O 0
genotype O 0
. O 0
. O 0

Transgenic O 0
mice O 0
expressing O 0
a O 0
truncated O 0
form O 0
of O 0
the O 0
high O 0
mobility O 0
group O 0
I O 0
- O 0
C O 0
protein O 0
develop O 0
adiposity O 0
and O 0
an O 0
abnormally O 0
high O 0
prevalence O 0
of O 0
lipomas B-Disease 0
. O 0

Chromosomal O 0
translocations O 0
in O 0
human O 0
lipomas B-Disease 0
frequently O 0
create O 0
fusion O 0
transcripts O 0
encoding O 0
high O 0
mobility O 0
group O 0
( O 0
HMG O 0
) O 0
I O 0
- O 0
C O 0
DNA O 0
- O 0
binding O 0
domains O 0
and O 0
C O 0
- O 0
terminal O 0
sequences O 0
from O 0
different O 0
presumed O 0
transcription O 0
factors O 0
, O 0
suggesting O 0
a O 0
potential O 0
role O 0
for O 0
HMG O 0
I O 0
- O 0
C O 0
in O 0
the O 0
development O 0
of O 0
lipomas B-Disease 0
. O 0

To O 0
evaluate O 0
the O 0
role O 0
of O 0
the O 0
HMG O 0
I O 0
- O 0
C O 0
component O 0
, O 0
the O 0
three O 0
DNA O 0
- O 0
binding O 0
domains O 0
of O 0
HMG O 0
I O 0
- O 0
C O 0
have O 0
now O 0
been O 0
expressed O 0
in O 0
transgenic O 0
mice O 0
. O 0

Despite O 0
the O 0
ubiquitous O 0
expression O 0
of O 0
the O 0
truncated O 0
HMG O 0
I O 0
- O 0
C O 0
protein O 0
, O 0
the O 0
transgenic O 0
mice O 0
develop O 0
a O 0
selective O 0
abundance O 0
of O 0
fat O 0
tissue O 0
early O 0
in O 0
life O 0
, O 0
show O 0
marked O 0
adipose B-Disease 1
tissue I-Disease 1
inflammation I-Disease 1
, O 0
and O 0
have O 0
an O 0
abnormally O 0
high O 0
incidence O 0
of O 0
lipomas B-Disease 0
. O 0

These O 0
findings O 0
demonstrate O 0
that O 0
the O 0
DNA O 0
- O 0
binding O 0
domains O 0
of O 0
HMG O 0
I O 0
- O 0
C O 0
, O 0
in O 0
the O 0
absence O 0
of O 0
a O 0
C O 0
- O 0
terminal O 0
fusion O 0
partner O 0
, O 0
are O 0
sufficient O 0
to O 0
perturb O 0
adipogenesis O 0
and O 0
predispose O 0
to O 0
lipomas B-Disease 0
. O 0

We O 0
provide O 0
data O 0
supporting O 0
the O 0
central O 0
utility O 0
of O 0
this O 0
animal O 0
model O 0
as O 0
a O 0
tool O 0
to O 0
understand O 0
the O 0
molecular O 0
mechanisms O 0
underlying O 0
the O 0
development O 0
of O 0
one O 0
of O 0
the O 0
most O 0
common O 0
kind O 0
of O 0
human O 0
benign B-Disease 0
tumors I-Disease 0
. O 0
. O 0

ATM O 0
phosphorylates O 0
p95 O 0
/ O 0
nbs1 O 0
in O 0
an O 0
S O 0
- O 0
phase O 0
checkpoint O 0
pathway O 0
. O 0

The O 0
rare B-Disease 0
diseases I-Disease 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
( O 0
AT B-Disease 0
) O 0
, O 0
caused O 0
by O 0
mutations O 0
in O 0
the O 0
ATM O 0
gene O 0
, O 0
and O 0
Nijmegen B-Disease 0
breakage I-Disease 0
syndrome I-Disease 0
( O 0
NBS B-Disease 0
) O 0
, O 0
with O 0
mutations O 0
in O 0
the O 0
p95 O 0
/ O 0
nbs1 O 0
gene O 0
, O 0
share O 0
a O 0
variety O 0
of O 0
phenotypic B-Disease 1
abnormalities I-Disease 1
such O 0
as O 0
chromosomal B-Disease 0
instability I-Disease 0
, O 0
radiation O 0
sensitivity O 0
and O 0
defects O 0
in O 0
cell O 0
- O 0
cycle O 0
checkpoints O 0
in O 0
response O 0
to O 0
ionizing O 0
radiation O 0
. O 0

The O 0
ATM O 0
gene O 0
encodes O 0
a O 0
protein O 0
kinase O 0
that O 0
is O 0
activated O 0
by O 0
ionizing O 0
radiation O 0
or O 0
radiomimetic O 0
drugs O 0
, O 0
whereas O 0
p95 O 0
/ O 0
nbs1 O 0
is O 0
part O 0
of O 0
a O 0
protein O 0
complex O 0
that O 0
is O 0
involved O 0
in O 0
responses O 0
to O 0
DNA O 0
double O 0
- O 0
strand O 0
breaks O 0
. O 0

Here O 0
, O 0
because O 0
of O 0
the O 0
similarities O 0
between O 0
AT B-Disease 0
and O 0
NBS B-Disease 0
, O 0
we O 0
evaluated O 0
the O 0
functional O 0
interactions O 0
between O 0
ATM O 0
and O 0
p95 O 0
/ O 0
nbs1 O 0
. O 0

Activation O 0
of O 0
the O 0
ATM O 0
kinase O 0
by O 0
ionizing O 0
radiation O 0
and O 0
induction O 0
of O 0
ATM O 0
- O 0
dependent O 0
responses O 0
in O 0
NBS B-Disease 0
cells O 0
indicated O 0
that O 0
p95 O 0
/ O 0
nbs1 O 0
may O 0
not O 0
be O 0
required O 0
for O 0
signalling O 0
to O 0
ATM O 0
after O 0
ionizing O 0
radiation O 0
. O 0

However O 0
, O 0
p95 O 0
/ O 0
nbs1 O 0
was O 0
phosphorylated O 0
on O 0
serine O 0
343 O 0
in O 0
an O 0
ATM O 0
- O 0
dependent O 0
manner O 0
in O 0
vitro O 0
and O 0
in O 0
vivo O 0
after O 0
ionizing O 0
radiation O 0
. O 0

A O 0
p95 O 0
/ O 0
nbs1 O 0
construct O 0
mutated O 0
at O 0
the O 0
ATM O 0
phosphorylation O 0
site O 0
abrogated O 0
an O 0
S O 0
- O 0
phase O 0
checkpoint O 0
induced O 0
by O 0
ionizing O 0
radiation O 0
in O 0
normal O 0
cells O 0
and O 0
failed O 0
to O 0
compensate O 0
for O 0
this O 0
functional O 0
deficiency O 0
in O 0
NBS B-Disease 0
cells O 0
. O 0

These O 0
observations O 0
link O 0
ATM O 0
and O 0
p95 O 0
/ O 0
nbs1 O 0
in O 0
a O 0
common O 0
signalling O 0
pathway O 0
and O 0
provide O 0
an O 0
explanation O 0
for O 0
phenotypic O 0
similarities O 0
in O 0
these O 0
two O 0
diseases O 0
. O 0
. O 0

Understanding O 0
the O 0
molecular O 0
basis O 0
of O 0
fragile B-Disease 1
X I-Disease 1
syndrome I-Disease 1
. O 0

Fragile B-Disease 0
X I-Disease 0
syndrome I-Disease 0
, O 0
a O 0
common O 0
form O 0
of O 0
inherited B-Disease 0
mental I-Disease 1
retardation I-Disease 1
, O 0
is O 0
mainly O 0
caused O 0
by O 0
massive O 0
expansion O 0
of O 0
CGG O 0
triplet O 0
repeats O 0
located O 0
in O 0
the O 0
5 O 0
- O 0
untranslated O 0
region O 0
of O 0
the O 0
fragile B-Disease 1
X I-Disease 1
mental I-Disease 1
retardation I-Disease 1
- O 0
1 O 0
( O 0
FMR1 O 0
) O 0
gene O 0
. O 0

In O 0
patients O 0
with O 0
fragile B-Disease 1
X I-Disease 1
syndrome I-Disease 1
, O 0
the O 0
expanded O 0
CGG O 0
triplet O 0
repeats O 0
are O 0
hypermethylated O 0
and O 0
the O 0
expression O 0
of O 0
the O 0
FMR1 O 0
gene O 0
is O 0
repressed O 0
, O 0
which O 0
leads O 0
to O 0
the O 0
absence O 0
of O 0
FMR1 O 0
protein O 0
( O 0
FMRP O 0
) O 0
and O 0
subsequent O 0
mental B-Disease 1
retardation I-Disease 1
. O 0

FMRP O 0
is O 0
an O 0
RNA O 0
- O 0
binding O 0
protein O 0
that O 0
shuttles O 0
between O 0
the O 0
nucleus O 0
and O 0
cytoplasm O 0
. O 0

This O 0
protein O 0
has O 0
been O 0
implicated O 0
in O 0
protein O 0
translation O 0
as O 0
it O 0
is O 0
found O 0
associated O 0
with O 0
polyribosomes O 0
and O 0
the O 0
rough O 0
endoplasmic O 0
reticulum O 0
. O 0

We O 0
discuss O 0
here O 0
the O 0
recent O 0
progress O 0
made O 0
towards O 0
understanding O 0
the O 0
molecular O 0
mechanism O 0
of O 0
CGG O 0
repeat O 0
expansion O 0
and O 0
physiological O 0
function O 0
( O 0
s O 0
) O 0
of O 0
FMRP O 0
. O 0

These O 0
studies O 0
will O 0
not O 0
only O 0
help O 0
to O 0
illuminate O 0
the O 0
molecular O 0
basis O 0
of O 0
the O 0
general O 0
class O 0
of O 0
human O 0
diseases O 0
with O 0
trinucleotide O 0
repeat O 0
expansion O 0
but O 0
also O 0
provide O 0
an O 0
avenue O 0
to O 0
understand O 0
aspects O 0
of O 0
human O 0
cognition O 0
and O 0
intelligence O 0
. O 0
. O 0

Haploinsufficiency B-Disease 1
of I-Disease 1
the I-Disease 1
transcription I-Disease 1
factors I-Disease 1
FOXC1 I-Disease 1
and I-Disease 1
FOXC2 I-Disease 1
results O 0
in O 0
aberrant O 0
ocular O 0
development O 0
. O 0

Anterior B-Disease 1
segment I-Disease 1
developmental I-Disease 1
disorders I-Disease 1
, O 0
including O 0
Axenfeld B-Disease 1
- I-Disease 1
Rieger I-Disease 1
anomaly I-Disease 1
( O 0
ARA B-Disease 0
) O 0
, O 0
variably O 0
associate O 0
with O 0
harmfully O 0
elevated O 0
intraocular O 0
pressure O 0
( O 0
IOP O 0
) O 0
, O 0
which O 0
causes O 0
glaucoma B-Disease 0
. O 0

Clinically O 0
observed O 0
dysgenesis O 0
does O 0
not O 0
correlate O 0
with O 0
IOP O 0
, O 0
however O 0
, O 0
and O 0
the O 0
etiology O 0
of O 0
glaucoma B-Disease 0
development O 0
is O 0
not O 0
understood O 0
. O 0

The O 0
forkhead O 0
transcription O 0
factor O 0
genes O 0
Foxc1 O 0
( O 0
formerly O 0
Mf1 O 0
) O 0
and O 0
Foxc2 O 0
( O 0
formerly O 0
Mfh1 O 0
) O 0
are O 0
expressed O 0
in O 0
the O 0
mesenchyme O 0
from O 0
which O 0
the O 0
ocular O 0
drainage O 0
structures O 0
derive O 0
. O 0

Mutations O 0
in O 0
the O 0
human O 0
homolog O 0
of O 0
Foxc1 O 0
, O 0
FKHL7 O 0
, O 0
cause O 0
dominant O 0
anterior B-Disease 0
segment I-Disease 0
defects I-Disease 0
and O 0
glaucoma B-Disease 0
in O 0
various O 0
families O 0
. O 0

We O 0
show O 0
that O 0
Foxc1 O 0
( O 0
+ O 0
/ O 0
- O 0
) O 0
mice O 0
have O 0
anterior B-Disease 1
segment I-Disease 1
abnormalities I-Disease 1
similar O 0
to O 0
those O 0
reported O 0
in O 0
human O 0
patients O 0
. O 0

These O 0
abnormalities O 0
include O 0
small O 0
or O 0
absent O 0
Schlemms O 0
canal O 0
, O 0
aberrantly O 0
developed O 0
trabecular O 0
meshwork O 0
, O 0
iris B-Disease 0
hypoplasia I-Disease 0
, O 0
severely O 0
eccentric O 0
pupils O 0
and O 0
displaced O 0
Schwalbes O 0
line O 0
. O 0

The O 0
penetrance O 0
of O 0
clinically O 0
obvious O 0
abnormalities O 0
varies O 0
with O 0
genetic O 0
background O 0
. O 0

In O 0
some O 0
affected O 0
eyes O 0
, O 0
collagen O 0
bundles O 0
were O 0
half O 0
normal O 0
diameter O 0
, O 0
or O 0
collagen O 0
and O 0
elastic O 0
tissue O 0
were O 0
very O 0
sparse O 0
. O 0

Thus O 0
, O 0
abnormalities O 0
in O 0
extracellular O 0
matrix O 0
synthesis O 0
or O 0
organization O 0
may O 0
contribute O 0
to O 0
development O 0
of O 0
the O 0
ocular O 0
phenotypes O 0
. O 0

Despite O 0
the O 0
abnormalities O 0
in O 0
ocular O 0
drainage O 0
structures O 0
in O 0
Foxc1 O 0
( O 0
+ O 0
/ O 0
- O 0
) O 0
mice O 0
, O 0
IOP O 0
was O 0
normal O 0
in O 0
almost O 0
all O 0
mice O 0
analyzed O 0
, O 0
on O 0
all O 0
genetic O 0
backgrounds O 0
and O 0
at O 0
all O 0
ages O 0
. O 0

Similar O 0
abnormalities O 0
were O 0
found O 0
in O 0
Foxc2 O 0
( O 0
+ O 0
/ O 0
- O 0
) O 0
mice O 0
, O 0
but O 0
no O 0
disease O 0
- O 0
associated O 0
mutations O 0
were O 0
identified O 0
in O 0
the O 0
human O 0
homolog O 0
FKHL14 O 0
in O 0
32 O 0
ARA B-Disease 0
patients O 0
. O 0

Foxc1 O 0
( O 0
+ O 0
/ O 0
- O 0
) O 0
and O 0
Foxc2 O 0
( O 0
+ O 0
/ O 0
- O 0
) O 0
mice O 0
are O 0
useful O 0
models O 0
for O 0
studying O 0
anterior O 0
segment O 0
development O 0
and O 0
its O 0
anomalies O 0
, O 0
and O 0
may O 0
allow O 0
identification O 0
of O 0
genes O 0
that O 0
interact O 0
with O 0
Foxc1 O 0
and O 0
Foxc2 O 0
( O 0
or O 0
FKHL7 O 0
and O 0
FKHL14 O 0
) O 0
to O 0
produce O 0
a O 0
phenotype O 0
with O 0
elevated O 0
IOP O 0
and O 0
glaucoma B-Disease 0
. O 0
. O 0

( O 0
Over O 0
) O 0
correction O 0
of O 0
FMR1 B-Disease 1
deficiency I-Disease 1
with O 0
YAC O 0
transgenics O 0
: O 0
behavioral O 0
and O 0
physical O 0
features O 0
. O 0

Fragile B-Disease 0
X I-Disease 0
syndrome I-Disease 0
is O 0
a O 0
common O 0
cause O 0
of O 0
mental B-Disease 1
retardation I-Disease 1
involving O 0
loss O 0
of O 0
expression O 0
of O 0
the O 0
FMR1 O 0
gene O 0
. O 0

The O 0
role O 0
of O 0
FMR1 O 0
remains O 0
undetermined O 0
but O 0
the O 0
protein O 0
appears O 0
to O 0
be O 0
involved O 0
in O 0
RNA O 0
metabolism O 0
. O 0

Fmr1 O 0
knockout O 0
mice O 0
exhibit O 0
a O 0
phenotype O 0
with O 0
some O 0
similarities O 0
to O 0
humans O 0
, O 0
such O 0
as O 0
macroorchidism B-Disease 0
and O 0
behavioral O 0
abnormalities O 0
. O 0

As O 0
a O 0
step O 0
toward O 0
understanding O 0
the O 0
function O 0
of O 0
FMR1 O 0
and O 0
the O 0
determination O 0
of O 0
the O 0
potential O 0
for O 0
therapeutic O 0
approaches O 0
to O 0
fragile B-Disease 1
X I-Disease 1
syndrome I-Disease 1
, O 0
yeast O 0
artificial O 0
chromosome O 0
( O 0
YAC O 0
) O 0
transgenic O 0
mice O 0
were O 0
generated O 0
in O 0
order O 0
to O 0
determine O 0
whether O 0
the O 0
Fmr1 O 0
knockout O 0
mouse O 0
phenotype O 0
could O 0
be O 0
rescued O 0
. O 0

Several O 0
transgenic O 0
lines O 0
were O 0
generated O 0
that O 0
carried O 0
the O 0
entire O 0
FMR1 O 0
locus O 0
with O 0
extensive O 0
amounts O 0
of O 0
flanking O 0
sequence O 0
. O 0

We O 0
observed O 0
that O 0
the O 0
YAC O 0
transgene O 0
supported O 0
production O 0
of O 0
the O 0
human O 0
protein O 0
( O 0
FMRP O 0
) O 0
which O 0
was O 0
present O 0
at O 0
levels O 0
10 O 0
to O 0
15 O 0
times O 0
that O 0
of O 0
endogenous O 0
protein O 0
and O 0
was O 0
expressed O 0
in O 0
a O 0
cell O 0
- O 0
and O 0
tissue O 0
- O 0
specific O 0
manner O 0
. O 0

Macro O 0
- O 0
orchidism O 0
was O 0
absent O 0
in O 0
knockout O 0
mice O 0
carrying O 0
the O 0
YAC O 0
transgene O 0
indicating O 0
functional O 0
rescue O 0
by O 0
the O 0
human O 0
protein O 0
. O 0

Given O 0
the O 0
complex O 0
behavioral O 0
phenotype O 0
in O 0
fragile B-Disease 1
X I-Disease 1
patients O 0
and O 0
the O 0
mild O 0
phenotype O 0
previously O 0
reported O 0
for O 0
the O 0
Fmr1 O 0
knockout O 0
mouse O 0
, O 0
we O 0
performed O 0
a O 0
more O 0
thorough O 0
evaluation O 0
of O 0
the O 0
Fmr1 O 0
knockout O 0
phenotype O 0
using O 0
additional O 0
behavioral O 0
assays O 0
that O 0
had O 0
not O 0
previously O 0
been O 0
reported O 0
for O 0
this O 0
animal O 0
model O 0
. O 0

The O 0
mouse O 0
displayed O 0
reduced O 0
anxiety B-Disease 1
- O 0
related O 0
responses O 0
with O 0
increased O 0
exploratory O 0
behavior O 0
. O 0

FMR1 O 0
YAC O 0
transgenic O 0
mice O 0
overexpressing O 0
the O 0
human O 0
protein O 0
did O 0
produce O 0
opposing O 0
behavioral O 0
responses O 0
and O 0
additional O 0
abnormal O 0
behaviors O 0
were O 0
also O 0
observed O 0
. O 0

These O 0
findings O 0
have O 0
significant O 0
implications O 0
for O 0
gene O 0
therapy O 0
for O 0
fragile B-Disease 1
X I-Disease 1
syndrome I-Disease 1
since O 0
overexpression O 0
of O 0
the O 0
gene O 0
may O 0
harbor O 0
its O 0
own O 0
phenotype O 0
. O 0
. O 0

Transgenic O 0
mice O 0
carrying O 0
large O 0
human O 0
genomic O 0
sequences O 0
with O 0
expanded O 0
CTG O 0
repeat O 0
mimic O 0
closely O 0
the O 0
DM B-Disease 0
CTG O 0
repeat O 0
intergenerational O 0
and O 0
somatic O 0
instability O 0
. O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
is O 0
caused O 0
by O 0
a O 0
CTG O 0
repeat O 0
expansion O 0
in O 0
the O 0
3UTR O 0
of O 0
the O 0
DM B-Disease 0
protein O 0
kinase O 0
( O 0
DMPK O 0
) O 0
gene O 0
. O 0

A O 0
very O 0
high O 0
level O 0
of O 0
instability O 0
is O 0
observed O 0
through O 0
successive O 0
generations O 0
and O 0
the O 0
size O 0
of O 0
the O 0
repeat O 0
is O 0
generally O 0
correlated O 0
with O 0
the O 0
severity O 0
of O 0
the O 0
disease O 0
and O 0
with O 0
age O 0
at O 0
onset O 0
. O 0

Furthermore O 0
, O 0
tissues O 0
from O 0
DM B-Disease 0
patients O 0
exhibit O 0
somatic O 0
mosaicism O 0
that O 0
increases O 0
with O 0
age O 0
. O 0

We O 0
generated O 0
transgenic O 0
mice O 0
carrying O 0
large O 0
human O 0
genomic O 0
sequences O 0
with O 0
20 O 0
, O 0
55 O 0
or O 0
> O 0
300 O 0
CTG O 0
, O 0
cloned O 0
from O 0
patients O 0
from O 0
the O 0
same O 0
affected O 0
DM B-Disease 0
family O 0
. O 0

Using O 0
large O 0
human O 0
flanking O 0
sequences O 0
and O 0
a O 0
large O 0
amplification O 0
, O 0
we O 0
demonstrate O 0
that O 0
the O 0
intergenerational O 0
CTG O 0
repeat O 0
instability O 0
is O 0
reproduced O 0
in O 0
mice O 0
, O 0
with O 0
a O 0
strong O 0
bias O 0
towards O 0
expansions O 0
and O 0
with O 0
the O 0
same O 0
sex O 0
- O 0
and O 0
size O 0
- O 0
dependent O 0
characteristics O 0
as O 0
in O 0
humans O 0
. O 0

Moreover O 0
, O 0
a O 0
high O 0
level O 0
of O 0
instability O 0
, O 0
increasing O 0
with O 0
age O 0
, O 0
can O 0
be O 0
observed O 0
in O 0
tissues O 0
and O 0
in O 0
sperm O 0
. O 0

Although O 0
we O 0
did O 0
not O 0
observe O 0
dramatic O 0
expansions O 0
( O 0
or O 0
big O 0
jumps O 0
over O 0
several O 0
hundred O 0
CTG O 0
repeats O 0
) O 0
as O 0
in O 0
congenital O 0
forms O 0
of O 0
DM B-Disease 0
, O 0
our O 0
model O 0
carrying O 0
> O 0
300 O 0
CTG O 0
is O 0
the O 0
first O 0
to O 0
show O 0
instability O 0
so O 0
close O 0
to O 0
the O 0
human O 0
DM B-Disease 0
situation O 0
. O 0

Our O 0
three O 0
models O 0
carrying O 0
different O 0
sizes O 0
of O 0
CTG O 0
repeat O 0
provide O 0
insight O 0
on O 0
the O 0
different O 0
factors O 0
modulating O 0
the O 0
CTG O 0
repeat O 0
instability O 0
. O 0
. O 0

Inactivation O 0
of O 0
the O 0
Friedreich B-Disease 1
ataxia I-Disease 1
mouse O 0
gene O 0
leads O 0
to O 0
early O 0
embryonic B-Disease 0
lethality I-Disease 0
without O 0
iron O 0
accumulation O 0
. O 0

Friedreich B-Disease 1
ataxia I-Disease 1
( O 0
FRDA B-Disease 0
) O 0
, O 0
the O 0
most O 0
common O 0
autosomal B-Disease 0
recessive I-Disease 0
ataxia I-Disease 0
, O 0
is O 0
caused O 0
in O 0
almost O 0
all O 0
cases O 0
by O 0
homozygous O 0
intronic O 0
expansions O 0
resulting O 0
in O 0
the O 0
loss O 0
of O 0
frataxin O 0
, O 0
a O 0
mitochondrial O 0
protein O 0
conserved O 0
through O 0
evolution O 0
, O 0
and O 0
involved O 0
in O 0
mitochondrial O 0
iron O 0
homeostasis O 0
. O 0

Yeast O 0
knockout O 0
models O 0
, O 0
and O 0
histological O 0
and O 0
biochemical O 0
data O 0
from O 0
patient O 0
heart O 0
biopsies O 0
or O 0
autopsies O 0
indicate O 0
that O 0
the O 0
frataxin O 0
defect O 0
causes O 0
a O 0
specific O 0
iron B-Disease 0
- I-Disease 0
sulfur I-Disease 0
protein I-Disease 0
deficiency I-Disease 0
and O 0
mitochondrial O 1
iron O 1
accumulation O 1
leading O 0
to O 0
the O 0
pathological O 0
changes O 0
. O 0

Affected O 0
human O 0
tissues O 0
are O 0
rarely O 0
available O 0
to O 0
further O 0
examine O 0
this O 0
hypothesis O 0
. O 0

To O 0
study O 0
the O 0
mechanism O 0
of O 0
the O 0
disease O 0
, O 0
we O 0
generated O 0
a O 0
mouse O 0
model O 0
by O 0
deletion O 0
of O 0
exon O 0
4 O 0
leading O 0
to O 0
inactivation O 0
of O 0
the O 0
Frda B-Disease 0
gene O 0
product O 0
. O 0

We O 0
show O 0
that O 0
homozygous O 0
deletions O 0
cause O 0
embryonic B-Disease 0
lethality I-Disease 0
a O 0
few O 0
days O 0
after O 0
implantation O 0
, O 0
demonstrating O 0
an O 0
important O 0
role O 0
for O 0
frataxin O 0
during O 0
early O 0
development O 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
the O 0
milder O 0
phenotype O 0
in O 0
humans O 0
is O 0
due O 0
to O 0
residual O 0
frataxin O 0
expression O 0
associated O 0
with O 0
the O 0
expansion O 0
mutations O 0
. O 0

Surprisingly O 0
, O 0
in O 0
the O 0
frataxin O 0
knockout O 0
mouse O 0
, O 0
no O 0
iron O 0
accumulation O 0
was O 0
observed O 0
during O 0
embryonic O 0
resorption O 0
, O 0
suggesting O 0
that O 0
cell O 0
death O 0
could O 0
be O 0
due O 0
to O 0
a O 0
mechanism O 0
independent O 0
of O 0
iron O 0
accumulation O 0
. O 0
. O 0

Gaucher B-Disease 1
disease I-Disease 1
: O 0
the O 0
origins O 0
of O 0
the O 0
Ashkenazi O 0
Jewish O 0
N370S O 0
and O 0
84GG O 0
acid O 0
beta O 0
- O 0
glucosidase O 0
mutations O 0
. O 0

Type O 0
1 O 0
Gaucher B-Disease 1
disease I-Disease 1
( O 0
GD B-Disease 1
) O 0
, O 0
a O 0
non O 0
- O 0
neuronopathic O 0
lysosomal B-Disease 0
storage I-Disease 0
disorder I-Disease 0
, O 0
results O 0
from O 0
the O 0
deficient O 0
activity O 0
of O 0
acid O 0
beta O 0
- O 0
glucosidase O 0
( O 0
GBA O 0
) O 0
. O 0

Type O 0
1 O 0
disease O 0
is O 0
panethnic O 0
but O 0
is O 0
more O 0
prevalent O 0
in O 0
individuals O 0
of O 0
Ashkenazi O 0
Jewish O 0
( O 0
AJ O 0
) O 0
descent O 0
. O 0

Of O 0
the O 0
causative O 0
GBA O 0
mutations O 0
, O 0
N370S O 0
is O 0
particularly O 0
frequent O 0
in O 0
the O 0
AJ O 0
population O 0
, O 0
( O 0
q O 0
approximately O 0
. O 0
03 O 0
) O 0
, O 0
whereas O 0
the O 0
84GG O 0
insertion O 0
( O 0
q O 0
approximately O 0
. O 0
003 O 0
) O 0
occurs O 0
exclusively O 0
in O 0
the O 0
Ashkenazim O 0
. O 0

To O 0
investigate O 0
the O 0
genetic O 0
history O 0
of O 0
these O 0
mutations O 0
in O 0
the O 0
AJ O 0
population O 0
, O 0
short O 0
tandem O 0
repeat O 0
( O 0
STR O 0
) O 0
markers O 0
were O 0
used O 0
to O 0
map O 0
a O 0
9 O 0
. O 0

3 O 0
- O 0
cM O 0
region O 0
containing O 0
the O 0
GBA O 0
locus O 0
and O 0
to O 0
genotype O 0
261 O 0
AJ O 0
N370S O 0
chromosomes O 0
, O 0
60 O 0
European O 0
non O 0
- O 0
Jewish O 0
N370S O 0
chromosomes O 0
, O 0
and O 0
62 O 0
AJ O 0
84GG O 0
chromosomes O 0
. O 0

A O 0
highly O 0
conserved O 0
haplotype O 0
at O 0
four O 0
markers O 0
flanking O 0
GBA O 0
( O 0
PKLR O 0
, O 0
D1S1595 O 0
, O 0
D1S2721 O 0
, O 0
and O 0
D1S2777 O 0
) O 0
was O 0
observed O 0
on O 0
both O 0
the O 0
AJ O 0
chromosomes O 0
and O 0
the O 0
non O 0
- O 0
Jewish O 0
N370S O 0
chromosomes O 0
, O 0
suggesting O 0
the O 0
occurrence O 0
of O 0
a O 0
founder O 0
common O 0
to O 0
both O 0
populations O 0
. O 0

Of O 0
note O 0
, O 0
the O 0
presence O 0
of O 0
different O 0
divergent O 0
haplotypes O 0
suggested O 0
the O 0
occurrence O 0
of O 0
de O 0
novo O 0
, O 0
recurrent O 0
N370S O 0
mutations O 0
. O 0

In O 0
contrast O 0
, O 0
a O 0
different O 0
conserved O 0
haplotype O 0
at O 0
these O 0
markers O 0
was O 0
identified O 0
on O 0
the O 0
84GG O 0
chromosomes O 0
, O 0
which O 0
was O 0
unique O 0
to O 0
the O 0
AJ O 0
population O 0
. O 0

On O 0
the O 0
basis O 0
of O 0
the O 0
linkage O 0
disequilibrium O 0
( O 0
LD O 0
) O 0
delta O 0
values O 0
, O 0
the O 0
non O 0
- O 0
Jewish O 0
European O 0
N370S O 0
chromosomes O 0
had O 0
greater O 0
haplotype O 0
diversity O 0
and O 0
less O 0
LD O 0
at O 0
the O 0
markers O 0
flanking O 0
the O 0
conserved O 0
haplotype O 0
than O 0
did O 0
the O 0
AJ O 0
N370S O 0
chromosomes O 0
. O 0

This O 0
finding O 0
is O 0
consistent O 0
with O 0
the O 0
presence O 0
of O 0
the O 0
N370S O 0
mutation O 0
in O 0
the O 0
non O 0
- O 0
Jewish O 0
European O 0
population O 0
prior O 0
to O 0
the O 0
founding O 0
of O 0
the O 0
AJ O 0
population O 0
. O 0

Coalescence O 0
analyses O 0
for O 0
the O 0
N370S O 0
and O 0
84GG O 0
mutations O 0
estimated O 0
similar O 0
coalescence O 0
times O 0
, O 0
of O 0
48 O 0
and O 0
55 O 0
. O 0
5 O 0
generations O 0
ago O 0
, O 0
respectively O 0
. O 0

The O 0
results O 0
of O 0
these O 0
studies O 0
are O 0
consistent O 0
with O 0
a O 0
significant O 0
bottleneck O 0
occurring O 0
in O 0
the O 0
AJ O 0
population O 0
during O 0
the O 0
first O 0
millennium O 0
, O 0
when O 0
the O 0
population O 0
became O 0
established O 0
in O 0
Europe O 0
. O 0

HLA O 0
B27 O 0
and O 0
the O 0
genetics O 0
of O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
. O 0

One O 0
hundred O 0
and O 0
twenty O 0
- O 0
eight O 0
of O 0
145 O 0
patients O 0
with O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
( O 0
AS B-Disease 0
) O 0
were O 0
found O 0
to O 0
be O 0
HLA O 0
B27 O 0
positive O 0
. O 0

Five O 0
patients O 0
had O 0
evidence O 0
of O 0
a O 0
sero O 0
- O 0
negative O 0
peripheral B-Disease 0
arthritis I-Disease 0
resembling O 0
peripheral B-Disease 0
psoriatic I-Disease 0
arthritis I-Disease 0
and O 0
3 O 0
of O 0
these O 0
were O 0
B27 O 0
negative O 0
. O 0

One O 0
further O 0
B27 O 0
negative O 0
patients O 0
had O 0
a O 0
sister O 0
with O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
and O 0
ulcerative B-Disease 0
colitis I-Disease 0
and O 0
a O 0
mother O 0
with O 0
ulcerative B-Disease 0
colitis I-Disease 0
. O 0

There O 0
was O 0
evidence O 0
of O 0
a O 0
somewhat O 0
later O 0
age O 0
of O 0
onset O 0
of O 0
symptoms O 0
in O 0
B27 O 0
negative O 0
patients O 0
. O 0

These O 0
findings O 0
are O 0
interpreted O 0
as O 0
suggesting O 0
some O 0
degree O 0
of O 0
clinical O 0
and O 0
genetic O 0
heterogeneity O 0
in O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
with O 0
genes O 0
for O 0
psoriasis B-Disease 1
and O 0
inflammatory B-Disease 1
bowel I-Disease 1
disease I-Disease 1
being O 0
important O 0
in O 0
some O 0
individuals O 0
, O 0
particularly O 0
those O 0
who O 0
are O 0
B27 O 0
negative O 0
. O 0

Twenty O 0
- O 0
five O 0
first O 0
- O 0
degree O 0
relatives O 0
with O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
were O 0
all O 0
B27 O 0
positive O 0
. O 0

The O 0
only O 0
instance O 0
of O 0
disassociation O 0
of O 0
B27 O 0
and O 0
spondylitis B-Disease 1
in O 0
a O 0
family O 0
was O 0
where O 0
the O 0
proband O 0
had O 0
ulcerative B-Disease 0
colitis I-Disease 0
as O 0
well O 0
as O 0
spondylitis B-Disease 1
. O 0

Of O 0
13 O 0
B27 O 0
positive O 0
fathers O 0
3 O 0
could O 0
be O 0
diagnosed O 0
as O 0
having O 0
definite O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
( O 0
23 O 0
% O 0
) O 0
. O 0

These O 0
findings O 0
are O 0
thought O 0
to O 0
provide O 0
evidence O 0
against O 0
the O 0
concept O 0
that O 0
the O 0
gene O 0
for O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
is O 0
not O 0
B27 O 0
but O 0
a O 0
closely O 0
linked O 0
gene O 0
and O 0
favour O 0
the O 0
occurrence O 0
of O 0
an O 0
environmental O 0
event O 0
affecting O 0
approximately O 0
one O 0
- O 0
fifth O 0
of O 0
B27 O 0
positive O 0
males O 0
to O 0
result O 0
in O 0
disease O 0
. O 0
. O 0

Founder O 0
mutations O 0
in O 0
the O 0
BRCA1 O 0
gene O 0
in O 0
Polish O 0
families O 0
with O 0
breast B-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
. O 0

We O 0
have O 0
undertaken O 0
a O 0
hospital O 0
- O 0
based O 0
study O 0
, O 0
to O 0
identify O 0
possible O 0
BRCA1 O 0
and O 0
BRCA2 O 0
founder O 0
mutations O 0
in O 0
the O 0
Polish O 0
population O 0
. O 0

The O 0
study O 0
group O 0
consisted O 0
of O 0
66 O 0
Polish O 0
families O 0
with O 0
cancer B-Disease 1
who O 0
have O 0
at O 0
least O 0
three O 0
related O 0
females O 0
affected O 0
with O 0
breast B-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
and O 0
who O 0
had O 0
cancer B-Disease 1
diagnosed O 0
, O 0
in O 0
at O 0
least O 0
one O 0
of O 0
the O 0
three O 0
affected O 0
females O 0
, O 0
at O 0
age O 0
< O 0
50 O 0
years O 0
. O 0

A O 0
total O 0
of O 0
26 O 0
families O 0
had O 0
both O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 1
cancers I-Disease 1
, O 0
4 O 0
families O 0
had O 0
ovarian B-Disease 1
cancers I-Disease 1
only O 0
, O 0
and O 0
36 O 0
families O 0
had O 0
breast B-Disease 0
cancers I-Disease 0
only O 0
. O 0

Genomic O 0
DNA O 0
was O 0
prepared O 0
from O 0
the O 0
peripheral O 0
blood O 0
leukocytes O 0
of O 0
at O 0
least O 0
one O 0
affected O 0
woman O 0
from O 0
each O 0
family O 0
. O 0

The O 0
entire O 0
coding O 0
region O 0
of O 0
BRCA1 O 0
and O 0
BRCA2 O 0
was O 0
screened O 0
for O 0
the O 0
presence O 0
of O 0
germline O 0
mutations O 0
, O 0
by O 0
use O 0
of O 0
SSCP O 0
followed O 0
by O 0
direct O 0
sequencing O 0
of O 0
observed O 0
variants O 0
. O 0

Mutations O 0
were O 0
found O 0
in O 0
35 O 0
( O 0
53 O 0
% O 0
) O 0
of O 0
the O 0
66 O 0
families O 0
studied O 0
. O 0

All O 0
but O 0
one O 0
of O 0
the O 0
mutations O 0
were O 0
detected O 0
within O 0
the O 0
BRCA1 O 0
gene O 0
. O 0

BRCA1 B-Disease 1
abnormalities I-Disease 1
were O 0
identified O 0
in O 0
all O 0
four O 0
families O 0
with O 0
ovarian B-Disease 0
cancer I-Disease 1
only O 0
, O 0
in O 0
67 O 0
% O 0
of O 0
27 O 0
families O 0
with O 0
both O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
, O 0
and O 0
in O 0
34 O 0
% O 0
of O 0
35 O 0
families O 0
with O 0
breast B-Disease 0
cancer I-Disease 1
only O 0
. O 0

The O 0
single O 0
family O 0
with O 0
a O 0
BRCA2 O 0
mutation O 0
had O 0
the O 0
breast B-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
syndrome I-Disease 0
. O 0

Seven O 0
distinct O 0
mutations O 0
were O 0
identified O 0
; O 0
five O 0
of O 0
these O 0
occurred O 0
in O 0
two O 0
or O 0
more O 0
families O 0
. O 0

In O 0
total O 0
, O 0
recurrent O 0
mutations O 0
were O 0
found O 0
in O 0
33 O 0
( O 0
94 O 0
% O 0
) O 0
of O 0
the O 0
35 O 0
families O 0
with O 0
detected O 0
mutations O 0
. O 0

Three O 0
BRCA1 B-Disease 1
abnormalities I-Disease 1
- O 0
5382insC O 0
, O 0
C61G O 0
, O 0
and O 0
4153delA O 0
- O 0
accounted O 0
for O 0
51 O 0
% O 0
, O 0
20 O 0
% O 0
, O 0
and O 0
11 O 0
% O 0
of O 0
the O 0
identified O 0
mutations O 0
, O 0
respectively O 0
. O 0
. O 0

Molecular O 0
basis O 0
of O 0
very B-Disease 0
long I-Disease 0
chain I-Disease 0
acyl I-Disease 0
- I-Disease 0
CoA I-Disease 0
dehydrogenase I-Disease 0
deficiency I-Disease 0
in O 0
three O 0
Israeli O 0
patients O 0
: O 0
identification O 0
of O 0
a O 0
complex O 0
mutant O 0
allele O 0
with O 0
P65L O 0
and O 0
K247Q O 0
mutations O 0
, O 0
the O 0
former O 0
being O 0
an O 0
exonic O 0
mutation O 0
causing O 0
exon O 0
3 O 0
skipping O 0
. O 0

Very B-Disease 0
long I-Disease 0
chain I-Disease 0
acyl I-Disease 0
- I-Disease 0
CoA I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
VLCAD I-Disease 0
) I-Disease 0
deficiency I-Disease 0
is O 0
a O 0
life O 0
- O 0
threatening O 0
disorder O 0
of O 0
mitochondrial O 0
fatty O 0
acid O 0
beta O 0
- O 0
oxidation O 0
. O 0

We O 0
identified O 0
four O 0
novel O 0
mutations O 0
in O 0
three O 0
unrelated O 0
patients O 0
. O 0

All O 0
patients O 0
had O 0
the O 0
severe O 0
childhood O 0
form O 0
of O 0
VLCAD B-Disease 0
deficiency I-Disease 0
with O 0
early O 0
onset O 0
and O 0
high O 0
mortality O 0
. O 0

Immunoblot O 0
analysis O 0
revealed O 0
that O 0
VLCAD O 0
protein O 0
was O 0
undetectable O 0
in O 0
patients O 0
2 O 0
and O 0
3 O 0
, O 0
whereas O 0
normal O 0
- O 0
size O 0
VLCAD O 0
protein O 0
and O 0
an O 0
aberrant O 0
form O 0
of O 0
VLCAD O 0
( O 0
4kDa O 0
smaller O 0
) O 0
were O 0
detected O 0
in O 0
patient O 0
1 O 0
. O 0

As O 0
expected O 0
, O 0
null O 0
mutations O 0
were O 0
found O 0
in O 0
patients O 0
2 O 0
and O 0
3 O 0
patient O 0
2 O 0
is O 0
homozygous O 0
for O 0
a O 0
frameshift O 0
mutation O 0
, O 0
del O 0
4 O 0
bp O 0
at O 0
798 O 0
- O 0
801 O 0
, O 0
and O 0
patient O 0
3 O 0
is O 0
homozygous O 0
for O 0
a O 0
nonsense O 0
mutation O 0
65C O 0
> O 0
A O 0
( O 0
S22X O 0
) O 0
. O 0

Patient O 0
1 O 0
was O 0
homozygous O 0
for O 0
a O 0
complex O 0
mutant O 0
allele O 0
containing O 0
two O 0
alterations O 0
, O 0
including O 0
a O 0
194C O 0
> O 0
T O 0
transition O 0
( O 0
P65L O 0
) O 0
and O 0
739A O 0
> O 0
C O 0
transversion O 0
( O 0
K247Q O 0
) O 0
; O 0
in O 0
the O 0
case O 0
of O 0
P65L O 0
, O 0
the O 0
amino O 0
acid O 0
change O 0
does O 0
not O 0
reduce O 0
enzyme O 0
activity O 0
. O 0

However O 0
, O 0
the O 0
nucleotide O 0
change O 0
resulted O 0
in O 0
exon O 0
3 O 0
skipping O 0
, O 0
whereas O 0
the O 0
latter O 0
K247Q O 0
mutation O 0
had O 0
a O 0
drastic O 0
effect O 0
on O 0
enzyme O 0
activity O 0
. O 0

We O 0
verified O 0
these O 0
events O 0
by O 0
in O 0
vivo O 0
splicing O 0
experiments O 0
and O 0
transient O 0
expression O 0
analysis O 0
of O 0
mutant O 0
cDNAs O 0
. O 0

The O 0
P65L O 0
mutation O 0
locates O 0
11 O 0
bases O 0
upstream O 0
of O 0
a O 0
splice O 0
donor O 0
site O 0
of O 0
intron O 0
3 O 0
. O 0

This O 0
is O 0
an O 0
example O 0
of O 0
an O 0
exonic O 0
mutation O 0
which O 0
affects O 0
exon O 0
- O 0
splicing O 0
. O 0
. O 0

Submicroscopic O 0
deletion O 0
in O 0
cousins O 0
with O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
causes O 0
a O 0
grandmatrilineal O 0
inheritance O 0
pattern O 0
: O 0
effects O 0
of O 0
imprinting O 0
. O 0

The O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
critical O 0
region O 0
on O 0
15q11 O 0
- O 0
q13 O 0
is O 0
subject O 0
to O 0
imprinting O 0
. O 0

PWS B-Disease 0
becomes O 0
apparent O 0
when O 0
genes O 0
on O 0
the O 0
paternally O 0
inherited O 0
chromosome O 0
are O 0
not O 0
expressed O 0
. O 0

Familial B-Disease 1
PWS I-Disease 1
is O 0
rare O 0
. O 0

We O 0
report O 0
on O 0
a O 0
family O 0
in O 0
which O 0
a O 0
male O 0
and O 0
a O 0
female O 0
paternal O 0
first O 0
cousin O 0
both O 0
have O 0
PWS B-Disease 0
with O 0
cytogenetically O 0
normal O 0
karyotypes O 0
. O 0

Fluorescence O 0
in O 0
situ O 0
hybridization O 0
( O 0
FISH O 0
) O 0
analysis O 0
shows O 0
a O 0
submicroscopic O 0
deletion O 0
of O 0
SNRPN O 0
, O 0
but O 0
not O 0
the O 0
closely O 0
associated O 0
loci O 0
D15S10 O 0
, O 0
D15S11 O 0
, O 0
D15S63 O 0
, O 0
and O 0
GABRB3 O 0
. O 0

The O 0
cousins O 0
fathers O 0
and O 0
two O 0
paternal O 0
aunts O 0
have O 0
the O 0
same O 0
deletion O 0
and O 0
are O 0
clinically O 0
normal O 0
. O 0

The O 0
grandmother O 0
of O 0
the O 0
cousins O 0
is O 0
deceased O 0
and O 0
not O 0
available O 0
for O 0
study O 0
, O 0
and O 0
their O 0
grandfather O 0
is O 0
not O 0
deleted O 0
for O 0
SNRPN O 0
. O 0

DNA O 0
methylation O 0
analysis O 0
of O 0
D15S63 O 0
is O 0
consistent O 0
with O 0
an O 0
abnormality O 0
of O 0
the O 0
imprinting O 0
center O 0
associated O 0
with O 0
PWS B-Disease 0
. O 0

" O 0
Grandmatrilineal O 0
" O 0
inheritance O 0
occurs O 0
when O 0
a O 0
woman O 0
with O 0
deletion O 0
of O 0
an O 0
imprinted O 0
, O 0
paternally O 0
expressed O 0
gene O 0
is O 0
at O 0
risk O 0
of O 0
having O 0
affected O 0
grandchildren O 0
through O 0
her O 0
sons O 0
. O 0

In O 0
this O 0
case O 0
, O 0
PWS B-Disease 0
does O 0
not O 0
become O 0
evident O 0
as O 0
long O 0
as O 0
the O 0
deletion O 0
is O 0
passed O 0
through O 0
the O 0
matrilineal O 0
line O 0
. O 0

This O 0
represents O 0
a O 0
unique O 0
inheritance O 0
pattern O 0
due O 0
to O 0
imprinting O 0
. O 0
. O 0

Human O 0
glycine O 0
decarboxylase O 0
gene O 0
( O 0
GLDC O 0
) O 0
and O 0
its O 0
highly O 0
conserved O 0
processed O 0
pseudogene O 0
( O 0
psiGLDC O 0
) O 0
: O 0
their O 0
structure O 0
and O 0
expression O 0
, O 0
and O 0
the O 0
identification O 0
of O 0
a O 0
large O 0
deletion O 0
in O 0
a O 0
family O 0
with O 0
nonketotic B-Disease 0
hyperglycinemia I-Disease 0
. O 0

Mutations O 0
in O 0
the O 0
glycine O 0
decarboxylase O 0
gene O 0
( O 0
GLDC O 0
) O 0
cause O 0
nonketotic B-Disease 0
hyperglycinemia I-Disease 0
( O 0
NKH B-Disease 1
) O 0
, O 0
an O 0
in B-Disease 0
- I-Disease 0
born I-Disease 0
error I-Disease 0
of I-Disease 0
metabolism I-Disease 0
characterized O 0
by O 0
severe O 0
neurological B-Disease 0
disturbance I-Disease 0
. O 0

We O 0
have O 0
determined O 0
the O 0
structure O 0
of O 0
GLDC O 0
and O 0
of O 0
its O 0
pseudogene O 0
( O 0
psiGLDC O 0
) O 0
and O 0
studied O 0
their O 0
expression O 0
for O 0
a O 0
molecular O 0
analysis O 0
of O 0
NKH B-Disease 1
. O 0

The O 0
GLDC O 0
gene O 0
spans O 0
at O 0
least O 0
135 O 0
kb O 0
and O 0
consists O 0
of O 0
25 O 0
exons O 0
. O 0

All O 0
donor O 0
and O 0
acceptor O 0
sites O 0
adhere O 0
to O 0
the O 0
canonical O 0
GT O 0
- O 0
AG O 0
rule O 0
, O 0
except O 0
for O 0
the O 0
donor O 0
site O 0
of O 0
intron O 0
21 O 0
, O 0
where O 0
a O 0
variant O 0
form O 0
GC O 0
is O 0
used O 0
instead O 0
of O 0
GT O 0
. O 0

The O 0
transcription O 0
initiation O 0
site O 0
has O 0
been O 0
assigned O 0
to O 0
a O 0
residue O 0
163 O 0
bp O 0
upstream O 0
from O 0
the O 0
translation O 0
initiation O 0
triplet O 0
by O 0
primer O 0
extension O 0
analysis O 0
. O 0

The O 0
psiGLDC O 0
gene O 0
has O 0
no O 0
intron O 0
and O 0
shares O 0
97 O 0
. O 0

5 O 0
% O 0
homology O 0
with O 0
the O 0
coding O 0
region O 0
of O 0
functional O 0
GLDC O 0
, O 0
suggesting O 0
that O 0
psiGLDC O 0
is O 0
a O 0
processed O 0
pseudogene O 0
that O 0
arose O 0
from O 0
the O 0
GLDC O 0
transcript O 0
about O 0
4 O 0
- O 0
8 O 0
million O 0
years O 0
ago O 0
. O 0

RNA O 0
blotting O 0
analysis O 0
has O 0
revealed O 0
that O 0
GLDC O 0
is O 0
expressed O 0
in O 0
human O 0
liver O 0
, O 0
kidney O 0
, O 0
brain O 0
, O 0
and O 0
placenta O 0
. O 0

We O 0
have O 0
also O 0
examined O 0
a O 0
patient O 0
with O 0
NKH B-Disease 1
with O 0
no O 0
detectable O 0
GLDC O 0
mRNA O 0
in O 0
his O 0
lymphoblasts O 0
. O 0

Exons O 0
1 O 0
- O 0
3 O 0
of O 0
the O 0
functional O 0
GLDC O 0
gene O 0
from O 0
this O 0
patient O 0
are O 0
not O 0
amplified O 0
by O 0
polymerase O 0
chain O 0
reaction O 0
( O 0
PCR O 0
) O 0
, O 0
whereas O 0
those O 0
from O 0
control O 0
subjects O 0
are O 0
. O 0

These O 0
results O 0
suggest O 0
a O 0
large O 0
homozygous O 0
deletion O 0
( O 0
at O 0
least O 0
30 O 0
kb O 0
) O 0
in O 0
the O 0
patient O 0
. O 0

Furthermore O 0
, O 0
we O 0
have O 0
devised O 0
a O 0
semi O 0
- O 0
quantitative O 0
PCR O 0
to O 0
estimate O 0
the O 0
number O 0
of O 0
GLDC O 0
alleles O 0
by O 0
using O 0
psiGLDC O 0
as O 0
an O 0
internal O 0
control O 0
and O 0
have O 0
confirmed O 0
the O 0
homozygosity O 0
and O 0
heterozygosity O 0
of O 0
the O 0
deletion O 0
in O 0
the O 0
patient O 0
and O 0
his O 0
parents O 0
, O 0
respectively O 0
. O 0

Structural O 0
information O 0
of O 0
GLDC O 0
and O 0
psiGLDC O 0
should O 0
facilitate O 0
the O 0
molecular O 0
analysis O 0
of O 0
NKH B-Disease 1
. O 0

De O 0
novo O 0
deletions O 0
of O 0
SNRPN O 0
exon O 0
1 O 0
in O 0
early O 0
human O 0
and O 0
mouse O 0
embryos O 0
result O 0
in O 0
a O 0
paternal O 0
to O 0
maternal O 0
imprint O 0
switch O 0
. O 0

Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
is O 0
a O 0
neurogenetic B-Disease 1
disease I-Disease 1
characterized O 0
by O 0
infantile B-Disease 0
hypotonia I-Disease 0
, O 0
gonadal B-Disease 0
hypoplasia I-Disease 0
, O 0
obsessive O 0
behaviour O 0
and O 0
neonatal O 0
feeding O 0
difficulties O 0
followed O 0
by O 0
hyperphagia B-Disease 0
, O 0
leading O 0
to O 0
profound O 0
obesity B-Disease 0
. O 0

PWS B-Disease 0
is O 0
due O 0
to O 0
a O 0
lack O 0
of O 0
paternal O 0
genetic O 0
information O 0
at O 0
15q11 O 0
- O 0
q13 O 0
( O 0
ref O 0
. O 0
2 O 0
) O 0
. O 0

Five O 0
imprinted O 0
, O 0
paternally O 0
expressed O 0
genes O 0
map O 0
to O 0
the O 0
PWS B-Disease 0
region O 0
, O 0
MKRN3 O 0
( O 0
ref O 0
. O 0
3 O 0
) O 0
, O 0
NDN O 0
( O 0
ref O 0
. O 0
4 O 0
) O 0
, O 0
NDNL1 O 0
( O 0
ref O 0
. O 0
5 O 0
) O 0
, O 0
SNRPN O 0
( O 0
refs O 0
6 O 0
- O 0
8 O 0
) O 0
and O 0
IPW O 0
( O 0
ref O 0
. O 0
9 O 0
) O 0
, O 0
as O 0
well O 0
as O 0
two O 0
poorly O 0
characterized O 0
framents O 0
designated O 0
PAR O 0
- O 0
1 O 0
and O 0
PAR O 0
- O 0
5 O 0
( O 0
ref O 0
. O 0
10 O 0
) O 0
. O 0

Imprinting O 0
of O 0
this O 0
region O 0
involves O 0
a O 0
bipartite O 0
imprinting O 0
centre O 0
( O 0
IC O 0
) O 0
, O 0
which O 0
overlaps O 0
SNRPN O 0
( O 0
refs O 0
10 O 0
, O 0
11 O 0
) O 0
. O 0

Deletion O 0
of O 0
the O 0
SNRPN O 0
promoter O 0
/ O 0
exon O 0
1 O 0
region O 0
( O 0
the O 0
PWS B-Disease 0
IC O 0
element O 0
) O 0
appears O 0
to O 0
impair O 0
the O 0
establishment O 0
of O 0
the O 0
paternal O 0
imprint O 0
in O 0
the O 0
male O 0
germ O 0
line O 0
and O 0
leads O 0
to O 0
PWS B-Disease 0
. O 0

Here O 0
we O 0
report O 0
a O 0
PWS B-Disease 0
family O 0
in O 0
which O 0
the O 0
father O 0
is O 0
mosaic O 0
for O 0
an O 0
IC O 0
deletion O 0
on O 0
his O 0
paternal O 0
chromosome O 0
. O 0

The O 0
deletion O 0
chromosome O 0
has O 0
acquired O 0
a O 0
maternal O 0
methylation O 0
imprint O 0
in O 0
his O 0
somatic O 0
cells O 0
. O 0

We O 0
have O 0
made O 0
identical O 0
findings O 0
in O 0
chimaeric O 0
mice O 0
generated O 0
from O 0
two O 0
independent O 0
embryonic O 0
stem O 0
( O 0
ES O 0
) O 0
cell O 0
lines O 0
harbouring O 0
a O 0
similar O 0
deletion O 0
. O 0

Our O 0
studies O 0
demonstrate O 0
that O 0
the O 0
PWS B-Disease 0
IC O 0
element O 0
is O 0
not O 0
only O 0
required O 0
for O 0
the O 0
establishment O 0
of O 0
the O 0
paternal O 0
imprint O 0
, O 0
but O 0
also O 0
for O 0
its O 0
postzygotic O 0
maintenance O 0
. O 0
. O 0

Mice O 0
deficient B-Disease 0
in I-Disease 0
Six5 I-Disease 0
develop O 0
cataracts B-Disease 1
: O 0
implications O 0
for O 0
myotonic B-Disease 1
dystrophy I-Disease 1
. O 0

Expansion O 0
of O 0
a O 0
CTG O 0
trinucleotide O 0
repeat O 0
in O 0
the O 0
3 O 0
UTR O 0
of O 0
the O 0
gene O 0
DMPK O 0
at O 0
the O 0
DM1 O 0
locus O 0
on O 0
chromosome O 0
19 O 0
causes O 0
myotonic B-Disease 1
dystrophy I-Disease 1
, O 0
a O 0
dominantly B-Disease 1
inherited I-Disease 1
disease I-Disease 1
characterized O 0
by O 0
skeletal O 0
muscle B-Disease 0
dystrophy I-Disease 0
and O 0
myotonia B-Disease 1
, O 0
cataracts B-Disease 1
and O 0
cardiac B-Disease 1
conduction I-Disease 1
defects I-Disease 1
. O 0

Targeted O 0
deletion O 0
of O 0
Dm15 O 0
, O 0
the O 0
mouse O 0
orthologue O 0
of O 0
human O 0
DMPK O 0
, O 0
produced O 0
mice O 0
with O 0
a O 0
mild O 0
myopathy B-Disease 1
and O 0
cardiac B-Disease 0
conduction I-Disease 0
abnormalities I-Disease 0
, O 0
but O 0
without O 0
other O 0
features O 0
of O 0
myotonic B-Disease 1
dystrophy I-Disease 1
, O 0
such O 0
as O 0
myotonia B-Disease 1
and O 0
cataracts B-Disease 1
. O 0

We O 0
, O 0
and O 0
others O 0
, O 0
have O 0
demonstrated O 0
that O 0
repeat O 0
expansion O 0
decreases O 0
expression O 0
of O 0
the O 0
adjacent O 0
gene O 0
SIX5 O 0
( O 0
refs O 0
7 O 0
, O 0
8 O 0
) O 0
, O 0
which O 0
encodes O 0
a O 0
homeodomain O 0
transcription O 0
factor O 0
. O 0

To O 0
determine O 0
whether O 0
SIX5 B-Disease 1
deficiency I-Disease 1
contributes O 0
to O 0
the O 0
myotonic B-Disease 1
dystrophy I-Disease 1
phenotype O 0
, O 0
we O 0
disrupted O 0
mouse O 0
Six5 O 0
by O 0
replacing O 0
the O 0
first O 0
exon O 0
with O 0
a O 0
beta O 0
- O 0
galactosidase O 0
reporter O 0
. O 0

Six5 O 0
- O 0
mutant O 0
mice O 0
showed O 0
reporter O 0
expression O 0
in O 0
multiple O 0
tissues O 0
, O 0
including O 0
the O 0
developing O 0
lens O 0
. O 0

Homozygous O 0
mutant O 0
mice O 0
had O 0
no O 0
apparent O 0
abnormalities B-Disease 0
of I-Disease 0
skeletal I-Disease 0
muscle I-Disease 0
function I-Disease 0
, O 0
but O 0
developed O 0
lenticular B-Disease 1
opacities I-Disease 1
at O 0
a O 0
higher O 0
rate O 0
than O 0
controls O 0
. O 0

Our O 0
results O 0
suggest O 0
that O 0
SIX5 B-Disease 1
deficiency I-Disease 1
contributes O 0
to O 0
the O 0
cataract B-Disease 0
phenotype O 0
in O 0
myotonic B-Disease 1
dystrophy I-Disease 1
, O 0
and O 0
that O 0
myotonic B-Disease 1
dystrophy I-Disease 1
represents O 0
a O 0
multigenic B-Disease 0
disorder I-Disease 0
. O 0
. O 0

Heterozygous O 0
loss O 0
of O 0
Six5 O 0
in O 0
mice O 0
is O 0
sufficient O 0
to O 0
cause O 0
ocular O 0
cataracts B-Disease 1
. O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
is O 0
an O 0
autosomal B-Disease 0
dominant I-Disease 0
disorder I-Disease 0
characterized O 0
by O 0
skeletal O 0
muscle B-Disease 1
wasting I-Disease 1
, O 0
myotonia B-Disease 1
, O 0
cardiac B-Disease 1
arrhythmia I-Disease 1
, O 0
hyperinsulinaemia B-Disease 1
, O 0
mental B-Disease 1
retardation I-Disease 1
and O 0
ocular O 0
cataracts B-Disease 1
. O 0

The O 0
genetic B-Disease 1
defect I-Disease 1
in O 0
DM B-Disease 0
is O 0
a O 0
CTG O 0
repeat O 0
expansion O 0
located O 0
in O 0
the O 0
3 O 0
untranslated O 0
region O 0
of O 0
DMPK O 0
and O 0
5 O 0
of O 0
a O 0
homeodomain O 0
- O 0
encoding O 0
gene O 0
, O 0
SIX5 O 0
( O 0
formerly O 0
DMAHP O 0
; O 0
refs O 0
2 O 0
- O 0
5 O 0
) O 0
. O 0

There O 0
are O 0
three O 0
mechanisms O 0
by O 0
which O 0
CTG O 0
expansion O 0
can O 0
result O 0
in O 0
DM B-Disease 0
. O 0

First O 0
, O 0
repeat O 0
expansion O 0
may O 0
alter O 0
the O 0
processing O 0
or O 0
transport O 0
of O 0
the O 0
mutant O 0
DMPK O 0
mRNA O 0
and O 0
consequently O 0
reduce O 0
DMPK O 0
levels O 0
. O 0

Second O 0
, O 0
CTG O 0
expansion O 0
may O 0
establish O 0
a O 0
region O 0
of O 0
heterochromatin O 0
3 O 0
of O 0
the O 0
repeat O 0
sequence O 0
and O 0
decrease O 0
SIX5 O 0
transcription O 0
. O 0

Third O 0
, O 0
toxic O 0
effects O 0
of O 0
the O 0
repeat O 0
expansion O 0
may O 0
be O 0
intrinsic O 0
to O 0
the O 0
repeated O 0
elements O 0
at O 0
the O 0
level O 0
of O 0
DNA O 0
or O 0
RNA O 0
( O 0
refs O 0
10 O 0
, O 0
11 O 0
) O 0
. O 0

Previous O 0
studies O 0
have O 0
demonstrated O 0
that O 0
a O 0
dose O 0
- O 0
dependent O 0
loss O 0
of O 0
Dm15 O 0
( O 0
the O 0
mouse O 0
DMPK O 0
homologue O 0
) O 0
in O 0
mice O 0
produces O 0
a O 0
partial O 0
DM B-Disease 0
phenotype O 0
characterized O 0
by O 0
decreased O 0
development O 0
of O 0
skeletal O 0
muscle O 0
force O 0
and O 0
cardiac B-Disease 1
conduction I-Disease 1
disorders I-Disease 1
. O 0

To O 0
test O 0
the O 0
role O 0
of O 0
Six5 O 0
loss O 0
in O 0
DM B-Disease 0
, O 0
we O 0
have O 0
analysed O 0
a O 0
strain O 0
of O 0
mice O 0
in O 0
which O 0
Six5 O 0
was O 0
deleted O 0
. O 0

Our O 0
results O 0
demonstrate O 0
that O 0
the O 0
rate O 0
and O 0
severity O 0
of O 0
cataract B-Disease 0
formation O 0
is O 0
inversely O 0
related O 0
to O 0
Six5 O 0
dosage O 0
and O 0
is O 0
temporally O 0
progressive O 0
. O 0

Six5 O 0
+ O 0
/ O 0
- O 0
and O 0
Six5 O 0
- O 0
/ O 0
- O 0
mice O 0
show O 0
increased O 0
steady O 0
- O 0
state O 0
levels O 0
of O 0
the O 0
Na O 0
+ O 0
/ O 0
K O 0
+ O 0
- O 0
ATPase O 0
alpha O 0
- O 0
1 O 0
subunit O 0
and O 0
decreased O 0
Dm15 O 0
mRNA O 0
levels O 0
. O 0

Thus O 0
, O 0
altered O 0
ion O 0
homeostasis O 0
within O 0
the O 0
lens O 0
may O 0
contribute O 0
to O 0
cataract B-Disease 0
formation O 0
. O 0

As O 0
ocular O 0
cataracts B-Disease 1
are O 0
a O 0
characteristic O 0
feature O 0
of O 0
DM B-Disease 0
, O 0
these O 0
results O 0
demonstrate O 0
that O 0
decreased O 0
SIX5 O 0
transcription O 0
is O 0
important O 0
in O 0
the O 0
aetiology O 0
of O 0
DM B-Disease 0
. O 0

Our O 0
data O 0
support O 0
the O 0
hypothesis O 0
that O 0
DM B-Disease 0
is O 0
a O 0
contiguous O 1
gene O 1
syndrome O 1
associated O 0
with O 0
the O 0
partial O 0
loss O 0
of O 0
both O 0
DMPK O 0
and O 0
SIX5 O 0
. O 0
. O 0

ATM O 0
- O 0
dependent O 0
phosphorylation O 0
of O 0
nibrin O 0
in O 0
response O 0
to O 0
radiation O 0
exposure O 0
. O 0

Mutations O 0
in O 0
the O 0
gene O 0
ATM O 0
are O 0
responsible O 0
for O 0
the O 0
genetic B-Disease 0
disorder I-Disease 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
( O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
) O 0
, O 0
which O 0
is O 0
characterized O 0
by O 0
cerebellar B-Disease 0
dysfunction I-Disease 0
, O 0
radiosensitivity O 0
, O 0
chromosomal O 0
instability O 0
and O 0
cancer B-Disease 1
predisposition O 0
. O 0

Both O 0
the O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
phenotype O 0
and O 0
the O 0
similarity O 0
of O 0
the O 0
ATM O 0
protein O 0
to O 0
other O 0
DNA O 0
- O 0
damage O 0
sensors O 0
suggests O 0
a O 0
role O 0
for O 0
ATM O 0
in O 0
biochemical O 0
pathways O 0
involved O 0
in O 0
the O 0
recognition O 0
, O 0
signalling O 0
and O 0
repair O 0
of O 0
DNA O 0
double O 0
- O 0
strand O 0
breaks O 0
( O 0
DSBs O 0
) O 0
. O 0

There O 0
are O 0
strong O 0
parallels O 0
between O 0
the O 0
pattern O 0
of O 0
radiosensitivity O 0
, O 0
chromosomal O 0
instability O 0
and O 0
cancer B-Disease 1
predisposition O 0
in O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
patients O 0
and O 0
that O 0
in O 0
patients O 0
with O 0
Nijmegen B-Disease 0
breakage I-Disease 0
syndrome I-Disease 0
( O 0
NBS B-Disease 0
) O 0
. O 0

The O 0
protein O 0
defective O 0
in O 0
NBS B-Disease 0
, O 0
nibrin O 0
( O 0
encoded O 0
by O 0
NBS1 O 0
) O 0
, O 0
forms O 0
a O 0
complex O 0
with O 0
MRE11 O 0
and O 0
RAD50 O 0
( O 0
refs O 0
1 O 0
, O 0
2 O 0
) O 0
. O 0

This O 0
complex O 0
localizes O 0
to O 0
DSBs O 0
within O 0
30 O 0
minutes O 0
after O 0
cellular O 0
exposure O 0
to O 0
ionizing O 0
radiation O 0
( O 0
IR O 0
) O 0
and O 0
is O 0
observed O 0
in O 0
brightly O 0
staining O 0
nuclear O 0
foci O 0
after O 0
a O 0
longer O 0
period O 0
of O 0
time O 0
. O 0

The O 0
overlap O 0
between O 0
clinical O 0
and O 0
cellular O 0
phenotypes O 0
in O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
and O 0
NBS B-Disease 0
suggests O 0
that O 0
ATM O 0
and O 0
nibrin O 0
may O 0
function O 0
in O 0
the O 0
same O 0
biochemical O 0
pathway O 0
. O 0

Here O 0
we O 0
demonstrate O 0
that O 0
nibrin O 0
is O 0
phosphorylated O 0
within O 0
one O 0
hour O 0
of O 0
treatment O 0
of O 0
cells O 0
with O 0
IR O 0
. O 0

This O 0
response O 0
is O 0
abrogated O 0
in O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
cells O 0
that O 0
either O 0
do O 0
not O 0
express O 0
ATM O 0
protein O 0
or O 0
express O 0
near O 0
full O 0
- O 0
length O 0
mutant O 0
protein O 0
. O 0

We O 0
also O 0
show O 0
that O 0
ATM O 0
physically O 0
interacts O 0
with O 0
and O 0
phosphorylates O 0
nibrin O 0
on O 0
serine O 0
343 O 0
both O 0
in O 0
vivo O 0
and O 0
in O 0
vitro O 0
. O 0

Phosphorylation O 0
of O 0
this O 0
site O 0
appears O 0
to O 0
be O 0
functionally O 0
important O 0
because O 0
mutated O 0
nibrin O 0
( O 0
S343A O 0
) O 0
does O 0
not O 0
completely O 0
complement O 0
radiosensitivity O 0
in O 0
NBS B-Disease 0
cells O 0
. O 0

ATM O 0
phosphorylation O 0
of O 0
nibrin O 0
does O 0
not O 0
affect O 0
nibrin O 0
- O 0
MRE11 O 0
- O 0
RAD50 O 0
association O 0
as O 0
revealed O 0
by O 0
radiation O 0
- O 0
induced O 0
foci O 0
formation O 0
. O 0

Our O 0
data O 0
provide O 0
a O 0
biochemical O 0
explanation O 0
for O 0
the O 0
similarity O 0
in O 0
phenotype O 0
between O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
and O 0
NBS B-Disease 0
. O 0
. O 0

Clinicopathologic O 0
features O 0
of O 0
BRCA B-Disease 1
- I-Disease 1
linked I-Disease 1
and I-Disease 1
sporadic I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
. O 0

CONTEXT O 0
Most O 0
hereditary B-Disease 0
ovarian I-Disease 1
cancers I-Disease 1
are O 0
associated O 0
with O 0
germline O 0
mutations O 0
in O 0
BRCA1 O 0
or O 0
BRCA2 O 0
. O 0

Attempts O 0
to O 0
define O 0
the O 0
clinical O 0
significance O 0
of O 0
BRCA O 0
mutation O 0
status O 0
in O 0
ovarian B-Disease 0
cancer I-Disease 1
have O 0
produced O 0
conflicting O 0
results O 0
, O 0
especially O 0
regarding O 0
survival O 0
. O 0

OBJECTIVE O 0
To O 0
determine O 0
whether O 0
hereditary B-Disease 0
ovarian I-Disease 1
cancers I-Disease 1
have O 0
distinct O 0
clinical O 0
and O 0
pathological O 0
features O 0
compared O 0
with O 0
sporadic B-Disease 1
( I-Disease 1
nonhereditary I-Disease 1
) I-Disease 1
ovarian I-Disease 1
cancers I-Disease 1
. O 0

DESIGN O 0
AND O 0
SETTING O 0
Retrospective O 0
cohort O 0
study O 0
of O 0
a O 0
consecutive O 0
series O 0
of O 0
933 O 0
ovarian B-Disease 1
cancers I-Disease 1
diagnosed O 0
and O 0
treated O 0
at O 0
our O 0
institution O 0
, O 0
which O 0
is O 0
a O 0
comprehensive O 0
cancer B-Disease 1
center O 0
as O 0
designated O 0
by O 0
the O 0
National O 0
Cancer B-Disease 1
Institute O 0
, O 0
over O 0
a O 0
12 O 0
- O 0
year O 0
period O 0
( O 0
December O 0
1986 O 0
to O 0
August O 0
1998 O 0
) O 0
. O 0

PATIENTS O 0
The O 0
study O 0
was O 0
restricted O 0
to O 0
patients O 0
of O 0
Jewish O 0
origin O 0
because O 0
of O 0
the O 0
ease O 0
of O 0
BRCA1 O 0
and O 0
BRCA2 O 0
genotyping O 0
in O 0
this O 0
ethnic O 0
group O 0
. O 0

From O 0
the O 0
189 O 0
patients O 0
who O 0
identified O 0
themselves O 0
as O 0
Jewish O 0
, O 0
88 O 0
hereditary O 0
cases O 0
were O 0
identified O 0
with O 0
the O 0
presence O 0
of O 0
a O 0
germline O 0
founder O 0
mutation O 0
in O 0
BRCA1 O 0
or O 0
BRCA2 O 0
. O 0

The O 0
remaining O 0
101 O 0
cases O 0
from O 0
the O 0
same O 0
series O 0
not O 0
associated O 0
with O 0
a O 0
BRCA O 0
mutation O 0
and O 0
2 O 0
additional O 0
groups O 0
( O 0
Gynecologic O 0
Oncology O 0
Group O 0
protocols O 0
52 O 0
and O 0
111 O 0
) O 0
with O 0
ovarian B-Disease 0
cancer I-Disease 1
from O 0
clinical O 0
trials O 0
( O 0
for O 0
the O 0
survival O 0
analysis O 0
) O 0
were O 0
included O 0
for O 0
comparison O 0
. O 0

MAIN O 0
OUTCOME O 0
MEASURES O 0
Age O 0
at O 0
diagnosis O 0
, O 0
surgical O 0
stage O 0
, O 0
histologic O 0
cell O 0
type O 0
and O 0
grade O 0
, O 0
and O 0
surgical O 0
outcome O 0
; O 0
and O 0
response O 0
to O 0
chemotherapy O 0
and O 0
survival O 0
for O 0
advanced O 0
- O 0
stage O 0
( O 0
II O 0
and O 0
IV O 0
) O 0
cases O 0
. O 0

RESULTS O 0
Hereditary B-Disease 0
cancers I-Disease 0
were O 0
rarely O 0
diagnosed O 0
before O 0
age O 0
40 O 0
years O 0
and O 0
were O 0
common O 0
after O 0
age O 0
60 O 0
years O 0
, O 0
with O 0
mean O 0
age O 0
at O 0
diagnosis O 0
being O 0
significantly O 0
younger O 0
for O 0
BRCA1 O 0
- O 0
vs O 0
BRCA2 O 0
- O 0
linked O 0
patients O 0
( O 0
54 O 0
vs O 0
62 O 0
years O 0
; O 0
P O 0
= O 0
. O 0
04 O 0
) O 0
. O 0

Histology O 0
, O 0
grade O 0
, O 0
stage O 0
, O 0
and O 0
success O 0
of O 0
cytoreductive O 0
surgery O 0
were O 0
similar O 0
for O 0
hereditary O 0
and O 0
sporadic O 0
cases O 0
. O 0

The O 0
hereditary O 0
group O 0
had O 0
a O 0
longer O 0
disease O 0
- O 0
free O 0
interval O 0
following O 0
primary O 0
chemotherapy O 0
in O 0
comparison O 0
with O 0
the O 0
nonhereditary O 0
group O 0
, O 0
with O 0
a O 0
median O 0
time O 0
to O 0
recurrence O 0
of O 0
14 O 0
months O 0
and O 0
7 O 0
months O 0
, O 0
respectively O 0
( O 0
P O 0
< O 0
. O 0
001 O 0
) O 0
. O 0

Those O 0
with O 0
hereditary B-Disease 1
cancers I-Disease 1
had O 0
improved O 0
survival O 0
compared O 0
with O 0
the O 0
nonhereditary O 0
group O 0
( O 0
P O 0
= O 0
. O 0
004 O 0
) O 0
. O 0

For O 0
stage B-Disease 1
III I-Disease 1
cancers I-Disease 1
, O 0
BRCA O 0
mutation O 0
status O 0
was O 0
an O 0
independent O 0
prognostic O 0
variable O 0
( O 0
P O 0
= O 0
. O 0
03 O 0
) O 0
. O 0

CONCLUSIONS O 0
Although O 0
BRCA B-Disease 1
- I-Disease 1
associated I-Disease 1
hereditary I-Disease 1
ovarian I-Disease 1
cancers I-Disease 1
in O 0
this O 0
population O 0
have O 0
surgical O 0
and O 0
pathological O 0
characteristics O 0
similar O 0
to O 0
those O 0
of O 0
sporadic B-Disease 0
cancers I-Disease 0
, O 0
advanced B-Disease 1
- I-Disease 1
stage I-Disease 1
hereditary I-Disease 1
cancer I-Disease 1
patients O 0
survive O 0
longer O 0
than O 0
nonhereditary B-Disease 0
cancer I-Disease 1
patients O 0
. O 0

Age O 0
penetrance O 0
is O 0
greater O 0
for O 0
BRCA1 B-Disease 0
- I-Disease 0
linked I-Disease 0
than I-Disease 0
for I-Disease 0
BRCA2 I-Disease 0
- I-Disease 0
linked I-Disease 0
cancers I-Disease 0
in O 0
this O 0
population O 0
. O 0

The O 0
gene O 0
for O 0
familial B-Disease 0
Mediterranean I-Disease 0
fever I-Disease 0
, O 0
MEFV O 0
, O 0
is O 0
expressed O 0
in O 0
early O 0
leukocyte O 0
development O 0
and O 0
is O 0
regulated O 0
in O 0
response O 0
to O 0
inflammatory O 0
mediators O 0
. O 0

Familial B-Disease 1
Mediterranean I-Disease 1
fever I-Disease 1
( O 0
FMF B-Disease 0
) O 0
is O 0
a O 0
recessive B-Disease 0
disorder I-Disease 0
characterized O 0
by O 0
episodes O 0
of O 0
fever B-Disease 0
and O 0
neutrophil B-Disease 0
- I-Disease 0
mediated I-Disease 0
serosal I-Disease 0
inflammation I-Disease 0
. O 0

We O 0
recently O 0
identified O 0
the O 0
gene O 0
causing O 0
FMF B-Disease 0
, O 0
designated O 0
MEFV O 0
, O 0
and O 0
found O 0
it O 0
to O 0
be O 0
expressed O 0
in O 0
mature O 0
neutrophils O 0
, O 0
suggesting O 0
that O 0
it O 0
functions O 0
as O 0
an O 0
inflammatory O 0
regulator O 0
. O 0

To O 0
facilitate O 0
our O 0
understanding O 0
of O 0
the O 0
normal O 0
function O 0
of O 0
MEFV O 0
, O 0
we O 0
extended O 0
our O 0
previous O 0
studies O 0
. O 0

MEFV O 0
messenger O 0
RNA O 0
was O 0
detected O 0
by O 0
reverse O 0
transcriptase O 0
- O 0
polymerase O 0
chain O 0
reaction O 0
in O 0
bone O 0
marrow O 0
leukocytes O 0
, O 0
with O 0
differential O 0
expression O 0
observed O 0
among O 0
cells O 0
by O 0
in O 0
situ O 0
hybridization O 0
. O 0

CD34 O 0
hematopoietic O 0
stem O 0
- O 0
cell O 0
cultures O 0
induced O 0
toward O 0
the O 0
granulocytic O 0
lineage O 0
expressed O 0
MEFV O 0
at O 0
the O 0
myelocyte O 0
stage O 0
, O 0
concurrently O 0
with O 0
lineage O 0
commitment O 0
. O 0

The O 0
prepromyelocytic O 0
cell O 0
line O 0
HL60 O 0
expressed O 0
MEFV O 0
only O 0
at O 0
granulocytic O 0
and O 0
monocytic O 0
differentiation O 0
. O 0

MEFV O 0
was O 0
also O 0
expressed O 0
in O 0
the O 0
monocytic O 0
cell O 0
lines O 0
U937 O 0
and O 0
THP O 0
- O 0
1 O 0
. O 0

Among O 0
peripheral O 0
blood O 0
leukocytes O 0
, O 0
MEFV O 0
expression O 0
was O 0
detected O 0
in O 0
neutrophils O 0
, O 0
eosinophils O 0
, O 0
and O 0
to O 0
varying O 0
degrees O 0
, O 0
monocytes O 0
. O 0

Consistent O 0
with O 0
the O 0
tissue O 0
specificity O 0
of O 0
expression O 0
, O 0
complete O 0
sequencing O 0
and O 0
analysis O 0
of O 0
upstream O 0
regulatory O 0
regions O 0
of O 0
MEFV O 0
revealed O 0
homology O 0
to O 0
myeloid O 0
- O 0
specific O 0
promoters O 0
and O 0
to O 0
more O 0
broadly O 0
expressed O 0
inflammatory O 0
promoter O 0
elements O 0
. O 0

In O 0
vitro O 0
stimulation O 0
of O 0
monocytes O 0
with O 0
the O 0
proinflammatory O 0
agents O 0
interferon O 0
( O 0
IFN O 0
) O 0
gamma O 0
, O 0
tumor B-Disease 0
necrosis O 0
factor O 0
, O 0
and O 0
lipopolysaccharide O 0
induced O 0
MEFV O 0
expression O 0
, O 0
whereas O 0
the O 0
antiinflammatory O 0
cytokines O 0
interleukin O 0
( O 0
IL O 0
) O 0
4 O 0
, O 0
IL O 0
- O 0
10 O 0
, O 0
and O 0
transforming O 0
growth O 0
factor O 0
beta O 0
inhibited O 0
such O 0
expression O 0
. O 0

Induction O 0
by O 0
IFN O 0
- O 0
gamma O 0
occurred O 0
rapidly O 0
and O 0
was O 0
resistant O 0
to O 0
cycloheximide O 0
. O 0

IFN O 0
- O 0
alpha O 0
also O 0
induced O 0
MEFV O 0
expression O 0
. O 0

In O 0
granulocytes O 0
, O 0
MEFV O 0
was O 0
up O 0
- O 0
regulated O 0
by O 0
IFN O 0
- O 0
gamma O 0
and O 0
the O 0
combination O 0
of O 0
IFN O 0
- O 0
alpha O 0
and O 0
colchicine O 0
. O 0

These O 0
results O 0
refine O 0
understanding O 0
of O 0
MEFV O 0
by O 0
placing O 0
the O 0
gene O 0
in O 0
the O 0
myelomonocytic O 0
- O 0
specific O 0
proinflammatory O 0
pathway O 0
and O 0
identifying O 0
it O 0
as O 0
an O 0
IFN O 0
- O 0
gamma O 0
immediate O 0
early O 0
gene O 0
. O 0
. O 0

Biochemical O 0
and O 0
structural O 0
analysis O 0
of O 0
missense O 0
mutations O 0
in O 0
N O 0
- O 0
acetylgalactosamine O 0
- O 0
6 O 0
- O 0
sulfate O 0
sulfatase O 0
causing O 0
mucopolysaccharidosis B-Disease 1
IVA I-Disease 1
phenotypes O 0
. O 0

Mucopolysaccharidosis B-Disease 0
IVA I-Disease 0
( O 0
MPS B-Disease 1
IVA I-Disease 1
; O 0
OMIM O 0
# O 0
253000 O 0
) O 0
, O 0
a O 0
lysosomal B-Disease 0
storage I-Disease 0
disorder I-Disease 0
caused O 0
by O 0
a O 0
deficiency B-Disease 1
of I-Disease 1
N I-Disease 1
- I-Disease 1
acetylgalactosamine I-Disease 1
- I-Disease 1
6 I-Disease 1
- I-Disease 1
sulfate I-Disease 1
sulfatase I-Disease 1
( O 0
GALNS O 0
) O 0
, O 0
has O 0
variable O 0
clinical O 0
phenotypes O 0
. O 0

To O 0
date O 0
we O 0
have O 0
identified O 0
65 O 0
missense O 0
mutations O 0
in O 0
the O 0
GALNS O 0
gene O 0
from O 0
MPS B-Disease 1
IVA I-Disease 1
patients O 0
, O 0
but O 0
the O 0
correlation O 0
between O 0
genotype O 0
and O 0
phenotype O 0
has O 0
remained O 0
unclear O 0
. O 0

We O 0
studied O 0
17 O 0
missense O 0
mutations O 0
using O 0
biochemical O 0
approaches O 0
and O 0
32 O 0
missense O 0
mutations O 0
, O 0
using O 0
structural O 0
analyses O 0
. O 0

Fifteen O 0
missense O 0
mutations O 0
and O 0
two O 0
newly O 0
engineered O 0
active O 0
site O 0
mutations O 0
( O 0
C79S O 0
, O 0
C79T O 0
) O 0
were O 0
characterized O 0
by O 0
transient O 0
expression O 0
analysis O 0
. O 0

Mutant O 0
proteins O 0
, O 0
except O 0
for O 0
C79S O 0
and O 0
C79T O 0
, O 0
were O 0
destabilized O 0
and O 0
detected O 0
as O 0
insoluble O 0
precursor O 0
forms O 0
while O 0
the O 0
C79S O 0
and O 0
C79T O 0
mutants O 0
were O 0
of O 0
a O 0
soluble O 0
mature O 0
size O 0
. O 0

Mutants O 0
found O 0
in O 0
the O 0
severe O 0
phenotype O 0
had O 0
no O 0
activity O 0
. O 0

Mutants O 0
found O 0
in O 0
the O 0
mild O 0
phenotype O 0
had O 0
a O 0
considerable O 0
residual O 0
activity O 0
( O 0
1 O 0
. O 0
3 O 0
- O 0
13 O 0
. O 0
3 O 0
% O 0
of O 0
wild O 0
- O 0
type O 0
GALNS O 0
activity O 0
) O 0
. O 0

Sulfatases O 0
, O 0
including O 0
GALNS O 0
, O 0
are O 0
members O 0
of O 0
a O 0
highly O 0
conserved O 0
gene O 0
family O 0
sharing O 0
an O 0
extensive O 0
sequence O 0
homology O 0
. O 0

Thus O 0
, O 0
a O 0
tertiary O 0
structural O 0
model O 0
of O 0
human O 0
GALNS O 0
was O 0
constructed O 0
from O 0
the O 0
X O 0
- O 0
ray O 0
crystal O 0
structure O 0
of O 0
N O 0
- O 0
acetylgalacto O 0
- O 0
samine O 0
- O 0
4 O 0
- O 0
sulfatase O 0
and O 0
arylsulfatase O 0
A O 0
, O 0
using O 0
homology O 0
modeling O 0
, O 0
and O 0
32 O 0
missense O 0
mutations O 0
were O 0
investigated O 0
. O 0

Consequently O 0
, O 0
we O 0
propose O 0
that O 0
there O 0
are O 0
at O 0
least O 0
three O 0
different O 0
reasons O 0
for O 0
the O 0
severe O 0
phenotype O 0
( O 0
i O 0
) O 0
destruction O 0
of O 0
the O 0
hydrophobic O 0
core O 0
or O 0
modification O 0
of O 0
the O 0
packing O 0
; O 0
( O 0
ii O 0
) O 0
removal O 0
of O 0
a O 0
salt O 0
bridge O 0
to O 0
destabilize O 0
the O 0
entire O 0
conformation O 0
; O 0
( O 0
iii O 0
) O 0
modification O 0
of O 0
the O 0
active O 0
site O 0
. O 0

In O 0
contrast O 0
, O 0
mild O 0
mutations O 0
were O 0
mostly O 0
located O 0
on O 0
the O 0
surface O 0
of O 0
the O 0
GALNS O 0
protein O 0
. O 0

These O 0
studies O 0
shed O 0
further O 0
light O 0
on O 0
the O 0
genotype O 0
- O 0
phenotype O 0
correlation O 0
of O 0
MPS B-Disease 1
IVA I-Disease 1
and O 0
structure O 0
- O 0
function O 0
relationship O 0
in O 0
the O 0
sulfatase O 0
family O 0
. O 0

Mutations O 0
at O 0
the O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
locus O 0
and O 0
clinical O 0
phenotypes O 0
of O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
patients O 0
. O 0

Mutations O 0
at O 0
the O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
( O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
) O 0
locus O 0
on O 0
chromosome O 0
band O 0
11q22 O 0
cause O 0
a O 0
distinctive O 0
autosomal B-Disease 1
recessive I-Disease 1
syndrome I-Disease 1
in O 0
homozygotes O 0
and O 0
predispose O 0
heterozygotes O 0
to O 0
cancer B-Disease 1
, O 0
ischemic B-Disease 1
heart I-Disease 1
disease I-Disease 1
, O 0
and O 0
early O 0
mortality O 0
. O 0

PCR O 0
amplification O 0
from O 0
genomic O 0
DNA O 0
and O 0
automated O 0
sequencing O 0
of O 0
the O 0
entire O 0
coding O 0
region O 0
( O 0
66 O 0
exons O 0
) O 0
and O 0
splice O 0
junctions O 0
detected O 0
77 O 0
mutations O 0
( O 0
85 O 0
% O 0
) O 0
in O 0
90 O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
chromosomes O 0
. O 0

Heteroduplex O 0
analysis O 0
detected O 0
another O 0
42 O 0
mutations O 0
at O 0
the O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
locus O 0
. O 0

Out O 0
of O 0
a O 0
total O 0
of O 0
71 O 0
unique O 0
mutations O 0
, O 0
50 O 0
were O 0
found O 0
only O 0
in O 0
a O 0
single O 0
family O 0
, O 0
and O 0
51 O 0
had O 0
not O 0
been O 0
reported O 0
previously O 0
. O 0

Most O 0
( O 0
58 O 0
/ O 0
71 O 0
, O 0
82 O 0
% O 0
) O 0
mutations O 0
were O 0
frameshift O 0
and O 0
nonsense O 0
mutations O 0
that O 0
are O 0
predicted O 0
to O 0
cause O 0
truncation O 0
of O 0
the O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
protein O 0
; O 0
the O 0
less O 0
common O 0
mutation O 0
types O 0
were O 0
missense O 0
( O 0
9 O 0
/ O 0
71 O 0
, O 0
13 O 0
% O 0
) O 0
, O 0
splicing O 0
( O 0
3 O 0
/ O 0
71 O 0
, O 0
4 O 0
% O 0
) O 0
and O 0
one O 0
in O 0
- O 0
frame O 0
deletion O 0
, O 0
2546 O 0
3 O 0
( O 0
1 O 0
/ O 0
71 O 0
, O 0
1 O 0
% O 0
) O 0
. O 0

The O 0
mean O 0
survival O 0
and O 0
height O 0
distribution O 0
of O 0
134 O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
patients O 0
correlated O 0
significantly O 0
with O 0
the O 0
specific O 0
mutations O 0
present O 0
in O 0
the O 0
patients O 0
. O 0

Patients O 0
homozygous O 0
for O 0
a O 0
single O 0
truncating O 0
mutation O 0
, O 0
typically O 0
near O 0
the O 0
N O 0
- O 0
terminal O 0
end O 0
of O 0
the O 0
gene O 0
, O 0
or O 0
heterozygous O 0
for O 0
the O 0
in O 0
- O 0
frame O 0
deletion O 0
2546 O 0
3 O 0
, O 0
were O 0
shorter O 0
and O 0
had O 0
significantly O 0
shorter O 0
survival O 0
than O 0
those O 0
heterozygous O 0
for O 0
a O 0
splice O 0
site O 0
or O 0
missense O 0
mutation O 0
, O 0
or O 0
heterozygous O 0
for O 0
two O 0
truncating O 0
mutations O 0
. O 0

Alterations O 0
of O 0
the O 0
length O 0
or O 0
amino O 0
acid O 0
composition O 0
of O 0
the O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
gene O 0
product O 0
affect O 0
the O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
clinical O 0
phenotype O 0
in O 0
different O 0
ways O 0
. O 0

Mutation O 0
analysis O 0
at O 0
the O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
locus O 0
may O 0
help O 0
estimate O 0
the O 0
prognosis O 0
of O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
patients O 0
. O 0
. O 0

Isolation O 0
, O 0
genomic O 0
organization O 0
, O 0
and O 0
expression O 0
analysis O 0
of O 0
the O 0
mouse O 0
and O 0
rat O 0
homologs O 0
of O 0
MEFV O 0
, O 0
the O 0
gene O 0
for O 0
familial B-Disease 1
mediterranean I-Disease 1
fever I-Disease 1
. O 0

Familial B-Disease 1
Mediterranean I-Disease 1
fever I-Disease 1
( O 0
FMF B-Disease 0
) O 0
is O 0
a O 0
recessive B-Disease 0
disorder I-Disease 0
characterized O 0
by O 0
episodes O 0
of O 0
fever B-Disease 0
with O 0
serositis B-Disease 1
or O 0
synovitis B-Disease 1
. O 0

Recently O 0
the O 0
FMF B-Disease 0
gene O 0
( O 0
MEFV O 0
) O 0
was O 0
cloned O 0
; O 0
the O 0
protein O 0
product O 0
, O 0
pyrin O 0
/ O 0
marenostrin O 0
, O 0
is O 0
thought O 0
to O 0
regulate O 0
inflammation O 0
in O 0
myeloid O 0
cells O 0
. O 0

In O 0
this O 0
manuscript O 0
we O 0
report O 0
the O 0
mouse O 0
and O 0
rat O 0
homologs O 0
of O 0
MEFV O 0
. O 0

The O 0
murine O 0
gene O 0
contains O 0
ten O 0
exons O 0
with O 0
a O 0
coding O 0
sequence O 0
of O 0
2304 O 0
bp O 0
, O 0
while O 0
the O 0
rat O 0
homolog O 0
has O 0
nine O 0
exons O 0
with O 0
a O 0
coding O 0
sequence O 0
of O 0
2253 O 0
bp O 0
. O 0

A O 0
considerable O 0
amino O 0
acid O 0
sequence O 0
homology O 0
was O 0
observed O 0
between O 0
the O 0
mouse O 0
and O 0
human O 0
( O 0
47 O 0
. O 0
6 O 0
% O 0
identity O 0
and O 0
65 O 0
. O 0
5 O 0
% O 0
similarity O 0
) O 0
and O 0
between O 0
the O 0
mouse O 0
and O 0
rat O 0
genes O 0
( O 0
73 O 0
. O 0
5 O 0
% O 0
identity O 0
and O 0
82 O 0
. O 0
1 O 0
% O 0
similarity O 0
) O 0
. O 0

The O 0
predicted O 0
rodent O 0
proteins O 0
have O 0
several O 0
important O 0
domains O 0
and O 0
signals O 0
found O 0
in O 0
human O 0
pyrin O 0
, O 0
including O 0
a O 0
B O 0
- O 0
box O 0
zinc O 0
finger O 0
domain O 0
, O 0
Robbins O 0
- O 0
Dingwall O 0
nuclear O 0
localization O 0
signal O 0
, O 0
and O 0
coiled O 0
- O 0
coil O 0
domain O 0
. O 0

However O 0
, O 0
perhaps O 0
because O 0
of O 0
an O 0
ancient O 0
frame O 0
- O 0
shift O 0
mutation O 0
, O 0
neither O 0
the O 0
mouse O 0
nor O 0
the O 0
rat O 0
protein O 0
has O 0
an O 0
intact O 0
C O 0
- O 0
terminal O 0
B30 O 0
. O 0

2 O 0
domain O 0
, O 0
in O 0
which O 0
most O 0
FMF B-Disease 0
- O 0
associated O 0
mutations O 0
have O 0
been O 0
found O 0
in O 0
human O 0
MEFV O 0
. O 0

Nevertheless O 0
, O 0
like O 0
the O 0
human O 0
gene O 0
, O 0
mouse O 0
Mefv O 0
is O 0
expressed O 0
in O 0
peripheral O 0
blood O 0
granulocytes O 0
but O 0
not O 0
lymphocytes O 0
. O 0

Consistent O 0
with O 0
its O 0
expression O 0
in O 0
granulocytes O 0
, O 0
Mefv O 0
was O 0
detected O 0
at O 0
high O 0
levels O 0
in O 0
the O 0
primary O 0
follicles O 0
and O 0
marginal O 0
zones O 0
of O 0
the O 0
splenic O 0
white O 0
pulp O 0
. O 0

Mefv O 0
is O 0
localized O 0
on O 0
mouse O 0
Chromosome O 0
( O 0
Chr O 0
) O 0
16 O 0
, O 0
region O 0
A3 O 0
- O 0
B1 O 0
, O 0
extending O 0
a O 0
region O 0
of O 0
synteny O 0
with O 0
human O 0
Chr O 0
16p13 O 0
. O 0

3 O 0
. O 0

Development O 0
of O 0
knockout O 0
and O 0
knockin O 0
mouse O 0
models O 0
may O 0
provide O 0
further O 0
insights O 0
into O 0
the O 0
functional O 0
evolution O 0
of O 0
this O 0
gene O 0
. O 0

Additional O 0
copies O 0
of O 0
the O 0
proteolipid O 0
protein O 0
gene O 0
causing O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
arise O 0
by O 0
separate O 0
integration O 0
into O 0
the O 0
X O 0
chromosome O 0
. O 0

The O 0
proteolipid O 0
protein O 0
gene O 0
( O 0
PLP O 0
) O 0
is O 0
normally O 0
present O 0
at O 0
chromosome O 0
Xq22 O 0
. O 0

Mutations O 0
and O 0
duplications O 0
of O 0
this O 0
gene O 0
are O 0
associated O 0
with O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
( O 0
PMD B-Disease 1
) O 0
. O 0

Here O 0
we O 0
describe O 0
two O 0
new O 0
families O 0
in O 0
which O 0
males O 0
affected O 0
with O 0
PMD B-Disease 1
were O 0
found O 0
to O 0
have O 0
a O 0
copy O 0
of O 0
PLP O 0
on O 0
the O 0
short O 0
arm O 0
of O 0
the O 0
X O 0
chromosome O 0
, O 0
in O 0
addition O 0
to O 0
a O 0
normal O 0
copy O 0
on O 0
Xq22 O 0
. O 0

In O 0
the O 0
first O 0
family O 0
, O 0
the O 0
extra O 0
copy O 0
was O 0
first O 0
detected O 0
by O 0
the O 0
presence O 0
of O 0
heterozygosity O 0
of O 0
the O 0
AhaII O 0
dimorphism O 0
within O 0
the O 0
PLP O 0
gene O 0
. O 0

The O 0
results O 0
of O 0
FISH O 0
analysis O 0
showed O 0
an O 0
additional O 0
copy O 0
of O 0
PLP O 0
in O 0
Xp22 O 0
. O 0

1 O 0
, O 0
although O 0
no O 0
chromosomal O 0
rearrangements O 0
could O 0
be O 0
detected O 0
by O 0
standard O 0
karyotype O 0
analysis O 0
. O 0

Another O 0
three O 0
affected O 0
males O 0
from O 0
the O 0
family O 0
had O 0
similar O 0
findings O 0
. O 0

In O 0
a O 0
second O 0
unrelated O 0
family O 0
with O 0
signs O 0
of O 0
PMD B-Disease 1
, O 0
cytogenetic O 0
analysis O 0
showed O 0
a O 0
pericentric O 0
inversion O 0
of O 0
the O 0
X O 0
chromosome O 0
. O 0

In O 0
the O 0
inv O 0
( O 0
X O 0
) O 0
carried O 0
by O 0
several O 0
affected O 0
family O 0
members O 0
, O 0
FISH O 0
showed O 0
PLP O 0
signals O 0
at O 0
Xp11 O 0
. O 0

4 O 0
and O 0
Xq22 O 0
. O 0

A O 0
third O 0
family O 0
has O 0
previously O 0
been O 0
reported O 0
, O 0
in O 0
which O 0
affected O 0
members O 0
had O 0
an O 0
extra O 0
copy O 0
of O 0
the O 0
PLP O 0
gene O 0
detected O 0
at O 0
Xq26 O 0
in O 0
a O 0
chromosome O 0
with O 0
an O 0
otherwise O 0
normal O 0
banding O 0
pattern O 0
. O 0

The O 0
identification O 0
of O 0
three O 0
separate O 0
families O 0
in O 0
which O 0
PLP O 0
is O 0
duplicated O 0
at O 0
a O 0
noncontiguous O 0
site O 0
suggests O 0
that O 0
such O 0
duplications O 0
could O 0
be O 0
a O 0
relatively O 0
common O 0
but O 0
previously O 0
undetected O 0
cause O 0
of O 0
genetic B-Disease 1
disorders I-Disease 1
. O 0

The O 0
exon O 0
13 O 0
duplication O 0
in O 0
the O 0
BRCA1 O 0
gene O 0
is O 0
a O 0
founder O 0
mutation O 0
present O 0
in O 0
geographically O 0
diverse O 0
populations O 0
. O 0

The O 0
BRCA1 O 0
Exon O 0
13 O 0
Duplication O 0
Screening O 0
Group O 0
. O 0

Recently O 0
, O 0
a O 0
6 O 0
- O 0
kb O 0
duplication O 0
of O 0
exon O 0
13 O 0
, O 0
which O 0
creates O 0
a O 0
frameshift O 0
in O 0
the O 0
coding O 0
sequence O 0
of O 0
the O 0
BRCA1 O 0
gene O 0
, O 0
has O 0
been O 0
described O 0
in O 0
three O 0
unrelated O 0
U O 0
. O 0

S O 0
S O 0
. O 0
families O 0
of O 0
European O 0
ancestry O 0
and O 0
in O 0
one O 0
Portuguese O 0
family O 0
. O 0

Here O 0
, O 0
our O 0
goal O 0
was O 0
to O 0
estimate O 0
the O 0
frequency O 0
and O 0
geographic O 0
diversity O 0
of O 0
carriers O 0
of O 0
this O 0
duplication O 0
. O 0

To O 0
do O 0
this O 0
, O 0
a O 0
collaborative O 0
screening O 0
study O 0
was O 0
set O 0
up O 0
that O 0
involved O 0
39 O 0
institutions O 0
from O 0
19 O 0
countries O 0
and O 0
included O 0
3 O 0
, O 0
580 O 0
unrelated O 0
individuals O 0
with O 0
a O 0
family O 0
history O 0
of O 0
the O 0
disease O 0
and O 0
934 O 0
early O 0
- O 0
onset O 0
breast B-Disease 1
and I-Disease 1
/ I-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
cases O 0
. O 0

A O 0
total O 0
of O 0
11 O 0
additional O 0
families O 0
carrying O 0
this O 0
mutation O 0
were O 0
identified O 0
in O 0
Australia O 0
( O 0
1 O 0
) O 0
, O 0
Belgium O 0
( O 0
1 O 0
) O 0
, O 0
Canada O 0
( O 0
1 O 0
) O 0
, O 0
Great O 0
Britain O 0
( O 0
6 O 0
) O 0
, O 0
and O 0
the O 0
United O 0
States O 0
( O 0
2 O 0
) O 0
. O 0

Haplotyping O 0
showed O 0
that O 0
they O 0
are O 0
likely O 0
to O 0
derive O 0
from O 0
a O 0
common O 0
ancestor O 0
, O 0
possibly O 0
of O 0
northern O 0
British O 0
origin O 0
. O 0

Our O 0
results O 0
demonstrate O 0
that O 0
it O 0
is O 0
strongly O 0
advisable O 0
, O 0
for O 0
laboratories O 0
carrying O 0
out O 0
screening O 0
either O 0
in O 0
English O 0
- O 0
speaking O 0
countries O 0
or O 0
in O 0
countries O 0
with O 0
historical O 0
links O 0
with O 0
Britain O 0
, O 0
to O 0
include O 0
within O 0
their O 0
BRCA1 O 0
screening O 0
protocols O 0
the O 0
polymerase O 0
chain O 0
reaction O 0
- O 0
based O 0
assay O 0
described O 0
in O 0
this O 0
report O 0
. O 0

Genotype O 0
- O 0
phenotype O 0
correlations O 0
in O 0
families O 0
with O 0
deletions O 0
in O 0
the O 0
von B-Disease 0
Hippel I-Disease 0
- I-Disease 0
Lindau I-Disease 0
( O 0
VHL B-Disease 1
) O 0
gene O 0
. O 0

Von B-Disease 0
Hippel I-Disease 0
- I-Disease 0
Lindau I-Disease 0
( I-Disease 0
VHL I-Disease 1
) I-Disease 0
disease I-Disease 0
is O 0
a O 0
hereditary B-Disease 1
tumor I-Disease 1
syndrome I-Disease 1
characterized O 0
by O 0
predisposition O 0
for O 0
bilateral B-Disease 1
and I-Disease 1
multi I-Disease 1
- I-Disease 1
centric I-Disease 1
hemangioblastoma I-Disease 1
in O 0
the O 0
retina O 0
and O 0
central O 0
nervous O 0
system O 0
, O 0
pheochromocytoma B-Disease 0
, O 0
renal B-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
, O 0
and O 0
cysts B-Disease 0
in I-Disease 0
the I-Disease 0
kidney I-Disease 0
, I-Disease 0
pancreas I-Disease 0
, I-Disease 0
and I-Disease 0
epididymis I-Disease 0
. O 0

We O 0
describe O 0
five O 0
families O 0
for O 0
which O 0
direct O 0
sequencing O 0
of O 0
the O 0
coding O 0
region O 0
of O 0
the O 0
VHL B-Disease 1
gene O 0
had O 0
failed O 0
to O 0
identify O 0
the O 0
family O 0
- O 0
specific O 0
mutation O 0
. O 0

Further O 0
molecular O 0
analysis O 0
revealed O 0
deletions O 0
involving O 0
the O 0
VHL B-Disease 1
gene O 0
in O 0
each O 0
of O 0
these O 0
families O 0
. O 0

In O 0
four O 0
families O 0
, O 0
partial O 0
deletions O 0
of O 0
one O 0
or O 0
more O 0
exons O 0
were O 0
detected O 0
by O 0
Southern O 0
blot O 0
analysis O 0
. O 0

In O 0
the O 0
fifth O 0
family O 0
, O 0
FISH O 0
analysis O 0
demonstrated O 0
the O 0
deletion O 0
of O 0
the O 0
entire O 0
VHL B-Disease 1
gene O 0
. O 0

Our O 0
results O 0
show O 0
that O 0
( O 0
quantitative O 0
) O 0
Southern O 0
blot O 0
analysis O 0
is O 0
a O 0
sensitive O 0
method O 0
for O 0
detecting O 0
germline O 0
deletions O 0
of O 0
the O 0
VHL B-Disease 1
gene O 0
and O 0
should O 0
be O 0
implemented O 0
in O 0
routine O 0
DNA O 0
diagnosis O 0
for O 0
VHL B-Disease 1
disease I-Disease 1
. O 0

Our O 0
data O 0
support O 0
the O 0
previously O 0
established O 0
observation O 0
that O 0
families O 0
with O 0
a O 0
germline O 0
deletion O 0
have O 0
a O 0
low O 0
risk O 0
for O 0
pheochromocytoma B-Disease 0
. O 0

Further O 0
unraveling O 0
of O 0
genotype O 0
- O 0
phenotype O 0
correlations O 0
in O 0
VHL B-Disease 1
disease I-Disease 1
has O 0
revealed O 0
that O 0
families O 0
with O 0
a O 0
full O 0
or O 0
partial O 0
deletion O 0
of O 0
the O 0
VHL B-Disease 1
gene O 0
exhibit O 0
a O 0
phenotype O 0
with O 0
a O 0
preponderance O 0
of O 0
central B-Disease 0
nervous I-Disease 0
system I-Disease 0
hemangioblastoma I-Disease 0
. O 0
. O 0

Age O 0
of O 0
the O 0
intronic O 0
GAA O 0
triplet O 0
repeat O 0
expansion O 0
mutation O 0
in O 0
Friedreich B-Disease 1
ataxia I-Disease 1
. O 0

Friedreich B-Disease 1
ataxia I-Disease 1
( O 0
FRDA B-Disease 0
) O 0
, O 0
the O 0
most O 0
frequently O 0
inherited B-Disease 0
ataxia I-Disease 0
, O 0
is O 0
due O 0
in O 0
the O 0
vast O 0
majority O 0
of O 0
cases O 0
to O 0
a O 0
large O 0
expansion O 0
of O 0
an O 0
intronic O 0
GAA O 0
repeat O 0
. O 0

Using O 0
linkage O 0
disequilibrium O 0
analysis O 0
based O 0
on O 0
haplotype O 0
data O 0
of O 0
seven O 0
polymorphic O 0
markers O 0
close O 0
to O 0
the O 0
frataxin O 0
gene O 0
, O 0
the O 0
age O 0
of O 0
FRDA B-Disease 0
founding O 0
mutational O 0
event O 0
( O 0
s O 0
) O 0
is O 0
estimated O 0
to O 0
be O 0
at O 0
least O 0
682 O 0
+ O 0
/ O 0
- O 0
203 O 0
generations O 0
( O 0
95 O 0
% O 0
confidence O 0
interval O 0
564 O 0
- O 0
801 O 0
g O 0
) O 0
, O 0
a O 0
dating O 0
which O 0
is O 0
consistent O 0
with O 0
little O 0
or O 0
no O 0
negative O 0
selection O 0
and O 0
provides O 0
further O 0
evidence O 0
for O 0
an O 0
ancient O 0
spread O 0
of O 0
a O 0
pre O 0
- O 0
mutation O 0
( O 0
at O 0
- O 0
risk O 0
alleles O 0
) O 0
in O 0
western O 0
Europe O 0
. O 0
. O 0

Functional O 0
link O 0
between O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
and O 0
Nijmegen B-Disease 0
breakage I-Disease 0
syndrome I-Disease 0
gene O 0
products O 0
. O 0

Ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
( O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
) O 0
and O 0
Nijmegen B-Disease 0
breakage I-Disease 0
syndrome I-Disease 0
( O 0
NBS B-Disease 0
) O 0
are O 0
recessive B-Disease 0
genetic I-Disease 1
disorders I-Disease 1
with O 0
susceptibility O 0
to O 0
cancer B-Disease 1
and O 0
similar O 0
cellular O 0
phenotypes O 0
. O 0

The O 0
protein O 0
product O 0
of O 0
the O 0
gene O 0
responsible O 0
for O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
, O 0
designated O 0
ATM O 0
, O 0
is O 0
a O 0
member O 0
of O 0
a O 0
family O 0
of O 0
kinases O 0
characterized O 0
by O 0
a O 0
carboxy O 0
- O 0
terminal O 0
phosphatidylinositol O 0
3 O 0
- O 0
kinase O 0
- O 0
like O 0
domain O 0
. O 0

The O 0
NBS1 O 0
protein O 0
is O 0
specifically O 0
mutated O 0
in O 0
patients O 0
with O 0
Nijmegen B-Disease 0
breakage I-Disease 0
syndrome I-Disease 0
and O 0
forms O 0
a O 0
complex O 0
with O 0
the O 0
DNA O 0
repair O 0
proteins O 0
Rad50 O 0
and O 0
Mrel1 O 0
. O 0

Here O 0
we O 0
show O 0
that O 0
phosphorylation O 0
of O 0
NBS1 O 0
, O 0
induced O 0
by O 0
ionizing O 0
radiation O 0
, O 0
requires O 0
catalytically O 0
active O 0
ATM O 0
. O 0

Complexes O 0
containing O 0
ATM O 0
and O 0
NBS1 O 0
exist O 0
in O 0
vivo O 0
in O 0
both O 0
untreated O 0
cells O 0
and O 0
cells O 0
treated O 0
with O 0
ionizing O 0
radiation O 0
. O 0

We O 0
have O 0
identified O 0
two O 0
residues O 0
of O 0
NBS1 O 0
, O 0
Ser O 0
278 O 0
and O 0
Ser O 0
343 O 0
that O 0
are O 0
phosphorylated O 0
in O 0
vitro O 0
by O 0
ATM O 0
and O 0
whose O 0
modification O 0
in O 0
vivo O 0
is O 0
essential O 0
for O 0
the O 0
cellular O 0
response O 0
to O 0
DNA O 0
damage O 0
. O 0

This O 0
response O 0
includes O 0
S O 0
- O 0
phase O 0
checkpoint O 0
activation O 0
, O 0
formation O 0
of O 0
the O 0
NBS1 O 0
/ O 0
Mrel1 O 0
/ O 0
Rad50 O 0
nuclear O 0
foci O 0
and O 0
rescue O 0
of O 0
hypersensitivity B-Disease 1
to I-Disease 1
ionizing I-Disease 1
radiation I-Disease 1
. O 0

Together O 0
, O 0
these O 0
results O 0
demonstrate O 0
a O 0
biochemical O 0
link O 0
between O 0
cell O 0
- O 0
cycle O 0
checkpoints O 0
activated O 0
by O 0
DNA O 0
damage O 0
and O 0
DNA O 0
repair O 0
in O 0
two O 0
genetic B-Disease 0
diseases I-Disease 0
with O 0
overlapping O 0
phenotypes O 0
. O 0
. O 0

Homozygosity O 0
mapping O 0
in O 0
a O 0
family O 0
with O 0
microcephaly B-Disease 1
, O 0
mental B-Disease 1
retardation I-Disease 1
, O 0
and O 0
short B-Disease 0
stature I-Disease 0
to O 0
a O 0
Cohen B-Disease 0
syndrome I-Disease 0
region O 0
on O 0
8q21 O 0
. O 0
3 O 0
- O 0
8q22 O 0
. O 0
1 O 0
: O 0
redefining O 0
a O 0
clinical O 0
entity O 0
. O 0

A O 0
syndrome O 0
of O 0
microcephaly B-Disease 1
, O 0
progressive O 0
postnatal B-Disease 0
growth I-Disease 0
deficiency I-Disease 0
, O 0
and O 0
mental B-Disease 1
retardation I-Disease 1
was O 0
observed O 0
in O 0
two O 0
brothers O 0
and O 0
their O 0
cousin O 0
from O 0
a O 0
multiply O 0
consanguineous O 0
kindred O 0
of O 0
Lebanese O 0
descent O 0
. O 0

Hypotonia B-Disease 1
, O 0
chorioretinal B-Disease 1
dystrophy I-Disease 1
, O 0
and O 0
myopia B-Disease 0
were O 0
also O 0
identified O 0
. O 0

The O 0
severity O 0
of O 0
the O 0
condition O 0
varied O 0
among O 0
the O 0
closely O 0
related O 0
patients O 0
. O 0

Because O 0
of O 0
absence O 0
of O 0
a O 0
distinctive O 0
facial O 0
appearance O 0
, O 0
the O 0
degree O 0
of O 0
mental B-Disease 1
retardation I-Disease 1
, O 0
and O 0
short B-Disease 0
stature I-Disease 0
, O 0
the O 0
initially O 0
considered O 0
clinical O 0
diagnosis O 0
of O 0
Cohen B-Disease 0
syndrome I-Disease 0
was O 0
withdrawn O 0
and O 0
a O 0
novel O 0
genetic O 0
entity O 0
was O 0
assumed O 0
. O 0

Homozygosity O 0
mapping O 0
in O 0
this O 0
family O 0
assigned O 0
the O 0
gene O 0
to O 0
a O 0
26 O 0
. O 0

8 O 0
- O 0
cM O 0
region O 0
on O 0
the O 0
chromosome O 0
band O 0
8q21 O 0
. O 0

3 O 0
- O 0
22 O 0
. O 0

1 O 0
, O 0
between O 0
the O 0
microsatellites O 0
at O 0
D8S270 O 0
and O 0
D8S514 O 0
. O 0

The O 0
maximum O 0
two O 0
- O 0
point O 0
LOD O 0
score O 0
was O 0
found O 0
for O 0
marker O 0
at O 0
D8S267 O 0
( O 0
Zmax O 0
= O 0
3 O 0
. O 0
. O 0
237 O 0
at O 0
Omax O 0
= O 0
0 O 0
. O 0
00 O 0
) O 0
. O 0

Intriguingly O 0
enough O 0
, O 0
the O 0
identified O 0
gene O 0
region O 0
overlaps O 0
the O 0
refined O 0
gene O 0
region O 0
for O 0
Cohen B-Disease 0
syndrome I-Disease 0
( O 0
COH1 O 0
) O 0
[ O 0
Kolehmainen O 0
et O 0
al O 0
. O 0
, O 0
1997 O 0
Euro O 0
J O 0
Hum O 0
Genet O 0
5 O 0
206 O 0
- O 0
213 O 0
] O 0
. O 0

This O 0
fact O 0
encourages O 0
the O 0
hypothesis O 0
that O 0
the O 0
described O 0
kindred O 0
segregates O 0
for O 0
a O 0
variant O 0
of O 0
Cohen B-Disease 0
syndrome I-Disease 0
and O 0
suggests O 0
a O 0
redefinition O 0
of O 0
its O 0
phenotype O 0

Polymorphisms O 0
of O 0
the O 0
CYP2D6 O 0
gene O 0
increase O 0
susceptibility O 0
to O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
. O 0

Ankylosing B-Disease 1
spondylitis I-Disease 1
( O 0
AS B-Disease 0
) O 0
is O 0
a O 0
common O 0
and O 0
highly O 0
familial O 0
rheumatic B-Disease 0
disorder I-Disease 0
. O 0

The O 0
sibling O 0
recurrence O 0
risk O 0
ratio O 0
for O 0
the O 0
disease O 0
is O 0
63 O 0
and O 0
heritability O 0
assessed O 0
in O 0
twins O 0
> O 0
90 O 0
% O 0
. O 0

Although O 0
MHC O 0
genes O 0
, O 0
including O 0
HLA O 0
- O 0
B27 O 0
, O 0
contribute O 0
only O 0
20 O 0
- O 0
50 O 0
% O 0
of O 0
the O 0
genetic O 0
risk O 0
for O 0
the O 0
disease O 0
, O 0
no O 0
non O 0
- O 0
MHC O 0
gene O 0
has O 0
yet O 0
been O 0
convincingly O 0
demonstrated O 0
to O 0
influence O 0
either O 0
susceptibility O 0
to O 0
the O 0
disease O 0
or O 0
its O 0
phenotypic O 0
expression O 0
. O 0

Previous O 0
linkage O 0
and O 0
association O 0
studies O 0
have O 0
suggested O 0
the O 0
presence O 0
of O 0
a O 0
susceptibility O 0
gene O 0
for O 0
AS B-Disease 0
close O 0
to O 0
, O 0
or O 0
within O 0
, O 0
the O 0
cytochrome O 0
P450 O 0
2D6 O 0
gene O 0
( O 0
CYP2D6 O 0
, O 0
debrisoquine O 0
hydroxylase O 0
) O 0
located O 0
at O 0
chromosome O 0
22q13 O 0
. O 0
1 O 0
. O 0

We O 0
performed O 0
a O 0
linkage O 0
study O 0
of O 0
chromosome O 0
22 O 0
in O 0
200 O 0
families O 0
with O 0
AS B-Disease 0
affected O 0
sibling O 0
- O 0
pairs O 0
. O 0

Association O 0
of O 0
alleles O 0
of O 0
the O 0
CYP2D6 O 0
gene O 0
was O 0
examined O 0
by O 0
both O 0
case O 0
- O 0
control O 0
and O 0
within O 0
- O 0
family O 0
means O 0
. O 0

For O 0
case O 0
- O 0
control O 0
studies O 0
, O 0
617 O 0
unrelated O 0
individuals O 0
with O 0
AS B-Disease 0
( O 0
361 O 0
probands O 0
from O 0
sibling O 0
- O 0
pair O 0
and O 0
parent O 0
- O 0
case O 0
trio O 0
families O 0
and O 0
256 O 0
unrelated O 0
non O 0
- O 0
familial O 0
sporadic O 0
cases O 0
) O 0
and O 0
402 O 0
healthy O 0
ethnically O 0
matched O 0
controls O 0
were O 0
employed O 0
. O 0

For O 0
within O 0
- O 0
family O 0
association O 0
studies O 0
, O 0
361 O 0
families O 0
including O 0
161 O 0
parent O 0
- O 0
case O 0
trios O 0
and O 0
200 O 0
affected O 0
sibling O 0
- O 0
pair O 0
families O 0
were O 0
employed O 0
. O 0

Homozygosity O 0
for O 0
poor O 0
metabolizer O 0
alleles O 0
was O 0
found O 0
to O 0
be O 0
associated O 0
with O 0
AS B-Disease 0
. O 0

Heterozygosity O 0
for O 0
the O 0
most O 0
frequent O 0
poor O 0
metabolizer O 0
allele O 0
( O 0
CYP2D6 O 0
* O 0
4 O 0
) O 0
was O 0
not O 0
associated O 0
with O 0
increased O 0
susceptibility O 0
to O 0
AS B-Disease 0
. O 0

Significant O 0
within O 0
- O 0
family O 0
association O 0
of O 0
CYP2D6 O 0
* O 0
4 O 0
alleles O 0
and O 0
AS B-Disease 0
was O 0
demonstrated O 0
. O 0

Weak O 0
linkage O 0
was O 0
also O 0
demonstrated O 0
between O 0
CYP2D6 O 0
and O 0
AS B-Disease 0
. O 0

We O 0
postulate O 0
that O 0
altered O 0
metabolism O 0
of O 0
a O 0
natural O 0
toxin O 0
or O 0
antigen O 0
by O 0
the O 0
CYP2D6 O 0
gene O 0
may O 0
increase O 0
susceptibility O 0
to O 0
AS B-Disease 0
. O 0

Functional O 0
differences O 0
of O 0
the O 0
PDS B-Disease 1
gene O 0
product O 0
are O 0
associated O 0
with O 0
phenotypic O 0
variation O 0
in O 0
patients O 0
with O 0
Pendred B-Disease 0
syndrome I-Disease 0
and O 0
non B-Disease 0
- I-Disease 0
syndromic I-Disease 0
hearing I-Disease 0
loss I-Disease 0
( O 0
DFNB4 B-Disease 1
) O 0
. O 0

The O 0
PDS B-Disease 1
gene O 0
encodes O 0
a O 0
transmembrane O 0
protein O 0
, O 0
known O 0
as O 0
pendrin O 0
, O 0
which O 0
functions O 0
as O 0
a O 0
transporter O 0
of O 0
iodide O 0
and O 0
chloride O 0
. O 0

Mutations O 0
in O 0
this O 0
gene O 0
are O 0
responsible O 0
for O 0
Pendred B-Disease 0
syndrome I-Disease 0
and O 0
autosomal B-Disease 0
recessive I-Disease 0
non I-Disease 0
- I-Disease 0
syndromic I-Disease 0
hearing I-Disease 0
loss I-Disease 0
at O 0
the O 0
DFNB4 B-Disease 1
locus O 0
on O 0
chromosome O 0
7q31 O 0
. O 0

A O 0
screen O 0
of O 0
20 O 0
individuals O 0
from O 0
the O 0
midwestern O 0
USA O 0
with O 0
non B-Disease 0
- I-Disease 0
syndromic I-Disease 0
hearing I-Disease 0
loss I-Disease 0
and O 0
dilated O 0
vestibular O 0
aqueducts O 0
identified O 0
three O 0
people O 0
( O 0
15 O 0
% O 0
) O 0
with O 0
PDS B-Disease 1
mutations O 0
. O 0

To O 0
determine O 0
whether O 0
PDS B-Disease 1
mutations O 0
in O 0
individuals O 0
with O 0
Pendred B-Disease 0
syndrome I-Disease 0
differ O 0
functionally O 0
from O 0
PDS B-Disease 1
mutations O 0
in O 0
individuals O 0
with O 0
non B-Disease 0
- I-Disease 0
syndromic I-Disease 0
hearing I-Disease 0
loss I-Disease 0
, O 0
we O 0
compared O 0
three O 0
common O 0
Pendred B-Disease 0
syndrome I-Disease 0
allele O 0
variants O 0
( O 0
L236P O 0
, O 0
T416P O 0
and O 0
E384G O 0
) O 0
, O 0
with O 0
three O 0
PDS B-Disease 1
mutations O 0
reported O 0
only O 0
in O 0
individuals O 0
with O 0
non B-Disease 0
- I-Disease 0
syndromic I-Disease 0
hearing I-Disease 0
loss I-Disease 0
( O 0
V480D O 0
, O 0
V653A O 0
and O 0
I490L O 0
/ O 0
G497S O 0
) O 0
. O 0

The O 0
mutations O 0
associated O 0
with O 0
Pendred B-Disease 0
syndrome I-Disease 0
have O 0
complete O 0
loss O 0
of O 0
pendrin O 0
- O 0
induced O 0
chloride O 0
and O 0
iodide O 0
transport O 0
, O 0
while O 0
alleles O 0
unique O 0
to O 0
people O 0
with O 0
DFNB4 B-Disease 1
are O 0
able O 0
to O 0
transport O 0
both O 0
iodide O 0
and O 0
chloride O 0
, O 0
albeit O 0
at O 0
a O 0
much O 0
lower O 0
level O 0
than O 0
wild O 0
- O 0
type O 0
pendrin O 0
. O 0

We O 0
hypothesize O 0
that O 0
this O 0
residual O 0
level O 0
of O 0
anion O 0
transport O 0
is O 0
sufficient O 0
to O 0
eliminate O 0
or O 0
postpone O 0
the O 0
onset O 0
of O 0
goiter B-Disease 1
in O 0
individuals O 0
with O 0
DFNB4 B-Disease 1
. O 0

We O 0
propose O 0
a O 0
model O 0
for O 0
pendrin O 0
function O 0
in O 0
the O 0
thyroid O 0
in O 0
which O 0
pendrin O 0
transports O 0
iodide O 0
across O 0
the O 0
apical O 0
membrane O 0
of O 0
the O 0
thyrocyte O 0
into O 0
the O 0
colloid O 0
space O 0
. O 0
. O 0

The O 0
human O 0
factor O 0
IX O 0
gene O 0
as O 0
germline O 0
mutagen O 0
test O 0
: O 0
samples O 0
from O 0
Mainland O 0
China O 0
have O 0
the O 0
putatively O 0
endogenous O 0
pattern O 0
of O 0
mutation O 0
. O 0

Germline O 0
mutations O 0
are O 0
the O 0
major O 0
source O 0
of O 0
genetic O 0
variation O 0
that O 0
allows O 0
a O 0
species O 0
to O 0
evolve O 0
over O 0
time O 0
but O 0
at O 0
the O 0
cost O 0
of O 0
Mendelian B-Disease 0
disease I-Disease 0
and O 0
genetic O 0
predisposition O 0
to O 0
multifactorial B-Disease 0
diseases I-Disease 0
. O 0

Previous O 0
analyses O 0
have O 0
revealed O 0
that O 0
the O 0
pattern O 0
of O 0
germline O 0
mutations O 0
in O 0
the O 0
factor O 0
IX O 0
gene O 0
( O 0
F9 O 0
) O 0
is O 0
similar O 0
among O 0
a O 0
variety O 0
of O 0
ethnically O 0
and O 0
geographically O 0
diverse O 0
populations O 0
and O 0
compatible O 0
with O 0
the O 0
ancient O 0
pattern O 0
that O 0
has O 0
shaped O 0
the O 0
mammalian O 0
genome O 0
. O 0

Here O 0
, O 0
we O 0
compare O 0
the O 0
pattern O 0
of O 0
germline O 0
mutation O 0
in O 0
a O 0
population O 0
of O 0
hemophilia B-Disease 1
B I-Disease 0
patients O 0
from O 0
Mainland O 0
China O 0
( O 0
n O 0
= O 0
66 O 0
) O 0
to O 0
that O 0
in O 0
U O 0
. O 0

S O 0
. O 0

Caucasians O 0
, O 0
Blacks O 0
, O 0
and O 0
Mexican O 0
Hispanics O 0
and O 0
stratify O 0
by O 0
disease O 0
severity O 0
and O 0
ethnicity O 0
. O 0

The O 0
similar O 0
pattern O 0
of O 0
germline O 0
mutation O 0
in O 0
all O 0
ethnic O 0
groups O 0
studied O 0
to O 0
date O 0
provides O 0
additional O 0
data O 0
compatible O 0
with O 0
the O 0
inference O 0
that O 0
endogenous O 0
processes O 0
predominate O 0
in O 0
germline O 0
mutations O 0
. O 0

Fas O 0
preassociation O 0
required O 0
for O 0
apoptosis O 0
signaling O 0
and O 0
dominant O 0
inhibition O 0
by O 0
pathogenic O 0
mutations O 0
. O 0

Heterozygous O 0
mutations O 0
encoding O 0
abnormal O 0
forms O 0
of O 0
the O 0
death O 0
receptor O 0
Fas O 0
dominantly O 0
interfere O 0
with O 0
Fas O 0
- O 0
induced O 0
lymphocyte O 0
apoptosis O 0
in O 0
human O 0
autoimmune B-Disease 1
lymphoproliferative I-Disease 1
syndrome I-Disease 1
. O 0

This O 0
effect O 0
, O 0
rather O 0
than O 0
depending O 0
on O 0
ligand O 0
- O 0
induced O 0
receptor O 0
oligomerization O 0
, O 0
was O 0
found O 0
to O 0
stem O 0
from O 0
ligand O 0
- O 0
independent O 0
interaction O 0
of O 0
wild O 0
- O 0
type O 0
and O 0
mutant O 0
Fas O 0
receptors O 0
through O 0
a O 0
specific O 0
region O 0
in O 0
the O 0
extracellular O 0
domain O 0
. O 0

Preassociated O 0
Fas O 0
complexes O 0
were O 0
found O 0
in O 0
living O 0
cells O 0
by O 0
means O 0
of O 0
fluorescence O 0
resonance O 0
energy O 0
transfer O 0
between O 0
variants O 0
of O 0
green O 0
fluorescent O 0
protein O 0
. O 0

These O 0
results O 0
show O 0
that O 0
formation O 0
of O 0
preassociated O 0
receptor O 0
complexes O 0
is O 0
necessary O 0
for O 0
Fas O 0
signaling O 0
and O 0
dominant O 0
interference O 0
in O 0
human O 0
disease O 0
. O 0
. O 0

Determination O 0
of O 0
carrier O 0
status O 0
for O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
by O 0
flow O 0
cytometric O 0
analysis O 0
of O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
protein O 0
expression O 0
in O 0
peripheral O 0
blood O 0
mononuclear O 0
cells O 0
. O 0

The O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
( O 0
WAS B-Disease 0
) O 0
is O 0
caused O 0
by O 0
defects O 0
in O 0
the O 0
WAS B-Disease 0
protein O 0
( O 0
WASP O 0
) O 0
gene O 0
on O 0
the O 0
X O 0
chromosome O 0
. O 0

Previous O 0
study O 0
disclosed O 0
that O 0
flow O 0
cytometric O 0
analysis O 0
of O 0
intracellular O 0
WASP O 0
expression O 0
( O 0
FCM O 0
- O 0
WASP O 0
analysis O 0
) O 0
in O 0
lymphocytes O 0
was O 0
useful O 0
for O 0
the O 0
diagnosis O 0
of O 0
WAS B-Disease 0
patients O 0
. O 0

Lymphocytes O 0
from O 0
all O 0
WAS B-Disease 0
patients O 0
showed O 0
WASPdim O 0
instead O 0
of O 0
WASPbright O 0
. O 0

Here O 0
we O 0
report O 0
that O 0
FCM O 0
- O 0
WASP O 0
analysis O 0
in O 0
monocytes O 0
could O 0
be O 0
a O 0
useful O 0
tool O 0
for O 0
the O 0
WAS B-Disease 0
carrier O 0
diagnosis O 0
. O 0

Monocytes O 0
from O 0
all O 0
nine O 0
WAS B-Disease 0
carriers O 0
showed O 0
varied O 0
population O 0
of O 0
WASPdim O 0
together O 0
with O 0
WASPbright O 0
. O 0

None O 0
of O 0
control O 0
individuals O 0
possessed O 0
the O 0
WASPdim O 0
population O 0
. O 0

In O 0
contrast O 0
, O 0
lymphocytes O 0
from O 0
all O 0
the O 0
carriers O 0
except O 0
two O 0
lacked O 0
the O 0
WASPdim O 0
population O 0
. O 0

The O 0
difference O 0
of O 0
the O 0
WASPdim O 0
population O 0
in O 0
monocytes O 0
and O 0
lymphocytes O 0
observed O 0
in O 0
WAS B-Disease 0
carriers O 0
suggests O 0
that O 0
WASP O 0
plays O 0
a O 0
more O 0
critical O 0
role O 0
in O 0
the O 0
development O 0
of O 0
lymphocytes O 0
than O 0
in O 0
that O 0
of O 0
monocytes O 0
. O 0

The O 0
present O 0
studies O 0
suggest O 0
that O 0
a O 0
skewed O 0
X O 0
- O 0
chromosomal O 0
inactivation O 0
pattern O 0
observed O 0
in O 0
WAS B-Disease 0
carrier O 0
peripheral O 0
blood O 0
cells O 0
is O 0
not O 0
fixed O 0
at O 0
the O 0
hemopoietic O 0
stem O 0
cell O 0
level O 0
but O 0
progresses O 0
after O 0
the O 0
lineage O 0
commitment O 0
. O 0
. O 0

Restoration O 0
of O 0
photoreceptor O 0
ultrastructure O 0
and O 0
function O 0
in O 0
retinal B-Disease 0
degeneration I-Disease 0
slow O 0
mice O 0
by O 0
gene O 0
therapy O 0
. O 0

The O 0
gene O 0
Prph2 O 0
encodes O 0
a O 0
photoreceptor O 0
- O 0
specific O 0
membrane O 0
glycoprotein O 0
, O 0
peripherin O 0
- O 0
2 O 0
( O 0
also O 0
known O 0
as O 0
peripherin O 0
/ O 0
rds O 0
) O 0
, O 0
which O 0
is O 0
inserted O 0
into O 0
the O 0
rims O 0
of O 0
photoreceptor O 0
outer O 0
segment O 0
discs O 0
in O 0
a O 0
complex O 0
with O 0
rom O 0
- O 0
1 O 0
( O 0
ref O 0
. O 0
2 O 0
) O 0
. O 0

The O 0
complex O 0
is O 0
necessary O 0
for O 0
the O 0
stabilization O 0
of O 0
the O 0
discs O 0
, O 0
which O 0
are O 0
renewed O 0
constantly O 0
throughout O 0
life O 0
, O 0
and O 0
which O 0
contain O 0
the O 0
visual O 0
pigments O 0
necessary O 0
for O 0
photon O 0
capture O 0
. O 0

Mutations O 0
in O 0
Prph2 O 0
have O 0
been O 0
shown O 0
to O 0
result O 0
in O 0
a O 0
variety O 0
of O 0
photoreceptor B-Disease 0
dystrophies I-Disease 0
, O 0
including O 0
autosomal B-Disease 1
dominant I-Disease 1
retinitis I-Disease 1
pigmentosa I-Disease 1
and O 0
macular B-Disease 1
dystrophy I-Disease 1
. O 0

A O 0
common O 0
feature O 0
of O 0
these O 0
diseases O 0
is O 0
the O 0
loss O 0
of O 0
photoreceptor O 0
function O 0
, O 0
also O 0
seen O 0
in O 0
the O 0
retinal B-Disease 0
degeneration I-Disease 0
slow O 0
( O 0
rds O 0
or O 0
Prph2 O 0
Rd2 O 0
/ O 0
Rd2 O 0
) O 0
mouse O 0
, O 0
which O 0
is O 0
homozygous O 0
for O 0
a O 0
null O 0
mutation O 0
in O 0
Prph2 O 0
. O 0

It O 0
is O 0
characterized O 0
by O 0
a O 0
complete O 0
failure O 0
to O 0
develop O 0
photoreceptor O 0
discs O 0
and O 0
outer O 0
segments O 0
, O 0
downregulation O 0
of O 0
rhodopsin O 0
and O 0
apoptotic O 0
loss O 0
of O 0
photoreceptor O 0
cells O 0
. O 0

The O 0
electroretinograms O 0
( O 0
ERGs O 0
) O 0
of O 0
Prph2Rd2 O 0
/ O 0
Rd2 O 0
mice O 0
have O 0
greatly O 0
diminished O 0
a O 0
- O 0
wave O 0
and O 0
b O 0
- O 0
wave O 0
amplitudes O 0
, O 0
which O 0
decline O 0
to O 0
virtually O 0
undetectable O 0
concentrations O 0
by O 0
two O 0
months O 0
. O 0

Subretinal O 0
injection O 0
of O 0
recombinant O 0
adeno O 0
- O 0
associated O 0
virus O 0
( O 0
AAV O 0
) O 0
encoding O 0
a O 0
Prph2 O 0
transgene O 0
results O 0
in O 0
stable O 0
generation O 0
of O 0
outer O 0
segment O 0
structures O 0
and O 0
formation O 0
of O 0
new O 0
stacks O 0
of O 0
discs O 0
containing O 0
both O 0
perpherin O 0
- O 0
2 O 0
and O 0
rhodopsin O 0
, O 0
which O 0
in O 0
many O 0
cases O 0
are O 0
morphologically O 0
similar O 0
to O 0
normal O 0
outer O 0
segments O 0
. O 0

Moreover O 0
, O 0
the O 0
re O 0
- O 0
establishment O 0
of O 0
the O 0
structural O 0
integrity O 0
of O 0
the O 0
photoreceptor O 0
layer O 0
also O 0
results O 0
in O 0
electrophysiological O 0
correction O 0
. O 0

These O 0
studies O 0
demonstrate O 0
for O 0
the O 0
first O 0
time O 0
that O 0
a O 0
complex O 0
ultrastructural O 0
cell O 0
defect O 0
can O 0
be O 0
corrected O 0
both O 0
morphologically O 0
and O 0
functionally O 0
by O 0
in O 0
vivo O 0
gene O 0
transfer O 0
. O 0
. O 0

Mutations O 0
in O 0
the O 0
fibrinogen O 0
aalpha O 0
gene O 0
account O 0
for O 0
the O 0
majority O 0
of O 0
cases O 0
of O 0
congenital B-Disease 1
afibrinogenemia I-Disease 1
. O 0

Congenital B-Disease 1
afibrinogenemia I-Disease 1
is O 0
a O 0
rare O 0
, O 0
autosomal B-Disease 0
, I-Disease 0
recessive I-Disease 0
disorder I-Disease 0
characterized O 0
by O 0
the O 0
complete O 0
absence O 0
of O 0
detectable O 0
fibrinogen O 0
. O 0

We O 0
previously O 0
identified O 0
the O 0
first O 0
causative O 0
mutations O 0
in O 0
a O 0
nonconsanguineous O 0
Swiss O 0
family O 0
; O 0
the O 0
4 O 0
affected O 0
persons O 0
have O 0
homozygous O 0
deletions O 0
of O 0
approximately O 0
11 O 0
kb O 0
of O 0
the O 0
fibrinogen O 0
alpha O 0
( O 0
FGA O 0
) O 0
gene O 0
. O 0

Haplotype O 0
data O 0
implied O 0
that O 0
these O 0
deletions O 0
occurred O 0
on O 0
distinct O 0
ancestral O 0
chromosomes O 0
, O 0
suggesting O 0
that O 0
this O 0
region O 0
may O 0
be O 0
susceptible O 0
to O 0
deletion O 0
by O 0
a O 0
common O 0
mechanism O 0
. O 0

We O 0
subsequently O 0
showed O 0
that O 0
all O 0
the O 0
deletions O 0
were O 0
identical O 0
to O 0
the O 0
base O 0
pair O 0
and O 0
probably O 0
resulted O 0
from O 0
a O 0
nonhomologous O 0
recombination O 0
mediated O 0
by O 0
7 O 0
- O 0
bp O 0
direct O 0
repeats O 0
. O 0

In O 0
this O 0
study O 0
, O 0
we O 0
have O 0
collected O 0
data O 0
on O 0
13 O 0
additional O 0
unrelated O 0
patients O 0
to O 0
identify O 0
the O 0
causative O 0
mutations O 0
and O 0
to O 0
determine O 0
the O 0
prevalence O 0
of O 0
the O 0
11 O 0
- O 0
kb O 0
deletion O 0
. O 0

A O 0
common O 0
recurrent O 0
mutation O 0
, O 0
at O 0
the O 0
donor O 0
splice O 0
site O 0
of O 0
FGA O 0
intron O 0
4 O 0
( O 0
IVS4 O 0
+ O 0
1 O 0
G O 0
> O 0
T O 0
) O 0
, O 0
accounted O 0
for O 0
14 O 0
of O 0
the O 0
26 O 0
( O 0
54 O 0
% O 0
) O 0
alleles O 0
. O 0

One O 0
patient O 0
was O 0
heterozygous O 0
for O 0
the O 0
previously O 0
identified O 0
deletion O 0
. O 0

Three O 0
more O 0
frameshift O 0
mutations O 0
, O 0
2 O 0
nonsense O 0
mutations O 0
, O 0
and O 0
a O 0
second O 0
splice O 0
site O 0
mutation O 0
were O 0
also O 0
identified O 0
. O 0

Consequently O 0
, O 0
86 O 0
% O 0
of O 0
afibrinogenemia B-Disease 1
alleles O 0
analyzed O 0
to O 0
date O 0
have O 0
truncating O 0
mutations O 0
of O 0
FGA O 0
, O 0
though O 0
mutations O 0
in O 0
all O 0
3 O 0
fibrinogen O 0
genes O 0
, O 0
FGG O 0
, O 0
FGA O 0
, O 0
and O 0
FGB O 0
, O 0
might O 0
be O 0
predicted O 0
to O 0
cause O 0
congenital B-Disease 1
afibrinogenemia I-Disease 1
. O 0
. O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
: O 0
the O 0
role O 0
of O 0
the O 0
CUG O 0
triplet O 0
repeats O 0
in O 0
splicing O 0
of O 0
a O 0
novel O 0
DMPK O 0
exon O 0
and O 0
altered O 0
cytoplasmic O 0
DMPK O 0
mRNA O 0
isoform O 0
ratios O 0
. O 0

The O 0
mechanism O 0
by O 0
which O 0
( O 0
CTG O 0
) O 0
n O 0
expansion O 0
in O 0
the O 0
3 O 0
UTR O 0
of O 0
the O 0
DMPK O 0
gene O 0
causes O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
is O 0
unknown O 0
. O 0

We O 0
identified O 0
four O 0
RNA O 0
splicing O 0
factors O 0
- O 0
- O 0
hnRNP O 0
C O 0
, O 0
U2AF O 0
( O 0
U2 O 0
auxiliary O 0
factor O 0
) O 0
, O 0
PTB O 0
( O 0
polypyrimidine O 0
tract O 0
binding O 0
protein O 0
) O 0
, O 0
and O 0
PSF O 0
( O 0
PTB O 0
associated O 0
splicing O 0
factor O 0
) O 0
- O 0
- O 0
that O 0
bind O 0
to O 0
two O 0
short O 0
regions O 0
3 O 0
of O 0
the O 0
( O 0
CUG O 0
) O 0
n O 0
, O 0
and O 0
found O 0
a O 0
novel O 0
3 O 0
DMPK O 0
exon O 0
resulting O 0
in O 0
an O 0
mRNA O 0
lacking O 0
the O 0
repeats O 0
. O 0

We O 0
propose O 0
that O 0
the O 0
( O 0
CUG O 0
) O 0
n O 0
is O 0
an O 0
essential O 0
cis O 0
acting O 0
element O 0
for O 0
this O 0
splicing O 0
event O 0
. O 0

In O 0
contrast O 0
to O 0
( O 0
CUG O 0
) O 0
n O 0
containing O 0
mRNAs O 0
, O 0
the O 0
novel O 0
isoform O 0
is O 0
not O 0
retained O 0
in O 0
the O 0
nucleus O 0
in O 0
DM B-Disease 0
cells O 0
, O 0
resulting O 0
in O 0
imbalances O 0
in O 0
relative O 0
levels O 0
of O 0
cytoplasmic O 0
DMPK O 0
mRNA O 0
isoforms O 0
and O 0
a O 0
new O 0
dominant O 0
effect O 0
of O 0
the O 0
mutation O 0
on O 0
DMPK O 0
. O 0
. O 0

Expression O 0
and O 0
imprinting O 0
of O 0
MAGEL2 O 0
suggest O 0
a O 0
role O 0
in O 0
Prader B-Disease 1
- I-Disease 1
willi I-Disease 1
syndrome I-Disease 1
and O 0
the O 0
homologous O 0
murine O 0
imprinting O 0
phenotype O 0
. O 0

Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
is O 0
caused O 0
by O 0
the O 0
loss O 0
of O 0
expression O 0
of O 0
imprinted O 0
genes O 0
in O 0
chromosome O 0
15q11 O 0
- O 0
q13 O 0
. O 0

Affected O 0
individuals O 0
exhibit O 0
neonatal B-Disease 0
hypotonia I-Disease 0
, O 0
developmental B-Disease 1
delay I-Disease 1
and O 0
childhood B-Disease 0
- I-Disease 0
onset I-Disease 0
obesity I-Disease 0
. O 0

Necdin O 0
, O 0
a O 0
protein O 0
implicated O 0
in O 0
the O 0
terminal O 0
differentiation O 0
of O 0
neurons O 0
, O 0
is O 0
the O 0
only O 0
PWS B-Disease 0
candidate O 0
gene O 0
to O 0
reduce O 0
viability O 0
when O 0
disrupted O 0
in O 0
a O 0
mouse O 0
model O 0
. O 0

In O 0
this O 0
study O 0
, O 0
we O 0
have O 0
characterized O 0
MAGEL2 O 0
( O 0
also O 0
known O 0
as O 0
NDNL1 O 0
) O 0
, O 0
a O 0
gene O 0
with O 0
51 O 0
% O 0
amino O 0
acid O 0
sequence O 0
similarity O 0
to O 0
necdin O 0
and O 0
located O 0
41 O 0
kb O 0
distal O 0
to O 0
NDN O 0
in O 0
the O 0
PWS B-Disease 0
deletion O 0
region O 0
. O 0

MAGEL2 O 0
is O 0
expressed O 0
predominantly O 0
in O 0
brain O 0
, O 0
the O 0
primary O 0
tissue O 0
affected O 0
in O 0
PWS B-Disease 0
and O 0
in O 0
several O 0
fetal O 0
tissues O 0
as O 0
shown O 0
by O 0
northern O 0
blot O 0
analysis O 0
. O 0

MAGEL2 O 0
is O 0
imprinted O 0
with O 0
monoallelic O 0
expression O 0
in O 0
control O 0
brain O 0
, O 0
and O 0
paternal O 0
- O 0
only O 0
expression O 0
in O 0
the O 0
central O 0
nervous O 0
system O 0
as O 0
demonstrated O 0
by O 0
its O 0
lack O 0
of O 0
expression O 0
in O 0
brain O 0
from O 0
a O 0
PWS B-Disease 0
- O 0
affected O 0
individual O 0
. O 0

The O 0
orthologous O 0
mouse O 0
gene O 0
( O 0
Magel2 O 0
) O 0
is O 0
located O 0
within O 0
150 O 0
kb O 0
of O 0
NDN O 0
, O 0
is O 0
imprinted O 0
with O 0
paternal O 0
- O 0
only O 0
expression O 0
and O 0
is O 0
expressed O 0
predominantly O 0
in O 0
late O 0
developmental O 0
stages O 0
and O 0
adult O 0
brain O 0
as O 0
shown O 0
by O 0
northern O 0
blotting O 0
, O 0
RT O 0
- O 0
PCR O 0
and O 0
whole O 0
- O 0
mount O 0
RNA O 0
in O 0
situ O 0
hybridization O 0
. O 0

Magel2 O 0
distribution O 0
partially O 0
overlaps O 0
that O 0
of O 0
NDN O 0
, O 0
with O 0
strong O 0
expression O 0
being O 0
detected O 0
in O 0
the O 0
central O 0
nervous O 0
system O 0
in O 0
mid O 0
- O 0
gestation O 0
mouse O 0
embryos O 0
by O 0
in O 0
situ O 0
hybridization O 0
. O 0

We O 0
hypothesize O 0
that O 0
, O 0
although O 0
loss O 0
of O 0
necdin O 0
expression O 0
may O 0
be O 0
important O 0
in O 0
the O 0
neonatal O 0
presentation O 0
of O 0
PWS B-Disease 0
, O 0
loss O 0
of O 0
MAGEL2 O 0
may O 0
be O 0
critical O 0
to O 0
abnormalities B-Disease 0
in I-Disease 0
brain I-Disease 0
development I-Disease 0
and O 0
dysmorphic B-Disease 0
features I-Disease 0
in O 0
individuals O 0
with O 0
PWS B-Disease 0
. O 0
. O 0

Retinoschisin O 0
, O 0
the O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
retinoschisis I-Disease 1
protein O 0
, O 0
is O 0
a O 0
secreted O 0
photoreceptor O 0
protein O 0
, O 0
and O 0
is O 0
expressed O 0
and O 0
released O 0
by O 0
Weri O 0
- O 0
Rb1 O 0
cells O 0
. O 0

X B-Disease 1
- I-Disease 1
linked I-Disease 1
retinoschisis I-Disease 1
is O 0
characterized O 0
by O 0
microcystic O 0
- O 0
like O 0
changes O 0
of O 0
the O 0
macular O 0
region O 0
and O 0
schisis O 0
within O 0
the O 0
inner O 0
retinal O 0
layers O 0
, O 0
leading O 0
to O 0
visual B-Disease 0
deterioration I-Disease 0
in O 0
males O 0
. O 0

Many O 0
missense O 0
and O 0
protein O 0
- O 0
truncating O 0
mutations O 0
of O 0
the O 0
causative O 0
gene O 0
RS1 O 0
have O 0
now O 0
been O 0
identified O 0
and O 0
are O 0
thought O 0
to O 0
be O 0
inactivating O 0
. O 0

RS1 O 0
encodes O 0
a O 0
224 O 0
amino O 0
acid O 0
protein O 0
, O 0
retinoschisin O 0
, O 0
which O 0
contains O 0
a O 0
discoidin O 0
domain O 0
but O 0
is O 0
of O 0
unknown O 0
function O 0
. O 0

We O 0
have O 0
generated O 0
a O 0
polyclonal O 0
antibody O 0
against O 0
a O 0
peptide O 0
from O 0
a O 0
unique O 0
region O 0
within O 0
retinoschisin O 0
, O 0
which O 0
detects O 0
a O 0
protein O 0
of O 0
approximately O 0
28 O 0
kDa O 0
in O 0
retinal O 0
samples O 0
reduced O 0
with O 0
dithiothreitol O 0
, O 0
but O 0
multimers O 0
sized O 0
> O 0
40 O 0
kDa O 0
under O 0
non O 0
- O 0
reducing O 0
conditions O 0
. O 0

A O 0
screen O 0
of O 0
human O 0
tissues O 0
with O 0
this O 0
antibody O 0
reveals O 0
retinoschisin O 0
to O 0
be O 0
retina O 0
specific O 0
and O 0
the O 0
antibody O 0
detects O 0
a O 0
protein O 0
of O 0
similar O 0
size O 0
in O 0
bovine O 0
and O 0
murine O 0
retinae O 0
. O 0

We O 0
investigated O 0
the O 0
expression O 0
pattern O 0
in O 0
the O 0
retina O 0
of O 0
both O 0
RS1 O 0
mRNA O 0
( O 0
using O 0
in O 0
situ O 0
hybridization O 0
with O 0
riboprobes O 0
) O 0
and O 0
retinoschisin O 0
( O 0
using O 0
immunohistochemistry O 0
) O 0
. O 0

The O 0
antisense O 0
riboprobe O 0
detected O 0
RS1 O 0
mRNA O 0
only O 0
in O 0
the O 0
photoreceptor O 0
layer O 0
but O 0
the O 0
protein O 0
product O 0
of O 0
the O 0
gene O 0
was O 0
present O 0
both O 0
in O 0
the O 0
photoreceptors O 0
and O 0
within O 0
the O 0
inner O 0
portions O 0
of O 0
the O 0
retina O 0
. O 0

Furthermore O 0
, O 0
differentiated O 0
retinoblastoma B-Disease 1
cells O 0
( O 0
Weri O 0
- O 0
Rb1 O 0
cells O 0
) O 0
were O 0
found O 0
to O 0
express O 0
RS1 O 0
mRNA O 0
and O 0
to O 0
release O 0
retinoschisin O 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
retinoschisin O 0
is O 0
released O 0
by O 0
photo O 0
- O 0
receptors O 0
and O 0
has O 0
functions O 0
within O 0
the O 0
inner O 0
retinal O 0
layers O 0
. O 0

Thus O 0
, O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
retinoschisis I-Disease 1
is O 0
caused O 0
by O 0
abnormalities O 0
in O 0
a O 0
putative O 0
secreted O 0
photoreceptor O 0
protein O 0
and O 0
is O 0
the O 0
first O 0
example O 0
of O 0
a O 0
secreted O 0
photo O 0
- O 0
receptor O 0
protein O 0
associated O 0
with O 0
a O 0
retinal B-Disease 0
dystrophy I-Disease 0
. O 0
. O 0

Study O 0
of O 0
the O 0
voltage O 0
- O 0
gated O 0
sodium O 0
channel O 0
beta O 0
1 O 0
subunit O 0
gene O 0
( O 0
SCN1B O 0
) O 0
in O 0
the O 0
benign B-Disease 0
familial I-Disease 0
infantile I-Disease 0
convulsions I-Disease 0
syndrome I-Disease 0
( O 0
BFIC B-Disease 0
) O 0
. O 0

Benign B-Disease 0
familial I-Disease 0
infantile I-Disease 0
convulsions I-Disease 0
( O 0
BFIC B-Disease 0
) O 0
is O 0
a O 0
rare O 0
autosomal B-Disease 1
dominant I-Disease 1
epilepsy I-Disease 1
syndrome I-Disease 1
. O 0

This O 0
syndrome O 0
has O 0
been O 0
recently O 0
described O 0
in O 0
Italian O 0
and O 0
French O 0
pedigrees O 0
. O 0

Patients O 0
present O 0
with O 0
partial O 0
, O 0
then O 0
generalized O 0
seizures O 0
, O 0
with O 0
onset O 0
at O 0
age O 0
three O 0
months O 0
. O 0

The O 0
seizures O 0
usually O 0
spontaneously O 0
cease O 0
after O 0
one O 0
year O 0
without O 0
treatment O 0
, O 0
leaving O 0
no O 0
neurological B-Disease 0
abnormalities I-Disease 0
. O 0

We O 0
have O 0
mapped O 0
BFIC B-Disease 0
to O 0
chromosome O 0
19q O 0
in O 0
five O 0
Italian O 0
pedigrees O 0
. O 0

The O 0
sodium O 0
channel O 0
beta1 O 0
subunit O 0
gene O 0
( O 0
SCN1B O 0
) O 0
maps O 0
to O 0
this O 0
candidate O 0
region O 0
and O 0
has O 0
been O 0
shown O 0
to O 0
be O 0
involved O 0
in O 0
one O 0
Australian O 0
pedigree O 0
with O 0
generalized B-Disease 0
epilepsy I-Disease 0
and I-Disease 0
febrile I-Disease 0
seizures I-Disease 0
" I-Disease 0
plus I-Disease 0
" I-Disease 0
( O 0
GEFS O 0
+ O 0
) O 0
. O 0

In O 0
this O 0
family O 0
, O 0
a O 0
missense O 0
mutation O 0
in O 0
SCN1B O 0
cosegregates O 0
with O 0
the O 0
GEFS O 0
+ O 0
phenotype O 0
. O 0

BFIC B-Disease 0
and O 0
GEFS O 0
+ O 0
have O 0
clinical O 0
features O 0
in O 0
common O 0
, O 0
therefore O 0
SCN1B O 0
is O 0
a O 0
candidate O 0
gene O 0
for O 0
BFIC B-Disease 0
. O 0

We O 0
studied O 0
SCN1B O 0
exons O 0
1 O 0
, O 0
2 O 0
, O 0
3 O 0
, O 0
4 O 0
, O 0
and O 0
5 O 0
, O 0
using O 0
four O 0
SSCP O 0
methods O 0
in O 0
10 O 0
Caucasian O 0
BFIC B-Disease 0
probands O 0
of O 0
Western O 0
Europe O 0
. O 0

We O 0
found O 0
no O 0
exon O 0
variants O 0
. O 0

One O 0
variant O 0
was O 0
identified O 0
in O 0
intron O 0
5 O 0
( O 0
IVS5 O 0
- O 0
10C O 0
> O 0
G O 0
) O 0
, O 0
which O 0
did O 0
not O 0
segregate O 0
with O 0
BFIC B-Disease 0
and O 0
was O 0
observed O 0
in O 0
9 O 0
. O 0

2 O 0
% O 0
controls O 0
. O 0

A O 0
second O 0
variant O 0
in O 0
intron O 0
5 O 0
was O 0
identified O 0
( O 0
IVS5 O 0
+ O 0
30G O 0
> O 0
A O 0
) O 0
. O 0

It O 0
was O 0
rare O 0
, O 0
as O 0
not O 0
observed O 0
in O 0
controls O 0
, O 0
but O 0
not O 0
segregating O 0
with O 0
the O 0
BFIC B-Disease 0
phenotype O 0
. O 0

Inactivation O 0
of O 0
germline O 0
mutant O 0
APC B-Disease 1
alleles O 0
by O 0
attenuated O 0
somatic O 0
mutations O 0
: O 0
a O 0
molecular O 0
genetic O 0
mechanism O 0
for O 0
attenuated B-Disease 0
familial I-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
. O 0

Germline O 0
mutations O 0
of O 0
the O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( I-Disease 0
APC I-Disease 1
) I-Disease 0
tumor I-Disease 0
- O 0
suppressor O 0
gene O 0
result O 0
in O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
( O 0
FAP B-Disease 0
) O 0
. O 0

Patients O 0
with O 0
FAP B-Disease 0
typically O 0
develop O 0
hundreds O 0
to O 0
thousands O 0
of O 0
benign B-Disease 1
colorectal I-Disease 1
tumors I-Disease 1
and O 0
early O 0
- O 0
onset O 0
colorectal B-Disease 1
cancer I-Disease 1
. O 0

A O 0
subset O 0
of O 0
germline O 0
APC B-Disease 1
mutations O 0
results O 0
in O 0
an O 0
attenuated B-Disease 1
FAP I-Disease 1
( O 0
AFAP B-Disease 1
) O 0
phenotype O 0
, O 0
in O 0
which O 0
patients O 0
develop O 0
fewer O 0
tumors B-Disease 0
and O 0
develop O 0
them O 0
at O 0
an O 0
older O 0
age O 0
. O 0

Although O 0
a O 0
genotype O 0
- O 0
phenotype O 0
correlation O 0
between O 0
the O 0
locations O 0
of O 0
APC B-Disease 1
germline O 0
mutations O 0
and O 0
the O 0
development O 0
of O 0
AFAP B-Disease 1
has O 0
been O 0
well O 0
documented O 0
, O 0
the O 0
mechanism O 0
for O 0
AFAP B-Disease 1
has O 0
not O 0
been O 0
well O 0
defined O 0
. O 0

We O 0
investigated O 0
the O 0
mechanism O 0
for O 0
AFAP B-Disease 1
in O 0
patients O 0
carrying O 0
a O 0
mutant O 0
APC B-Disease 1
allele O 0
( O 0
APC O 1
( O 0
AS9 O 0
) O 0
) O 0
that O 0
has O 0
a O 0
mutation O 0
in O 0
the O 0
alternatively O 0
spliced O 0
region O 0
of O 0
exon O 0
9 O 0
. O 0

APC O 1
( O 0
AS9 O 0
) O 0
was O 0
found O 0
to O 0
down O 0
- O 0
regulate O 0
beta O 0
- O 0
catenin O 0
- O 0
regulated O 0
transcription O 0
, O 0
the O 0
major O 0
tumor B-Disease 0
- O 0
suppressor O 0
function O 0
of O 0
APC O 1
, O 0
as O 0
did O 0
the O 0
wild O 0
- O 0
type O 0
APC O 1
. O 0

Mutation O 0
analysis O 0
showed O 0
that O 0
both O 0
APC O 1
( O 0
AS9 O 0
) O 0
and O 0
the O 0
wild O 0
- O 0
type O 0
APC B-Disease 1
alleles O 0
were O 0
somatically O 0
mutated O 0
in O 0
most O 0
colorectal B-Disease 1
tumors I-Disease 1
from O 0
these O 0
patients O 0
. O 0

Functional O 0
analysis O 0
showed O 0
that O 0
4666insA O 0
, O 0
a O 0
common O 0
somatic O 0
mutation O 0
in O 0
APC O 1
( O 0
AS9 O 0
) O 0
in O 0
these O 0
tumors B-Disease 0
, O 0
did O 0
not O 0
inactivate O 0
the O 0
wild O 0
- O 0
type O 0
APC O 1
. O 0

Our O 0
results O 0
indicate O 0
that O 0
carriers O 0
of O 0
APC O 1
( O 0
AS9 O 0
) O 0
develop O 0
fewer O 0
colorectal B-Disease 1
tumors I-Disease 1
than O 0
do O 0
typical O 0
patients O 0
with O 0
FAP B-Disease 0
because O 0
somatic O 0
inactivation O 0
of O 0
both O 0
APC B-Disease 1
alleles O 0
is O 0
necessary O 0
for O 0
colorectal O 0
tumorigenesis O 0
. O 0

However O 0
, O 0
these O 0
patients O 0
develop O 0
colorectal B-Disease 1
tumors I-Disease 1
more O 0
frequently O 0
than O 0
does O 0
the O 0
general O 0
population O 0
because O 0
APC O 1
( O 0
AS9 O 0
) O 0
is O 0
inactivated O 0
by O 0
mutations O 0
that O 0
do O 0
not O 0
inactivate O 0
the O 0
wild O 0
- O 0
type O 0
APC O 1
. O 0
. O 0

Iron O 0
- O 0
dependent O 0
self O 0
- O 0
assembly O 0
of O 0
recombinant O 0
yeast O 0
frataxin O 0
: O 0
implications O 0
for O 0
Friedreich B-Disease 1
ataxia I-Disease 1
. O 0

Frataxin B-Disease 1
deficiency I-Disease 1
is O 0
the O 0
primary O 0
cause O 0
of O 0
Friedreich B-Disease 1
ataxia I-Disease 1
( O 0
FRDA B-Disease 0
) O 0
, O 0
an O 0
autosomal B-Disease 0
recessive I-Disease 0
cardiodegenerative I-Disease 0
and I-Disease 0
neurodegenerative I-Disease 0
disease I-Disease 0
. O 0

Frataxin O 0
is O 0
a O 0
nuclear O 0
- O 0
encoded O 0
mitochondrial O 0
protein O 0
that O 0
is O 0
widely O 0
conserved O 0
among O 0
eukaryotes O 0
. O 0

Genetic O 0
inactivation O 0
of O 0
the O 0
yeast O 0
frataxin O 0
homologue O 0
( O 0
Yfh1p O 0
) O 0
results O 0
in O 0
mitochondrial B-Disease 1
iron I-Disease 1
accumulation I-Disease 1
and O 0
hypersensitivity B-Disease 1
to I-Disease 1
oxidative I-Disease 1
stress I-Disease 1
. O 0

Increased O 0
iron O 0
deposition O 0
and O 0
evidence O 0
of O 0
oxidative O 0
damage O 0
have O 0
also O 0
been O 0
observed O 0
in O 0
cardiac O 0
tissue O 0
and O 0
cultured O 0
fibroblasts O 0
from O 0
patients O 0
with O 0
FRDA B-Disease 0
. O 0

These O 0
findings O 0
indicate O 0
that O 0
frataxin O 0
is O 0
essential O 0
for O 0
mitochondrial O 0
iron O 0
homeostasis O 0
and O 0
protection O 0
from O 0
iron O 0
- O 0
induced O 0
formation O 0
of O 0
free O 0
radicals O 0
. O 0

The O 0
functional O 0
mechanism O 0
of O 0
frataxin O 0
, O 0
however O 0
, O 0
is O 0
still O 0
unknown O 0
. O 0

We O 0
have O 0
expressed O 0
the O 0
mature O 0
form O 0
of O 0
Yfh1p O 0
( O 0
mYfh1p O 0
) O 0
in O 0
Escherichia O 0
coli O 0
and O 0
have O 0
analyzed O 0
its O 0
function O 0
in O 0
vitro O 0
. O 0

Isolated O 0
mYfh1p O 0
is O 0
a O 0
soluble O 0
monomer O 0
( O 0
13 O 0
, O 0
783 O 0
Da O 0
) O 0
that O 0
contains O 0
no O 0
iron O 0
and O 0
shows O 0
no O 0
significant O 0
tendency O 0
to O 0
self O 0
- O 0
associate O 0
. O 0

Aerobic O 0
addition O 0
of O 0
ferrous O 0
iron O 0
to O 0
mYfh1p O 0
results O 0
in O 0
assembly O 0
of O 0
regular O 0
spherical O 0
multimers O 0
with O 0
a O 0
molecular O 0
mass O 0
of O 0
approximately O 0
1 O 0
. O 0

1 O 0
MDa O 0
( O 0
megadaltons O 0
) O 0
and O 0
a O 0
diameter O 0
of O 0
13 O 0
+ O 0
/ O 0
- O 0
2 O 0
nm O 0
. O 0

Each O 0
multimer O 0
consists O 0
of O 0
approximately O 0
60 O 0
subunits O 0
and O 0
can O 0
sequester O 0
> O 0
3 O 0
, O 0
000 O 0
atoms O 0
of O 0
iron O 0
. O 0

Titration O 0
of O 0
mYfh1p O 0
with O 0
increasing O 0
iron O 0
concentrations O 0
supports O 0
a O 0
stepwise O 0
mechanism O 0
of O 0
multimer O 0
assembly O 0
. O 0

Sequential O 0
addition O 0
of O 0
an O 0
iron O 0
chelator O 0
and O 0
a O 0
reducing O 0
agent O 0
results O 0
in O 0
quantitative O 0
iron O 0
release O 0
with O 0
concomitant O 0
disassembly O 0
of O 0
the O 0
multimer O 0
, O 0
indicating O 0
that O 0
mYfh1p O 0
sequesters O 0
iron O 0
in O 0
an O 0
available O 0
form O 0
. O 0

In O 0
yeast O 0
mitochondria O 0
, O 0
native O 0
mYfh1p O 0
exists O 0
as O 0
monomer O 0
and O 0
a O 0
higher O 0
- O 0
order O 0
species O 0
with O 0
a O 0
molecular O 0
weight O 0
> O 0
600 O 0
, O 0
000 O 0
. O 0

After O 0
addition O 0
of O 0
( O 0
55 O 0
) O 0
Fe O 0
to O 0
the O 0
medium O 0
, O 0
immunoprecipitates O 0
of O 0
this O 0
species O 0
contain O 0
> O 0
16 O 0
atoms O 0
of O 0
( O 0
55 O 0
) O 0
Fe O 0
per O 0
molecule O 0
of O 0
mYfh1p O 0
. O 0

We O 0
propose O 0
that O 0
iron O 0
- O 0
dependent O 0
self O 0
- O 0
assembly O 0
of O 0
recombinant O 0
mYfh1p O 0
reflects O 0
a O 0
physiological O 0
role O 0
for O 0
frataxin O 0
in O 0
mitochondrial O 0
iron O 0
sequestration O 0
and O 0
bioavailability O 0
. O 0
. O 0

A O 0
mutation O 0
in O 0
the O 0
pleckstrin O 0
homology O 0
( O 0
PH O 0
) O 0
domain O 0
of O 0
the O 0
FGD1 O 0
gene O 0
in O 0
an O 0
Italian O 0
family O 0
with O 0
faciogenital B-Disease 1
dysplasia I-Disease 1
( O 0
Aarskog B-Disease 1
- I-Disease 1
Scott I-Disease 1
syndrome I-Disease 1
) O 0
. O 0

Aarskog B-Disease 1
- I-Disease 1
Scott I-Disease 1
Syndrome I-Disease 1
( O 0
AAS B-Disease 1
) O 0
is O 0
an O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
disorder I-Disease 1
characterised O 0
by O 0
short B-Disease 0
stature I-Disease 0
and O 0
multiple O 0
facial B-Disease 1
, I-Disease 1
limb I-Disease 1
and I-Disease 1
genital I-Disease 1
abnormalities I-Disease 1
. O 0

A O 0
gene O 0
, O 0
FGD1 O 0
, O 0
altered O 0
in O 0
a O 0
patient O 0
with O 0
AAS B-Disease 1
phenotype O 0
, O 0
has O 0
been O 0
identified O 0
and O 0
found O 0
to O 0
encode O 0
a O 0
protein O 0
with O 0
homology O 0
to O 0
Rho O 0
/ O 0
Rac O 0
guanine O 0
nucleotide O 0
exchange O 0
factors O 0
( O 0
Rho O 0
/ O 0
Rac O 0
GEF O 0
) O 0
. O 0

However O 0
, O 0
since O 0
this O 0
original O 0
report O 0
on O 0
identification O 0
of O 0
a O 0
mutated O 0
FGD1 O 0
gene O 0
in O 0
an O 0
AAS B-Disease 1
patient O 0
, O 0
no O 0
additional O 0
mutations O 0
in O 0
the O 0
FGD1 O 0
gene O 0
have O 0
been O 0
described O 0
. O 0

We O 0
analysed O 0
13 O 0
independent O 0
patients O 0
with O 0
clinical O 0
diagnosis O 0
of O 0
AAS B-Disease 1
. O 0

One O 0
patient O 0
presented O 0
a O 0
mutation O 0
that O 0
results O 0
in O 0
a O 0
nucleotide O 0
change O 0
in O 0
exon O 0
10 O 0
of O 0
the O 0
FGD1 O 0
gene O 0
( O 0
G2559 O 0
> O 0
A O 0
) O 0
substituting O 0
a O 0
Gln O 0
for O 0
Arg O 0
in O 0
position O 0
610 O 0
. O 0

The O 0
mutation O 0
was O 0
found O 0
to O 0
segregate O 0
with O 0
the O 0
AAS B-Disease 1
phenotype O 0
in O 0
affected O 0
males O 0
and O 0
carrier O 0
females O 0
in O 0
the O 0
family O 0
of O 0
this O 0
patient O 0
. O 0

Interestingly O 0
, O 0
Arg O 0
- O 0
610 O 0
is O 0
located O 0
within O 0
one O 0
of O 0
the O 0
two O 0
pleckstrin O 0
homology O 0
( O 0
PH O 0
) O 0
domains O 0
of O 0
the O 0
FGD1 O 0
gene O 0
and O 0
it O 0
corresponds O 0
to O 0
a O 0
highly O 0
conserved O 0
residue O 0
which O 0
has O 0
been O 0
involved O 0
in O 0
InsP O 0
binding O 0
in O 0
PH O 0
domains O 0
of O 0
other O 0
proteins O 0
. O 0

The O 0
same O 0
residue O 0
is O 0
often O 0
mutated O 0
in O 0
the O 0
Brutons O 0
tyrosine O 0
kinase O 0
( O 0
Btk O 0
) O 0
gene O 0
in O 0
patients O 0
with O 0
an O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
agammaglobulinemia I-Disease 0
. O 0

The O 0
Arg610Gln O 0
mutation O 0
represents O 0
the O 0
first O 0
case O 0
of O 0
a O 0
mutation O 0
in O 0
the O 0
PH O 0
domain O 0
of O 0
the O 0
FGD1 O 0
gene O 0
and O 0
additional O 0
evidence O 0
that O 0
mutations O 0
in O 0
PH O 0
domains O 0
can O 0
be O 0
associated O 0
to O 0
human O 0
diseases O 0
. O 0
. O 0

Amino O 0
- O 0
terminal O 0
fragments O 0
of O 0
mutant O 0
huntingtin O 0
show O 0
selective O 0
accumulation O 0
in O 0
striatal O 0
neurons O 0
and O 0
synaptic O 0
toxicity O 0
. O 0

Huntington B-Disease 1
disease I-Disease 1
( O 0
HD B-Disease 1
) O 0
is O 0
caused O 0
by O 0
expansion O 0
of O 0
a O 0
glutamine O 0
repeat O 0
in O 0
the O 0
amino O 0
- O 0
terminal O 0
region O 0
of O 0
huntingtin O 0
. O 0

Despite O 0
its O 0
widespread O 0
expression O 0
, O 0
mutant O 0
huntingtin O 0
induces O 0
selective O 0
neuronal O 0
loss O 0
in O 0
striatal O 0
neurons O 0
. O 0

Here O 0
we O 0
report O 0
that O 0
, O 0
in O 0
mutant O 0
mice O 0
expressing O 0
HD B-Disease 1
repeats O 0
, O 0
the O 0
production O 0
and O 0
aggregation O 0
of O 0
N O 0
- O 0
terminal O 0
huntingtin O 0
fragments O 0
preferentially O 0
occur O 0
in O 0
HD B-Disease 1
- O 0
affected O 0
neurons O 0
and O 0
their O 0
processes O 0
and O 0
axonal O 0
terminals O 0
. O 0

N O 0
- O 0
terminal O 0
fragments O 0
of O 0
mutant O 0
huntingtin O 0
form O 0
aggregates O 0
and O 0
induce O 0
neuritic B-Disease 1
degeneration I-Disease 1
in O 0
cultured O 0
striatal O 0
neurons O 0
. O 0

N O 0
- O 0
terminal O 0
mutant O 0
huntingtin O 0
also O 0
binds O 0
to O 0
synaptic O 0
vesicles O 0
and O 0
inhibits O 0
their O 0
glutamate O 0
uptake O 0
in O 0
vitro O 0
. O 0

The O 0
specific O 0
processing O 0
and O 0
accumulation O 0
of O 0
toxic O 0
fragments O 0
of O 0
N O 0
- O 0
terminal O 0
huntingtin O 0
in O 0
HD B-Disease 1
- O 0
affected O 0
striatal O 0
neurons O 0
, O 0
especially O 0
in O 0
their O 0
neuronal O 0
processes O 0
and O 0
axonal O 0
terminals O 0
, O 0
may O 0
contribute O 0
to O 0
the O 0
selective O 0
neuropathology O 0
of O 0
HD B-Disease 1
. O 0
. O 0

BRCA1 O 0
is O 0
associated O 0
with O 0
a O 0
human O 0
SWI O 0
/ O 0
SNF O 0
- O 0
related O 0
complex O 0
: O 0
linking O 0
chromatin O 0
remodeling O 0
to O 0
breast B-Disease 0
cancer I-Disease 1
. O 0

Germline O 0
mutations O 0
in O 0
the O 0
tumor B-Disease 0
suppressor O 0
gene O 0
, O 0
BRCA1 O 0
, O 0
predispose O 0
individuals O 0
to O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 1
cancers I-Disease 1
. O 0

Using O 0
a O 0
combination O 0
of O 0
affinity O 0
- O 0
and O 0
conventional O 0
chromatographic O 0
techniques O 0
, O 0
we O 0
have O 0
isolated O 0
a O 0
predominant O 0
form O 0
of O 0
a O 0
multiprotein O 0
BRCA1 O 0
- O 0
containing O 0
complex O 0
from O 0
human O 0
cells O 0
displaying O 0
chromatin O 0
- O 0
remodeling O 0
activity O 0
. O 0

Mass O 0
spectrometric O 0
sequencing O 0
of O 0
components O 0
of O 0
this O 0
complex O 0
indicated O 0
that O 0
BRCA1 O 0
is O 0
associated O 0
with O 0
a O 0
SWI O 0
/ O 0
SNF O 0
- O 0
related O 0
complex O 0
. O 0

We O 0
show O 0
that O 0
BRCA1 O 0
can O 0
directly O 0
interact O 0
with O 0
the O 0
BRG1 O 0
subunit O 0
of O 0
the O 0
SWI O 0
/ O 0
SNF O 0
complex O 0
. O 0

Moreover O 0
, O 0
p53 O 0
- O 0
mediated O 0
stimulation O 0
of O 0
transcription O 0
by O 0
BRCA1 O 0
was O 0
completely O 0
abrogated O 0
by O 0
either O 0
a O 0
dominant O 0
- O 0
negative O 0
mutant O 0
of O 0
BRG1 O 0
or O 0
the O 0
cancer B-Disease 1
- O 0
causing O 0
deletion O 0
in O 0
exon O 0
11 O 0
of O 0
BRCA1 O 0
. O 0

These O 0
findings O 0
reveal O 0
a O 0
direct O 0
function O 0
for O 0
BRCA1 O 0
in O 0
transcriptional O 0
control O 0
through O 0
modulation O 0
of O 0
chromatin O 0
structure O 0
. O 0
. O 0

Asef O 0
, O 0
a O 0
link O 0
between O 0
the O 0
tumor B-Disease 0
suppressor O 0
APC O 1
and O 0
G O 0
- O 0
protein O 0
signaling O 0
. O 0

The O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
gene O 0
( O 0
APC O 1
) O 0
is O 0
mutated O 0
in O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
and O 0
in O 0
sporadic O 0
colorectal B-Disease 1
tumors I-Disease 1
. O 0

Here O 0
the O 0
APC B-Disease 1
gene O 0
product O 0
is O 0
shown O 0
to O 0
bind O 0
through O 0
its O 0
armadillo O 0
repeat O 0
domain O 0
to O 0
a O 0
Rac O 0
- O 0
specific O 0
guanine O 0
nucleotide O 0
exchange O 0
factor O 0
( O 0
GEF O 0
) O 0
, O 0
termed O 0
Asef O 0
. O 0

Endogenous O 0
APC O 1
colocalized O 0
with O 0
Asef O 0
in O 0
mouse O 0
colon O 0
epithelial O 0
cells O 0
and O 0
neuronal O 0
cells O 0
. O 0

Furthermore O 0
, O 0
APC O 1
enhanced O 0
the O 0
GEF O 0
activity O 0
of O 0
Asef O 0
and O 0
stimulated O 0
Asef O 0
- O 0
mediated O 0
cell O 0
flattening O 0
, O 0
membrane O 0
ruffling O 0
, O 0
and O 0
lamellipodia O 0
formation O 0
in O 0
MDCK O 0
cells O 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
the O 0
APC O 1
- O 0
Asef O 0
complex O 0
may O 0
regulate O 0
the O 0
actin O 0
cytoskeletal O 0
network O 0
, O 0
cell O 0
morphology O 0
and O 0
migration O 0
, O 0
and O 0
neuronal O 0
function O 0
. O 0
. O 0

Function O 0
of O 0
an O 0
axonal O 0
chemoattractant O 0
modulated O 0
by O 0
metalloprotease O 0
activity O 0
. O 0

The O 0
axonal O 0
chemoattractant O 0
netrin O 0
- O 0
1 O 0
guides O 0
spinal O 0
commissural O 0
axons O 0
by O 0
activating O 0
its O 0
receptor O 0
DCC O 0
( O 0
Deleted O 0
in O 0
Colorectal B-Disease 0
Cancer I-Disease 1
) O 0
. O 0

We O 0
have O 0
found O 0
that O 0
chemical O 0
inhibitors O 0
of O 0
metalloproteases O 0
potentiate O 0
netrin O 0
- O 0
mediated O 0
axon O 0
outgrowth O 0
in O 0
vitro O 0
. O 0

We O 0
have O 0
also O 0
found O 0
that O 0
DCC O 0
is O 0
a O 0
substrate O 0
for O 0
metalloprotease O 0
- O 0
dependent O 0
ectodomain O 0
shedding O 0
, O 0
and O 0
that O 0
the O 0
inhibitors O 0
block O 0
proteolytic O 0
processing O 0
of O 0
DCC O 0
and O 0
cause O 0
an O 0
increase O 0
in O 0
DCC O 0
protein O 0
levels O 0
on O 0
axons O 0
within O 0
spinal O 0
cord O 0
explants O 0
. O 0

Thus O 0
, O 0
potentiation O 0
of O 0
netrin O 0
activity O 0
by O 0
inhibitors O 0
may O 0
result O 0
from O 0
stabilization O 0
of O 0
DCC O 0
on O 0
the O 0
axons O 0
, O 0
and O 0
proteolytic O 0
activity O 0
may O 0
regulate O 0
axon O 0
migration O 0
by O 0
controlling O 0
the O 0
number O 0
of O 0
functional O 0
extracellular O 0
axon O 0
guidance O 0
receptors O 0
. O 0
. O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
in O 0
transgenic O 0
mice O 0
expressing O 0
an O 0
expanded O 0
CUG O 0
repeat O 0
. O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
, O 0
the O 0
most O 0
common O 0
form O 0
of O 0
muscular B-Disease 0
dystrophy I-Disease 0
in O 0
adult O 0
humans O 0
, O 0
results O 0
from O 0
expansion O 0
of O 0
a O 0
CTG O 0
repeat O 0
in O 0
the O 0
3 O 0
untranslated O 0
region O 0
of O 0
the O 0
DMPK O 0
gene O 0
. O 0

The O 0
mutant O 0
DMPK O 0
messenger O 0
RNA O 0
( O 0
mRNA O 0
) O 0
contains O 0
an O 0
expanded O 0
CUG O 0
repeat O 0
and O 0
is O 0
retained O 0
in O 0
the O 0
nucleus O 0
. O 0

We O 0
have O 0
expressed O 0
an O 0
untranslated O 0
CUG O 0
repeat O 0
in O 0
an O 0
unrelated O 0
mRNA O 0
in O 0
transgenic O 0
mice O 0
. O 0

Mice O 0
that O 0
expressed O 0
expanded O 0
CUG O 0
repeats O 0
developed O 0
myotonia B-Disease 1
and O 0
myopathy B-Disease 1
, O 0
whereas O 0
mice O 0
expressing O 0
a O 0
nonexpanded O 0
repeat O 0
did O 0
not O 0
. O 0

Thus O 0
, O 0
transcripts O 0
with O 0
expanded O 0
CUG O 0
repeats O 0
are O 0
sufficient O 0
to O 0
generate O 0
a O 0
DM B-Disease 0
phenotype O 0
. O 0

This O 0
result O 0
supports O 0
a O 0
role O 0
for O 0
RNA O 0
gain O 0
of O 0
function O 0
in O 0
disease O 0
pathogenesis O 0
. O 0
. O 0

Genomic O 0
rearrangements O 0
of O 0
the O 0
APC B-Disease 1
tumor I-Disease 1
- O 0
suppressor O 0
gene O 0
in O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
. O 0

Germline O 0
mutations O 0
of O 0
the O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( I-Disease 0
APC I-Disease 1
) I-Disease 0
tumor I-Disease 0
- O 0
suppressor O 0
gene O 0
result O 0
in O 0
the O 0
hereditary B-Disease 0
colorectal I-Disease 1
cancer I-Disease 1
syndrome I-Disease 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
( O 0
FAP B-Disease 0
) O 0
. O 0

Almost O 0
all O 0
APC B-Disease 1
mutations O 0
that O 0
have O 0
been O 0
identified O 0
are O 0
single O 0
- O 0
nucleotide O 0
alterations O 0
, O 0
small O 0
insertions O 0
, O 0
or O 0
small O 0
deletions O 0
that O 0
would O 0
truncate O 0
the O 0
protein O 0
product O 0
of O 0
the O 0
gene O 0
. O 0

No O 0
well O 0
- O 0
characterized O 0
intragenic O 0
rearrangement O 0
of O 0
APC O 1
has O 0
been O 0
described O 0
, O 0
and O 0
the O 0
prevalence O 0
of O 0
this O 0
type O 0
of O 0
mutation O 0
in O 0
FAP B-Disease 0
patients O 0
is O 0
not O 0
clear O 0
. O 0

We O 0
screened O 0
49 O 0
potential O 0
FAP B-Disease 0
families O 0
and O 0
identified O 0
26 O 0
different O 0
germline O 0
APC B-Disease 1
mutations O 0
in O 0
30 O 0
families O 0
. O 0

Four O 0
of O 0
these O 0
mutations O 0
were O 0
genomic O 0
rearrangements O 0
resulting O 0
from O 0
homologous O 0
and O 0
nonhomologous O 0
recombinations O 0
mediated O 0
by O 0
Alu O 0
elements O 0
. O 0

Two O 0
of O 0
these O 0
four O 0
rearrangements O 0
were O 0
complex O 0
, O 0
involving O 0
deletion O 0
and O 0
insertion O 0
of O 0
nucleotides O 0
. O 0

Of O 0
these O 0
four O 0
rearrangements O 0
, O 0
one O 0
resulted O 0
in O 0
the O 0
deletion O 0
of O 0
exons O 0
11 O 0
and O 0
12 O 0
and O 0
two O 0
others O 0
resulted O 0
in O 0
either O 0
complete O 0
or O 0
partial O 0
deletion O 0
of O 0
exon O 0
14 O 0
. O 0

The O 0
fourth O 0
rearrangement O 0
grossly O 0
altered O 0
the O 0
sequence O 0
within O 0
intron O 0
14 O 0
. O 0

Although O 0
this O 0
rearrangement O 0
did O 0
not O 0
affect O 0
any O 0
coding O 0
sequence O 0
of O 0
APC O 1
at O 0
the O 0
genomic O 0
DNA O 0
level O 0
, O 0
it O 0
caused O 0
inappropriate O 0
splicing O 0
of O 0
exon O 0
14 O 0
. O 0

These O 0
rearrangements O 0
were O 0
initially O 0
revealed O 0
by O 0
analyzing O 0
cDNAs O 0
and O 0
could O 0
not O 0
have O 0
been O 0
identified O 0
by O 0
using O 0
mutation O 0
detection O 0
methods O 0
that O 0
screened O 0
each O 0
exon O 0
individually O 0
. O 0

The O 0
identification O 0
of O 0
a O 0
rearrangement O 0
that O 0
did O 0
not O 0
alter O 0
any O 0
coding O 0
exons O 0
yet O 0
affected O 0
the O 0
splicing O 0
further O 0
underscores O 0
the O 0
importance O 0
of O 0
using O 0
cDNA O 0
for O 0
mutation O 0
analysis O 0
. O 0

The O 0
identification O 0
of O 0
four O 0
genomic O 0
rearrangements O 0
among O 0
30 O 0
mutations O 0
suggests O 0
that O 0
genomic O 0
rearrangements O 0
are O 0
frequent O 0
germline O 0
APC B-Disease 1
mutations O 0
. O 0
. O 0

Detection O 0
of O 0
a O 0
novel O 0
missense O 0
mutation O 0
and O 0
second O 0
recurrent O 0
mutation O 0
in O 0
the O 0
CACNA1A O 0
gene O 0
in O 0
individuals O 0
with O 0
EA B-Disease 0
- I-Disease 0
2 I-Disease 0
and O 0
FHM B-Disease 0
. O 0

Mutations O 0
in O 0
the O 0
brain O 0
specific O 0
P O 0
/ O 0
Q O 0
type O 0
Ca2 O 0
+ O 0
channel O 0
alpha1 O 0
subunit O 0
gene O 0
, O 0
CACNA1A O 0
, O 0
have O 0
been O 0
identified O 0
in O 0
three O 0
clinically O 0
distinct O 0
disorders O 0
, O 0
viz O 0
. O 0
episodic B-Disease 1
ataxia I-Disease 1
type I-Disease 1
2 I-Disease 1
( O 0
EA B-Disease 0
- I-Disease 0
2 I-Disease 0
) O 0
, O 0
familial B-Disease 0
hemiplegic I-Disease 0
migraine I-Disease 0
( O 0
FHM B-Disease 0
) O 0
and O 0
spinocerebellar B-Disease 0
ataxia I-Disease 0
6 I-Disease 0
( O 0
SCA6 B-Disease 1
) O 0
. O 0

For O 0
individuals O 0
with O 0
EA B-Disease 0
- I-Disease 0
2 I-Disease 0
, O 0
the O 0
mutations O 0
described O 0
thus O 0
far O 0
are O 0
presumed O 0
to O 0
result O 0
in O 0
a O 0
truncated O 0
protein O 0
product O 0
. O 0

Several O 0
different O 0
missense O 0
mutations O 0
have O 0
been O 0
identified O 0
in O 0
patients O 0
with O 0
FHM B-Disease 0
. O 0

At O 0
least O 0
two O 0
of O 0
these O 0
mutations O 0
have O 0
been O 0
identified O 0
on O 0
two O 0
different O 0
chromosome O 0
19p13 O 0
haplotypes O 0
and O 0
thus O 0
represent O 0
recurrent O 0
mutations O 0
. O 0

In O 0
the O 0
present O 0
study O 0
, O 0
we O 0
have O 0
screened O 0
several O 0
individuals O 0
for O 0
mutations O 0
in O 0
all O 0
47 O 0
exons O 0
in O 0
the O 0
CACNA1A O 0
gene O 0
by O 0
single O 0
- O 0
strand O 0
conformation O 0
analysis O 0
. O 0

We O 0
have O 0
characterised O 0
a O 0
novel O 0
missense O 0
mutation O 0
, O 0
G5260A O 0
, O 0
in O 0
exon O 0
32 O 0
in O 0
a O 0
family O 0
segregating O 0
for O 0
EA B-Disease 0
- I-Disease 0
2 I-Disease 0
. O 0

The O 0
consequence O 0
of O 0
this O 0
mutation O 0
is O 0
an O 0
amino O 0
acid O 0
substitution O 0
at O 0
a O 0
highly O 0
conserved O 0
position O 0
within O 0
the O 0
CACNA1A O 0
gene O 0
. O 0

This O 0
represents O 0
the O 0
first O 0
point O 0
mutation O 0
not O 0
resulting O 0
in O 0
a O 0
proposed O 0
truncated O 0
protein O 0
. O 0

Furthermore O 0
, O 0
this O 0
mutation O 0
has O 0
been O 0
detected O 0
in O 0
a O 0
family O 0
member O 0
with O 0
mild O 0
clinical O 0
signs O 0
including O 0
only O 0
migraine B-Disease 0
. O 0

Additionally O 0
, O 0
a O 0
second O 0
previously O 0
identified O 0
recurrent O 0
muta O 0
tion O 0
, O 0
C2272T O 0
, O 0
in O 0
exon O 0
16 O 0
has O 0
been O 0
discovered O 0
in O 0
a O 0
patient O 0
with O 0
FHM B-Disease 0
. O 0
. O 0

Analbuminemia B-Disease 0
in O 0
a O 0
neonate O 0
. O 0

A O 0
small O 0
- O 0
for O 0
- O 0
gestational O 0
- O 0
age O 0
infant O 0
, O 0
found O 0
to O 0
have O 0
analbuminemia B-Disease 1
in O 0
the O 0
neonatal O 0
period O 0
, O 0
is O 0
reported O 0
and O 0
the O 0
twelve O 0
cases O 0
recorded O 0
in O 0
the O 0
world O 0
literature O 0
are O 0
reviewed O 0
. O 0

Patients O 0
lacking O 0
this O 0
serum O 0
protein O 0
are O 0
essentially O 0
asymptomatic O 0
, O 0
apart O 0
from O 0
minimal O 0
ankle B-Disease 1
edema I-Disease 1
and O 0
ease B-Disease 0
of I-Disease 0
fatigue I-Disease 0
. O 0

Apparent O 0
compensatory O 0
mechanisms O 0
which O 0
come O 0
into O 0
play O 0
when O 0
serum O 0
albumin O 0
is O 0
low O 0
include O 0
prolonged O 0
half O 0
- O 0
life O 0
of O 0
albumin O 0
and O 0
transferrin O 0
, O 0
an O 0
increase O 0
in O 0
serum O 0
globulins O 0
, O 0
beta O 0
lipoprotein O 0
, O 0
and O 0
glycoproteins O 0
, O 0
arterial B-Disease 1
hypotension I-Disease 1
with O 0
reduced O 0
capillary O 0
hydrostatic O 0
pressure O 0
, O 0
and O 0
the O 0
ability O 0
to O 0
respond O 0
with O 0
rapid O 0
sodium O 0
and O 0
chloride O 0
diuresis O 0
in O 0
response O 0
to O 0
small O 0
volume O 0
changes O 0
. O 0

Examination O 0
of O 0
plasma O 0
amino O 0
acids O 0
, O 0
an O 0
investigation O 0
not O 0
previously O 0
reported O 0
, O 0
revealed O 0
an O 0
extremely O 0
low O 0
plasma O 0
tryptophan O 0
level O 0
, O 0
a O 0
finding O 0
which O 0
may O 0
be O 0
important O 0
in O 0
view O 0
of O 0
the O 0
role O 0
of O 0
tryptophan O 0
in O 0
albumin O 0
synthesis O 0
. O 0
. O 0

Histidinemia B-Disease 1
. O 0

Classical O 0
and O 0
atypical O 0
form O 0
in O 0
siblings O 0
. O 0

Two O 0
brothers O 0
, O 0
6 O 0
and O 0
13 O 0
years O 0
old O 0
, O 0
had O 0
histidinemia B-Disease 1
. O 0

On O 0
the O 0
basis O 0
of O 0
clinical O 0
and O 0
biochemical O 0
observations O 0
, O 0
the O 0
younger O 0
boy O 0
was O 0
considered O 0
to O 0
have O 0
a O 0
classical O 0
type O 0
of O 0
the O 0
disease O 0
, O 0
while O 0
the O 0
older O 0
boy O 0
had O 0
an O 0
atypical O 0
form O 0
characterized O 0
by O 0
partial O 0
impairment O 0
of O 0
the O 0
skin O 0
histidase O 0
activity O 0
and O 0
a O 0
moderately O 0
prolonged O 0
half O 0
- O 0
life O 0
of O 0
blood O 0
histidine O 0
. O 0

The O 0
mother O 0
is O 0
a O 0
heterozygous O 0
carrier O 0
, O 0
while O 0
the O 0
father O 0
and O 0
sister O 0
seem O 0
to O 0
be O 0
normal O 0
. O 0
. O 0

Carrier O 0
detection O 0
of O 0
pyruvate B-Disease 0
carboxylase I-Disease 0
deficiency I-Disease 0
in O 0
fibroblasts O 0
and O 0
lymphocytes O 0
. O 0

Pyruvate O 0
carboxylase O 0
( O 0
E O 0
. O 0
C O 0
. O 0
6 O 0
. O 0
4 O 0
. O 0
1 O 0
. O 0
1 O 0
) O 0
activity O 0
was O 0
determined O 0
in O 0
the O 0
circulating O 0
peripheral O 0
lymphocytes O 0
and O 0
cultured O 0
skin O 0
fibroblasts O 0
from O 0
the O 0
family O 0
of O 0
a O 0
patient O 0
with O 0
hepatic O 0
, O 0
cerebral O 0
, O 0
renal O 0
cortical O 0
, O 0
leukocyte O 0
, O 0
and O 0
fibroblast O 0
pyruvate B-Disease 0
carboxylase I-Disease 0
deficiency I-Disease 0
( O 0
PC B-Disease 1
Portland I-Disease 1
deficiency I-Disease 1
) O 0
. O 0

Lymphocyte O 0
activities O 0
were O 0
mother O 0
, O 0
33 O 0
- O 0
- O 0
39 O 0
% O 0
; O 0
father O 0
, O 0
11 O 0
- O 0
- O 0
29 O 0
% O 0
; O 0
brother O 0
, O 0
82 O 0
- O 0
- O 0
103 O 0
% O 0
; O 0
and O 0
sister O 0
, O 0
38 O 0
- O 0
- O 0
48 O 0
% O 0
of O 0
the O 0
lowest O 0
normal O 0
. O 0

Fibroblasts O 0
from O 0
the O 0
patients O 0
mother O 0
and O 0
father O 0
had O 0
42 O 0
and O 0
34 O 0
% O 0
, O 0
respectively O 0
, O 0
of O 0
the O 0
activity O 0
of O 0
the O 0
lowest O 0
normal O 0
. O 0

These O 0
data O 0
demonstrate O 0
that O 0
the O 0
disease O 0
is O 0
inherited O 0
in O 0
an O 0
autosomal O 0
recessive O 0
manner O 0
and O 0
that O 0
lymphocytes O 0
and O 0
fibroblasts O 0
can O 0
be O 0
used O 0
to O 0
detect O 0
carriers O 0
. O 0

Neither O 0
pyruvate O 0
carboxylase O 0
nor O 0
mitochondrial O 0
PEPCK O 0
activity O 0
in O 0
lymphocytes O 0
was O 0
increased O 0
by O 0
a O 0
21 O 0
- O 0
hr O 0
fast O 0
. O 0

Glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
variants O 0
from O 0
Italian O 0
subjects O 0
associated O 0
with O 0
severe B-Disease 1
neonatal I-Disease 1
jaundice I-Disease 1
. O 0

Screening O 0
for O 0
the O 0
G6PD B-Disease 0
deficiency I-Disease 0
was O 0
carried O 0
out O 0
at O 0
the O 0
Maternity O 0
Division O 0
of O 0
the O 0
Galliera O 0
Hospital O 0
in O 0
Genoa O 0
, O 0
Italy O 0
. O 0

Two O 0
groups O 0
of O 0
subjects O 0
with O 0
hyperbilirubinaemia B-Disease 0
of O 0
non O 0
- O 0
immunological O 0
origin O 0
were O 0
examined O 0
( O 0
a O 0
) O 0
302 O 0
newborn O 0
babies O 0
of O 0
Sardinian O 0
extraction O 0
( O 0
on O 0
cord O 0
blood O 0
) O 0
and O 0
( O 0
b O 0
) O 0
201 O 0
newborn O 0
babies O 0
of O 0
south O 0
Italian O 0
ancestry O 0
( O 0
on O 0
peripheral O 0
blood O 0
) O 0
. O 0

Among O 0
503 O 0
subjects O 0
, O 0
43 O 0
showed O 0
an O 0
enzyme O 0
deficiency O 0
; O 0
in O 0
39 O 0
the O 0
defect O 0
was O 0
of O 0
the O 0
Mediterranean O 0
type O 0
. O 0

In O 0
one O 0
case O 0
, O 0
previously O 0
described O 0
, O 0
the O 0
enzyme O 0
was O 0
of O 0
the O 0
A O 0
- O 0
type O 0
. O 0

In O 0
the O 0
remaining O 0
cases O 0
three O 0
different O 0
variants O 0
were O 0
identified O 0
. O 0

In O 0
the O 0
present O 0
work O 0
these O 0
three O 0
cases O 0
, O 0
each O 0
with O 0
severe B-Disease 1
neonatal I-Disease 1
jaundice I-Disease 1
, O 0
are O 0
reported O 0
. O 0

Their O 0
parents O 0
originated O 0
from O 0
Calabria O 0
, O 0
from O 0
Sardinia O 0
and O 0
from O 0
Sicily O 0
. O 0

The O 0
abnormal O 0
enzymes O 0
are O 0
respectively O 0
designated O 0
as O 0
GdDcbrousse O 0
- O 0
like O 0
, O 0
GdGallura O 0
and O 0
GdAgrigento O 0
. O 0
. O 0

Cytogenetic O 0
investigations O 0
in O 0
families O 0
with O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
. O 0

Chromosomal O 0
studies O 0
were O 0
performed O 0
on O 0
peripheral O 0
blood O 0
lymphocytes O 0
and O 0
cultured O 0
skin O 0
fibroblasts O 0
from O 0
five O 0
Israeli O 0
- O 0
Moroccan O 0
families O 0
with O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
. O 0

A O 0
total O 0
of O 0
24 O 0
individuals O 0
, O 0
including O 0
seven O 0
propositi O 0
, O 0
was O 0
investigated O 0
. O 0

Among O 0
the O 0
probands O 0
, O 0
significantly O 0
elevated O 0
rates O 0
of O 0
chromosome O 0
damage O 0
were O 0
observed O 0
in O 0
both O 0
blood O 0
and O 0
skin O 0
. O 0

Skin O 0
fibroblasts O 0
of O 0
affected O 0
individuals O 0
showed O 0
several O 0
orders O 0
of O 0
magnitude O 0
more O 0
chromosome O 0
breakage O 0
than O 0
lymphocytes O 0
. O 0

Increased O 0
rates O 0
of O 0
chromosome O 0
damage O 0
were O 0
also O 0
observed O 0
in O 0
the O 0
fibroblasts O 0
of O 0
some O 0
phenotypically O 0
normal O 0
family O 0
members O 0
( O 0
obligate O 0
heterozygotes O 0
and O 0
sibs O 0
) O 0
when O 0
compared O 0
to O 0
normal O 0
controls O 0
. O 0

An O 0
apparent O 0
abnormal O 0
clone O 0
of O 0
cells O 0
, O 0
possessing O 0
a O 0
large O 0
acrocentric O 0
marker O 0
chromosome O 0
( O 0
14q O 0
+ O 0
) O 0
, O 0
was O 0
observed O 0
in O 0
varying O 0
proportions O 0
among O 0
cells O 0
of O 0
all O 0
the O 0
propositi O 0
( O 0
2 O 0
- O 0
5 O 0
% O 0
of O 0
lymphocytes O 0
; O 0
1 O 0
- O 0
9 O 0
% O 0
of O 0
fibroblasts O 0
) O 0
. O 0
. O 0

Prenatal O 0
diagnosis O 0
of O 0
Wolman B-Disease 0
disease I-Disease 0
. O 0

Two O 0
pregnancies O 0
at O 0
risk O 0
for O 0
Wolman B-Disease 0
disease I-Disease 0
were O 0
monitored O 0
by O 0
assay O 0
and O 0
electrophoresis O 0
of O 0
acid O 0
lipase O 0
in O 0
cultured O 0
amniotic O 0
- O 0
fluid O 0
cells O 0
. O 0

Cells O 0
from O 0
patient O 0
1 O 0
had O 0
5 O 0
% O 0
of O 0
control O 0
levels O 0
of O 0
acid O 0
lipase O 0
, O 0
using O 0
14C O 0
- O 0
triolein O 0
as O 0
substrate O 0
; O 0
however O 0
, O 0
when O 0
artificial O 0
substrates O 0
( O 0
esters O 0
of O 0
4 O 0
- O 0
methylumbelliferone O 0
and O 0
p O 0
- O 0
nitrophenol O 0
) O 0
were O 0
used O 0
to O 0
measure O 0
acid O 0
lipase O 0
, O 0
these O 0
cells O 0
had O 0
30 O 0
% O 0
of O 0
control O 0
levels O 0
. O 0

Electrophoresis O 0
of O 0
cell O 0
extracts O 0
revealed O 0
the O 0
absence O 0
of O 0
the O 0
A O 0
form O 0
of O 0
acid O 0
lipase O 0
, O 0
consistent O 0
with O 0
the O 0
diagnosis O 0
of O 0
Wolman B-Disease 0
disease I-Disease 0
. O 0

Analysis O 0
of O 0
fetal O 0
tissues O 0
following O 0
prostaglandin O 0
termination O 0
of O 0
this O 0
pregnancy O 0
confirmed O 0
the O 0
diagnosis O 0
. O 0

Assay O 0
of O 0
fetal O 0
- O 0
skin O 0
fibroblasts O 0
with O 0
14C O 0
- O 0
triolein O 0
, O 0
as O 0
well O 0
as O 0
with O 0
artificial O 0
substrates O 0
, O 0
showed O 0
marked O 0
deficiency O 0
of O 0
acid O 0
lipase O 0
activity O 0
. O 0

Electrophoresis O 0
of O 0
fetal O 0
- O 0
tissue O 0
extracts O 0
also O 0
demonstrated O 0
the O 0
absence O 0
of O 0
the O 0
A O 0
form O 0
of O 0
acid O 0
lipase O 0
. O 0

Amniotic O 0
- O 0
fluid O 0
cells O 0
from O 0
patient O 0
2 O 0
showed O 0
normal O 0
levels O 0
of O 0
acid O 0
lipase O 0
with O 0
all O 0
substrates O 0
tested O 0
; O 0
the O 0
electrophoretic O 0
pattern O 0
of O 0
acid O 0
lipase O 0
was O 0
normal O 0
. O 0

The O 0
results O 0
suggest O 0
that O 0
the O 0
prenatal O 0
diagnosis O 0
of O 0
Wolman B-Disease 0
disease I-Disease 0
be O 0
made O 0
using O 0
the O 0
radioassay O 0
of O 0
acid O 0
lipase O 0
and O 0
/ O 0
or O 0
electrophoresis O 0
. O 0
. O 0

Malignant B-Disease 1
neoplasms I-Disease 1
in O 0
the O 0
families O 0
of O 0
patients O 0
with O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
. O 0

Ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
( O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
) O 0
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
syndrome I-Disease 1
associated O 0
with O 0
a O 0
greatly O 0
increased O 0
incidence O 0
of O 0
malignant B-Disease 0
neoplasms I-Disease 1
in O 0
homozygous O 0
affected O 0
individuals O 0
. O 0

Heterozygotes O 0
for O 0
the O 0
gene O 0
for O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
are O 0
thought O 0
to O 0
comprise O 0
about O 0
1 O 0
% O 0
of O 0
the O 0
general O 0
population O 0
and O 0
, O 0
therefore O 0
, O 0
it O 0
is O 0
important O 0
to O 0
know O 0
whether O 0
this O 0
gene O 0
also O 0
predisposes O 0
the O 0
heterozygous O 0
carrier O 0
to O 0
cancers B-Disease 0
. O 0

Heterozygous O 0
carriers O 0
of O 0
this O 0
gene O 0
are O 0
common O 0
among O 0
the O 0
close O 0
relatives O 0
of O 0
patients O 0
with O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
, O 0
although O 0
individual O 0
carriers O 0
cannot O 0
be O 0
identified O 0
by O 0
any O 0
clinical O 0
criterion O 0
or O 0
laboratory O 0
test O 0
. O 0

For O 0
this O 0
reason O 0
, O 0
we O 0
compared O 0
the O 0
incidence O 0
of O 0
death O 0
from O 0
malignant B-Disease 0
neoplasms I-Disease 1
in O 0
2 O 0
families O 0
of O 0
patients O 0
with O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
to O 0
that O 0
expected O 0
in O 0
a O 0
random O 0
sample O 0
of O 0
the O 0
general O 0
population O 0
. O 0

There O 0
were O 0
59 O 0
deaths O 0
from O 0
malignant B-Disease 0
neoplasms I-Disease 1
in O 0
relatives O 0
dying O 0
before O 0
age O 0
75 O 0
, O 0
compared O 0
to O 0
42 O 0
. O 0

6 O 0
expected O 0
( O 0
p O 0
less O 0
than O 0
0 O 0
. O 0
02 O 0
) O 0
. O 0

For O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
heterozygotes O 0
younger O 0
than O 0
age O 0
45 O 0
, O 0
the O 0
risk O 0
of O 0
dying O 0
from O 0
a O 0
malignant B-Disease 1
neoplasm I-Disease 1
was O 0
estimated O 0
to O 0
be O 0
greater O 0
than O 0
5 O 0
times O 0
the O 0
risk O 0
for O 0
the O 0
general O 0
population O 0
. O 0

A B-Disease 1
- I-Disease 1
T I-Disease 1
heterozygotes O 0
may O 0
comprise O 0
more O 0
than O 0
5 O 0
% O 0
of O 0
all O 0
persons O 0
dying O 0
from O 0
a O 0
cancer B-Disease 1
before O 0
age O 0
45 O 0
. O 0

The O 0
incidence O 0
of O 0
ovarian B-Disease 1
, I-Disease 1
gastric I-Disease 1
, I-Disease 1
and I-Disease 1
biliary I-Disease 1
system I-Disease 1
carcinomas I-Disease 1
and O 0
of O 0
leukemia B-Disease 1
and O 0
lymphoma B-Disease 1
was O 0
increased O 0
in O 0
these O 0
A B-Disease 1
- I-Disease 1
T I-Disease 1
families O 0
. O 0

Other O 0
neoplasms B-Disease 1
that O 0
may O 0
be O 0
associated O 0
with O 0
this O 0
gene O 0
in O 0
heterozygotes O 0
include O 0
pancreatic B-Disease 0
, I-Disease 0
basal I-Disease 0
cell I-Disease 0
, I-Disease 0
colonic I-Disease 0
, I-Disease 0
breast I-Disease 0
, I-Disease 0
and I-Disease 0
cervical I-Disease 0
carcinomas I-Disease 0
. O 0

Striking O 0
prevalence O 0
of O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
in O 0
" O 0
healthy O 0
" O 0
w27 O 0
positive O 0
males O 0
and O 0
females O 0
. O 0

Ankylosing B-Disease 1
spondylitis I-Disease 1
is O 0
diagnosed O 0
once O 0
or O 0
twice O 0
in O 0
each O 0
1000 O 0
males O 0
and O 0
one O 0
tenth O 0
as O 0
frequently O 0
in O 0
females O 0
, O 0
but O 0
the O 0
true O 0
prevalence O 0
is O 0
unknown O 0
. O 0

Indentification O 0
of O 0
genetic O 0
marker O 0
, O 0
HL O 0
- O 0
A O 0
W27 O 0
, O 0
for O 0
susceptible O 0
persons O 0
has O 0
provided O 0
a O 0
tool O 0
facilitating O 0
epidemiologic O 0
studies O 0
and O 0
allowing O 0
identification O 0
of O 0
" O 0
control O 0
" O 0
populations O 0
without O 0
the O 0
marker O 0
. O 0

Evaluation O 0
by O 0
postal O 0
questionnaires O 0
, O 0
and O 0
pelvic O 0
radiography O 0
of O 0
78 O 0
HL O 0
- O 0
A O 0
27W O 0
- O 0
positive O 0
blood O 0
donors O 0
selected O 0
from O 0
a O 0
group O 0
of O 0
apparently O 0
healthy O 0
subjects O 0
revealed O 0
14 O 0
who O 0
satisfied O 0
the O 0
criteria O 0
for O 0
definite O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
. O 0

The O 0
prevalence O 0
was O 0
similar O 0
in O 0
both O 0
sexes O 0
. O 0

One O 0
hundred O 0
and O 0
twenty O 0
- O 0
six O 0
W27 O 0
- O 0
negative O 0
controls O 0
matched O 0
for O 0
race O 0
, O 0
sex O 0
, O 0
and O 0
age O 0
failed O 0
to O 0
yield O 0
a O 0
single O 0
case O 0
. O 0

For O 0
a O 0
person O 0
of O 0
either O 0
sex O 0
with O 0
HL O 0
- O 0
A O 0
W27 O 0
, O 0
there O 0
appears O 0
to O 0
be O 0
about O 0
a O 0
20 O 0
per O 0
cent O 0
chance O 0
that O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
will O 0
develop O 0
, O 0
suggesting O 0
a O 0
prevalence O 0
of O 0
10 O 0
to O 0
15 O 0
per O 0
thousand O 0
. O 0

Hitherto O 0
accepted O 0
figures O 0
may O 0
underestimate O 0
the O 0
frequency O 0
by O 0
a O 0
factor O 0
of O 0
10 O 0
to O 0
20 O 0
. O 0
. O 0

Analbuminemia B-Disease 0
in O 0
an O 0
American O 0
Indian O 0
girl O 0
. O 0

Analbuminemia B-Disease 0
was O 0
fortuitously O 0
detected O 0
in O 0
a O 0
nonedematous O 0
12 O 0
- O 0
year O 0
- O 0
old O 0
American O 0
Indian O 0
girl O 0
with O 0
atopic B-Disease 0
dermatitis I-Disease 0
, O 0
mild O 0
bronchial B-Disease 0
asthma I-Disease 0
, O 0
a O 0
mild O 0
seizure B-Disease 0
disorder I-Disease 0
, O 0
and O 0
hyperlipoproteinemia B-Disease 1
with O 0
a O 0
corneal B-Disease 1
arcus I-Disease 1
. O 0

Immunologic O 0
methods O 0
revealed O 0
trace O 0
amounts O 0
( O 0
17 O 0
mg O 0
/ O 0
100 O 0
ml O 0
) O 0
of O 0
apparently O 0
normal O 0
serum O 0
albumin O 0
. O 0

The O 0
patients O 0
parents O 0
were O 0
remotely O 0
related O 0
. O 0

The O 0
pedigree O 0
and O 0
clinical O 0
findings O 0
were O 0
compatible O 0
with O 0
autosomal O 0
recessive O 0
transmission O 0
of O 0
analbuminemia B-Disease 1
. O 0

Heterozygotes O 0
had O 0
subnormal O 0
levels O 0
of O 0
serum O 0
albumin O 0
. O 0

The O 0
Gc O 0
- O 0
locus O 0
is O 0
closely O 0
linked O 0
to O 0
the O 0
structural O 0
albumin O 0
locus O 0
. O 0

Gc O 0
- O 0
protein O 0
levels O 0
were O 0
normal O 0
in O 0
the O 0
patient O 0
and O 0
together O 0
with O 0
normal O 0
chromosomal O 0
banding O 0
studies O 0
make O 0
it O 0
unlikely O 0
that O 0
a O 0
chromosomal O 0
deletion O 0
caused O 0
analbuminemia B-Disease 1
. O 0

Gc O 0
- O 0
types O 0
in O 0
the O 0
family O 0
were O 0
compatible O 0
with O 0
, O 0
but O 0
did O 0
not O 0
prove O 0
, O 0
linkage O 0
of O 0
analbuminemia B-Disease 1
to O 0
the O 0
Gc O 0
- O 0
locus O 0
. O 0

These O 0
findings O 0
suggest O 0
a O 0
" O 0
thalassemia B-Disease 0
" O 0
- O 0
like O 0
mutation O 0
for O 0
this O 0
disorder O 0
. O 0
. O 0

Deletion O 0
of O 0
the O 0
KIT O 0
and O 0
PDGFRA O 0
genes O 0
in O 0
a O 0
patient O 0
with O 0
piebaldism B-Disease 1
. O 0

We O 0
have O 0
previously O 0
shown O 0
that O 0
human O 0
piebaldism B-Disease 1
results O 0
from O 0
mutations O 0
of O 0
the O 0
KIT O 0
gene O 0
, O 0
which O 0
encodes O 0
the O 0
receptor O 0
for O 0
the O 0
mast O 0
/ O 0
stem O 0
cell O 0
growth O 0
factor O 0
and O 0
is O 0
located O 0
in O 0
chromosome O 0
segment O 0
4q12 O 0
. O 0

Using O 0
DNA O 0
of O 0
a O 0
patient O 0
with O 0
piebaldism B-Disease 1
, O 0
mental B-Disease 1
retardation I-Disease 1
, O 0
and O 0
multiple B-Disease 0
congenital I-Disease 0
anomalies I-Disease 0
associated O 0
with O 0
a O 0
46 O 0
, O 0
XY O 0
, O 0
del O 0
( O 0
4 O 0
) O 0
( O 0
q12q21 O 0
. O 0
1 O 0
) O 0
karyotype O 0
, O 0
we O 0
carried O 0
out O 0
quantitative O 0
Southern O 0
blot O 0
hybridization O 0
analyses O 0
of O 0
the O 0
KIT O 0
gene O 0
and O 0
the O 0
adjacent O 0
PDGFRA O 0
( O 0
platelet O 0
- O 0
derived O 0
growth O 0
factor O 0
receptor O 0
alpha O 0
subunit O 0
) O 0
genes O 0
. O 0

The O 0
patient O 0
was O 0
hemizygous O 0
for O 0
both O 0
the O 0
KIT O 0
and O 0
PDGFRA O 0
genes O 0
, O 0
indicating O 0
that O 0
both O 0
of O 0
these O 0
genes O 0
are O 0
included O 0
within O 0
the O 0
deleted O 0
region O 0
. O 0

Therefore O 0
, O 0
deletion O 0
of O 0
the O 0
KIT O 0
and O 0
PDGFRA O 0
genes O 0
may O 0
account O 0
for O 0
the O 0
piebald B-Disease 1
phenotype O 0
in O 0
this O 0
patient O 0
. O 0

A O 0
germ O 0
line O 0
mutation O 0
within O 0
the O 0
coding O 0
sequence O 0
for O 0
the O 0
putative O 0
5 O 0
- O 0
phosphoribosyl O 0
- O 0
1 O 0
- O 0
pyrophosphate O 0
binding O 0
site O 0
of O 0
hypoxanthine O 0
- O 0
guanine O 0
phosphoribosyltransferase O 0
( O 0
HPRT O 0
) O 0
in O 0
a O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
patient O 0
: O 0
missense O 0
mutations O 0
within O 0
a O 0
functionally O 0
important O 0
region O 0
probably O 0
cause O 0
disease O 0
. O 0

Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
caused O 0
by O 0
a O 0
complete B-Disease 1
deficiency I-Disease 1
of I-Disease 1
hypoxanthine I-Disease 1
guanine I-Disease 1
phosphoribosyltransferase I-Disease 1
( O 0
HPRT O 0
) O 0
is O 0
the O 0
result O 0
of O 0
a O 0
heterogeneous O 0
group O 0
of O 0
germ O 0
line O 0
mutations O 0
. O 0

Identification O 0
of O 0
each O 0
mutant O 0
gene O 0
provides O 0
valuable O 0
information O 0
as O 0
to O 0
the O 0
type O 0
of O 0
mutation O 0
that O 0
occurs O 0
spontaneously O 0
. O 0

We O 0
report O 0
here O 0
a O 0
newly O 0
identified O 0
HPRT O 0
mutation O 0
in O 0
a O 0
Japanese O 0
patient O 0
with O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
. O 0

This O 0
gene O 0
, O 0
designated O 0
HPRT O 0
Tokyo O 0
, O 0
had O 0
a O 0
single O 0
nucleotide O 0
change O 0
from O 0
G O 0
to O 0
A O 0
, O 0
as O 0
identified O 0
by O 0
sequencing O 0
cDNA O 0
amplified O 0
by O 0
the O 0
polymerase O 0
chain O 0
reaction O 0
. O 0

Allele O 0
specific O 0
oligonucleotide O 0
hybridization O 0
analysis O 0
using O 0
amplified O 0
genomic O 0
DNA O 0
showed O 0
that O 0
the O 0
mutant O 0
gene O 0
was O 0
transmitted O 0
from O 0
the O 0
maternal O 0
germ O 0
line O 0
. O 0

This O 0
mutation O 0
would O 0
lead O 0
to O 0
an O 0
amino O 0
acid O 0
substitution O 0
of O 0
Asp O 0
for O 0
Gly O 0
at O 0
the O 0
amino O 0
acid O 0
position O 0
140 O 0
located O 0
within O 0
the O 0
putative O 0
5 O 0
- O 0
phosphoribosyl O 0
- O 0
1 O 0
- O 0
pyrophosphate O 0
( O 0
PRPP O 0
) O 0
binding O 0
region O 0
. O 0

Missense O 0
mutations O 0
in O 0
human O 0
HPRT B-Disease 1
deficient I-Disease 1
patients O 0
thus O 0
far O 0
reported O 0
tend O 0
to O 0
accumulate O 0
in O 0
this O 0
functionally O 0
active O 0
region O 0
. O 0

However O 0
, O 0
a O 0
comparison O 0
of O 0
the O 0
data O 0
suggested O 0
that O 0
both O 0
missense O 0
and O 0
synonymous O 0
mutations O 0
can O 0
occur O 0
at O 0
any O 0
coding O 0
sequence O 0
of O 0
the O 0
human O 0
germ O 0
line O 0
HPRT O 0
gene O 0
, O 0
but O 0
that O 0
a O 0
limited O 0
percentage O 0
of O 0
all O 0
the O 0
missense O 0
mutations O 0
cause O 0
disease O 0
. O 0

The O 0
probability O 0
that O 0
a O 0
mutation O 0
will O 0
cause O 0
disease O 0
tends O 0
to O 0
be O 0
higher O 0
when O 0
the O 0
missense O 0
mutation O 0
is O 0
within O 0
a O 0
functionally O 0
important O 0
sequence O 0
. O 0
. O 0

Characterisation O 0
of O 0
a O 0
new O 0
rare O 0
fragile O 0
site O 0
easily O 0
confused O 0
with O 0
the O 0
fragile B-Disease 1
X I-Disease 1
. O 0

A O 0
new O 0
fragile O 0
site O 0
( O 0
FRAXE O 0
) O 0
in O 0
Xq28 O 0
is O 0
described O 0
. O 0

It O 0
appears O 0
to O 0
be O 0
a O 0
typical O 0
folate O 0
sensitive O 0
fragile O 0
site O 0
. O 0

The O 0
fragile O 0
site O 0
is O 0
not O 0
associated O 0
with O 0
mental B-Disease 1
retardation I-Disease 1
, O 0
it O 0
does O 0
not O 0
give O 0
abnormal O 0
results O 0
when O 0
subjected O 0
to O 0
Southern O 0
analysis O 0
with O 0
probe O 0
pfxa3 O 0
which O 0
detects O 0
the O 0
unstable O 0
DNA O 0
sequence O 0
characteristic O 0
of O 0
fragile B-Disease 1
X I-Disease 1
syndrome I-Disease 1
. O 0

In O 0
situ O 0
hybridization O 0
mapping O 0
locates O 0
the O 0
fragile O 0
site O 0
between O 0
150 O 0
kb O 0
and O 0
600 O 0
kb O 0
distal O 0
to O 0
FRAXA O 0
. O 0

The O 0
distinction O 0
between O 0
the O 0
two O 0
fragile O 0
sites O 0
is O 0
important O 0
clinically O 0
since O 0
cytogenetic O 0
detection O 0
of O 0
FRAXE O 0
, O 0
without O 0
molecular O 0
analysis O 0
, O 0
could O 0
result O 0
in O 0
misdiagnosis O 0
of O 0
fragile B-Disease 1
X I-Disease 1
syndrome I-Disease 1
. O 0
. O 0

The O 0
Norrie B-Disease 1
disease I-Disease 1
gene O 0
maps O 0
to O 0
a O 0
150 O 0
kb O 0
region O 0
on O 0
chromosome O 0
Xp11 O 0
. O 0
3 O 0
. O 0

Norrie B-Disease 1
disease I-Disease 1
is O 0
a O 0
human O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
recessive I-Disease 1
disorder I-Disease 1
of O 0
unknown O 0
etiology O 0
characterized O 0
by O 0
congenital B-Disease 0
blindness I-Disease 1
, O 0
sensory B-Disease 1
neural I-Disease 1
deafness I-Disease 1
and O 0
mental B-Disease 1
retardation I-Disease 1
. O 0

This O 0
disease O 0
gene O 0
was O 0
previously O 0
linked O 0
to O 0
the O 0
DXS7 O 0
( O 0
L1 O 0
. O 0
28 O 0
) O 0
locus O 0
and O 0
the O 0
MAO O 0
genes O 0
in O 0
band O 0
Xp11 O 0
. O 0

3 O 0
3 O 0
. O 0

We O 0
report O 0
here O 0
fine O 0
physical O 0
mapping O 0
of O 0
the O 0
obligate O 0
region O 0
containing O 0
the O 0
Norrie B-Disease 1
disease I-Disease 1
gene O 0
( O 0
NDP O 0
) O 0
defined O 0
by O 0
a O 0
recombination O 0
and O 0
by O 0
the O 0
smallest O 0
submicroscopic O 0
chromosomal O 0
deletion O 0
associated O 0
with O 0
Norrie B-Disease 1
disease I-Disease 1
identified O 0
to O 0
date O 0
. O 0

Analysis O 0
, O 0
using O 0
in O 0
addition O 0
two O 0
overlapping O 0
YAC O 0
clones O 0
from O 0
this O 0
region O 0
, O 0
allowed O 0
orientation O 0
of O 0
the O 0
MAOA O 0
and O 0
MAOB O 0
genes O 0
in O 0
a O 0
5 O 0
- O 0
3 O 0
- O 0
3 O 0
- O 0
5 O 0
configuration O 0
. O 0

A O 0
recombination O 0
event O 0
between O 0
a O 0
( O 0
GT O 0
) O 0
n O 0
polymorphism O 0
in O 0
intron O 0
2 O 0
of O 0
the O 0
MAOB O 0
gene O 0
and O 0
the O 0
NDP O 0
locus O 0
, O 0
in O 0
a O 0
family O 0
previously O 0
reported O 0
to O 0
have O 0
a O 0
recombination O 0
between O 0
DXS7 O 0
and O 0
NDP O 0
, O 0
delineates O 0
a O 0
flanking O 0
marker O 0
telomeric O 0
to O 0
this O 0
disease O 0
gene O 0
. O 0

An O 0
anonymous O 0
DNA O 0
probe O 0
, O 0
dc12 O 0
, O 0
present O 0
in O 0
one O 0
of O 0
the O 0
YACs O 0
and O 0
in O 0
a O 0
patient O 0
with O 0
a O 0
submicroscopic O 0
deletion O 0
which O 0
includes O 0
MAOA O 0
and O 0
MAOB O 0
but O 0
not O 0
L1 O 0
. O 0

28 O 0
, O 0
serves O 0
as O 0
a O 0
flanking O 0
marker O 0
centromeric O 0
to O 0
the O 0
disease O 0
gene O 0
. O 0

An O 0
Alu O 0
- O 0
PCR O 0
fragment O 0
from O 0
the O 0
right O 0
arm O 0
of O 0
the O 0
MAO O 0
YAC O 0
( O 0
YMAO O 0
. O 0
AluR O 0
) O 0
is O 0
not O 0
deleted O 0
in O 0
this O 0
patient O 0
and O 0
also O 0
delineates O 0
the O 0
centromeric O 0
extent O 0
of O 0
the O 0
obligate O 0
disease O 0
region O 0
. O 0

The O 0
apparent O 0
order O 0
of O 0
these O 0
loci O 0
is O 0
telomere O 0
. O 0

DXS7 O 0
- O 0
MAOA O 0
- O 0
MAOB O 0
- O 0
NDP O 0
- O 0
dc12 O 0
- O 0
YMAO O 0
DXS7 O 0
- O 0
MAOA O 0
- O 0
MAOB O 0
- O 0
NDP O 0
- O 0
dc12 O 0
- O 0
YMAO O 0
. O 0

AluR O 0
. O 0
centromere O 0
. O 0

Together O 0
these O 0
data O 0
define O 0
the O 0
obligate O 0
region O 0
containing O 0
the O 0
NDP O 0
gene O 0
to O 0
a O 0
chromosomal O 0
segment O 0
less O 0
than O 0
150 O 0
kb O 0
. O 0

Molecular O 0
basis O 0
of O 0
phenylketonuria B-Disease 0
and O 0
related O 0
hyperphenylalaninemias B-Disease 0
: O 0
mutations O 0
and O 0
polymorphisms O 0
in O 0
the O 0
human O 0
phenylalanine O 0
hydroxylase O 0
gene O 0
. O 0

Mutations O 0
in O 0
the O 0
human O 0
phenylalanine O 0
hydroxylase O 0
gene O 0
producing O 0
phenylketonuria B-Disease 0
or O 0
hyperphenylalaninemia B-Disease 1
have O 0
now O 0
been O 0
identified O 0
in O 0
many O 0
patients O 0
from O 0
various O 0
ethnic O 0
groups O 0
. O 0

These O 0
mutations O 0
all O 0
exhibit O 0
a O 0
high O 0
degree O 0
of O 0
association O 0
with O 0
specific O 0
restriction O 0
fragment O 0
- O 0
length O 0
polymorphism O 0
haplotypes O 0
at O 0
the O 0
PAH O 0
locus O 0
. O 0

About O 0
50 O 0
of O 0
these O 0
mutations O 0
are O 0
single O 0
- O 0
base O 0
substitutions O 0
, O 0
including O 0
six O 0
nonsense O 0
mutations O 0
and O 0
eight O 0
splicing O 0
mutations O 0
, O 0
with O 0
the O 0
remainder O 0
being O 0
missense O 0
mutations O 0
. O 0

One O 0
splicing O 0
mutation O 0
results O 0
in O 0
a O 0
3 O 0
amino O 0
acid O 0
in O 0
- O 0
frame O 0
insertion O 0
. O 0

Two O 0
or O 0
3 O 0
large O 0
deletions O 0
, O 0
2 O 0
single O 0
codon O 0
deletions O 0
, O 0
and O 0
2 O 0
single O 0
base O 0
deletions O 0
have O 0
been O 0
found O 0
. O 0

Twelve O 0
of O 0
the O 0
missense O 0
mutations O 0
apparently O 0
result O 0
from O 0
the O 0
methylation O 0
and O 0
subsequent O 0
deamination O 0
of O 0
highly O 0
mutagenic O 0
CpG O 0
dinucleotides O 0
. O 0

Recurrent O 0
mutation O 0
has O 0
been O 0
observed O 0
at O 0
several O 0
of O 0
these O 0
sites O 0
, O 0
producing O 0
associations O 0
with O 0
different O 0
haplotypes O 0
in O 0
different O 0
populations O 0
. O 0

About O 0
half O 0
of O 0
all O 0
missense O 0
mutations O 0
have O 0
been O 0
examined O 0
by O 0
in O 0
vitro O 0
expression O 0
analysis O 0
, O 0
and O 0
a O 0
significant O 0
correlation O 0
has O 0
been O 0
observed O 0
between O 0
residual O 0
PAH O 0
activity O 0
and O 0
disease O 0
phenotype O 0
. O 0

Since O 0
continuing O 0
advances O 0
in O 0
molecular O 0
methodologies O 0
have O 0
dramatically O 0
accelerated O 0
the O 0
rate O 0
in O 0
which O 0
new O 0
mutations O 0
are O 0
being O 0
identified O 0
and O 0
characterized O 0
, O 0
this O 0
register O 0
of O 0
mutations O 0
will O 0
be O 0
updated O 0
periodically O 0
. O 0
. O 0

A O 0
glycine250 O 0
- O 0
- O 0
> O 0
aspartate O 0
substitution O 0
in O 0
the O 0
alpha O 0
- O 0
subunit O 0
of O 0
hexosaminidase O 0
A O 0
causes O 0
juvenile O 0
- O 0
onset O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
in O 0
a O 0
Lebanese O 0
- O 0
Canadian O 0
family O 0
. O 0

The O 0
mutation O 0
causing O 0
juvenile O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
( O 0
TSD B-Disease 0
) O 0
in O 0
two O 0
sibs O 0
of O 0
Lebanese O 0
- O 0
Maronite O 0
origin O 0
is O 0
described O 0
. O 0

An O 0
mRNA O 0
- O 0
containing O 0
extract O 0
of O 0
cultured O 0
fibroblasts O 0
obtained O 0
from O 0
one O 0
of O 0
the O 0
probands O 0
was O 0
used O 0
as O 0
a O 0
template O 0
to O 0
amplify O 0
the O 0
coding O 0
sequence O 0
of O 0
the O 0
hexosaminidase O 0
A O 0
( O 0
Hex O 0
A O 0
) O 0
alpha O 0
- O 0
subunit O 0
. O 0

Sequencing O 0
of O 0
amplified O 0
cDNA O 0
fragments O 0
revealed O 0
a O 0
single O 0
alteration O 0
, O 0
guanine O 0
to O 0
adenine O 0
at O 0
nt O 0
749 O 0
creating O 0
a O 0
G250D O 0
mutation O 0
. O 0

The O 0
mutation O 0
introduces O 0
a O 0
new O 0
recognition O 0
site O 0
for O 0
the O 0
restriction O 0
enzyme O 0
Eco O 0
RV O 0
, O 0
permitting O 0
identification O 0
of O 0
heterozygotes O 0
for O 0
this O 0
allele O 0
following O 0
PCR O 0
amplification O 0
and O 0
Eco O 0
RV O 0
digestion O 0
of O 0
exon O 0
7 O 0
sequences O 0
from O 0
genomic O 0
DNA O 0
templates O 0
. O 0

In O 0
order O 0
to O 0
test O 0
the O 0
effect O 0
of O 0
this O 0
substitution O 0
, O 0
an O 0
in O 0
vitro O 0
mutagenized O 0
cDNA O 0
construct O 0
was O 0
introduced O 0
into O 0
a O 0
mammalian O 0
expression O 0
vector O 0
and O 0
transfected O 0
into O 0
monkey O 0
Cos O 0
- O 0
1 O 0
cells O 0
separately O 0
or O 0
along O 0
with O 0
a O 0
beta O 0
- O 0
cDNA O 0
expression O 0
vector O 0
. O 0

When O 0
the O 0
mutant O 0
alpha O 0
- O 0
cDNA O 0
was O 0
the O 0
only O 0
gene O 0
introduced O 0
into O 0
COS O 0
cells O 0
no O 0
enzymatic O 0
activity O 0
above O 0
endogenous O 0
COS O 0
cell O 0
activity O 0
was O 0
detected O 0
. O 0

Cotransfection O 0
of O 0
normal O 0
alpha O 0
- O 0
cDNA O 0
and O 0
beta O 0
- O 0
cDNA O 0
followed O 0
by O 0
immunoprecipitation O 0
of O 0
human O 0
Hex O 0
A O 0
resulted O 0
in O 0
20 O 0
- O 0
fold O 0
increase O 0
in O 0
the O 0
ratio O 0
between O 0
positive O 0
and O 0
negative O 0
( O 0
mock O 0
transfection O 0
) O 0
control O 0
values O 0
. O 0

This O 0
allowed O 0
the O 0
detection O 0
of O 0
some O 0
residual O 0
activity O 0
( O 0
12 O 0
% O 0
of O 0
the O 0
positive O 0
control O 0
) O 0
when O 0
the O 0
mutant O 0
alpha O 0
- O 0
cDNA O 0
replaced O 0
its O 0
wild O 0
- O 0
type O 0
counterpart O 0
. O 0

The O 0
predicted O 0
protein O 0
environment O 0
in O 0
which O 0
the O 0
mutation O 0
occurs O 0
is O 0
compared O 0
to O 0
that O 0
of O 0
the O 0
adult O 0
- O 0
onset O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
mutation O 0
caused O 0
by O 0
a O 0
Gly269 O 0
- O 0
- O 0
> O 0
Ser O 0
substitution O 0
in O 0
exon O 0
7 O 0
. O 0

( O 0
ABSTRACT O 0
TRUNCATED O 0
AT O 0
250 O 0
WORDS O 0
) O 0
. O 0

Novel O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
mutations O 0
from O 0
China O 0
. O 0

We O 0
describe O 0
three O 0
HEXA O 0
mutations O 0
associated O 0
with O 0
infantile O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
( O 0
TSD B-Disease 0
) O 0
in O 0
three O 0
unrelated O 0
nonconsanguineous O 0
Chinese O 0
families O 0
. O 0

Novel O 0
mutations O 0
were O 0
found O 0
in O 0
two O 0
of O 0
these O 0
families O 0
. O 0

The O 0
third O 0
is O 0
a O 0
previously O 0
reported O 0
mutation O 0
( O 0
G O 0
- O 0
- O 0
> O 0
A O 0
transition O 0
at O 0
nt O 0
1444 O 0
) O 0
( O 0
Nakano O 0
et O 0
al O 0
. O 0
, O 0
1988 O 0
) O 0
. O 0

Direct O 0
sequencing O 0
of O 0
PCR O 0
products O 0
identified O 0
a O 0
novel O 0
insertion O 0
of O 0
an O 0
A O 0
after O 0
nt O 0
547 O 0
in O 0
family O 0
1 O 0
. O 0

This O 0
change O 0
generates O 0
an O 0
early O 0
termination O 0
codon O 0
6 O 0
bp O 0
downstream O 0
from O 0
the O 0
insertion O 0
site O 0
. O 0

Allele O 0
- O 0
specific O 0
oligonucleotide O 0
hybridization O 0
confirmed O 0
homozygosity O 0
in O 0
the O 0
proband O 0
. O 0

Single O 0
strand O 0
conformational O 0
polymorphism O 0
analysis O 0
and O 0
direct O 0
sequencing O 0
of O 0
amplified O 0
exon O 0
13 O 0
revealed O 0
a O 0
T O 0
- O 0
- O 0
> O 0
C O 0
transition O 0
at O 0
nt O 0
1453 O 0
with O 0
the O 0
corresponding O 0
amino O 0
acid O 0
substitution O 0
W485R O 0
in O 0
the O 0
second O 0
family O 0
. O 0

This O 0
mutation O 0
creates O 0
an O 0
Fnu4HI O 0
restriction O 0
site O 0
. O 0

The O 0
proband O 0
is O 0
homozygous O 0
for O 0
this O 0
allele O 0
. O 0

When O 0
the O 0
site O 0
- O 0
specific O 0
mutagenized O 0
alpha O 0
cDNA O 0
carrying O 0
the O 0
T O 0
- O 0
- O 0
> O 0
C O 0
transition O 0
at O 0
nt O 0
1453 O 0
was O 0
expressed O 0
in O 0
COS O 0
1 O 0
cells O 0
hexosaminidase O 0
S O 0
activity O 0
was O 0
not O 0
detectable O 0
above O 0
background O 0
. O 0

A O 0
G O 0
- O 0
- O 0
> O 0
A O 0
transition O 0
at O 0
nt O 0
1444 O 0
( O 0
exon O 0
13 O 0
) O 0
corresponding O 0
to O 0
the O 0
E482K O 0
substitution O 0
was O 0
found O 0
in O 0
the O 0
third O 0
family O 0
. O 0

This O 0
mutation O 0
occurs O 0
at O 0
a O 0
CpG O 0
dinucleotide O 0
. O 0

It O 0
has O 0
been O 0
reported O 0
in O 0
an O 0
Italian O 0
TSD B-Disease 0
proband O 0
and O 0
causes O 0
defective O 0
intracellular O 0
transport O 0
of O 0
the O 0
alpha O 0
- O 0
subunit O 0
from O 0
the O 0
rough O 0
endoplasmic O 0
reticulum O 0
to O 0
the O 0
Golgi O 0
apparatus O 0
. O 0

Two O 0
missense O 0
mutations O 0
causing O 0
mild O 0
hyperphenylalaninemia B-Disease 1
associated O 0
with O 0
DNA O 0
haplotype O 0
12 O 0
. O 0

The O 0
genetic B-Disease 0
defects I-Disease 0
responsible O 0
for O 0
most O 0
phenylketonuria B-Disease 0
( O 0
PKU B-Disease 0
) O 0
and O 0
hyperphenylalaninemia B-Disease 1
( O 0
HPA B-Disease 0
) O 0
cases O 0
are O 0
located O 0
in O 0
the O 0
phenylalanine O 0
hydroxylase O 0
( O 0
PAH O 0
) O 0
gene O 0
. O 0

Approximately O 0
50 O 0
- O 0
60 O 0
mutations O 0
have O 0
been O 0
reported O 0
in O 0
Caucasians O 0
and O 0
are O 0
reflected O 0
in O 0
a O 0
wide O 0
range O 0
of O 0
clinical O 0
severities O 0
. O 0

Most O 0
mutations O 0
are O 0
linked O 0
to O 0
specific O 0
haplotypes O 0
, O 0
as O 0
defined O 0
by O 0
eight O 0
polymorphic O 0
restriction O 0
sites O 0
in O 0
the O 0
PAH O 0
gene O 0
. O 0

We O 0
hypothesized O 0
that O 0
there O 0
is O 0
at O 0
least O 0
one O 0
mild O 0
mutation O 0
linked O 0
to O 0
haplotype O 0
12 O 0
in O 0
the O 0
Swedish O 0
PKU B-Disease 0
/ O 0
HPA B-Disease 0
population O 0
, O 0
since O 0
7 O 0
of O 0
8 O 0
patients O 0
carrying O 0
haplotype O 0
12 O 0
had O 0
mild O 0
HPA B-Disease 0
. O 0

Sequence O 0
analysis O 0
revealed O 0
a O 0
C O 0
- O 0
to O 0
- O 0
G O 0
transversion O 0
at O 0
the O 0
second O 0
base O 0
of O 0
codon O 0
322 O 0
, O 0
resulting O 0
in O 0
a O 0
substitution O 0
of O 0
glycine O 0
for O 0
alanine O 0
, O 0
in O 0
four O 0
mutant O 0
haplotype O 0
12 O 0
genes O 0
, O 0
and O 0
a O 0
G O 0
- O 0
to O 0
- O 0
A O 0
transition O 0
at O 0
the O 0
second O 0
base O 0
of O 0
codon O 0
408 O 0
, O 0
resulting O 0
in O 0
a O 0
substitution O 0
of O 0
glutamine O 0
for O 0
arginine O 0
, O 0
in O 0
another O 0
three O 0
mutant O 0
haplotype O 0
12 O 0
genes O 0
. O 0

These O 0
mutations O 0
segregated O 0
with O 0
mutant O 0
haplotype O 0
12 O 0
alleles O 0
in O 0
nuclear O 0
families O 0
but O 0
were O 0
not O 0
present O 0
on O 0
normal O 0
or O 0
other O 0
mutant O 0
alleles O 0
. O 0

Both O 0
mutations O 0
were O 0
tested O 0
in O 0
a O 0
eukaryotic O 0
expression O 0
system O 0
in O 0
which O 0
enzyme O 0
activities O 0
of O 0
different O 0
mutant O 0
PAH O 0
enzymes O 0
reflect O 0
the O 0
relative O 0
severities O 0
of O 0
the O 0
mutations O 0
, O 0
although O 0
these O 0
in O 0
vitro O 0
activities O 0
cannot O 0
be O 0
translated O 0
directly O 0
into O 0
in O 0
vivo O 0
hepatic O 0
activities O 0
. O 0

The O 0
A322G O 0
mutant O 0
PAH O 0
had O 0
about O 0
75 O 0
% O 0
and O 0
the O 0
R408Q O 0
mutant O 0
PAH O 0
about O 0
55 O 0
% O 0
of O 0
the O 0
wild O 0
- O 0
type O 0
PAH O 0
enzyme O 0
activity O 0
. O 0

These O 0
in O 0
vitro O 0
activities O 0
are O 0
the O 0
highest O 0
reported O 0
for O 0
mutant O 0
PAH O 0
enzymes O 0
produced O 0
in O 0
the O 0
same O 0
expression O 0
system O 0
. O 0

( O 0
ABSTRACT O 0
TRUNCATED O 0
AT O 0
250 O 0
WORDS O 0
) O 0
. O 0

In O 0
vitro O 0
and O 0
in O 0
vivo O 0
correlations O 0
for O 0
I65T O 0
and O 0
M1V O 0
mutations O 0
at O 0
the O 0
phenylalanine O 0
hydroxylase O 0
locus O 0
. O 0

Mutations O 0
at O 0
the O 0
phenylalanine O 0
hydroxylase O 0
( O 0
PAH O 0
) O 0
locus O 0
are O 0
the O 0
major O 0
cause O 0
of O 0
hyperphenylalaninemia B-Disease 1
. O 0

We O 0
have O 0
previously O 0
described O 0
four O 0
mutations O 0
( O 0
M1V O 0
, O 0
IVS12nt1 O 0
, O 0
R408W O 0
, O 0
and O 0
S349P O 0
) O 0
at O 0
the O 0
PAH O 0
locus O 0
in O 0
French O 0
Canadians O 0
with O 0
ancestry O 0
in O 0
eastern O 0
Quebec O 0
. O 0

Here O 0
we O 0
report O 0
( O 0
1 O 0
) O 0
identification O 0
of O 0
another O 0
mutation O 0
, O 0
on O 0
a O 0
haplotype O 0
9 O 0
chromosome O 0
, O 0
which O 0
converts O 0
codon O 0
65 O 0
from O 0
isoleucine O 0
( O 0
ATT O 0
) O 0
to O 0
threonine O 0
( O 0
ACT O 0
) O 0
, O 0
( O 0
2 O 0
) O 0
expression O 0
analysis O 0
of O 0
the O 0
I65T O 0
mutation O 0
in O 0
COS O 0
cells O 0
demonstrating O 0
75 O 0
% O 0
loss O 0
of O 0
both O 0
immunoreactive O 0
protein O 0
and O 0
enzyme O 0
activity O 0
, O 0
and O 0
( O 0
3 O 0
) O 0
expression O 0
analysis O 0
of O 0
the O 0
most O 0
prevalent O 0
PKU B-Disease 0
allele O 0
( O 0
M1V O 0
) O 0
in O 0
eastern O 0
Quebec O 0
, O 0
showing O 0
nondetectable O 0
levels O 0
of O 0
PAH O 0
protein O 0
and O 0
activity O 0
, O 0
a O 0
finding O 0
compatible O 0
with O 0
a O 0
mutation O 0
in O 0
the O 0
translation O 0
initiation O 0
codon O 0
. O 0

Homozygosity O 0
for O 0
M1V O 0
and O 0
codominant O 0
inheritance O 0
of O 0
I65T O 0
/ O 0
R408W O 0
were O 0
both O 0
associated O 0
with O 0
classical B-Disease 0
phenylketonuria I-Disease 0
. O 0
. O 0

Molecular O 0
basis O 0
of O 0
hexosaminidase B-Disease 1
A I-Disease 1
deficiency I-Disease 1
and O 0
pseudodeficiency O 0
in O 0
the O 0
Berks O 0
County O 0
Pennsylvania O 0
Dutch O 0
. O 0

Following O 0
the O 0
birth O 0
of O 0
two O 0
infants O 0
with O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
( O 0
TSD B-Disease 0
) O 0
, O 0
a O 0
non O 0
- O 0
Jewish O 0
, O 0
Pennsylvania O 0
Dutch O 0
kindred O 0
was O 0
screened O 0
for O 0
TSD B-Disease 0
carriers O 0
using O 0
the O 0
biochemical O 0
assay O 0
. O 0

A O 0
high O 0
frequency O 0
of O 0
individuals O 0
who O 0
appeared O 0
to O 0
be O 0
TSD B-Disease 0
heterozygotes O 0
was O 0
detected O 0
( O 0
Kelly O 0
et O 0
al O 0
. O 0
, O 0
1975 O 0
) O 0
. O 0

Clinical O 0
and O 0
biochemical O 0
evidence O 0
suggested O 0
that O 0
the O 0
increased O 0
carrier O 0
frequency O 0
was O 0
due O 0
to O 0
at O 0
least O 0
two O 0
altered O 0
alleles O 0
for O 0
the O 0
hexosaminidase O 0
A O 0
alpha O 0
- O 0
subunit O 0
. O 0

We O 0
now O 0
report O 0
two O 0
mutant O 0
alleles O 0
in O 0
this O 0
Pennsylvania O 0
Dutch O 0
kindred O 0
, O 0
and O 0
one O 0
polymorphism O 0
. O 0

One O 0
allele O 0
, O 0
reported O 0
originally O 0
in O 0
a O 0
French O 0
TSD B-Disease 0
patient O 0
( O 0
Akli O 0
et O 0
al O 0
. O 0
, O 0
1991 O 0
) O 0
, O 0
is O 0
a O 0
GT O 0
- O 0
- O 0
> O 0
AT O 0
transition O 0
at O 0
the O 0
donor O 0
splice O 0
- O 0
site O 0
of O 0
intron O 0
9 O 0
. O 0

The O 0
second O 0
, O 0
a O 0
C O 0
- O 0
- O 0
> O 0
T O 0
transition O 0
at O 0
nucleotide O 0
739 O 0
( O 0
Arg247Trp O 0
) O 0
, O 0
has O 0
been O 0
shown O 0
by O 0
Triggs O 0
- O 0
Raine O 0
et O 0
al O 0
. O 0

( O 0
1992 O 0
) O 0
to O 0
be O 0
a O 0
clinically O 0
benign O 0
" O 0
pseudodeficient O 0
" O 0
allele O 0
associated O 0
with O 0
reduced O 0
enzyme O 0
activity O 0
against O 0
artificial O 0
substrate O 0
. O 0

Finally O 0
, O 0
a O 0
polymorphism O 0
[ O 0
G O 0
- O 0
- O 0
> O 0
A O 0
( O 0
759 O 0
) O 0
] O 0
, O 0
which O 0
leaves O 0
valine O 0
at O 0
codon O 0
253 O 0
unchanged O 0
, O 0
is O 0
described O 0
. O 0

A O 0
mutation O 0
common O 0
in O 0
non O 0
- O 0
Jewish O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
: O 0
frequency O 0
and O 0
RNA O 0
studies O 0
. O 0

Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
( O 0
TSD B-Disease 0
) O 0
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
genetic I-Disease 1
disorder I-Disease 1
resulting O 0
from O 0
mutation O 0
of O 0
the O 0
HEXA O 0
gene O 0
encoding O 0
the O 0
alpha O 0
- O 0
subunit O 0
of O 0
the O 0
lysosomal O 0
enzyme O 0
, O 0
beta O 0
- O 0
N O 0
- O 0
acetylhexosaminidase O 0
A O 0
( O 0
Hex O 0
A O 0
) O 0
. O 0

We O 0
have O 0
discovered O 0
that O 0
a O 0
Tay B-Disease 0
- I-Disease 0
Sachs I-Disease 0
mutation O 0
, O 0
IVS O 0
- O 0
9 O 0
+ O 0
1 O 0
G O 0
- O 0
- O 0
> O 0
A O 0
, O 0
first O 0
detected O 0
by O 0
Akli O 0
et O 0
al O 0
. O 0

( O 0
Genomics O 0
11 O 0
124 O 0
- O 0
134 O 0
, O 0
1991 O 0
) O 0
, O 0
is O 0
a O 0
common O 0
disease O 0
allele O 0
in O 0
non O 0
- O 0
Jewish O 0
Caucasians O 0
( O 0
10 O 0
/ O 0
58 O 0
alleles O 0
examined O 0
) O 0
. O 0

A O 0
PCR O 0
- O 0
based O 0
diagnostic O 0
test O 0
, O 0
which O 0
detects O 0
an O 0
NlaIII O 0
site O 0
generated O 0
by O 0
the O 0
mutation O 0
, O 0
revealed O 0
a O 0
frequency O 0
among O 0
enzyme O 0
- O 0
defined O 0
carriers O 0
of O 0
9 O 0
/ O 0
64 O 0
( O 0
14 O 0
% O 0
) O 0
. O 0

Most O 0
of O 0
those O 0
carrying O 0
the O 0
allele O 0
trace O 0
their O 0
origins O 0
to O 0
the O 0
United O 0
Kingdom O 0
, O 0
Ireland O 0
, O 0
or O 0
Western O 0
Europe O 0
. O 0

It O 0
was O 0
not O 0
identified O 0
among O 0
12 O 0
Black O 0
American O 0
TSD B-Disease 0
alleles O 0
or O 0
in O 0
any O 0
of O 0
18 O 0
Ashkenazi O 0
Jewish O 0
, O 0
enzyme O 0
- O 0
defined O 0
carriers O 0
who O 0
did O 0
not O 0
carry O 0
any O 0
of O 0
the O 0
mutations O 0
common O 0
to O 0
this O 0
population O 0
. O 0

No O 0
normally O 0
spliced O 0
RNA O 0
was O 0
detected O 0
in O 0
PCR O 0
products O 0
generated O 0
from O 0
reverse O 0
transcription O 0
of O 0
RNA O 0
carrying O 0
the O 0
IVS O 0
- O 0
9 O 0
mutation O 0
. O 0

Instead O 0
, O 0
the O 0
low O 0
levels O 0
of O 0
mRNA O 0
from O 0
this O 0
allele O 0
were O 0
comprised O 0
of O 0
aberrant O 0
species O 0
resulting O 0
from O 0
the O 0
use O 0
of O 0
either O 0
of O 0
two O 0
cryptic O 0
donor O 0
sites O 0
, O 0
one O 0
truncating O 0
exon O 0
9 O 0
and O 0
the O 0
other O 0
within O 0
IVS O 0
- O 0
9 O 0
, O 0
spliced O 0
to O 0
exon O 0
10 O 0
. O 0

Numerous O 0
additional O 0
splice O 0
products O 0
were O 0
detected O 0
, O 0
most O 0
involving O 0
skipping O 0
of O 0
one O 0
or O 0
more O 0
surrounding O 0
exons O 0
. O 0

Together O 0
with O 0
a O 0
recently O 0
identified O 0
allele O 0
responsible O 0
for O 0
Hex O 0
A O 0
pseudodeficiency O 0
( O 0
Triggs O 0
- O 0
Raine O 0
et O 0
al O 0
. O 0
Am O 0
J O 0
Hum O 0
Genet O 0
, O 0
1992 O 0
) O 0
, O 0
these O 0
two O 0
alleles O 0
accounted O 0
for O 0
almost O 0
50 O 0
% O 0
( O 0
29 O 0
/ O 0
64 O 0
) O 0
of O 0
TSD B-Disease 0
or O 0
carrier O 0
alleles O 0
ascertained O 0
by O 0
enzyme O 0
screening O 0
tests O 0
in O 0
non O 0
- O 0
Jewish O 0
Caucasians O 0
. O 0
. O 0

Aberrant O 0
splicing O 0
of O 0
the O 0
CHM B-Disease 1
gene O 0
is O 0
a O 0
significant O 0
cause O 0
of O 0
choroideremia B-Disease 1
. O 0

Choroideremia B-Disease 0
( O 0
CHM B-Disease 1
) O 0
is O 0
an O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
progressive I-Disease 1
degeneration I-Disease 1
of I-Disease 1
the I-Disease 1
choroid I-Disease 1
and I-Disease 1
retina I-Disease 1
. O 0

12 O 0
% O 0
of O 0
unrelated O 0
male O 0
patients O 0
carry O 0
deletions O 0
of O 0
the O 0
partially O 0
cloned O 0
CHM B-Disease 1
gene O 0
. O 0

In O 0
Finland O 0
, O 0
there O 0
are O 0
more O 0
than O 0
120 O 0
living O 0
CHM B-Disease 1
patients O 0
belonging O 0
to O 0
eight O 0
apparently O 0
unrelated O 0
pedigrees O 0
. O 0

Molecular O 0
deletions O 0
involving O 0
the O 0
CHM B-Disease 1
gene O 0
have O 0
been O 0
detected O 0
in O 0
three O 0
families O 0
. O 0

We O 0
have O 0
screened O 0
the O 0
remaining O 0
five O 0
families O 0
for O 0
point O 0
mutations O 0
. O 0

In O 0
one O 0
large O 0
family O 0
a O 0
single O 0
nucleotide O 0
( O 0
T O 0
) O 0
insertion O 0
into O 0
the O 0
donor O 0
splice O 0
site O 0
of O 0
exon O 0
C O 0
leads O 0
to O 0
two O 0
aberrantly O 0
spliced O 0
mRNAs O 0
both O 0
producing O 0
a O 0
premature O 0
stop O 0
codon O 0
. O 0

The O 0
mutation O 0
can O 0
be O 0
assayed O 0
easily O 0
by O 0
amplification O 0
and O 0
digestion O 0
with O 0
Msel O 0
. O 0

Our O 0
findings O 0
provide O 0
additional O 0
evidence O 0
for O 0
the O 0
pathogenetic O 0
role O 0
of O 0
CHM B-Disease 1
mutations O 0
and O 0
provide O 0
a O 0
diagnostic O 0
tool O 0
for O 0
one O 0
fifth O 0
of O 0
the O 0
worlds O 0
known O 0
CHM B-Disease 1
patients O 0
. O 0
. O 0

Germline O 0
intronic O 0
and O 0
exonic O 0
mutations O 0
in O 0
the O 0
Wilms B-Disease 0
' I-Disease 0
tumour I-Disease 1
gene O 0
( O 0
WT1 O 0
) O 0
affecting O 0
urogenital O 0
development O 0
. O 0

Denys B-Disease 1
- I-Disease 1
Drash I-Disease 1
syndrome I-Disease 1
is O 0
a O 0
rare O 0
human O 0
developmental B-Disease 0
disorder I-Disease 0
affecting O 0
the O 0
urogenital O 0
system O 0
and O 0
leading O 0
to O 0
renal B-Disease 0
failure I-Disease 0
, O 0
intersex B-Disease 0
disorders I-Disease 0
and O 0
Wilms B-Disease 1
tumour I-Disease 1
. O 0

In O 0
this O 0
report O 0
, O 0
four O 0
individuals O 0
with O 0
this O 0
syndrome O 0
are O 0
described O 0
carrying O 0
germline O 0
point O 0
mutations O 0
in O 0
the O 0
Wilms B-Disease 1
tumour I-Disease 1
suppressor O 0
gene O 0
, O 0
WT1 O 0
. O 0

Three O 0
of O 0
these O 0
mutations O 0
were O 0
in O 0
the O 0
zinc O 0
finger O 0
domains O 0
of O 0
WT1 O 0
. O 0

The O 0
fourth O 0
occurred O 0
within O 0
intron O 0
9 O 0
, O 0
preventing O 0
splicing O 0
at O 0
one O 0
of O 0
the O 0
alternatively O 0
chosen O 0
splice O 0
donor O 0
sites O 0
of O 0
exon O 0
9 O 0
when O 0
assayed O 0
in O 0
vitro O 0
. O 0

These O 0
results O 0
provide O 0
genetic O 0
evidence O 0
for O 0
distinct O 0
functional O 0
roles O 0
of O 0
the O 0
WT1 O 0
isoforms O 0
in O 0
urogenital O 0
development O 0
. O 0
. O 0

Characterization O 0
of O 0
the O 0
myotonic B-Disease 1
dystrophy I-Disease 1
region O 0
predicts O 0
multiple O 0
protein O 0
isoform O 0
- O 0
encoding O 0
mRNAs O 0
. O 0

The O 0
mutation O 0
underlying O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
has O 0
been O 0
identified O 0
as O 0
an O 0
expansion O 0
of O 0
a O 0
polymorphic O 0
CTG O 0
- O 0
repeat O 0
in O 0
a O 0
gene O 0
encoding O 0
protein O 0
kinase O 0
activity O 0
. O 0

Brain O 0
and O 0
heart O 0
transcripts O 0
of O 0
the O 0
DM O 0
- O 0
kinase O 0
( O 0
DMR O 0
- O 0
B15 O 0
) O 0
gene O 0
are O 0
subject O 0
to O 0
alternative O 0
RNA O 0
splicing O 0
in O 0
both O 0
human O 0
and O 0
mouse O 0
. O 0

The O 0
unstable O 0
[ O 0
CTG O 0
] O 0
5 O 0
- O 0
30 O 0
motif O 0
is O 0
found O 0
uniquely O 0
in O 0
humans O 0
, O 0
although O 0
the O 0
flanking O 0
nucleotides O 0
are O 0
also O 0
present O 0
in O 0
mouse O 0
. O 0

Characterization O 0
of O 0
the O 0
DM B-Disease 0
region O 0
of O 0
both O 0
species O 0
reveals O 0
another O 0
active O 0
gene O 0
( O 0
DMR O 0
- O 0
N9 O 0
) O 0
in O 0
close O 0
proximity O 0
to O 0
the O 0
kinase O 0
gene O 0
. O 0

DMR O 0
- O 0
N9 O 0
transcripts O 0
, O 0
mainly O 0
expressed O 0
in O 0
brain O 0
and O 0
testis O 0
, O 0
possess O 0
a O 0
single O 0
, O 0
large O 0
open O 0
reading O 0
frame O 0
, O 0
but O 0
the O 0
function O 0
of O 0
its O 0
protein O 0
product O 0
is O 0
unknown O 0
. O 0

Clinical O 0
manifestation O 0
of O 0
DM B-Disease 0
may O 0
be O 0
caused O 0
by O 0
the O 0
expanded O 0
CTG O 0
- O 0
repeat O 0
compromising O 0
the O 0
( O 0
alternative O 0
) O 0
expression O 0
of O 0
DM O 0
- O 0
kinase O 0
or O 0
DMR O 0
- O 0
N9 O 0
proteins O 0
. O 0
. O 0

Fragile B-Disease 0
X I-Disease 0
syndrome I-Disease 0
without O 0
CCG O 0
amplification O 0
has O 0
an O 0
FMR1 O 0
deletion O 0
. O 0

We O 0
describe O 0
a O 0
patient O 0
with O 0
typical O 0
clinical O 0
features O 0
of O 0
the O 0
fragile B-Disease 1
X I-Disease 1
syndrome I-Disease 1
, O 0
but O 0
without O 0
cytogenetic O 0
expression O 0
of O 0
the O 0
fragile B-Disease 1
X I-Disease 1
or O 0
an O 0
amplified O 0
CCG O 0
trinucleotide O 0
repeat O 0
fragment O 0
. O 0

The O 0
patient O 0
has O 0
a O 0
previously O 0
uncharacterized O 0
submicroscopic O 0
deletion O 0
encompassing O 0
the O 0
CCG O 0
repeat O 0
, O 0
the O 0
entire O 0
FMR1 O 0
gene O 0
and O 0
about O 0
2 O 0
. O 0

5 O 0
megabases O 0
of O 0
flanking O 0
sequences O 0
. O 0

This O 0
finding O 0
confirms O 0
that O 0
the O 0
fragile B-Disease 1
X I-Disease 1
phenotype O 0
can O 0
exist O 0
, O 0
without O 0
amplification O 0
of O 0
the O 0
CCG O 0
repeat O 0
or O 0
cytogenetic O 0
expression O 0
of O 0
the O 0
fragile B-Disease 1
X I-Disease 1
, O 0
and O 0
that O 0
fragile B-Disease 1
X I-Disease 1
syndrome I-Disease 1
is O 0
a O 0
genetically O 0
homogeneous O 0
disorder O 0
involving O 0
FMR1 O 0
. O 0

We O 0
also O 0
found O 0
random O 0
X O 0
- O 0
inactivation O 0
in O 0
the O 0
mother O 0
of O 0
the O 0
patient O 0
who O 0
was O 0
shown O 0
to O 0
be O 0
a O 0
carrier O 0
of O 0
this O 0
deletion O 0
. O 0

Cloning O 0
of O 0
the O 0
Huntington B-Disease 1
disease I-Disease 1
region O 0
in O 0
yeast O 0
artificial O 0
chromosomes O 0
. O 0

The O 0
gene O 0
responsible O 0
for O 0
Huntington B-Disease 1
disease I-Disease 1
has O 0
been O 0
localized O 0
to O 0
a O 0
2 O 0
. O 0

5 O 0
million O 0
base O 0
pair O 0
( O 0
Mb O 0
) O 0
region O 0
between O 0
the O 0
loci O 0
D4S10 O 0
and O 0
D4S168 O 0
on O 0
the O 0
short O 0
arm O 0
of O 0
chromosome O 0
4 O 0
. O 0

As O 0
part O 0
of O 0
a O 0
strategy O 0
to O 0
clone O 0
the O 0
HD B-Disease 1
gene O 0
on O 0
the O 0
basis O 0
of O 0
its O 0
chromosomal O 0
location O 0
, O 0
we O 0
isolated O 0
genomic O 0
DNA O 0
from O 0
the O 0
HD B-Disease 1
region O 0
as O 0
a O 0
set O 0
of O 0
overlapping O 0
yeast O 0
artificial O 0
chromosome O 0
( O 0
YAC O 0
) O 0
clones O 0
. O 0

Twenty O 0
- O 0
eight O 0
YAC O 0
clones O 0
were O 0
identified O 0
by O 0
screening O 0
human O 0
YAC O 0
libraries O 0
with O 0
twelve O 0
PCR O 0
- O 0
based O 0
sequence O 0
- O 0
tagged O 0
sites O 0
( O 0
STSs O 0
) O 0
from O 0
the O 0
region O 0
. O 0

We O 0
assembled O 0
the O 0
YAC O 0
clones O 0
into O 0
overlapping O 0
sets O 0
by O 0
hybridizing O 0
them O 0
to O 0
a O 0
large O 0
number O 0
of O 0
DNA O 0
probes O 0
from O 0
the O 0
HD B-Disease 1
region O 0
, O 0
including O 0
the O 0
STSs O 0
. O 0

In O 0
addition O 0
, O 0
we O 0
isolated O 0
the O 0
ends O 0
of O 0
the O 0
human O 0
DNA O 0
inserts O 0
of O 0
most O 0
of O 0
the O 0
YAC O 0
clones O 0
to O 0
assist O 0
in O 0
the O 0
construction O 0
of O 0
the O 0
contig O 0
. O 0

Although O 0
almost O 0
half O 0
of O 0
the O 0
YACs O 0
appear O 0
to O 0
contain O 0
chimeric O 0
inserts O 0
and O 0
several O 0
contain O 0
internal O 0
deletions O 0
or O 0
other O 0
rearrangements O 0
, O 0
we O 0
were O 0
able O 0
to O 0
obtain O 0
over O 0
2 O 0
. O 0

2 O 0
Mb O 0
of O 0
the O 0
HD B-Disease 1
region O 0
in O 0
YACs O 0
, O 0
including O 0
one O 0
continuous O 0
segment O 0
of O 0
2 O 0
. O 0

0 O 0
Mb O 0
covering O 0
the O 0
region O 0
that O 0
most O 0
likely O 0
contains O 0
the O 0
HD B-Disease 1
gene O 0
. O 0

Ten O 0
of O 0
the O 0
twenty O 0
eight O 0
YAC O 0
clones O 0
comprise O 0
a O 0
minimal O 0
set O 0
spanning O 0
the O 0
2 O 0
. O 0

2 O 0
Mb O 0
. O 0

These O 0
clones O 0
provide O 0
reagents O 0
for O 0
the O 0
complete O 0
characterization O 0
of O 0
this O 0
region O 0
of O 0
the O 0
genome O 0
and O 0
for O 0
the O 0
eventual O 0
isolation O 0
of O 0
the O 0
HD B-Disease 1
gene O 0
. O 0

Characterization O 0
of O 0
a O 0
YAC O 0
containing O 0
part O 0
or O 0
all O 0
of O 0
the O 0
Norrie B-Disease 1
disease I-Disease 1
locus O 0
. O 0

It O 0
has O 0
been O 0
shown O 0
from O 0
pulsed O 0
- O 0
field O 0
gel O 0
electrophoresis O 0
( O 0
PFGE O 0
) O 0
that O 0
the O 0
monoamine O 0
oxidase O 0
genes O 0
A O 0
and O 0
B O 0
( O 0
MAOA O 0
& O 0
MAOB O 0
) O 0
and O 0
DXS7 O 0
loci O 0
are O 0
physically O 0
very O 0
close O 0
. O 0

We O 0
have O 0
therefore O 0
extended O 0
studies O 0
on O 0
their O 0
relationship O 0
through O 0
the O 0
characterisation O 0
of O 0
a O 0
650 O 0
kb O 0
YAC O 0
isolated O 0
using O 0
L1 O 0
. O 0

28 O 0
( O 0
recognising O 0
the O 0
DXS7 O 0
locus O 0
) O 0
as O 0
a O 0
probe O 0
. O 0

Restriction O 0
mapping O 0
of O 0
the O 0
YAC O 0
indicates O 0
that O 0
it O 0
contains O 0
both O 0
MAOA O 0
and O 0
MAOB O 0
genes O 0
in O 0
addition O 0
to O 0
the O 0
DXS7 O 0
locus O 0
. O 0

The O 0
map O 0
derived O 0
from O 0
the O 0
YL1 O 0
. O 0

28 O 0
- O 0
YAC O 0
is O 0
compatible O 0
both O 0
with O 0
the O 0
map O 0
from O 0
an O 0
independently O 0
derived O 0
YAC O 0
carrying O 0
MAOA O 0
and O 0
B O 0
genes O 0
and O 0
with O 0
the O 0
long O 0
range O 0
genomic O 0
map O 0
for O 0
the O 0
region O 0
. O 0

A O 0
series O 0
of O 0
subclones O 0
prepared O 0
from O 0
a O 0
phage O 0
library O 0
( O 0
lambda O 0
DASH O 0
II O 0
) O 0
of O 0
the O 0
YAC O 0
have O 0
been O 0
characterised O 0
and O 0
have O 0
been O 0
employed O 0
to O 0
determine O 0
the O 0
end O 0
point O 0
of O 0
the O 0
deletion O 0
of O 0
a O 0
Norrie B-Disease 1
disease I-Disease 1
( O 0
NDP B-Disease 0
) O 0
patient O 0
who O 0
has O 0
been O 0
shown O 0
to O 0
lack O 0
both O 0
DXS7 O 0
and O 0
MAO O 0
coding O 0
sequences O 0
. O 0

The O 0
pattern O 0
of O 0
retention O 0
of O 0
subclones O 0
in O 0
the O 0
deletion O 0
patient O 0
place O 0
the O 0
end O 0
point O 0
of O 0
the O 0
deletion O 0
within O 0
30 O 0
- O 0
130 O 0
kb O 0
of O 0
the O 0
proximal O 0
end O 0
of O 0
the O 0
YAC O 0
. O 0

By O 0
combining O 0
the O 0
data O 0
with O 0
established O 0
recombination O 0
analysis O 0
, O 0
we O 0
provide O 0
evidence O 0
that O 0
all O 0
or O 0
part O 0
of O 0
the O 0
NDP O 0
lies O 0
in O 0
the O 0
interval O 0
of O 0
approximately O 0
250kb O 0
within O 0
the O 0
YAC O 0
. O 0

Both O 0
mutations O 0
in O 0
G6PD O 1
A O 1
- O 1
are O 0
necessary O 0
to O 0
produce O 0
the O 0
G6PD B-Disease 1
deficient I-Disease 1
phenotype O 0
. O 0

The O 0
high O 0
prevalence O 0
of O 0
glucose B-Disease 1
6 I-Disease 1
- I-Disease 1
phosphate I-Disease 1
dehydrogenase I-Disease 1
( I-Disease 1
G6PD I-Disease 1
) I-Disease 1
deficiency I-Disease 1
in O 0
African O 0
populations O 0
is O 0
due O 0
almost O 0
entirely O 0
to O 0
the O 0
enzyme O 0
variant O 0
A O 0
- O 0
, O 0
which O 0
differs O 0
from O 0
the O 0
wild O 0
- O 0
type O 0
G6PD O 0
B O 0
by O 0
two O 0
amino O 0
acid O 0
replacements O 0
, O 0
68 O 0
Val O 0
- O 0
- O 0
> O 0
Met O 0
and O 0
126 O 0
Asn O 0
- O 0
- O 0
> O 0
Asp O 0
. O 0

The O 0
non O 0
- O 0
deficient O 0
polymorphic O 0
variant O 0
G6PD O 0
A O 0
contains O 0
only O 0
the O 0
mutation O 0
126 O 0
Asn O 0
- O 0
- O 0
> O 0
Asp O 0
. O 0

The O 0
frequencies O 0
of O 0
the O 0
G6PD O 0
A O 0
and O 0
of O 0
the O 0
G6PD O 1
A O 1
- O 1
genes O 0
in O 0
parts O 0
of O 0
Africa O 0
are O 0
both O 0
about O 0
0 O 0
. O 0

2 O 0
. O 0

The O 0
68 O 0
Val O 0
- O 0
- O 0
> O 0
Met O 0
mutation O 0
has O 0
not O 0
been O 0
found O 0
in O 0
a O 0
B O 0
background O 0
. O 0

This O 0
could O 0
be O 0
because O 0
the O 0
68 O 0
Val O 0
- O 0
- O 0
> O 0
Met O 0
mutation O 0
happened O 0
to O 0
arise O 0
in O 0
an O 0
A O 0
gene O 0
in O 0
the O 0
first O 0
instance O 0
, O 0
or O 0
because O 0
the O 0
68 O 0
Val O 0
- O 0
- O 0
> O 0
Met O 0
mutation O 0
alone O 0
is O 0
not O 0
sufficient O 0
to O 0
cause O 0
G6PD B-Disease 0
deficiency I-Disease 0
. O 0

We O 0
have O 0
approached O 0
this O 0
question O 0
by O 0
producing O 0
G6PD O 0
B O 0
, O 0
A O 0
, O 0
A O 0
- O 0
, O 0
and O 0
G6PD O 0
68 O 0
Val O 0
- O 0
- O 0
> O 0
Met O 0
in O 0
a O 0
bacterial O 0
expression O 0
system O 0
and O 0
analysing O 0
their O 0
biochemical O 0
properties O 0
. O 0

With O 0
each O 0
single O 0
mutation O 0
we O 0
found O 0
a O 0
slight O 0
decrease O 0
in O 0
both O 0
the O 0
specific O 0
activity O 0
and O 0
the O 0
yield O 0
of O 0
enzyme O 0
when O 0
compared O 0
to O 0
G6PD O 0
B O 0
. O 0

When O 0
both O 0
mutations O 0
were O 0
introduced O 0
together O 0
, O 0
there O 0
was O 0
a O 0
roughly O 0
additive O 0
effect O 0
on O 0
specific O 0
activity O 0
, O 0
but O 0
a O 0
much O 0
more O 0
drastic O 0
effect O 0
on O 0
enzyme O 0
yield O 0
( O 0
4 O 0
% O 0
of O 0
normal O 0
) O 0
. O 0

This O 0
synergistic O 0
effect O 0
was O 0
also O 0
demonstrated O 0
on O 0
thermal O 0
stability O 0
, O 0
especially O 0
at O 0
low O 0
NADP O 0
concentrations O 0
. O 0

Comparable O 0
results O 0
were O 0
produced O 0
when O 0
the O 0
replacement O 0
119 O 0
Gln O 0
- O 0
- O 0
> O 0
Glu O 0
was O 0
studied O 0
instead O 0
of O 0
126 O 0
Asn O 0
- O 0
- O 0
> O 0
Asp O 0
. O 0

We O 0
infer O 0
that O 0
the O 0
coexistence O 0
of O 0
the O 0
two O 0
mutations O 0
is O 0
responsible O 0
for O 0
enzyme B-Disease 1
deficiency I-Disease 1
in I-Disease 1
G6PD I-Disease 1
A O 0
- O 0
because O 0
they O 0
act O 0
synergistically O 0
in O 0
causing O 0
instability O 0
of O 0
the O 0
enzyme O 0
. O 0

Small O 0
nuclear O 0
ribonucleoprotein O 0
polypeptide O 0
N O 0
( O 0
SNRPN O 0
) O 0
, O 0
an O 0
expressed O 0
gene O 0
in O 0
the O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
critical O 0
region O 0
. O 0

Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
is O 0
associated O 0
with O 0
paternally O 0
derived O 0
chromosomal O 0
deletions O 0
in O 0
region O 0
15q11 O 0
- O 0
13 O 0
or O 0
with O 0
maternal B-Disease 0
disomy I-Disease 0
for I-Disease 0
chromosome I-Disease 0
15 I-Disease 0
. O 0

Therefore O 0
, O 0
loss O 0
of O 0
the O 0
expressed O 0
paternal O 0
alleles O 0
of O 0
maternally O 0
imprinted O 0
genes O 0
must O 0
be O 0
responsible O 0
for O 0
the O 0
PWS B-Disease 0
phenotype O 0
. O 0

We O 0
have O 0
mapped O 0
the O 0
gene O 0
encoding O 0
the O 0
small O 0
nuclear O 0
RNA O 0
associated O 0
polypeptide O 0
SmN O 0
( O 0
SNRPN O 0
) O 0
to O 0
human O 0
chromosome O 0
15q12 O 0
and O 0
a O 0
processed O 0
pseudogene O 0
SNRPNP1 O 0
to O 0
chromosome O 0
region O 0
6pter O 0
- O 0
p21 O 0
. O 0

Furthermore O 0
, O 0
SNRPN O 0
was O 0
mapped O 0
to O 0
the O 0
minimal O 0
deletion O 0
interval O 0
that O 0
is O 0
critical O 0
for O 0
PWS B-Disease 0
. O 0

The O 0
fact O 0
that O 0
the O 0
mouse O 0
Snrpn O 0
gene O 0
is O 0
maternally O 0
imprinted O 0
in O 0
brain O 0
suggests O 0
that O 0
loss O 0
of O 0
the O 0
paternally O 0
derived O 0
SNRPN O 0
allele O 0
may O 0
be O 0
involved O 0
in O 0
the O 0
PWS B-Disease 0
phenotype O 0
. O 0
. O 0

The O 0
presence O 0
of O 0
two O 0
different O 0
infantile O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
mutations O 0
in O 0
a O 0
Cajun O 0
population O 0
. O 0

A O 0
study O 0
was O 0
undertaken O 0
to O 0
characterize O 0
the O 0
mutation O 0
( O 0
s O 0
) O 0
responsible O 0
for O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
( O 0
TSD B-Disease 0
) O 0
in O 0
a O 0
Cajun O 0
population O 0
in O 0
southwest O 0
Louisiana O 0
and O 0
to O 0
identify O 0
the O 0
origins O 0
of O 0
these O 0
mutations O 0
. O 0

Eleven O 0
of O 0
12 O 0
infantile O 0
TSD B-Disease 0
alleles O 0
examined O 0
in O 0
six O 0
families O 0
had O 0
the O 0
beta O 0
- O 0
hexosaminidase O 0
A O 0
( O 0
Hex O 0
A O 0
) O 0
alpha O 0
- O 0
subunit O 0
exon O 0
11 O 0
insertion O 0
mutation O 0
that O 0
is O 0
present O 0
in O 0
approximately O 0
70 O 0
% O 0
of O 0
Ashkenazi O 0
Jewish O 0
TSD B-Disease 0
heterozygotes O 0
. O 0

The O 0
mutation O 0
in O 0
the O 0
remaining O 0
allele O 0
was O 0
a O 0
single O 0
- O 0
base O 0
transition O 0
in O 0
the O 0
donor O 0
splice O 0
site O 0
of O 0
the O 0
alpha O 0
- O 0
subunit O 0
intron O 0
9 O 0
. O 0

To O 0
determine O 0
the O 0
origins O 0
of O 0
these O 0
two O 0
mutations O 0
in O 0
the O 0
Cajun O 0
population O 0
, O 0
the O 0
TSD B-Disease 0
carrier O 0
status O 0
was O 0
enzymatically O 0
determined O 0
for O 0
90 O 0
members O 0
of O 0
four O 0
of O 0
the O 0
six O 0
families O 0
, O 0
and O 0
extensive O 0
pedigrees O 0
were O 0
constructed O 0
for O 0
all O 0
carriers O 0
. O 0

A O 0
single O 0
ancestral O 0
couple O 0
from O 0
France O 0
was O 0
found O 0
to O 0
be O 0
common O 0
to O 0
most O 0
of O 0
the O 0
carriers O 0
of O 0
the O 0
exon O 0
11 O 0
insertion O 0
. O 0

Pedigree O 0
data O 0
suggest O 0
that O 0
this O 0
mutation O 0
has O 0
been O 0
in O 0
the O 0
Cajun O 0
population O 0
since O 0
its O 0
founding O 0
over O 0
2 O 0
centuries O 0
ago O 0
and O 0
that O 0
it O 0
may O 0
be O 0
widely O 0
distributed O 0
within O 0
the O 0
population O 0
. O 0

In O 0
contrast O 0
, O 0
the O 0
intron O 0
9 O 0
mutation O 0
apparently O 0
was O 0
introduced O 0
within O 0
the O 0
last O 0
century O 0
and O 0
probably O 0
is O 0
limited O 0
to O 0
a O 0
few O 0
Louisiana O 0
families O 0
. O 0
. O 0

Mutations O 0
in O 0
the O 0
candidate O 0
gene O 0
for O 0
Norrie B-Disease 1
disease I-Disease 1
. O 0

Recently O 0
, O 0
we O 0
and O 0
others O 0
have O 0
isolated O 0
a O 0
candidate O 0
gene O 0
for O 0
X B-Disease 0
linked I-Disease 0
Norrie I-Disease 1
disease I-Disease 1
( O 0
ND B-Disease 0
) O 0
which O 0
was O 0
found O 0
to O 0
be O 0
deleted O 0
or O 0
disrupted O 0
in O 0
several O 0
patients O 0
. O 0

As O 0
a O 0
prerequisite O 0
for O 0
the O 0
identification O 0
of O 0
point O 0
mutations O 0
in O 0
the O 0
ND B-Disease 0
gene O 0
we O 0
have O 0
established O 0
the O 0
exon O 0
- O 0
intron O 0
structure O 0
of O 0
this O 0
gene O 0
. O 0

In O 0
17 O 0
unrelated O 0
patients O 0
and O 0
15 O 0
controls O 0
, O 0
PCR O 0
products O 0
derived O 0
from O 0
the O 0
promoter O 0
region O 0
, O 0
exons O 0
1 O 0
and O 0
2 O 0
as O 0
well O 0
as O 0
the O 0
coding O 0
part O 0
of O 0
exon O 0
3 O 0
were O 0
analysed O 0
with O 0
the O 0
single O 0
strand O 0
conformation O 0
polymorphism O 0
( O 0
SSCP O 0
) O 0
technique O 0
. O 0

In O 0
12 O 0
patients O 0
altered O 0
PCR O 0
fragments O 0
were O 0
detected O 0
which O 0
were O 0
studied O 0
in O 0
detail O 0
by O 0
direct O 0
sequencing O 0
. O 0

Eleven O 0
different O 0
mutations O 0
were O 0
found O 0
, O 0
and O 0
all O 0
but O 0
one O 0
are O 0
likely O 0
to O 0
give O 0
rise O 0
to O 0
significant O 0
structural O 0
changes O 0
in O 0
the O 0
predicted O 0
protein O 0
. O 0

These O 0
findings O 0
, O 0
and O 0
the O 0
absence O 0
of O 0
functionally O 0
relevant O 0
base O 0
changes O 0
in O 0
healthy O 0
controls O 0
, O 0
emphasize O 0
the O 0
causal O 0
role O 0
of O 0
this O 0
candidate O 0
gene O 0
in O 0
Norrie B-Disease 1
disease I-Disease 1
and O 0
pave O 0
the O 0
way O 0
for O 0
reliable O 0
diagnosis O 0
and O 0
carrier O 0
detection O 0
. O 0
. O 0

Detection O 0
of O 0
a O 0
nonsense O 0
mutation O 0
in O 0
the O 0
dystrophin O 0
gene O 0
by O 0
multiple O 0
SSCP O 0
. O 0

A O 0
combination O 0
of O 0
multiplex O 0
PCR O 0
with O 0
the O 0
single O 0
strand O 0
conformation O 0
polymorphism O 0
( O 0
SSCP O 0
) O 0
technique O 0
was O 0
employed O 0
to O 0
screen O 0
for O 0
point O 0
mutations O 0
in O 0
the O 0
human O 0
dystrophin O 0
gene O 0
. O 0

Co O 0
- O 0
amplification O 0
of O 0
11 O 0
exons O 0
from O 0
genomic O 0
DNA O 0
of O 0
Duchenne B-Disease 0
and I-Disease 0
Becker I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
( O 0
DMD B-Disease 0
/ O 0
BMD B-Disease 1
) O 0
patients O 0
with O 0
no O 0
deletion O 0
or O 0
duplication O 0
was O 0
performed O 0
and O 0
the O 0
samples O 0
subjected O 0
to O 0
multiple O 0
SSCP O 0
analysis O 0
. O 0

We O 0
report O 0
the O 0
case O 0
of O 0
a O 0
nonsense O 0
mutation O 0
in O 0
a O 0
Duchenne B-Disease 0
patient O 0
identified O 0
by O 0
this O 0
approach O 0
. O 0

The O 0
mutation O 0
introduces O 0
a O 0
termination O 0
codon O 0
within O 0
exon O 0
8 O 0
of O 0
the O 0
dystrophin O 0
gene O 0
. O 0

It O 0
is O 0
predicted O 0
to O 0
cause O 0
a O 0
very O 0
premature O 0
translational O 0
termination O 0
accounting O 0
for O 0
the O 0
severe O 0
phenotype O 0
observed O 0
. O 0

The O 0
patient O 0
inherited O 0
this O 0
mutation O 0
from O 0
his O 0
mother O 0
. O 0

In O 0
addition O 0
the O 0
analysis O 0
revealed O 0
5 O 0
polymorphisms O 0
useful O 0
for O 0
internal O 0
control O 0
. O 0
. O 0

Proliferation O 0
- O 0
related O 0
expression O 0
of O 0
p19 O 0
/ O 0
nm23 O 0
nucleoside O 0
diphosphate O 0
kinase O 0
. O 0

High O 0
level O 0
expression O 0
of O 0
the O 0
nm23 O 0
- O 0
H1 O 0
gene O 0
, O 0
which O 0
encodes O 0
for O 0
a O 0
nucleoside O 0
diphosphate O 0
kinase O 0
, O 0
has O 0
been O 0
found O 0
to O 0
correlate O 0
with O 0
diminished O 0
metastasis O 0
in O 0
some O 0
tumors B-Disease 0
but O 0
not O 0
in O 0
others O 0
. O 0

We O 0
have O 0
previously O 0
identified O 0
the O 0
protein O 0
product O 0
of O 0
the O 0
nm23 O 0
- O 0
H1 O 0
gene O 0
in O 0
two O 0
- O 0
dimensional O 0
electrophoretic O 0
gels O 0
and O 0
have O 0
designated O 0
it O 0
p19 O 0
/ O 0
nm23 O 0
. O 0

In O 0
neuroblastoma B-Disease 1
, O 0
higher O 0
levels O 0
of O 0
p19 O 0
/ O 0
nm23 O 0
, O 0
which O 0
are O 0
associated O 0
with O 0
amplification O 0
of O 0
the O 0
N O 0
- O 0
myc O 0
oncogene O 0
, O 0
large O 0
tumor B-Disease 0
mass O 0
, O 0
and O 0
metastasis O 0
, O 0
were O 0
observed O 0
in O 0
advanced O 0
stage O 0
tumors B-Disease 0
compared O 0
with O 0
limited O 0
stage O 0
disease O 0
. O 0

Because O 0
of O 0
the O 0
variable O 0
expression O 0
of O 0
nm23 O 0
- O 0
H1 O 0
in O 0
different O 0
tumors B-Disease 0
, O 0
we O 0
have O 0
investigated O 0
the O 0
relationship O 0
between O 0
amounts O 0
of O 0
the O 0
protein O 0
and O 0
cell O 0
proliferation O 0
. O 0

The O 0
levels O 0
of O 0
p19 O 0
/ O 0
nm23 O 0
were O 0
compared O 0
between O 0
resting O 0
and O 0
mitotically O 0
stimulated O 0
normal O 0
human O 0
PBLs O 0
and O 0
in O 0
leukemia B-Disease 1
cells O 0
. O 0

The O 0
amount O 0
of O 0
p19 O 0
/ O 0
nm23 O 0
increased O 0
in O 0
normal O 0
lymphocytes O 0
in O 0
response O 0
to O 0
mitotic O 0
stimulation O 0
and O 0
paralleled O 0
the O 0
increase O 0
in O 0
DNA O 0
synthesis O 0
. O 0

In O 0
leukemia B-Disease 1
cells O 0
obtained O 0
from O 0
patients O 0
with O 0
different O 0
subtypes O 0
of O 0
acute B-Disease 0
leukemia I-Disease 1
, O 0
p19 O 0
/ O 0
nm23 O 0
levels O 0
were O 0
also O 0
increased O 0
relative O 0
to O 0
resting O 0
normal O 0
lymphocytes O 0
. O 0

Treatment O 0
of O 0
mitotically O 0
stimulated O 0
lymphocytes O 0
with O 0
cyclosporin O 0
, O 0
which O 0
inhibits O 0
proliferation O 0
, O 0
blocked O 0
the O 0
increase O 0
in O 0
p19 O 0
/ O 0
nm23 O 0
; O 0
treatment O 0
of O 0
the O 0
leukemia B-Disease 1
cell O 0
line O 0
HL O 0
- O 0
60 O 0
with O 0
dimethylsulfoxide O 0
, O 0
which O 0
induces O 0
terminal O 0
differentiation O 0
, O 0
resulted O 0
in O 0
diminished O 0
levels O 0
of O 0
p19 O 0
/ O 0
nm23 O 0
. O 0

Our O 0
data O 0
therefore O 0
provide O 0
evidence O 0
that O 0
nm23 O 0
- O 0
H1 O 0
expression O 0
is O 0
related O 0
to O 0
cell O 0
proliferative O 0
activity O 0
. O 0
. O 0

An O 0
intrachromosomal O 0
insertion O 0
causing O 0
5q22 O 0
deletion O 0
and O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
coli I-Disease 1
in O 0
two O 0
generations O 0
. O 0

We O 0
report O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
coli I-Disease 1
( O 0
FAPC B-Disease 1
) O 0
with O 0
epidermoid B-Disease 1
cysts I-Disease 1
, O 0
osteomata B-Disease 0
, O 0
and O 0
areas O 0
of O 0
congenital B-Disease 1
hypertrophy I-Disease 1
of I-Disease 1
the I-Disease 1
retinal I-Disease 1
pigment I-Disease 1
epithelium I-Disease 1
( O 0
CHRPEs B-Disease 0
) O 0
in O 0
a O 0
male O 0
patient O 0
and O 0
his O 0
maternal O 0
aunt O 0
, O 0
both O 0
of O 0
whom O 0
suffered O 0
a O 0
mild O 0
to O 0
moderate O 0
degree O 0
of O 0
mental B-Disease 0
handicap I-Disease 0
. O 0

Both O 0
had O 0
an O 0
interstitial O 0
deletion O 0
of O 0
the O 0
long O 0
arm O 0
of O 0
chromosome O 0
5 O 0
( O 0
del O 0
( O 0
5 O 0
) O 0
( O 0
q22q23 O 0
. O 0
2 O 0
) O 0
) O 0
. O 0

Two O 0
other O 0
normal O 0
family O 0
members O 0
had O 0
the O 0
underlying O 0
direct O 0
insertion O 0
of O 0
chromosome O 0
5 O 0
( O 0
dir O 0
ins O 0
( O 0
5 O 0
) O 0
( O 0
q31 O 0
. O 0
3q22q23 O 0
3q22q23 O 0
. O 0
2 O 0
) O 0
) O 0
. O 0

Molecular O 0
genetic O 0
and O 0
fluorescent O 0
hybridisation O 0
studies O 0
have O 0
shown O 0
that O 0
loci O 0
D5S37 O 0
and O 0
D5S98 O 0
are O 0
outside O 0
the O 0
deletion O 0
whereas O 0
loci O 0
detected O 0
by O 0
probes O 0
EF5 O 0
. O 0

44 O 0
and O 0
YN5 O 0
. O 0

48 O 0
are O 0
lost O 0
. O 0

As O 0
expected O 0
, O 0
the O 0
molecular O 0
analyses O 0
indicate O 0
loss O 0
of O 0
one O 0
allele O 0
at O 0
the O 0
MCC O 0
and O 0
APC B-Disease 1
loci O 0
. O 0

The O 0
APC B-Disease 1
gene O 0
is O 0
located O 0
within O 0
band O 0
5q22 O 0
. O 0

Familial O 0
direct O 0
insertions O 0
should O 0
be O 0
considered O 0
as O 0
a O 0
cause O 0
of O 0
recurrent O 0
microdeletion O 0
syndromes O 0
. O 0

Chromosome O 0
mapping O 0
of O 0
the O 0
rod O 0
photoreceptor O 0
cGMP O 0
phosphodiesterase O 0
beta O 0
- O 0
subunit O 0
gene O 0
in O 0
mouse O 0
and O 0
human O 0
: O 0
tight O 0
linkage O 0
to O 0
the O 0
Huntington B-Disease 1
disease I-Disease 1
region O 0
( O 0
4p16 O 0
. O 0
3 O 0
) O 0
. O 0

The O 0
retinal B-Disease 0
degeneration I-Disease 0
mouse O 0
( O 0
gene O 0
symbol O 0
, O 0
rd O 0
) O 0
is O 0
an O 0
animal O 0
model O 0
for O 0
certain O 0
forms O 0
of O 0
human O 0
hereditary B-Disease 1
retinopathies I-Disease 1
. O 0

Recent O 0
findings O 0
of O 0
a O 0
nonsense O 0
mutation O 0
in O 0
the O 0
rd O 0
mouse O 0
PDE O 0
beta O 0
- O 0
subunit O 0
gene O 0
( O 0
Pdeb O 0
) O 0
prompted O 0
us O 0
to O 0
investigate O 0
the O 0
chromosome O 0
locations O 0
of O 0
the O 0
mouse O 0
and O 0
human O 0
genes O 0
. O 0

We O 0
have O 0
utilized O 0
backcross O 0
analysis O 0
in O 0
mice O 0
to O 0
verify O 0
and O 0
define O 0
more O 0
precisely O 0
the O 0
location O 0
of O 0
the O 0
Pdeb O 0
locus O 0
6 O 0
. O 0

1 O 0
+ O 0
/ O 0
- O 0
2 O 0
. O 0

3 O 0
cM O 0
distal O 0
of O 0
Mgsa O 0
on O 0
mouse O 0
chromosome O 0
5 O 0
. O 0

We O 0
have O 0
determined O 0
that O 0
the O 0
human O 0
gene O 0
( O 0
PDEB O 0
) O 0
maps O 0
to O 0
4p16 O 0
. O 0

3 O 0
, O 0
very O 0
close O 0
to O 0
the O 0
Huntington B-Disease 1
disease I-Disease 1
( O 0
HD B-Disease 1
) O 0
region O 0
. O 0

Analysis O 0
of O 0
the O 0
comparative O 0
map O 0
for O 0
mice O 0
and O 0
humans O 0
shows O 0
that O 0
the O 0
mouse O 0
homologue O 0
of O 0
the O 0
HD B-Disease 1
gene O 0
will O 0
reside O 0
on O 0
chromosome O 0
5 O 0
. O 0

Linkage O 0
of O 0
the O 0
mouse O 0
Pdeb O 0
locus O 0
with O 0
other O 0
homologues O 0
in O 0
the O 0
human O 0
4p16 O 0
. O 0

3 O 0
region O 0
is O 0
maintained O 0
but O 0
gene O 0
order O 0
is O 0
not O 0
, O 0
suggesting O 0
at O 0
least O 0
three O 0
possible O 0
sites O 0
for O 0
the O 0
corresponding O 0
mouse O 0
HD B-Disease 1
gene O 0
. O 0

Coincident O 0
Kaposi B-Disease 1
sarcoma I-Disease 1
and O 0
T B-Disease 1
- I-Disease 1
cell I-Disease 1
lymphoma I-Disease 1
in O 0
a O 0
patient O 0
with O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
. O 0

A O 0
24 O 0
year O 0
old O 0
male O 0
with O 0
a O 0
history O 0
of O 0
eczema B-Disease 0
, O 0
recurrent O 0
mild O 0
infections O 0
, O 0
and O 0
thrombocytopenia B-Disease 0
consistent O 0
with O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
( O 0
WAS B-Disease 0
) O 0
presented O 0
with O 0
a O 0
mediastinal O 0
mass O 0
, O 0
generalized O 0
lymphadenopathy B-Disease 0
, O 0
splenomegaly B-Disease 0
, O 0
and O 0
severe O 0
thrombocytopenia B-Disease 0
. O 0

Studies O 0
of O 0
immune O 0
function O 0
including O 0
immunoglobulin O 0
levels O 0
and O 0
T O 0
- O 0
cell O 0
subsets O 0
were O 0
normal O 0
. O 0

Furthermore O 0
, O 0
his O 0
T O 0
lymphocytes O 0
proliferated O 0
normally O 0
in O 0
response O 0
to O 0
phytohemagglutinin O 0
, O 0
concanavalin O 0
A O 0
, O 0
and O 0
the O 0
combination O 0
of O 0
neuraminidase O 0
/ O 0
galactose O 0
oxidase O 0
. O 0

However O 0
, O 0
their O 0
proliferative O 0
responses O 0
to O 0
anti O 0
- O 0
CD43 O 0
antibody O 0
and O 0
periodate O 0
were O 0
diminished O 0
, O 0
consistent O 0
with O 0
the O 0
clinical O 0
diagnosis O 0
of O 0
WAS B-Disease 0
. O 0

An O 0
initial O 0
inguinal O 0
lymph O 0
node O 0
biopsy O 0
surprisingly O 0
revealed O 0
Kaposi B-Disease 1
sarcoma I-Disease 1
. O 0

However O 0
, O 0
following O 0
splenectomy O 0
to O 0
increase O 0
the O 0
platelet O 0
count O 0
, O 0
biopsy O 0
of O 0
the O 0
mediastinal O 0
mass O 0
revealed O 0
T B-Disease 1
- I-Disease 1
cell I-Disease 1
large I-Disease 1
cell I-Disease 1
lymphoma I-Disease 1
. O 0

Studies O 0
of O 0
biopsied O 0
tissue O 0
for O 0
the O 0
presence O 0
of O 0
Epstein B-Disease 1
- I-Disease 1
Barr I-Disease 1
virus I-Disease 1
and O 0
cytomegalovirus B-Disease 1
were O 0
negative O 0
, O 0
as O 0
were O 0
studies O 0
of O 0
blood O 0
, O 0
including O 0
the O 0
polymerase O 0
chain O 0
reaction O 0
, O 0
for O 0
the O 0
presence O 0
of O 0
the O 0
human B-Disease 1
immunodeficiency I-Disease 1
virus I-Disease 1
( O 0
HIV B-Disease 0
) O 0
. O 0

This O 0
is O 0
the O 0
first O 0
report O 0
of O 0
Kaposi B-Disease 1
sarcoma I-Disease 1
arising O 0
in O 0
a O 0
patient O 0
with O 0
a O 0
congenital B-Disease 0
immunodeficiency I-Disease 0
syndrome I-Disease 0
. O 0

Although O 0
Kaposi B-Disease 1
sarcoma I-Disease 1
can O 0
arise O 0
in O 0
the O 0
face O 0
of O 0
the O 0
severe O 0
immunosuppression O 0
that O 0
follows O 0
allograft O 0
transplantation O 0
and O 0
in O 0
patients O 0
infected O 0
with O 0
HIV B-Disease 0
, O 0
we O 0
postulate O 0
that O 0
longevity O 0
in O 0
the O 0
face O 0
of O 0
mild O 0
immunosuppression O 0
was O 0
the O 0
major O 0
factor O 0
in O 0
the O 0
development O 0
of O 0
Kaposi B-Disease 1
sarcoma I-Disease 1
in O 0
this O 0
patient O 0
. O 0
. O 0

The O 0
APC B-Disease 1
gene O 0
, O 0
responsible O 0
for O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
, O 0
is O 0
mutated O 0
in O 0
human O 0
gastric B-Disease 0
cancer I-Disease 1
. O 0

Although O 0
gastric B-Disease 0
cancer I-Disease 1
is O 0
the O 0
most O 0
common O 0
cancer B-Disease 1
in O 0
the O 0
world O 0
, O 0
genetic O 0
changes O 0
during O 0
its O 0
carcinogenesis O 0
are O 0
not O 0
well O 0
understood O 0
. O 0

Since O 0
some O 0
gastric B-Disease 0
cancers I-Disease 0
are O 0
considered O 0
to O 0
originate O 0
from O 0
the O 0
intestinal O 0
metaplasia O 0
, O 0
it O 0
is O 0
likely O 0
that O 0
the O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( O 0
APC B-Disease 1
) O 0
gene O 0
, O 0
the O 0
mutation O 0
of O 0
which O 0
causes O 0
adenomatous B-Disease 0
polyps I-Disease 0
in I-Disease 0
the I-Disease 0
colon I-Disease 0
, O 0
is O 0
associated O 0
with O 0
carcinogenesis O 0
of O 0
gastric B-Disease 0
cancer I-Disease 1
. O 0

Based O 0
on O 0
this O 0
idea O 0
, O 0
DNAs O 0
isolated O 0
from O 0
gastric B-Disease 0
cancers I-Disease 0
were O 0
examined O 0
by O 0
means O 0
of O 0
a O 0
RNase O 0
protection O 0
analysis O 0
coupled O 0
with O 0
polymerase O 0
chain O 0
reaction O 0
followed O 0
by O 0
sequencing O 0
of O 0
the O 0
polymerase O 0
chain O 0
reaction O 0
products O 0
. O 0

By O 0
screening O 0
nearly O 0
one O 0
- O 0
half O 0
of O 0
the O 0
coding O 0
region O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
in O 0
44 O 0
tumors B-Disease 0
, O 0
somatic O 0
mutations O 0
were O 0
detected O 0
in O 0
three O 0
tumors B-Disease 0
a O 0
missense O 0
mutation O 0
, O 0
a O 0
nonsense O 0
mutation O 0
, O 0
and O 0
a O 0
5 O 0
- O 0
base O 0
pair O 0
deletion O 0
resulting O 0
in O 0
a O 0
frame O 0
shift O 0
which O 0
causes O 0
truncation O 0
of O 0
the O 0
gene O 0
product O 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
the O 0
mutation O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
also O 0
plays O 0
an O 0
important O 0
role O 0
during O 0
the O 0
carcinogenesis O 0
of O 0
at O 0
least O 0
some O 0
gastric B-Disease 0
cancers I-Disease 0
. O 0
. O 0

A O 0
71 O 0
- O 0
kilodalton O 0
protein O 0
is O 0
a O 0
major O 0
product O 0
of O 0
the O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
gene O 0
in O 0
brain O 0
and O 0
other O 0
nonmuscle O 0
tissues O 0
. O 0

The O 0
known O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
gene O 0
products O 0
, O 0
the O 0
muscle O 0
- O 0
and O 0
brain O 0
- O 0
type O 0
dystrophin O 0
isoforms O 0
, O 0
are O 0
427 O 0
- O 0
kDa O 0
proteins O 0
translated O 0
from O 0
14 O 0
- O 0
kilobase O 0
( O 0
kb O 0
) O 0
mRNAs O 0
. O 0

Recently O 0
we O 0
described O 0
a O 0
6 O 0
. O 0

5 O 0
- O 0
kb O 0
mRNA O 0
that O 0
also O 0
is O 0
transcribed O 0
from O 0
the O 0
DMD B-Disease 0
gene O 0
. O 0

Cloning O 0
and O 0
in O 0
vitro O 0
transcription O 0
and O 0
translation O 0
of O 0
the O 0
entire O 0
coding O 0
region O 0
show O 0
that O 0
the O 0
6 O 0
. O 0

5 O 0
- O 0
kb O 0
mRNA O 0
encodes O 0
a O 0
70 O 0
. O 0

8 O 0
- O 0
kDa O 0
protein O 0
that O 0
is O 0
a O 0
major O 0
product O 0
of O 0
the O 0
DMD B-Disease 0
gene O 0
. O 0

It O 0
contains O 0
the O 0
C O 0
- O 0
terminal O 0
and O 0
the O 0
cysteine O 0
- O 0
rich O 0
domains O 0
of O 0
dystrophin O 0
, O 0
seven O 0
additional O 0
amino O 0
acids O 0
at O 0
the O 0
N O 0
terminus O 0
, O 0
and O 0
some O 0
modifications O 0
formed O 0
by O 0
alternative O 0
splicing O 0
in O 0
the O 0
C O 0
- O 0
terminal O 0
domain O 0
. O 0

It O 0
lacks O 0
the O 0
entire O 0
large O 0
domain O 0
of O 0
spectrin O 0
- O 0
like O 0
repeats O 0
and O 0
the O 0
actin O 0
- O 0
binding O 0
N O 0
- O 0
terminal O 0
domain O 0
of O 0
dystrophin O 0
. O 0

This O 0
protein O 0
is O 0
the O 0
major O 0
DMD B-Disease 0
gene O 0
product O 0
in O 0
brain O 0
and O 0
other O 0
nonmuscle O 0
tissues O 0
but O 0
is O 0
undetectable O 0
in O 0
skeletal O 0
muscle O 0
extracts O 0
. O 0

Correlation O 0
between O 0
the O 0
location O 0
of O 0
germ O 0
- O 0
line O 0
mutations O 0
in O 0
the O 0
APC B-Disease 1
gene O 0
and O 0
the O 0
number O 0
of O 0
colorectal B-Disease 1
polyps I-Disease 1
in O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
patients O 0
. O 0

Recently O 0
we O 0
have O 0
isolated O 0
the O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( O 0
APC B-Disease 1
) O 0
gene O 0
which O 0
causes O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
( O 0
FAP B-Disease 0
) O 0
, O 0
and O 0
its O 0
germ O 0
- O 0
line O 0
mutations O 0
in O 0
a O 0
substantial O 0
number O 0
of O 0
FAP B-Disease 0
patients O 0
have O 0
been O 0
identified O 0
. O 0

On O 0
the O 0
basis O 0
of O 0
this O 0
information O 0
, O 0
we O 0
compared O 0
the O 0
location O 0
of O 0
germ O 0
- O 0
line O 0
mutations O 0
in O 0
the O 0
APC B-Disease 1
gene O 0
in O 0
22 O 0
unrelated O 0
patients O 0
( O 0
12 O 0
of O 0
whom O 0
have O 0
been O 0
reported O 0
previously O 0
) O 0
with O 0
the O 0
number O 0
of O 0
colorectal B-Disease 1
polyps I-Disease 1
developed O 0
in O 0
FAP B-Disease 0
patients O 0
; O 0
17 O 0
were O 0
sparse O 0
types O 0
and O 0
five O 0
were O 0
profuse O 0
types O 0
. O 0

All O 0
but O 0
one O 0
of O 0
the O 0
mutations O 0
were O 0
considered O 0
to O 0
cause O 0
truncation O 0
of O 0
the O 0
gene O 0
product O 0
by O 0
frame O 0
- O 0
shift O 0
due O 0
to O 0
deletion O 0
( O 0
14 O 0
cases O 0
) O 0
or O 0
nonsense O 0
mutation O 0
( O 0
seven O 0
cases O 0
) O 0
. O 0

The O 0
location O 0
of O 0
the O 0
germ O 0
- O 0
line O 0
mutations O 0
seems O 0
to O 0
correlate O 0
with O 0
the O 0
two O 0
clinical O 0
types O 0
; O 0
germ O 0
- O 0
line O 0
mutations O 0
in O 0
five O 0
FAP B-Disease 0
patients O 0
with O 0
profuse O 0
polyps B-Disease 0
were O 0
observed O 0
between O 0
codon O 0
1250 O 0
and O 0
codon O 0
1464 O 0
, O 0
whereas O 0
mutations O 0
in O 0
17 O 0
FAP B-Disease 0
patients O 0
with O 0
fewer O 0
polyps B-Disease 0
were O 0
observed O 0
in O 0
the O 0
other O 0
regions O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
. O 0

The O 0
result O 0
suggests O 0
that O 0
the O 0
number O 0
of O 0
colorectal B-Disease 1
polyps I-Disease 1
in O 0
FAP B-Disease 0
patients O 0
may O 0
be O 0
associated O 0
with O 0
a O 0
difference O 0
in O 0
the O 0
stability O 0
or O 0
biological O 0
function O 0
of O 0
the O 0
truncated O 0
APC B-Disease 1
protein O 0
. O 0
. O 0

Identification O 0
and O 0
rapid O 0
detection O 0
of O 0
three O 0
Tay B-Disease 0
- I-Disease 0
Sachs I-Disease 0
mutations O 0
in O 0
the O 0
Moroccan O 0
Jewish O 0
population O 0
. O 0

Infantile O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
( O 0
TSD B-Disease 0
) O 0
is O 0
caused O 0
by O 0
mutations O 0
in O 0
the O 0
HEXA O 0
gene O 0
that O 0
result O 0
in O 0
the O 0
complete O 0
absence O 0
of O 0
beta O 0
- O 0
hexosaminidase O 0
A O 0
activity O 0
. O 0

It O 0
is O 0
well O 0
known O 0
that O 0
an O 0
elevated O 0
frequency O 0
of O 0
TSD B-Disease 0
mutations O 0
exists O 0
among O 0
Ashkenazi O 0
Jews O 0
. O 0

More O 0
recently O 0
it O 0
has O 0
become O 0
apparent O 0
that O 0
elevated O 0
carrier O 0
frequencies O 0
for O 0
TSD B-Disease 0
also O 0
occur O 0
in O 0
several O 0
other O 0
ethnic O 0
groups O 0
, O 0
including O 0
Moroccan O 0
Jews O 0
, O 0
a O 0
subgroup O 0
of O 0
Sephardic O 0
Jews O 0
. O 0

Elsewhere O 0
we O 0
reported O 0
an O 0
in O 0
- O 0
frame O 0
deletion O 0
of O 0
one O 0
of O 0
the O 0
two O 0
adjacent O 0
phenylalanine O 0
codons O 0
at O 0
position O 0
304 O 0
or O 0
305 O 0
( O 0
delta O 0
F304 O 0
/ O 0
305 O 0
) O 0
in O 0
one O 0
HEXA O 0
allele O 0
of O 0
a O 0
Moroccan O 0
Jewish O 0
TSD B-Disease 0
patient O 0
and O 0
in O 0
three O 0
obligate O 0
carriers O 0
from O 0
six O 0
unrelated O 0
Moroccan O 0
Jewish O 0
families O 0
. O 0

We O 0
have O 0
now O 0
identified O 0
two O 0
additional O 0
mutations O 0
within O 0
exon O 0
5 O 0
of O 0
the O 0
HEXA O 0
gene O 0
that O 0
account O 0
for O 0
the O 0
remaining O 0
TSD B-Disease 0
alleles O 0
in O 0
the O 0
patient O 0
and O 0
carriers O 0
. O 0

One O 0
of O 0
the O 0
mutations O 0
is O 0
a O 0
novel O 0
C O 0
- O 0
to O 0
- O 0
G O 0
transversion O 0
, O 0
resulting O 0
in O 0
a O 0
replacement O 0
of O 0
Tyr180 O 0
by O 0
a O 0
stop O 0
codon O 0
. O 0

The O 0
other O 0
mutation O 0
is O 0
a O 0
G O 0
- O 0
to O 0
- O 0
A O 0
transition O 0
resulting O 0
in O 0
an O 0
Arg170 O 0
- O 0
to O 0
- O 0
Gln O 0
substitution O 0
. O 0

This O 0
mutation O 0
is O 0
at O 0
a O 0
CpG O 0
site O 0
in O 0
a O 0
Japanese O 0
infant O 0
with O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
and O 0
was O 0
described O 0
elsewhere O 0
. O 0

Analysis O 0
of O 0
nine O 0
obligate O 0
carriers O 0
from O 0
seven O 0
unrelated O 0
families O 0
showed O 0
that O 0
four O 0
harbor O 0
the O 0
delta O 0
F304 O 0
/ O 0
305 O 0
mutation O 0
, O 0
two O 0
the O 0
Arg170 O 0
- O 0
- O 0
- O 0
- O 0
Gln O 0
mutation O 0
, O 0
and O 0
one O 0
the O 0
Tyr180 O 0
- O 0
- O 0
- O 0
- O 0
Stop O 0
mutation O 0
. O 0

We O 0
also O 0
have O 0
developed O 0
rapid O 0
, O 0
nonradioactive O 0
assays O 0
for O 0
the O 0
detection O 0
of O 0
each O 0
mutation O 0
, O 0
which O 0
should O 0
be O 0
helpful O 0
for O 0
carrier O 0
screening O 0
. O 0
. O 0

Molecular O 0
characterization O 0
of O 0
glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
) I-Disease 0
deficiency I-Disease 0
by O 0
natural O 0
and O 0
amplification O 0
created O 0
restriction O 0
sites O 0
: O 0
five O 0
mutations O 0
account O 0
for O 0
most O 0
G6PD B-Disease 0
deficiency I-Disease 0
cases O 0
in O 0
Taiwan O 0
. O 0

We O 0
have O 0
developed O 0
a O 0
rapid O 0
and O 0
simple O 0
method O 0
to O 0
diagnose O 0
the O 0
molecular O 0
defects O 0
of O 0
glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
) I-Disease 0
deficiency I-Disease 0
in O 0
Chinese O 0
in O 0
Taiwan O 0
. O 0

This O 0
method O 0
involves O 0
the O 0
selective O 0
amplification O 0
of O 0
a O 0
DNA O 0
fragment O 0
from O 0
human O 0
G6PD O 0
gene O 0
with O 0
specific O 0
oligonucleotide O 0
primers O 0
followed O 0
by O 0
digestion O 0
with O 0
restriction O 0
enzymes O 0
that O 0
recognize O 0
artificially O 0
created O 0
or O 0
naturally O 0
occurring O 0
restriction O 0
sites O 0
. O 0

Ninety O 0
- O 0
four O 0
Chinese O 0
males O 0
with O 0
G6PD B-Disease 0
deficiency I-Disease 0
were O 0
studied O 0
. O 0

The O 0
results O 0
show O 0
that O 0
50 O 0
% O 0
( O 0
47 O 0
of O 0
94 O 0
) O 0
were O 0
G O 0
to O 0
T O 0
mutation O 0
at O 0
nucleotide O 0
( O 0
nt O 0
) O 0
1376 O 0
, O 0
21 O 0
. O 0

3 O 0
% O 0
( O 0
20 O 0
of O 0
94 O 0
) O 0
were O 0
G O 0
to O 0
A O 0
mutation O 0
at O 0
nt O 0
1388 O 0
, O 0
7 O 0
. O 0

4 O 0
% O 0
( O 0
7 O 0
of O 0
94 O 0
) O 0
were O 0
A O 0
to O 0
G O 0
mutation O 0
at O 0
nt O 0
493 O 0
, O 0
7 O 0
. O 0

4 O 0
% O 0
( O 0
7 O 0
of O 0
94 O 0
) O 0
were O 0
A O 0
to O 0
G O 0
mutation O 0
at O 0
nt O 0
95 O 0
, O 0
4 O 0
. O 0

2 O 0
% O 0
( O 0
4 O 0
of O 0
94 O 0
) O 0
were O 0
C O 0
to O 0
T O 0
mutation O 0
at O 0
nt O 0
1024 O 0
, O 0
1 O 0
. O 0

1 O 0
% O 0
( O 0
1 O 0
of O 0
94 O 0
) O 0
was O 0
G O 0
to O 0
T O 0
mutation O 0
at O 0
nt O 0
392 O 0
, O 0
and O 0
1 O 0
. O 0

1 O 0
% O 0
( O 0
1 O 0
of O 0
94 O 0
) O 0
was O 0
G O 0
to O 0
A O 0
mutation O 0
at O 0
nt O 0
487 O 0
. O 0

These O 0
results O 0
show O 0
that O 0
the O 0
former O 0
five O 0
mutations O 0
account O 0
for O 0
more O 0
than O 0
90 O 0
% O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
cases O 0
in O 0
Taiwan O 0
. O 0

Aside O 0
from O 0
showing O 0
that O 0
G O 0
to O 0
T O 0
change O 0
at O 0
nt O 0
1376 O 0
is O 0
the O 0
most O 0
common O 0
mutation O 0
, O 0
our O 0
research O 0
indicates O 0
that O 0
nt O 0
493 O 0
mutation O 0
is O 0
a O 0
frequent O 0
mutation O 0
among O 0
Chinese O 0
in O 0
Taiwan O 0
. O 0

We O 0
compared O 0
G6PD O 0
activity O 0
among O 0
different O 0
mutations O 0
, O 0
without O 0
discovering O 0
significant O 0
differences O 0
between O 0
them O 0
. O 0

Eight O 0
novel O 0
inactivating O 0
germ O 0
line O 0
mutations O 0
at O 0
the O 0
APC B-Disease 1
gene O 0
identified O 0
by O 0
denaturing O 0
gradient O 0
gel O 0
electrophoresis O 0
. O 0

Familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
( O 0
FAP B-Disease 0
) O 0
is O 0
a O 0
dominantly O 0
inherited O 0
condition O 0
predisposing O 0
to O 0
colorectal B-Disease 1
cancer I-Disease 1
. O 0

The O 0
recent O 0
isolation O 0
of O 0
the O 0
responsible O 0
gene O 0
( O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
or O 0
APC B-Disease 1
) O 0
has O 0
facilitated O 0
the O 0
search O 0
for O 0
germ O 0
line O 0
mutations O 0
in O 0
affected O 0
individuals O 0
. O 0

Previous O 0
authors O 0
have O 0
used O 0
the O 0
RNase O 0
protection O 0
assay O 0
and O 0
the O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphisms O 0
procedure O 0
to O 0
screen O 0
for O 0
mutations O 0
. O 0

In O 0
this O 0
study O 0
we O 0
used O 0
denaturing O 0
gradient O 0
gel O 0
electrophoresis O 0
( O 0
DGGE O 0
) O 0
. O 0

DGGE O 0
analysis O 0
of O 0
10 O 0
APC B-Disease 1
exons O 0
( O 0
4 O 0
, O 0
5 O 0
, O 0
7 O 0
, O 0
8 O 0
, O 0
9 O 0
, O 0
10 O 0
, O 0
12 O 0
, O 0
13 O 0
, O 0
14 O 0
, O 0
and O 0
part O 0
of O 0
15 O 0
) O 0
in O 0
33 O 0
unrelated O 0
Dutch O 0
FAP B-Disease 0
patients O 0
has O 0
led O 0
to O 0
the O 0
identification O 0
of O 0
eight O 0
novel O 0
germ O 0
line O 0
mutations O 0
resulting O 0
in O 0
stop O 0
codons O 0
or O 0
frameshifts O 0
. O 0

The O 0
results O 0
reported O 0
here O 0
indicate O 0
that O 0
( O 0
1 O 0
) O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
is O 0
caused O 0
by O 0
an O 0
extremely O 0
heterogeneous O 0
spectrum O 0
of O 0
point O 0
mutations O 0
; O 0
( O 0
2 O 0
) O 0
all O 0
the O 0
mutations O 0
found O 0
in O 0
this O 0
study O 0
are O 0
chain O 0
terminating O 0
; O 0
and O 0
( O 0
3 O 0
) O 0
DGGE O 0
represents O 0
a O 0
rapid O 0
and O 0
sensitive O 0
technique O 0
for O 0
the O 0
detection O 0
of O 0
mutations O 0
in O 0
the O 0
unusually O 0
large O 0
APC B-Disease 1
gene O 0
. O 0

An O 0
extension O 0
of O 0
the O 0
DGGE O 0
analysis O 0
to O 0
the O 0
entire O 0
coding O 0
region O 0
in O 0
a O 0
sufficient O 0
number O 0
of O 0
clinically O 0
well O 0
- O 0
characterized O 0
, O 0
unrelated O 0
patients O 0
will O 0
facilitate O 0
the O 0
establishment O 0
of O 0
genotype O 0
- O 0
phenotype O 0
correlations O 0
. O 0

On O 0
the O 0
other O 0
hand O 0
, O 0
the O 0
occurrence O 0
of O 0
an O 0
extremely O 0
heterogeneous O 0
spectrum O 0
of O 0
mutations O 0
spread O 0
throughout O 0
the O 0
entire O 0
length O 0
of O 0
the O 0
large O 0
APC B-Disease 1
gene O 0
among O 0
the O 0
FAP B-Disease 0
patients O 0
indicates O 0
that O 0
this O 0
approach O 0
may O 0
not O 0
be O 0
useful O 0
as O 0
a O 0
rapid O 0
presymptomatic O 0
diagnostic O 0
procedure O 0
in O 0
a O 0
routine O 0
laboratory O 0
. O 0

Nevertheless O 0
, O 0
the O 0
above O 0
DGGE O 0
approach O 0
has O 0
incidentally O 0
led O 0
to O 0
the O 0
identification O 0
of O 0
a O 0
common O 0
polymorphism O 0
in O 0
exon O 0
13 O 0
. O 0

Such O 0
intragenic O 0
polymorphisms O 0
offer O 0
a O 0
practical O 0
approach O 0
to O 0
a O 0
more O 0
rapid O 0
procedure O 0
for O 0
presymptomatic O 0
diagnosis O 0
of O 0
FAP B-Disease 0
by O 0
linkage O 0
analysis O 0
in O 0
informative O 0
families O 0
. O 0
. O 0

Yeast O 0
artificial O 0
chromosomes O 0
for O 0
the O 0
molecular O 0
analysis O 0
of O 0
the O 0
familial B-Disease 1
polyposis I-Disease 1
APC I-Disease 1
gene O 0
region O 0
. O 0

Two O 0
yeast O 0
artificial O 0
chromosomes O 0
( O 0
YACs O 0
) O 0
spanning O 0
a O 0
total O 0
distance O 0
of O 0
1 O 0
. O 0

1 O 0
megabase O 0
pairs O 0
of O 0
DNA O 0
around O 0
the O 0
MCC O 0
( O 0
for O 0
mutated O 0
in O 0
colorectal B-Disease 0
carcinoma I-Disease 0
) O 0
and O 0
APC B-Disease 1
( O 0
for O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
) O 0
genes O 0
at O 0
5q21 O 0
have O 0
been O 0
isolated O 0
and O 0
characterized O 0
. O 0

Starting O 0
from O 0
the O 0
MCC O 0
gene O 0
, O 0
a O 0
strategy O 0
was O 0
undertaken O 0
to O 0
identify O 0
constitutional O 0
submicroscopic O 0
deletions O 0
in O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
patients O 0
that O 0
might O 0
considerably O 0
narrow O 0
down O 0
the O 0
position O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
. O 0

To O 0
this O 0
end O 0
, O 0
YACs O 0
identified O 0
by O 0
the O 0
MCC O 0
gene O 0
were O 0
screened O 0
across O 0
a O 0
chromosome O 0
5 O 0
- O 0
specific O 0
cosmid O 0
library O 0
to O 0
provide O 0
a O 0
source O 0
of O 0
DNA O 0
probes O 0
for O 0
genomic O 0
scanning O 0
. O 0

The O 0
cosmids O 0
isolated O 0
from O 0
these O 0
experiments O 0
were O 0
used O 0
to O 0
screen O 0
a O 0
panel O 0
of O 0
somatic O 0
cell O 0
hybrids O 0
containing O 0
chromosome O 0
5 O 0
segregated O 0
from O 0
patients O 0
suspected O 0
to O 0
carry O 0
putative O 0
interstitial O 0
deletions O 0
. O 0

This O 0
screening O 0
approach O 0
led O 0
to O 0
the O 0
confirmation O 0
of O 0
a O 0
small O 0
heterozygous O 0
deletion O 0
in O 0
a O 0
polyposis B-Disease 1
patient O 0
that O 0
overlaps O 0
one O 0
of O 0
the O 0
two O 0
isolated O 0
YACs O 0
. O 0

This O 0
YAC O 0
has O 0
been O 0
shown O 0
to O 0
contain O 0
the O 0
entire O 0
APC B-Disease 1
gene O 0
, O 0
in O 0
addition O 0
to O 0
a O 0
significant O 0
portion O 0
of O 0
DNA O 0
flanking O 0
the O 0
5 O 0
end O 0
of O 0
the O 0
gene O 0
, O 0
and O 0
should O 0
therefore O 0
prove O 0
a O 0
valuable O 0
resource O 0
for O 0
functional O 0
studies O 0
by O 0
transfer O 0
to O 0
colorectal B-Disease 0
tumor I-Disease 0
- O 0
derived O 0
cell O 0
lines O 0
. O 0

Inherited O 0
WT1 O 0
mutation O 0
in O 0
Denys B-Disease 1
- I-Disease 1
Drash I-Disease 1
syndrome I-Disease 1
. O 0

Patients O 0
with O 0
the O 0
Denys B-Disease 1
- I-Disease 1
Drash I-Disease 1
syndrome I-Disease 1
( O 0
Wilms B-Disease 1
tumor I-Disease 1
, O 0
genital B-Disease 0
anomalies I-Disease 0
, O 0
and O 0
nephropathy B-Disease 1
) O 0
have O 0
been O 0
demonstrated O 0
to O 0
carry O 0
de O 0
novo O 0
constitutional O 0
mutations O 0
in O 0
WT1 O 0
, O 0
the O 0
Wilms B-Disease 1
tumor I-Disease 1
gene O 0
at O 0
chromosome O 0
11p13 O 0
. O 0

We O 0
report O 0
three O 0
new O 0
cases O 0
, O 0
two O 0
carrying O 0
a O 0
previously O 0
described O 0
WT1 O 0
exon O 0
9 O 0
mutation O 0
and O 0
one O 0
with O 0
a O 0
novel O 0
WT1 O 0
exon O 0
8 O 0
mutation O 0
. O 0

However O 0
, O 0
unlike O 0
patients O 0
in O 0
previous O 0
reports O 0
, O 0
one O 0
of O 0
our O 0
three O 0
patients O 0
inherited O 0
the O 0
affected O 0
allele O 0
from O 0
his O 0
phenotypically O 0
unaffected O 0
father O 0
. O 0

This O 0
observation O 0
indicates O 0
that O 0
the O 0
WT1 O 0
exon O 0
9 O 0
mutation O 0
affecting O 0
394Arg O 0
demonstrated O 0
in O 0
over O 0
one O 0
- O 0
half O 0
of O 0
the O 0
patients O 0
with O 0
the O 0
Denys B-Disease 1
- I-Disease 1
Drash I-Disease 1
syndrome I-Disease 1
may O 0
exhibit O 0
incomplete O 0
penetrance O 0
. O 0

Consequently O 0
, O 0
familial O 0
studies O 0
in O 0
patients O 0
affected O 0
by O 0
this O 0
syndrome O 0
are O 0
recommended O 0
. O 0
. O 0

Submicroscopic O 0
deletions O 0
at O 0
the O 0
WAGR B-Disease 0
locus O 0
, O 0
revealed O 0
by O 0
nonradioactive O 0
in O 0
situ O 0
hybridization O 0
. O 0

Fluorescence O 0
in O 0
situ O 0
hybridization O 0
( O 0
FISH O 0
) O 0
with O 0
biotin O 0
- O 0
labeled O 0
probes O 0
mapping O 0
to O 0
11p13 O 0
has O 0
been O 0
used O 0
for O 0
the O 0
molecular O 0
analysis O 0
of O 0
deletions O 0
of O 0
the O 0
WAGR B-Disease 0
( O 0
Wilms B-Disease 1
tumor I-Disease 1
, O 0
aniridia B-Disease 0
, O 0
genitourinary B-Disease 0
abnormalities I-Disease 0
, O 0
and O 0
mental B-Disease 1
retardation I-Disease 1
) O 0
locus O 0
. O 0

We O 0
have O 0
detected O 0
a O 0
submicroscopic O 0
11p13 O 0
deletion O 0
in O 0
a O 0
child O 0
with O 0
inherited O 0
aniridia B-Disease 0
who O 0
subsequently O 0
presented O 0
with O 0
Wilms B-Disease 1
tumor I-Disease 1
in O 0
a O 0
horseshoe O 0
kidney O 0
, O 0
only O 0
revealed O 0
at O 0
surgery O 0
. O 0

The O 0
mother O 0
, O 0
who O 0
has O 0
aniridia B-Disease 0
, O 0
was O 0
also O 0
found O 0
to O 0
carry O 0
a O 0
deletion O 0
including O 0
both O 0
the O 0
aniridia B-Disease 0
candidate O 0
gene O 0
( O 0
AN2 O 0
) O 0
and O 0
the O 0
Wilms B-Disease 1
tumor I-Disease 1
predisposition O 0
gene O 0
( O 0
WT1 O 0
) O 0
. O 0

This O 0
is O 0
therefore O 0
a O 0
rare O 0
case O 0
of O 0
an O 0
inherited O 0
WAGR B-Disease 0
deletion O 0
. O 0

Wilms B-Disease 1
tumor I-Disease 1
has O 0
so O 0
far O 0
only O 0
been O 0
associated O 0
with O 0
sporadic O 0
de O 0
novo O 0
aniridia B-Disease 0
cases O 0
. O 0

We O 0
have O 0
shown O 0
that O 0
a O 0
cosmid O 0
probe O 0
for O 0
a O 0
candidate O 0
aniridia B-Disease 0
gene O 0
, O 0
homologous O 0
to O 0
the O 0
mouse O 0
Pax O 0
- O 0
6 O 0
gene O 0
, O 0
is O 0
deleted O 0
in O 0
cell O 0
lines O 0
from O 0
aniridia B-Disease 0
patients O 0
with O 0
previously O 0
characterized O 0
deletions O 0
at O 0
11p13 O 0
, O 0
while O 0
another O 0
cosmid O 0
marker O 0
mapping O 0
between O 0
two O 0
aniridia B-Disease 0
- O 0
associated O 0
translocation O 0
breakpoints O 0
( O 0
and O 0
hence O 0
a O 0
second O 0
candidate O 0
marker O 0
) O 0
is O 0
present O 0
on O 0
both O 0
chromosomes O 0
. O 0

These O 0
results O 0
support O 0
the O 0
Pax O 0
- O 0
6 O 0
homologue O 0
as O 0
a O 0
strong O 0
candidate O 0
for O 0
the O 0
AN2 O 0
gene O 0
. O 0

FISH O 0
with O 0
cosmid O 0
probes O 0
has O 0
proved O 0
to O 0
be O 0
a O 0
fast O 0
and O 0
reliable O 0
technique O 0
for O 0
the O 0
molecular O 0
analysis O 0
of O 0
deletions O 0
. O 0

It O 0
can O 0
be O 0
used O 0
with O 0
limited O 0
amounts O 0
of O 0
material O 0
and O 0
has O 0
strong O 0
potential O 0
for O 0
clinical O 0
applications O 0
. O 0
. O 0

Linkage O 0
of O 0
gene O 0
for O 0
C2 B-Disease 1
deficiency I-Disease 1
and O 0
the O 0
major O 0
histocompatibility O 0
complex O 0
MHC O 0
in O 0
man O 0
. O 0

Family O 0
study O 0
of O 0
a O 0
further O 0
case O 0
. O 0

Close O 0
linkage O 0
between O 0
HL O 0
- O 0
A O 0
and O 0
C2 B-Disease 1
deficiency I-Disease 1
was O 0
first O 0
reported O 0
by O 0
FU O 0
and O 0
co O 0
- O 0
workers O 0
in O 0
1974 O 0
. O 0

We O 0
present O 0
here O 0
a O 0
pedigree O 0
of O 0
a O 0
31 O 0
- O 0
year O 0
- O 0
old O 0
C2 B-Disease 1
- I-Disease 1
deficient I-Disease 1
individual O 0
with O 0
clinical O 0
manifestations O 0
of O 0
Hodgkins B-Disease 0
disease I-Disease 0
. O 0

The O 0
following O 0
markers O 0
were O 0
tested O 0
C2 O 0
levels O 0
, O 0
factor O 0
B O 0
polymorphism O 0
, O 0
blood O 0
groups O 0
, O 0
and O 0
enzyme O 0
typing O 0
. O 0

In O 0
addition O 0
to O 0
close O 0
linkage O 0
between O 0
HL O 0
- O 0
A O 0
and O 0
C2 B-Disease 1
deficiency I-Disease 1
, O 0
both O 0
parents O 0
were O 0
heterozygous O 0
for O 0
Bf O 0
( O 0
HL O 0
- O 0
A O 0
linked O 0
, O 0
electrophoretic O 0
variation O 0
of O 0
B O 0
) O 0
. O 0

The O 0
two O 0
HL O 0
- O 0
A O 0
haplotypes O 0
closely O 0
linked O 0
to O 0
C2 B-Disease 1
deficiency I-Disease 1
are O 0
different O 0
2 O 0
, O 0
W18 O 0
and O 0
W24 O 0
, O 0
W18 O 0
. O 0

They O 0
share O 0
, O 0
however O 0
, O 0
the O 0
SD2 O 0
antigen O 0
W18 O 0
and O 0
the O 0
LD O 0
type O 0
7a O 0
. O 0
. O 0

Screening O 0
for O 0
germ O 0
- O 0
line O 0
mutations O 0
in O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
patients O 0
: O 0
61 O 0
new O 0
patients O 0
and O 0
a O 0
summary O 0
of O 0
150 O 0
unrelated O 0
patients O 0
. O 0

We O 0
report O 0
here O 0
the O 0
result O 0
of O 0
a O 0
screening O 0
for O 0
germ O 0
- O 0
line O 0
mutations O 0
in O 0
the O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( O 0
APC B-Disease 1
) O 0
gene O 0
in O 0
61 O 0
new O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
( O 0
FAP B-Disease 0
) O 0
patients O 0
as O 0
well O 0
as O 0
a O 0
summary O 0
of O 0
the O 0
results O 0
of O 0
150 O 0
patients O 0
. O 0

Examination O 0
of O 0
the O 0
entire O 0
coding O 0
region O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
, O 0
based O 0
on O 0
a O 0
ribonuclease O 0
protection O 0
assay O 0
coupled O 0
with O 0
the O 0
polymerase O 0
chain O 0
reaction O 0
( O 0
PCR O 0
) O 0
, O 0
disclosed O 0
mutations O 0
that O 0
were O 0
considered O 0
to O 0
cause O 0
significant O 0
defects O 0
in O 0
the O 0
APC B-Disease 1
product O 0
in O 0
97 O 0
of O 0
150 O 0
unrelated O 0
FAP B-Disease 0
patients O 0
. O 0

Our O 0
findings O 0
revealed O 0
the O 0
following O 0
characteristics O 0
of O 0
the O 0
germ O 0
- O 0
line O 0
mutations O 0
of O 0
APC O 1
1 O 0
) O 0
the O 0
great O 0
majority O 0
of O 0
the O 0
mutations O 0
were O 0
found O 0
to O 0
truncate O 0
the O 0
APC B-Disease 1
product O 0
; O 0
2 O 0
) O 0
almost O 0
all O 0
of O 0
the O 0
mutations O 0
were O 0
located O 0
within O 0
the O 0
first O 0
half O 0
of O 0
the O 0
coding O 0
region O 0
; O 0
3 O 0
) O 0
no O 0
correlation O 0
was O 0
observed O 0
between O 0
the O 0
locations O 0
of O 0
germ O 0
- O 0
line O 0
mutations O 0
and O 0
extracolonic O 0
manifestations O 0
in O 0
FAP B-Disease 0
patients O 0
; O 0
4 O 0
) O 0
more O 0
than O 0
80 O 0
% O 0
of O 0
base O 0
substitutions O 0
in O 0
the O 0
APC B-Disease 1
gene O 0
were O 0
from O 0
cytosine O 0
to O 0
other O 0
nucleotides O 0
, O 0
nearly O 0
one O 0
- O 0
third O 0
of O 0
which O 0
occurred O 0
at O 0
the O 0
GpG O 0
site O 0
. O 0

Our O 0
results O 0
provide O 0
information O 0
helpful O 0
to O 0
an O 0
understanding O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
and O 0
will O 0
also O 0
contribute O 0
to O 0
presymptomatic O 0
diagnosis O 0
of O 0
members O 0
in O 0
FAP B-Disease 0
families O 0
. O 0
. O 0

Somatic O 0
mutations O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
in O 0
colorectal B-Disease 1
tumors I-Disease 1
: O 0
mutation O 0
cluster O 0
region O 0
in O 0
the O 0
APC B-Disease 1
gene O 0
. O 0

We O 0
examined O 0
somatic O 0
mutations O 0
of O 0
the O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( O 0
APC B-Disease 1
) O 0
gene O 0
in O 0
63 O 0
colorectal B-Disease 1
tumors I-Disease 1
( O 0
16 O 0
adenomas B-Disease 0
and O 0
47 O 0
carcinomas B-Disease 0
) O 0
developed O 0
in O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
( O 0
FAP B-Disease 0
) O 0
and O 0
non O 0
- O 0
FAP O 0
patients O 0
. O 0

In O 0
addition O 0
to O 0
loss O 0
of O 0
heterozygosity O 0
( O 0
LOH O 0
) O 0
at O 0
the O 0
APC B-Disease 1
locus O 0
in O 0
30 O 0
tumors B-Disease 0
, O 0
43 O 0
other O 0
somatic O 0
mutations O 0
were O 0
detected O 0
. O 0

Twenty O 0
- O 0
one O 0
of O 0
them O 0
were O 0
point O 0
mutations O 0
; O 0
16 O 0
nonsense O 0
and O 0
two O 0
missense O 0
mutations O 0
, O 0
and O 0
three O 0
occurred O 0
in O 0
introns O 0
at O 0
the O 0
splicing O 0
site O 0
. O 0

Twenty O 0
- O 0
two O 0
tumors B-Disease 0
had O 0
frameshift O 0
mutations O 0
due O 0
to O 0
deletion O 0
or O 0
insertion O 0
; O 0
nineteen O 0
of O 0
them O 0
were O 0
deletions O 0
of O 0
one O 0
to O 0
31 O 0
bp O 0
and O 0
three O 0
were O 0
a O 0
1 O 0
- O 0
bp O 0
insertion O 0
. O 0

One O 0
tumor B-Disease 0
had O 0
a O 0
1 O 0
- O 0
bp O 0
deletion O 0
in O 0
an O 0
intron O 0
near O 0
the O 0
splicing O 0
site O 0
. O 0

Hence O 0
, O 0
41 O 0
( O 0
95 O 0
% O 0
) O 0
of O 0
43 O 0
mutations O 0
resulted O 0
in O 0
truncation O 0
of O 0
the O 0
APC B-Disease 1
protein O 0
. O 0

Over O 0
60 O 0
% O 0
of O 0
the O 0
somatic O 0
mutations O 0
in O 0
the O 0
APC B-Disease 1
gene O 0
were O 0
clustered O 0
within O 0
a O 0
small O 0
region O 0
of O 0
exon O 0
15 O 0
, O 0
designated O 0
as O 0
MCR O 0
( O 0
mutation O 0
cluster O 0
region O 0
) O 0
, O 0
which O 0
accounted O 0
for O 0
less O 0
than O 0
10 O 0
% O 0
of O 0
the O 0
coding O 0
region O 0
. O 0

Combining O 0
these O 0
data O 0
and O 0
the O 0
results O 0
of O 0
LOH O 0
, O 0
more O 0
than O 0
80 O 0
% O 0
of O 0
tumors B-Disease 0
( O 0
14 O 0
adenomas B-Disease 0
and O 0
39 O 0
carcinomas B-Disease 0
) O 0
had O 0
at O 0
least O 0
one O 0
mutation O 0
in O 0
the O 0
APC B-Disease 1
gene O 0
, O 0
of O 0
which O 0
more O 0
than O 0
60 O 0
% O 0
( O 0
9 O 0
adenomas B-Disease 0
and O 0
23 O 0
carcinomas B-Disease 0
) O 0
had O 0
two O 0
mutations O 0
. O 0

These O 0
results O 0
strongly O 0
suggest O 0
that O 0
somatic O 0
mutations O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
are O 0
associated O 0
with O 0
development O 0
of O 0
a O 0
great O 0
majority O 0
of O 0
colorectal B-Disease 1
tumors I-Disease 1
. O 0
. O 0

Constitutional O 0
mutations O 0
in O 0
the O 0
WT1 O 0
gene O 0
in O 0
patients O 0
with O 0
Denys B-Disease 1
- I-Disease 1
Drash I-Disease 1
syndrome I-Disease 1
. O 0

The O 0
Denys B-Disease 1
- I-Disease 1
Drash I-Disease 1
syndrome I-Disease 1
is O 0
characterised O 0
by O 0
a O 0
typical O 0
nephropathy B-Disease 1
, O 0
genital B-Disease 1
abnormalities I-Disease 1
and O 0
also O 0
predisposes O 0
to O 0
the O 0
development O 0
of O 0
Wilms B-Disease 1
tumor I-Disease 1
. O 0

These O 0
patients O 0
eventually O 0
go O 0
into O 0
end O 0
stage O 0
renal B-Disease 0
failure I-Disease 0
. O 0

A O 0
candidate O 0
Wilms B-Disease 1
tumor I-Disease 1
gene O 0
, O 0
WT1 O 0
, O 0
from O 0
the O 0
11p13 O 0
chromosome O 0
region O 0
has O 0
recently O 0
been O 0
cloned O 0
. O 0

We O 0
have O 0
analysed O 0
the O 0
DNA O 0
sequence O 0
in O 0
constitutional O 0
cells O 0
from O 0
eight O 0
patients O 0
and O 0
have O 0
shown O 0
heterozygous O 0
mutations O 0
in O 0
six O 0
of O 0
them O 0
. O 0

Four O 0
of O 0
the O 0
mutations O 0
were O 0
in O 0
exon O 0
9 O 0
, O 0
all O 0
resulting O 0
in O 0
missense O 0
mutations O 0
. O 0

Three O 0
were O 0
at O 0
nucleotide O 0
position O 0
1180 O 0
resulting O 0
in O 0
an O 0
arg O 0
> O 0
trp O 0
amino O 0
acid O 0
change O 0
. O 0

The O 0
other O 0
was O 0
at O 0
position O 0
1186 O 0
converting O 0
an O 0
asp O 0
> O 0
asn O 0
in O 0
the O 0
predicted O 0
resultant O 0
protein O 0
. O 0

One O 0
patient O 0
had O 0
a O 0
missense O 0
mutation O 0
in O 0
exon O 0
8 O 0
, O 0
converting O 0
an O 0
arg O 0
> O 0
his O 0
. O 0

A O 0
single O 0
base O 0
pair O 0
insertion O 0
at O 0
nucleotide O 0
position O 0
821 O 0
in O 0
exon O 0
6 O 0
resulted O 0
in O 0
the O 0
generation O 0
of O 0
a O 0
premature O 0
stop O 0
codon O 0
in O 0
the O 0
last O 0
patient O 0
. O 0

We O 0
were O 0
unable O 0
to O 0
find O 0
a O 0
mutation O 0
in O 0
one O 0
patient O 0
despite O 0
complete O 0
sequencing O 0
of O 0
the O 0
genomic O 0
sequence O 0
of O 0
the O 0
gene O 0
. O 0

The O 0
last O 0
patient O 0
carried O 0
a O 0
constitutional O 0
deletion O 0
of O 0
the O 0
11p13 O 0
region O 0
and O 0
no O 0
additional O 0
mutation O 0
was O 0
found O 0
. O 0

There O 0
was O 0
no O 0
obvious O 0
correlation O 0
between O 0
the O 0
type O 0
of O 0
mutation O 0
and O 0
phenotypic O 0
expression O 0
. O 0

These O 0
results O 0
further O 0
demonstrate O 0
that O 0
the O 0
WT1 O 0
gene O 0
is O 0
important O 0
in O 0
both O 0
the O 0
development O 0
of O 0
the O 0
kidney O 0
and O 0
the O 0
genito O 0
- O 0
urinary O 0
system O 0
. O 0
. O 0

Linkage O 0
disequilibrium O 0
mapping O 0
in O 0
isolated O 0
founder O 0
populations O 0
: O 0
diastrophic B-Disease 1
dysplasia I-Disease 1
in O 0
Finland O 0
. O 0

Linkage O 0
disequilibrium O 0
mapping O 0
in O 0
isolated O 0
populations O 0
provides O 0
a O 0
powerful O 0
tool O 0
for O 0
fine O 0
structure O 0
localization O 0
of O 0
disease O 0
genes O 0
. O 0

Here O 0
, O 0
Luria O 0
and O 0
Delbrucks O 0
classical O 0
methods O 0
for O 0
analysing O 0
bacterial O 0
cultures O 0
are O 0
adapted O 0
to O 0
the O 0
study O 0
of O 0
human O 0
isolated O 0
founder O 0
populations O 0
in O 0
order O 0
to O 0
estimate O 0
( O 0
i O 0
) O 0
the O 0
recombination O 0
fraction O 0
between O 0
a O 0
disease O 0
locus O 0
and O 0
a O 0
marker O 0
; O 0
( O 0
ii O 0
) O 0
the O 0
expected O 0
degree O 0
of O 0
allelic O 0
homogeneity O 0
in O 0
a O 0
population O 0
; O 0
and O 0
( O 0
iii O 0
) O 0
the O 0
mutation O 0
rate O 0
of O 0
marker O 0
loci O 0
. O 0

Using O 0
these O 0
methods O 0
, O 0
we O 0
report O 0
striking O 0
linkage O 0
disequilibrium O 0
for O 0
diastrophic B-Disease 1
dysplasia I-Disease 1
( O 0
DTD B-Disease 1
) O 0
in O 0
Finland O 0
indicating O 0
that O 0
the O 0
DTD B-Disease 1
gene O 0
should O 0
lie O 0
within O 0
0 O 0
. O 0

06 O 0
centimorgans O 0
( O 0
or O 0
about O 0
60 O 0
kilobases O 0
) O 0
of O 0
the O 0
CSF1R O 0
gene O 0
. O 0

Predictions O 0
about O 0
allelic O 0
homogeneity O 0
in O 0
Finland O 0
and O 0
mutation O 0
rates O 0
in O 0
simple O 0
sequence O 0
repeats O 0
are O 0
confirmed O 0
by O 0
independent O 0
observations O 0
. O 0

The O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
: O 0
refinement O 0
of O 0
the O 0
localization O 0
on O 0
Xp O 0
and O 0
identification O 0
of O 0
another O 0
closely O 0
linked O 0
marker O 0
locus O 0
, O 0
OATL1 O 0
. O 0

The O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
( O 0
WAS B-Disease 0
) O 0
has O 0
previously O 0
been O 0
mapped O 0
to O 0
the O 0
proximal O 0
short O 0
arm O 0
of O 0
the O 0
X O 0
chromosome O 0
between O 0
the O 0
DXS14 O 0
and O 0
DXS7 O 0
loci O 0
. O 0

In O 0
this O 0
study O 0
, O 0
further O 0
segregation O 0
analysis O 0
has O 0
been O 0
performed O 0
using O 0
a O 0
newly O 0
identified O 0
WAS B-Disease 0
family O 0
as O 0
well O 0
as O 0
an O 0
additional O 0
marker O 0
probe O 0
, O 0
HOATL1 O 0
. O 0

The O 0
results O 0
indicate O 0
close O 0
linkage O 0
between O 0
the O 0
WAS B-Disease 0
and O 0
OATL1 O 0
loci O 0
( O 0
Z O 0
= O 0
6 O 0
. O 0
08 O 0
at O 0
theta O 0
= O 0
0 O 0
. O 0
00 O 0
) O 0
and O 0
localize O 0
the O 0
TIMP O 0
, O 0
OATL1 O 0
, O 0
DXS255 O 0
, O 0
and O 0
WAS B-Disease 0
loci O 0
distal O 0
to O 0
DXS146 O 0
and O 0
the O 0
OATL1 O 0
and O 0
WAS B-Disease 0
loci O 0
proximal O 0
to O 0
TIMP O 0
. O 0

These O 0
linkage O 0
data O 0
narrow O 0
the O 0
boundaries O 0
within O 0
which O 0
the O 0
WAS B-Disease 0
locus O 0
maps O 0
to O 0
the O 0
chromosomal O 0
region O 0
bracketed O 0
by O 0
TIMP O 0
and O 0
DXS146 O 0
and O 0
support O 0
the O 0
loci O 0
order O 0
Xpter O 0
- O 0
DXS7 O 0
- O 0
TIMP O 0
- O 0
( O 0
OATL1 O 0
, O 0
WAS O 0
, O 0
DXS255 O 0
) O 0
- O 0
DXS146 O 0
. O 0

Detection O 0
of O 0
an O 0
unstable O 0
fragment O 0
of O 0
DNA O 0
specific O 0
to O 0
individuals O 0
with O 0
myotonic B-Disease 1
dystrophy I-Disease 1
. O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
is O 0
the O 0
most O 0
common O 0
form O 0
of O 0
adult O 0
muscular B-Disease 0
dystrophy I-Disease 0
, O 0
with O 0
a O 0
prevalence O 0
of O 0
2 O 0
- O 0
14 O 0
per O 0
100 O 0
, O 0
000 O 0
individuals O 0
. O 0

The O 0
disease O 0
is O 0
characterized O 0
by O 0
progressive O 0
muscle B-Disease 1
weakness I-Disease 1
and O 0
sustained B-Disease 1
muscle I-Disease 1
contraction I-Disease 1
, O 0
often O 0
with O 0
a O 0
wide O 0
range O 0
of O 0
accompanying O 0
symptoms O 0
. O 0

The O 0
age O 0
at O 0
onset O 0
and O 0
severity O 0
of O 0
the O 0
disease O 0
show O 0
extreme O 0
variation O 0
, O 0
both O 0
within O 0
and O 0
between O 0
families O 0
. O 0

Despite O 0
its O 0
clinical O 0
variability O 0
, O 0
this O 0
dominant O 0
condition O 0
segregates O 0
as O 0
a O 0
single O 0
locus O 0
at O 0
chromosome O 0
19q13 O 0
. O 0

3 O 0
in O 0
every O 0
population O 0
studied O 0
. O 0

It O 0
is O 0
flanked O 0
by O 0
the O 0
tightly O 0
linked O 0
genetic O 0
markers O 0
ERCC1 O 0
proximally O 0
and O 0
D19S51 O 0
distally O 0
; O 0
these O 0
define O 0
the O 0
DM B-Disease 0
critical O 0
region O 0
. O 0

We O 0
report O 0
the O 0
isolation O 0
of O 0
an O 0
expressed O 0
sequence O 0
from O 0
this O 0
region O 0
which O 0
detects O 0
a O 0
DNA O 0
fragment O 0
that O 0
is O 0
larger O 0
in O 0
affected O 0
individuals O 0
than O 0
in O 0
normal O 0
siblings O 0
or O 0
unaffected O 0
controls O 0
. O 0

The O 0
size O 0
of O 0
this O 0
fragment O 0
varies O 0
between O 0
affected O 0
siblings O 0
, O 0
and O 0
increases O 0
in O 0
size O 0
through O 0
generations O 0
in O 0
parallel O 0
with O 0
increasing O 0
severity O 0
of O 0
the O 0
disease O 0
. O 0

We O 0
postulate O 0
that O 0
this O 0
unstable O 0
DNA O 0
sequence O 0
is O 0
the O 0
molecular O 0
feature O 0
that O 0
underlies O 0
DM B-Disease 0
. O 0

Common O 0
sequence O 0
motifs O 0
at O 0
the O 0
rearrangement O 0
sites O 0
of O 0
a O 0
constitutional O 0
X O 0
/ O 0
autosome O 0
translocation O 0
and O 0
associated O 0
deletion O 0
. O 0

Reciprocal O 0
chromosome O 0
translocations O 0
are O 0
common O 0
de O 0
novo O 0
rearrangements O 0
that O 0
occur O 0
randomly O 0
throughout O 0
the O 0
human O 0
genome O 0
. O 0

To O 0
learn O 0
about O 0
causative O 0
mechanisms O 0
, O 0
we O 0
have O 0
cloned O 0
and O 0
sequenced O 0
the O 0
breakpoints O 0
of O 0
a O 0
cytologically O 0
balanced O 0
constitutional O 0
reciprocal O 0
translocation O 0
, O 0
t O 0
( O 0
X O 0
; O 0
4 O 0
) O 0
( O 0
p21 O 0
. O 0
2 O 0
; O 0
q31 O 0
. O 0
22 O 0
) O 0
, O 0
present O 0
in O 0
a O 0
girl O 0
with O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
. O 0

Physical O 0
mapping O 0
of O 0
the O 0
derivative O 0
chromosomes O 0
, O 0
after O 0
their O 0
separation O 0
in O 0
somatic O 0
cell O 0
hybrids O 0
, O 0
reveals O 0
that O 0
the O 0
translocation O 0
disrupts O 0
the O 0
DMD B-Disease 0
gene O 0
in O 0
Xp21 O 0
within O 0
the O 0
18 O 0
- O 0
kb O 0
intron O 0
16 O 0
. O 0

Restriction O 0
mapping O 0
and O 0
sequencing O 0
of O 0
clones O 0
that O 0
span O 0
both O 0
translocation O 0
breakpoints O 0
as O 0
well O 0
as O 0
the O 0
corresponding O 0
normal O 0
regions O 0
indicate O 0
the O 0
loss O 0
of O 0
approximately O 0
5 O 0
kb O 0
in O 0
the O 0
formation O 0
of O 0
the O 0
derivative O 0
X O 0
chromosome O 0
, O 0
with O 0
4 O 0
- O 0
6 O 0
bp O 0
deleted O 0
from O 0
chromosome O 0
4 O 0
. O 0

RFLP O 0
and O 0
Southern O 0
analyses O 0
indicate O 0
that O 0
the O 0
de O 0
novo O 0
translocation O 0
is O 0
a O 0
paternal O 0
origin O 0
and O 0
that O 0
the O 0
fathers O 0
X O 0
chromosome O 0
contains O 0
the O 0
DNA O 0
that O 0
is O 0
deleted O 0
in O 0
the O 0
derivative O 0
X O 0
. O 0

Most O 0
likely O 0
, O 0
deletion O 0
and O 0
translation O 0
arose O 0
simultaneously O 0
from O 0
a O 0
complex O 0
rearrangement O 0
event O 0
that O 0
involves O 0
three O 0
chromosomal O 0
breakpoints O 0
. O 0

Short O 0
regions O 0
of O 0
sequence O 0
homology O 0
were O 0
present O 0
at O 0
the O 0
three O 0
sites O 0
. O 0

A O 0
5 O 0
- O 0
bp O 0
sequence O 0
, O 0
GGAAT O 0
, O 0
found O 0
exactly O 0
at O 0
the O 0
translocation O 0
breakpoints O 0
on O 0
both O 0
normal O 0
chromosomes O 0
X O 0
and O 0
4 O 0
, O 0
has O 0
been O 0
preserved O 0
only O 0
on O 0
the O 0
der O 0
( O 0
4 O 0
) O 0
chromosome O 0
. O 0

It O 0
is O 0
likely O 0
that O 0
the O 0
X O 0
- O 0
derived O 0
sequence O 0
GGAATCA O 0
has O 0
been O 0
lost O 0
in O 0
the O 0
formation O 0
of O 0
the O 0
der O 0
( O 0
X O 0
) O 0
chromosome O 0
, O 0
as O 0
it O 0
matches O 0
an O 0
inverted O 0
GAATCA O 0
sequence O 0
present O 0
on O 0
the O 0
opposite O 0
strand O 0
exactly O 0
at O 0
the O 0
other O 0
end O 0
of O 0
the O 0
deleted O 0
5 O 0
- O 0
kb O 0
fragment O 0
. O 0

A O 0
genetic O 0
etiology O 0
for O 0
DiGeorge B-Disease 1
syndrome I-Disease 1
: O 0
consistent O 0
deletions O 0
and O 0
microdeletions O 0
of O 0
22q11 O 0
. O 0

DiGeorge B-Disease 1
syndrome I-Disease 1
( O 0
DGS B-Disease 0
) O 0
, O 0
a O 0
developmental O 0
field O 0
defect O 0
of O 0
the O 0
third O 0
and O 0
fourth O 0
pharyngeal O 0
pouches O 0
, O 0
is O 0
characterized O 0
by O 0
aplasia B-Disease 0
or I-Disease 0
hypoplasia I-Disease 0
of I-Disease 0
the I-Disease 0
thymus I-Disease 0
and I-Disease 0
parathyroid I-Disease 0
glands I-Disease 0
and O 0
by O 0
conotruncal B-Disease 1
cardiac I-Disease 1
malformations I-Disease 1
. O 0

Cytogenetic O 0
studies O 0
support O 0
the O 0
presence O 0
of O 0
a O 0
DGS B-Disease 0
critical O 0
region O 0
in O 0
band O 0
22q11 O 0
. O 0

In O 0
the O 0
present O 0
study O 0
, O 0
we O 0
report O 0
the O 0
results O 0
of O 0
clinical O 0
, O 0
cytogenetic O 0
, O 0
and O 0
molecular O 0
studies O 0
of O 0
14 O 0
patients O 0
with O 0
DGS B-Disease 0
. O 0

Chromosome O 0
analysis O 0
, O 0
utilizing O 0
high O 0
- O 0
resolution O 0
banding O 0
techniques O 0
, O 0
detected O 0
interstitial O 0
deletions O 0
in O 0
five O 0
probands O 0
and O 0
was O 0
inconclusive O 0
for O 0
a O 0
deletion O 0
in O 0
three O 0
probands O 0
. O 0

The O 0
remaining O 0
six O 0
patients O 0
had O 0
normal O 0
karyotypes O 0
. O 0

In O 0
contrast O 0
, O 0
molecular O 0
analysis O 0
detected O 0
DNA O 0
deletions O 0
in O 0
all O 0
14 O 0
probands O 0
. O 0

Two O 0
of O 0
10 O 0
loci O 0
tested O 0
, O 0
D22S75 O 0
and O 0
D22S259 O 0
, O 0
are O 0
deleted O 0
in O 0
all O 0
14 O 0
patients O 0
. O 0

A O 0
third O 0
locus O 0
, O 0
D22S66 O 0
, O 0
is O 0
deleted O 0
in O 0
the O 0
eight O 0
DGS B-Disease 0
probands O 0
tested O 0
. O 0

Physical O 0
mapping O 0
using O 0
somatic O 0
cell O 0
hybrids O 0
places O 0
D22S66 O 0
between O 0
D22S75 O 0
and O 0
D22S259 O 0
, O 0
suggesting O 0
that O 0
it O 0
should O 0
be O 0
deleted O 0
in O 0
the O 0
remaining O 0
six O 0
cases O 0
. O 0

Parent O 0
- O 0
of O 0
- O 0
origin O 0
studies O 0
were O 0
performed O 0
in O 0
five O 0
families O 0
. O 0

Four O 0
probands O 0
failed O 0
to O 0
inherit O 0
a O 0
maternal O 0
allele O 0
, O 0
and O 0
one O 0
failed O 0
to O 0
inherit O 0
a O 0
paternal O 0
allele O 0
. O 0

On O 0
the O 0
basis O 0
of O 0
these O 0
families O 0
, O 0
and O 0
of O 0
six O 0
maternally O 0
and O 0
five O 0
paternally O 0
derived O 0
unbalanced O 0
- O 0
translocation O 0
DGS B-Disease 0
probands O 0
in O 0
the O 0
literature O 0
, O 0
parent O 0
of O 0
origin O 0
or O 0
imprinting O 0
does O 0
not O 0
appear O 0
to O 0
play O 0
an O 0
important O 0
role O 0
in O 0
the O 0
pathogenesis O 0
of O 0
DGS B-Disease 0
. O 0

Deletion O 0
of O 0
the O 0
same O 0
three O 0
loci O 0
in O 0
all O 0
14 O 0
DGS B-Disease 0
probands O 0
begins O 0
to O 0
delineate O 0
the O 0
region O 0
of O 0
chromosome O 0
22 O 0
critical O 0
for O 0
DGS B-Disease 0
and O 0
confirms O 0
the O 0
hypothesis O 0
that O 0
submicroscopic O 0
deletions O 0
of O 0
22q11 O 0
are O 0
etiologic O 0
in O 0
the O 0
vast O 0
majority O 0
of O 0
cases O 0
. O 0
. O 0

Loss O 0
of O 0
normal O 0
allele O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
in O 0
an O 0
adrenocortical B-Disease 0
carcinoma I-Disease 0
from O 0
a O 0
patient O 0
with O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
. O 0

Endocrine B-Disease 1
neoplasms I-Disease 1
have O 0
been O 0
reported O 0
occasionally O 0
in O 0
patients O 0
with O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
( O 0
FAP B-Disease 0
) O 0
. O 0

An O 0
adrenocorotical B-Disease 0
carcinoma I-Disease 0
was O 0
studied O 0
in O 0
a O 0
patient O 0
with O 0
a O 0
family O 0
history O 0
of O 0
FAP B-Disease 0
. O 0

Loss O 0
of O 0
heterozygosity O 0
( O 0
LOH O 0
) O 0
in O 0
the O 0
region O 0
close O 0
to O 0
the O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( O 0
APC B-Disease 1
) O 0
gene O 0
was O 0
detected O 0
in O 0
this O 0
carcinoma B-Disease 0
, O 0
and O 0
evidence O 0
was O 0
obtained O 0
that O 0
there O 0
was O 0
a O 0
loss O 0
of O 0
the O 0
normal O 0
allele O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
. O 0

This O 0
is O 0
the O 0
first O 0
demonstration O 0
of O 0
LOH O 0
at O 0
the O 0
APC B-Disease 1
locus O 0
in O 0
adrenocortical B-Disease 0
tumors I-Disease 0
. O 0

The O 0
present O 0
results O 0
and O 0
our O 0
previous O 0
data O 0
on O 0
LOH O 0
in O 0
a O 0
recurring O 0
desmoid B-Disease 1
tumor I-Disease 1
suggest O 0
that O 0
the O 0
heterozygous O 0
mutant O 0
/ O 0
wild O 0
- O 0
type O 0
condition O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
may O 0
give O 0
rise O 0
to O 0
benign B-Disease 0
tumors I-Disease 0
, O 0
and O 0
that O 0
functional O 0
loss O 0
of O 0
this O 0
gene O 0
leads O 0
to O 0
development O 0
of O 0
tumors B-Disease 0
not O 0
only O 0
in O 0
the O 0
colon O 0
but O 0
also O 0
in O 0
other O 0
various O 0
parts O 0
of O 0
the O 0
body O 0
in O 0
FAP B-Disease 0
patients O 0
. O 0
. O 0

Oncogenic O 0
point O 0
mutations O 0
in O 0
exon O 0
20 O 0
of O 0
the O 0
RB1 O 0
gene O 0
in O 0
families O 0
showing O 0
incomplete O 0
penetrance O 0
and O 0
mild O 0
expression O 0
of O 0
the O 0
retinoblastoma B-Disease 1
phenotype O 0
. O 0

The O 0
retinoblastoma B-Disease 1
- O 0
predisposition O 0
gene O 0
, O 0
RB1 O 0
, O 0
segregates O 0
as O 0
an O 0
autosomal O 0
dominant O 0
trait O 0
with O 0
high O 0
( O 0
90 O 0
% O 0
) O 0
penetrance O 0
. O 0

Certain O 0
families O 0
, O 0
however O 0
, O 0
show O 0
an O 0
unusual O 0
low O 0
- O 0
penetrance O 0
phenotype O 0
with O 0
many O 0
individuals O 0
being O 0
unaffected O 0
, O 0
unilaterally O 0
affected O 0
, O 0
or O 0
with O 0
evidence O 0
of O 0
spontaneously O 0
regressed O 0
tumors B-Disease 0
. O 0

We O 0
have O 0
used O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphism O 0
analysis O 0
and O 0
PCR O 0
sequencing O 0
to O 0
study O 0
two O 0
such O 0
families O 0
. O 0

Mutations O 0
were O 0
found O 0
in O 0
exon O 0
20 O 0
of O 0
RB1 O 0
in O 0
both O 0
cases O 0
. O 0

In O 0
one O 0
family O 0
a O 0
C O 0
- O 0
- O 0
- O 0
- O 0
T O 0
transition O 0
in O 0
codon O 0
661 O 0
converts O 0
an O 0
arginine O 0
( O 0
CGG O 0
) O 0
to O 0
a O 0
tryptophan O 0
( O 0
TGG O 0
) O 0
codon O 0
. O 0

In O 0
this O 0
family O 0
, O 0
incomplete O 0
penetrance O 0
and O 0
mild O 0
phenotypic O 0
expression O 0
were O 0
observed O 0
in O 0
virtually O 0
all O 0
patients O 0
, O 0
possibly O 0
indicating O 0
that O 0
single O 0
amino O 0
acid O 0
changes O 0
may O 0
modify O 0
protein O 0
structure O 0
/ O 0
function O 0
such O 0
that O 0
tumorigenesis O 0
is O 0
not O 0
inevitable O 0
. O 0

In O 0
the O 0
second O 0
family O 0
the O 0
mutation O 0
in O 0
codon O 0
675 O 0
is O 0
a O 0
G O 0
- O 0
- O 0
- O 0
- O 0
T O 0
transversion O 0
that O 0
converts O 0
a O 0
glutamine O 0
( O 0
GAA O 0
) O 0
to O 0
a O 0
stop O 0
( O 0
TAA O 0
) O 0
codon O 0
. O 0

However O 0
, O 0
this O 0
mutation O 0
also O 0
occurs O 0
near O 0
a O 0
potential O 0
cryptic O 0
splice O 0
acceptor O 0
site O 0
, O 0
raising O 0
the O 0
possibility O 0
of O 0
alternative O 0
splicing O 0
resulting O 0
in O 0
a O 0
less O 0
severely O 0
disrupted O 0
protein O 0
. O 0
. O 0

Late O 0
- O 0
onset O 0
metachromatic B-Disease 1
leukodystrophy I-Disease 1
: O 0
molecular O 0
pathology O 0
in O 0
two O 0
siblings O 0
. O 0

We O 0
report O 0
on O 0
a O 0
new O 0
allele O 0
at O 0
the O 0
arylsulfatase O 0
A O 0
( O 0
ARSA O 0
) O 0
locus O 0
causing O 0
late O 0
- O 0
onset O 0
metachromatic B-Disease 1
leukodystrophy I-Disease 1
( O 0
MLD B-Disease 0
) O 0
. O 0

In O 0
that O 0
allele O 0
arginine84 O 0
, O 0
a O 0
residue O 0
that O 0
is O 0
highly O 0
conserved O 0
in O 0
the O 0
arylsulfatase O 0
gene O 0
family O 0
, O 0
is O 0
replaced O 0
by O 0
glutamine O 0
. O 0

In O 0
contrast O 0
to O 0
alleles O 0
that O 0
cause O 0
early O 0
- O 0
onset O 0
MLD B-Disease 0
, O 0
the O 0
arginine84 O 0
to O 0
glutamine O 0
substitution O 0
is O 0
associated O 0
with O 0
some O 0
residual O 0
ARSA O 0
activity O 0
. O 0

A O 0
comparison O 0
of O 0
genotypes O 0
, O 0
ARSA O 0
activities O 0
, O 0
and O 0
clinical O 0
data O 0
on O 0
4 O 0
individuals O 0
carrying O 0
the O 0
allele O 0
of O 0
81 O 0
patients O 0
with O 0
MLD B-Disease 0
examined O 0
, O 0
further O 0
validates O 0
the O 0
concept O 0
that O 0
different O 0
degrees O 0
of O 0
residual O 0
ARSA O 0
activity O 0
are O 0
the O 0
basis O 0
of O 0
phenotypical O 0
variation O 0
in O 0
MLD B-Disease 0
. O 0
. O 0

Trisomy B-Disease 1
15 I-Disease 1
with O 0
loss O 0
of O 0
the O 0
paternal O 0
15 O 0
as O 0
a O 0
cause O 0
of O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
due O 0
to O 0
maternal B-Disease 0
disomy I-Disease 0
. O 0

Uniparental B-Disease 1
disomy I-Disease 1
has O 0
recently O 0
been O 0
recognized O 0
to O 0
cause O 0
human O 0
disorders O 0
, O 0
including O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
. O 0

We O 0
describe O 0
a O 0
particularly O 0
instructive O 0
case O 0
which O 0
raises O 0
important O 0
issues O 0
concerning O 0
the O 0
mechanisms O 0
producing O 0
uniparental B-Disease 0
disomy I-Disease 0
and O 0
whose O 0
evaluation O 0
provides O 0
evidence O 0
that O 0
trisomy O 0
may O 0
precede O 0
uniparental B-Disease 0
disomy I-Disease 0
in O 0
a O 0
fetus O 0
. O 0

Chorionic O 0
villus O 0
sampling O 0
performed O 0
for O 0
advanced O 0
maternal O 0
age O 0
revealed O 0
trisomy B-Disease 1
15 I-Disease 1
in O 0
all O 0
direct O 0
and O 0
cultured O 0
cells O 0
, O 0
though O 0
the O 0
fetus O 0
appeared O 0
normal O 0
. O 0

Chromosome O 0
analysis O 0
of O 0
amniocytes O 0
obtained O 0
at O 0
15 O 0
wk O 0
was O 0
normal O 0
in O 0
over O 0
100 O 0
cells O 0
studied O 0
. O 0

The O 0
child O 0
was O 0
hypotonic B-Disease 1
at O 0
birth O 0
, O 0
and O 0
high O 0
- O 0
resolution O 0
banding O 0
failed O 0
to O 0
reveal O 0
the O 0
deletion O 0
of O 0
15q11 O 0
- O 0
13 O 0
, O 0
a O 0
deletion O 0
which O 0
is O 0
found O 0
in O 0
50 O 0
% O 0
- O 0
70 O 0
% O 0
of O 0
patients O 0
with O 0
PWS B-Disease 0
. O 0

Over O 0
time O 0
, O 0
typical O 0
features O 0
of O 0
PWS B-Disease 0
developed O 0
. O 0

Molecular O 0
genetic O 0
analysis O 0
using O 0
probes O 0
for O 0
chromosome O 0
15 O 0
revealed O 0
maternal O 0
disomy O 0
. O 0

Maternal O 0
nondisjunction O 0
with O 0
fertilization O 0
of O 0
a O 0
disomic O 0
egg O 0
by O 0
a O 0
normal O 0
sperm O 0
, O 0
followed O 0
by O 0
loss O 0
of O 0
the O 0
paternal O 0
15 O 0
, O 0
is O 0
a O 0
likely O 0
cause O 0
of O 0
confined O 0
placental O 0
mosaicism O 0
and O 0
uniparental B-Disease 0
disomy I-Disease 0
in O 0
this O 0
case O 0
of O 0
PWS B-Disease 0
, O 0
and O 0
advanced O 0
maternal O 0
age O 0
may O 0
be O 0
a O 0
predisposing O 0
factor O 0
. O 0
. O 0

Genetic O 0
heterogeneity O 0
in O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
amelogenesis I-Disease 1
imperfecta I-Disease 1
. O 0

The O 0
AMELX O 0
gene O 0
located O 0
at O 0
Xp22 O 0
. O 0

1 O 0
- O 0
p22 O 0
. O 0

3 O 0
encodes O 0
for O 0
the O 0
enamel O 0
protein O 0
amelogenin O 0
and O 0
has O 0
been O 0
implicated O 0
as O 0
the O 0
gene O 0
responsible O 0
for O 0
the O 0
inherited B-Disease 0
dental I-Disease 0
abnormality I-Disease 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
amelogenesis I-Disease 1
imperfecta I-Disease 1
( O 0
XAI B-Disease 1
) O 0
. O 0

Three O 0
families O 0
with O 0
XAI B-Disease 1
have O 0
been O 0
investigated O 0
using O 0
polymorphic O 0
DNA O 0
markers O 0
flanking O 0
the O 0
position O 0
of O 0
AMELX O 0
. O 0

Using O 0
two O 0
- O 0
point O 0
linkage O 0
analysis O 0
, O 0
linkage O 0
was O 0
established O 0
between O 0
XAI B-Disease 1
and O 0
several O 0
of O 0
these O 0
markers O 0
in O 0
two O 0
families O 0
, O 0
with O 0
a O 0
combined O 0
lod O 0
score O 0
of O 0
6 O 0
. O 0

05 O 0
for O 0
DXS16 O 0
at O 0
theta O 0
= O 0
0 O 0
. O 0

04 O 0
04 O 0
. O 0

This O 0
supports O 0
the O 0
involvement O 0
of O 0
AMELX O 0
, O 0
located O 0
close O 0
to O 0
DXS16 O 0
, O 0
in O 0
the O 0
XAI B-Disease 1
disease I-Disease 1
process O 0
( O 0
AIH1 O 1
) O 0
in O 0
those O 0
families O 0
. O 0

Using O 0
multipoint O 0
linkage O 0
analysis O 0
, O 0
the O 0
combined O 0
maximum O 0
lod O 0
score O 0
for O 0
these O 0
two O 0
families O 0
was O 0
7 O 0
. O 0

30 O 0
for O 0
a O 0
location O 0
of O 0
AIH1 O 1
at O 0
2 O 0
cM O 0
distal O 0
to O 0
DXS16 O 0
. O 0

The O 0
support O 0
interval O 0
around O 0
this O 0
location O 0
extended O 0
about O 0
8 O 0
cM O 0
proximal O 0
to O 0
DXS92 O 0
, O 0
and O 0
the O 0
AIH1 O 1
location O 0
could O 0
not O 0
be O 0
precisely O 0
defined O 0
by O 0
multipoint O 0
mapping O 0
. O 0

Study O 0
of O 0
recombination O 0
events O 0
indicated O 0
that O 0
AIH1 O 1
lies O 0
in O 0
the O 0
interval O 0
between O 0
DXS143 O 0
and O 0
DXS85 O 0
. O 0

There O 0
was O 0
significant O 0
evidence O 0
against O 0
linkage O 0
to O 0
this O 0
region O 0
in O 0
the O 0
third O 0
family O 0
, O 0
indicating O 0
locus O 0
heterogeneity O 0
in O 0
XAI B-Disease 1
. O 0

Further O 0
analysis O 0
with O 0
markers O 0
on O 0
the O 0
long O 0
arm O 0
of O 0
the O 0
X O 0
chromosome O 0
showed O 0
evidence O 0
of O 0
linkage O 0
to O 0
DXS144E O 0
and O 0
F9 O 0
with O 0
no O 0
recombination O 0
with O 0
either O 0
of O 0
these O 0
markers O 0
. O 0

Two O 0
- O 0
point O 0
analysis O 0
gave O 0
a O 0
peak O 0
lod O 0
score O 0
at O 0
DXS144E O 0
with O 0
a O 0
maximum O 0
lod O 0
score O 0
of O 0
2 O 0
. O 0

83 O 0
at O 0
theta O 0
= O 0
0 O 0
, O 0
with O 0
a O 0
peak O 0
lod O 0
score O 0
in O 0
multipoint O 0
linkage O 0
analysis O 0
of O 0
2 O 0
. O 0

84 O 0
at O 0
theta O 0
= O 0
0 O 0
. O 0

The O 0
support O 0
interval O 0
extended O 0
9 O 0
cM O 0
proximal O 0
to O 0
DXS144E O 0
and O 0
14 O 0
cM O 0
distal O 0
to O 0
F9 O 0
. O 0

( O 0
ABSTRACT O 0
TRUNCATED O 0
AT O 0
250 O 0
WORDS O 0
) O 0
. O 0

Multiple O 0
origins O 0
for O 0
phenylketonuria B-Disease 0
in O 0
Europe O 0
. O 0

Phenylketonuria B-Disease 0
( O 0
PKU B-Disease 0
) O 0
, O 0
a O 0
disorder B-Disease 0
of I-Disease 0
amino I-Disease 0
acid I-Disease 0
metabolism I-Disease 0
prevalent O 0
among O 0
Caucasians O 0
and O 0
other O 0
ethnic O 0
groups O 0
, O 0
is O 0
caused O 0
primarily O 0
by O 0
a O 0
deficiency B-Disease 1
of I-Disease 1
the I-Disease 1
hepatic I-Disease 1
enzyme I-Disease 1
phenylalanine I-Disease 1
hydroxylase I-Disease 1
( O 0
PAH O 0
) O 0
. O 0

PKU B-Disease 0
is O 0
a O 0
highly O 0
heterogeneous O 0
disorder O 0
, O 0
with O 0
more O 0
than O 0
60 O 0
molecular O 0
lesions O 0
identified O 0
in O 0
the O 0
PAH O 0
gene O 0
. O 0

The O 0
haplotype O 0
associations O 0
, O 0
relative O 0
frequencies O 0
, O 0
and O 0
distributions O 0
of O 0
five O 0
prevalent O 0
PAH O 0
mutations O 0
( O 0
R158Q O 0
, O 0
R261Q O 0
, O 0
IVS10nt546 O 0
, O 0
R408W O 0
, O 0
and O 0
IVS12n1 O 0
) O 0
were O 0
established O 0
in O 0
a O 0
comprehensive O 0
European O 0
sample O 0
population O 0
and O 0
subsequently O 0
were O 0
examined O 0
to O 0
determine O 0
the O 0
potential O 0
roles O 0
of O 0
several O 0
genetic O 0
mechanisms O 0
in O 0
explaining O 0
the O 0
present O 0
distribution O 0
of O 0
the O 0
major O 0
PKU B-Disease 0
alleles O 0
. O 0

Each O 0
of O 0
these O 0
five O 0
mutations O 0
was O 0
strongly O 0
associated O 0
with O 0
only O 0
one O 0
of O 0
the O 0
more O 0
than O 0
70 O 0
chromosomal O 0
haplotypes O 0
defined O 0
by O 0
eight O 0
RFLPs O 0
in O 0
or O 0
near O 0
the O 0
PAH O 0
gene O 0
. O 0

These O 0
findings O 0
suggest O 0
that O 0
each O 0
of O 0
these O 0
mutations O 0
arose O 0
through O 0
a O 0
single O 0
founding O 0
event O 0
that O 0
occurred O 0
within O 0
time O 0
periods O 0
ranging O 0
from O 0
several O 0
hundred O 0
to O 0
several O 0
thousand O 0
years O 0
ago O 0
. O 0

From O 0
the O 0
significant O 0
differences O 0
observed O 0
in O 0
the O 0
relative O 0
frequencies O 0
and O 0
distributions O 0
of O 0
these O 0
five O 0
alleles O 0
throughout O 0
Europe O 0
, O 0
four O 0
of O 0
these O 0
putative O 0
founding O 0
events O 0
could O 0
be O 0
localized O 0
to O 0
specific O 0
ethnic O 0
subgroups O 0
. O 0

Together O 0
, O 0
these O 0
data O 0
suggest O 0
that O 0
there O 0
were O 0
multiple O 0
, O 0
geographically O 0
and O 0
ethnically O 0
distinct O 0
origins O 0
for O 0
PKU B-Disease 0
within O 0
the O 0
European O 0
population O 0
. O 0
. O 0

Complement B-Disease 0
factor I-Disease 0
2 I-Disease 0
deficiency I-Disease 0
: O 0
a O 0
clinical O 0
and O 0
serological O 0
family O 0
study O 0
. O 0

Inherited B-Disease 0
complement I-Disease 0
deficiencies I-Disease 0
are O 0
associated O 0
with O 0
a O 0
variety O 0
of O 0
connective O 0
tissue O 0
diseases O 0
. O 0

A O 0
family O 0
with O 0
inherited B-Disease 1
deficiency I-Disease 1
of I-Disease 1
complement I-Disease 1
factor I-Disease 1
2 I-Disease 1
( O 0
C2 O 0
) O 0
is O 0
described O 0
in O 0
which O 0
two O 0
family O 0
members O 0
with O 0
homozygous O 0
C2 B-Disease 1
deficiency I-Disease 1
developed O 0
cutaneous B-Disease 0
vasculitis I-Disease 0
and O 0
sicca B-Disease 1
syndrome I-Disease 1
. O 0

The O 0
other O 0
family O 0
members O 0
had O 0
heterozygous O 0
C2 B-Disease 1
deficiency I-Disease 1
and O 0
each O 0
member O 0
had O 0
the O 0
HLA O 0
- O 0
A25 O 0
, O 0
B18 O 0
, O 0
DR2 O 0
( O 0
w15 O 0
) O 0
haplotype O 0
. O 0

The O 0
mother O 0
had O 0
seropositive B-Disease 0
rheumatoid I-Disease 0
arthritis I-Disease 0
. O 0

Further O 0
studies O 0
showed O 0
the O 0
presence O 0
of O 0
cryoglobulins O 0
, O 0
antibodies O 0
against O 0
endothelial O 0
cells O 0
, O 0
and O 0
anticardiolipin O 0
antibodies O 0
. O 0
. O 0

New O 0
variant O 0
in O 0
exon O 0
3 O 0
of O 0
the O 0
proteolipid O 0
protein O 0
( O 0
PLP O 0
) O 0
gene O 0
in O 0
a O 0
family O 0
with O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
. O 0

A O 0
C O 0
- O 0
- O 0
greater O 0
than O 0
G O 0
transversion O 0
has O 0
been O 0
found O 0
in O 0
exon O 0
3 O 0
of O 0
the O 0
PLP O 0
gene O 0
of O 0
affected O 0
males O 0
and O 0
their O 0
mother O 0
in O 0
a O 0
single O 0
sibship O 0
with O 0
Pelizaeus B-Disease 1
- I-Disease 1
merzbacher I-Disease 1
disease I-Disease 1
( O 0
PMD B-Disease 1
) O 0
. O 0

The O 0
transversion O 0
should O 0
not O 0
result O 0
in O 0
an O 0
amino O 0
acid O 0
change O 0
in O 0
the O 0
protein O 0
but O 0
it O 0
does O 0
result O 0
in O 0
the O 0
loss O 0
of O 0
a O 0
HaeIII O 0
restriction O 0
endonuclease O 0
cleavage O 0
site O 0
. O 0

It O 0
is O 0
concordant O 0
with O 0
the O 0
disease O 0
in O 0
this O 0
family O 0
. O 0

One O 0
- O 0
hundred O 0
- O 0
ten O 0
unrelated O 0
X O 0
chromosomes O 0
are O 0
negative O 0
for O 0
this O 0
mutation O 0
. O 0

No O 0
other O 0
sequence O 0
defect O 0
was O 0
found O 0
in O 0
the O 0
PLP O 0
exons O 0
of O 0
the O 0
affected O 0
males O 0
. O 0

The O 0
cause O 0
of O 0
disease O 0
in O 0
this O 0
family O 0
remains O 0
unknown O 0
, O 0
but O 0
the O 0
association O 0
between O 0
this O 0
rare O 0
mutation O 0
and O 0
PMD B-Disease 1
is O 0
intriguing O 0
. O 0

The O 0
mutation O 0
can O 0
serve O 0
as O 0
a O 0
marker O 0
for O 0
following O 0
segregation O 0
of O 0
the O 0
PLP O 0
gene O 0
. O 0
. O 0

Uncoupling O 0
of O 0
hypomyelination B-Disease 1
and O 0
glial B-Disease 1
cell I-Disease 1
death I-Disease 1
by O 0
a O 0
mutation O 0
in O 0
the O 0
proteolipid O 0
protein O 0
gene O 0
. O 0

Proteolipid O 0
protein O 0
( O 0
PLP O 0
; O 0
M O 0
( O 0
r O 0
) O 0
30 O 0
, O 0
000 O 0
) O 0
is O 0
a O 0
highly O 0
conserved O 0
major O 0
polytopic O 0
membrane O 0
protein O 0
in O 0
myelin O 0
but O 0
its O 0
cellular O 0
function O 0
remains O 0
obscure O 0
. O 0

Neurological O 0
mutant O 0
mice O 0
can O 0
often O 0
provide O 0
model O 0
systems O 0
for O 0
human O 0
genetic B-Disease 1
disorders I-Disease 1
. O 0

Mutations O 0
of O 0
the O 0
X O 0
- O 0
chromosome O 0
- O 0
linked O 0
PLP O 0
gene O 0
are O 0
lethal O 0
, O 0
identified O 0
first O 0
in O 0
the O 0
jimpy O 0
mouse O 0
and O 0
subsequently O 0
in O 0
patients O 0
with O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
. O 0

The O 0
unexplained O 0
phenotype O 0
of O 0
these O 0
mutations O 0
includes O 0
degeneration B-Disease 0
and I-Disease 0
premature I-Disease 0
cell I-Disease 0
death I-Disease 0
of I-Disease 0
oligodendrocytes I-Disease 0
with O 0
associated O 0
hypomyelination B-Disease 1
. O 0

Here O 0
we O 0
show O 0
that O 0
a O 0
new O 0
mouse O 0
mutant O 0
rumpshaker O 0
is O 0
defined O 0
by O 0
the O 0
amino O 0
- O 0
acid O 0
substitution O 0
Ile O 0
- O 0
to O 0
- O 0
Thr O 0
at O 0
residue O 0
186 O 0
in O 0
a O 0
membrane O 0
- O 0
embedded O 0
domain O 0
of O 0
PLP O 0
. O 0

Surprisingly O 0
, O 0
rumpshaker O 0
mice O 0
, O 0
although O 0
myelin B-Disease 0
- I-Disease 0
deficient I-Disease 0
, O 0
have O 0
normal O 0
longevity O 0
and O 0
a O 0
full O 0
complement O 0
of O 0
morphologically O 0
normal O 0
oligodendrocytes O 0
. O 0

Hypomyelination B-Disease 1
can O 0
thus O 0
be O 0
genetically O 0
separated O 0
from O 0
the O 0
PLP O 0
- O 0
dependent O 0
oligodendrocyte B-Disease 0
degeneration I-Disease 0
. O 0

We O 0
suggest O 0
that O 0
PLP O 0
has O 0
a O 0
vital O 0
function O 0
in O 0
glial O 0
cell O 0
development O 0
, O 0
distinct O 0
from O 0
its O 0
later O 0
role O 0
in O 0
myelin O 0
assembly O 0
, O 0
and O 0
that O 0
this O 0
dichotomy O 0
of O 0
action O 0
may O 0
explain O 0
the O 0
clinical O 0
spectrum O 0
of O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
. O 0
. O 0

A O 0
pseudodeficiency O 0
allele O 0
common O 0
in O 0
non O 0
- O 0
Jewish O 0
Tay B-Disease 0
- I-Disease 0
Sachs I-Disease 0
carriers O 0
: O 0
implications O 0
for O 0
carrier O 0
screening O 0
. O 0

Deficiency B-Disease 0
of I-Disease 0
beta I-Disease 0
- I-Disease 0
hexosaminidase I-Disease 0
A I-Disease 0
( O 0
Hex O 0
A O 0
) O 0
activity O 0
typically O 0
results O 0
in O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
. O 0

However O 0
, O 0
healthy O 0
subjects O 0
found O 0
to O 0
be O 0
deficient B-Disease 0
in I-Disease 0
Hex I-Disease 0
A I-Disease 0
activity O 0
( O 0
i O 0
. O 0
e O 0
. O 0
, O 0
pseudodeficient O 0
) O 0
by O 0
means O 0
of O 0
in O 0
vitro O 0
biochemical O 0
tests O 0
have O 0
been O 0
described O 0
. O 0

We O 0
analyzed O 0
the O 0
HEXA O 0
gene O 0
of O 0
one O 0
pseudodeficient O 0
subject O 0
and O 0
identified O 0
both O 0
a O 0
C739 O 0
- O 0
to O 0
- O 0
T O 0
substitution O 0
that O 0
changes O 0
Arg247 O 0
- O 0
- O 0
- O 0
- O 0
Trp O 0
on O 0
one O 0
allele O 0
and O 0
a O 0
previously O 0
identified O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
mutation O 0
on O 0
the O 0
second O 0
allele O 0
. O 0

Six O 0
additional O 0
pseudodeficient O 0
subjects O 0
were O 0
found O 0
to O 0
have O 0
the O 0
C739 O 0
- O 0
to O 0
- O 0
T O 0
mutation O 0
. O 0

This O 0
allele O 0
accounted O 0
for O 0
32 O 0
% O 0
( O 0
20 O 0
/ O 0
62 O 0
) O 0
of O 0
non O 0
- O 0
Jewish O 0
enzyme O 0
- O 0
defined O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
carriers O 0
but O 0
for O 0
none O 0
of O 0
36 O 0
Jewish O 0
enzyme O 0
- O 0
defined O 0
carriers O 0
who O 0
did O 0
not O 0
have O 0
one O 0
of O 0
three O 0
known O 0
mutations O 0
common O 0
to O 0
this O 0
group O 0
. O 0

The O 0
C739 O 0
- O 0
to O 0
- O 0
T O 0
allele O 0
, O 0
together O 0
with O 0
a O 0
" O 0
true O 0
" O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
allele O 0
, O 0
causes O 0
Hex O 0
A O 0
pseudodeficiency O 0
. O 0

Given O 0
both O 0
the O 0
large O 0
proportion O 0
of O 0
non O 0
- O 0
Jewish O 0
carriers O 0
with O 0
this O 0
allele O 0
and O 0
that O 0
standard O 0
biochemical O 0
screening O 0
cannot O 0
differentiate O 0
between O 0
heterozygotes O 0
for O 0
the O 0
C739 O 0
- O 0
to O 0
- O 0
T O 0
mutations O 0
and O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
carriers O 0
, O 0
DNA O 0
testing O 0
for O 0
this O 0
mutation O 0
in O 0
at O 0
- O 0
risk O 0
couples O 0
is O 0
essential O 0
. O 0

Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
: O 0
detection O 0
of O 0
mutations O 0
Thr181 O 0
- O 0
- O 0
- O 0
- O 0
Pro O 0
and O 0
Leu223 O 0
- O 0
- O 0
- O 0
- O 0
Pro O 0
in O 0
the O 0
proteolipid O 0
protein O 0
gene O 0
, O 0
and O 0
prenatal O 0
diagnosis O 0
. O 0

A O 0
family O 0
with O 0
an O 0
apparent O 0
history O 0
of O 0
X O 0
- O 0
linked O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
presented O 0
for O 0
genetic O 0
counseling O 0
, O 0
requesting O 0
carrier O 0
detection O 0
and O 0
prenatal O 0
diagnosis O 0
. O 0

RFLP O 0
analysis O 0
using O 0
the O 0
proteolipid O 0
protein O 0
( O 0
PLP O 0
) O 0
gene O 0
probe O 0
was O 0
uninformative O 0
in O 0
this O 0
family O 0
. O 0

A O 0
prenatal O 0
diagnosis O 0
on O 0
a O 0
chorionic O 0
villus O 0
sample O 0
( O 0
CVS O 0
) O 0
was O 0
carried O 0
out O 0
using O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphism O 0
( O 0
SSCP O 0
) O 0
analysis O 0
of O 0
a O 0
variant O 0
in O 0
exon O 0
4 O 0
of O 0
the O 0
PLP O 0
gene O 0
. O 0

The O 0
fetus O 0
was O 0
predicted O 0
to O 0
be O 0
unaffected O 0
. O 0

Sequencing O 0
of O 0
the O 0
exon O 0
from O 0
the O 0
CVS O 0
, O 0
the O 0
predicted O 0
- O 0
carrier O 0
mother O 0
, O 0
and O 0
the O 0
obligate O 0
- O 0
carrier O 0
grandmother O 0
revealed O 0
an O 0
A O 0
- O 0
to O 0
- O 0
C O 0
change O 0
at O 0
nucleotide O 0
541 O 0
in O 0
the O 0
two O 0
women O 0
but O 0
not O 0
in O 0
the O 0
fetus O 0
. O 0

As O 0
this O 0
change O 0
results O 0
in O 0
a O 0
Thr O 0
- O 0
to O 0
- O 0
Pro O 0
change O 0
at O 0
amino O 0
acid O 0
181 O 0
in O 0
a O 0
region O 0
of O 0
the O 0
gene O 0
predicted O 0
to O 0
be O 0
part O 0
of O 0
a O 0
transmembrane O 0
segment O 0
, O 0
it O 0
was O 0
concluded O 0
that O 0
this O 0
was O 0
the O 0
mutation O 0
causing O 0
the O 0
disease O 0
in O 0
this O 0
family O 0
. O 0

In O 0
addition O 0
, O 0
in O 0
a O 0
second O 0
family O 0
, O 0
an O 0
exon O 0
5 O 0
variant O 0
band O 0
pattern O 0
on O 0
SSCP O 0
analysis O 0
was O 0
shown O 0
by O 0
sequencing O 0
to O 0
be O 0
due O 0
to O 0
a O 0
T O 0
- O 0
to O 0
- O 0
C O 0
change O 0
at O 0
nucleotide O 0
668 O 0
. O 0

This O 0
results O 0
in O 0
a O 0
Leu O 0
- O 0
to O 0
- O 0
Pro O 0
change O 0
in O 0
a O 0
carrier O 0
mother O 0
and O 0
in O 0
her O 0
two O 0
affected O 0
sons O 0
. O 0

These O 0
results O 0
provide O 0
further O 0
examples O 0
of O 0
mutations O 0
in O 0
PLP O 0
that O 0
cause O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
and O 0
illustrate O 0
the O 0
value O 0
of O 0
SSCP O 0
in O 0
genetic O 0
analysis O 0
. O 0
. O 0

von B-Disease 1
Willebrand I-Disease 1
disease I-Disease 1
type I-Disease 1
B I-Disease 1
: O 0
a O 0
missense O 0
mutation O 0
selectively O 0
abolishes O 0
ristocetin O 0
- O 0
induced O 0
von B-Disease 1
Willebrand I-Disease 1
factor O 0
binding O 0
to O 0
platelet O 0
glycoprotein O 0
Ib O 0
. O 0

von B-Disease 1
Willebrand I-Disease 1
factor O 0
( O 0
vWF O 0
) O 0
is O 0
a O 0
multimeric O 0
glycoprotein O 0
that O 0
mediates O 0
the O 0
adhesion O 0
of O 0
platelets O 0
to O 0
the O 0
subendothelium O 0
by O 0
binding O 0
to O 0
platelet O 0
glycoprotein O 0
Ib O 0
. O 0

For O 0
human O 0
vWF O 0
, O 0
this O 0
interaction O 0
can O 0
be O 0
induced O 0
in O 0
vitro O 0
by O 0
the O 0
antibiotic O 0
ristocetin O 0
or O 0
the O 0
snake O 0
venom O 0
protein O 0
botrocetin O 0
. O 0

A O 0
missense O 0
mutation O 0
, O 0
Gly O 0
- O 0
561 O 0
- O 0
- O 0
> O 0
Ser O 0
, O 0
was O 0
identified O 0
within O 0
the O 0
proposed O 0
glycoprotein O 0
Ib O 0
binding O 0
domain O 0
of O 0
vWF O 0
in O 0
the O 0
proband O 0
with O 0
von B-Disease 1
Willebrand I-Disease 1
disease I-Disease 1
type I-Disease 1
B I-Disease 1
, O 0
a O 0
unique O 0
variant O 0
characterized O 0
by O 0
no O 0
ristocetin O 0
- O 0
induced O 0
, O 0
but O 0
normal O 0
botrocetin O 0
- O 0
induced O 0
, O 0
binding O 0
to O 0
glycoprotein O 0
Ib O 0
. O 0

The O 0
corresponding O 0
mutant O 0
recombinant O 0
protein O 0
, O 0
rvWF O 0
( O 0
G561S O 0
) O 0
, O 0
formed O 0
normal O 0
multimers O 0
and O 0
exhibited O 0
the O 0
same O 0
functional O 0
defect O 0
as O 0
the O 0
patients O 0
plasma O 0
vWF O 0
, O 0
confirming O 0
that O 0
this O 0
mutation O 0
causes O 0
von B-Disease 1
Willebrand I-Disease 1
disease I-Disease 1
type I-Disease 1
B I-Disease 1
. O 0

These O 0
data O 0
show O 0
that O 0
botrocetin O 0
and O 0
ristocetin O 0
cofactor O 0
activities O 0
of O 0
vWF O 0
can O 0
be O 0
dissociated O 0
by O 0
a O 0
point O 0
mutation O 0
and O 0
confirm O 0
that O 0
these O 0
mediators O 0
promote O 0
vWF O 0
binding O 0
to O 0
platelets O 0
by O 0
different O 0
mechanisms O 0
. O 0

The O 0
normal O 0
botrocetin O 0
- O 0
induced O 0
binding O 0
and O 0
the O 0
defective O 0
ristocetin O 0
- O 0
induced O 0
binding O 0
of O 0
rvWF O 0
( O 0
G561S O 0
) O 0
suggest O 0
that O 0
the O 0
primary O 0
defect O 0
in O 0
von B-Disease 1
Willebrand I-Disease 1
disease I-Disease 1
type I-Disease 1
B I-Disease 1
may O 0
be O 0
a O 0
failure O 0
of O 0
normal O 0
allosteric O 0
regulation O 0
of O 0
the O 0
glycoprotein O 0
Ib O 0
binding O 0
function O 0
of O 0
vWF O 0
. O 0
. O 0

Typical O 0
and O 0
partial O 0
cat B-Disease 0
eye I-Disease 0
syndrome I-Disease 0
: O 0
identification O 0
of O 0
the O 0
marker O 0
chromosome O 0
by O 0
FISH O 0
. O 0

Three O 0
children O 0
are O 0
reported O 0
with O 0
typical O 0
cat B-Disease 0
eye I-Disease 0
syndrome I-Disease 0
( O 0
CES B-Disease 1
) O 0
and O 0
three O 0
more O 0
children O 0
with O 0
partial O 0
CES B-Disease 1
because O 0
of O 0
absence O 0
of O 0
coloboma O 0
, O 0
in O 0
which O 0
the O 0
supernumerary O 0
marker O 0
chromosome O 0
was O 0
studied O 0
by O 0
FISH O 0
. O 0

Using O 0
a O 0
genomic O 0
library O 0
, O 0
and O 0
also O 0
a O 0
centromeric O 0
and O 0
particularly O 0
a O 0
cosmid O 0
probe O 0
of O 0
22q11 O 0
, O 0
partial O 0
tetrasomy B-Disease 0
was O 0
shown O 0
in O 0
all O 0
cases O 0
. O 0
. O 0

[ O 0
Genetic O 0
heterogeneity O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
: O 0
mutant O 0
alleles O 0
of O 0
G6PD O 0
in O 0
the O 0
Shekii O 0
district O 0
of O 0
Azerbaijan O 0
] O 0

Examination O 0
on O 0
G6PD B-Disease 0
deficiency I-Disease 0
in O 0
349 O 0
patients O 0
of O 0
Shekii O 0
district O 0
hospital O 0
( O 0
Azerbaijan O 0
) O 0
revealed O 0
16 O 0
hemi O 0
- O 0
, O 0
4 O 0
homo O 0
- O 0
and O 0
9 O 0
heterozygotic O 0
carriers O 0
of O 0
the O 0
defect O 0
. O 0

Gd O 0
- O 0
frequency O 0
, O 0
calculated O 0
from O 0
the O 0
data O 0
obtained O 0
( O 0
7 O 0
. O 0
7 O 0
% O 0
) O 0
, O 0
may O 0
be O 0
compared O 0
to O 0
neighbouring O 0
regions O 0
frequencies O 0
( O 0
6 O 0
- O 0
30 O 0
% O 0
) O 0
. O 0

Carriers O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
are O 0
residents O 0
of O 0
11 O 0
villages O 0
located O 0
in O 0
Alasani O 0
- O 0
Aphtalan O 0
valley O 0
, O 0
highly O 0
endemic O 0
with O 0
malaria B-Disease 1
in O 0
the O 0
past O 0
; O 0
nearly O 0
all O 0
marriages O 0
are O 0
endogamic O 0
. O 0

Physico O 0
- O 0
chemical O 0
and O 0
kinetic O 0
study O 0
of O 0
10 O 0
mutant O 0
forms O 0
of O 0
G6PD O 0
, O 0
according O 0
to O 0
WHO O 0
program O 0
, O 0
led O 0
to O 0
identification O 0
of O 0
5 O 0
variants O 0
of O 0
the O 0
II O 0
class O 0
( O 0
Shekii O 0
, O 0
Bideiz O 0
, O 0
Shirin O 0
- O 0
Bulakh O 0
, O 0
Okhut O 0
I O 0
and O 0
Zakataly O 0
) O 0
and O 0
2 O 0
variants O 0
of O 0
the O 0
III O 0
class O 0
( O 0
Okhut O 0
II O 0
and O 0
Martinique O 0
- O 0
like O 0
) O 0
. O 0

Resemblance O 0
of O 0
the O 0
majority O 0
of O 0
variants O 0
in O 0
electrophoretic O 0
mobility O 0
and O 0
the O 0
level O 0
of O 0
erythrocyte O 0
enzyme O 0
activity O 0
permit O 0
to O 0
suggest O 0
the O 0
existence O 0
of O 0
a O 0
common O 0
parental O 0
mutant O 0
G6PD O 0
allele O 0
distributed O 0
in O 0
this O 0
area O 0
. O 0

Craniofrontonasal B-Disease 0
dysplasia I-Disease 0
. O 0

We O 0
report O 0
on O 0
nine O 0
patients O 0
with O 0
craniofrontonasal B-Disease 1
dysplasia I-Disease 1
( O 0
CFND B-Disease 1
) O 0
. O 0

Seven O 0
classical O 0
cases O 0
had O 0
facial O 0
features O 0
suggestive O 0
of O 0
frontonasal B-Disease 0
dysplasia I-Disease 0
and O 0
coronal B-Disease 1
craniosynostosis I-Disease 1
. O 0

Extracranial B-Disease 0
abnormalities I-Disease 0
such O 0
as O 0
brittle B-Disease 0
nails I-Disease 0
with I-Disease 0
prominent I-Disease 0
longitudinal I-Disease 0
grooves I-Disease 0
or O 0
syndactyly B-Disease 1
of I-Disease 1
fingers I-Disease 1
and I-Disease 1
toes I-Disease 1
were O 0
observed O 0
in O 0
individual O 0
patients O 0
. O 0

In O 0
two O 0
families O 0
the O 0
father O 0
of O 0
classical O 0
cases O 0
showed O 0
a O 0
milder O 0
pattern O 0
of O 0
abnormalities O 0
, O 0
consistent O 0
with O 0
the O 0
diagnosis O 0
. O 0

We O 0
present O 0
a O 0
2 O 0
- O 0
to O 0
13 O 0
- O 0
year O 0
follow O 0
- O 0
up O 0
on O 0
our O 0
patients O 0
. O 0

Hypotonia B-Disease 1
and O 0
laxity B-Disease 1
of I-Disease 1
joints I-Disease 1
are O 0
common O 0
and O 0
may O 0
necessitate O 0
supportive O 0
measures O 0
. O 0

Mild O 0
developmental B-Disease 1
delay I-Disease 1
was O 0
noted O 0
in O 0
three O 0
out O 0
of O 0
six O 0
classical O 0
cases O 0
studied O 0
in O 0
detail O 0
. O 0

Unlike O 0
almost O 0
all O 0
other O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
disorders I-Disease 1
, O 0
clinical O 0
expression O 0
in O 0
CFND B-Disease 1
is O 0
generally O 0
much O 0
more O 0
severe O 0
in O 0
females O 0
than O 0
in O 0
males O 0
. O 0

In O 0
contrast O 0
to O 0
previous O 0
reports O 0
of O 0
this O 0
condition O 0
, O 0
one O 0
of O 0
our O 0
severely O 0
affected O 0
cases O 0
is O 0
a O 0
male O 0
. O 0
. O 0

The O 0
intron O 0
7 O 0
donor O 0
splice O 0
site O 0
transition O 0
: O 0
a O 0
second O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
mutation O 0
in O 0
French O 0
Canada O 0
. O 0

Mutations O 0
at O 0
the O 0
hexosaminidase O 0
A O 0
( O 0
HEXA O 0
) O 0
gene O 0
which O 0
cause O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
( O 0
TSD B-Disease 0
) O 0
have O 0
elevated O 0
frequency O 0
in O 0
the O 0
Ashkenazi O 0
Jewish O 0
and O 0
French O 0
- O 0
Canadian O 0
populations O 0
. O 0

We O 0
report O 0
a O 0
novel O 0
TSD B-Disease 0
allele O 0
in O 0
the O 0
French O 0
- O 0
Canadian O 0
population O 0
associated O 0
with O 0
the O 0
infantile O 0
form O 0
of O 0
the O 0
disease O 0
. O 0

The O 0
mutation O 0
, O 0
a O 0
G O 0
- O 0
- O 0
> O 0
A O 0
transition O 0
at O 0
the O 0
+ O 0
1 O 0
position O 0
of O 0
intron O 0
7 O 0
, O 0
abolishes O 0
the O 0
donor O 0
splice O 0
site O 0
. O 0

Cultured O 0
human O 0
fibroblasts O 0
from O 0
a O 0
compound O 0
heterozygote O 0
for O 0
this O 0
transition O 0
( O 0
and O 0
for O 0
a O 0
deletion O 0
mutation O 0
) O 0
produce O 0
no O 0
detectable O 0
HEXA O 0
mRNA O 0
. O 0

The O 0
intron O 0
7 O 0
+ O 0
1 O 0
mutation O 0
occurs O 0
in O 0
the O 0
base O 0
adjacent O 0
to O 0
the O 0
site O 0
of O 0
the O 0
adult O 0
- O 0
onset O 0
TSD B-Disease 0
mutation O 0
( O 0
G805A O 0
) O 0
. O 0

In O 0
both O 0
mutations O 0
a O 0
restriction O 0
site O 0
for O 0
the O 0
endonuclease O 0
EcoRII O 0
is O 0
abolished O 0
. O 0

Unambiguous O 0
diagnosis O 0
, O 0
therefore O 0
, O 0
requires O 0
allele O 0
- O 0
specific O 0
oligonucleotide O 0
hybridization O 0
to O 0
distinguish O 0
between O 0
these O 0
two O 0
mutant O 0
alleles O 0
. O 0

The O 0
intron O 0
7 O 0
+ O 0
1 O 0
mutation O 0
has O 0
been O 0
detected O 0
in O 0
three O 0
unrelated O 0
families O 0
. O 0

Obligate O 0
heterozygotes O 0
for O 0
the O 0
intron O 0
7 O 0
+ O 0
1 O 0
mutation O 0
were O 0
born O 0
in O 0
the O 0
Saguenay O 0
- O 0
Lac O 0
- O 0
St O 0
- O 0
Jean O 0
region O 0
of O 0
Quebec O 0
. O 0

The O 0
most O 0
recent O 0
ancestors O 0
common O 0
to O 0
obligate O 0
carriers O 0
of O 0
this O 0
mutation O 0
were O 0
from O 0
the O 0
Charlevoix O 0
region O 0
of O 0
the O 0
province O 0
of O 0
Quebec O 0
. O 0

This O 0
mutation O 0
thus O 0
has O 0
a O 0
different O 0
geographic O 0
centre O 0
of O 0
diffusion O 0
and O 0
is O 0
probably O 0
less O 0
common O 0
than O 0
the O 0
exon O 0
1 O 0
deletion O 0
TSD B-Disease 0
mutation O 0
in O 0
French O 0
Canadians O 0
. O 0

Neither O 0
mutation O 0
has O 0
been O 0
detected O 0
in O 0
France O 0
, O 0
the O 0
ancestral O 0
homeland O 0
of O 0
French O 0
Canada O 0
. O 0
. O 0

Assignment O 0
of O 0
the O 0
aspartylglucosaminidase O 0
gene O 0
( O 0
AGA O 0
) O 0
to O 0
4q33 O 0
- O 0
- O 0
- O 0
- O 0
q35 O 0
based O 0
on O 0
decreased O 0
activity O 0
in O 0
a O 0
girl O 0
with O 0
a O 0
46 O 0
, O 0
XX O 0
, O 0
del O 0
( O 0
4 O 0
) O 0
( O 0
q33 O 0
) O 0
karyotype O 0
. O 0

Aspartylglucosaminuria B-Disease 1
( O 0
AGU B-Disease 0
) O 0
is O 0
a O 0
recessive O 0
autosomally O 0
inherited O 0
lysosomal B-Disease 0
storage I-Disease 0
disorder I-Disease 0
due O 0
to O 0
deficiency B-Disease 0
of I-Disease 0
the I-Disease 0
enzyme I-Disease 0
aspartylglucosaminidase I-Disease 0
( O 0
AGA O 0
) O 0
. O 0

The O 0
structural O 0
gene O 0
for O 0
this O 0
human O 0
enzyme O 0
( O 0
AGA O 0
) O 0
has O 0
been O 0
assigned O 0
to O 0
the O 0
region O 0
4q21 O 0
- O 0
- O 0
- O 0
- O 0
qter O 0
. O 0

We O 0
determined O 0
the O 0
AGA O 0
activity O 0
in O 0
cultured O 0
fibroblasts O 0
of O 0
a O 0
girl O 0
with O 0
a O 0
46 O 0
, O 0
XX O 0
, O 0
del O 0
( O 0
4 O 0
) O 0
( O 0
q33 O 0
) O 0
karyotype O 0
. O 0

The O 0
results O 0
indicate O 0
that O 0
the O 0
girl O 0
is O 0
a O 0
hemizygote O 0
for O 0
AGA O 0
, O 0
permitting O 0
the O 0
assignment O 0
of O 0
human O 0
AGA O 0
to O 0
the O 0
region O 0
4q33 O 0
- O 0
- O 0
- O 0
- O 0
qter O 0
. O 0
. O 0

Resolution O 0
of O 0
the O 0
two O 0
loci O 0
for O 0
autosomal O 0
dominant O 0
aniridia B-Disease 0
, O 0
AN1 O 0
and O 0
AN2 O 0
, O 0
to O 0
a O 0
single O 0
locus O 0
on O 0
chromosome O 0
11p13 O 0
. O 0

Two O 0
distinct O 0
loci O 0
have O 0
been O 0
proposed O 0
for O 0
aniridia B-Disease 0
; O 0
AN1 O 0
for O 0
autosomal O 0
dominant O 0
aniridia B-Disease 0
on O 0
chromosome O 0
2p O 0
and O 0
AN2 O 0
for O 0
the O 0
aniridia B-Disease 0
in O 0
the O 0
WAGR B-Disease 1
contiguous I-Disease 1
gene I-Disease 1
syndrome I-Disease 1
on O 0
chromosome O 0
11p13 O 0
. O 0

In O 0
this O 0
report O 0
, O 0
the O 0
kindred O 0
segregating O 0
for O 0
autosomal O 0
dominant O 0
aniridia B-Disease 0
, O 0
which O 0
suggested O 0
linkage O 0
to O 0
acid O 0
phosphatase O 0
- O 0
1 O 0
( O 0
ACP1 O 0
) O 0
and O 0
led O 0
to O 0
the O 0
assignment O 0
of O 0
the O 0
AN1 O 0
locus O 0
on O 0
chromosome O 0
2p O 0
, O 0
has O 0
been O 0
updated O 0
and O 0
expanded O 0
. O 0

Linkage O 0
analysis O 0
between O 0
the O 0
aniridia B-Disease 0
phenotype O 0
and O 0
ACP1 O 0
does O 0
not O 0
support O 0
the O 0
original O 0
linkage O 0
results O 0
, O 0
excluding O 0
linkage O 0
up O 0
to O 0
theta O 0
= O 0
0 O 0
. O 0

17 O 0
with O 0
Z O 0
= O 0
- O 0
2 O 0
. O 0

Tests O 0
for O 0
linkage O 0
to O 0
other O 0
chromosome O 0
2p O 0
markers O 0
. O 0

APOB O 0
, O 0
D2S71 O 0
, O 0
D2S5 O 0
, O 0
and O 0
D2S1 O 0
, O 0
also O 0
excluded O 0
linkage O 0
to O 0
aniridia B-Disease 0
. O 0

Markers O 0
that O 0
have O 0
been O 0
isolated O 0
from O 0
the O 0
chromosome O 0
11p13 O 0
region O 0
were O 0
then O 0
analyzed O 0
in O 0
this O 0
aniridia B-Disease 0
family O 0
. O 0

Two O 0
RFLPs O 0
at O 0
the O 0
D11S323 O 0
locus O 0
give O 0
significant O 0
evidence O 0
for O 0
linkage O 0
. O 0

The O 0
PvuII O 0
polymorphism O 0
detected O 0
by O 0
probe O 0
p5S1 O 0
. O 0

6 O 0
detects O 0
no O 0
recombinants O 0
, O 0
with O 0
a O 0
maximum O 0
lod O 0
score O 0
of O 0
Z O 0
= O 0
6 O 0
. O 0

97 O 0
at O 0
theta O 0
= O 0
0 O 0
. O 0

00 O 0
00 O 0
. O 0

The O 0
HaeIII O 0
polymorphism O 0
detected O 0
by O 0
the O 0
probe O 0
p5BE1 O 0
. O 0

2 O 0
gives O 0
a O 0
maximum O 0
lod O 0
score O 0
of O 0
Z O 0
= O 0
2 O 0
. O 0

57 O 0
at O 0
theta O 0
= O 0
0 O 0
. O 0

00 O 0
00 O 0
. O 0

Locus O 0
D11S325 O 0
gives O 0
a O 0
lod O 0
score O 0
of O 0
Z O 0
= O 0
1 O 0
. O 0

53 O 0
at O 0
theta O 0
= O 0
0 O 0
. O 0

00 O 0
00 O 0
. O 0

These O 0
data O 0
suggest O 0
that O 0
a O 0
locus O 0
for O 0
aniridia B-Disease 0
( O 0
AN1 O 0
) O 0
on O 0
chromosome O 0
2p O 0
has O 0
been O 0
misassigned O 0
and O 0
that O 0
this O 0
autosomal O 0
dominant O 0
aniridia B-Disease 0
family O 0
is O 0
segregating O 0
for O 0
an O 0
aniridia B-Disease 0
mutation O 0
linked O 0
to O 0
markers O 0
in O 0
the O 0
11p13 O 0
region O 0
. O 0

Fatal O 0
pyoderma B-Disease 0
gangrenosum I-Disease 0
in O 0
association O 0
with O 0
C7 B-Disease 0
deficiency I-Disease 0
. O 0

Although O 0
pyoderma B-Disease 0
gangrenosum I-Disease 0
( O 0
PG B-Disease 1
) O 0
is O 0
often O 0
associated O 0
with O 0
systemic B-Disease 0
diseases I-Disease 0
, O 0
it O 0
has O 0
not O 0
been O 0
reported O 0
in O 0
association O 0
with O 0
congenital B-Disease 1
complement I-Disease 1
deficiencies I-Disease 1
. O 0

We O 0
describe O 0
an O 0
aggressive O 0
and O 0
ultimately O 0
fatal O 0
case O 0
of O 0
PG B-Disease 1
in O 0
a O 0
patient O 0
with O 0
a O 0
congenital O 0
C7 B-Disease 0
deficiency I-Disease 0
. O 0

Deficiencies B-Disease 1
of I-Disease 1
C7 I-Disease 1
can O 0
be O 0
associated O 0
with O 0
decreased O 0
neutrophil O 0
chemotaxis O 0
, O 0
phagocytosis O 0
, O 0
and O 0
opsonization O 0
, O 0
similar O 0
to O 0
the O 0
immunologic B-Disease 1
abnormalities I-Disease 1
described O 0
in O 0
patients O 0
with O 0
PG B-Disease 1
. O 0

Our O 0
patients O 0
decreased O 0
complement O 0
level O 0
, O 0
if O 0
not O 0
directly O 0
related O 0
to O 0
the O 0
development O 0
of O 0
PG B-Disease 1
, O 0
may O 0
have O 0
contributed O 0
to O 0
the O 0
aggressive O 0
nature O 0
of O 0
her O 0
disease O 0
. O 0
. O 0

Diverse O 0
point O 0
mutations O 0
result O 0
in O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
polymorphism O 0
in O 0
Taiwan O 0
. O 0

Glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
PHOSPHATE I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
; I-Disease 0
EC I-Disease 0
1 I-Disease 0
. I-Disease 0
1 I-Disease 0
. I-Disease 0
1 I-Disease 0
. I-Disease 0
49 I-Disease 0
) I-Disease 0
deficiency I-Disease 0
is O 0
the O 0
most O 0
common O 0
human O 0
enzymopathy B-Disease 0
, O 0
affecting O 0
more O 0
than O 0
200 O 0
million O 0
people O 0
worldwide O 0
. O 0

Although O 0
greater O 0
than O 0
400 O 0
variants O 0
have O 0
been O 0
described O 0
based O 0
on O 0
clinical O 0
and O 0
biochemical O 0
criteria O 0
, O 0
little O 0
is O 0
known O 0
about O 0
the O 0
molecular O 0
basis O 0
of O 0
these O 0
G6PD B-Disease 0
deficiencies I-Disease 0
. O 0

Recently O 0
, O 0
the O 0
gene O 0
that O 0
encodes O 0
human O 0
G6PD O 0
has O 0
been O 0
cloned O 0
and O 0
sequenced O 0
, O 0
which O 0
enables O 0
us O 0
to O 0
examine O 0
directly O 0
the O 0
heterogeneity O 0
of O 0
G6PD O 0
at O 0
the O 0
DNA O 0
level O 0
. O 0

During O 0
the O 0
past O 0
10 O 0
years O 0
, O 0
we O 0
examined O 0
the O 0
G6PD O 0
activity O 0
in O 0
21 O 0
, O 0
271 O 0
newborn O 0
Chinese O 0
infants O 0
( O 0
11 O 0
, O 0
400 O 0
males O 0
and O 0
9 O 0
, O 0
871 O 0
females O 0
) O 0
and O 0
identified O 0
314 O 0
( O 0
2 O 0
. O 0
8 O 0
% O 0
) O 0
males O 0
and O 0
246 O 0
( O 0
2 O 0
. O 0
5 O 0
% O 0
) O 0
females O 0
having O 0
low O 0
G6PD O 0
activity O 0
. O 0

The O 0
G6PD O 0
gene O 0
from O 0
10 O 0
randomly O 0
selected O 0
affected O 0
individuals O 0
and O 0
their O 0
relatives O 0
was O 0
polymerase O 0
chain O 0
reaction O 0
( O 0
PCR O 0
) O 0
amplified O 0
, O 0
subcloned O 0
, O 0
and O 0
sequenced O 0
. O 0

Our O 0
results O 0
indicate O 0
that O 0
at O 0
least O 0
four O 0
types O 0
of O 0
mutation O 0
are O 0
responsible O 0
for O 0
the O 0
G6PD O 0
polymorphism O 0
in O 0
Taiwan O 0
. O 0

The O 0
first O 0
type O 0
of O 0
mutation O 0
( O 0
487 O 0
G O 0
- O 0
- O 0
- O 0
- O 0
A O 0
) O 0
was O 0
found O 0
in O 0
an O 0
affected O 0
Chinese O 0
with O 0
a O 0
G O 0
to O 0
A O 0
change O 0
at O 0
nucleotide O 0
487 O 0
, O 0
which O 0
results O 0
in O 0
a O 0
( O 0
163 O 0
) O 0
Gly O 0
to O 0
Ser O 0
substitution O 0
. O 0

The O 0
second O 0
type O 0
of O 0
mutation O 0
( O 0
493 O 0
A O 0
- O 0
- O 0
- O 0
- O 0
G O 0
) O 0
is O 0
a O 0
novel O 0
mutation O 0
that O 0
has O 0
not O 0
been O 0
reported O 0
in O 0
any O 0
other O 0
ethnic O 0
group O 0
and O 0
was O 0
identified O 0
in O 0
two O 0
affected O 0
Chinese O 0
. O 0

This O 0
mutation O 0
causes O 0
an O 0
A O 0
to O 0
G O 0
change O 0
at O 0
nucleotide O 0
position O 0
493 O 0
, O 0
producing O 0
an O 0
( O 0
165 O 0
) O 0
Asn O 0
to O 0
Asp O 0
substitution O 0
. O 0

Interestingly O 0
, O 0
the O 0
487 O 0
G O 0
- O 0
- O 0
- O 0
- O 0
A O 0
and O 0
493 O 0
A O 0
- O 0
- O 0
- O 0
- O 0
G O 0
mutations O 0
create O 0
Alu O 0
I O 0
and O 0
Ava O 0
II O 0
recognition O 0
sites O 0
, O 0
respectively O 0
, O 0
which O 0
enabled O 0
us O 0
to O 0
rapidly O 0
detect O 0
these O 0
two O 0
mutations O 0
by O 0
PCR O 0
/ O 0
restriction O 0
enzyme O 0
( O 0
RE O 0
) O 0
digestion O 0
method O 0
. O 0

The O 0
third O 0
mutation O 0
( O 0
1376 O 0
G O 0
- O 0
- O 0
- O 0
- O 0
T O 0
) O 0
was O 0
found O 0
in O 0
four O 0
affected O 0
Chinese O 0
. O 0

This O 0
mutation O 0
causes O 0
a O 0
G O 0
to O 0
T O 0
change O 0
at O 0
nucleotide O 0
position O 0
1376 O 0
that O 0
results O 0
in O 0
an O 0
( O 0
459 O 0
) O 0
Arg O 0
to O 0
Leu O 0
substitution O 0
. O 0

The O 0
1376 O 0
G O 0
- O 0
- O 0
- O 0
- O 0
T O 0
mutation O 0
seems O 0
to O 0
be O 0
the O 0
dominant O 0
allele O 0
that O 0
causes O 0
G6PD B-Disease 0
deficiency I-Disease 0
in O 0
Taiwan O 0
. O 0

Finally O 0
, O 0
two O 0
affected O 0
Chinese O 0
were O 0
identified O 0
as O 0
having O 0
the O 0
fourth O 0
mutation O 0
( O 0
1388 O 0
G O 0
- O 0
- O 0
- O 0
- O 0
A O 0
) O 0
. O 0

This O 0
mutation O 0
causes O 0
a O 0
G O 0
to O 0
A O 0
change O 0
at O 0
nucleotide O 0
1388 O 0
that O 0
produces O 0
an O 0
( O 0
463 O 0
) O 0
Arg O 0
to O 0
His O 0
substitution O 0
. O 0

Our O 0
studies O 0
provide O 0
the O 0
direct O 0
proof O 0
of O 0
the O 0
genetic O 0
heterogeneity O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
in O 0
the O 0
Chinese O 0
populations O 0
of O 0
Taiwan O 0
and O 0
the O 0
PCR O 0
/ O 0
RE O 0
digestion O 0
method O 0
is O 0
suitable O 0
for O 0
simultaneous O 0
detection O 0
of O 0
the O 0
487 O 0
G O 0
- O 0
- O 0
- O 0
- O 0
A O 0
and O 0
493 O 0
A O 0
- O 0
- O 0
- O 0
- O 0
G O 0
mutations O 0
. O 0

An O 0
error O 0
in O 0
dystrophin O 0
mRNA O 0
processing O 0
in O 0
golden B-Disease 1
retriever I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
, O 0
an O 0
animal O 0
homologue O 0
of O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
. O 0

Golden B-Disease 1
retriever I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
( O 0
GRMD B-Disease 1
) O 0
is O 0
a O 0
spontaneous O 0
, O 0
X O 0
- O 0
linked O 0
, O 0
progressively O 0
fatal O 0
disease O 0
of O 0
dogs O 0
and O 0
is O 0
also O 0
a O 0
homologue O 0
of O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
. O 0

Two O 0
- O 0
thirds O 0
of O 0
DMD B-Disease 0
patients O 0
carry O 0
detectable O 0
deletions O 0
in O 0
their O 0
dystrophin O 0
gene O 0
. O 0

The O 0
defect O 0
underlying O 0
the O 0
remaining O 0
one O 0
- O 0
third O 0
of O 0
DMD B-Disease 0
patients O 0
is O 0
undetermined O 0
. O 0

Analysis O 0
of O 0
the O 0
canine O 0
dystrophin O 0
gene O 0
in O 0
normal O 0
and O 0
GRMD B-Disease 1
dogs O 0
has O 0
failed O 0
to O 0
demonstrate O 0
any O 0
detectable O 0
loss O 0
of O 0
exons O 0
. O 0

Here O 0
, O 0
we O 0
have O 0
demonstrated O 0
a O 0
RNA O 0
processing O 0
error O 0
in O 0
GRMD B-Disease 1
that O 0
results O 0
from O 0
a O 0
single O 0
base O 0
change O 0
in O 0
the O 0
3 O 0
consensus O 0
splice O 0
site O 0
of O 0
intron O 0
6 O 0
. O 0

The O 0
seventh O 0
exon O 0
is O 0
then O 0
skipped O 0
, O 0
which O 0
predicts O 0
a O 0
termination O 0
of O 0
the O 0
dystrophin O 0
reading O 0
frame O 0
within O 0
its O 0
N O 0
- O 0
terminal O 0
domain O 0
in O 0
exon O 0
8 O 0
. O 0

This O 0
is O 0
the O 0
first O 0
example O 0
of O 0
dystrophin B-Disease 1
deficiency I-Disease 1
caused O 0
by O 0
a O 0
splice O 0
- O 0
site O 0
mutation O 0
. O 0
. O 0

Type B-Disease 1
I I-Disease 1
human I-Disease 1
complement I-Disease 1
C2 I-Disease 1
deficiency I-Disease 1
. O 0

A O 0
28 O 0
- O 0
base O 0
pair O 0
gene O 0
deletion O 0
causes O 0
skipping O 0
of O 0
exon O 0
6 O 0
during O 0
RNA O 0
splicing O 0
. O 0

Two O 0
variants O 0
of O 0
a O 0
genetic O 0
deficiency B-Disease 0
of I-Disease 0
complement I-Disease 0
protein I-Disease 0
C2 I-Disease 0
( O 0
C2D O 0
) O 0
have O 0
been O 0
previously O 0
identified O 0
. O 0

No O 0
C2 O 0
protein O 0
translation O 0
is O 0
detected O 0
in O 0
type O 0
I O 0
deficiency O 0
, O 0
while O 0
type O 0
II O 0
deficiency O 0
is O 0
characterized O 0
by O 0
a O 0
selective O 0
block O 0
in O 0
C2 O 0
secretion O 0
. O 0

Type B-Disease 0
I I-Disease 0
C2 I-Disease 1
deficiency I-Disease 1
was O 0
described O 0
in O 0
a O 0
family O 0
in O 0
which O 0
the O 0
C2 O 0
null O 0
allele O 0
( O 0
C2Q0 O 0
) O 0
is O 0
associated O 0
with O 0
the O 0
major O 0
histocompatibility O 0
haplotype O 0
/ O 0
complotype O 0
HLA O 0
- O 0
A25 O 0
, O 0
B18 O 0
, O 0
C2Q0 O 0
, O 0
BfS O 0
, O 0
C4A4 O 0
, O 0
C4B2 O 0
, O 0
Drw2 O 0
; O 0
this O 0
extended O 0
haplotype O 0
occurs O 0
in O 0
over O 0
90 O 0
% O 0
of O 0
C2 B-Disease 1
- I-Disease 1
deficient I-Disease 1
individuals O 0
( O 0
common O 0
complotype O 0
/ O 0
haplotype O 0
) O 0
. O 0

To O 0
determine O 0
the O 0
molecular O 0
basis O 0
of O 0
type B-Disease 0
I I-Disease 0
C2 I-Disease 1
deficiency I-Disease 1
, O 0
the O 0
C2 O 0
gene O 0
and O 0
cDNA O 0
were O 0
characterized O 0
from O 0
a O 0
homozygous O 0
type B-Disease 0
I I-Disease 0
C2 I-Disease 1
- I-Disease 1
deficient I-Disease 1
individual O 0
with O 0
the O 0
common O 0
associated O 0
haplotype O 0
/ O 0
complotype O 0
. O 0

We O 0
found O 0
a O 0
28 O 0
- O 0
base O 0
pair O 0
deletion O 0
in O 0
the O 0
type O 0
I O 0
C2Q0 O 0
gene O 0
, O 0
beginning O 0
9 O 0
base O 0
pairs O 0
upstream O 0
of O 0
the O 0
3 O 0
- O 0
end O 0
of O 0
exon O 0
6 O 0
, O 0
that O 0
generates O 0
a O 0
C2 O 0
transcript O 0
with O 0
a O 0
complete O 0
deletion O 0
of O 0
exon O 0
6 O 0
( O 0
134 O 0
base O 0
pair O 0
) O 0
and O 0
a O 0
premature O 0
termination O 0
codon O 0
. O 0

In O 0
studies O 0
of O 0
eight O 0
kindred O 0
, O 0
the O 0
28 O 0
- O 0
base O 0
pair O 0
deletion O 0
was O 0
observed O 0
in O 0
all O 0
C2Q0 O 0
alleles O 0
associated O 0
with O 0
the O 0
common O 0
type O 0
I O 0
deficient O 0
complotype O 0
/ O 0
haplotype O 0
; O 0
this O 0
deletion O 0
was O 0
not O 0
present O 0
in O 0
normal O 0
C2 O 0
nor O 0
in O 0
type B-Disease 1
II I-Disease 1
C2 I-Disease 1
- I-Disease 1
deficient I-Disease 1
genes O 0
. O 0

These O 0
data O 0
demonstrate O 0
that O 0
1 O 0
) O 0
type B-Disease 1
I I-Disease 1
human I-Disease 1
complement I-Disease 1
C2 I-Disease 1
deficiency I-Disease 1
is O 0
caused O 0
by O 0
a O 0
28 O 0
- O 0
base O 0
pair O 0
genomic O 0
deletion O 0
that O 0
causes O 0
skipping O 0
of O 0
exon O 0
6 O 0
during O 0
RNA O 0
splicing O 0
, O 0
resulting O 0
in O 0
generation O 0
of O 0
a O 0
premature O 0
termination O 0
codon O 0
, O 0
2 O 0
) O 0
the O 0
28 O 0
- O 0
base O 0
pair O 0
deletion O 0
in O 0
the O 0
type O 0
I O 0
C2Q0 O 0
gene O 0
is O 0
strongly O 0
associated O 0
with O 0
the O 0
HLA O 0
haplotype O 0
/ O 0
complotype O 0
A25 O 0
, O 0
B18 O 0
, O 0
C2Q0 O 0
, O 0
BfS O 0
, O 0
C4A4 O 0
, O 0
C4B2 O 0
, O 0
Drw2 O 0
, O 0
suggesting O 0
that O 0
all O 0
C2 B-Disease 1
- I-Disease 1
deficient I-Disease 1
individuals O 0
with O 0
this O 0
haplotype O 0
/ O 0
complotype O 0
will O 0
harbor O 0
the O 0
28 O 0
- O 0
base O 0
pair O 0
C2 O 0
gene O 0
deletion O 0
, O 0
and O 0
3 O 0
) O 0
type B-Disease 1
II I-Disease 1
C2 I-Disease 1
deficiency I-Disease 1
is O 0
caused O 0
by O 0
a O 0
different O 0
, O 0
as O 0
yet O 0
uncharacterized O 0
, O 0
molecular O 0
genetic B-Disease 1
defect I-Disease 1
. O 0
. O 0

Molecular O 0
characterization O 0
of O 0
two O 0
galactosemia B-Disease 0
mutations O 0
and O 0
one O 0
polymorphism O 0
: O 0
implications O 0
for O 0
structure O 0
- O 0
function O 0
analysis O 0
of O 0
human O 0
galactose O 0
- O 0
1 O 0
- O 0
phosphate O 0
uridyltransferase O 0
. O 0

We O 0
report O 0
here O 0
the O 0
molecular O 0
characterization O 0
of O 0
two O 0
galactosemia B-Disease 0
mutations O 0
, O 0
L74P O 0
and O 0
F171S O 0
, O 0
and O 0
one O 0
polymorphism O 0
, O 0
S135L O 0
, O 0
in O 0
human O 0
galactose O 0
- O 0
1 O 0
- O 0
phosphate O 0
uridyltransferase O 0
( O 0
GALT O 0
) O 0
. O 0

Both O 0
galactosemia B-Disease 0
mutations O 0
result O 0
in O 0
reduced O 0
enzymatic O 0
activity O 0
when O 0
reconstructed O 0
in O 0
the O 0
cDNA O 0
and O 0
overexpressed O 0
. O 0

The O 0
polymorphism O 0
, O 0
in O 0
contrast O 0
, O 0
has O 0
near O 0
normal O 0
activity O 0
. O 0

Both O 0
mutations O 0
affect O 0
evolutionarily O 0
conserved O 0
residues O 0
, O 0
suggesting O 0
that O 0
they O 0
are O 0
functionally O 0
important O 0
, O 0
while O 0
the O 0
polymorphism O 0
occurs O 0
in O 0
a O 0
nonconserved O 0
domain O 0
which O 0
is O 0
presumably O 0
not O 0
critical O 0
for O 0
enzymatic O 0
function O 0
. O 0

The O 0
F171S O 0
mutation O 0
is O 0
close O 0
to O 0
the O 0
putative O 0
active O 0
- O 0
site O 0
nucleophile O 0
. O 0

Our O 0
data O 0
further O 0
support O 0
the O 0
notion O 0
of O 0
molecular O 0
heterogeneity O 0
of O 0
galactosemia B-Disease 0
and O 0
suggest O 0
that O 0
galactosemia B-Disease 0
mutations O 0
and O 0
GALT O 0
polymorphisms O 0
may O 0
be O 0
useful O 0
tools O 0
in O 0
highlighting O 0
different O 0
functional O 0
domains O 0
in O 0
human O 0
GALT O 0
. O 0
. O 0

Linkage O 0
relationship O 0
of O 0
C2 B-Disease 1
deficiency I-Disease 1
, O 0
HLA O 0
and O 0
glyoxalase O 0
I O 0
loci O 0
. O 0

Immunogenetic O 0
analysis O 0
of O 0
a O 0
homozygous O 0
C2 B-Disease 1
- I-Disease 1
deficient I-Disease 1
individual O 0
and O 0
family O 0
members O 0
demonstrated O 0
linkage O 0
of O 0
HLA O 0
- O 0
A25 O 0
, O 0
B18 O 0
and O 0
C2o O 0
. O 0

HLA O 0
- O 0
D O 0
typing O 0
showed O 0
that O 0
5 O 0
members O 0
typed O 0
with O 0
homozygous O 0
Dw2 O 0
typing O 0
cells O 0
from O 0
an O 0
individual O 0
with O 0
C2 B-Disease 1
deficiency I-Disease 1
but O 0
not O 0
with O 0
Dw2 O 0
typing O 0
cells O 0
from O 0
2 O 0
individuals O 0
with O 0
normal O 0
C2 O 0
. O 0

The O 0
homozygous O 0
C2 B-Disease 1
- I-Disease 1
deficient I-Disease 1
propositus O 0
and O 0
brother O 0
were O 0
HLA O 0
- O 0
A O 0
and O 0
B O 0
homozygous O 0
but O 0
heterozygous O 0
at O 0
the O 0
HLA O 0
- O 0
D O 0
and O 0
glyoxalase O 0
I O 0
loci O 0
. O 0

Therefore O 0
, O 0
in O 0
this O 0
family O 0
, O 0
the O 0
C2o O 0
gene O 0
is O 0
linked O 0
with O 0
two O 0
distinct O 0
haplotypes O 0
HLA O 0
- O 0
A25 O 0
, O 0
B18 O 0
, O 0
Dw2 O 0
, O 0
GLO1 O 0
and O 0
HLA O 0
- O 0
A25 O 0
, O 0
B18 O 0
, O 0
D O 0
unknown O 0
, O 0
GL02 O 0
. O 0

These O 0
results O 0
could O 0
be O 0
explained O 0
by O 0
an O 0
ancestral O 0
recombinant O 0
event O 0
, O 0
which O 0
occurred O 0
between O 0
the O 0
C2o O 0
locus O 0
and O 0
HLA O 0
- O 0
D O 0
locus O 0
in O 0
which O 0
C2o O 0
segregated O 0
with O 0
HLA O 0
- O 0
B O 0
. O 0

This O 0
would O 0
suggest O 0
that O 0
the O 0
locus O 0
for O 0
the O 0
C2o O 0
gene O 0
maps O 0
between O 0
HLA O 0
- O 0
B O 0
and O 0
HLA O 0
- O 0
D O 0
on O 0
the O 0
sixth O 0
chromosome O 0
. O 0
. O 0

Germline O 0
mutations O 0
in O 0
the O 0
Wilms B-Disease 0
' I-Disease 0
tumor I-Disease 0
suppressor O 0
gene O 0
are O 0
associated O 0
with O 0
abnormal O 0
urogenital O 0
development O 0
in O 0
Denys B-Disease 1
- I-Disease 1
Drash I-Disease 1
syndrome I-Disease 1
. O 0

Denys B-Disease 1
- I-Disease 1
Drash I-Disease 1
syndrome I-Disease 1
is O 0
a O 0
rare O 0
human O 0
condition O 0
in O 0
which O 0
severe O 0
urogenital B-Disease 0
aberrations I-Disease 0
result O 0
in O 0
renal B-Disease 0
failure I-Disease 0
, O 0
pseudohermaphroditism B-Disease 0
, O 0
and O 0
Wilms B-Disease 1
tumor I-Disease 1
( O 0
nephroblastoma B-Disease 1
) O 0
. O 0

To O 0
investigate O 0
its O 0
possible O 0
role O 0
, O 0
we O 0
have O 0
analyzed O 0
the O 0
coding O 0
exons O 0
of O 0
the O 0
Wilms B-Disease 1
tumor I-Disease 1
suppressor O 0
gene O 0
( O 0
WT1 O 0
) O 0
for O 0
germline O 0
mutations O 0
. O 0

In O 0
ten O 0
independent O 0
cases O 0
of O 0
Denys B-Disease 1
- I-Disease 1
Drash I-Disease 1
syndrome I-Disease 1
, O 0
point O 0
mutations O 0
in O 0
the O 0
zinc O 0
finger O 0
domains O 0
of O 0
one O 0
WT1 O 0
gene O 0
copy O 0
were O 0
found O 0
. O 0

Nine O 0
of O 0
these O 0
mutations O 0
are O 0
found O 0
within O 0
exon O 0
9 O 0
( O 0
zinc O 0
finger O 0
III O 0
) O 0
; O 0
the O 0
remaining O 0
mutation O 0
is O 0
in O 0
exon O 0
8 O 0
( O 0
zinc O 0
finger O 0
II O 0
) O 0
. O 0

These O 0
mutations O 0
directly O 0
affect O 0
DNA O 0
sequence O 0
recognition O 0
. O 0

In O 0
two O 0
families O 0
analyzed O 0
, O 0
the O 0
mutations O 0
were O 0
shown O 0
to O 0
arise O 0
de O 0
novo O 0
. O 0

Wilms B-Disease 0
tumors I-Disease 0
from O 0
three O 0
individuals O 0
and O 0
one O 0
juvenile O 0
granulosa O 0
cell O 0
tumor B-Disease 0
demonstrate O 0
reduction O 0
to O 0
homozygosity O 0
for O 0
the O 0
mutated O 0
WT1 O 0
allele O 0
. O 0

Our O 0
results O 0
provide O 0
evidence O 0
of O 0
a O 0
direct O 0
role O 0
for O 0
WT1 O 0
in O 0
Denys B-Disease 1
- I-Disease 1
Drash I-Disease 1
syndrome I-Disease 1
and O 0
thus O 0
urogenital O 0
system O 0
development O 0
. O 0
. O 0

Linkage O 0
analysis O 0
in O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
and O 0
application O 0
in O 0
post O 0
- O 0
and O 0
prenatal O 0
diagnosis O 0
. O 0

We O 0
have O 0
performed O 0
linkage O 0
analysis O 0
with O 0
the O 0
DNA O 0
markers O 0
DXS52 O 0
and O 0
the O 0
clotting O 0
factor O 0
VIII O 0
gene O 0
( O 0
F8C O 0
) O 0
, O 0
in O 0
several O 0
large O 0
families O 0
with O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
( O 0
ALD B-Disease 0
) O 0
. O 0

The O 0
tight O 0
linkage O 0
to O 0
DXS52 O 0
could O 0
be O 0
extended O 0
giving O 0
a O 0
maximal O 0
LOD O 0
score O 0
of O 0
22 O 0
. O 0

5 O 0
at O 0
1 O 0
cM O 0
. O 0

F8C O 0
was O 0
also O 0
tightly O 0
linked O 0
to O 0
ALD B-Disease 0
with O 0
a O 0
maximal O 0
LOD O 0
score O 0
of O 0
7 O 0
. O 0

8 O 0
without O 0
recombination O 0
. O 0

Multipoint O 0
linkage O 0
analysis O 0
with O 0
the O 0
markers O 0
DXS304 O 0
, O 0
DXS52 O 0
, O 0
and O 0
F8C O 0
indicated O 0
that O 0
both O 0
the O 0
gene O 0
for O 0
ALD B-Disease 0
and O 0
for O 0
F8C O 0
are O 0
distal O 0
to O 0
DXS52 O 0
. O 0

In O 0
four O 0
patients O 0
with O 0
ALD B-Disease 0
, O 0
no O 0
major O 0
structural O 0
rearrangement O 0
in O 0
the O 0
Xqter O 0
region O 0
was O 0
observed O 0
; O 0
in O 0
particular O 0
, O 0
there O 0
were O 0
no O 0
abnormalities B-Disease 1
in I-Disease 1
the I-Disease 1
vision I-Disease 1
blindness I-Disease 1
genes I-Disease 1
. O 0

DNA O 0
analysis O 0
appeared O 0
to O 0
be O 0
of O 0
use O 0
in O 0
determination O 0
of O 0
the O 0
carrier O 0
status O 0
of O 0
females O 0
at O 0
risk O 0
, O 0
for O 0
the O 0
determination O 0
of O 0
the O 0
origin O 0
of O 0
the O 0
mutation O 0
in O 0
a O 0
particular O 0
family O 0
, O 0
and O 0
for O 0
prenatal O 0
diagnosis O 0
. O 0

Two O 0
distinct O 0
mutations O 0
at O 0
a O 0
single O 0
BamHI O 0
site O 0
in O 0
phenylketonuria B-Disease 0
. O 0

Classical B-Disease 1
phenylketonuria I-Disease 1
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
disease I-Disease 1
caused O 0
by O 0
a O 0
deficiency B-Disease 0
of I-Disease 0
hepatic I-Disease 0
phenylalanine I-Disease 0
hydroxylase I-Disease 0
( O 0
PAH O 0
) O 0
. O 0

The O 0
abolition O 0
of O 0
an O 0
invariant O 0
BamHI O 0
site O 0
located O 0
in O 0
the O 0
coding O 0
sequence O 0
of O 0
the O 0
PAH O 0
gene O 0
( O 0
exon O 0
7 O 0
) O 0
led O 0
to O 0
the O 0
recognition O 0
of O 0
two O 0
new O 0
point O 0
mutations O 0
at O 0
codon O 0
272 O 0
and O 0
273 O 0
( O 0
272gly O 0
- O 0
- O 0
- O 0
- O 0
stop O 0
and O 0
273ser O 0
- O 0
- O 0
- O 0
- O 0
phe O 0
, O 0
respectively O 0
) O 0
. O 0

Both O 0
mutations O 0
were O 0
detected O 0
in O 0
north O 0
eastern O 0
France O 0
or O 0
Belgium O 0
and O 0
occurred O 0
on O 0
the O 0
background O 0
of O 0
RFLP O 0
haplotype O 0
7 O 0
alleles O 0
. O 0

The O 0
present O 0
study O 0
supports O 0
the O 0
view O 0
that O 0
the O 0
clinical O 0
heterogeneity O 0
in O 0
PKU B-Disease 0
is O 0
accounted O 0
for O 0
by O 0
the O 0
large O 0
variety O 0
of O 0
mutant O 0
genotypes O 0
associated O 0
with O 0
PAH B-Disease 0
deficiencies I-Disease 0
. O 0
. O 0

A O 0
detailed O 0
multipoint O 0
map O 0
of O 0
human O 0
chromosome O 0
4 O 0
provides O 0
evidence O 0
for O 0
linkage O 0
heterogeneity O 0
and O 0
position O 0
- O 0
specific O 0
recombination O 0
rates O 0
. O 0

Utilizing O 0
the O 0
CEPH O 0
reference O 0
panel O 0
and O 0
genotypic O 0
data O 0
for O 0
53 O 0
markers O 0
, O 0
we O 0
have O 0
constructed O 0
a O 0
20 O 0
- O 0
locus O 0
multipoint O 0
genetic O 0
map O 0
of O 0
human O 0
chromosome O 0
4 O 0
. O 0

New O 0
RFLPs O 0
are O 0
reported O 0
for O 0
four O 0
loci O 0
. O 0

The O 0
map O 0
integrates O 0
a O 0
high O 0
- O 0
resolution O 0
genetic O 0
map O 0
of O 0
4p16 O 0
into O 0
a O 0
continuous O 0
map O 0
extending O 0
to O 0
4q31 O 0
and O 0
an O 0
unlinked O 0
cluster O 0
of O 0
three O 0
loci O 0
at O 0
4q35 O 0
. O 0

The O 0
20 O 0
linked O 0
markers O 0
form O 0
a O 0
continuous O 0
linkage O 0
group O 0
of O 0
152 O 0
cM O 0
in O 0
males O 0
and O 0
202 O 0
cM O 0
in O 0
females O 0
. O 0

Likely O 0
genetic O 0
locations O 0
are O 0
provided O 0
for O 0
25 O 0
polymorphic O 0
anonymous O 0
sequences O 0
and O 0
28 O 0
gene O 0
- O 0
specific O 0
RFLPs O 0
. O 0

The O 0
map O 0
was O 0
constructed O 0
employing O 0
the O 0
LINKAGE O 0
and O 0
CRIMAP O 0
computational O 0
methodologies O 0
to O 0
build O 0
the O 0
multipoint O 0
map O 0
via O 0
a O 0
stepwise O 0
algorithm O 0
. O 0

A O 0
detailed O 0
10 O 0
- O 0
point O 0
map O 0
of O 0
the O 0
4p16 O 0
region O 0
constructed O 0
from O 0
the O 0
CEPH O 0
panel O 0
provides O 0
evidence O 0
for O 0
heterogeneity O 0
in O 0
the O 0
linkage O 0
maps O 0
constructed O 0
from O 0
families O 0
segregating O 0
for O 0
Huntington B-Disease 1
disease I-Disease 1
( O 0
HD B-Disease 1
) O 0
. O 0

It O 0
additionally O 0
provides O 0
evidence O 0
for O 0
position O 0
- O 0
specific O 0
recombination O 0
frequencies O 0
in O 0
the O 0
telomeric O 0
region O 0
of O 0
4p O 0
. O 0
. O 0

Carrier O 0
detection O 0
and O 0
prenatal O 0
diagnosis O 0
of O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
using O 0
a O 0
combination O 0
of O 0
anonymous O 0
DNA O 0
polymorphisms O 0
and O 0
the O 0
proteolipid O 0
protein O 0
( O 0
PLP O 0
) O 0
gene O 0
cDNA O 0
. O 0

We O 0
report O 0
carrier O 0
identification O 0
and O 0
a O 0
prenatal O 0
diagnosis O 0
using O 0
DNA O 0
polymorphisms O 0
in O 0
2 O 0
families O 0
with O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
Pelizaeus I-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
( O 0
PMD B-Disease 1
) O 0
. O 0

In O 0
both O 0
families O 0
, O 0
the O 0
proteolipid O 0
protein O 0
( O 0
PLP O 0
) O 0
gene O 0
in O 0
the O 0
single O 0
affected O 0
male O 0
could O 0
be O 0
traced O 0
back O 0
to O 0
his O 0
unaffected O 0
maternal O 0
grandfather O 0
. O 0

Therefore O 0
, O 0
each O 0
family O 0
contains O 0
a O 0
new O 0
mutation O 0
. O 0

In O 0
the O 0
case O 0
of O 0
the O 0
prenatal O 0
diagnosis O 0
, O 0
the O 0
fetus O 0
was O 0
shown O 0
by O 0
cytogenetic O 0
analysis O 0
to O 0
be O 0
a O 0
female O 0
, O 0
who O 0
we O 0
predict O 0
will O 0
be O 0
a O 0
noncarrier O 0
of O 0
PMD B-Disease 1
based O 0
on O 0
her O 0
genotype O 0
with O 0
the O 0
PLP O 0
intragenic O 0
polymorphism O 0
. O 0
. O 0

Identification O 0
of O 0
deletion O 0
mutations O 0
and O 0
three O 0
new O 0
genes O 0
at O 0
the O 0
familial B-Disease 0
polyposis I-Disease 1
locus O 0
. O 0

Small O 0
( O 0
100 O 0
- O 0
260 O 0
kb O 0
) O 0
, O 0
nested O 0
deletions O 0
were O 0
characterized O 0
in O 0
DNA O 0
from O 0
two O 0
unrelated O 0
patients O 0
with O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
coli I-Disease 1
( O 0
APC B-Disease 1
) O 0
. O 0

Three O 0
candidate O 0
genes O 0
located O 0
within O 0
the O 0
deleted O 0
region O 0
were O 0
ascertained O 0
and O 0
a O 0
previous O 0
candidate O 0
gene O 0
, O 0
MCC O 0
, O 0
was O 0
shown O 0
to O 0
be O 0
located O 0
outside O 0
the O 0
deleted O 0
region O 0
. O 0

One O 0
of O 0
the O 0
new O 0
genes O 0
contained O 0
sequence O 0
identical O 0
to O 0
SRP19 O 0
, O 0
the O 0
gene O 0
coding O 0
for O 0
the O 0
19 O 0
kd O 0
component O 0
of O 0
the O 0
ribosomal O 0
signal O 0
recognition O 0
particle O 0
. O 0

The O 0
second O 0
, O 0
provisionally O 0
designated O 0
DP1 O 0
( O 0
deleted O 0
in O 0
polyposis O 1
1 O 0
) O 0
, O 0
was O 0
found O 0
to O 0
be O 0
transcribed O 0
in O 0
the O 0
same O 0
orientation O 0
as O 0
MCC O 0
. O 0

Two O 0
other O 0
cDNAs O 0
, O 0
DP2 O 0
and O 0
DP3 O 0
, O 0
were O 0
found O 0
to O 0
overlap O 0
, O 0
forming O 0
a O 0
single O 0
gene O 0
, O 0
DP2 O 0
. O 0

5 O 0
, O 0
that O 0
is O 0
transcribed O 0
in O 0
the O 0
same O 0
orientation O 0
as O 0
SRP19 O 0
. O 0

Exclusion O 0
of O 0
linkage O 0
between O 0
familial B-Disease 0
Mediterranean I-Disease 0
fever I-Disease 0
and O 0
the O 0
human O 0
serum O 0
amyloid O 0
A O 0
( O 0
SAA O 0
) O 0
gene O 0
cluster O 0
. O 0

We O 0
studied O 0
the O 0
relationship O 0
between O 0
the O 0
autosomal O 0
recessive O 0
trait O 0
familial B-Disease 0
Mediterranean I-Disease 0
fever I-Disease 0
( O 0
FMF B-Disease 0
) O 0
and O 0
the O 0
serum O 0
amyloid O 0
A O 0
( O 0
SAA O 0
) O 0
genes O 0
by O 0
comparing O 0
alleles O 0
of O 0
a O 0
highly O 0
polymorphic O 0
dinucleotide O 0
repeat O 0
and O 0
a O 0
conventional O 0
restriction O 0
fragment O 0
length O 0
polymorphism O 0
( O 0
RFLP O 0
) O 0
in O 0
the O 0
SAA O 0
gene O 0
cluster O 0
in O 0
Israeli O 0
FMF B-Disease 0
kindreds O 0
. O 0

By O 0
haplotype O 0
analysis O 0
, O 0
our O 0
data O 0
indicate O 0
a O 0
minimum O 0
crossover O 0
frequency O 0
of O 0
22 O 0
% O 0
between O 0
the O 0
SAA O 0
gene O 0
marker O 0
and O 0
FMF B-Disease 0
. O 0

By O 0
conventional O 0
linkage O 0
analysis O 0
this O 0
eliminates O 0
a O 0
minimum O 0
of O 0
10 O 0
. O 0

4 O 0
cM O 0
including O 0
and O 0
surrounding O 0
the O 0
SAA O 0
gene O 0
cluster O 0
as O 0
the O 0
site O 0
of O 0
the O 0
FMF B-Disease 0
mutation O 0
although O 0
SAA O 0
proteins O 0
are O 0
prominent O 0
physiologic O 0
markers O 0
of O 0
the O 0
acute O 0
attacks O 0
. O 0

PRAD1 O 0
, O 0
a O 0
candidate O 0
BCL1 O 0
oncogene O 0
: O 0
mapping O 0
and O 0
expression O 0
in O 0
centrocytic B-Disease 1
lymphoma I-Disease 1
. O 0

Rearrangement O 0
of O 0
the O 0
BCL1 O 0
( O 0
B O 0
- O 0
cell O 0
lymphoma O 1
1 O 0
) O 0
region O 0
on O 0
chromosome O 0
11q13 O 0
appears O 0
to O 0
be O 0
highly O 0
characteristic O 0
of O 0
centrocytic B-Disease 1
lymphoma I-Disease 1
and O 0
also O 0
is O 0
found O 0
infrequently O 0
in O 0
other O 0
B B-Disease 0
- I-Disease 0
cell I-Disease 0
neoplasms I-Disease 1
. O 0

Rearrangement O 0
is O 0
thought O 0
to O 0
deregulate O 0
a O 0
nearby O 0
protooncogene O 0
, O 0
but O 0
transcribed O 0
sequences O 0
in O 0
the O 0
immediate O 0
vicinity O 0
of O 0
BCL1 O 0
breakpoints O 0
had O 0
not O 0
been O 0
identified O 0
. O 0

PRAD1 O 0
, O 0
previously O 0
designated O 0
D11S287E O 0
, O 0
was O 0
identified O 0
on O 0
11q13 O 0
as O 0
a O 0
chromosomal O 0
breakpoint O 0
region O 0
rearranged O 0
with O 0
the O 0
parathyroid O 0
hormone O 0
gene O 0
in O 0
a O 0
subset O 0
of O 0
parathyroid B-Disease 0
adenomas I-Disease 0
; O 0
this O 0
highly O 0
conserved O 0
putative O 0
oncogene O 0
, O 0
which O 0
encodes O 0
a O 0
novel O 0
cyclin O 0
, O 0
has O 0
been O 0
linked O 0
to O 0
BCL1 O 0
and O 0
implicated O 0
also O 0
in O 0
subsets O 0
of O 0
breast B-Disease 1
and I-Disease 1
squamous I-Disease 1
cell I-Disease 1
neoplasms I-Disease 1
with O 0
11q13 O 0
amplification O 0
. O 0

We O 0
report O 0
pulsed O 0
- O 0
field O 0
gel O 0
electrophoresis O 0
data O 0
showing O 0
BCL1 O 0
and O 0
PRAD1 O 0
to O 0
be O 0
no O 0
more O 0
than O 0
130 O 0
kilobases O 0
apart O 0
. O 0

PRAD1 O 0
mRNA O 0
is O 0
abundantly O 0
expressed O 0
in O 0
seven O 0
of O 0
seven O 0
centrocytic B-Disease 0
lymphomas I-Disease 0
( O 0
Kiel O 0
classification O 0
) O 0
, O 0
in O 0
contrast O 0
to O 0
13 O 0
closely O 0
related O 0
but O 0
noncentrocytic B-Disease 1
lymphomas I-Disease 1
. O 0

Three O 0
of O 0
the O 0
seven O 0
centrocytic B-Disease 0
lymphomas I-Disease 0
had O 0
detectable O 0
BCL1 O 0
DNA O 0
rearrangement O 0
. O 0

Also O 0
, O 0
two O 0
unusual O 0
cases O 0
of O 0
CLL O 0
with O 0
BCL1 O 0
rearrangement O 0
overexpressed O 0
PRAD1 O 0
, O 0
in O 0
contrast O 0
to O 0
five O 0
CLL O 0
controls O 0
. O 0

Thus O 0
, O 0
PRAD1 O 0
is O 0
an O 0
excellent O 0
candidate O 0
" O 0
BCL1 O 0
oncogene O 0
. O 0

" O 0
Its O 0
overexpression O 0
may O 0
be O 0
a O 0
key O 0
consequence O 0
of O 0
rearrangement O 0
of O 0
the O 0
BCL1 O 0
vicinity O 0
in O 0
B B-Disease 0
- I-Disease 0
cell I-Disease 0
neoplasms I-Disease 1
and O 0
a O 0
unifying O 0
pathogenetic O 0
feature O 0
in O 0
centrocytic B-Disease 1
lymphoma I-Disease 1
. O 0

Two O 0
new O 0
arylsulfatase O 0
A O 0
( O 0
ARSA O 0
) O 0
mutations O 0
in O 0
a O 0
juvenile O 0
metachromatic B-Disease 1
leukodystrophy I-Disease 1
( O 0
MLD B-Disease 0
) O 0
patient O 0
. O 0

Fragments O 0
of O 0
the O 0
arylsulfatase O 0
A O 0
( O 0
ARSA O 0
) O 0
gene O 0
from O 0
a O 0
patient O 0
with O 0
juvenile O 0
- O 0
onset O 0
metachromatic B-Disease 1
leukodystrophy I-Disease 1
( O 0
MLD B-Disease 0
) O 0
were O 0
amplified O 0
by O 0
PCR O 0
and O 0
ligated O 0
into O 0
MP13 O 0
cloning O 0
vectors O 0
. O 0

Clones O 0
hybridizing O 0
with O 0
cDNA O 0
for O 0
human O 0
ARSA O 0
were O 0
selected O 0
, O 0
examined O 0
for O 0
appropriate O 0
size O 0
inserts O 0
, O 0
and O 0
used O 0
to O 0
prepare O 0
single O 0
- O 0
stranded O 0
phage O 0
DNA O 0
. O 0

Examination O 0
of O 0
the O 0
entire O 0
coding O 0
and O 0
most O 0
of O 0
the O 0
intronic O 0
sequence O 0
revealed O 0
two O 0
putative O 0
disease O 0
- O 0
related O 0
mutations O 0
. O 0

One O 0
, O 0
a O 0
point O 0
mutation O 0
in O 0
exon O 0
3 O 0
, O 0
resulted O 0
in O 0
the O 0
substitution O 0
of O 0
isoleucine O 0
by O 0
serine O 0
. O 0

Introduction O 0
of O 0
this O 0
alteration O 0
into O 0
the O 0
normal O 0
ARSA O 0
cDNA O 0
sequence O 0
resulted O 0
in O 0
a O 0
substantial O 0
decrease O 0
in O 0
ARSA O 0
activity O 0
on O 0
transient O 0
expression O 0
in O 0
cultured O 0
baby O 0
hamster O 0
kidney O 0
cells O 0
. O 0

About O 0
5 O 0
% O 0
of O 0
the O 0
control O 0
expression O 0
was O 0
observed O 0
, O 0
suggesting O 0
a O 0
small O 0
residual O 0
activity O 0
in O 0
the O 0
mutated O 0
ARSA O 0
. O 0

The O 0
second O 0
mutation O 0
, O 0
a O 0
G O 0
- O 0
to O 0
- O 0
A O 0
transition O 0
, O 0
occurred O 0
in O 0
the O 0
other O 0
allele O 0
and O 0
resulted O 0
in O 0
an O 0
altered O 0
splice O 0
- O 0
recognition O 0
sequence O 0
between O 0
exon O 0
7 O 0
and O 0
the O 0
following O 0
intron O 0
. O 0

The O 0
mutation O 0
also O 0
resulted O 0
in O 0
the O 0
loss O 0
of O 0
a O 0
restriction O 0
site O 0
. O 0

Apparently O 0
normal O 0
levels O 0
of O 0
mRNA O 0
were O 0
generated O 0
from O 0
this O 0
allele O 0
, O 0
but O 0
no O 0
ARSA O 0
activity O 0
or O 0
immuno O 0
- O 0
cross O 0
- O 0
reactive O 0
material O 0
could O 0
be O 0
detected O 0
. O 0

A O 0
collection O 0
of O 0
DNA O 0
samples O 0
from O 0
known O 0
or O 0
suspected O 0
MLD B-Disease 0
patients O 0
, O 0
members O 0
of O 0
their O 0
families O 0
, O 0
and O 0
normal O 0
controls O 0
was O 0
screened O 0
for O 0
these O 0
mutations O 0
. O 0

Four O 0
additional O 0
individuals O 0
carrying O 0
each O 0
of O 0
the O 0
mutations O 0
were O 0
found O 0
among O 0
the O 0
nearly O 0
100 O 0
MLD B-Disease 0
patients O 0
in O 0
the O 0
sample O 0
. O 0

Gene O 0
segregation O 0
in O 0
the O 0
original O 0
patients O 0
family O 0
was O 0
consistent O 0
with O 0
available O 0
clinical O 0
and O 0
biochemical O 0
data O 0
. O 0

No O 0
individuals O 0
homozygous O 0
for O 0
either O 0
of O 0
these O 0
two O 0
mutations O 0
were O 0
identified O 0
. O 0

However O 0
, O 0
combinations O 0
with O 0
other O 0
MLD B-Disease 0
mutations O 0
suggest O 0
that O 0
the O 0
point O 0
mutation O 0
in O 0
exon O 0
3 O 0
does O 0
result O 0
in O 0
some O 0
residual O 0
enzyme O 0
activity O 0
and O 0
is O 0
associated O 0
with O 0
late O 0
- O 0
onset O 0
forms O 0
of O 0
the O 0
disease O 0
. O 0

The O 0
splice O 0
- O 0
site O 0
mutation O 0
following O 0
exon O 0
7 O 0
produces O 0
late O 0
- O 0
infantile O 0
MLD B-Disease 0
when O 0
combined O 0
with O 0
other O 0
enzyme O 0
- O 0
null O 0
mutations O 0
, O 0
implying O 0
that O 0
it O 0
is O 0
completely O 0
silent O 0
enzymatically O 0
. O 0
. O 0

Analysis O 0
of O 0
X O 0
- O 0
chromosome O 0
inactivation O 0
and O 0
presumptive O 0
expression O 0
of O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
( O 0
WAS B-Disease 0
) O 0
gene O 0
in O 0
hematopoietic O 0
cell O 0
lineages O 0
of O 0
a O 0
thrombocytopenic O 0
carrier O 0
female O 0
of O 0
WAS B-Disease 0
. O 0

We O 0
report O 0
on O 0
a O 0
thrombocytopenic B-Disease 0
female O 0
belonging O 0
to O 0
a O 0
pedigree O 0
with O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
( O 0
WAS B-Disease 0
) O 0
. O 0

Restriction O 0
fragment O 0
length O 0
polymorphism O 0
( O 0
RFLP O 0
) O 0
analysis O 0
with O 0
probe O 0
M27 O 0
beta O 0
, O 0
closely O 0
linked O 0
to O 0
the O 0
WAS B-Disease 0
gene O 0
, O 0
demonstrated O 0
that O 0
she O 0
is O 0
a O 0
carrier O 0
of O 0
WAS B-Disease 0
. O 0

Both O 0
small O 0
- O 0
sized O 0
and O 0
normal O 0
- O 0
sized O 0
platelets O 0
were O 0
present O 0
, O 0
suggesting O 0
that O 0
, O 0
unlike O 0
the O 0
vast O 0
majority O 0
of O 0
WAS B-Disease 0
carriers O 0
, O 0
she O 0
does O 0
not O 0
manifest O 0
nonrandom O 0
X O 0
- O 0
chromosome O 0
inactivation O 0
in O 0
the O 0
thrombopoietic O 0
cell O 0
lineage O 0
. O 0

Study O 0
of O 0
X O 0
- O 0
chromosome O 0
inactivation O 0
by O 0
means O 0
of O 0
RFLP O 0
and O 0
methylation O 0
analysis O 0
demonstrated O 0
that O 0
the O 0
pattern O 0
of O 0
X O 0
- O 0
chromosome O 0
inactivation O 0
was O 0
nonrandom O 0
in O 0
T O 0
lymphocytes O 0
, O 0
but O 0
random O 0
in O 0
granulocytes O 0
. O 0

While O 0
this O 0
is O 0
the O 0
first O 0
complete O 0
report O 0
on O 0
the O 0
occurrence O 0
of O 0
thrombocytopenia B-Disease 0
in O 0
a O 0
carrier O 0
female O 0
of O 0
WAS B-Disease 0
as O 0
the O 0
result O 0
of O 0
atypical O 0
lyonization O 0
, O 0
it O 0
also O 0
suggests O 0
that O 0
expression O 0
of O 0
the O 0
WAS B-Disease 0
gene O 0
occurs O 0
at O 0
( O 0
or O 0
extends O 0
up O 0
to O 0
) O 0
a O 0
later O 0
stage O 0
than O 0
the O 0
multipotent O 0
stem O 0
cell O 0
along O 0
the O 0
hematopoietic O 0
differentiation O 0
pathway O 0
. O 0
. O 0

A O 0
new O 0
mutation O 0
in O 0
the O 0
proteolipid O 0
protein O 0
( O 0
PLP O 0
) O 0
gene O 0
in O 0
a O 0
German O 0
family O 0
with O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
. O 0

A O 0
C O 0
- O 0
to O 0
- O 0
T O 0
transition O 0
in O 0
exon O 0
4 O 0
of O 0
the O 0
PLP O 0
gene O 0
was O 0
found O 0
in O 0
2 O 0
affected O 0
males O 0
and O 0
two O 0
obligate O 0
carriers O 0
in O 0
a O 0
German O 0
family O 0
with O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
. O 0

The O 0
mutation O 0
, O 0
which O 0
causes O 0
loss O 0
of O 0
an O 0
HphI O 0
site O 0
and O 0
changes O 0
amino O 0
acid O 0
155 O 0
from O 0
threonine O 0
to O 0
isoleucine O 0
, O 0
was O 0
absent O 0
from O 0
108 O 0
normal O 0
chromosomes O 0
. O 0

There O 0
are O 0
5 O 0
concordances O 0
and O 0
1 O 0
discrepancy O 0
between O 0
these O 0
results O 0
and O 0
those O 0
obtained O 0
by O 0
magnetic O 0
resonance O 0
imaging O 0
in O 0
this O 0
family O 0
. O 0
. O 0

A O 0
3 O 0
- O 0
base O 0
pair O 0
in O 0
- O 0
frame O 0
deletion O 0
of O 0
the O 0
phenylalanine O 0
hydroxylase O 0
gene O 0
results O 0
in O 0
a O 0
kinetic O 0
variant O 0
of O 0
phenylketonuria B-Disease 0
. O 0

Phenylketonuria B-Disease 0
( O 0
PKU B-Disease 0
) O 0
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
disease I-Disease 1
due O 0
to O 0
deficiency B-Disease 0
of I-Disease 0
a I-Disease 0
hepatic I-Disease 0
enzyme I-Disease 0
, I-Disease 0
phenylalanine I-Disease 0
hydroxylase I-Disease 0
( O 0
PAH O 0
) O 0
. O 0

The O 0
absence O 0
of O 0
PAH O 0
activity O 0
results O 0
in O 0
typical O 0
PKU B-Disease 0
while O 0
persistence O 0
of O 0
a O 0
residual O 0
enzyme O 0
activity O 0
gives O 0
rise O 0
to O 0
variant O 0
forms O 0
of O 0
the O 0
disease O 0
. O 0

We O 0
report O 0
here O 0
a O 0
3 O 0
- O 0
base O 0
pair O 0
in O 0
- O 0
frame O 0
deletion O 0
of O 0
the O 0
PAH O 0
gene O 0
( O 0
delta O 0
194 O 0
) O 0
in O 0
a O 0
mild O 0
variant O 0
, O 0
with O 0
markedly O 0
reduced O 0
affinity O 0
of O 0
the O 0
enzyme O 0
for O 0
phenylalanine O 0
( O 0
Km O 0
= O 0
160 O 0
nM O 0
) O 0
, O 0
and O 0
we O 0
provide O 0
functional O 0
evidence O 0
for O 0
responsibility O 0
of O 0
the O 0
deletion O 0
in O 0
the O 0
mutant O 0
phenotype O 0
. O 0

Since O 0
the O 0
deletion O 0
was O 0
located O 0
in O 0
the O 0
third O 0
exon O 0
of O 0
the O 0
gene O 0
, O 0
which O 0
presents O 0
no O 0
homology O 0
with O 0
other O 0
hydroxylases O 0
, O 0
we O 0
suggest O 0
that O 0
exon O 0
3 O 0
is O 0
involved O 0
in O 0
the O 0
specificity O 0
of O 0
the O 0
enzyme O 0
for O 0
phenylalanine O 0
. O 0

Finally O 0
, O 0
since O 0
none O 0
of O 0
the O 0
98 O 0
PKU B-Disease 0
patients O 0
tested O 0
were O 0
found O 0
to O 0
carry O 0
this O 0
particular O 0
deletion O 0
, O 0
our O 0
study O 0
suggests O 0
that O 0
this O 0
molecular O 0
event O 0
probably O 0
occurred O 0
recently O 0
on O 0
the O 0
background O 0
of O 0
a O 0
haplotype O 0
2 O 0
gene O 0
in O 0
Portugal O 0
. O 0
. O 0

Mutation O 0
of O 0
the O 0
KIT O 0
( O 0
mast O 0
/ O 0
stem O 0
cell O 0
growth O 0
factor O 0
receptor O 0
) O 0
protooncogene O 0
in O 0
human O 0
piebaldism B-Disease 1
. O 0

Piebaldism B-Disease 1
is O 0
an O 0
autosomal B-Disease 0
dominant I-Disease 0
genetic I-Disease 0
disorder I-Disease 0
characterized O 0
by O 0
cogenital O 0
patches O 0
of O 0
skin O 0
and O 0
hair O 0
from O 0
which O 0
melanocytes O 0
are O 0
completely O 0
absent O 0
. O 0

A O 0
similar O 0
disorder O 0
of O 0
mouse O 0
, O 0
dominant O 0
white O 0
spotting O 0
( O 0
W O 0
) O 0
, O 0
results O 0
from O 0
mutations O 0
of O 0
the O 0
c O 0
- O 0
Kit O 0
protooncogene O 0
, O 0
which O 0
encodes O 0
and O 0
receptor O 0
for O 0
mast O 0
/ O 0
stem O 0
cell O 0
growth O 0
factor O 0
. O 0

We O 0
identified O 0
a O 0
KIT O 0
gene O 0
mutation O 0
in O 0
a O 0
proband O 0
with O 0
classic O 0
autosomal O 0
dominant O 0
piebaldism B-Disease 1
. O 0

This O 0
mutation O 0
results O 0
in O 0
a O 0
Gly O 0
- O 0
- O 0
- O 0
- O 0
Arg O 0
substitution O 0
at O 0
codon O 0
664 O 0
, O 0
within O 0
the O 0
tyrosine O 0
kinase O 0
domain O 0
. O 0

This O 0
substitution O 0
was O 0
not O 0
seen O 0
in O 0
any O 0
normal O 0
individuals O 0
and O 0
was O 0
completely O 0
linked O 0
to O 0
the O 0
piebald B-Disease 1
phenotype O 0
in O 0
the O 0
probands O 0
family O 0
. O 0

Piebaldism B-Disease 1
in O 0
this O 0
family O 0
thus O 0
appears O 0
to O 0
be O 0
the O 0
human O 0
homologue O 0
to O 0
dominant O 0
white O 0
spotting O 0
( O 0
W O 0
) O 0
of O 0
the O 0
mouse O 0
. O 0
. O 0

Genetic O 0
analysis O 0
of O 0
a O 0
Japanese O 0
family O 0
with O 0
normotriglyceridemic B-Disease 1
abetalipoproteinemia I-Disease 1
indicates O 0
a O 0
lack O 0
of O 0
linkage O 0
to O 0
the O 0
apolipoprotein O 0
B O 0
gene O 0
. O 0

Normotriglyceridemic B-Disease 0
abetalipoproteinemia I-Disease 0
is O 0
a O 0
rare O 0
familial B-Disease 1
disorder I-Disease 1
characterized O 0
by O 0
an O 0
isolated O 0
deficiency B-Disease 1
of I-Disease 1
apoB I-Disease 1
- I-Disease 1
100 I-Disease 1
. O 0

We O 0
have O 0
previously O 0
reported O 0
a O 0
patient O 0
with O 0
this O 0
disease O 0
, O 0
who O 0
had O 0
normal O 0
apoB O 0
- O 0
48 O 0
but O 0
no O 0
apoB O 0
- O 0
100 O 0
. O 0

To O 0
elucidate O 0
the O 0
genetic B-Disease 0
abnormalities I-Disease 0
in O 0
this O 0
family O 0
, O 0
we O 0
studied O 0
the O 0
linkage O 0
of O 0
apoB O 0
gene O 0
using O 0
three O 0
genetic O 0
markers O 0
. O 0

The O 0
proband O 0
and O 0
her O 0
affected O 0
brother O 0
showed O 0
completely O 0
different O 0
apoB O 0
gene O 0
alleles O 0
, O 0
suggesting O 0
that O 0
the O 0
apoB O 0
gene O 0
itself O 0
is O 0
not O 0
related O 0
to O 0
this O 0
disorder O 0
in O 0
this O 0
family O 0
. O 0

By O 0
contrast O 0
, O 0
an O 0
American O 0
case O 0
had O 0
a O 0
point O 0
substitution O 0
in O 0
the O 0
apoB O 0
gene O 0
generating O 0
an O 0
in O 0
- O 0
frame O 0
stop O 0
codon O 0
. O 0

These O 0
results O 0
indicate O 0
that O 0
this O 0
disorder O 0
can O 0
be O 0
caused O 0
by O 0
defect O 0
( O 0
s O 0
) O 0
of O 0
either O 0
an O 0
apoB O 0
gene O 0
or O 0
other O 0
genes O 0
. O 0
. O 0

Localisation O 0
of O 0
the O 0
gene O 0
for O 0
Norrie B-Disease 1
disease I-Disease 1
to O 0
between O 0
DXS7 O 0
and O 0
DXS426 O 0
on O 0
Xp O 0
. O 0

A O 0
highly O 0
informative O 0
microsatellite O 0
marker O 0
, O 0
DXS426 O 0
, O 0
which O 0
maps O 0
proximal O 0
to O 0
DXS7 O 0
in O 0
the O 0
interval O 0
Xp11 O 0
. O 0

4 O 0
- O 0
Xp11 O 0
4 O 0
- O 0
Xp11 O 0
. O 0

23 O 0
, O 0
has O 0
been O 0
used O 0
to O 0
refine O 0
further O 0
the O 0
localisation O 0
of O 0
the O 0
gene O 0
for O 0
Norrie B-Disease 1
disease I-Disease 1
( O 0
NDP B-Disease 0
) O 0
. O 0

The O 0
results O 0
from O 0
a O 0
multiply O 0
informative O 0
crossover O 0
localize O 0
the O 0
NDP B-Disease 0
gene O 0
proximal O 0
to O 0
DXS7 O 0
. O 0

In O 0
conjunction O 0
with O 0
information O 0
from O 0
2 O 0
NDP B-Disease 0
patients O 0
who O 0
have O 0
a O 0
deletion O 0
for O 0
DXS7 O 0
but O 0
not O 0
for O 0
DSX426 O 0
, O 0
our O 0
data O 0
indicate O 0
that O 0
the O 0
NDP B-Disease 0
gene O 0
lies O 0
between O 0
DXS7 O 0
and O 0
DXS426 O 0
on O 0
proximal O 0
Xp O 0
. O 0

Aberrant O 0
splicing O 0
of O 0
phenylalanine O 0
hydroxylase O 0
mRNA O 0
: O 0
the O 0
major O 0
cause O 0
for O 0
phenylketonuria B-Disease 0
in O 0
parts O 0
of O 0
southern O 0
Europe O 0
. O 0

We O 0
report O 0
a O 0
mutation O 0
within O 0
the O 0
phenylalanine O 0
hydroxylase O 0
( O 0
PAH O 0
) O 0
gene O 0
that O 0
causes O 0
aberrant O 0
splicing O 0
of O 0
the O 0
mRNA O 0
and O 0
that O 0
is O 0
in O 0
tight O 0
association O 0
with O 0
chromosomal O 0
haplotypes O 0
6 O 0
, O 0
10 O 0
, O 0
and O 0
36 O 0
. O 0

Because O 0
of O 0
the O 0
high O 0
frequency O 0
of O 0
these O 0
particular O 0
haplotypes O 0
in O 0
Bulgaria O 0
, O 0
Italy O 0
, O 0
and O 0
Turkey O 0
, O 0
it O 0
appears O 0
to O 0
be O 0
one O 0
of O 0
the O 0
more O 0
frequent O 0
defects O 0
in O 0
the O 0
PAH O 0
gene O 0
causing O 0
classical O 0
phenylketonuria B-Disease 0
in O 0
this O 0
part O 0
of O 0
Europe O 0
. O 0

The O 0
mutation O 0
is O 0
a O 0
G O 0
to O 0
A O 0
transition O 0
at O 0
position O 0
546 O 0
in O 0
intron O 0
10 O 0
of O 0
the O 0
PAH O 0
gene O 0
, O 0
11 O 0
bp O 0
upstream O 0
from O 0
the O 0
intron O 0
10 O 0
/ O 0
exon O 0
11 O 0
boundary O 0
. O 0

It O 0
activates O 0
a O 0
cryptic O 0
splice O 0
site O 0
and O 0
results O 0
in O 0
an O 0
in O 0
- O 0
frame O 0
insertion O 0
of O 0
9 O 0
nucleotides O 0
between O 0
exon O 0
10 O 0
and O 0
exon O 0
11 O 0
of O 0
the O 0
processed O 0
mRNA O 0
. O 0

Normal O 0
amounts O 0
of O 0
liver O 0
PAH O 0
protein O 0
are O 0
present O 0
in O 0
homozygous O 0
patients O 0
, O 0
but O 0
no O 0
catalytic O 0
activity O 0
can O 0
be O 0
detected O 0
. O 0

This O 0
loss O 0
of O 0
enzyme O 0
activity O 0
is O 0
probably O 0
caused O 0
by O 0
conformational O 0
changes O 0
resulting O 0
from O 0
the O 0
insertion O 0
of O 0
three O 0
additional O 0
amino O 0
acids O 0
( O 0
Gly O 0
- O 0
Leu O 0
- O 0
Gln O 0
) O 0
between O 0
the O 0
normal O 0
sequences O 0
encoded O 0
by O 0
exon O 0
10 O 0
and O 0
exon O 0
11 O 0
. O 0
. O 0

Gardner B-Disease 0
syndrome I-Disease 0
in O 0
a O 0
boy O 0
with O 0
interstitial O 0
deletion O 0
of O 0
the O 0
long O 0
arm O 0
of O 0
chromosome O 0
5 O 0
. O 0

We O 0
described O 0
a O 0
15 O 0
- O 0
year O 0
- O 0
old O 0
boy O 0
with O 0
Gardner B-Disease 0
syndrome I-Disease 0
( O 0
GS B-Disease 1
) O 0
, O 0
mental B-Disease 1
retardation I-Disease 1
, O 0
and O 0
craniofacial B-Disease 1
abnormalities I-Disease 1
. O 0

High O 0
- O 0
resolution O 0
banding O 0
analysis O 0
showed O 0
an O 0
interstitial O 0
deletion O 0
of O 0
the O 0
long O 0
arm O 0
of O 0
chromosome O 0
5 O 0
( O 0
q22 O 0
. O 0
1 O 0
- O 0
- O 0
- O 0
- O 0
q31 O 0
1 O 0
- O 0
- O 0
- O 0
- O 0
q31 O 0
. O 0
1 O 0
) O 0
. O 0

The O 0
breakpoints O 0
in O 0
the O 0
present O 0
case O 0
and O 0
in O 0
3 O 0
previously O 0
reported O 0
5q O 0
- O 0
patients O 0
with O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
suggest O 0
that O 0
the O 0
gene O 0
responsible O 0
for O 0
GS B-Disease 1
/ O 0
or O 0
familial B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( O 0
FPC B-Disease 0
) O 0
is O 0
in O 0
the O 0
5q22 O 0
region O 0
, O 0
a O 0
result O 0
consistent O 0
with O 0
the O 0
findings O 0
of O 0
linkage O 0
studies O 0

Huntington B-Disease 1
disease I-Disease 1
and O 0
childhood O 0
- O 0
onset O 0
Tourette B-Disease 0
syndrome I-Disease 0
. O 0

A O 0
40 O 0
- O 0
year O 0
- O 0
old O 0
man O 0
with O 0
childhood O 0
- O 0
onset O 0
Tourette B-Disease 0
syndrome I-Disease 0
( O 0
TS B-Disease 1
) O 0
developed O 0
Huntington B-Disease 1
disease I-Disease 1
( O 0
HD B-Disease 1
) O 0
. O 0

We O 0
believe O 0
this O 0
to O 0
be O 0
the O 0
first O 0
reported O 0
case O 0
of O 0
childhood O 0
- O 0
onset O 0
TS B-Disease 1
with O 0
adult O 0
onset O 0
HD B-Disease 1
. O 0

Discovery O 0
of O 0
other O 0
cases O 0
with O 0
both O 0
disorders O 0
may O 0
provide O 0
clues O 0
to O 0
the O 0
pathophysiology O 0
of O 0
both O 0
conditions O 0
. O 0
. O 0

Sequence O 0
of O 0
DNA O 0
flanking O 0
the O 0
exons O 0
of O 0
the O 0
HEXA O 0
gene O 0
, O 0
and O 0
identification O 0
of O 0
mutations O 0
in O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
. O 0

The O 0
rapid O 0
identification O 0
of O 0
mutations O 0
causing O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
requires O 0
the O 0
capacity O 0
to O 0
readily O 0
screen O 0
the O 0
regions O 0
of O 0
the O 0
HEXA O 0
gene O 0
most O 0
likely O 0
to O 0
be O 0
affected O 0
by O 0
mutation O 0
. O 0

We O 0
have O 0
sequenced O 0
the O 0
portions O 0
of O 0
the O 0
introns O 0
flanking O 0
each O 0
of O 0
the O 0
14 O 0
HEXA O 0
exons O 0
in O 0
order O 0
to O 0
specify O 0
oligonucleotide O 0
primers O 0
for O 0
the O 0
PCR O 0
- O 0
dependent O 0
amplification O 0
of O 0
each O 0
exon O 0
and O 0
splice O 0
- O 0
junction O 0
sequence O 0
. O 0

The O 0
amplified O 0
products O 0
were O 0
analyzed O 0
, O 0
by O 0
electrophoresis O 0
in O 0
nondenaturing O 0
polyacrylamide O 0
gels O 0
, O 0
for O 0
the O 0
presence O 0
of O 0
either O 0
heteroduplexes O 0
, O 0
derived O 0
from O 0
the O 0
annealing O 0
of O 0
normal O 0
and O 0
mutant O 0
DNA O 0
strands O 0
, O 0
or O 0
single O 0
- O 0
strand O 0
conformational O 0
polymorphisms O 0
( O 0
SSCP O 0
) O 0
, O 0
derived O 0
from O 0
the O 0
renaturation O 0
of O 0
single O 0
- O 0
stranded O 0
DNA O 0
. O 0

Five O 0
novel O 0
mutations O 0
from O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
patients O 0
were O 0
detected O 0
a O 0
5 O 0
- O 0
bp O 0
deletion O 0
of O 0
TCTCC O 0
in O 0
IVS O 0
- O 0
9 O 0
; O 0
a O 0
2 O 0
- O 0
bp O 0
deletion O 0
of O 0
TG O 0
in O 0
exon O 0
5 O 0
; O 0
G78 O 0
to O 0
A O 0
, O 0
giving O 0
a O 0
stop O 0
codon O 0
in O 0
exon O 0
1 O 0
; O 0
G533 O 0
to O 0
T O 0
in O 0
exon O 0
5 O 0
, O 0
producing O 0
the O 0
third O 0
amino O 0
acid O 0
substitution O 0
detected O 0
at O 0
this O 0
site O 0
; O 0
and O 0
G O 0
to O 0
C O 0
at O 0
position O 0
1 O 0
of O 0
IVS O 0
- O 0
2 O 0
, O 0
expected O 0
to O 0
produce O 0
abnormal O 0
splicing O 0
. O 0

In O 0
addition O 0
, O 0
two O 0
mutations O 0
, O 0
( O 0
G1496 O 0
to O 0
A O 0
in O 0
exon O 0
13 O 0
and O 0
a O 0
4 O 0
- O 0
bp O 0
insertion O 0
in O 0
exon O 0
11 O 0
) O 0
that O 0
have O 0
previously O 0
been O 0
reported O 0
were O 0
identified O 0
. O 0
. O 0

Molecular O 0
characterization O 0
of O 0
two O 0
galactosemia B-Disease 0
mutations O 0
: O 0
correlation O 0
of O 0
mutations O 0
with O 0
highly O 0
conserved O 0
domains O 0
in O 0
galactose O 0
- O 0
1 O 0
- O 0
phosphate O 0
uridyl O 0
transferase O 0
. O 0

Galactosemia B-Disease 1
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
of I-Disease 0
human I-Disease 0
galactose I-Disease 0
metabolism I-Disease 0
caused O 0
by O 0
deficiency B-Disease 0
of I-Disease 0
the I-Disease 0
enzyme I-Disease 0
galactose I-Disease 0
- I-Disease 0
1 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
uridyl I-Disease 0
transferase I-Disease 0
( O 0
GALT O 0
) O 0
. O 0

The O 0
molecular O 0
basis O 0
of O 0
this O 0
disorder O 0
is O 0
at O 0
present O 0
not O 0
well O 0
understood O 0
. O 0

We O 0
report O 0
here O 0
two O 0
missense O 0
mutations O 0
which O 0
result O 0
in O 0
low O 0
or O 0
undetectable O 0
enzymatic O 0
activity O 0
. O 0

First O 0
, O 0
we O 0
identified O 0
at O 0
nucleotide O 0
591 O 0
a O 0
transition O 0
which O 0
substitutes O 0
glutamine O 0
188 O 0
by O 0
arginine O 0
. O 0

The O 0
mutated O 0
glutamine O 0
is O 0
not O 0
only O 0
highly O 0
conserved O 0
in O 0
evolution O 0
( O 0
conserved O 0
also O 0
in O 0
Escherichia O 0
coli O 0
and O 0
Saccharomyces O 0
cerevisiae O 0
) O 0
, O 0
but O 0
is O 0
also O 0
two O 0
amino O 0
acid O 0
residues O 0
downstream O 0
from O 0
the O 0
active O 0
site O 0
histidine O 0
- O 0
proline O 0
- O 0
histidine O 0
triad O 0
and O 0
results O 0
in O 0
about O 0
10 O 0
% O 0
of O 0
normal O 0
enzymatic O 0
activity O 0
. O 0

The O 0
arginine O 0
188 O 0
mutation O 0
is O 0
the O 0
most O 0
common O 0
galactosemia B-Disease 0
mutation O 0
characterized O 0
to O 0
date O 0
. O 0

It O 0
accounts O 0
for O 0
one O 0
- O 0
fourth O 0
of O 0
the O 0
galactosemia B-Disease 0
alleles O 0
studied O 0
. O 0

Second O 0
, O 0
we O 0
report O 0
the O 0
substitution O 0
of O 0
arginine O 0
333 O 0
by O 0
tryptophan O 0
, O 0
caused O 0
by O 0
a O 0
transition O 0
at O 0
nucleotide O 0
1025 O 0
. O 0

The O 0
area O 0
surrounding O 0
this O 0
missense O 0
mutation O 0
is O 0
the O 0
most O 0
highly O 0
conserved O 0
domain O 0
in O 0
the O 0
homologous O 0
enzymes O 0
from O 0
E O 0
. O 0
coli O 0
, O 0
yeast O 0
, O 0
and O 0
humans O 0
, O 0
and O 0
this O 0
mutation O 0
results O 0
in O 0
undetectable O 0
enzymatic O 0
activity O 0
, O 0
suggesting O 0
that O 0
this O 0
is O 0
a O 0
severe O 0
mutation O 0
. O 0

This O 0
second O 0
mutation O 0
appears O 0
to O 0
be O 0
rare O 0
, O 0
since O 0
it O 0
was O 0
found O 0
only O 0
in O 0
the O 0
patient O 0
we O 0
sequenced O 0
. O 0

Our O 0
data O 0
provide O 0
further O 0
evidence O 0
for O 0
the O 0
heterogeneity O 0
of O 0
galactosemia B-Disease 0
at O 0
the O 0
molecular O 0
level O 0
, O 0
heterogeneity O 0
which O 0
might O 0
be O 0
related O 0
to O 0
the O 0
variable O 0
clinical O 0
outcome O 0
observed O 0
in O 0
this O 0
disorder O 0
. O 0
. O 0

Hypoxanthine B-Disease 0
- I-Disease 0
guanine I-Disease 0
phosphoribosyltransferase I-Disease 0
deficiency I-Disease 0
: O 0
analysis O 0
of O 0
HPRT O 0
mutations O 0
by O 0
direct O 0
sequencing O 0
and O 0
allele O 0
- O 0
specific O 0
amplification O 0
. O 0

The O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
is O 0
a O 0
severe O 0
X B-Disease 0
chromosome I-Disease 0
- I-Disease 0
linked I-Disease 0
human I-Disease 0
disease I-Disease 0
caused O 0
by O 0
a O 0
virtual O 0
absence B-Disease 0
of I-Disease 0
hypoxanthine I-Disease 0
- I-Disease 0
guanine I-Disease 0
phosphoribosyltransferase I-Disease 0
( I-Disease 0
HPRT I-Disease 0
) I-Disease 0
activity I-Disease 0
. O 0

A O 0
partial O 0
deficiency O 0
in O 0
the O 0
activity O 0
of O 0
this O 0
enzyme O 0
can O 0
result O 0
in O 0
gouty B-Disease 0
arthritis I-Disease 0
. O 0

To O 0
determine O 0
the O 0
genetic O 0
basis O 0
for O 0
reduction O 0
or O 0
loss O 0
of O 0
enzyme O 0
activity O 0
, O 0
we O 0
have O 0
amplified O 0
and O 0
sequenced O 0
the O 0
coding O 0
region O 0
of O 0
HPRT O 0
cDNA O 0
from O 0
four O 0
patients O 0
one O 0
with O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
( O 0
HPRTPerth O 0
) O 0
and O 0
three O 0
with O 0
partial B-Disease 1
deficiencies I-Disease 1
of I-Disease 1
HPRT I-Disease 1
activity I-Disease 1
, O 0
which O 0
have O 0
been O 0
designated O 0
HPRTUrangan O 0
, O 0
HPRTSwan O 0
and O 0
HPRTToowong O 0
. O 0

In O 0
all O 0
four O 0
patients O 0
, O 0
the O 0
only O 0
mutation O 0
identified O 0
was O 0
a O 0
single O 0
base O 0
substitution O 0
in O 0
exons O 0
2 O 0
or O 0
3 O 0
of O 0
the O 0
coding O 0
region O 0
, O 0
which O 0
in O 0
each O 0
case O 0
predicts O 0
a O 0
single O 0
amino O 0
acid O 0
substitution O 0
in O 0
the O 0
translated O 0
protein O 0
. O 0

Each O 0
base O 0
change O 0
was O 0
confirmed O 0
by O 0
allele O 0
- O 0
specific O 0
amplification O 0
of O 0
the O 0
patients O 0
genomic O 0
DNA O 0
. O 0

It O 0
is O 0
interesting O 0
to O 0
note O 0
that O 0
the O 0
mutation O 0
found O 0
for O 0
HPRTPerth O 0
is O 0
identical O 0
to O 0
that O 0
reported O 0
for O 0
HPRTFlint O 0
. O 0

It O 0
appears O 0
that O 0
the O 0
two O 0
mutations O 0
are O 0
de O 0
novo O 0
events O 0
. O 0
. O 0

Molecular O 0
and O 0
metabolic O 0
basis O 0
for O 0
the O 0
metabolic B-Disease 0
disorder I-Disease 0
normotriglyceridemic B-Disease 1
abetalipoproteinemia I-Disease 1
. O 0

We O 0
have O 0
previously O 0
described O 0
a O 0
disorder O 0
, O 0
normotriglyceridemic B-Disease 1
abetalipoproteinemia I-Disease 1
, O 0
that O 0
is O 0
characterized O 0
by O 0
the O 0
virtual O 0
absence O 0
of O 0
plasma O 0
low O 0
density O 0
lipoproteins O 0
and O 0
complete O 0
absence O 0
of O 0
apoB O 0
- O 0
100 O 0
, O 0
but O 0
with O 0
apparently O 0
normal O 0
secretion O 0
of O 0
triglyceride O 0
- O 0
rich O 0
lipoproteins O 0
containing O 0
apoB O 0
- O 0
48 O 0
. O 0

The O 0
patients O 0
plasma O 0
lipoproteins O 0
were O 0
shown O 0
on O 0
polyacrylamide O 0
gels O 0
and O 0
by O 0
antibody O 0
mapping O 0
to O 0
have O 0
a O 0
new O 0
truncated O 0
apoB O 0
variant O 0
, O 0
apoB O 0
- O 0
50 O 0
, O 0
circulating O 0
along O 0
with O 0
her O 0
apoB O 0
- O 0
48 O 0
. O 0

We O 0
have O 0
found O 0
this O 0
individual O 0
to O 0
be O 0
homozygous O 0
for O 0
a O 0
single O 0
C O 0
- O 0
to O 0
- O 0
T O 0
nucleotide O 0
substitution O 0
at O 0
apoB O 0
codon O 0
2252 O 0
, O 0
which O 0
produces O 0
a O 0
premature O 0
in O 0
- O 0
frame O 0
stop O 0
codon O 0
. O 0

Thus O 0
, O 0
this O 0
is O 0
a O 0
rare O 0
example O 0
of O 0
homozygous B-Disease 0
hypobetalipoproteinemia I-Disease 1
. O 0

Electron O 0
photomicrographs O 0
revealed O 0
that O 0
the O 0
diameters O 0
of O 0
particles O 0
in O 0
the O 0
d O 0
less O 0
than O 0
1 O 0
. O 0

006 O 0
g O 0
/ O 0
ml O 0
lipoprotein O 0
fraction O 0
, O 0
in O 0
both O 0
the O 0
postprandial O 0
and O 0
postabsorptive O 0
state O 0
, O 0
are O 0
bimodally O 0
distributed O 0
. O 0

The O 0
molar O 0
ratio O 0
of O 0
apoE O 0
to O 0
apoB O 0
in O 0
these O 0
particles O 0
is O 0
3 O 0
. O 0

5 O 0
1 O 0
, O 0
similar O 0
to O 0
normal O 0
VLDL O 0
. O 0

The O 0
plasma O 0
LDL O 0
interval O 0
contains O 0
both O 0
spherical O 0
and O 0
cuboidal O 0
particles O 0
. O 0

Autologous O 0
reinfusion O 0
of O 0
labeled O 0
d O 0
less O 0
than O 0
1 O 0
. O 0

006 O 0
g O 0
/ O 0
ml O 0
lipoproteins O 0
showed O 0
exponential O 0
disappearance O 0
from O 0
plasma O 0
, O 0
with O 0
an O 0
apparent O 0
half O 0
- O 0
removal O 0
time O 0
of O 0
50 O 0
min O 0
, O 0
somewhat O 0
slower O 0
than O 0
for O 0
normal O 0
chylomicrons O 0
but O 0
within O 0
the O 0
normal O 0
range O 0
for O 0
VLDL O 0
. O 0

The O 0
calculated O 0
production O 0
rate O 0
for O 0
apoB O 0
was O 0
within O 0
the O 0
normal O 0
range O 0
in O 0
this O 0
subject O 0
. O 0

A O 0
single O 0
origin O 0
of O 0
phenylketonuria B-Disease 0
in O 0
Yemenite O 0
Jews O 0
. O 0

Phenylketonuria B-Disease 0
( O 0
PKU B-Disease 0
) O 0
is O 0
a O 0
metabolic B-Disease 0
disease I-Disease 0
caused O 0
by O 0
recessive O 0
mutations O 0
of O 0
the O 0
gene O 0
encoding O 0
the O 0
hepatic O 0
enzyme O 0
phenylalanine O 0
hydroxylase O 0
( O 0
PAH O 0
) O 0
. O 0

The O 0
incidence O 0
of O 0
PKU B-Disease 0
varies O 0
widely O 0
across O 0
different O 0
geographic O 0
areas O 0
, O 0
and O 0
is O 0
highest O 0
( O 0
about O 0
1 O 0
in O 0
5 O 0
, O 0
000 O 0
live O 0
births O 0
) O 0
in O 0
Ireland O 0
and O 0
western O 0
Scotland O 0
, O 0
and O 0
among O 0
Yemenite O 0
Jews O 0
. O 0

A O 0
limited O 0
number O 0
of O 0
point O 0
mutations O 0
account O 0
for O 0
most O 0
of O 0
the O 0
PKU B-Disease 0
cases O 0
in O 0
the O 0
European O 0
population O 0
. O 0

Here O 0
we O 0
report O 0
that O 0
a O 0
single O 0
molecular O 0
defect O 0
- O 0
- O 0
a O 0
deletion O 0
spanning O 0
the O 0
third O 0
exon O 0
of O 0
the O 0
PAH O 0
gene O 0
- O 0
- O 0
is O 0
responsible O 0
for O 0
all O 0
the O 0
PKU B-Disease 0
cases O 0
among O 0
the O 0
Yemenite O 0
Jews O 0
. O 0

Examination O 0
of O 0
a O 0
random O 0
sample O 0
of O 0
Yemenite O 0
Jews O 0
using O 0
a O 0
molecular O 0
probe O 0
that O 0
detects O 0
the O 0
carriers O 0
of O 0
this O 0
deletion O 0
indicated O 0
a O 0
high O 0
frequency O 0
of O 0
the O 0
defective O 0
gene O 0
in O 0
this O 0
community O 0
. O 0

Although O 0
the O 0
deleted O 0
PAH O 0
gene O 0
was O 0
traced O 0
to O 0
25 O 0
different O 0
locations O 0
throughout O 0
Yemen O 0
, O 0
family O 0
histories O 0
and O 0
official O 0
documents O 0
of O 0
the O 0
Yemenite O 0
Jewish O 0
community O 0
showed O 0
that O 0
the O 0
common O 0
ancestor O 0
of O 0
all O 0
the O 0
carriers O 0
of O 0
this O 0
genetic B-Disease 1
defect I-Disease 1
lived O 0
in O 0
Sana O 0
, O 0
the O 0
capital O 0
of O 0
Yemen O 0
, O 0
before O 0
the O 0
eighteenth O 0
century O 0
. O 0
. O 0

Linkage O 0
of O 0
aspartylglucosaminuria B-Disease 0
( O 0
AGU B-Disease 0
) O 0
to O 0
marker O 0
loci O 0
on O 0
the O 0
long O 0
arm O 0
of O 0
chromosome O 0
4 O 0
. O 0

Aspartylglucosaminuria B-Disease 1
( O 0
AGU B-Disease 0
) O 0
is O 0
caused O 0
by O 0
deficient O 0
activity O 0
of O 0
the O 0
enzyme O 0
aspartylglucosaminidase O 0
( O 0
AGA O 0
) O 0
. O 0

The O 0
structural O 0
gene O 0
for O 0
AGA O 0
has O 0
been O 0
assigned O 0
to O 0
the O 0
region O 0
4q21 O 0
- O 0
qter O 0
of O 0
chromosome O 0
4 O 0
. O 0

We O 0
have O 0
studied O 0
the O 0
map O 0
position O 0
of O 0
the O 0
AGU O 0
locus O 0
in O 0
relation O 0
to O 0
other O 0
marker O 0
loci O 0
on O 0
the O 0
long O 0
arm O 0
of O 0
chromosome O 0
4 O 0
using O 0
linkage O 0
analyses O 0
. O 0

Restriction O 0
fragment O 0
length O 0
polymorphism O 0
alleles O 0
for O 0
the O 0
ADH2 O 0
, O 0
ADH3 O 0
, O 0
EGF O 0
, O 0
FG O 0
alpha O 0
and O 0
FG O 0
beta O 0
loci O 0
and O 0
blood O 0
group O 0
antigens O 0
for O 0
the O 0
MNS O 0
locus O 0
were O 0
determined O 0
in O 0
a O 0
panel O 0
of O 0
12 O 0
Finnish O 0
AGU B-Disease 0
families O 0
. O 0

The O 0
heterozygous O 0
family O 0
members O 0
were O 0
identified O 0
by O 0
reduced O 0
activity O 0
of O 0
AGA O 0
in O 0
lymphocytes O 0
. O 0

Linkage O 0
studies O 0
were O 0
performed O 0
using O 0
both O 0
pairwise O 0
and O 0
multipoint O 0
analyses O 0
. O 0

Loose O 0
linkage O 0
of O 0
the O 0
AGU B-Disease 0
locus O 0
to O 0
the O 0
FG O 0
and O 0
MNS O 0
loci O 0
was O 0
observed O 0
( O 0
z O 0
= O 0
1 O 0
. O 0
16 O 0
, O 0
z O 0
= O 0
1 O 0
. O 0
39 O 0
, O 0
respectively O 0
) O 0
. O 0

Multipoint O 0
analysis O 0
to O 0
the O 0
fixed O 0
map O 0
[ O 0
ADH O 0
- O 0
( O 0
0 O 0
. O 0
03 O 0
) O 0
- O 0
EGF O 0
- O 0
( O 0
0 O 0
. O 0
35 O 0
) O 0
- O 0
FG O 0
- O 0
( O 0
0 O 0
. O 0
11 O 0
) O 0
- O 0
MNS O 0
] O 0
suggests O 0
that O 0
the O 0
location O 0
of O 0
the O 0
AGU O 0
locus O 0
is O 0
0 O 0
. O 0

05 O 0
- O 0
0 O 0
. O 0

30 O 0
recombination O 0
units O 0
distal O 0
to O 0
MNS O 0
( O 0
z O 0
= O 0
3 O 0
. O 0
03 O 0
) O 0
. O 0

The O 0
order O 0
cen O 0
- O 0
ADH O 0
- O 0
EGF O 0
- O 0
FG O 0
- O 0
MNS O 0
- O 0
AGU O 0
is O 0
35 O 0
times O 0
more O 0
likely O 0
than O 0
the O 0
next O 0
best O 0
order O 0
cen O 0
- O 0
ADH O 0
- O 0
EGF O 0
- O 0
AGU O 0
- O 0
FG O 0
- O 0
MNS O 0
. O 0

Linkage O 0
relationships O 0
of O 0
the O 0
apolipoprotein O 0
C1 O 0
gene O 0
and O 0
a O 0
cytochrome O 0
P450 O 0
gene O 0
( O 0
CYP2A O 0
) O 0
to O 0
myotonic B-Disease 1
dystrophy I-Disease 1
. O 0

We O 0
have O 0
studied O 0
the O 0
genetic O 0
linkage O 0
of O 0
two O 0
markers O 0
, O 0
the O 0
apolipoprotein O 0
C1 O 0
( O 0
APOC1 O 0
) O 0
gene O 0
and O 0
a O 0
cytochrome O 0
P450 O 0
( O 0
CYP2A O 0
) O 0
gene O 0
, O 0
in O 0
relation O 0
to O 0
the O 0
gene O 0
for O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
. O 0

A O 0
peak O 0
lod O 0
score O 0
of O 0
9 O 0
. O 0

29 O 0
at O 0
2 O 0
cM O 0
was O 0
observed O 0
for O 0
APOC1 O 0
- O 0
DM O 0
, O 0
with O 0
a O 0
lod O 0
score O 0
of O 0
8 O 0
. O 0

55 O 0
at O 0
4 O 0
cM O 0
for O 0
CYP2A O 0
- O 0
DM O 0
. O 0

These O 0
two O 0
markers O 0
also O 0
show O 0
close O 0
linkage O 0
to O 0
each O 0
other O 0
( O 0
theta O 0
max O 0
= O 0
0 O 0
. O 0
05 O 0
, O 0
Zmax O 0
= O 0
9 O 0
. O 0
09 O 0
) O 0
. O 0

From O 0
examination O 0
of O 0
the O 0
genotypes O 0
of O 0
the O 0
recombinant O 0
individuals O 0
, O 0
CYP2A O 0
appears O 0
to O 0
map O 0
proximal O 0
to O 0
DM O 0
because O 0
in O 0
one O 0
recombinant O 0
individual O 0
CYP2A O 0
, O 0
APOC2 O 0
and O 0
CKMM O 0
had O 0
all O 0
recombined O 0
with O 0
DM O 0
. O 0

Evidence O 0
from O 0
another O 0
CYP2A O 0
- O 0
DM O 0
recombinant O 0
individual O 0
places O 0
CYP2A O 0
proximal O 0
to O 0
APOC2 O 0
and O 0
CKMM O 0
. O 0

Localisation O 0
of O 0
CYP2A O 0
on O 0
a O 0
panel O 0
of O 0
somatic O 0
cell O 0
hybrids O 0
also O 0
suggests O 0
that O 0
it O 0
is O 0
proximal O 0
to O 0
DM O 0
and O 0
APOC2 O 0
/ O 0
C1 O 0
/ O 0
E O 0
gene O 0
cluster O 0
. O 0

Genetic O 0
linkage O 0
map O 0
of O 0
six O 0
polymorphic O 0
DNA O 0
markers O 0
around O 0
the O 0
gene O 0
for O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
on O 0
chromosome O 0
5 O 0
. O 0

A O 0
genetic O 0
linkage O 0
map O 0
of O 0
six O 0
polymorphic O 0
DNA O 0
markers O 0
close O 0
to O 0
the O 0
gene O 0
( O 0
APC O 1
) O 0
for O 0
familial B-Disease 1
adenomatous I-Disease 1
polyposis I-Disease 1
( O 0
FAP B-Disease 0
) O 0
on O 0
chromosome O 0
5q O 0
is O 0
reported O 0
. O 0

One O 0
hundred O 0
fifty O 0
- O 0
five O 0
typed O 0
members O 0
of O 0
nine O 0
FAP B-Disease 0
kindred O 0
provided O 0
more O 0
than O 0
90 O 0
meioses O 0
for O 0
linkage O 0
analysis O 0
. O 0

A O 0
number O 0
of O 0
crucial O 0
recombination O 0
events O 0
have O 0
been O 0
identified O 0
which O 0
are O 0
informative O 0
at O 0
three O 0
or O 0
more O 0
loci O 0
, O 0
allowing O 0
confident O 0
ordering O 0
of O 0
parts O 0
of O 0
the O 0
map O 0
. O 0

There O 0
was O 0
no O 0
evidence O 0
of O 0
genetic O 0
heterogeneity O 0
, O 0
with O 0
all O 0
families O 0
showing O 0
linkage O 0
of O 0
at O 0
least O 0
one O 0
chromosome O 0
5 O 0
marker O 0
to O 0
the O 0
gene O 0
. O 0

Recombination O 0
data O 0
and O 0
two O 0
- O 0
point O 0
linkage O 0
analysis O 0
support O 0
a O 0
locus O 0
order O 0
of O 0
centromere O 0
- O 0
pi O 0
227 O 0
- O 0
C11P11 O 0
- O 0
ECB27 O 0
- O 0
L5 O 0
. O 0

62 O 0
- O 0
APC O 1
- O 0
EF5 O 0
62 O 0
- O 0
APC O 1
- O 0
EF5 O 0
. O 0

44 O 0
- O 0
YN5 O 0
44 O 0
- O 0
YN5 O 0
. O 0

48 O 0
- O 0
telomer O 0
e O 0
, O 0
although O 0
EF5 O 0
. O 0

44 O 0
could O 0
lie O 0
in O 0
the O 0
interval O 0
L5 O 0
. O 0

62 O 0
- O 0
APC O 1
or O 0
ECB27 O 0
- O 0
L5 O 0
. O 0

62 O 0
. O 0

No O 0
recombinants O 0
were O 0
identified O 0
between O 0
APC O 1
and O 0
either O 0
EF5 O 0
. O 0

44 O 0
or O 0
YN5 O 0
. O 0

48 O 0
, O 0
but O 0
published O 0
deletion O 0
mapping O 0
in O 0
colorectal B-Disease 0
carcinomas I-Disease 0
and O 0
linkage O 0
analysis O 0
in O 0
FAP B-Disease 0
suggest O 0
that O 0
YN5 O 0
. O 0

48 O 0
is O 0
1 O 0
- O 0
3 O 0
cM O 0
from O 0
APC O 1
. O 0

The O 0
present O 0
study O 0
suggests O 0
that O 0
YN5 O 0
. O 0

48 O 0
and O 0
L5 O 0
. O 0

62 O 0
delineate O 0
a O 0
small O 0
region O 0
of O 0
chromosome O 0
5 O 0
within O 0
which O 0
the O 0
EF5 O 0
. O 0

44 O 0
locus O 0
lies O 0
very O 0
close O 0
to O 0
the O 0
APC B-Disease 1
gene O 0
. O 0

These O 0
data O 0
not O 0
only O 0
allow O 0
use O 0
of O 0
flanking O 0
markers O 0
for O 0
presymptomatic O 0
diagnosis O 0
of O 0
FAP B-Disease 0
but O 0
also O 0
provide O 0
a O 0
high O 0
- O 0
density O 0
map O 0
of O 0
the O 0
region O 0
for O 0
isolation O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
itself O 0
and O 0
for O 0
further O 0
assessment O 0
of O 0
the O 0
role O 0
of O 0
chromosome O 0
5 O 0
deletions O 0
in O 0
the O 0
biology O 0
of O 0
sporadic O 0
colorectal B-Disease 1
cancer I-Disease 1
. O 0

Serum O 0
amyloid O 0
A O 0
and O 0
P O 0
protein O 0
genes O 0
in O 0
familial B-Disease 0
Mediterranean I-Disease 0
fever I-Disease 0
. O 0

Two O 0
recent O 0
studies O 0
have O 0
suggested O 0
the O 0
involvement O 0
of O 0
serum O 0
amyloid O 0
A O 0
( O 0
SAA O 0
) O 0
and O 0
P O 0
( O 0
APCS O 0
) O 0
genes O 0
in O 0
familial B-Disease 0
Mediterranean I-Disease 0
fever I-Disease 0
( O 0
MEF B-Disease 1
) O 0
. O 0

To O 0
test O 0
the O 0
role O 0
of O 0
SAA O 0
and O 0
APCS O 0
in O 0
MEF B-Disease 1
and O 0
MEF B-Disease 1
- I-Disease 1
amyloidosis I-Disease 1
, O 0
we O 0
studied O 0
17 O 0
informative O 0
families O 0
( O 0
15 O 0
Armenians O 0
, O 0
2 O 0
non O 0
- O 0
Ashkenazi O 0
Jews O 0
) O 0
and O 0
8 O 0
MEF B-Disease 1
patients O 0
with O 0
amyloidosis B-Disease 0
using O 0
a O 0
candidate O 0
gene O 0
approach O 0
. O 0

No O 0
evidence O 0
for O 0
any O 0
MEF B-Disease 1
- O 0
associated O 0
polymorphism O 0
was O 0
found O 0
in O 0
any O 0
of O 0
the O 0
41 O 0
Armenian O 0
and O 0
Jewish O 0
MEF B-Disease 1
patients O 0
tested O 0
. O 0

Our O 0
family O 0
studies O 0
allowed O 0
us O 0
to O 0
rule O 0
out O 0
tight O 0
linkage O 0
between O 0
SAA O 0
and O 0
MEF B-Disease 1
( O 0
lod O 0
score O 0
= O 0
- O 0
2 O 0
. O 0
16 O 0
, O 0
theta O 0
less O 0
than O 0
or O 0
equal O 0
to O 0
0 O 0
. O 0
06 O 0
) O 0
. O 0

For O 0
APCS O 0
we O 0
found O 0
that O 0
the O 0
allele O 0
frequency O 0
in O 0
the O 0
MEF B-Disease 1
- I-Disease 1
amyloidosis I-Disease 1
patients O 0
was O 0
similar O 0
to O 0
that O 0
in O 0
18 O 0
unrelated O 0
MEF B-Disease 1
patients O 0
without O 0
amyloidosis B-Disease 0
and O 0
their O 0
33 O 0
healthy O 0
parents O 0
. O 0

Some O 0
Mexican O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
variants O 0
revisited O 0
. O 0

Glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
) I-Disease 0
deficiency I-Disease 0
appears O 0
to O 0
be O 0
fairly O 0
common O 0
in O 0
Mexico O 0
. O 0

We O 0
have O 0
now O 0
examined O 0
the O 0
DNA O 0
of O 0
three O 0
previously O 0
reported O 0
electrophoretically O 0
fast O 0
Mexican O 0
G6PD O 0
variants O 0
, O 0
- O 0
G6PD O 0
Distrito O 0
Federal O 0
, O 0
G6PD O 0
Tepic O 0
, O 0
and O 0
G6PD O 0
Castilla O 0
. O 0

All O 0
three O 0
of O 0
these O 0
variants O 0
, O 0
believed O 0
on O 0
the O 0
basis O 0
of O 0
biochemical O 0
characterization O 0
and O 0
population O 0
origin O 0
to O 0
be O 0
unique O 0
, O 0
have O 0
the O 0
G O 0
- O 0
- O 0
- O 0
- O 0
A O 0
transition O 0
at O 0
nucleotide O 0
202 O 0
and O 0
the O 0
A O 0
- O 0
- O 0
- O 0
- O 0
G O 0
transition O 0
at O 0
nucleotide O 0
376 O 0
, O 0
mutations O 0
that O 0
we O 0
now O 0
recognize O 0
to O 0
be O 0
characteristic O 0
of O 0
G6PD O 1
A O 1
- O 1
. O 0

Two O 0
other O 0
Mexican O 0
males O 0
with O 0
G6PD B-Disease 0
deficiency I-Disease 0
were O 0
found O 0
to O 0
have O 0
the O 0
same O 0
mutation O 0
. O 0

All O 0
five O 0
have O 0
the O 0
( O 0
NlaIII O 0
/ O 0
FokI O 0
/ O 0
PvuII O 0
/ O 0
PstI O 0
) O 0
haplotype O 0
characteristic O 0
of O 0
G6PD O 1
A O 1
- O 1
in O 0
Africa O 0
. O 0

Since O 0
the O 0
PvuII O 0
+ O 0
genotype O 0
seems O 0
to O 0
be O 0
rare O 0
in O 0
Europe O 0
, O 0
we O 0
conclude O 0
that O 0
all O 0
of O 0
these O 0
G6PD O 1
A O 1
- O 1
genes O 0
had O 0
their O 0
ancient O 0
origin O 0
in O 0
Africa O 0
, O 0
although O 0
in O 0
many O 0
of O 0
the O 0
Mexican O 0
patients O 0
with O 0
G6PD O 1
A O 1
- O 1
202A O 0
/ O 0
376G O 0
the O 0
gene O 0
may O 0
have O 0
been O 0
imported O 0
more O 0
recently O 0
from O 0
Spain O 0
, O 0
where O 0
this O 0
variant O 0
, O 0
formerly O 0
known O 0
as O 0
G6PD O 0
Betica O 0
, O 0
is O 0
also O 0
prevalent O 0
. O 0
. O 0

Hereditary O 0
deficiency B-Disease 0
of I-Disease 0
C5 I-Disease 0
in O 0
association O 0
with O 0
discoid B-Disease 1
lupus I-Disease 1
erythematosus I-Disease 1
. O 0

A O 0
29 O 0
- O 0
year O 0
- O 0
old O 0
woman O 0
with O 0
discoid B-Disease 1
lupus I-Disease 1
erythematosus I-Disease 1
had O 0
undetectable O 0
classic O 0
pathway O 0
complement O 0
activity O 0
. O 0

Hypocomplementemia B-Disease 0
was O 0
due O 0
to O 0
selective O 0
deficiency B-Disease 0
of I-Disease 0
C5 I-Disease 0
. O 0

One O 0
of O 0
her O 0
children O 0
was O 0
also O 0
deficient O 0
. O 0

To O 0
our O 0
knowledge O 0
this O 0
is O 0
the O 0
first O 0
documented O 0
case O 0
of O 0
an O 0
association O 0
between O 0
discoid B-Disease 1
lupus I-Disease 1
erythematosus I-Disease 1
and O 0
C5 B-Disease 0
deficiency I-Disease 0
. O 0
. O 0

Founder O 0
effect O 0
of O 0
a O 0
prevalent O 0
phenylketonuria B-Disease 0
mutation O 0
in O 0
the O 0
Oriental O 0
population O 0
. O 0

A O 0
missense O 0
mutation O 0
has O 0
been O 0
identified O 0
in O 0
the O 0
human O 0
phenylalanine O 0
hydroxylase O 0
[ O 0
PAH O 0
; O 0
phenylalanine O 0
4 O 0
- O 0
monooxygenase O 0
; O 0
L O 0
- O 0
phenylalanine O 0
, O 0
tetrahydrobiopterin O 0
oxygen O 0
oxidoreductase O 0
( O 0
4 O 0
- O 0
hydroxylating O 0
) O 0
, O 0
EC O 0
1 O 0
. O 0
14 O 0
. O 0
16 O 0
. O 0
1 O 0
] O 0
gene O 0
in O 0
a O 0
Chinese O 0
patient O 0
with O 0
classic O 0
phenylketonuria B-Disease 0
( O 0
PKU B-Disease 0
) O 0
. O 0

A O 0
G O 0
- O 0
to O 0
- O 0
C O 0
transition O 0
at O 0
the O 0
second O 0
base O 0
of O 0
codon O 0
413 O 0
in O 0
exon O 0
12 O 0
of O 0
the O 0
gene O 0
results O 0
in O 0
the O 0
substitution O 0
of O 0
Pro413 O 0
for O 0
Arg413 O 0
in O 0
the O 0
mutant O 0
protein O 0
. O 0

This O 0
mutation O 0
( O 0
R413P O 0
) O 0
results O 0
in O 0
negligible O 0
enzymatic O 0
activity O 0
when O 0
expressed O 0
in O 0
heterologous O 0
mammalian O 0
cells O 0
and O 0
is O 0
compatible O 0
with O 0
a O 0
classic O 0
PKU B-Disease 0
phenotype O 0
in O 0
the O 0
patient O 0
. O 0

Population O 0
genetic O 0
studies O 0
reveal O 0
that O 0
this O 0
mutation O 0
is O 0
tightly O 0
linked O 0
to O 0
restriction O 0
fragment O 0
length O 0
polymorphism O 0
haplotype O 0
4 O 0
, O 0
which O 0
is O 0
the O 0
predominant O 0
haplotype O 0
of O 0
the O 0
PAH O 0
locus O 0
in O 0
the O 0
Oriental O 0
population O 0
. O 0

It O 0
accounts O 0
for O 0
13 O 0
. O 0

8 O 0
% O 0
of O 0
northern O 0
Chinese O 0
and O 0
27 O 0
% O 0
of O 0
Japanese O 0
PKU B-Disease 0
alleles O 0
, O 0
but O 0
it O 0
is O 0
rare O 0
in O 0
southern O 0
Chinese O 0
( O 0
2 O 0
. O 0
2 O 0
% O 0
) O 0
and O 0
is O 0
absent O 0
in O 0
the O 0
Caucasian O 0
population O 0
. O 0

The O 0
data O 0
demonstrate O 0
unambiguously O 0
that O 0
the O 0
mutation O 0
occurred O 0
after O 0
racial O 0
divergence O 0
of O 0
Orientals O 0
and O 0
Caucasians O 0
and O 0
suggest O 0
that O 0
the O 0
allele O 0
has O 0
spread O 0
throughout O 0
the O 0
Orient O 0
by O 0
a O 0
founder O 0
effect O 0
. O 0

Previous O 0
protein O 0
polymorphism O 0
studies O 0
in O 0
eastern O 0
Asia O 0
have O 0
led O 0
to O 0
the O 0
hypothesis O 0
that O 0
" O 0
northern O 0
Mongoloids O 0
" O 0
represented O 0
a O 0
founding O 0
population O 0
in O 0
Asia O 0
. O 0

Our O 0
results O 0
are O 0
compatible O 0
with O 0
this O 0
hypothesis O 0
in O 0
that O 0
the O 0
PKU B-Disease 0
mutation O 0
might O 0
have O 0
occurred O 0
in O 0
northern O 0
Mongoloids O 0
and O 0
subsequently O 0
spread O 0
to O 0
the O 0
Chinese O 0
and O 0
Japanese O 0
populations O 0
. O 0

Glucose B-Disease 1
/ I-Disease 1
galactose I-Disease 1
malabsorption I-Disease 1
caused O 0
by O 0
a O 0
defect O 0
in O 0
the O 0
Na O 0
+ O 0
/ O 0
glucose O 0
cotransporter O 0
. O 0

Glucose B-Disease 1
/ I-Disease 1
galactose I-Disease 1
malabsorption I-Disease 1
( O 0
GGM B-Disease 1
) O 0
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
disease I-Disease 1
manifesting O 0
within O 0
the O 0
first O 0
weeks O 0
of O 0
life O 0
and O 0
characterized O 0
by O 0
a O 0
selective O 0
failure O 0
to O 0
absorb O 0
dietary O 0
glucose O 0
and O 0
galactose O 0
from O 0
the O 0
intestine O 0
. O 0

The O 0
consequent O 0
severe O 0
diarrhoea B-Disease 0
and O 0
dehydration B-Disease 0
are O 0
usually O 0
fatal O 0
unless O 0
these O 0
sugars O 0
are O 0
eliminated O 0
from O 0
the O 0
diet O 0
. O 0

Intestinal O 0
biopsies O 0
of O 0
GGM B-Disease 1
patients O 0
have O 0
revealed O 0
a O 0
specific O 0
defect O 0
in O 0
Na O 0
( O 0
+ O 0
) O 0
- O 0
dependent O 0
absorption O 0
of O 0
glucose O 0
in O 0
the O 0
brush O 0
border O 0
. O 0

Normal O 0
glucose O 0
absorption O 0
is O 0
mediated O 0
by O 0
the O 0
Na O 0
+ O 0
/ O 0
glucose O 0
cotransporter O 0
in O 0
the O 0
brush O 0
border O 0
membrane O 0
of O 0
the O 0
intestinal O 0
epithelium O 0
. O 0

Cellular O 0
influx O 0
is O 0
driven O 0
by O 0
the O 0
transmembrane O 0
Na O 0
+ O 0
electrochemical O 0
potential O 0
gradient O 0
; O 0
thereafter O 0
the O 0
sugar O 0
moves O 0
to O 0
the O 0
blood O 0
across O 0
the O 0
basolateral O 0
membrane O 0
via O 0
the O 0
facilitated O 0
glucose O 0
carrier O 0
. O 0

We O 0
have O 0
previously O 0
cloned O 0
and O 0
sequenced O 0
a O 0
Na O 0
+ O 0
/ O 0
glucose O 0
cotransporter O 0
from O 0
normal O 0
human O 0
ileum O 0
and O 0
shown O 0
that O 0
this O 0
gene O 0
, O 0
SGLT1 O 0
, O 0
resides O 0
on O 0
the O 0
distal O 0
q O 0
arm O 0
of O 0
chromosome O 0
22 O 0
. O 0

We O 0
have O 0
now O 0
amplified O 0
SGLT1 O 0
complementary O 0
DNA O 0
and O 0
genomic O 0
DNA O 0
from O 0
members O 0
of O 0
a O 0
family O 0
affected O 0
with O 0
GGM B-Disease 1
by O 0
the O 0
polymerase O 0
chain O 0
reaction O 0
. O 0

Sequence O 0
analysis O 0
of O 0
the O 0
amplified O 0
products O 0
has O 0
revealed O 0
a O 0
single O 0
missense O 0
mutation O 0
in O 0
SGLT1 O 0
which O 0
cosegregates O 0
with O 0
the O 0
GGM B-Disease 1
phenotype O 0
and O 0
results O 0
in O 0
a O 0
complete O 0
loss O 0
of O 0
Na O 0
( O 0
+ O 0
) O 0
- O 0
dependent O 0
glucose O 0
transport O 0
in O 0
Xenopus O 0
oocytes O 0
injected O 0
with O 0
this O 0
complementary O 0
RNA O 0
. O 0
. O 0

A O 0
de O 0
novo O 0
unbalanced O 0
reciprocal O 0
translocation O 0
identified O 0
as O 0
paternal O 0
in O 0
origin O 0
in O 0
the O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
. O 0

Interstitial O 0
cytogenetic O 0
deletions O 0
involving O 0
the O 0
paternally O 0
derived O 0
chromosome O 0
15q11 O 0
- O 0
13 O 0
have O 0
been O 0
described O 0
in O 0
patients O 0
with O 0
the O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
. O 0

We O 0
report O 0
a O 0
child O 0
with O 0
PWS B-Disease 0
and O 0
a O 0
de O 0
novo O 0
unbalanced O 0
karyotype O 0
- O 0
45 O 0
, O 0
XY O 0
, O 0
- O 0
9 O 0
, O 0
- O 0
15 O 0
, O 0
+ O 0
der O 0
( O 0
9 O 0
) O 0
t O 0
( O 0
9 O 0
; O 0
15 O 0
) O 0
( O 0
q34 O 0
; O 0
q13 O 0
) O 0
. O 0

Molecular O 0
studies O 0
with O 0
the O 0
DNA O 0
probe O 0
pML34 O 0
confirmed O 0
that O 0
only O 0
a O 0
single O 0
Prader B-Disease 1
Willi I-Disease 1
critical O 0
region O 0
( O 0
PWCR O 0
15q11 O 0
. O 0
2 O 0
- O 0
q12 O 0
) O 0
copy O 0
was O 0
present O 0
. O 0

Hybridisation O 0
of O 0
patient O 0
and O 0
parental O 0
DNA O 0
with O 0
the O 0
multi O 0
- O 0
allelic O 0
probe O 0
CMW1 O 0
, O 0
which O 0
maps O 0
to O 0
pter O 0
- O 0
15q13 O 0
, O 0
showed O 0
that O 0
the O 0
chromosome O 0
involved O 0
in O 0
the O 0
translocation O 0
was O 0
paternal O 0
in O 0
origin O 0
. O 0

This O 0
is O 0
the O 0
first O 0
example O 0
of O 0
a O 0
paternally O 0
- O 0
derived O 0
PWCR O 0
allele O 0
loss O 0
caused O 0
by O 0
an O 0
unbalanced O 0
translocation O 0
that O 0
has O 0
arisen O 0
de O 0
novo O 0
. O 0

Localisation O 0
of O 0
the O 0
myotonic B-Disease 1
dystrophy I-Disease 1
locus O 0
to O 0
19q13 O 0
. O 0
2 O 0
- O 0
19q13 O 0
. O 0
3 O 0
and O 0
its O 0
relationship O 0
to O 0
twelve O 0
polymorphic O 0
loci O 0
on O 0
19q O 0
. O 0

The O 0
order O 0
of O 0
fourteen O 0
polymorphic O 0
markers O 0
localised O 0
to O 0
the O 0
long O 0
arm O 0
of O 0
human O 0
chromosome O 0
19 O 0
has O 0
been O 0
established O 0
by O 0
multipoint O 0
mapping O 0
in O 0
a O 0
set O 0
of O 0
40 O 0
CEPH O 0
( O 0
Centre O 0
dEtude O 0
de O 0
Polymorphisme O 0
Humain O 0
, O 0
Paris O 0
) O 0
reference O 0
families O 0
. O 0

We O 0
report O 0
here O 0
the O 0
linkage O 0
relationship O 0
of O 0
the O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
locus O 0
to O 0
twelve O 0
of O 0
these O 0
markers O 0
as O 0
studied O 0
in O 0
45 O 0
families O 0
with O 0
DM B-Disease 0
. O 0

The O 0
resulting O 0
genetic O 0
map O 0
is O 0
supported O 0
by O 0
the O 0
localisation O 0
of O 0
the O 0
DNA O 0
markers O 0
in O 0
a O 0
panel O 0
of O 0
somatic O 0
cell O 0
hybrids O 0
. O 0

Ten O 0
of O 0
the O 0
twelve O 0
markers O 0
have O 0
been O 0
shown O 0
to O 0
be O 0
proximal O 0
to O 0
the O 0
DM B-Disease 0
gene O 0
and O 0
two O 0
, O 0
PRKCG O 0
and O 0
D19S22 O 0
, O 0
distal O 0
but O 0
at O 0
distances O 0
of O 0
approximately O 0
25 O 0
cM O 0
and O 0
15 O 0
cM O 0
, O 0
respectively O 0
. O 0

The O 0
closest O 0
proximal O 0
markers O 0
are O 0
APOC2 O 0
( O 0
apolipoprotein O 0
C O 0
- O 0
II O 0
) O 0
and O 0
CKM O 0
( O 0
creatine O 0
kinase O 0
, O 0
muscle O 0
) O 0
approximately O 0
3 O 0
cM O 0
and O 0
2 O 0
cM O 0
from O 0
the O 0
DM B-Disease 0
gene O 0
respectively O 0
, O 0
in O 0
the O 0
order O 0
APOC2 O 0
- O 0
CKM O 0
- O 0
DM O 0
. O 0

The O 0
distance O 0
between O 0
APOC2 O 0
, O 0
CKM O 0
and O 0
DM B-Disease 0
( O 0
of O 0
the O 0
order O 0
of O 0
2 O 0
million O 0
base O 0
pairs O 0
) O 0
and O 0
their O 0
known O 0
orientation O 0
should O 0
permit O 0
directional O 0
chromosome O 0
walking O 0
and O 0
jumping O 0
. O 0

The O 0
data O 0
presented O 0
here O 0
should O 0
enable O 0
us O 0
to O 0
determine O 0
whether O 0
or O 0
not O 0
new O 0
markers O 0
are O 0
distal O 0
to O 0
APOC2 O 0
/ O 0
CKM O 0
and O 0
thus O 0
potentially O 0
flank O 0
the O 0
DM B-Disease 0
gene O 0
. O 0
. O 0

Localization O 0
of O 0
histidase O 0
to O 0
human O 0
chromosome O 0
region O 0
12q22 O 0
- O 0
- O 0
- O 0
- O 0
q24 O 0
. O 0
1 O 0
and O 0
mouse O 0
chromosome O 0
region O 0
10C2 O 0
- O 0
- O 0
- O 0
- O 0
D1 O 0
. O 0

The O 0
human O 0
gene O 0
for O 0
histidase O 0
( O 0
histidine O 0
ammonia O 0
- O 0
lyase O 0
; O 0
HAL O 0
) O 0
, O 0
the O 0
enzyme O 0
deficient O 0
in O 0
histidinemia B-Disease 1
, O 0
was O 0
assigned O 0
to O 0
human O 0
chromosome O 0
12 O 0
by O 0
Southern O 0
blot O 0
analysis O 0
of O 0
human O 0
X O 0
mouse O 0
somatic O 0
cell O 0
hybrid O 0
DNA O 0
. O 0

The O 0
gene O 0
was O 0
sublocalized O 0
to O 0
region O 0
12q22 O 0
- O 0
- O 0
- O 0
- O 0
q24 O 0
. O 0

1 O 0
by O 0
in O 0
situ O 0
hybridization O 0
, O 0
using O 0
a O 0
human O 0
histidase O 0
cDNA O 0
. O 0

The O 0
homologous O 0
locus O 0
in O 0
the O 0
mouse O 0
( O 0
Hal O 0
) O 0
was O 0
mapped O 0
to O 0
region O 0
10C2 O 0
- O 0
- O 0
- O 0
- O 0
D1 O 0
by O 0
in O 0
situ O 0
hybridization O 0
, O 0
using O 0
a O 0
cell O 0
line O 0
from O 0
a O 0
mouse O 0
homozygous O 0
for O 0
a O 0
1 O 0
. O 0

10 O 0
Robertsonian O 0
translocation O 0
. O 0

These O 0
assignments O 0
extend O 0
the O 0
conserved O 0
syntenic O 0
region O 0
between O 0
human O 0
chromosome O 0
12 O 0
and O 0
mouse O 0
chromosome O 0
10 O 0
that O 0
includes O 0
the O 0
genes O 0
for O 0
phenylalanine O 0
hydroxylase O 0
, O 0
gamma O 0
interferon O 0
, O 0
peptidase O 0
, O 0
and O 0
citrate O 0
synthase O 0
. O 0

The O 0
localization O 0
of O 0
histidase O 0
to O 0
mouse O 0
chromosome O 0
10 O 0
suggests O 0
that O 0
the O 0
histidase O 0
regulatory O 0
locus O 0
( O 0
Hsd O 0
) O 0
and O 0
the O 0
histidinemia O 1
mutation O 0
( O 0
his O 0
) O 0
, O 0
which O 0
are O 0
both O 0
known O 0
to O 0
be O 0
on O 0
chromosome O 0
10 O 0
, O 0
may O 0
be O 0
alleles O 0
of O 0
the O 0
histidase O 0
structural O 0
gene O 0
locus O 0
. O 0

Determination O 0
of O 0
the O 0
mutations O 0
responsible O 0
for O 0
the O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
in O 0
17 O 0
subjects O 0
. O 0

Hypoxanthine O 0
- O 0
- O 0
guanine O 0
phosphoribosyltransferase O 0
( O 0
HPRT O 0
) O 0
is O 0
a O 0
purine O 0
salvage O 0
enzyme O 0
that O 0
catalyzes O 0
the O 0
conversion O 0
of O 0
hypoxanthine O 0
to O 0
inosine O 0
monophosphate O 0
and O 0
guanine O 0
to O 0
guanosine O 0
monophosphate O 0
. O 0

Previous O 0
studies O 0
of O 0
mutant O 0
HPRT O 0
proteins O 0
analyzed O 0
at O 0
the O 0
molecular O 0
level O 0
have O 0
shown O 0
a O 0
significant O 0
heterogeneity O 0
. O 0

This O 0
investigation O 0
further O 0
verifies O 0
this O 0
heterogeneity O 0
and O 0
identifies O 0
insertions O 0
, O 0
deletions O 0
, O 0
and O 0
point O 0
mutations O 0
. O 0

The O 0
direct O 0
sequencing O 0
of O 0
the O 0
polymerase O 0
chain O 0
reaction O 0
- O 0
amplified O 0
product O 0
of O 0
reverse O 0
- O 0
transcribed O 0
HPRT O 0
mRNA O 0
enabled O 0
the O 0
rapid O 0
identification O 0
of O 0
the O 0
mutations O 0
found O 0
in O 0
17 O 0
previously O 0
uncharacterized O 0
cell O 0
lines O 0
derived O 0
from O 0
patients O 0
with O 0
the O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
. O 0
. O 0

Linkage O 0
of O 0
DNA O 0
markers O 0
at O 0
Xq28 O 0
to O 0
adrenoleukodystrophy B-Disease 1
and O 0
adrenomyeloneuropathy B-Disease 1
present O 0
within O 0
the O 0
same O 0
family O 0
. O 0

We O 0
present O 0
a O 0
large O 0
kindred O 0
that O 0
contained O 0
patients O 0
with O 0
either O 0
adrenoleukodystrophy B-Disease 1
( O 0
ALD B-Disease 0
) O 0
or O 0
adrenomyeloneuropathy B-Disease 1
( O 0
AMN B-Disease 0
) O 0
. O 0

The O 0
pedigree O 0
clearly O 0
supported O 0
the O 0
X O 0
- O 0
linked O 0
mode O 0
of O 0
inheritance O 0
of O 0
the O 0
nonneonatal O 0
form O 0
of O 0
ALD B-Disease 0
/ O 0
AMN B-Disease 0
. O 0

Analysis O 0
with O 0
DNA O 0
markers O 0
at O 0
Xq28 O 0
suggested O 0
segregation O 0
of O 0
both O 0
ALD B-Disease 0
and O 0
AMN B-Disease 0
with O 0
an O 0
identical O 0
haplotype O 0
. O 0

This O 0
indicated O 0
that O 0
nonneonatal O 0
ALD B-Disease 0
and O 0
AMN B-Disease 0
are O 0
caused O 0
by O 0
a O 0
mutation O 0
in O 0
the O 0
same O 0
gene O 0
at O 0
Xq28 O 0
. O 0

It O 0
showed O 0
, O 0
furthermore O 0
, O 0
that O 0
phenotypic O 0
differences O 0
between O 0
ALD B-Disease 0
and O 0
AMN B-Disease 0
are O 0
not O 0
necessarily O 0
the O 0
consequence O 0
of O 0
allelic O 0
heterogeneity O 0
due O 0
to O 0
different O 0
mutations O 0
within O 0
the O 0
same O 0
gene O 0
. O 0

The O 0
maximal O 0
lod O 0
score O 0
for O 0
linkage O 0
of O 0
the O 0
ALD B-Disease 0
/ O 0
AMN B-Disease 0
gene O 0
and O 0
the O 0
multiallelic O 0
anonymous O 0
DNA O 0
marker O 0
at O 0
DXS52 O 0
was O 0
3 O 0
. O 0

0 O 0
at O 0
a O 0
recombination O 0
fraction O 0
of O 0
0 O 0
. O 0

00 O 0
. O 0

This O 0
made O 0
a O 0
prenatal O 0
or O 0
presymptomatic O 0
diagnosis O 0
and O 0
heterozygote O 0
detection O 0
by O 0
DNA O 0
analysis O 0
with O 0
this O 0
marker O 0
reliable O 0
. O 0

Skewed O 0
X O 0
inactivation O 0
in O 0
a O 0
female O 0
MZ O 0
twin O 0
results O 0
in O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
. O 0

One O 0
of O 0
female O 0
MZ O 0
twins O 0
presented O 0
with O 0
muscular B-Disease 0
dystrophy I-Disease 0
. O 0

Physical O 0
examination O 0
, O 0
creatine O 0
phosphokinase O 0
levels O 0
, O 0
and O 0
muscle O 0
biopsy O 0
were O 0
consistent O 0
with O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
. O 0

However O 0
, O 0
because O 0
of O 0
her O 0
sex O 0
she O 0
was O 0
diagnosed O 0
as O 0
having O 0
limb B-Disease 0
- I-Disease 0
girdle I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
. O 0

With O 0
cDNA O 0
probes O 0
to O 0
the O 0
DMD B-Disease 0
gene O 0
, O 0
a O 0
gene O 0
deletion O 0
was O 0
detected O 0
in O 0
the O 0
twins O 0
and O 0
their O 0
mother O 0
. O 0

The O 0
de O 0
novo O 0
mutation O 0
which O 0
arose O 0
in O 0
the O 0
mother O 0
was O 0
shown O 0
by O 0
novel O 0
junction O 0
fragments O 0
generated O 0
by O 0
HindIII O 0
, O 0
PstI O 0
, O 0
or O 0
TaqI O 0
when O 0
probed O 0
with O 0
cDNA8 O 0
. O 0

Additional O 0
evidence O 0
of O 0
a O 0
large O 0
gene O 0
deletion O 0
was O 0
given O 0
by O 0
novel O 0
SfiI O 0
junction O 0
fragments O 0
detected O 0
by O 0
probes O 0
p20 O 0
, O 0
J O 0
- O 0
Bir O 0
, O 0
and O 0
J O 0
- O 0
66 O 0
on O 0
pulsed O 0
- O 0
field O 0
gel O 0
electrophoresis O 0
( O 0
PFGE O 0
) O 0
. O 0

Immunoblot O 0
analysis O 0
of O 0
muscle O 0
from O 0
the O 0
affected O 0
twin O 0
showed O 0
dystrophin O 0
of O 0
normal O 0
size O 0
but O 0
of O 0
reduced O 0
amount O 0
. O 0

Immunofluorescent O 0
visualization O 0
of O 0
dystrophin O 0
revealed O 0
foci O 0
of O 0
dystrophin O 0
- O 0
positive O 0
fibers O 0
adjacent O 0
to O 0
foci O 0
of O 0
dystrophin O 0
- O 0
negative O 0
fibers O 0
. O 0

These O 0
data O 0
indicate O 0
that O 0
the O 0
affected O 0
twin O 0
is O 0
a O 0
manifesting O 0
carrier O 0
of O 0
an O 0
abnormal O 0
DMD B-Disease 0
gene O 0
, O 0
her O 0
myopathy B-Disease 1
being O 0
a O 0
direct O 0
result O 0
of O 0
underexpression O 0
of O 0
dystrophin O 0
. O 0

Cytogenetic O 0
analysis O 0
revealed O 0
normal O 0
karyotypes O 0
, O 0
eliminating O 0
the O 0
possibility O 0
of O 0
a O 0
translocation O 0
affecting O 0
DMD B-Disease 0
gene O 0
function O 0
. O 0

Both O 0
linkage O 0
analysis O 0
and O 0
DNA O 0
fingerprint O 0
analysis O 0
revealed O 0
that O 0
each O 0
twin O 0
has O 0
two O 0
different O 0
X O 0
chromosomes O 0
, O 0
eliminating O 0
the O 0
possibility O 0
of O 0
uniparental B-Disease 0
disomy I-Disease 0
as O 0
a O 0
mechanism O 0
for O 0
DMD B-Disease 0
expression O 0
. O 0

On O 0
the O 0
basis O 0
of O 0
methylation O 0
differences O 0
of O 0
the O 0
paternal O 0
and O 0
maternal O 0
X O 0
chromosomes O 0
in O 0
these O 0
MZ O 0
twins O 0
, O 0
we O 0
propose O 0
uneven O 0
lyonization O 0
( O 0
X O 0
chromosome O 0
inactivation O 0
) O 0
as O 0
the O 0
underlying O 0
mechanism O 0
for O 0
disease O 0
expression O 0
in O 0
the O 0
affected O 0
female O 0
. O 0
. O 0

Adrenoleukodystrophy B-Disease 0
and O 0
adrenomyeloneuropathy B-Disease 1
associated O 0
with O 0
partial O 0
adrenal B-Disease 0
insufficiency I-Disease 0
in O 0
three O 0
generations O 0
of O 0
a O 0
kindred O 0
. O 0

Four O 0
cases O 0
of O 0
adrenoleukodystrophy B-Disease 1
( O 0
ALD B-Disease 0
) O 0
and O 0
one O 0
case O 0
of O 0
adrenomyeloneuropathy B-Disease 1
( O 0
AMN B-Disease 0
) O 0
have O 0
developed O 0
in O 0
a O 0
kindred O 0
over O 0
three O 0
generations O 0
demonstrating O 0
that O 0
AMN B-Disease 0
is O 0
a O 0
clinical O 0
variant O 0
of O 0
ALD B-Disease 0
. O 0

Pituitary O 0
- O 0
adrenal O 0
function O 0
studies O 0
were O 0
performed O 0
in O 0
10 O 0
family O 0
members O 0
, O 0
including O 0
two O 0
affected O 0
males O 0
and O 0
four O 0
females O 0
identified O 0
as O 0
carriers O 0
of O 0
ALD B-Disease 0
/ O 0
AMN B-Disease 0
. O 0

No O 0
pituitary B-Disease 0
- I-Disease 0
adrenal I-Disease 0
abnormality I-Disease 0
was O 0
found O 0
in O 0
the O 0
carriers O 0
. O 0

However O 0
, O 0
basal O 0
morning O 0
plasma O 0
adrenocorticotropic O 0
hormone O 0
( O 0
ACTH O 0
) O 0
levels O 0
were O 0
markedly O 0
elevated O 0
in O 0
the O 0
two O 0
males O 0
with O 0
ALD B-Disease 0
and O 0
AMN B-Disease 0
, O 0
despite O 0
the O 0
fact O 0
that O 0
they O 0
had O 0
no O 0
clinical O 0
signs O 0
of O 0
adrenal B-Disease 0
insufficiency I-Disease 0
and O 0
that O 0
morning O 0
plasma O 0
cortisol O 0
levels O 0
and O 0
their O 0
response O 0
to O 0
maximal O 0
exogenous O 0
ACTH O 0
stimulation O 0
appeared O 0
to O 0
be O 0
normal O 0
. O 0

In O 0
addition O 0
, O 0
the O 0
integrated O 0
24 O 0
- O 0
hour O 0
response O 0
to O 0
the O 0
administration O 0
were O 0
also O 0
subnormal O 0
in O 0
these O 0
two O 0
cases O 0
. O 0

Thus O 0
, O 0
people O 0
with O 0
ALD B-Disease 0
and O 0
AMN B-Disease 0
may O 0
have O 0
subclinical O 0
partial O 0
adrenocrotical B-Disease 1
insufficiency I-Disease 1
. O 0

No O 0
other O 0
endocrinologic B-Disease 1
dysfunction I-Disease 1
was O 0
identified O 0
. O 0
. O 0

Regional O 0
localisation O 0
of O 0
the O 0
Friedreich B-Disease 1
ataxia I-Disease 1
locus O 0
to O 0
human O 0
chromosome O 0
9q13 O 0
- O 0
- O 0
- O 0
- O 0
q21 O 0
. O 0
1 O 0
. O 0

We O 0
have O 0
previously O 0
assigned O 0
the O 0
Friedreich B-Disease 1
ataxia I-Disease 1
locus O 0
( O 0
FRDA O 0
) O 0
to O 0
chromosome O 0
9 O 0
; O 0
the O 0
current O 0
maximal O 0
lod O 0
score O 0
between O 0
FRDA O 0
and O 0
MCT112 O 0
( O 0
D9S15 O 0
) O 0
is O 0
greater O 0
than O 0
50 O 0
at O 0
a O 0
recombination O 0
fraction O 0
of O 0
theta O 0
= O 0
0 O 0
. O 0

The O 0
physical O 0
assignment O 0
of O 0
the O 0
locus O 0
defined O 0
by O 0
MCT112 O 0
, O 0
and O 0
hence O 0
FRDA O 0
, O 0
has O 0
not O 0
been O 0
determined O 0
, O 0
although O 0
linkage O 0
analysis O 0
of O 0
MCT112 O 0
with O 0
other O 0
chromosome O 0
9 O 0
markers O 0
inferred O 0
a O 0
location O 0
close O 0
to O 0
the O 0
centromere O 0
. O 0

We O 0
have O 0
used O 0
in O 0
situ O 0
hybridisation O 0
with O 0
MCT112 O 0
, O 0
a O 0
corresponding O 0
cosmid O 0
MJ1 O 0
, O 0
and O 0
DR47 O 0
( O 0
D9S5 O 0
) O 0
, O 0
coupled O 0
with O 0
mapping O 0
studies O 0
on O 0
hybrid O 0
cell O 0
panels O 0
, O 0
to O 0
define O 0
more O 0
precisely O 0
the O 0
location O 0
of O 0
the O 0
disease O 0
locus O 0
. O 0

The O 0
in O 0
situ O 0
location O 0
of O 0
all O 0
three O 0
probes O 0
is O 0
9q13 O 0
- O 0
- O 0
- O 0
- O 0
q21 O 0
. O 0

1 O 0
, O 0
distal O 0
to O 0
the O 0
variable O 0
heterochromatin O 0
region O 0
. O 0

Physical O 0
assignment O 0
of O 0
FRDA O 0
will O 0
allow O 0
us O 0
to O 0
identify O 0
hybrid O 0
cell O 0
lines O 0
containing O 0
the O 0
mutated O 0
gene O 0
. O 0

Increased O 0
high O 0
- O 0
density O 0
lipoprotein O 0
levels O 0
caused O 0
by O 0
a O 0
common O 0
cholesteryl O 0
- O 0
ester O 0
transfer O 0
protein O 0
gene O 0
mutation O 0
. O 0

BACKGROUND O 0
AND O 0
METHODS O 0
. O 0

The O 0
plasma O 0
cholesteryl O 0
- O 0
ester O 0
transfer O 0
protein O 0
( O 0
CETP O 0
) O 0
catalyzes O 0
the O 0
transfer O 0
of O 0
cholesteryl O 0
esters O 0
from O 0
high O 0
- O 0
density O 0
lipoprotein O 0
( O 0
HDL O 0
) O 0
to O 0
other O 0
lipoproteins O 0
. O 0

We O 0
recently O 0
described O 0
a O 0
Japanese O 0
family O 0
with O 0
increased O 0
HDL O 0
levels O 0
and O 0
CETP B-Disease 0
deficiency I-Disease 0
due O 0
to O 0
a O 0
splicing O 0
defect O 0
of O 0
the O 0
CETP O 0
gene O 0
. O 0

To O 0
assess O 0
the O 0
frequency O 0
and O 0
phenotype O 0
of O 0
this O 0
condition O 0
, O 0
we O 0
screened O 0
11 O 0
additional O 0
families O 0
with O 0
high O 0
HDL O 0
levels O 0
by O 0
means O 0
of O 0
a O 0
radioimmunoassay O 0
for O 0
CETP O 0
and O 0
DNA O 0
analysis O 0
. O 0

RESULTS O 0
. O 0

We O 0
found O 0
the O 0
same O 0
CETP O 0
gene O 0
mutation O 0
in O 0
four O 0
families O 0
from O 0
three O 0
different O 0
regions O 0
of O 0
Japan O 0
. O 0

Analysis O 0
of O 0
restriction O 0
- O 0
fragment O 0
- O 0
length O 0
polymorphisms O 0
of O 0
the O 0
mutant O 0
CETP O 0
allele O 0
showed O 0
that O 0
all O 0
probands O 0
were O 0
homozygous O 0
for O 0
the O 0
identical O 0
haplotype O 0
. O 0

Family O 0
members O 0
homozygous O 0
for O 0
CETP B-Disease 0
deficiency I-Disease 0
( O 0
n O 0
= O 0
10 O 0
) O 0
had O 0
moderate O 0
hypercholesterolemia B-Disease 0
( O 0
mean O 0
total O 0
cholesterol O 0
level O 0
[ O 0
+ O 0
/ O 0
- O 0
SD O 0
] O 0
, O 0
7 O 0
. O 0
01 O 0
+ O 0
/ O 0
- O 0
0 O 0
. O 0
83 O 0
mmol O 0
per O 0
liter O 0
) O 0
, O 0
markedly O 0
increased O 0
levels O 0
of O 0
HDL O 0
cholesterol O 0
( O 0
4 O 0
. O 0
24 O 0
+ O 0
/ O 0
- O 0
1 O 0
. O 0
01 O 0
mmol O 0
per O 0
liter O 0
) O 0
and O 0
apolipoprotein O 0
A O 0
- O 0
I O 0
, O 0
and O 0
decreased O 0
levels O 0
of O 0
low O 0
- O 0
density O 0
lipoprotein O 0
cholesterol O 0
( O 0
1 O 0
. O 0
99 O 0
+ O 0
/ O 0
- O 0
0 O 0
. O 0
80 O 0
mmol O 0
per O 0
liter O 0
) O 0
and O 0
apolipoprotein O 0
B O 0
. O 0

Members O 0
heterozygous O 0
for O 0
the O 0
deficiency O 0
( O 0
n O 0
= O 0
20 O 0
) O 0
, O 0
whose O 0
CETP O 0
levels O 0
were O 0
in O 0
the O 0
lower O 0
part O 0
of O 0
the O 0
normal O 0
range O 0
, O 0
had O 0
moderately O 0
increased O 0
levels O 0
of O 0
HDL O 0
cholesterol O 0
and O 0
apolipoprotein O 0
A O 0
- O 0
I O 0
and O 0
an O 0
increased O 0
ratio O 0
of O 0
HDL O 0
subclass O 0
2 O 0
to O 0
HDL O 0
subclass O 0
3 O 0
, O 0
as O 0
compared O 0
with O 0
unaffected O 0
family O 0
members O 0
( O 0
1 O 0
. O 0
5 O 0
+ O 0
/ O 0
- O 0
0 O 0
. O 0
8 O 0
vs O 0
. O 0
0 O 0
. O 0
7 O 0
+ O 0
/ O 0
- O 0
0 O 0
. O 0
4 O 0
) O 0
. O 0

CETP B-Disease 0
deficiency I-Disease 0
was O 0
not O 0
found O 0
in O 0
six O 0
unrelated O 0
subjects O 0
with O 0
elevated O 0
HDL O 0
cholesterol O 0
levels O 0
who O 0
were O 0
from O 0
different O 0
parts O 0
of O 0
the O 0
United O 0
States O 0
. O 0

CONCLUSIONS O 0
. O 0

CETP B-Disease 0
deficiency I-Disease 0
appears O 0
to O 0
be O 0
a O 0
frequent O 0
cause O 0
of O 0
increased O 0
HDL O 0
levels O 0
in O 0
the O 0
population O 0
of O 0
Japan O 0
, O 0
possibly O 0
because O 0
of O 0
a O 0
founder O 0
effect O 0
. O 0

The O 0
results O 0
that O 0
we O 0
observed O 0
in O 0
heterozygotes O 0
suggest O 0
that O 0
CETP O 0
normally O 0
plays O 0
a O 0
part O 0
in O 0
the O 0
regulation O 0
of O 0
levels O 0
of O 0
HDL O 0
subclass O 0
2 O 0
. O 0

There O 0
was O 0
no O 0
evidence O 0
of O 0
premature B-Disease 1
atherosclerosis I-Disease 1
in O 0
the O 0
families O 0
with O 0
CETP B-Disease 0
deficiency I-Disease 0
. O 0

In O 0
fact O 0
, O 0
the O 0
lipoprotein O 0
profile O 0
of O 0
persons O 0
with O 0
CETP B-Disease 0
deficiency I-Disease 0
is O 0
potentially O 0
antiatherogenic O 0
and O 0
may O 0
be O 0
associated O 0
with O 0
an O 0
increased O 0
life O 0
span O 0
. O 0

Further O 0
mapping O 0
of O 0
an O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
locus O 0
to O 0
the O 0
chromosome O 0
11q23 O 0
region O 0
. O 0

We O 0
recently O 0
mapped O 0
the O 0
gene O 0
for O 0
ataxia B-Disease 0
- I-Disease 0
telangiectasia I-Disease 0
group O 0
A O 0
( O 0
ATA O 0
) O 0
to O 0
chromosome O 0
11q22 O 0
- O 0
23 O 0
by O 0
linkage O 0
analysis O 0
, O 0
using O 0
the O 0
genetic O 0
markers O 0
THY1 O 0
and O 0
pYNB3 O 0
. O 0

12 O 0
( O 0
D11S144 O 0
) O 0
. O 0

The O 0
most O 0
likely O 0
order O 0
was O 0
cent O 0
- O 0
AT O 0
- O 0
S144 O 0
- O 0
THY1 O 0
. O 0

The O 0
present O 0
paper O 0
describes O 0
further O 0
mapping O 0
of O 0
the O 0
AT B-Disease 0
locus O 0
by O 0
means O 0
of O 0
a O 0
panel O 0
of O 0
10 O 0
markers O 0
that O 0
span O 0
approximately O 0
60 O 0
cM O 0
in O 0
the O 0
11q22 O 0
- O 0
23 O 0
region O 0
centered O 0
around O 0
S144 O 0
and O 0
THY1 O 0
. O 0

Location O 0
scores O 0
indicate O 0
that O 0
three O 0
contiguous O 0
subsegments O 0
within O 0
the O 0
[ O 0
S144 O 0
- O 0
THY1 O 0
] O 0
segment O 0
, O 0
as O 0
well O 0
as O 0
three O 0
contiguous O 0
segments O 0
telomeric O 0
to O 0
THY1 O 0
, O 0
are O 0
each O 0
unlikely O 0
to O 0
contain O 0
the O 0
AT B-Disease 0
locus O 0
, O 0
while O 0
the O 0
more O 0
centromeric O 0
[ O 0
STMY O 0
- O 0
S144 O 0
] O 0
segment O 0
is O 0
most O 0
likely O 0
to O 0
contain O 0
the O 0
AT B-Disease 0
locus O 0
. O 0

These O 0
data O 0
, O 0
together O 0
with O 0
recent O 0
refinements O 0
in O 0
the O 0
linkage O 0
and O 0
physical O 0
maps O 0
of O 0
11q22 O 0
- O 0
23 O 0
, O 0
place O 0
the O 0
AT B-Disease 0
locus O 0
at O 0
11q23 O 0
. O 0

Recurrent O 0
meningitis B-Disease 1
in O 0
a O 0
patient O 0
with O 0
congenital B-Disease 0
deficiency I-Disease 0
of I-Disease 0
the I-Disease 0
C9 I-Disease 0
component I-Disease 0
of I-Disease 0
complement I-Disease 0
. O 0

First O 0
case O 0
of O 0
C9 B-Disease 1
deficiency I-Disease 1
in O 0
Europe O 0
. O 0

We O 0
describe O 0
the O 0
first O 0
cases O 0
, O 0
to O 0
our O 0
knowledge O 0
, O 0
of O 0
C9 B-Disease 1
deficiency I-Disease 1
in O 0
Europe O 0
that O 0
were O 0
detected O 0
in O 0
a O 0
Swiss O 0
family O 0
, O 0
of O 0
which O 0
two O 0
members O 0
- O 0
- O 0
one O 0
with O 0
a O 0
complete O 0
deficiency O 0
and O 0
the O 0
other O 0
with O 0
approximately O 0
half O 0
- O 0
normal O 0
C9 O 0
levels O 0
- O 0
- O 0
experienced O 0
bacterial B-Disease 1
meningitis I-Disease 1
. O 0

The O 0
index O 0
patient O 0
, O 0
a O 0
56 O 0
- O 0
year O 0
- O 0
old O 0
white O 0
man O 0
with O 0
a O 0
history O 0
of O 0
purulent B-Disease 0
meningitis I-Disease 1
at O 0
the O 0
age O 0
of O 0
23 O 0
years O 0
, O 0
presented O 0
with O 0
an O 0
acute B-Disease 0
meningococcal I-Disease 0
meningitis I-Disease 1
. O 0

No O 0
impairment B-Disease 1
of I-Disease 1
cellular I-Disease 1
immunity I-Disease 1
or O 0
immunoglobulin B-Disease 1
deficiency I-Disease 1
could O 0
be O 0
found O 0
. O 0

Complement O 0
assays O 0
showed O 0
a O 0
complete B-Disease 1
deficiency I-Disease 1
of I-Disease 1
the I-Disease 1
C9 I-Disease 1
component I-Disease 1
, O 0
while O 0
the O 0
other O 0
individual O 0
component O 0
levels O 0
were O 0
normal O 0
and O 0
the O 0
hemolytic O 0
activity O 0
( O 0
measured O 0
using O 0
the O 0
CH50 O 0
assay O 0
) O 0
was O 0
only O 0
slightly O 0
reduced O 0
. O 0

A O 0
family O 0
study O 0
revealed O 0
complete B-Disease 0
C9 I-Disease 1
deficiency I-Disease 1
in O 0
the O 0
patients O 0
healthy O 0
brother O 0
and O 0
half O 0
- O 0
normal O 0
C9 O 0
concentrations O 0
in O 0
his O 0
sister O 0
, O 0
his O 0
son O 0
( O 0
who O 0
also O 0
had O 0
experienced O 0
an O 0
episode O 0
of O 0
bacterial B-Disease 1
meningitis I-Disease 1
) O 0
, O 0
and O 0
his O 0
niece O 0
, O 0
consistent O 0
with O 0
an O 0
inherited O 0
C9 B-Disease 1
deficiency I-Disease 1
. O 0

This O 0
first O 0
case O 0
of O 0
recurrent B-Disease 1
meningitis I-Disease 1
in O 0
a O 0
white O 0
patient O 0
with O 0
complete B-Disease 0
C9 I-Disease 1
deficiency I-Disease 1
suggests O 0
that O 0
this O 0
complement B-Disease 0
defect I-Disease 0
may O 0
also O 0
be O 0
a O 0
risk O 0
factor O 0
for O 0
bacterial B-Disease 1
, I-Disease 1
especially I-Disease 1
neisserial I-Disease 1
, I-Disease 1
infections I-Disease 1
. O 0
. O 0

Detection O 0
of O 0
98 O 0
% O 0
of O 0
DMD B-Disease 0
/ O 0
BMD B-Disease 1
gene O 0
deletions O 0
by O 0
polymerase O 0
chain O 0
reaction O 0
. O 0

We O 0
describe O 0
oligonucleotide O 0
primer O 0
sequences O 0
that O 0
can O 0
be O 0
used O 0
to O 0
amplify O 0
eight O 0
exons O 0
plus O 0
the O 0
muscle O 0
promoter O 0
of O 0
the O 0
dystrophin O 0
gene O 0
in O 0
a O 0
single O 0
multiplex O 0
polymerase O 0
chain O 0
reaction O 0
( O 0
PCR O 0
) O 0
. O 0

When O 0
used O 0
in O 0
conjunction O 0
with O 0
an O 0
existing O 0
primer O 0
set O 0
, O 0
these O 0
two O 0
multiplex O 0
reactions O 0
detect O 0
about O 0
98 O 0
% O 0
of O 0
deletions O 0
in O 0
patients O 0
with O 0
Duchenne B-Disease 0
or I-Disease 0
Becker I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
( O 0
DMD B-Disease 0
, O 0
BMD B-Disease 1
) O 0
. O 0

Furthermore O 0
, O 0
these O 0
primers O 0
amplify O 0
most O 0
of O 0
the O 0
exons O 0
in O 0
the O 0
deletion O 0
prone O 0
" O 0
hot O 0
spot O 0
" O 0
region O 0
around O 0
exons O 0
44 O 0
to O 0
53 O 0
, O 0
allowing O 0
determination O 0
of O 0
deletion O 0
endpoints O 0
and O 0
prediction O 0
of O 0
mutational O 0
effects O 0
on O 0
the O 0
translational O 0
reading O 0
frame O 0
. O 0

Thus O 0
, O 0
use O 0
of O 0
these O 0
PCR O 0
- O 0
based O 0
assays O 0
will O 0
allow O 0
deletion O 0
detection O 0
and O 0
prenatal O 0
diagnosis O 0
for O 0
most O 0
DMD B-Disease 0
/ O 0
BMD B-Disease 1
patients O 0
in O 0
a O 0
fraction O 0
of O 0
the O 0
time O 0
required O 0
for O 0
Southern O 0
blot O 0
analysis O 0
. O 0
. O 0

Genetic O 0
heterogeneity O 0
at O 0
the O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
locus O 0
in O 0
southern O 0
Italy O 0
: O 0
a O 0
study O 0
on O 0
a O 0
population O 0
from O 0
the O 0
Matera O 0
district O 0
. O 0

Glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
has O 0
been O 0
analyzed O 0
by O 0
gel O 0
electrophoresis O 0
and O 0
by O 0
quantitative O 0
assay O 0
in O 0
an O 0
unselected O 0
sample O 0
of O 0
1524 O 0
schoolboys O 0
from O 0
the O 0
province O 0
of O 0
Matera O 0
( O 0
Lucania O 0
) O 0
in O 0
southern O 0
Italy O 0
. O 0

We O 0
have O 0
identified O 0
43 O 0
subjects O 0
with O 0
a O 0
G6PD O 0
variant O 0
. O 0

Of O 0
these O 0
, O 0
31 O 0
had O 0
severe O 0
G6PD B-Disease 0
deficiency I-Disease 0
, O 0
nine O 0
had O 0
mild O 0
to O 0
moderate O 0
deficiency O 0
, O 0
and O 0
three O 0
had O 0
a O 0
non O 0
- O 0
deficient O 0
electrophoretic O 0
variant O 0
. O 0

The O 0
overall O 0
rate O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
was O 0
2 O 0
. O 0

6 O 0
% O 0
. O 0

The O 0
frequency O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
, O 0
ranging O 0
from O 0
7 O 0
. O 0

2 O 0
% O 0
on O 0
the O 0
Ionian O 0
Coast O 0
to O 0
zero O 0
on O 0
the O 0
eastern O 0
side O 0
of O 0
the O 0
Lucanian O 0
Apennines O 0
, O 0
appears O 0
to O 0
be O 0
inversely O 0
related O 0
to O 0
the O 0
distance O 0
of O 0
each O 0
town O 0
examined O 0
from O 0
the O 0
Ionian O 0
Coast O 0
, O 0
suggesting O 0
that O 0
this O 0
geographic O 0
distribution O 0
may O 0
reflect O 0
, O 0
at O 0
least O 0
in O 0
part O 0
, O 0
gene O 0
flow O 0
from O 0
Greek O 0
settlers O 0
. O 0

Biochemical O 0
characterization O 0
has O 0
shown O 0
that O 0
most O 0
of O 0
the O 0
G6PD B-Disease 0
deficiency I-Disease 0
in O 0
this O 0
population O 0
is O 0
accounted O 0
for O 0
by O 0
G6PD O 0
Mediterranean O 0
. O 0

In O 0
addition O 0
, O 0
we O 0
have O 0
found O 0
several O 0
examples O 0
of O 0
two O 0
other O 0
known O 0
polymorphic O 0
variants O 0
( O 0
G6PD O 0
Cagliari O 0
and O 0
G6PD O 1
A O 1
- O 1
) O 0
; O 0
three O 0
new O 0
polymorphic O 0
variants O 0
, O 0
G6PD O 0
Metaponto O 0
( O 0
class O 0
III O 0
) O 0
, O 0
G6PD O 0
Montalbano O 0
( O 0
class O 0
III O 0
) O 0
, O 0
and O 0
G6PD O 0
Pisticci O 0
( O 0
class O 0
IV O 0
) O 0
; O 0
and O 0
two O 0
sporadic O 0
variants O 0
, O 0
G6PD O 0
Tursi O 0
( O 0
class O 0
III O 0
) O 0
and O 0
G6PD O 0
Ferrandina O 0
( O 0
class O 0
II O 0
) O 0
. O 0

These O 0
data O 0
provide O 0
further O 0
evidence O 0
for O 0
the O 0
marked O 0
genetic O 0
heterogeneity O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
within O 0
a O 0
relatively O 0
narrow O 0
geographic O 0
area O 0
and O 0
they O 0
prove O 0
the O 0
presence O 0
in O 0
the O 0
Italian O 0
peninsula O 0
of O 0
a O 0
gene O 0
( O 0
GdA O 0
- O 0
) O 0
regarded O 0
as O 0
characteristically O 0
African O 0
. O 0

Deficiency B-Disease 1
of I-Disease 1
the I-Disease 1
murine I-Disease 1
fifth I-Disease 1
complement I-Disease 1
component I-Disease 1
( I-Disease 1
C5 I-Disease 1
) I-Disease 1
. O 0

A O 0
2 O 0
- O 0
base O 0
pair O 0
gene O 0
deletion O 0
in O 0
a O 0
5 O 0
' O 0
- O 0
exon O 0
. O 0

To O 0
ascertain O 0
the O 0
molecular O 0
mechanism O 0
that O 0
causes O 0
murine O 0
C5 B-Disease 0
deficiency I-Disease 0
, O 0
genomic O 0
and O 0
cDNA O 0
libraries O 0
were O 0
constructed O 0
from O 0
mouse O 0
liver O 0
DNA O 0
and O 0
mRNA O 0
employing O 0
the O 0
congenic O 0
strains O 0
B10 O 0
. O 0

D2 O 0
/ O 0
nSnJ O 0
and O 0
B10 O 0
. O 0

D2 O 0
/ O 0
oSnJ O 0
that O 0
are O 0
sufficient O 0
and O 0
deficient B-Disease 1
for I-Disease 1
C5 I-Disease 1
, O 0
respectively O 0
. O 0

Genomic O 0
fragments O 0
were O 0
isolated O 0
which O 0
correspond O 0
to O 0
PvuII O 0
and O 0
HindIII O 0
restriction O 0
fragment O 0
length O 0
polymorphisms O 0
associated O 0
with O 0
C5 B-Disease 0
deficiency I-Disease 0
. O 0

Sequence O 0
analyses O 0
demonstrated O 0
that O 0
each O 0
of O 0
these O 0
polymorphisms O 0
resulted O 0
from O 0
single O 0
base O 0
pair O 0
substitutions O 0
and O 0
that O 0
neither O 0
substitution O 0
would O 0
probably O 0
cause O 0
or O 0
contribute O 0
to O 0
the O 0
C5 B-Disease 0
deficiency I-Disease 0
. O 0

Sequence O 0
analyses O 0
of O 0
C5 O 0
sufficient O 0
and O 0
deficient O 0
cDNAs O 0
revealed O 0
a O 0
2 O 0
base O 0
- O 0
pair O 0
deletion O 0
in O 0
the O 0
deficient O 0
cDNAs O 0
. O 0

The O 0
" O 0
TA O 0
" O 0
deletion O 0
was O 0
located O 0
near O 0
the O 0
5 O 0
end O 0
of O 0
the O 0
cDNA O 0
. O 0

This O 0
deletion O 0
shifts O 0
the O 0
reading O 0
frame O 0
of O 0
the O 0
C5 O 0
mRNA O 0
so O 0
that O 0
the O 0
termination O 0
codon O 0
UGA O 0
is O 0
present O 0
4 O 0
base O 0
pairs O 0
downstream O 0
from O 0
the O 0
deletion O 0
. O 0

Genomic O 0
DNA O 0
was O 0
amplified O 0
and O 0
sequenced O 0
corresponding O 0
to O 0
the O 0
area O 0
surrounding O 0
the O 0
2 O 0
- O 0
base O 0
pair O 0
deletion O 0
. O 0

Six O 0
C5 B-Disease 1
- I-Disease 1
deficient I-Disease 1
strains O 0
, O 0
A O 0
/ O 0
HeJ O 0
, O 0
AKR O 0
/ O 0
J O 0
, O 0
DBA O 0
/ O 0
2J O 0
, O 0
NZB O 0
/ O 0
B1NJ O 0
, O 0
SWR O 0
/ O 0
J O 0
, O 0
and O 0
B10 O 0
. O 0

D2 O 0
/ O 0
oSnJ O 0
, O 0
and O 0
four O 0
C5 O 0
- O 0
sufficient O 0
strains O 0
, O 0
Balb O 0
/ O 0
CJ O 0
, O 0
C57Bl O 0
/ O 0
6J O 0
, O 0
DBA O 0
/ O 0
1J O 0
, O 0
and O 0
B10 O 0
. O 0

D2 O 0
/ O 0
nSnJ O 0
, O 0
were O 0
analyzed O 0
. O 0

The O 0
sequencing O 0
data O 0
revealed O 0
that O 0
the O 0
2 O 0
base O 0
pairs O 0
were O 0
deleted O 0
from O 0
the O 0
C5 O 0
gene O 0
of O 0
each O 0
deficient O 0
mouse O 0
tested O 0
but O 0
not O 0
from O 0
the O 0
C5 O 0
gene O 0
of O 0
any O 0
sufficient O 0
mouse O 0
. O 0

These O 0
data O 0
demonstrate O 0
that O 0
1 O 0
) O 0
there O 0
is O 0
an O 0
identical O 0
2 O 0
- O 0
base O 0
pair O 0
deletion O 0
in O 0
an O 0
exon O 0
of O 0
the O 0
C5 O 0
gene O 0
in O 0
several O 0
different O 0
C5 B-Disease 1
- I-Disease 1
deficient I-Disease 1
mouse O 0
strains O 0
; O 0
2 O 0
) O 0
the O 0
mRNA O 0
transcribed O 0
from O 0
the O 0
C5D O 1
gene O 0
retains O 0
this O 0
deletion O 0
; O 0
and O 0
3 O 0
) O 0
this O 0
mutation O 0
should O 0
result O 0
in O 0
C5 B-Disease 1
protein I-Disease 1
deficiency I-Disease 1
. O 0

Molecular O 0
genetics O 0
of O 0
PKU B-Disease 0
in O 0
eastern O 0
Europe O 0
: O 0
a O 0
nonsense O 0
mutation O 0
associated O 0
with O 0
haplotype O 0
4 O 0
of O 0
the O 0
phenylalanine O 0
hydroxylase O 0
gene O 0
. O 0

Phenylketonuria B-Disease 0
( O 0
PKU B-Disease 0
) O 0
is O 0
a O 0
genetic B-Disease 0
disorder I-Disease 0
secondary O 0
to O 0
a O 0
deficiency B-Disease 0
of I-Disease 0
hepatic I-Disease 0
phenylalanine I-Disease 0
hydroxylase I-Disease 0
( O 0
PAH O 0
) O 0
. O 0

Several O 0
mutations O 0
in O 0
the O 0
PAH O 0
gene O 0
have O 0
recently O 0
been O 0
reported O 0
, O 0
and O 0
linkage O 0
disequilibrium O 0
was O 0
observed O 0
between O 0
RFLP O 0
haplotypes O 0
and O 0
specific O 0
mutations O 0
. O 0

A O 0
new O 0
molecular B-Disease 0
lesion I-Disease 0
has O 0
been O 0
identified O 0
in O 0
exon O 0
7 O 0
of O 0
the O 0
PAH O 0
gene O 0
in O 0
a O 0
Hungarian O 0
PKU B-Disease 0
patient O 0
by O 0
direct O 0
sequencing O 0
of O 0
PCR O 0
- O 0
amplified O 0
DNA O 0
. O 0

The O 0
C O 0
- O 0
to O 0
- O 0
T O 0
transition O 0
causes O 0
the O 0
substitution O 0
of O 0
Arg243 O 0
to O 0
a O 0
termination O 0
codon O 0
, O 0
and O 0
the O 0
mutant O 0
allele O 0
is O 0
associated O 0
with O 0
haplotype O 0
4 O 0
of O 0
the O 0
PAH O 0
gene O 0
. O 0

The O 0
mutation O 0
is O 0
present O 0
in O 0
two O 0
of O 0
nine O 0
mutant O 0
haplotype O 0
4 O 0
alleles O 0
among O 0
Eastern O 0
Europeans O 0
and O 0
is O 0
not O 0
present O 0
among O 0
Western O 0
Europeans O 0
and O 0
Asians O 0
. O 0

The O 0
rarity O 0
of O 0
this O 0
mutant O 0
allele O 0
and O 0
its O 0
restricted O 0
geographic O 0
distribution O 0
suggest O 0
that O 0
the O 0
mutational O 0
event O 0
occurred O 0
recently O 0
on O 0
a O 0
normal O 0
haplotype O 0
4 O 0
background O 0
in O 0
Eastern O 0
Europe O 0
. O 0
. O 0

The O 0
red O 0
- O 0
green O 0
visual O 0
pigment O 0
gene O 0
region O 0
in O 0
adrenoleukodystrophy B-Disease 1
. O 0

Although O 0
recent O 0
data O 0
established O 0
that O 0
a O 0
specific O 0
very O 0
- O 0
long O 0
- O 0
chain O 0
fatty O 0
acyl O 0
- O 0
CoA O 0
synthetase O 0
is O 0
defective O 0
in O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
( O 0
ALD B-Disease 0
) O 0
, O 0
the O 0
ALD B-Disease 0
gene O 0
is O 0
still O 0
unidentified O 0
. O 0

The O 0
ALD B-Disease 0
locus O 0
has O 0
been O 0
mapped O 0
to O 0
Xq28 O 0
, O 0
like O 0
the O 0
red O 0
and O 0
green O 0
color O 0
pigment O 0
genes O 0
. O 0

Abnormal B-Disease 0
color I-Disease 0
vision I-Disease 0
has O 0
been O 0
observed O 0
in O 0
12 O 0
of O 0
27 O 0
patients O 0
with O 0
adrenomyeloneuropathy B-Disease 1
( O 0
AMN B-Disease 0
) O 0
, O 0
a O 0
milder O 0
form O 0
of O 0
ALD B-Disease 0
. O 0

Furthermore O 0
, O 0
rearrangements O 0
of O 0
the O 0
color O 0
vision O 0
gene O 0
cluster O 0
were O 0
found O 0
in O 0
four O 0
of O 0
eight O 0
ALD B-Disease 0
kindreds O 0
. O 0

This O 0
led O 0
us O 0
to O 0
propose O 0
that O 0
a O 0
single O 0
DNA O 0
rearrangement O 0
could O 0
underlie O 0
both O 0
ALD B-Disease 0
and O 0
abnormal B-Disease 0
color I-Disease 0
vision I-Disease 0
in O 0
these O 0
patients O 0
. O 0

Study O 0
of O 0
34 O 0
French O 0
ALD B-Disease 0
patients O 0
failed O 0
to O 0
reveal O 0
a O 0
higher O 0
than O 0
expected O 0
frequency O 0
of O 0
green O 0
/ O 0
red O 0
visual O 0
pigment O 0
rearrangements O 0
3 O 0
to O 0
the O 0
red O 0
/ O 0
green O 0
color O 0
vision O 0
gene O 0
complex O 0
. O 0

The O 0
previous O 0
report O 0
of O 0
such O 0
rearrangements O 0
was O 0
based O 0
on O 0
small O 0
numbers O 0
and O 0
lack O 0
of O 0
knowledge O 0
that O 0
the O 0
frequency O 0
of O 0
" O 0
abnormal O 0
" O 0
color O 0
vision O 0
arrays O 0
on O 0
molecular O 0
analysis O 0
was O 0
twice O 0
as O 0
high O 0
as O 0
expected O 0
on O 0
the O 0
basis O 0
of O 0
the O 0
frequency O 0
of O 0
phenotypic B-Disease 1
color I-Disease 1
vision I-Disease 1
defects I-Disease 1
. O 0

The O 0
red O 0
/ O 0
green O 0
color O 0
pigment O 0
( O 0
R O 0
/ O 0
GCP O 0
) O 0
region O 0
was O 0
studied O 0
by O 0
pulsed O 0
- O 0
field O 0
gel O 0
electrophoresis O 0
in O 0
14 O 0
of O 0
these O 0
patients O 0
, O 0
and O 0
we O 0
did O 0
not O 0
find O 0
any O 0
fragment O 0
size O 0
difference O 0
between O 0
the O 0
patients O 0
and O 0
normal O 0
individuals O 0
who O 0
have O 0
the O 0
same O 0
number O 0
of O 0
pigment O 0
genes O 0
. O 0

The O 0
R O 0
/ O 0
GCP O 0
region O 0
was O 0
also O 0
analyzed O 0
in O 0
29 O 0
French O 0
and O 0
seven O 0
North O 0
American O 0
ALD B-Disease 0
patients O 0
by O 0
using O 0
six O 0
genomic O 0
DNA O 0
probes O 0
, O 0
isolated O 0
from O 0
a O 0
cosmid O 0
walk O 0
, O 0
that O 0
flank O 0
the O 0
color O 0
vision O 0
genes O 0
. O 0

No O 0
deletions O 0
were O 0
found O 0
with O 0
probes O 0
that O 0
lie O 0
3 O 0
of O 0
the O 0
green O 0
pigment O 0
genes O 0
. O 0

One O 0
of O 0
the O 0
eight O 0
previously O 0
reported O 0
ALD B-Disease 0
individuals O 0
has O 0
a O 0
long O 0
deletion O 0
5 O 0
of O 0
the O 0
red O 0
pigment O 0
gene O 0
, O 0
a O 0
deletion O 0
causing O 0
blue O 0
cone O 0
monochromacy O 0
. O 0

This O 0
finding O 0
and O 0
the O 0
previous O 0
findings O 0
of O 0
a O 0
45 O 0
% O 0
frequency O 0
of O 0
phenotypic O 1
color O 1
vision O 1
defects O 1
in O 0
patients O 0
with O 0
AMN B-Disease 0
may O 0
suggest O 0
that O 0
the O 0
ALD B-Disease 0
/ O 0
AMN B-Disease 0
gene O 0
lies O 0
5 O 0
to O 0
the O 0
red O 0
pigment O 0
gene O 0
and O 0
that O 0
the O 0
frequent O 0
phenotypic O 0
color B-Disease 0
vision I-Disease 0
anomalies I-Disease 0
owe O 0
their O 0
origin O 0
to O 0
deleted O 0
DNA O 0
that O 0
includes O 0
regulatory O 0
genes O 0
for O 0
color O 0
vision O 0
. O 0

It O 0
is O 0
possible O 0
, O 0
however O 0
, O 0
that O 0
phenotypic O 0
color B-Disease 0
vision I-Disease 0
anomalies I-Disease 0
in O 0
AMN B-Disease 0
may O 0
be O 0
phenocopies O 0
secondary O 0
to O 0
retinal O 0
or O 0
neural O 0
involvement O 0
by O 0
the O 0
disease O 0
. O 0

The O 0
single O 0
case O 0
of O 0
blue O 0
cone O 0
monochromacy O 0
may O 0
therefore O 0
be O 0
a O 0
fortuitous O 0
coincidence O 0
of O 0
two O 0
diseases O 0
. O 0
. O 0

Paroxysmal B-Disease 0
nocturnal I-Disease 0
haemoglobinuria I-Disease 1
with O 0
coexisting O 0
deficiency B-Disease 0
of I-Disease 0
the I-Disease 0
ninth I-Disease 0
component I-Disease 0
of I-Disease 0
complement I-Disease 0
: O 0
lack O 0
of O 0
massive O 0
haemolytic B-Disease 0
attack I-Disease 0
. O 0

A O 0
47 O 0
- O 0
year O 0
- O 0
old O 0
woman O 0
with O 0
paroxysmal B-Disease 0
nocturnal I-Disease 0
haemoglobinuria I-Disease 1
( O 0
PNH B-Disease 0
) O 0
was O 0
found O 0
to O 0
have O 0
an O 0
inherited B-Disease 1
deficiency I-Disease 1
in I-Disease 1
the I-Disease 1
ninth I-Disease 1
complement I-Disease 1
component I-Disease 1
( O 0
C9 O 0
) O 0
. O 0

In O 0
complement O 0
- O 0
sensitivity O 0
lysis O 0
tests O 0
, O 0
80 O 0
% O 0
of O 0
her O 0
erythrocytes O 0
were O 0
markedly O 0
complement O 0
- O 0
sensitive O 0
( O 0
PNH O 0
- O 0
III O 0
) O 0
. O 0

Laser O 0
cytofluorimetry O 0
with O 0
a O 0
monoclonal O 0
antibody O 0
against O 0
decay O 0
- O 0
accelerating O 0
factor O 0
( O 0
DAF O 0
) O 0
revealed O 0
that O 0
95 O 0
% O 0
of O 0
her O 0
erythrocytes O 0
were O 0
DAF O 0
- O 0
negative O 0
. O 0

Surprisingly O 0
, O 0
she O 0
has O 0
suffered O 0
only O 0
mild O 0
haemolysis B-Disease 0
and O 0
has O 0
never O 0
experienced O 0
massive O 0
spontaneous O 0
haemolysis B-Disease 0
. O 0

Gross O 0
haemoglobinuria B-Disease 1
and O 0
jaundice B-Disease 0
occurred O 0
only O 0
after O 0
receiving O 0
postoperative O 0
transfusion O 0
of O 0
whole O 0
blood O 0
. O 0

In O 0
her O 0
serum O 0
, O 0
C9 O 0
was O 0
not O 0
detectable O 0
either O 0
by O 0
immunological O 0
or O 0
by O 0
functional O 0
assays O 0
. O 0

Both O 0
the O 0
Ham O 0
test O 0
and O 0
the O 0
sugar O 0
water O 0
test O 0
using O 0
normal O 0
human O 0
serum O 0
or O 0
plasma O 0
yielded O 0
marked O 0
haemolysis O 0
of O 0
the O 0
patients O 0
erythrocytes O 0
. O 0

When O 0
the O 0
patients O 0
serum O 0
or O 0
plasma O 0
was O 0
used O 0
, O 0
only O 0
a O 0
trace O 0
of O 0
lysis O 0
was O 0
detected O 0
. O 0

Addition O 0
of O 0
purified O 0
human O 0
C9 O 0
to O 0
her O 0
plasma O 0
fully O 0
restored O 0
haemolysis O 0
. O 0

These O 0
observations O 0
indicated O 0
that O 0
C9 O 0
may O 0
play O 0
a O 0
critical O 0
role O 0
in O 0
haemolytic B-Disease 0
attacks I-Disease 0
in O 0
patients O 0
with O 0
PNH B-Disease 0
and O 0
that O 0
characteristic O 0
haemolysis B-Disease 0
in O 0
PNH B-Disease 0
may O 0
be O 0
tempered O 0
by O 0
coexisting O 0
C9 B-Disease 1
deficiency I-Disease 1
. O 0
. O 0

Duplicational O 0
mutation O 0
at O 0
the O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
locus O 0
: O 0
its O 0
frequency O 0
, O 0
distribution O 0
, O 0
origin O 0
, O 0
and O 0
phenotypegenotype O 0
correlation O 0
. O 0

Partial O 0
gene O 0
deletion O 0
is O 0
the O 0
major O 0
cause O 0
of O 0
mutation O 0
leading O 0
to O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
and O 0
Becker B-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
( O 0
BMD B-Disease 1
) O 0
. O 0

Partial O 0
gene O 0
duplication O 0
has O 0
also O 0
been O 0
recognized O 0
in O 0
a O 0
few O 0
cases O 0
. O 0

We O 0
have O 0
conducted O 0
a O 0
survey O 0
for O 0
duplication O 0
in O 0
72 O 0
unrelated O 0
nondeletion O 0
patients O 0
, O 0
analyzed O 0
by O 0
Southern O 0
blot O 0
hybridization O 0
with O 0
clones O 0
representing O 0
the O 0
entire O 0
DMD B-Disease 0
cDNA O 0
. O 0

With O 0
careful O 0
quantitative O 0
analysis O 0
of O 0
hybridization O 0
band O 0
intensity O 0
, O 0
10 O 0
cases O 0
were O 0
found O 0
to O 0
carry O 0
a O 0
duplication O 0
of O 0
part O 0
of O 0
the O 0
gene O 0
, O 0
a O 0
frequency O 0
of O 0
14 O 0
% O 0
for O 0
nondeletion O 0
cases O 0
( O 0
10 O 0
/ O 0
72 O 0
) O 0
, O 0
or O 0
6 O 0
% O 0
for O 0
all O 0
cases O 0
( O 0
10 O 0
/ O 0
181 O 0
) O 0
. O 0

The O 0
extent O 0
of O 0
these O 0
duplications O 0
has O 0
been O 0
characterized O 0
according O 0
to O 0
the O 0
published O 0
exon O 0
- O 0
containing O 0
HindIII O 0
fragment O 0
map O 0
, O 0
and O 0
in O 0
six O 0
of O 0
the O 0
10 O 0
duplications O 0
a O 0
novel O 0
restriction O 0
fragment O 0
that O 0
spanned O 0
the O 0
duplication O 0
junction O 0
was O 0
detected O 0
. O 0

The O 0
resulting O 0
translational O 0
reading O 0
frame O 0
of O 0
mRNA O 0
has O 0
been O 0
predicted O 0
for O 0
nine O 0
duplications O 0
. O 0

A O 0
shift O 0
of O 0
the O 0
reading O 0
frame O 0
was O 0
predicted O 0
in O 0
four O 0
of O 0
the O 0
six O 0
DMD B-Disease 0
cases O 0
and O 0
in O 0
one O 0
of O 0
the O 0
two O 0
intermediate O 0
cases O 0
, O 0
while O 0
the O 0
reading O 0
frame O 0
remained O 0
uninterrupted O 0
in O 0
both O 0
BMD B-Disease 1
cases O 0
. O 0

RFLP O 0
and O 0
quantitative O 0
Southern O 0
blot O 0
analyses O 0
revealed O 0
a O 0
grandpaternal O 0
origin O 0
of O 0
duplication O 0
in O 0
four O 0
families O 0
and O 0
grandmaternal O 0
origin O 0
in O 0
one O 0
family O 0
. O 0

In O 0
all O 0
five O 0
families O 0
, O 0
the O 0
duplication O 0
was O 0
found O 0
to O 0
originate O 0
from O 0
a O 0
single O 0
X O 0
chromosome O 0
. O 0

Unequal O 0
sister O 0
- O 0
chromatid O 0
exchange O 0
is O 0
proposed O 0
to O 0
be O 0
the O 0
mechanism O 0
for O 0
the O 0
formation O 0
of O 0
these O 0
duplications O 0
. O 0
. O 0

Glucose O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
variants O 0
: O 0
Gd O 0
( O 0
+ O 0
) O 0
Alexandra O 0
associated O 0
with O 0
neonatal B-Disease 1
jaundice I-Disease 1
and O 0
Gd O 0
( O 0
- O 0
) O 0
Camperdown O 0
in O 0
a O 0
young O 0
man O 0
with O 0
lamellar B-Disease 1
cataracts I-Disease 1
. O 0

Two O 0
male O 0
subjects O 0
are O 0
described O 0
, O 0
with O 0
unusual O 0
clinical O 0
presentations O 0
and O 0
with O 0
hitherto O 0
undescribed O 0
G6PD O 0
variants O 0
. O 0

The O 0
first O 0
, O 0
of O 0
Italian O 0
extraction O 0
, O 0
suffered O 0
from O 0
severe O 1
neonatal B-Disease 1
jaundice I-Disease 1
following O 0
maternal O 0
ingestion O 0
of O 0
fresh O 0
broad O 0
beans O 0
( O 0
Vicia O 0
fava O 0
) O 0
both O 0
prenatally O 0
and O 0
postnatally O 0
the O 0
expression O 0
of O 0
the O 0
enzymatic O 0
defect O 0
was O 0
much O 0
more O 0
severe O 0
in O 0
the O 0
neonatal O 0
period O 0
than O 0
on O 0
retesting O 0
in O 0
adolescence O 0
, O 0
when O 0
biochemical O 0
characterization O 0
showed O 0
unique O 0
features O 0
which O 0
justify O 0
designation O 0
as O 0
a O 0
new O 0
variant O 0
Gd O 0
( O 0
+ O 0
) O 0
Alexandra O 0
. O 0

The O 0
second O 0
patient O 0
, O 0
a O 0
boy O 0
of O 0
Maltese O 0
extraction O 0
who O 0
was O 0
found O 0
to O 0
have O 0
bilateral B-Disease 1
lamellar I-Disease 1
cataracts I-Disease 1
at O 0
the O 0
age O 0
of O 0
4 O 0
years O 0
, O 0
was O 0
identified O 0
as O 0
G6PD B-Disease 1
deficient I-Disease 1
only O 0
as O 0
a O 0
result O 0
of O 0
a O 0
survey O 0
of O 0
children O 0
of O 0
Mediterranean O 0
origin O 0
with O 0
unexplained O 0
cataract B-Disease 0
formation O 0
; O 0
he O 0
has O 0
approximately O 0
15 O 0
% O 0
of O 0
normal O 0
enzyme O 0
activity O 0
, O 0
with O 0
another O 0
unique O 0
combination O 0
of O 0
biochemical O 0
characteristics O 0
which O 0
has O 0
led O 0
to O 0
its O 0
designation O 0
as O 0
Gd O 0
( O 0
- O 0
) O 0
Camperdown O 0
. O 0

Although O 0
this O 0
association O 0
may O 0
be O 0
coincidental O 0
, O 0
it O 0
prompts O 0
further O 0
attention O 0
to O 0
the O 0
possibility O 0
that O 0
under O 0
certain O 0
circumstances O 0
G6PD B-Disease 0
deficiency I-Disease 0
may O 0
favor O 0
cataract B-Disease 0
formation O 0
. O 0

The O 0
two O 0
cases O 0
illustrate O 0
the O 0
value O 0
of O 0
characterization O 0
of O 0
the O 0
mutant O 0
enzyme O 0
whenever O 0
unexpected O 0
clinical O 0
or O 0
laboratory O 0
results O 0
are O 0
obtained O 0
. O 0
. O 0

Statistical O 0
analysis O 0
of O 0
the O 0
two O 0
stage O 0
mutation O 0
model O 0
in O 0
von B-Disease 0
Hippel I-Disease 0
- I-Disease 0
Lindau I-Disease 0
disease I-Disease 0
, O 0
and O 0
in O 0
sporadic B-Disease 1
cerebellar I-Disease 1
haemangioblastoma I-Disease 1
and O 0
renal B-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
. O 0

Analysis O 0
of O 0
the O 0
age O 0
incidence O 0
curves O 0
for O 0
unilateral B-Disease 0
and I-Disease 0
bilateral I-Disease 0
retinoblastoma I-Disease 1
led O 0
Knudson O 0
to O 0
propose O 0
that O 0
hereditary B-Disease 1
tumours I-Disease 1
may O 0
arise O 0
by O 0
a O 0
single O 0
event O 0
and O 0
sporadic B-Disease 1
tumours I-Disease 1
by O 0
a O 0
two O 0
stage O 0
mutation O 0
process O 0
. O 0

It O 0
has O 0
been O 0
suggested O 0
recently O 0
that O 0
sporadic B-Disease 0
renal I-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
may O 0
arise O 0
from O 0
a O 0
two O 0
stage O 0
mutation O 0
process O 0
. O 0

We O 0
analysed O 0
the O 0
age O 0
incidence O 0
curves O 0
for O 0
symptomatic O 0
renal B-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
( O 0
n O 0
= O 0
26 O 0
) O 0
and O 0
cerebellar B-Disease 0
haemangioblastoma I-Disease 0
( O 0
n O 0
= O 0
68 O 0
) O 0
in O 0
109 O 0
patients O 0
with O 0
von B-Disease 0
Hippel I-Disease 0
- I-Disease 0
Lindau I-Disease 0
( I-Disease 0
VHL I-Disease 1
) I-Disease 0
disease I-Disease 0
, O 0
and O 0
compared O 0
them O 0
to O 0
104 O 0
patients O 0
with O 0
sporadic B-Disease 0
renal I-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
and O 0
43 O 0
patients O 0
with O 0
sporadic B-Disease 1
cerebellar I-Disease 1
haemangioblastoma I-Disease 1
. O 0

The O 0
age O 0
incidence O 0
curves O 0
for O 0
renal B-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
and O 0
cerebellar B-Disease 0
haemangioblastoma I-Disease 0
in O 0
VHL B-Disease 1
disease I-Disease 1
were O 0
compatible O 0
with O 0
a O 0
single O 0
mutation O 0
model O 0
, O 0
whereas O 0
the O 0
age O 0
incidence O 0
curves O 0
for O 0
sporadic B-Disease 0
renal I-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
and O 0
cerebellar B-Disease 0
haemangioblastoma I-Disease 0
suggested O 0
a O 0
two O 0
stage O 0
mutation O 0
process O 0
. O 0

These O 0
data O 0
are O 0
compatible O 0
with O 0
the O 0
VHL B-Disease 1
gene O 0
functioning O 0
as O 0
a O 0
recessive O 0
tumour B-Disease 1
suppressor O 0
gene O 0
. O 0

Sporadic B-Disease 1
cerebellar I-Disease 1
haemangioblastoma I-Disease 1
and O 0
some O 0
renal B-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
may O 0
arise O 0
from O 0
somatic O 0
mutations O 0
inactivating O 0
both O 0
alleles O 0
at O 0
the O 0
VHL B-Disease 1
locus O 0
. O 0
. O 0

Screening O 0
for O 0
carriers O 0
of O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
among O 0
Ashkenazi O 0
Jews O 0
. O 0

A O 0
comparison O 0
of O 0
DNA O 0
- O 0
based O 0
and O 0
enzyme O 0
- O 0
based O 0
tests O 0
. O 0

BACKGROUND O 0
AND O 0
METHODS O 0
. O 0

The O 0
prevention O 0
of O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
( O 0
GM2 B-Disease 1
gangliosidosis I-Disease 1
, I-Disease 1
type I-Disease 1
1 I-Disease 1
) O 0
depends O 0
on O 0
the O 0
identification O 0
of O 0
carriers O 0
of O 0
the O 0
gene O 0
for O 0
this O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
. O 0

We O 0
compared O 0
the O 0
enzyme O 0
- O 0
based O 0
test O 0
widely O 0
used O 0
in O 0
screening O 0
for O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
with O 0
a O 0
test O 0
based O 0
on O 0
analysis O 0
of O 0
DNA O 0
. O 0

We O 0
developed O 0
methods O 0
to O 0
detect O 0
the O 0
three O 0
mutations O 0
in O 0
the O 0
HEXA O 0
gene O 0
that O 0
occur O 0
with O 0
high O 0
frequency O 0
among O 0
Ashkenazi O 0
Jews O 0
two O 0
mutations O 0
cause O 0
infantile O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
, O 0
and O 0
the O 0
third O 0
causes O 0
the O 0
adult O 0
- O 0
onset O 0
form O 0
of O 0
the O 0
disease O 0
. O 0

DNA O 0
segments O 0
containing O 0
these O 0
mutation O 0
sites O 0
were O 0
amplified O 0
with O 0
the O 0
polymerase O 0
chain O 0
reaction O 0
and O 0
analyzed O 0
for O 0
the O 0
presence O 0
of O 0
the O 0
mutations O 0
. O 0

RESULTS O 0
. O 0

Among O 0
62 O 0
Ashkenazi O 0
obligate O 0
carriers O 0
of O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
, O 0
the O 0
three O 0
specific O 0
mutations O 0
accounted O 0
for O 0
all O 0
but O 0
one O 0
of O 0
the O 0
mutant O 0
alleles O 0
( O 0
98 O 0
percent O 0
) O 0
. O 0

In O 0
216 O 0
Ashkenazi O 0
carriers O 0
identified O 0
by O 0
the O 0
enzyme O 0
test O 0
, O 0
DNA O 0
analysis O 0
showed O 0
that O 0
177 O 0
( O 0
82 O 0
percent O 0
) O 0
had O 0
one O 0
of O 0
the O 0
identified O 0
mutations O 0
. O 0

Of O 0
the O 0
177 O 0
, O 0
79 O 0
percent O 0
had O 0
the O 0
exon O 0
11 O 0
insertion O 0
mutation O 0
, O 0
18 O 0
percent O 0
had O 0
the O 0
intron O 0
12 O 0
splice O 0
- O 0
junction O 0
mutation O 0
, O 0
and O 0
3 O 0
percent O 0
had O 0
the O 0
less O 0
severe O 0
exon O 0
7 O 0
mutation O 0
associated O 0
with O 0
adult O 0
- O 0
onset O 0
disease O 0
. O 0

The O 0
results O 0
of O 0
the O 0
enzyme O 0
tests O 0
in O 0
the O 0
39 O 0
subjects O 0
( O 0
18 O 0
percent O 0
) O 0
who O 0
were O 0
defined O 0
as O 0
carriers O 0
but O 0
in O 0
whom O 0
DNA O 0
analysis O 0
did O 0
not O 0
identify O 0
a O 0
mutant O 0
allele O 0
were O 0
probably O 0
false O 0
positive O 0
( O 0
although O 0
there O 0
remains O 0
some O 0
possibility O 0
of O 0
unidentified O 0
mutations O 0
) O 0
. O 0

In O 0
addition O 0
, O 0
of O 0
152 O 0
persons O 0
defined O 0
as O 0
noncarriers O 0
by O 0
the O 0
enzyme O 0
- O 0
based O 0
test O 0
, O 0
1 O 0
was O 0
identified O 0
as O 0
a O 0
carrier O 0
by O 0
DNA O 0
analysis O 0
( O 0
i O 0
. O 0
e O 0
e O 0
. O 0
, O 0
a O 0
false O 0
negative O 0
enzyme O 0
- O 0
test O 0
result O 0
) O 0
. O 0

CONCLUSIONS O 0
. O 0

The O 0
increased O 0
specificity O 0
and O 0
predictive O 0
value O 0
of O 0
the O 0
DNA O 0
- O 0
based O 0
test O 0
make O 0
it O 0
a O 0
useful O 0
adjunct O 0
to O 0
the O 0
diagnostic O 0
tests O 0
currently O 0
used O 0
to O 0
screen O 0
for O 0
carriers O 0
of O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
. O 0

Total B-Disease 0
deficiency I-Disease 0
of I-Disease 0
plasma I-Disease 0
cholesteryl I-Disease 0
ester I-Disease 0
transfer I-Disease 0
protein I-Disease 0
in O 0
subjects O 0
homozygous O 0
and O 0
heterozygous O 0
for O 0
the O 0
intron O 0
14 O 0
splicing O 0
defect O 0
. O 0

The O 0
molecular O 0
basis O 0
of O 0
cholesteryl B-Disease 0
ester I-Disease 0
transfer I-Disease 0
protein I-Disease 0
( I-Disease 0
CETP I-Disease 0
) I-Disease 0
deficiency I-Disease 0
was O 0
investigated O 0
in O 0
4 O 0
unrelated O 0
CETP B-Disease 1
- I-Disease 1
deficient I-Disease 1
families O 0
. O 0

The O 0
high O 0
density O 0
lipoprotein O 0
- O 0
cholesterol O 0
levels O 0
of O 0
the O 0
probands O 0
exceeded O 0
150 O 0
mg O 0
/ O 0
dl O 0
. O 0

The O 0
plasma O 0
of O 0
the O 0
probands O 0
was O 0
totally O 0
deficient O 0
in O 0
CETP O 0
activity O 0
and O 0
mass O 0
. O 0

The O 0
genomic O 0
DNA O 0
of O 0
the O 0
patients O 0
was O 0
amplified O 0
by O 0
polymerase O 0
chain O 0
reaction O 0
, O 0
using O 0
two O 0
oligonucleotide O 0
primers O 0
located O 0
in O 0
the O 0
intron O 0
12 O 0
and O 0
14 O 0
of O 0
the O 0
CETP O 0
gene O 0
, O 0
and O 0
the O 0
amplified O 0
products O 0
were O 0
directly O 0
sequenced O 0
. O 0

Two O 0
patients O 0
were O 0
homozygous O 0
for O 0
a O 0
G O 0
- O 0
to O 0
- O 0
A O 0
change O 0
at O 0
the O 0
5 O 0
- O 0
splice O 0
donor O 0
site O 0
of O 0
the O 0
intron O 0
14 O 0
. O 0

The O 0
G O 0
- O 0
to O 0
- O 0
A O 0
change O 0
would O 0
cause O 0
impaired O 0
splicing O 0
of O 0
pre O 0
- O 0
messenger O 0
RNA O 0
. O 0

The O 0
other O 0
two O 0
probands O 0
were O 0
heterozygous O 0
for O 0
the O 0
mutation O 0
, O 0
but O 0
totally O 0
lacked O 0
CETP O 0
. O 0

Their O 0
lipoprotein O 0
patterns O 0
were O 0
also O 0
similar O 0
to O 0
those O 0
of O 0
the O 0
two O 0
homozygotes O 0
. O 0

Thus O 0
, O 0
other O 0
genetic B-Disease 0
defects I-Disease 0
or O 0
metabolic O 0
factors O 0
influencing O 0
CETP O 0
expression O 0
are O 0
implicated O 0
. O 0

The O 0
data O 0
suggest O 0
that O 0
the O 0
G O 0
- O 0
to O 0
- O 0
A O 0
mutation O 0
may O 0
be O 0
common O 0
in O 0
human O 0
plasma O 0
CETP B-Disease 0
deficiency I-Disease 0
. O 0

Furthermore O 0
, O 0
there O 0
could O 0
be O 0
compound O 0
heterozygotes O 0
who O 0
totally O 0
lack O 0
plasma O 0
CETP O 0
and O 0
have O 0
lipoprotein O 0
profiles O 0
similar O 0
to O 0
those O 0
of O 0
homozygotes O 0
. O 0
. O 0

Molecular O 0
genetics O 0
of O 0
the O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
Mediterranean O 0
variant O 0
and O 0
description O 0
of O 0
a O 0
new O 0
G6PD O 0
mutant O 0
, O 0
G6PD O 0
Andalus1361A O 0
. O 0

Glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
; I-Disease 0
E I-Disease 0
. I-Disease 0
C I-Disease 0
. I-Disease 0
1 I-Disease 0
. I-Disease 0
1 I-Disease 0
. I-Disease 0
1 I-Disease 0
. I-Disease 0
49 I-Disease 0
) I-Disease 0
deficiency I-Disease 0
is O 0
the O 0
most O 0
common O 0
human O 0
enzymopathy B-Disease 0
; O 0
more O 0
than O 0
300 O 0
different O 0
biochemical O 0
variants O 0
of O 0
the O 0
enzyme O 0
have O 0
been O 0
described O 0
. O 0

In O 0
many O 0
parts O 0
of O 0
the O 0
world O 0
the O 0
Mediterranean O 0
type O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
is O 0
prevalent O 0
. O 0

However O 0
, O 0
G6PD O 0
Mediterranean O 0
has O 0
come O 0
to O 0
be O 0
regarded O 0
as O 0
a O 0
generic O 0
term O 0
applied O 0
to O 0
similar O 0
G6PD O 0
mutations O 0
thought O 0
, O 0
however O 0
, O 0
to O 0
represent O 0
a O 0
somewhat O 0
heterogeneous O 0
group O 0
. O 0

A O 0
C O 0
- O 0
- O 0
- O 0
- O 0
T O 0
mutation O 0
at O 0
nucleotide O 0
563 O 0
of O 0
G6PD O 0
Mediterranean O 0
has O 0
been O 0
identified O 0
by O 0
Vulliamy O 0
et O 0
al O 0
. O 0
, O 0
and O 0
the O 0
same O 0
mutation O 0
has O 0
been O 0
found O 0
by O 0
De O 0
Vita O 0
et O 0
al O 0
. O 0
in O 0
G6PD O 0
Mediterranean O 0
, O 0
G6PD O 0
Sassari O 0
, O 0
and O 0
G6PD O 0
Cagliari O 0
. O 0

The O 0
latter O 0
subjects O 0
had O 0
an O 0
additional O 0
mutation O 0
, O 0
at O 0
nucleotide O 0
1311 O 0
, O 0
that O 0
did O 0
not O 0
produce O 0
a O 0
coding O 0
change O 0
. O 0

We O 0
have O 0
examined O 0
genomic O 0
DNA O 0
of O 0
five O 0
patients O 0
- O 0
- O 0
four O 0
of O 0
Spanish O 0
origin O 0
and O 0
one O 0
of O 0
Jewish O 0
origin O 0
- O 0
- O 0
having O 0
enzymatically O 0
documented O 0
G6PD O 0
Mediterranean O 0
. O 0

All O 0
had O 0
both O 0
the O 0
mutation O 0
at O 0
nucleotide O 0
563 O 0
and O 0
that O 0
at O 0
nucleotide O 0
1311 O 0
. O 0

A O 0
sixth O 0
sample O 0
, O 0
resembling O 0
G6PD O 0
Mediterranean O 0
kinetically O 0
but O 0
with O 0
a O 0
slightly O 0
rapid O 0
electrophoretic O 0
mobility O 0
, O 0
was O 0
designated O 0
G6PD O 0
Andalus O 0
and O 0
was O 0
found O 0
to O 0
have O 0
a O 0
different O 0
mutation O 0
, O 0
a O 0
G O 0
- O 0
- O 0
- O 0
- O 0
A O 0
transition O 0
at O 0
nucleotide O 0
1361 O 0
, O 0
producing O 0
an O 0
arginine O 0
- O 0
to O 0
- O 0
histidine O 0
substitution O 0
. O 0

These O 0
studies O 0
suggest O 0
that O 0
G6PD O 0
Mediterranean O 0
is O 0
, O 0
after O 0
all O 0
, O 0
relatively O 0
homogeneous O 0
. O 0

A O 0
normal O 0
male O 0
with O 0
an O 0
inherited O 0
deletion O 0
of O 0
one O 0
exon O 0
within O 0
the O 0
DMD B-Disease 0
gene O 0
. O 0

We O 0
describe O 0
two O 0
brothers O 0
with O 0
identical O 0
inherited O 0
deletions O 0
of O 0
one O 0
single O 0
exon O 0
within O 0
the O 0
middle O 0
of O 0
the O 0
DMD B-Disease 0
gene O 0
; O 0
one O 0
brother O 0
has O 0
Becker B-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
diagnosed O 0
at O 0
11 O 0
years O 0
of O 0
age O 0
, O 0
whereas O 0
the O 0
older O 0
brother O 0
is O 0
normal O 0
at O 0
18 O 0
. O 0

These O 0
results O 0
have O 0
implications O 0
for O 0
genetic O 0
counselling O 0
and O 0
prenatal O 0
diagnosis O 0
in O 0
families O 0
with O 0
Becker B-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
. O 0
. O 0

Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
gene O 0
expression O 0
in O 0
normal O 0
and O 0
diseased O 0
human O 0
muscle O 0
. O 0

A O 0
probe O 0
for O 0
the O 0
5 O 0
end O 0
of O 0
the O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
gene O 0
was O 0
used O 0
to O 0
study O 0
expression O 0
of O 0
the O 0
gene O 0
in O 0
normal O 0
human O 0
muscle O 0
, O 0
myogenic O 0
cell O 0
cultures O 0
, O 0
and O 0
muscle O 0
from O 0
patients O 0
with O 0
DMD B-Disease 0
. O 0

Expression O 0
was O 0
found O 0
in O 0
RNA O 0
from O 0
normal O 0
fetal O 0
muscle O 0
, O 0
adult O 0
cardiac O 0
and O 0
skeletal O 0
muscle O 0
, O 0
and O 0
cultured O 0
muscle O 0
after O 0
myoblast O 0
fusion O 0
. O 0

In O 0
DMD B-Disease 0
muscle O 0
, O 0
expression O 0
of O 0
this O 0
portion O 0
of O 0
the O 0
gene O 0
was O 0
also O 0
revealed O 0
by O 0
in O 0
situ O 0
RNA O 0
hybridization O 0
, O 0
particularly O 0
in O 0
regenerating O 0
muscle O 0
fibers O 0
. O 0
. O 0

Molecular O 0
and O 0
phenotypic O 0
analysis O 0
of O 0
patients O 0
with O 0
deletions O 0
within O 0
the O 0
deletion O 0
- O 0
rich O 0
region O 0
of O 0
the O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
gene O 0
. O 0

Eighty O 0
unrelated O 0
individuals O 0
with O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
or O 0
Becker B-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
( O 0
BMD B-Disease 1
) O 0
were O 0
found O 0
to O 0
have O 0
deletions O 0
in O 0
the O 0
major O 0
deletion O 0
- O 0
rich O 0
region O 0
of O 0
the O 0
DMD B-Disease 0
locus O 0
. O 0

This O 0
region O 0
includes O 0
the O 0
last O 0
five O 0
exons O 0
detected O 0
by O 0
cDNA5b O 0
- O 0
7 O 0
, O 0
all O 0
exons O 0
detected O 0
by O 0
cDNA8 O 0
, O 0
and O 0
the O 0
first O 0
two O 0
exons O 0
detected O 0
by O 0
cDNA9 O 0
. O 0

These O 0
80 O 0
individuals O 0
account O 0
for O 0
approximately O 0
75 O 0
% O 0
of O 0
109 O 0
deletions O 0
of O 0
the O 0
gene O 0
, O 0
detected O 0
among O 0
181 O 0
patients O 0
analyzed O 0
with O 0
the O 0
entire O 0
dystrophin O 0
cDNA O 0
. O 0

Endpoints O 0
for O 0
many O 0
of O 0
these O 0
deletions O 0
were O 0
further O 0
characterized O 0
using O 0
two O 0
genomic O 0
probes O 0
, O 0
p20 O 0
( O 0
DXS269 O 0
; O 0
Wapenaar O 0
et O 0
al O 0
. O 0
) O 0
and O 0
GMGX11 O 0
( O 0
DXS239 O 0
; O 0
present O 0
paper O 0
) O 0
. O 0

Clinical O 0
findings O 0
are O 0
presented O 0
for O 0
all O 0
80 O 0
patients O 0
allowing O 0
a O 0
correlation O 0
of O 0
phenotypic O 0
severity O 0
with O 0
the O 0
genotype O 0
. O 0

Thirty O 0
- O 0
eight O 0
independent O 0
patients O 0
were O 0
old O 0
enough O 0
to O 0
be O 0
classified O 0
as O 0
DMD B-Disease 0
, O 0
BMD B-Disease 1
, O 0
or O 0
intermediate O 0
phenotype O 0
and O 0
had O 0
deletions O 0
of O 0
exons O 0
with O 0
sequenced O 0
intron O 0
/ O 0
exon O 0
boundaries O 0
. O 0

Of O 0
these O 0
, O 0
eight O 0
BMD B-Disease 1
patients O 0
and O 0
one O 0
intermediate O 0
patient O 0
had O 0
gene O 0
deletions O 0
predicted O 0
to O 0
leave O 0
the O 0
reading O 0
frame O 0
intact O 0
, O 0
while O 0
21 O 0
DMD B-Disease 0
patients O 0
, O 0
7 O 0
intermediate O 0
patients O 0
, O 0
and O 0
1 O 0
BMD B-Disease 1
patient O 0
had O 0
gene O 0
deletions O 0
predicted O 0
to O 0
disrupt O 0
the O 0
reading O 0
frame O 0
. O 0

Thus O 0
, O 0
with O 0
two O 0
exceptions O 0
, O 0
frameshift O 0
deletions O 0
of O 0
the O 0
gene O 0
resulted O 0
in O 0
more O 0
severe O 0
phenotype O 0
than O 0
did O 0
in O 0
- O 0
frame O 0
deletions O 0
. O 0

This O 0
is O 0
in O 0
agreement O 0
with O 0
recent O 0
findings O 0
by O 0
Baumbach O 0
et O 0
al O 0
. O 0
and O 0
Koenig O 0
et O 0
al O 0
. O 0
but O 0
is O 0
in O 0
contrast O 0
to O 0
findings O 0
, O 0
by O 0
Malhotra O 0
et O 0
al O 0
. O 0
at O 0
the O 0
5 O 0
' O 0
end O 0
of O 0
the O 0
gene O 0
. O 0

Cloning O 0
of O 0
breakpoints O 0
of O 0
a O 0
chromosome O 0
translocation O 0
identifies O 0
the O 0
AN2 O 0
locus O 0
. O 0

Chromosome O 0
translocations O 0
involving O 0
11p13 O 0
have O 0
been O 0
associated O 0
with O 0
familial B-Disease 0
aniridia I-Disease 0
in O 0
two O 0
kindreds O 0
highlighting O 0
the O 0
chromosomal O 0
localization O 0
of O 0
the O 0
AN2 O 0
locus O 0
. O 0

This O 0
locus O 0
is O 0
also O 0
part O 0
of O 0
the O 0
WAGR B-Disease 0
complex O 0
( O 0
Wilms B-Disease 1
tumor I-Disease 1
, O 0
aniridia B-Disease 0
, O 0
genitourinary B-Disease 0
abnormalities I-Disease 0
, O 0
and O 0
mental B-Disease 1
retardation I-Disease 1
) O 0
. O 0

In O 0
one O 0
kindred O 0
, O 0
the O 0
translocation O 0
is O 0
associated O 0
with O 0
a O 0
deletion O 0
, O 0
and O 0
probes O 0
for O 0
this O 0
region O 0
were O 0
used O 0
to O 0
identify O 0
and O 0
clone O 0
the O 0
breakpoints O 0
of O 0
the O 0
translocation O 0
in O 0
the O 0
second O 0
kindred O 0
. O 0

Comparison O 0
of O 0
phage O 0
restriction O 0
maps O 0
exclude O 0
the O 0
presence O 0
of O 0
any O 0
sizable O 0
deletion O 0
in O 0
this O 0
case O 0
. O 0

Sequences O 0
at O 0
the O 0
chromosome O 0
11 O 0
breakpoint O 0
are O 0
conserved O 0
in O 0
multiple O 0
species O 0
, O 0
suggesting O 0
that O 0
the O 0
translocation O 0
falls O 0
within O 0
the O 0
AN2 O 0
gene O 0
. O 0
. O 0

Linkage O 0
analysis O 0
of O 0
the O 0
apolipoprotein O 0
C2 O 0
gene O 0
and O 0
myotonic B-Disease 1
dystrophy I-Disease 1
on O 0
human O 0
chromosome O 0
19 O 0
reveals O 0
linkage O 0
disequilibrium O 0
in O 0
a O 0
French O 0
- O 0
Canadian O 0
population O 0
. O 0

The O 0
gene O 0
for O 0
human O 0
apolipoprotein O 0
C2 O 0
( O 0
APOC2 O 0
) O 0
, O 0
situated O 0
on O 0
the O 0
proximal O 0
long O 0
arm O 0
of O 0
chromosome O 0
19 O 0
, O 0
is O 0
closely O 0
linked O 0
to O 0
the O 0
gene O 0
for O 0
the O 0
most O 0
common O 0
form O 0
of O 0
adult O 0
muscular B-Disease 0
dystrophy I-Disease 0
, O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
. O 0

Six O 0
APOC2 O 0
RFLPs O 0
( O 0
TaqI O 0
, O 0
BglI O 0
, O 0
BanI O 0
, O 0
BamHI O 0
, O 0
NcoI O 0
, O 0
and O 0
AvaII O 0
) O 0
have O 0
been O 0
identified O 0
to O 0
date O 0
. O 0

We O 0
have O 0
conducted O 0
a O 0
comprehensive O 0
DM B-Disease 0
linkage O 0
study O 0
utilizing O 0
all O 0
six O 0
RFLPs O 0
and O 0
involving O 0
50 O 0
families O 0
and O 0
372 O 0
individuals O 0
. O 0

The O 0
most O 0
informative O 0
RFLPs O 0
are O 0
, O 0
in O 0
descending O 0
order O 0
, O 0
NcoI O 0
( O 0
lod O 0
= O 0
6 O 0
. O 0
64 O 0
, O 0
theta O 0
= O 0
0 O 0
. O 0
05 O 0
) O 0
, O 0
BglI O 0
( O 0
lod O 0
= O 0
6 O 0
. O 0
12 O 0
, O 0
theta O 0
= O 0
0 O 0
. O 0
05 O 0
) O 0
, O 0
AvaII O 0
( O 0
lod O 0
= O 0
6 O 0
. O 0
02 O 0
, O 0
theta O 0
= O 0
0 O 0
. O 0
03 O 0
) O 0
, O 0
BanI O 0
( O 0
lod O 0
= O 0
5 O 0
. O 0
76 O 0
, O 0
theta O 0
= O 0
0 O 0
. O 0
04 O 0
) O 0
, O 0
TaqI O 0
( O 0
lod O 0
= O 0
4 O 0
. O 0
29 O 0
, O 0
theta O 0
= O 0
0 O 0
. O 0
06 O 0
) O 0
, O 0
and O 0
BamHI O 0
( O 0
lod O 0
= O 0
1 O 0
. O 0
75 O 0
, O 0
theta O 0
= O 0
0 O 0
. O 0
01 O 0
) O 0
. O 0

A O 0
substantial O 0
increase O 0
in O 0
the O 0
lod O 0
scores O 0
over O 0
those O 0
seen O 0
with O 0
the O 0
individual O 0
RFLPs O 0
was O 0
obtained O 0
when O 0
the O 0
linkage O 0
of O 0
the O 0
entire O 0
APOC2 O 0
haplotype O 0
( O 0
composed O 0
of O 0
the O 0
six O 0
RFLPs O 0
) O 0
was O 0
studied O 0
( O 0
lod O 0
= O 0
17 O 0
. O 0
87 O 0
, O 0
theta O 0
= O 0
0 O 0
. O 0
04 O 0
) O 0
. O 0

We O 0
have O 0
observed O 0
significant O 0
inter O 0
- O 0
APOC2 O 0
RFLP O 0
linkage O 0
disequilibrium O 0
. O 0

Consequently O 0
, O 0
the O 0
three O 0
most O 0
informative O 0
RFLPs O 0
have O 0
been O 0
found O 0
to O 0
be O 0
BanI O 0
, O 0
TaqI O 0
, O 0
and O 0
either O 0
BglI O 0
, O 0
AvaII O 0
, O 0
or O 0
NcoI O 0
polymorphisms O 0
. O 0

We O 0
also O 0
demonstrate O 0
linkage O 0
disequilibrium O 0
between O 0
DM O 0
and O 0
APOC2 O 0
in O 0
our O 0
French O 0
- O 0
Canadian O 0
population O 0
( O 0
standardized O 0
disequilibrium O 0
constant O 0
phi O 0
= O 0
. O 0
22 O 0
, O 0
chi O 0
2 O 0
= O 0
5 O 0
. O 0
12 O 0
, O 0
df O 0
= O 0
1 O 0
, O 0
P O 0
less O 0
than O 0
0 O 0
. O 0
04 O 0
) O 0
. O 0

This O 0
represents O 0
the O 0
first O 0
evidence O 0
of O 0
linkage O 0
disequilibrium O 0
between O 0
APOC2 O 0
and O 0
the O 0
DM B-Disease 0
locus O 0
. O 0

Phenylalanine O 0
hydroxylase O 0
gene O 0
haplotypes O 0
in O 0
Polynesians O 0
: O 0
evolutionary O 0
origins O 0
and O 0
absence O 0
of O 0
alleles O 0
associated O 0
with O 0
severe O 0
phenylketonuria B-Disease 0
. O 0

A O 0
total O 0
of O 0
630 O 0
haplotypes O 0
for O 0
the O 0
phenylalanine O 0
hydroxylase O 0
( O 0
PAH O 0
) O 0
gene O 0
locus O 0
were O 0
established O 0
in O 0
five O 0
groups O 0
of O 0
Polynesians O 0
comprising O 0
Samoans O 0
, O 0
Tongans O 0
, O 0
Cook O 0
Islanders O 0
, O 0
Maori O 0
, O 0
and O 0
Niueans O 0
. O 0

Considerable O 0
genetic O 0
continuity O 0
was O 0
demonstrated O 0
between O 0
these O 0
widely O 0
dispersed O 0
populations O 0
, O 0
since O 0
three O 0
common O 0
haplotypes O 0
( O 0
4 O 0
, O 0
1 O 0
, O 0
and O 0
7 O 0
) O 0
constituted O 0
over O 0
95 O 0
% O 0
of O 0
alleles O 0
. O 0

A O 0
control O 0
group O 0
of O 0
individuals O 0
from O 0
Southeast O 0
Asia O 0
shared O 0
the O 0
same O 0
major O 0
haplotypes O 0
, O 0
4 O 0
, O 0
1 O 0
, O 0
and O 0
7 O 0
, O 0
with O 0
Polynesians O 0
. O 0

These O 0
data O 0
provide O 0
further O 0
support O 0
for O 0
the O 0
theories O 0
of O 0
genetic O 0
homogeneity O 0
and O 0
of O 0
Asian O 0
affinities O 0
of O 0
the O 0
Polynesian O 0
precursor O 0
populations O 0
. O 0

The O 0
absence O 0
of O 0
severe O 0
phenylketonuria B-Disease 0
( O 0
PKU B-Disease 0
) O 0
in O 0
both O 0
Polynesians O 0
and O 0
Southeast O 0
Asians O 0
is O 0
consistent O 0
with O 0
the O 0
lack O 0
of O 0
PAH O 0
haplotypes O 0
2 O 0
and O 0
3 O 0
, O 0
on O 0
which O 0
the O 0
severe O 0
PKU B-Disease 0
mutants O 0
have O 0
arisen O 0
among O 0
Caucasians O 0
. O 0
. O 0

Preferential O 0
germline O 0
mutation O 0
of O 0
the O 0
paternal O 0
allele O 0
in O 0
retinoblastoma B-Disease 1
. O 0

The O 0
event O 0
triggering O 0
malignant O 0
proliferation O 0
in O 0
70 O 0
% O 0
of O 0
retinoblastoma B-Disease 1
tumours I-Disease 0
is O 0
loss O 0
of O 0
heterozygosity O 0
for O 0
chromosome O 0
13q14 O 0
, O 0
whereby O 0
the O 0
normal O 0
retinoblastoma B-Disease 1
gene O 0
( O 0
RB1 O 0
) O 0
allele O 0
is O 0
lost O 0
and O 0
an O 0
already O 0
mutated O 0
RB1 O 0
allele O 0
remains O 0
in O 0
the O 0
tumour B-Disease 1
. O 0

The O 0
first O 0
allele O 0
suffers O 0
a O 0
mutational O 0
event O 0
- O 0
- O 0
deletion O 0
, O 0
duplication O 0
or O 0
point O 0
mutation O 0
( O 0
manuscript O 0
in O 0
preparation O 0
) O 0
- O 0
- O 0
either O 0
in O 0
the O 0
germ O 0
line O 0
( O 0
all O 0
bilateral O 0
patients O 0
) O 0
or O 0
in O 0
a O 0
somatic O 0
retinal O 0
cell O 0
( O 0
most O 0
unilateral O 0
patients O 0
) O 0
. O 0

Most O 0
bilateral O 0
patients O 0
have O 0
no O 0
family O 0
history O 0
of O 0
retinoblastoma B-Disease 1
and O 0
are O 0
presumed O 0
to O 0
have O 0
new O 0
germline O 0
mutations O 0
which O 0
arose O 0
in O 0
the O 0
egg O 0
, O 0
sperm O 0
or O 0
early O 0
embryo O 0
. O 0

We O 0
have O 0
determined O 0
the O 0
parental O 0
origin O 0
of O 0
the O 0
retained O 0
allele O 0
in O 0
nine O 0
retinoblastoma B-Disease 1
tumours I-Disease 0
from O 0
eight O 0
unrelated O 0
non O 0
- O 0
familial O 0
cases O 0
by O 0
using O 0
RB1 O 0
- O 0
linked O 0
genetic O 0
markers O 0
. O 0

Six O 0
tumours B-Disease 1
retained O 0
the O 0
paternal O 0
allele O 0
and O 0
three O 0
retained O 0
the O 0
maternal O 0
allele O 0
. O 0

Of O 0
the O 0
three O 0
unilateral B-Disease 1
tumours I-Disease 1
, O 0
only O 0
one O 0
retained O 0
the O 0
paternal O 0
RB1 O 0
allele O 0
. O 0

Thus O 0
, O 0
there O 0
is O 0
no O 0
evidence O 0
that O 0
the O 0
paternal O 0
RB1 O 0
allele O 0
is O 0
preferentially O 0
retained O 0
in O 0
retinoblastoma B-Disease 1
, O 0
as O 0
has O 0
been O 0
suggested O 0
to O 0
be O 0
the O 0
case O 0
in O 0
osteosarcoma B-Disease 0
. O 0

By O 0
contrast O 0
, O 0
tumours B-Disease 1
from O 0
four O 0
of O 0
the O 0
five O 0
bilateral O 0
patients O 0
retained O 0
the O 0
paternal O 0
RB1 O 0
allele O 0
. O 0

This O 0
suggests O 0
either O 0
that O 0
new O 0
germline O 0
RB1 O 0
mutations O 0
arise O 0
more O 0
frequently O 0
during O 0
spermatogenesis O 0
than O 0
during O 0
oogenesis O 0
, O 0
or O 0
that O 0
imprinting O 0
in O 0
the O 0
early O 0
embryo O 0
affects O 0
chromosomal O 0
susceptibility O 0
to O 0
mutation O 0
. O 0
. O 0

Haplotype O 0
analysis O 0
of O 0
the O 0
phenylalanine O 0
hydroxylase O 0
gene O 0
in O 0
Turkish O 0
phenylketonuria B-Disease 0
families O 0
. O 0

We O 0
have O 0
estimated O 0
the O 0
haplotype O 0
distribution O 0
of O 0
mutant O 0
and O 0
normal O 0
phenylalanine O 0
hydroxylase O 0
( O 0
PAH O 0
) O 0
alleles O 0
for O 0
17 O 0
Turkish O 0
phenylketonuria B-Disease 0
( O 0
PKU B-Disease 0
) O 0
families O 0
20 O 0
normal O 0
and O 0
27 O 0
mutated O 0
PAH O 0
alleles O 0
could O 0
be O 0
identified O 0
. O 0

Of O 0
the O 0
latter O 0
, O 0
the O 0
most O 0
prevalent O 0
were O 0
associated O 0
with O 0
haplotype O 0
6 O 0
( O 0
29 O 0
. O 0
6 O 0
% O 0
) O 0
, O 0
1 O 0
( O 0
18 O 0
. O 0
5 O 0
% O 0
) O 0
and O 0
36 O 0
( O 0
11 O 0
. O 0
1 O 0
% O 0
) O 0
, O 0
while O 0
the O 0
normal O 0
alleles O 0
were O 0
preferentially O 0
associated O 0
with O 0
haplotype O 0
1 O 0
( O 0
20 O 0
% O 0
) O 0
. O 0

Of O 0
the O 0
19 O 0
different O 0
haplotypes O 0
observed O 0
, O 0
5 O 0
have O 0
not O 0
been O 0
described O 0
previously O 0
. O 0

The O 0
haplotype O 0
distribution O 0
differed O 0
significantly O 0
from O 0
that O 0
of O 0
the O 0
Northern O 0
European O 0
population O 0
. O 0

Two O 0
of O 0
the O 0
eight O 0
polymorphic O 0
sites O 0
were O 0
in O 0
association O 0
with O 0
PKU B-Disease 0
. O 0

No O 0
deletions O 0
of O 0
exon O 0
sequences O 0
were O 0
found O 0
in O 0
the O 0
families O 0
analysed O 0
. O 0

Huntington B-Disease 1
disease I-Disease 1
: O 0
no O 0
evidence O 0
for O 0
locus O 0
heterogeneity O 0
. O 0

A O 0
total O 0
of O 0
63 O 0
families O 0
with O 0
Huntington B-Disease 1
disease I-Disease 1
( O 0
HD B-Disease 1
) O 0
were O 0
examined O 0
for O 0
linkage O 0
between O 0
HD B-Disease 1
and O 0
G8 O 0
( O 0
D4S10 O 0
) O 0
. O 0

The O 0
families O 0
included O 0
57 O 0
Caucasian O 0
, O 0
four O 0
Black O 0
American O 0
, O 0
and O 0
two O 0
Japanese O 0
. O 0

The O 0
combined O 0
maximum O 0
lod O 0
score O 0
was O 0
87 O 0
. O 0

69 O 0
at O 0
theta O 0
= O 0
0 O 0
. O 0

04 O 0
( O 0
99 O 0
% O 0
confidence O 0
interval O 0
0 O 0
. O 0
018 O 0
- O 0
0 O 0
. O 0
071 O 0
) O 0
. O 0

The O 0
maximum O 0
frequency O 0
of O 0
recombination O 0
was O 0
0 O 0
. O 0

03 O 0
in O 0
males O 0
and O 0
0 O 0
. O 0

05 O 0
in O 0
females O 0
. O 0

Fifty O 0
- O 0
seven O 0
families O 0
gave O 0
positive O 0
lod O 0
scores O 0
; O 0
five O 0
small O 0
families O 0
gave O 0
mildly O 0
negative O 0
lod O 0
scores O 0
. O 0

The O 0
maximum O 0
likelihood O 0
estimate O 0
of O 0
alpha O 0
, O 0
the O 0
proportion O 0
of O 0
linked O 0
loci O 0
, O 0
was O 0
1 O 0
. O 0

0 O 0
with O 0
a O 0
lower O 0
99 O 0
% O 0
confidence O 0
interval O 0
of O 0
0 O 0
. O 0

88 O 0
. O 0

These O 0
data O 0
suggest O 0
that O 0
there O 0
is O 0
only O 0
one O 0
HD B-Disease 1
locus O 0
, O 0
although O 0
a O 0
second O 0
rare O 0
locus O 0
cannot O 0
be O 0
ruled O 0
out O 0
. O 0

Haplotype O 0
and O 0
multipoint O 0
linkage O 0
analysis O 0
in O 0
Finnish O 0
choroideremia B-Disease 1
families O 0
. O 0

Multipoint O 0
linkage O 0
analysis O 0
of O 0
choroideremia B-Disease 1
( O 0
TCD B-Disease 0
) O 0
and O 0
seven O 0
X O 0
chromosomal O 0
restriction O 0
fragment O 0
length O 0
polymorphisms O 0
( O 0
RFLPs O 0
) O 0
was O 0
carried O 0
out O 0
in O 0
18 O 0
Finnish O 0
TCD B-Disease 0
families O 0
. O 0

The O 0
data O 0
place O 0
TCD B-Disease 0
distal O 0
to O 0
PGK O 0
and O 0
DXS72 O 0
, O 0
very O 0
close O 0
to O 0
DXYS1 O 0
and O 0
DXYS5 O 0
( O 0
Zmax O 0
= O 0
24 O 0
at O 0
theta O 0
= O 0
0 O 0
) O 0
and O 0
proximal O 0
to O 0
DXYS4 O 0
and O 0
DXYS12 O 0
. O 0

This O 0
agrees O 0
with O 0
the O 0
data O 0
obtained O 0
from O 0
other O 0
linkage O 0
studies O 0
and O 0
from O 0
physical O 0
mapping O 0
. O 0

All O 0
the O 0
TCD B-Disease 0
males O 0
and O 0
carrier O 0
females O 0
studied O 0
have O 0
the O 0
same O 0
DXYS1 O 0
allele O 0
in O 0
coupling O 0
with O 0
TCD B-Disease 0
. O 0

In O 0
Northeastern O 0
Finland O 0
, O 0
66 O 0
/ O 0
69 O 0
chromosomes O 0
carrying O 0
TCD B-Disease 0
had O 0
the O 0
same O 0
haplotype O 0
at O 0
loci O 0
DXS72 O 0
, O 0
DXYS1 O 0
, O 0
DXYS4 O 0
, O 0
and O 0
DXYS12 O 0
. O 0

The O 0
same O 0
haplotype O 0
is O 0
seen O 0
in O 0
only O 0
15 O 0
/ O 0
99 O 0
chromosomes O 0
not O 0
carrying O 0
TCD B-Disease 0
. O 0

Moreover O 0
, O 0
in O 0
71 O 0
/ O 0
104 O 0
non O 0
- O 0
TCD O 0
chromosomes O 0
, O 0
the O 0
haplotype O 0
at O 0
six O 0
marker O 0
loci O 0
is O 0
different O 0
from O 0
those O 0
seen O 0
in O 0
any O 0
of O 0
the O 0
76 O 0
TCD B-Disease 0
chromosomes O 0
. O 0

This O 0
supports O 0
the O 0
previously O 0
described O 0
hypothesis O 0
that O 0
the O 0
large O 0
Northern O 0
Finnish O 0
choroideremia B-Disease 1
pedigrees O 0
, O 0
comprising O 0
a O 0
total O 0
of O 0
over O 0
80 O 0
living O 0
patients O 0
representing O 0
more O 0
than O 0
a O 0
fifth O 0
of O 0
all O 0
TCD B-Disease 0
patients O 0
described O 0
worldwide O 0
, O 0
carry O 0
the O 0
same O 0
mutation O 0
. O 0

These O 0
linkage O 0
and O 0
haplotype O 0
data O 0
provide O 0
improved O 0
opportunities O 0
for O 0
prenatal O 0
diagnosis O 0
based O 0
on O 0
RFLP O 0
studies O 0
. O 0
. O 0

Autosomal O 0
dominant O 0
aniridia B-Disease 0
linked O 0
to O 0
the O 0
chromosome O 0
11p13 O 0
markers O 0
catalase O 0
and O 0
D11S151 O 0
in O 0
a O 0
large O 0
Dutch O 0
family O 0
. O 0

In O 0
a O 0
large O 0
pedigree O 0
with O 0
autosomal O 0
dominant O 0
aniridia B-Disease 0
, O 0
we O 0
found O 0
close O 0
linkage O 0
between O 0
the O 0
aniridia B-Disease 0
locus O 0
AN2 O 0
and O 0
the O 0
markers O 0
catalase O 0
( O 0
CAT O 0
) O 0
( O 0
zeta O 0
= O 0
7 O 0
. O 0
27 O 0
at O 0
theta O 0
= O 0
0 O 0
. O 0
00 O 0
) O 0
and O 0
D11S151 O 0
( O 0
zeta O 0
= O 0
3 O 0
. O 0
86 O 0
at O 0
theta O 0
= O 0
0 O 0
. O 0
10 O 0
) O 0
flanking O 0
the O 0
AN2 O 0
locus O 0
on O 0
11p13 O 0
. O 0

Positive O 0
lod O 0
scores O 0
were O 0
also O 0
obtained O 0
for O 0
the O 0
11p13 O 0
- O 0
- O 0
- O 0
- O 0
11p14 O 0
markers O 0
D11S16 O 0
and O 0
FSHB O 0
with O 0
the O 0
linkage O 0
group O 0
CAT O 0
/ O 0
AN2 O 0
/ O 0
D11S151 O 0
. O 0

We O 0
conclude O 0
that O 0
the O 0
autosomal O 0
dominant O 0
aniridia B-Disease 0
in O 0
this O 0
family O 0
is O 0
due O 0
to O 0
a O 0
mutation O 0
at O 0
the O 0
AN2 O 0
locus O 0
on O 0
11p13 O 0
. O 0

We O 0
have O 0
excluded O 0
linkage O 0
( O 0
zeta O 0
less O 0
than O 0
- O 0
2 O 0
at O 0
theta O 0
less O 0
than O 0
0 O 0
. O 0
18 O 0
) O 0
between O 0
the O 0
aniridia B-Disease 0
and O 0
the O 0
chromosome O 0
2p25 O 0
marker O 0
D2S1 O 0
( O 0
linked O 0
to O 0
ACP1 O 0
) O 0
. O 0

Recombination O 0
events O 0
that O 0
locate O 0
myotonic B-Disease 1
dystrophy I-Disease 1
distal O 0
to O 0
APOC2 O 0
on O 0
19q O 0
. O 0

We O 0
previously O 0
reported O 0
a O 0
recombination O 0
in O 0
an O 0
individual O 0
with O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
which O 0
placed O 0
the O 0
markers O 0
D19S19 O 0
and O 0
APOC2 O 0
on O 0
the O 0
same O 0
side O 0
of O 0
the O 0
DM B-Disease 0
locus O 0
. O 0

Haplotyping O 0
of O 0
this O 0
family O 0
with O 0
more O 0
recently O 0
characterized O 0
probes O 0
which O 0
are O 0
either O 0
tightly O 0
linked O 0
to O 0
DM B-Disease 0
or O 0
distal O 0
to O 0
the O 0
linkage O 0
group O 0
at O 0
q13 O 0
. O 0

2 O 0
shows O 0
that O 0
the O 0
DM B-Disease 0
locus O 0
is O 0
distal O 0
to O 0
APOC2 O 0
. O 0

This O 0
is O 0
confirmed O 0
by O 0
other O 0
recombinants O 0
where O 0
DM B-Disease 0
segregates O 0
with O 0
distal O 0
probes O 0
. O 0

Additional O 0
marker O 0
to O 0
marker O 0
recombinations O 0
in O 0
unaffected O 0
individuals O 0
are O 0
reported O 0
and O 0
support O 0
the O 0
order O 0
and O 0
orientation O 0
of O 0
the O 0
DM B-Disease 0
linkage O 0
group O 0
as O 0
pter O 0
- O 0
( O 0
INSR O 0
, O 0
LDLR O 0
, O 0
S9 O 0
) O 0
- O 0
( O 0
S19 O 0
, O 0
BCL3 O 0
, O 0
APOC2 O 0
) O 0
- O 0
( O 0
CKMM O 0
, O 0
DM O 0
) O 0
- O 0
( O 0
S22 O 0
, O 0
+ O 0
+ O 0
+ O 0
PRKCG O 0
) O 0
- O 0
qter O 0
. O 0

The O 0
data O 0
presented O 0
here O 0
cannot O 0
determine O 0
whether O 0
DM B-Disease 0
is O 0
proximal O 0
or O 0
distal O 0
to O 0
CKMM O 0
. O 0

The O 0
consequences O 0
of O 0
this O 0
probe O 0
order O 0
for O 0
antenatal O 0
diagnosis O 0
and O 0
future O 0
research O 0
aiming O 0
to O 0
isolate O 0
the O 0
gene O 0
which O 0
is O 0
affected O 0
in O 0
DM B-Disease 0
are O 0
discussed O 0
. O 0

Mutations O 0
in O 0
the O 0
RB1 O 0
gene O 0
and O 0
their O 0
effects O 0
on O 0
transcription O 0
. O 0

Inactivation O 0
of O 0
both O 0
alleles O 0
of O 0
the O 0
RB1 O 0
gene O 0
during O 0
normal O 0
retinal O 0
development O 0
initiates O 0
the O 0
formation O 0
of O 0
a O 0
retinoblastoma B-Disease 1
( I-Disease 1
RB I-Disease 1
) I-Disease 1
tumor I-Disease 1
. O 0

To O 0
identify O 0
the O 0
mutations O 0
which O 0
inactivate O 0
RB1 O 0
, O 0
21 O 0
RB B-Disease 1
tumors I-Disease 1
isolated O 0
from O 0
19 O 0
patients O 0
were O 0
analyzed O 0
with O 0
the O 0
polymerase O 0
chain O 0
reaction O 0
or O 0
an O 0
RNase O 0
protection O 0
assay O 0
or O 0
both O 0
. O 0

Mutations O 0
were O 0
identified O 0
in O 0
13 O 0
of O 0
21 O 0
RB B-Disease 1
tumors I-Disease 1
; O 0
in O 0
8 O 0
tumors B-Disease 0
, O 0
the O 0
precise O 0
errors O 0
in O 0
nucleotide O 0
sequence O 0
were O 0
characterized O 0
. O 0

Each O 0
of O 0
four O 0
germ O 0
line O 0
mutations O 0
involved O 0
a O 0
small O 0
deletion O 0
or O 0
duplication O 0
, O 0
while O 0
three O 0
somatic O 0
mutations O 0
were O 0
point O 0
mutations O 0
leading O 0
to O 0
splice O 0
alterations O 0
and O 0
loss O 0
of O 0
an O 0
exon O 0
from O 0
the O 0
mature O 0
RB1 O 0
mRNA O 0
. O 0

We O 0
were O 0
unable O 0
to O 0
detect O 0
expression O 0
of O 0
the O 0
mutant O 0
allele O 0
in O 0
lymphoblasts O 0
of O 0
three O 0
bilaterally O 0
affected O 0
patients O 0
, O 0
although O 0
the O 0
mutation O 0
was O 0
present O 0
in O 0
the O 0
genomic O 0
DNA O 0
and O 0
transcripts O 0
containing O 0
the O 0
mutations O 0
were O 0
obvious O 0
in O 0
the O 0
RB B-Disease 1
tumors I-Disease 1
in O 0
the O 0
absence O 0
of O 0
a O 0
normal O 0
RB1 O 0
allele O 0
. O 0

The O 0
variations O 0
in O 0
the O 0
level O 0
of O 0
expression O 0
of O 0
mutant O 0
transcripts O 0
suggest O 0
deregulation O 0
of O 0
RB1 O 0
transcription O 0
in O 0
the O 0
absence O 0
of O 0
a O 0
functional O 0
RB1 O 0
gene O 0
product O 0
. O 0
. O 0

Partial O 0
deletion O 0
8q O 0
without O 0
Langer B-Disease 0
- I-Disease 0
Giedion I-Disease 0
syndrome I-Disease 0
: O 0
a O 0
recognisable O 0
syndrome O 0
. O 0

We O 0
report O 0
two O 0
de O 0
novo O 0
cases O 0
of O 0
del O 0
( O 0
8 O 0
) O 0
( O 0
pter O 0
- O 0
- O 0
- O 0
- O 0
q24 O 0
. O 0
1 O 0
) O 0
with O 0
breakpoints O 0
involving O 0
the O 0
distal O 0
part O 0
of O 0
band O 0
8q24 O 0
. O 0

1 O 0
1 O 0
. O 0

The O 0
clinical O 0
features O 0
were O 0
similar O 0
and O 0
there O 0
were O 0
no O 0
obvious O 0
stigmata O 0
of O 0
Langer B-Disease 0
- I-Disease 0
Giedion I-Disease 0
syndrome I-Disease 0
( O 0
LGS B-Disease 1
) O 0
. O 0

There O 0
are O 0
three O 0
other O 0
cases O 0
reported O 0
with O 0
a O 0
deletion O 0
of O 0
chromosome O 0
8 O 0
at O 0
approximately O 0
the O 0
same O 0
breakpoint O 0
, O 0
one O 0
without O 0
LGS B-Disease 1
and O 0
some O 0
similarities O 0
to O 0
our O 0
cases O 0
, O 0
the O 0
other O 0
two O 0
with O 0
LGS B-Disease 1
. O 0

Our O 0
findings O 0
would O 0
support O 0
the O 0
observation O 0
that O 0
the O 0
critical O 0
segment O 0
for O 0
the O 0
assignment O 0
of O 0
LGS B-Disease 1
is O 0
proximal O 0
to O 0
or O 0
involves O 0
the O 0
proximal O 0
part O 0
of O 0
8q24 O 0
. O 0

1 O 0
, O 0
but O 0
a O 0
review O 0
of O 0
published O 0
reports O 0
suggests O 0
that O 0
the O 0
aetiology O 0
of O 0
LGS B-Disease 1
may O 0
be O 0
a O 0
more O 0
complex O 0
issue O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
is O 0
closely O 0
linked O 0
to O 0
the O 0
gene O 0
for O 0
muscle O 0
- O 0
type O 0
creatine O 0
kinase O 0
( O 0
CKMM O 0
) O 0
. O 0

We O 0
have O 0
studied O 0
genetic O 0
linkage O 0
between O 0
the O 0
gene O 0
for O 0
creatine O 0
kinase O 0
muscle O 0
type O 0
( O 0
CKMM O 0
) O 0
and O 0
the O 0
gene O 0
for O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
. O 0

In O 0
a O 0
panel O 0
of O 0
65 O 0
myotonic B-Disease 1
dystrophy I-Disease 1
families O 0
from O 0
Canada O 0
and O 0
the O 0
Netherlands O 0
, O 0
a O 0
maximum O 0
lod O 0
score O 0
( O 0
Zmax O 0
) O 0
of O 0
22 O 0
. O 0

8 O 0
at O 0
a O 0
recombination O 0
frequency O 0
( O 0
theta O 0
) O 0
of O 0
0 O 0
. O 0

03 O 0
was O 0
obtained O 0
. O 0

Tight O 0
linkage O 0
was O 0
also O 0
demonstrated O 0
for O 0
CKMM O 0
and O 0
the O 0
gene O 0
for O 0
apolipoprotein O 0
C2 O 0
( O 0
ApoC2 O 0
) O 0
. O 0

This O 0
establishes O 0
CKMM O 0
as O 0
a O 0
useful O 0
marker O 0
for O 0
myotonic B-Disease 1
dystrophy I-Disease 1

Color B-Disease 0
vision I-Disease 0
defects I-Disease 0
in O 0
adrenomyeloneuropathy B-Disease 1
. O 0

The O 0
relationship O 0
between O 0
abnormal B-Disease 0
color I-Disease 0
vision I-Disease 0
and O 0
adrenomyeloneuropathy B-Disease 1
( O 0
AMN B-Disease 0
) O 0
was O 0
investigated O 0
in O 0
27 O 0
AMN B-Disease 0
patients O 0
and O 0
31 O 0
age O 0
- O 0
matched O 0
controls O 0
by O 0
using O 0
the O 0
Farnsworth O 0
- O 0
Munsell O 0
100 O 0
Hue O 0
test O 0
. O 0

Twelve O 0
( O 0
44 O 0
% O 0
) O 0
of O 0
27 O 0
patients O 0
showed O 0
test O 0
scores O 0
significantly O 0
above O 0
normal O 0
. O 0

The O 0
axes O 0
of O 0
bipolarity O 0
determined O 0
by O 0
the O 0
testing O 0
differed O 0
widely O 0
between O 0
the O 0
patients O 0
with O 0
abnormal O 0
scores O 0
, O 0
compatible O 0
with O 0
the O 0
notion O 0
that O 0
different O 0
alterations O 0
in O 0
visual O 0
pigment O 0
genes O 0
occur O 0
in O 0
different O 0
AMN B-Disease 0
kindreds O 0
. O 0

These O 0
observations O 0
confirm O 0
our O 0
earlier O 0
impression O 0
that O 0
the O 0
frequency O 0
of O 0
abnormal B-Disease 0
color I-Disease 0
vision I-Disease 0
is O 0
increased O 0
in O 0
these O 0
kindreds O 0
, O 0
and O 0
it O 0
supports O 0
our O 0
contentions O 0
that O 0
( O 0
1 O 0
) O 0
AMN B-Disease 0
( O 0
and O 0
its O 0
companion O 0
, O 0
adrenoleukodystrophy B-Disease 1
) O 0
are O 0
very O 0
closely O 0
linked O 0
to O 0
the O 0
visual O 0
pigment O 0
loci O 0
at O 0
Xq28 O 0
and O 0
( O 0
2 O 0
) O 0
this O 0
proximity O 0
might O 0
provide O 0
the O 0
opportunity O 0
to O 0
observe O 0
contiguous B-Disease 1
gene I-Disease 1
defects I-Disease 1
. O 0
. O 0

Molecular O 0
analysis O 0
of O 0
a O 0
female O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
patient O 0
. O 0

We O 0
report O 0
the O 0
identification O 0
of O 0
a O 0
female O 0
patient O 0
with O 0
the O 0
X O 0
- O 0
linked O 0
recessive O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
( O 0
hypoxanthine B-Disease 1
phosphoribosyltransferase I-Disease 1
[ I-Disease 1
HPRT I-Disease 1
] I-Disease 1
deficiency I-Disease 1
) O 0
. O 0

Cytogenetic O 0
and O 0
carrier O 0
studies O 0
revealed O 0
structurally O 0
normal O 0
chromosomes O 0
for O 0
this O 0
patient O 0
and O 0
her O 0
parents O 0
and O 0
demonstrated O 0
that O 0
this O 0
mutation O 0
arose O 0
through O 0
a O 0
de O 0
novo O 0
gametic O 0
event O 0
. O 0

Comparison O 0
of O 0
this O 0
patients O 0
DNA O 0
with O 0
the O 0
DNA O 0
of O 0
her O 0
parents O 0
revealed O 0
that O 0
a O 0
microdeletion O 0
, O 0
which O 0
occurred O 0
within O 0
a O 0
maternal O 0
gamete O 0
and O 0
involved O 0
the O 0
entire O 0
HPRT O 0
gene O 0
, O 0
was O 0
partially O 0
responsible O 0
for O 0
the O 0
disease O 0
in O 0
this O 0
patient O 0
. O 0

Somatic O 0
cell O 0
hybrids O 0
, O 0
generated O 0
to O 0
separate O 0
maternal O 0
and O 0
paternal O 0
X O 0
chromosomes O 0
, O 0
showed O 0
that O 0
expression O 0
of O 0
two O 0
additional O 0
X O 0
- O 0
linked O 0
enzymes O 0
, O 0
phosphoglycerate O 0
kinase O 0
and O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
, O 0
were O 0
expressed O 0
only O 0
in O 0
cells O 0
that O 0
contained O 0
the O 0
maternal O 0
X O 0
chromosome O 0
, O 0
suggesting O 0
the O 0
presence O 0
of O 0
a O 0
functionally O 0
inactive O 0
paternal O 0
X O 0
chromosome O 0
. O 0

Furthermore O 0
, O 0
comparison O 0
of O 0
methylation O 0
patterns O 0
within O 0
a O 0
region O 0
of O 0
the O 0
HPRT O 0
gene O 0
known O 0
to O 0
be O 0
important O 0
in O 0
gene O 0
regulation O 0
revealed O 0
differences O 0
between O 0
DNA O 0
from O 0
the O 0
father O 0
and O 0
the O 0
patient O 0
, O 0
in O 0
keeping O 0
with O 0
an O 0
active O 0
HPRT O 0
locus O 0
in O 0
the O 0
father O 0
and O 0
an O 0
inactive O 0
HPRT O 0
locus O 0
in O 0
the O 0
patient O 0
. O 0

Together O 0
these O 0
data O 0
indicate O 0
that O 0
nonrandom O 0
inactivation O 0
of O 0
the O 0
cytogenetically O 0
normal O 0
paternal O 0
X O 0
chromosome O 0
and O 0
a O 0
microdeletion O 0
of O 0
the O 0
HPRT O 0
gene O 0
on O 0
an O 0
active O 0
maternal O 0
X O 0
chromosome O 0
were O 0
responsible O 0
for O 0
the O 0
absence O 0
of O 0
HPRT O 0
in O 0
this O 0
patient O 0
. O 0
. O 0

Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
: O 0
an O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
neurologic I-Disease 1
disorder I-Disease 1
of I-Disease 1
myelin I-Disease 1
metabolism I-Disease 1
with O 0
a O 0
novel O 0
mutation O 0
in O 0
the O 0
gene O 0
encoding O 0
proteolipid O 0
protein O 0
. O 0

The O 0
nosology O 0
of O 0
the O 0
inborn B-Disease 1
errors I-Disease 1
of I-Disease 1
myelin I-Disease 1
metabolism I-Disease 1
has O 0
been O 0
stymied O 0
by O 0
the O 0
lack O 0
of O 0
molecular O 0
genetic O 0
analysis O 0
. O 0

Historically O 0
, O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
has O 0
encompassed O 0
a O 0
host O 0
of O 0
neurologic B-Disease 0
disorders I-Disease 0
that O 0
present O 0
with O 0
a O 0
deficit B-Disease 0
of I-Disease 0
myelin I-Disease 0
, O 0
the O 0
membrane O 0
elaborated O 0
by O 0
glial O 0
cells O 0
that O 0
encircles O 0
and O 0
successively O 0
enwraps O 0
axons O 0
. O 0

We O 0
describe O 0
here O 0
a O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
pedigree O 0
of O 0
the O 0
classical O 0
type O 0
, O 0
with O 0
X O 0
- O 0
linked O 0
inheritance O 0
, O 0
a O 0
typical O 0
clinical O 0
progression O 0
, O 0
and O 0
a O 0
pathologic O 0
loss O 0
of O 0
myelinating O 0
cells O 0
and O 0
myelin O 0
in O 0
the O 0
central O 0
nervous O 0
system O 0
. O 0

To O 0
discriminate O 0
variants O 0
of O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
, O 0
a O 0
set O 0
of O 0
oligonucleotide O 0
primers O 0
was O 0
constructed O 0
to O 0
polymerase O 0
- O 0
chain O 0
- O 0
reaction O 0
( O 0
PCR O 0
) O 0
amplify O 0
and O 0
sequence O 0
the O 0
gene O 0
encoding O 0
proteolipid O 0
protein O 0
( O 0
PLP O 0
) O 0
, O 0
a O 0
structural O 0
protein O 0
that O 0
comprises O 0
half O 0
of O 0
the O 0
protein O 0
of O 0
the O 0
myelin O 0
sheath O 0
. O 0

The O 0
PLP O 0
gene O 0
in O 0
one O 0
of O 0
two O 0
affected O 0
males O 0
and O 0
the O 0
carrier O 0
mother O 0
of O 0
this O 0
family O 0
exhibited O 0
a O 0
single O 0
base O 0
difference O 0
in O 0
the O 0
more O 0
than O 0
2 O 0
kb O 0
of O 0
the O 0
PLP O 0
gene O 0
sequenced O 0
, O 0
a O 0
C O 0
- O 0
- O 0
- O 0
- O 0
T O 0
transition O 0
that O 0
would O 0
create O 0
a O 0
serine O 0
substitution O 0
for O 0
proline O 0
at O 0
the O 0
carboxy O 0
end O 0
of O 0
the O 0
protein O 0
. O 0

Our O 0
results O 0
delineate O 0
the O 0
clinical O 0
features O 0
of O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
, O 0
define O 0
the O 0
possible O 0
molecular O 0
pathology O 0
of O 0
this O 0
dysmyelinating B-Disease 0
disorder I-Disease 0
, O 0
and O 0
address O 0
the O 0
molecular O 0
classification O 0
of O 0
inborn B-Disease 1
errors I-Disease 1
of I-Disease 1
myelin I-Disease 1
metabolism I-Disease 1
. O 0

Patients O 0
with O 0
the O 0
classical O 0
form O 0
( O 0
type O 0
I O 0
) O 0
and O 0
the O 0
more O 0
severely O 0
affected O 0
, O 0
connatal O 0
variant O 0
of O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
( I-Disease 0
type I-Disease 0
II I-Disease 0
) I-Disease 0
would O 0
be O 0
predicted O 0
to O 0
display O 0
mutation O 0
at O 0
the O 0
PLP O 0
locus O 0
. O 0

The O 0
other O 0
variants O 0
( O 0
types O 0
III O 0
- O 0
VI O 0
) O 0
, O 0
which O 0
have O 0
sometimes O 0
been O 0
categorized O 0
as O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
, O 0
may O 0
represent O 0
mutations O 0
in O 0
genes O 0
encoding O 0
other O 0
structural O 0
myelin O 0
proteins O 0
or O 0
proteins O 0
critical O 0
to O 0
myelination O 0
. O 0
. O 0

Molecular O 0
basis O 0
of O 0
human O 0
von B-Disease 1
Willebrand I-Disease 1
disease I-Disease 1
: O 0
analysis O 0
of O 0
platelet O 0
von B-Disease 1
Willebrand I-Disease 1
factor O 0
mRNA O 0
. O 0

von B-Disease 1
Willebrand I-Disease 1
disease I-Disease 1
( O 0
vWD B-Disease 1
) O 0
, O 0
the O 0
most O 0
common O 0
inherited B-Disease 1
bleeding I-Disease 1
disorder I-Disease 1
in O 0
humans O 0
, O 0
can O 0
result O 0
from O 0
either O 0
a O 0
quantitative O 0
or O 0
a O 0
qualitative O 0
defect O 0
in O 0
the O 0
adhesive O 0
glycoprotein O 0
, O 0
von B-Disease 1
Willebrand I-Disease 1
factor O 0
( O 0
vWF O 0
) O 0
. O 0

Molecular O 0
studies O 0
of O 0
vWD B-Disease 1
have O 0
been O 0
limited O 0
by O 0
the O 0
large O 0
size O 0
of O 0
the O 0
vWF O 0
gene O 0
and O 0
difficulty O 0
in O 0
obtaining O 0
the O 0
vWF O 0
mRNA O 0
from O 0
patients O 0
. O 0

By O 0
use O 0
of O 0
an O 0
adaptation O 0
of O 0
the O 0
polymerase O 0
chain O 0
reaction O 0
, O 0
vWF O 0
mRNA O 0
was O 0
amplified O 0
and O 0
sequenced O 0
from O 0
peripheral O 0
blood O 0
platelets O 0
. O 0

A O 0
silent O 0
vWF O 0
allele O 0
was O 0
identified O 0
, O 0
resulting O 0
from O 0
a O 0
cis O 0
defect O 0
in O 0
vWF O 0
mRNA O 0
transcription O 0
or O 0
processing O 0
. O 0

In O 0
two O 0
type B-Disease 0
IIA I-Disease 0
vWD I-Disease 1
patients O 0
, O 0
two O 0
different O 0
but O 0
adjacent O 0
missense O 0
mutations O 0
were O 0
identified O 0
, O 0
the O 0
locations O 0
of O 0
which O 0
may O 0
identify O 0
an O 0
important O 0
vWF O 0
functional O 0
domain O 0
. O 0

Expression O 0
in O 0
heterologous O 0
cells O 0
of O 0
recombinant O 0
vWF O 0
containing O 0
one O 0
of O 0
these O 0
latter O 0
mutations O 0
reproduced O 0
the O 0
characteristic O 0
structural O 0
abnormality O 0
seen O 0
in O 0
type B-Disease 0
IIA I-Disease 0
vWD I-Disease 1
plasma O 0
. O 0
. O 0

Familial B-Disease 1
deficiency I-Disease 1
of I-Disease 1
the I-Disease 1
seventh I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
associated O 0
with O 0
recurrent O 0
meningococcal B-Disease 0
infections I-Disease 0
. O 0

We O 0
describe O 0
an O 0
11 O 0
- O 0
year O 0
- O 0
old O 0
girl O 0
suffering O 0
from O 0
recurrent B-Disease 1
meningitis I-Disease 1
with O 0
a O 0
complete O 0
absence B-Disease 1
of I-Disease 1
the I-Disease 1
seventh I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
( O 0
C7 O 0
) O 0
. O 0

Diagnosis O 0
was O 0
established O 0
by O 0
haemolytic O 0
titration O 0
and O 0
western O 0
blotting O 0
. O 0

The O 0
patients O 0
serum O 0
lacked O 0
the O 0
85 O 0
kDa O 0
C7 O 0
chain O 0
. O 0

Haemolytic O 0
activity O 0
of O 0
serum O 0
was O 0
reconstituted O 0
with O 0
either O 0
pooled O 0
normal O 0
human O 0
serum O 0
or O 0
with O 0
purified O 0
C7 O 0
. O 0

The O 0
relatives O 0
( O 0
parents O 0
and O 0
one O 0
sister O 0
) O 0
had O 0
half O 0
- O 0
normal O 0
levels O 0
of O 0
both O 0
immunochemically O 0
and O 0
functionally O 0
determined O 0
C7 O 0
, O 0
indicating O 0
a O 0
heterozygous O 0
state O 0
for O 0
C7 B-Disease 0
deficiency I-Disease 0
. O 0
. O 0

Translocation O 0
t O 0
( O 0
5 O 0
; O 0
11 O 0
) O 0
( O 0
q13 O 0
. O 0
1 O 0
; O 0
p13 O 0
) O 0
associated O 0
with O 0
familial O 0
isolated B-Disease 0
aniridia I-Disease 0
. O 0

A O 0
father O 0
and O 0
daughter O 0
with O 0
isolated B-Disease 0
aniridia I-Disease 0
were O 0
observed O 0
to O 0
have O 0
an O 0
apparently O 0
balanced O 0
, O 0
reciprocal O 0
translocation O 0
involving O 0
chromosomes O 0
5 O 0
and O 0
11 O 0
[ O 0
t O 0
( O 0
5 O 0
; O 0
11 O 0
) O 0
( O 0
q13 O 0
. O 0
1 O 0
; O 0
p13 O 0
) O 0
] O 0
. O 0

No O 0
other O 0
clinical O 0
characteristics O 0
often O 0
associated O 0
with O 0
the O 0
deletion O 0
of O 0
11p13 O 0
were O 0
observed O 0
in O 0
this O 0
family O 0
. O 0

This O 0
finding O 0
, O 0
in O 0
association O 0
with O 0
3 O 0
other O 0
instances O 0
of O 0
single O 0
breaks O 0
at O 0
11p13 O 0
and O 0
aniridia B-Disease 0
, O 0
supports O 0
the O 0
assignment O 0
of O 0
AN2 O 0
to O 0
11p13 O 0
. O 0

Homozygous B-Disease 0
hypobetalipoproteinemia I-Disease 1
: O 0
a O 0
disease O 0
distinct O 0
from O 0
abetalipoproproteinemia B-Disease 1
at O 0
the O 0
molecular O 0
level O 0
. O 0

apoB O 0
DNA O 0
, O 0
RNA O 0
, O 0
and O 0
protein O 0
from O 0
two O 0
patients O 0
with O 0
homozygous B-Disease 0
hypobetalipoproteinemia I-Disease 1
( O 0
HBL B-Disease 0
) O 0
were O 0
evaluated O 0
and O 0
compared O 0
with O 0
normal O 0
individuals O 0
. O 0

Southern O 0
blot O 0
analysis O 0
with O 0
10 O 0
different O 0
cDNA O 0
probes O 0
revealed O 0
a O 0
normal O 0
gene O 0
without O 0
major O 0
insertions O 0
, O 0
deletions O 0
, O 0
or O 0
rearrangements O 0
. O 0

Northern O 0
and O 0
slot O 0
blot O 0
analyses O 0
of O 0
total O 0
liver O 0
mRNA O 0
from O 0
HBL B-Disease 0
patients O 0
documented O 0
a O 0
normal O 0
size O 0
apoB O 0
mRNA O 0
that O 0
was O 0
present O 0
in O 0
greatly O 0
reduced O 0
quantities O 0
. O 0

ApoB O 0
protein O 0
was O 0
detected O 0
within O 0
HBL B-Disease 0
hepatocytes O 0
utilizing O 0
immunohistochemical O 0
techniques O 0
; O 0
however O 0
, O 0
it O 0
was O 0
markedly O 0
reduced O 0
in O 0
quantity O 0
when O 0
compared O 0
with O 0
control O 0
samples O 0
. O 0

No O 0
apoB O 0
was O 0
detectable O 0
in O 0
the O 0
plasma O 0
of O 0
HBL B-Disease 0
individuals O 0
with O 0
an O 0
ELISA O 0
assay O 0
. O 0

These O 0
data O 0
are O 0
most O 0
consistent O 0
with O 0
a O 0
mutation O 0
in O 0
the O 0
coding O 0
portion O 0
of O 0
the O 0
apoB O 0
gene O 0
in O 0
HBL B-Disease 0
patients O 0
, O 0
leading O 0
to O 0
an O 0
abnormal O 0
apoB O 0
protein O 0
and O 0
apoB O 0
mRNA O 0
instability O 0
. O 0

These O 0
results O 0
are O 0
distinct O 0
from O 0
those O 0
previously O 0
noted O 0
in O 0
abetalipoproteinemia B-Disease 0
, O 0
which O 0
was O 0
characterized O 0
by O 0
an O 0
elevated O 0
level O 0
of O 0
hepatic O 0
apoB O 0
mRNA O 0
and O 0
accumulation O 0
of O 0
intracellular O 0
hepatic O 0
apoB O 0
protein O 0
. O 0
. O 0

Spontaneous O 0
reversion O 0
of O 0
novel O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
mutation O 0
by O 0
HPRT O 0
gene O 0
rearrangement O 0
. O 0

Molecular O 0
analysis O 0
of O 0
an O 0
unusual O 0
patient O 0
with O 0
the O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
has O 0
suggested O 0
that O 0
the O 0
mutation O 0
is O 0
due O 0
to O 0
a O 0
partial O 0
HPRT O 0
gene O 0
duplication O 0
. O 0

We O 0
now O 0
report O 0
the O 0
cloning O 0
and O 0
sequencing O 0
of O 0
the O 0
mutant O 0
HPRT O 0
cDNA O 0
which O 0
shows O 0
the O 0
precise O 0
duplication O 0
of O 0
exons O 0
2 O 0
and O 0
3 O 0
. O 0

This O 0
mutation O 0
is O 0
the O 0
result O 0
of O 0
an O 0
internal O 0
duplication O 0
of O 0
16 O 0
- O 0
20 O 0
kilobases O 0
of O 0
the O 0
gene O 0
. O 0

The O 0
structure O 0
of O 0
the O 0
mutant O 0
gene O 0
suggests O 0
that O 0
the O 0
duplication O 0
was O 0
not O 0
generated O 0
by O 0
a O 0
single O 0
unequal O 0
crossing O 0
- O 0
over O 0
event O 0
between O 0
two O 0
normal O 0
HPRT O 0
alleles O 0
. O 0

Growth O 0
of O 0
Epstein B-Disease 1
- I-Disease 1
Barr I-Disease 1
virus O 1
- O 0
transformed O 0
lymphoblasts O 0
from O 0
this O 0
patient O 0
in O 0
selective O 0
medium O 0
has O 0
permitted O 0
isolation O 0
of O 0
spontaneous O 0
HPRT O 0
+ O 0
revertants O 0
of O 0
this O 0
mutation O 0
. O 0

The O 0
reversion O 0
event O 0
involves O 0
a O 0
second O 0
major O 0
HPRT O 0
gene O 0
rearrangement O 0
where O 0
most O 0
or O 0
all O 0
of O 0
the O 0
duplicated O 0
portion O 0
of O 0
the O 0
mutant O 0
gene O 0
is O 0
deleted O 0
. O 0

The O 0
original O 0
mutation O 0
therefore O 0
has O 0
the O 0
potential O 0
for O 0
spontaneous O 0
somatic O 0
reversion O 0
. O 0

This O 0
may O 0
explain O 0
the O 0
relatively O 0
mild O 0
symptoms O 0
of O 0
the O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
exhibited O 0
by O 0
this O 0
patient O 0
. O 0
. O 0

Complex B-Disease 0
glycerol I-Disease 0
kinase I-Disease 0
deficiency I-Disease 0
: O 0
molecular O 0
- O 0
genetic O 0
, O 0
cytogenetic O 0
, O 0
and O 0
clinical O 0
studies O 0
of O 0
five O 0
Japanese O 0
patients O 0
. O 0

Five O 0
male O 0
Japanese O 0
patients O 0
with O 0
complex B-Disease 1
glycerol I-Disease 1
kinase I-Disease 1
deficiency I-Disease 1
( O 0
CGKD B-Disease 1
) O 0
and O 0
their O 0
relatives O 0
were O 0
studied O 0
clinically O 0
, O 0
cytogenetically O 0
, O 0
and O 0
molecular O 0
- O 0
genetically O 0
. O 0

All O 0
patients O 0
had O 0
muscular B-Disease 0
dystrophy I-Disease 0
or O 0
muscle B-Disease 1
weakness I-Disease 1
, O 0
mental B-Disease 1
retardation I-Disease 1
, O 0
congenital B-Disease 0
adrenal I-Disease 0
hypoplasia I-Disease 0
, O 0
and O 0
glycerol B-Disease 0
kinase I-Disease 0
deficiency I-Disease 0
. O 0

High O 0
- O 0
resolution O 0
GTG O 0
- O 0
banded O 0
chromosomes O 0
showed O 0
a O 0
microdeletion O 0
in O 0
the O 0
Xp21 O 0
region O 0
in O 0
all O 0
four O 0
patients O 0
examined O 0
and O 0
in O 0
all O 0
five O 0
mothers O 0
. O 0

Southern O 0
hybridizations O 0
, O 0
after O 0
digestions O 0
by O 0
restriction O 0
endonucleases O 0
, O 0
with O 0
various O 0
cloned O 0
DNAs O 0
( O 0
D2 O 0
, O 0
99 O 0
- O 0
6 O 0
, O 0
B24 O 0
, O 0
C7 O 0
, O 0
L1 O 0
- O 0
4 O 0
, O 0
cDMD13 O 0
- O 0
14 O 0
, O 0
J66 O 0
- O 0
HI O 0
, O 0
P20 O 0
, O 0
J O 0
- O 0
Bir O 0
, O 0
ERT87 O 0
- O 0
30 O 0
, O 0
ERT87 O 0
- O 0
15 O 0
, O 0
ERT87 O 0
- O 0
8 O 0
, O 0
ERT87 O 0
- O 0
1 O 0
, O 0
XJ O 0
- O 0
1 O 0
. O 0
1 O 0
, O 0
754 O 0
, O 0
cx5 O 0
. O 0
7 O 0
, O 0
and O 0
OTC O 0
- O 0
1 O 0
) O 0
that O 0
are O 0
located O 0
around O 0
Xp21 O 0
also O 0
showed O 0
a O 0
deletion O 0
in O 0
the O 0
genome O 0
of O 0
all O 0
patients O 0
and O 0
mothers O 0
. O 0

Although O 0
the O 0
deletion O 0
differed O 0
in O 0
size O 0
among O 0
patients O 0
, O 0
a O 0
segment O 0
commonly O 0
absent O 0
was O 0
located O 0
between O 0
the O 0
genomic O 0
sequences O 0
corresponding O 0
to O 0
L1 O 0
- O 0
4 O 0
and O 0
cDMD13 O 0
- O 0
14 O 0
. O 0

This O 0
finding O 0
indicated O 0
that O 0
the O 0
gene O 0
coding O 0
for O 0
glycerol O 0
kinase O 0
( O 0
GK O 0
) O 0
is O 0
located O 0
within O 0
this O 0
segment O 0
. O 0

A O 0
comparison O 0
of O 0
the O 0
clinical O 0
manifestations O 0
of O 0
the O 0
present O 0
five O 0
patients O 0
and O 0
reported O 0
CGKD B-Disease 1
or O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
patients O 0
with O 0
DNA O 0
deletion O 0
suggests O 0
the O 0
existence O 0
of O 0
a O 0
certain O 0
gene O 0
responsible O 0
for O 0
gonadotropin B-Disease 0
deficiency I-Disease 0
( O 0
GTD B-Disease 0
) O 0
. O 0

The O 0
result O 0
of O 0
the O 0
present O 0
study O 0
and O 0
results O 0
of O 0
previous O 0
studies O 0
suggest O 0
that O 0
genes O 0
for O 0
ornithine O 0
transcarbamylase O 0
( O 0
OTC O 0
) O 0
, O 0
DMD B-Disease 0
, O 0
and O 0
GK O 0
and O 0
putative O 0
genes O 0
responsible O 0
for O 0
congenital B-Disease 0
adrenal I-Disease 0
hypoplasia I-Disease 0
( O 0
AHC B-Disease 0
) O 0
and O 0
GTD B-Disease 0
are O 0
arranged O 0
from O 0
telomere O 0
to O 0
centromere O 0
as O 0
pter O 0
- O 0
- O 0
GTD O 0
- O 0
- O 0
AHC O 0
- O 0
- O 0
GK O 0
- O 0
- O 0
DMD O 0
- O 0
- O 0
OTC O 0
- O 0
- O 0
cen O 0

Genetically O 0
determined O 0
low O 0
C4 O 0
: O 0
a O 0
predisposing O 0
factor O 0
to O 0
autoimmune B-Disease 0
chronic I-Disease 0
active I-Disease 0
hepatitis I-Disease 0
. O 0

Of O 0
26 O 0
patients O 0
with O 0
autoimmune B-Disease 0
chronic I-Disease 0
active I-Disease 0
hepatitis I-Disease 0
( O 0
CAH B-Disease 1
) O 0
starting O 0
in O 0
childhood O 0
18 O 0
( O 0
69 O 0
% O 0
) O 0
had O 0
low O 0
C4 O 0
and O 0
5 O 0
( O 0
19 O 0
% O 0
) O 0
had O 0
low O 0
C3 O 0
serum O 0
levels O 0
. O 0

Impaired O 0
hepatic O 0
synthesis O 0
and O 0
immune O 0
- O 0
consumption O 0
were O 0
unlikely O 0
since O 0
transferrin O 0
levels O 0
were O 0
normal O 0
in O 0
all O 0
patients O 0
, O 0
albumin O 0
levels O 0
were O 0
persistently O 0
low O 0
in O 0
only O 0
3 O 0
, O 0
and O 0
only O 0
3 O 0
had O 0
raised O 0
levels O 0
of O 0
activation O 0
fragment O 0
C3d O 0
. O 0

C4d O 0
was O 0
normal O 0
in O 0
all O 0
patients O 0
studied O 0
. O 0

In O 0
the O 0
families O 0
of O 0
12 O 0
probands O 0
with O 0
low O 0
C4 O 0
, O 0
7 O 0
parents O 0
had O 0
low O 0
C4 O 0
and O 0
2 O 0
had O 0
levels O 0
which O 0
were O 0
at O 0
the O 0
lower O 0
limit O 0
of O 0
normal O 0
. O 0

5 O 0
of O 0
10 O 0
siblings O 0
from O 0
5 O 0
families O 0
had O 0
low O 0
C4 O 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
low O 0
C4 O 0
levels O 0
in O 0
CAH B-Disease 1
are O 0
genetically O 0
determined O 0
. O 0

C4 O 0
phenotyping O 0
in O 0
20 O 0
patients O 0
and O 0
in O 0
26 O 0
parents O 0
showed O 0
that O 0
90 O 0
% O 0
and O 0
81 O 0
% O 0
, O 0
respectively O 0
, O 0
had O 0
null O 0
allotypes O 0
at O 0
either O 0
the O 0
C4A O 0
or O 0
C4B O 0
locus O 0
compared O 0
with O 0
59 O 0
% O 0
in O 0
controls O 0
, O 0
indicating O 0
that O 0
defective O 0
expression O 0
of O 0
structural O 0
genes O 0
may O 0
contribute O 0
to O 0
the O 0
observed O 0
C4 B-Disease 0
deficiency I-Disease 0
. O 0
. O 0

An O 0
amino O 0
- O 0
acid O 0
substitution O 0
involved O 0
in O 0
phenylketonuria B-Disease 0
is O 0
in O 0
linkage O 0
disequilibrium O 0
with O 0
DNA O 0
haplotype O 0
2 O 0
. O 0

Phenylketonuria B-Disease 0
( O 0
PKU B-Disease 0
) O 0
is O 0
an O 0
autosomal B-Disease 0
recessive I-Disease 0
human I-Disease 0
genetic I-Disease 0
disorder I-Disease 0
caused O 0
by O 0
a O 0
deficiency B-Disease 0
of I-Disease 0
hepatic I-Disease 0
phenylalanine I-Disease 0
hydroxylase I-Disease 0
( O 0
PAH O 0
, O 0
phenylalanine O 0
4 O 0
- O 0
monooxygenase O 0
, O 0
EC O 0
1 O 0
. O 0
14 O 0
. O 0
16 O 0
. O 0
1 O 0
) O 0
. O 0

PKU B-Disease 0
is O 0
a O 0
common O 0
inborn B-Disease 1
error I-Disease 1
of I-Disease 1
amino I-Disease 1
- I-Disease 1
acid I-Disease 1
metabolism I-Disease 1
in O 0
caucasian O 0
populations O 0
and O 0
approximately O 0
1 O 0
in O 0
50 O 0
individuals O 0
are O 0
carriers O 0
of O 0
a O 0
PKU B-Disease 0
allele O 0
. O 0

To O 0
define O 0
the O 0
molecular O 0
basis O 0
of O 0
PKU B-Disease 0
, O 0
we O 0
characterized O 0
twelve O 0
restriction O 0
fragment O 0
- O 0
length O 0
polymorphism O 0
( O 0
RFLP O 0
) O 0
haplotypes O 0
of O 0
the O 0
PAH O 0
locus O 0
in O 0
the O 0
northern O 0
European O 0
population O 0
and O 0
observed O 0
that O 0
90 O 0
% O 0
of O 0
the O 0
PKU B-Disease 0
alleles O 0
in O 0
this O 0
population O 0
are O 0
confined O 0
to O 0
four O 0
common O 0
RFLP O 0
haplotypes O 0
. O 0

We O 0
have O 0
recently O 0
reported O 0
a O 0
splicing O 0
mutation O 0
in O 0
the O 0
PAH O 0
gene O 0
that O 0
is O 0
associated O 0
with O 0
RFLP O 0
haplotype O 0
3 O 0
which O 0
is O 0
present O 0
at O 0
about O 0
40 O 0
% O 0
of O 0
mutant O 0
alleles O 0
. O 0

We O 0
now O 0
report O 0
the O 0
molecular B-Disease 0
lesion I-Disease 0
associated O 0
with O 0
the O 0
RFLP O 0
haplotype O 0
2 O 0
mutant O 0
allele O 0
. O 0

This O 0
defect O 0
is O 0
caused O 0
by O 0
a O 0
C O 0
- O 0
to O 0
- O 0
T O 0
transition O 0
in O 0
exon O 0
12 O 0
resulting O 0
in O 0
an O 0
amino O 0
- O 0
acid O 0
substitution O 0
( O 0
Arg O 0
to O 0
Trp O 0
) O 0
at O 0
residue O 0
408 O 0
of O 0
PAH O 0
. O 0

Direct O 0
hybridization O 0
analysis O 0
of O 0
the O 0
point O 0
mutation O 0
using O 0
a O 0
specific O 0
oligonucleotide O 0
probe O 0
demonstrated O 0
that O 0
this O 0
mutation O 0
is O 0
also O 0
in O 0
linkage O 0
disequilibrium O 0
with O 0
RFLP O 0
haplotype O 0
2 O 0
alleles O 0
that O 0
make O 0
up O 0
about O 0
20 O 0
% O 0
of O 0
mutant O 0
PAH O 0
genes O 0

Choroideremia B-Disease 0
: O 0
close O 0
linkage O 0
to O 0
DXYS1 O 0
and O 0
DXYS12 O 0
demonstrated O 0
by O 0
segregation O 0
analysis O 0
and O 0
historical O 0
- O 0
genealogical O 0
evidence O 0
. O 0

Linkage O 0
studies O 0
using O 0
restriction O 0
fragment O 0
length O 0
polymorphisms O 0
were O 0
conducted O 0
in O 0
the O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
disorder I-Disease 1
, O 0
choroideremia B-Disease 1
, O 0
designated O 0
TCD B-Disease 0
for O 0
Progressive B-Disease 0
Tapeto I-Disease 0
- I-Disease 0
Choroidal I-Disease 0
Dystrophy I-Disease 0
. O 0

Previously O 0
demonstrated O 0
close O 0
linkage O 0
with O 0
locus O 0
DXYS1 O 0
was O 0
confirmed O 0
( O 0
lod O 0
11 O 0
. O 0
44 O 0
at O 0
0 O 0
recombination O 0
distance O 0
) O 0
. O 0

In O 0
addition O 0
, O 0
locus O 0
DXYS12 O 0
was O 0
found O 0
to O 0
be O 0
closely O 0
linked O 0
with O 0
TCD B-Disease 0
( O 0
lod O 0
3 O 0
. O 0
31 O 0
at O 0
0 O 0
recombination O 0
distance O 0
) O 0
. O 0

The O 0
disease O 0
mainly O 0
occurs O 0
in O 0
three O 0
large O 0
kindreds O 0
in O 0
remote O 0
Northern O 0
Finland O 0
. O 0

While O 0
formal O 0
genealogical O 0
proof O 0
is O 0
lacking O 0
, O 0
all O 0
presently O 0
living O 0
( O 0
more O 0
than O 0
80 O 0
affected O 0
males O 0
and O 0
120 O 0
carrier O 0
females O 0
) O 0
probably O 0
originate O 0
from O 0
a O 0
common O 0
founder O 0
couple O 0
born O 0
in O 0
1644 O 0
and O 0
1646 O 0
, O 0
twelve O 0
generations O 0
ago O 0
. O 0

All O 0
36 O 0
patients O 0
and O 0
48 O 0
carriers O 0
tested O 0
from O 0
the O 0
three O 0
kindreds O 0
had O 0
the O 0
same O 0
haplotype O 0
( O 0
TCD B-Disease 0
/ O 0
DXYS1 O 0
, O 0
11kb O 0
/ O 0
DXYS12 O 0
, O 0
1 O 0
. O 0
6kb O 0
) O 0
. O 0

Given O 0
that O 0
at O 0
least O 0
105 O 0
female O 0
meioses O 0
transmitting O 0
TCD B-Disease 0
have O 0
occurred O 0
since O 0
1650 O 0
in O 0
these O 0
kindreds O 0
, O 0
extremely O 0
close O 0
linkage O 0
between O 0
TCD B-Disease 0
, O 0
DXYS1 O 0
and O 0
DXYS12 O 0
is O 0
suggested O 0
. O 0

The O 0
above O 0
haplotype O 0
is O 0
a O 0
very O 0
useful O 0
diagnostic O 0
tool O 0
in O 0
these O 0
TCD B-Disease 0
families O 0
. O 0

We O 0
suggest O 0
that O 0
our O 0
historical O 0
- O 0
genealogical O 0
approach O 0
to O 0
linkage O 0
analysis O 0
may O 0
be O 0
possible O 0
elsewhere O 0
in O 0
similar O 0
isolated O 0
populations O 0

Von B-Disease 1
Hippel I-Disease 1
- I-Disease 1
Lindau I-Disease 1
disease I-Disease 1
maps O 0
to O 0
the O 0
region O 0
of O 0
chromosome O 0
3 O 0
associated O 0
with O 0
renal B-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
. O 0

Von B-Disease 1
Hippel I-Disease 1
- I-Disease 1
Lindau I-Disease 1
disease I-Disease 1
( O 0
VHL B-Disease 1
) O 0
is O 0
an O 0
autosomal B-Disease 0
dominant I-Disease 0
disorder I-Disease 0
with O 0
inherited O 0
susceptibility O 0
to O 0
various O 0
forms O 0
of O 0
cancer B-Disease 1
, O 0
including O 0
hemangioblastomas B-Disease 1
of O 0
the O 0
central O 0
nervous O 0
system O 0
, O 0
phaeochromocytomas B-Disease 0
, O 0
pancreatic B-Disease 0
malignancies I-Disease 0
, O 0
and O 0
renal B-Disease 0
cell I-Disease 0
carcinomas I-Disease 0
. O 0

Renal B-Disease 0
cell I-Disease 0
carcinomas I-Disease 0
constitute O 0
a O 0
particularly O 0
frequent O 0
cause O 0
of O 0
death O 0
in O 0
this O 0
disorder O 0
, O 0
occurring O 0
as O 0
bilateral B-Disease 1
and I-Disease 1
multifocal I-Disease 1
tumours I-Disease 1
, O 0
and O 0
presenting O 0
at O 0
an O 0
earlier O 0
age O 0
than O 0
in O 0
sporadic O 0
, O 0
non O 0
- O 0
familial O 0
cases O 0
of O 0
this O 0
tumour B-Disease 1
type O 0
. O 0

We O 0
report O 0
here O 0
that O 0
the O 0
VHL B-Disease 1
gene O 0
is O 0
linked O 0
to O 0
the O 0
locus O 0
encoding O 0
the O 0
human O 0
homologoue O 0
of O 0
the O 0
RAF1 O 0
oncogene O 0
, O 0
which O 0
maps O 0
to O 0
chromosome O 0
3p25 O 0
( O 0
ref O 0
. O 0
4 O 0
) O 0
. O 0

Crossovers O 0
with O 0
the O 0
VHL B-Disease 1
locus O 0
suggest O 0
that O 0
the O 0
defect O 0
responsible O 0
for O 0
the O 0
VHL B-Disease 1
phenotype O 0
is O 0
not O 0
a O 0
mutation O 0
in O 0
the O 0
RAF1 O 0
gene O 0
itself O 0
. O 0

An O 0
alternative O 0
or O 0
prior O 0
event O 0
to O 0
oncogene O 0
activation O 0
in O 0
tumour B-Disease 1
formation O 0
may O 0
be O 0
the O 0
inactivation O 0
of O 0
a O 0
putative O 0
tumour B-Disease 1
suppressor O 0
which O 0
can O 0
be O 0
associated O 0
with O 0
both O 0
the O 0
inherited B-Disease 0
and I-Disease 0
sporadic I-Disease 0
forms I-Disease 0
of I-Disease 0
the I-Disease 0
cancer I-Disease 1
. O 0

Sporadic B-Disease 0
renal I-Disease 0
cell I-Disease 0
carcinomas I-Disease 0
have O 0
previously O 0
been O 0
associated O 0
with O 0
the O 0
loss O 0
of O 0
regions O 0
on O 0
chromosome O 0
3p O 0
( O 0
refs O 0
5 O 0
, O 0
6 O 0
) O 0
. O 0

Consequently O 0
, O 0
sporadic O 0
and O 0
VHL O 1
- O 0
associated O 0
forms O 0
of O 0
renal B-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
might O 0
both O 0
result O 0
from O 0
alterations O 0
causing O 0
loss O 0
of O 0
function O 0
of O 0
the O 0
same O 0
tumour B-Disease 1
suppressor O 0
gene O 0
on O 0
this O 0
chromosome O 0
. O 0
. O 0

Tightly O 0
linked O 0
flanking O 0
markers O 0
for O 0
the O 0
Lowe B-Disease 0
oculocerebrorenal I-Disease 1
syndrome I-Disease 1
, O 0
with O 0
application O 0
to O 0
carrier O 0
assessment O 0
. O 0

The O 0
Lowe B-Disease 0
oculocerebrorenal I-Disease 1
syndrome I-Disease 1
( O 0
OCRL B-Disease 1
) O 0
is O 0
characterized O 0
by O 0
congenital O 1
cataract B-Disease 1
, O 0
mental B-Disease 1
retardation I-Disease 1
, O 0
and O 0
defective B-Disease 0
renal I-Disease 0
tubular I-Disease 0
function I-Disease 0
. O 0

A O 0
map O 0
assignment O 0
of O 0
OCRL B-Disease 1
to O 0
Xq24 O 0
- O 0
q26 O 0
has O 0
been O 0
made O 0
previously O 0
by O 0
linkage O 0
analysis O 0
with O 0
DXS42 O 0
at O 0
Xq24 O 0
- O 0
q26 O 0
( O 0
theta O 0
= O 0
0 O 0
, O 0
z O 0
= O 0
5 O 0
. O 0
09 O 0
) O 0
and O 0
with O 0
DXS10 O 0
at O 0
Xq26 O 0
( O 0
theta O 0
= O 0
0 O 0
, O 0
z O 0
= O 0
6 O 0
. O 0
45 O 0
) O 0
. O 0

Two O 0
additional O 0
families O 0
were O 0
studied O 0
and O 0
three O 0
additional O 0
polymorphisms O 0
were O 0
identified O 0
at O 0
DXS42 O 0
by O 0
using O 0
a O 0
35 O 0
- O 0
kb O 0
sequence O 0
isolated O 0
with O 0
the O 0
probe O 0
detecting O 0
the O 0
original O 0
polymorphism O 0
at O 0
DXS42 O 0
. O 0

With O 0
additional O 0
OCRL B-Disease 1
families O 0
made O 0
informative O 0
for O 0
DXS42 O 0
, O 0
theta O 0
remained O 0
0 O 0
with O 0
z O 0
= O 0
6 O 0
. O 0

63 O 0
; O 0
and O 0
for O 0
DXS10 O 0
theta O 0
= O 0
0 O 0
. O 0

03 O 0
and O 0
z O 0
= O 0
7 O 0
. O 0

07 O 0
. O 0

Evidence O 0
for O 0
placing O 0
OCRL O 1
at O 0
Xq25 O 0
also O 0
comes O 0
from O 0
a O 0
female O 0
with O 0
Lowe B-Disease 1
syndrome I-Disease 1
and O 0
an O 0
X O 0
; O 0
3 O 0
translocation O 0
. O 0

We O 0
have O 0
used O 0
the O 0
Xq25 O 0
breakpoint O 0
in O 0
this O 0
patient O 0
to O 0
determine O 0
the O 0
position O 0
of O 0
OCRL O 1
relative O 0
to O 0
the O 0
two O 0
linked O 0
markers O 0
. O 0

Each O 0
derivative O 0
chromosome O 0
was O 0
isolated O 0
away O 0
from O 0
its O 0
normal O 0
counterpart O 0
in O 0
somatic O 0
cell O 0
hybrids O 0
. O 0

DXS42 O 0
was O 0
mapped O 0
to O 0
the O 0
derivative O 0
chromosome O 0
X O 0
containing O 0
Xpterq25 O 0
, O 0
and O 0
DXS10 O 0
was O 0
mapped O 0
to O 0
the O 0
derivative O 0
chromosome O 0
3 O 0
containing O 0
Xq25 O 0
- O 0
qter O 0
. O 0

The O 0
markers O 0
DXS10 O 0
and O 0
DXS42 O 0
therefore O 0
show O 0
tight O 0
linkage O 0
with O 0
OCRL B-Disease 1
in O 0
six O 0
families O 0
and O 0
flank O 0
the O 0
Xq25 O 0
breakpoint O 0
in O 0
a O 0
female O 0
patient O 0
with O 0
an O 0
X O 0
; O 0
3 O 0
translocation O 0
. O 0

Linkage O 0
analysis O 0
with O 0
flanking O 0
markers O 0
was O 0
used O 0
to O 0
assess O 0
OCRL B-Disease 1
carrier O 0
status O 0
in O 0
women O 0
at O 0
risk O 0
. O 0

Results O 0
, O 0
when O 0
compared O 0
with O 0
carrier O 0
determination O 0
by O 0
ophthalmologic O 0
examination O 0
, O 0
indicated O 0
that O 0
the O 0
slit O 0
- O 0
lamp O 0
exam O 0
can O 0
be O 0
a O 0
sensitive O 0
and O 0
specific O 0
method O 0
of O 0
carrier O 0
determination O 0
in O 0
many O 0
cases O 0

Identification O 0
of O 0
a O 0
single O 0
nucleotide O 0
change O 0
in O 0
the O 0
hypoxanthine O 0
- O 0
guanine O 0
phosphoribosyltransferase O 0
gene O 0
( O 0
HPRTYale O 0
) O 0
responsible O 0
for O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
. O 0

Complete O 0
deficiency B-Disease 0
of I-Disease 0
hypoxanthine I-Disease 0
- I-Disease 0
guanine I-Disease 0
phosphoribosyltransferase I-Disease 0
( O 0
HPRT O 0
) O 0
causes O 0
the O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
. O 0

Previous O 0
characterization O 0
of O 0
a O 0
mutant O 0
form O 0
of O 0
HPRT O 0
, O 0
HPRTYale O 0
, O 0
from O 0
a O 0
subject O 0
with O 0
the O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
revealed O 0
normal O 0
mRNA O 0
and O 0
protein O 0
concentrations O 0
, O 0
no O 0
residual O 0
catalytic O 0
activity O 0
, O 0
and O 0
cathodal O 0
migration O 0
upon O 0
PAGE O 0
. O 0

We O 0
have O 0
cloned O 0
and O 0
sequenced O 0
HPRTYale O 0
cDNA O 0
. O 0

The O 0
nucleotide O 0
sequence O 0
of O 0
full O 0
- O 0
length O 0
HPRTYale O 0
cDNA O 0
revealed O 0
a O 0
single O 0
nucleotide O 0
substitution O 0
compared O 0
with O 0
normal O 0
HPRT O 0
cDNA O 0
G O 0
- O 0
- O 0
- O 0
- O 0
C O 0
at O 0
nucleotide O 0
position O 0
211 O 0
. O 0

This O 0
transversion O 0
predicts O 0
substitution O 0
of O 0
arginine O 0
for O 0
glycine O 0
at O 0
amino O 0
acid O 0
position O 0
71 O 0
, O 0
explaining O 0
the O 0
cathodal O 0
migration O 0
of O 0
HPRTYale O 0
. O 0

Chou O 0
- O 0
Fasman O 0
secondary O 0
structure O 0
analysis O 0
predicts O 0
a O 0
change O 0
in O 0
the O 0
probability O 0
of O 0
beta O 0
- O 0
turn O 0
formation O 0
in O 0
the O 0
region O 0
containing O 0
the O 0
mutation O 0
. O 0

Inclusion O 0
of O 0
the O 0
bulky O 0
arginine O 0
side O 0
chain O 0
in O 0
place O 0
of O 0
glycine O 0
probably O 0
disrupts O 0
protein O 0
folding O 0
as O 0
well O 0
. O 0

Cloning O 0
mutant O 0
forms O 0
of O 0
cDNA O 0
allows O 0
identification O 0
of O 0
specific O 0
mutations O 0
, O 0
provides O 0
insight O 0
into O 0
mutational O 0
mechanisms O 0
, O 0
and O 0
facilitates O 0
structure O 0
- O 0
function O 0
analysis O 0
of O 0
mutant O 0
proteins O 0
. O 0
. O 0

Two O 0
point O 0
mutations O 0
are O 0
responsible O 0
for O 0
G6PD O 0
polymorphism O 0
in O 0
Sardinia O 0
. O 0

The O 0
human O 0
X O 0
- O 0
linked O 0
gene O 0
encoding O 0
glucose O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
is O 0
highly O 0
polymorphic O 0
; O 0
more O 0
than O 0
300 O 0
G6PD O 0
variants O 0
have O 0
been O 0
identified O 0
. O 0

G6PD B-Disease 0
deficiency I-Disease 0
in O 0
different O 0
geographical O 0
areas O 0
appears O 0
to O 0
have O 0
arisen O 0
through O 0
independent O 0
mutational O 0
events O 0
, O 0
but O 0
within O 0
the O 0
same O 0
population O 0
it O 0
may O 0
also O 0
be O 0
heterogeneous O 0
. O 0

One O 0
example O 0
is O 0
the O 0
island O 0
of O 0
Sardinia O 0
, O 0
where O 0
careful O 0
clinical O 0
and O 0
biochemical O 0
studies O 0
have O 0
identified O 0
four O 0
different O 0
G6PD O 0
variants O 0
. O 0

We O 0
cloned O 0
and O 0
sequenced O 0
the O 0
four O 0
G6PD O 0
variants O 0
from O 0
Sardinia O 0
and O 0
found O 0
that O 0
only O 0
two O 0
mutations O 0
are O 0
responsible O 0
for O 0
G6PD B-Disease 0
deficiency I-Disease 0
in O 0
this O 0
area O 0
one O 0
mutation O 0
is O 0
the O 0
cause O 0
of O 0
the O 0
G6PD B-Disease 1
Seattle I-Disease 1
- I-Disease 1
like I-Disease 1
phenotype I-Disease 1
, O 0
a O 0
milder O 0
form O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
; O 0
the O 0
other O 0
mutation O 0
is O 0
responsible O 0
for O 0
all O 0
forms O 0
of O 0
very O 0
severe O 0
G6PD B-Disease 0
deficiency I-Disease 0
in O 0
Sardinia O 0
and O 0
, O 0
possibly O 0
, O 0
in O 0
the O 0
Mediterranean O 0
. O 0
. O 0

Chronic B-Disease 1
nonspherocytic I-Disease 1
hemolytic I-Disease 1
anemia I-Disease 1
( O 0
CNSHA B-Disease 0
) O 0
and O 0
glucose B-Disease 1
6 I-Disease 1
phosphate I-Disease 1
dehydrogenase I-Disease 1
( I-Disease 1
G6PD I-Disease 1
) I-Disease 1
deficiency I-Disease 1
in O 0
a O 0
patient O 0
with O 0
familial B-Disease 0
amyloidotic I-Disease 0
polyneuropathy I-Disease 0
( O 0
FAP B-Disease 0
) O 0
. O 0

Molecular O 0
study O 0
of O 0
a O 0
new O 0
variant O 0
( O 0
G6PD O 0
Clinic O 0
) O 0
with O 0
markedly O 0
acidic O 0
pH O 0
optimum O 0
. O 0

A O 0
new O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
variant O 0
with O 0
severe O 0
erythrocytic B-Disease 1
G6PD I-Disease 1
deficiency I-Disease 1
and O 0
a O 0
unique O 0
pH O 0
optimum O 0
is O 0
described O 0
in O 0
a O 0
young O 0
patient O 0
with O 0
chronic B-Disease 0
nonspherocytic I-Disease 0
hemolytic I-Disease 1
anemia I-Disease 1
( O 0
CNSHA B-Disease 0
) O 0
and O 0
familial B-Disease 0
amyloidotic I-Disease 0
polyneuropathy I-Disease 0
( O 0
FAP B-Disease 0
) O 0
. O 0

Chronic B-Disease 0
hemolysis I-Disease 1
was O 0
present O 0
in O 0
the O 0
absence O 0
of O 0
infections O 0
, O 0
oxidant O 0
drugs O 0
or O 0
ingestion O 0
of O 0
faba O 0
beans O 0
. O 0

Residual O 0
enzyme O 0
activity O 0
was O 0
about O 0
2 O 0
. O 0

6 O 0
% O 0
and O 0
63 O 0
% O 0
of O 0
normal O 0
activity O 0
in O 0
erythrocytes O 0
and O 0
leucocytes O 0
, O 0
respectively O 0
. O 0

A O 0
molecular O 0
study O 0
using O 0
standard O 0
methods O 0
showed O 0
G6PD O 0
in O 0
the O 0
patient O 0
to O 0
have O 0
normal O 0
electrophoretic O 0
mobility O 0
( O 0
at O 0
pH O 0
7 O 0
. O 0
0 O 0
, O 0
8 O 0
. O 0
0 O 0
and O 0
8 O 0
. O 0
8 O 0
) O 0
, O 0
normal O 0
apparent O 0
affinity O 0
for O 0
substrates O 0
( O 0
Km O 0
, O 0
G6P O 0
and O 0
NADP O 0
) O 0
and O 0
a O 0
slightly O 0
abnormal O 0
utilization O 0
of O 0
substrate O 0
analogues O 0
( O 0
decreased O 0
deamino O 0
- O 0
NADP O 0
and O 0
increased O 0
2 O 0
- O 0
deoxyglucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
utilization O 0
) O 0
. O 0

Heat O 0
stability O 0
was O 0
found O 0
to O 0
be O 0
markedly O 0
decreased O 0
( O 0
8 O 0
% O 0
of O 0
residual O 0
activity O 0
after O 0
20 O 0
min O 0
of O 0
incubation O 0
at O 0
46 O 0
degrees O 0
C O 0
) O 0
and O 0
a O 0
particular O 0
characteristic O 0
of O 0
this O 0
enzyme O 0
was O 0
a O 0
biphasic O 0
pH O 0
curve O 0
with O 0
a O 0
greatly O 0
increased O 0
activity O 0
at O 0
low O 0
pH O 0
. O 0

Although O 0
molecular O 0
characteristics O 0
of O 0
this O 0
variant O 0
closely O 0
resemble O 0
those O 0
of O 0
G6PD O 0
Bangkok O 0
and O 0
G6PD O 0
Duarte O 0
, O 0
it O 0
can O 0
be O 0
distinguished O 0
from O 0
these O 0
and O 0
all O 0
other O 0
previously O 0
reported O 0
variants O 0
by O 0
virtue O 0
of O 0
its O 0
unusual O 0
pH O 0
curve O 0
. O 0

Therefore O 0
the O 0
present O 0
variant O 0
has O 0
been O 0
designated O 0
G6PD O 0
Clinic O 0
to O 0
distinguish O 0
it O 0
from O 0
other O 0
G6PD O 0
variants O 0
previously O 0
described O 0

Molecular O 0
detection O 0
of O 0
chromosomal O 0
translocations O 0
that O 0
disrupt O 0
the O 0
putative O 0
retinoblastoma B-Disease 1
susceptibility O 0
locus O 0
. O 0

A O 0
candidate O 0
DNA O 0
sequence O 0
with O 0
many O 0
of O 0
the O 0
properties O 0
predicted O 0
for O 0
the O 0
retinoblastoma B-Disease 1
susceptibility O 0
( O 0
RB1 O 0
) O 0
locus O 0
has O 0
been O 0
cloned O 0
( O 0
S O 0
. O 0
H O 1
. O 0
Friend O 0
, O 0
R O 0
. O 0
Bernards O 0
, O 0
S O 0
. O 0
Rogelj O 0
, O 0
R O 0
. O 0
A O 0
. O 0
Weinberg O 0
, O 0
J O 0
. O 0
M O 0
. O 0
Rapaport O 0
, O 0
D O 0
. O 0
M O 0
. O 0
Albert O 0
, O 0
and O 0
T O 0
. O 0
P O 0
. O 0
Dryja O 0
, O 0
Nature O 0
[ O 0
London O 0
] O 0
323 O 0
643 O 0
- O 0
645 O 0
, O 0
1986 O 0
) O 0
. O 0

The O 0
large O 0
size O 0
of O 0
this O 0
gene O 0
( O 0
ca O 0
. O 0
200 O 0
kilobases O 0
[ O 0
kb O 0
] O 0
) O 0
and O 0
its O 0
multiple O 0
dispersed O 0
exons O 0
( O 0
Wiggs O 0
et O 0
al O 0
. O 0
, O 0
N O 0
. O 0
Engl O 0
. O 0
J O 0
. O 0
Med O 0
. O 0
318 O 0
151 O 0
- O 0
157 O 0
, O 0
1988 O 0
) O 0
complicate O 0
molecular O 0
screening O 0
strategies O 0
important O 0
in O 0
prenatal O 0
and O 0
presymptomatic O 0
diagnosis O 0
and O 0
in O 0
carrier O 0
detection O 0
. O 0

Here O 0
we O 0
used O 0
field O 0
inversion O 0
gel O 0
electrophoresis O 0
( O 0
FIGE O 0
) O 0
to O 0
construct O 0
a O 0
restriction O 0
map O 0
of O 0
approximately O 0
1 O 0
, O 0
000 O 0
kb O 0
of O 0
DNA O 0
surrounding O 0
the O 0
RB1 O 0
locus O 0
and O 0
to O 0
detect O 0
the O 0
translocation O 0
breakpoints O 0
in O 0
three O 0
retinoblastoma B-Disease 1
patients O 0
. O 0

DNA O 0
probes O 0
from O 0
either O 0
the O 0
5 O 0
or O 0
3 O 0
end O 0
of O 0
the O 0
gene O 0
were O 0
used O 0
to O 0
detect O 0
a O 0
250 O 0
- O 0
kb O 0
EagI O 0
restriction O 0
fragment O 0
in O 0
DNA O 0
from O 0
unaffected O 0
individuals O 0
. O 0

Both O 0
probes O 0
identified O 0
an O 0
additional O 0
hybridizing O 0
fragment O 0
in O 0
the O 0
DNA O 0
from O 0
each O 0
patient O 0
, O 0
permitting O 0
the O 0
breakpoints O 0
in O 0
all O 0
three O 0
to O 0
be O 0
mapped O 0
within O 0
the O 0
cloned O 0
RB1 O 0
gene O 0
. O 0

Analysis O 0
of O 0
the O 0
breakpoint O 0
in O 0
one O 0
translocation O 0
cell O 0
line O 0
allowed O 0
the O 0
RB1 O 0
gene O 0
to O 0
be O 0
oriented O 0
with O 0
its O 0
5 O 0
end O 0
toward O 0
the O 0
centromere O 0
. O 0

The O 0
5 O 0
end O 0
of O 0
the O 0
gene O 0
also O 0
appeared O 0
to O 0
be O 0
associated O 0
with O 0
a O 0
clustering O 0
of O 0
sites O 0
for O 0
several O 0
infrequently O 0
cleaving O 0
restriction O 0
enzymes O 0
, O 0
indicating O 0
the O 0
presence O 0
of O 0
an O 0
HpaII O 0
tiny O 0
fragment O 0
island O 0
. O 0

The O 0
detection O 0
and O 0
mapping O 0
of O 0
the O 0
translocation O 0
breakpoints O 0
of O 0
all O 0
three O 0
retinoblastoma B-Disease 1
patients O 0
to O 0
within O 0
the O 0
putative O 0
RB1 O 0
gene O 0
substantiated O 0
the O 0
authenticity O 0
of O 0
this O 0
candidate O 0
sequence O 0
and O 0
demonstrated O 0
the O 0
utility O 0
of O 0
FIGE O 0
in O 0
detecting O 0
chromosomal O 0
rearrangements O 0
affecting O 0
this O 0
locus O 0
. O 0

Inherited O 0
C3 B-Disease 0
deficiency I-Disease 0
with O 0
recurrent O 0
infections O 0
and O 0
glomerulonephritis B-Disease 0
. O 0

A O 0
10 O 0
- O 0
year O 0
- O 0
old O 0
Laotian O 0
boy O 0
had O 0
homozygous O 0
deficiency B-Disease 0
of I-Disease 0
the I-Disease 0
third I-Disease 0
component I-Disease 0
of I-Disease 0
complement I-Disease 0
and O 0
recurrent O 0
bacterial B-Disease 1
infections I-Disease 1
beginning O 0
at O 0
age O 0
5 O 0
months O 0
. O 0

Cellular O 0
and O 0
humoral O 0
immunity O 0
were O 0
normal O 0
, O 0
as O 0
were O 0
polymorphonuclear O 0
leukocyte O 0
chemotaxis O 0
and O 0
bactericidal O 0
activities O 0
. O 0

Serum O 0
complement O 0
- O 0
mediated O 0
hemolytic O 0
, O 0
chemotactic O 0
, O 0
and O 0
opsonic O 0
activities O 0
were O 0
deficient O 0
. O 0

In O 0
vitro O 0
addition O 0
of O 0
purified O 0
C3 O 0
to O 0
patient O 0
serum O 0
restored O 0
hemolytic O 0
complement O 0
to O 0
normal O 0
levels O 0
, O 0
and O 0
plasma O 0
infusion O 0
during O 0
each O 0
of O 0
four O 0
episodes O 0
of O 0
pneumonia B-Disease 0
significantly O 0
enhanced O 0
serum O 0
opsonic O 0
activity O 0
for O 0
as O 0
long O 0
as O 0
36 O 0
hours O 0
. O 0

A O 0
renal O 0
biopsy O 0
specimen O 0
revealed O 0
mesangiopathic B-Disease 1
glomerulonephritis I-Disease 1
, O 0
although O 0
significant O 0
levels O 0
of O 0
circulating O 0
IgG O 0
immune O 0
complexes O 0
were O 0
not O 0
detected O 0
. O 0

These O 0
findings O 0
further O 0
support O 0
the O 0
association O 0
of O 0
C3 B-Disease 0
deficiency I-Disease 0
with O 0
immune B-Disease 1
- I-Disease 1
complex I-Disease 1
disease I-Disease 1
and O 0
suggest O 0
that O 0
plasma O 0
infusion O 0
may O 0
be O 0
an O 0
adjunct O 0
to O 0
antibiotic O 0
therapy O 0
in O 0
the O 0
management O 0
of O 0
severe O 0
pyogenic B-Disease 0
infections I-Disease 0
in O 0
patients O 0
with O 0
C3 B-Disease 0
deficiency I-Disease 0
. O 0
. O 0

DNA O 0
restriction O 0
fragments O 0
associated O 0
with O 0
alpha O 0
1 O 0
- O 0
antitrypsin O 0
indicate O 0
a O 0
single O 0
origin O 0
for O 0
deficiency O 0
allele O 0
PI O 0
Z O 0
. O 0

The O 0
alpha O 0
1 O 0
- O 0
protease O 0
inhibitor O 0
, O 0
or O 0
alpha O 0
- O 0
antitrypsin O 0
( O 0
AAT O 0
) O 0
, O 0
a O 0
major O 0
plasma O 0
inhibitor O 0
of O 0
leukocyte O 0
elastase O 0
and O 0
bacterial O 0
proteases O 0
, O 0
is O 0
encoded O 0
at O 0
the O 0
PI O 0
locus O 0
on O 0
chromosome O 0
14 O 0
( O 0
14q24 O 0
. O 0
3 O 0
- O 0
q32 O 0
. O 0
1 O 0
) O 0
. O 0

A O 0
deficiency B-Disease 0
of I-Disease 0
AAT I-Disease 0
in O 0
individuals O 0
homozygous O 0
for O 0
the O 0
PI O 0
Z O 0
allele O 0
occurs O 0
in O 0
about O 0
1 O 0
in O 0
2 O 0
, O 0
000 O 0
- O 0
8 O 0
, O 0
000 O 0
caucasians O 0
and O 0
is O 0
associated O 0
with O 0
an O 0
increased O 0
risk O 0
of O 0
early O 0
adult O 0
onset O 0
emphysema B-Disease 1
and O 0
liver B-Disease 0
disease I-Disease 0
in O 0
childhood O 0
. O 0

We O 0
have O 0
now O 0
used O 0
DNA O 0
polymorphisms O 0
associated O 0
with O 0
the O 0
AAT O 0
gene O 0
to O 0
investigate O 0
the O 0
origin O 0
of O 0
the O 0
PI O 0
Z O 0
allele O 0
. O 0

Using O 0
two O 0
genomic O 0
probes O 0
extending O 0
into O 0
the O 0
5 O 0
and O 0
3 O 0
flanking O 0
regions O 0
, O 0
respectively O 0
, O 0
we O 0
have O 0
identified O 0
eight O 0
polymorphic O 0
restriction O 0
sites O 0
. O 0

Extensive O 0
linkage O 0
disequilibrium O 0
occurs O 0
throughout O 0
the O 0
probed O 0
region O 0
with O 0
the O 0
PI O 0
Z O 0
allele O 0
, O 0
but O 0
not O 0
with O 0
normal O 0
PI O 0
M O 0
alleles O 0
. O 0

The O 0
Z O 0
allele O 0
occurs O 0
mainly O 0
with O 0
one O 0
haplotype O 0
, O 0
indicating O 0
a O 0
single O 0
, O 0
relatively O 0
recent O 0
, O 0
origin O 0
in O 0
caucasians O 0

Segregation O 0
analysis O 0
of O 0
a O 0
marker O 0
localised O 0
Xp21 O 0
. O 0
2 O 0
- O 0
Xp21 O 0
. O 0
3 O 0
in O 0
Duchenne B-Disease 0
and I-Disease 0
Becker I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
families O 0
. O 0

A O 0
DNA O 0
marker O 0
C7 O 0
, O 0
localised O 0
Xp21 O 0
. O 0

1 O 0
- O 0
Xp21 O 0
. O 0

3 O 0
, O 0
has O 0
been O 0
studied O 0
in O 0
kindreds O 0
segregating O 0
for O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
and O 0
Becker B-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
( O 0
BMD B-Disease 1
) O 0
. O 0

In O 0
DMD B-Disease 0
families O 0
four O 0
crossovers O 0
were O 0
observed O 0
in O 0
38 O 0
informative O 0
meioses O 0
between O 0
C7 O 0
and O 0
the O 0
DMD B-Disease 0
locus O 0
( O 0
theta O 0
= O 0
0 O 0
. O 0
12 O 0
, O 0
z O 0
max O 0
= O 0
+ O 0
2 O 0
. O 0
72 O 0
) O 0
. O 0

In O 0
BMD B-Disease 1
families O 0
no O 0
recombinants O 0
were O 0
observed O 0
in O 0
the O 0
16 O 0
informative O 0
meioses O 0
studied O 0
. O 0

These O 0
data O 0
are O 0
consistent O 0
with O 0
the O 0
localisation O 0
of O 0
the O 0
mutations O 0
in O 0
these O 0
disorders O 0
being O 0
in O 0
the O 0
same O 0
region O 0
of O 0
Xp21 O 0
. O 0

Studies O 0
in O 0
families O 0
also O 0
segregating O 0
for O 0
the O 0
DNA O 0
marker O 0
754 O 0
support O 0
the O 0
previously O 0
reported O 0
physical O 0
order O 0
of O 0
these O 0
loci O 0
as O 0
X O 0
centromere O 0
- O 0
754 O 0
- O 0
DMD O 0
- O 0
BMD O 1
- O 0
C7 O 0
- O 0
X O 0
telomere O 0
. O 0

A O 0
recombination O 0
fraction O 0
of O 0
0 O 0
. O 0

11 O 0
( O 0
z O 0
max O 0
= O 0
+ O 0
5 O 0
. O 0
58 O 0
) O 0
was O 0
found O 0
between O 0
DMD O 0
- O 0
754 O 0
by O 0
combining O 0
our O 0
previously O 0
published O 0
data O 0
with O 0
the O 0
data O 0
presented O 0
here O 0
. O 0

C7 O 0
and O 0
754 O 0
thus O 0
provide O 0
good O 0
bridging O 0
markers O 0
for O 0
the O 0
diagnosis O 0
of O 0
DMD B-Disease 0
and O 0
BMD B-Disease 1

Isolation O 0
of O 0
molecular O 0
probes O 0
associated O 0
with O 0
the O 0
chromosome O 0
15 O 0
instability O 0
in O 0
the O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
. O 0

Flow O 0
cytometry O 0
and O 0
recombinant O 0
DNA O 0
techniques O 0
have O 0
been O 0
used O 0
to O 0
obtain O 0
reagents O 0
for O 0
a O 0
molecular O 0
analysis O 0
of O 0
the O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
. O 0

HindIII O 0
total O 0
- O 0
digest O 0
libraries O 0
were O 0
prepared O 0
in O 0
lambda O 0
phage O 0
Charon O 0
21A O 0
from O 0
flow O 0
- O 0
sorted O 0
inverted O 0
duplicated O 0
no O 0
. O 0
15 O 0
human O 0
chromosomes O 0
and O 0
propagated O 0
on O 0
recombination O 0
- O 0
proficient O 0
( O 0
LE392 O 0
) O 0
and O 0
recBC O 0
- O 0
, O 0
sbcB O 0
- O 0
( O 0
DB1257 O 0
) O 0
bacteria O 0
. O 0

Twelve O 0
distinct O 0
chromosome O 0
15 O 0
- O 0
specific O 0
probes O 0
have O 0
been O 0
isolated O 0
. O 0

Eight O 0
localized O 0
to O 0
the O 0
region O 0
15q11 O 0
- O 0
- O 0
- O 0
- O 0
13 O 0
. O 0

Four O 0
of O 0
these O 0
eight O 0
sublocalized O 0
to O 0
band O 0
15q11 O 0
. O 0

2 O 0
and O 0
are O 0
shown O 0
to O 0
be O 0
deleted O 0
in O 0
DNA O 0
of O 0
one O 0
of O 0
two O 0
patients O 0
examined O 0
with O 0
the O 0
PWS B-Disease 0
. O 0

Heteroduplex O 0
analysis O 0
of O 0
two O 0
of O 0
these O 0
clones O 0
, O 0
which O 0
grew O 0
on O 0
DB1257 O 0
but O 0
not O 0
on O 0
LE392 O 0
, O 0
revealed O 0
stem O 0
- O 0
loop O 0
structures O 0
in O 0
the O 0
inserts O 0
, O 0
indicative O 0
of O 0
inverted O 0
, O 0
repeated O 0
DNA O 0
elements O 0
. O 0

Such O 0
DNA O 0
repeats O 0
might O 0
account O 0
for O 0
some O 0
of O 0
the O 0
cloning O 0
instability O 0
of O 0
DNA O 0
segments O 0
from O 0
proximal O 0
15q O 0
. O 0

Analysis O 0
of O 0
the O 0
genetic O 0
and O 0
physical O 0
instability O 0
associated O 0
with O 0
the O 0
repeated O 0
sequences O 0
we O 0
have O 0
isolated O 0
from O 0
band O 0
15q11 O 0
. O 0

2 O 0
may O 0
elucidate O 0
the O 0
molecular O 0
basis O 0
for O 0
the O 0
instability O 0
of O 0
this O 0
chromosomal O 0
region O 0
in O 0
patients O 0
with O 0
the O 0
PWS B-Disease 0
or O 0
other O 0
diseases O 0
associated O 0
with O 0
chromosomal B-Disease 0
abnormalities I-Disease 0
in O 0
the O 0
proximal O 0
long O 0
arm O 0
of O 0
human O 0
chromosome O 0
15 O 0

Analysis O 0
of O 0
deletions O 0
in O 0
DNA O 0
from O 0
patients O 0
with O 0
Becker B-Disease 0
and I-Disease 0
Duchenne I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
. O 0

Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
is O 0
an O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
recessive I-Disease 0
genetic I-Disease 0
disorder I-Disease 0
for O 0
which O 0
the O 0
biochemical O 0
defect O 0
is O 0
as O 0
yet O 0
unknown O 0
. O 0

Recently O 0
, O 0
two O 0
cloned O 0
segments O 0
of O 0
human O 0
X O 0
- O 0
chromosome O 0
DNA O 0
have O 0
been O 0
described O 0
which O 0
detect O 0
structural O 0
alterations O 0
within O 0
or O 0
near O 0
the O 0
genetic O 0
locus O 0
responsible O 0
for O 0
the O 0
disorder O 0
. O 0

Both O 0
of O 0
these O 0
cloned O 0
segments O 0
were O 0
described O 0
as O 0
tightly O 0
linked O 0
to O 0
the O 0
locus O 0
and O 0
were O 0
capable O 0
of O 0
detecting O 0
deletions O 0
in O 0
the O 0
DNA O 0
of O 0
boys O 0
affected O 0
with O 0
DMD B-Disease 0
. O 0

In O 0
an O 0
attempt O 0
to O 0
determine O 0
more O 0
precisely O 0
the O 0
occurrence O 0
of O 0
these O 0
deletions O 0
within O 0
a O 0
large O 0
population O 0
of O 0
DMD B-Disease 0
patients O 0
and O 0
the O 0
accuracy O 0
of O 0
one O 0
of O 0
the O 0
segments O 0
, O 0
DXS164 O 0
( O 0
pERT87 O 0
) O 0
, O 0
in O 0
determining O 0
the O 0
inheritance O 0
of O 0
the O 0
DMD B-Disease 0
X O 0
chromosome O 0
, O 0
the O 0
subclones O 0
1 O 0
, O 0
8 O 0
and O 0
15 O 0
were O 0
made O 0
available O 0
to O 0
many O 0
investigators O 0
throughout O 0
the O 0
world O 0
. O 0

Here O 0
we O 0
describe O 0
the O 0
combined O 0
results O 0
of O 0
more O 0
than O 0
20 O 0
research O 0
laboratories O 0
with O 0
respect O 0
to O 0
the O 0
occurrence O 0
of O 0
deletions O 0
at O 0
the O 0
DXS164 O 0
locus O 0
in O 0
DNA O 0
samples O 0
isolated O 0
from O 0
patients O 0
with O 0
DMD B-Disease 0
and O 0
Becker B-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
( O 0
BMD B-Disease 1
) O 0
. O 0

The O 0
results O 0
indicate O 0
that O 0
the O 0
DXS164 O 0
locus O 0
apparently O 0
recombines O 0
with O 0
DMD B-Disease 0
5 O 0
% O 0
of O 0
the O 0
time O 0
, O 0
but O 0
is O 0
probably O 0
located O 0
between O 0
independent O 0
sites O 0
of O 0
mutation O 0
which O 0
yield O 0
DMD B-Disease 0
. O 0

The O 0
breakpoints O 0
of O 0
some O 0
deletions O 0
are O 0
delineated O 0
within O 0
the O 0
DXS164 O 0
locus O 0
, O 0
and O 0
it O 0
is O 0
evident O 0
that O 0
the O 0
deletions O 0
at O 0
the O 0
DMD B-Disease 0
locus O 0
are O 0
frequent O 0
and O 0
extremely O 0
large O 0
. O 0
. O 0

A O 0
potential O 0
animal O 0
model O 0
for O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
through O 0
introduction O 0
of O 0
HPRT O 0
mutations O 0
into O 0
mice O 0
. O 0

The O 0
human O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
is O 0
a O 0
rare O 0
neurological B-Disease 0
and I-Disease 0
behavioural I-Disease 0
disorder I-Disease 0
, O 0
affecting O 0
only O 0
males O 0
, O 0
which O 0
is O 0
caused O 0
by O 0
an O 0
inherited B-Disease 1
deficiency I-Disease 1
in O 0
the O 0
level O 0
of O 0
activity O 0
of O 0
the O 0
purine O 0
salvage O 0
enzyme O 0
hypoxanthine O 0
- O 0
guanosine O 0
phosphoribosyl O 0
transferase O 0
( O 0
HPRT O 0
) O 0
. O 0

How O 0
the O 0
resulting O 0
alterations O 0
in O 0
purine O 0
metabolism O 0
lead O 0
to O 0
the O 0
severe O 0
symptoms O 0
characteristic O 0
of O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
patients O 0
is O 0
still O 0
not O 0
understood O 0
. O 0

No O 0
mutations O 0
at O 0
the O 0
Hprt O 0
locus O 0
leading O 0
to O 0
loss O 0
of O 0
activity O 0
have O 0
been O 0
described O 0
in O 0
laboratory O 0
animals O 0
. O 0

To O 0
derive O 0
an O 0
animal O 0
model O 0
for O 0
the O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
, O 0
we O 0
have O 0
used O 0
cultured O 0
mouse O 0
embryonic O 0
stem O 0
cells O 0
, O 0
mutagenized O 0
by O 0
retroviral O 0
insertion O 0
and O 0
selected O 0
for O 0
loss O 0
of O 0
HPRT O 0
activity O 0
, O 0
to O 0
construct O 0
chimaeric O 0
mice O 0
. O 0

Two O 0
clonal O 0
lines O 0
carrying O 0
different O 0
mutant O 0
Hprt O 0
alleles O 0
have O 0
given O 0
rise O 0
to O 0
germ O 0
cells O 0
in O 0
chimaeras O 0
, O 0
allowing O 0
the O 0
derivation O 0
of O 0
strains O 0
of O 0
mutant O 0
mice O 0
having O 0
the O 0
same O 0
biochemical O 0
defect O 0
as O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
patients O 0
. O 0

Male O 0
mice O 0
carrying O 0
the O 0
mutant O 0
alleles O 0
are O 0
viable O 0
and O 0
analysis O 0
of O 0
their O 0
cells O 0
shows O 0
a O 0
total O 0
lack O 0
of O 0
HPRT O 0
activity O 0
. O 0
. O 0

Re O 0
- O 0
evaluation O 0
of O 0
the O 0
sublocalization O 0
of O 0
esterase O 0
D O 0
and O 0
its O 0
relation O 0
to O 0
the O 0
retinoblastoma B-Disease 1
locus O 0
by O 0
in O 0
situ O 0
hybridization O 0
. O 0

In O 0
situ O 0
hybridization O 0
of O 0
a O 0
cDNA O 0
probe O 0
for O 0
the O 0
esterase O 0
D O 0
gene O 0
( O 0
ESD O 0
) O 0
was O 0
carried O 0
out O 0
on O 0
human O 0
chromosomes O 0
. O 0

The O 0
probe O 0
hybridized O 0
most O 0
strongly O 0
to O 0
13q14 O 0
. O 0

2 O 0
and O 0
13q14 O 0
. O 0

3 O 0
. O 0

This O 0
observation O 0
raises O 0
doubts O 0
concerning O 0
the O 0
most O 0
recently O 0
published O 0
assignment O 0
of O 0
ESD O 0
to O 0
13q14 O 0
. O 0

1 O 0
. O 0

A O 0
deletion O 0
in O 0
an O 0
individual O 0
with O 0
retinoblastoma B-Disease 1
was O 0
reported O 0
to O 0
separate O 0
the O 0
closely O 0
linked O 0
ESD O 0
and O 0
retinoblastoma B-Disease 1
( O 0
RB1 O 0
) O 0
loci O 0
, O 0
placing O 0
ESD O 0
proximal O 0
to O 0
RB1 O 0
. O 0

Quantitative O 0
in O 0
situ O 0
hybridization O 0
studies O 0
of O 0
this O 0
deletion O 0
do O 0
not O 0
confirm O 0
this O 0
interpretation O 0
. O 0

Rather O 0
, O 0
they O 0
suggest O 0
that O 0
ESD O 0
is O 0
missing O 0
from O 0
the O 0
deleted O 0
chromosome O 0
13 O 0
and O 0
duplicated O 0
on O 0
the O 0
normal O 0
homolog O 0
. O 0

From O 0
these O 0
findings O 0
, O 0
we O 0
conclude O 0
that O 0
the O 0
deletion O 0
in O 0
this O 0
individual O 0
cannot O 0
be O 0
used O 0
to O 0
determine O 0
the O 0
orientation O 0
nor O 0
the O 0
sublocalization O 0
of O 0
ESD O 0
and O 0
RB1 O 0
within O 0
the O 0
13q14 O 0
region O 0
. O 0

Hereditary B-Disease 1
C2 I-Disease 1
deficiency I-Disease 1
associated O 0
with O 0
common O 0
variable O 0
immunodeficiency B-Disease 0
. O 0

Homozygous O 0
C2 B-Disease 1
deficiency I-Disease 1
in O 0
a O 0
19 O 0
- O 0
year O 0
- O 0
old O 0
boy O 0
was O 0
associated O 0
with O 0
variable O 0
immunodeficiency B-Disease 0
manifested O 0
by O 0
marked O 0
hypoimmunoglobulinemia B-Disease 0
and O 0
impaired O 0
antibody O 0
responses O 0
, O 0
normal O 0
circulating O 0
B O 0
lymphocytes O 0
, O 0
and O 0
subnormal O 0
T O 0
- O 0
cell O 0
functions O 0
. O 0

Neither O 0
antilymphocytic O 0
autoantibodies O 0
nor O 0
chromosomal B-Disease 0
abnormalities I-Disease 0
were O 0
found O 0
. O 0

Serum O 0
immunoglobulin O 0
levels O 0
were O 0
within O 0
normal O 0
limits O 0
in O 0
his O 0
parents O 0
and O 0
brother O 0
who O 0
were O 0
heterozygous O 0
for O 0
C2 B-Disease 1
deficiency I-Disease 1
. O 0

The O 0
patients O 0
lymphocytes O 0
were O 0
homozygous O 0
at O 0
the O 0
HLA O 0
- O 0
D O 0
locus O 0
but O 0
expressed O 0
an O 0
antigen O 0
different O 0
from O 0
DW2 O 0
. O 0
. O 0

Mild O 0
and O 0
severe O 0
muscular B-Disease 0
dystrophy I-Disease 0
associated O 0
with O 0
deletions O 0
in O 0
Xp21 O 0
of O 0
the O 0
human O 0
X O 0
chromosome O 0
. O 0

We O 0
have O 0
analysed O 0
over O 0
300 O 0
patients O 0
suffering O 0
from O 0
Duchenne B-Disease 0
or I-Disease 0
Becker I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
( O 0
DMD B-Disease 0
or O 0
BMD B-Disease 1
) O 0
. O 0

Deletions O 0
have O 0
been O 0
characterised O 0
which O 0
encompass O 0
either O 0
the O 0
pERT87 O 0
( O 0
DXS164 O 0
) O 0
locus O 0
only O 0
, O 0
the O 0
XJ1 O 0
. O 0

1 O 0
( O 0
DXS206 O 0
) O 0
and O 0
HIP25 O 0
loci O 0
only O 0
, O 0
or O 0
all O 0
three O 0
loci O 0
. O 0

These O 0
loci O 0
have O 0
been O 0
shown O 0
to O 0
lie O 0
within O 0
the O 0
DMD B-Disease 0
region O 0
covering O 0
several O 0
hundred O 0
kilobases O 0
( O 0
kb O 0
) O 0
of O 0
DNA O 0
. O 0

One O 0
mildly O 0
affected O 0
BMD B-Disease 1
patient O 0
possesses O 0
a O 0
deletion O 0
of O 0
at O 0
least O 0
110 O 0
kb O 0
including O 0
exons O 0
of O 0
the O 0
DMD B-Disease 0
gene O 0
. O 0

Other O 0
patients O 0
with O 0
similar O 0
exon O 0
deletions O 0
, O 0
or O 0
smaller O 0
deletions O 0
, O 0
show O 0
the O 0
more O 0
severe O 0
phenotype O 0
typical O 0
of O 0
DMD B-Disease 0
. O 0

We O 0
conclude O 0
from O 0
these O 0
studies O 0
that O 0
the O 0
severity O 0
of O 0
the O 0
clinical O 0
phenotype O 0
cannot O 0
be O 0
explained O 0
on O 0
the O 0
basis O 0
of O 0
the O 0
size O 0
of O 0
the O 0
deletion O 0
. O 0

We O 0
discuss O 0
this O 0
in O 0
the O 0
context O 0
of O 0
candidate O 0
gene O 0
sequences O 0
. O 0

Patterns O 0
of O 0
exon O 0
deletions O 0
in O 0
Duchenne B-Disease 0
and I-Disease 0
Becker I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
. O 0

A O 0
panel O 0
of O 0
patients O 0
with O 0
Duchenne B-Disease 0
and I-Disease 0
Becker I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
( O 0
DMD B-Disease 0
and O 0
BMD B-Disease 1
) O 0
has O 0
been O 0
screened O 0
with O 0
the O 0
cDNA O 0
probes O 0
Cf56a O 0
and O 0
Cf23a O 0
, O 0
which O 0
detect O 0
exons O 0
in O 0
the O 0
central O 0
part O 0
of O 0
the O 0
DMD B-Disease 0
gene O 0
. O 0

One O 0
or O 0
more O 0
exons O 0
were O 0
deleted O 0
in O 0
60 O 0
% O 0
of O 0
patients O 0
. O 0

The O 0
deletions O 0
were O 0
mapped O 0
and O 0
prove O 0
to O 0
be O 0
heterogeneous O 0
in O 0
size O 0
and O 0
extent O 0
, O 0
particularly O 0
in O 0
DMD B-Disease 0
. O 0

Deletions O 0
specific O 0
to O 0
DMD B-Disease 0
and O 0
to O 0
BMD B-Disease 1
are O 0
described O 0
. O 0

Half O 0
of O 0
all O 0
BMD B-Disease 1
patients O 0
have O 0
a O 0
deletion O 0
of O 0
one O 0
particular O 0
small O 0
group O 0
of O 0
exons O 0
; O 0
smaller O 0
deletions O 0
within O 0
this O 0
same O 0
group O 0
produce O 0
the O 0
more O 0
severe O 0
DMD B-Disease 0
. O 0
. O 0

Hereditary B-Disease 0
deficiency I-Disease 0
of I-Disease 0
the I-Disease 0
third I-Disease 0
component I-Disease 0
of I-Disease 0
complement I-Disease 0
in O 0
a O 0
child O 0
with O 0
fever B-Disease 0
, O 0
skin B-Disease 1
rash I-Disease 1
, O 0
and O 0
arthralgias B-Disease 1
: O 0
response O 0
to O 0
transfusion O 0
of O 0
whole O 0
blood O 0
. O 0

A O 0
previously O 0
well O 0
34 O 0
- O 0
month O 0
- O 0
old O 0
male O 0
presenting O 0
with O 0
fever B-Disease 0
, O 0
skin B-Disease 1
rash I-Disease 1
, O 0
and O 0
arthralgias B-Disease 1
was O 0
found O 0
to O 0
lack O 0
C3 O 0
by O 0
immunochemical O 0
( O 0
undetectable O 0
) O 0
and O 0
hemolytic O 0
( O 0
1 O 0
% O 0
normal O 0
) O 0
assays O 0
. O 0

No O 0
infectious O 0
agent O 0
could O 0
be O 0
demonstrated O 0
. O 0

Protein O 0
levels O 0
of O 0
Clq O 0
. O 0

C4 O 0
, O 0
C5 O 0
, O 0
properdin O 0
, O 0
and O 0
C3b O 0
- O 0
INA O 0
and O 0
hemolytic O 0
activities O 0
of O 0
complement O 0
components O 0
C1 O 0
to O 0
C9 O 0
except O 0
C3 O 0
were O 0
normal O 0
or O 0
elevated O 0
; O 0
total O 0
hemolytic O 0
complement O 0
activity O 0
was O 0
13 O 0
% O 0
of O 0
normal O 0
and O 0
was O 0
reconstituted O 0
by O 0
purified O 0
C3 O 0
. O 0

Properdin O 0
factor O 0
B O 0
was O 0
702 O 0
( O 0
normal O 0
175 O 0
to O 0
275 O 0
) O 0
mug O 0
/ O 0
ml O 0
, O 0
and O 0
was O 0
not O 0
cleaver O 0
upon O 0
addition O 0
of O 0
zymosan O 0
or O 0
cobra O 0
venom O 0
factor O 0
. O 0

The O 0
serum O 0
had O 0
normal O 0
immune O 0
adherence O 0
activity O 0
, O 0
but O 0
was O 0
deficient O 0
in O 0
ability O 0
to O 0
opsonize O 0
Candida O 0
albicans O 0
for O 0
uptake O 0
and O 0
Escherichia O 0
coli O 0
for O 0
killing O 0
by O 0
neurophils O 0
, O 0
generate O 0
neutrophil O 0
chemotactic O 0
factors O 0
and O 0
inhibit O 0
the O 0
growth O 0
of O 0
E O 0
. O 0
coli O 0
; O 0
these O 0
activities O 0
were O 0
restored O 0
by O 0
purified O 0
C3 O 0
. O 0

A O 0
transfusion O 0
of O 0
320 O 0
ml O 0
1 O 0
- O 0
hour O 0
- O 0
old O 0
normal O 0
whole O 0
blood O 0
on O 0
the O 0
fifty O 0
- O 0
second O 0
day O 0
resulted O 0
in O 0
transitory O 0
elevation O 0
of O 0
the O 0
C3 O 0
level O 0
to O 0
25 O 0
mg O 0
/ O 0
dl O 0
with O 0
a O 0
fall O 0
- O 0
off O 0
( O 0
approximately O 0
2 O 0
1 O 0
/ O 0
2 O 0
% O 0
per O 0
hour O 0
) O 0
to O 0
undetectable O 0
levels O 0
by O 0
69 O 0
hours O 0
; O 0
it O 0
was O 0
followed O 0
by O 0
disappearance O 0
of O 0
the O 0
skin B-Disease 1
rash I-Disease 1
and O 0
arthralgias B-Disease 1
and O 0
return O 0
to O 0
normal O 0
of O 0
the O 0
previously O 0
elevated O 0
temperature O 0
and O 0
CRP O 0
levels O 0
. O 0

C3 O 0
levels O 0
in O 0
family O 0
members O 0
( O 0
seven O 0
of O 0
24 O 0
half O 0
- O 0
normal O 0
) O 0
, O 0
lack O 0
of O 0
anti O 0
- O 0
C3 O 0
activity O 0
, O 0
normal O 0
C3b O 0
- O 0
INA O 0
levels O 0
and O 0
a O 0
normal O 0
rate O 0
of O 0
catabolism O 0
of O 0
transfused O 0
C3 O 0
indicated O 0
that O 0
the O 0
deficiency O 0
was O 0
inherited O 0
with O 0
autosomal O 0
codominance O 0
and O 0
involved O 0
decreased B-Disease 0
synthesis I-Disease 0
of I-Disease 0
C3 I-Disease 0
. O 0

Thus O 0
, O 0
this O 0
child O 0
is O 0
a O 0
unique O 0
individual O 0
with O 0
inherited B-Disease 1
C3 I-Disease 1
deficiency I-Disease 1
presenting O 0
with O 0
absence O 0
of O 0
repeated O 0
infections O 0
, O 0
whose O 0
symptoms O 0
of O 0
fever B-Disease 0
, O 0
skin B-Disease 1
rash I-Disease 1
, O 0
and O 0
arthralgia B-Disease 0
were O 0
abated O 0
by O 0
whole O 0
blood O 0
transfusion O 0
. O 0
. O 0

Glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
variants O 0
and O 0
their O 0
frequency O 0
in O 0
Guangdong O 0
, O 0
China O 0
. O 0

Erythrocyte O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
was O 0
characterized O 0
in O 0
blood O 0
samples O 0
obtained O 0
from O 0
97 O 0
randomly O 0
selected O 0
males O 0
with O 0
enzyme B-Disease 0
deficiency I-Disease 0
from O 0
various O 0
regions O 0
of O 0
Guangdong O 0
Province O 0
, O 0
China O 0
. O 0

Nine O 0
new O 0
variants O 0
( O 0
Gd O 0
Kaiping O 0
, O 0
Gd O 0
Boluo O 0
, O 0
Gd O 0
Huiyang O 0
, O 0
Gd O 0
Gaomin O 0
, O 0
Gd O 0
Qing O 0
- O 0
Baijiang O 0
, O 0
Gd O 0
Gaozhou O 0
, O 0
Gd O 0
Huazhou O 0
, O 0
Gd O 0
Nanhai O 0
, O 0
and O 0
Gd O 0
Guangzhou O 0
) O 0
were O 0
identified O 0
. O 0

Of O 0
the O 0
31 O 0
variants O 0
found O 0
in O 0
this O 0
province O 0
, O 0
Gd O 0
Kaiping O 0
, O 0
Gd O 0
Taiwan O 0
- O 0
Hakka O 0
, O 0
Gd O 0
Haad O 0
Yai O 0
, O 0
Gd O 0
Haad O 0
Yai O 0
- O 0
like O 0
and O 0
Gd O 0
Huiyang O 0
occurred O 0
most O 0
frequently O 0
. O 0

The O 0
frequency O 0
of O 0
each O 0
variant O 0
was O 0
calculated O 0
. O 0

The O 0
results O 0
demonstrated O 0
that O 0
the O 0
genetic O 0
heterogeneity O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
was O 0
high O 0
in O 0
this O 0
area O 0
. O 0
. O 0

Homozygous O 0
and O 0
heterozygous O 0
deletions O 0
of O 0
the O 0
von B-Disease 1
Willebrand I-Disease 1
factor O 0
gene O 0
in O 0
patients O 0
and O 0
carriers O 0
of O 0
severe B-Disease 1
von I-Disease 1
Willebrand I-Disease 1
disease I-Disease 1
. O 0

Severe B-Disease 1
von I-Disease 1
Willebrand I-Disease 1
disease I-Disease 1
is O 0
characterized O 0
by O 0
undetectable O 0
or O 0
trace O 0
quantities O 0
of O 0
von B-Disease 1
Willebrand I-Disease 1
factor O 0
in O 0
plasma O 0
and O 0
tissue O 0
stores O 0
. O 0

We O 0
have O 0
studied O 0
the O 0
genomic O 0
DNA O 0
of O 0
10 O 0
affected O 0
individuals O 0
from O 0
six O 0
families O 0
with O 0
this O 0
disorder O 0
using O 0
probes O 0
from O 0
the O 0
5 O 0
and O 0
3 O 0
ends O 0
of O 0
the O 0
vWF O 0
cDNA O 0
and O 0
with O 0
a O 0
probe O 0
extending O 0
from O 0
the O 0
5 O 0
end O 0
into O 0
the O 0
central O 0
region O 0
. O 0

Southern O 0
blots O 0
of O 0
restriction O 0
endonuclease O 0
digests O 0
and O 0
gene O 0
dosage O 0
analysis O 0
measurements O 0
carried O 0
out O 0
with O 0
quantitative O 0
slot O 0
blots O 0
of O 0
undigested O 0
genomic O 0
DNA O 0
separated O 0
these O 0
patients O 0
into O 0
three O 0
groups O 0
. O 0

The O 0
first O 0
group O 0
consisted O 0
of O 0
a O 0
family O 0
with O 0
complete O 0
homozygous O 0
deletions O 0
of O 0
the O 0
vWF O 0
gene O 0
in O 0
the O 0
four O 0
probands O 0
. O 0

Gene O 0
dosage O 0
analysis O 0
was O 0
consistent O 0
with O 0
heterozygous O 0
deletions O 0
in O 0
both O 0
of O 0
the O 0
asymptomatic O 0
parents O 0
and O 0
four O 0
asymptomatic O 0
siblings O 0
of O 0
this O 0
kindred O 0
( O 0
P O 0
less O 0
than O 0
0 O 0
. O 0
01 O 0
) O 0
. O 0

The O 0
second O 0
group O 0
was O 0
comprised O 0
of O 0
a O 0
family O 0
in O 0
which O 0
there O 0
was O 0
a O 0
complete O 0
heterozygous O 0
deletion O 0
of O 0
the O 0
vWF O 0
gene O 0
in O 0
the O 0
proband O 0
and O 0
one O 0
asymptomatic O 0
parent O 0
, O 0
suggesting O 0
that O 0
a O 0
different O 0
type O 0
of O 0
genetic B-Disease 1
abnormality I-Disease 1
was O 0
inherited O 0
from O 0
the O 0
other O 0
parent O 0
. O 0

Thus O 0
, O 0
the O 0
patient O 0
appeared O 0
to O 0
be O 0
doubly O 0
heterozygous O 0
for O 0
interacting O 0
genetic B-Disease 0
abnormalities I-Disease 0
affecting O 0
vWF O 0
expression O 0
. O 0

In O 0
the O 0
third O 0
group O 0
, O 0
no O 0
gene O 0
deletions O 0
could O 0
be O 0
detected O 0
. O 0

Alloantibodies O 0
developed O 0
only O 0
in O 0
the O 0
kindred O 0
with O 0
homozygous O 0
deletions O 0
. O 0

These O 0
techniques O 0
should O 0
prove O 0
useful O 0
in O 0
identifying O 0
carriers O 0
of O 0
severe B-Disease 1
von I-Disease 1
Willebrand I-Disease 1
disease I-Disease 1
and O 0
also O 0
in O 0
defining O 0
patients O 0
predictably O 0
at O 0
risk O 0
of O 0
developing O 0
alloantibodies O 0
to O 0
vWF O 0
. O 0

Sjogren B-Disease 1
- I-Disease 1
Larsson I-Disease 1
syndrome I-Disease 1
. O 0

Impaired O 0
fatty O 0
alcohol O 0
oxidation O 0
in O 0
cultured O 0
fibroblasts O 0
due O 0
to O 0
deficient O 0
fatty O 0
alcohol O 0
: O 0
nicotinamide O 0
adenine O 0
dinucleotide O 0
oxidoreductase O 0
activity O 0
. O 0

Lipid O 0
metabolism O 0
was O 0
studied O 0
in O 0
cultured O 0
skin O 0
fibroblasts O 0
from O 0
patients O 0
with O 0
the O 0
inherited B-Disease 0
disorder I-Disease 0
, O 0
Sjogren B-Disease 1
- I-Disease 1
Larsson I-Disease 1
syndrome I-Disease 1
( O 0
SLS B-Disease 0
) O 0
. O 0

Intact O 0
SLS B-Disease 0
fibroblasts O 0
incubated O 0
in O 0
the O 0
presence O 0
of O 0
[ O 0
1 O 0
- O 0
14C O 0
] O 0
palmitate O 0
accumulated O 0
more O 0
radioactive O 0
hexadecanol O 0
than O 0
did O 0
normal O 0
cells O 0
, O 0
whereas O 0
incorporation O 0
of O 0
radioactivity O 0
into O 0
other O 0
cellular O 0
lipids O 0
was O 0
unaltered O 0
. O 0

The O 0
hexadecanol O 0
content O 0
of O 0
SLS B-Disease 0
fibroblasts O 0
was O 0
abnormally O 0
elevated O 0
. O 0

Hexadecanol O 0
accumulation O 0
was O 0
not O 0
due O 0
to O 0
increased O 0
fatty O 0
alcohol O 0
synthesis O 0
nor O 0
its O 0
deficient O 0
utilization O 0
for O 0
glycerol O 0
ether O 0
synthesis O 0
. O 0

The O 0
half O 0
- O 0
life O 0
of O 0
intracellular O 0
hexadecanol O 0
loaded O 0
into O 0
SLS B-Disease 0
fibroblasts O 0
was O 0
increased O 0
( O 0
70 O 0
min O 0
) O 0
compared O 0
with O 0
normal O 0
( O 0
15 O 0
min O 0
) O 0
, O 0
and O 0
intact O 0
SLS B-Disease 0
fibroblasts O 0
showed O 0
impaired O 0
oxidation O 0
of O 0
[ O 0
14C O 0
] O 0
- O 0
hexadecanol O 0
to O 0
fatty O 0
acid O 0
. O 0

Fatty O 0
alcohol O 0
NAD O 0
+ O 0
oxidoreductase O 0
, O 0
the O 0
enzyme O 0
catalyzing O 0
this O 0
reaction O 0
, O 0
was O 0
deficient O 0
in O 0
SLS B-Disease 0
fibroblasts O 0
. O 0

Mean O 0
total O 0
activity O 0
in O 0
SLS B-Disease 0
fibroblasts O 0
( O 0
n O 0
= O 0
5 O 0
) O 0
was O 0
13 O 0
% O 0
of O 0
that O 0
in O 0
normal O 0
fibroblasts O 0
, O 0
and O 0
palmitoyl O 0
CoA O 0
- O 0
inhibitable O 0
activity O 0
was O 0
1 O 0
% O 0
of O 0
normal O 0
. O 0

Fibroblasts O 0
from O 0
two O 0
obligate O 0
SLS B-Disease 0
heterozygotes O 0
had O 0
enzyme O 0
activities O 0
intermediate O 0
between O 0
that O 0
in O 0
normal O 0
fibroblasts O 0
and O 0
individuals O 0
with O 0
SLS B-Disease 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
the O 0
primary O 0
defect O 0
in O 0
SLS B-Disease 0
is O 0
deficiency B-Disease 1
of I-Disease 1
fatty I-Disease 1
alcohol I-Disease 1
NAD I-Disease 1
+ I-Disease 1
oxidoreductase I-Disease 1
. O 0

SLS B-Disease 0
represents O 0
the O 0
first O 0
inherited B-Disease 0
disorder I-Disease 0
in O 0
man O 0
associated O 0
with O 0
an O 0
isolated O 0
abnormality B-Disease 0
in I-Disease 0
fatty I-Disease 0
alcohol I-Disease 0
metabolism I-Disease 0
. O 0
. O 0

Germinal O 0
mosaicism O 0
in O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
. O 0

We O 0
have O 0
identified O 0
a O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
pedigree O 0
where O 0
the O 0
disease O 0
is O 0
associated O 0
with O 0
a O 0
molecular O 0
deletion O 0
within O 0
the O 0
DMD B-Disease 0
locus O 0
. O 0

We O 0
have O 0
examined O 0
the O 0
meiotic O 0
segregation O 0
products O 0
of O 0
the O 0
common O 0
female O 0
ancestor O 0
using O 0
marker O 0
restriction O 0
fragment O 0
length O 0
polymorphisms O 0
( O 0
RFLPs O 0
) O 0
detected O 0
by O 0
probes O 0
that O 0
lie O 0
within O 0
this O 0
deletion O 0
. O 0

These O 0
studies O 0
show O 0
that O 0
this O 0
female O 0
has O 0
transmitted O 0
three O 0
distinct O 0
types O 0
of O 0
X O 0
chromosome O 0
to O 0
her O 0
offspring O 0
. O 0

This O 0
observation O 0
may O 0
be O 0
explained O 0
by O 0
postulating O 0
that O 0
the O 0
mutation O 0
arose O 0
as O 0
a O 0
postzygotic O 0
deletion O 0
within O 0
this O 0
common O 0
ancestor O 0
, O 0
who O 0
was O 0
consequently O 0
germinally O 0
mosaic O 0
. O 0
. O 0

Nebulin O 0
seen O 0
in O 0
DMD B-Disease 0
males O 0
including O 0
one O 0
patient O 0
with O 0
a O 0
large O 0
DNA O 0
deletion O 0
encompassing O 0
the O 0
DMD B-Disease 0
gene O 0
. O 0

The O 0
presence O 0
of O 0
nebulin O 0
in O 0
a O 0
muscle O 0
specimen O 0
from O 0
a O 0
patient O 0
with O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
due O 0
to O 0
a O 0
large O 0
deletion O 0
precludes O 0
the O 0
possibility O 0
that O 0
this O 0
protein O 0
is O 0
the O 0
DMD B-Disease 0
gene O 0
product O 0
. O 0
. O 0

Expression O 0
of O 0
the O 0
murine O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
gene O 0
in O 0
muscle O 0
and O 0
brain O 0
. O 0

Complementary O 0
DNA O 0
clones O 0
were O 0
isolated O 0
that O 0
represent O 0
the O 0
5 O 0
terminal O 0
2 O 0
. O 0

5 O 0
kilobases O 0
of O 0
the O 0
murine O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
Dmd O 0
) O 0
messenger O 0
RNA O 0
( O 0
mRNA O 0
) O 0
. O 0

Mouse O 0
Dmd O 0
mRNA O 0
was O 0
detectable O 0
in O 0
skeletal O 0
and O 0
cardiac O 0
muscle O 0
and O 0
at O 0
a O 0
level O 0
approximately O 0
90 O 0
percent O 0
lower O 0
in O 0
brain O 0
. O 0

Dmd O 0
mRNA O 0
is O 0
also O 0
present O 0
, O 0
but O 0
at O 0
much O 0
lower O 0
than O 0
normal O 0
levels O 0
, O 0
in O 0
both O 0
the O 0
muscle O 0
and O 0
brain O 0
of O 0
three O 0
different O 0
strains O 0
of O 0
dystrophic B-Disease 0
mdx O 0
mice O 0
. O 0

The O 0
identification O 0
of O 0
Dmd O 0
mRNA O 0
in O 0
brain O 0
raises O 0
the O 0
possibility O 0
of O 0
a O 0
relation O 0
between O 0
human O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
gene O 0
expression O 0
and O 0
the O 0
mental B-Disease 1
retardation I-Disease 1
found O 0
in O 0
some O 0
DMD B-Disease 0
males O 0
. O 0

These O 0
results O 0
also O 0
provide O 0
evidence O 0
that O 0
the O 0
mdx O 0
mutations O 0
are O 0
allelic O 0
variants O 0
of O 0
mouse O 0
Dmd O 0
gene O 0
mutations O 0
. O 0

Glucose B-Disease 1
6 I-Disease 1
- I-Disease 1
phosphate I-Disease 1
dehydrogenase I-Disease 1
deficiency I-Disease 1
and O 0
incidence O 0
of O 0
hematologic B-Disease 0
malignancy I-Disease 0
. O 0

We O 0
have O 0
evaluated O 0
the O 0
hypothesis O 0
of O 0
a O 0
negative O 0
association O 0
between O 0
glucose B-Disease 1
6 I-Disease 1
- I-Disease 1
phosphate I-Disease 1
dehydrogenase I-Disease 1
( I-Disease 1
G6PD I-Disease 1
) I-Disease 1
deficiency I-Disease 1
and O 0
cancer B-Disease 1
in O 0
a O 0
cohort O 0
of O 0
481 O 0
Sardinian O 0
males O 0
with O 0
hematological B-Disease 0
malignancies I-Disease 0
. O 0

The O 0
frequency O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
in O 0
the O 0
patients O 0
was O 0
not O 0
different O 0
from O 0
the O 0
incidence O 0
in O 0
a O 0
group O 0
of O 0
16 O 0
, O 0
219 O 0
controls O 0
. O 0

The O 0
same O 0
conclusion O 0
resulted O 0
from O 0
the O 0
comparison O 0
of O 0
the O 0
frequency O 0
of O 0
expression O 0
of O 0
the O 0
GdB O 0
gene O 0
in O 0
23 O 0
heterozygous O 0
women O 0
having O 0
a O 0
clonal O 0
hematologic B-Disease 1
disease I-Disease 1
and O 0
a O 0
control O 0
group O 0
of O 0
37 O 0
healthy O 0
heterozygotes O 0
. O 0

Therefore O 0
at O 0
present O 0
there O 0
is O 0
no O 0
evidence O 0
that O 0
G6PD B-Disease 0
deficiency I-Disease 0
has O 0
a O 0
protective O 0
effect O 0
against O 0
development O 0
of O 0
hematologic B-Disease 0
neoplasms I-Disease 1
. O 0
. O 0

Hepatoblastoma B-Disease 0
, O 0
pigmented B-Disease 0
ocular I-Disease 0
fundus I-Disease 0
lesions I-Disease 0
and O 0
jaw B-Disease 1
lesions I-Disease 1
in O 0
Gardner B-Disease 0
syndrome I-Disease 0
. O 0

Hepatoblastoma B-Disease 0
is O 0
a O 0
rare O 0
neoplasm B-Disease 0
of O 0
infants O 0
and O 0
children O 0
only O 0
recently O 0
documented O 0
in O 0
association O 0
with O 0
hereditary B-Disease 0
adenomatous I-Disease 0
polyposis I-Disease 1
of I-Disease 0
the I-Disease 0
colon I-Disease 0
[ O 0
Kingston O 0
et O 0
al O 0
. O 0
, O 0
1983 O 0
] O 0
. O 0

We O 0
report O 0
four O 0
children O 0
with O 0
hepatoblastoma B-Disease 0
from O 0
four O 0
unrelated O 0
families O 0
with O 0
Gardner B-Disease 0
syndrome I-Disease 0
( O 0
GS B-Disease 1
) O 0
. O 0

One O 0
child O 0
, O 0
now O 0
19 O 0
years O 0
old O 0
, O 0
survived O 0
after O 0
a O 0
resection O 0
of O 0
a O 0
hepatoblastoma B-Disease 0
in O 0
infancy O 0
and O 0
recently O 0
was O 0
found O 0
to O 0
have O 0
GS B-Disease 1
. O 0

He O 0
has O 0
an O 0
associated O 0
odontoma B-Disease 0
and O 0
pigmented B-Disease 0
ocular I-Disease 0
fundus I-Disease 0
lesions I-Disease 0
, O 0
both O 0
of O 0
which O 0
have O 0
been O 0
shown O 0
to O 0
be O 0
clinical O 0
markers O 0
of O 0
GS B-Disease 1
. O 0

Many O 0
individuals O 0
in O 0
these O 0
four O 0
GS B-Disease 1
families O 0
, O 0
both O 0
affected O 0
and O 0
at O 0
risk O 0
, O 0
have O 0
osteomatous B-Disease 0
jaw I-Disease 1
lesions I-Disease 1
and O 0
pigmented B-Disease 0
ocular I-Disease 0
fundus I-Disease 0
lesions I-Disease 0
. O 0

A O 0
search O 0
for O 0
colonic B-Disease 1
polyps I-Disease 1
should O 0
be O 0
made O 0
in O 0
families O 0
of O 0
infants O 0
and O 0
children O 0
with O 0
hepatoblastoma B-Disease 0
. O 0

If O 0
the O 0
child O 0
survives O 0
, O 0
he O 0
or O 0
she O 0
should O 0
be O 0
monitored O 0
for O 0
the O 0
later O 0
appearance O 0
of O 0
colonic B-Disease 1
polyps I-Disease 1
. O 0

The O 0
finding O 0
of O 0
jaw B-Disease 1
lesions I-Disease 1
and O 0
/ O 0
or O 0
pigmented B-Disease 0
ocular I-Disease 0
fundus I-Disease 0
lesions I-Disease 0
in O 0
relatives O 0
at O 0
risk O 0
are O 0
indications O 0
of O 0
the O 0
possible O 0
presence O 0
of O 0
the O 0
GS B-Disease 1
gene O 0
. O 0

Identification O 0
of O 0
an O 0
altered O 0
splice O 0
site O 0
in O 0
Ashkenazi O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
. O 0

Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
genetic I-Disease 1
disorder I-Disease 1
resulting O 0
from O 0
mutation O 0
of O 0
the O 0
HEXA O 0
gene O 0
encoding O 0
the O 0
alpha O 0
- O 0
subunit O 0
of O 0
the O 0
lysosomal O 0
enzyme O 0
, O 0
beta O 0
- O 0
N O 0
- O 0
acetylhexosaminidase O 0
A O 0
( O 0
ref O 0
. O 0
1 O 0
) O 0
. O 0

A O 0
relatively O 0
high O 0
frequency O 0
of O 0
carriers O 0
( O 0
1 O 0
/ O 0
27 O 0
) O 0
of O 0
a O 0
lethal O 0
, O 0
infantile O 0
form O 0
of O 0
the O 0
disease O 0
is O 0
found O 0
in O 0
the O 0
Ashkenazi O 0
Jewish O 0
population O 0
, O 0
but O 0
it O 0
is O 0
not O 0
yet O 0
evident O 0
whether O 0
this O 0
has O 0
resulted O 0
from O 0
a O 0
founder O 0
effect O 0
and O 0
random O 0
genetic O 0
drift O 0
or O 0
from O 0
a O 0
selective O 0
advantage O 0
of O 0
heterozygotes O 0
. O 0

We O 0
have O 0
identified O 0
a O 0
single O 0
- O 0
base O 0
mutation O 0
in O 0
a O 0
cloned O 0
fragment O 0
of O 0
the O 0
HEXA O 0
gene O 0
from O 0
an O 0
Ashkenazi O 0
Jewish O 0
patient O 0
. O 0

This O 0
change O 0
, O 0
the O 0
substitution O 0
of O 0
a O 0
C O 0
for O 0
G O 0
in O 0
the O 0
first O 0
nucleotide O 0
of O 0
intron O 0
12 O 0
is O 0
expected O 0
to O 0
result O 0
in O 0
defective O 0
splicing O 0
of O 0
the O 0
messenger O 0
RNA O 0
. O 0

A O 0
test O 0
for O 0
the O 0
mutant O 0
allele O 0
based O 0
on O 0
amplification O 0
of O 0
DNA O 0
by O 0
the O 0
polymerase O 0
chain O 0
rection O 0
and O 0
cleavage O 0
of O 0
a O 0
DdeI O 0
restriction O 0
site O 0
generated O 0
by O 0
the O 0
mutation O 0
revealed O 0
that O 0
this O 0
case O 0
and O 0
two O 0
other O 0
cases O 0
of O 0
the O 0
Ashkenazi O 0
, O 0
infantile O 0
form O 0
of O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
are O 0
heterozygous O 0
for O 0
two O 0
different O 0
mutations O 0
. O 0

The O 0
occurrence O 0
of O 0
multiple O 0
mutant O 0
alleles O 0
warrants O 0
further O 0
examination O 0
of O 0
the O 0
selective O 0
advantage O 0
hypothesis O 0
. O 0
. O 0

X B-Disease 0
- I-Disease 0
linked I-Disease 0
glucose I-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
deficiency I-Disease 0
in O 0
Mus O 0
musculus O 0
. O 0

A O 0
mouse O 0
with O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
glucose I-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
) I-Disease 0
deficiency I-Disease 0
has O 0
been O 0
recovered O 0
in O 0
offspring O 0
of O 0
1 O 0
- O 0
ethyl O 0
- O 0
1 O 0
- O 0
nitrosourea O 0
- O 0
treated O 0
male O 0
mice O 0
. O 0

The O 0
activity O 0
alteration O 0
was O 0
detected O 0
in O 0
blood O 0
but O 0
can O 0
also O 0
be O 0
observed O 0
in O 0
other O 0
tissue O 0
extracts O 0
. O 0

Hemizygous O 0
, O 0
heterozygous O 0
, O 0
and O 0
homozygous O 0
mutants O 0
have O 0
, O 0
respectively O 0
, O 0
about O 0
15 O 0
, O 0
60 O 0
, O 0
and O 0
15 O 0
% O 0
G6PD O 0
remaining O 0
activity O 0
in O 0
the O 0
blood O 0
as O 0
compared O 0
to O 0
the O 0
wild O 0
type O 0
. O 0

Erythrocyte O 0
indices O 0
did O 0
not O 0
show O 0
differences O 0
between O 0
mutants O 0
and O 0
wild O 0
types O 0
. O 0

The O 0
mutation O 0
does O 0
not O 0
affect O 0
the O 0
electrophoretic O 0
migration O 0
, O 0
the O 0
isoelectric O 0
point O 0
, O 0
or O 0
the O 0
thermal O 0
stability O 0
. O 0

Kinetic O 0
properties O 0
, O 0
such O 0
as O 0
the O 0
Km O 0
for O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
or O 0
for O 0
NADP O 0
and O 0
the O 0
relative O 0
utilization O 0
of O 0
substrate O 0
analogues O 0
, O 0
showed O 0
no O 0
differences O 0
between O 0
wild O 0
types O 0
and O 0
mutants O 0
with O 0
the O 0
exception O 0
of O 0
the O 0
relative O 0
utilization O 0
of O 0
deamino O 0
- O 0
NADP O 0
which O 0
was O 0
significantly O 0
lower O 0
in O 0
mutants O 0
. O 0

This O 0
is O 0
presently O 0
the O 0
only O 0
animal O 0
model O 0
for O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
G6PD I-Disease 0
deficiency I-Disease 0
in O 0
humans O 0
. O 0
. O 0

Diverse O 0
point O 0
mutations O 0
in O 0
the O 0
human O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
gene O 0
cause O 0
enzyme B-Disease 0
deficiency I-Disease 0
and O 0
mild O 0
or O 0
severe O 0
hemolytic B-Disease 1
anemia I-Disease 1
. O 0

Glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
; I-Disease 0
EC I-Disease 0
1 I-Disease 0
. I-Disease 0
1 I-Disease 0
. I-Disease 0
1 I-Disease 0
. I-Disease 0
49 I-Disease 0
) I-Disease 0
deficiency I-Disease 0
is O 0
a O 0
common O 0
genetic B-Disease 1
abnormality I-Disease 1
affecting O 0
an O 0
estimated O 0
400 O 0
million O 0
people O 0
worldwide O 0
. O 0

Clinical O 0
and O 0
biochemical O 0
analyses O 0
have O 0
identified O 0
many O 0
variants O 0
exhibiting O 0
a O 0
range O 0
of O 0
phenotypes O 0
, O 0
which O 0
have O 0
been O 0
well O 0
characterized O 0
from O 0
the O 0
hematological O 0
point O 0
of O 0
view O 0
. O 0

However O 0
, O 0
until O 0
now O 0
, O 0
their O 0
precise O 0
molecular O 0
basis O 0
has O 0
remained O 0
unknown O 0
. O 0

We O 0
have O 0
cloned O 0
and O 0
sequenced O 0
seven O 0
mutant O 0
G6PD O 0
alleles O 0
. O 0

In O 0
the O 0
nondeficient O 0
polymorphic O 0
African O 0
variant O 0
G6PD O 0
A O 0
we O 0
have O 0
found O 0
a O 0
single O 0
point O 0
mutation O 0
. O 0

The O 0
other O 0
six O 0
mutants O 0
investigated O 0
were O 0
all O 0
associated O 0
with O 0
enzyme B-Disease 0
deficiency I-Disease 0
. O 0

In O 0
one O 0
of O 0
the O 0
commonest O 0
, O 0
G6PD O 0
Mediterranean O 0
, O 0
which O 0
is O 0
associated O 0
with O 0
favism B-Disease 1
among O 0
other O 0
clinical O 0
manifestations O 0
, O 0
a O 0
single O 0
amino O 0
acid O 0
replacement O 0
was O 0
found O 0
( O 0
serine O 0
- O 0
- O 0
- O 0
- O 0
phenylalanine O 0
) O 0
it O 0
must O 0
be O 0
responsible O 0
for O 0
the O 0
decreased O 0
stability O 0
and O 0
the O 0
reduced O 0
catalytic O 0
efficiency O 0
of O 0
this O 0
enzyme O 0
. O 0

Single O 0
point O 0
mutations O 0
were O 0
also O 0
found O 0
in O 0
G6PD O 0
Metaponto O 0
( O 0
Southern O 0
Italy O 0
) O 0
and O 0
in O 0
G6PD O 0
Ilesha O 0
( O 0
Nigeria O 0
) O 0
, O 0
which O 0
are O 0
asymptomatic O 0
, O 0
and O 0
in O 0
G6PD O 0
Chatham O 0
, O 0
which O 0
was O 0
observed O 0
in O 0
an O 0
Indian O 0
boy O 0
with O 0
neonatal B-Disease 1
jaundice I-Disease 1
. O 0

In O 0
G6PD O 0
" O 0
Matera O 0
, O 0
" O 0
which O 0
is O 0
now O 0
known O 0
to O 0
be O 0
the O 0
same O 0
as O 0
G6PD O 1
A O 1
- O 1
, O 0
two O 0
separate O 0
point O 0
mutations O 0
were O 0
found O 0
, O 0
one O 0
of O 0
which O 0
is O 0
the O 0
same O 0
as O 0
in O 0
G6PD O 0
A O 0
. O 0

In O 0
G6PD O 0
Santiago O 0
, O 0
a O 0
de O 0
novo O 0
mutation O 0
( O 0
glycine O 0
- O 0
- O 0
- O 0
- O 0
arginine O 0
) O 0
is O 0
associated O 0
with O 0
severe O 0
chronic O 1
hemolytic B-Disease 1
anemia I-Disease 1
. O 0

The O 0
mutations O 0
observed O 0
show O 0
a O 0
striking O 0
predominance O 0
of O 0
C O 0
- O 0
- O 0
- O 0
- O 0
T O 0
transitions O 0
, O 0
with O 0
CG O 0
doublets O 0
involved O 0
in O 0
four O 0
of O 0
seven O 0
cases O 0
. O 0

Thus O 0
, O 0
diverse O 0
point O 0
mutations O 0
may O 0
account O 0
largely O 0
for O 0
the O 0
phenotypic O 0
heterogeneity O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
. O 0

Tight O 0
linkage O 0
between O 0
myotonic B-Disease 1
dystrophy I-Disease 1
and O 0
apolipoprotein O 0
E O 0
genes O 0
revealed O 0
with O 0
allele O 0
- O 0
specific O 0
oligonucleotides O 0
. O 0

In O 0
16 O 0
families O 0
with O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
a O 0
novel O 0
approach O 0
based O 0
on O 0
use O 0
of O 0
allele O 0
- O 0
specific O 0
oligonucleotides O 0
has O 0
been O 0
employed O 0
to O 0
study O 0
the O 0
linkage O 0
relationship O 0
between O 0
the O 0
apolipoprotein O 0
E O 0
( O 0
APOE O 0
) O 0
gene O 0
and O 0
DM B-Disease 0
. O 0

Synthetic O 0
oligonucleotides O 0
, O 0
designed O 0
to O 0
discriminate O 0
between O 0
APOE O 0
alleles O 0
epsilon O 0
3 O 0
and O 0
epsilon O 0
4 O 0
, O 0
enabled O 0
us O 0
to O 0
distinguish O 0
heterozygous O 0
carriers O 0
in O 0
a O 0
hybridization O 0
assay O 0
. O 0

In O 0
a O 0
subset O 0
of O 0
families O 0
, O 0
the O 0
relevant O 0
segment O 0
of O 0
the O 0
APOE O 0
gene O 0
was O 0
enzymatically O 0
amplified O 0
to O 0
increase O 0
the O 0
sensitivity O 0
of O 0
the O 0
method O 0
. O 0

For O 0
DM O 0
and O 0
APOE O 0
, O 0
a O 0
maximum O 0
lod O 0
score O 0
( O 0
zmax O 0
of O 0
7 O 0
. O 0

47 O 0
was O 0
obtained O 0
at O 0
a O 0
recombination O 0
frequency O 0
( O 0
theta O 0
) O 0
of O 0
0 O 0
. O 0

047 O 0
( O 0
male O 0
theta O 0
= O 0
female O 0
theta O 0
) O 0
. O 0

No O 0
recombination O 0
( O 0
maximum O 0
lod O 0
score O 0
of O 0
5 O 0
. O 0
61 O 0
at O 0
theta O 0
= O 0
0 O 0
. O 0
0 O 0
) O 0
was O 0
found O 0
between O 0
APOE O 0
and O 0
the O 0
apolipoprotein O 0
CII O 0
( O 0
APOC2 O 0
) O 0
gene O 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
, O 0
in O 0
addition O 0
to O 0
APOC2 O 0
, O 0
APOE O 0
is O 0
a O 0
useful O 0
marker O 0
for O 0
presymptomatic O 0
DM B-Disease 0
diagnosis O 0
. O 0

Regional O 0
localization O 0
of O 0
polymorphic O 0
DNA O 0
loci O 0
on O 0
the O 0
proximal O 0
long O 0
arm O 0
of O 0
the O 0
X O 0
chromosome O 0
using O 0
deletions O 0
associated O 0
with O 0
choroideremia B-Disease 1
. O 0

In O 0
two O 0
unrelated O 0
families O 0
, O 0
males O 0
have O 0
been O 0
identified O 0
who O 0
suffer O 0
from O 0
choroideremia B-Disease 1
and O 0
at O 0
the O 0
same O 0
time O 0
have O 0
an O 0
interstitial O 0
deletion O 0
on O 0
the O 0
proximal O 0
long O 0
arm O 0
of O 0
the O 0
X O 0
chromosome O 0
. O 0

By O 0
high O 0
- O 0
resolution O 0
banding O 0
we O 0
have O 0
characterized O 0
the O 0
deletion O 0
chromosomes O 0
as O 0
del O 0
( O 0
X O 0
) O 0
( O 0
q21 O 0
. O 0
1 O 0
- O 0
q21 O 0
1 O 0
- O 0
q21 O 0
. O 0
33 O 0
) O 0
and O 0
del O 0
( O 0
X O 0
) O 0
( O 0
q21 O 0
. O 0
2 O 0
- O 0
q21 O 0
2 O 0
- O 0
q21 O 0
. O 0
31 O 0
) O 0
respectively O 0
. O 0

By O 0
Southern O 0
blot O 0
analysis O 0
we O 0
have O 0
mapped O 0
ten O 0
different O 0
polymorphic O 0
DNA O 0
loci O 0
relative O 0
to O 0
the O 0
position O 0
of O 0
the O 0
deletion O 0
and O 0
the O 0
choroideremia B-Disease 1
locus O 0
TCD O 0
. O 0

One O 0
probe O 0
, O 0
p31 O 0
, O 0
was O 0
shown O 0
to O 0
cover O 0
one O 0
of O 0
the O 0
breakpoints O 0
of O 0
the O 0
smallest O 0
deletion O 0
. O 0

The O 0
following O 0
order O 0
of O 0
the O 0
loci O 0
was O 0
suggested O 0
by O 0
deletion O 0
mapping O 0
cen O 0
- O 0
DXS106 O 0
- O 0
DXS72 O 0
- O 0
TCD O 0
- O 0
( O 0
DXYS1 O 0
/ O 0
DXYS23 O 0
/ O 0
DXYS5 O 0
) O 0
- O 0
DXYS2 O 0
- O 0
( O 0
DXYS12 O 0
/ O 0
DXS3 O 0
) O 0
- O 0
( O 0
DXS17 O 0
/ O 0
DXS101 O 0
) O 0
- O 0
Xqter O 0
. O 0

Retroviral O 0
- O 0
mediated O 0
gene O 0
transfer O 0
of O 0
human O 0
phenylalanine O 0
hydroxylase O 0
into O 0
NIH O 0
3T3 O 0
and O 0
hepatoma B-Disease 1
cells O 0
. O 0

Phenylketonuria B-Disease 0
( O 0
PKU B-Disease 0
) O 0
is O 0
caused O 0
by O 0
deficiency B-Disease 1
of I-Disease 1
the I-Disease 1
hepatic I-Disease 1
enzyme I-Disease 1
phenylalanine I-Disease 1
hydroxylase I-Disease 1
( O 0
PAH O 0
) O 0
. O 0

A O 0
full O 0
- O 0
length O 0
human O 0
PAH O 0
cDNA O 0
sequence O 0
has O 0
been O 0
inserted O 0
into O 0
pzip O 0
- O 0
neoSV O 0
( O 0
X O 0
) O 0
, O 0
which O 0
is O 0
a O 0
retroviral O 0
vector O 0
containing O 0
the O 0
bacterial O 0
neo O 0
gene O 0
. O 0

The O 0
recombinant O 0
has O 0
been O 0
transfected O 0
into O 0
psi O 0
2 O 0
cells O 0
, O 0
which O 0
provide O 0
synthesis O 0
of O 0
the O 0
retroviral O 0
capsid O 0
. O 0

Recombinant O 0
virus O 0
was O 0
detected O 0
in O 0
the O 0
culture O 0
medium O 0
of O 0
the O 0
transfected O 0
psi O 0
2 O 0
cells O 0
, O 0
which O 0
is O 0
capable O 0
of O 0
transmitting O 0
the O 0
human O 0
PAH O 0
gene O 0
into O 0
mouse O 0
NIH O 0
3T3 O 0
cells O 0
by O 0
infection O 0
leading O 0
to O 0
stable O 0
incorporation O 0
of O 0
the O 0
recombinant O 0
provirus O 0
. O 0

Infected O 0
cells O 0
express O 0
PAH O 0
mRNA O 0
, O 0
immunoreactive O 0
PAH O 0
protein O 0
, O 0
and O 0
exhibit O 0
pterin O 0
- O 0
dependent O 0
phenylalanine O 0
hydroxylase O 0
activity O 0
. O 0

The O 0
recombinant O 0
virus O 0
is O 0
also O 0
capable O 0
of O 0
infecting O 0
a O 0
mouse O 0
hepatoma B-Disease 1
cell O 0
line O 0
that O 0
does O 0
not O 0
normally O 0
synthesize O 0
PAH O 0
. O 0

PAH O 0
activity O 0
is O 0
present O 0
in O 0
the O 0
cellular O 0
extracts O 0
and O 0
the O 0
entire O 0
hydroxylation O 0
system O 0
is O 0
reconstituted O 0
in O 0
the O 0
hepatoma B-Disease 1
cells O 0
infected O 0
with O 0
the O 0
recombinant O 0
viruses O 0
. O 0

Thus O 0
, O 0
recombinant O 0
viruses O 0
containing O 0
human O 0
PAH O 0
cDNA O 0
provide O 0
a O 0
means O 0
for O 0
introducing O 0
functional O 0
PAH O 0
into O 0
mammalian O 0
cells O 0
of O 0
hepatic O 0
origin O 0
and O 0
can O 0
potentially O 0
be O 0
introduced O 0
into O 0
whole O 0
animals O 0
as O 0
a O 0
model O 0
for O 0
somatic O 0
gene O 0
therapy O 0
for O 0
PKU B-Disease 0
. O 0
. O 0

Estimation O 0
of O 0
the O 0
male O 0
to O 0
female O 0
ratio O 0
of O 0
mutation O 0
rates O 0
from O 0
the O 0
segregation O 0
of O 0
X O 0
- O 0
chromosomal O 0
DNA O 0
haplotypes O 0
in O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
families O 0
. O 0

A O 0
novel O 0
procedure O 0
is O 0
presented O 0
to O 0
estimate O 0
the O 0
ratio O 0
of O 0
male O 0
to O 0
female O 0
mutation O 0
rates O 0
for O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
. O 0

X O 0
- O 0
specific O 0
restriction O 0
fragment O 0
length O 0
polymorphisms O 0
are O 0
used O 0
to O 0
establish O 0
DNA O 0
haplotypes O 0
in O 0
three O 0
- O 0
generation O 0
DMD B-Disease 0
families O 0
. O 0

From O 0
the O 0
proportion O 0
of O 0
DMD B-Disease 0
patients O 0
who O 0
have O 0
inherited O 0
their O 0
maternal O 0
grandfathers O 0
X O 0
chromosome O 0
, O 0
the O 0
ratio O 0
of O 0
mutation O 0
rates O 0
can O 0
be O 0
calculated O 0
. O 0

In O 0
contrast O 0
to O 0
classical O 0
methods O 0
, O 0
the O 0
proposed O 0
procedure O 0
is O 0
not O 0
restricted O 0
to O 0
sporadic O 0
or O 0
familiar O 0
cases O 0
nor O 0
is O 0
any O 0
information O 0
on O 0
the O 0
carrier O 0
status O 0
of O 0
female O 0
relatives O 0
required O 0
. O 0
. O 0

Deletions O 0
of O 0
a O 0
DNA O 0
sequence O 0
in O 0
retinoblastomas B-Disease 1
and O 0
mesenchymal B-Disease 1
tumors I-Disease 1
: O 0
organization O 0
of O 0
the O 0
sequence O 0
and O 0
its O 0
encoded O 0
protein O 0
. O 0

Retinoblastoma B-Disease 0
is O 0
a O 0
childhood B-Disease 0
tumor I-Disease 0
that O 0
can O 0
arise O 0
because O 0
of O 0
mutant O 0
alleles O 0
acquired O 0
as O 0
somatic O 0
or O 0
germinal O 0
mutations O 0
. O 0

The O 0
mutant O 0
allele O 0
can O 0
be O 0
carried O 0
in O 0
the O 0
germ O 0
line O 0
. O 0

The O 0
mutations O 0
creating O 0
these O 0
alleles O 0
act O 0
by O 0
inactivating O 0
copies O 0
of O 0
a O 0
recessive O 0
oncogene O 0
located O 0
within O 0
band O 0
q14 O 0
of O 0
chromosome O 0
13 O 0
and O 0
termed O 0
the O 0
RB1 O 0
locus O 0
. O 0

We O 0
have O 0
reported O 0
isolation O 0
of O 0
a O 0
cDNA O 0
fragment O 0
that O 0
recognizes O 0
chromosomal O 0
sequences O 0
possessing O 0
many O 0
of O 0
the O 0
attributes O 0
of O 0
the O 0
retinoblastoma B-Disease 1
gene O 0
associated O 0
with O 0
the O 0
RB1 O 0
locus O 0
. O 0

We O 0
now O 0
report O 0
that O 0
this O 0
segment O 0
is O 0
additionally O 0
the O 0
target O 0
of O 0
somatic O 0
mutations O 0
in O 0
mesenchymal B-Disease 1
tumors I-Disease 1
among O 0
patients O 0
having O 0
no O 0
apparent O 0
predisposition O 0
to O 0
retinoblastoma B-Disease 1
and O 0
no O 0
previous O 0
evidence O 0
of O 0
retinoblastoma B-Disease 1
. O 0

These O 0
tumors B-Disease 0
provide O 0
additional O 0
evidence O 0
that O 0
the O 0
cloned O 0
sequences O 0
are O 0
representative O 0
of O 0
a O 0
gene O 0
that O 0
is O 0
a O 0
frequent O 0
target O 0
of O 0
inactivation O 0
during O 0
tumorigenesis O 0
. O 0

Sequence O 0
analysis O 0
of O 0
this O 0
cDNA O 0
provides O 0
little O 0
insight O 0
into O 0
its O 0
normal O 0
functional O 0
role O 0
. O 0
. O 0

Treatment O 0
of O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
with O 0
growth O 0
hormone O 0
inhibitors O 0
. O 0

A O 0
controlled O 0
, O 0
double O 0
- O 0
blind O 0
therapeutic O 0
trial O 0
with O 0
the O 0
drug O 0
mazindol O 0
, O 0
a O 0
growth O 0
hormone O 0
inhibitor O 0
, O 0
was O 0
performed O 0
in O 0
a O 0
pair O 0
of O 0
7 O 0
1 O 0
/ O 0
2 O 0
year O 0
- O 0
old O 0
monozygotic O 0
twins O 0
, O 0
with O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
. O 0

The O 0
rationale O 0
for O 0
this O 0
trial O 0
was O 0
based O 0
on O 0
a O 0
patient O 0
( O 0
reported O 0
previously O 0
) O 0
affected O 0
simultaneously O 0
with O 0
DMD B-Disease 0
and O 0
growth B-Disease 1
hormone I-Disease 1
( I-Disease 1
GH I-Disease 1
) I-Disease 1
deficiency I-Disease 1
, O 0
who O 0
is O 0
showing O 0
a O 0
benign O 0
course O 0
of O 0
the O 0
dystrophic B-Disease 1
process I-Disease 1
and O 0
is O 0
still O 0
walking O 0
at O 0
18 O 0
years O 0
. O 0

One O 0
of O 0
the O 0
twins O 0
received O 0
2 O 0
mg O 0
of O 0
mazindol O 0
daily O 0
, O 0
while O 0
the O 0
other O 0
received O 0
a O 0
placebo O 0
. O 0

The O 0
assessment O 0
, O 0
repeated O 0
every O 0
2 O 0
months O 0
, O 0
included O 0
weight O 0
and O 0
height O 0
measurements O 0
, O 0
functional O 0
and O 0
motor O 0
ability O 0
tests O 0
, O 0
ergometry O 0
and O 0
determinations O 0
of O 0
serum O 0
enzymes O 0
and O 0
GH O 1
levels O 0
. O 0

After O 0
one O 0
year O 0
of O 0
trial O 0
the O 0
code O 0
was O 0
broken O 0
and O 0
it O 0
was O 0
seen O 0
that O 0
the O 0
twin O 0
under O 0
placebo O 0
treatment O 0
was O 0
strikingly O 0
worse O 0
than O 0
his O 0
brother O 0
, O 0
the O 0
progression O 0
of O 0
whose O 0
condition O 0
was O 0
practically O 0
arrested O 0
. O 0

These O 0
results O 0
strongly O 0
suggest O 0
that O 0
treatment O 0
with O 0
a O 0
GH O 1
inhibitor O 0
is O 0
beneficial O 0
for O 0
DMD B-Disease 0
patients O 0
. O 0
. O 0

Identification O 0
and O 0
localization O 0
of O 0
mutations O 0
at O 0
the O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
locus O 0
by O 0
ribonuclease O 0
A O 0
cleavage O 0
. O 0

Many O 0
mutations O 0
leading O 0
to O 0
human O 0
disease O 0
are O 0
the O 0
result O 0
of O 0
single O 0
DNA O 0
base O 0
pair O 0
changes O 0
that O 0
cannot O 0
be O 0
identified O 0
by O 0
Southern O 0
analysis O 0
. O 0

This O 0
has O 0
prompted O 0
the O 0
development O 0
of O 0
alternative O 0
assays O 0
for O 0
point O 0
mutation O 0
detection O 0
. O 0

The O 0
recently O 0
described O 0
ribonuclease O 0
A O 0
cleavage O 0
procedure O 0
, O 0
with O 0
a O 0
polyuridylic O 0
acid O 0
- O 0
paper O 0
affinity O 0
chromatography O 0
step O 0
, O 0
has O 0
been O 0
used O 0
to O 0
identify O 0
the O 0
mutational O 0
lesions O 0
in O 0
the O 0
hypoxanthine O 0
phosphoribosyltransferase O 0
( O 0
HPRT O 0
) O 0
messenger O 0
RNAs O 0
of O 0
patients O 0
with O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
. O 0

Distinctive O 0
ribonuclease O 0
A O 0
cleavage O 0
patterns O 0
were O 0
identified O 0
in O 0
messenger O 0
RNA O 0
from O 0
5 O 0
of O 0
14 O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
patients O 0
who O 0
were O 0
chosen O 0
because O 0
no O 0
HPRT O 0
Southern O 0
or O 0
Northern O 0
blotting O 0
pattern O 0
changes O 0
had O 0
been O 0
found O 0
. O 0

This O 0
approach O 0
now O 0
allows O 0
HPRT O 0
mutation O 0
detection O 0
in O 0
50 O 0
percent O 0
of O 0
the O 0
cases O 0
of O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
. O 0

The O 0
polyuridylic O 0
acid O 0
- O 0
paper O 0
affinity O 0
procedure O 0
provides O 0
a O 0
general O 0
method O 0
for O 0
analysis O 0
of O 0
low O 0
abundance O 0
messenger O 0
RNAs O 0
. O 0
. O 0

Two O 0
new O 0
variants O 0
of O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
associated O 0
with O 0
hereditary B-Disease 0
non I-Disease 0
- I-Disease 0
spherocytic I-Disease 0
hemolytic I-Disease 1
anemia I-Disease 1
: O 0
G6PD O 0
Wayne O 0
and O 0
G6PD O 0
Huron O 0
. O 0

Two O 0
new O 0
deficient O 0
variants O 0
of O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
causing O 0
hereditary B-Disease 1
nonspherocytic I-Disease 1
hemolytic I-Disease 1
anemia I-Disease 1
( O 0
HNSHA B-Disease 0
) O 0
are O 0
described O 0
. O 0

Both O 0
of O 0
these O 0
are O 0
unique O 0
and O 0
they O 0
have O 0
been O 0
named O 0
G6PD O 0
Wayne O 0
and O 0
G6PD O 0
Huron O 0
. O 0

Patients O 0
with O 0
G6PD O 0
Wayne O 0
underwent O 0
splenectomy O 0
and O 0
no O 0
objective O 0
improvement O 0
was O 0
noted O 0
. O 0

The O 0
patients O 0
with O 0
G6PD O 0
Huron O 0
were O 0
under O 0
medical O 0
observation O 0
for O 0
a O 0
considerable O 0
period O 0
of O 0
time O 0
without O 0
the O 0
diagnosis O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
being O 0
entertained O 0
because O 0
the O 0
family O 0
was O 0
of O 0
Northern O 0
European O 0
origin O 0
. O 0

Since O 0
sporadic O 0
variants O 0
of O 0
G6PD O 0
causing O 0
HNSHA B-Disease 0
show O 0
no O 0
special O 0
racial O 0
predilection O 0
, O 0
the O 0
diagnosis O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
should O 0
always O 0
be O 0
considered O 0
in O 0
patients O 0
with O 0
this O 0
syndrome O 0
. O 0
. O 0

Sialophorin O 0
, O 0
a O 0
surface O 0
sialoglycoprotein O 0
defective O 0
in O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
, O 0
is O 0
involved O 0
in O 0
human O 0
T O 0
lymphocyte O 0
proliferation O 0
. O 0

The O 0
mAb O 0
L10 O 0
was O 0
used O 0
to O 0
determine O 0
the O 0
distribution O 0
and O 0
the O 0
function O 0
of O 0
sialophorin O 0
, O 0
the O 0
heavily O 0
glycosylated O 0
surface O 0
molecule O 0
that O 0
is O 0
deficient O 0
/ O 0
defective O 0
in O 0
lymphocytes O 0
of O 0
patients O 0
with O 0
the O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
immunodeficiency I-Disease 1
Wiskott I-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
. O 0

Dual O 0
- O 0
parameter O 0
FACS O 0
analysis O 0
indicated O 0
that O 0
sialophorin O 0
is O 0
expressed O 0
on O 0
CD4 O 0
+ O 0
and O 0
CD8 O 0
+ O 0
lymphocytes O 0
, O 0
on O 0
a O 0
subpopulation O 0
of O 0
peripheral O 0
blood O 0
B O 0
lymphocytes O 0
, O 0
on O 0
all O 0
thymocytes O 0
, O 0
and O 0
on O 0
a O 0
subpopulation O 0
of O 0
bone O 0
marrow O 0
cells O 0
. O 0

Functional O 0
studies O 0
demonstrated O 0
that O 0
L10 O 0
mAb O 0
stimulates O 0
the O 0
proliferation O 0
of O 0
peripheral O 0
blood O 0
T O 0
lymphocytes O 0
as O 0
measured O 0
by O 0
stimulation O 0
of O 0
[ O 0
3H O 0
] O 0
thymidine O 0
incorporation O 0
. O 0

The O 0
time O 0
course O 0
and O 0
magnitude O 0
of O 0
increased O 0
[ O 0
3H O 0
] O 0
thymidine O 0
incorporation O 0
by O 0
T O 0
lymphocytes O 0
in O 0
response O 0
to O 0
L10 O 0
mAb O 0
paralleled O 0
that O 0
induced O 0
by O 0
anti O 0
- O 0
CD3 O 0
mAb O 0
. O 0

Effective O 0
stimulation O 0
was O 0
dependent O 0
on O 0
the O 0
presence O 0
of O 0
monocytes O 0
and O 0
the O 0
Fc O 0
portion O 0
of O 0
L10 O 0
mAb O 0
. O 0

Stimulation O 0
of O 0
lymphocytes O 0
by O 0
L10 O 0
, O 0
like O 0
stimulation O 0
by O 0
anti O 0
- O 0
CD3 O 0
mAb O 0
, O 0
involves O 0
increased O 0
expression O 0
of O 0
4F2 O 0
, O 0
HLA O 0
- O 0
DR O 0
, O 0
and O 0
IL O 0
- O 0
2 O 0
- O 0
R O 0
. O 0

These O 0
observations O 0
suggest O 0
that O 0
sialophorin O 0
functions O 0
in O 0
T O 0
cell O 0
activation O 0
. O 0
. O 0

Hypopigmentation B-Disease 1
in O 0
the O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
. O 0

Cutaneous B-Disease 0
and I-Disease 0
ocular I-Disease 0
pigmentation I-Disease 0
were O 0
evaluated O 0
in O 0
29 O 0
individuals O 0
with O 0
the O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
. O 0

Criteria O 0
for O 0
hypopigmentation B-Disease 1
included O 0
the O 0
presence O 0
of O 0
type O 0
I O 0
or O 0
II O 0
skin O 0
, O 0
the O 0
lightest O 0
skin O 0
type O 0
in O 0
the O 0
family O 0
by O 0
history O 0
, O 0
and O 0
iris O 0
translucency O 0
on O 0
globe O 0
transillumination O 0
. O 0

On O 0
the O 0
basis O 0
of O 0
these O 0
criteria O 0
, O 0
48 O 0
% O 0
of O 0
the O 0
PWS B-Disease 0
individuals O 0
were O 0
hypopigmented B-Disease 1
. O 0

The O 0
presence O 0
of O 0
hypopigmentation B-Disease 1
correlated O 0
with O 0
a O 0
small O 0
interstitial O 0
deletion O 0
on O 0
the O 0
proximal O 0
long O 0
arm O 0
of O 0
chromosome O 0
15 O 0
; O 0
however O 0
, O 0
this O 0
deletion O 0
was O 0
also O 0
found O 0
in O 0
individuals O 0
who O 0
did O 0
not O 0
meet O 0
the O 0
full O 0
criteria O 0
for O 0
hypopigmentation B-Disease 1
. O 0

Hairbulb O 0
tyrosinase O 0
activity O 0
and O 0
glutathione O 0
content O 0
, O 0
as O 0
well O 0
as O 0
urine O 0
cysteinyldopa O 0
excretion O 0
, O 0
were O 0
low O 0
in O 0
PWS B-Disease 0
individuals O 0
with O 0
and O 0
without O 0
hypopigmentation B-Disease 1
and O 0
did O 0
not O 0
separate O 0
these O 0
two O 0
groups O 0
. O 0

We O 0
conclude O 0
that O 0
hypopigmentation B-Disease 1
is O 0
found O 0
in O 0
a O 0
significant O 0
proportion O 0
of O 0
individuals O 0
with O 0
PWS B-Disease 0
and O 0
that O 0
the O 0
hypopigmentation B-Disease 1
may O 0
be O 0
associated O 0
with O 0
a O 0
deletion O 0
of O 0
the O 0
long O 0
arm O 0
of O 0
chromosome O 0
15 O 0
. O 0

The O 0
mechanism O 0
for O 0
the O 0
hypopigmentation B-Disease 1
is O 0
unknown O 0
. O 0
. O 0

Phenotype O 0
heterogeneity O 0
among O 0
hemizygotes O 0
in O 0
a O 0
family O 0
biochemically O 0
screened O 0
for O 0
adrenoleukodystrophy B-Disease 1
. O 0

We O 0
report O 0
on O 0
two O 0
clinically O 0
, O 0
neurologically O 0
normal O 0
relatives O 0
of O 0
a O 0
boy O 0
affected O 0
by O 0
adrenoleukodystrophy B-Disease 1
( O 0
ALD B-Disease 0
) O 0
; O 0
they O 0
were O 0
found O 0
repeatedly O 0
to O 0
have O 0
the O 0
biochemical O 0
defect O 0
of O 0
an O 0
ALD B-Disease 0
hemizygote O 0
. O 0

The O 0
assay O 0
consisted O 0
in O 0
the O 0
determination O 0
of O 0
very O 0
- O 0
long O 0
- O 0
chain O 0
fatty O 0
acids O 0
in O 0
lyophilized O 0
and O 0
reconstituted O 0
plasma O 0
. O 0

While O 0
no O 0
evidence O 0
of O 0
neurologic B-Disease 1
disease I-Disease 1
( O 0
leukodystrophy B-Disease 1
or O 0
myeloneuropathy B-Disease 1
) O 0
was O 0
present O 0
in O 0
these O 0
hemizygotes O 0
, O 0
adrenocortical B-Disease 1
insufficiency I-Disease 1
provoking O 0
compensatory O 0
high O 0
ACTH O 0
release O 0
was O 0
found O 0
in O 0
both O 0
. O 0

These O 0
findings O 0
should O 0
be O 0
taken O 0
into O 0
consideration O 0
when O 0
counseling O 0
families O 0
in O 0
which O 0
cases O 0
with O 0
clinically O 0
expressed O 0
ALD B-Disease 0
are O 0
represented O 0
in O 0
several O 0
generations O 0
. O 0
. O 0

The O 0
mapping O 0
of O 0
a O 0
cDNA O 0
from O 0
the O 0
human O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
Duchenne I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
gene O 0
to O 0
the O 0
mouse O 0
X O 0
chromosome O 0
. O 0

The O 0
recent O 0
discovery O 0
of O 0
sequences O 0
at O 0
the O 0
site O 0
of O 0
the O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
gene O 0
in O 0
humans O 0
has O 0
opened O 0
up O 0
the O 0
possibility O 0
of O 0
a O 0
detailed O 0
molecular O 0
analysis O 0
of O 0
the O 0
genes O 0
in O 0
humans O 0
and O 0
in O 0
related O 0
mammalian O 0
species O 0
. O 0

Until O 0
relatively O 0
recently O 0
, O 0
there O 0
was O 0
no O 0
obvious O 0
mouse O 0
model O 0
of O 0
this O 0
genetic B-Disease 1
disease I-Disease 1
for O 0
the O 0
development O 0
of O 0
therapeutic O 0
strategies O 0
. O 0

The O 0
identification O 0
of O 0
a O 0
mouse O 0
X O 0
- O 0
linked O 0
mutant O 0
showing O 0
muscular B-Disease 0
dystrophy I-Disease 0
, O 0
mdx O 0
, O 0
has O 0
provided O 0
a O 0
candidate O 0
mouse O 0
genetic O 0
homologue O 0
to O 0
the O 0
DMD B-Disease 0
locus O 0
; O 0
the O 0
relatively O 0
mild O 0
pathological O 0
features O 0
of O 0
mdx O 0
suggest O 0
it O 0
may O 0
have O 0
more O 0
in O 0
common O 0
with O 0
mutations O 0
of O 0
the O 0
Becker B-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
type O 0
at O 0
the O 0
same O 0
human O 0
locus O 0
, O 0
however O 0
. O 0

But O 0
the O 0
close O 0
genetic O 0
linkage O 0
of O 0
mdx O 0
to O 0
G6PD O 0
and O 0
Hprt O 0
on O 0
the O 0
mouse O 0
X O 0
chromosome O 0
, O 0
coupled O 0
with O 0
its O 0
comparatively O 0
mild O 0
pathology O 0
, O 0
have O 0
suggested O 0
that O 0
the O 0
mdx O 0
mutation O 0
may O 0
instead O 0
correspond O 0
to O 0
Emery B-Disease 1
Dreifuss I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
which O 0
itself O 0
is O 0
closely O 0
linked O 0
to O 0
DNA O 0
markers O 0
at O 0
Xq28 O 0
- O 0
qter O 0
in O 0
the O 0
region O 0
of O 0
G6PD O 0
on O 0
the O 0
human O 0
X O 0
chromosome O 0
. O 0

Using O 0
an O 0
interspecific O 0
mouse O 0
domesticus O 0
/ O 0
spretus O 0
cross O 0
, O 0
segregating O 0
for O 0
a O 0
variety O 0
of O 0
markers O 0
on O 0
the O 0
mouse O 0
X O 0
chromosome O 0
, O 0
we O 0
have O 0
positioned O 0
on O 0
the O 0
mouse O 0
X O 0
chromosome O 0
sequences O 0
homologous O 0
to O 0
a O 0
DMD B-Disease 0
cDNA O 0
clone O 0
. O 0

These O 0
sequences O 0
map O 0
provocatively O 0
close O 0
to O 0
the O 0
mdx O 0
mutation O 0
and O 0
unexpectedly O 0
distant O 0
from O 0
sparse O 0
fur O 0
, O 0
spf O 0
, O 0
the O 0
mouse O 0
homologue O 0
of O 0
OTC O 0
( O 0
ornithine O 0
transcarbamylase O 0
) O 0
which O 0
is O 0
closely O 0
linked O 0
to O 0
DMD B-Disease 0
on O 0
the O 0
human O 0
X O 0
chromosome O 0
. O 0
. O 0

Localization O 0
of O 0
the O 0
region O 0
homologous O 0
to O 0
the O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
locus O 0
on O 0
the O 0
mouse O 0
X O 0
chromosome O 0
. O 0

Recent O 0
progress O 0
has O 0
resulted O 0
in O 0
part O 0
of O 0
the O 0
gene O 0
mutated O 0
in O 0
Duchenne B-Disease 1
and I-Disease 1
the I-Disease 1
milder I-Disease 1
Becker I-Disease 1
muscular I-Disease 1
dystrophies I-Disease 1
being O 0
cloned O 0
and O 0
has O 0
suggested O 0
that O 0
the O 0
gene O 0
itself O 0
extends O 0
over O 0
1 O 0
, O 0
000 O 0
to O 0
2 O 0
, O 0
000 O 0
kilobases O 0
( O 0
kb O 0
) O 0
. O 0

To O 0
study O 0
how O 0
mutations O 0
in O 0
this O 0
gene O 0
affect O 0
muscle O 0
development O 0
and O 0
integrity O 0
, O 0
it O 0
would O 0
be O 0
of O 0
interest O 0
to O 0
have O 0
available O 0
a O 0
mouse O 0
model O 0
of O 0
the O 0
human O 0
disease O 0
. O 0

The O 0
mouse O 0
mdx O 0
mutation O 0
affects O 0
muscle O 0
and O 0
confers O 0
a O 0
mild O 0
dystrophic B-Disease 0
syndrome I-Disease 0
, O 0
but O 0
it O 0
is O 0
not O 0
clear O 0
whether O 0
this O 0
mutation O 0
is O 0
equivalent O 0
to O 0
Duchenne B-Disease 0
/ I-Disease 0
Becker I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
in O 0
man O 0
. O 0

Here O 0
we O 0
describe O 0
the O 0
use O 0
of O 0
two O 0
sequences O 0
from O 0
the O 0
human O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
gene O 0
that O 0
cross O 0
- O 0
hybridize O 0
to O 0
mouse O 0
X O 0
- O 0
linked O 0
sequences O 0
to O 0
localize O 0
the O 0
gene O 0
homologous O 0
to O 0
DMD B-Disease 0
in O 0
the O 0
mouse O 0
. O 0

Both O 0
sequences O 0
map O 0
to O 0
the O 0
region O 0
of O 0
10 O 0
centimorgan O 0
lying O 0
between O 0
the O 0
Tabby O 0
( O 0
Ta O 0
) O 0
and O 0
St14 O 0
- O 0
1 O 0
( O 0
DxPas8 O 0
) O 0
loci O 0
, O 0
close O 0
to O 0
the O 0
phosphorylase O 0
b O 0
kinase O 0
locus O 0
( O 0
Phk O 0
) O 0
. O 0

By O 0
analogy O 0
with O 0
the O 0
human O 0
X O 0
- O 0
chromosome O 0
, O 0
we O 0
conclude O 0
that O 0
the O 0
region O 0
in O 0
the O 0
mouse O 0
around O 0
the O 0
G6pd O 0
and O 0
St14 O 0
- O 0
1 O 0
loci O 0
may O 0
contain O 0
two O 0
genes O 0
corresponding O 0
to O 0
distinct O 0
human O 0
myopathies B-Disease 0
Emery B-Disease 1
Dreifuss I-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
which O 0
is O 0
known O 0
to O 0
be O 0
closely O 0
linked O 0
to O 0
St14 O 0
- O 0
1 O 0
in O 0
man O 0
and O 0
the O 0
DMD B-Disease 0
homologue O 0
described O 0
here O 0
. O 0
. O 0

GT O 0
to O 0
AT O 0
transition O 0
at O 0
a O 0
splice O 0
donor O 0
site O 0
causes O 0
skipping O 0
of O 0
the O 0
preceding O 0
exon O 0
in O 0
phenylketonuria B-Disease 0
. O 0

Classical B-Disease 0
Phenylketonuria I-Disease 0
( O 0
PKU B-Disease 0
) O 0
is O 0
an O 0
autosomal B-Disease 0
recessive I-Disease 0
human I-Disease 0
genetic I-Disease 0
disorder I-Disease 0
caused O 0
by O 0
a O 0
deficiency B-Disease 0
of I-Disease 0
hepatic I-Disease 0
phenylalanine I-Disease 0
hydroxylase I-Disease 0
( O 0
PAH O 0
) O 0
. O 0

We O 0
isolated O 0
several O 0
mutant O 0
PAH O 0
cDNA O 0
clones O 0
from O 0
a O 0
PKU B-Disease 0
carrier O 0
individual O 0
and O 0
showed O 0
that O 0
they O 0
contained O 0
an O 0
internal O 0
116 O 0
base O 0
pair O 0
deletion O 0
, O 0
corresponding O 0
precisely O 0
to O 0
exon O 0
12 O 0
of O 0
the O 0
human O 0
chromosomal O 0
PAH O 0
gene O 0
. O 0

The O 0
deletion O 0
causes O 0
the O 0
synthesis O 0
of O 0
a O 0
truncated O 0
protein O 0
lacking O 0
the O 0
C O 0
- O 0
terminal O 0
52 O 0
amino O 0
acids O 0
. O 0

Gene O 0
transfer O 0
and O 0
expression O 0
studies O 0
using O 0
the O 0
mutant O 0
PAH O 0
cDNA O 0
indicated O 0
that O 0
the O 0
deletion O 0
abolishes O 0
PAH O 0
activity O 0
in O 0
the O 0
cell O 0
as O 0
a O 0
result O 0
of O 0
protein O 0
instability O 0
. O 0

To O 0
determine O 0
the O 0
molecular O 0
basis O 0
of O 0
the O 0
deletion O 0
, O 0
the O 0
mutant O 0
chromosomal O 0
PAH O 0
gene O 0
was O 0
isolated O 0
from O 0
this O 0
individual O 0
and O 0
shown O 0
to O 0
contain O 0
a O 0
GT O 0
- O 0
- O 0
greater O 0
than O 0
AT O 0
substitution O 0
at O 0
the O 0
5 O 0
splice O 0
donor O 0
site O 0
of O 0
intron O 0
12 O 0
. O 0

Thus O 0
, O 0
the O 0
consequence O 0
of O 0
the O 0
splice O 0
donor O 0
site O 0
mutation O 0
in O 0
the O 0
human O 0
liver O 0
is O 0
the O 0
skipping O 0
of O 0
the O 0
preceding O 0
exon O 0
during O 0
RNA O 0
splicing O 0
. O 0
. O 0

Conservation O 0
of O 0
the O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
gene O 0
in O 0
mice O 0
and O 0
humans O 0
. O 0

A O 0
portion O 0
of O 0
the O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
gene O 0
transcript O 0
from O 0
human O 0
fetal O 0
skeletal O 0
muscle O 0
and O 0
mouse O 0
adult O 0
heart O 0
was O 0
sequenced O 0
, O 0
representing O 0
approximately O 0
25 O 0
percent O 0
of O 0
the O 0
total O 0
, O 0
14 O 0
- O 0
kb O 0
DMD B-Disease 0
transcript O 0
. O 0

The O 0
nucleic O 0
acid O 0
and O 0
predicted O 0
amino O 0
acid O 0
sequences O 0
from O 0
the O 0
two O 0
species O 0
are O 0
nearly O 0
90 O 0
percent O 0
homologous O 0
. O 0

The O 0
amino O 0
acid O 0
sequence O 0
that O 0
is O 0
predicted O 0
from O 0
this O 0
portion O 0
of O 0
the O 0
DMD B-Disease 0
gene O 0
indicates O 0
that O 0
the O 0
protein O 0
product O 0
might O 0
serve O 0
a O 0
structural O 0
role O 0
in O 0
muscle O 0
, O 0
but O 0
the O 0
abundance O 0
and O 0
tissue O 0
distribution O 0
of O 0
the O 0
messenger O 0
RNA O 0
suggests O 0
that O 0
the O 0
DMD B-Disease 0
protein O 0
is O 0
not O 0
nebulin O 0
. O 0
. O 0

Familial O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
with O 0
apparently O 0
normal O 0
chromosomes O 0
. O 0

We O 0
report O 0
on O 0
4 O 0
sibs O 0
( O 0
2F O 0
, O 0
2M O 0
) O 0
with O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
. O 0

Diagnosis O 0
was O 0
made O 0
clinically O 0
on O 0
the O 0
basis O 0
of O 0
history O 0
, O 0
behavior O 0
, O 0
and O 0
physical O 0
findings O 0
in O 0
3 O 0
of O 0
the O 0
sibs O 0
. O 0

The O 0
other O 0
child O 0
had O 0
died O 0
at O 0
age O 0
10 O 0
months O 0
with O 0
a O 0
history O 0
and O 0
clinical O 0
findings O 0
typical O 0
of O 0
first O 0
phase O 0
of O 0
PWS B-Disease 0
. O 0

Results O 0
of O 0
chromosome O 0
studies O 0
on O 0
the O 0
parents O 0
and O 0
surviving O 0
sibs O 0
were O 0
normal O 0
. O 0

The O 0
implications O 0
of O 0
this O 0
unusual O 0
familial O 0
occurrence O 0
for O 0
our O 0
understanding O 0
of O 0
PWS B-Disease 0
are O 0
discussed O 0
. O 0
. O 0

Nebulin O 0
and O 0
titin O 0
expression O 0
in O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
appears O 0
normal O 0
. O 0

Monoclonal O 0
antibodies O 0
which O 0
recognize O 0
different O 0
epitopes O 0
on O 0
either O 0
titin O 0
or O 0
nebulin O 0
show O 0
normal O 0
staining O 0
patterns O 0
on O 0
frozen O 0
sections O 0
of O 0
three O 0
muscle O 0
biopsies O 0
of O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
. O 0

Gel O 0
electrophoresis O 0
and O 0
immunoblotting O 0
performed O 0
on O 0
two O 0
of O 0
these O 0
muscle O 0
biopsies O 0
show O 0
the O 0
normal O 0
pattern O 0
of O 0
titin O 0
and O 0
nebulin O 0
polypeptides O 0
. O 0

Since O 0
the O 0
donor O 0
of O 0
one O 0
of O 0
these O 0
biopsies O 0
has O 0
a O 0
large O 0
deletion O 0
of O 0
the O 0
5 O 0
- O 0
region O 0
of O 0
the O 0
DMD B-Disease 0
gene O 0
, O 0
our O 0
results O 0
argue O 0
against O 0
the O 0
recent O 0
proposal O 0
that O 0
nebulin O 0
is O 0
the O 0
gene O 0
mutated O 0
in O 0
DMD B-Disease 0
. O 0
. O 0

Heterozygous B-Disease 1
C2 I-Disease 1
deficiency I-Disease 1
associated O 0
with O 0
angioedema B-Disease 1
, O 0
myasthenia B-Disease 1
gravis I-Disease 1
, O 0
and O 0
systemic B-Disease 0
lupus I-Disease 0
erythematosus I-Disease 0
. O 0

We O 0
describe O 0
a O 0
patient O 0
with O 0
myasthenia B-Disease 1
gravis I-Disease 1
, O 0
systemic B-Disease 0
lupus I-Disease 0
erythematosus I-Disease 0
, O 0
and O 0
angioedema B-Disease 1
associated O 0
with O 0
heterozygous O 0
complement B-Disease 0
factor I-Disease 0
2 I-Disease 0
( I-Disease 0
C2 I-Disease 0
) I-Disease 0
deficiency I-Disease 0
. O 0

The O 0
significance O 0
of O 0
this O 0
association O 0
is O 0
controversial O 0
, O 0
though O 0
the O 0
association O 0
of O 0
C2 B-Disease 1
deficiency I-Disease 1
with O 0
certain O 0
histocompatibility O 0
antigens O 0
suggests O 0
possible O 0
linkage O 0
to O 0
immune O 0
response O 0
genes O 0
. O 0

To O 0
our O 0
knowledge O 0
this O 0
is O 0
the O 0
first O 0
report O 0
of O 0
heterozygous O 0
C2 B-Disease 1
deficiency I-Disease 1
in O 0
association O 0
with O 0
this O 0
combination O 0
of O 0
autoimmune B-Disease 0
disorders I-Disease 0
, O 0
and O 0
we O 0
discuss O 0
the O 0
aetiological O 0
implications O 0
. O 0
. O 0

Genetic O 0
analysis O 0
of O 0
an O 0
inherited O 1
deficiency B-Disease 1
of I-Disease 0
the I-Disease 0
third I-Disease 0
component I-Disease 0
of I-Disease 0
complement I-Disease 0
in O 0
Brittany O 0
spaniel O 0
dogs O 0
. O 0

Genetically O 0
determined O 0
C3 B-Disease 0
deficiency I-Disease 0
in O 0
Brittany O 0
spaniel O 0
dogs O 0
shares O 0
a O 0
number O 0
of O 0
biochemical O 0
and O 0
clinical O 0
characteristics O 0
with O 0
the O 0
human O 0
disorder O 0
. O 0

In O 0
humans O 0
, O 0
the O 0
gene O 0
for O 0
C3 B-Disease 0
deficiency I-Disease 0
is O 0
a O 0
null O 0
gene O 0
that O 0
is O 0
allelic O 0
to O 0
the O 0
structural O 0
gene O 0
for O 0
C3 O 0
and O 0
is O 0
not O 0
linked O 0
to O 0
the O 0
major O 0
histocompatibility O 0
locus O 0
. O 0

The O 0
current O 0
study O 0
used O 0
allotype O 0
analysis O 0
of O 0
canine O 0
C3 O 0
in O 0
order O 0
to O 0
demonstrate O 0
that O 0
the O 0
gene O 0
for O 0
C3 B-Disease 0
deficiency I-Disease 0
in O 0
these O 0
dogs O 0
is O 0
also O 0
a O 0
null O 0
gene O 0
allelic O 0
to O 0
the O 0
structural O 0
gene O 0
for O 0
C3 O 0
. O 0

In O 0
addition O 0
, O 0
preliminary O 0
pedigree O 0
analysis O 0
suggests O 0
that O 0
the O 0
gene O 0
for O 0
canine O 0
C3 B-Disease 0
deficiency I-Disease 0
is O 0
apparently O 0
not O 0
closely O 0
linked O 0
to O 0
the O 0
major O 0
histocompatibility O 0
complex O 0
of O 0
the O 0
dog O 0
. O 0

Thus O 0
, O 0
it O 0
appears O 0
that O 0
C3 B-Disease 0
deficiency I-Disease 0
in O 0
Brittany O 0
spaniel O 0
dogs O 0
not O 0
only O 0
shares O 0
biochemical O 0
and O 0
clinical O 0
features O 0
with O 0
C3 B-Disease 0
deficiency I-Disease 0
in O 0
humans O 0
, O 0
but O 0
also O 0
shares O 0
some O 0
genetic O 0
characteristics O 0
with O 0
the O 0
human O 0
disorder O 0
. O 0
. O 0

Gene O 0
transfer O 0
and O 0
expression O 0
of O 0
human O 0
phenylalanine O 0
hydroxylase O 0
. O 0

Phenylketonuria B-Disease 0
( O 0
PKU B-Disease 0
) O 0
is O 0
caused O 0
by O 0
a O 0
genetic O 0
deficiency B-Disease 1
of I-Disease 1
the I-Disease 1
enzyme I-Disease 1
phenylalanine I-Disease 1
hydroxylase I-Disease 1
( O 0
PAH O 0
) O 0
. O 0

A O 0
full O 0
- O 0
length O 0
complementary O 0
DNA O 0
clone O 0
of O 0
human O 0
PAH O 0
was O 0
inserted O 0
into O 0
a O 0
eukaryotic O 0
expression O 0
vector O 0
and O 0
transferred O 0
into O 0
mouse O 0
NIH3T3 O 0
cells O 0
which O 0
do O 0
not O 0
normally O 0
express O 0
PAH O 0
. O 0

The O 0
transformed O 0
mouse O 0
cells O 0
expressed O 0
PAH O 0
messenger O 0
RNA O 0
, O 0
immunoreactive O 0
protein O 0
, O 0
and O 0
enzymatic O 0
activity O 0
that O 0
are O 0
characteristic O 0
of O 0
the O 0
normal O 0
human O 0
liver O 0
products O 0
, O 0
demonstrating O 0
that O 0
a O 0
single O 0
gene O 0
contains O 0
all O 0
of O 0
the O 0
necessary O 0
genetic O 0
information O 0
to O 0
code O 0
for O 0
functional O 0
PAH O 0
. O 0

These O 0
results O 0
support O 0
the O 0
use O 0
of O 0
the O 0
human O 0
PAH O 0
probe O 0
in O 0
prenatal O 0
diagnosis O 0
and O 0
detection O 0
of O 0
carriers O 0
, O 0
to O 0
provide O 0
new O 0
opportunities O 0
for O 0
the O 0
biochemical O 0
characterization O 0
of O 0
normal O 0
and O 0
mutant O 0
enzymes O 0
, O 0
and O 0
in O 0
the O 0
investigation O 0
of O 0
alternative O 0
genetic O 0
therapies O 0
for O 0
PKU B-Disease 0
. O 0
. O 0

Regional O 0
mapping O 0
of O 0
the O 0
phenylalanine O 0
hydroxylase O 0
gene O 0
and O 0
the O 0
phenylketonuria B-Disease 0
locus O 0
in O 0
the O 0
human O 0
genome O 0
. O 0

Phenylketonuria B-Disease 0
( O 0
PKU B-Disease 0
) O 0
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
of O 0
amino O 0
acid O 0
metabolism O 0
caused O 0
by O 0
a O 0
deficiency B-Disease 1
of I-Disease 1
the I-Disease 1
hepatic I-Disease 1
enzyme I-Disease 1
phenylalanine I-Disease 1
hydroxylase I-Disease 1
( O 0
PAH O 0
; O 0
phenylalanine O 0
4 O 0
- O 0
monooxygenase O 0
, O 0
EC O 0
1 O 0
. O 0
14 O 0
. O 0
16 O 0
. O 0
1 O 0
) O 0
. O 0

A O 0
cDNA O 0
clone O 0
for O 0
human O 0
PAH O 0
has O 0
previously O 0
been O 0
used O 0
to O 0
assign O 0
the O 0
corresponding O 0
gene O 0
to O 0
human O 0
chromosome O 0
12 O 0
. O 0

To O 0
define O 0
the O 0
regional O 0
map O 0
position O 0
of O 0
the O 0
disease O 0
locus O 0
and O 0
the O 0
PAH O 0
gene O 0
on O 0
human O 0
chromosome O 0
12 O 0
, O 0
DNA O 0
was O 0
isolated O 0
from O 0
human O 0
- O 0
hamster O 0
somatic O 0
cell O 0
hybrids O 0
with O 0
various O 0
deletions O 0
of O 0
human O 0
chromosome O 0
12 O 0
and O 0
was O 0
analyzed O 0
by O 0
Southern O 0
blot O 0
analysis O 0
using O 0
the O 0
human O 0
cDNA O 0
PAH O 0
clone O 0
as O 0
a O 0
hybridization O 0
probe O 0
. O 0

From O 0
these O 0
results O 0
, O 0
together O 0
with O 0
detailed O 0
biochemical O 0
and O 0
cytogenetic O 0
characterization O 0
of O 0
the O 0
hybrid O 0
cells O 0
, O 0
the O 0
region O 0
on O 0
chromosome O 0
12 O 0
containing O 0
the O 0
human O 0
PAH O 0
gene O 0
has O 0
been O 0
defined O 0
as O 0
12q14 O 0
. O 0

3 O 0
- O 0
- O 0
- O 0
- O 0
qter O 0
3 O 0
- O 0
- O 0
- O 0
- O 0
qter O 0
. O 0

The O 0
PAH O 0
map O 0
position O 0
on O 0
chromosome O 0
12 O 0
was O 0
further O 0
localized O 0
by O 0
in O 0
situ O 0
hybridization O 0
of O 0
125I O 0
- O 0
labeled O 0
human O 0
PAH O 0
cDNA O 0
to O 0
chromosomes O 0
prepared O 0
from O 0
a O 0
human O 0
lymphoblastoid O 0
cell O 0
line O 0
. O 0

Results O 0
of O 0
these O 0
experiments O 0
demonstrated O 0
that O 0
the O 0
region O 0
on O 0
chromosome O 0
12 O 0
containing O 0
the O 0
PAH O 0
gene O 0
and O 0
the O 0
PKU B-Disease 0
locus O 0
in O 0
man O 0
is O 0
12q22 O 0
- O 0
- O 0
- O 0
- O 0
12q24 O 0
. O 0

1 O 0
. O 0

These O 0
results O 0
not O 0
only O 0
provide O 0
a O 0
regionalized O 0
map O 0
position O 0
for O 0
a O 0
major O 0
human O 0
disease O 0
locus O 0
but O 0
also O 0
can O 0
serve O 0
as O 0
a O 0
reference O 0
point O 0
for O 0
linkage O 0
analysis O 0
with O 0
other O 0
DNA O 0
markers O 0
on O 0
human O 0
chromosome O 0
12 O 0

Heterogeneity O 0
of O 0
type B-Disease 0
I I-Disease 0
von I-Disease 1
Willebrand I-Disease 1
disease I-Disease 1
: O 0
evidence O 0
for O 0
a O 0
subgroup O 0
with O 0
an O 0
abnormal O 0
von B-Disease 1
Willebrand I-Disease 1
factor O 0
. O 0

Type B-Disease 0
I I-Disease 0
von I-Disease 1
Willebrand I-Disease 1
disease I-Disease 1
( O 0
vWD B-Disease 1
) O 0
is O 0
characterized O 0
by O 0
equally O 0
low O 0
plasma O 0
concentrations O 0
of O 0
von B-Disease 1
Willebrand I-Disease 1
factor O 0
antigen O 0
( O 0
vWF O 0
Ag O 0
) O 0
and O 0
ristocetin O 0
cofactor O 0
( O 0
RiCof O 0
) O 0
and O 0
by O 0
the O 0
presence O 0
of O 0
all O 0
vWF O 0
multimers O 0
in O 0
sodium O 0
dodecyl O 0
sulfate O 0
( O 0
SDS O 0
) O 0
- O 0
agarose O 0
gel O 0
electrophoresis O 0
. O 0

For O 0
17 O 0
patients O 0
( O 0
13 O 0
kindreds O 0
) O 0
diagnosed O 0
with O 0
these O 0
criteria O 0
, O 0
we O 0
have O 0
studied O 0
the O 0
platelet O 0
contents O 0
of O 0
vWF O 0
Ag O 0
and O 0
RiCof O 0
and O 0
the O 0
changes O 0
of O 0
these O 0
in O 0
plasma O 0
after O 0
DDAVP O 0
infusion O 0
. O 0

Platelet O 0
vWF O 0
Ag O 0
and O 0
RiCof O 0
were O 0
normal O 0
in O 0
four O 0
kindreds O 0
( O 0
called O 0
" O 0
platelet O 0
normal O 0
" O 0
subgroup O 0
) O 0
; O 0
following O 0
1 O 0
- O 0
deamino O 0
- O 0
8 O 0
- O 0
D O 0
- O 0
arginine O 0
vasopressin O 0
; O 0
plasma O 0
vWF O 0
Ag O 0
, O 0
RiCof O 0
and O 0
the O 0
bleeding O 0
time O 0
( O 0
BT O 0
) O 0
became O 0
normal O 0
. O 0

In O 0
six O 0
kindreds O 0
, O 0
platelet O 0
vWF O 0
Ag O 0
and O 0
RiCof O 0
were O 0
equally O 0
low O 0
( O 0
platelet O 0
low O 0
) O 0
; O 0
after O 0
DDAVP O 0
, O 0
plasma O 0
vWF O 0
Ag O 0
and O 0
RiCof O 0
remained O 0
low O 0
, O 0
and O 0
the O 0
BT O 0
was O 0
prolonged O 0
. O 0

In O 0
three O 0
additional O 0
kindreds O 0
, O 0
platelets O 0
contained O 0
normal O 0
concentrations O 0
of O 0
vWF O 0
Ag O 0
, O 0
but O 0
RiCof O 0
was O 0
very O 0
low O 0
( O 0
platelet O 0
discordant O 0
) O 0
; O 0
even O 0
though O 0
a O 0
complete O 0
set O 0
of O 0
multimers O 0
was O 0
found O 0
in O 0
plasma O 0
and O 0
platelets O 0
, O 0
there O 0
was O 0
a O 0
relatively O 0
small O 0
amount O 0
of O 0
large O 0
multimers O 0
. O 0

After O 0
DDAVP O 0
, O 0
plasma O 0
vWF O 0
Ag O 0
became O 0
normal O 0
, O 0
but O 0
RiCof O 0
remained O 0
low O 0
and O 0
the O 0
BT O 0
was O 0
very O 0
prolonged O 0
. O 0

These O 0
findings O 0
demonstrated O 0
that O 0
there O 0
can O 0
be O 0
an O 0
abnormal O 0
vWF O 0
( O 0
RiCof O 0
less O 0
than O 0
vWF O 0
Ag O 0
) O 0
even O 0
in O 0
type B-Disease 0
I I-Disease 0
vWD I-Disease 1
, O 0
coexisting O 0
with O 0
a O 0
complete O 0
set O 0
of O 0
vWF O 0
multimers O 0
( O 0
platelet O 0
discordant O 0
) O 0
; O 0
that O 0
the O 0
abnormal O 0
vWF O 0
can O 0
be O 0
shown O 0
more O 0
clearly O 0
in O 0
platelets O 0
than O 0
in O 0
plasma O 0
or O 0
else O 0
in O 0
plasma O 0
after O 0
DDAVP O 0
infusion O 0
; O 0
and O 0
that O 0
DDAVP O 0
normalizes O 0
the O 0
BT O 0
only O 0
in O 0
those O 0
patients O 0
with O 0
normal O 0
platelet O 0
levels O 0
of O 0
both O 0
vWF O 0
Ag O 0
and O 0
RiCof O 0
( O 0
platelet O 0
normal O 0
) O 0
. O 0
. O 0

Genetic O 0
analysis O 0
in O 0
families O 0
with O 0
van B-Disease 1
der I-Disease 1
Woude I-Disease 1
syndrome I-Disease 1
. O 0

We O 0
have O 0
brought O 0
together O 0
information O 0
on O 0
864 O 0
affected O 0
individuals O 0
in O 0
164 O 0
families O 0
( O 0
including O 0
three O 0
new O 0
pedigrees O 0
) O 0
reported O 0
in O 0
the O 0
137 O 0
year O 0
period O 0
since O 0
1845 O 0
when O 0
Demarquay O 0
first O 0
described O 0
a O 0
family O 0
with O 0
what O 0
was O 0
later O 0
called O 0
van B-Disease 1
der I-Disease 1
Woude I-Disease 1
syndrome I-Disease 1
( O 0
VWS B-Disease 0
) O 0
. O 0

Both O 0
types O 0
of O 0
oral B-Disease 1
cleft I-Disease 1
, O 0
cleft B-Disease 0
palate I-Disease 0
( O 0
CP B-Disease 0
) O 0
and O 0
cleft B-Disease 1
lip I-Disease 1
with O 0
or O 0
without O 0
CP B-Disease 0
( O 0
CLP B-Disease 1
) O 0
, O 0
segregate O 0
in O 0
these O 0
families O 0
together O 0
with O 0
lower O 0
lip B-Disease 0
pits I-Disease 0
or O 0
fistulae B-Disease 1
in O 0
an O 0
autosomal O 0
dominant O 0
mode O 0
with O 0
high O 0
penetrance O 0
estimated O 0
to O 0
be O 0
K O 0
= O 0
. O 0

89 O 0
and O 0
. O 0

99 O 0
by O 0
different O 0
methods O 0
. O 0

Cleft O 0
types O 0
( O 0
CLP B-Disease 1
and O 0
CP B-Disease 0
) O 0
occur O 0
in O 0
VWS B-Disease 0
in O 0
the O 0
same O 0
proportions O 0
as O 0
in O 0
the O 0
general O 0
non O 0
- O 0
VWS O 0
population O 0
, O 0
ie O 0
, O 0
about O 0
twice O 0
as O 0
many O 0
cleft O 0
- O 0
bearing O 0
individuals O 0
have O 0
CLP B-Disease 1
as O 0
have O 0
CP B-Disease 0
. O 0

On O 0
the O 0
other O 0
hand O 0
, O 0
we O 0
do O 0
not O 0
find O 0
the O 0
usually O 0
observed O 0
excess O 0
of O 0
females O 0
with O 0
CP B-Disease 0
and O 0
excess O 0
of O 0
males O 0
with O 0
CLP B-Disease 1
; O 0
in O 0
VWS B-Disease 0
the O 0
sex O 0
ratios O 0
are O 0
more O 0
nearly O 0
equal O 0
. O 0

Lip B-Disease 0
pits I-Disease 0
also O 0
are O 0
equally O 0
distributed O 0
between O 0
the O 0
sexes O 0
. O 0

Affected O 0
males O 0
and O 0
females O 0
are O 0
equally O 0
likely O 0
to O 0
transmit O 0
VWS B-Disease 0
. O 0

However O 0
, O 0
there O 0
is O 0
an O 0
excess O 0
of O 0
less O 0
severely O 0
affected O 0
individuals O 0
among O 0
transmitters O 0
and O 0
a O 0
deficiency O 0
of O 0
more O 0
severely O 0
affected O 0
, O 0
brought O 0
about O 0
by O 0
a O 0
proband O 0
bias O 0
and O 0
differential O 0
fecundity O 0
. O 0

The O 0
expression O 0
of O 0
VWS B-Disease 0
is O 0
significantly O 0
modified O 0
by O 0
the O 0
genetic O 0
background O 0
More O 0
extreme O 0
phenotypes O 0
in O 0
parents O 0
tend O 0
to O 0
produce O 0
more O 0
extreme O 0
expression O 0
in O 0
their O 0
children O 0
. O 0

For O 0
a O 0
VWS B-Disease 0
gene O 0
carrier O 0
the O 0
relative O 0
risk O 0
of O 0
transmitting O 0
a O 0
cleft O 0
is O 0
26 O 0
. O 0

45 O 0
% O 0
; O 0
that O 0
of O 0
transmitting O 0
lower O 0
lip B-Disease 0
pits I-Disease 0
is O 0
23 O 0
. O 0

55 O 0
% O 0
. O 0

Three O 0
pedigrees O 0
of O 0
lip B-Disease 0
pits I-Disease 0
in O 0
the O 0
literature O 0
show O 0
no O 0
clefts O 0
among O 0
a O 0
significant O 0
number O 0
of O 0
affected O 0
individuals O 0
. O 0

Control O 0
of O 0
gene O 0
expression O 0
in O 0
VWS B-Disease 0
in O 0
the O 0
three O 0
target O 0
tissues O 0
appears O 0
to O 0
be O 0
independent O 0
and O 0
separately O 0
designated O 0
. O 0

Mutation O 0
rate O 0
of O 0
the O 0
VWS B-Disease 0
gene O 0
is O 0
calculated O 0
to O 0
be O 0
1 O 0
. O 0

8 O 0
X O 0
10 O 0
( O 0
- O 0
5 O 0
) O 0

Hereditary B-Disease 1
C7 I-Disease 1
deficiency I-Disease 1
. O 0

Diagnosis O 0
and O 0
HLA O 0
studies O 0
in O 0
a O 0
French O 0
- O 0
Canadian O 0
family O 0
. O 0

The O 0
serum O 0
of O 0
a O 0
44 O 0
- O 0
yr O 0
- O 0
old O 0
woman O 0
of O 0
French O 0
- O 0
Canadian O 0
descent O 0
having O 0
a O 0
B O 0
- O 0
27 O 0
positive O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
was O 0
deficient B-Disease 1
in I-Disease 1
the I-Disease 1
seventh I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
( O 0
C7 O 0
) O 0
as O 0
determined O 0
by O 0
hemolytic O 0
and O 0
immunochemical O 0
methods O 0
. O 0

No O 0
inhibitor O 0
against O 0
C7 O 0
was O 0
detected O 0
, O 0
and O 0
the O 0
levels O 0
of O 0
all O 0
other O 0
complement O 0
components O 0
were O 0
normal O 0
. O 0

No O 0
deficiency O 0
in O 0
the O 0
opsonic O 0
activity O 0
of O 0
the O 0
serum O 0
was O 0
found O 0
, O 0
and O 0
the O 0
results O 0
of O 0
basic O 0
coagulation O 0
studies O 0
of O 0
the O 0
plasma O 0
were O 0
normal O 0
. O 0

On O 0
investigation O 0
of O 0
the O 0
patients O 0
family O 0
, O 0
two O 0
sisters O 0
were O 0
found O 0
to O 0
have O 0
the O 0
same O 0
deficiency O 0
but O 0
were O 0
otherwise O 0
in O 0
good O 0
health O 0
. O 0

The O 0
seven O 0
other O 0
siblings O 0
were O 0
heterozygous O 0
for O 0
C7 B-Disease 0
deficiency I-Disease 0
, O 0
while O 0
the O 0
paternal O 0
aunt O 0
had O 0
a O 0
normal O 0
C7 O 0
level O 0
. O 0

In O 0
the O 0
third O 0
generation O 0
, O 0
six O 0
children O 0
of O 0
the O 0
three O 0
homozygous O 0
sisters O 0
and O 0
five O 0
children O 0
of O 0
heterozygotes O 0
were O 0
available O 0
for O 0
testing O 0
. O 0

Studies O 0
of O 0
the O 0
HLA O 0
antigens O 0
in O 0
all O 0
the O 0
22 O 0
subjects O 0
and O 0
in O 0
three O 0
spouses O 0
indicated O 0
no O 0
close O 0
linkage O 0
between O 0
the O 0
CM B-Disease 0
deficienty I-Disease 0
and O 0
the O 0
HLA O 0
system O 0
. O 0

In O 0
addition O 0
, O 0
the O 0
simultaneous O 0
occurrence O 0
of O 0
two O 0
hereditary O 0
complement B-Disease 1
deficiencies I-Disease 1
( I-Disease 1
C2 I-Disease 1
and I-Disease 1
C7 I-Disease 1
) I-Disease 1
was O 0
discovered O 0
in O 0
one O 0
family O 0
of O 0
this O 0
remarkable O 0
kindred O 0
. O 0
. O 0

Genetic O 0
defect B-Disease 1
in I-Disease 1
secretion I-Disease 1
of I-Disease 1
complement I-Disease 1
C5 I-Disease 1
in O 0
mice O 0
. O 0

A O 0
genetic O 0
deficiency B-Disease 0
of I-Disease 0
the I-Disease 0
fifth I-Disease 0
( I-Disease 0
C5 I-Disease 0
) I-Disease 0
component I-Disease 0
of I-Disease 0
complement1 I-Disease 0
- I-Disease 0
3 I-Disease 0
, O 0
a O 0
serum O 0
glycoprotein O 0
of O 0
molecular O 0
weight O 0
( O 0
MW O 0
) O 0
220 O 0
, O 0
000 O 0
( O 0
ref O 0
. O 0
4 O 0
) O 0
, O 0
has O 0
been O 0
found O 0
in O 0
39 O 0
% O 0
of O 0
inbred O 0
strains O 0
of O 0
mice3 O 0
. O 0

Sera O 0
of O 0
deficient O 0
mice O 0
lack O 0
detectable O 0
C5 O 0
activity O 0
and O 0
protein2 O 0
, O 0
3 O 0
. O 0

In O 0
addition O 0
deficient O 0
mice O 0
produce O 0
antibody O 0
to O 0
mouse O 0
C5 O 0
when O 0
injected O 0
with O 0
sera O 0
from O 0
C5 O 0
sufficient O 0
( O 0
normal O 0
) O 0
strains O 0
. O 0

Levy O 0
et O 0
al O 0
. O 0

5 O 0
showed O 0
that O 0
somatic O 0
cell O 0
hybrids O 0
between O 0
C5 O 0
deficient O 0
( O 0
B10 O 0
. O 0
D2 O 0
/ O 0
old O 0
line O 0
) O 0
macrophages O 0
and O 0
either O 0
C5 O 0
sufficient O 0
( O 0
B10 O 0
. O 0
D2 O 0
/ O 0
new O 0
line O 0
) O 0
mouse O 0
kidney O 0
or O 0
chicken O 0
erythroblasts O 0
secreted O 0
haemolytically O 0
active O 0
mouse O 0
C5 O 0
in O 0
vitro O 0
. O 0

Several O 0
possible O 0
molecular O 0
mechanisms O 0
to O 0
account O 0
for O 0
the O 0
findings O 0
were O 0
considered O 0
, O 0
but O 0
insufficient O 0
direct O 0
data O 0
were O 0
available O 0
to O 0
choose O 0
among O 0
them O 0
. O 0

We O 0
recently O 0
reported O 0
that O 0
mouse O 0
( O 0
CD O 0
. O 0
1 O 0
strain O 0
) O 0
peritoneal O 0
cells O 0
in O 0
culture O 0
synthesise O 0
and O 0
secrete O 0
a O 0
single O 0
chain O 0
precursor O 0
, O 0
pro O 0
- O 0
C5 O 0
( O 0
MW O 0
approximately O 0
210 O 0
, O 0
000 O 0
) O 0
, O 0
of O 0
the O 0
two O 0
- O 0
chain O 0
( O 0
alpha O 0
chain O 0
, O 0
125 O 0
, O 0
000 O 0
and O 0
beta O 0
chain O 0
83 O 0
, O 0
000 O 0
MW O 0
) O 0
C5 O 0
protein6 O 0
. O 0

Radiolabelled O 0
precursor O 0
C5 O 0
was O 0
contained O 0
within O 0
the O 0
cells O 0
and O 0
was O 0
secreted O 0
into O 0
the O 0
tissue O 0
culture O 0
media O 0
. O 0

Using O 0
similar O 0
methods O 0
, O 0
we O 0
now O 0
find O 0
that O 0
C5 B-Disease 0
deficiency I-Disease 0
in O 0
each O 0
of O 0
five O 0
different O 0
mouse O 0
strains O 0
( O 0
AKR O 0
, O 0
SWR O 0
, O 0
DBA O 0
/ O 0
2J8 O 0
A O 0
/ O 0
HeJ O 0
and O 0
B10 O 0
. O 0
D2 O 0
/ O 0
old O 0
line O 0
) O 0
is O 0
due O 0
to O 0
a O 0
failure O 0
in O 0
secretion O 0
of O 0
C5 O 0
protein O 0
and O 0
not O 0
to O 0
a O 0
failure O 0
in O 0
biosynthesis O 0
of O 0
pro O 0
- O 0
C5 O 0

Recurrent O 0
meningococcal B-Disease 0
meningitis I-Disease 1
with O 0
absence B-Disease 1
of I-Disease 1
the I-Disease 1
sixth I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
: O 0
an O 0
evaluation O 0
of O 0
underlying O 0
immunologic O 0
mechanisms O 0
. O 0

A O 0
51 O 0
/ O 0
2 O 0
- O 0
year O 0
- O 0
old O 0
black O 0
girl O 0
with O 0
recurrent O 0
meningococcal B-Disease 0
meningitis I-Disease 1
and O 0
absence B-Disease 1
of I-Disease 1
the I-Disease 1
sixth I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
( O 0
C6 O 0
) O 0
is O 0
reported O 0
. O 0

To O 0
explore O 0
the O 0
pathogenesis O 0
of O 0
recurrent O 0
neisserial B-Disease 0
infections I-Disease 0
in O 0
C6 B-Disease 1
deficiency I-Disease 1
, O 0
a O 0
detailed O 0
analysis O 0
of O 0
her O 0
immune O 0
competence O 0
was O 0
conducted O 0
. O 0

Her O 0
serum O 0
had O 0
normal O 0
chemotactic O 0
, O 0
opsonic O 0
, O 0
alternative O 0
complement O 0
pathway O 0
, O 0
and O 0
specific O 0
antibody O 0
activity O 0
, O 0
but O 0
lacked O 0
complement O 0
- O 0
mediated O 0
bacteriolytic O 0
activity O 0
. O 0

In O 0
addition O 0
, O 0
her O 0
C6 B-Disease 1
- I-Disease 1
deficient I-Disease 1
serum O 0
was O 0
indistinguishable O 0
from O 0
normal O 0
serum O 0
in O 0
a O 0
complement O 0
- O 0
dependent O 0
assay O 0
of O 0
phagocyte O 0
bactericidal O 0
activity O 0
. O 0

Absent O 0
bacteriolysis O 0
remains O 0
the O 0
only O 0
consistent O 0
defect O 0
associated O 0
with O 0
recurrent O 0
neisserial B-Disease 0
infections I-Disease 0
and O 0
absence O 0
of O 0
one O 0
of O 0
the O 0
late O 0
- O 0
acting O 0
complement O 0
components O 0
. O 0
. O 0

Deficiency B-Disease 1
of I-Disease 1
the I-Disease 1
fifth I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
in O 0
human O 0
subjects O 0
. O 0

Clinical O 0
, O 0
genetic O 0
and O 0
immunologic O 0
studies O 0
in O 0
a O 0
large O 0
kindred O 0
. O 0

The O 0
discovery O 0
of O 0
a O 0
large O 0
kindred O 0
with O 0
a O 0
heritable O 0
deficiency B-Disease 1
of I-Disease 1
the I-Disease 1
fifth I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
( O 0
C5 O 0
) O 0
has O 0
permitted O 0
the O 0
accumulation O 0
of O 0
new O 0
clinical O 0
, O 0
genetic O 0
and O 0
immunologic O 0
data O 0
concerning O 0
the O 0
role O 0
of O 0
C5 O 0
in O 0
human O 0
subjects O 0
. O 0

The O 0
proband O 0
, O 0
who O 0
has O 0
had O 0
nine O 0
episodes O 0
of O 0
disseminated O 0
gonococcal B-Disease 1
infection I-Disease 1
, O 0
has O 0
a O 0
hemolytic O 0
C5 O 0
level O 0
of O 0
approximately O 0
0 O 0
. O 0

5 O 0
per O 0
cent O 0
of O 0
normal O 0
. O 0

No O 0
C5 O 0
protein O 0
was O 0
detectable O 0
, O 0
but O 0
low O 0
levels O 0
of O 0
functional O 0
C5 O 0
activity O 0
could O 0
be O 0
found O 0
using O 0
a O 0
sensitive O 0
bactericidal O 0
assay O 0
. O 0

The O 0
probands O 0
twin O 0
as O 0
well O 0
as O 0
another O 0
sister O 0
also O 0
had O 0
extremely O 0
low O 0
levels O 0
of O 0
hemolytic O 0
C5 O 0
( O 0
approximately O 0
0 O 0
. O 0
5 O 0
per O 0
cent O 0
normal O 0
) O 0
, O 0
but O 0
both O 0
these O 0
subjects O 0
have O 0
been O 0
healthy O 0
. O 0

Hemolytic O 0
complement O 0
and O 0
bacteriolytic O 0
activity O 0
could O 0
be O 0
restored O 0
by O 0
the O 0
addition O 0
of O 0
purified O 0
C5 O 0
. O 0

No O 0
chemotactic O 0
activity O 0
for O 0
polymorphonuclear O 0
leukocytes O 0
could O 0
be O 0
generated O 0
in O 0
the O 0
C5 B-Disease 1
- I-Disease 1
deficient I-Disease 1
serums O 0
upon O 0
activation O 0
of O 0
either O 0
the O 0
classic O 0
or O 0
alternative O 0
pathways O 0
, O 0
again O 0
demonstrating O 0
the O 0
importance O 0
of O 0
C5 O 0
in O 0
human O 0
subjects O 0
for O 0
the O 0
production O 0
of O 0
chemotactic O 0
factors O 0
. O 0

The O 0
chemotactic O 0
responsiveness O 0
of O 0
the O 0
patients O 0
polymorphonuclear O 0
leukocytes O 0
and O 0
monocytes O 0
to O 0
preformed O 0
chemotactic O 0
factors O 0
was O 0
not O 0
depressed O 0
. O 0

Twenty O 0
- O 0
two O 0
of O 0
32 O 0
other O 0
family O 0
members O 0
from O 0
three O 0
generations O 0
had O 0
depressed O 0
whole O 0
hemolytic O 0
complement O 0
levels O 0
. O 0

In O 0
19 O 0
of O 0
30 O 0
family O 0
members O 0
, O 0
levels O 0
of O 0
hemolytic O 0
C5 O 0
ranged O 0
from O 0
13 O 0
to O 0
64 O 0
per O 0
cent O 0
of O 0
normal O 0
. O 0

No O 0
linkage O 0
for O 0
C5 B-Disease 0
deficiency I-Disease 0
and O 0
the O 0
A O 0
or O 0
B O 0
loci O 0
of O 0
the O 0
major O 0
histocompatibility O 0
complex O 0
could O 0
be O 0
found O 0
. O 0

These O 0
data O 0
suggest O 0
an O 0
autosomal O 0
codominant O 0
mode O 0
of O 0
inheritance O 0
of O 0
C5 B-Disease 0
deficiency I-Disease 0
. O 0

Deficiency B-Disease 0
of I-Disease 0
C5 I-Disease 0
is O 0
compatible O 0
with O 0
good O 0
health O 0
, O 0
but O 0
it O 0
can O 0
be O 0
associated O 0
with O 0
repeated O 0
disseminated O 0
gonococcal B-Disease 1
infection I-Disease 1

Incidence O 0
and O 0
characteristics O 0
of O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
variants O 0
in O 0
Japan O 0
. O 0

A O 0
total O 0
of O 0
3000 O 0
men O 0
living O 0
in O 0
Yamaguchi O 0
were O 0
screened O 0
for O 0
glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
) I-Disease 0
deficiency I-Disease 0
using O 0
Beutlers O 0
spot O 0
test O 0
and O 0
three O 0
types O 0
of O 0
starch O 0
gel O 0
electrophoresis O 0
. O 0

These O 0
electrophoresis O 0
used O 0
a O 0
phosphate O 0
buffer O 0
system O 0
at O 0
pH O 0
7 O 0
. O 0

0 O 0
, O 0
a O 0
TRIS O 0
- O 0
EDTA O 0
- O 0
borate O 0
buffer O 0
system O 0
at O 0
pH O 0
8 O 0
. O 0

6 O 0
, O 0
and O 0
a O 0
TRIS O 0
- O 0
hydrochloride O 0
buffer O 0
system O 0
at O 0
pH O 0
8 O 0
. O 0
. O 0

Fifteen O 0
G6PD B-Disease 1
- I-Disease 1
deficient I-Disease 1
variants O 0
were O 0
found O 0
at O 0
the O 0
rate O 0
of O 0
0 O 0
. O 0

5 O 0
% O 0
and O 0
classified O 0
into O 0
four O 0
groups O 0
. O 0

As O 0
new O 0
variants O 0
, O 0
G6PD O 0
Konan O 0
, O 0
Kamiube O 0
, O 0
and O 0
Kiwa O 0
were O 0
identified O 0
. O 0

These O 0
three O 0
variants O 0
had O 0
a O 0
mild O 0
to O 0
moderate O 0
G6PD B-Disease 0
deficiency I-Disease 0
and O 0
were O 0
not O 0
associated O 0
with O 0
any O 0
clinical O 0
signs O 0
. O 0

G6PD O 0
Konan O 0
had O 0
fast O 0
electrophoretic O 0
mobility O 0
as O 0
compared O 0
with O 0
normal O 0
levels O 0
, O 0
G6PD O 0
Kiwa O 0
had O 0
slightly O 0
elevated O 0
electrophoretic O 0
mobility O 0
, O 0
and O 0
G6PD O 0
Kamiube O 0
had O 0
normal O 0
electrophoretic O 0
mobility O 0
. O 0

These O 0
three O 0
variants O 0
had O 0
normal O 0
levels O 0
of O 0
Km O 0
G6P O 0
, O 0
Km O 0
NADP O 0
, O 0
and O 0
Ki O 0
NADPH O 0
, O 0
normal O 0
utilizations O 0
of O 0
both O 0
2 O 0
- O 0
deoxy O 0
- O 0
G6P O 0
and O 0
deamino O 0
- O 0
NAPD O 0
, O 0
normal O 0
heat O 0
stability O 0
, O 0
and O 0
a O 0
normal O 0
pH O 0
curve O 0
. O 0

The O 0
other O 0
variant O 0
was O 0
G6PD O 0
Ube O 0
, O 0
which O 0
we O 0
had O 0
previously O 0
found O 0
in O 0
Yamaguchi O 0
( O 0
Nakashima O 0
et O 0
al O 0
. O 0
, O 0
1977 O 0
) O 0
. O 0

One O 0
boy O 0
with O 0
G6PD O 0
Ube O 0
was O 0
Korean O 0

Utilization O 0
of O 0
purines O 0
by O 0
an O 0
HPRT O 0
variant O 0
in O 0
an O 0
intelligent O 0
, O 0
nonmutilative O 0
patient O 0
with O 0
features O 0
of O 0
the O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
. O 0

The O 0
patient O 0
, O 0
H O 1
. O 0

Chr O 0
. O 0

B O 0
. O 0
, O 0
was O 0
among O 0
the O 0
first O 0
reported O 0
with O 0
hyperuricemia B-Disease 0
and O 0
central B-Disease 1
nervous I-Disease 1
system I-Disease 1
symptoms I-Disease 1
. O 0

He O 0
has O 0
been O 0
found O 0
to O 0
have O 0
a O 0
variant O 0
of O 0
hypoxanthine O 0
guanine O 0
phosphoribosyl O 0
transferase O 0
( O 0
HPRT O 0
; O 0
E O 0
. O 0
C O 0
. O 0
2 O 0
. O 0
4 O 0
. O 0
2 O 0
. O 0
8 O 0
) O 0
distinct O 0
from O 0
the O 0
enzyme O 0
present O 0
in O 0
patients O 0
with O 0
the O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
. O 0

The O 0
patient O 0
had O 0
chroeoathetosis B-Disease 0
, O 0
spasticity B-Disease 0
, O 0
dysarthric B-Disease 0
speech I-Disease 0
, O 0
and O 0
hyperuricemia B-Disease 0
. O 0

However O 0
, O 0
his O 0
intelligence O 0
was O 0
normal O 0
and O 0
he O 0
had O 0
no O 0
evidence O 0
of O 0
self O 0
- O 0
mutilation O 0
. O 0

There O 0
was O 0
no O 0
activity O 0
of O 0
HPRT O 0
in O 0
the O 0
lysates O 0
of O 0
erythrocytes O 0
and O 0
cultured O 0
fibroblasts O 0
when O 0
analyzed O 0
in O 0
the O 0
usual O 0
manner O 0
. O 0

Using O 0
a O 0
newly O 0
developed O 0
method O 0
for O 0
the O 0
study O 0
of O 0
purine O 0
metabolism O 0
in O 0
intact O 0
cultured O 0
cells O 0
, O 0
this O 0
patient O 0
was O 0
found O 0
to O 0
metabolize O 0
some O 0
9 O 0
% O 0
of O 0
8 O 0
- O 0
14C O 0
- O 0
hypoxanthine O 0
, O 0
and O 0
90 O 0
% O 0
of O 0
the O 0
isotope O 0
utilized O 0
was O 0
converted O 0
to O 0
adenine O 0
and O 0
guanine O 0
nucleotides O 0
. O 0

In O 0
contrast O 0
, O 0
cells O 0
from O 0
patients O 0
with O 0
the O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
were O 0
virtually O 0
completely O 0
unable O 0
to O 0
convert O 0
hypoxanthine O 0
to O 0
nucleotides O 0
. O 0

The O 0
patients O 0
fibroblasts O 0
were O 0
even O 0
more O 0
efficient O 0
in O 0
the O 0
metabolism O 0
of O 0
8 O 0
- O 0
14C O 0
- O 0
guanine O 0
, O 0
which O 0
was O 0
utilized O 0
to O 0
the O 0
extent O 0
of O 0
27 O 0
% O 0
, O 0
over O 0
80 O 0
% O 0
of O 0
which O 0
was O 0
converted O 0
to O 0
guanine O 0
and O 0
adenine O 0
nucleotides O 0
. O 0

The O 0
growth O 0
of O 0
the O 0
cultured O 0
fibroblasts O 0
of O 0
this O 0
patient O 0
was O 0
intermediate O 0
in O 0
media O 0
containing O 0
hypoxanthine O 0
aminopterin O 0
thymidine O 0
( O 0
HAT O 0
) O 0
, O 0
whereas O 0
the O 0
growth O 0
of O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
cells O 0
was O 0
inhibited O 0
and O 0
normal O 0
cells O 0
grew O 0
normally O 0
. O 0

Similarly O 0
in O 0
8 O 0
- O 0
azaguanine O 0
, O 0
6 O 0
- O 0
thioguanine O 0
, O 0
and O 0
8 O 0
- O 0
azahypoxanthine O 0
, O 0
the O 0
growth O 0
of O 0
the O 0
patients O 0
cells O 0
was O 0
intermediate O 0
between O 0
normal O 0
and O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
cells O 0
. O 0

These O 0
observations O 0
provide O 0
further O 0
evidence O 0
for O 0
genetic O 0
heterogeneity O 0
among O 0
patients O 0
with O 0
disorders O 0
in O 0
purine O 0
metabolism O 0
involving O 0
the O 0
HPRT O 0
gene O 0
. O 0

They O 0
document O 0
that O 0
this O 0
famous O 0
patient O 0
did O 0
not O 0
have O 0
the O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0

Localisation O 0
of O 0
the O 0
Becker B-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
gene O 0
on O 0
the O 0
short O 0
arm O 0
of O 0
the O 0
X O 0
chromosome O 0
by O 0
linkage O 0
to O 0
cloned O 0
DNA O 0
sequences O 0
. O 0

A O 0
linkage O 0
study O 0
in O 0
30 O 0
Becker B-Disease 1
muscular I-Disease 1
dystrophy I-Disease 1
( O 0
BMD B-Disease 1
) O 0
kindreds O 0
using O 0
three O 0
cloned O 0
DNA O 0
sequences O 0
from O 0
the O 0
X O 0
chromosome O 0
which O 0
demonstrate O 0
restriction O 0
fragment O 0
length O 0
polymorphisms O 0
( O 0
RFLPs O 0
) O 0
, O 0
suggests O 0
that O 0
the O 0
BMD B-Disease 1
gene O 0
is O 0
located O 0
on O 0
the O 0
short O 0
arm O 0
of O 0
the O 0
X O 0
chromosome O 0
, O 0
in O 0
the O 0
p21 O 0
region O 0
. O 0

The O 0
genes O 0
for O 0
Becker B-Disease 0
and I-Disease 0
Duchenne I-Disease 0
dystrophies I-Disease 0
must O 0
therefore O 0
be O 0
closely O 0
linked O 0
, O 0
if O 0
not O 0
allelic O 0
, O 0
and O 0
any O 0
future O 0
DNA O 0
probes O 0
found O 0
to O 0
be O 0
of O 0
practical O 0
use O 0
in O 0
one O 0
disorder O 0
should O 0
be O 0
equally O 0
applicable O 0
to O 0
the O 0
other O 0
. O 0

The O 0
linkage O 0
analysis O 0
also O 0
provides O 0
data O 0
on O 0
the O 0
frequency O 0
of O 0
recombination O 0
along O 0
the O 0
short O 0
arm O 0
of O 0
the O 0
X O 0
chromosome O 0
, O 0
and O 0
across O 0
the O 0
centromeric O 0
region O 0
. O 0
. O 0

Molecular O 0
evidence O 0
for O 0
new O 0
mutation O 0
at O 0
the O 0
hprt O 0
locus O 0
in O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
patients O 0
. O 0

Hypoxanthine O 0
- O 0
guanine O 0
phosphoribosyltransferase O 0
( O 0
HPRT O 0
; O 0
EC2 O 0
. O 0
4 O 0
. O 0
2 O 0
. O 0
8 O 0
) O 0
, O 0
which O 0
functions O 0
in O 0
the O 0
metabolic O 0
salvage O 0
of O 0
purines O 0
, O 0
is O 0
encoded O 0
by O 0
an O 0
X O 0
- O 0
linked O 0
gene O 0
in O 0
man O 0
. O 0

Partial O 0
HPRT B-Disease 0
deficiencies I-Disease 0
are O 0
associated O 0
with O 0
gouty B-Disease 0
arthritis I-Disease 0
, O 0
while O 0
absence O 0
of O 0
activity O 0
results O 0
in O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
( O 0
L B-Disease 0
- I-Disease 0
N I-Disease 0
) O 0
. O 0

L B-Disease 0
- I-Disease 0
N I-Disease 0
patients O 0
fail O 0
to O 0
reproduce O 0
and O 0
the O 0
heterozygous O 0
state O 0
appears O 0
to O 0
confer O 0
no O 0
selective O 0
advantage O 0
. O 0

Thus O 0
, O 0
Haldanes O 0
principle O 0
predicts O 0
that O 0
new O 0
mutations O 0
at O 0
the O 0
hprt O 0
locus O 0
must O 0
occur O 0
frequently O 0
in O 0
order O 0
for O 0
L B-Disease 1
- I-Disease 1
N I-Disease 1
syndrome I-Disease 1
to O 0
be O 0
maintained O 0
in O 0
the O 0
population O 0
. O 0

This O 0
constant O 0
introduction O 0
of O 0
new O 0
mutations O 0
would O 0
be O 0
expected O 0
to O 0
result O 0
in O 0
a O 0
heterogeneous O 0
collection O 0
of O 0
genetic B-Disease 1
lesions I-Disease 1
, O 0
some O 0
of O 0
which O 0
may O 0
be O 0
novel O 0
. O 0

As O 0
we O 0
report O 0
here O 0
, O 0
the O 0
mutations O 0
in O 0
the O 0
hprt O 0
gene O 0
of O 0
seven O 0
L B-Disease 0
- I-Disease 0
N I-Disease 0
patients O 0
, O 0
selected O 0
from O 0
an O 0
initial O 0
survey O 0
of O 0
28 O 0
patients O 0
, O 0
have O 0
been O 0
characterized O 0
and O 0
all O 0
were O 0
found O 0
to O 0
be O 0
distinctly O 0
different O 0
, O 0
as O 0
predicted O 0
. O 0

The O 0
origin O 0
of O 0
one O 0
unusual O 0
mutation O 0
has O 0
been O 0
identified O 0
by O 0
analysis O 0
of O 0
DNA O 0
from O 0
four O 0
generations O 0
of O 0
family O 0
members O 0
. O 0

Further O 0
molecular O 0
analysis O 0
of O 0
the O 0
origin O 0
of O 0
new O 0
mutations O 0
at O 0
the O 0
hprt O 0
locus O 0
should O 0
aid O 0
in O 0
resolving O 0
the O 0
issue O 0
of O 0
an O 0
apparent O 0
difference O 0
in O 0
the O 0
frequency O 0
of O 0
hprt O 0
mutations O 0
in O 0
males O 0
and O 0
females O 0

Allelic O 0
exclusion O 0
of O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
in O 0
platelets O 0
and O 0
T O 0
lymphocytes O 0
from O 0
a O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
carrier O 0
. O 0

An O 0
obligate O 0
carrier O 0
of O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
( O 0
WAS B-Disease 0
) O 0
who O 0
was O 0
also O 0
heterozygous O 0
for O 0
the O 0
A O 0
and O 0
B O 0
types O 0
of O 0
X O 0
- O 0
linked O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
was O 0
found O 0
. O 0

With O 0
her O 0
it O 0
became O 0
possible O 0
to O 0
determine O 0
whether O 0
allelic O 0
exclusion O 0
occurs O 0
in O 0
particular O 0
cell O 0
- O 0
types O 0
of O 0
the O 0
WAS B-Disease 0
carrier O 0
. O 0

If O 0
so O 0
, O 0
the O 0
remaining O 0
cells O 0
of O 0
a O 0
particular O 0
cell O 0
- O 0
type O 0
would O 0
express O 0
only O 0
the O 0
normal O 0
X O 0
chromosome O 0
and O 0
only O 0
one O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
isoenzyme O 0
would O 0
be O 0
demonstrable O 0
. O 0

This O 0
carrier O 0
had O 0
only O 0
the O 0
B O 0
isoenzyme O 0
of O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
in O 0
platelets O 0
and O 0
thymus O 0
- O 0
derived O 0
T O 0
lymphocytes O 0
, O 0
although O 0
both O 0
isoenzymes O 0
A O 0
and O 0
B O 0
were O 0
present O 0
in O 0
erythrocytes O 0
and O 0
neutrophils O 0
. O 0

These O 0
findings O 0
suggest O 0
that O 0
selection O 0
against O 0
the O 0
WAS B-Disease 0
gene O 0
occurs O 0
in O 0
platelets O 0
and O 0
thymus O 0
- O 0
derived O 0
T O 0
lymphocytes O 0
and O 0
that O 0
the O 0
defects O 0
associated O 0
with O 0
WAS B-Disease 0
expressed O 0
in O 0
these O 0
cell O 0
- O 0
types O 0
may O 0
be O 0
implicated O 0
in O 0
the O 0
genesis O 0
of O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
. O 0
. O 0

Complement B-Disease 0
deficiency I-Disease 0
and O 0
nephritis B-Disease 0
. O 0

A O 0
report O 0
of O 0
a O 0
family O 0
. O 0

A O 0
family O 0
is O 0
described O 0
in O 0
which O 0
three O 0
children O 0
had O 0
homozygous O 0
deficiency B-Disease 0
of I-Disease 0
C3 I-Disease 0
and O 0
in O 0
which O 0
both O 0
parents O 0
and O 0
two O 0
other O 0
children O 0
were O 0
heterozygous O 0
for O 0
the O 0
C3 O 0
null O 0
gene O 0
. O 0

One O 0
child O 0
with O 0
heterozygous O 0
C3 B-Disease 0
deficiency I-Disease 0
was O 0
found O 0
to O 0
have O 0
membranoproliferative O 0
glomerulonephritis B-Disease 0
; O 0
proteinuria B-Disease 1
and O 0
/ O 0
or O 0
microscopical O 0
haematuria B-Disease 0
was O 0
present O 0
in O 0
all O 0
three O 0
homozygous O 0
C3 B-Disease 0
- I-Disease 0
deficient I-Disease 0
children O 0
. O 0

All O 0
children O 0
with O 0
homozygous O 0
or O 0
heterozygous O 0
C3 B-Disease 0
deficiency I-Disease 0
were O 0
, O 0
to O 0
a O 0
varying O 0
degree O 0
, O 0
susceptible O 0
to O 0
infection O 0
. O 0

The O 0
only O 0
child O 0
of O 0
the O 0
family O 0
with O 0
normal O 0
complement O 0
had O 0
no O 0
increased O 0
risk O 0
of O 0
infection O 0
and O 0
no O 0
renal B-Disease 0
disease I-Disease 0
. O 0

This O 0
family O 0
study O 0
provides O 0
further O 0
support O 0
for O 0
the O 0
proposal O 0
that O 0
C3 B-Disease 0
deficiency I-Disease 0
predisposes O 0
to O 0
nephritis B-Disease 0
. O 0
. O 0

Heterogeneity O 0
of O 0
glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
deficiency I-Disease 0
in O 0
Algeria O 0
. O 0

Study O 0
in O 0
Northern O 0
Algeria O 0
with O 0
description O 0
of O 0
five O 0
new O 0
variants O 0
. O 0

Glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
) I-Disease 0
deficiency I-Disease 0
was O 0
found O 0
in O 0
3 O 0
. O 0

2 O 0
% O 0
of O 0
the O 0
male O 0
population O 0
living O 0
in O 0
the O 0
urban O 0
area O 0
of O 0
Algiers O 0
. O 0

The O 0
deficient O 0
subjects O 0
originated O 0
from O 0
multiple O 0
geographic O 0
regions O 0
of O 0
Northern O 0
Algeria O 0
, O 0
with O 0
prevalence O 0
of O 0
individuals O 0
of O 0
Berber O 0
- O 0
Kabyle O 0
origin O 0
. O 0

Red O 0
blood O 0
cell O 0
G6PD O 0
was O 0
partially O 0
purified O 0
and O 0
characterized O 0
in O 0
deficient O 0
males O 0
from O 0
17 O 0
families O 0
, O 0
and O 0
six O 0
different O 0
variants O 0
were O 0
found O 0
. O 0

Among O 0
them O 0
, O 0
only O 0
one O 0
, O 0
the O 0
Gd O 0
( O 0
- O 0
) O 0
Kabyle O 0
variant O 0
, O 0
had O 0
been O 0
previously O 0
described O 0
. O 0

It O 0
was O 0
detected O 0
in O 0
nine O 0
families O 0
. O 0

The O 0
other O 0
five O 0
variants O 0
were O 0
new O 0
Gd O 0
( O 0
- O 0
) O 0
Laghouat O 0
( O 0
four O 0
cases O 0
) O 0
, O 0
Gd O 0
( O 0
- O 0
) O 0
Blida O 0
( O 0
one O 0
case O 0
) O 0
, O 0
Gd O 0
( O 0
- O 0
) O 0
Thenia O 0
( O 0
one O 0
case O 0
) O 0
, O 0
Gd O 0
( O 0
- O 0
) O 0
Titteri O 0
( O 0
one O 0
case O 0
) O 0
, O 0
and O 0
Gd O 0
( O 0
- O 0
) O 0
Alger O 0
( O 0
two O 0
brothers O 0
) O 0
. O 0

Strikingly O 0
, O 0
the O 0
common O 0
Mediterranean O 0
variant O 0
was O 0
not O 0
found O 0
. O 0

G6PD B-Disease 0
deficiency I-Disease 0
is O 0
heterogeneous O 0
in O 0
northern O 0
Algeria O 0
where O 0
autochtonous O 0
variants O 0
seem O 0
to O 0
prevail O 0
. O 0

The O 0
Kabyle O 0
variant O 0
may O 0
be O 0
common O 0
in O 0
this O 0
country O 0
. O 0

Glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
deficiency I-Disease 0
inhibits O 0
in O 0
vitro O 0
growth O 0
of O 0
Plasmodium O 0
falciparum O 0
. O 0

Glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
; I-Disease 0
EC I-Disease 0
1 I-Disease 0
. I-Disease 0
1 I-Disease 0
. I-Disease 0
1 I-Disease 0
. I-Disease 0
49 I-Disease 0
) I-Disease 0
- I-Disease 0
deficient I-Disease 0
red O 0
blood O 0
cells O 0
from O 0
male O 0
hemizygotes O 0
and O 0
female O 0
heterozygotes O 0
from O 0
the O 0
island O 0
of O 0
Sardinia O 0
were O 0
studied O 0
for O 0
their O 0
ability O 0
to O 0
support O 0
growth O 0
in O 0
vitro O 0
of O 0
the O 0
malaria B-Disease 1
- O 0
causing O 0
organism O 0
Plasmodium O 0
falciparum O 0
. O 0

Parasite O 0
growth O 0
was O 0
approximately O 0
one O 0
- O 0
third O 0
of O 0
normal O 0
in O 0
both O 0
hemi O 0
- O 0
and O 0
heterozygotes O 0
for O 0
G6PD B-Disease 0
deficiency I-Disease 0
. O 0

In O 0
Sardinians O 0
with O 0
the O 0
beta O 0
0 O 0
- O 0
thalassemia O 0
trait O 0
, O 0
parasite O 0
growth O 0
was O 0
normal O 0
except O 0
when O 0
G6PD B-Disease 0
deficiency I-Disease 0
occurred O 0
together O 0
with O 0
the O 0
thalassemia B-Disease 0
trait O 0
. O 0

The O 0
data O 0
support O 0
the O 0
hypothesis O 0
that O 0
G6PD B-Disease 0
deficiency I-Disease 0
may O 0
confer O 0
a O 0
selective O 0
advantage O 0
in O 0
a O 0
malarious B-Disease 1
area O 0
; O 0
the O 0
female O 0
heterozygote O 0
may O 0
be O 0
at O 0
a O 0
particular O 0
advantage O 0
because O 0
resistance O 0
to O 0
malaria B-Disease 1
equals O 0
that O 0
of O 0
male O 0
hemizygotes O 0
, O 0
but O 0
the O 0
risk O 0
of O 0
fatal B-Disease 1
hemolysis I-Disease 1
may O 0
be O 0
less O 0
. O 0

However O 0
, O 0
more O 0
female O 0
heterozygotes O 0
must O 0
be O 0
studied O 0
to O 0
confirm O 0
this O 0
hypothesis O 0
. O 0

No O 0
protective O 0
effect O 0
of O 0
beta O 0
0 O 0
- O 0
thalassemia O 0
trait O 0
could O 0
be O 0
demonstrated O 0
in O 0
vitro O 0
. O 0

Bone O 0
marrow O 0
transplant O 0
in O 0
adrenoleukodystrophy B-Disease 1
. O 0

An O 0
allogeneic O 0
bone O 0
marrow O 0
transplant O 0
( O 0
BMT O 0
) O 0
from O 0
a O 0
normal O 0
HLA O 0
identical O 0
sibling O 0
donor O 0
was O 0
performed O 0
in O 0
a O 0
13 O 0
- O 0
year O 0
- O 0
old O 0
boy O 0
with O 0
rapidly O 0
progressive O 0
adrenoleukodystrophy B-Disease 1
( O 0
ALD B-Disease 0
) O 0
. O 0

Engraftment O 0
and O 0
complete O 0
hematologic O 0
recovery O 0
occurred O 0
within O 0
4 O 0
weeks O 0
, O 0
but O 0
neurologic B-Disease 0
deterioration I-Disease 0
continued O 0
. O 0

The O 0
patient O 0
died O 0
of O 0
an O 0
adenovirus B-Disease 0
infection I-Disease 0
141 O 0
days O 0
after O 0
BMT O 0
. O 0

ALD B-Disease 0
is O 0
characterized O 0
by O 0
abnormally O 0
high O 0
plasma O 0
levels O 0
of O 0
very O 0
long O 0
chain O 0
fatty O 0
acids O 0
( O 0
VLCFA O 0
) O 0
as O 0
a O 0
result O 0
of O 0
impaired O 0
capacity O 0
to O 0
degrade O 0
them O 0
. O 0

Ten O 0
days O 0
after O 0
BMT O 0
, O 0
the O 0
white O 0
blood O 0
cell O 0
VLCFA O 0
levels O 0
and O 0
enzyme O 0
activity O 0
became O 0
normal O 0
; O 0
after O 0
3 O 0
months O 0
, O 0
there O 0
was O 0
progressive O 0
reduction O 0
of O 0
plasma O 0
VLCFA O 0
to O 0
levels O 0
only O 0
slightly O 0
above O 0
normal O 0
. O 0
. O 0

[ O 0
Gd O 0
- O 0
allele O 0
distribution O 0
patterns O 0
in O 0
Azerbaijan O 0
. O 0
III O 0
. O 0
The O 0
identification O 0
of O 0
mutant O 0
forms O 0
of O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
] O 0

In O 0
28 O 0
families O 0
with O 0
G6PD B-Disease 0
deficiency I-Disease 0
living O 0
in O 0
3 O 0
settlements O 0
of O 0
Shekii O 0
district O 0
of O 0
Azerbaijan O 0
11 O 0
G6PD O 0
variants O 0
of O 0
II O 0
and O 0
III O 0
classes O 0
differing O 0
by O 0
kinetic O 0
properties O 0
were O 0
identified O 0
according O 0
WHO O 0
program O 0
. O 0

9 O 0
of O 0
them O 0
are O 0
characterized O 0
with O 0
the O 0
same O 0
electrophoretic O 0
mobility O 0
. O 0

Comparison O 0
of O 0
G6PD O 0
spectra O 0
in O 0
two O 0
subpopulations O 0
and O 0
in O 0
a O 0
mixed O 0
group O 0
permits O 0
to O 0
make O 0
a O 0
conclusion O 0
about O 0
existence O 0
of O 0
common O 0
and O 0
rare O 0
G6PD O 0
alleles O 0
in O 0
examined O 0
population O 0
. O 0

They O 0
distribute O 0
by O 0
gene O 0
drift O 0
supported O 0
by O 0
natural O 0
selection O 0
. O 0

Among O 0
7 O 0
samples O 0
of O 0
G6PD O 0
with O 0
normal O 0
and O 0
increased O 0
activity O 0
two O 0
new O 0
variants O 0
of O 0
IV O 0
class O 0
- O 0
- O 0
Nukha O 0
and O 0
Bash O 0
- O 0
Kungut O 0
- O 0
- O 0
were O 0
found O 0
. O 0
. O 0

Adrenoleukodystrophy B-Disease 0
: O 0
survey O 0
of O 0
303 O 0
cases O 0
: O 0
biochemistry O 0
, O 0
diagnosis O 0
, O 0
and O 0
therapy O 0
. O 0

Adrenoleukodystrophy B-Disease 0
( O 0
ALD B-Disease 0
) O 0
is O 0
a O 0
genetically O 0
determined O 0
disorder O 0
associated O 0
with O 0
progressive B-Disease 0
central I-Disease 0
demyelination I-Disease 1
and O 0
adrenal B-Disease 0
cortical I-Disease 0
insufficiency I-Disease 0
. O 0

All O 0
affected O 0
persons O 0
show O 0
increased O 0
levels O 0
of O 0
saturated O 0
unbranched O 0
very O 0
- O 0
long O 0
- O 0
chain O 0
fatty O 0
acids O 0
, O 0
particularly O 0
hexacosanoate O 0
( O 0
C26 O 0
0 O 0
) O 0
, O 0
because O 0
of O 0
impaired O 0
capacity O 0
to O 0
degrade O 0
these O 0
acids O 0
. O 0

This O 0
degradation O 0
normally O 0
takes O 0
place O 0
in O 0
a O 0
subcellular O 0
organelle O 0
called O 0
the O 0
peroxisome O 0
, O 0
and O 0
ALD B-Disease 0
, O 0
together O 0
with O 0
Zellwegers B-Disease 1
cerebrohepatorenal I-Disease 1
syndrome I-Disease 1
, O 0
is O 0
now O 0
considered O 0
to O 0
belong O 0
to O 0
the O 0
newly O 0
formed O 0
category O 0
of O 0
peroxisomal B-Disease 1
disorders I-Disease 1
. O 0

Biochemical O 0
assays O 0
permit O 0
prenatal O 0
diagnosis O 0
, O 0
as O 0
well O 0
as O 0
identification O 0
of O 0
most O 0
heterozygotes O 0
. O 0

We O 0
have O 0
identified O 0
303 O 0
patients O 0
with O 0
ALD B-Disease 0
in O 0
217 O 0
kindreds O 0
. O 0

These O 0
patients O 0
show O 0
a O 0
wide O 0
phenotypic O 0
variation O 0
. O 0

Sixty O 0
percent O 0
of O 0
patients O 0
had O 0
childhood O 0
ALD B-Disease 0
and O 0
17 O 0
% O 0
adrenomyeloneuropathy B-Disease 1
, O 0
both O 0
of O 0
which O 0
are O 0
X O 0
- O 0
linked O 0
, O 0
with O 0
the O 0
gene O 0
mapped O 0
to O 0
Xq28 O 0
. O 0

Neonatal B-Disease 0
ALD I-Disease 0
, O 0
a O 0
distinct O 0
entity O 0
with O 0
autosomal O 0
recessive O 0
inheritance O 0
and O 0
points O 0
of O 0
resemblance O 0
to O 0
Zellwegers B-Disease 0
syndrome I-Disease 0
, O 0
accounted O 0
for O 0
7 O 0
% O 0
of O 0
the O 0
cases O 0
. O 0

Although O 0
excess O 0
C26 O 0
0 O 0
in O 0
the O 0
brain O 0
of O 0
patients O 0
with O 0
ALD B-Disease 0
is O 0
partially O 0
of O 0
dietary O 0
origin O 0
, O 0
dietary O 0
C26 O 0
0 O 0
restriction O 0
did O 0
not O 0
produce O 0
clear O 0
benefit O 0
. O 0

Bone O 0
marrow O 0
transplant O 0
lowered O 0
the O 0
plasma O 0
C26 O 0
0 O 0
level O 0
but O 0
failed O 0
to O 0
arrest O 0
neurological O 0
progression O 0
. O 0
. O 0

Genetic O 0
polymorphism O 0
of O 0
G6PD O 0
in O 0
a O 0
Bulgarian O 0
population O 0
. O 0

Considerable O 0
genetic O 0
heterogeneity O 0
in O 0
G6PD O 0
was O 0
found O 0
in O 0
the O 0
Bulgarian O 0
population O 0
- O 0
14 O 0
G6PD O 0
variants O 0
isolated O 0
from O 0
117 O 0
hemizygous O 0
carriers O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
. O 0

Of O 0
these O 0
, O 0
G6PD O 0
Mediterranean O 0
type O 0
was O 0
a O 0
polymorphic O 0
variant O 0
and O 0
G6PD O 0
Corinth O 0
occurred O 0
with O 0
high O 0
frequency O 0
. O 0

Two O 0
new O 0
variants O 0
were O 0
identified O 0
- O 0
G6PD O 0
Rudosem O 0
and O 0
G6PD O 0
Nedelino O 0
. O 0

In O 0
a O 0
selected O 0
group O 0
of O 0
78 O 0
subjects O 0
with O 0
clinical O 0
manifestations O 0
, O 0
four O 0
variants O 0
were O 0
established O 0
G6PD O 0
Mediterranian O 0
, O 0
G6PD O 0
Corinth O 0
, O 0
G6PD O 0
Seattle O 0
and O 0
G6PD O 0
Ohut O 0
II O 0
. O 0
. O 0

Clinical O 0
use O 0
of O 0
DNA O 0
markers O 0
linked O 0
to O 0
the O 0
gene O 0
for O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
. O 0

Seventy O 0
families O 0
with O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
known O 0
to O 0
the O 0
Institute O 0
of O 0
Child O 0
Health O 0
fall O 0
into O 0
three O 0
categories O 0
with O 0
respect O 0
to O 0
potential O 0
linkage O 0
analysis O 0
with O 0
the O 0
X O 0
chromosome O 0
DNA O 0
markers O 0
RC8 O 0
and O 0
L1 O 0
. O 0

28 O 0
that O 0
bridge O 0
the O 0
DMD B-Disease 0
gene O 0
. O 0

Families O 0
in O 0
which O 0
there O 0
is O 0
at O 0
least O 0
one O 0
obligatory O 0
female O 0
heterozygote O 0
( O 0
n O 0
= O 0
13 O 0
) O 0
. O 0

Here O 0
prediction O 0
and O 0
exclusion O 0
of O 0
DMD B-Disease 0
gene O 0
transmission O 0
may O 0
be O 0
possible O 0
, O 0
the O 0
accuracy O 0
being O 0
dependent O 0
on O 0
the O 0
closeness O 0
of O 0
the O 0
linkage O 0
of O 0
the O 0
DNA O 0
marker O 0
( O 0
s O 0
) O 0
to O 0
the O 0
DMD B-Disease 0
gene O 0
; O 0
an O 0
illustrative O 0
case O 0
is O 0
reported O 0
. O 0

Families O 0
in O 0
which O 0
there O 0
is O 0
a O 0
single O 0
affected O 0
boy O 0
, O 0
who O 0
also O 0
has O 0
one O 0
or O 0
more O 0
healthy O 0
brothers O 0
( O 0
n O 0
= O 0
26 O 0
) O 0
. O 0

Given O 0
an O 0
informative O 0
restriction O 0
fragment O 0
length O 0
polymorphism O 0
( O 0
RFLP O 0
) O 0
, O 0
the O 0
probability O 0
that O 0
the O 0
boy O 0
represents O 0
a O 0
new O 0
mutation O 0
can O 0
be O 0
reassessed O 0
; O 0
it O 0
is O 0
also O 0
possible O 0
to O 0
exclude O 0
the O 0
DMD B-Disease 0
gene O 0
in O 0
a O 0
sister O 0
. O 0

Families O 0
with O 0
a O 0
single O 0
affected O 0
boy O 0
with O 0
no O 0
brother O 0
( O 0
n O 0
= O 0
30 O 0
) O 0
. O 0

Here O 0
exclusion O 0
of O 0
the O 0
DMD B-Disease 0
gene O 0
in O 0
a O 0
sister O 0
may O 0
be O 0
possible O 0
. O 0

Only O 0
in O 0
one O 0
family O 0
was O 0
there O 0
no O 0
possibility O 0
of O 0
useful O 0
linkage O 0
analysis O 0
. O 0

The O 0
linkage O 0
analysis O 0
required O 0
is O 0
described O 0
, O 0
and O 0
the O 0
need O 0
to O 0
check O 0
DMD B-Disease 0
families O 0
for O 0
informative O 0
RFLPs O 0
is O 0
stressed O 0
. O 0

Family O 0
studies O 0
in O 0
Bechterew B-Disease 1
' I-Disease 1
s I-Disease 1
syndrome I-Disease 1
( O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
) O 0
III O 0
. O 0

Genetics O 0
. O 0

The O 0
results O 0
of O 0
segregation O 0
analyses O 0
in O 0
75 O 0
families O 0
where O 0
the O 0
proband O 0
had O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
, O 0
are O 0
presented O 0
. O 0

Of O 0
the O 0
278 O 0
adult O 0
, O 0
living O 0
first O 0
degree O 0
relatives O 0
, O 0
approximately O 0
85 O 0
% O 0
cooperated O 0
in O 0
the O 0
study O 0
. O 0

Clinical O 0
and O 0
radiographical O 0
examinations O 0
were O 0
performed O 0
and O 0
HLA O 0
typing O 0
was O 0
conducted O 0
. O 0

The O 0
results O 0
were O 0
in O 0
agreement O 0
with O 0
our O 0
hypothesis O 0
that O 0
ankylosing B-Disease 0
spondylitis I-Disease 1
is O 0
part O 0
of O 0
a O 0
syndrome O 0
where O 0
different O 0
genetic O 0
factors O 0
interact O 0
. O 0

Such O 0
known O 0
factors O 0
are O 0
HLA O 0
B27 O 0
associated O 0
disease O 0
susceptibility O 0
, O 0
susceptibility O 0
to O 0
psoriatic B-Disease 1
arthropathy I-Disease 1
and O 0
susceptibility O 0
to O 0
entero B-Disease 0
- I-Disease 0
arthropathy I-Disease 0
. O 0

Radiographical O 0
sacro B-Disease 1
- I-Disease 1
iliitis I-Disease 1
was O 0
restricted O 0
to O 0
HLA O 0
B27 O 0
positive O 0
relatives O 0
, O 0
and O 0
was O 0
more O 0
frequently O 0
found O 0
in O 0
relatives O 0
to O 0
probands O 0
with O 0
psoriasis B-Disease 1
than O 0
in O 0
relatives O 0
to O 0
probands O 0
without O 0
psoriasis B-Disease 1
. O 0

Environmental O 0
factors O 0
( O 0
intestinal O 0
bacteria O 0
) O 0
are O 0
known O 0
to O 0
trigger O 0
the O 0
disease O 0
at O 0
least O 0
in O 0
some O 0
persons O 0
, O 0
and O 0
we O 0
have O 0
postulated O 0
that O 0
all O 0
or O 0
most O 0
of O 0
them O 0
have O 0
the O 0
predisposition O 0
to O 0
develop O 0
disease O 0
. O 0

Thus O 0
, O 0
the O 0
syndrome O 0
has O 0
a O 0
multifactorial O 0
etiology O 0
. O 0

The O 0
phenotypic O 0
expressions O 0
of O 0
the O 0
different O 0
genetic O 0
predispositions O 0
involved O 0
, O 0
include O 0
sacro B-Disease 1
- I-Disease 1
iliitis I-Disease 1
, O 0
psoriasis B-Disease 1
, O 0
acute B-Disease 1
anterior I-Disease 1
uveitis I-Disease 1
, O 0
peripheral O 0
arthropathy B-Disease 0
and O 0
inflammatory B-Disease 1
bowel I-Disease 1
disease I-Disease 1
. O 0

We O 0
suggest O 0
the O 0
descriptive O 0
name O 0
HEREDITARY B-Disease 1
MULTIFOCAL I-Disease 1
RELAPSING I-Disease 1
INFLAMMATION I-Disease 1
( O 0
HEMRI B-Disease 1
) O 0
for O 0
this O 0
syndrome O 0
. O 0

Ankylosing B-Disease 1
spondylitis I-Disease 1
, O 0
psoriatic B-Disease 1
arthropathy I-Disease 1
and O 0
entero B-Disease 0
- I-Disease 0
arthropathy I-Disease 0
may O 0
be O 0
regarded O 0
as O 0
clinical O 0
sub O 0
- O 0
types O 0
of O 0
the O 0
syndrome O 0
. O 0
. O 0

Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
and O 0
chromosome O 0
15 O 0
. O 0

A O 0
clinical O 0
discussion O 0
of O 0
20 O 0
cases O 0
. O 0

A O 0
chromosome B-Disease 0
15 I-Disease 0
anomaly I-Disease 0
was O 0
observed O 0
in O 0
12 O 0
of O 0
20 O 0
patients O 0
, O 0
17 O 0
of O 0
whom O 0
were O 0
clinically O 0
suspected O 0
of O 0
having O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
. O 0

The O 0
clinical O 0
features O 0
of O 0
eight O 0
cases O 0
with O 0
15q11 O 0
- O 0
12 O 0
deletion O 0
were O 0
very O 0
similar O 0
to O 0
those O 0
originally O 0
described O 0
in O 0
PWS B-Disease 0
. O 0

On O 0
the O 0
other O 0
hand O 0
, O 0
the O 0
group O 0
of O 0
normal O 0
karyotype O 0
patients O 0
is O 0
heterogeneous O 0
, O 0
and O 0
their O 0
features O 0
do O 0
not O 0
strictly O 0
correspond O 0
to O 0
the O 0
clinical O 0
definition O 0
of O 0
PWS B-Disease 0
. O 0

However O 0
, O 0
the O 0
hypothesis O 0
that O 0
PWS B-Disease 0
is O 0
associated O 0
with O 0
deletion O 0
of O 0
15q11 O 0
- O 0
12 O 0
can O 0
neither O 0
explain O 0
the O 0
apparently O 0
balanced O 0
translocations O 0
of O 0
chromosome O 0
15 O 0
nor O 0
account O 0
for O 0
the O 0
small O 0
supernumerary O 0
metacentric O 0
chromosomes O 0
corresponding O 0
to O 0
an O 0
isochromosome O 0
15 O 0
for O 0
band O 0
15q11 O 0
observed O 0
in O 0
some O 0
cases O 0
. O 0
. O 0

The O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
gene O 0
in O 0
North O 0
American O 0
Jewish O 0
populations O 0
: O 0
geographic O 0
variations O 0
and O 0
origin O 0
. O 0

From O 0
data O 0
collected O 0
in O 0
a O 0
North O 0
American O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
( O 0
TSD B-Disease 0
) O 0
heterozygote O 0
screening O 0
program O 0
, O 0
the O 0
TSD B-Disease 0
carrier O 0
frequency O 0
among O 0
46 O 0
, O 0
304 O 0
Jewish O 0
individuals O 0
was O 0
found O 0
to O 0
be O 0
. O 0

0324 O 0
( O 0
1 O 0
in O 0
31 O 0
individuals O 0
) O 0
. O 0

This O 0
frequency O 0
is O 0
consistent O 0
with O 0
earlier O 0
estimates O 0
based O 0
on O 0
TSD B-Disease 0
incidence O 0
data O 0
. O 0

TSD B-Disease 0
carrier O 0
frequencies O 0
were O 0
then O 0
examined O 0
by O 0
single O 0
country O 0
and O 0
single O 0
region O 0
of O 0
origin O 0
in O 0
28 O 0
, O 0
029 O 0
Jews O 0
within O 0
this O 0
sample O 0
for O 0
whom O 0
such O 0
data O 0
were O 0
available O 0
for O 0
analysis O 0
. O 0

Jews O 0
with O 0
Polish O 0
and O 0
/ O 0
or O 0
Russian O 0
ancestry O 0
constituted O 0
88 O 0
% O 0
of O 0
this O 0
sample O 0
and O 0
had O 0
a O 0
TSD B-Disease 0
carrier O 0
frequency O 0
of O 0
. O 0

0327 O 0
. O 0

No O 0
TSD B-Disease 0
carriers O 0
were O 0
observed O 0
among O 0
the O 0
166 O 0
Jews O 0
of O 0
Near O 0
Eastern O 0
origins O 0
. O 0

Relative O 0
to O 0
Jews O 0
of O 0
Polish O 0
and O 0
Russian O 0
origins O 0
, O 0
there O 0
was O 0
at O 0
least O 0
a O 0
twofold O 0
increase O 0
in O 0
the O 0
TSD B-Disease 0
carrier O 0
frequency O 0
in O 0
Jews O 0
of O 0
Austrian O 0
, O 0
Hungarian O 0
, O 0
and O 0
Czechoslovakian O 0
origins O 0
( O 0
P O 0
less O 0
than O 0
. O 0
005 O 0
) O 0
. O 0

These O 0
findings O 0
suggest O 0
that O 0
the O 0
TSD B-Disease 0
gene O 0
proliferated O 0
among O 0
the O 0
antecedents O 0
of O 0
modern O 0
Ashkenazi O 0
Jewry O 0
after O 0
the O 0
Second O 0
Diaspora O 0
( O 0
70 O 0
A O 0
. O 0
D O 0
. O 0
) O 0
and O 0
before O 0
their O 0
major O 0
migrations O 0
to O 0
regions O 0
of O 0
Poland O 0
and O 0
Russia O 0
( O 0
before O 0
1100 O 0
A O 0
. O 0
D O 0
. O 0
) O 0
. O 0

Human O 0
deficiency B-Disease 1
of I-Disease 1
the I-Disease 1
sixth I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
in O 0
a O 0
patient O 0
with O 0
meningococcal B-Disease 0
meningitis I-Disease 1
and O 0
no O 0
haemostasis B-Disease 1
abnormality I-Disease 1
. O 0

A O 0
case O 0
of O 0
human O 0
complete O 0
C6 B-Disease 1
deficiency I-Disease 1
is O 0
reported O 0
. O 0

The O 0
patient O 0
, O 0
a O 0
31 O 0
year O 0
old O 0
white O 0
male O 0
, O 0
was O 0
seen O 0
on O 0
the O 0
occasion O 0
of O 0
an O 0
isolated O 0
episode O 0
of O 0
meningococcal B-Disease 0
meningitis I-Disease 1
. O 0

Serum O 0
complement O 0
hemolytic O 0
and O 0
bactericidal O 0
activities O 0
were O 0
lacking O 0
and O 0
could O 0
be O 0
restored O 0
to O 0
normal O 0
by O 0
addition O 0
of O 0
appropriate O 0
amounts O 0
of O 0
purified O 0
C6 O 0
. O 0

No O 0
hemostatic B-Disease 0
abnormalities I-Disease 0
were O 0
observed O 0
. O 0
. O 0

Absence B-Disease 0
of I-Disease 0
the I-Disease 0
seventh I-Disease 0
component I-Disease 0
of I-Disease 0
complement I-Disease 0
in O 0
a O 0
patient O 0
with O 0
chronic B-Disease 0
meningococcemia I-Disease 0
presenting O 0
as O 0
vasculitis B-Disease 0
. O 0

A O 0
previously O 0
healthy O 0
40 O 0
- O 0
year O 0
- O 0
old O 0
man O 0
presenting O 0
with O 0
fever B-Disease 0
, O 0
arthritis B-Disease 0
, O 0
and O 0
cutaneous B-Disease 0
vasculitis I-Disease 0
was O 0
found O 0
to O 0
have O 0
chronic B-Disease 0
meningococcemia I-Disease 0
. O 0

Evaluation O 0
of O 0
his O 0
complement O 0
system O 0
showed O 0
an O 0
absence O 0
of O 0
functional O 0
and O 0
antigenic O 0
C7 O 0
, O 0
compatible O 0
with O 0
a O 0
complete O 0
deficiency B-Disease 1
of I-Disease 1
the I-Disease 1
seventh I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
. O 0

Study O 0
of O 0
the O 0
patients O 0
family O 0
spanning O 0
four O 0
generations O 0
showed O 0
heterozygous O 0
deficiency B-Disease 1
of I-Disease 1
C7 I-Disease 1
in O 0
five O 0
members O 0
. O 0

Chronic B-Disease 0
neisserial I-Disease 0
infection I-Disease 0
can O 0
be O 0
associated O 0
with O 0
C7 B-Disease 0
deficiency I-Disease 0
and O 0
must O 0
be O 0
distinguished O 0
from O 0
other O 0
causes O 0
of O 0
cutaneous B-Disease 0
vasculitis I-Disease 0
. O 0
. O 0

Familial B-Disease 1
discoid I-Disease 1
lupus I-Disease 1
erythematosus I-Disease 1
associated O 0
with O 0
heterozygote O 0
C2 B-Disease 1
deficiency I-Disease 1
. O 0

Two O 0
siblings O 0
with O 0
chronic B-Disease 1
discoid I-Disease 1
lupus I-Disease 1
erythematosus I-Disease 1
and O 0
several O 0
family O 0
members O 0
were O 0
found O 0
with O 0
heterozygous O 0
C2 B-Disease 1
deficiency I-Disease 1
. O 0

An O 0
association O 0
with O 0
histocompatibility O 0
markers O 0
HLA O 0
- O 0
B18 O 0
and O 0
HLA O 0
- O 0
Dw2 O 0
was O 0
demonstrated O 0
, O 0
and O 0
the O 0
slow O 0
allotype O 0
of O 0
factor O 0
B O 0
was O 0
present O 0
. O 0

Linkage O 0
studies O 0
in O 0
this O 0
family O 0
suggested O 0
a O 0
close O 0
linkage O 0
between O 0
the O 0
C2 B-Disease 1
deficiency I-Disease 1
gene O 0
and O 0
genes O 0
coding O 0
for O 0
B18 O 0
, O 0
Dw2 O 0
, O 0
and O 0
BfS O 0
antigens O 0
. O 0

One O 0
HLA O 0
- O 0
ACB O 0
/ O 0
DBf O 0
recombinant O 0
was O 0
observed O 0
showing O 0
closer O 0
linkage O 0
between O 0
HLA O 0
- O 0
D O 0
and O 0
Bf O 0
than O 0
between O 0
HLA O 0
- O 0
B O 0
and O 0
Bf O 0
. O 0
. O 0

Severe B-Disease 0
- I-Disease 0
glucose I-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
) I-Disease 0
deficiency I-Disease 0
associated O 0
with O 0
chronic O 1
hemolytic B-Disease 1
anemia I-Disease 1
, O 0
granulocyte B-Disease 0
dysfunction I-Disease 0
, O 0
and O 0
increased O 0
susceptibility O 0
to O 0
infections O 0
: O 0
description O 0
of O 0
a O 0
new O 0
molecular O 0
variant O 0
( O 0
G6PD O 0
Barcelona O 0
) O 0
. O 0

Molecular O 0
, O 0
kinetic O 0
, O 0
and O 0
functional O 0
studies O 0
were O 0
carried O 0
out O 0
on O 0
erythrocytes O 0
and O 0
leukocytes O 0
in O 0
a O 0
Spanish O 0
male O 0
with O 0
G6PD B-Disease 0
deficiency I-Disease 0
, O 0
congenital B-Disease 1
nonspherocytic I-Disease 1
hemolytic I-Disease 1
anemia I-Disease 1
( O 0
CNSHA B-Disease 0
) O 0
, O 0
and O 0
increased O 0
susceptibility O 0
to O 0
infections O 0
. O 0

G6PD O 0
activity O 0
was O 0
absent O 0
in O 0
patients O 0
red O 0
cells O 0
and O 0
was O 0
about O 0
2 O 0
% O 0
of O 0
normal O 0
in O 0
leukocytes O 0
. O 0

Molecular O 0
studies O 0
using O 0
standard O 0
methods O 0
( O 0
WHO O 0
, O 0
1967 O 0
) O 0
showed O 0
G6PD O 0
in O 0
the O 0
patient O 0
to O 0
have O 0
a O 0
slightly O 0
fast O 0
electrophoretic O 0
mobility O 0
at O 0
pH O 0
8 O 0
. O 0

0 O 0
with O 0
otherwise O 0
normal O 0
properties O 0
( O 0
heat O 0
stability O 0
at O 0
46 O 0
degrees O 0
C O 0
, O 0
apparent O 0
affinity O 0
for O 0
substrates O 0
, O 0
optimum O 0
pH O 0
, O 0
and O 0
utilization O 0
of O 0
substrate O 0
analogues O 0
) O 0
. O 0

Other O 0
tests O 0
showed O 0
the O 0
patients O 0
granulocytes O 0
to O 0
engulf O 0
latex O 0
particles O 0
normally O 0
, O 0
but O 0
to O 0
have O 0
impaired O 0
reduction O 0
of O 0
nitroblue O 0
tetrazolium O 0
and O 0
ferricytochrome O 0
- O 0
c O 0
as O 0
well O 0
as O 0
reduced O 0
iodination O 0
. O 0

Chemotaxis O 0
and O 0
random O 0
migration O 0
of O 0
the O 0
patients O 0
granulocytes O 0
were O 0
normal O 0
as O 0
were O 0
myeloperoxidase O 0
, O 0
leukocyte O 0
alkaline O 0
phosphatase O 0
( O 0
LAP O 0
) O 0
, O 0
and O 0
ultrastructural O 0
features O 0
. O 0

The O 0
molecular O 0
characteristics O 0
of O 0
G6PD O 0
in O 0
the O 0
patient O 0
differed O 0
from O 0
those O 0
of O 0
all O 0
previously O 0
reported O 0
variants O 0
associated O 0
with O 0
CNSHA B-Disease 0
, O 0
so O 0
the O 0
present O 0
variant O 0
was O 0
provisionally O 0
called O 0
G6PD O 0
Barcelona O 0
to O 0
distinguish O 0
it O 0
from O 0
other O 0
G6PD O 0
variants O 0
previously O 0
described O 0
. O 0

Possible O 0
mechanisms O 0
for O 0
the O 0
severe O 0
deficiency B-Disease 0
of I-Disease 0
G6PD I-Disease 0
in O 0
erythrocytes O 0
and O 0
granulocytes O 0
was O 0
investigated O 0
by O 0
studies O 0
on O 0
the O 0
immunologic O 0
specific O 0
activity O 0
of O 0
the O 0
mutant O 0
enzyme O 0
. O 0

Glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
deficiency I-Disease 0
in O 0
Papua O 0
New O 0
Guinea O 0
. O 0

The O 0
description O 0
of O 0
13 O 0
new O 0
variants O 0
. O 0

A O 0
total O 0
of O 0
362 O 0
males O 0
from O 0
various O 0
regions O 0
of O 0
Papua O 0
New O 0
Guinea O 0
were O 0
screened O 0
for O 0
red O 0
cell O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
activity O 0
. O 0

Twenty O 0
- O 0
six O 0
G6PD B-Disease 1
deficient I-Disease 1
individuals O 0
were O 0
identified O 0
. O 0

Biochemical O 0
characterization O 0
of O 0
G6PD O 0
purified O 0
from O 0
these O 0
subjects O 0
has O 0
revealed O 0
13 O 0
new O 0
variants O 0
and O 0
several O 0
copies O 0
of O 0
previously O 0
described O 0
forms O 0
of O 0
G6PD O 0
. O 0

This O 0
study O 0
illustrates O 0
the O 0
extreme O 0
heterogeneity O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
among O 0
the O 0
people O 0
of O 0
Papua O 0
New O 0
Guinea O 0
. O 0
. O 0

Heterogeneity O 0
of O 0
" O 0
Mediterranean O 0
type O 0
" O 0
glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
) I-Disease 0
deficiency I-Disease 0
in O 0
Spain O 0
and O 0
description O 0
of O 0
two O 0
new O 0
variants O 0
associated O 0
with O 0
favism B-Disease 1
. O 0

Glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
; O 0
EC O 0
1 O 0
. O 0

1 O 0
. O 0

1 O 0
. O 0

49 O 0
from O 0
thirty O 0
- O 0
six O 0
unrelated O 0
Spanish O 0
males O 0
was O 0
partially O 0
purified O 0
from O 0
blood O 0
, O 0
and O 0
the O 0
variants O 0
were O 0
characterized O 0
biochemically O 0
and O 0
electrophoretically O 0
according O 0
to O 0
the O 0
methods O 0
recommended O 0
by O 0
the O 0
world O 0
Health O 0
Organization O 0
. O 0

Subjects O 0
were O 0
from O 0
multiple O 0
geographic O 0
regions O 0
within O 0
Spain O 0
, O 0
and O 0
all O 0
suffered O 0
from O 0
hemolytic B-Disease 1
anemia I-Disease 1
, O 0
either O 0
acute O 0
( O 0
34 O 0
cases O 0
) O 0
or O 0
chronic O 0
nonspherocytic O 0
( O 0
2 O 0
cases O 0
) O 0
. O 0

Almost O 0
all O 0
the O 0
variants O 0
studied O 0
presented O 0
residual O 0
erythrocyte O 0
G6PD O 0
activity O 0
ranging O 0
from O 0
0 O 0
to O 0
10 O 0
% O 0
of O 0
normal O 0
, O 0
and O 0
five O 0
different O 0
mutants O 0
were O 0
responsible O 0
for O 0
the O 0
deficient O 0
phenotype O 0
. O 0

Three O 0
variants O 0
were O 0
similar O 0
to O 0
others O 0
previously O 0
described O 0
G6PD O 0
Mediterranean O 0
( O 0
11 O 0
cases O 0
) O 0
, O 0
G6PD O 0
Athens O 0
- O 0
like O 0
( O 0
3 O 0
cases O 0
) O 0
, O 0
and O 0
G6PD O 0
Union O 0
( O 0
2 O 0
cases O 0
) O 0
. O 0

The O 0
remaining O 0
variants O 0
were O 0
different O 0
from O 0
the O 0
numerous O 0
variants O 0
already O 0
reported O 0
and O 0
have O 0
been O 0
considered O 0
as O 0
new O 0
mutants O 0
. O 0

Provisionally O 0
they O 0
are O 0
called O 0
G6PD O 0
Betica O 0
( O 0
19 O 0
cases O 0
) O 0
and O 0
G6PD O 0
Menorca O 0
( O 0
1 O 0
case O 0
) O 0
. O 0

The O 0
present O 0
study O 0
constitutes O 0
the O 0
first O 0
attempt O 0
to O 0
characterize O 0
the O 0
deficient B-Disease 1
G6PD I-Disease 1
variants O 0
found O 0
in O 0
Spain O 0
and O 0
supplies O 0
new O 0
data O 0
on O 0
the O 0
relationship O 0
between O 0
molecular O 0
characteristics O 0
of O 0
deficient O 0
variants O 0
and O 0
their O 0
clinical O 0
manifestations O 0
. O 0

The O 0
most O 0
important O 0
findings O 0
can O 0
be O 0
summarized O 0
as O 0
follows O 0
( O 0
1 O 0
) O 0
The O 0
Spanish O 0
population O 0
is O 0
characterized O 0
by O 0
an O 0
important O 0
heterogeneity O 0
in O 0
G6PD B-Disease 0
deficiency I-Disease 0
. O 0

( O 0
2 O 0
) O 0
Although O 0
G6PD O 0
Mediterranean O 0
is O 0
very O 0
frequent O 0
, O 0
it O 0
presents O 0
a O 0
relatively O 0
high O 0
degree O 0
of O 0
polymorphism O 0
. O 0

( O 0
3 O 0
) O 0
Favism B-Disease 1
has O 0
been O 0
observed O 0
associated O 0
with O 0
all O 0
kinds O 0
of O 0
variants O 0
described O 0
here O 0
. O 0

( O 0
4 O 0
) O 0
G6PD O 0
Betica O 0
, O 0
which O 0
is O 0
the O 0
most O 0
frequent O 0
variant O 0
found O 0
in O 0
subjects O 0
of O 0
Southern O 0
Spanish O 0
origin O 0
, O 0
has O 0
been O 0
observed O 0
associated O 0
with O 0
favism B-Disease 1
in O 0
all O 0
cases O 0
except O 0
one O 0
. O 0

A O 0
new O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
variant O 0
( O 0
G6PD O 0
Nagano O 0
) O 0
associated O 0
with O 0
congenital B-Disease 0
hemolytic I-Disease 1
anemia I-Disease 1
. O 0

A O 0
new O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
variant O 0
associated O 0
with O 0
chronic B-Disease 0
nonspherocytic I-Disease 0
hemolytic I-Disease 1
anemia I-Disease 1
was O 0
reported O 0
. O 0

The O 0
patient O 0
, O 0
a O 0
6 O 0
- O 0
year O 0
- O 0
old O 0
Japanese O 0
male O 0
, O 0
was O 0
noticed O 0
to O 0
have O 0
hemolytic B-Disease 1
anemia I-Disease 1
soon O 0
after O 0
birth O 0
, O 0
and O 0
a O 0
diagnosis O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
was O 0
made O 0
at O 0
the O 0
age O 0
of O 0
2 O 0
. O 0

He O 0
had O 0
episodes O 0
of O 0
hemolytic B-Disease 0
crisis I-Disease 0
several O 0
times O 0
after O 0
upper B-Disease 1
respiratory I-Disease 1
infection I-Disease 1
. O 0

G6PD O 0
activity O 0
of O 0
the O 0
patient O 0
was O 0
5 O 0
. O 0

5 O 0
% O 0
of O 0
normal O 0
. O 0

The O 0
enzymatic O 0
characteristics O 0
were O 0
examined O 0
when O 0
he O 0
was O 0
5 O 0
years O 0
old O 0
, O 0
and O 0
his O 0
G6PD O 0
showed O 0
faster O 0
- O 0
than O 0
- O 0
normal O 0
electrophoretic O 0
mobility O 0
, O 0
low O 0
Km O 0
G6P O 0
, O 0
high O 0
Km O 0
NADP O 0
, O 0
low O 0
Ki O 0
NADPH O 0
, O 0
normal O 0
utilization O 0
of O 0
substrate O 0
analogues O 0
, O 0
heat O 0
instability O 0
, O 0
and O 0
a O 0
normal O 0
pH O 0
optimum O 0
curve O 0
. O 0

From O 0
these O 0
results O 0
, O 0
this O 0
was O 0
considered O 0
to O 0
be O 0
a O 0
new O 0
variant O 0
and O 0
was O 0
designated O 0
G6PD O 0
Nagano O 0
. O 0

Infection O 0
- O 0
induced O 0
hemolysis B-Disease 1
and O 0
chronic B-Disease 1
hemolytic I-Disease 1
anemia I-Disease 1
seem O 0
to O 0
be O 0
due O 0
to O 0
markedly O 0
impaired O 0
enzyme O 0
activity O 0
and O 0
thermal O 0
instability O 0
. O 0

Heterozygous O 0
C2 B-Disease 0
- I-Disease 0
deficiency I-Disease 0
and O 0
myasthenia B-Disease 1
gravis I-Disease 1
. O 0

Complement B-Disease 0
deficiency I-Disease 0
states O 0
in O 0
myasthenia B-Disease 1
gravis I-Disease 1
( O 0
MG B-Disease 0
) O 0
have O 0
not O 0
been O 0
reported O 0
previously O 0
. O 0

We O 0
describe O 0
a O 0
19 O 0
- O 0
year O 0
- O 0
old O 0
woman O 0
with O 0
typical O 0
MG B-Disease 0
and O 0
heterozygous O 0
C2 B-Disease 1
deficiency I-Disease 1
, O 0
along O 0
with O 0
HLA O 0
typing O 0
of O 0
the O 0
patient O 0
and O 0
her O 0
immediate O 0
family O 0
. O 0
. O 0

Adrenoleukodystrophy B-Disease 0
: O 0
increased O 0
plasma O 0
content O 0
of O 0
saturated O 0
very O 0
long O 0
chain O 0
fatty O 0
acids O 0
. O 0

With O 0
a O 0
new O 0
method O 0
we O 0
measured O 0
the O 0
saturated O 0
very O 0
long O 0
chain O 0
fatty O 0
acids O 0
in O 0
the O 0
plasma O 0
of O 0
adrenoleukodystrophy B-Disease 1
( O 0
ALD B-Disease 0
) O 0
hemizygotes O 0
, O 0
ALD B-Disease 0
heterozygotes O 0
, O 0
and O 0
controls O 0
. O 0

ALD B-Disease 0
hemizygotes O 0
showed O 0
increased O 0
levels O 0
of O 0
hexacosanoate O 0
( O 0
C26 O 0
fatty O 0
acid O 0
) O 0
which O 0
represented O 0
0 O 0
. O 0

081 O 0
+ O 0
/ O 0
- O 0
0 O 0
. O 0

0066 O 0
% O 0
( O 0
SEM O 0
) O 0
of O 0
total O 0
fatty O 0
acids O 0
, O 0
compared O 0
to O 0
0 O 0
. O 0

015 O 0
+ O 0
/ O 0
- O 0
0 O 0
. O 0

0032 O 0
% O 0
in O 0
the O 0
controls O 0
. O 0

C25 O 0
, O 0
C24 O 0
, O 0
and O 0
C23 O 0
fatty O 0
acids O 0
were O 0
also O 0
increased O 0
, O 0
but O 0
the O 0
C22 O 0
and O 0
C20 O 0
fatty O 0
acids O 0
were O 0
normal O 0
. O 0

C26 O 0
levels O 0
were O 0
also O 0
increased O 0
in O 0
most O 0
ALD B-Disease 0
heterozygotes O 0
, O 0
with O 0
a O 0
mean O 0
level O 0
0 O 0
. O 0

057 O 0
+ O 0
/ O 0
- O 0
0 O 0
. O 0

0063 O 0
% O 0
of O 0
total O 0
fatty O 0
acids O 0
. O 0

The O 0
technique O 0
can O 0
be O 0
used O 0
for O 0
diagnosis O 0
and O 0
carrier O 0
identification O 0
, O 0
and O 0
in O 0
the O 0
evaluation O 0
of O 0
therapy O 0
. O 0

Abnormal O 0
high O 0
density O 0
lipoproteins O 0
in O 0
cerebrotendinous B-Disease 1
xanthomatosis I-Disease 1
. O 0

The O 0
plasma O 0
lipoprotein O 0
profiles O 0
and O 0
high O 0
density O 0
lipoproteins O 0
( O 0
HDL O 0
) O 0
were O 0
characterized O 0
in O 0
patients O 0
with O 0
the O 0
genetic B-Disease 1
disease I-Disease 1
cerebrotendinous B-Disease 0
xanthomatosis I-Disease 0
( O 0
CTX B-Disease 0
) O 0
. O 0

Abnormalities B-Disease 0
in I-Disease 0
the I-Disease 0
HDL I-Disease 0
may O 0
contribute O 0
to O 0
their O 0
increased O 0
atherogenesis O 1
and O 0
excessive O 0
deposits O 0
of O 0
tissue O 0
sterols O 0
in O 0
the O 0
presence O 0
of O 0
low O 0
or O 0
low O 0
- O 0
normal O 0
concentrations O 0
of O 0
plasma O 0
cholesterol O 0
( O 0
165 O 0
+ O 0
/ O 0
- O 0
25 O 0
mg O 0
/ O 0
dl O 0
) O 0
and O 0
low O 0
density O 0
lipoproteins O 0
( O 0
LDL O 0
) O 0
. O 0

The O 0
mean O 0
HDL O 0
- O 0
cholesterol O 0
concentration O 0
in O 0
the O 0
CTX B-Disease 0
plasmas O 0
was O 0
14 O 0
. O 0

5 O 0
+ O 0
/ O 0
- O 0
3 O 0
. O 0

2 O 0
mg O 0
/ O 0
dl O 0
, O 0
about O 0
one O 0
- O 0
third O 0
the O 0
normal O 0
value O 0
. O 0

The O 0
low O 0
HDL O 0
- O 0
cholesterol O 0
reflects O 0
a O 0
low O 0
concentration O 0
and O 0
an O 0
abnormal O 0
lipid O 0
composition O 0
of O 0
the O 0
plasma O 0
HDL O 0
. O 0

Relative O 0
to O 0
normal O 0
HDL O 0
, O 0
the O 0
cholesteryl O 0
esters O 0
are O 0
low O 0
, O 0
free O 0
cholesterol O 0
and O 0
phospholipids O 0
essentially O 0
normal O 0
, O 0
and O 0
triglycerides O 0
increased O 0
. O 0

The O 0
ratio O 0
of O 0
apoprotein O 0
( O 0
apo O 0
) O 0
to O 0
total O 0
cholesterol O 0
in O 0
the O 0
HDL O 0
of O 0
CTX B-Disease 0
was O 0
two O 0
to O 0
three O 0
times O 0
greater O 0
than O 0
normal O 0
. O 0

In O 0
the O 0
CTX B-Disease 0
HDL O 0
, O 0
the O 0
ratio O 0
of O 0
apoAI O 0
to O 0
apoAII O 0
was O 0
high O 0
, O 0
the O 0
proportion O 0
of O 0
apoC O 0
low O 0
, O 0
and O 0
a O 0
normally O 0
minor O 0
form O 0
of O 0
apoAI O 0
increased O 0
relative O 0
to O 0
other O 0
forms O 0
. O 0

The O 0
HDL O 0
in O 0
electron O 0
micrographs O 0
appeared O 0
normal O 0
morphologically O 0
and O 0
in O 0
particle O 0
size O 0
. O 0

The O 0
abnormalities O 0
in O 0
lipoprotein O 0
distribution O 0
profile O 0
and O 0
composition O 0
of O 0
the O 0
plasma O 0
HDL O 0
result O 0
from O 0
metabolic O 0
defects O 0
that O 0
are O 0
not O 0
understood O 0
but O 0
may O 0
be O 0
linked O 0
to O 0
the O 0
genetic B-Disease 1
defect I-Disease 1
in O 0
bile O 0
acid O 0
synthesis O 0
in O 0
CTX B-Disease 0
. O 0

As O 0
a O 0
consequence O 0
, O 0
it O 0
is O 0
probable O 0
that O 0
the O 0
normal O 0
functions O 0
of O 0
the O 0
HDL O 0
, O 0
possibly O 0
including O 0
modulation O 0
of O 0
LDL O 0
- O 0
cholesterol O 0
uptake O 0
and O 0
the O 0
removal O 0
of O 0
excess O 0
cholesterol O 0
from O 0
peripheral O 0
tissues O 0
, O 0
are O 0
perturbed O 0
significantly O 0
in O 0
this O 0
disease O 0
. O 0

Genetics O 0
of O 0
cerebrotendinous B-Disease 1
xanthomatosis I-Disease 1
( O 0
CTX B-Disease 0
) O 0
: O 0
an O 0
autosomal O 0
recessive O 0
trait O 0
with O 0
high O 0
gene O 0
frequency O 0
in O 0
Sephardim O 0
of O 0
Moroccan O 0
origin O 0
. O 0

We O 0
described O 0
6 O 0
patients O 0
( O 0
from O 0
3 O 0
families O 0
) O 0
affected O 0
with O 0
cerebrotendinous B-Disease 1
xanthomatosis I-Disease 1
( O 0
CTX B-Disease 0
) O 0
. O 0

All O 0
are O 0
Sephardic O 0
Jews O 0
of O 0
Moroccan O 0
extraction O 0
. O 0

In O 0
view O 0
of O 0
the O 0
small O 0
number O 0
of O 0
CTX B-Disease 0
patients O 0
diagnosed O 0
in O 0
the O 0
world O 0
( O 0
a O 0
total O 0
of O 0
50 O 0
including O 0
our O 0
6 O 0
patients O 0
) O 0
, O 0
we O 0
are O 0
probably O 0
dealing O 0
with O 0
an O 0
ethnic O 0
subgroup O 0
with O 0
a O 0
high O 0
CTX O 0
gene O 0
frequency O 0
, O 0
which O 0
we O 0
have O 0
estimated O 0
to O 0
be O 0
1 O 0
/ O 0
108 O 0
. O 0

Since O 0
there O 0
are O 0
differences O 0
in O 0
expression O 0
in O 0
this O 0
disease O 0
, O 0
we O 0
recommend O 0
cholestanol O 0
study O 0
in O 0
cases O 0
of O 0
undiagnosed O 0
cataract B-Disease 0
or O 0
tendinous B-Disease 0
xanthomas I-Disease 0
in O 0
childhood O 0
or O 0
early O 0
adolescence O 0
. O 0

The O 0
diagnosis O 0
in O 0
CTX B-Disease 0
is O 0
important O 0
not O 0
only O 0
for O 0
genetic O 0
counseling O 0
, O 0
but O 0
also O 0
in O 0
veiw O 0
of O 0
possible O 0
treatment O 0
. O 0
. O 0

New O 0
genetic O 0
variants O 0
of O 0
glucose O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
in O 0
Italy O 0
. O 0

Six O 0
new O 0
variants O 0
of O 0
human O 0
erythrocyte O 0
G6PD O 0
have O 0
been O 0
characterized O 0
. O 0

All O 0
of O 0
them O 0
were O 0
found O 0
in O 0
Italian O 0
males O 0
and O 0
all O 0
were O 0
associated O 0
with O 0
enzyme B-Disease 0
deficiency I-Disease 0
, O 0
but O 0
only O 0
two O 0
with O 0
signs O 0
of O 0
haemolysis B-Disease 0
. O 0

These O 0
and O 0
other O 0
variants O 0
reported O 0
in O 0
the O 0
literature O 0
, O 0
which O 0
must O 0
thus O 0
far O 0
be O 0
regarded O 0
as O 0
sporadic O 0
, O 0
are O 0
found O 0
to O 0
map O 0
in O 0
parts O 0
of O 0
Italy O 0
where O 0
common O 0
types O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
are O 0
also O 0
prevalent O 0
. O 0
. O 0

Variants O 0
of O 0
erythrocyte O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
( O 0
G6PD O 0
) O 0
in O 0
Bulgarian O 0
populations O 0
. O 0

Ten O 0
variants O 0
of O 0
erythrocyte O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
were O 0
identified O 0
in O 0
22 O 0
patients O 0
with O 0
G6PD B-Disease 0
deficiency I-Disease 0
from O 0
three O 0
districts O 0
of O 0
Bulgaria O 0
. O 0

Corinth O 0
- O 0
like O 0
and O 0
Fayoum O 0
- O 0
like O 0
variants O 0
were O 0
the O 0
most O 0
frequent O 0
; O 0
Mediterranean O 0
, O 0
Ohut O 0
II O 0
, O 0
Kilgore O 0
, O 0
Boston O 0
, O 0
Poznan O 0
, O 0
and O 0
Panay O 0
variants O 0
and O 0
two O 0
new O 0
variants O 0
, O 0
Petrich O 0
and O 0
Gotze O 0
Delchev O 0
, O 0
were O 0
each O 0
found O 0
in O 0
one O 0
or O 0
two O 0
carriers O 0
. O 0

No O 0
correlation O 0
was O 0
revealed O 0
between O 0
clinical O 0
and O 0
biochemical O 0
polymorphism O 0
. O 0
. O 0

Nephropathy B-Disease 0
in O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
. O 0

Nephropathy B-Disease 0
was O 0
detected O 0
in O 0
five O 0
of O 0
32 O 0
patients O 0
with O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
who O 0
were O 0
participating O 0
in O 0
a O 0
study O 0
of O 0
transfer O 0
factor O 0
( O 0
TF O 0
) O 0
therapy O 0
. O 0

In O 0
two O 0
patients O 0
, O 0
nephropathy B-Disease 1
was O 0
present O 0
before O 0
TF O 0
and O 0
did O 0
not O 0
appear O 0
changed O 0
by O 0
TF O 0
therapy O 0
. O 0

One O 0
of O 0
these O 0
patients O 0
subsequently O 0
developed O 0
progressive O 0
renal B-Disease 0
failure I-Disease 0
requiring O 0
dialysis O 0
beginning O 0
5 O 0
1 O 0
/ O 0
2 O 0
years O 0
after O 0
TF O 0
therapy O 0
. O 0

In O 0
two O 0
patients O 0
, O 0
decreased O 0
renal O 0
function O 0
appeared O 0
very O 0
soon O 0
after O 0
the O 0
administration O 0
of O 0
TF O 0
. O 0

One O 0
patient O 0
showed O 0
gradually O 0
decreasing O 0
renal O 0
function O 0
beginning O 0
after O 0
two O 0
years O 0
of O 0
TF O 0
therapy O 0
. O 0

An O 0
additional O 0
patient O 0
was O 0
identified O 0
who O 0
died O 0
with O 0
renal B-Disease 0
failure I-Disease 0
without O 0
having O 0
received O 0
TF O 0
. O 0

The O 0
results O 0
suggest O 0
that O 0
renal B-Disease 0
failure I-Disease 0
occurs O 0
in O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
more O 0
frequently O 0
than O 0
generally O 0
recognized O 0
and O 0
that O 0
administration O 0
of O 0
TF O 0
may O 0
precipitate O 0
or O 0
accelerate O 0
the O 0
renal B-Disease 0
disease I-Disease 0
in O 0
patients O 0
with O 0
this O 0
syndrome O 0
. O 0
. O 0

Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
: O 0
cellular O 0
impairments O 0
and O 0
their O 0
implication O 0
for O 0
carrier O 0
detection O 0
. O 0

A O 0
family O 0
in O 0
which O 0
two O 0
male O 0
siblings O 0
were O 0
affected O 0
with O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
( O 0
WAS B-Disease 0
) O 0
was O 0
studied O 0
using O 0
G O 0
- O 0
6 O 0
- O 0
PD O 0
isoenzymes O 0
as O 0
an O 0
X O 0
- O 0
linked O 0
marker O 0
in O 0
order O 0
to O 0
investigate O 0
the O 0
nature O 0
of O 0
cellular O 0
abnormalities O 0
. O 0

Isolated O 0
peripheral O 0
blood O 0
cell O 0
types O 0
from O 0
the O 0
doubly O 0
heterozygous O 0
mother O 0
of O 0
the O 0
affected O 0
males O 0
seemingly O 0
failed O 0
to O 0
express O 0
the O 0
G O 0
- O 0
6 O 0
- O 0
PD O 0
allele O 0
in O 0
cis O 0
position O 0
with O 0
the O 0
WAS B-Disease 0
allele O 0
while O 0
her O 0
cultured O 0
skin O 0
fibroblasts O 0
expressed O 0
both O 0
G O 0
- O 0
6 O 0
- O 0
PD O 0
alleles O 0
. O 0

Additionally O 0
, O 0
a O 0
histogram O 0
analysis O 0
of O 0
platelet O 0
size O 0
revealed O 0
a O 0
single O 0
population O 0
of O 0
abnormally O 0
small O 0
platelets O 0
in O 0
the O 0
affected O 0
propositus O 0
, O 0
whereas O 0
the O 0
heterozygous O 0
mother O 0
had O 0
no O 0
appreciable O 0
small O 0
platelet O 0
subpopulation O 0
. O 0

In O 0
vitro O 0
culture O 0
of O 0
hemopoietic O 0
progenitor O 0
cells O 0
of O 0
the O 0
heterozygous O 0
mother O 0
showed O 0
that O 0
the O 0
majority O 0
of O 0
progenitor O 0
cells O 0
did O 0
not O 0
express O 0
the O 0
WAS B-Disease 0
allele O 0
. O 0

However O 0
, O 0
a O 0
small O 0
number O 0
of O 0
cells O 0
expressing O 0
the O 0
G O 0
- O 0
6 O 0
- O 0
PD O 0
type O 0
linked O 0
with O 0
the O 0
WAS B-Disease 0
allele O 0
were O 0
detected O 0
. O 0

The O 0
proportion O 0
of O 0
the O 0
latter O 0
progenitors O 0
was O 0
significantly O 0
higher O 0
among O 0
more O 0
primitive O 0
progenitors O 0
( O 0
those O 0
giving O 0
rise O 0
to O 0
later O 0
appearing O 0
colonies O 0
) O 0
. O 0

This O 0
observation O 0
suggests O 0
that O 0
selection O 0
against O 0
cells O 0
expressing O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
defect I-Disease 1
takes O 0
place O 0
in O 0
the O 0
hemopoietic O 0
system O 0
of O 0
the O 0
heterozygous O 0
female O 0
and O 0
offers O 0
a O 0
possible O 0
means O 0
of O 0
carrier O 0
detection O 0
in O 0
some O 0
women O 0
. O 0

Linkage O 0
studies O 0
in O 0
this O 0
family O 0
revealed O 0
one O 0
example O 0
of O 0
probable O 0
recombination O 0
between O 0
the O 0
loci O 0
for O 0
WAS B-Disease 0
and O 0
G O 0
- O 0
6 O 0
- O 0
PD O 0
among O 0
three O 0
informative O 0
subjects O 0
, O 0
suggesting O 0
that O 0
these O 0
two O 0
loci O 0
may O 0
not O 0
be O 0
closely O 0
linked O 0
on O 0
the O 0
X O 0
- O 0
chromosome O 0
. O 0
. O 0

A O 0
new O 0
CT O 0
pattern O 0
in O 0
adrenoleukodystrophy B-Disease 1
. O 0

A O 0
new O 0
CT O 0
pattern O 0
was O 0
observed O 0
in O 0
2 O 0
patients O 0
with O 0
adrenoleukodystrophy B-Disease 1
( O 0
ALD B-Disease 0
) O 0
. O 0

This O 0
pattern O 0
, O 0
which O 0
the O 0
authors O 0
call O 0
Type O 0
II O 0
, O 0
is O 0
characterized O 0
by O 0
the O 0
absence O 0
of O 0
posterior O 0
periventricular O 0
areas O 0
of O 0
decreased O 0
attenuation O 0
around O 0
the O 0
trigone O 0
on O 0
non O 0
- O 0
contrast O 0
scans O 0
after O 0
contrast O 0
infusion O 0
, O 0
however O 0
, O 0
there O 0
is O 0
striking O 0
enhancement O 0
of O 0
various O 0
white O 0
- O 0
matter O 0
structures O 0
( O 0
tracts O 0
or O 0
fiber O 0
systems O 0
) O 0
such O 0
as O 0
the O 0
internal O 0
capsules O 0
, O 0
corpus O 0
callosum O 0
, O 0
corona O 0
radiata O 0
, O 0
forceps O 0
major O 0
, O 0
and O 0
cerebral O 0
peduncles O 0
. O 0

This O 0
is O 0
different O 0
from O 0
numerous O 0
previous O 0
descriptions O 0
of O 0
the O 0
CT O 0
pattern O 0
in O 0
ALD B-Disease 0
. O 0

Type B-Disease 1
II I-Disease 1
ALD I-Disease 1
does O 0
not O 0
appear O 0
to O 0
have O 0
been O 0
seen O 0
in O 0
any O 0
other O 0
leukoencephalopathy B-Disease 1
and O 0
is O 0
probably O 0
specific O 0
for O 0
a O 0
phenotypic O 0
variant O 0
or O 0
an O 0
evolving O 0
stage O 0
of O 0
ALD B-Disease 0
. O 0
. O 0

Further O 0
evidence O 0
for O 0
heterogeneity O 0
of O 0
glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
deficiency I-Disease 0
in O 0
Papua O 0
New O 0
Guinea O 0
. O 0

Four O 0
new O 0
G6PD O 0
variants O 0
have O 0
been O 0
characterized O 0
in O 0
individuals O 0
from O 0
Papua O 0
New O 0
Guinea O 0
. O 0

This O 0
study O 0
demonstrates O 0
that O 0
the O 0
previously O 0
reported O 0
Markham O 0
variant O 0
and O 0
the O 0
newly O 0
characterized O 0
Salata O 0
variant O 0
may O 0
be O 0
widely O 0
distributed O 0
in O 0
Papua O 0
New O 0
Guinea O 0
. O 0

Th O 0
data O 0
presented O 0
here O 0
together O 0
with O 0
those O 0
of O 0
previously O 0
published O 0
studies O 0
demonstrate O 0
a O 0
degree O 0
of O 0
heterogeneity O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
that O 0
is O 0
much O 0
higher O 0
than O 0
that O 0
in O 0
other O 0
regions O 0
of O 0
the O 0
world O 0
where O 0
G6PD B-Disease 0
deficiency I-Disease 0
is O 0
common O 0
. O 0
. O 0

Increased O 0
incidence O 0
of O 0
cataracts B-Disease 1
in O 0
male O 0
subjects O 0
deficient B-Disease 0
in I-Disease 0
glucose I-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
. O 0

Glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
) I-Disease 0
deficiency I-Disease 0
in O 0
RBCs O 0
was O 0
found O 0
significantly O 0
more O 0
frequently O 0
in O 0
210 O 0
male O 0
cataractous B-Disease 1
patients O 0
than O 0
in O 0
672 O 0
control O 0
subjects O 0
of O 0
Sardinian O 0
origin O 0
. O 0

The O 0
frequency O 0
of O 0
the O 0
deficiency O 0
was O 0
increasingly O 0
higher O 0
in O 0
presenile O 0
cataracts B-Disease 1
. O 0

In O 0
the O 0
G6PD B-Disease 1
- I-Disease 1
deficient I-Disease 1
group O 0
, O 0
the O 0
incidence O 0
of O 0
cortical B-Disease 0
and I-Disease 0
total I-Disease 0
cataracts I-Disease 1
was O 0
also O 0
increased O 0
. O 0

It O 0
is O 0
suggested O 0
that O 0
decrease O 0
of O 0
the O 0
G6PD O 0
activity O 0
in O 0
the O 0
lens O 0
, O 0
which O 0
accompanies O 0
its O 0
deficiency O 0
in O 0
the O 0
erythrocyte O 0
, O 0
might O 0
play O 0
a O 0
role O 0
in O 0
the O 0
cataracto O 0
- O 0
genesis O 0
of O 0
these O 0
patients O 0
. O 0

Moreover O 0
, O 0
G6PD B-Disease 0
deficiency I-Disease 0
should O 0
be O 0
added O 0
to O 0
other O 0
conditions O 0
, O 0
such O 0
as O 0
the O 0
galactosemic B-Disease 0
states O 0
and O 0
riboflavin B-Disease 0
deficiency I-Disease 0
, O 0
where O 0
cataracts B-Disease 1
represent O 0
a O 0
sensitive O 0
indicator O 0
of O 0
metabolic B-Disease 1
abnormalities I-Disease 1
of O 0
the O 0
RBC O 0
. O 0
. O 0

Molecular O 0
basis O 0
of O 0
human O 0
mitochondrial O 0
very B-Disease 1
- I-Disease 1
long I-Disease 1
- I-Disease 1
chain I-Disease 1
acyl I-Disease 1
- I-Disease 1
CoA I-Disease 1
dehydrogenase I-Disease 1
deficiency I-Disease 1
causing O 0
cardiomyopathy B-Disease 1
and O 0
sudden B-Disease 1
death I-Disease 1
in O 0
childhood O 0
. O 0

beta O 0
- O 0
Oxidation O 0
of O 0
long O 0
- O 0
chain O 0
fatty O 0
acids O 0
provides O 0
the O 0
major O 0
source O 0
of O 0
energy O 0
in O 0
the O 0
heart O 0
. O 0

Defects O 0
in O 0
enzymes O 0
of O 0
the O 0
beta O 0
- O 0
oxidation O 0
pathway O 0
cause O 0
sudden B-Disease 0
, I-Disease 0
unexplained I-Disease 0
death I-Disease 0
in O 0
childhood O 0
, O 0
acute O 0
hepatic B-Disease 0
encephalopathy I-Disease 0
or O 0
liver B-Disease 1
failure I-Disease 1
, O 0
skeletal B-Disease 1
myopathy I-Disease 1
, O 0
and O 0
cardiomyopathy B-Disease 1
. O 0

Very O 0
- O 0
long O 0
- O 0
chain O 0
acyl O 0
- O 0
CoA O 0
dehydrogenase O 0
[ O 0
VLCAD O 0
; O 0
very O 0
- O 0
long O 0
- O 0
chain O 0
- O 0
acyl O 0
- O 0
CoA O 0
( O 0
acceptor O 0
) O 0
2 O 0
, O 0
3 O 0
- O 0
oxidoreductase O 0
, O 0
EC O 0
1 O 0
. O 0
3 O 0
3 O 0
. O 0
99 O 0
99 O 0
. O 0
13 O 0
] O 0
catalyzes O 0
the O 0
first O 0
step O 0
in O 0
beta O 0
- O 0
oxidation O 0
. O 0

We O 0
have O 0
isolated O 0
the O 0
human O 0
VLCAD O 0
cDNA O 0
and O 0
gene O 0
and O 0
determined O 0
the O 0
complete O 0
nucleotide O 0
sequences O 0
. O 0

Polymerase O 0
chain O 0
reaction O 0
amplification O 0
of O 0
VLCAD O 0
mRNA O 0
and O 0
genomic O 0
exons O 0
defined O 0
the O 0
molecular O 0
defects O 0
in O 0
two O 0
patients O 0
with O 0
VLCAD B-Disease 0
deficiency I-Disease 0
who O 0
presented O 0
with O 0
unexplained O 0
cardiac B-Disease 0
arrest I-Disease 0
and O 0
cardiomyopathy B-Disease 1
. O 0

In O 0
one O 0
, O 0
a O 0
homozygous O 0
mutation O 0
in O 0
the O 0
consensus O 0
dinucleotide O 0
of O 0
the O 0
donor O 0
splice O 0
site O 0
( O 0
g O 0
+ O 0
1 O 0
- O 0
- O 0
> O 0
a O 0
) O 0
was O 0
associated O 0
with O 0
universal O 0
skipping O 0
of O 0
the O 0
prior O 0
exon O 0
( O 0
exon O 0
11 O 0
) O 0
. O 0

The O 0
second O 0
patient O 0
was O 0
a O 0
compound O 0
heterozygote O 0
, O 0
with O 0
a O 0
missense O 0
mutation O 0
, O 0
C1837 O 0
- O 0
- O 0
> O 0
T O 0
, O 0
changing O 0
the O 0
arginine O 0
at O 0
residue O 0
613 O 0
to O 0
tryptophan O 0
on O 0
one O 0
allele O 0
and O 0
a O 0
single O 0
base O 0
deletion O 0
at O 0
the O 0
intron O 0
- O 0
exon O 0
6 O 0
boundary O 0
as O 0
the O 0
second O 0
mutation O 0
. O 0

This O 0
initial O 0
delineation O 0
of O 0
human O 0
mutations O 0
in O 0
VLCAD O 0
suggests O 0
that O 0
VLCAD B-Disease 0
deficiency I-Disease 0
reduces O 0
myocardial O 0
fatty O 0
acid O 0
beta O 0
- O 0
oxidation O 0
and O 0
energy O 0
production O 0
and O 0
is O 0
associated O 0
with O 0
cardiomyopathy B-Disease 1
and O 0
sudden B-Disease 1
death I-Disease 1
in O 0
childhood O 0
. O 0

Aberrant O 0
subcellular O 0
localization O 0
of O 0
BRCA1 O 0
in O 0
breast B-Disease 0
cancer I-Disease 1
. O 0

The O 0
BRCA1 O 0
gene O 0
product O 0
was O 0
identified O 0
as O 0
a O 0
220 O 0
- O 0
kilodalton O 0
nuclear O 0
phosphoprotein O 0
in O 0
normal O 0
cells O 0
, O 0
including O 0
breast O 0
ductal O 0
epithelial O 0
cells O 0
, O 0
and O 0
in O 0
18 O 0
of O 0
20 O 0
tumor B-Disease 0
cell O 0
lines O 0
derived O 0
from O 0
tissues O 0
other O 0
than O 0
breast O 0
and O 0
ovary O 0
. O 0

In O 0
16 O 0
of O 0
17 O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
lines O 0
and O 0
17 O 0
of O 0
17 O 0
samples O 0
of O 0
cells O 0
obtained O 0
from O 0
malignant O 0
effusions O 0
, O 0
however O 0
, O 0
BRCA1 O 0
localized O 0
mainly O 0
in O 0
cytoplasm O 0
. O 0

Absence O 0
of O 0
BRCA1 O 0
or O 0
aberrant O 0
subcellular O 0
location O 0
was O 0
also O 0
observed O 0
to O 0
a O 0
variable O 0
extent O 0
in O 0
histological O 0
sections O 0
of O 0
many O 0
breast B-Disease 0
cancer I-Disease 1
biopsies O 0
. O 0

These O 0
findings O 0
suggest O 0
that O 0
BRCA1 B-Disease 1
abnormalities I-Disease 1
may O 0
be O 0
involved O 0
in O 0
the O 0
pathogenesis O 0
of O 0
many O 0
breast B-Disease 0
cancers I-Disease 0
, O 0
sporadic O 0
as O 0
well O 0
as O 0
familial O 0
. O 0
. O 0

Mapping O 0
of O 0
the O 0
mouse O 0
homologue O 0
of O 0
the O 0
Wilson B-Disease 0
disease I-Disease 0
gene O 0
to O 0
mouse O 0
chromosome O 0
8 O 0
. O 0

ATP7B O 0
, O 0
the O 0
gene O 0
altered O 0
in O 0
Wilson B-Disease 0
disease I-Disease 0
( O 0
WD B-Disease 1
) O 0
patients O 0
, O 0
lies O 0
in O 0
a O 0
block O 0
of O 0
homology O 0
shared O 0
between O 0
human O 0
chromosome O 0
13q14 O 0
and O 0
the O 0
central O 0
region O 0
of O 0
mouse O 0
chromosome O 0
14 O 0
. O 0

However O 0
, O 0
we O 0
have O 0
mapped O 0
the O 0
murine O 0
homologue O 0
of O 0
ATP7B O 0
( O 0
Atp7b O 0
) O 0
to O 0
mouse O 0
chromosome O 0
8 O 0
by O 0
somatic O 0
cell O 0
hybrid O 0
analysis O 0
. O 0

Analysis O 0
of O 0
80 O 0
interspecific O 0
backcross O 0
offspring O 0
was O 0
used O 0
to O 0
position O 0
Atp7b O 0
close O 0
to O 0
D8Mit3 O 0
and O 0
another O 0
ATPase O 0
locus O 0
, O 0
Atp4b O 0
, O 0
on O 0
mouse O 0
chromosome O 0
8 O 0
. O 0

ATP4B O 0
lies O 0
in O 0
13q34 O 0
and O 0
is O 0
separated O 0
from O 0
ATP7B O 0
by O 0
several O 0
loci O 0
whose O 0
mouse O 0
homologues O 0
map O 0
to O 0
mouse O 0
chromosome O 0
14 O 0
. O 0

The O 0
assignment O 0
of O 0
Atp7b O 0
to O 0
mouse O 0
chromosome O 0
8 O 0
identifies O 0
a O 0
previously O 0
unrecognized O 0
region O 0
of O 0
homology O 0
between O 0
this O 0
chromosome O 0
and O 0
human O 0
chromosome O 0
13 O 0
. O 0

This O 0
assignment O 0
suggests O 0
a O 0
possible O 0
location O 0
for O 0
the O 0
toxic O 0
milk O 0
mutation O 0
in O 0
the O 0
mouse O 0
, O 0
which O 0
has O 0
been O 0
proposed O 0
as O 0
a O 0
homologue O 0
of O 0
WD B-Disease 1
. O 0
. O 0

Germline O 0
mutations O 0
of O 0
the O 0
BRCA1 O 0
gene O 0
in O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
families O 0
provide O 0
evidence O 0
for O 0
a O 0
genotype O 0
- O 0
phenotype O 0
correlation O 0
. O 0

Mutations O 0
in O 0
the O 0
BRCA1 O 0
gene O 0
, O 0
discovered O 0
in O 0
1994 O 0
, O 0
are O 0
associated O 0
with O 0
an O 0
80 O 0
- O 0
90 O 0
% O 0
lifetime O 0
risk O 0
of O 0
breast B-Disease 0
cancer I-Disease 1
. O 0

We O 0
have O 0
analysed O 0
60 O 0
families O 0
with O 0
a O 0
history O 0
of O 0
breast B-Disease 1
and I-Disease 1
/ I-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
for O 0
germline O 0
mutations O 0
in O 0
BRCA1 O 0
. O 0

Twenty O 0
- O 0
two O 0
different O 0
mutations O 0
were O 0
detected O 0
in O 0
32 O 0
families O 0
( O 0
53 O 0
% O 0
) O 0
, O 0
of O 0
which O 0
14 O 0
are O 0
previously O 0
unreported O 0
. O 0

We O 0
observed O 0
a O 0
significant O 0
correlation O 0
between O 0
the O 0
location O 0
of O 0
the O 0
mutation O 0
in O 0
the O 0
gene O 0
and O 0
the O 0
ratio O 0
of O 0
breast B-Disease 0
to I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
incidence O 0
within O 0
each O 0
family O 0
. O 0

Our O 0
data O 0
suggest O 0
a O 0
transition O 0
in O 0
risk O 0
such O 0
that O 0
mutations O 0
in O 0
the O 0
3 O 0
third O 0
of O 0
the O 0
gene O 0
are O 0
associated O 0
with O 0
a O 0
lower O 0
proportion O 0
of O 0
ovarian B-Disease 0
cancer I-Disease 1
. O 0

Haplotype O 0
analysis O 0
supports O 0
previous O 0
data O 0
which O 0
suggest O 0
some O 0
BRCA1 O 0
mutation O 0
carriers O 0
have O 0
common O 0
ancestors O 0
; O 0
however O 0
, O 0
we O 0
have O 0
found O 0
at O 0
least O 0
two O 0
examples O 0
where O 0
recurrent O 0
mutations O 0
appear O 0
to O 0
have O 0
arisen O 0
independently O 0
. O 0
. O 0

Hereditary O 0
deficiency B-Disease 1
of I-Disease 1
the I-Disease 1
seventh I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
and O 0
recurrent O 0
meningococcal B-Disease 0
infection I-Disease 0
: O 0
investigations O 0
of O 0
an O 0
Irish O 0
family O 0
using O 0
a O 0
novel O 0
haemolytic O 0
screening O 0
assay O 0
for O 0
complement O 0
activity O 0
and O 0
C7 O 0
M O 0
/ O 0
N O 0
allotyping O 0
. O 0

Terminal B-Disease 0
complement I-Disease 0
component I-Disease 0
deficiency I-Disease 0
predisposes O 0
to O 0
meningococcal B-Disease 0
infection I-Disease 0
and O 0
is O 0
inherited O 0
in O 0
an O 0
autosomal O 0
co O 0
- O 0
dominant O 0
manner O 0
. O 0

An O 0
Irish O 0
family O 0
is O 0
described O 0
, O 0
in O 0
which O 0
2 O 0
of O 0
3 O 0
brothers O 0
had O 0
recurrent O 0
meningococcal B-Disease 0
infection I-Disease 0
. O 0

A O 0
novel O 0
screening O 0
assay O 0
was O 0
used O 0
to O 0
investigate O 0
for O 0
terminal B-Disease 0
complement I-Disease 1
deficiency I-Disease 1
and O 0
the O 0
2 O 0
affected O 0
brothers O 0
were O 0
found O 0
to O 0
be O 0
completely B-Disease 1
deficient I-Disease 1
in I-Disease 1
the I-Disease 1
seventh I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
( O 0
C7 O 0
) O 0
. O 0

Enzyme O 0
- O 0
linked O 0
immunosorbent O 0
assay O 0
for O 0
C7 O 0
revealed O 0
lower O 0
than O 0
normal O 0
levels O 0
in O 0
the O 0
remaining O 0
brother O 0
and O 0
parents O 0
. O 0

C7 O 0
M O 0
/ O 0
N O 0
protein O 0
polymorphism O 0
allotyping O 0
, O 0
used O 0
to O 0
investigate O 0
the O 0
segregation O 0
of O 0
the O 0
C7 B-Disease 0
deficiency I-Disease 0
genes O 0
, O 0
showed O 0
that O 0
the O 0
apparently O 0
complement O 0
sufficient O 0
brother O 0
was O 0
heterozygous O 0
C7 B-Disease 1
deficient I-Disease 1
and O 0
a O 0
carrier O 0
of O 0
one O 0
of O 0
the O 0
deficiency O 0
genes O 0
. O 0

Complement O 0
screening O 0
should O 0
be O 0
carried O 0
out O 0
in O 0
any O 0
individual O 0
suffering O 0
recurrent O 0
meningococcal B-Disease 0
infection I-Disease 0
or O 0
infection O 0
with O 0
an O 0
uncommon O 0
meningococcal B-Disease 0
serogroup O 0
. O 0

Identification O 0
of O 0
complement B-Disease 0
deficient I-Disease 0
patients O 0
allows O 0
the O 0
implementation O 0
of O 0
strategies O 0
to O 0
prevent O 0
recurrent O 0
infection O 0
. O 0
. O 0

Molecular O 0
basis O 0
of O 0
subtotal B-Disease 0
complement I-Disease 0
C6 I-Disease 1
deficiency I-Disease 1
. O 0

A O 0
carboxy O 0
- O 0
terminally O 0
truncated O 0
but O 0
functionally O 0
active O 0
C6 O 0
. O 0

Individuals O 0
with O 0
subtotal B-Disease 0
complement I-Disease 0
C6 I-Disease 1
deficiency I-Disease 1
possess O 0
a O 0
C6 O 0
molecule O 0
that O 0
is O 0
14 O 0
% O 0
shorter O 0
than O 0
normal O 0
C6 O 0
and O 0
present O 0
in O 0
low O 0
but O 0
detectable O 0
concentrations O 0
( O 0
1 O 0
- O 0
2 O 0
% O 0
of O 0
the O 0
normal O 0
mean O 0
) O 0
. O 0

We O 0
now O 0
show O 0
that O 0
this O 0
dysmorphic O 0
C6 O 0
is O 0
bactericidally O 0
active O 0
and O 0
lacks O 0
an O 0
epitope O 0
that O 0
was O 0
mapped O 0
to O 0
the O 0
most O 0
carboxy O 0
- O 0
terminal O 0
part O 0
of O 0
C6 O 0
using O 0
C6 O 0
cDNA O 0
fragments O 0
expressed O 0
as O 0
fusion O 0
proteins O 0
in O 0
the O 0
pUEX O 0
expression O 0
system O 0
. O 0

We O 0
thus O 0
predicted O 0
that O 0
the O 0
abnormal O 0
C6 O 0
molecule O 0
might O 0
be O 0
carboxy O 0
- O 0
terminally O 0
truncated O 0
and O 0
sought O 0
a O 0
mutation O 0
in O 0
an O 0
area O 0
approximately O 0
14 O 0
% O 0
from O 0
the O 0
carboxy O 0
- O 0
terminal O 0
end O 0
of O 0
the O 0
coding O 0
sequence O 0
. O 0

By O 0
sequencing O 0
PCR O 0
- O 0
amplified O 0
products O 0
from O 0
this O 0
region O 0
, O 0
we O 0
found O 0
, O 0
in O 0
three O 0
individuals O 0
from O 0
two O 0
families O 0
, O 0
a O 0
mutation O 0
that O 0
might O 0
plausibly O 0
be O 0
responsible O 0
for O 0
the O 0
defect O 0
. O 0

All O 0
three O 0
have O 0
an O 0
abnormal O 0
5 O 0
splice O 0
donor O 0
site O 0
of O 0
intron O 0
15 O 0
, O 0
which O 0
would O 0
probably O 0
prevent O 0
splicing O 0
. O 0

An O 0
in O 0
- O 0
frame O 0
stop O 0
codon O 0
is O 0
found O 0
17 O 0
codons O 0
downstream O 0
from O 0
the O 0
intron O 0
boundary O 0
, O 0
which O 0
would O 0
lead O 0
to O 0
a O 0
truncated O 0
polypeptide O 0
13 O 0
. O 0

5 O 0
% O 0
smaller O 0
than O 0
normal O 0
C6 O 0
. O 0

This O 0
result O 0
was O 0
unexpected O 0
, O 0
as O 0
earlier O 0
studies O 0
mapped O 0
the O 0
C5b O 0
binding O 0
site O 0
, O 0
or O 0
a O 0
putative O 0
enzymatic O 0
region O 0
, O 0
to O 0
this O 0
part O 0
of O 0
C6 O 0
. O 0

Interestingly O 0
, O 0
all O 0
three O 0
subjects O 0
were O 0
probably O 0
heterozygous O 0
for O 0
both O 0
subtotal B-Disease 1
C6 I-Disease 1
and I-Disease 1
complete I-Disease 1
C6 I-Disease 1
deficiency I-Disease 1
. O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
: O 0
evidence O 0
for O 0
a O 0
possible O 0
dominant O 0
- O 0
negative O 0
RNA O 0
mutation O 0
. O 0

The O 0
trinucleotide O 0
expansion O 0
mutation O 0
causing O 0
myotonic B-Disease 1
dystrophy I-Disease 1
is O 0
in O 0
the O 0
3 O 0
untranslated O 0
region O 0
of O 0
a O 0
protein O 0
kinase O 0
gene O 0
. O 0

The O 0
molecular O 0
mechanisms O 0
by O 0
which O 0
the O 0
expanded O 0
repeat O 0
causes O 0
the O 0
clinically O 0
variable O 0
and O 0
multisystemic B-Disease 0
disease I-Disease 0
, O 0
myotonic B-Disease 1
dystrophy I-Disease 1
, O 0
are O 0
not O 0
understood O 0
. O 0

It O 0
has O 0
been O 0
particularly O 0
difficult O 0
to O 0
rationalize O 0
the O 0
dominant O 0
inheritance O 0
with O 0
the O 0
fact O 0
that O 0
the O 0
expansion O 0
mutation O 0
lies O 0
outside O 0
of O 0
the O 0
protein O 0
- O 0
encoding O 0
gene O 0
elements O 0
, O 0
and O 0
should O 0
not O 0
be O 0
translated O 0
into O 0
protein O 0
. O 0

Here O 0
we O 0
use O 0
muscle O 0
biopsies O 0
from O 0
classical O 0
adult O 0
- O 0
onset O 0
myotonic B-Disease 1
dystrophy I-Disease 1
patients O 0
to O 0
study O 0
the O 0
accumulation O 0
of O 0
transcripts O 0
from O 0
both O 0
the O 0
normal O 0
and O 0
expanded O 0
DM B-Disease 0
kinase O 0
genes O 0
in O 0
patient O 0
muscle O 0
, O 0
and O 0
compare O 0
the O 0
results O 0
to O 0
normal O 0
and O 0
myopathic B-Disease 1
controls O 0
. O 0

We O 0
found O 0
relatively O 0
small O 0
decreases O 0
of O 0
DM B-Disease 0
kinase O 0
RNA O 0
in O 0
the O 0
total O 0
RNA O 0
pool O 0
from O 0
muscle O 0
; O 0
however O 0
, O 0
these O 0
reductions O 0
were O 0
not O 0
disease O 0
specific O 0
. O 0

Analysis O 0
of O 0
poly O 0
( O 0
A O 0
) O 0
+ O 0
RNA O 0
showed O 0
dramatic O 0
decreases O 0
of O 0
both O 0
the O 0
mutant O 0
and O 0
normal O 0
DM B-Disease 0
kinase O 0
RNAs O 0
, O 0
and O 0
these O 0
changes O 0
were O 0
disease O 0
- O 0
specific O 0
. O 0

Our O 0
findings O 0
are O 0
consistent O 0
with O 0
a O 0
novel O 0
molecular O 0
pathogenetic O 0
mechanism O 0
for O 0
myotonic B-Disease 1
dystrophy I-Disease 1
both O 0
the O 0
normal O 0
and O 0
expanded O 0
DM B-Disease 0
kinase O 0
genes O 0
are O 0
transcribed O 0
in O 0
patient O 0
muscle O 0
, O 0
but O 0
the O 0
abnormal O 0
expansion O 0
- O 0
containing O 0
RNA O 0
has O 0
a O 0
dominant O 0
effect O 0
on O 0
RNA O 0
metabolism O 0
by O 0
preventing O 0
the O 0
accumulation O 0
of O 0
poly O 0
( O 0
A O 0
) O 0
+ O 0
RNA O 0
. O 0

The O 0
ability O 0
of O 0
the O 0
expansion O 0
mutation O 0
to O 0
alter O 0
accumulation O 0
of O 0
poly O 0
( O 0
A O 0
) O 0
+ O 0
RNA O 0
in O 0
trans O 0
suggests O 0
that O 0
myotonic B-Disease 1
dystrophy I-Disease 1
may O 0
be O 0
the O 0
first O 0
example O 0
of O 0
a O 0
dominant O 0
- O 0
negative O 0
mutation O 0
manifested O 0
at O 0
the O 0
RNA O 0
level O 0
. O 0
. O 0

A O 0
strong O 0
candidate O 0
for O 0
the O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
susceptibility O 0
gene O 0
BRCA1 O 0
. O 0

A O 0
strong O 0
candidate O 0
for O 0
the O 0
17q O 0
- O 0
linked O 0
BRCA1 O 0
gene O 0
, O 0
which O 0
influences O 0
susceptibility O 0
to O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
, O 0
has O 0
been O 0
identified O 0
by O 0
positional O 0
cloning O 0
methods O 0
. O 0

Probable O 0
predisposing O 0
mutations O 0
have O 0
been O 0
detected O 0
in O 0
five O 0
of O 0
eight O 0
kindreds O 0
presumed O 0
to O 0
segregate O 0
BRCA1 O 0
susceptibility O 0
alleles O 0
. O 0

The O 0
mutations O 0
include O 0
an O 0
11 O 0
- O 0
base O 0
pair O 0
deletion O 0
, O 0
a O 0
1 O 0
- O 0
base O 0
pair O 0
insertion O 0
, O 0
a O 0
stop O 0
codon O 0
, O 0
a O 0
missense O 0
substitution O 0
, O 0
and O 0
an O 0
inferred O 0
regulatory O 0
mutation O 0
. O 0

The O 0
BRCA1 O 0
gene O 0
is O 0
expressed O 0
in O 0
numerous O 0
tissues O 0
, O 0
including O 0
breast O 0
and O 0
ovary O 0
, O 0
and O 0
encodes O 0
a O 0
predicted O 0
protein O 0
of O 0
1863 O 0
amino O 0
acids O 0
. O 0

This O 0
protein O 0
contains O 0
a O 0
zinc O 0
finger O 0
domain O 0
in O 0
its O 0
amino O 0
- O 0
terminal O 0
region O 0
, O 0
but O 0
is O 0
otherwise O 0
unrelated O 0
to O 0
previously O 0
described O 0
proteins O 0
. O 0

Identification O 0
of O 0
BRCA1 O 0
should O 0
facilitate O 0
early O 0
diagnosis O 0
of O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
susceptibility O 0
in O 0
some O 0
individuals O 0
as O 0
well O 0
as O 0
a O 0
better O 0
understanding O 0
of O 0
breast B-Disease 0
cancer I-Disease 1
biology O 0
. O 0
. O 0

Molecular O 0
characterization O 0
of O 0
galactosemia B-Disease 0
( O 0
type O 0
1 O 0
) O 0
mutations O 0
in O 0
Japanese O 0
. O 0

We O 0
characterized O 0
two O 0
novel O 0
mutations O 0
of O 0
the O 0
galactose O 0
- O 0
1 O 0
- O 0
phosphate O 0
uridyltransferase O 0
( O 0
GALT O 0
) O 0
gene O 0
in O 0
two O 0
Japanese O 0
patients O 0
with O 0
GALT B-Disease 0
deficiency I-Disease 0
and O 0
identified O 0
N314D O 0
and O 0
R333W O 0
mutations O 0
, O 0
previously O 0
found O 0
in O 0
Caucasians O 0
. O 0

One O 0
novel O 0
missense O 0
mutation O 0
was O 0
an O 0
G O 0
- O 0
to O 0
- O 0
A O 0
transition O 0
in O 0
exon O 0
8 O 0
, O 0
resulting O 0
in O 0
the O 0
substitution O 0
of O 0
arginine O 0
by O 0
histidine O 0
at O 0
the O 0
codon O 0
231 O 0
( O 0
R231H O 0
) O 0
. O 0

GALT O 0
activity O 0
of O 0
the O 0
R231H O 0
mutant O 0
construct O 0
was O 0
reduced O 0
to O 0
15 O 0
% O 0
of O 0
normal O 0
controls O 0
in O 0
a O 0
COS O 0
cell O 0
expression O 0
system O 0
. O 0

The O 0
other O 0
was O 0
a O 0
splicing O 0
mutation O 0
, O 0
an O 0
A O 0
- O 0
to O 0
- O 0
G O 0
transition O 0
at O 0
the O 0
38th O 0
nucleotide O 0
in O 0
exon O 0
3 O 0
( O 0
318A O 0
- O 0
- O 0
> O 0
G O 0
) O 0
, O 0
resulting O 0
in O 0
a O 0
38 O 0
- O 0
bp O 0
deletion O 0
in O 0
the O 0
GALT O 0
cDNA O 0
by O 0
activating O 0
a O 0
cryptic O 0
splice O 0
acceptor O 0
site O 0
. O 0

In O 0
seven O 0
Japanese O 0
families O 0
( O 0
14 O 0
alleles O 0
for O 0
classic O 0
form O 0
and O 0
one O 0
allele O 0
for O 0
Duarte O 0
variant O 0
) O 0
with O 0
GALT B-Disease 0
deficiency I-Disease 0
, O 0
the O 0
R231H O 0
and O 0
318A O 0
- O 0
- O 0
> O 0
G O 0
mutations O 0
were O 0
found O 0
only O 0
on O 0
both O 0
alleles O 0
of O 0
the O 0
proband O 0
. O 0

The O 0
N314D O 0
and O 0
R333W O 0
mutations O 0
were O 0
found O 0
on O 0
one O 0
allele O 0
each O 0
. O 0

The O 0
Q188R O 0
was O 0
prevalent O 0
in O 0
the O 0
United O 0
States O 0
but O 0
not O 0
in O 0
Japanese O 0
patients O 0
. O 0

The O 0
N314D O 0
mutation O 0
was O 0
associated O 0
with O 0
the O 0
Duarte O 0
variant O 0
in O 0
Japanese O 0
persons O 0
, O 0
as O 0
well O 0
as O 0
in O 0
the O 0
United O 0
States O 0
. O 0

We O 0
speculate O 0
that O 0
classic B-Disease 1
galactosemia I-Disease 1
mutations O 0
appear O 0
to O 0
differ O 0
between O 0
Japanese O 0
and O 0
Caucasian O 0
patients O 0
. O 0

Our O 0
limited O 0
data O 0
set O 0
on O 0
galactosemia B-Disease 0
mutations O 0
in O 0
Japanese O 0
suggests O 0
that O 0
the O 0
N314D O 0
GALT O 0
mutation O 0
encoding O 0
the O 0
Duarte O 0
variant O 0
arose O 0
before O 0
Asian O 0
and O 0
Caucasian O 0
people O 0
diverged O 0
and O 0
that O 0
classic B-Disease 1
galactosemia I-Disease 1
mutations O 0
arose O 0
and O 0
/ O 0
or O 0
accumulated O 0
after O 0
the O 0
divergence O 0
of O 0
Asian O 0
and O 0
Caucasian O 0
populations O 0
. O 0
. O 0

Three O 0
novel O 0
aniridia B-Disease 0
mutations O 0
in O 0
the O 0
human O 0
PAX6 O 0
gene O 0
. O 0

Aniridia B-Disease 0
( O 0
iris B-Disease 0
hypoplasia I-Disease 0
) O 0
is O 0
an O 0
autosomal B-Disease 0
dominant I-Disease 0
congenital I-Disease 0
disorder I-Disease 0
of I-Disease 0
the I-Disease 0
eye I-Disease 0
. O 0

Mutations O 0
in O 0
the O 0
human O 0
aniridia B-Disease 0
( O 0
PAX6 O 0
) O 0
gene O 0
have O 0
now O 0
been O 0
identified O 0
in O 0
many O 0
patients O 0
from O 0
various O 0
ethnic O 0
groups O 0
. O 0

In O 0
the O 0
study O 0
reported O 0
here O 0
we O 0
describe O 0
PAX6 O 0
mutations O 0
in O 0
one O 0
sporadic O 0
and O 0
five O 0
familial O 0
cases O 0
with O 0
aniridia B-Disease 0
. O 0

Of O 0
the O 0
four O 0
different O 0
mutations O 0
identified O 0
, O 0
one O 0
was O 0
identical O 0
to O 0
a O 0
previously O 0
reported O 0
mutation O 0
( O 0
C O 0
- O 0
- O 0
> O 0
T O 0
transition O 0
at O 0
codon O 0
240 O 0
) O 0
, O 0
and O 0
three O 0
were O 0
novel O 0
two O 0
in O 0
the O 0
glycine O 0
- O 0
rich O 0
region O 0
and O 0
one O 0
in O 0
the O 0
proline O 0
/ O 0
serine O 0
/ O 0
threonine O 0
- O 0
rich O 0
( O 0
PST O 0
) O 0
region O 0
. O 0

One O 0
PAX6 O 0
mutation O 0
found O 0
in O 0
the O 0
PST O 0
region O 0
was O 0
associated O 0
with O 0
cataracts B-Disease 1
in O 0
an O 0
aniridia B-Disease 0
family O 0
. O 0

Another O 0
splice O 0
mutation O 0
in O 0
the O 0
PST O 0
domain O 0
occurred O 0
in O 0
an O 0
aniridia B-Disease 0
patient O 0
with O 0
anosmia B-Disease 1
( O 0
inability O 0
to O 0
smell O 0
) O 0
. O 0

The O 0
six O 0
new O 0
aniridia B-Disease 0
cases O 0
reported O 0
here O 0
have O 0
mutations O 0
predicted O 0
to O 0
generate O 0
incomplete O 0
PAX6 O 0
proteins O 0
. O 0

These O 0
results O 0
support O 0
the O 0
theory O 0
that O 0
human O 0
aniridia B-Disease 0
is O 0
caused O 0
by O 0
haploinsufficiency B-Disease 0
of I-Disease 0
PAX6 I-Disease 0
. O 0
. O 0

The O 0
carrier O 0
frequency O 0
of O 0
the O 0
BRCA1 O 0
185delAG O 0
mutation O 0
is O 0
approximately O 0
1 O 0
percent O 0
in O 0
Ashkenazi O 0
Jewish O 0
individuals O 0
. O 0

Since O 0
BRCA1 O 0
, O 0
the O 0
first O 0
major O 0
gene O 0
responsible O 0
for O 0
inherited B-Disease 0
breast I-Disease 0
cancer I-Disease 1
, O 0
was O 0
cloned O 0
, O 0
more O 0
than O 0
50 O 0
unique O 0
mutations O 0
have O 0
been O 0
detected O 0
in O 0
the O 0
germline O 0
of O 0
individuals O 0
with O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
. O 0

In O 0
high O 0
- O 0
risk O 0
pedigrees O 0
, O 0
female O 0
carriers O 0
of O 0
BRCA1 O 0
mutations O 0
have O 0
an O 0
80 O 0
- O 0
90 O 0
% O 0
lifetime O 0
risk O 0
of O 0
breast B-Disease 0
cancer I-Disease 1
, O 0
and O 0
a O 0
40 O 0
- O 0
50 O 0
% O 0
risk O 0
of O 0
ovarian B-Disease 0
cancer I-Disease 1
. O 0

However O 0
, O 0
the O 0
mutation O 0
stats O 0
of O 0
individuals O 0
unselected O 0
for O 0
breast B-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
has O 0
not O 0
been O 0
determined O 0
, O 0
and O 0
it O 0
is O 0
not O 0
known O 0
whether O 0
mutations O 0
in O 0
such O 0
individuals O 0
confer O 0
the O 0
same O 0
risk O 0
of O 0
cancer B-Disease 1
as O 0
in O 0
individuals O 0
from O 0
the O 0
high O 0
- O 0
risk O 0
families O 0
studied O 0
so O 0
far O 0
. O 0

Following O 0
the O 0
finding O 0
of O 0
a O 0
185delAG O 0
frameshift O 0
mutation O 0
in O 0
several O 0
Ashkenazi O 0
Jewish O 0
breast O 0
/ O 0
ovarian O 0
families O 0
, O 0
we O 0
have O 0
determined O 0
the O 0
frequency O 0
of O 0
this O 0
mutation O 0
in O 0
858 O 0
Ashkenazim O 0
seeking O 0
genetic O 0
testing O 0
for O 0
conditions O 0
unrelated O 0
to O 0
cancer B-Disease 1
, O 0
and O 0
in O 0
815 O 0
reference O 0
individuals O 0
not O 0
selected O 0
for O 0
ethnic O 0
origin O 0
. O 0

We O 0
observed O 0
the O 0
185delAG O 0
mutation O 0
in O 0
0 O 0
. O 0

9 O 0
% O 0
of O 0
Ashkenazim O 0
( O 0
95 O 0
% O 0
confidence O 0
limit O 0
, O 0
0 O 0
. O 0
4 O 0
- O 0
1 O 0
. O 0
8 O 0
% O 0
) O 0
and O 0
in O 0
none O 0
of O 0
the O 0
reference O 0
samples O 0
. O 0

Our O 0
results O 0
suggest O 0
that O 0
one O 0
in O 0
a O 0
hundred O 0
women O 0
of O 0
Ashkenazi O 0
descent O 0
may O 0
be O 0
at O 0
especially O 0
high O 0
risk O 0
of O 0
developing O 0
breast B-Disease 1
and I-Disease 1
/ I-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
. O 0

Identification O 0
and O 0
localization O 0
of O 0
huntingtin O 0
in O 0
brain O 0
and O 0
human O 0
lymphoblastoid O 0
cell O 0
lines O 0
with O 0
anti O 0
- O 0
fusion O 0
protein O 0
antibodies O 0
. O 0

The O 0
Huntington B-Disease 1
disease I-Disease 1
( O 0
HD B-Disease 1
) O 0
phenotype O 0
is O 0
associated O 0
with O 0
expansion O 0
of O 0
a O 0
trinucleotide O 0
repeat O 0
in O 0
the O 0
IT15 O 0
gene O 0
, O 0
which O 0
is O 0
predicted O 0
to O 0
encode O 0
a O 0
348 O 0
- O 0
kDa O 0
protein O 0
named O 0
huntington O 0
. O 0

We O 0
used O 0
polyclonal O 0
and O 0
monoclonal O 0
anti O 0
- O 0
fusion O 0
protein O 0
antibodies O 0
to O 0
identify O 0
native O 0
huntingtin O 0
in O 0
rat O 0
, O 0
monkey O 0
, O 0
and O 0
human O 0
. O 0

Western O 0
blots O 0
revealed O 0
a O 0
protein O 0
with O 0
the O 0
expected O 0
molecular O 0
weight O 0
which O 0
is O 0
present O 0
in O 0
the O 0
soluble O 0
fraction O 0
of O 0
rat O 0
and O 0
monkey O 0
brain O 0
tissues O 0
and O 0
lymphoblastoid O 0
cells O 0
from O 0
control O 0
cases O 0
. O 0

In O 0
lymphoblastoid O 0
cell O 0
lines O 0
from O 0
juvenile O 0
- O 0
onset O 0
heterozygote O 0
HD B-Disease 1
cases O 0
, O 0
both O 0
normal O 0
and O 0
mutant O 0
huntingtin O 0
are O 0
expressed O 0
, O 0
and O 0
increasing O 0
repeat O 0
expansion O 0
leads O 0
to O 0
lower O 0
levels O 0
of O 0
the O 0
mutant O 0
protein O 0
. O 0

Immunocytochemistry O 0
indicates O 0
that O 0
huntingtin O 0
is O 0
located O 0
in O 0
neurons O 0
throughout O 0
the O 0
brain O 0
, O 0
with O 0
the O 0
highest O 0
levels O 0
evident O 0
in O 0
larger O 0
neurons O 0
. O 0

In O 0
the O 0
human O 0
striatum O 0
, O 0
huntingtin O 0
is O 0
enriched O 0
in O 0
a O 0
patch O 0
- O 0
like O 0
distribution O 0
, O 0
potentially O 0
corresponding O 0
to O 0
the O 0
first O 0
areas O 0
affected O 0
in O 0
HD B-Disease 1
. O 0

Subcellular O 0
localization O 0
of O 0
huntingtin O 0
is O 0
consistent O 0
with O 0
a O 0
cytosolic O 0
protein O 0
primarily O 0
found O 0
in O 0
somatodendritic O 0
regions O 0
. O 0

Huntingtin O 0
appears O 0
to O 0
particularly O 0
associate O 0
with O 0
microtubules O 0
, O 0
although O 0
some O 0
is O 0
also O 0
associated O 0
with O 0
synaptic O 0
vesicles O 0
. O 0

On O 0
the O 0
basis O 0
of O 0
the O 0
localization O 0
of O 0
huntingtin O 0
in O 0
association O 0
with O 0
microtubules O 0
, O 0
we O 0
speculate O 0
that O 0
the O 0
mutation O 0
impairs O 0
the O 0
cytoskeletal O 0
anchoring O 0
or O 0
transport O 0
of O 0
mitochondria O 0
, O 0
vesicles O 0
, O 0
or O 0
other O 0
organelles O 0
or O 0
molecules O 0
. O 0
. O 0

Marked O 0
phenotypic O 0
heterogeneity O 0
associated O 0
with O 0
expansion O 0
of O 0
a O 0
CAG O 0
repeat O 0
sequence O 0
at O 0
the O 0
spinocerebellar B-Disease 1
ataxia I-Disease 1
3 I-Disease 1
/ I-Disease 1
Machado I-Disease 1
- I-Disease 1
Joseph I-Disease 1
disease I-Disease 1
locus O 0
. O 0

The O 0
spinocerebellar B-Disease 0
ataxia I-Disease 0
3 I-Disease 0
locus O 0
( O 0
SCA3 B-Disease 1
) O 0
for O 0
type B-Disease 0
I I-Disease 0
autosomal I-Disease 0
dominant I-Disease 0
cerebellar I-Disease 0
ataxia I-Disease 0
( O 0
ADCA B-Disease 1
type I-Disease 1
I I-Disease 1
) O 0
, O 0
a O 0
clinically O 0
and O 0
genetically O 0
heterogeneous O 0
group O 0
of O 0
neurodegenerative B-Disease 1
disorders I-Disease 1
, O 0
has O 0
been O 0
mapped O 0
to O 0
chromosome O 0
14q32 O 0
. O 0

1 O 0
1 O 0
. O 0

ADCA B-Disease 1
type I-Disease 1
I I-Disease 1
patients O 0
from O 0
families O 0
segregating O 0
SCA3 B-Disease 1
share O 0
clinical O 0
features O 0
in O 0
common O 0
with O 0
those O 0
with O 0
Machado B-Disease 0
- I-Disease 0
Joseph I-Disease 0
disease I-Disease 0
( O 0
MJD B-Disease 0
) O 0
, O 0
the O 0
gene O 0
of O 0
which O 0
maps O 0
to O 0
the O 0
same O 0
region O 0
. O 0

We O 0
show O 0
here O 0
that O 0
the O 0
disease O 0
gene O 0
segregating O 0
in O 0
each O 0
of O 0
three O 0
French O 0
ADCA B-Disease 1
type I-Disease 1
I I-Disease 1
kindreds O 0
and O 0
in O 0
a O 0
French O 0
family O 0
with O 0
neuropathological O 0
findings O 0
suggesting O 0
the O 0
ataxochoreic O 0
form O 0
of O 0
dentatorubropallidoluysian B-Disease 1
atrophy I-Disease 1
carries O 0
an O 0
expanded O 0
CAG O 0
repeat O 0
sequence O 0
located O 0
at O 0
the O 0
same O 0
locus O 0
as O 0
that O 0
for O 0
MJD B-Disease 0
. O 0

Analysis O 0
of O 0
the O 0
mutation O 0
in O 0
these O 0
families O 0
shows O 0
a O 0
strong O 0
negative O 0
correlation O 0
between O 0
size O 0
of O 0
the O 0
expanded O 0
CAG O 0
repeat O 0
and O 0
age O 0
at O 0
onset O 0
of O 0
clinical O 0
disease O 0
. O 0

Instability O 0
of O 0
the O 0
expanded O 0
triplet O 0
repeat O 0
was O 0
not O 0
found O 0
to O 0
be O 0
affected O 0
by O 0
sex O 0
of O 0
the O 0
parent O 0
transmitting O 0
the O 0
mutation O 0
. O 0

Evidence O 0
was O 0
found O 0
for O 0
somatic O 0
and O 0
gonadal O 0
mosaicism O 0
for O 0
alleles O 0
carrying O 0
expanded O 0
trinucleotide O 0
repeats O 0
. O 0

Overexpression O 0
of O 0
DM20 O 0
messenger O 0
RNA O 0
in O 0
two O 0
brothers O 0
with O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
. O 0

Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
is O 0
a O 0
rare B-Disease 0
, I-Disease 0
sex I-Disease 0
- I-Disease 0
linked I-Disease 0
recessive I-Disease 0
, I-Disease 0
dysmyelinating I-Disease 0
disease I-Disease 0
of I-Disease 0
the I-Disease 0
central I-Disease 0
nervous I-Disease 0
system I-Disease 0
that O 0
has O 0
been O 0
associated O 0
with O 0
mutations O 0
in O 0
the O 0
myelin O 0
proteolipid O 0
protein O 0
( O 0
PLP O 0
) O 0
gene O 0
. O 0

Only O 0
25 O 0
% O 0
of O 0
patients O 0
studied O 0
with O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
have O 0
exonic O 0
mutations O 0
in O 0
this O 0
gene O 0
, O 0
the O 0
underlying O 0
cause O 0
of O 0
the O 0
disease O 0
in O 0
the O 0
remaining O 0
patients O 0
is O 0
unknown O 0
. O 0

The O 0
PLP O 0
gene O 0
encodes O 0
two O 0
major O 0
alternatively O 0
spliced O 0
transcripts O 0
called O 0
PLP O 0
and O 0
DM20 O 0
. O 0

PLP O 0
messenger O 0
RNA O 0
is O 0
specifically O 0
expressed O 0
in O 0
central O 0
nervous O 0
system O 0
tissue O 0
, O 0
whereas O 0
DM20 O 0
messenger O 0
RNA O 0
is O 0
found O 0
in O 0
central O 0
nervous O 0
system O 0
, O 0
cardiac O 0
, O 0
and O 0
other O 0
tissues O 0
. O 0

We O 0
studied O 0
cultured O 0
skin O 0
fibroblasts O 0
from O 0
2 O 0
brothers O 0
with O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
who O 0
exhibited O 0
no O 0
detectable O 0
exonic O 0
mutation O 0
of O 0
the O 0
PLP O 0
gene O 0
. O 0

Examination O 0
of O 0
RNA O 0
from O 0
these O 0
cells O 0
showed O 0
that O 0
the O 0
level O 0
of O 0
DM20 O 0
messenger O 0
RNA O 0
is O 0
elevated O 0
sixfold O 0
relative O 0
to O 0
male O 0
control O 0
skin O 0
fibroblasts O 0
. O 0

An O 0
unrelated O 0
female O 0
carrier O 0
, O 0
also O 0
with O 0
no O 0
detectable O 0
exonic O 0
mutation O 0
, O 0
showed O 0
a O 0
threefold O 0
increase O 0
in O 0
DM20 O 0
messenger O 0
RNA O 0
in O 0
cultured O 0
skin O 0
fibroblasts O 0
. O 0

Our O 0
findings O 0
suggest O 0
that O 0
in O 0
some O 0
patients O 0
, O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
is O 0
caused O 0
by O 0
overexpression O 0
of O 0
PLP O 0
gene O 0
transcripts O 0
, O 0
and O 0
that O 0
in O 0
these O 0
families O 0
a O 0
50 O 0
% O 0
increase O 0
of O 0
DM20 O 0
messenger O 0
RNA O 0
in O 0
females O 0
, O 0
relative O 0
to O 0
the O 0
increase O 0
in O 0
affected O 0
males O 0
, O 0
can O 0
identify O 0
a O 0
female O 0
carrier O 0
. O 0
. O 0

The O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
and O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
congenital I-Disease 0
thrombocytopenia I-Disease 0
are O 0
caused O 0
by O 0
mutations O 0
of O 0
the O 0
same O 0
gene O 0
. O 0

The O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
( O 0
WAS B-Disease 0
) O 0
is O 0
an O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
recessive I-Disease 1
disorder I-Disease 1
characterized O 0
by O 0
thrombocytopenia B-Disease 0
, O 0
small O 0
platelets O 0
, O 0
eczema B-Disease 0
, O 0
recurrent O 0
infections O 0
, O 0
and O 0
immunodeficiency B-Disease 0
. O 0

Besides O 0
the O 0
classic O 0
WAS B-Disease 0
phenotype O 0
, O 0
there O 0
is O 0
a O 0
group O 0
of O 0
patients O 0
with O 0
congenital B-Disease 1
X I-Disease 1
- I-Disease 1
linked I-Disease 1
thrombocytopenia I-Disease 1
( O 0
XLT B-Disease 1
) O 0
who O 0
have O 0
small O 0
platelets O 0
but O 0
only O 0
transient O 0
eczema B-Disease 0
, O 0
if O 0
any O 0
, O 0
and O 0
minimal O 0
immune B-Disease 1
deficiency I-Disease 1
. O 0

Because O 0
the O 0
gene O 0
responsible O 0
for O 0
WAS B-Disease 0
has O 0
been O 0
sequenced O 0
, O 0
it O 0
was O 0
possible O 0
to O 0
correlate O 0
the O 0
WAS B-Disease 0
phenotypes O 0
with O 0
WAS B-Disease 0
gene O 0
mutations O 0
. O 0

Using O 0
a O 0
fingerprinting O 0
screening O 0
technique O 0
, O 0
we O 0
determined O 0
the O 0
approximate O 0
location O 0
of O 0
the O 0
mutation O 0
in O 0
13 O 0
unrelated O 0
WAS B-Disease 0
patients O 0
with O 0
mild O 0
to O 0
severe O 0
clinical O 0
symptoms O 0
. O 0

Direct O 0
sequence O 0
analysis O 0
of O 0
cDNA O 0
and O 0
genomic O 0
DNA O 0
obtained O 0
from O 0
patient O 0
- O 0
derived O 0
cell O 0
lines O 0
showed O 0
12 O 0
unique O 0
mutations O 0
distributed O 0
throughout O 0
the O 0
WAS B-Disease 0
gene O 0
, O 0
including O 0
insertions O 0
, O 0
deletions O 0
, O 0
and O 0
point O 0
mutations O 0
resulting O 0
in O 0
amino O 0
acid O 0
substitutions O 0
, O 0
termination O 0
, O 0
exon O 0
skipping O 0
, O 0
or O 0
splicing O 0
defects O 0
. O 0

Of O 0
4 O 0
unrelated O 0
patients O 0
with O 0
the O 0
XLT B-Disease 1
phenotype O 0
, O 0
3 O 0
had O 0
missense O 0
mutations O 0
affecting O 0
exon O 0
2 O 0
and O 0
1 O 0
had O 0
a O 0
splice O 0
- O 0
site O 0
mutation O 0
affecting O 0
exon O 0
9 O 0
. O 0

Patients O 0
with O 0
classic O 0
WAS B-Disease 0
had O 0
more O 0
complex O 0
mutations O 0
, O 0
resulting O 0
in O 0
termination O 0
codons O 0
, O 0
frameshift O 0
, O 0
and O 0
early O 0
termination O 0
. O 0

These O 0
findings O 0
provide O 0
direct O 0
evidence O 0
that O 0
XLT B-Disease 1
and O 0
WAS B-Disease 0
are O 0
caused O 0
by O 0
mutations O 0
of O 0
the O 0
same O 0
gene O 0
and O 0
suggest O 0
that O 0
severe O 0
clinical O 0
phenotypes O 0
are O 0
associated O 0
with O 0
complex O 0
mutations O 0
. O 0
. O 0

Myotonia B-Disease 0
levior I-Disease 0
is O 0
a O 0
chloride B-Disease 0
channel I-Disease 0
disorder I-Disease 0
. O 0

The O 0
group O 0
of O 0
dominant B-Disease 1
non I-Disease 1
- I-Disease 1
dystrophic I-Disease 1
myotonias I-Disease 1
, O 0
comprising O 0
disorders O 0
characterized O 0
by O 0
clinically O 0
similar O 0
forms O 0
of O 0
myogenic O 0
muscle O 0
stiffness O 0
, O 0
is O 0
genetically O 0
inhomogeneous O 0
. O 0

Dominant B-Disease 1
myotonia I-Disease 1
congenita I-Disease 1
( O 0
Thomsens B-Disease 0
disease I-Disease 0
) O 0
is O 0
linked O 0
to O 0
CLCN1 O 0
, O 0
the O 0
gene O 0
encoding O 0
the O 0
major O 0
muscle O 0
chloride O 0
channel O 0
, O 0
localized O 0
on O 0
chromosome O 0
7q35 O 0
. O 0

In O 0
contrast O 0
, O 0
dominant B-Disease 1
myotonias I-Disease 1
sensitive O 0
to O 0
potassium O 0
are O 0
caused O 0
by O 0
point O 0
mutations O 0
in O 0
SCN4A O 0
on O 0
chromosome O 0
17q O 0
, O 0
the O 0
gene O 0
for O 0
the O 0
alpha O 0
subunit O 0
of O 0
the O 0
adult O 0
skeletal O 0
muscle O 0
sodium O 0
channel O 0
. O 0

No O 0
linkage O 0
or O 0
molecular O 0
genetic O 0
data O 0
are O 0
as O 0
yet O 0
available O 0
on O 0
myotonia B-Disease 1
levior I-Disease 1
characterized O 0
by O 0
milder O 0
symptoms O 0
and O 0
later O 0
onset O 0
of O 0
myotonia B-Disease 1
than O 0
in O 0
Thomsens B-Disease 0
disease I-Disease 0
, O 0
and O 0
absence O 0
of O 0
muscle B-Disease 1
hypertrophy I-Disease 1
. O 0

We O 0
report O 0
a O 0
CLCN1 O 0
Gln O 0
- O 0
552 O 0
- O 0
Arg O 0
substitution O 0
for O 0
a O 0
family O 0
with O 0
dominant O 0
inheritance O 0
previously O 0
diagnosed O 0
to O 0
have O 0
myotonia B-Disease 1
levior I-Disease 1
. O 0

Thus O 0
, O 0
this O 0
disorder O 0
appears O 0
as O 0
a O 0
variant O 0
of O 0
Thomsens B-Disease 0
disease I-Disease 0
due O 0
to O 0
mutations O 0
leading O 0
to O 0
low O 0
clinical O 0
expressivity O 0
. O 0

In O 0
addition O 0
, O 0
we O 0
report O 0
a O 0
novel O 0
Ile O 0
- O 0
290 O 0
- O 0
Met O 0
CLCN1 O 0
mutation O 0
for O 0
a O 0
typical O 0
Thomsen O 0
pedigree O 0
. O 0

In O 0
another O 0
family O 0
previously O 0
diagnosed O 0
as O 0
having O 0
Thomsens B-Disease 0
disease I-Disease 0
, O 0
we O 0
unexpectedly O 0
found O 0
a O 0
CLCN1 O 0
14 O 0
bp O 0
deletion O 0
known O 0
to O 0
cause O 0
recessive B-Disease 1
myotonia I-Disease 1
, O 0
and O 0
a O 0
rare O 0
Trp O 0
- O 0
118 O 0
- O 0
Gly O 0
polymorphism O 0
. O 0
. O 0

Southern O 0
analysis O 0
reveals O 0
a O 0
large O 0
deletion O 0
at O 0
the O 0
hypoxanthine O 0
phosphoribosyltransferase O 0
locus O 0
in O 0
a O 0
patient O 0
with O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
. O 0

Whole O 0
genomic O 0
hprt O 0
clones O 0
were O 0
used O 0
in O 0
Southern O 0
analysis O 0
to O 0
screen O 0
the O 0
integrity O 0
of O 0
the O 0
hprt O 0
gene O 0
in O 0
a O 0
family O 0
that O 0
includes O 0
a O 0
patient O 0
with O 0
HPRT B-Disease 1
enzyme I-Disease 1
deficiency I-Disease 1
causal O 0
to O 0
Lesch B-Disease 1
- I-Disease 1
Nyhan I-Disease 1
syndrome I-Disease 0
. O 0

A O 0
5 O 0
kb O 0
DNA O 0
sequence O 0
deletion O 0
was O 0
found O 0
to O 0
have O 0
its O 0
endpoints O 0
in O 0
the O 0
first O 0
and O 0
third O 0
introns O 0
. O 0

The O 0
probes O 0
identified O 0
the O 0
carrier O 0
status O 0
of O 0
female O 0
family O 0
members O 0
, O 0
aided O 0
by O 0
an O 0
RFLP O 0
carried O 0
by O 0
the O 0
mothers O 0
normal O 0
X O 0
- O 0
chromosome O 0
. O 0
. O 0

Characterisation O 0
of O 0
molecular O 0
defects O 0
in O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
amelogenesis I-Disease 1
imperfecta I-Disease 1
( O 0
AIH1 O 1
) O 0
. O 0

Amelogenins O 0
are O 0
an O 0
heterogenous O 0
family O 0
of O 0
proteins O 0
produced O 0
by O 0
ameloblasts O 0
of O 0
the O 0
enamel O 0
organ O 0
during O 0
tooth O 0
development O 0
. O 0

Disturbances O 0
of O 0
enamel O 0
formation O 0
occur O 0
in O 0
amelogenesis B-Disease 1
imperfecta I-Disease 1
, O 0
a O 0
clinically O 0
heterogenous O 0
group O 0
of O 0
inherited B-Disease 1
disorders I-Disease 1
characterised O 0
by O 0
defective O 0
enamel O 0
biomineralisation O 0
. O 0

An O 0
amelogenin O 0
gene O 0
, O 0
AMGX O 0
, O 0
has O 0
been O 0
mapped O 0
to O 0
the O 0
short O 0
of O 0
the O 0
X O 0
chromosome O 0
( O 0
Xp22 O 0
. O 0
1 O 0
- O 0
p22 O 0
. O 0
3 O 0
) O 0
and O 0
has O 0
been O 0
implicated O 0
in O 0
the O 0
molecular O 0
pathology O 0
of O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
amelogenesis I-Disease 1
imperfecta I-Disease 1
( O 0
AIH1 B-Disease 1
) O 0
. O 0

We O 0
have O 0
identified O 0
three O 0
families O 0
exhibiting O 0
AIH1 B-Disease 1
and O 0
screened O 0
the O 0
AMGX O 0
gene O 0
for O 0
mutations O 0
using O 0
single O 0
- O 0
strand O 0
conformational O 0
polymorphism O 0
analysis O 0
and O 0
DNA O 0
sequencing O 0
. O 0

Three O 0
novel O 0
mutations O 0
were O 0
identified O 0
a O 0
C O 0
- O 0
T O 0
substitution O 0
in O 0
exon O 0
5 O 0
, O 0
and O 0
a O 0
G O 0
- O 0
T O 0
substitution O 0
and O 0
single O 0
cytosine O 0
deletion O 0
in O 0
exon O 0
6 O 0
, O 0
confirming O 0
the O 0
existence O 0
of O 0
extensive O 0
allelic O 0
heterogeneity O 0
in O 0
this O 0
condition O 0
. O 0

The O 0
identification O 0
of O 0
family O 0
- O 0
specific O 0
mutations O 0
will O 0
enable O 0
early O 0
identification O 0
of O 0
affected O 0
individuals O 0
and O 0
correlation O 0
of O 0
clinical O 0
phenotype O 0
with O 0
genotype O 0
will O 0
facilitate O 0
an O 0
objective O 0
system O 0
of O 0
disease O 0
classification O 0
. O 0

Frequency O 0
of O 0
exon O 0
15 O 0
missense O 0
mutation O 0
( O 0
442D O 0
: O 0
G O 0
) O 0
in O 0
cholesteryl O 0
ester O 0
transfer O 0
protein O 0
gene O 0
in O 0
hyperalphalipoproteinemic B-Disease 0
Japanese O 0
subjects O 0
. O 0

Cholesteryl O 0
ester O 0
transfer O 0
protein O 0
( O 0
CETP O 0
) O 0
transfers O 0
cholesteryl O 0
ester O 0
from O 0
high O 0
density O 0
lipoprotein O 0
( O 0
HDL O 0
) O 0
to O 0
apo O 0
B O 0
- O 0
containing O 0
lipoproteins O 0
. O 0

The O 0
hyperalphalipoproteinemia B-Disease 0
caused O 0
by O 0
CETP B-Disease 0
deficiency I-Disease 0
is O 0
fairly O 0
common O 0
in O 0
Japan O 0
and O 0
one O 0
of O 0
the O 0
most O 0
common O 0
mutations O 0
in O 0
the O 0
CETP O 0
gene O 0
is O 0
the O 0
splicing O 0
defect O 0
of O 0
the O 0
intron O 0
14 O 0
, O 0
the O 0
allelic O 0
frequency O 0
of O 0
which O 0
has O 0
been O 0
shown O 0
to O 0
be O 0
0 O 0
. O 0

0049 O 0
in O 0
the O 0
Japanese O 0
general O 0
population O 0
. O 0

Recently O 0
, O 0
we O 0
have O 0
reported O 0
a O 0
missense O 0
mutation O 0
in O 0
exon O 0
15 O 0
of O 0
the O 0
CETP O 0
gene O 0
( O 0
442D O 0
G O 0
) O 0
, O 0
showing O 0
a O 0
dominant O 0
effect O 0
on O 0
the O 0
CETP O 0
activity O 0
and O 0
HDL O 0
- O 0
cholesterol O 0
level O 0
. O 0

In O 0
the O 0
current O 0
study O 0
, O 0
we O 0
determined O 0
the O 0
frequency O 0
of O 0
this O 0
new O 0
mutation O 0
in O 0
Japanese O 0
hyperalphalipoproteinemic B-Disease 0
( O 0
HDL O 0
- O 0
cholesterol O 0
> O 0
or O 0
= O 0
100 O 0
mg O 0
/ O 0
dl O 0
) O 0
subjects O 0
. O 0

A O 0
rapid O 0
and O 0
easy O 0
screening O 0
method O 0
for O 0
this O 0
new O 0
mutation O 0
was O 0
developed O 0
using O 0
a O 0
polymerase O 0
chain O 0
reaction O 0
( O 0
PCR O 0
) O 0
- O 0
mediated O 0
site O 0
- O 0
directed O 0
mutagenesis O 0
. O 0

Among O 0
117 O 0
Japanese O 0
hyperalphalipoproteinemic B-Disease 0
subjects O 0
( O 0
HDL O 0
- O 0
cholesterol O 0
; O 0
116 O 0
. O 0
7 O 0
+ O 0
/ O 0
- O 0
16 O 0
. O 0
5 O 0
mg O 0
/ O 0
dl O 0
, O 0
mean O 0
+ O 0
/ O 0
- O 0
S O 0
. O 0
D O 0
. O 0
) O 0
without O 0
the O 0
intron O 0
14 O 0
splice O 0
defect O 0
, O 0
three O 0
homozygotes O 0
( O 0
2 O 0
. O 0
5 O 0
% O 0
) O 0
and O 0
34 O 0
heterozygotes O 0
( O 0
29 O 0
. O 0
1 O 0
% O 0
) O 0
were O 0
found O 0
to O 0
have O 0
the O 0
442D O 0
G O 0
mutation O 0
. O 0

The O 0
relative O 0
allelic O 0
frequency O 0
of O 0
this O 0
mutation O 0
was O 0
calculated O 0
to O 0
be O 0
0 O 0
. O 0

17 O 0
. O 0

One O 0
of O 0
the O 0
homozygotes O 0
for O 0
the O 0
442D O 0
G O 0
mutation O 0
was O 0
the O 0
patient O 0
previously O 0
described O 0
by O 0
us O 0
as O 0
having O 0
hyperalphalipoproteinemia B-Disease 0
with O 0
corneal B-Disease 0
opacity I-Disease 0
and O 0
coronary B-Disease 1
heart I-Disease 1
disease I-Disease 1
. O 0

This O 0
was O 0
the O 0
first O 0
reported O 0
subject O 0
homozygous O 0
for O 0
the O 0
CETP B-Disease 0
deficiency I-Disease 0
who O 0
also O 0
demonstrated O 0
atherosclerotic B-Disease 1
symptoms I-Disease 1
. O 0

In O 0
homozygous O 0
subjects O 0
, O 0
CETP O 0
activity O 0
ranged O 0
from O 0
37 O 0
% O 0
to O 0
62 O 0
% O 0
of O 0
the O 0
normal O 0
value O 0
, O 0
which O 0
was O 0
consistent O 0
with O 0
the O 0
results O 0
obtained O 0
from O 0
the O 0
transient O 0
expression O 0
experiment O 0
previously O 0
reported O 0
; O 0
however O 0
, O 0
the O 0
specific O 0
activity O 0
of O 0
CETP O 0
was O 0
not O 0
as O 0
low O 0
as O 0
expected O 0
. O 0

( O 0
ABSTRACT O 0
TRUNCATED O 0
AT O 0
250 O 0
WORDS O 0
) O 0

Mucopolysaccharidosis B-Disease 0
type I-Disease 0
IVA I-Disease 0
: O 0
common O 0
double O 0
deletion O 0
in O 0
the O 0
N O 0
- O 0
acetylgalactosamine O 0
- O 0
6 O 0
- O 0
sulfatase O 0
gene O 0
( O 0
GALNS O 0
) O 0
. O 0

Mucopolysaccharidosis B-Disease 0
IVA I-Disease 0
( O 0
MPS B-Disease 1
IVA I-Disease 1
) O 0
is O 0
an O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
caused O 0
by O 0
a O 0
deficiency B-Disease 1
in I-Disease 1
N I-Disease 1
- I-Disease 1
acetylgalactosamine I-Disease 1
- I-Disease 1
6 I-Disease 1
- I-Disease 1
sulfatase I-Disease 1
( O 0
GALNS O 0
) O 0
. O 0

We O 0
found O 0
two O 0
separate O 0
deletions O 0
of O 0
nearly O 0
8 O 0
. O 0

0 O 0
and O 0
6 O 0
. O 0

0 O 0
kb O 0
in O 0
the O 0
GALNS O 0
gene O 0
, O 0
including O 0
some O 0
exons O 0
. O 0

There O 0
are O 0
Alu O 0
repetitive O 0
elements O 0
near O 0
the O 0
breakpoints O 0
of O 0
the O 0
8 O 0
. O 0

0 O 0
- O 0
kb O 0
deletion O 0
, O 0
and O 0
this O 0
deletion O 0
resulted O 0
from O 0
an O 0
Alu O 0
- O 0
Alu O 0
recombination O 0
. O 0

The O 0
other O 0
6 O 0
. O 0

0 O 0
- O 0
kb O 0
deletion O 0
involved O 0
illegitimate O 0
recombinational O 0
events O 0
between O 0
incomplete O 0
short O 0
direct O 0
repeats O 0
of O 0
8 O 0
bp O 0
at O 0
deletion O 0
breakpoints O 0
. O 0

The O 0
same O 0
rearrangement O 0
has O 0
been O 0
observed O 0
in O 0
a O 0
heteroallelic O 0
state O 0
in O 0
four O 0
unrelated O 0
patients O 0
. O 0

This O 0
is O 0
the O 0
first O 0
documentation O 0
of O 0
a O 0
common O 0
double O 0
deletion O 0
a O 0
gene O 0
that O 0
is O 0
not O 0
a O 0
member O 0
of O 0
a O 0
gene O 0
cluster O 0
. O 0

Detection O 0
of O 0
eight O 0
BRCA1 O 0
mutations O 0
in O 0
10 O 0
breast B-Disease 0
/ I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
families O 0
, O 0
including O 0
1 O 0
family O 0
with O 0
male B-Disease 0
breast I-Disease 0
cancer I-Disease 1
. O 0

Genetic O 0
epidemiological O 0
evidence O 0
suggests O 0
that O 0
mutations O 0
in O 0
BRCA1 O 0
may O 0
be O 0
responsible O 0
for O 0
approximately O 0
one O 0
half O 0
of O 0
early O 0
onset O 0
familial B-Disease 1
breast I-Disease 1
cancer I-Disease 1
and O 0
the O 0
majority O 0
of O 0
familial B-Disease 0
breast I-Disease 0
/ I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
. O 0

The O 0
recent O 0
cloning O 0
of O 0
BRCA1 O 0
allows O 0
for O 0
the O 0
direct O 0
detection O 0
of O 0
mutations O 0
, O 0
but O 0
the O 0
feasibility O 0
of O 0
presymptomatic O 0
screening O 0
for O 0
cancer B-Disease 1
susceptibility O 0
is O 0
unknown O 0
. O 0

We O 0
analyzed O 0
genomic O 0
DNA O 0
from O 0
one O 0
affected O 0
individual O 0
from O 0
each O 0
of O 0
24 O 0
families O 0
with O 0
at O 0
least O 0
three O 0
cases O 0
of O 0
ovarian B-Disease 1
or I-Disease 1
breast I-Disease 1
cancer I-Disease 1
, O 0
using O 0
SSCP O 0
assays O 0
. O 0

Variant O 0
SSCP O 0
bands O 0
were O 0
subcloned O 0
and O 0
sequenced O 0
. O 0

Allele O 0
- O 0
specific O 0
oligonucleotide O 0
hybridization O 0
was O 0
used O 0
to O 0
verify O 0
sequence O 0
changes O 0
and O 0
to O 0
screen O 0
DNA O 0
from O 0
control O 0
individuals O 0
. O 0

Six O 0
frameshift O 0
and O 0
two O 0
missense O 0
mutations O 0
were O 0
detected O 0
in O 0
10 O 0
different O 0
families O 0
. O 0

A O 0
frameshift O 0
mutation O 0
was O 0
detected O 0
in O 0
a O 0
male O 0
proband O 0
affected O 0
with O 0
both O 0
breast B-Disease 0
and I-Disease 0
prostate I-Disease 1
cancer I-Disease 1
. O 0

A O 0
40 O 0
- O 0
bp O 0
deletion O 0
was O 0
detected O 0
in O 0
a O 0
patient O 0
who O 0
developed O 0
intra B-Disease 0
- I-Disease 0
abdominal I-Disease 0
carcinomatosis I-Disease 0
1 O 0
year O 0
after O 0
prophylactic O 0
oophorectomy O 0
. O 0

Mutations O 0
were O 0
detected O 0
throughout O 0
the O 0
gene O 0
, O 0
and O 0
only O 0
one O 0
was O 0
detected O 0
in O 0
more O 0
than O 0
a O 0
single O 0
family O 0
. O 0

These O 0
results O 0
provide O 0
further O 0
evidence O 0
that O 0
inherited B-Disease 1
breast I-Disease 1
and I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
can O 0
occur O 0
as O 0
a O 0
consequence O 0
of O 0
a O 0
wide O 0
array O 0
of O 0
BRCA1 O 0
mutations O 0
. O 0

These O 0
results O 0
suggests O 0
that O 0
development O 0
of O 0
a O 0
screening O 0
test O 0
for O 0
BRCA1 O 0
mutations O 0
will O 0
be O 0
technically O 0
challenging O 0
. O 0

The O 0
finding O 0
of O 0
a O 0
mutation O 0
in O 0
a O 0
family O 0
with O 0
male B-Disease 0
breast I-Disease 0
cancer I-Disease 1
, O 0
not O 0
previously O 0
thought O 0
to O 0
be O 0
related O 0
to O 0
BRCA1 O 0
, O 0
also O 0
illustrates O 0
the O 0
potential O 0
difficulties O 0
of O 0
genetic O 0
counseling O 0
for O 0
individuals O 0
known O 0
to O 0
carry O 0
mutations O 0
. O 0
. O 0

Natural O 0
selection O 0
of O 0
hemi O 0
- O 0
and O 0
heterozygotes O 0
for O 0
G6PD B-Disease 0
deficiency I-Disease 0
in O 0
Africa O 0
by O 0
resistance O 0
to O 0
severe O 0
malaria B-Disease 1
. O 0

Glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
) I-Disease 0
deficiency I-Disease 0
, O 0
the O 0
most O 0
common O 0
enzymopathy B-Disease 0
of O 0
humans O 0
, O 0
affects O 0
over O 0
400 O 0
million O 0
people O 0
. O 0

The O 0
geographical O 0
correlation O 0
of O 0
its O 0
distribution O 0
with O 0
the O 0
historical O 0
endemicity O 0
of O 0
malaria B-Disease 1
suggests O 0
that O 0
this O 0
disorder O 0
has O 0
risen O 0
in O 0
frequency O 0
through O 0
natural O 0
selection O 0
by O 0
malaria B-Disease 1
. O 0

However O 0
, O 0
attempts O 0
to O 0
confirm O 0
that O 0
G6PD B-Disease 0
deficiency I-Disease 0
is O 0
protective O 0
in O 0
case O 0
- O 0
control O 0
studies O 0
of O 0
malaria B-Disease 1
have O 0
yielded O 0
conflicting O 0
results O 0
. O 0

Hence O 0
, O 0
for O 0
this O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
disorder I-Disease 1
, O 0
it O 0
is O 0
unclear O 0
whether O 0
both O 0
male O 0
hemizygotes O 0
and O 0
female O 0
heterozygotes O 0
are O 0
protected O 0
or O 0
, O 0
as O 0
frequently O 0
suggested O 0
, O 0
only O 0
females O 0
. O 0

Furthermore O 0
, O 0
how O 0
much O 0
protection O 0
may O 0
be O 0
afforded O 0
is O 0
unknown O 0
. O 0

Here O 0
we O 0
report O 0
that O 0
, O 0
in O 0
two O 0
large O 0
case O 0
- O 0
control O 0
studies O 0
of O 0
over O 0
2 O 0
, O 0
000 O 0
African O 0
children O 0
, O 0
the O 0
common O 0
African O 0
form O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
( O 0
G6PD B-Disease 1
A I-Disease 1
- I-Disease 1
) O 0
is O 0
associated O 0
with O 0
a O 0
46 O 0
- O 0
58 O 0
% O 0
reduction O 0
in O 0
risk O 0
of O 0
severe O 0
malaria B-Disease 1
for O 0
both O 0
female O 0
heterozygotes O 0
and O 0
male O 0
hemizygotes O 0
. O 0

A O 0
mathematical O 0
model O 0
incorporating O 0
the O 0
measured O 0
selective O 0
advantage O 0
against O 0
malaria B-Disease 1
suggests O 0
that O 0
a O 0
counterbalancing O 0
selective O 0
disadvantage O 0
, O 0
associated O 0
with O 0
this O 0
enzyme B-Disease 0
deficiency I-Disease 0
, O 0
has O 0
retarded O 0
its O 0
rise O 0
in O 0
frequency O 0
in O 0
malaria B-Disease 1
- O 0
endemic O 0
regions O 0
. O 0

Although O 0
G6PD B-Disease 0
deficiency I-Disease 0
is O 0
now O 0
regarded O 0
as O 0
a O 0
generally O 0
benign O 0
disorder O 0
, O 0
in O 0
earlier O 0
environmental O 0
conditions O 0
it O 0
could O 0
have O 0
been O 0
significantly O 0
disadvantageous O 0
. O 0
. O 0

The O 0
alveolar B-Disease 1
rhabdomyosarcoma I-Disease 1
PAX3 O 0
/ O 0
FKHR O 0
fusion O 0
protein O 0
is O 0
a O 0
transcriptional O 0
activator O 0
. O 0

Chimeric O 0
transcription O 0
factors O 0
, O 0
created O 0
by O 0
gene O 0
fusions O 0
as O 0
the O 0
result O 0
of O 0
chromosomal O 0
translocations O 0
, O 0
have O 0
been O 0
implicated O 0
in O 0
the O 0
pathogenesis O 0
of O 0
several O 0
pathologically O 0
disparate O 0
solid B-Disease 0
tumors I-Disease 0
. O 0

The O 0
PAX3 O 0
/ O 0
FKHR O 0
fusion O 0
gene O 0
, O 0
formed O 0
by O 0
a O 0
t O 0
( O 0
2 O 0
; O 0
13 O 0
) O 0
( O 0
q35 O 0
; O 0
q14 O 0
) O 0
in O 0
alveolar B-Disease 1
rhabdomyosarcoma I-Disease 1
, O 0
encodes O 0
a O 0
hybrid O 0
protein O 0
that O 0
contains O 0
both O 0
PAX3 O 0
DNA O 0
binding O 0
domains O 0
, O 0
the O 0
paired O 0
box O 0
and O 0
homeodomain O 0
, O 0
linked O 0
to O 0
the O 0
bisected O 0
DNA O 0
binding O 0
domain O 0
of O 0
FKHR O 0
, O 0
a O 0
member O 0
of O 0
the O 0
forkhead O 0
family O 0
of O 0
transcription O 0
factors O 0
. O 0

Here O 0
we O 0
report O 0
that O 0
PAX3 O 0
and O 0
PAX3 O 0
/ O 0
FKHR O 0
display O 0
similar O 0
, O 0
but O 0
not O 0
identical O 0
transactivation O 0
activities O 0
when O 0
tested O 0
with O 0
model O 0
Pax O 0
recognition O 0
sequences O 0
. O 0

No O 0
functional O 0
role O 0
could O 0
be O 0
ascribed O 0
solely O 0
to O 0
the O 0
residual O 0
FKHR O 0
binding O 0
domain O 0
present O 0
in O 0
the O 0
fusion O 0
protein O 0
, O 0
but O 0
FKHR O 0
was O 0
found O 0
to O 0
contribute O 0
a O 0
strong O 0
carboxyl O 0
terminal O 0
activation O 0
domain O 0
replacing O 0
the O 0
one O 0
located O 0
in O 0
the O 0
unrearranged O 0
PAX3 O 0
gene O 0
. O 0

We O 0
show O 0
that O 0
the O 0
native O 0
PAX3 O 0
/ O 0
FKHR O 0
protein O 0
present O 0
in O 0
tumor B-Disease 0
cells O 0
with O 0
this O 0
translocation O 0
has O 0
transcriptional O 0
characteristics O 0
similar O 0
to O 0
the O 0
in O 0
vitro O 0
expressed O 0
protein O 0
. O 0

The O 0
ability O 0
of O 0
the O 0
PAX3 O 0
/ O 0
FKHR O 0
hybrid O 0
protein O 0
to O 0
bind O 0
DNA O 0
in O 0
a O 0
sequence O 0
specific O 0
manner O 0
and O 0
to O 0
transactivate O 0
the O 0
expression O 0
of O 0
artificial O 0
reporter O 0
genes O 0
suggests O 0
that O 0
its O 0
aberrant O 0
expression O 0
could O 0
subvert O 0
the O 0
transcriptional O 0
programs O 0
that O 0
normally O 0
control O 0
the O 0
growth O 0
, O 0
differentiation O 0
, O 0
and O 0
survival O 0
of O 0
primitive O 0
myogenic O 0
precursors O 0
in O 0
vivo O 0
. O 0
. O 0

A O 0
p16INK4a O 0
- O 0
insensitive O 0
CDK4 O 0
mutant O 0
targeted O 0
by O 0
cytolytic O 0
T O 0
lymphocytes O 0
in O 0
a O 0
human O 0
melanoma B-Disease 0
. O 0

A O 0
mutated O 0
cyclin O 0
- O 0
dependent O 0
kinase O 0
4 O 0
( O 0
CDK4 O 0
) O 0
was O 0
identified O 0
as O 0
a O 0
tumor B-Disease 0
- O 0
specific O 0
antigen O 0
recognized O 0
by O 0
HLA O 0
- O 0
A2 O 0
. O 0

1 O 0
- O 0
restricted O 0
autologous O 0
cytolytic O 0
T O 0
lymphocytes O 0
( O 0
CTLs O 0
) O 0
in O 0
a O 0
human O 0
melanoma B-Disease 0
. O 0

The O 0
mutated O 0
CDK4 O 0
allele O 0
was O 0
present O 0
in O 0
autologous O 0
cultured O 0
melanoma B-Disease 0
cells O 0
and O 0
metastasis O 0
tissue O 0
, O 0
but O 0
not O 0
in O 0
the O 0
patients O 0
lymphocytes O 0
. O 0

The O 0
mutation O 0
, O 0
an O 0
arginine O 0
- O 0
to O 0
- O 0
cysteine O 0
exchange O 0
at O 0
residue O 0
24 O 0
, O 0
was O 0
part O 0
of O 0
the O 0
CDK4 O 0
peptide O 0
recognized O 0
by O 0
CTLs O 0
and O 0
prevented O 0
binding O 0
of O 0
the O 0
CDK4 O 0
inhibitor O 0
p16INK4a O 0
, O 0
but O 0
not O 0
of O 0
p21 O 0
or O 0
of O 0
p27KIP1 O 0
. O 0

The O 0
same O 0
mutation O 0
was O 0
found O 0
in O 0
one O 0
additional O 0
melanoma B-Disease 0
among O 0
28 O 0
melanomas B-Disease 1
analyzed O 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
mutation O 0
of O 0
CDK4 O 0
can O 0
create O 0
a O 0
tumor B-Disease 0
- O 0
specific O 0
antigen O 0
and O 0
can O 0
disrupt O 0
the O 0
cell O 0
- O 0
cycle O 0
regulation O 0
exerted O 0
by O 0
the O 0
tumor B-Disease 0
suppressor O 0
p16INK4a O 0
. O 0
. O 0

Rapid O 0
detection O 0
of O 0
BRCA1 O 0
mutations O 0
by O 0
the O 0
protein O 0
truncation O 0
test O 0
. O 0

More O 0
than O 0
75 O 0
% O 0
of O 0
the O 0
reported O 0
mutations O 0
in O 0
the O 0
hereditary B-Disease 1
breast I-Disease 1
and I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
gene O 0
, O 0
BRCA1 O 0
, O 0
result O 0
in O 0
truncated O 0
proteins O 0
. O 0

We O 0
have O 0
used O 0
the O 0
protein O 0
truncation O 0
test O 0
( O 0
PTT O 0
) O 0
to O 0
screen O 0
for O 0
mutations O 0
in O 0
exon O 0
11 O 0
, O 0
which O 0
encodes O 0
61 O 0
% O 0
of O 0
BRCA1 O 0
. O 0

In O 0
45 O 0
patients O 0
from O 0
breast B-Disease 1
and I-Disease 1
/ I-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
families O 0
we O 0
found O 0
six O 0
novel O 0
mutations O 0
two O 0
single O 0
nucleotide O 0
insertions O 0
, O 0
three O 0
small O 0
deletions O 0
( O 0
1 O 0
- O 0
5 O 0
bp O 0
) O 0
and O 0
a O 0
nonsense O 0
mutation O 0
identified O 0
two O 0
unrelated O 0
families O 0
. O 0

Furthermore O 0
, O 0
we O 0
were O 0
able O 0
to O 0
amplify O 0
the O 0
remaining O 0
coding O 0
region O 0
by O 0
RT O 0
- O 0
PCR O 0
using O 0
lymphocyte O 0
RNA O 0
. O 0

Combined O 0
with O 0
PTT O 0
, O 0
we O 0
detected O 0
aberrantly O 0
spliced O 0
products O 0
affecting O 0
exons O 0
5 O 0
and O 0
6 O 0
in O 0
one O 0
of O 0
two O 0
BRCA1 O 0
- O 0
linked O 0
families O 0
examined O 0
. O 0

The O 0
protein O 0
truncation O 0
test O 0
promises O 0
to O 0
become O 0
a O 0
valuable O 0
technique O 0
in O 0
detecting O 0
BRCA1 O 0
mutations O 0
. O 0
. O 0

Cloning O 0
of O 0
human O 0
very O 0
- O 0
long O 0
- O 0
chain O 0
acyl O 0
- O 0
coenzyme O 0
A O 0
dehydrogenase O 0
and O 0
molecular O 0
characterization O 0
of O 0
its O 0
deficiency O 0
in O 0
two O 0
patients O 0
. O 0

Two O 0
overlapping O 0
cDNA O 0
clones O 0
( O 0
1 O 0
, O 0
991 O 0
bp O 0
and O 0
736 O 0
bp O 0
, O 0
respectively O 0
) O 0
encoding O 0
the O 0
precursor O 0
of O 0
human O 0
mitochondrial O 0
very O 0
- O 0
long O 0
- O 0
chain O 0
acyl O 0
- O 0
coenzyme O 0
A O 0
dehydrogenase O 0
( O 0
VLCAD O 0
) O 0
were O 0
cloned O 0
and O 0
sequenced O 0
. O 0

The O 0
cDNA O 0
inserts O 0
of O 0
these O 0
clones O 0
together O 0
encompass O 0
a O 0
region O 0
of O 0
2 O 0
, O 0
177 O 0
bases O 0
, O 0
encoding O 0
the O 0
entire O 0
protein O 0
of O 0
655 O 0
amino O 0
acids O 0
, O 0
including O 0
a O 0
40 O 0
- O 0
amino O 0
acid O 0
leader O 0
peptide O 0
and O 0
a O 0
615 O 0
- O 0
amino O 0
acid O 0
mature O 0
polypeptide O 0
. O 0

PCR O 0
- O 0
amplified O 0
VLCAD O 0
cDNAs O 0
were O 0
sequenced O 0
in O 0
cultured O 0
fibroblasts O 0
from O 0
two O 0
VLCAD B-Disease 0
- I-Disease 0
deficient I-Disease 0
patients O 0
. O 0

In O 0
both O 0
patients O 0
, O 0
a O 0
105 O 0
- O 0
bp O 0
deletion O 0
encompassing O 0
bases O 0
1078 O 0
- O 0
1182 O 0
in O 0
VLCAD O 0
cDNA O 0
was O 0
identified O 0
. O 0

The O 0
deletion O 0
seems O 0
to O 0
occur O 0
due O 0
to O 0
exon O 0
skipping O 0
during O 0
processing O 0
of O 0
VLCAD O 0
pre O 0
- O 0
mRNA O 0
. O 0

This O 0
is O 0
the O 0
first O 0
demonstration O 0
of O 0
a O 0
mutation O 0
causing O 0
VLCAD B-Disease 0
deficiency I-Disease 0
. O 0

Quantitative O 0
cDNA O 0
expression O 0
of O 0
normal O 0
human O 0
VLCAD O 0
was O 0
performed O 0
in O 0
the O 0
patients O 0
fibroblasts O 0
, O 0
using O 0
vaccinia O 0
viral O 0
system O 0
, O 0
which O 0
demonstrated O 0
that O 0
the O 0
deficiency B-Disease 0
of I-Disease 0
the I-Disease 0
normal I-Disease 0
VLCAD I-Disease 0
protein I-Disease 0
causes O 0
impaired O 0
long O 0
- O 0
chain O 0
fatty O 0
acid O 0
beta O 0
- O 0
oxidation O 0
activity O 0
in O 0
the O 0
patients O 0
fibroblasts O 0
. O 0

In O 0
patient O 0
fibroblasts O 0
, O 0
raising O 0
VLCAD O 0
activity O 0
to O 0
approximately O 0
20 O 0
% O 0
of O 0
normal O 0
control O 0
fibroblast O 0
activity O 0
raised O 0
palmitic O 0
acid O 0
beta O 0
- O 0
oxidation O 0
flux O 0
to O 0
the O 0
level O 0
found O 0
in O 0
control O 0
fibroblasts O 0
, O 0
which O 0
may O 0
offer O 0
important O 0
information O 0
for O 0
the O 0
rational O 0
design O 0
of O 0
future O 0
somatic O 0
gene O 0
therapy O 0
for O 0
VLCAD B-Disease 0
deficiency I-Disease 0
. O 0
. O 0

Brain B-Disease 0
disease I-Disease 0
and O 0
molecular O 0
analysis O 0
in O 0
myotonic B-Disease 1
dystrophy I-Disease 1
. O 0

Abnormal O 0
amplification O 0
of O 0
a O 0
CTG O 0
repeat O 0
on O 0
chromosome O 0
19 O 0
is O 0
the O 0
molecular O 0
basis O 0
of O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
. O 0

Expansion O 0
of O 0
the O 0
repeat O 0
has O 0
been O 0
correlated O 0
with O 0
severity O 0
of O 0
several O 0
clinical O 0
features O 0
of O 0
the O 0
disease O 0
. O 0

We O 0
performed O 0
extensive O 0
cognitive O 0
testing O 0
, O 0
cerebral O 0
magnetic O 0
resonance O 0
imaging O 0
( O 0
MRI O 0
) O 0
and O 0
a O 0
molecular O 0
analysis O 0
in O 0
28 O 0
cases O 0
of O 0
DM B-Disease 0
to O 0
determine O 0
the O 0
relationship O 0
between O 0
the O 0
molecular O 0
defect O 0
and O 0
brain B-Disease 1
disease I-Disease 1
. O 0

Performance O 0
in O 0
two O 0
or O 0
more O 0
cognitive O 0
tests O 0
was O 0
pathological O 0
in O 0
10 O 0
cases O 0
. O 0

Fourteen O 0
patients O 0
had O 0
subcortical O 0
white B-Disease 0
matter I-Disease 0
lesions I-Disease 0
on O 0
MRI O 0
, O 0
14 O 0
had O 0
cerebral B-Disease 0
atrophy I-Disease 0
. O 0

Amplification O 0
of O 0
the O 0
CTG O 0
repeat O 0
showed O 0
a O 0
strong O 0
correlation O 0
with O 0
cognitive O 0
test O 0
deficits O 0
when O 0
exceeding O 0
a O 0
length O 0
of O 0
over O 0
1000 O 0
trinucleotides O 0
. O 0

MRI O 0
lesions O 0
were O 0
associated O 0
with O 0
impaired O 0
psychometric O 0
performance O 0
, O 0
but O 0
MRI O 0
and O 0
molecular O 0
findings O 0
were O 0
only O 0
weakly O 0
related O 0
. O 0

Disease O 0
duration O 0
influenced O 0
the O 0
appearance O 0
and O 0
amount O 0
of O 0
white B-Disease 0
matter I-Disease 0
lesions I-Disease 0
on O 0
MRI O 0
. O 0

Quantification O 0
of O 0
CTG O 0
repeat O 0
size O 0
may O 0
allow O 0
an O 0
early O 0
estimate O 0
on O 0
the O 0
probability O 0
of O 0
brain O 0
involvement O 0
in O 0
DM B-Disease 0
; O 0
cognitive B-Disease 1
dysfunction I-Disease 1
is O 0
associated O 0
with O 0
white B-Disease 0
matter I-Disease 0
lesions I-Disease 0
and O 0
cerebral B-Disease 0
atrophy I-Disease 0
later O 0
on O 0
in O 0
the O 0
course O 0
. O 0
. O 0

Mutations O 0
in O 0
the O 0
gene O 0
for O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
in O 0
patients O 0
with O 0
different O 0
clinical O 0
phenotypes O 0
. O 0

Recently O 0
, O 0
the O 0
gene O 0
for O 0
the O 0
most O 0
common O 0
peroxisomal B-Disease 1
disorder I-Disease 1
, O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
( O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
) O 0
, O 0
has O 0
been O 0
described O 0
encoding O 0
a O 0
peroxisomal O 0
membrane O 0
transporter O 0
protein O 0
. O 0

We O 0
analyzed O 0
the O 0
entire O 0
protein O 0
- O 0
coding O 0
sequence O 0
of O 0
this O 0
gene O 0
by O 0
reverse O 0
- O 0
transcription O 0
PCR O 0
, O 0
SSCP O 0
, O 0
and O 0
DNA O 0
sequencing O 0
in O 0
five O 0
patients O 0
with O 0
different O 0
clinical O 0
expression O 0
of O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
and O 0
in O 0
their O 0
female O 0
relatives O 0
; O 0
these O 0
clinical O 0
expressions O 0
were O 0
cerebral O 0
childhood O 0
ALD B-Disease 0
, O 0
adrenomyeloneuropathy B-Disease 1
( O 0
AMN B-Disease 0
) O 0
, O 0
and O 0
" O 0
Addison B-Disease 1
disease I-Disease 1
only I-Disease 1
" O 0
( O 0
ADO B-Disease 1
) O 0
phenotype O 0
. O 0

In O 0
the O 0
three O 0
patients O 0
exhibiting O 0
the O 0
classical O 0
picture O 0
of O 0
severe O 0
childhood O 0
ALD B-Disease 0
we O 0
identified O 0
in O 0
the O 0
5 O 0
portion O 0
of O 0
the O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
gene O 0
a O 0
38 O 0
- O 0
bp O 0
deletion O 0
that O 0
causes O 0
a O 0
frameshift O 0
mutation O 0
, O 0
a O 0
3 O 0
- O 0
bp O 0
deletion O 0
leading O 0
to O 0
a O 0
deletion O 0
of O 0
an O 0
amino O 0
acid O 0
in O 0
the O 0
ATP O 0
- O 0
binding O 0
domain O 0
of O 0
the O 0
ALD B-Disease 0
protein O 0
, O 0
and O 0
a O 0
missense O 0
mutation O 0
. O 0

In O 0
the O 0
patient O 0
with O 0
the O 0
clinical O 0
phenotype O 0
of O 0
AMN B-Disease 0
, O 0
a O 0
nonsense O 0
mutation O 0
in O 0
codon O 0
212 O 0
, O 0
along O 0
with O 0
a O 0
second O 0
site O 0
mutation O 0
at O 0
codon O 0
178 O 0
, O 0
was O 0
observed O 0
. O 0

Analysis O 0
of O 0
the O 0
patient O 0
with O 0
the O 0
ADO B-Disease 1
phenotype O 0
revealed O 0
a O 0
further O 0
missense O 0
mutation O 0
at O 0
a O 0
highly O 0
conserved O 0
position O 0
in O 0
the O 0
ALDP O 0
/ O 0
PMP70 O 0
comparison O 0
. O 0

The O 0
disruptive O 0
nature O 0
of O 0
two O 0
mutations O 0
( O 0
i O 0
. O 0
e O 0
. O 0
, O 0
the O 0
frameshift O 0
and O 0
the O 0
nonsense O 0
mutation O 0
) O 0
in O 0
patients O 0
with O 0
biochemically O 0
proved O 0
childhood O 0
ALD B-Disease 0
and O 0
AMN B-Disease 0
further O 0
strongly O 0
supports O 0
the O 0
hypothesis O 0
that O 0
alterations O 0
in O 0
this O 0
gene O 0
play O 0
a O 0
crucial O 0
role O 0
in O 0
the O 0
pathogenesis O 0
of O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
. O 0

Since O 0
the O 0
current O 0
biochemical O 0
techniques O 0
for O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
carrier O 0
detection O 0
in O 0
affected O 0
families O 0
lack O 0
sufficient O 0
reliability O 0
, O 0
our O 0
procedure O 0
described O 0
for O 0
systematic O 0
mutation O 0
scanning O 0
is O 0
also O 0
capable O 0
of O 0
improving O 0
genetic O 0
counseling O 0
and O 0
prenatal O 0
diagnosis O 0

Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
and O 0
myotonic B-Disease 1
dystrophy I-Disease 1
in O 0
the O 0
same O 0
patient O 0
. O 0

We O 0
report O 0
on O 0
the O 0
first O 0
patient O 0
identified O 0
with O 0
myotonic B-Disease 1
dystrophy I-Disease 1
and O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
. O 0

The O 0
family O 0
of O 0
the O 0
propositus O 0
had O 0
a O 0
strong O 0
history O 0
of O 0
myotonic B-Disease 1
dystrophy I-Disease 1
, O 0
and O 0
there O 0
was O 0
an O 0
intrafamilial O 0
pathological O 0
expansion O 0
of O 0
the O 0
responsible O 0
CTG O 0
repeat O 0
between O 0
the O 0
mildly O 0
affected O 0
mother O 0
( O 0
160 O 0
repeats O 0
; O 0
normal O 0
27 O 0
repeats O 0
) O 0
and O 0
her O 0
more O 0
severely O 0
affected O 0
son O 0
( O 0
650 O 0
repeats O 0
) O 0
, O 0
and O 0
his O 0
sister O 0
( O 0
650 O 0
repeats O 0
) O 0
. O 0

The O 0
propositus O 0
was O 0
an O 0
isolated O 0
case O 0
of O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
with O 0
marked O 0
dystrophin B-Disease 1
deficiency I-Disease 1
in O 0
muscle O 0
biopsy O 0
. O 0

The O 0
patient O 0
was O 0
still O 0
ambulatory O 0
post O 0
age O 0
16 O 0
. O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
could O 0
interfere O 0
to O 0
some O 0
extent O 0
with O 0
the O 0
progression O 0
of O 0
Duchenne B-Disease 0
dystrophy I-Disease 0
. O 0

However O 0
, O 0
other O 0
interpretations O 0
are O 0
possible O 0
. O 0

Twelve O 0
percent O 0
of O 0
dystrophin O 0
revertant O 0
fibers O 0
as O 0
observed O 0
by O 0
immunohistochemistry O 0
could O 0
be O 0
sufficient O 0
to O 0
ameliorate O 0
typical O 0
DMD B-Disease 0
clinical O 0
severity O 0
, O 0
or O 0
the O 0
patient O 0
may O 0
present O 0
a O 0
somatic O 0
mosaic O 0
. O 0

The O 0
pathophysiological O 0
interactions O 0
of O 0
these O 0
two O 0
unlinked O 0
disorders O 0
are O 0
discussed O 0
at O 0
the O 0
clinical O 0
and O 0
histopathological O 0
levels O 0
. O 0
. O 0

Age O 0
at O 0
diagnosis O 0
as O 0
an O 0
indicator O 0
of O 0
eligibility O 0
for O 0
BRCA1 O 0
DNA O 0
testing O 0
in O 0
familial B-Disease 1
breast I-Disease 1
cancer I-Disease 1
. O 0

We O 0
searched O 0
for O 0
criteria O 0
that O 0
could O 0
indicate O 0
breast B-Disease 0
cancer I-Disease 1
families O 0
with O 0
a O 0
high O 0
prior O 0
probability O 0
of O 0
being O 0
caused O 0
by O 0
the O 0
breast B-Disease 0
/ I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
susceptibility O 0
locus O 0
BRCA1 O 0
on O 0
chromosome O 0
17 O 0
. O 0

To O 0
this O 0
end O 0
, O 0
we O 0
performed O 0
a O 0
linkage O 0
study O 0
with O 0
59 O 0
consecutively O 0
collected O 0
Dutch O 0
breast B-Disease 0
cancer I-Disease 1
families O 0
, O 0
including O 0
16 O 0
with O 0
at O 0
least O 0
one O 0
case O 0
of O 0
ovarian B-Disease 0
cancer I-Disease 1
. O 0

We O 0
used O 0
an O 0
intake O 0
cut O 0
- O 0
off O 0
of O 0
at O 0
least O 0
three O 0
first O 0
- O 0
degree O 0
relatives O 0
with O 0
breast B-Disease 1
and I-Disease 1
/ I-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
at O 0
any O 0
age O 0
. O 0

Significant O 0
evidence O 0
for O 0
linkage O 0
was O 0
found O 0
only O 0
among O 0
the O 0
13 O 0
breast B-Disease 0
cancer I-Disease 1
families O 0
with O 0
a O 0
mean O 0
age O 0
at O 0
diagnosis O 0
of O 0
less O 0
than O 0
45 O 0
years O 0
. O 0

An O 0
unexpectedly O 0
low O 0
proportion O 0
of O 0
the O 0
breast B-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
families O 0
were O 0
estimated O 0
to O 0
be O 0
linked O 0
to O 0
BRCA1 O 0
, O 0
which O 0
could O 0
be O 0
due O 0
to O 0
a O 0
founder O 0
effect O 0
in O 0
the O 0
Dutch O 0
population O 0
. O 0

Given O 0
the O 0
expected O 0
logistical O 0
problems O 0
in O 0
clinical O 0
management O 0
now O 0
that O 0
BRCA1 O 0
has O 0
been O 0
identified O 0
, O 0
we O 0
propose O 0
an O 0
interim O 0
period O 0
in O 0
which O 0
only O 0
families O 0
with O 0
a O 0
strong O 0
positive O 0
family O 0
history O 0
for O 0
early O 0
onset O 0
breast B-Disease 1
and I-Disease 1
/ I-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
will O 0
be O 0
offered O 0
BRCA1 O 0
mutation O 0
testing O 0
. O 0
. O 0

Linkage O 0
analysis O 0
of O 0
26 O 0
Canadian O 0
breast B-Disease 0
and I-Disease 0
breast I-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
families O 0
. O 0

We O 0
have O 0
examined O 0
26 O 0
Canadian O 0
families O 0
with O 0
hereditary B-Disease 0
breast I-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
for O 0
linkage O 0
to O 0
markers O 0
flanking O 0
the O 0
BRCA1 O 0
gene O 0
on O 0
chromosome O 0
17q12 O 0
- O 0
q21 O 0
. O 0

Of O 0
the O 0
15 O 0
families O 0
that O 0
contain O 0
cases O 0
of O 0
ovarian B-Disease 0
cancer I-Disease 1
, O 0
94 O 0
% O 0
were O 0
estimated O 0
to O 0
be O 0
linked O 0
to O 0
BRCA1 O 0
. O 0

In O 0
contrast O 0
, O 0
there O 0
was O 0
no O 0
overall O 0
evidence O 0
of O 0
linkage O 0
in O 0
the O 0
group O 0
of O 0
10 O 0
families O 0
with O 0
breast B-Disease 0
cancer I-Disease 1
without O 0
ovarian B-Disease 0
cancer I-Disease 1
. O 0

A O 0
genetic O 0
recombinant O 0
in O 0
a O 0
breast B-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
family O 0
indicates O 0
a O 0
placement O 0
of O 0
BRCA1 O 0
telomeric O 0
to O 0
D17S776 O 0
, O 0
and O 0
helps O 0
to O 0
define O 0
the O 0
region O 0
of O 0
assignment O 0
of O 0
the O 0
cancer B-Disease 1
susceptibility O 0
gene O 0
. O 0

Other O 0
cancers B-Disease 0
of O 0
interest O 0
that O 0
appeared O 0
in O 0
the O 0
BRCA1 O 0
- O 0
linked O 0
families O 0
included O 0
primary B-Disease 0
peritoneal I-Disease 0
cancer I-Disease 1
, O 0
cancer B-Disease 1
of I-Disease 1
the I-Disease 1
fallopian I-Disease 1
tube I-Disease 1
, O 0
and O 0
malignant B-Disease 0
melanoma I-Disease 0
. O 0
. O 0

Structural O 0
analysis O 0
of O 0
the O 0
5 O 0
' O 0
region O 0
of O 0
mouse O 0
and O 0
human O 0
Huntington B-Disease 1
disease I-Disease 1
genes O 0
reveals O 0
conservation O 0
of O 0
putative O 0
promoter O 0
region O 0
and O 0
di O 0
- O 0
and O 0
trinucleotide O 0
polymorphisms O 0
. O 0

We O 0
have O 0
previously O 0
cloned O 0
and O 0
characterized O 0
the O 0
murine O 0
homologue O 0
of O 0
the O 0
Huntington B-Disease 1
disease I-Disease 1
( O 0
HD B-Disease 1
) O 0
gene O 0
and O 0
shown O 0
that O 0
it O 0
maps O 0
to O 0
mouse O 0
chromosome O 0
5 O 0
within O 0
a O 0
region O 0
of O 0
conserved O 0
synteny O 0
with O 0
human O 0
chromosome O 0
4p16 O 0
. O 0

3 O 0
3 O 0
. O 0

Here O 0
we O 0
present O 0
a O 0
detailed O 0
comparison O 0
of O 0
the O 0
sequence O 0
of O 0
the O 0
putative O 0
promoter O 0
and O 0
the O 0
organization O 0
of O 0
the O 0
5 O 0
genomic O 0
region O 0
of O 0
the O 0
murine O 0
( O 0
Hdh O 0
) O 0
and O 0
human O 0
HD B-Disease 1
genes O 0
encompassing O 0
the O 0
first O 0
five O 0
exons O 0
. O 0

We O 0
show O 0
that O 0
in O 0
this O 0
region O 0
these O 0
two O 0
genes O 0
share O 0
identical O 0
exon O 0
boundaries O 0
, O 0
but O 0
have O 0
different O 0
- O 0
size O 0
introns O 0
. O 0

Two O 0
dinucleotide O 0
( O 0
CT O 0
) O 0
and O 0
one O 0
trinucleotide O 0
intronic O 0
polymorphism O 0
in O 0
Hdh O 0
and O 0
an O 0
intronic O 0
CA O 0
polymorphism O 0
in O 0
the O 0
HD B-Disease 1
gene O 0
were O 0
identified O 0
. O 0

Comparison O 0
of O 0
940 O 0
- O 0
bp O 0
sequence O 0
5 O 0
to O 0
the O 0
putative O 0
translation O 0
start O 0
site O 0
reveals O 0
a O 0
highly O 0
conserved O 0
region O 0
( O 0
78 O 0
. O 0
8 O 0
% O 0
nucleotide O 0
identity O 0
) O 0
between O 0
Hdh O 0
and O 0
the O 0
HD B-Disease 1
gene O 0
from O 0
nucleotide O 0
- O 0
56 O 0
to O 0
- O 0
206 O 0
( O 0
of O 0
Hdh O 0
) O 0
. O 0

Neither O 0
Hdh O 0
nor O 0
the O 0
HD B-Disease 1
gene O 0
have O 0
typical O 0
TATA O 0
or O 0
CCAAT O 0
elements O 0
, O 0
but O 0
both O 0
show O 0
one O 0
putative O 0
AP2 O 0
binding O 0
site O 0
and O 0
numerous O 0
potential O 0
Sp1 O 0
binding O 0
sites O 0
. O 0

The O 0
high O 0
sequence O 0
identity O 0
between O 0
Hdh O 0
and O 0
the O 0
HD B-Disease 1
gene O 0
for O 0
approximately O 0
200 O 0
bp O 0
5 O 0
to O 0
the O 0
putative O 0
translation O 0
start O 0
site O 0
indicates O 0
that O 0
these O 0
sequences O 0
may O 0
play O 0
a O 0
role O 0
in O 0
regulating O 0
expression O 0
of O 0
the O 0
Huntington B-Disease 1
disease I-Disease 1
gene O 0

The O 0
protein O 0
deficient O 0
in O 0
Lowe B-Disease 1
syndrome I-Disease 1
is O 0
a O 0
phosphatidylinositol O 0
- O 0
4 O 0
, O 0
5 O 0
- O 0
bisphosphate O 0
5 O 0
- O 0
phosphatase O 0
. O 0

Lowe B-Disease 1
syndrome I-Disease 1
, O 0
also O 0
known O 0
as O 0
oculocerebrorenal B-Disease 1
syndrome I-Disease 1
, O 0
is O 0
caused O 0
by O 0
mutations O 0
in O 0
the O 0
X O 0
chromosome O 0
- O 0
encoded O 0
OCRL O 1
gene O 0
. O 0

The O 0
OCRL O 1
protein O 0
is O 0
51 O 0
% O 0
identical O 0
to O 0
inositol O 0
polyphosphate O 0
5 O 0
- O 0
phosphatase O 0
II O 0
( O 0
5 O 0
- O 0
phosphatase O 0
II O 0
) O 0
from O 0
human O 0
platelets O 0
over O 0
a O 0
span O 0
of O 0
744 O 0
aa O 0
, O 0
suggesting O 0
that O 0
OCRL O 1
may O 0
be O 0
a O 0
similar O 0
enzyme O 0
. O 0

We O 0
engineered O 0
a O 0
construct O 0
of O 0
the O 0
OCRL O 1
cDNA O 0
that O 0
encodes O 0
amino O 0
acids O 0
homologous O 0
to O 0
the O 0
platelet O 0
5 O 0
- O 0
phosphatase O 0
for O 0
expression O 0
in O 0
baculovirus O 0
- O 0
infected O 0
Sf9 O 0
insect O 0
cells O 0
. O 0

This O 0
cDNA O 0
encodes O 0
aa O 0
264 O 0
- O 0
968 O 0
of O 0
the O 0
OCRL O 1
protein O 0
. O 0

The O 0
recombinant O 0
protein O 0
was O 0
found O 0
to O 0
catalyze O 0
the O 0
reactions O 0
also O 0
carried O 0
out O 0
by O 0
platelet O 0
5 O 0
- O 0
phosphatase O 0
II O 0
. O 0

Thus O 0
OCRL O 1
converts O 0
inositol O 0
1 O 0
, O 0
4 O 0
, O 0
5 O 0
- O 0
trisphosphate O 0
to O 0
inositol O 0
1 O 0
, O 0
4 O 0
- O 0
bisphosphate O 0
, O 0
and O 0
it O 0
converts O 0
inositol O 0
1 O 0
, O 0
3 O 0
, O 0
4 O 0
, O 0
5 O 0
- O 0
tetrakisphosphate O 0
to O 0
inositol O 0
1 O 0
, O 0
3 O 0
, O 0
4 O 0
- O 0
trisphosphate O 0
. O 0

Most O 0
important O 0
, O 0
the O 0
enzyme O 0
converts O 0
phosphatidylinositol O 0
4 O 0
, O 0
5 O 0
- O 0
bisphosphate O 0
to O 0
phosphatidylinositol O 0
4 O 0
- O 0
phosphate O 0
. O 0

The O 0
relative O 0
ability O 0
of O 0
OCRL O 1
to O 0
catalyze O 0
the O 0
three O 0
reactions O 0
is O 0
different O 0
from O 0
that O 0
of O 0
5 O 0
- O 0
phosphatase O 0
II O 0
and O 0
from O 0
that O 0
of O 0
another O 0
5 O 0
- O 0
phosphatase O 0
isoenzyme O 0
from O 0
platelets O 0
, O 0
5 O 0
- O 0
phosphatase O 0
I O 0
. O 0

The O 0
recombinant O 0
OCRL O 1
protein O 0
hydrolyzes O 0
the O 0
phospholipid O 0
substrate O 0
10 O 0
- O 0
to O 0
30 O 0
- O 0
fold O 0
better O 0
than O 0
5 O 0
- O 0
phosphatase O 0
II O 0
, O 0
and O 0
5 O 0
- O 0
phosphatase O 0
I O 0
does O 0
not O 0
cleave O 0
the O 0
lipid O 0
at O 0
all O 0
. O 0

We O 0
also O 0
show O 0
that O 0
OCRL O 1
functions O 0
as O 0
a O 0
phosphatidylinositol O 0
4 O 0
, O 0
5 O 0
- O 0
bisphosphate O 0
5 O 0
- O 0
phosphatase O 0
in O 0
OCRL O 1
- O 0
expressing O 0
Sf9 O 0
cells O 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
OCRL O 1
is O 0
mainly O 0
a O 0
lipid O 0
phosphatase O 0
that O 0
may O 0
control O 0
cellular O 0
levels O 0
of O 0
a O 0
critical O 0
metabolite O 0
, O 0
phosphatidylinositol O 0
4 O 0
, O 0
5 O 0
- O 0
bisphosphate O 0
. O 0

Deficiency O 0
of O 0
this O 0
enzyme O 0
apparently O 0
causes O 0
the O 0
protean O 0
manifestations O 0
of O 0
Lowe B-Disease 1
syndrome I-Disease 1
. O 0
. O 0

New O 0
founder O 0
haplotypes O 0
at O 0
the O 0
myotonic B-Disease 1
dystrophy I-Disease 1
locus O 0
in O 0
southern O 0
Africa O 0
. O 0

The O 0
association O 0
between O 0
normal O 0
alleles O 0
at O 0
the O 0
CTG O 0
repeat O 0
and O 0
two O 0
nearby O 0
polymorphisms O 0
in O 0
the O 0
myotonin O 0
protein O 0
kinase O 0
gene O 0
, O 0
the O 0
Alu O 0
insertion O 0
/ O 0
deletion O 0
polymorphism O 0
and O 0
the O 0
myotonic B-Disease 1
dystrophy I-Disease 1
kinase O 0
( O 0
DMK O 0
) O 0
( O 0
G O 0
/ O 0
T O 0
) O 0
intron O 0
9 O 0
/ O 0
HinfI O 0
polymorphism O 0
, O 0
has O 0
been O 0
analyzed O 0
in O 0
South O 0
African O 0
Negroids O 0
, O 0
a O 0
population O 0
in O 0
which O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
has O 0
not O 0
been O 0
described O 0
. O 0

South O 0
African O 0
Negroids O 0
have O 0
a O 0
CTG O 0
allelic O 0
distribution O 0
that O 0
is O 0
significantly O 0
different O 0
from O 0
that O 0
in O 0
Caucasoids O 0
and O 0
Japanese O 0
the O 0
CTG O 0
repeat O 0
lengths O 0
of O 0
> O 0
or O 0
= O 0
19 O 0
are O 0
very O 0
rare O 0
. O 0

The O 0
striking O 0
linkage O 0
disequilibrium O 0
between O 0
specific O 0
alleles O 0
at O 0
the O 0
Alu O 0
polymorphism O 0
( O 0
Alu O 0
( O 0
ins O 0
) O 0
and O 0
Alu O 0
( O 0
del O 0
) O 0
) O 0
, O 0
the O 0
HinfI O 0
polymorphism O 0
( O 0
HinfI O 0
- O 0
1 O 0
and O 0
HinfI O 0
- O 0
2 O 0
) O 0
, O 0
and O 0
the O 0
CTG O 0
repeat O 0
polymorphism O 0
seen O 0
in O 0
Caucasoid O 0
( O 0
Europeans O 0
and O 0
Canadians O 0
) O 0
populations O 0
was O 0
also O 0
found O 0
in O 0
the O 0
South O 0
African O 0
Negroid O 0
population O 0
. O 0

Numerous O 0
haplotypes O 0
, O 0
not O 0
previously O 0
described O 0
in O 0
Europeans O 0
, O 0
were O 0
, O 0
however O 0
, O 0
found O 0
. O 0

It O 0
thus O 0
seems O 0
likely O 0
that O 0
only O 0
a O 0
small O 0
number O 0
of O 0
these O 0
" O 0
African O 0
" O 0
chromosomes O 0
were O 0
present O 0
in O 0
the O 0
progenitors O 0
of O 0
all O 0
non O 0
- O 0
African O 0
peoples O 0
. O 0

These O 0
data O 0
provide O 0
support O 0
for O 0
the O 0
" O 0
out O 0
of O 0
Africa O 0
" O 0
model O 0
for O 0
the O 0
origin O 0
of O 0
modern O 0
humans O 0
and O 0
suggest O 0
that O 0
the O 0
rare O 0
ancestral O 0
DM B-Disease 0
mutation O 0
event O 0
may O 0
have O 0
occurred O 0
after O 0
the O 0
migration O 0
from O 0
Africa O 0
, O 0
hence O 0
the O 0
absence O 0
of O 0
DM B-Disease 0
in O 0
sub O 0
- O 0
Saharan O 0
Negroid O 0
peoples O 0
. O 0
. O 0

Discordant O 0
clinical O 0
outcome O 0
in O 0
myotonic B-Disease 1
dystrophy I-Disease 1
relatives O 0
showing O 0
( O 0
CTG O 0
) O 0
n O 0
> O 0
700 O 0
repeats O 0
. O 0

A O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
family O 0
is O 0
described O 0
in O 0
which O 0
discordant O 0
DM B-Disease 0
phenotypes O 0
were O 0
found O 0
in O 0
the O 0
children O 0
of O 0
two O 0
affected O 0
sisters O 0
with O 0
similar O 0
CTG O 0
expansion O 0
and O 0
clinical O 0
manifestations O 0
. O 0

In O 0
this O 0
family O 0
, O 0
congenital O 0
as O 0
well O 0
as O 0
early O 0
severe O 0
childhood O 0
and O 0
later O 0
childhood O 0
onset O 0
DM B-Disease 0
coexist O 0
. O 0

This O 0
observation O 0
strengthens O 0
the O 0
limited O 0
ability O 0
of O 0
lymphocytes O 0
CTG O 0
repeat O 0
number O 0
analysis O 0
in O 0
predicting O 0
genotype O 0
- O 0
phenotype O 0
correlations O 0
in O 0
DM B-Disease 0
patients O 0
. O 0
. O 0

Purification O 0
of O 0
human O 0
very O 0
- O 0
long O 0
- O 0
chain O 0
acyl O 0
- O 0
coenzyme O 0
A O 0
dehydrogenase O 0
and O 0
characterization O 0
of O 0
its O 0
deficiency O 0
in O 0
seven O 0
patients O 0
. O 0

Mitochondrial O 0
very O 0
- O 0
long O 0
- O 0
chain O 0
acyl O 0
- O 0
coenzyme O 0
A O 0
dehydrogenase O 0
( O 0
VLCAD O 0
) O 0
was O 0
purified O 0
from O 0
human O 0
liver O 0
. O 0

The O 0
molecular O 0
masses O 0
of O 0
the O 0
native O 0
enzyme O 0
and O 0
the O 0
subunit O 0
were O 0
estimated O 0
to O 0
be O 0
154 O 0
and O 0
70 O 0
kD O 0
, O 0
respectively O 0
. O 0

The O 0
enzyme O 0
was O 0
found O 0
to O 0
catalyze O 0
the O 0
major O 0
part O 0
of O 0
mitochondrial O 0
palmitoylcoenzyme O 0
A O 0
dehydrogenation O 0
in O 0
liver O 0
, O 0
heart O 0
, O 0
skeletal O 0
muscle O 0
, O 0
and O 0
skin O 0
fibroblasts O 0
( O 0
89 O 0
- O 0
97 O 0
, O 0
86 O 0
- O 0
99 O 0
, O 0
96 O 0
- O 0
99 O 0
, O 0
and O 0
78 O 0
- O 0
87 O 0
% O 0
, O 0
respectively O 0
) O 0
. O 0

Skin O 0
fibroblasts O 0
from O 0
26 O 0
patients O 0
suspected O 0
of O 0
having O 0
a O 0
disorder O 0
of O 0
mitochondrial O 0
beta O 0
- O 0
oxidation O 0
were O 0
analyzed O 0
for O 0
VLCAD O 0
protein O 0
using O 0
immunoblotting O 0
, O 0
and O 0
7 O 0
of O 0
them O 0
contained O 0
undetectable O 0
or O 0
trace O 0
levels O 0
of O 0
the O 0
enzyme O 0
. O 0

The O 0
seven O 0
deficient O 0
fibroblast O 0
lines O 0
were O 0
characterized O 0
by O 0
measuring O 0
acyl O 0
- O 0
coenzyme O 0
A O 0
dehydrogenation O 0
activities O 0
, O 0
overall O 0
palmitic O 0
acid O 0
oxidation O 0
, O 0
and O 0
VLCAD O 0
protein O 0
synthesis O 0
using O 0
pulse O 0
- O 0
chase O 0
, O 0
further O 0
confirming O 0
the O 0
diagnosis O 0
of O 0
VLCAD B-Disease 0
deficiency I-Disease 0
. O 0

These O 0
results O 0
suggested O 0
the O 0
heterogenous O 0
nature O 0
of O 0
the O 0
mutations O 0
causing O 0
the O 0
deficiency O 0
in O 0
the O 0
seven O 0
patients O 0
. O 0

Clinically O 0
, O 0
all O 0
patients O 0
with O 0
VLCAD B-Disease 0
deficiency I-Disease 0
exhibited O 0
cardiac B-Disease 1
disease I-Disease 1
. O 0

At O 0
least O 0
four O 0
of O 0
them O 0
presented O 0
with O 0
hypertrophic B-Disease 0
cardiomyopathy I-Disease 1
. O 0

This O 0
frequency O 0
( O 0
> O 0
57 O 0
% O 0
) O 0
was O 0
much O 0
higher O 0
than O 0
that O 0
observed O 0
in O 0
patients O 0
with O 0
other O 0
disorders O 0
of O 0
mitochondrial O 0
long O 0
- O 0
chain O 0
fatty O 0
acid O 0
oxidation O 0
that O 0
may O 0
be O 0
accompanied O 0
by O 0
cardiac B-Disease 1
disease I-Disease 1
in O 0
infants O 0
. O 0
. O 0

Hereditary B-Disease 0
deficiency I-Disease 1
of I-Disease 1
the I-Disease 1
fifth I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
in O 0
man O 0
. O 0

II O 0
. O 0

Biological O 0
properties O 0
of O 0
C5 B-Disease 1
- I-Disease 1
deficient I-Disease 1
human O 0
serum O 0
. O 0

The O 0
first O 0
known O 0
human O 0
kindred O 0
with O 0
hereditary B-Disease 1
deficiency I-Disease 1
of I-Disease 1
the I-Disease 1
fifth I-Disease 1
component I-Disease 1
of I-Disease 1
complement I-Disease 1
( O 0
C5 O 0
) O 0
was O 0
documented O 0
in O 0
the O 0
accompanying O 0
report O 0
. O 0

This O 0
study O 0
examines O 0
several O 0
biological O 0
properties O 0
of O 0
C5 B-Disease 1
- I-Disease 1
deficient I-Disease 1
( O 0
C5D B-Disease 1
) O 0
human O 0
serum O 0
, O 0
particularly O 0
sera O 0
obtained O 0
from O 0
two O 0
C5D B-Disease 1
homozygotes O 0
. O 0

The O 0
proband O 0
, O 0
who O 0
has O 0
inactive O 0
systemic B-Disease 0
lupus I-Disease 0
erythematosus I-Disease 0
is O 0
completely O 0
lacking O 0
C5 O 0
, O 0
while O 0
her O 0
healthy O 0
half O 0
- O 0
sister O 0
has O 0
1 O 0
- O 0
2 O 0
% O 0
of O 0
normal O 0
levels O 0
. O 0

Both O 0
sera O 0
were O 0
severely O 0
impaired O 0
in O 0
their O 0
ability O 0
to O 0
generate O 0
chemotactic O 0
activity O 0
for O 0
normal O 0
human O 0
neutrophils O 0
upon O 0
incubation O 0
with O 0
aggregated O 0
human O 0
gamma O 0
- O 0
globulin O 0
or O 0
Escherichia O 0
coli O 0
endotoxin O 0
. O 0

This O 0
function O 0
was O 0
fully O 0
restored O 0
in O 0
the O 0
siblings O 0
serum O 0
, O 0
and O 0
substantially O 0
improved O 0
in O 0
the O 0
probands O 0
serum O 0
, O 0
by O 0
addition O 0
of O 0
highly O 0
purified O 0
human O 0
C5 O 0
to O 0
normal O 0
serum O 0
concentrations O 0
. O 0

Sera O 0
from O 0
eight O 0
family O 0
members O 0
who O 0
were O 0
apparently O 0
heterozygous O 0
for O 0
C5 B-Disease 0
deficiency I-Disease 0
gave O 0
normal O 0
chemotactic O 0
scores O 0
. O 0

The O 0
ability O 0
of O 0
C5D B-Disease 1
serum O 0
to O 0
opsonize O 0
Saccharomyces O 0
cerevisiae O 0
( O 0
bakers O 0
yeast O 0
) O 0
or O 0
Candida O 0
albicans O 0
for O 0
ingestion O 0
by O 0
normal O 0
neutrophils O 0
was O 0
completely O 0
normal O 0
. O 0

In O 0
addition O 0
, O 0
C5D B-Disease 1
serum O 0
was O 0
capable O 0
of O 0
promoting O 0
normal O 0
phagocytosis O 0
and O 0
intracellular O 0
killing O 0
of O 0
Staphylococcus O 0
aureus O 0
. O 0

The O 0
probands O 0
serum O 0
was O 0
incapable O 0
of O 0
mediating O 0
lysis O 0
of O 0
erythrocytes O 0
from O 0
a O 0
patient O 0
with O 0
paroxysmal B-Disease 1
nocturnal I-Disease 1
hemoglobinuria I-Disease 1
in O 0
both O 0
the O 0
sucrose O 0
hemolysia O 0
and O 0
acid O 0
hemolysis O 1
tests O 0
, O 0
and O 0
also O 0
lacked O 0
bactericidal O 0
activity O 0
against O 0
sensitized O 0
or O 0
unsensitized O 0
Salmonella O 0
typhi O 0
. O 0

The O 0
siblings O 0
serum O 0
, O 0
containing O 0
only O 0
1 O 0
- O 0
2 O 0
% O 0
of O 0
normal O 0
C5 O 0
, O 0
effectively O 0
lysed O 0
S O 0
. O 0
typhi O 0
, O 0
but O 0
only O 0
at O 0
eightfold O 0
lower O 0
serum O 0
dilutions O 0
as O 0
compared O 0
to O 0
normals O 0
. O 0

These O 0
findings O 0
underscore O 0
the O 0
critical O 0
role O 0
of O 0
C5 O 0
in O 0
the O 0
generation O 0
of O 0
chemotactic O 0
activity O 0
and O 0
in O 0
cytolytic O 0
reactions O 0
, O 0
as O 0
opposed O 0
to O 0
a O 0
nonobligatory O 0
or O 0
minimal O 0
role O 0
in O 0
opsonization O 0
, O 0
at O 0
least O 0
for O 0
the O 0
organisms O 0
under O 0
study O 0
. O 0
. O 0

Human O 0
peroxisomal O 0
targeting O 0
signal O 0
- O 0
1 O 0
receptor O 0
restores O 0
peroxisomal O 0
protein O 0
import O 0
in O 0
cells O 0
from O 0
patients O 0
with O 0
fatal O 0
peroxisomal B-Disease 1
disorders I-Disease 1
. O 0

Two O 0
peroxisomal O 0
targeting O 0
signals O 0
, O 0
PTS1 O 0
and O 0
PTS2 O 0
, O 0
are O 0
involved O 0
in O 0
the O 0
import O 0
of O 0
proteins O 0
into O 0
the O 0
peroxisome O 0
matrix O 0
. O 0

Human O 0
patients O 0
with O 0
fatal O 0
generalized O 0
peroxisomal B-Disease 1
deficiency I-Disease 1
disorders I-Disease 1
fall O 0
into O 0
at O 0
least O 0
nine O 0
genetic O 0
complementation O 0
groups O 0
. O 0

Cells O 0
from O 0
many O 0
of O 0
these O 0
patients O 0
are O 0
deficient O 0
in O 0
the O 0
import O 0
of O 0
PTS1 O 0
- O 0
containing O 0
proteins O 0
, O 0
but O 0
the O 0
causes O 0
of O 0
the O 0
protein O 0
- O 0
import O 0
defect O 0
in O 0
these O 0
patients O 0
are O 0
unknown O 0
. O 0

We O 0
have O 0
cloned O 0
and O 0
sequenced O 0
the O 0
human O 0
cDNA O 0
homologue O 0
( O 0
PTS1R O 0
) O 0
of O 0
the O 0
Pichia O 0
pastoris O 0
PAS8 O 0
gene O 0
, O 0
the O 0
PTS1 O 0
receptor O 0
( O 0
McCollum O 0
, O 0
D O 0
. O 0
, O 0
E O 0
. O 0
Monosov O 0
, O 0
and O 0
S O 0
. O 0
Subramani O 0
. O 0
1993 O 0
. O 0
J O 0
. O 0
Cell O 0
Biol O 0
. O 0
121 O 0
761 O 0
- O 0
774 O 0
) O 0
. O 0

The O 0
PTS1R O 0
mRNA O 0
is O 0
expressed O 0
in O 0
all O 0
human O 0
tissues O 0
examined O 0
. O 0

Antibodies O 0
to O 0
the O 0
human O 0
PTS1R O 0
recognize O 0
this O 0
protein O 0
in O 0
human O 0
, O 0
monkey O 0
, O 0
rat O 0
, O 0
and O 0
hamster O 0
cells O 0
. O 0

The O 0
protein O 0
is O 0
localized O 0
mainly O 0
in O 0
the O 0
cytosol O 0
but O 0
is O 0
also O 0
found O 0
to O 0
be O 0
associated O 0
with O 0
peroxisomes O 0
. O 0

Part O 0
of O 0
the O 0
peroxisomal O 0
PTS1R O 0
protein O 0
is O 0
tightly O 0
bound O 0
to O 0
the O 0
peroxisomal O 0
membrane O 0
. O 0

Antibodies O 0
to O 0
PTS1R O 0
inhibit O 0
peroxisomal O 0
protein O 0
- O 0
import O 0
of O 0
PTS1 O 0
- O 0
containing O 0
proteins O 0
in O 0
a O 0
permeabilized O 0
CHO O 0
cell O 0
system O 0
. O 0

In O 0
vitro O 0
- O 0
translated O 0
PTS1R O 0
protein O 0
specifically O 0
binds O 0
a O 0
serine O 0
- O 0
lysine O 0
- O 0
leucine O 0
- O 0
peptide O 0
. O 0

A O 0
PAS8 O 0
- O 0
PTS1R O 0
fusion O 0
protein O 0
complements O 0
the O 0
P O 0
. O 0
pastoris O 0
pas8 O 0
mutant O 0
. O 0

The O 0
PTS1R O 0
cDNA O 0
also O 0
complements O 0
the O 0
PTS1 B-Disease 0
protein I-Disease 0
- I-Disease 0
import I-Disease 0
defect I-Disease 0
in O 0
skin O 0
fibroblasts O 0
from O 0
patients O 0
- O 0
- O 0
belonging O 0
to O 0
complementation O 0
group O 0
two O 0
- O 0
- O 0
diagnosed O 0
as O 0
having O 0
neonatal B-Disease 1
adrenoleukodystrophy I-Disease 1
or O 0
Zellweger B-Disease 1
syndrome I-Disease 1
. O 0

The O 0
PTS1R O 0
gene O 0
has O 0
been O 0
localized O 0
to O 0
a O 0
chromosomal O 0
location O 0
where O 0
no O 0
other O 0
peroxisomal B-Disease 1
disorder I-Disease 1
genes O 0
are O 0
known O 0
to O 0
map O 0
. O 0

Our O 0
findings O 0
represent O 0
the O 0
only O 0
case O 0
in O 0
which O 0
the O 0
molecular O 0
basis O 0
of O 0
the O 0
protein B-Disease 1
- I-Disease 1
import I-Disease 1
deficiency I-Disease 1
in O 0
human O 0
peroxisomal B-Disease 1
disorders I-Disease 1
is O 0
understood O 0
. O 0

Spectrum O 0
of O 0
germline O 0
mutations O 0
in O 0
the O 0
RB1 O 0
gene O 0
: O 0
a O 0
study O 0
of O 0
232 O 0
patients O 0
with O 0
hereditary B-Disease 1
and I-Disease 1
non I-Disease 1
hereditary I-Disease 1
retinoblastoma I-Disease 1
. O 0

Germline O 0
mutations O 0
in O 0
the O 0
RB1 O 0
gene O 0
confer O 0
hereditary O 0
predisposition O 0
to O 0
retinoblastoma B-Disease 1
. O 0

We O 0
have O 0
performed O 0
a O 0
mutation O 0
survey O 0
of O 0
the O 0
RB1 O 0
gene O 0
in O 0
232 O 0
patients O 0
with O 0
hereditary B-Disease 1
or I-Disease 1
non I-Disease 1
hereditary I-Disease 1
retinoblastoma I-Disease 1
. O 0

We O 0
systematically O 0
explored O 0
all O 0
27 O 0
exons O 0
and O 0
flanking O 0
sequences O 0
as O 0
well O 0
as O 0
the O 0
promotor O 0
. O 0

All O 0
types O 0
of O 0
point O 0
mutations O 0
are O 0
represented O 0
and O 0
are O 0
found O 0
unequally O 0
distributed O 0
along O 0
the O 0
RB1 O 0
gene O 0
sequence O 0
. O 0

In O 0
the O 0
population O 0
we O 0
studied O 0
, O 0
exons O 0
3 O 0
, O 0
8 O 0
, O 0
18 O 0
and O 0
19 O 0
are O 0
preferentially O 0
altered O 0
. O 0

The O 0
range O 0
of O 0
frequency O 0
of O 0
detection O 0
of O 0
germline O 0
mutations O 0
is O 0
about O 0
20 O 0
% O 0
, O 0
indicating O 0
that O 0
other O 0
mechanisms O 0
of O 0
inactivation O 0
of O 0
RB1 O 0
should O 0
be O 0
involved O 0
. O 0

The O 0
spectrum O 0
of O 0
mutations O 0
presented O 0
here O 0
should O 0
help O 0
to O 0
improve O 0
the O 0
clinical O 0
management O 0
of O 0
retinoblastoma B-Disease 1
and O 0
to O 0
understand O 0
the O 0
molecular O 0
mechanisms O 0
leading O 0
to O 0
tumorigenesis O 0
. O 0
. O 0

Aniridia B-Disease 0
- O 0
associated O 0
cytogenetic O 0
rearrangements O 0
suggest O 0
that O 0
a O 0
position O 0
effect O 0
may O 0
cause O 0
the O 0
mutant O 0
phenotype O 0
. O 0

Current O 0
evidence O 0
suggests O 0
that O 0
aniridia B-Disease 0
( O 0
absence B-Disease 0
of I-Disease 0
iris I-Disease 0
) O 0
is O 0
caused O 0
by O 0
loss O 0
of O 0
function O 0
of O 0
one O 0
copy O 0
of O 0
the O 0
PAX6 O 0
gene O 0
, O 0
which O 0
maps O 0
to O 0
11p13 O 0
. O 0

We O 0
present O 0
the O 0
further O 0
characterisation O 0
of O 0
two O 0
aniridia B-Disease 0
pedigrees O 0
in O 0
which O 0
the O 0
disease O 0
segregates O 0
with O 0
chromosomal O 0
rearrangements O 0
which O 0
involve O 0
11p13 O 0
but O 0
do O 0
not O 0
disrupt O 0
the O 0
PAX6 O 0
gene O 0
. O 0

We O 0
have O 0
isolated O 0
three O 0
human O 0
YAC O 0
clones O 0
which O 0
encompass O 0
the O 0
PAX6 O 0
locus O 0
and O 0
we O 0
have O 0
used O 0
these O 0
to O 0
show O 0
that O 0
in O 0
both O 0
cases O 0
the O 0
chromosomal O 0
breakpoint O 0
is O 0
at O 0
least O 0
85 O 0
kb O 0
distal O 0
of O 0
the O 0
3 O 0
end O 0
of O 0
PAX6 O 0
. O 0

In O 0
addition O 0
, O 0
the O 0
open O 0
reading O 0
frame O 0
of O 0
PAX6 O 0
is O 0
apparently O 0
free O 0
of O 0
mutations O 0
. O 0

We O 0
propose O 0
that O 0
the O 0
PAX6 O 0
gene O 0
on O 0
the O 0
rearranged O 0
chromosome O 0
11 O 0
is O 0
in O 0
an O 0
inappropriate O 0
chromatin O 0
environment O 0
for O 0
normal O 0
expression O 0
and O 0
therefore O 0
that O 0
a O 0
position O 0
effect O 0
is O 0
the O 0
underlying O 0
mechanism O 0
of O 0
disease O 0
in O 0
these O 0
families O 0
. O 0
. O 0

Somatic O 0
mutations O 0
in O 0
the O 0
BRCA1 O 0
gene O 0
in O 0
sporadic B-Disease 0
ovarian I-Disease 0
tumours I-Disease 1
. O 0

The O 0
BRCA1 O 0
gene O 0
on O 0
chromosome O 0
17q21 O 0
is O 0
responsible O 0
for O 0
an O 0
autosomal B-Disease 1
dominant I-Disease 1
syndrome I-Disease 1
of O 0
increased O 0
susceptibility O 0
to O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
but O 0
no O 0
somatic O 0
mutations O 0
in O 0
tumours B-Disease 1
have O 0
yet O 0
been O 0
described O 0
. O 0

To O 0
study O 0
the O 0
potential O 0
role O 0
of O 0
BRCA1 O 0
in O 0
sporadic O 0
carcinogenesis O 0
, O 0
we O 0
analysed O 0
the O 0
genomic O 0
DNA O 0
of O 0
tumour B-Disease 1
and O 0
normal O 0
fractions O 0
of O 0
47 O 0
ovarian B-Disease 1
cancers I-Disease 1
for O 0
mutations O 0
in O 0
BRCA1 O 0
using O 0
the O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphism O 0
technique O 0
. O 0

We O 0
now O 0
describe O 0
somatic O 0
mutations O 0
in O 0
the O 0
DNA O 0
of O 0
four O 0
tumours B-Disease 1
which O 0
also O 0
had O 0
loss O 0
of O 0
heterozygosity O 0
( O 0
LOH O 0
) O 0
at O 0
a O 0
BRCA1 O 0
intragenic O 0
marker O 0
. O 0

Our O 0
data O 0
support O 0
a O 0
tumour B-Disease 1
suppressor O 0
mechanism O 0
for O 0
BRCA1 O 0
; O 0
somatic O 0
mutations O 0
and O 0
LOH O 0
may O 0
result O 0
in O 0
inactivation O 0
of O 0
BRCA1 O 0
in O 0
at O 0
least O 0
a O 0
small O 0
number O 0
of O 0
ovarian B-Disease 1
cancers I-Disease 1
. O 0
. O 0

Decreased O 0
expression O 0
of O 0
BRCA1 O 0
accelerates O 0
growth O 0
and O 0
is O 0
often O 0
present O 0
during O 0
sporadic B-Disease 0
breast I-Disease 0
cancer I-Disease 1
progression O 0
. O 0

We O 0
have O 0
characterized O 0
expression O 0
of O 0
the O 0
familial B-Disease 0
breast I-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
gene O 0
, O 0
BRCA1 O 0
, O 0
in O 0
cases O 0
of O 0
non B-Disease 1
- I-Disease 1
hereditary I-Disease 1
( I-Disease 1
sporadic I-Disease 1
) I-Disease 1
breast I-Disease 1
cancer I-Disease 1
and O 0
analyzed O 0
the O 0
effect O 0
of O 0
antisense O 0
inhibition O 0
of O 0
BRCA1 O 0
on O 0
the O 0
proliferative O 0
rate O 0
of O 0
mammary O 0
epithelial O 0
cells O 0
. O 0

BRCA1 O 0
mRNA O 0
levels O 0
are O 0
markedly O 0
decreased O 0
during O 0
the O 0
transition O 0
from O 0
carcinoma B-Disease 1
in I-Disease 1
situ I-Disease 1
to O 0
invasive B-Disease 0
cancer I-Disease 1
. O 0

Experimental O 0
inhibition O 0
of O 0
BRCA1 O 0
expression O 0
with O 0
antisense O 0
oligonucleotides O 0
produced O 0
accelerated O 0
growth O 0
of O 0
normal O 0
and O 0
malignant O 0
mammary O 0
cells O 0
, O 0
but O 0
had O 0
no O 0
effect O 0
on O 0
non O 0
- O 0
mammary O 0
epithelial O 0
cells O 0
. O 0

These O 0
studies O 0
suggest O 0
that O 0
BRCA1 O 0
may O 0
normally O 0
serve O 0
as O 0
a O 0
negative O 0
regulator O 0
of O 0
mammary O 0
epithelial O 0
cell O 0
growth O 0
whose O 0
function O 0
is O 0
compromised O 0
in O 0
breast B-Disease 0
cancer I-Disease 1
either O 0
by O 0
direct O 0
mutation O 0
or O 0
alterations O 0
in O 0
gene O 0
expression O 0
. O 0
. O 0

Additional O 0
case O 0
of O 0
female O 0
monozygotic O 0
twins O 0
discordant O 0
for O 0
the O 0
clinical O 0
manifestations O 0
of O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
due O 0
to O 0
opposite O 0
X O 0
- O 0
chromosome O 0
inactivation O 0
. O 0

A O 0
pair O 0
of O 0
female O 0
monozygotic O 0
( O 0
MZ O 0
) O 0
twins O 0
, O 0
heterozygous O 0
carriers O 0
for O 0
a O 0
deletion O 0
in O 0
the O 0
DMD B-Disease 0
gene O 0
and O 0
discordant O 0
for O 0
the O 0
clinical O 0
manifestations O 0
of O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
, O 0
were O 0
analyzed O 0
by O 0
molecular O 0
studies O 0
, O 0
in O 0
situ O 0
hybridization O 0
, O 0
and O 0
methylation O 0
pattern O 0
of O 0
X O 0
chromosomes O 0
to O 0
search O 0
for O 0
opposite O 0
X O 0
inactivation O 0
as O 0
an O 0
explanation O 0
of O 0
their O 0
clinical O 0
discordance O 0
. O 0

Results O 0
in O 0
lymphocytes O 0
and O 0
skin O 0
fibroblast O 0
cell O 0
lines O 0
suggest O 0
a O 0
partial O 0
mirror O 0
inactivation O 0
with O 0
the O 0
normal O 0
X O 0
chromosome O 0
preferentially O 0
active O 0
in O 0
the O 0
unaffected O 0
twin O 0
, O 0
and O 0
the O 0
maternal O 0
deleted O 0
X O 0
chromosome O 0
preferentially O 0
active O 0
in O 0
the O 0
affected O 0
twin O 0
. O 0

A O 0
review O 0
shows O 0
that O 0
MZ O 0
female O 0
twins O 0
discordant O 0
for O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
diseases I-Disease 0
are O 0
not O 0
uncommon O 0
. O 0

Twinning O 0
and O 0
X O 0
inactivation O 0
may O 0
be O 0
interrelated O 0
and O 0
could O 0
explain O 0
the O 0
female O 0
twins O 0
discordant O 0
for O 0
X O 0
- O 0
linked O 0
traits O 0
. O 0
. O 0

X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
( O 0
ALD B-Disease 0
) O 0
: O 0
a O 0
novel O 0
mutation O 0
of O 0
the O 0
ALD B-Disease 0
gene O 0
in O 0
6 O 0
members O 0
of O 0
a O 0
family O 0
presenting O 0
with O 0
5 O 0
different O 0
phenotypes O 0
. O 0

Fragments O 0
of O 0
the O 0
adrenoleukodystrophy B-Disease 1
( O 0
ALD B-Disease 0
) O 0
cDNA O 0
from O 0
a O 0
patient O 0
with O 0
adolescent B-Disease 0
ALD I-Disease 0
were O 0
amplified O 0
by O 0
polymerase O 0
chain O 0
reaction O 0
and O 0
subcloned O 0
. O 0

Bidirectional O 0
sequencing O 0
of O 0
the O 0
entire O 0
coding O 0
ALD B-Disease 0
gene O 0
disclosed O 0
a O 0
cytosine O 0
to O 0
guanine O 0
transversion O 0
at O 0
nucleotide O 0
1451 O 0
in O 0
exon O 0
five O 0
, O 0
resulting O 0
in O 0
substitution O 0
of O 0
proline O 0
484 O 0
by O 0
arginine O 0
. O 0

Five O 0
of O 0
nine O 0
siblings O 0
of O 0
the O 0
patient O 0
, O 0
comprising O 0
two O 0
cerebral B-Disease 1
ALD I-Disease 1
, O 0
one O 0
adrenomyeloneuropathy B-Disease 1
, O 0
one O 0
Addison B-Disease 1
only I-Disease 1
as O 0
well O 0
as O 0
the O 0
symptomatic O 0
mother O 0
( O 0
all O 0
accumulating O 0
very O 0
long O 0
chain O 0
fatty O 0
acids O 0
) O 0
carried O 0
this O 0
mutation O 0
, O 0
which O 0
was O 0
not O 0
found O 0
in O 0
the O 0
unaffected O 0
persons O 0
, O 0
in O 0
five O 0
unrelated O 0
ALD B-Disease 0
patients O 0
, O 0
and O 0
in O 0
twenty O 0
controls O 0
. O 0

We O 0
propose O 0
that O 0
this O 0
missense O 0
mutation O 0
generated O 0
the O 0
disease O 0
per O 0
se O 0
as O 0
well O 0
as O 0
the O 0
metabolic O 0
defect O 0
; O 0
the O 0
different O 0
phenotypes O 0
, O 0
however O 0
, O 0
must O 0
have O 0
originated O 0
by O 0
means O 0
of O 0
additional O 0
pathogenetic O 0
factors O 0
. O 0
. O 0

Novel O 0
mutation O 0
at O 0
the O 0
initiation O 0
codon O 0
in O 0
the O 0
Norrie B-Disease 1
disease I-Disease 1
gene O 0
in O 0
two O 0
Japanese O 0
families O 0
. O 0

We O 0
have O 0
identified O 0
a O 0
new O 0
mutation O 0
of O 0
Norrie B-Disease 1
disease I-Disease 1
( O 0
ND B-Disease 0
) O 0
gene O 0
in O 0
two O 0
Japanese O 0
males O 0
from O 0
unrelated O 0
families O 0
; O 0
they O 0
showed O 0
typical O 0
ocular O 0
features O 0
of O 0
ND B-Disease 0
but O 0
no O 0
mental B-Disease 1
retardation I-Disease 1
or O 0
hearing B-Disease 0
impairment I-Disease 0
. O 0

A O 0
mutation O 0
was O 0
found O 0
in O 0
both O 0
patients O 0
at O 0
the O 0
initiation O 0
codon O 0
of O 0
exon O 0
2 O 0
of O 0
the O 0
ND B-Disease 0
gene O 0
( O 0
ATG O 0
to O 0
GTG O 0
) O 0
, O 0
with O 0
otherwise O 0
normal O 0
nucleotide O 0
sequences O 0
. O 0

Their O 0
mothers O 0
had O 0
the O 0
normal O 0
and O 0
mutant O 0
types O 0
of O 0
the O 0
gene O 0
, O 0
which O 0
was O 0
expected O 0
for O 0
heterozygotes O 0
of O 0
the O 0
disease O 0
. O 0

The O 0
mutation O 0
of O 0
the O 0
initiation O 0
codon O 0
would O 0
cause O 0
the O 0
failure O 0
of O 0
ND B-Disease 0
gene O 0
expression O 0
or O 0
a O 0
defect O 0
in O 0
translation O 0
thereby O 0
truncating O 0
the O 0
amino O 0
terminus O 0
of O 0
ND B-Disease 0
protein O 0
. O 0

In O 0
view O 0
of O 0
the O 0
rarity O 0
and O 0
marked O 0
heterogeneity O 0
of O 0
mutations O 0
in O 0
the O 0
ND B-Disease 0
gene O 0
, O 0
the O 0
present O 0
apparently O 0
unrelated O 0
Japanese O 0
families O 0
who O 0
have O 0
lived O 0
in O 0
the O 0
same O 0
area O 0
for O 0
over O 0
two O 0
centuries O 0
presumably O 0
share O 0
the O 0
origin O 0
of O 0
the O 0
mutation O 0
. O 0
. O 0

Anticipation O 0
resulting O 0
in O 0
elimination O 0
of O 0
the O 0
myotonic B-Disease 1
dystrophy I-Disease 1
gene O 0
: O 0
a O 0
follow O 0
up O 0
study O 0
of O 0
one O 0
extended O 0
family O 0
. O 0

We O 0
have O 0
re O 0
- O 0
examined O 0
an O 0
extended O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
family O 0
, O 0
previously O 0
described O 0
in O 0
1955 O 0
, O 0
in O 0
order O 0
to O 0
study O 0
the O 0
long O 0
term O 0
effects O 0
of O 0
anticipation O 0
in O 0
DM B-Disease 0
and O 0
in O 0
particular O 0
the O 0
implications O 0
for O 0
families O 0
affected O 0
by O 0
this O 0
disease O 0
. O 0

This O 0
follow O 0
up O 0
study O 0
provides O 0
data O 0
on O 0
35 O 0
gene O 0
carriers O 0
and O 0
46 O 0
asymptomatic O 0
at O 0
risk O 0
family O 0
members O 0
in O 0
five O 0
generations O 0
. O 0

Clinical O 0
anticipation O 0
, O 0
defined O 0
as O 0
the O 0
cascade O 0
of O 0
mild O 0
, O 0
adult O 0
, O 0
childhood O 0
, O 0
or O 0
congenital B-Disease 0
disease I-Disease 0
in O 0
subsequent O 0
generations O 0
, O 0
appeared O 0
to O 0
be O 0
a O 0
relentless O 0
process O 0
, O 0
occurring O 0
in O 0
all O 0
affected O 0
branches O 0
of O 0
the O 0
family O 0
. O 0

The O 0
cascade O 0
was O 0
found O 0
to O 0
proceed O 0
asynchronously O 0
in O 0
the O 0
different O 0
branches O 0
, O 0
mainly O 0
because O 0
of O 0
an O 0
unequal O 0
number O 0
of O 0
generations O 0
with O 0
mild O 0
disease O 0
. O 0

The O 0
transition O 0
from O 0
the O 0
mild O 0
to O 0
the O 0
adult O 0
type O 0
was O 0
associated O 0
with O 0
transmission O 0
through O 0
a O 0
male O 0
parent O 0
. O 0

Stable O 0
transmission O 0
of O 0
the O 0
asymptomatic O 0
/ O 0
mild O 0
phenotype O 0
showed O 0
a O 0
female O 0
transmission O 0
bias O 0
. O 0

We O 0
further O 0
examined O 0
the O 0
extent O 0
and O 0
causes O 0
of O 0
gene O 0
loss O 0
in O 0
this O 0
pedigree O 0
. O 0

Gene O 0
loss O 0
in O 0
the O 0
patient O 0
group O 0
was O 0
complete O 0
, O 0
owing O 0
to O 0
infertility B-Disease 0
of O 0
the O 0
male O 0
patients O 0
with O 0
adult O 0
onset O 0
disease O 0
and O 0
the O 0
fact O 0
that O 0
mentally B-Disease 1
retarded I-Disease 1
patients O 0
did O 0
not O 0
procreate O 0
. O 0

Out O 0
of O 0
the O 0
46 O 0
at O 0
risk O 0
subjects O 0
in O 0
the O 0
two O 0
youngest O 0
generations O 0
, O 0
only O 0
one O 0
was O 0
found O 0
to O 0
have O 0
a O 0
full O 0
mutation O 0
. O 0

This O 0
is O 0
the O 0
only O 0
subject O 0
who O 0
may O 0
transmit O 0
the O 0
gene O 0
to O 0
the O 0
sixth O 0
generation O 0
. O 0

No O 0
protomutation O 0
carriers O 0
were O 0
found O 0
in O 0
the O 0
fourth O 0
and O 0
fifth O 0
generations O 0
. O 0

Therefore O 0
it O 0
is O 0
highly O 0
probable O 0
that O 0
the O 0
DM B-Disease 0
gene O 0
will O 0
be O 0
eliminated O 0
from O 0
this O 0
pedigree O 0
within O 0
one O 0
generation O 0
. O 0

The O 0
high O 0
population O 0
frequency O 0
of O 0
DM B-Disease 0
can O 0
at O 0
present O 0
not O 0
be O 0
explained O 0
by O 0
the O 0
contribution O 0
of O 0
asymptomatic O 0
cases O 0
in O 0
the O 0
younger O 0
generations O 0
of O 0
known O 0
families O 0
, O 0
but O 0
is O 0
probably O 0
caused O 0
by O 0
the O 0
events O 0
in O 0
the O 0
ancestral O 0
generations O 0
. O 0
. O 0

The O 0
gene O 0
for O 0
spinal B-Disease 1
cerebellar I-Disease 1
ataxia I-Disease 1
3 O 0
( O 0
SCA3 O 1
) O 0
is O 0
located O 0
in O 0
a O 0
region O 0
of O 0
approximately O 0
3 O 0
cM O 0
on O 0
chromosome O 0
14q24 O 0
. O 0
3 O 0
- O 0
q32 O 0
. O 0
2 O 0
. O 0

SCA3 O 1
, O 0
the O 0
gene O 0
for O 0
spinal B-Disease 1
cerebellar I-Disease 1
ataxia I-Disease 1
3 O 0
, O 0
was O 0
recently O 0
mapped O 0
to O 0
a O 0
15 O 0
- O 0
cM O 0
interval O 0
between O 0
D14S67 O 0
and O 0
D14S81 O 0
on O 0
chromosome O 0
14q O 0
, O 0
by O 0
linkage O 0
analysis O 0
in O 0
two O 0
families O 0
of O 0
French O 0
ancestry O 0
. O 0

The O 0
SCA3 O 1
candidate O 0
region O 0
has O 0
now O 0
been O 0
refined O 0
by O 0
linkage O 0
analysis O 0
with O 0
four O 0
new O 0
microsatellite O 0
markers O 0
( O 0
D14S256 O 0
, O 0
D14S291 O 0
, O 0
D14S280 O 0
, O 0
and O 0
AFM343vf1 O 0
) O 0
in O 0
the O 0
same O 0
two O 0
families O 0
, O 0
in O 0
which O 0
19 O 0
additional O 0
individuals O 0
were O 0
genotyped O 0
, O 0
and O 0
in O 0
a O 0
third O 0
French O 0
family O 0
. O 0

Combined O 0
two O 0
- O 0
point O 0
linkage O 0
analyses O 0
show O 0
that O 0
the O 0
new O 0
markers O 0
, O 0
D14S280 O 0
and O 0
AFM343vf1 O 0
, O 0
are O 0
tightly O 0
linked O 0
to O 0
the O 0
SCA3 O 1
locus O 0
, O 0
with O 0
maximal O 0
lod O 0
scores O 0
, O 0
at O 0
recombination O 0
fraction O 0
, O 0
( O 0
theta O 0
) O 0
= O 0
. O 0

00 O 0
, O 0
of O 0
7 O 0
. O 0

05 O 0
and O 0
13 O 0
. O 0

70 O 0
, O 0
respectively O 0
. O 0

Combined O 0
multipoint O 0
and O 0
recombinant O 0
haplotype O 0
analyses O 0
localize O 0
the O 0
SCA3 O 1
locus O 0
to O 0
a O 0
3 O 0
- O 0
cM O 0
interval O 0
flanked O 0
by O 0
D14S291 O 0
and O 0
D14S81 O 0
. O 0

The O 0
same O 0
allele O 0
for O 0
D14S280 O 0
segregates O 0
with O 0
the O 0
disease O 0
locus O 0
in O 0
the O 0
three O 0
kindreds O 0
. O 0

This O 0
allele O 0
is O 0
frequent O 0
in O 0
the O 0
French O 0
population O 0
, O 0
however O 0
, O 0
and O 0
linkage O 0
disequilibrium O 0
is O 0
not O 0
clearly O 0
established O 0
. O 0

The O 0
SCA3 O 1
locus O 0
remains O 0
within O 0
the O 0
29 O 0
- O 0
cM O 0
region O 0
on O 0
14q24 O 0
. O 0

3 O 0
- O 0
q32 O 0
. O 0

2 O 0
containing O 0
the O 0
gene O 0
for O 0
the O 0
Machado B-Disease 0
- I-Disease 0
Joseph I-Disease 0
disease I-Disease 0
, O 0
which O 0
is O 0
clinically O 0
related O 0
to O 0
the O 0
phenotype O 0
determined O 0
by O 0
SCA3 O 1
, O 0
but O 0
it O 0
cannot O 0
yet O 0
be O 0
concluded O 0
that O 0
both O 0
diseases O 0
result O 0
from O 0
alterations O 0
of O 0
the O 0
same O 0
gene O 0

An O 0
evaluation O 0
of O 0
genetic O 0
heterogeneity O 0
in O 0
145 O 0
breast B-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
families O 0
. O 0

Breast B-Disease 0
Cancer I-Disease 1
Linkage O 0
Consortium O 0
. O 0

The O 0
breast B-Disease 1
- I-Disease 1
ovary I-Disease 1
cancer I-Disease 1
- I-Disease 1
family I-Disease 1
syndrome I-Disease 1
is O 0
a O 0
dominant O 0
predisposition O 0
to O 0
cancer B-Disease 1
of I-Disease 0
the I-Disease 0
breast I-Disease 0
and I-Disease 0
ovaries I-Disease 0
which O 0
has O 0
been O 0
mapped O 0
to O 0
chromosome O 0
region O 0
17q12 O 0
- O 0
q21 O 0
. O 0

The O 0
majority O 0
, O 0
but O 0
not O 0
all O 0
, O 0
of O 0
breast B-Disease 1
- I-Disease 1
ovary I-Disease 1
cancer I-Disease 1
families O 0
show O 0
linkage O 0
to O 0
this O 0
susceptibility O 0
locus O 0
, O 0
designated O 0
BRCA1 O 0
. O 0

We O 0
report O 0
here O 0
the O 0
results O 0
of O 0
a O 0
linkage O 0
analysis O 0
of O 0
145 O 0
families O 0
with O 0
both O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
. O 0

These O 0
families O 0
contain O 0
either O 0
a O 0
total O 0
of O 0
three O 0
or O 0
more O 0
cases O 0
of O 0
early O 0
- O 0
onset O 0
( O 0
before O 0
age O 0
60 O 0
years O 0
) O 0
breast B-Disease 0
cancer I-Disease 1
or O 0
ovarian B-Disease 0
cancer I-Disease 1
. O 0

All O 0
families O 0
contained O 0
at O 0
least O 0
one O 0
case O 0
of O 0
ovarian B-Disease 0
cancer I-Disease 1
. O 0

Overall O 0
, O 0
an O 0
estimated O 0
76 O 0
% O 0
of O 0
the O 0
145 O 0
families O 0
are O 0
linked O 0
to O 0
the O 0
BRCA1 O 0
locus O 0
. O 0

None O 0
of O 0
the O 0
13 O 0
families O 0
with O 0
cases O 0
of O 0
male B-Disease 0
breast I-Disease 0
cancer I-Disease 1
appear O 0
to O 0
be O 0
linked O 0
, O 0
but O 0
it O 0
is O 0
estimated O 0
that O 0
92 O 0
% O 0
( O 0
95 O 0
% O 0
confidence O 0
interval O 0
76 O 0
% O 0
- O 0
100 O 0
% O 0
) O 0
of O 0
families O 0
with O 0
no O 0
male B-Disease 0
breast I-Disease 0
cancer I-Disease 1
and O 0
with O 0
two O 0
or O 0
more O 0
ovarian B-Disease 1
cancers I-Disease 1
are O 0
linked O 0
to O 0
BRCA1 O 0
. O 0

These O 0
data O 0
suggest O 0
that O 0
the O 0
breast B-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
- I-Disease 0
family I-Disease 0
syndrome I-Disease 0
is O 0
genetically O 0
heterogeneous O 0
. O 0

However O 0
, O 0
the O 0
large O 0
majority O 0
of O 0
families O 0
with O 0
early O 0
- O 0
onset O 0
breast B-Disease 0
cancer I-Disease 1
and O 0
with O 0
two O 0
or O 0
more O 0
cases O 0
of O 0
ovarian B-Disease 0
cancer I-Disease 1
are O 0
likely O 0
to O 0
be O 0
due O 0
to O 0
BRCA1 O 0
mutations O 0
. O 0
. O 0

Molecular O 0
basis O 0
of O 0
essential B-Disease 1
fructosuria I-Disease 1
: O 0
molecular O 0
cloning O 0
and O 0
mutational O 0
analysis O 0
of O 0
human O 0
ketohexokinase O 0
( O 0
fructokinase O 0
) O 0
. O 0

Essential B-Disease 1
fructosuria I-Disease 1
is O 0
one O 0
of O 0
the O 0
oldest O 0
known O 0
inborn B-Disease 0
errors I-Disease 0
of I-Disease 0
metabolism I-Disease 0
. O 0

It O 0
is O 0
a O 0
benign O 0
condition O 0
which O 0
is O 0
believed O 0
to O 0
result O 0
from O 0
deficiency B-Disease 1
of I-Disease 1
hepatic I-Disease 1
fructokinase I-Disease 1
( O 0
ketohexokinase O 0
, O 0
KHK O 0
, O 0
E O 0
. O 0
C O 0
. O 0
2 O 0
. O 0
7 O 0
. O 0
1 O 0
. O 0
3 O 0
) O 0
. O 0

This O 0
enzyme O 0
catalyses O 0
the O 0
first O 0
step O 0
of O 0
metabolism O 0
of O 0
dietary O 0
fructose O 0
, O 0
conversion O 0
of O 0
fructose O 0
to O 0
fructose O 0
- O 0
1 O 0
- O 0
phosphate O 0
. O 0

Despite O 0
the O 0
early O 0
recognition O 0
of O 0
this O 0
disorder O 0
, O 0
the O 0
primary O 0
structure O 0
of O 0
human O 0
KHK O 0
and O 0
the O 0
molecular O 0
basis O 0
of O 0
essential B-Disease 1
fructosuria I-Disease 1
have O 0
not O 0
been O 0
previously O 0
defined O 0
. O 0

In O 0
this O 0
report O 0
, O 0
the O 0
isolation O 0
and O 0
sequencing O 0
of O 0
full O 0
- O 0
length O 0
cDNA O 0
clones O 0
encoding O 0
human O 0
ketohexokinase O 0
are O 0
described O 0
. O 0

Alternative O 0
mRNA O 0
species O 0
and O 0
alternative O 0
KHK O 0
isozymes O 0
are O 0
produced O 0
by O 0
alternative O 0
polyadenylation O 0
and O 0
splicing O 0
of O 0
the O 0
KHK O 0
gene O 0
. O 0

The O 0
KHK O 0
proteins O 0
show O 0
a O 0
high O 0
level O 0
of O 0
sequence O 0
conservation O 0
relative O 0
to O 0
rat O 0
KHK O 0
. O 0

Direct O 0
evidence O 0
that O 0
mutation O 0
of O 0
the O 0
KHK O 0
structural O 0
gene O 0
is O 0
the O 0
cause O 0
of O 0
essential B-Disease 1
fructosuria I-Disease 1
was O 0
also O 0
obtained O 0
. O 0

In O 0
a O 0
well O 0
- O 0
characterized O 0
family O 0
, O 0
in O 0
which O 0
three O 0
of O 0
eight O 0
siblings O 0
have O 0
fructosuria B-Disease 1
, O 0
all O 0
affected O 0
individuals O 0
are O 0
compound O 0
heterozygotes O 0
for O 0
two O 0
mutations O 0
Gly40Arg O 0
and O 0
Ala43Thr O 0
. O 0

Both O 0
mutations O 0
result O 0
from O 0
G O 0
- O 0
- O 0
> O 0
A O 0
transitions O 0
, O 0
and O 0
each O 0
alters O 0
the O 0
same O 0
conserved O 0
region O 0
of O 0
the O 0
KHK O 0
protein O 0
. O 0

Neither O 0
mutation O 0
was O 0
seen O 0
in O 0
a O 0
sample O 0
of O 0
52 O 0
unrelated O 0
control O 0
individuals O 0
. O 0

An O 0
additional O 0
conservative O 0
amino O 0
acid O 0
change O 0
( O 0
Val49IIe O 0
) O 0
was O 0
present O 0
on O 0
the O 0
KHK O 0
allele O 0
bearing O 0
Ala43Thr O 0

Homozygous O 0
presence O 0
of O 0
the O 0
crossover O 0
( O 0
fusion O 0
gene O 0
) O 0
mutation O 0
identified O 0
in O 0
a O 0
type B-Disease 1
II I-Disease 1
Gaucher I-Disease 1
disease I-Disease 1
fetus O 0
: O 0
is O 0
this O 0
analogous O 0
to O 0
the O 0
Gaucher O 0
knock O 0
- O 0
out O 0
mouse O 0
model O 0
? O 0

Gaucher B-Disease 1
disease I-Disease 1
( O 0
GD B-Disease 1
) O 0
is O 0
an O 0
inherited O 1
deficiency B-Disease 1
of I-Disease 0
beta I-Disease 0
- I-Disease 0
glucocerebrosidase I-Disease 0
( O 0
EC O 0
3 O 0
. O 0
1 O 0
. O 0
2 O 0
. O 0
45 O 0
, O 0
gene O 0
symbol O 0
GBA O 0
) O 0
. O 0

In O 0
type B-Disease 1
I I-Disease 1
GD I-Disease 1
, O 0
the O 0
CNS O 0
is O 0
not O 0
involved O 0
( O 0
nonneuronopathic O 0
) O 0
, O 0
whereas O 0
in O 0
type B-Disease 0
II I-Disease 0
GD I-Disease 1
( O 0
acute O 0
neuronopathic O 0
) O 0
CNS O 0
involvement O 0
is O 0
early O 0
and O 0
rapidly O 0
progressive O 0
, O 0
while O 0
in O 0
type B-Disease 1
III I-Disease 1
GD I-Disease 1
( O 0
subacute O 0
neuronopathic O 0
) O 0
CNS O 0
involvement O 0
occurs O 0
later O 0
and O 0
is O 0
slowly O 0
progressive O 0
. O 0

The O 0
T6433C O 0
( O 0
L444P O 0
) O 0
substitution O 0
is O 0
prevalent O 0
in O 0
type B-Disease 0
GD I-Disease 1
II I-Disease 0
. O 0

It O 0
may O 0
occur O 0
alone O 0
as O 0
a O 0
single O 0
base O 0
- O 0
pair O 0
mutation O 0
but O 0
often O 0
is O 0
found O 0
as O 0
part O 0
of O 0
a O 0
complex O 0
allele O 0
containing O 0
additional O 0
GBA O 0
nucleotide O 0
substitutions O 0
, O 0
G6468C O 0
( O 0
A456P O 0
) O 0
and O 0
G6482C O 0
( O 0
V460V O 0
) O 0
, O 0
without O 0
( O 0
recNciI O 0
) O 0
or O 0
with O 0
( O 0
recTL O 0
) O 0
G5957C O 0
( O 0
D409H O 0
) O 0
. O 0

This O 0
complex O 0
allele O 0
is O 0
presumed O 0
to O 0
have O 0
formed O 0
by O 0
recombination O 0
( O 0
crossover O 0
, O 0
fusion O 0
) O 0
of O 0
the O 0
structural O 0
gene O 0
with O 0
the O 0
pseudogene O 0
, O 0
which O 0
contains O 0
the O 0
mutated O 0
sequences O 0
. O 0

Two O 0
complex O 0
alleles O 0
have O 0
never O 0
been O 0
demonstrated O 0
to O 0
coexist O 0
in O 0
any O 0
individual O 0
. O 0

We O 0
devised O 0
a O 0
selective O 0
PCR O 0
method O 0
for O 0
the O 0
specific O 0
amplification O 0
of O 0
the O 0
normal O 0
and O 0
/ O 0
or O 0
fusion O 0
gene O 0
. O 0

Using O 0
this O 0
procedure O 0
we O 0
demonstrated O 0
the O 0
fusion O 0
gene O 0
in O 0
homozygous O 0
form O 0
for O 0
the O 0
first O 0
time O 0
, O 0
in O 0
a O 0
Macedonian O 0
/ O 0
Ashkenazi O 0
Jewish O 0
GD B-Disease 1
type I-Disease 1
II I-Disease 1
fetus O 0
. O 0

Both O 0
parents O 0
were O 0
carriers O 0
of O 0
the O 0
recombination O 0
. O 0

This O 0
was O 0
confirmed O 0
by O 0
direct O 0
sequence O 0
analysis O 0
. O 0

A O 0
previous O 0
conceptus O 0
in O 0
this O 0
family O 0
was O 0
stillborn B-Disease 0
at O 0
36 O 0
weeks O 0
, O 0
with O 0
features O 0
of O 0
severe O 0
type B-Disease 0
II I-Disease 0
GD I-Disease 1
. O 0

Neonates O 0
showing O 0
a O 0
severe O 0
clinical O 0
phenotype O 0
, O 0
analogous O 0
to O 0
the O 0
early O 0
neonatal O 0
lethal O 0
disease O 0
occurring O 0
in O 0
mice O 0
homozygous O 0
for O 0
a O 0
null O 0
allele O 0
produced O 0
by O 0
targeted O 0
disruption O 0
of O 0
GBA O 0
, O 0
have O 0
been O 0
described O 0
elsewhere O 0
, O 0
but O 0
the O 0
specific O 0
mutations O 0
in O 0
these O 0
cases O 0
have O 0
not O 0
yet O 0
been O 0
characterized O 0
. O 0

( O 0
ABSTRACT O 0
TRUNCATED O 0
AT O 0
250 O 0
WORDS O 0
) O 0

Late O 0
infantile O 0
metachromatic B-Disease 1
leukodystrophy I-Disease 1
in O 0
Israel O 0
. O 0

Metachromatic B-Disease 0
Leukodystrophy I-Disease 0
( O 0
MLD B-Disease 0
) O 0
is O 0
a O 0
neurodegenerative B-Disease 0
disease I-Disease 0
in O 0
which O 0
the O 0
lysosomal O 0
enzyme O 0
, O 0
Aryl O 0
sulfatase O 0
A O 0
( O 0
ARSA O 0
) O 0
is O 0
deficient O 0
. O 0

The O 0
disease O 0
is O 0
inherited O 0
as O 0
an O 0
autosomal O 0
recessive O 0
trait O 0
and O 0
its O 0
frequency O 0
is O 0
estimated O 0
to O 0
be O 0
1 O 0
/ O 0
40 O 0
, O 0
000 O 0
live O 0
births O 0
. O 0

The O 0
gene O 0
of O 0
ARSA O 0
has O 0
been O 0
cloned O 0
and O 0
up O 0
to O 0
now O 0
eight O 0
mutations O 0
causing O 0
MLD B-Disease 0
have O 0
been O 0
reported O 0
. O 0

Another O 0
mutation O 0
, O 0
PD O 0
, O 0
leads O 0
to O 0
the O 0
deficiency O 0
of O 0
the O 0
enzyme O 0
in O 0
vitro O 0
( O 0
pseudodeficiency O 0
) O 0
without O 0
any O 0
known O 0
clinical O 0
effect O 0
. O 0

The O 0
PD O 0
mutation O 0
is O 0
frequent O 0
in O 0
all O 0
populations O 0
. O 0

In O 0
Israel O 0
, O 0
late O 0
infantile O 0
MLD B-Disease 0
was O 0
found O 0
to O 0
be O 0
very O 0
frequent O 0
in O 0
a O 0
small O 0
Jewish O 0
isolate O 0
, O 0
the O 0
Habbanite O 0
Jews O 0
( O 0
1 O 0
/ O 0
75 O 0
live O 0
births O 0
) O 0
. O 0

The O 0
molecular O 0
analysis O 0
demonstrated O 0
that O 0
in O 0
the O 0
Habbanite O 0
population O 0
, O 0
the O 0
mutation O 0
occurred O 0
on O 0
an O 0
allele O 0
with O 0
the O 0
PD O 0
mutation O 0
. O 0

The O 0
loss O 0
of O 0
ARSA O 0
activity O 0
is O 0
due O 0
to O 0
a O 0
point O 0
mutation O 0
C O 0
> O 0
T O 0
leading O 0
to O 0
a O 0
change O 0
of O 0
proline O 0
to O 0
leucine O 0
. O 0

MLD B-Disease 0
is O 0
also O 0
frequent O 0
among O 0
Moslem O 0
Arabs O 0
in O 0
Jerusalem O 0
. O 0

The O 0
mutation O 0
is O 0
a O 0
transition O 0
G O 0
> O 0
A O 0
destroying O 0
the O 0
splice O 0
donor O 0
site O 0
of O 0
exon O 0
2 O 0
. O 0

This O 0
mutation O 0
has O 0
been O 0
reported O 0
in O 0
patients O 0
with O 0
the O 0
late O 0
infantile O 0
MLD B-Disease 0
from O 0
different O 0
ethnic O 0
groups O 0
. O 0

The O 0
Christian O 0
Arabs O 0
in O 0
Israel O 0
also O 0
have O 0
a O 0
high O 0
incidence O 0
of O 0
the O 0
disease O 0
( O 0
1 O 0
/ O 0
10 O 0
, O 0
000 O 0
live O 0
births O 0
) O 0
; O 0
the O 0
mutation O 0
in O 0
this O 0
population O 0
is O 0
still O 0
unknown O 0
. O 0

Knowledge O 0
of O 0
the O 0
different O 0
mutations O 0
causing O 0
MLD B-Disease 0
in O 0
these O 0
defined O 0
populations O 0
will O 0
allow O 0
a O 0
carrier O 0
screening O 0
program O 0
to O 0
be O 0
carried O 0
out O 0
and O 0
prevent O 0
the O 0
birth O 0
of O 0
additional O 0
affected O 0
children O 0
. O 0
. O 0

A O 0
single O 0
amino O 0
acid O 0
substitution O 0
( O 0
G103D O 0
) O 0
in O 0
the O 0
type O 0
II O 0
collagen O 0
triple O 0
helix O 0
produces O 0
Kniest B-Disease 0
dysplasia I-Disease 0
. O 0

Kniest B-Disease 0
dysplasia I-Disease 0
is O 0
a O 0
moderately O 0
severe O 0
chondrodysplasia B-Disease 1
phenotype O 0
that O 0
results O 0
from O 0
mutations O 0
in O 0
the O 0
gene O 0
for O 0
type O 0
II O 0
collagen O 0
, O 0
COL2A1 O 0
. O 0

Characteristics O 0
of O 0
the O 0
disorder O 0
include O 0
a O 0
short B-Disease 0
trunk I-Disease 0
and I-Disease 0
extremities I-Disease 0
, O 0
mid B-Disease 1
- I-Disease 1
face I-Disease 1
hypoplasia I-Disease 1
, O 0
cleft B-Disease 0
palate I-Disease 0
, O 0
myopia B-Disease 0
, O 0
retinal B-Disease 1
detachment I-Disease 1
, O 0
and O 0
hearing B-Disease 0
loss I-Disease 0
. O 0

Recently O 0
, O 0
deletions O 0
of O 0
all O 0
or O 0
part O 0
of O 0
exon O 0
12 O 0
have O 0
been O 0
identified O 0
in O 0
individuals O 0
with O 0
Kniest B-Disease 0
dysplasia I-Disease 0
, O 0
suggesting O 0
that O 0
mutations O 0
within O 0
this O 0
region O 0
of O 0
the O 0
protein O 0
may O 0
primarily O 0
result O 0
in O 0
the O 0
Kniest B-Disease 0
dysplasia I-Disease 0
phenotype O 0
. O 0

We O 0
used O 0
SSCP O 0
to O 0
analyze O 0
an O 0
amplified O 0
genomic O 0
DNA O 0
fragment O 0
containing O 0
exon O 0
12 O 0
from O 0
seven O 0
individuals O 0
with O 0
Kniest B-Disease 0
dysplasia I-Disease 0
. O 0

An O 0
abnormality O 0
was O 0
identified O 0
in O 0
one O 0
patient O 0
. O 0

DNA O 0
sequence O 0
analysis O 0
demonstrated O 0
that O 0
the O 0
patient O 0
was O 0
heterozygous O 0
for O 0
a O 0
G O 0
to O 0
A O 0
transition O 0
that O 0
implied O 0
substitution O 0
of O 0
glycine103 O 0
of O 0
the O 0
triple O 0
helical O 0
domain O 0
by O 0
aspartate O 0
. O 0

The O 0
mutation O 0
was O 0
not O 0
observed O 0
in O 0
DNA O 0
from O 0
either O 0
of O 0
the O 0
clinically O 0
unaffected O 0
parents O 0
of O 0
the O 0
proband O 0
. O 0

Protein O 0
microsequencing O 0
demonstrated O 0
expression O 0
of O 0
the O 0
abnormal O 0
allele O 0
in O 0
cartilage O 0
. O 0

These O 0
data O 0
demonstrate O 0
that O 0
point O 0
mutations O 0
which O 0
result O 0
in O 0
single O 0
amino O 0
acid O 0
substitutions O 0
can O 0
produce O 0
Kniest B-Disease 0
dysplasia I-Disease 0
and O 0
further O 0
support O 0
the O 0
hypothesis O 0
that O 0
alteration O 0
of O 0
a O 0
domain O 0
, O 0
which O 0
includes O 0
the O 0
region O 0
encoded O 0
by O 0
exon O 0
12 O 0
, O 0
in O 0
the O 0
type O 0
II O 0
collagen O 0
protein O 0
leads O 0
to O 0
this O 0
disorder O 0
. O 0
. O 0

CAG O 0
expansions O 0
in O 0
a O 0
novel O 0
gene O 0
for O 0
Machado B-Disease 0
- I-Disease 0
Joseph I-Disease 0
disease I-Disease 0
at O 0
chromosome O 0
14q32 O 0
. O 0
1 O 0
. O 0

We O 0
have O 0
identified O 0
a O 0
novel O 0
gene O 0
containing O 0
CAG O 0
repeats O 0
and O 0
mapped O 0
it O 0
to O 0
chromosome O 0
14q32 O 0
. O 0

1 O 0
, O 0
the O 0
genetic O 0
locus O 0
for O 0
Machado B-Disease 0
- I-Disease 0
Joseph I-Disease 0
disease I-Disease 0
( O 0
MJD B-Disease 0
) O 0
. O 0

In O 0
normal O 0
individuals O 0
the O 0
gene O 0
contains O 0
between O 0
13 O 0
and O 0
36 O 0
CAG O 0
repeats O 0
, O 0
whereas O 0
most O 0
of O 0
the O 0
clinically O 0
diagnosed O 0
patients O 0
and O 0
all O 0
of O 0
the O 0
affected O 0
members O 0
of O 0
a O 0
family O 0
with O 0
the O 0
clinical O 0
and O 0
pathological O 0
diagnosis O 0
of O 0
MJD B-Disease 0
show O 0
expansion O 0
of O 0
the O 0
repeat O 0
- O 0
number O 0
( O 0
from O 0
68 O 0
- O 0
79 O 0
) O 0
. O 0

Southern O 0
blot O 0
analyses O 0
and O 0
genomic O 0
cloning O 0
demonstrates O 0
the O 0
existence O 0
of O 0
related O 0
genes O 0
. O 0

These O 0
results O 0
raise O 0
the O 0
possibility O 0
that O 0
similar O 0
abnormalities O 0
in O 0
related O 0
genes O 0
may O 0
give O 0
rise O 0
to O 0
diseases O 0
similar O 0
to O 0
MJD B-Disease 0
. O 0

Mutations O 0
in O 0
the O 0
BRCA1 O 0
gene O 0
in O 0
families O 0
with O 0
early O 0
- O 0
onset O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
. O 0

We O 0
analysed O 0
50 O 0
probands O 0
with O 0
a O 0
family O 0
history O 0
of O 0
breast B-Disease 1
and I-Disease 1
/ I-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
for O 0
germline O 0
mutations O 0
in O 0
the O 0
coding O 0
region O 0
of O 0
the O 0
BRCA1 O 0
candidate O 0
gene O 0
, O 0
using O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphism O 0
( O 0
SSCP O 0
) O 0
analysis O 0
on O 0
PCR O 0
- O 0
amplified O 0
genomic O 0
DNA O 0
. O 0

A O 0
total O 0
of O 0
eight O 0
putative O 0
disease O 0
- O 0
causing O 0
alterations O 0
were O 0
identified O 0
four O 0
of O 0
these O 0
are O 0
frameshifts O 0
and O 0
two O 0
are O 0
nonsense O 0
mutations O 0
. O 0

In O 0
addition O 0
, O 0
we O 0
found O 0
two O 0
missense O 0
mutations O 0
, O 0
one O 0
of O 0
which O 0
changes O 0
the O 0
final O 0
cysteine O 0
of O 0
the O 0
BRCA1 O 0
zinc O 0
finger O 0
motif O 0
to O 0
glycine O 0
. O 0

These O 0
data O 0
are O 0
consistent O 0
with O 0
a O 0
tumour B-Disease 1
suppressor O 0
model O 0
, O 0
and O 0
support O 0
the O 0
notion O 0
that O 0
this O 0
candidate O 0
gene O 0
is O 0
in O 0
fact O 0
BRCA1 O 0
. O 0

The O 0
heterogeneity O 0
of O 0
mutations O 0
, O 0
coupled O 0
with O 0
the O 0
large O 0
size O 0
of O 0
the O 0
gene O 0
, O 0
indicates O 0
that O 0
clinical O 0
application O 0
of O 0
BRCA1 O 0
mutation O 0
testing O 0
will O 0
be O 0
technically O 0
challenging O 0
. O 0
. O 0

Confirmation O 0
of O 0
BRCA1 O 0
by O 0
analysis O 0
of O 0
germline O 0
mutations O 0
linked O 0
to O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
in O 0
ten O 0
families O 0
. O 0

We O 0
provide O 0
genetic O 0
evidence O 0
supporting O 0
the O 0
identity O 0
of O 0
the O 0
candidate O 0
gene O 0
for O 0
BRCA1 O 0
through O 0
the O 0
characterization O 0
of O 0
germline O 0
mutations O 0
in O 0
63 O 0
breast B-Disease 0
cancer I-Disease 1
patients O 0
and O 0
10 O 0
ovarian B-Disease 0
cancer I-Disease 1
patients O 0
in O 0
ten O 0
families O 0
with O 0
cancer B-Disease 1
linked O 0
to O 0
chromosome O 0
17q21 O 0
. O 0

Nine O 0
different O 0
mutations O 0
were O 0
detected O 0
by O 0
screening O 0
BRCA1 O 0
DNA O 0
and O 0
RNA O 0
by O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphism O 0
analysis O 0
and O 0
direct O 0
sequencing O 0
. O 0

Seven O 0
mutations O 0
lead O 0
to O 0
protein O 0
truncations O 0
at O 0
sites O 0
throughout O 0
the O 0
gene O 0
. O 0

One O 0
missense O 0
mutation O 0
( O 0
which O 0
occurred O 0
independently O 0
in O 0
two O 0
families O 0
) O 0
leads O 0
to O 0
loss O 0
of O 0
a O 0
cysteine O 0
in O 0
the O 0
zinc O 0
binding O 0
domain O 0
. O 0

An O 0
intronic O 0
single O 0
basepair O 0
substitution O 0
destroys O 0
an O 0
acceptor O 0
site O 0
and O 0
activates O 0
a O 0
cryptic O 0
splice O 0
site O 0
, O 0
leading O 0
to O 0
a O 0
59 O 0
basepair O 0
insertion O 0
and O 0
chain O 0
termination O 0
. O 0

The O 0
four O 0
families O 0
with O 0
both O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
had O 0
chain O 0
termination O 0
mutations O 0
in O 0
the O 0
N O 0
- O 0
terminal O 0
half O 0
of O 0
the O 0
protein O 0
. O 0
. O 0

High O 0
resolution O 0
genetic O 0
analysis O 0
suggests O 0
one O 0
ancestral O 0
predisposing O 0
haplotype O 0
for O 0
the O 0
origin O 0
of O 0
the O 0
myotonic B-Disease 1
dystrophy I-Disease 1
mutation O 0
. O 0

The O 0
mutation O 0
causing O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
has O 0
been O 0
identified O 0
as O 0
an O 0
amplification O 0
of O 0
an O 0
unstable O 0
trinucleotide O 0
( O 0
CTG O 0
) O 0
n O 0
repeat O 0
in O 0
over O 0
99 O 0
% O 0
of O 0
the O 0
global O 0
DM B-Disease 0
population O 0
. O 0

It O 0
is O 0
in O 0
complete O 0
linkage O 0
disequilibrium O 0
with O 0
an O 0
Alu O 0
element O 0
polymorphism O 0
within O 0
the O 0
DM B-Disease 0
kinase O 0
gene O 0
, O 0
suggesting O 0
that O 0
DM B-Disease 0
is O 0
a O 0
consequence O 0
of O 0
one O 0
or O 0
few O 0
ancestral O 0
mutations O 0
. O 0

A O 0
recent O 0
analysis O 0
utilizing O 0
this O 0
polymorphism O 0
as O 0
well O 0
as O 0
a O 0
flanking O 0
dinucleotide O 0
marker O 0
, O 0
suggested O 0
that O 0
similar O 0
to O 0
Fragile B-Disease 0
X I-Disease 0
syndrome I-Disease 0
, O 0
DM B-Disease 0
exhibited O 0
a O 0
founder O 0
effect O 0
( O 0
Imbert O 0
et O 0
al O 0
. O 0
, O 0
1993 O 0
Nature O 0
Genet O 0
. O 0
4 O 0
, O 0
72 O 0
- O 0
76 O 0
) O 0
. O 0

In O 0
contrast O 0
, O 0
the O 0
low O 0
reproductive O 0
fitness O 0
of O 0
individuals O 0
with O 0
congenital O 0
DM B-Disease 0
( O 0
the O 0
endpoint O 0
of O 0
genetic O 0
anticipation O 0
in O 0
myotonic B-Disease 1
dystrophy I-Disease 1
) O 0
suggests O 0
a O 0
higher O 0
rate O 0
of O 0
new O 0
mutations O 0
. O 0

We O 0
present O 0
a O 0
high O 0
resolution O 0
genetic O 0
analysis O 0
of O 0
the O 0
DM B-Disease 0
locus O 0
using O 0
PCR O 0
based O 0
assays O 0
of O 0
nine O 0
polymorphisms O 0
, O 0
spanning O 0
a O 0
physical O 0
distance O 0
of O 0
30 O 0
kb O 0
, O 0
within O 0
and O 0
immediately O 0
flanking O 0
the O 0
DM B-Disease 0
kinase O 0
gene O 0
. O 0

The O 0
persistent O 0
complete O 0
allelic O 0
association O 0
of O 0
the O 0
DM B-Disease 0
mutation O 0
with O 0
all O 0
these O 0
polymorphisms O 0
provides O 0
further O 0
support O 0
to O 0
previous O 0
observations O 0
and O 0
suggests O 0
more O 0
strongly O 0
that O 0
the O 0
DM B-Disease 0
mutation O 0
occurred O 0
on O 0
the O 0
background O 0
of O 0
a O 0
particular O 0
haplotype O 0
in O 0
which O 0
the O 0
( O 0
CTG O 0
) O 0
n O 0
repeat O 0
became O 0
inherently O 0
unstable O 0
and O 0
therefore O 0
predisposed O 0
to O 0
amplification O 0
. O 0

Genetic O 0
instability O 0
in O 0
human O 0
ovarian B-Disease 0
cancer I-Disease 1
cell O 0
lines O 0
. O 0

We O 0
have O 0
analyzed O 0
the O 0
stability O 0
of O 0
microsatellites O 0
in O 0
cell O 0
lines O 0
derived O 0
from O 0
human O 0
ovarian B-Disease 1
cancers I-Disease 1
and O 0
found O 0
that O 0
5 O 0
out O 0
of O 0
10 O 0
of O 0
the O 0
ovarian B-Disease 0
tumor I-Disease 0
cell O 0
lines O 0
are O 0
genetically O 0
unstable O 0
at O 0
the O 0
majority O 0
of O 0
the O 0
loci O 0
analyzed O 0
. O 0

In O 0
clones O 0
and O 0
subclones O 0
derived O 0
serially O 0
from O 0
one O 0
of O 0
these O 0
cell O 0
lines O 0
( O 0
2774 O 0
; O 0
serous B-Disease 0
cystadenocarcinoma I-Disease 0
) O 0
, O 0
a O 0
very O 0
high O 0
proportion O 0
of O 0
microsatellites O 0
distributed O 0
in O 0
many O 0
different O 0
regions O 0
of O 0
the O 0
genome O 0
change O 0
their O 0
size O 0
in O 0
a O 0
mercurial O 0
fashion O 0
. O 0

We O 0
conclude O 0
that O 0
genomic O 0
instability O 0
in O 0
ovarian B-Disease 1
tumors I-Disease 1
is O 0
a O 0
dynamic O 0
and O 0
ongoing O 0
process O 0
whose O 0
high O 0
frequency O 0
may O 0
have O 0
been O 0
previously O 0
underestimated O 0
by O 0
PCR O 0
- O 0
based O 0
allelotyping O 0
of O 0
bulk O 0
tumor B-Disease 0
tissue O 0
. O 0

We O 0
have O 0
identified O 0
the O 0
source O 0
of O 0
the O 0
genetic O 0
instability O 0
in O 0
one O 0
ovarian B-Disease 0
tumor I-Disease 0
as O 0
a O 0
point O 0
mutation O 0
( O 0
R524P O 0
) O 0
in O 0
the O 0
human O 0
mismatch O 0
- O 0
repair O 0
gene O 0
MSH2 O 0
( O 0
Salmonella O 0
MutS O 0
homologue O 0
) O 0
, O 0
which O 0
has O 0
recently O 0
been O 0
shown O 0
to O 0
be O 0
involved O 0
in O 0
hereditary B-Disease 0
nonpolyposis I-Disease 0
colorectal I-Disease 1
cancer I-Disease 1
. O 0

Patient O 0
2774 O 0
was O 0
a O 0
38 O 0
- O 0
year O 0
- O 0
old O 0
heterozygote O 0
, O 0
and O 0
her O 0
normal O 0
tissue O 0
carried O 0
both O 0
mutant O 0
and O 0
wild O 0
- O 0
type O 0
alleles O 0
of O 0
the O 0
human O 0
MSH2 O 0
gene O 0
. O 0

However O 0
the O 0
wild O 0
- O 0
type O 0
allele O 0
was O 0
lost O 0
at O 0
some O 0
point O 0
early O 0
during O 0
tumorigenesis O 0
so O 0
that O 0
DNA O 0
isolated O 0
either O 0
from O 0
the O 0
patients O 0
ovarian B-Disease 0
tumor I-Disease 0
or O 0
from O 0
the O 0
2774 O 0
cell O 0
line O 0
carries O 0
only O 0
the O 0
mutant O 0
allele O 0
of O 0
the O 0
human O 0
MSH2 O 0
gene O 0
. O 0

The O 0
genetic O 0
instability O 0
observed O 0
in O 0
the O 0
tumor B-Disease 0
and O 0
cell O 0
line O 0
DNA O 0
, O 0
together O 0
with O 0
the O 0
germ O 0
- O 0
line O 0
mutation O 0
in O 0
a O 0
mismatch O 0
- O 0
repair O 0
gene O 0
, O 0
suggest O 0
that O 0
the O 0
MSH2 O 0
gene O 0
is O 0
involved O 0
in O 0
the O 0
onset O 0
and O 0
/ O 0
or O 0
progression O 0
in O 0
a O 0
subset O 0
of O 0
ovarian B-Disease 0
cancer I-Disease 1
. O 0
. O 0

BRCA1 O 0
mutations O 0
in O 0
primary O 0
breast B-Disease 1
and I-Disease 1
ovarian I-Disease 1
carcinomas I-Disease 1
. O 0

Loss O 0
of O 0
heterozygosity O 0
data O 0
from O 0
familial B-Disease 1
tumors I-Disease 1
suggest O 0
that O 0
BRCA1 O 0
, O 0
a O 0
gene O 0
that O 0
confers O 0
susceptibility O 0
to O 0
ovarian B-Disease 0
and I-Disease 0
early I-Disease 0
- I-Disease 0
onset I-Disease 0
breast B-Disease 0
cancer I-Disease 1
, O 0
encodes O 0
a O 0
tumor B-Disease 0
suppressor O 0
. O 0

The O 0
BRCA1 O 0
region O 0
is O 0
also O 0
subject O 0
to O 0
allelic O 0
loss O 0
in O 0
sporadic B-Disease 1
breast I-Disease 1
and I-Disease 1
ovarian I-Disease 1
cancers I-Disease 1
, O 0
an O 0
indication O 0
that O 0
BRCA1 O 0
mutations O 0
may O 0
occur O 0
somatically O 0
in O 0
these O 0
tumors B-Disease 0
. O 0

The O 0
BRCA1 O 0
coding O 0
region O 0
was O 0
examined O 0
for O 0
mutations O 0
in O 0
primary O 0
breast B-Disease 1
and I-Disease 1
ovarian I-Disease 1
tumors I-Disease 1
that O 0
show O 0
allele O 0
loss O 0
at O 0
the O 0
BRCA1 O 0
locus O 0
. O 0

Mutations O 0
were O 0
detected O 0
in O 0
3 O 0
of O 0
32 O 0
breast O 0
and O 0
1 O 0
of O 0
12 O 0
ovarian B-Disease 0
carcinomas I-Disease 0
; O 0
all O 0
four O 0
mutations O 0
were O 0
germline O 0
alterations O 0
and O 0
occurred O 0
in O 0
early O 0
- O 0
onset O 0
cancers B-Disease 0
. O 0

These O 0
results O 0
suggest O 0
that O 0
mutation O 0
of O 0
BRCA1 O 0
may O 0
not O 0
be O 0
critical O 0
in O 0
the O 0
development O 0
of O 0
the O 0
majority O 0
of O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 1
cancers I-Disease 1
that O 0
arise O 0
in O 0
the O 0
absence O 0
of O 0
a O 0
mutant O 0
germline O 0
allele O 0
. O 0
. O 0

PAX6 O 0
gene O 0
dosage O 0
effect O 0
in O 0
a O 0
family O 0
with O 0
congenital B-Disease 1
cataracts I-Disease 1
, O 0
aniridia B-Disease 0
, O 0
anophthalmia B-Disease 0
and O 0
central B-Disease 1
nervous I-Disease 1
system I-Disease 1
defects I-Disease 1
. O 0

The O 0
human O 0
eye O 0
malformation O 0
aniridia B-Disease 0
results O 0
from O 0
haploinsufficiency B-Disease 0
of I-Disease 0
PAX6 I-Disease 0
, O 0
a O 0
paired O 0
box O 0
DNA O 0
- O 0
binding O 0
protein O 0
. O 0

To O 0
study O 0
this O 0
dosage O 0
effect O 0
, O 0
we O 0
characterized O 0
two O 0
PAX6 O 0
mutations O 0
in O 0
a O 0
family O 0
segregating O 0
aniridia B-Disease 0
and O 0
a O 0
milder O 0
syndrome O 0
consisting O 0
of O 0
congenital B-Disease 1
cataracts I-Disease 1
and O 0
late O 0
onset O 0
corneal B-Disease 0
dystrophy I-Disease 0
. O 0

The O 0
nonsense O 0
mutations O 0
, O 0
at O 0
codons O 0
103 O 0
and O 0
353 O 0
, O 0
truncate O 0
PAX6 O 0
within O 0
the O 0
N O 0
- O 0
terminal O 0
paired O 0
and O 0
C O 0
- O 0
terminal O 0
PST O 0
domains O 0
, O 0
respectively O 0
. O 0

The O 0
wild O 0
- O 0
type O 0
PST O 0
domain O 0
activates O 0
transcription O 0
autonomously O 0
and O 0
the O 0
mutant O 0
form O 0
has O 0
partial O 0
activity O 0
. O 0

A O 0
compound O 0
heterozygote O 0
had O 0
severe O 0
craniofacial B-Disease 1
and I-Disease 1
central I-Disease 1
nervous I-Disease 1
system I-Disease 1
defects I-Disease 1
and O 0
no B-Disease 0
eyes I-Disease 0
. O 0

The O 0
pattern O 0
of O 0
malformations O 0
is O 0
similar O 0
to O 0
that O 0
in O 0
homozygous O 0
Sey O 0
mice O 0
and O 0
suggests O 0
a O 0
critical O 0
role O 0
for O 0
PAX6 O 0
in O 0
controlling O 0
the O 0
migration O 0
and O 0
differentiation O 0
of O 0
specific O 0
neuronal O 0
progenitor O 0
cells O 0
in O 0
the O 0
brain O 0
. O 0
. O 0

A O 0
physical O 0
map O 0
and O 0
candidate O 0
genes O 0
in O 0
the O 0
BRCA1 O 0
region O 0
on O 0
chromosome O 0
17q12 O 0
- O 0
21 O 0
. O 0

We O 0
have O 0
constructed O 0
a O 0
physical O 0
map O 0
of O 0
a O 0
4 O 0
cM O 0
region O 0
on O 0
chromosome O 0
17q12 O 0
- O 0
21 O 0
that O 0
contains O 0
the O 0
hereditary B-Disease 1
breast I-Disease 1
and I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
gene O 0
BRCA1 O 0
. O 0

The O 0
map O 0
comprises O 0
a O 0
contig O 0
of O 0
137 O 0
overlapping O 0
yeast O 0
artificial O 0
chromosomes O 0
and O 0
P1 O 0
clones O 0
, O 0
onto O 0
which O 0
we O 0
have O 0
placed O 0
112 O 0
PCR O 0
markers O 0
. O 0

We O 0
have O 0
localized O 0
more O 0
than O 0
20 O 0
genes O 0
on O 0
this O 0
map O 0
, O 0
ten O 0
of O 0
which O 0
had O 0
not O 0
been O 0
mapped O 0
to O 0
the O 0
region O 0
previously O 0
, O 0
and O 0
have O 0
isolated O 0
30 O 0
cDNA O 0
clones O 0
representing O 0
partial O 0
sequences O 0
of O 0
as O 0
yet O 0
unidentified O 0
genes O 0
. O 0

Two O 0
genes O 0
that O 0
lie O 0
within O 0
a O 0
narrow O 0
region O 0
defined O 0
by O 0
meiotic O 0
breakpoints O 0
in O 0
BRCA1 O 0
patients O 0
have O 0
been O 0
sequenced O 0
in O 0
breast B-Disease 0
cancer I-Disease 1
patients O 0
without O 0
revealing O 0
any O 0
deleterious O 0
mutations O 0
. O 0

These O 0
new O 0
reagents O 0
should O 0
facilitate O 0
the O 0
identification O 0
of O 0
BRCA1 O 0
. O 0
. O 0

The O 0
LEC O 0
rat O 0
has O 0
a O 0
deletion O 0
in O 0
the O 0
copper O 0
transporting O 0
ATPase O 0
gene O 0
homologous O 0
to O 0
the O 0
Wilson B-Disease 0
disease I-Disease 0
gene O 0
. O 0

The O 0
Long O 0
- O 0
Evans O 0
Cinnamon O 0
( O 0
LEC O 0
) O 0
rat O 0
shows O 0
similarity O 0
to O 0
Wilson B-Disease 0
disease I-Disease 0
in O 0
many O 0
clinical O 0
and O 0
biochemical O 0
features O 0
. O 0

We O 0
have O 0
cloned O 0
cDNAs O 0
for O 0
the O 0
rat O 0
gene O 0
( O 0
Atp7b O 0
) O 0
homologous O 0
to O 0
the O 0
human O 0
Wilson B-Disease 0
disease I-Disease 0
gene O 0
( O 0
ATP7B O 0
) O 0
and O 0
have O 0
used O 0
them O 0
to O 0
identify O 0
a O 0
partial O 0
deletion O 0
in O 0
the O 0
Atp7b O 0
gene O 0
in O 0
the O 0
LEC O 0
rat O 0
. O 0

The O 0
deletion O 0
removes O 0
at O 0
least O 0
900 O 0
bp O 0
of O 0
the O 0
coding O 0
region O 0
at O 0
the O 0
3 O 0
end O 0
, O 0
includes O 0
the O 0
crucial O 0
ATP O 0
binding O 0
domain O 0
and O 0
extends O 0
downstream O 0
of O 0
the O 0
gene O 0
. O 0

Our O 0
results O 0
provide O 0
convincing O 0
evidence O 0
for O 0
defining O 0
the O 0
LEC O 0
rat O 0
as O 0
an O 0
animal O 0
model O 0
for O 0
Wilson B-Disease 0
disease I-Disease 0
. O 0

This O 0
model O 0
will O 0
be O 0
important O 0
for O 0
studying O 0
liver O 0
pathophysiology O 0
, O 0
for O 0
developing O 0
therapy O 0
for O 0
Wilson B-Disease 0
disease I-Disease 0
and O 0
for O 0
studying O 0
the O 0
pathway O 0
of O 0
copper O 0
transport O 0
and O 0
its O 0
possible O 0
interaction O 0
with O 0
other O 0
heavy O 0
metals O 0
. O 0
. O 0

Genomic O 0
organization O 0
of O 0
the O 0
adrenoleukodystrophy B-Disease 1
gene O 0
. O 0

Adrenoleukodystrophy B-Disease 0
( O 0
ALD B-Disease 0
) O 0
, O 0
the O 0
most O 0
frequent O 0
peroxisomal B-Disease 1
disorder I-Disease 1
, O 0
is O 0
a O 0
severe O 0
neurodegenerative B-Disease 0
disease I-Disease 0
associated O 0
with O 0
an O 0
impairment B-Disease 1
of I-Disease 1
very I-Disease 1
long I-Disease 1
chain I-Disease 1
fatty I-Disease 1
acids I-Disease 1
beta I-Disease 1
- I-Disease 1
oxidation I-Disease 1
. O 0

We O 0
have O 0
recently O 0
identified O 0
by O 0
positional O 0
cloning O 0
the O 0
gene O 0
responsible O 0
for O 0
ALD B-Disease 0
, O 0
located O 0
in O 0
Xq28 O 0
. O 0

It O 0
encodes O 0
a O 0
new O 0
member O 0
of O 0
the O 0
" O 0
ABC O 0
" O 0
superfamily O 0
of O 0
membrane O 0
- O 0
associated O 0
transporters O 0
that O 0
shows O 0
, O 0
in O 0
particular O 0
, O 0
significant O 0
homology O 0
to O 0
the O 0
70 O 0
- O 0
kDa O 0
peroxisomal O 0
membrane O 0
protein O 0
( O 0
PMP70 O 0
) O 0
. O 0

We O 0
report O 0
here O 0
a O 0
detailed O 0
characterization O 0
of O 0
the O 0
ALD B-Disease 0
gene O 0
structure O 0
. O 0

It O 0
extends O 0
over O 0
21 O 0
kb O 0
and O 0
consists O 0
of O 0
10 O 0
exons O 0
. O 0

To O 0
facilitate O 0
the O 0
detection O 0
of O 0
mutations O 0
in O 0
ALD B-Disease 0
patients O 0
, O 0
we O 0
have O 0
determined O 0
the O 0
intronic O 0
sequences O 0
flanking O 0
the O 0
exons O 0
as O 0
well O 0
as O 0
the O 0
sequence O 0
of O 0
the O 0
3 O 0
untranslated O 0
region O 0
and O 0
of O 0
the O 0
immediate O 0
5 O 0
promoter O 0
region O 0
. O 0

Sequences O 0
present O 0
in O 0
distal O 0
exons O 0
cross O 0
- O 0
hybridize O 0
strongly O 0
to O 0
additional O 0
sequences O 0
in O 0
the O 0
human O 0
genome O 0
. O 0

The O 0
ALD B-Disease 0
gene O 0
has O 0
been O 0
positioned O 0
on O 0
a O 0
pulsed O 0
- O 0
field O 0
map O 0
between O 0
DXS15 O 0
and O 0
the O 0
L1CAM O 0
gene O 0
, O 0
about O 0
650 O 0
kb O 0
upstream O 0
from O 0
the O 0
color O 0
pigment O 0
genes O 0
. O 0

The O 0
frequent O 0
occurrence O 0
of O 0
color O 0
vision O 0
anomalies O 0
observed O 0
in O 0
patients O 0
with O 0
adrenomyeloneuropathy B-Disease 1
( O 0
the O 0
adult O 0
onset O 0
form O 0
of O 0
ALD B-Disease 0
) O 0
thus O 0
does O 0
not O 0
represent O 0
a O 0
contiguous B-Disease 1
gene I-Disease 1
syndrome I-Disease 1
but O 0
a O 0
secondary O 0
manifestation O 0
of O 0
ALD B-Disease 0
. O 0
. O 0

The O 0
murine O 0
homologues O 0
of O 0
the O 0
Huntington B-Disease 1
disease I-Disease 1
gene O 0
( O 0
Hdh O 0
) O 0
and O 0
the O 0
alpha O 0
- O 0
adducin O 0
gene O 0
( O 0
Add1 O 0
) O 0
map O 0
to O 0
mouse O 0
chromosome O 0
5 O 0
within O 0
a O 0
region O 0
of O 0
conserved O 0
synteny O 0
with O 0
human O 0
chromosome O 0
4p16 O 0
. O 0
3 O 0
. O 0

Huntington B-Disease 1
disease I-Disease 1
( O 0
HD B-Disease 1
) O 0
is O 0
a O 0
severe O 0
autosomal B-Disease 1
dominant I-Disease 1
neurodegenerative I-Disease 1
disorder I-Disease 1
associated O 0
with O 0
a O 0
novel O 0
gene O 0
( O 0
IT15 O 0
) O 0
. O 0

Recently O 0
, O 0
we O 0
reported O 0
the O 0
cloning O 0
of O 0
Hdh O 0
, O 0
the O 0
murine O 0
homologue O 0
of O 0
IT15 O 0
. O 0

Here O 0
, O 0
using O 0
an O 0
interspecific O 0
backcross O 0
, O 0
we O 0
have O 0
mapped O 0
both O 0
Hdh O 0
and O 0
the O 0
mouse O 0
homologue O 0
of O 0
human O 0
alpha O 0
- O 0
adducin O 0
( O 0
Add1 O 0
) O 0
, O 0
a O 0
membrane O 0
- O 0
associated O 0
cytoskeletal O 0
protein O 0
gene O 0
. O 0

Both O 0
of O 0
these O 0
genes O 0
map O 0
in O 0
the O 0
same O 0
position O 0
on O 0
mouse O 0
chromosome O 0
5 O 0
in O 0
a O 0
region O 0
associated O 0
with O 0
ancestral O 0
chromosomal O 0
rearrangements O 0
and O 0
show O 0
no O 0
recombination O 0
with O 0
D5H4S43 O 0
, O 0
D5H4S115 O 0
, O 0
and O 0
D5H4S62 O 0
, O 0
the O 0
murine O 0
homologues O 0
of O 0
D4S43 O 0
, O 0
D4S115 O 0
, O 0
and O 0
D4S62 O 0
, O 0
respectively O 0
. O 0

Further O 0
mapping O 0
studies O 0
of O 0
humans O 0
, O 0
mice O 0
, O 0
and O 0
other O 0
mammalian O 0
species O 0
should O 0
reveal O 0
the O 0
nature O 0
of O 0
the O 0
rearrangements O 0
affecting O 0
this O 0
chromosomal O 0
segment O 0
during O 0
mammalian O 0
evolution O 0
. O 0
. O 0

Genetic O 0
cholesteryl B-Disease 0
ester I-Disease 0
transfer I-Disease 0
protein I-Disease 0
deficiency I-Disease 0
caused O 0
by O 0
two O 0
prevalent O 0
mutations O 0
as O 0
a O 0
major O 0
determinant O 0
of O 0
increased O 0
levels O 0
of O 0
high O 0
density O 0
lipoprotein O 0
cholesterol O 0
. O 0

Genetic O 0
determinants O 0
of O 0
HDL O 0
cholesterol O 0
( O 0
HDL O 0
- O 0
C O 0
) O 0
levels O 0
in O 0
the O 0
general O 0
population O 0
are O 0
poorly O 0
understood O 0
. O 0

We O 0
previously O 0
described O 0
plasma O 0
cholesteryl B-Disease 0
ester I-Disease 0
transfer I-Disease 0
protein I-Disease 0
( I-Disease 0
CETP I-Disease 0
) I-Disease 0
deficiency I-Disease 0
due O 0
to O 0
an O 0
intron O 0
14 O 0
G O 0
( O 0
+ O 0
1 O 0
) O 0
- O 0
to O 0
- O 0
A O 0
mutation O 0
( O 0
Int14 O 0
A O 0
) O 0
in O 0
several O 0
families O 0
with O 0
very O 0
high O 0
HDL O 0
- O 0
C O 0
levels O 0
in O 0
Japan O 0
. O 0

Subjects O 0
with O 0
HDL O 0
- O 0
C O 0
> O 0
or O 0
= O 0
100 O 0
mg O 0
/ O 0
dl O 0
( O 0
n O 0
= O 0
130 O 0
) O 0
were O 0
screened O 0
by O 0
PCR O 0
single O 0
strand O 0
conformational O 0
polymorphism O 0
analysis O 0
of O 0
the O 0
CETP O 0
gene O 0
. O 0

Two O 0
other O 0
mutations O 0
were O 0
identified O 0
by O 0
DNA O 0
sequencing O 0
or O 0
primer O 0
- O 0
mediated O 0
restriction O 0
map O 0
modification O 0
of O 0
PCR O 0
products O 0
a O 0
novel O 0
intron O 0
14 O 0
splice O 0
donor O 0
site O 0
mutation O 0
caused O 0
by O 0
a O 0
T O 0
insertion O 0
at O 0
position O 0
+ O 0
3 O 0
from O 0
the O 0
exon14 O 0
/ O 0
intron14 O 0
boundary O 0
( O 0
Int14 O 0
T O 0
) O 0
and O 0
a O 0
missense O 0
mutation O 0
( O 0
Asp442 O 0
to O 0
Gly O 0
) O 0
within O 0
exon O 0
15 O 0
( O 0
D442G O 0
) O 0
. O 0

The O 0
Int14 O 0
T O 0
mutation O 0
was O 0
only O 0
found O 0
in O 0
one O 0
family O 0
. O 0

However O 0
, O 0
the O 0
D442G O 0
and O 0
Int14 O 0
A O 0
mutations O 0
were O 0
highly O 0
prevalent O 0
in O 0
subjects O 0
with O 0
HDL O 0
- O 0
C O 0
> O 0
or O 0
= O 0
60 O 0
mg O 0
/ O 0
dl O 0
, O 0
with O 0
combined O 0
allele O 0
frequencies O 0
of O 0
9 O 0
% O 0
, O 0
12 O 0
% O 0
, O 0
21 O 0
% O 0
and O 0
43 O 0
% O 0
for O 0
HDL O 0
- O 0
C O 0
60 O 0
- O 0
79 O 0
, O 0
80 O 0
- O 0
99 O 0
, O 0
100 O 0
- O 0
119 O 0
, O 0
and O 0
> O 0
or O 0
= O 0
120 O 0
mg O 0
/ O 0
dl O 0
, O 0
respectively O 0
. O 0

Furthermore O 0
, O 0
prevalences O 0
of O 0
the O 0
D442G O 0
and O 0
Int14 O 0
A O 0
mutations O 0
were O 0
extremely O 0
high O 0
in O 0
a O 0
general O 0
sample O 0
of O 0
Japanese O 0
men O 0
( O 0
n O 0
= O 0
236 O 0
) O 0
, O 0
with O 0
heterozygote O 0
frequencies O 0
of O 0
7 O 0
% O 0
and O 0
2 O 0
% O 0
, O 0
respectively O 0
. O 0

These O 0
two O 0
mutations O 0
accounted O 0
for O 0
about O 0
10 O 0
% O 0
of O 0
the O 0
total O 0
variance O 0
of O 0
HDL O 0
- O 0
C O 0
in O 0
this O 0
population O 0
. O 0

The O 0
phenotype O 0
in O 0
a O 0
genetic O 0
compound O 0
heterozygote O 0
( O 0
Int14 O 0
T O 0
and O 0
Int14 O 0
A O 0
) O 0
was O 0
similar O 0
to O 0
that O 0
of O 0
Int14 O 0
A O 0
homozygotes O 0
( O 0
no O 0
detectable O 0
CETP O 0
and O 0
markedly O 0
increased O 0
HDL O 0
- O 0
C O 0
) O 0
, O 0
indicating O 0
that O 0
the O 0
Int14 O 0
T O 0
produces O 0
a O 0
null O 0
allele O 0
. O 0

In O 0
four O 0
D442G O 0
homozygotes O 0
, O 0
mean O 0
HDL O 0
- O 0
C O 0
levels O 0
( O 0
86 O 0
+ O 0
/ O 0
- O 0
26 O 0
mg O 0
/ O 0
dl O 0
) O 0
were O 0
lower O 0
than O 0
in O 0
Int14 O 0
A O 0
homozygotes O 0
( O 0
158 O 0
+ O 0
/ O 0
- O 0
35 O 0
mg O 0
/ O 0
dl O 0
) O 0
, O 0
reflecting O 0
residual O 0
CETP O 0
activity O 0
in O 0
plasma O 0
. O 0

In O 0
47 O 0
D442G O 0
heterozygotes O 0
, O 0
mean O 0
HDL O 0
- O 0
C O 0
levels O 0
were O 0
91 O 0
+ O 0
/ O 0
- O 0
23 O 0
mg O 0
/ O 0
dl O 0
, O 0
similar O 0
to O 0
the O 0
level O 0
in O 0
D442G O 0
homozygotes O 0
, O 0
and O 0
significantly O 0
greater O 0
than O 0
mean O 0
HDL O 0
- O 0
C O 0
levels O 0
in O 0
Int14 O 0
A O 0
heterozygotes O 0
( O 0
69 O 0
+ O 0
/ O 0
- O 0
15 O 0
mg O 0
/ O 0
dl O 0
) O 0
. O 0

Thus O 0
, O 0
the O 0
D442G O 0
mutation O 0
acts O 0
differently O 0
to O 0
the O 0
null O 0
mutations O 0
with O 0
weaker O 0
effects O 0
on O 0
HDL O 0
in O 0
the O 0
homozygous O 0
state O 0
and O 0
stronger O 0
effects O 0
in O 0
the O 0
heterozygotes O 0
, O 0
suggesting O 0
dominant O 0
expression O 0
of O 0
a O 0
partially O 0
defective O 0
allele O 0
. O 0

CETP B-Disease 0
deficiency I-Disease 0
, O 0
reflecting O 0
two O 0
prevalent O 0
mutations O 0
( O 0
D442G O 0
and O 0
Int14 O 0
A O 0
) O 0
, O 0
is O 0
the O 0
first O 0
example O 0
of O 0
a O 0
genetic B-Disease 0
deficiency I-Disease 0
state O 0
which O 0
is O 0
sufficiently O 0
common O 0
to O 0
explain O 0
a O 0
significant O 0
fraction O 0
of O 0
the O 0
variation O 0
in O 0
HDL O 0
- O 0
C O 0
in O 0
the O 0
general O 0
population O 0
. O 0
. O 0

Treatment O 0
of O 0
cerebrotendinous B-Disease 1
xanthomatosis I-Disease 1
: O 0
effects O 0
of O 0
chenodeoxycholic O 0
acid O 0
, O 0
pravastatin O 0
, O 0
and O 0
combined O 0
use O 0
. O 0

Treatments O 0
by O 0
oral O 0
administration O 0
of O 0
chenodeoxycholic O 0
acid O 0
( O 0
CDCA O 0
) O 0
alone O 0
, O 0
3 O 0
- O 0
hydroxy O 0
- O 0
3 O 0
- O 0
methylglutaryl O 0
( O 0
HMG O 0
) O 0
CoA O 0
reductase O 0
inhibitor O 0
( O 0
pravastatin O 0
) O 0
alone O 0
, O 0
and O 0
combination O 0
of O 0
the O 0
two O 0
drugs O 0
were O 0
attempted O 0
for O 0
7 O 0
patients O 0
with O 0
cerebrotendinous B-Disease 1
xanthomatosis I-Disease 1
( O 0
CTX B-Disease 0
) O 0
. O 0

CDCA O 0
treatment O 0
at O 0
a O 0
dose O 0
of O 0
300 O 0
mg O 0
/ O 0
day O 0
reduced O 0
serum O 0
cholestanol O 0
( O 0
67 O 0
. O 0
3 O 0
% O 0
reduction O 0
) O 0
, O 0
lathosterol O 0
( O 0
50 O 0
. O 0
8 O 0
% O 0
) O 0
, O 0
campesterol O 0
( O 0
61 O 0
. O 0
7 O 0
% O 0
) O 0
and O 0
sitosterol O 0
( O 0
12 O 0
. O 0
7 O 0
% O 0
) O 0
. O 0

However O 0
, O 0
the O 0
sera O 0
of O 0
the O 0
patients O 0
changed O 0
to O 0
be O 0
" O 0
atherogenic O 0
" O 0
; O 0
total O 0
cholesterol O 0
, O 0
triglyceride O 0
and O 0
low O 0
- O 0
density O 0
lipoprotein O 0
( O 0
LDL O 0
) O 0
- O 0
cholesterol O 0
were O 0
increased O 0
, O 0
while O 0
high O 0
- O 0
density O 0
lipoprotein O 0
( O 0
HDL O 0
) O 0
- O 0
cholesterol O 0
was O 0
decreased O 0
. O 0

Contrarily O 0
, O 0
pravastatin O 0
at O 0
a O 0
dose O 0
of O 0
10 O 0
mg O 0
/ O 0
day O 0
improved O 0
the O 0
sera O 0
of O 0
the O 0
patients O 0
to O 0
be O 0
markedly O 0
" O 0
anti O 0
- O 0
atherogenic O 0
" O 0
, O 0
but O 0
the O 0
reductions O 0
of O 0
cholestanol O 0
( O 0
30 O 0
. O 0
4 O 0
% O 0
) O 0
, O 0
lathosterol O 0
( O 0
44 O 0
. O 0
0 O 0
% O 0
) O 0
, O 0
campesterol O 0
( O 0
22 O 0
. O 0
9 O 0
% O 0
) O 0
and O 0
sitosterol O 0
( O 0
9 O 0
. O 0
6 O 0
% O 0
) O 0
were O 0
inadequate O 0
. O 0

Combined O 0
treatment O 0
with O 0
CDCA O 0
and O 0
pravastatin O 0
showed O 0
good O 0
overlapping O 0
of O 0
the O 0
effects O 0
of O 0
each O 0
drug O 0
alone O 0
. O 0

The O 0
sera O 0
of O 0
the O 0
patients O 0
were O 0
apparently O 0
more O 0
" O 0
anti O 0
- O 0
atherogenic O 0
" O 0
than O 0
those O 0
after O 0
CDCA O 0
treatment O 0
. O 0

Serum O 0
cholestanol O 0
concentration O 0
was O 0
still O 0
2 O 0
. O 0

7 O 0
times O 0
higher O 0
than O 0
in O 0
controls O 0
, O 0
but O 0
the O 0
serum O 0
lathosterol O 0
level O 0
was O 0
within O 0
the O 0
normal O 0
range O 0
, O 0
indicating O 0
that O 0
the O 0
enhancement O 0
of O 0
overall O 0
cholesterol O 0
synthesis O 0
in O 0
the O 0
patients O 0
was O 0
sufficiently O 0
suppressed O 0
. O 0

Plant O 0
sterol O 0
levels O 0
were O 0
also O 0
within O 0
the O 0
normal O 0
range O 0
. O 0

The O 0
combination O 0
of O 0
CDCA O 0
and O 0
pravastatin O 0
was O 0
a O 0
good O 0
treatment O 0
for O 0
CTX B-Disease 0
, O 0
based O 0
on O 0
the O 0
improvement O 0
of O 0
serum O 0
lipoprotein O 0
metabolism O 0
, O 0
the O 0
suppression O 0
of O 0
cholesterol O 0
synthesis O 0
, O 0
and O 0
reductions O 0
of O 0
cholestanol O 0
and O 0
plant O 0
sterol O 0
levels O 0
. O 0

In O 0
all O 0
of O 0
7 O 0
patients O 0
, O 0
the O 0
progression O 0
of O 0
disease O 0
was O 0
arrested O 0
, O 0
but O 0
dramatic O 0
effects O 0
on O 0
clinical O 0
manifestations O 0
, O 0
xanthoma B-Disease 1
, O 0
and O 0
electrophysiological O 0
findings O 0
could O 0
not O 0
be O 0
found O 0
after O 0
the O 0
treatment O 0
of O 0
these O 0
drugs O 0

Mutation O 0
spectrum O 0
in O 0
the O 0
CHM B-Disease 1
gene O 0
of O 0
Danish O 0
and O 0
Swedish O 0
choroideremia B-Disease 1
patients O 0
. O 0

The O 0
recent O 0
isolation O 0
of O 0
the O 0
complete O 0
open O 0
reading O 0
frame O 0
of O 0
the O 0
choroideremia B-Disease 1
( O 0
CHM B-Disease 1
) O 0
gene O 0
and O 0
the O 0
characterization O 0
of O 0
the O 0
exon O 0
- O 0
intron O 0
boundaries O 0
has O 0
paved O 0
the O 0
way O 0
to O 0
mutation O 0
detection O 0
in O 0
patients O 0
with O 0
classical O 0
choroideremia B-Disease 1
. O 0

We O 0
have O 0
performed O 0
mutation O 0
screening O 0
in O 0
patients O 0
from O 0
15 O 0
Danish O 0
and O 0
Swedish O 0
families O 0
by O 0
using O 0
Southern O 0
blot O 0
hybridization O 0
and O 0
the O 0
polymerase O 0
chain O 0
reaction O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphism O 0
( O 0
PCR O 0
- O 0
SSCP O 0
) O 0
technique O 0
. O 0

Causative O 0
mutations O 0
in O 0
the O 0
CHM B-Disease 1
gene O 0
were O 0
detected O 0
in O 0
at O 0
least O 0
12 O 0
families O 0
, O 0
indicating O 0
that O 0
a O 0
substantial O 0
part O 0
of O 0
the O 0
mutations O 0
can O 0
be O 0
identified O 0
by O 0
this O 0
approach O 0
. O 0

In O 0
four O 0
of O 0
these O 0
families O 0
deletions O 0
of O 0
different O 0
sizes O 0
were O 0
found O 0
. O 0

Thus O 0
, O 0
in O 0
one O 0
patient O 0
, O 0
the O 0
deletion O 0
resulted O 0
in O 0
the O 0
absence O 0
of O 0
only O 0
one O 0
exon O 0
, O 0
while O 0
in O 0
another O 0
the O 0
deletion O 0
comprised O 0
the O 0
entire O 0
CHM B-Disease 1
gene O 0
. O 0

Mapping O 0
of O 0
the O 0
deletion O 0
endpoints O 0
in O 0
these O 0
four O 0
patients O 0
and O 0
in O 0
another O 0
11 O 0
male O 0
patients O 0
with O 0
sizeable O 0
deletions O 0
enabled O 0
us O 0
to O 0
construct O 0
a O 0
very O 0
detailed O 0
map O 0
of O 0
intervals O 0
2 O 0
and O 0
3 O 0
of O 0
Xq21 O 0
. O 0

In O 0
the O 0
remaining O 0
11 O 0
Danish O 0
and O 0
Swedish O 0
families O 0
at O 0
least O 0
8 O 0
causative O 0
mutations O 0
were O 0
found O 0
by O 0
PCR O 0
- O 0
SSCP O 0
analysis O 0
and O 0
direct O 0
sequencing O 0
. O 0

Interestingly O 0
, O 0
all O 0
CHM B-Disease 1
gene O 0
mutations O 0
detected O 0
thus O 0
far O 0
in O 0
choroideremia B-Disease 1
patients O 0
give O 0
rise O 0
to O 0
the O 0
introduction O 0
of O 0
a O 0
premature O 0
stop O 0
codon O 0
. O 0
. O 0

Predominance O 0
of O 0
the O 0
adrenomyeloneuropathy B-Disease 1
phenotype O 0
of O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
in O 0
The O 0
Netherlands O 0
: O 0
a O 0
survey O 0
of O 0
30 O 0
kindreds O 0
. O 0

X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
( O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
) O 0
is O 0
an O 0
inherited B-Disease 0
disorder I-Disease 0
of O 0
peroxisomal O 0
beta O 0
- O 0
oxidation O 0
associated O 0
with O 0
accumulation O 0
of O 0
saturated O 0
very O 0
long O 0
- O 0
chain O 0
fatty O 0
acids O 0
, O 0
which O 0
results O 0
in O 0
central O 0
and O 0
peripheral O 0
demyelination B-Disease 1
and O 0
in O 0
impaired B-Disease 1
function I-Disease 1
of I-Disease 1
adrenal I-Disease 1
cortex I-Disease 1
and I-Disease 1
testes I-Disease 1
. O 0

The O 0
phenotypic O 0
expression O 0
is O 0
highly O 0
variable O 0
, O 0
childhood B-Disease 0
cerebral I-Disease 1
ALD I-Disease 1
( O 0
CCALD B-Disease 0
) O 0
and O 0
adrenomyeloneuropathy B-Disease 1
( O 0
AMN B-Disease 0
) O 0
being O 0
the O 0
main O 0
variants O 0
. O 0

We O 0
explored O 0
the O 0
30 O 0
Dutch O 0
kindreds O 0
well O 0
known O 0
to O 0
the O 0
Dutch O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
/ O 0
AMN B-Disease 0
Study O 0
Group O 0
and O 0
phenotyped O 0
77 O 0
male O 0
patients O 0
35 O 0
( O 0
46 O 0
% O 0
) O 0
had O 0
AMN B-Disease 0
and O 0
24 O 0
( O 0
31 O 0
% O 0
) O 0
CCALD B-Disease 0
or O 0
adolescent B-Disease 1
cerebral I-Disease 1
ALD I-Disease 1
( O 0
AdolCALD B-Disease 1
) O 0
. O 0

These O 0
percentages O 0
differ O 0
significantly O 0
from O 0
previous O 0
reports O 0
, O 0
in O 0
which O 0
25 O 0
to O 0
28 O 0
% O 0
of O 0
the O 0
patients O 0
developed O 0
AMN B-Disease 0
and O 0
53 O 0
to O 0
57 O 0
% O 0
CCALD B-Disease 0
or O 0
AdolCALD B-Disease 1
. O 0

Our O 0
findings O 0
indicate O 0
that O 0
- O 0
- O 0
at O 0
least O 0
in O 0
the O 0
Netherlands O 0
- O 0
- O 0
AMN B-Disease 0
may O 0
be O 0
the O 0
most O 0
frequent O 0
phenotype O 0
of O 0
X B-Disease 1
- I-Disease 1
ALD I-Disease 1
. O 0
. O 0

Adrenoleukodystrophy B-Disease 0
gene O 0
encodes O 0
an O 0
80 O 0
kDa O 0
membrane O 0
protein O 0
. O 0

An O 0
antibody O 0
against O 0
the O 0
synthetic O 0
C O 0
- O 0
terminal O 0
peptides O 0
deduced O 0
from O 0
the O 0
cDNA O 0
of O 0
the O 0
gene O 0
responsible O 0
for O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
( O 0
ALD B-Disease 0
) O 0
was O 0
produced O 0
to O 0
characterize O 0
the O 0
product O 0
of O 0
the O 0
ALD B-Disease 0
gene O 0
. O 0

The O 0
antibody O 0
reacted O 0
with O 0
the O 0
80 O 0
kDa O 0
band O 0
protein O 0
in O 0
control O 0
fibroblasts O 0
, O 0
while O 0
no O 0
bands O 0
were O 0
detected O 0
in O 0
the O 0
fibroblasts O 0
from O 0
a O 0
patient O 0
with O 0
ALD B-Disease 0
( O 0
# O 0
163 O 0
) O 0
, O 0
in O 0
which O 0
mRNA O 0
of O 0
the O 0
ALD B-Disease 0
gene O 0
was O 0
undetectable O 0
based O 0
on O 0
Northern O 0
blot O 0
analysis O 0
. O 0

The O 0
293T O 0
cells O 0
transfected O 0
with O 0
the O 0
full O 0
- O 0
coding O 0
cDNA O 0
inserted O 0
in O 0
the O 0
expression O 0
vector O 0
produced O 0
a O 0
new O 0
80 O 0
kDa O 0
protein O 0
, O 0
as O 0
detected O 0
by O 0
Western O 0
blot O 0
. O 0

In O 0
an O 0
immunocytological O 0
study O 0
, O 0
the O 0
staining O 0
was O 0
in O 0
a O 0
punctate O 0
pattern O 0
, O 0
in O 0
the O 0
normal O 0
fibroblasts O 0
. O 0

However O 0
, O 0
there O 0
was O 0
no O 0
punctate O 0
staining O 0
in O 0
the O 0
# O 0
163 O 0
cells O 0
. O 0

These O 0
data O 0
thus O 0
indicate O 0
that O 0
the O 0
ALD B-Disease 0
gene O 0
encodes O 0
an O 0
80 O 0
kDa O 0
membrane O 0
protein O 0
. O 0
. O 0

Isolation O 0
of O 0
the O 0
gene O 0
for O 0
McLeod B-Disease 0
syndrome I-Disease 0
that O 0
encodes O 0
a O 0
novel O 0
membrane O 0
transport O 0
protein O 0
. O 0

McLeod B-Disease 0
syndrome I-Disease 0
is O 0
an O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
multisystem I-Disease 0
disorder I-Disease 0
characterized O 0
by O 0
abnormalities O 0
in O 0
the O 0
neuromuscular O 0
and O 0
hematopoietic O 0
systems O 0
. O 0

We O 0
have O 0
assembled O 0
a O 0
cosmid O 0
contig O 0
of O 0
360 O 0
kb O 0
that O 0
encompasses O 0
the O 0
McLeod B-Disease 0
gene O 0
locus O 0
. O 0

A O 0
50 O 0
kb O 0
deletion O 0
was O 0
detected O 0
by O 0
screening O 0
DNA O 0
from O 0
patients O 0
with O 0
radiolabeled O 0
whole O 0
cosmids O 0
, O 0
and O 0
two O 0
transcription O 0
units O 0
were O 0
identified O 0
within O 0
this O 0
deletion O 0
. O 0

The O 0
mRNA O 0
expression O 0
pattern O 0
of O 0
one O 0
of O 0
them O 0
, O 0
designated O 0
as O 0
XK O 0
, O 0
correlates O 0
closely O 0
to O 0
the O 0
McLeod B-Disease 0
phenotype O 0
. O 0

XK O 0
encodes O 0
a O 0
novel O 0
protein O 0
with O 0
structural O 0
characteristics O 0
of O 0
prokaryotic O 0
and O 0
eukaryotic O 0
membrane O 0
transport O 0
proteins O 0
. O 0

Nucleotide O 0
sequence O 0
analysis O 0
of O 0
XK O 0
from O 0
two O 0
unrelated O 0
McLeod B-Disease 0
patients O 0
has O 0
identified O 0
point O 0
mutations O 0
at O 0
conserved O 0
splice O 0
donor O 0
and O 0
acceptor O 0
sites O 0
. O 0

These O 0
findings O 0
provide O 0
direct O 0
evidence O 0
that O 0
XK O 0
is O 0
responsible O 0
for O 0
McLeod B-Disease 0
syndrome I-Disease 0
. O 0
. O 0

X B-Disease 0
- I-Disease 0
linked I-Disease 0
spastic I-Disease 0
paraplegia I-Disease 0
and O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
are O 0
allelic B-Disease 1
disorders I-Disease 1
at O 0
the O 0
proteolipid O 0
protein O 0
locus O 0
. O 0

Three O 0
forms O 0
of O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
spastic I-Disease 0
paraplegia I-Disease 0
( O 0
SPG B-Disease 0
) O 0
have O 0
been O 0
defined O 0
. O 0

One O 0
locus O 0
( O 0
SPG O 0
1 O 0
) O 0
maps O 0
to O 0
Xq28 O 0
while O 0
two O 0
clinically O 0
distinct O 0
forms O 0
map O 0
to O 0
Xq22 O 0
( O 0
SPG2 O 0
) O 0
. O 0

A O 0
rare O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
dysmyelinating I-Disease 1
disorder I-Disease 1
of O 0
the O 0
central O 0
nervous O 0
system O 0
, O 0
Pelizaeus B-Disease 1
- I-Disease 1
Merzbacher I-Disease 1
disease I-Disease 1
( O 0
PMD B-Disease 1
) O 0
, O 0
has O 0
also O 0
been O 0
mapped O 0
to O 0
Xq21 O 0
- O 0
q22 O 0
, O 0
and O 0
is O 0
caused O 0
by O 0
mutations O 0
in O 0
the O 0
proteolipid O 0
protein O 0
gene O 0
( O 0
PLP O 0
) O 0
which O 0
encodes O 0
two O 0
myelin O 0
proteins O 0
, O 0
PLP O 0
and O 0
DM20 O 0
. O 0

While O 0
narrowing O 0
the O 0
genetic O 0
interval O 0
containing O 0
SPG2 O 0
in O 0
a O 0
large O 0
pedigree O 0
, O 0
we O 0
found O 0
that O 0
PLP O 0
was O 0
the O 0
closest O 0
marker O 0
to O 0
the O 0
disease O 0
locus O 0
, O 0
implicating O 0
PLP O 0
as O 0
a O 0
possible O 0
candidate O 0
gene O 0
. O 0

We O 0
have O 0
found O 0
that O 0
a O 0
point O 0
mutation O 0
( O 0
His139Tyr O 0
) O 0
in O 0
exon O 0
3B O 0
of O 0
an O 0
affected O 0
male O 0
produces O 0
a O 0
mutant O 0
PLP O 0
but O 0
a O 0
normal O 0
DM20 O 0
, O 0
and O 0
segregates O 0
with O 0
the O 0
disease O 0
( O 0
Zmax O 0
= O 0
6 O 0
. O 0
63 O 0
, O 0
theta O 0
= O 0
0 O 0
. O 0
00 O 0
) O 0
. O 0

It O 0
appears O 0
, O 0
therefore O 0
, O 0
that O 0
SPG2 O 0
and O 0
PMD B-Disease 1
are O 0
allelic B-Disease 1
disorders I-Disease 1

Canavan B-Disease 1
disease I-Disease 0
: O 0
mutations O 0
among O 0
Jewish O 0
and O 0
non O 0
- O 0
Jewish O 0
patients O 0
. O 0

Canavan B-Disease 1
disease I-Disease 0
is O 0
an O 0
autosomal B-Disease 0
recessive I-Disease 0
leukodystrophy I-Disease 1
caused O 0
by O 0
the O 0
deficiency B-Disease 0
of I-Disease 0
aspartoacylase I-Disease 0
( O 0
ASPA O 0
) O 0
. O 0

Sixty O 0
- O 0
four O 0
probands O 0
were O 0
analyzed O 0
for O 0
mutations O 0
in O 0
the O 0
ASPA O 0
gene O 0
. O 0

Three O 0
point O 0
mutations O 0
- O 0
- O 0
693C O 0
- O 0
- O 0
> O 0
A O 0
, O 0
854A O 0
- O 0
- O 0
> O 0
C O 0
, O 0
and O 0
914C O 0
- O 0
- O 0
> O 0
A O 0
- O 0
- O 0
were O 0
identified O 0
in O 0
the O 0
coding O 0
sequence O 0
. O 0

The O 0
693C O 0
- O 0
- O 0
> O 0
A O 0
and O 0
914C O 0
- O 0
- O 0
> O 0
A O 0
base O 0
changes O 0
, O 0
resulting O 0
in O 0
nonsense O 0
tyr231 O 0
- O 0
- O 0
> O 0
ter O 0
and O 0
missense O 0
ala305 O 0
- O 0
- O 0
> O 0
glu O 0
mutations O 0
, O 0
respectively O 0
, O 0
lead O 0
to O 0
complete O 0
loss O 0
of O 0
ASPA O 0
activity O 0
in O 0
in O 0
vitro O 0
expression O 0
studies O 0
. O 0

The O 0
854A O 0
- O 0
- O 0
> O 0
C O 0
transversion O 0
converted O 0
glu O 0
to O 0
ala O 0
in O 0
codon O 0
285 O 0
. O 0

The O 0
glu285 O 0
- O 0
- O 0
> O 0
ala O 0
mutant O 0
ASPA O 0
has O 0
2 O 0
. O 0

5 O 0
% O 0
of O 0
the O 0
activity O 0
expressed O 0
by O 0
the O 0
wild O 0
- O 0
type O 0
enzyme O 0
. O 0

A O 0
fourth O 0
mutation O 0
, O 0
433 O 0
- O 0
- O 0
2 O 0
( O 0
A O 0
- O 0
- O 0
> O 0
G O 0
) O 0
transition O 0
, O 0
was O 0
identified O 0
at O 0
the O 0
splice O 0
- O 0
acceptor O 0
site O 0
in O 0
intron O 0
2 O 0
. O 0

The O 0
splice O 0
- O 0
site O 0
mutation O 0
would O 0
lead O 0
to O 0
skipping O 0
of O 0
exon O 0
3 O 0
, O 0
accompanied O 0
by O 0
a O 0
frameshift O 0
, O 0
and O 0
thus O 0
would O 0
produce O 0
aberrant O 0
ASPA O 0
. O 0

Of O 0
the O 0
128 O 0
unrelated O 0
Canavan B-Disease 1
chromosomes O 0
analyzed O 0
, O 0
88 O 0
were O 0
from O 0
probands O 0
of O 0
Ashkenazi O 0
Jewish O 0
descent O 0
. O 0

The O 0
glu285 O 0
- O 0
- O 0
> O 0
ala O 0
mutation O 0
was O 0
predominant O 0
( O 0
82 O 0
. O 0
9 O 0
% O 0
) O 0
in O 0
this O 0
population O 0
, O 0
followed O 0
by O 0
the O 0
tyr231 O 0
- O 0
- O 0
> O 0
ter O 0
( O 0
14 O 0
. O 0
8 O 0
% O 0
) O 0
and O 0
433 O 0
- O 0
- O 0
2 O 0
( O 0
A O 0
- O 0
- O 0
> O 0
G O 0
) O 0
( O 0
1 O 0
. O 0
1 O 0
% O 0
) O 0
mutations O 0
. O 0

The O 0
three O 0
mutations O 0
account O 0
for O 0
98 O 0
. O 0

8 O 0
% O 0
of O 0
the O 0
Canavan B-Disease 1
chromosomes O 0
of O 0
Ashkenazi O 0
Jewish O 0
origin O 0
. O 0

The O 0
ala305 O 0
- O 0
- O 0
> O 0
glu O 0
mutation O 0
was O 0
found O 0
exclusively O 0
in O 0
non O 0
- O 0
Jewish O 0
probands O 0
of O 0
European O 0
descent O 0
and O 0
constituted O 0
60 O 0
% O 0
of O 0
the O 0
40 O 0
mutant O 0
chromosomes O 0
. O 0

Predominant O 0
occurrence O 0
of O 0
certain O 0
mutations O 0
among O 0
Ashkenazi O 0
Jewish O 0
and O 0
non O 0
- O 0
Jewish O 0
patients O 0
with O 0
Canavan B-Disease 1
disease I-Disease 0
would O 0
suggest O 0
a O 0
founding O 0
- O 0
father O 0
effect O 0
in O 0
propagation O 0
of O 0
these O 0
mutant O 0
chromosomes O 0

Intelligence O 0
quotient O 0
profile O 0
in O 0
myotonic B-Disease 1
dystrophy I-Disease 1
, O 0
intergenerational O 0
deficit O 0
, O 0
and O 0
correlation O 0
with O 0
CTG O 0
amplification O 0
. O 0

An O 0
abbreviated O 0
Wechsler O 0
Adult O 0
Intelligence O 0
Scale O 0
Revised O 0
( O 0
WAIS O 0
- O 0
R O 0
) O 0
was O 0
used O 0
to O 0
assess O 0
verbal O 0
and O 0
arithmetical O 0
cognitive O 0
performance O 0
in O 0
55 O 0
subjects O 0
with O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
, O 0
covering O 0
all O 0
grades O 0
of O 0
disease O 0
severity O 0
, O 0
and O 0
31 O 0
controls O 0
at O 0
50 O 0
% O 0
risk O 0
of O 0
inheriting O 0
DM B-Disease 0
. O 0

Scaled O 0
scores O 0
from O 0
the O 0
assessment O 0
were O 0
converted O 0
into O 0
an O 0
intelligence O 0
quotient O 0
( O 0
IQ O 0
) O 0
estimation O 0
on O 0
each O 0
person O 0
. O 0

Significant O 0
IQ O 0
differences O 0
were O 0
found O 0
between O 0
( O 0
1 O 0
) O 0
all O 0
55 O 0
DM B-Disease 0
subjects O 0
( O 0
mean O 0
90 O 0
. O 0
2 O 0
, O 0
SD O 0
16 O 0
. O 0
1 O 0
) O 0
and O 0
31 O 0
controls O 0
( O 0
102 O 0
. O 0
6 O 0
, O 0
SD O 0
9 O 0
. O 0
4 O 0
) O 0
, O 0
with O 0
no O 0
sex O 0
differences O 0
in O 0
either O 0
group O 0
; O 0
( O 0
2 O 0
) O 0
15 O 0
affected O 0
parents O 0
( O 0
99 O 0
. O 0
3 O 0
, O 0
SD O 0
12 O 0
. O 0
2 O 0
) O 0
and O 0
their O 0
affected O 0
children O 0
( O 0
88 O 0
. O 0
1 O 0
, O 0
SD O 0
17 O 0
. O 0
2 O 0
) O 0
, O 0
where O 0
significance O 0
was O 0
dependent O 0
on O 0
parental O 0
sex O 0
being O 0
female O 0
; O 0
and O 0
( O 0
3 O 0
) O 0
15 O 0
pairs O 0
of O 0
affected O 0
sibs O 0
( O 0
89 O 0
. O 0
6 O 0
, O 0
SD O 0
13 O 0
. O 0
2 O 0
) O 0
and O 0
their O 0
normal O 0
sibs O 0
( O 0
100 O 0
. O 0
2 O 0
, O 0
SD O 0
7 O 0
. O 0
6 O 0
) O 0
. O 0

IQ O 0
steadily O 0
declined O 0
as O 0
( O 0
1 O 0
) O 0
the O 0
age O 0
of O 0
onset O 0
of O 0
signs O 0
and O 0
symptoms O 0
decreased O 0
, O 0
and O 0
( O 0
2 O 0
) O 0
the O 0
CTG O 0
expansion O 0
size O 0
increased O 0
. O 0

The O 0
correlation O 0
appeared O 0
to O 0
be O 0
more O 0
linear O 0
with O 0
age O 0
of O 0
onset O 0
. O 0

The O 0
correlation O 0
of O 0
IQ O 0
difference O 0
and O 0
CTG O 0
expansion O 0
difference O 0
in O 0
both O 0
the O 0
DM B-Disease 0
parent O 0
- O 0
child O 0
pairs O 0
and O 0
normal O 0
sib O 0
- O 0
affected O 0
sib O 0
pairs O 0
was O 0
poor O 0
, O 0
indicating O 0
that O 0
CTG O 0
expansion O 0
is O 0
not O 0
a O 0
reliable O 0
predictor O 0
of O 0
IQ O 0
either O 0
in O 0
individual O 0
persons O 0
or O 0
families O 0
. O 0

Further O 0
analysis O 0
of O 0
cognitive O 0
function O 0
in O 0
DM B-Disease 0
is O 0
required O 0
to O 0
clarify O 0
specific O 0
deficits O 0
characteristic O 0
of O 0
this O 0
patient O 0
group O 0

Adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
and O 0
a O 0
cytogenetic O 0
deletion O 0
of O 0
chromosome O 0
5 O 0
resulting O 0
from O 0
a O 0
maternal O 0
intrachromosomal O 0
insertion O 0
. O 0

We O 0
present O 0
the O 0
clinical O 0
and O 0
laboratory O 0
findings O 0
in O 0
an O 0
institutionalised O 0
adult O 0
patient O 0
originally O 0
referred O 0
for O 0
autism B-Disease 1
. O 0

A O 0
high O 0
risk O 0
of O 0
colorectal B-Disease 1
cancer I-Disease 1
was O 0
predicted O 0
when O 0
an O 0
interstitial O 0
deletion O 0
of O 0
the O 0
long O 0
arm O 0
of O 0
chromosome O 0
5 O 0
, O 0
del O 0
( O 0
5 O 0
) O 0
( O 0
q15q22 O 0
. O 0
3 O 0
) O 0
, O 0
was O 0
detected O 0
in O 0
her O 0
lymphocytes O 0
and O 0
deletion O 0
of O 0
the O 0
MCC O 0
and O 0
APC B-Disease 1
genes O 0
confirmed O 0
by O 0
molecular O 0
analysis O 0
. O 0

Adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
and O 0
carcinoma B-Disease 1
of I-Disease 1
the I-Disease 1
rectum I-Disease 1
were O 0
subsequently O 0
diagnosed O 0
in O 0
the O 0
patient O 0
. O 0

She O 0
was O 0
profoundly O 0
mentally B-Disease 1
retarded I-Disease 1
, O 0
autistic B-Disease 1
, O 0
and O 0
had O 0
minor O 0
dysmorphic B-Disease 0
features I-Disease 0
consistent O 0
with O 0
those O 0
of O 0
previous O 0
patients O 0
with O 0
similar O 0
deletions O 0
. O 0

The O 0
deletion O 0
arose O 0
as O 0
a O 0
result O 0
of O 0
recombination O 0
within O 0
the O 0
small O 0
insertion O 0
loop O 0
formed O 0
at O 0
meiosis O 0
by O 0
the O 0
direct O 0
insertion O 0
( O 0
dir O 0
ins O 0
( O 0
5 O 0
) O 0
( O 0
q22 O 0
. O 0
3q14 O 0
. O 0
2q15 O 0
) O 0
) O 0
found O 0
in O 0
the O 0
patients O 0
mother O 0
. O 0

This O 0
family O 0
further O 0
confirms O 0
the O 0
cytogenetic O 0
mapping O 0
of O 0
both O 0
MCC O 0
and O 0
APC B-Disease 1
genes O 0
to O 0
5q22 O 0
and O 0
comparison O 0
with O 0
other O 0
recent O 0
cases O 0
suggests O 0
that O 0
both O 0
genes O 0
and O 0
their O 0
closely O 0
linked O 0
markers O 0
lie O 0
within O 0
the O 0
5q22 O 0
. O 0

1 O 0
subband O 0

Familial B-Disease 0
male I-Disease 0
breast I-Disease 0
cancer I-Disease 1
is O 0
not O 0
linked O 0
to O 0
the O 0
BRCA1 O 0
locus O 0
on O 0
chromosome O 0
17q O 0
. O 0

Breast B-Disease 0
cancer I-Disease 1
in O 0
men O 0
is O 0
about O 0
a O 0
hundredfold O 0
less O 0
common O 0
than O 0
in O 0
women O 0
and O 0
this O 0
has O 0
hindered O 0
research O 0
into O 0
its O 0
genetic O 0
basis O 0
. O 0

We O 0
have O 0
examined O 0
22 O 0
families O 0
with O 0
at O 0
least O 0
one O 0
case O 0
of O 0
male B-Disease 0
breast I-Disease 0
cancer I-Disease 1
for O 0
linkage O 0
to O 0
the O 0
hereditary B-Disease 1
breast I-Disease 1
and I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
locus O 0
, O 0
BRCA1 O 0
, O 0
on O 0
chromosome O 0
17q O 0
. O 0

We O 0
found O 0
strong O 0
evidence O 0
against O 0
linkage O 0
to O 0
BRCA1 O 0
( O 0
lod O 0
score O 0
- O 0
16 O 0
. O 0
63 O 0
) O 0
and O 0
the O 0
best O 0
estimate O 0
of O 0
the O 0
proportion O 0
of O 0
linked O 0
families O 0
was O 0
0 O 0
% O 0
( O 0
95 O 0
% O 0
CI O 0
0 O 0
- O 0
18 O 0
% O 0
) O 0
. O 0

Our O 0
results O 0
indicate O 0
that O 0
there O 0
is O 0
a O 0
gene O 0
( O 0
s O 0
) O 0
other O 0
than O 0
BRCA1 O 0
which O 0
predisposes O 0
to O 0
early O 0
- O 0
onset O 0
breast B-Disease 0
cancer I-Disease 1
in O 0
women O 0
and O 0
which O 0
confers O 0
a O 0
higher O 0
risk O 0
of O 0
male B-Disease 0
breast I-Disease 0
cancer I-Disease 1
. O 0

Identification O 0
of O 0
additional O 0
pedigrees O 0
that O 0
include O 0
cases O 0
of O 0
male B-Disease 0
breast I-Disease 0
cancer I-Disease 1
may O 0
therefore O 0
facilitate O 0
the O 0
mapping O 0
and O 0
isolation O 0
of O 0
this O 0
gene O 0
. O 0

The O 0
EWS O 0
gene O 0
, O 0
involved O 0
in O 0
Ewing B-Disease 1
family I-Disease 1
of I-Disease 1
tumors I-Disease 1
, O 0
malignant B-Disease 0
melanoma I-Disease 0
of I-Disease 0
soft I-Disease 0
parts I-Disease 0
and O 0
desmoplastic B-Disease 1
small I-Disease 1
round I-Disease 1
cell I-Disease 1
tumors I-Disease 1
, O 0
codes O 0
for O 0
an O 0
RNA O 0
binding O 0
protein O 0
with O 0
novel O 0
regulatory O 0
domains O 0
. O 0

The O 0
EWS O 0
gene O 0
, O 0
which O 0
maps O 0
to O 0
band O 0
q12 O 0
of O 0
human O 0
chromosome O 0
22 O 0
, O 0
is O 0
involved O 0
in O 0
a O 0
wide O 0
variety O 0
of O 0
human O 0
solid B-Disease 0
tumors I-Disease 0
including O 0
Ewing B-Disease 1
sarcoma I-Disease 1
, O 0
related O 0
primitive O 0
neuroectodermal B-Disease 0
tumors I-Disease 0
, O 0
malignant B-Disease 0
melanoma I-Disease 0
of I-Disease 0
soft I-Disease 0
parts I-Disease 0
and O 0
desmoplastic B-Disease 1
small I-Disease 1
round I-Disease 1
cell I-Disease 1
tumors I-Disease 1
. O 0

In O 0
these O 0
tumors B-Disease 0
, O 0
the O 0
EWS O 0
is O 0
fused O 0
to O 0
genes O 0
encoding O 0
transcriptional O 0
activators O 0
/ O 0
repressors O 0
, O 0
like O 0
Fli O 0
- O 0
1 O 0
or O 0
erg O 0
or O 0
ATF O 0
1 O 0
or O 0
wt1 O 0
. O 0

To O 0
better O 0
understand O 0
the O 0
function O 0
of O 0
the O 0
EWS O 0
protein O 0
, O 0
we O 0
cloned O 0
the O 0
EWS O 0
cDNA O 0
. O 0

Sequence O 0
analysis O 0
of O 0
this O 0
cDNA O 0
revealed O 0
differential O 0
splicing O 0
involving O 0
two O 0
exons O 0
encoding O 0
72 O 0
amino O 0
acids O 0
. O 0

Both O 0
alternatively O 0
spliced O 0
transcripts O 0
, O 0
EWS O 0
and O 0
EWS O 0
- O 0
b O 0
, O 0
are O 0
expressed O 0
in O 0
a O 0
variety O 0
of O 0
cells O 0
. O 0

Because O 0
EWS O 0
proteins O 0
contain O 0
putative O 0
conserved O 0
RNA O 0
binding O 0
motifs O 0
, O 0
we O 0
studied O 0
the O 0
RNA O 0
binding O 0
properties O 0
of O 0
the O 0
EWS O 0
protein O 0
. O 0

The O 0
EWS O 0
- O 0
b O 0
protein O 0
binds O 0
to O 0
RNA O 0
in O 0
vitro O 0
and O 0
, O 0
specifically O 0
, O 0
to O 0
poly O 0
G O 0
and O 0
poly O 0
U O 0
. O 0

The O 0
RNA O 0
binding O 0
activity O 0
was O 0
localized O 0
to O 0
the O 0
carboxy O 0
terminal O 0
86 O 0
amino O 0
acids O 0
, O 0
which O 0
constitute O 0
RGG O 0
box O 0
. O 0

Thus O 0
the O 0
amino O 0
terminal O 0
domain O 0
of O 0
EWS O 0
( O 0
NTD O 0
- O 0
EWS O 0
) O 0
, O 0
which O 0
is O 0
involved O 0
in O 0
chromosome O 0
translocation O 0
may O 0
regulate O 0
the O 0
specificity O 0
of O 0
RNA O 0
binding O 0
activity O 0
of O 0
EWS O 0
. O 0

An O 0
EWS O 0
- O 0
erg O 0
chimeric O 0
protein O 0
, O 0
which O 0
is O 0
found O 0
in O 0
Ewings B-Disease 1
sarcoma I-Disease 1
cells O 0
, O 0
functions O 0
as O 0
a O 0
transcriptional O 0
activator O 0
. O 0

Mutational O 0
analysis O 0
of O 0
EWS O 0
- O 0
erg O 0
chimeric O 0
protein O 0
revealed O 0
that O 0
NTD O 0
- O 0
EWS O 0
functions O 0
as O 0
a O 0
regulatory O 0
domain O 0
for O 0
the O 0
transcriptional O 0
activation O 0
properties O 0
of O 0
EWS O 0
- O 0
erg O 0
chimeric O 0
protein O 0
. O 0
. O 0

Canavan B-Disease 1
disease I-Disease 0
: O 0
genomic O 0
organization O 0
and O 0
localization O 0
of O 0
human O 0
ASPA O 0
to O 0
17p13 O 0
- O 0
ter O 0
and O 0
conservation O 0
of O 0
the O 0
ASPA O 0
gene O 0
during O 0
evolution O 0
. O 0

Canavan B-Disease 1
disease I-Disease 0
, O 0
or O 0
spongy B-Disease 1
degeneration I-Disease 1
of I-Disease 1
the I-Disease 1
brain I-Disease 1
, O 0
is O 0
a O 0
severe O 0
leukodystrophy B-Disease 1
caused O 0
by O 0
the O 0
deficiency B-Disease 0
of I-Disease 0
aspartoacylase I-Disease 0
( O 0
ASPA O 0
) O 0
. O 0

Recently O 0
, O 0
a O 0
missense O 0
mutation O 0
was O 0
identified O 0
in O 0
human O 0
ASPA O 0
coding O 0
sequence O 0
from O 0
patients O 0
with O 0
Canavan B-Disease 1
disease I-Disease 0
. O 0

The O 0
human O 0
ASPA O 0
gene O 0
has O 0
been O 0
cloned O 0
and O 0
found O 0
to O 0
span O 0
29 O 0
kb O 0
of O 0
the O 0
genome O 0
. O 0

Human O 0
aspartoacylase O 0
is O 0
coded O 0
by O 0
six O 0
exons O 0
intervened O 0
by O 0
five O 0
introns O 0
. O 0

The O 0
exons O 0
vary O 0
from O 0
94 O 0
( O 0
exon O 0
III O 0
) O 0
to O 0
514 O 0
( O 0
exon O 0
VI O 0
) O 0
bases O 0
. O 0

The O 0
exon O 0
/ O 0
intron O 0
splice O 0
junction O 0
sites O 0
follow O 0
the O 0
gt O 0
/ O 0
ag O 0
consensus O 0
sequence O 0
rule O 0
. O 0

Southern O 0
blot O 0
analysis O 0
of O 0
genomic O 0
DNA O 0
from O 0
human O 0
/ O 0
mouse O 0
somatic O 0
cell O 0
hybrid O 0
cell O 0
lines O 0
localized O 0
ASPA O 0
to O 0
human O 0
chromosome O 0
17 O 0
. O 0

The O 0
human O 0
ASPA O 0
locus O 0
was O 0
further O 0
mapped O 0
in O 0
the O 0
17p13 O 0
- O 0
ter O 0
region O 0
by O 0
fluorescence O 0
in O 0
situ O 0
hybridization O 0
. O 0

The O 0
bovine O 0
aspa O 0
gene O 0
has O 0
also O 0
been O 0
cloned O 0
, O 0
and O 0
its O 0
exon O 0
/ O 0
intron O 0
organization O 0
is O 0
identical O 0
to O 0
that O 0
of O 0
the O 0
human O 0
gene O 0
. O 0

The O 0
500 O 0
- O 0
base O 0
sequence O 0
upstream O 0
of O 0
the O 0
initiator O 0
ATG O 0
codon O 0
in O 0
the O 0
human O 0
gene O 0
and O 0
that O 0
in O 0
the O 0
bovine O 0
gene O 0
are O 0
77 O 0
% O 0
identical O 0
. O 0

Human O 0
ASPA O 0
coding O 0
sequences O 0
cross O 0
- O 0
hybridize O 0
with O 0
genomic O 0
DNA O 0
from O 0
yeast O 0
, O 0
chicken O 0
, O 0
rabbit O 0
, O 0
cow O 0
, O 0
dog O 0
, O 0
mouse O 0
, O 0
rat O 0
, O 0
and O 0
monkey O 0
. O 0

The O 0
specificity O 0
of O 0
cross O 0
- O 0
species O 0
hybridization O 0
of O 0
coding O 0
sequences O 0
suggests O 0
that O 0
aspartoacylase O 0
has O 0
been O 0
conserved O 0
during O 0
evolution O 0
. O 0

It O 0
should O 0
now O 0
be O 0
possible O 0
to O 0
identify O 0
mutations O 0
in O 0
the O 0
noncoding O 0
genomic O 0
sequences O 0
that O 0
lead O 0
to O 0
Canavan B-Disease 1
disease I-Disease 0
and O 0
to O 0
study O 0
the O 0
regulation O 0
of O 0
ASPA O 0
. O 0
. O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
: O 0
size O 0
- O 0
and O 0
sex O 0
- O 0
dependent O 0
dynamics O 0
of O 0
CTG O 0
meiotic O 0
instability O 0
, O 0
and O 0
somatic O 0
mosaicism O 0
. O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
is O 0
a O 0
progressive O 0
neuromuscular B-Disease 0
disorder I-Disease 0
which O 0
results O 0
from O 0
elongations O 0
of O 0
an O 0
unstable O 0
( O 0
CTG O 0
) O 0
n O 0
repeat O 0
, O 0
located O 0
in O 0
the O 0
3 O 0
untranslated O 0
region O 0
of O 0
the O 0
DM B-Disease 0
gene O 0
. O 0

A O 0
correlation O 0
has O 0
been O 0
demonstrated O 0
between O 0
the O 0
increase O 0
in O 0
the O 0
repeat O 0
number O 0
of O 0
this O 0
sequence O 0
and O 0
the O 0
severity O 0
of O 0
the O 0
disease O 0
. O 0

However O 0
, O 0
the O 0
clinical O 0
status O 0
of O 0
patients O 0
cannot O 0
be O 0
unambiguously O 0
ascertained O 0
solely O 0
on O 0
the O 0
basis O 0
of O 0
the O 0
number O 0
of O 0
CTG O 0
repeats O 0
. O 0

Moreover O 0
, O 0
the O 0
exclusive O 0
maternal O 0
inheritance O 0
of O 0
the O 0
congenital O 0
form O 0
remains O 0
unexplained O 0
. O 0

Our O 0
observation O 0
of O 0
differently O 0
sized O 0
repeats O 0
in O 0
various O 0
DM B-Disease 0
tissues O 0
from O 0
the O 0
same O 0
individual O 0
may O 0
explain O 0
why O 0
the O 0
size O 0
of O 0
the O 0
mutation O 0
observed O 0
in O 0
lymphocytes O 0
does O 0
not O 0
necessarily O 0
correlate O 0
with O 0
the O 0
severity O 0
and O 0
nature O 0
of O 0
symptoms O 0
. O 0

Through O 0
a O 0
molecular O 0
and O 0
genetic O 0
study O 0
of O 0
142 O 0
families O 0
including O 0
418 O 0
DM B-Disease 0
patients O 0
, O 0
we O 0
have O 0
investigated O 0
the O 0
dynamics O 0
of O 0
the O 0
CTG O 0
repeat O 0
meiotic O 0
instability O 0
. O 0

A O 0
positive O 0
correlation O 0
between O 0
the O 0
size O 0
of O 0
the O 0
repeat O 0
and O 0
the O 0
intergenerational O 0
enlargement O 0
was O 0
observed O 0
similarly O 0
through O 0
male O 0
and O 0
female O 0
meioses O 0
for O 0
< O 0
or O 0
= O 0
0 O 0
. O 0

5 O 0
- O 0
kb O 0
CTG O 0
sequences O 0
. O 0

Beyond O 0
0 O 0
. O 0

5 O 0
kb O 0
, O 0
the O 0
intergenerational O 0
variation O 0
was O 0
more O 0
important O 0
through O 0
female O 0
meioses O 0
, O 0
whereas O 0
a O 0
tendency O 0
to O 0
compression O 0
was O 0
observed O 0
almost O 0
exclusively O 0
in O 0
male O 0
meioses O 0
, O 0
for O 0
> O 0
or O 0
= O 0
1 O 0
. O 0

5 O 0
- O 0
kb O 0
fragments O 0
. O 0

This O 0
implies O 0
a O 0
size O 0
- O 0
and O 0
sex O 0
- O 0
dependent O 0
meiotic O 0
instability O 0
. O 0

Moreover O 0
, O 0
segregation O 0
analysis O 0
supports O 0
the O 0
hypothesis O 0
of O 0
a O 0
maternal O 0
as O 0
well O 0
as O 0
a O 0
familial O 0
predisposition O 0
for O 0
the O 0
occurrence O 0
of O 0
the O 0
congenital O 0
form O 0
. O 0

Finally O 0
, O 0
this O 0
analysis O 0
reveals O 0
a O 0
significant O 0
excess O 0
of O 0
transmitting O 0
grandfathers O 0
partially O 0
accounted O 0
for O 0
by O 0
increased O 0
fertility O 0
in O 0
affected O 0
males O 0

Illegitimate O 0
transcription O 0
of O 0
the O 0
phenylalanine O 0
hydroxylase O 0
gene O 0
in O 0
lymphocytes O 0
for O 0
identification O 0
of O 0
mutations O 0
in O 0
phenylketonuria B-Disease 0
. O 0

Taking O 0
advantage O 0
of O 0
the O 0
illegitimate O 0
transcription O 0
of O 0
the O 0
phenylalanine O 0
hydroxylase O 0
( O 0
PAH O 0
) O 0
gene O 0
, O 0
we O 0
have O 0
been O 0
able O 0
to O 0
analyse O 0
the O 0
PAH O 0
cDNA O 0
sequence O 0
of O 0
hyperphenylalaninemic B-Disease 1
children O 0
in O 0
circulating O 0
lymphocytes O 0
. O 0

Using O 0
this O 0
approach O 0
, O 0
we O 0
have O 0
also O 0
identified O 0
3 O 0
novel O 0
mutations O 0
in O 0
cDNA O 0
from O 0
liver O 0
and O 0
lymphocytes O 0
of O 0
two O 0
patients O 0
. O 0

One O 0
mutation O 0
, O 0
detected O 0
by O 0
the O 0
abnormal O 0
pattern O 0
of O 0
migration O 0
of O 0
an O 0
amplified O 0
fragment O 0
, O 0
is O 0
a O 0
C O 0
to O 0
T O 0
transition O 0
in O 0
the O 0
splice O 0
acceptor O 0
site O 0
of O 0
intron O 0
10 O 0
, O 0
which O 0
resulted O 0
in O 0
the O 0
skipping O 0
of O 0
exon O 0
11 O 0
with O 0
the O 0
premature O 0
termination O 0
of O 0
RNA O 0
translation O 0
downstream O 0
from O 0
exon O 0
12 O 0
( O 0
- O 0
3 O 0
IVS10 O 0
) O 0
. O 0

The O 0
other O 0
two O 0
mutations O 0
are O 0
missense O 0
mutations O 0
in O 0
exons O 0
10 O 0
and O 0
11 O 0
( O 0
respectively O 0
, O 0
L333F O 0
and O 0
E390G O 0
) O 0
. O 0

The O 0
present O 0
study O 0
supports O 0
the O 0
view O 0
that O 0
circulating O 0
lymphocytes O 0
give O 0
easy O 0
access O 0
to O 0
PAH O 0
gene O 0
transcripts O 0
whose O 0
nucleotide O 0
sequence O 0
is O 0
identical O 0
to O 0
that O 0
reported O 0
in O 0
liver O 0
and O 0
therefore O 0
represent O 0
a O 0
useful O 0
tool O 0
for O 0
molecular O 0
genetic O 0
studies O 0
in O 0
phenylketonuria B-Disease 0
. O 0
. O 0

High O 0
residual O 0
arylsulfatase O 0
A O 0
( O 0
ARSA O 0
) O 0
activity O 0
in O 0
a O 0
patient O 0
with O 0
late B-Disease 1
- I-Disease 1
infantile I-Disease 1
metachromatic I-Disease 1
leukodystrophy I-Disease 1
. O 0

We O 0
identified O 0
a O 0
patient O 0
suffering O 0
from O 0
late B-Disease 1
- I-Disease 1
infantile I-Disease 1
metachromatic I-Disease 1
leukodystrophy I-Disease 1
( O 0
MLD B-Disease 0
) O 0
who O 0
has O 0
a O 0
residual O 0
arylsulfatase O 0
A O 0
( O 0
ARSA O 0
) O 0
activity O 0
of O 0
about O 0
10 O 0
% O 0
. O 0

Fibroblasts O 0
of O 0
the O 0
patient O 0
show O 0
significant O 0
sulfatide O 0
degradation O 0
activity O 0
exceeding O 0
that O 0
of O 0
adult B-Disease 1
MLD I-Disease 1
patients O 0
. O 0

Analysis O 0
of O 0
the O 0
ARSA O 0
gene O 0
in O 0
this O 0
patient O 0
revealed O 0
heterozygosity O 0
for O 0
two O 0
new O 0
mutant O 0
alleles O 0
in O 0
one O 0
allele O 0
, O 0
deletion O 0
of O 0
C O 0
447 O 0
in O 0
exon O 0
2 O 0
leads O 0
to O 0
a O 0
frameshift O 0
and O 0
to O 0
a O 0
premature O 0
stop O 0
codon O 0
at O 0
amino O 0
acid O 0
position O 0
105 O 0
; O 0
in O 0
the O 0
second O 0
allele O 0
, O 0
a O 0
G O 0
- O 0
- O 0
> O 0
A O 0
transition O 0
in O 0
exon O 0
5 O 0
causes O 0
a O 0
Gly309 O 0
- O 0
- O 0
> O 0
Ser O 0
substitution O 0
. O 0

Transient O 0
expression O 0
of O 0
the O 0
mutant O 0
Ser309 O 0
- O 0
ARSA O 0
resulted O 0
in O 0
only O 0
13 O 0
% O 0
enzyme O 0
activity O 0
of O 0
that O 0
observed O 0
in O 0
cells O 0
expressing O 0
normal O 0
ARSA O 0
. O 0

The O 0
mutant O 0
ARSA O 0
is O 0
correctly O 0
targeted O 0
to O 0
the O 0
lysosomes O 0
but O 0
is O 0
unstable O 0
. O 0

These O 0
findings O 0
are O 0
in O 0
contrast O 0
to O 0
previous O 0
results O 0
showing O 0
that O 0
the O 0
late B-Disease 0
- I-Disease 0
infantile I-Disease 0
type I-Disease 0
of I-Disease 0
MLD I-Disease 0
is O 0
always O 0
associated O 0
with O 0
the O 0
complete O 0
absence O 0
of O 0
ARSA O 0
activity O 0
. O 0

The O 0
expression O 0
of O 0
the O 0
mutant O 0
ARSA O 0
protein O 0
may O 0
be O 0
influenced O 0
by O 0
particular O 0
features O 0
of O 0
oligodendrocytes O 0
, O 0
such O 0
that O 0
the O 0
level O 0
of O 0
mutant O 0
enzyme O 0
is O 0
lower O 0
in O 0
these O 0
cells O 0
than O 0
in O 0
others O 0
. O 0
. O 0

An O 0
arylsulfatase O 0
A O 0
( O 0
ARSA O 0
) O 0
missense O 0
mutation O 0
( O 0
T274M O 0
) O 0
causing O 0
late B-Disease 1
- I-Disease 1
infantile I-Disease 1
metachromatic I-Disease 1
leukodystrophy I-Disease 1
. O 0

Metachromatic B-Disease 0
leukodystrophy I-Disease 1
( O 0
MLD B-Disease 0
) O 0
is O 0
an O 0
autosomal B-Disease 0
recessive I-Disease 0
lysosomal I-Disease 0
storage I-Disease 0
disorder I-Disease 0
caused O 0
by O 0
a O 0
deficiency B-Disease 1
of I-Disease 1
arylsulfatase I-Disease 1
A I-Disease 1
( O 0
ARSA O 0
; O 0
EC O 0
3 O 0
. O 0
1 O 0
. O 0
6 O 0
. O 0
8 O 0
) O 0
. O 0

The O 0
8 O 0
ARSA O 0
exons O 0
and O 0
adjacent O 0
intron O 0
boundaries O 0
from O 0
a O 0
patient O 0
with O 0
late B-Disease 1
- I-Disease 1
infantile I-Disease 1
metachromatic I-Disease 1
leukodystrophy I-Disease 1
were O 0
polymerase O 0
chain O 0
reaction O 0
( O 0
PCR O 0
) O 0
amplified O 0
in O 0
seven O 0
discrete O 0
reactions O 0
. O 0

Amplified O 0
ARSA O 0
exons O 0
were O 0
analysed O 0
for O 0
the O 0
presence O 0
of O 0
sequence O 0
alterations O 0
by O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphism O 0
analysis O 0
, O 0
followed O 0
by O 0
direct O 0
sequencing O 0
of O 0
PCR O 0
products O 0
. O 0

The O 0
patient O 0
was O 0
found O 0
to O 0
be O 0
homozygous O 0
for O 0
a O 0
C O 0
- O 0
- O 0
> O 0
T O 0
transition O 0
in O 0
exon O 0
IV O 0
that O 0
results O 0
in O 0
the O 0
substitution O 0
of O 0
a O 0
highly O 0
conserved O 0
threonine O 0
residue O 0
at O 0
amino O 0
acid O 0
274 O 0
with O 0
a O 0
methionine O 0
( O 0
T274M O 0
) O 0
. O 0

Analysis O 0
of O 0
a O 0
further O 0
29 O 0
MLD B-Disease 0
patients O 0
revealed O 0
the O 0
presence O 0
of O 0
five O 0
additional O 0
homozygotes O 0
for O 0
T274M O 0
. O 0

All O 0
6 O 0
T274M O 0
homozygotes O 0
( O 0
representing O 0
four O 0
families O 0
) O 0
were O 0
of O 0
Lebanese O 0
descent O 0
, O 0
and O 0
all O 0
were O 0
known O 0
to O 0
be O 0
the O 0
result O 0
of O 0
consanguineous O 0
marriages O 0
. O 0

The O 0
altered O 0
amino O 0
acid O 0
is O 0
rigidly O 0
conserved O 0
among O 0
10 O 0
sulfatases O 0
from O 0
Escherichia O 0
coli O 0
to O 0
humans O 0
; O 0
therefore O 0
, O 0
it O 0
is O 0
most O 0
likely O 0
that O 0
the O 0
resultant O 0
mutant O 0
protein O 0
will O 0
have O 0
little O 0
or O 0
no O 0
enzyme O 0
activity O 0
. O 0

This O 0
is O 0
consistent O 0
with O 0
the O 0
very O 0
low O 0
ARSA O 0
activity O 0
measured O 0
in O 0
these O 0
patients O 0
and O 0
their O 0
uniformly O 0
severe O 0
clinical O 0
presentation O 0

Mutations O 0
in O 0
the O 0
PAX6 O 0
gene O 0
in O 0
patients O 0
with O 0
hereditary O 0
aniridia B-Disease 0
. O 0

The O 0
14 O 0
exons O 0
of O 0
the O 0
PAX6 O 0
gene O 0
have O 0
been O 0
analysed O 0
exon O 0
- O 0
by O 0
- O 0
exon O 0
using O 0
SSCP O 0
in O 0
6 O 0
aniridia B-Disease 0
families O 0
. O 0

In O 0
each O 0
family O 0
band O 0
shifts O 0
were O 0
observed O 0
on O 0
the O 0
SSCP O 0
gels O 0
for O 0
only O 0
one O 0
exon O 0
and O 0
direct O 0
PCR O 0
- O 0
sequencing O 0
revealed O 0
mutations O 0
in O 0
each O 0
case O 0
. O 0

Two O 0
mutations O 0
involved O 0
C O 0
- O 0
- O 0
> O 0
T O 0
transitions O 0
in O 0
CGAarg O 0
codons O 0
in O 0
exons O 0
9 O 0
and O 0
11 O 0
. O 0

Another O 0
C O 0
- O 0
- O 0
> O 0
T O 0
transition O 0
converted O 0
a O 0
CAG O 0
- O 0
glutamine O 0
to O 0
a O 0
TAG O 0
- O 0
stop O 0
in O 0
exon O 0
7 O 0
. O 0

Small O 0
insertions O 0
created O 0
frameshifts O 0
which O 0
produced O 0
downstream O 0
stop O 0
codons O 0
in O 0
another O 0
two O 0
patients O 0
and O 0
an O 0
A O 0
- O 0
- O 0
> O 0
T O 0
mutation O 0
disrupted O 0
the O 0
splice O 0
donor O 0
site O 0
of O 0
exon O 0
5 O 0
in O 0
the O 0
remaining O 0
family O 0
. O 0

Thus O 0
, O 0
complete O 0
inactivation O 0
of O 0
the O 0
PAX6 O 0
gene O 0
is O 0
predicted O 0
in O 0
all O 0
cases O 0
. O 0

Analysis O 0
of O 0
other O 0
affected O 0
members O 0
of O 0
the O 0
families O 0
showed O 0
that O 0
, O 0
in O 0
each O 0
case O 0
, O 0
all O 0
affected O 0
individuals O 0
carried O 0
the O 0
same O 0
family O 0
- O 0
specific O 0
mutation O 0
. O 0

One O 0
polymorphism O 0
was O 0
found O 0
in O 0
exon O 0
7 O 0
. O 0

This O 0
data O 0
strongly O 0
supports O 0
the O 0
candidature O 0
of O 0
PAX6 O 0
as O 0
the O 0
gene O 0
responsible O 0
for O 0
hereditary O 0
aniridia B-Disease 0
. O 0
. O 0

Three O 0
novel O 0
mutations O 0
in O 0
five O 0
unrelated O 0
subjects O 0
with O 0
hereditary O 0
protein B-Disease 0
S I-Disease 0
deficiency I-Disease 0
type I-Disease 0
I I-Disease 0
. O 0

A O 0
panel O 0
of O 0
eight O 0
unrelated O 0
subjects O 0
with O 0
inherited O 0
type B-Disease 0
I I-Disease 0
protein I-Disease 0
S I-Disease 0
deficiency I-Disease 0
was O 0
screened O 0
for O 0
mutations O 0
in O 0
the O 0
PROS1 O 0
gene O 0
. O 0

In O 0
five O 0
subjects O 0
an O 0
abnormality O 0
was O 0
found O 0
but O 0
mutations O 0
were O 0
not O 0
detected O 0
in O 0
the O 0
remaining O 0
three O 0
subjects O 0
. O 0

Two O 0
subjects O 0
shared O 0
a O 0
G O 0
- O 0
- O 0
> O 0
A O 0
transition O 0
at O 0
position O 0
+ O 0
5 O 0
of O 0
the O 0
donor O 0
splice O 0
site O 0
consensus O 0
sequence O 0
of O 0
intron O 0
10 O 0
. O 0

Also O 0
in O 0
two O 0
subjects O 0
an O 0
A O 0
- O 0
- O 0
> O 0
T O 0
transversion O 0
was O 0
detected O 0
in O 0
the O 0
stopcodon O 0
of O 0
the O 0
PROS1 O 0
gene O 0
; O 0
this O 0
transversion O 0
predicts O 0
a O 0
protein O 0
S O 0
molecule O 0
that O 0
is O 0
extended O 0
by O 0
14 O 0
amino O 0
acids O 0
. O 0

The O 0
fifth O 0
subject O 0
was O 0
found O 0
to O 0
possess O 0
two O 0
sequence O 0
abnormalities O 0
. O 0

One O 0
allele O 0
carried O 0
a O 0
G O 0
- O 0
- O 0
> O 0
A O 0
transition O 0
near O 0
the O 0
donor O 0
splice O 0
junction O 0
of O 0
intron O 0
2 O 0
, O 0
but O 0
this O 0
abnormality O 0
is O 0
probably O 0
neutral O 0
, O 0
since O 0
it O 0
was O 0
inherited O 0
from O 0
the O 0
parent O 0
with O 0
normal O 0
protein O 0
S O 0
antigen O 0
levels O 0
. O 0

In O 0
the O 0
other O 0
allele O 0
a O 0
single O 0
T O 0
insertion O 0
in O 0
codon O 0
- O 0
25 O 0
was O 0
found O 0
. O 0

Analysis O 0
of O 0
platelet O 0
RNA O 0
showed O 0
that O 0
only O 0
the O 0
mRNA O 0
with O 0
the O 0
A O 0
- O 0
- O 0
> O 0
T O 0
mutation O 0
in O 0
the O 0
stopcodon O 0
is O 0
present O 0
in O 0
amounts O 0
comparable O 0
to O 0
wildtype O 0
RNA O 0
. O 0

mRNA O 0
from O 0
the O 0
alleles O 0
with O 0
the O 0
other O 0
two O 0
mutations O 0
was O 0
either O 0
undetectable O 0
or O 0
present O 0
in O 0
greatly O 0
reduced O 0
amounts O 0
. O 0

The O 0
latter O 0
indicates O 0
that O 0
a O 0
mRNA O 0
based O 0
approach O 0
is O 0
not O 0
feasible O 0
for O 0
the O 0
genetic O 0
analysis O 0
of O 0
protein B-Disease 0
S I-Disease 0
deficiency I-Disease 0
type I-Disease 0
I I-Disease 0
. O 0
. O 0

Characteristics O 0
of O 0
intergenerational O 0
contractions O 0
of O 0
the O 0
CTG O 0
repeat O 0
in O 0
myotonic B-Disease 1
dystrophy I-Disease 1
. O 0

In O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
, O 0
the O 0
size O 0
of O 0
a O 0
CTG O 0
repeat O 0
in O 0
the O 0
DM B-Disease 0
kinase O 0
gene O 0
generally O 0
increases O 0
in O 0
successive O 0
generations O 0
with O 0
clinical O 0
evidence O 0
of O 0
anticipation O 0
. O 0

However O 0
, O 0
there O 0
have O 0
also O 0
been O 0
cases O 0
with O 0
an O 0
intergenerational O 0
contraction O 0
of O 0
the O 0
repeat O 0
. O 0

We O 0
examined O 0
1 O 0
, O 0
489 O 0
DM B-Disease 0
parent O 0
- O 0
offspring O 0
pairs O 0
, O 0
of O 0
which O 0
95 O 0
( O 0
6 O 0
. O 0
4 O 0
% O 0
) O 0
showed O 0
such O 0
contractions O 0
in O 0
peripheral O 0
blood O 0
leukocytes O 0
( O 0
PBL O 0
) O 0
. O 0

In O 0
56 O 0
of O 0
the O 0
95 O 0
pairs O 0
, O 0
clinical O 0
data O 0
allowed O 0
an O 0
analysis O 0
of O 0
their O 0
anticipation O 0
status O 0
. O 0

It O 0
is O 0
surprising O 0
that O 0
anticipation O 0
occurred O 0
in O 0
27 O 0
( O 0
48 O 0
% O 0
) O 0
of O 0
these O 0
56 O 0
pairs O 0
, O 0
while O 0
none O 0
clearly O 0
showed O 0
a O 0
later O 0
onset O 0
of O 0
DM B-Disease 0
in O 0
the O 0
symptomatic O 0
offspring O 0
. O 0

The O 0
contraction O 0
occurred O 0
in O 0
76 O 0
( O 0
10 O 0
% O 0
) O 0
of O 0
753 O 0
paternal O 0
transmissions O 0
and O 0
in O 0
19 O 0
( O 0
3 O 0
% O 0
) O 0
of O 0
736 O 0
maternal O 0
transmissions O 0
. O 0

Anticipation O 0
was O 0
observed O 0
more O 0
frequently O 0
in O 0
maternal O 0
( O 0
85 O 0
% O 0
) O 0
than O 0
in O 0
paternal O 0
( O 0
37 O 0
% O 0
) O 0
transmissions O 0
( O 0
P O 0
< O 0
. O 0
001 O 0
) O 0
. O 0

The O 0
parental O 0
repeat O 0
size O 0
correlated O 0
with O 0
the O 0
size O 0
of O 0
intergenerational O 0
contraction O 0
( O 0
r2 O 0
= O 0
. O 0
50 O 0
, O 0
P O 0
< O 0
< O 0
. O 0
001 O 0
) O 0
, O 0
and O 0
the O 0
slope O 0
of O 0
linear O 0
regression O 0
was O 0
steeper O 0
in O 0
paternal O 0
( O 0
- O 0
. O 0
62 O 0
) O 0
than O 0
in O 0
maternal O 0
( O 0
- O 0
. O 0
30 O 0
) O 0
transmissions O 0
( O 0
P O 0
< O 0
< O 0
. O 0
001 O 0
) O 0
. O 0

Sixteen O 0
DM B-Disease 0
parents O 0
had O 0
multiple O 0
DM B-Disease 0
offspring O 0
with O 0
the O 0
CTG O 0
repeat O 0
contractions O 0
. O 0

This O 0
frequency O 0
was O 0
higher O 0
than O 0
the O 0
frequency O 0
expected O 0
from O 0
the O 0
probability O 0
of O 0
the O 0
repeat O 0
contractions O 0
( O 0
6 O 0
. O 0
4 O 0
% O 0
) O 0
and O 0
the O 0
size O 0
of O 0
DM B-Disease 0
sib O 0
population O 0
( O 0
1 O 0
. O 0
54 O 0
DM B-Disease 0
offspring O 0
per O 0
DM B-Disease 0
parent O 0
, O 0
in O 0
968 O 0
DM B-Disease 0
parents O 0
) O 0
. O 0

We O 0
conclude O 0
that O 0
( O 0
1 O 0
) O 0
intergenerational O 0
contractions O 0
of O 0
the O 0
CTG O 0
repeat O 0
in O 0
leukocyte O 0
DNA O 0
frequently O 0
accompanies O 0
apparent O 0
anticipation O 0
, O 0
especially O 0
when O 0
DM B-Disease 0
is O 0
maternally O 0
transmitted O 0
, O 0
and O 0
( O 0
2 O 0
) O 0
the O 0
paternal O 0
origin O 0
of O 0
the O 0
repeat O 0
and O 0
the O 0
presence O 0
of O 0
the O 0
repeat O 0
contraction O 0
in O 0
a O 0
sibling O 0
increase O 0
the O 0
probability O 0
of O 0
the O 0
CTG O 0
repeat O 0
contraction O 0

Gonosomal O 0
mosaicism O 0
in O 0
myotonic B-Disease 1
dystrophy I-Disease 1
patients O 0
: O 0
involvement O 0
of O 0
mitotic O 0
events O 0
in O 0
( O 0
CTG O 0
) O 0
n O 0
repeat O 0
variation O 0
and O 0
selection O 0
against O 0
extreme O 0
expansion O 0
in O 0
sperm O 0
. O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
is O 0
caused O 0
by O 0
abnormal O 0
expansion O 0
of O 0
a O 0
polymorphic O 0
( O 0
CTG O 0
) O 0
n O 0
repeat O 0
, O 0
located O 0
in O 0
the O 0
DM B-Disease 0
protein O 0
kinase O 0
gene O 0
. O 0

We O 0
determined O 0
the O 0
( O 0
CTG O 0
) O 0
n O 0
repeat O 0
lengths O 0
in O 0
a O 0
broad O 0
range O 0
of O 0
tissue O 0
DNAs O 0
from O 0
patients O 0
with O 0
mild O 0
, O 0
classical O 0
, O 0
or O 0
congenital O 0
manifestation O 0
of O 0
DM B-Disease 0
. O 0

Differences O 0
in O 0
the O 0
repeat O 0
length O 0
were O 0
seen O 0
in O 0
somatic O 0
tissues O 0
from O 0
single O 0
DM B-Disease 0
individuals O 0
and O 0
twins O 0
. O 0

Repeats O 0
appeared O 0
to O 0
expand O 0
to O 0
a O 0
similar O 0
extent O 0
in O 0
tissues O 0
originating O 0
from O 0
the O 0
same O 0
embryonal O 0
origin O 0
. O 0

In O 0
most O 0
male O 0
patients O 0
carrying O 0
intermediate O 0
- O 0
or O 0
small O 0
- O 0
sized O 0
expansions O 0
in O 0
blood O 0
, O 0
the O 0
repeat O 0
lengths O 0
covered O 0
a O 0
markedly O 0
wider O 0
range O 0
in O 0
sperm O 0
. O 0

In O 0
contrast O 0
, O 0
male O 0
patients O 0
with O 0
large O 0
allele O 0
expansions O 0
in O 0
blood O 0
( O 0
> O 0
700 O 0
CTGs O 0
) O 0
had O 0
similar O 0
or O 0
smaller O 0
repeats O 0
in O 0
sperm O 0
, O 0
when O 0
detectable O 0
. O 0

Sperm O 0
alleles O 0
with O 0
> O 0
1 O 0
, O 0
000 O 0
CTGs O 0
were O 0
not O 0
seen O 0
. O 0

We O 0
conclude O 0
that O 0
DM B-Disease 0
patients O 0
can O 0
be O 0
considered O 0
gonosomal O 0
mosaics O 0
, O 0
i O 0
. O 0

e O 0
e O 0
. O 0
, O 0
combined O 0
somatic O 0
and O 0
germ O 0
- O 0
line O 0
tissue O 0
mosaics O 0
. O 0

Most O 0
remarkably O 0
, O 0
we O 0
observed O 0
multiple O 0
cases O 0
where O 0
the O 0
length O 0
distributions O 0
of O 0
intermediate O 0
- O 0
or O 0
small O 0
- O 0
sized O 0
alleles O 0
in O 0
fathers O 0
sperm O 0
were O 0
significantly O 0
different O 0
from O 0
that O 0
in O 0
their O 0
offsprings O 0
blood O 0
. O 0

Our O 0
combined O 0
findings O 0
indicate O 0
that O 0
intergenerational O 0
length O 0
changes O 0
in O 0
the O 0
unstable O 0
CTG O 0
repeat O 0
are O 0
most O 0
likely O 0
to O 0
occur O 0
during O 0
early O 0
embryonic O 0
mitotic O 0
divisions O 0
in O 0
both O 0
somatic O 0
and O 0
germ O 0
- O 0
line O 0
tissue O 0
formation O 0
. O 0

Both O 0
the O 0
initial O 0
CTG O 0
length O 0
, O 0
the O 0
overall O 0
number O 0
of O 0
cell O 0
divisions O 0
involved O 0
in O 0
tissue O 0
formation O 0
, O 0
and O 0
perhaps O 0
a O 0
specific O 0
selection O 0
process O 0
in O 0
spermatogenesis O 0
may O 0
influence O 0
the O 0
dynamics O 0
of O 0
this O 0
process O 0
. O 0

A O 0
model O 0
explaining O 0
mitotic O 0
instability O 0
and O 0
sex O 0
- O 0
dependent O 0
segregation O 0
phenomena O 0
in O 0
DM B-Disease 0
manifestation O 0
is O 0
discussed O 0

Regionally O 0
clustered O 0
APC B-Disease 1
mutations O 0
are O 0
associated O 0
with O 0
a O 0
severe O 0
phenotype O 0
and O 0
occur O 0
at O 0
a O 0
high O 0
frequency O 0
in O 0
new O 0
mutation O 0
cases O 0
of O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
. O 0

Germline O 0
mutation O 0
in O 0
APC O 1
at O 0
5q21 O 0
- O 0
22 O 0
results O 0
in O 0
the O 0
dominantly O 0
inherited O 0
syndrome O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
( O 0
APC B-Disease 1
) O 0
. O 0

Somatic O 0
mutation O 0
in O 0
this O 0
gene O 0
is O 0
an O 0
early O 0
event O 0
in O 0
colorectal O 0
tumourigenesis O 0
. O 0

Both O 0
types O 0
of O 0
mutation O 0
are O 0
concentrated O 0
in O 0
the O 0
5 O 0
half O 0
of O 0
exon O 0
15 O 0
. O 0

We O 0
have O 0
used O 0
single O 0
strand O 0
conformational O 0
polymorphism O 0
( O 0
SSCP O 0
) O 0
and O 0
heteroduplex O 0
analysis O 0
to O 0
screen O 0
for O 0
variants O 0
in O 0
this O 0
region O 0
of O 0
the O 0
gene O 0
in O 0
a O 0
total O 0
of O 0
45 O 0
affected O 0
but O 0
unrelated O 0
individuals O 0
. O 0

Eighteen O 0
patients O 0
had O 0
no O 0
family O 0
history O 0
of O 0
the O 0
disease O 0
; O 0
of O 0
these O 0
11 O 0
were O 0
classified O 0
as O 0
having O 0
a O 0
severe O 0
phenotype O 0
, O 0
based O 0
on O 0
an O 0
early O 0
age O 0
at O 0
presentation O 0
or O 0
cancer B-Disease 1
development O 0
. O 0

This O 0
compared O 0
with O 0
6 O 0
of O 0
27 O 0
familial O 0
cases O 0
. O 0

A O 0
5 O 0
bp O 0
deletion O 0
at O 0
codon O 0
1309 O 0
reported O 0
to O 0
occur O 0
in O 0
10 O 0
- O 0
15 O 0
% O 0
of O 0
unselected O 0
APC B-Disease 1
patients O 0
worldwide O 0
, O 0
was O 0
found O 0
in O 0
5 O 0
of O 0
the O 0
18 O 0
new O 0
mutation O 0
cases O 0
and O 0
4 O 0
of O 0
the O 0
27 O 0
familial O 0
cases O 0
all O 0
nine O 0
were O 0
classed O 0
as O 0
severe O 0
. O 0

A O 0
further O 0
3 O 0
new O 0
mutations O 0
and O 0
1 O 0
familial O 0
mutation O 0
were O 0
located O 0
downstream O 0
from O 0
codon O 0
1309 O 0
, O 0
these O 0
individuals O 0
similarly O 0
being O 0
classed O 0
as O 0
phenotypically O 0
severe O 0
. O 0

In O 0
contrast O 0
all O 0
of O 0
the O 0
APC B-Disease 1
mutations O 0
detected O 0
in O 0
affected O 0
individuals O 0
with O 0
an O 0
average O 0
phenotype O 0
were O 0
located O 0
prior O 0
to O 0
codon O 0
1309 O 0
. O 0

The O 0
frequent O 0
association O 0
of O 0
a O 0
severe O 0
phenotype O 0
with O 0
fresh O 0
mutation O 0
may O 0
explain O 0
the O 0
apparent O 0
conflict O 0
of O 0
a O 0
high O 0
mutation O 0
rate O 0
( O 0
20 O 0
- O 0
30 O 0
% O 0
) O 0
in O 0
a O 0
condition O 0
, O 0
which O 0
on O 0
average O 0
, O 0
is O 0
lethal O 0
at O 0
a O 0
post O 0
- O 0
reproductive O 0
age O 0
. O 0
. O 0

Mutations O 0
at O 0
the O 0
PAX6 O 0
locus O 0
are O 0
found O 0
in O 0
heterogeneous O 0
anterior B-Disease 0
segment I-Disease 0
malformations I-Disease 0
including O 0
Peters B-Disease 0
' I-Disease 0
anomaly I-Disease 0
. O 0

Mutation O 0
or O 0
deletion O 0
of O 0
the O 0
PAX6 O 0
gene O 0
underlies O 0
many O 0
cases O 0
of O 0
aniridia B-Disease 0
. O 0

Three O 0
lines O 0
of O 0
evidence O 0
now O 0
converge O 0
to O 0
implicate O 0
PAX6 O 0
more O 0
widely O 0
in O 0
anterior B-Disease 0
segment I-Disease 0
malformations I-Disease 0
including O 0
Peters B-Disease 1
anomaly I-Disease 1
. O 0

First O 0
, O 0
a O 0
child O 0
with O 0
Peters B-Disease 1
anomaly I-Disease 1
is O 0
deleted O 0
for O 0
one O 0
copy O 0
of O 0
PAX6 O 0
. O 0

Second O 0
, O 0
affected O 0
members O 0
of O 0
a O 0
family O 0
with O 0
dominantly O 0
inherited O 0
anterior B-Disease 0
segment I-Disease 0
malformations I-Disease 0
, O 0
including O 0
Peters B-Disease 1
anomaly I-Disease 1
are O 0
heterozygous O 0
for O 0
an O 0
R26G O 0
mutation O 0
in O 0
the O 0
PAX6 O 0
paired O 0
box O 0
. O 0

Third O 0
, O 0
a O 0
proportion O 0
of O 0
Sey O 0
/ O 0
+ O 0
Smalleye O 0
mice O 0
, O 0
heterozygous O 0
for O 0
a O 0
nonsense O 0
mutation O 0
in O 0
murine O 0
Pax O 0
- O 0
6 O 0
, O 0
have O 0
an O 0
ocular O 0
phenotype O 0
resembling O 0
Peters B-Disease 1
anomaly I-Disease 1
. O 0

We O 0
therefore O 0
propose O 0
that O 0
a O 0
variety O 0
of O 0
anterior B-Disease 1
segment I-Disease 1
anomalies I-Disease 1
may O 0
be O 0
associated O 0
with O 0
PAX6 O 0
mutations O 0
. O 0
. O 0

Huntington B-Disease 1
disease I-Disease 1
without O 0
CAG O 0
expansion O 0
: O 0
phenocopies O 0
or O 0
errors O 0
in O 0
assignment O 0
? O 0

Huntington B-Disease 1
disease I-Disease 1
( O 0
HD B-Disease 1
) O 0
has O 0
been O 0
shown O 0
to O 0
be O 0
associated O 0
with O 0
an O 0
expanded O 0
CAG O 0
repeat O 0
within O 0
a O 0
novel O 0
gene O 0
on O 0
4p16 O 0
. O 0

3 O 0
( O 0
IT15 O 0
) O 0
. O 0

A O 0
total O 0
of O 0
30 O 0
of O 0
1 O 0
, O 0
022 O 0
affected O 0
persons O 0
( O 0
2 O 0
. O 0
9 O 0
% O 0
of O 0
our O 0
cohort O 0
) O 0
did O 0
not O 0
have O 0
an O 0
expanded O 0
CAG O 0
in O 0
the O 0
disease O 0
range O 0
. O 0

The O 0
reasons O 0
for O 0
not O 0
observing O 0
expansion O 0
in O 0
affected O 0
individuals O 0
are O 0
important O 0
for O 0
determining O 0
the O 0
sensitivity O 0
of O 0
using O 0
repeat O 0
length O 0
both O 0
for O 0
diagnosis O 0
of O 0
affected O 0
patients O 0
and O 0
for O 0
predictive O 0
testing O 0
programs O 0
and O 0
may O 0
have O 0
biological O 0
relevance O 0
for O 0
the O 0
understanding O 0
of O 0
the O 0
molecular O 0
mechanism O 0
underlying O 0
HD B-Disease 1
. O 0

Here O 0
we O 0
show O 0
that O 0
the O 0
majority O 0
( O 0
18 O 0
) O 0
of O 0
the O 0
individuals O 0
with O 0
normal O 0
sized O 0
alleles O 0
represent O 0
misdiagnosis O 0
, O 0
sample O 0
mix O 0
- O 0
up O 0
, O 0
or O 0
clerical O 0
error O 0
. O 0

The O 0
remaining O 0
12 O 0
patients O 0
represent O 0
possible O 0
phenocopies O 0
for O 0
HD B-Disease 1
. O 0

In O 0
at O 0
least O 0
four O 0
cases O 0
, O 0
family O 0
studies O 0
of O 0
these O 0
phenocopies O 0
excluded O 0
4p16 O 0
. O 0

3 O 0
as O 0
the O 0
region O 0
responsible O 0
for O 0
the O 0
phenotype O 0
. O 0

Mutations O 0
in O 0
the O 0
HD B-Disease 1
gene O 0
that O 0
are O 0
other O 0
than O 0
CAG O 0
expansion O 0
have O 0
not O 0
been O 0
excluded O 0
for O 0
the O 0
remaining O 0
eight O 0
cases O 0
; O 0
however O 0
, O 0
in O 0
as O 0
many O 0
as O 0
seven O 0
of O 0
these O 0
persons O 0
, O 0
retrospective O 0
review O 0
of O 0
these O 0
patients O 0
clinical O 0
features O 0
identified O 0
characteristics O 0
not O 0
typical O 0
for O 0
HD B-Disease 1
. O 0

This O 0
study O 0
shows O 0
that O 0
on O 0
rare O 0
occasions O 0
mutations O 0
in O 0
other O 0
, O 0
as O 0
- O 0
yet O 0
- O 0
undefined O 0
genes O 0
can O 0
present O 0
with O 0
a O 0
clinical O 0
phenotype O 0
very O 0
similar O 0
to O 0
that O 0
of O 0
HD B-Disease 1

Frequent O 0
detection O 0
of O 0
codon O 0
877 O 0
mutation O 0
in O 0
the O 0
androgen O 0
receptor O 0
gene O 0
in O 0
advanced B-Disease 1
prostate I-Disease 1
cancers I-Disease 1
. O 0

Prostatic O 0
tissue O 0
specimens O 0
derived O 0
from O 0
transurethral O 0
resections O 0
of O 0
patients O 0
with O 0
metastatic B-Disease 0
prostate I-Disease 1
cancer I-Disease 1
were O 0
analyzed O 0
for O 0
genetic O 0
alterations O 0
in O 0
the O 0
hormone O 0
- O 0
binding O 0
domain O 0
of O 0
the O 0
androgen O 0
receptor O 0
( O 0
AR O 0
) O 0
gene O 0
. O 0

Direct O 0
sequencing O 0
of O 0
the O 0
polymerase O 0
chain O 0
reaction O 0
- O 0
derived O 0
DNAs O 0
of O 0
6 O 0
of O 0
24 O 0
specimens O 0
revealed O 0
a O 0
codon O 0
877 O 0
mutation O 0
( O 0
ACT O 0
- O 0
- O 0
> O 0
GCT O 0
, O 0
Thr O 0
- O 0
- O 0
> O 0
Ala O 0
) O 0
in O 0
the O 0
hormone O 0
- O 0
binding O 0
domain O 0
of O 0
the O 0
AR O 0
gene O 0
. O 0

This O 0
same O 0
AR O 0
mutation O 0
has O 0
been O 0
reported O 0
previously O 0
in O 0
a O 0
metastatic B-Disease 0
prostate I-Disease 1
cancer I-Disease 1
cell O 0
line O 0
, O 0
LNCaP O 0
, O 0
where O 0
this O 0
mutation O 0
confers O 0
upon O 0
the O 0
AR O 0
an O 0
altered O 0
ligand O 0
- O 0
binding O 0
specificity O 0
which O 0
is O 0
stimulated O 0
by O 0
estrogens O 0
, O 0
progestagens O 0
, O 0
and O 0
antiandrogens O 0
. O 0

It O 0
is O 0
possible O 0
that O 0
analogous O 0
to O 0
an O 0
activated O 0
/ O 0
altered O 0
growth O 0
factor O 0
receptor O 0
oncogene O 0
, O 0
codon O 0
877 O 0
mutant O 0
AR O 0
with O 0
altered O 0
ligand O 0
binding O 0
may O 0
provide O 0
a O 0
selective O 0
growth O 0
advantage O 0
in O 0
the O 0
genesis O 0
of O 0
a O 0
subset O 0
of O 0
advanced B-Disease 1
prostate I-Disease 1
cancer I-Disease 1
. O 0

Although O 0
estrogens O 0
are O 0
used O 0
infrequently O 0
, O 0
antiandrogens O 0
are O 0
used O 0
increasingly O 0
in O 0
hormonal O 0
therapy O 0
for O 0
patients O 0
with O 0
advanced B-Disease 1
prostate I-Disease 1
cancer I-Disease 1
. O 0

The O 0
stimulatory O 0
effect O 0
of O 0
these O 0
therapeutic O 0
agents O 0
on O 0
the O 0
codon O 0
877 O 0
mutant O 0
AR O 0
further O 0
suggests O 0
that O 0
this O 0
frequently O 0
observed O 0
AR O 0
mutation O 0
may O 0
contribute O 0
to O 0
the O 0
treatment O 0
refractory O 0
disease O 0
. O 0
. O 0

The O 0
human O 0
gene O 0
for O 0
alkaptonuria B-Disease 0
( O 0
AKU B-Disease 0
) O 0
maps O 0
to O 0
chromosome O 0
3q O 0
. O 0

Alkaptonuria B-Disease 1
( O 0
AKU B-Disease 0
; O 0
McKusick O 0
no O 0
. O 0
203500 O 0
) O 0
is O 0
a O 0
rare O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
caused O 0
by O 0
the O 0
lack O 0
of O 0
homogentisic O 0
acid O 0
oxidase O 0
activity O 0
. O 0

Patients O 0
excrete O 0
large O 0
amounts O 0
of O 0
homogentisic O 0
acid O 0
in O 0
their O 0
urine O 0
and O 0
a O 0
black O 0
ochronotic O 0
pigment O 0
is O 0
deposited O 0
in O 0
their O 0
cartilage O 0
and O 0
collagenous O 0
tissues O 0
. O 0

Ochronosis B-Disease 0
is O 0
the O 0
predominant O 0
clinical O 0
complication O 0
of O 0
the O 0
disease O 0
leading O 0
to O 0
ochronotic B-Disease 0
arthropathy I-Disease 0
, O 0
dark O 0
urine O 0
, O 0
pigment O 0
changes O 0
of O 0
the O 0
skin O 0
, O 0
and O 0
other O 0
clinical O 0
features O 0
. O 0

A O 0
mutation O 0
causing O 0
alkaptonuria B-Disease 0
in O 0
the O 0
mouse O 0
has O 0
mapped O 0
to O 0
chromosome O 0
16 O 0
. O 0

Considering O 0
conserved O 0
synteny O 0
, O 0
we O 0
were O 0
able O 0
to O 0
map O 0
the O 0
human O 0
gene O 0
to O 0
chromosome O 0
3q O 0
in O 0
six O 0
alkaptonuria B-Disease 0
pedigrees O 0
of O 0
Slovak O 0
origin O 0
. O 0
. O 0

Structure O 0
of O 0
the O 0
human O 0
Na O 0
+ O 0
/ O 0
glucose O 0
cotransporter O 0
gene O 0
SGLT1 O 0
. O 0

Intestinal O 0
uptake O 0
of O 0
dietary O 0
glucose O 0
and O 0
galactose O 0
is O 0
mediated O 0
by O 0
the O 0
SGLT1 O 0
Na O 0
+ O 0
/ O 0
glucose O 0
cotransporter O 0
of O 0
the O 0
brush O 0
border O 0
. O 0

An O 0
SGLT1 O 0
missense O 0
mutation O 0
underlies O 0
hereditary B-Disease 0
glucose I-Disease 0
/ I-Disease 0
galactose I-Disease 0
malabsorption I-Disease 0
, O 0
characterized O 0
by O 0
potentially O 0
fatal O 0
diarrhea B-Disease 1
; O 0
conversely O 0
, O 0
oral O 0
rehydration O 0
therapy O 0
exploits O 0
normal O 0
transport O 0
to O 0
alleviate O 0
life O 0
- O 0
threatening O 0
diarrhea B-Disease 1
of O 0
infectious O 0
origin O 0
. O 0

We O 0
have O 0
mapped O 0
the O 0
entire O 0
human O 0
SGLT1 O 0
Na O 0
+ O 0
/ O 0
glucose O 0
cotransporter O 0
gene O 0
from O 0
cosmid O 0
and O 0
lambda O 0
phage O 0
clones O 0
representing O 0
a O 0
genomic O 0
region O 0
of O 0
112 O 0
kilobases O 0
. O 0

Transcription O 0
initiation O 0
occurred O 0
from O 0
a O 0
site O 0
27 O 0
base O 0
pairs O 0
3 O 0
of O 0
a O 0
TATAA O 0
sequence O 0
. O 0

All O 0
exon O 0
- O 0
flanking O 0
regions O 0
were O 0
sequenced O 0
, O 0
and O 0
the O 0
entire O 0
112 O 0
- O 0
kilobase O 0
region O 0
mapped O 0
with O 0
four O 0
restriction O 0
enzymes O 0
. O 0

SGLT1 O 0
is O 0
comprised O 0
of O 0
15 O 0
exons O 0
( O 0
spanning O 0
72 O 0
kilobases O 0
) O 0
; O 0
a O 0
possible O 0
evolutionary O 0
origin O 0
from O 0
a O 0
six O 0
- O 0
membrane O 0
- O 0
span O 0
ancestral O 0
precursor O 0
via O 0
a O 0
gene O 0
duplication O 0
event O 0
is O 0
suggested O 0
from O 0
comparison O 0
of O 0
exons O 0
against O 0
protein O 0
secondary O 0
structure O 0
and O 0
from O 0
sequence O 0
considerations O 0
. O 0

A O 0
new O 0
missense O 0
mutation O 0
in O 0
exon O 0
1 O 0
causing O 0
glucose B-Disease 0
/ I-Disease 0
galactose I-Disease 0
malabsorption I-Disease 0
is O 0
also O 0
described O 0
. O 0

This O 0
is O 0
the O 0
first O 0
Na O 0
( O 0
+ O 0
) O 0
- O 0
dependent O 0
cotransporter O 0
gene O 0
structure O 0
reported O 0
. O 0

These O 0
data O 0
facilitate O 0
the O 0
search O 0
for O 0
new O 0
glucose B-Disease 0
/ I-Disease 0
galactose I-Disease 0
malabsorption I-Disease 0
- O 0
related O 0
mutations O 0
in O 0
this O 0
important O 0
gene O 0
and O 0
provide O 0
a O 0
basis O 0
for O 0
future O 0
evolutionary O 0
comparisons O 0
with O 0
other O 0
Na O 0
( O 0
+ O 0
) O 0
- O 0
dependent O 0
cotransporters O 0
. O 0
. O 0

Four O 0
novel O 0
PEPD O 0
alleles O 0
causing O 0
prolidase B-Disease 1
deficiency I-Disease 1
. O 0

Mutations O 0
at O 0
the O 0
PEPD O 0
locus O 0
cause O 0
prolidase B-Disease 1
deficiency I-Disease 1
( O 0
McKusick O 0
170100 O 0
) O 0
, O 0
a O 0
rare O 0
autosomal B-Disease 1
recessive I-Disease 1
disorder I-Disease 1
characterized O 0
by O 0
iminodipeptiduria B-Disease 0
, O 0
skin B-Disease 1
ulcers I-Disease 1
, O 0
mental B-Disease 1
retardation I-Disease 1
, O 0
and O 0
recurrent O 0
infections O 0
. O 0

Four O 0
PEPD O 0
mutations O 0
from O 0
five O 0
severely O 0
affected O 0
individuals O 0
were O 0
characterized O 0
by O 0
analysis O 0
of O 0
reverse O 0
- O 0
transcribed O 0
, O 0
PCR O 0
- O 0
amplified O 0
( O 0
RT O 0
- O 0
PCR O 0
) O 0
cDNA O 0
. O 0

We O 0
used O 0
SSCP O 0
analysis O 0
on O 0
four O 0
overlapping O 0
cDNA O 0
fragments O 0
covering O 0
the O 0
entire O 0
coding O 0
region O 0
of O 0
the O 0
PEPD O 0
gene O 0
and O 0
detected O 0
abnormal O 0
SSCP O 0
bands O 0
for O 0
the O 0
fragment O 0
spanning O 0
all O 0
or O 0
part O 0
of O 0
exons O 0
13 O 0
- O 0
15 O 0
in O 0
three O 0
of O 0
the O 0
probands O 0
. O 0

Direct O 0
sequencing O 0
of O 0
the O 0
mutant O 0
cDNAs O 0
showed O 0
a O 0
G O 0
- O 0
- O 0
> O 0
A O 0
, O 0
1342 O 0
substitution O 0
( O 0
G448R O 0
) O 0
in O 0
two O 0
patients O 0
and O 0
a O 0
3 O 0
- O 0
bp O 0
deletion O 0
( O 0
delta O 0
E452 O 0
or O 0
delta O 0
E453 O 0
) O 0
in O 0
another O 0
. O 0

In O 0
the O 0
other O 0
two O 0
probands O 0
the O 0
amplified O 0
products O 0
were O 0
of O 0
reduced O 0
size O 0
. O 0

Direct O 0
sequencing O 0
of O 0
these O 0
mutant O 0
cDNAs O 0
revealed O 0
a O 0
deletion O 0
of O 0
exon O 0
5 O 0
in O 0
one O 0
patient O 0
and O 0
of O 0
exon O 0
7 O 0
in O 0
the O 0
other O 0
. O 0

Intronic O 0
sequences O 0
flanking O 0
exons O 0
5 O 0
and O 0
7 O 0
were O 0
identified O 0
using O 0
inverse O 0
PCR O 0
followed O 0
by O 0
direct O 0
sequencing O 0
. O 0

Conventional O 0
PCR O 0
and O 0
direct O 0
sequencing O 0
then O 0
established O 0
the O 0
intron O 0
- O 0
exon O 0
borders O 0
of O 0
the O 0
mutant O 0
genomic O 0
DNA O 0
revealing O 0
two O 0
splice O 0
acceptor O 0
mutations O 0
a O 0
G O 0
- O 0
- O 0
> O 0
C O 0
substitution O 0
at O 0
position O 0
- O 0
1 O 0
of O 0
intron O 0
4 O 0
and O 0
an O 0
A O 0
- O 0
- O 0
> O 0
G O 0
substitution O 0
at O 0
position O 0
- O 0
2 O 0
of O 0
intron O 0
6 O 0
. O 0

Our O 0
results O 0
indicate O 0
that O 0
the O 0
severe O 0
form O 0
of O 0
prolidase B-Disease 1
deficiency I-Disease 1
is O 0
caused O 0
by O 0
multiple O 0
PEPD O 0
alleles O 0
. O 0

In O 0
this O 0
report O 0
we O 0
attempt O 0
to O 0
begin O 0
the O 0
process O 0
of O 0
describing O 0
these O 0
alleles O 0
and O 0
cataloging O 0
their O 0
phenotypic O 0
expression O 0
. O 0
. O 0

Recombinations O 0
in O 0
individuals O 0
homozygous O 0
by O 0
descent O 0
localize O 0
the O 0
Friedreich B-Disease 1
ataxia I-Disease 1
locus O 0
in O 0
a O 0
cloned O 0
450 O 0
- O 0
kb O 0
interval O 0
. O 0

The O 0
locus O 0
for O 0
Friedreich B-Disease 1
ataxia I-Disease 1
( O 0
FRDA B-Disease 0
) O 0
, O 0
a O 0
severe O 0
neurodegenerative B-Disease 0
disease I-Disease 0
, O 0
is O 0
tightly O 0
linked O 0
to O 0
markers O 0
D9S5 O 0
and O 0
D9S15 O 0
, O 0
and O 0
analysis O 0
of O 0
rare O 0
recombination O 0
events O 0
has O 0
suggested O 0
the O 0
order O 0
cen O 0
- O 0
FRDA O 0
- O 0
D9S5 O 0
- O 0
D9S15 O 0
- O 0
qter O 0
. O 0

We O 0
report O 0
here O 0
the O 0
construction O 0
of O 0
a O 0
YAC O 0
contig O 0
extending O 0
800 O 0
kb O 0
centromeric O 0
to O 0
D9S5 O 0
and O 0
the O 0
isolation O 0
of O 0
five O 0
new O 0
microsatellite O 0
markers O 0
from O 0
this O 0
region O 0
. O 0

In O 0
order O 0
to O 0
map O 0
these O 0
markers O 0
with O 0
respect O 0
to O 0
the O 0
FRDA B-Disease 0
locus O 0
, O 0
all O 0
within O 0
a O 0
1 O 0
- O 0
cM O 0
confidence O 0
interval O 0
, O 0
we O 0
sought O 0
to O 0
increase O 0
the O 0
genetic O 0
information O 0
of O 0
available O 0
FRDA B-Disease 0
families O 0
by O 0
considering O 0
homozygosity O 0
by O 0
descent O 0
and O 0
association O 0
with O 0
founder O 0
haplotypes O 0
in O 0
isolated O 0
populations O 0
. O 0

This O 0
approach O 0
allowed O 0
us O 0
to O 0
identify O 0
one O 0
phase O 0
- O 0
known O 0
recombination O 0
and O 0
one O 0
probable O 0
historic O 0
recombination O 0
on O 0
haplotypes O 0
from O 0
Reunion O 0
Island O 0
patients O 0
, O 0
both O 0
of O 0
which O 0
place O 0
three O 0
of O 0
the O 0
five O 0
markers O 0
proximal O 0
to O 0
FRDA B-Disease 0
. O 0

This O 0
represents O 0
the O 0
first O 0
identification O 0
of O 0
close O 0
FRDA B-Disease 0
flanking O 0
markers O 0
on O 0
the O 0
centromeric O 0
side O 0
. O 0

The O 0
two O 0
other O 0
markers O 0
allowed O 0
us O 0
to O 0
narrow O 0
the O 0
breakpoint O 0
of O 0
a O 0
previously O 0
identified O 0
distal O 0
recombination O 0
that O 0
is O 0
> O 0
180 O 0
kb O 0
from O 0
D9S5 O 0
( O 0
26P O 0
) O 0
. O 0

Taken O 0
together O 0
, O 0
the O 0
results O 0
place O 0
the O 0
FRDA B-Disease 0
locus O 0
in O 0
a O 0
450 O 0
- O 0
kb O 0
interval O 0
, O 0
which O 0
is O 0
small O 0
enough O 0
for O 0
direct O 0
search O 0
of O 0
candidate O 0
genes O 0
. O 0

A O 0
detailed O 0
rare O 0
cutter O 0
restriction O 0
map O 0
and O 0
a O 0
cosmid O 0
contig O 0
covering O 0
this O 0
interval O 0
were O 0
constructed O 0
and O 0
should O 0
facilitate O 0
the O 0
search O 0
of O 0
genes O 0
in O 0
this O 0
region O 0
. O 0
. O 0

Investigation O 0
of O 0
thermoregulatory O 0
characteristics O 0
in O 0
patients O 0
with O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
. O 0

A O 0
survey O 0
instrument O 0
is O 0
used O 0
to O 0
assess O 0
temperature O 0
regulation O 0
characteristics O 0
in O 0
children O 0
with O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
compared O 0
to O 0
3 O 0
control O 0
groups O 0
sibs O 0
of O 0
PWS B-Disease 0
patients O 0
( O 0
SIB O 0
) O 0
, O 0
neurodevelopmentally B-Disease 0
handicapped I-Disease 0
children O 0
( O 0
ND O 0
) O 0
, O 0
and O 0
age O 0
and O 0
gender O 0
matched O 0
well O 0
children O 0
( O 0
WC O 0
) O 0
. O 0

Significant O 0
differences O 0
were O 0
found O 0
between O 0
PWS B-Disease 0
patients O 0
, O 0
SIB O 0
controls O 0
, O 0
and O 0
WC O 0
controls O 0
in O 0
the O 0
prevalence O 0
of O 0
febrile O 0
convulsions O 0
, O 0
fever O 0
- O 0
associated O 0
symptoms O 0
, O 0
and O 0
temperature O 0
less O 0
than O 0
94 O 0
degrees O 0
F O 0
. O 0

No O 0
differences O 0
were O 0
noted O 0
in O 0
any O 0
variable O 0
between O 0
the O 0
PWS B-Disease 0
patients O 0
and O 0
the O 0
ND O 0
controls O 0
, O 0
suggesting O 0
that O 0
these O 0
abnormalities O 0
are O 0
not O 0
unique O 0
to O 0
PWS B-Disease 0
, O 0
but O 0
can O 0
occur O 0
in O 0
any O 0
neurodevelopmentally B-Disease 0
handicapped I-Disease 0
individual O 0
, O 0
further O 0
suggesting O 0
these O 0
do O 0
not O 0
necessarily O 0
reflect O 0
syndrome O 0
- O 0
specific O 0
hypothalamic B-Disease 1
abnormalities I-Disease 1
. O 0
. O 0

Phenotypic O 0
variation O 0
including O 0
retinitis B-Disease 0
pigmentosa I-Disease 0
, O 0
pattern B-Disease 0
dystrophy I-Disease 0
, O 0
and O 0
fundus B-Disease 1
flavimaculatus I-Disease 1
in O 0
a O 0
single O 0
family O 0
with O 0
a O 0
deletion O 0
of O 0
codon O 0
153 O 0
or O 0
154 O 0
of O 0
the O 0
peripherin O 0
/ O 0
RDS O 0
gene O 0
. O 0

BACKGROUND O 0
AND O 0
OBJECTIVES O 0
Mutations O 0
of O 0
the O 0
peripherin O 0
/ O 0
RDS O 0
gene O 0
have O 0
been O 0
reported O 0
in O 0
autosomal B-Disease 1
dominant I-Disease 1
retinitis I-Disease 1
pigmentosa I-Disease 1
, O 0
pattern O 0
macular B-Disease 1
dystrophy I-Disease 1
, O 0
and O 0
retinitis B-Disease 0
punctata I-Disease 0
albescens I-Disease 0
. O 0

We O 0
report O 0
herein O 0
the O 0
occurrence O 0
of O 0
three O 0
separate O 0
phenotypes O 0
within O 0
a O 0
single O 0
family O 0
with O 0
a O 0
novel O 0
3 O 0
- O 0
base O 0
pair O 0
deletion O 0
of O 0
codon O 0
153 O 0
or O 0
154 O 0
of O 0
the O 0
peripherin O 0
/ O 0
RDS O 0
gene O 0
. O 0

DESIGN O 0
Case O 0
reports O 0
with O 0
clinical O 0
features O 0
, O 0
fluorescein O 0
angiography O 0
, O 0
kinetic O 0
perimetry O 0
, O 0
electrophysiological O 0
studies O 0
, O 0
and O 0
molecular O 0
genetics O 0
. O 0

SETTING O 0
University O 0
medical O 0
centers O 0
. O 0

PATIENTS O 0
A O 0
75 O 0
- O 0
year O 0
- O 0
old O 0
woman O 0
, O 0
her O 0
two O 0
daughters O 0
( O 0
aged O 0
44 O 0
and O 0
50 O 0
years O 0
) O 0
, O 0
and O 0
her O 0
49 O 0
- O 0
year O 0
- O 0
old O 0
son O 0
were O 0
screened O 0
for O 0
peripherin O 0
/ O 0
RDS O 0
mutations O 0
because O 0
of O 0
the O 0
presence O 0
of O 0
multiple O 0
phenotypes O 0
within O 0
the O 0
same O 0
family O 0
. O 0

RESULTS O 0
The O 0
mother O 0
presented O 0
at O 0
age O 0
63 O 0
years O 0
with O 0
a O 0
profoundly O 0
abnormal O 0
electroretinogram O 0
( O 0
ERG O 0
) O 0
and O 0
adult O 0
- O 0
onset O 0
retinitis B-Disease 0
pigmentosa I-Disease 0
that O 0
progressed O 0
dramatically O 0
over O 0
12 O 0
years O 0
, O 0
with O 0
marked O 0
loss O 0
of O 0
peripheral O 0
visual O 0
field O 0
. O 0

One O 0
daughter O 0
developed O 0
pattern B-Disease 0
macular I-Disease 1
dystrophy I-Disease 1
at O 0
age O 0
31 O 0
years O 0
. O 0

At O 0
age O 0
44 O 0
years O 0
, O 0
her O 0
ERG O 0
was O 0
moderately O 0
abnormal O 0
but O 0
her O 0
clinical O 0
disease O 0
was O 0
limited O 0
to O 0
the O 0
macula O 0
. O 0

Another O 0
daughter O 0
presented O 0
at O 0
age O 0
42 O 0
years O 0
with O 0
macular B-Disease 0
degeneration I-Disease 0
and O 0
over O 0
10 O 0
years O 0
developed O 0
the O 0
clinical O 0
picture O 0
of O 0
fundus B-Disease 1
flavimaculatus I-Disease 1
. O 0

Her O 0
peripheral O 0
visual O 0
field O 0
was O 0
preserved O 0
but O 0
her O 0
ERG O 0
was O 0
moderately O 0
abnormal O 0
. O 0

The O 0
son O 0
had O 0
onset O 0
of O 0
macular B-Disease 0
degeneration I-Disease 0
at O 0
age O 0
44 O 0
years O 0
. O 0

Pericentral B-Disease 0
scotomas I-Disease 0
were O 0
present O 0
and O 0
the O 0
ERG O 0
was O 0
markedly O 0
abnormal O 0
. O 0

Fluorescein O 0
angiography O 0
revealed O 0
punctate O 0
pigment O 0
epithelial O 0
transmission O 0
defects O 0
. O 0

CONCLUSIONS O 0
A O 0
3 O 0
- O 0
base O 0
pair O 0
deletion O 0
of O 0
codon O 0
153 O 0
or O 0
154 O 0
of O 0
the O 0
peripherin O 0
/ O 0
RDS O 0
gene O 0
can O 0
produce O 0
clinically O 0
disparate O 0
phenotypes O 0
even O 0
within O 0
the O 0
same O 0
family O 0
. O 0
. O 0

Assignment O 0
of O 0
the O 0
human O 0
Na O 0
+ O 0
/ O 0
glucose O 0
cotransporter O 0
gene O 0
SGLT1 O 0
to O 0
chromosome O 0
22q13 O 0
. O 0
1 O 0
. O 0

The O 0
Na O 0
+ O 0
/ O 0
glucose O 0
cotransporter O 0
gene O 0
SGLT1 O 0
encodes O 0
the O 0
primary O 0
carrier O 0
protein O 0
responsible O 0
for O 0
the O 0
uptake O 0
of O 0
the O 0
dietary O 0
sugars O 0
glucose O 0
and O 0
galactose O 0
from O 0
the O 0
intestinal O 0
lumen O 0
. O 0

SGLT1 O 0
transport O 0
activity O 0
is O 0
currently O 0
exploited O 0
in O 0
oral O 0
rehydration O 0
therapy O 0
. O 0

The O 0
75 O 0
- O 0
kDa O 0
glycoprotein O 0
is O 0
localized O 0
in O 0
the O 0
brush O 0
border O 0
of O 0
the O 0
intestinal O 0
epithelium O 0
and O 0
is O 0
predicted O 0
to O 0
comprise O 0
12 O 0
membrane O 0
spans O 0
. O 0

In O 0
two O 0
patients O 0
with O 0
the O 0
autosomal B-Disease 1
recessive I-Disease 1
disease I-Disease 1
glucose I-Disease 0
/ I-Disease 0
galactose I-Disease 0
malabsorption I-Disease 0
, O 0
the O 0
underlying O 0
cause O 0
was O 0
found O 0
to O 0
be O 0
a O 0
missense O 0
mutation O 0
in O 0
SGLT1 O 0
, O 0
and O 0
the O 0
Asp28 O 0
- O 0
- O 0
> O 0
Asn O 0
change O 0
was O 0
demonstrated O 0
in O 0
vitro O 0
to O 0
eliminate O 0
SGLT1 O 0
transport O 0
activity O 0
. O 0

The O 0
SGLT1 O 0
gene O 0
was O 0
previously O 0
shown O 0
to O 0
reside O 0
on O 0
the O 0
distal O 0
q O 0
arm O 0
of O 0
chromosome O 0
22 O 0
( O 0
11 O 0
. O 0
2 O 0
- O 0
- O 0
> O 0
qter O 0
) O 0
. O 0

We O 0
have O 0
used O 0
a O 0
cosmid O 0
probe O 0
for O 0
fluorescence O 0
in O 0
situ O 0
hybridization O 0
, O 0
which O 0
refines O 0
the O 0
localization O 0
to O 0
22q13 O 0
. O 0

1 O 0
, O 0
and O 0
provide O 0
an O 0
example O 0
of O 0
the O 0
utility O 0
of O 0
the O 0
SGLT1 O 0
probe O 0
as O 0
a O 0
diagnostic O 0
for O 0
genetic B-Disease 0
diseases I-Disease 0
associated O 0
with O 0
translocations O 0
of O 0
chromosome O 0
22 O 0
. O 0

Restriction O 0
of O 0
ocular O 0
fundus O 0
lesions O 0
to O 0
a O 0
specific O 0
subgroup O 0
of O 0
APC B-Disease 1
mutations O 0
in O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
patients O 0
. O 0

In O 0
humans O 0
, O 0
alteration O 0
of O 0
the O 0
tumor B-Disease 0
suppressor O 0
gene O 0
, O 0
APC B-Disease 1
, O 0
causes O 0
adenomatous B-Disease 0
polyposis I-Disease 1
coli I-Disease 0
, O 0
a O 0
condition O 0
causing O 0
predisposition O 0
to O 0
colorectal B-Disease 1
cancer I-Disease 1
. O 0

The O 0
syndrome O 0
inconsistently O 0
associates O 0
characteristic O 0
patches O 0
of O 0
congenital B-Disease 1
hypertrophy I-Disease 1
of I-Disease 1
the I-Disease 1
retinal I-Disease 1
pigment I-Disease 1
epithelium I-Disease 1
( O 0
CHRPE B-Disease 1
) O 0
. O 0

Ocular O 0
examination O 0
revealed O 0
that O 0
patients O 0
expressing O 0
CHRPE B-Disease 1
tend O 0
to O 0
cluster O 0
within O 0
specific O 0
families O 0
. O 0

The O 0
exact O 0
APC B-Disease 1
mutation O 0
was O 0
identified O 0
in O 0
42 O 0
unrelated O 0
patients O 0
. O 0

In O 0
all O 0
cases O 0
these O 0
mutations O 0
were O 0
predicted O 0
to O 0
lead O 0
to O 0
the O 0
synthesis O 0
of O 0
a O 0
truncated O 0
protein O 0
. O 0

The O 0
extent O 0
of O 0
CHRPE B-Disease 1
was O 0
found O 0
to O 0
be O 0
dependent O 0
on O 0
the O 0
position O 0
of O 0
the O 0
mutation O 0
along O 0
the O 0
coding O 0
sequence O 0
. O 0

CHRPE B-Disease 1
lesions O 0
are O 0
almost O 0
always O 0
absent O 0
if O 0
the O 0
mutation O 0
occurs O 0
before O 0
exon O 0
9 O 0
, O 0
but O 0
are O 0
systematically O 0
present O 0
if O 0
it O 0
occurs O 0
after O 0
this O 0
exon O 0
. O 0

Thus O 0
, O 0
the O 0
range O 0
of O 0
phenotypic O 0
expression O 0
observed O 0
among O 0
affected O 0
patients O 0
may O 0
result O 0
in O 0
part O 0
from O 0
different O 0
allelic O 0
manifestations O 0
of O 0
APC B-Disease 1
mutations O 0
. O 0
. O 0

The O 0
effects O 0
of O 0
dystrophin O 0
gene O 0
mutations O 0
on O 0
the O 0
ERG O 0
in O 0
mice O 0
and O 0
humans O 0
. O 0

PURPOSE O 0
. O 0

The O 0
authors O 0
earlier O 0
findings O 0
of O 0
a O 0
negative O 0
electroretinogram O 0
( O 0
ERG O 0
) O 0
in O 0
a O 0
boy O 0
with O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
led O 0
them O 0
to O 0
investigate O 0
dystrophin O 0
gene O 0
deletions O 0
and O 0
ERGs O 0
in O 0
five O 0
boys O 0
with O 0
DMD B-Disease 0
. O 0

The O 0
authors O 0
wanted O 0
to O 0
determined O 0
whether O 0
there O 0
were O 0
similar O 0
ERG O 0
findings O 0
in O 0
an O 0
animal O 0
model O 0
for O 0
DMD B-Disease 0
, O 0
the O 0
mdx O 0
mouse O 0
. O 0

METHODS O 0
. O 0

Ganzfeld O 0
ERGs O 0
were O 0
recorded O 0
in O 0
five O 0
boys O 0
with O 0
DMD B-Disease 0
after O 0
a O 0
complete O 0
ophthalmic O 0
examination O 0
. O 0

The O 0
dystrophin O 0
gene O 0
was O 0
analyzed O 0
by O 0
Southern O 0
blot O 0
hybridization O 0
. O 0

ERGs O 0
were O 0
recorded O 0
in O 0
anesthetized O 0
mdx O 0
and O 0
control O 0
mice O 0
with O 0
a O 0
modified O 0
Grass O 0
photostimulator O 0
( O 0
Grass O 0
Instrument O 0
Company O 0
, O 0
Quincy O 0
, O 0
MA O 0
) O 0
. O 0

RESULTS O 0
. O 0

Ophthalmic O 0
examinations O 0
in O 0
all O 0
five O 0
boys O 0
had O 0
normal O 0
findings O 0
, O 0
yet O 0
an O 0
abnormal O 0
negative O 0
ERG O 0
was O 0
recorded O 0
for O 0
each O 0
subject O 0
. O 0

The O 0
subjects O 0
gene O 0
deletions O 0
were O 0
variable O 0
, O 0
ranging O 0
from O 0
large O 0
deletions O 0
to O 0
no O 0
detectable O 0
deletions O 0
. O 0

The O 0
ERGs O 0
of O 0
the O 0
mdx O 0
mice O 0
were O 0
normal O 0
and O 0
did O 0
not O 0
differ O 0
significantly O 0
from O 0
those O 0
of O 0
the O 0
control O 0
mice O 0
. O 0

CONCLUSIONS O 0
. O 0

The O 0
authors O 0
believe O 0
the O 0
unique O 0
ERG O 0
recorded O 0
for O 0
the O 0
human O 0
subjects O 0
is O 0
a O 0
manifestation O 0
of O 0
DMD B-Disease 0
associated O 0
with O 0
defects O 0
at O 0
the O 0
dystrophin O 0
gene O 0
locus O 0
and O 0
represents O 0
a O 0
new O 0
clinical O 0
entity O 0
. O 0

The O 0
ERG O 0
of O 0
the O 0
mdx O 0
mouse O 0
may O 0
be O 0
spared O 0
for O 0
several O 0
reasons O 0
, O 0
including O 0
milder O 0
effects O 0
of O 0
the O 0
mouse O 0
gene O 0
defect O 0
, O 0
differences O 0
in O 0
muscle O 0
and O 0
retinal O 0
gene O 0
product O 0
, O 0
or O 0
species O 0
differences O 0
in O 0
the O 0
biochemical O 0
role O 0
of O 0
dystrophin O 0
. O 0

The O 0
ERG O 0
shows O 0
promise O 0
of O 0
becoming O 0
a O 0
noninvasive O 0
diagnostic O 0
tool O 0
for O 0
DMD B-Disease 0
and O 0
its O 0
milder O 0
allelic O 0
forms O 0
. O 0
. O 0

Association O 0
of O 0
the O 0
APC B-Disease 1
tumor I-Disease 1
suppressor O 0
protein O 0
with O 0
catenins O 0
. O 0

Mutations O 0
of O 0
APC O 1
appear O 0
to O 0
initiate O 0
sporadic O 0
and O 0
inherited O 0
forms O 0
of O 0
human O 0
colorectal B-Disease 1
cancer I-Disease 1
. O 0

Although O 0
these O 0
mutations O 0
have O 0
been O 0
well O 0
characterized O 0
, O 0
little O 0
is O 0
known O 0
about O 0
the O 0
function O 0
of O 0
the O 0
APC B-Disease 1
gene O 0
product O 0
. O 0

Two O 0
cellular O 0
proteins O 0
that O 0
associate O 0
with O 0
APC B-Disease 1
were O 0
identified O 0
by O 0
nucleotide O 0
sequence O 0
analysis O 0
and O 0
peptide O 0
mapping O 0
as O 0
the O 0
E O 0
- O 0
cadherin O 0
- O 0
associated O 0
proteins O 0
alpha O 0
- O 0
and O 0
beta O 0
- O 0
catenin O 0
. O 0

A O 0
27 O 0
- O 0
residue O 0
fragment O 0
of O 0
APC O 1
containing O 0
a O 0
15 O 0
- O 0
amino O 0
acid O 0
repeat O 0
was O 0
sufficient O 0
for O 0
the O 0
interaction O 0
with O 0
the O 0
catenins O 0
. O 0

These O 0
results O 0
suggest O 0
an O 0
important O 0
link O 0
between O 0
tumor B-Disease 0
initiation O 0
and O 0
cell O 0
adhesion O 0
. O 0
. O 0

Difference O 0
in O 0
methylation O 0
patterns O 0
within O 0
the O 0
D15S9 O 0
region O 0
of O 0
chromosome O 0
15q11 O 0
- O 0
13 O 0
in O 0
first O 0
cousins O 0
with O 0
Angelman B-Disease 1
syndrome I-Disease 1
and O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
. O 0

Abnormalities O 0
of O 0
chromosome O 0
region O 0
15q11 O 0
- O 0
13 O 0
are O 0
associated O 0
with O 0
Angelman B-Disease 1
syndrome I-Disease 1
( O 0
AS B-Disease 0
) O 0
and O 0
Prader B-Disease 1
- I-Disease 1
Willi I-Disease 1
syndrome I-Disease 1
( O 0
PWS B-Disease 0
) O 0
. O 0

Differences O 0
between O 0
the O 0
methylation O 0
patterns O 0
of O 0
the O 0
region O 0
of O 0
chromosome O 0
15q11 O 0
- O 0
13 O 0
which O 0
hybridizes O 0
to O 0
the O 0
highly O 0
conserved O 0
DNA O 0
, O 0
DN34 O 0
, O 0
in O 0
normal O 0
individuals O 0
and O 0
in O 0
patients O 0
with O 0
AS B-Disease 0
and O 0
PWS B-Disease 0
have O 0
been O 0
described O 0
. O 0

We O 0
report O 0
on O 0
a O 0
family O 0
in O 0
which O 0
first O 0
cousins O 0
are O 0
affected O 0
by O 0
AS B-Disease 0
and O 0
PWS B-Disease 0
as O 0
a O 0
result O 0
of O 0
a O 0
familial O 0
paracentric O 0
inversion O 0
of O 0
15q11 O 0
- O 0
q13 O 0
. O 0

The O 0
results O 0
of O 0
the O 0
studies O 0
on O 0
this O 0
family O 0
demonstrate O 0
the O 0
differences O 0
in O 0
the O 0
methylation O 0
patterns O 0
in O 0
the O 0
2 O 0
conditions O 0
and O 0
the O 0
phenomenon O 0
of O 0
genomic O 0
imprinting O 0
, O 0
whereby O 0
genetic O 0
information O 0
is O 0
expressed O 0
differently O 0
dependent O 0
on O 0
the O 0
parent O 0
of O 0
origin O 0
. O 0
. O 0

Haplotype O 0
studies O 0
in O 0
Wilson B-Disease 0
disease I-Disease 0
. O 0

In O 0
51 O 0
families O 0
with O 0
Wilson B-Disease 0
disease I-Disease 0
, O 0
we O 0
have O 0
studied O 0
DNA O 0
haplotypes O 0
of O 0
dinucleotide O 0
repeat O 0
polymorphisms O 0
( O 0
CA O 0
repeats O 0
) O 0
in O 0
the O 0
13q14 O 0
. O 0

3 O 0
region O 0
, O 0
to O 0
examine O 0
these O 0
markers O 0
for O 0
association O 0
with O 0
the O 0
Wilson B-Disease 0
disease I-Disease 0
gene O 0
( O 0
WND B-Disease 0
) O 0
. O 0

In O 0
addition O 0
to O 0
a O 0
marker O 0
( O 0
D13S133 O 0
) O 0
described O 0
elsewhere O 0
, O 0
we O 0
have O 0
developed O 0
three O 0
new O 0
highly O 0
polymorphic O 0
markers O 0
( O 0
D13S314 O 0
, O 0
D13S315 O 0
, O 0
and O 0
D13S316 O 0
) O 0
close O 0
to O 0
the O 0
WND B-Disease 0
locus O 0
. O 0

We O 0
have O 0
examined O 0
the O 0
distribution O 0
of O 0
marker O 0
alleles O 0
at O 0
the O 0
loci O 0
studied O 0
and O 0
have O 0
found O 0
that O 0
D13S314 O 0
, O 0
D13S133 O 0
, O 0
and O 0
D13S316 O 0
each O 0
show O 0
nonrandom O 0
distribution O 0
on O 0
chromosomes O 0
carrying O 0
the O 0
WND B-Disease 0
mutation O 0
. O 0

We O 0
have O 0
studied O 0
haplotypes O 0
of O 0
these O 0
three O 0
markers O 0
and O 0
have O 0
found O 0
that O 0
there O 0
are O 0
highly O 0
significant O 0
differences O 0
between O 0
WND B-Disease 0
and O 0
normal O 0
haplotypes O 0
in O 0
northern O 0
European O 0
families O 0
. O 0

These O 0
findings O 0
have O 0
important O 0
implications O 0
for O 0
mutation O 0
detection O 0
and O 0
molecular O 0
diagnosis O 0
in O 0
families O 0
with O 0
Wilson B-Disease 0
disease I-Disease 0
. O 0

Genetic O 0
analysis O 0
of O 0
the O 0
BRCA1 O 0
region O 0
in O 0
a O 0
large O 0
breast O 0
/ O 0
ovarian O 0
family O 0
: O 0
refinement O 0
of O 0
the O 0
minimal O 0
region O 0
containing O 0
BRCA1 O 0
. O 0

We O 0
have O 0
analyzed O 0
a O 0
single O 0
multi O 0
- O 0
affected O 0
breast B-Disease 0
/ I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
pedigree O 0
( O 0
BOV3 O 0
) O 0
and O 0
have O 0
shown O 0
consistent O 0
inheritance O 0
of O 0
markers O 0
on O 0
chromosome O 0
17q O 0
with O 0
the O 0
disease O 0
confirming O 0
that O 0
this O 0
family O 0
is O 0
due O 0
to O 0
the O 0
BRCA1 O 0
gene O 0
. O 0

Analysis O 0
of O 0
17q O 0
haplotypes O 0
shows O 0
a O 0
recombination O 0
event O 0
in O 0
a O 0
bilateral O 0
breast B-Disease 0
cancer I-Disease 1
case O 0
which O 0
suggests O 0
that O 0
the O 0
BRCA1 O 0
gene O 0
lies O 0
distal O 0
to O 0
D17S857 O 0
; O 0
D17S857 O 0
is O 0
thus O 0
the O 0
new O 0
proximal O 0
boundary O 0
for O 0
the O 0
region O 0
containing O 0
BRCA1 O 0
. O 0

Combining O 0
this O 0
information O 0
with O 0
previously O 0
published O 0
mapping O 0
information O 0
suggests O 0
that O 0
BRCA1 O 0
is O 0
contained O 0
in O 0
a O 0
region O 0
estimated O 0
at O 0
1 O 0
- O 0
1 O 0
. O 0

5 O 0
Mb O 0
in O 0
length O 0
. O 0

All O 0
seven O 0
breast B-Disease 1
tumour I-Disease 1
/ O 0
blood O 0
pairs O 0
examined O 0
from O 0
this O 0
family O 0
show O 0
loss O 0
of O 0
heterozygosity O 0
in O 0
the O 0
tumours B-Disease 1
. O 0

The O 0
allel O 0
retained O 0
in O 0
each O 0
tumour B-Disease 1
was O 0
from O 0
the O 0
disease O 0
- O 0
bearing O 0
chromosome O 0
implicating O 0
BRCA1 O 0
as O 0
a O 0
tumour B-Disease 1
suppressor O 0
gene O 0
. O 0

We O 0
have O 0
sequenced O 0
the O 0
17 O 0
beta O 0
- O 0
oestradiol O 0
dehydrogenase O 0
genes O 0
( O 0
EDH17B1 O 0
and O 0
EDH17B2 O 0
) O 0
which O 0
have O 0
been O 0
suggested O 0
as O 0
candidate O 0
genes O 0
for O 0
BRCA1 O 0
in O 0
four O 0
members O 0
of O 0
this O 0
family O 0
. O 0

No O 0
germline O 0
mutations O 0
were O 0
detected O 0
. O 0

Myotonic B-Disease 1
dystrophy I-Disease 1
kinase O 0
is O 0
a O 0
component O 0
of O 0
neuromuscular O 0
junctions O 0
. O 0

The O 0
clinical O 0
manifestation O 0
of O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
is O 0
correlated O 0
to O 0
the O 0
extent O 0
of O 0
expansion O 0
of O 0
an O 0
unstable O 0
[ O 0
CTG O 0
] O 0
n O 0
DNA O 0
motif O 0
. O 0

Recent O 0
studies O 0
have O 0
demonstrated O 0
that O 0
this O 0
trinucleotide O 0
motif O 0
forms O 0
part O 0
of O 0
the O 0
last O 0
, O 0
3 O 0
untranslated O 0
exon O 0
of O 0
a O 0
gene O 0
which O 0
potentially O 0
encodes O 0
multiple O 0
protein O 0
isoforms O 0
of O 0
a O 0
serine O 0
/ O 0
threonine O 0
protein O 0
kinase O 0
( O 0
myotonic B-Disease 1
dystrophy I-Disease 1
protein O 0
kinase O 0
, O 0
DM O 0
- O 0
PK O 0
) O 0
. O 0

We O 0
report O 0
here O 0
on O 0
the O 0
development O 0
of O 0
antisera O 0
against O 0
synthetic O 0
DM O 0
- O 0
PK O 0
peptide O 0
antigens O 0
and O 0
their O 0
use O 0
in O 0
biochemical O 0
and O 0
histochemical O 0
studies O 0
. O 0

Immunoreactive O 0
DM O 0
- O 0
kinase O 0
protein O 0
of O 0
53 O 0
kD O 0
is O 0
present O 0
at O 0
low O 0
levels O 0
in O 0
skeletal O 0
and O 0
cardiac O 0
muscle O 0
extracts O 0
of O 0
DM B-Disease 0
patients O 0
and O 0
normal O 0
controls O 0
. O 0

Immunohistochemical O 0
staining O 0
revealed O 0
that O 0
DM O 0
- O 0
PK O 0
is O 0
localised O 0
prominently O 0
at O 0
sites O 0
of O 0
neuromuscular O 0
and O 0
myotendinous O 0
junctions O 0
( O 0
NMJs O 0
and O 0
MTJs O 0
) O 0
of O 0
human O 0
and O 0
rodent O 0
skeletal O 0
muscles O 0
. O 0

Furthermore O 0
, O 0
very O 0
low O 0
levels O 0
of O 0
immunoreactive O 0
DM O 0
- O 0
PK O 0
protein O 0
are O 0
present O 0
in O 0
the O 0
sarcoplasm O 0
of O 0
predominantly O 0
type O 0
I O 0
fibres O 0
in O 0
various O 0
muscles O 0
. O 0

Strikingly O 0
, O 0
presence O 0
of O 0
the O 0
protein O 0
can O 0
also O 0
be O 0
demonstrated O 0
for O 0
NMJs O 0
of O 0
muscular O 0
tissues O 0
of O 0
adult O 0
and O 0
congenital O 0
cases O 0
of O 0
DM B-Disease 0
, O 0
with O 0
no O 0
gross O 0
changes O 0
in O 0
structural O 0
organisation O 0
. O 0

Our O 0
findings O 0
provide O 0
a O 0
basis O 0
for O 0
further O 0
characterisation O 0
of O 0
the O 0
role O 0
of O 0
the O 0
kinase O 0
in O 0
protein O 0
assembly O 0
processes O 0
or O 0
signal O 0
mediation O 0
at O 0
synaptic O 0
sites O 0
and O 0
ultimately O 0
for O 0
the O 0
understanding O 0
of O 0
the O 0
complex O 0
pathophysiology O 0
of O 0
DM B-Disease 0
. O 0
. O 0

Markedly O 0
accelerated O 0
catabolism O 0
of O 0
apolipoprotein O 0
A O 0
- O 0
II O 0
( O 0
ApoA O 0
- O 0
II O 0
) O 0
and O 0
high O 0
density O 0
lipoproteins O 0
containing O 0
ApoA O 0
- O 0
II O 0
in O 0
classic O 0
lecithin O 0
: O 0
cholesterol B-Disease 0
acyltransferase I-Disease 0
deficiency I-Disease 0
and O 0
fish B-Disease 1
- I-Disease 1
eye I-Disease 1
disease I-Disease 1
. O 0

Classic B-Disease 0
( I-Disease 0
complete I-Disease 0
) I-Disease 0
lecithin I-Disease 0
cholesterol I-Disease 0
acyltransferase I-Disease 0
( I-Disease 0
LCAT I-Disease 0
) I-Disease 0
deficiency I-Disease 0
and O 0
Fish B-Disease 1
- I-Disease 1
eye I-Disease 1
disease I-Disease 1
( O 0
partial B-Disease 1
LCAT I-Disease 1
deficiency I-Disease 1
) O 0
are O 0
genetic O 0
syndromes O 0
associated O 0
with O 0
markedly O 0
decreased O 0
plasma O 0
levels O 0
of O 0
high O 0
density O 0
lipoprotein O 0
( O 0
HDL O 0
) O 0
cholesterol O 0
but O 0
not O 0
with O 0
an O 0
increased O 0
risk O 0
of O 0
atherosclerotic B-Disease 1
cardiovascular I-Disease 1
disease I-Disease 1
. O 0

We O 0
investigated O 0
the O 0
metabolism O 0
of O 0
the O 0
HDL O 0
apolipoproteins O 0
( O 0
apo O 0
) O 0
apoA O 0
- O 0
I O 0
and O 0
apoA O 0
- O 0
II O 0
in O 0
a O 0
total O 0
of O 0
five O 0
patients O 0
with O 0
LCAT B-Disease 1
deficiency I-Disease 1
, O 0
one O 0
with O 0
classic B-Disease 1
LCAT I-Disease 1
deficiency I-Disease 1
and O 0
four O 0
with O 0
Fish B-Disease 1
- I-Disease 1
eye I-Disease 1
disease I-Disease 1
. O 0

Plasma O 0
levels O 0
of O 0
apoA O 0
- O 0
II O 0
were O 0
decreased O 0
to O 0
a O 0
proportionately O 0
greater O 0
extent O 0
( O 0
23 O 0
% O 0
of O 0
normal O 0
) O 0
than O 0
apoA O 0
- O 0
I O 0
( O 0
30 O 0
% O 0
of O 0
normal O 0
) O 0
. O 0

In O 0
addition O 0
, O 0
plasma O 0
concentrations O 0
of O 0
HDL O 0
particles O 0
containing O 0
both O 0
apoA O 0
- O 0
I O 0
and O 0
apoA O 0
- O 0
II O 0
( O 0
LpA O 0
- O 0
I O 0
A O 0
- O 0
II O 0
) O 0
were O 0
much O 0
lower O 0
( O 0
18 O 0
% O 0
of O 0
normal O 0
) O 0
than O 0
those O 0
of O 0
particles O 0
containing O 0
only O 0
apoA O 0
- O 0
I O 0
( O 0
LpA O 0
- O 0
I O 0
) O 0
( O 0
51 O 0
% O 0
of O 0
normal O 0
) O 0
. O 0

The O 0
metabolic O 0
basis O 0
for O 0
the O 0
low O 0
levels O 0
of O 0
apoA O 0
- O 0
II O 0
and O 0
LpA O 0
- O 0
I O 0
A O 0
- O 0
II O 0
was O 0
investigated O 0
in O 0
all O 0
five O 0
patients O 0
using O 0
both O 0
exogenous O 0
radiotracer O 0
and O 0
endogenous O 0
stable O 0
isotope O 0
labeling O 0
techniques O 0
. O 0

The O 0
mean O 0
plasma O 0
residence O 0
time O 0
of O 0
apoA O 0
- O 0
I O 0
was O 0
decreased O 0
at O 0
2 O 0
. O 0

08 O 0
+ O 0
/ O 0
- O 0
0 O 0
. O 0

27 O 0
d O 0
( O 0
controls O 0
4 O 0
. O 0
74 O 0
+ O 0
/ O 0
- O 0
0 O 0
. O 0
65 O 0
days O 0
) O 0
; O 0
however O 0
, O 0
the O 0
residence O 0
time O 0
of O 0
apoA O 0
- O 0
II O 0
was O 0
even O 0
shorter O 0
at O 0
1 O 0
. O 0

66 O 0
+ O 0
/ O 0
- O 0
0 O 0
. O 0

24 O 0
d O 0
( O 0
controls O 0
5 O 0
. O 0
25 O 0
+ O 0
/ O 0
- O 0
0 O 0
. O 0
61 O 0
d O 0
) O 0
. O 0

In O 0
addition O 0
, O 0
the O 0
catabolism O 0
of O 0
apoA O 0
- O 0
I O 0
in O 0
LpA O 0
- O 0
I O 0
A O 0
- O 0
II O 0
was O 0
substantially O 0
faster O 0
than O 0
that O 0
of O 0
apoA O 0
- O 0
I O 0
in O 0
LpA O 0
- O 0
I O 0
. O 0

In O 0
summary O 0
, O 0
genetic O 0
syndromes O 0
of O 0
either O 0
complete B-Disease 0
or I-Disease 0
partial I-Disease 1
LCAT I-Disease 1
deficiency I-Disease 1
result O 0
in O 0
low O 0
levels O 0
of O 0
HDL O 0
through O 0
preferential O 0
hypercatabolism O 0
of O 0
apoA O 0
- O 0
II O 0
and O 0
HDL O 0
particles O 0
containing O 0
apoA O 0
- O 0
II O 0
. O 0

Because O 0
LpA O 0
- O 0
I O 0
has O 0
been O 0
proposed O 0
to O 0
be O 0
more O 0
protective O 0
than O 0
LpA O 0
- O 0
I O 0
A O 0
- O 0
II O 0
against O 0
atherosclerosis B-Disease 0
, O 0
this O 0
selective O 0
effect O 0
on O 0
the O 0
metabolism O 0
of O 0
LpA O 0
- O 0
I O 0
A O 0
- O 0
II O 0
may O 0
provide O 0
a O 0
potential O 0
explanation O 0
why O 0
patients O 0
with O 0
classic B-Disease 1
LCAT I-Disease 1
deficiency I-Disease 1
and O 0
Fish B-Disease 1
- I-Disease 1
eye I-Disease 1
disease I-Disease 1
are O 0
not O 0
at O 0
increased O 0
risk O 0
for O 0
premature O 1
atherosclerosis B-Disease 1
despite O 0
markedly O 0
decreased O 0
levels O 0
of O 0
HDL O 0
cholesterol O 0
and O 0
apoA O 0
- O 0
I O 0

X B-Disease 0
linked I-Disease 0
recessive I-Disease 0
thrombocytopenia I-Disease 0
. O 0

A O 0
Saudi O 0
Arab O 0
boy O 0
presented O 0
in O 0
early O 0
childhood O 0
with O 0
thrombocytopenia B-Disease 0
, O 0
morphologically O 0
large O 0
and O 0
normal O 0
sized O 0
platelets O 0
, O 0
increased O 0
mean O 0
platelet O 0
volume O 0
, O 0
and O 0
a O 0
hypermegakaryocytic O 0
bone O 0
marrow O 0
. O 0

There O 0
was O 0
no O 0
clinical O 0
and O 0
laboratory O 0
evidence O 0
of O 0
any O 0
significant O 0
immunological B-Disease 0
abnormalities I-Disease 0
. O 0

Similar O 0
findings O 0
in O 0
two O 0
other O 0
brothers O 0
suggested O 0
strongly O 0
that O 0
they O 0
were O 0
all O 0
suffering O 0
from O 0
an O 0
X B-Disease 0
linked I-Disease 0
recessive I-Disease 0
thrombocytopenic I-Disease 0
disorder I-Disease 0
. O 0

Results O 0
of O 0
DNA O 0
analysis O 0
with O 0
the O 0
probe O 0
M27 O 0
beta O 0
are O 0
consistent O 0
with O 0
X O 0
linkage O 0
and O 0
indicate O 0
also O 0
that O 0
the O 0
locus O 0
of O 0
the O 0
relevant O 0
gene O 0
lies O 0
close O 0
to O 0
or O 0
is O 0
identical O 0
to O 0
the O 0
locus O 0
of O 0
the O 0
gene O 0
for O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
( O 0
WAS B-Disease 0
) O 0
. O 0

Because O 0
of O 0
various O 0
features O 0
which O 0
include O 0
the O 0
presence O 0
of O 0
large O 0
and O 0
normal O 0
sized O 0
platelets O 0
( O 0
rather O 0
than O 0
small O 0
platelets O 0
) O 0
and O 0
freedom O 0
from O 0
significant O 0
immune B-Disease 1
deficiencies I-Disease 1
, O 0
it O 0
is O 0
likely O 0
that O 0
the O 0
X B-Disease 0
linked I-Disease 0
recessive I-Disease 0
thrombocytopenia I-Disease 0
in O 0
this O 0
family O 0
is O 0
an O 0
isolated O 0
entity O 0
quite O 0
distinct O 0
from O 0
the O 0
classical O 0
WAS B-Disease 0
phenotype O 0
. O 0

However O 0
, O 0
a O 0
modified O 0
expression O 0
of O 0
the O 0
WAS B-Disease 0
gene O 0
producing O 0
a O 0
mild O 0
phenotypic O 0
variant O 0
cannot O 0
be O 0
excluded O 0
entirely O 0
. O 0
. O 0

Macular B-Disease 0
dystrophy I-Disease 0
associated O 0
with O 0
mutations O 0
at O 0
codon O 0
172 O 0
in O 0
the O 0
human O 0
retinal B-Disease 0
degeneration I-Disease 0
slow O 0
gene O 0
. O 0

BACKGROUND O 0
Recently O 0
, O 0
mutations O 0
in O 0
the O 0
retinal B-Disease 0
degeneration I-Disease 0
slow O 0
( O 0
rds O 0
) O 0
gene O 0
which O 0
codes O 0
for O 0
peripherin O 0
- O 0
rds O 0
have O 0
been O 0
implicated O 0
as O 0
a O 0
cause O 0
of O 0
autosomal B-Disease 1
dominant I-Disease 1
retinitis I-Disease 1
pigmentosa I-Disease 1
. O 0

Because O 0
this O 0
gene O 0
is O 0
expressed O 0
in O 0
both O 0
rods O 0
and O 0
cones O 0
, O 0
mutations O 0
in O 0
the O 0
rds O 0
gene O 0
might O 0
be O 0
expected O 0
to O 0
cause O 0
degeneration O 0
affecting O 0
either O 0
the O 0
scotopic O 0
or O 0
photopic O 0
systems O 0
. O 0

Mutations O 0
at O 0
codon O 0
172 O 0
of O 0
the O 0
rds O 0
gene O 0
have O 0
been O 0
identified O 0
in O 0
three O 0
families O 0
with O 0
autosomal O 0
dominantly O 0
inherited O 0
, O 0
progressive O 0
macular B-Disease 1
dystrophy I-Disease 1
. O 0

METHODS O 0
Affected O 0
individuals O 0
underwent O 0
ophthalmic O 0
examination O 0
, O 0
scotopic O 0
perimetry O 0
, O 0
dark O 0
adaptometry O 0
, O 0
measurement O 0
of O 0
color O 0
- O 0
contrast O 0
sensitivity O 0
, O 0
and O 0
electroretinography O 0
to O 0
characterize O 0
the O 0
photoreceptor O 0
dysfunction O 0
. O 0

RESULTS O 0
In O 0
all O 0
but O 0
one O 0
affected O 0
member O 0
, O 0
symptoms O 0
of O 0
progressive O 0
central O 0
visual B-Disease 1
loss I-Disease 1
developed O 0
in O 0
the O 0
third O 0
or O 0
fourth O 0
decade O 0
of O 0
life O 0
accompanied O 0
by O 0
central B-Disease 1
scotoma I-Disease 1
and O 0
well O 0
- O 0
demarcated O 0
atrophy B-Disease 0
of I-Disease 0
the I-Disease 0
retinal I-Disease 0
pigment I-Disease 0
epithelium I-Disease 0
and O 0
choriocapillaris B-Disease 1
of I-Disease 1
the I-Disease 1
macula I-Disease 1
. O 0

In O 0
general O 0
, O 0
cone O 0
and O 0
rod O 0
thresholds O 0
were O 0
elevated O 0
, O 0
and O 0
color O 0
- O 0
contrast O 0
sensitivity O 0
was O 0
absent O 0
in O 0
the O 0
central O 0
visual O 0
field O 0
. O 0

Peripherally O 0
, O 0
the O 0
scotopic O 0
sensitivities O 0
were O 0
normal O 0
, O 0
as O 0
was O 0
the O 0
recovery O 0
from O 0
bleach O 0
. O 0

Cone O 0
electroretinograms O 0
were O 0
diminished O 0
in O 0
amplitude O 0
, O 0
and O 0
delayed O 0
in O 0
all O 0
affected O 0
adults O 0
except O 0
one O 0
. O 0

Rod O 0
electroretinograms O 0
were O 0
normal O 0
or O 0
near O 0
normal O 0
in O 0
amplitude O 0
, O 0
and O 0
had O 0
normal O 0
implicit O 0
times O 0
. O 0

Affected O 0
asymptomatic O 0
children O 0
had O 0
macular O 0
changes O 0
, O 0
abnormal O 0
color O 0
- O 0
contrast O 0
sensitivity O 0
, O 0
and O 0
reduced O 0
pattern O 0
and O 0
cone O 0
electroretinograms O 0
. O 0

CONCLUSION O 0
These O 0
results O 0
indicate O 0
that O 0
mutations O 0
in O 0
the O 0
rds O 0
gene O 0
can O 0
be O 0
expressed O 0
as O 0
a O 0
macular B-Disease 1
dystrophy I-Disease 1
, O 0
with O 0
evidence O 0
of O 0
primary O 0
cone B-Disease 1
dysfunction I-Disease 1
and O 0
preservation O 0
of O 0
peripheral O 0
rod O 0
function O 0
. O 0
. O 0

Anonymous O 0
marker O 0
loci O 0
within O 0
400 O 0
kb O 0
of O 0
HLA O 0
- O 0
A O 0
generate O 0
haplotypes O 0
in O 0
linkage O 0
disequilibrium O 0
with O 0
the O 0
hemochromatosis B-Disease 1
gene O 0
( O 0
HFE O 0
) O 0

The O 0
hemochromatosis B-Disease 1
gene O 0
( O 0
HFE O 0
) O 0
maps O 0
to O 0
6p21 O 0
. O 0

3 O 0
and O 0
is O 0
less O 0
than O 0
1 O 0
cM O 0
from O 0
the O 0
HLA O 0
class O 0
I O 0
genes O 0
; O 0
however O 0
, O 0
the O 0
precise O 0
physical O 0
location O 0
of O 0
the O 0
gene O 0
has O 0
remained O 0
elusive O 0
and O 0
controversial O 0
. O 0

The O 0
unambiguous O 0
identification O 0
of O 0
a O 0
crossover O 0
event O 0
within O 0
hemochromatosis B-Disease 1
families O 0
is O 0
very O 0
difficult O 0
; O 0
it O 0
is O 0
particularly O 0
hampered O 0
by O 0
the O 0
variability O 0
of O 0
the O 0
phenotypic O 0
expression O 0
as O 0
well O 0
as O 0
by O 0
the O 0
sex O 0
- O 0
and O 0
age O 0
- O 0
related O 0
penetrance O 0
of O 0
the O 0
disease O 0
. O 0

For O 0
these O 0
practical O 0
considerations O 0
, O 0
traditional O 0
linkage O 0
analysis O 0
could O 0
prove O 0
of O 0
limited O 0
value O 0
in O 0
further O 0
refining O 0
the O 0
extrapolated O 0
physical O 0
position O 0
of O 0
HFE O 0
. O 0

We O 0
therefore O 0
embarked O 0
upon O 0
a O 0
linkage O 0
- O 0
disequilibrium O 0
analysis O 0
of O 0
HFE O 0
and O 0
normal O 0
chromosomes O 0
from O 0
the O 0
Brittany O 0
population O 0
. O 0

In O 0
the O 0
present O 0
report O 0
, O 0
66 O 0
hemochromatosis B-Disease 1
families O 0
yielding O 0
151 O 0
hemochromatosis B-Disease 1
chromosomes O 0
and O 0
182 O 0
normal O 0
chromosomes O 0
were O 0
RFLP O 0
- O 0
typed O 0
with O 0
a O 0
battery O 0
of O 0
probes O 0
, O 0
including O 0
two O 0
newly O 0
derived O 0
polymorphic O 0
markers O 0
from O 0
the O 0
6 O 0
. O 0

7 O 0
and O 0
HLA O 0
- O 0
F O 0
loci O 0
located O 0
150 O 0
and O 0
250 O 0
kb O 0
telomeric O 0
to O 0
HLA O 0
- O 0
A O 0
, O 0
respectively O 0
. O 0

The O 0
results O 0
suggest O 0
a O 0
strong O 0
peak O 0
of O 0
existing O 0
linkage O 0
disequilibrium O 0
focused O 0
within O 0
the O 0
i82 O 0
- O 0
to O 0
- O 0
6 O 0
. O 0

7 O 0
interval O 0
( O 0
approximately O 0
250 O 0
kb O 0
) O 0
. O 0

The O 0
zone O 0
of O 0
linkage O 0
disequilibrium O 0
is O 0
flanked O 0
by O 0
the O 0
i97 O 0
locus O 0
, O 0
positioned O 0
30 O 0
kb O 0
proximal O 0
to O 0
i82 O 0
, O 0
and O 0
the O 0
HLA O 0
- O 0
F O 0
gene O 0
, O 0
found O 0
250 O 0
kb O 0
distal O 0
to O 0
HLA O 0
- O 0
A O 0
, O 0
markers O 0
of O 0
which O 0
display O 0
no O 0
significant O 0
association O 0
with O 0
HFE O 0
. O 0

These O 0
data O 0
support O 0
the O 0
possibility O 0
that O 0
HFE O 0
resides O 0
within O 0
the O 0
400 O 0
- O 0
kb O 0
expanse O 0
of O 0
DNA O 0
between O 0
i97 O 0
and O 0
HLA O 0
- O 0
F O 0
. O 0

Alternatively O 0
, O 0
the O 0
very O 0
tight O 0
association O 0
of O 0
HLA O 0
- O 0
A3 O 0
and O 0
allele O 0
1 O 0
of O 0
the O 0
6 O 0
. O 0

7 O 0
locus O 0
, O 0
both O 0
of O 0
which O 0
are O 0
comprised O 0
by O 0
the O 0
major O 0
ancestral O 0
or O 0
founder O 0
HFE O 0
haplotype O 0
in O 0
Brittany O 0
, O 0
supports O 0
the O 0
possibility O 0
that O 0
the O 0
disease O 0
gene O 0
may O 0
reside O 0
immediately O 0
telomeric O 0
to O 0
the O 0
6 O 0
. O 0

7 O 0
locus O 0
within O 0
the O 0
linkage O 0
- O 0
disequilibrium O 0
zone O 0
. O 0

Additionally O 0
, O 0
hemochromatosis B-Disease 1
haplotypes O 0
possessing O 0
HLA O 0
- O 0
A11 O 0
and O 0
the O 0
low O 0
- O 0
frequency O 0
HLA O 0
- O 0
F O 0
polymorphism O 0
( O 0
allele O 0
2 O 0
) O 0
are O 0
supportive O 0
of O 0
a O 0
separate O 0
founder O 0
chromosome O 0
containing O 0
a O 0
second O 0
, O 0
independently O 0
arising O 0
mutant O 0
allele O 0
. O 0

Overall O 0
, O 0
the O 0
establishment O 0
of O 0
a O 0
likely O 0
" O 0
hemochromatosis B-Disease 1
critical O 0
region O 0
" O 0
centromeric O 0
boundary O 0
and O 0
the O 0
identification O 0
of O 0
a O 0
linkage O 0
- O 0
disequilibrium O 0
zone O 0
both O 0
significantly O 0
contribute O 0
to O 0
a O 0
reduction O 0
in O 0
the O 0
amount O 0
of O 0
DNA O 0
required O 0
to O 0
be O 0
searched O 0
for O 0
novel O 0
coding O 0
sequences O 0
constituting O 0
the O 0
HFE B-Disease 1
defect I-Disease 1

Genomic O 0
structure O 0
of O 0
the O 0
EWS O 0
gene O 0
and O 0
its O 0
relationship O 0
to O 0
EWSR1 O 0
, O 0
a O 0
site O 0
of O 0
tumor B-Disease 0
- O 0
associated O 0
chromosome O 0
translocation O 0
. O 0

The O 0
EWS O 0
gene O 0
has O 0
been O 0
identified O 0
based O 0
on O 0
its O 0
location O 0
at O 0
the O 0
chromosome O 0
22 O 0
breakpoint O 0
of O 0
the O 0
t O 0
( O 0
11 O 0
; O 0
22 O 0
) O 0
( O 0
q24 O 0
; O 0
q12 O 0
) O 0
translocation O 0
that O 0
characterizes O 0
Ewing B-Disease 1
sarcoma I-Disease 1
and O 0
related O 0
neuroectodermal B-Disease 0
tumors I-Disease 0
. O 0

The O 0
EWS O 0
gene O 0
spans O 0
about O 0
40 O 0
kb O 0
of O 0
DNA O 0
and O 0
is O 0
encoded O 0
by O 0
17 O 0
exons O 0
. O 0

The O 0
nucleotide O 0
sequence O 0
of O 0
the O 0
exons O 0
is O 0
identical O 0
to O 0
that O 0
of O 0
the O 0
previously O 0
described O 0
cDNA O 0
. O 0

The O 0
first O 0
7 O 0
exons O 0
encode O 0
the O 0
N O 0
- O 0
terminal O 0
domain O 0
of O 0
EWS O 0
, O 0
which O 0
consists O 0
of O 0
a O 0
repeated O 0
degenerated O 0
polypeptide O 0
of O 0
7 O 0
to O 0
12 O 0
residues O 0
rich O 0
in O 0
tyrosine O 0
, O 0
serine O 0
, O 0
threonine O 0
, O 0
glycine O 0
, O 0
and O 0
glutamine O 0
. O 0

Exons O 0
11 O 0
, O 0
12 O 0
, O 0
and O 0
13 O 0
encode O 0
the O 0
putative O 0
RNA O 0
binding O 0
domain O 0
. O 0

The O 0
three O 0
glycine O 0
- O 0
and O 0
arginine O 0
- O 0
rich O 0
motifs O 0
of O 0
the O 0
gene O 0
are O 0
mainly O 0
encoded O 0
by O 0
exons O 0
8 O 0
- O 0
9 O 0
, O 0
14 O 0
, O 0
and O 0
16 O 0
. O 0

The O 0
DNA O 0
sequence O 0
in O 0
the O 0
5 O 0
region O 0
of O 0
the O 0
gene O 0
has O 0
features O 0
of O 0
a O 0
CpG O 0
- O 0
rich O 0
island O 0
and O 0
lacks O 0
canonical O 0
promoter O 0
elements O 0
, O 0
such O 0
as O 0
TATA O 0
and O 0
CCAAT O 0
consensus O 0
sequences O 0
. O 0

Positions O 0
of O 0
the O 0
chromosome O 0
22 O 0
breakpoints O 0
were O 0
determined O 0
for O 0
19 O 0
Ewing B-Disease 1
tumors I-Disease 1
. O 0

They O 0
were O 0
localized O 0
in O 0
introns O 0
7 O 0
or O 0
8 O 0
in O 0
18 O 0
cases O 0
and O 0
in O 0
intron O 0
10 O 0
in O 0
1 O 0
case O 0
. O 0
. O 0

Norrie B-Disease 1
disease I-Disease 1
gene O 0
: O 0
characterization O 0
of O 0
deletions O 0
and O 0
possible O 0
function O 0
. O 0

Positional O 0
cloning O 0
experiments O 0
have O 0
resulted O 0
recently O 0
in O 0
the O 0
isolation O 0
of O 0
a O 0
candidate O 0
gene O 0
for O 0
Norrie B-Disease 1
disease I-Disease 1
( O 0
pseudoglioma B-Disease 0
; O 0
NDP B-Disease 0
) O 0
, O 0
a O 0
severe O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
neurodevelopmental I-Disease 0
disorder I-Disease 0
. O 0

Here O 0
we O 0
report O 0
the O 0
isolation O 0
and O 0
analysis O 0
of O 0
human O 0
genomic O 0
DNA O 0
clones O 0
encompassing O 0
the O 0
NDP B-Disease 0
gene O 0
. O 0

The O 0
gene O 0
spans O 0
28 O 0
kb O 0
and O 0
consists O 0
of O 0
3 O 0
exons O 0
, O 0
the O 0
first O 0
of O 0
which O 0
is O 0
entirely O 0
contained O 0
within O 0
the O 0
5 O 0
untranslated O 0
region O 0
. O 0

Detailed O 0
analysis O 0
of O 0
genomic O 0
deletions O 0
in O 0
Norrie B-Disease 1
patients O 0
shows O 0
that O 0
they O 0
are O 0
heterogeneous O 0
, O 0
both O 0
in O 0
size O 0
and O 0
in O 0
position O 0
. O 0

By O 0
PCR O 0
analysis O 0
, O 0
we O 0
found O 0
that O 0
expression O 0
of O 0
the O 0
NDP B-Disease 0
gene O 0
was O 0
not O 0
confined O 0
to O 0
the O 0
eye O 0
or O 0
to O 0
the O 0
brain O 0
. O 0

An O 0
extensive O 0
DNA O 0
and O 0
protein O 0
sequence O 0
comparison O 0
between O 0
the O 0
human O 0
NDP B-Disease 0
gene O 0
and O 0
related O 0
genes O 0
from O 0
the O 0
database O 0
revealed O 0
homology O 0
with O 0
cysteine O 0
- O 0
rich O 0
protein O 0
- O 0
binding O 0
domains O 0
of O 0
immediate O 0
- O 0
- O 0
early O 0
genes O 0
implicated O 0
in O 0
the O 0
regulation O 0
of O 0
cell O 0
proliferation O 0
. O 0

We O 0
propose O 0
that O 0
NDP O 0
is O 0
a O 0
molecule O 0
related O 0
in O 0
function O 0
to O 0
these O 0
genes O 0
and O 0
may O 0
be O 0
involved O 0
in O 0
a O 0
pathway O 0
that O 0
regulates O 0
neural O 0
cell O 0
differentiation O 0
and O 0
proliferation O 0
. O 0
. O 0

The O 0
normal O 0
Huntington B-Disease 1
disease I-Disease 1
( O 0
HD B-Disease 1
) O 0
allele O 0
, O 0
or O 0
a O 0
closely O 0
linked O 0
gene O 0
, O 0
influences O 0
age O 0
at O 0
onset O 0
of O 0
HD B-Disease 1
. O 0

We O 0
evaluated O 0
the O 0
hypothesis O 0
that O 0
Huntington B-Disease 1
disease I-Disease 1
( O 0
HD B-Disease 1
) O 0
is O 0
influenced O 0
by O 0
the O 0
normal O 0
HD B-Disease 1
allele O 0
by O 0
comparing O 0
transmission O 0
patterns O 0
of O 0
genetically O 0
linked O 0
markers O 0
at O 0
the O 0
D4S10 O 0
locus O 0
in O 0
the O 0
normal O 0
parent O 0
against O 0
age O 0
at O 0
onset O 0
in O 0
the O 0
affected O 0
offspring O 0
. O 0

Analysis O 0
of O 0
information O 0
from O 0
21 O 0
sibships O 0
in O 0
14 O 0
kindreds O 0
showed O 0
a O 0
significant O 0
tendency O 0
for O 0
sibs O 0
who O 0
have O 0
similar O 0
onset O 0
ages O 0
to O 0
share O 0
the O 0
same O 0
D4S10 O 0
allele O 0
from O 0
the O 0
normal O 0
parent O 0
. O 0

Affected O 0
sibs O 0
who O 0
inherited O 0
different O 0
D4S10 O 0
alleles O 0
from O 0
the O 0
normal O 0
parent O 0
tended O 0
to O 0
have O 0
more O 0
variable O 0
ages O 0
at O 0
onset O 0
. O 0

These O 0
findings O 0
suggest O 0
that O 0
the O 0
expression O 0
of O 0
HD B-Disease 1
is O 0
modulated O 0
by O 0
the O 0
normal O 0
HD B-Disease 1
allele O 0
or O 0
by O 0
a O 0
closely O 0
linked O 0
locus O 0
. O 0
. O 0

Further O 0
investigation O 0
of O 0
the O 0
HEXA O 0
gene O 0
intron O 0
9 O 0
donor O 0
splice O 0
site O 0
mutation O 0
frequently O 0
found O 0
in O 0
non O 0
- O 0
Jewish O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
patients O 0
from O 0
the O 0
British O 0
Isles O 0
. O 0

In O 0
a O 0
previous O 0
study O 0
we O 0
found O 0
that O 0
a O 0
Tay B-Disease 1
- I-Disease 1
Sachs I-Disease 1
disease I-Disease 1
( O 0
TSD B-Disease 0
) O 0
causing O 0
mutation O 0
in O 0
the O 0
intron O 0
9 O 0
donor O 0
splice O 0
site O 0
of O 0
the O 0
HEXA O 0
gene O 0
occurs O 0
at O 0
high O 0
frequency O 0
in O 0
non O 0
- O 0
Jewish O 0
patients O 0
and O 0
carriers O 0
from O 0
the O 0
British O 0
Isles O 0
. O 0

It O 0
was O 0
found O 0
more O 0
frequently O 0
in O 0
subjects O 0
of O 0
Irish O 0
, O 0
Scottish O 0
, O 0
and O 0
Welsh O 0
origin O 0
compared O 0
with O 0
English O 0
origin O 0
( O 0
63 O 0
% O 0
and O 0
31 O 0
% O 0
respectively O 0
) O 0
. O 0

We O 0
have O 0
now O 0
tested O 0
, O 0
in O 0
a O 0
blind O 0
study O 0
, O 0
26 O 0
American O 0
TSD B-Disease 0
carriers O 0
and O 0
28 O 0
non O 0
- O 0
carriers O 0
who O 0
have O 0
British O 0
ancestry O 0
for O 0
the O 0
intron O 0
9 O 0
splice O 0
site O 0
mutation O 0
. O 0

Six O 0
of O 0
the O 0
carriers O 0
and O 0
none O 0
of O 0
the O 0
controls O 0
were O 0
positive O 0
for O 0
the O 0
mutation O 0
. O 0

All O 0
six O 0
had O 0
Irish O 0
ancestry O 0
, O 0
compared O 0
with O 0
nine O 0
of O 0
the O 0
20 O 0
other O 0
( O 0
intron O 0
9 O 0
mutation O 0
negative O 0
) O 0
TSD B-Disease 0
carriers O 0
( O 0
p O 0
< O 0
0 O 0
. O 0
05 O 0
) O 0
. O 0

These O 0
results O 0
confirm O 0
the O 0
previously O 0
found O 0
high O 0
frequency O 0
of O 0
the O 0
intron O 0
9 O 0
mutation O 0
in O 0
non O 0
- O 0
Jewish O 0
TSD B-Disease 0
families O 0
of O 0
British O 0
Isles O 0
, O 0
particularly O 0
Irish O 0
, O 0
origin O 0
, O 0
and O 0
reinforce O 0
the O 0
need O 0
to O 0
screen O 0
such O 0
families O 0
for O 0
this O 0
mutation O 0
. O 0

Molecular O 0
mechanisms O 0
of O 0
oncogenic O 0
mutations O 0
in O 0
tumors B-Disease 0
from O 0
patients O 0
with O 0
bilateral B-Disease 1
and I-Disease 1
unilateral I-Disease 1
retinoblastoma I-Disease 1
. O 0

The O 0
RB1 O 0
gene O 0
from O 0
12 O 0
human O 0
retinoblastoma B-Disease 1
tumors I-Disease 0
has O 0
been O 0
analyzed O 0
exon O 0
- O 0
by O 0
- O 0
exon O 0
with O 0
the O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphism O 0
technique O 0
. O 0

Mutations O 0
were O 0
found O 0
in O 0
all O 0
tumors B-Disease 0
, O 0
and O 0
one O 0
- O 0
third O 0
of O 0
the O 0
tumors B-Disease 0
had O 0
independent O 0
mutations O 0
in O 0
both O 0
alleles O 0
neither O 0
of O 0
which O 0
were O 0
found O 0
in O 0
the O 0
germ O 0
line O 0
, O 0
confirming O 0
their O 0
true O 0
sporadic O 0
nature O 0
. O 0

In O 0
the O 0
remaining O 0
two O 0
- O 0
thirds O 0
of O 0
the O 0
tumors B-Disease 0
only O 0
one O 0
mutation O 0
was O 0
found O 0
, O 0
consistent O 0
with O 0
the O 0
loss O 0
- O 0
of O 0
- O 0
heterozygosity O 0
theory O 0
of O 0
tumorigenesis O 0
. O 0

Point O 0
mutations O 0
, O 0
the O 0
majority O 0
of O 0
which O 0
were O 0
C O 0
- O 0
- O 0
> O 0
T O 0
transitions O 0
, O 0
were O 0
the O 0
most O 0
common O 0
abnormality O 0
and O 0
usually O 0
resulted O 0
in O 0
the O 0
conversion O 0
of O 0
an O 0
arginine O 0
codon O 0
to O 0
a O 0
stop O 0
codon O 0
. O 0

Small O 0
deletions O 0
were O 0
the O 0
second O 0
most O 0
common O 0
abnormality O 0
and O 0
most O 0
often O 0
created O 0
a O 0
downstream O 0
stop O 0
codon O 0
as O 0
the O 0
result O 0
of O 0
a O 0
reading O 0
frameshift O 0
. O 0

Deletions O 0
and O 0
point O 0
mutations O 0
also O 0
affected O 0
splice O 0
junctions O 0
. O 0

Direct O 0
repeats O 0
were O 0
present O 0
at O 0
the O 0
breakpoint O 0
junctions O 0
in O 0
the O 0
majority O 0
of O 0
deletions O 0
, O 0
supporting O 0
a O 0
slipped O 0
- O 0
mispairing O 0
mechanism O 0
. O 0

Point O 0
mutations O 0
generally O 0
produced O 0
DNA O 0
sequences O 0
which O 0
resulted O 0
in O 0
perfect O 0
homology O 0
with O 0
endogenous O 0
sequences O 0
which O 0
lay O 0
within O 0
14 O 0
bp O 0
. O 0
. O 0

PAX6 O 0
mutations O 0
in O 0
aniridia B-Disease 0
. O 0

Aniridia B-Disease 0
is O 0
a O 0
congenital B-Disease 1
malformation I-Disease 1
of I-Disease 1
the I-Disease 1
eye I-Disease 1
, O 0
chiefly O 0
characterised O 0
by O 0
iris B-Disease 0
hypoplasia I-Disease 0
, O 0
which O 0
can O 0
cause O 0
blindness B-Disease 1
. O 0

The O 0
PAX6 O 0
gene O 0
was O 0
isolated O 0
as O 0
a O 0
candidate O 0
aniridia B-Disease 0
gene O 0
by O 0
positional O 0
cloning O 0
from O 0
the O 0
smallest O 0
region O 0
of O 0
overlap O 0
of O 0
aniridia B-Disease 0
- O 0
associated O 0
deletions O 0
. O 0

Subsequently O 0
PAX6 O 0
intragenic O 0
mutations O 0
were O 0
demonstrated O 0
in O 0
Smalleye O 0
, O 0
a O 0
mouse O 0
mutant O 0
which O 0
is O 0
an O 0
animal O 0
model O 0
for O 0
aniridia B-Disease 0
, O 0
and O 0
six O 0
human O 0
aniridia B-Disease 0
patients O 0
. O 0

In O 0
this O 0
paper O 0
we O 0
describe O 0
four O 0
additional O 0
PAX6 O 0
point O 0
mutations O 0
in O 0
aniridia B-Disease 0
patients O 0
, O 0
both O 0
sporadic O 0
and O 0
familial O 0
. O 0

These O 0
mutations O 0
highlight O 0
regions O 0
of O 0
the O 0
gene O 0
which O 0
are O 0
essential O 0
for O 0
normal O 0
PAX6 O 0
function O 0
. O 0

In O 0
addition O 0
, O 0
the O 0
frequency O 0
at O 0
which O 0
we O 0
have O 0
found O 0
PAX6 O 0
mutations O 0
suggests O 0
that O 0
lesions O 0
in O 0
PAX6 O 0
will O 0
account O 0
for O 0
most O 0
cases O 0
of O 0
aniridia B-Disease 0
. O 0
. O 0

Detection O 0
of O 0
a O 0
novel O 0
arginine O 0
vasopressin O 0
defect O 0
by O 0
dideoxy O 0
fingerprinting O 0
. O 0

Autosomal B-Disease 1
dominant I-Disease 1
neurohypophyseal I-Disease 1
diabetes I-Disease 1
insipidus I-Disease 1
is O 0
a O 0
familial O 0
form O 0
of O 0
diabetes B-Disease 1
insipidus I-Disease 1
. O 0

This O 0
disorder O 0
is O 0
associated O 0
with O 0
variable O 0
levels O 0
of O 0
arginine O 0
vasopressin O 0
( O 0
AVP O 0
) O 0
and O 0
diabetes B-Disease 1
insipidus I-Disease 1
of O 0
varying O 0
severity O 0
, O 0
which O 0
responds O 0
to O 0
exogenous O 0
AVP O 0
. O 0

To O 0
determine O 0
the O 0
molecular O 0
basis O 0
of O 0
autosomal B-Disease 0
dominant I-Disease 0
neurohypophyseal I-Disease 0
diabetes I-Disease 1
insipidus I-Disease 1
, O 0
the O 0
AVP O 0
genes O 0
of O 0
members O 0
of O 0
a O 0
large O 0
kindred O 0
were O 0
analyzed O 0
. O 0

A O 0
new O 0
method O 0
, O 0
called O 0
dideoxy O 0
fingerprinting O 0
, O 0
was O 0
used O 0
to O 0
detect O 0
an O 0
AVP O 0
mutation O 0
that O 0
was O 0
characterized O 0
by O 0
DNA O 0
sequencing O 0
. O 0

The O 0
novel O 0
defect O 0
found O 0
changes O 0
the O 0
last O 0
codon O 0
of O 0
the O 0
AVP O 0
signal O 0
peptide O 0
from O 0
alanine O 0
to O 0
threonine O 0
, O 0
which O 0
should O 0
perturb O 0
cleavage O 0
of O 0
mature O 0
AVP O 0
from O 0
its O 0
precursor O 0
protein O 0
and O 0
inhibit O 0
its O 0
secretion O 0
or O 0
action O 0
. O 0
. O 0

Germinal O 0
mosaicism O 0
in O 0
a O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
family O 0
: O 0
implications O 0
for O 0
genetic O 0
counselling O 0
. O 0

In O 0
this O 0
study O 0
we O 0
describe O 0
a O 0
three O 0
- O 0
generation O 0
family O 0
in O 0
which O 0
two O 0
siblings O 0
were O 0
affected O 0
by O 0
Duchenne B-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
DMD B-Disease 0
) O 0
. O 0

Immunohistochemical O 0
analysis O 0
of O 0
muscle O 0
dystrophin O 0
and O 0
haplotype O 0
analysis O 0
of O 0
the O 0
DMD B-Disease 0
locus O 0
revealed O 0
that O 0
the O 0
X O 0
chromosome O 0
carrying O 0
the O 0
DMD B-Disease 0
gene O 0
was O 0
transmitted O 0
from O 0
the O 0
healthy O 0
maternal O 0
grandfather O 0
to O 0
his O 0
three O 0
daughters O 0
, O 0
including O 0
the O 0
probands O 0
mother O 0
. O 0

These O 0
findings O 0
indicate O 0
that O 0
the O 0
grandfather O 0
was O 0
a O 0
germinal O 0
mosaic O 0
for O 0
the O 0
DMD B-Disease 0
gene O 0
. O 0

The O 0
definition O 0
of O 0
the O 0
carrier O 0
status O 0
in O 0
two O 0
possible O 0
carriers O 0
led O 0
us O 0
to O 0
give O 0
accurate O 0
genetic O 0
counselling O 0
and O 0
to O 0
prevent O 0
the O 0
birth O 0
of O 0
an O 0
affected O 0
boy O 0
. O 0

The O 0
results O 0
of O 0
this O 0
study O 0
demonstrate O 0
the O 0
usefulness O 0
of O 0
haplotype O 0
analysis O 0
and O 0
immunohistochemical O 0
muscle O 0
dystrophin O 0
studies O 0
to O 0
detect O 0
hidden O 0
germinal O 0
mosaicism O 0
and O 0
to O 0
improve O 0
genetic O 0
counselling O 0
. O 0
. O 0

Genetic O 0
mapping O 0
of O 0
the O 0
breast B-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
syndrome I-Disease 0
to O 0
a O 0
small O 0
interval O 0
on O 0
chromosome O 0
17q12 O 0
- O 0
21 O 0
: O 0
exclusion O 0
of O 0
candidate O 0
genes O 0
EDH17B2 O 0
and O 0
RARA O 0
. O 0

A O 0
susceptibility O 0
gene O 0
for O 0
hereditary B-Disease 0
breast I-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
, O 0
BRCA1 O 0
, O 0
has O 0
been O 0
assigned O 0
by O 0
linkage O 0
analysis O 0
to O 0
chromosome O 0
17q21 O 0
. O 0

Candidate O 0
genes O 0
in O 0
this O 0
region O 0
include O 0
EDH17B2 O 0
, O 0
which O 0
encodes O 0
estradiol O 0
17 O 0
beta O 0
- O 0
hydroxysteroid O 0
dehydrogenase O 0
II O 0
( O 0
17 O 0
beta O 0
- O 0
HSD O 0
II O 0
) O 0
, O 0
and O 0
RARA O 0
, O 0
the O 0
gene O 0
for O 0
retinoic O 0
acid O 0
receptor O 0
alpha O 0
. O 0

We O 0
have O 0
typed O 0
22 O 0
breast B-Disease 0
and I-Disease 0
breast I-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
families O 0
with O 0
eight O 0
polymorphisms O 0
from O 0
the O 0
chromosome O 0
17q12 O 0
- O 0
21 O 0
region O 0
, O 0
including O 0
two O 0
in O 0
the O 0
EDH17B2 O 0
gene O 0
. O 0

Genetic O 0
recombination O 0
with O 0
the O 0
breast B-Disease 0
cancer I-Disease 1
trait O 0
excludes O 0
RARA O 0
from O 0
further O 0
consideration O 0
as O 0
a O 0
candidate O 0
gene O 0
for O 0
BRCA1 O 0
. O 0

Both O 0
BRCA1 O 0
and O 0
EDH17B2 O 0
map O 0
to O 0
a O 0
6 O 0
cM O 0
interval O 0
( O 0
between O 0
THRA1 O 0
and O 0
D17S579 O 0
) O 0
and O 0
no O 0
recombination O 0
was O 0
observed O 0
between O 0
the O 0
two O 0
genes O 0
. O 0

However O 0
, O 0
direct O 0
sequencing O 0
of O 0
overlapping O 0
PCR O 0
products O 0
containing O 0
the O 0
entire O 0
EDH17B2 O 0
gene O 0
in O 0
four O 0
unrelated O 0
affected O 0
women O 0
did O 0
not O 0
uncover O 0
any O 0
sequence O 0
variation O 0
, O 0
other O 0
than O 0
previously O 0
described O 0
polymorphisms O 0
. O 0

Mutations O 0
in O 0
the O 0
EDH17B2 O 0
gene O 0
, O 0
therefore O 0
do O 0
not O 0
appear O 0
to O 0
be O 0
responsible O 0
for O 0
the O 0
hereditary B-Disease 1
breast I-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
syndrome I-Disease 1
. O 0

Single O 0
meiotic O 0
crossovers O 0
in O 0
affected O 0
women O 0
suggest O 0
that O 0
BRCA1 O 0
is O 0
flanked O 0
by O 0
the O 0
loci O 0
RARA O 0
and O 0
D17S78 O 0
. O 0
. O 0

A O 0
missense O 0
mutation O 0
in O 0
the O 0
cholesteryl O 0
ester O 0
transfer O 0
protein O 0
gene O 0
with O 0
possible O 0
dominant O 0
effects O 0
on O 0
plasma O 0
high O 0
density O 0
lipoproteins O 0
. O 0

Plasma O 0
HDL O 0
are O 0
a O 0
negative O 0
risk O 0
factor O 0
for O 0
atherosclerosis B-Disease 0
. O 0

Cholesteryl O 0
ester O 0
transfer O 0
protein O 0
( O 0
CETP O 0
; O 0
476 O 0
amino O 0
acids O 0
) O 0
transfers O 0
cholesteryl O 0
ester O 0
from O 0
HDL O 0
to O 0
other O 0
lipoproteins O 0
. O 0

Subjects O 0
with O 0
homozygous O 0
CETP B-Disease 0
deficiency I-Disease 0
caused O 0
by O 0
a O 0
gene O 0
splicing O 0
defect O 0
have O 0
markedly O 0
elevated O 0
HDL O 0
; O 0
however O 0
, O 0
heterozygotes O 0
have O 0
only O 0
mild O 0
increases O 0
in O 0
HDL O 0
. O 0

We O 0
describe O 0
two O 0
probands O 0
with O 0
a O 0
CETP O 0
missense O 0
mutation O 0
( O 0
442 O 0
D O 0
G O 0
) O 0
. O 0

Although O 0
heterozygous O 0
, O 0
they O 0
have O 0
threefold O 0
increases O 0
in O 0
HDL O 0
concentration O 0
and O 0
markedly O 0
decreased O 0
plasma O 0
CETP O 0
mass O 0
and O 0
activity O 0
, O 0
suggesting O 0
that O 0
the O 0
mutation O 0
has O 0
dominant O 0
effects O 0
on O 0
CETP O 0
and O 0
HDL O 0
in O 0
vivo O 0
. O 0

Cellular O 0
expression O 0
of O 0
mutant O 0
cDNA O 0
results O 0
in O 0
secretion O 0
of O 0
only O 0
30 O 0
% O 0
of O 0
wild O 0
type O 0
CETP O 0
activity O 0
. O 0

Moreover O 0
, O 0
coexpression O 0
of O 0
wild O 0
type O 0
and O 0
mutant O 0
cDNAs O 0
leads O 0
to O 0
inhibition O 0
of O 0
wild O 0
type O 0
secretion O 0
and O 0
activity O 0
. O 0

The O 0
dominant O 0
effects O 0
of O 0
the O 0
CETP O 0
missense O 0
mutation O 0
during O 0
cellular O 0
expression O 0
probably O 0
explains O 0
why O 0
the O 0
probands O 0
have O 0
markedly O 0
increased O 0
HDL O 0
in O 0
the O 0
heterozygous O 0
state O 0
, O 0
and O 0
suggests O 0
that O 0
the O 0
active O 0
molecular O 0
species O 0
of O 0
CETP O 0
may O 0
be O 0
multimeric O 0
. O 0
. O 0

Familial B-Disease 1
Mediterranean I-Disease 1
fever I-Disease 1
in O 0
the O 0
colchicine O 0
era O 0
: O 0
the O 0
fate O 0
of O 0
one O 0
family O 0
. O 0

In O 0
order O 0
to O 0
demonstrate O 0
the O 0
effect O 0
of O 0
prophylactic O 0
colchicine O 0
treatment O 0
on O 0
the O 0
natural O 0
history O 0
of O 0
familial B-Disease 0
Mediterranean I-Disease 0
fever I-Disease 0
( O 0
FMF B-Disease 0
) O 0
, O 0
a O 0
family O 0
is O 0
presented O 0
with O 0
6 O 0
out O 0
of O 0
9 O 0
siblings O 0
affected O 0
by O 0
FMF B-Disease 0
. O 0

Each O 0
patient O 0
represents O 0
a O 0
different O 0
stage O 0
of O 0
the O 0
amyloidotic B-Disease 1
kidney I-Disease 1
disease I-Disease 1
of O 0
FMF B-Disease 0
and O 0
the O 0
effect O 0
of O 0
continuous O 0
colchicine O 0
treatment O 0
on O 0
its O 0
course O 0
. O 0

Considered O 0
together O 0
, O 0
the O 0
members O 0
of O 0
this O 0
family O 0
present O 0
an O 0
almost O 0
complete O 0
clinical O 0
, O 0
genetic O 0
, O 0
and O 0
behavioral O 0
picture O 0
of O 0
the O 0
disease O 0
. O 0
. O 0

Detection O 0
of O 0
a O 0
new O 0
submicroscopic O 0
Norrie B-Disease 1
disease I-Disease 1
deletion O 0
interval O 0
with O 0
a O 0
novel O 0
DNA O 0
probe O 0
isolated O 0
by O 0
differential O 0
Alu O 0
PCR O 0
fingerprint O 0
cloning O 0
. O 0

Differential O 0
Alu O 0
PCR O 0
fingerprint O 0
cloning O 0
was O 0
used O 0
to O 0
isolate O 0
a O 0
DNA O 0
probe O 0
from O 0
the O 0
Xp11 O 0
. O 0

4 O 0
- O 0
- O 0
> O 0
p11 O 0
. O 0

21 O 0
region O 0
of O 0
the O 0
human O 0
X O 0
chromosome O 0
. O 0

This O 0
novel O 0
sequence O 0
, O 0
cpXr318 O 0
( O 0
DXS742 O 0
) O 0
, O 0
detects O 0
a O 0
new O 0
submicroscopic O 0
deletion O 0
interval O 0
at O 0
the O 0
Norrie B-Disease 1
disease I-Disease 1
locus O 0
( O 0
NDP O 0
) O 0
. O 0

Combining O 0
our O 0
data O 0
with O 0
the O 0
consensus O 0
genetic O 0
map O 0
of O 0
the O 0
proximal O 0
short O 0
arm O 0
of O 0
the O 0
X O 0
chromosome O 0
, O 0
we O 0
propose O 0
the O 0
physical O 0
order O 0
Xcen O 0
- O 0
DXS14 O 0
- O 0
DXS255 O 0
- O 0
( O 0
DXS426 O 0
, O 0
TIMP O 0
) O 0
- O 0
( O 0
DXS742 O 0
- O 0
( O 0
[ O 0
MAOB O 0
- O 0
MAOA O 0
- O 0
DXS7 O 0
] O 0
, O 0
NDP O 0
) O 0
- O 0
DXS77 O 0
- O 0
DXS228 O 0
) O 0
- O 0
DXS209 O 0
- O 0
DXS148 O 0
- O 0
DXS196 O 0
- O 0
+ O 0
+ O 0
+ O 0
Xpter O 0
. O 0

The O 0
cpXr318 O 0
probe O 0
and O 0
a O 0
subclone O 0
from O 0
a O 0
cosmid O 0
corresponding O 0
to O 0
the O 0
DXS7 O 0
locus O 0
were O 0
converted O 0
into O 0
sequence O 0
- O 0
tagged O 0
sites O 0
. O 0

Finally O 0
, O 0
DXS742 O 0
, O 0
DSX7 O 0
, O 0
DXS77 O 0
, O 0
and O 0
MAOA O 0
were O 0
integrated O 0
into O 0
a O 0
physical O 0
map O 0
spanning O 0
the O 0
Norrie B-Disease 1
disease I-Disease 1
locus O 0

Putative O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
adrenoleukodystrophy I-Disease 1
gene O 0
shares O 0
unexpected O 0
homology O 0
with O 0
ABC O 0
transporters O 0
. O 0

Adrenoleukodystrophy B-Disease 0
( O 0
ALD B-Disease 0
) O 0
is O 0
an O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
disease I-Disease 0
affecting O 0
1 O 0
/ O 0
20 O 0
, O 0
000 O 0
males O 0
either O 0
as O 0
cerebral B-Disease 1
ALD I-Disease 1
in O 0
childhood O 0
or O 0
as O 0
adrenomyeloneuropathy B-Disease 1
( O 0
AMN B-Disease 0
) O 0
in O 0
adults O 0
. O 0

Childhood O 0
ALD B-Disease 0
is O 0
the O 0
more O 0
severe O 0
form O 0
, O 0
with O 0
onset O 0
of O 0
neurological O 0
symptoms O 0
between O 0
5 O 0
- O 0
12 O 0
years O 0
of O 0
age O 0
. O 0

Central B-Disease 1
nervous I-Disease 1
system I-Disease 1
demyelination I-Disease 1
progresses O 0
rapidly O 0
and O 0
death O 0
occurs O 0
within O 0
a O 0
few O 0
years O 0
. O 0

AMN B-Disease 0
is O 0
a O 0
milder O 0
form O 0
of O 0
the O 0
disease O 0
with O 0
onset O 0
at O 0
15 O 0
- O 0
30 O 0
years O 0
of O 0
age O 0
and O 0
a O 0
more O 0
progressive O 0
course O 0
. O 0

Adrenal B-Disease 1
insufficiency I-Disease 1
( O 0
Addisons B-Disease 1
disease I-Disease 1
) O 0
may O 0
remain O 0
the O 0
only O 0
clinical O 0
manifestation O 0
of O 0
ALD B-Disease 0
. O 0

The O 0
principal O 0
biochemical O 0
abnormality O 0
of O 0
ALD B-Disease 0
is O 0
the O 0
accumulation O 0
of O 0
very O 0
- O 0
long O 0
- O 0
chain O 0
fatty O 0
acids O 0
( O 0
VLCFA O 0
) O 0
because O 0
of O 0
impaired O 0
beta O 0
- O 0
oxidation O 0
in O 0
peroxisomes O 0
. O 0

The O 0
normal O 0
oxidation O 0
of O 0
VLCFA O 0
- O 0
CoA O 0
in O 0
patients O 0
fibroblasts O 0
suggested O 0
that O 0
the O 0
gene O 0
coding O 0
for O 0
the O 0
VLCFA O 0
- O 0
CoA O 0
synthetase O 0
could O 0
be O 0
a O 0
candidate O 0
gene O 0
for O 0
ALD B-Disease 0
. O 0

Here O 0
we O 0
use O 0
positional O 0
cloning O 0
to O 0
identify O 0
a O 0
gene O 0
partially O 0
deleted O 0
in O 0
6 O 0
of O 0
85 O 0
independent O 0
patients O 0
with O 0
ALD B-Disease 0
. O 0

In O 0
familial O 0
cases O 0
, O 0
the O 0
deletions O 0
segregated O 0
with O 0
the O 0
disease O 0
. O 0

An O 0
identical O 0
deletion O 0
was O 0
detected O 0
in O 0
two O 0
brothers O 0
presenting O 0
with O 0
different O 0
clinical O 0
ALD B-Disease 0
phenotypes O 0
. O 0

Candidate O 0
exons O 0
were O 0
identified O 0
by O 0
computer O 0
analysis O 0
of O 0
genomic O 0
sequences O 0
and O 0
used O 0
to O 0
isolate O 0
complementary O 0
DNAs O 0
by O 0
exon O 0
connection O 0
and O 0
screening O 0
of O 0
cDNA O 0
libraries O 0
. O 0

The O 0
deduced O 0
protein O 0
sequence O 0
shows O 0
significant O 0
sequence O 0
identity O 0
to O 0
a O 0
peroxisomal O 0
membrane O 0
protein O 0
of O 0
M O 0
( O 0
r O 0
) O 0
70K O 0
that O 0
is O 0
involved O 0
in O 0
peroxisome O 0
biogenesis O 0
and O 0
belongs O 0
to O 0
the O 0
ATP O 0
- O 0
binding O 0
cassette O 0
superfamily O 0
of O 0
transporters O 0
. O 0
. O 0

Targeted O 0
modification O 0
of O 0
the O 0
apolipoprotein O 0
B O 0
gene O 0
results O 0
in O 0
hypobetalipoproteinemia B-Disease 1
and O 0
developmental B-Disease 1
abnormalities I-Disease 1
in O 0
mice O 0
. O 0

Familial B-Disease 1
hypobetalipoproteinemia I-Disease 1
is O 0
an O 0
autosomal B-Disease 0
codominant I-Disease 0
disorder I-Disease 0
resulting O 0
in O 0
a O 0
dramatic O 0
reduction O 0
in O 0
plasma O 0
concentrations O 0
of O 0
apolipoprotein O 0
( O 0
apo O 0
) O 0
B O 0
, O 0
cholesterol O 0
, O 0
and O 0
beta O 0
- O 0
migrating O 0
lipoproteins O 0
. O 0

A O 0
benefit O 0
of O 0
hypobetalipoproteinemia B-Disease 1
is O 0
that O 0
mildly O 0
affected O 0
individuals O 0
may O 0
be O 0
protected O 0
from O 0
coronary B-Disease 0
vascular I-Disease 0
disease I-Disease 0
. O 0

We O 0
have O 0
used O 0
gene O 0
targeting O 0
to O 0
generate O 0
mice O 0
with O 0
a O 0
modified O 0
Apob O 0
allele O 0
. O 0

Mice O 0
containing O 0
this O 0
allele O 0
display O 0
all O 0
of O 0
the O 0
hallmarks O 0
of O 0
human O 0
hypobetalipoproteinemia B-Disease 1
they O 0
produce O 0
a O 0
truncated O 0
apoB O 0
protein O 0
, O 0
apoB70 O 0
, O 0
and O 0
have O 0
markedly O 0
decreased O 0
plasma O 0
concentrations O 0
of O 0
apoB O 0
, O 0
beta O 0
- O 0
lipoproteins O 0
, O 0
and O 0
total O 0
cholesterol O 0
. O 0

In O 0
addition O 0
, O 0
the O 0
mice O 0
manifest O 0
several O 0
characteristics O 0
that O 0
are O 0
occasionally O 0
observed O 0
in O 0
human O 0
hypobetalipoproteinemia B-Disease 1
, O 0
including O 0
reduced O 0
plasma O 0
triglyceride O 0
concentrations O 0
, O 0
fasting O 0
chylomicronemia B-Disease 1
, O 0
and O 0
reduced O 0
high O 0
density O 0
lipoprotein O 0
cholesterol O 0
. O 0

An O 0
unexpected O 0
finding O 0
is O 0
that O 0
the O 0
modified O 0
Apob O 0
allele O 0
is O 0
strongly O 0
associated O 0
with O 0
exencephalus B-Disease 1
and O 0
hydrocephalus B-Disease 1
. O 0

These O 0
mice O 0
should O 0
help O 0
increase O 0
our O 0
understanding O 0
of O 0
hypobetalipoproteinemia B-Disease 1
, O 0
atherogenesis B-Disease 1
, O 0
and O 0
the O 0
etiology O 0
of O 0
exencephalus B-Disease 1
and O 0
hydrocephalus B-Disease 1
. O 0
. O 0

A O 0
novel O 0
disease O 0
with O 0
deficiency B-Disease 0
of I-Disease 0
mitochondrial I-Disease 0
very I-Disease 0
- I-Disease 0
long I-Disease 0
- I-Disease 0
chain I-Disease 0
acyl I-Disease 0
- I-Disease 0
CoA I-Disease 0
dehydrogenase I-Disease 0
. O 0

Palmitoyl O 0
- O 0
CoA O 0
dehydrogenase O 0
activity O 0
in O 0
skin O 0
fibroblasts O 0
from O 0
seven O 0
patients O 0
with O 0
unidentified O 0
defects O 0
of O 0
fatty O 0
acid O 0
oxidation O 0
was O 0
measured O 0
in O 0
the O 0
presence O 0
and O 0
absence O 0
of O 0
antibodies O 0
against O 0
medium O 0
- O 0
chain O 0
, O 0
long O 0
- O 0
chain O 0
, O 0
and O 0
very O 0
- O 0
long O 0
- O 0
chain O 0
acyl O 0
- O 0
CoA O 0
dehydrogenases O 0
( O 0
VLCAD O 0
) O 0
. O 0

Two O 0
of O 0
the O 0
patients O 0
, O 0
4 O 0
- O 0
5 O 0
month O 0
old O 0
boys O 0
, O 0
were O 0
found O 0
to O 0
have O 0
a O 0
novel O 0
disease O 0
, O 0
VLCAD B-Disease 0
deficiency I-Disease 0
, O 0
as O 0
judged O 0
from O 0
the O 0
results O 0
of O 0
very O 0
low O 0
palmitoyl O 0
- O 0
CoA O 0
dehydrogenase O 0
activity O 0
and O 0
the O 0
lack O 0
of O 0
immunoreactivity O 0
toward O 0
antibody O 0
raised O 0
to O 0
purified O 0
VLCAD O 0
. O 0
. O 0

Molecular O 0
characterization O 0
of O 0
glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
) I-Disease 0
deficiency I-Disease 0
in O 0
patients O 0
of O 0
Chinese O 0
descent O 0
and O 0
identification O 0
of O 0
new O 0
base O 0
substitutions O 0
in O 0
the O 0
human O 0
G6PD O 0
gene O 0
. O 0

The O 0
underlying O 0
DNA O 0
changes O 0
associated O 0
with O 0
glucose B-Disease 0
- I-Disease 0
6 I-Disease 0
- I-Disease 0
phosphate I-Disease 0
dehydrogenase I-Disease 0
( I-Disease 0
G6PD I-Disease 0
) I-Disease 0
- I-Disease 0
deficient I-Disease 0
Asians O 0
have O 0
not O 0
been O 0
extensively O 0
investigated O 0
. O 0

To O 0
fill O 0
this O 0
gap O 0
, O 0
we O 0
sequenced O 0
the O 0
G6PD O 0
gene O 0
of O 0
43 O 0
G6PD B-Disease 1
- I-Disease 1
deficient I-Disease 1
Chinese O 0
whose O 0
G6PD O 0
was O 0
well O 0
characterized O 0
biochemically O 0
. O 0

DNA O 0
samples O 0
were O 0
obtained O 0
from O 0
peripheral O 0
blood O 0
of O 0
these O 0
individuals O 0
for O 0
sequencing O 0
using O 0
a O 0
direct O 0
polymerase O 0
chain O 0
reaction O 0
( O 0
PCR O 0
) O 0
sequencing O 0
procedure O 0
. O 0

From O 0
these O 0
43 O 0
samples O 0
, O 0
we O 0
have O 0
identified O 0
five O 0
different O 0
types O 0
of O 0
nucleotide O 0
substitutions O 0
in O 0
the O 0
G6PD O 0
gene O 0
at O 0
cDNA O 0
1388 O 0
from O 0
G O 0
to O 0
A O 0
( O 0
Arg O 0
to O 0
His O 0
) O 0
; O 0
at O 0
cDNA O 0
1376 O 0
from O 0
G O 0
to O 0
T O 0
( O 0
Arg O 0
to O 0
Leu O 0
) O 0
; O 0
at O 0
cDNA O 0
1024 O 0
from O 0
C O 0
to O 0
T O 0
( O 0
Leu O 0
to O 0
Phe O 0
) O 0
; O 0
at O 0
cDNA O 0
392 O 0
from O 0
G O 0
to O 0
T O 0
( O 0
Gly O 0
to O 0
Val O 0
) O 0
; O 0
at O 0
cDNA O 0
95 O 0
from O 0
A O 0
to O 0
G O 0
( O 0
His O 0
to O 0
Arg O 0
) O 0
. O 0

These O 0
five O 0
nucleotide O 0
substitutions O 0
account O 0
for O 0
over O 0
83 O 0
% O 0
of O 0
our O 0
43 O 0
G6PD B-Disease 1
- I-Disease 1
deficient I-Disease 1
samples O 0
and O 0
these O 0
substitutions O 0
have O 0
not O 0
been O 0
reported O 0
in O 0
non O 0
- O 0
Asians O 0
. O 0

The O 0
substitutions O 0
found O 0
at O 0
cDNA O 0
392 O 0
and O 0
cDNA O 0
1024 O 0
are O 0
new O 0
findings O 0
. O 0

The O 0
substitutions O 0
at O 0
cDNA O 0
1376 O 0
and O 0
1388 O 0
account O 0
for O 0
over O 0
50 O 0
% O 0
of O 0
the O 0
43 O 0
samples O 0
examined O 0
indicating O 0
a O 0
high O 0
prevalence O 0
of O 0
these O 0
two O 0
alleles O 0
among O 0
G6PD B-Disease 1
- I-Disease 1
deficient I-Disease 1
Chinese O 0
. O 0

Our O 0
findings O 0
add O 0
support O 0
to O 0
the O 0
notion O 0
that O 0
diverse O 0
point O 0
mutations O 0
may O 0
account O 0
largely O 0
for O 0
much O 0
of O 0
the O 0
phenotypic O 0
heterogeneity O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
. O 0
. O 0

Identification O 0
of O 0
mutations O 0
in O 0
Danish O 0
choroideremia B-Disease 1
families O 0
. O 0

We O 0
have O 0
searched O 0
for O 0
mutations O 0
in O 0
the O 0
choroideremia B-Disease 1
gene O 0
( O 0
CHM B-Disease 1
) O 0
in O 0
patients O 0
from O 0
12 O 0
Danish O 0
families O 0
in O 0
which O 0
CHM B-Disease 1
is O 0
segregating O 0
. O 0

Employing O 0
polymerase O 0
chain O 0
reaction O 0
( O 0
PCR O 0
) O 0
, O 0
single O 0
strand O 0
conformation O 0
polymorphism O 0
( O 0
SSCP O 0
) O 0
analysis O 0
, O 0
and O 0
direct O 0
DNA O 0
sequencing O 0
, O 0
different O 0
mutations O 0
have O 0
been O 0
identified O 0
in O 0
6 O 0
patients O 0
. O 0

All O 0
the O 0
mutations O 0
will O 0
interfere O 0
with O 0
the O 0
correct O 0
translation O 0
of O 0
the O 0
mRNA O 0
predicting O 0
a O 0
truncated O 0
protein O 0
or O 0
no O 0
gene O 0
product O 0
at O 0
all O 0
. O 0
. O 0

Structure O 0
and O 0
genomic O 0
sequence O 0
of O 0
the O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
kinase O 0
) O 0
gene O 0
. O 0

The O 0
mutation O 0
causing O 0
myotonic B-Disease 1
dystrophy I-Disease 1
( O 0
DM B-Disease 0
) O 0
has O 0
recently O 0
been O 0
identified O 0
as O 0
an O 0
unstable O 0
CTG O 0
trinucleotide O 0
repeat O 0
located O 0
in O 0
the O 0
3 O 0
untranslated O 0
region O 0
of O 0
a O 0
gene O 0
encoding O 0
for O 0
a O 0
protein O 0
with O 0
putative O 0
serine O 0
- O 0
threonine O 0
protein O 0
kinase O 0
activity O 0
. O 0

In O 0
this O 0
report O 0
we O 0
present O 0
the O 0
genomic O 0
sequences O 0
of O 0
the O 0
human O 0
and O 0
murine O 0
DM B-Disease 0
kinase O 0
gene O 0
. O 0

A O 0
comparison O 0
of O 0
these O 0
sequences O 0
with O 0
each O 0
other O 0
and O 0
with O 0
known O 0
cDNA O 0
sequences O 0
from O 0
both O 0
species O 0
, O 0
led O 0
us O 0
to O 0
predict O 0
a O 0
translation O 0
initiation O 0
codon O 0
, O 0
as O 0
well O 0
as O 0
determine O 0
the O 0
organization O 0
of O 0
the O 0
DM B-Disease 0
kinase O 0
gene O 0
. O 0

Several O 0
polymorphisms O 0
within O 0
the O 0
human O 0
DM B-Disease 0
kinase O 0
gene O 0
have O 0
been O 0
identified O 0
, O 0
and O 0
PCR O 0
assays O 0
to O 0
detect O 0
two O 0
of O 0
these O 0
are O 0
described O 0
. O 0

The O 0
complete O 0
sequence O 0
and O 0
characterization O 0
of O 0
the O 0
structure O 0
of O 0
the O 0
DM B-Disease 0
kinase O 0
gene O 0
, O 0
as O 0
well O 0
as O 0
the O 0
identification O 0
of O 0
novel O 0
polymorphisms O 0
within O 0
the O 0
gene O 0
, O 0
represent O 0
an O 0
important O 0
step O 0
in O 0
a O 0
further O 0
understanding O 0
of O 0
the O 0
genetics O 0
of O 0
myotonic B-Disease 1
dystrophy I-Disease 1
and O 0
the O 0
molecular O 0
biology O 0
of O 0
the O 0
gene O 0
. O 0
. O 0

Autosomal O 0
recessive O 0
transmission O 0
of O 0
hemophilia B-Disease 1
A I-Disease 0
due O 0
to O 0
a O 0
von B-Disease 1
Willebrand I-Disease 1
factor O 0
mutation O 0
. O 0

The O 0
differential O 0
diagnosis O 0
of O 0
the O 0
genetic B-Disease 0
bleeding I-Disease 0
disorders I-Disease 0
, O 0
hemophilia B-Disease 1
A I-Disease 0
and O 0
von B-Disease 1
Willebrand I-Disease 1
disease I-Disease 1
, O 0
is O 0
occasionally O 0
confounded O 0
by O 0
the O 0
close O 0
molecular O 0
relationship O 0
of O 0
coagulation O 0
factor O 0
VIII O 0
and O 0
von B-Disease 1
Willebrand I-Disease 1
factor O 0
( O 0
vWF O 0
) O 0
. O 0

This O 0
report O 0
describes O 0
the O 0
autosomal O 0
inheritance O 0
of O 0
a O 0
hemophilia B-Disease 1
A I-Disease 0
phenotype O 0
due O 0
to O 0
a O 0
mutation O 0
of O 0
vWF O 0
that O 0
results O 0
in O 0
defective O 0
factor O 0
VIII O 0
binding O 0
. O 0

The O 0
proband O 0
was O 0
a O 0
female O 0
patient O 0
with O 0
low O 0
levels O 0
of O 0
factor O 0
VIII O 0
activity O 0
. O 0

Polymerase O 0
chain O 0
reaction O 0
( O 0
PCR O 0
) O 0
amplification O 0
and O 0
DNA O 0
sequencing O 0
were O 0
employed O 0
to O 0
examine O 0
exons O 0
encoding O 0
the O 0
putative O 0
factor O 0
VIII O 0
binding O 0
domain O 0
of O 0
vWF O 0
. O 0

The O 0
patient O 0
was O 0
found O 0
to O 0
be O 0
homozygous O 0
for O 0
a O 0
single O 0
point O 0
mutation O 0
causing O 0
a O 0
Thr O 0
- O 0
- O 0
> O 0
Met O 0
substitution O 0
at O 0
amino O 0
acid O 0
position O 0
28 O 0
in O 0
the O 0
mature O 0
vWF O 0
subunit O 0
. O 0

The O 0
phenotypic O 0
expression O 0
of O 0
the O 0
mutation O 0
was O 0
determined O 0
to O 0
be O 0
recessive O 0
because O 0
heterozygous O 0
family O 0
members O 0
were O 0
clinically O 0
unaffected O 0
. O 0

Recombinant O 0
vWF O 0
containing O 0
the O 0
observed O 0
amino O 0
acid O 0
substitution O 0
was O 0
expressed O 0
in O 0
COS O 0
- O 0
1 O 0
cells O 0
. O 0

The O 0
mutant O 0
vWF O 0
was O 0
processed O 0
and O 0
secreted O 0
normally O 0
, O 0
and O 0
was O 0
functionally O 0
equivalent O 0
to O 0
wild O 0
- O 0
type O 0
vWF O 0
in O 0
its O 0
ability O 0
to O 0
bind O 0
to O 0
platelets O 0
. O 0

However O 0
, O 0
the O 0
mutant O 0
failed O 0
to O 0
bind O 0
factor O 0
VIII O 0
, O 0
demonstrating O 0
that O 0
the O 0
mutation O 0
was O 0
functionally O 0
related O 0
to O 0
the O 0
observed O 0
hemophilia B-Disease 1
phenotype O 0
. O 0

The O 0
family O 0
we O 0
describe O 0
demonstrates O 0
the O 0
recessive O 0
inheritance O 0
of O 0
a O 0
recently O 0
recognized O 0
class O 0
of O 0
genetic O 0
bleeding O 0
disorders O 0
, O 0
we O 0
call O 0
" O 0
autosomal O 0
hemophilia B-Disease 1
. O 0

" O 0
We O 0
conclude O 0
that O 0
vWF O 0
mutation O 0
may O 0
be O 0
an O 0
under O 0
recognized O 0
cause O 0
of O 0
hemophilia B-Disease 1
, O 0
especially O 0
in O 0
cases O 0
where O 0
the O 0
inheritance O 0
pattern O 0
is O 0
not O 0
consistent O 0
with O 0
X O 0
- O 0
linked O 0
transmission O 0
. O 0

Somatic O 0
von B-Disease 0
Hippel I-Disease 0
- I-Disease 0
Lindau I-Disease 0
mutation O 0
in O 0
clear O 0
cell O 0
papillary B-Disease 1
cystadenoma I-Disease 1
of I-Disease 1
the I-Disease 1
epididymis I-Disease 1
. O 0

Papillary B-Disease 0
cystadenoma I-Disease 0
of I-Disease 0
the I-Disease 0
epididymis I-Disease 0
is O 0
an O 0
uncommon O 0
benign O 0
lesion O 0
that O 0
may O 0
occur O 0
sporadically O 0
or O 0
as O 0
a O 0
manifestation O 0
of O 0
von B-Disease 0
Hippel I-Disease 0
- I-Disease 0
Lindau I-Disease 0
( I-Disease 0
VHL I-Disease 1
) I-Disease 0
disease I-Disease 0
. O 0

Neither O 0
immunohistochemical O 0
studies O 0
nor O 0
molecular O 0
genetic O 0
analyses O 0
of O 0
the O 0
VHL B-Disease 1
gene O 0
have O 0
been O 0
reported O 0
previously O 0
for O 0
this O 0
lesion O 0
. O 0

The O 0
authors O 0
describe O 0
two O 0
cases O 0
of O 0
clear O 0
cell O 0
papillary B-Disease 1
cystadenoma I-Disease 1
of I-Disease 1
the I-Disease 1
epididymis I-Disease 1
, O 0
both O 0
of O 0
which O 0
were O 0
initially O 0
confused O 0
with O 0
metastatic B-Disease 0
renal I-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
. O 0

Both O 0
lesions O 0
showed O 0
positive O 0
immunohistochemical O 0
staining O 0
for O 0
low O 0
and O 0
intermediate O 0
molecular O 0
weight O 0
keratins O 0
( O 0
Cam O 0
5 O 0
. O 0
2 O 0
and O 0
AE1 O 0
/ O 0
AE3 O 0
) O 0
, O 0
EMA O 0
, O 0
vimentin O 0
, O 0
alpha O 0
1 O 0
- O 0
antitrypsin O 0
, O 0
and O 0
alpha O 0
1 O 0
- O 0
antichymotrypsin O 0
. O 0

Each O 0
was O 0
negative O 0
for O 0
CEA O 0
. O 0

Because O 0
clear O 0
cell O 0
papillary B-Disease 0
cystadenoma I-Disease 0
is O 0
similar O 0
to O 0
renal B-Disease 0
cell I-Disease 0
carcinoma I-Disease 0
histologically O 0
, O 0
and O 0
because O 0
both O 0
occur O 0
as O 0
components O 0
of O 0
the O 0
von B-Disease 0
Hippel I-Disease 0
- I-Disease 0
Lindau I-Disease 0
disease I-Disease 0
complex O 0
, O 0
the O 0
authors O 0
analyzed O 0
both O 0
cases O 0
for O 0
the O 0
presence O 0
of O 0
mutations O 0
in O 0
the O 0
VHL B-Disease 1
gene O 0
. O 0

A O 0
somatic O 0
VHL B-Disease 1
gene O 0
mutation O 0
was O 0
detected O 0
in O 0
one O 0
of O 0
the O 0
two O 0
tumors B-Disease 0
by O 0
polymerase O 0
chain O 0
reaction O 0
followed O 0
by O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphism O 0
analysis O 0
. O 0

Direct O 0
sequencing O 0
revealed O 0
a O 0
cytosine O 0
to O 0
thymine O 0
transition O 0
at O 0
nucleotide O 0
694 O 0
, O 0
resulting O 0
in O 0
the O 0
replacement O 0
of O 0
an O 0
arginine O 0
with O 0
a O 0
stop O 0
codon O 0
after O 0
the O 0
sixth O 0
amino O 0
acid O 0
of O 0
exon O 0
3 O 0
. O 0

As O 0
the O 0
VHL B-Disease 1
gene O 0
is O 0
believed O 0
to O 0
function O 0
as O 0
a O 0
tumor B-Disease 0
suppressor O 0
gene O 0
, O 0
VHL B-Disease 1
gene O 0
mutations O 0
may O 0
play O 0
a O 0
role O 0
in O 0
the O 0
initiation O 0
of O 0
tumorigenesis O 0
in O 0
sporadic O 0
cystadenomas B-Disease 0
of I-Disease 0
the I-Disease 0
epididymis I-Disease 0
. O 0

Identification O 0
of O 0
WASP O 0
mutations O 0
in O 0
patients O 0
with O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
and O 0
isolated B-Disease 0
thrombocytopenia I-Disease 0
reveals O 0
allelic O 0
heterogeneity O 0
at O 0
the O 0
WAS B-Disease 0
locus O 0
. O 0

Mutation O 0
in O 0
the O 0
gene O 0
encoding O 0
the O 0
recently O 0
isolated O 0
WASP O 0
protein O 0
has O 0
now O 0
been O 0
identified O 0
as O 0
the O 0
genetic B-Disease 1
defect I-Disease 1
responsible O 0
for O 0
the O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
Wiskott I-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
( O 0
WAS B-Disease 0
) O 0
, O 0
a O 0
primary O 0
immunodeficiency B-Disease 0
disease I-Disease 0
associated O 0
with O 0
extensive O 0
phenotypic O 0
variability O 0
. O 0

To O 0
elucidate O 0
the O 0
range O 0
of O 0
WASP O 0
mutations O 0
responsible O 0
for O 0
WAS B-Disease 0
, O 0
we O 0
used O 0
PCR O 0
- O 0
SSCP O 0
analysis O 0
to O 0
screen O 0
for O 0
WASP O 0
gene O 0
mutation O 0
in O 0
19 O 0
unrelated O 0
boys O 0
with O 0
the O 0
diagnosis O 0
of O 0
classical O 0
or O 0
attenuated O 0
WAS B-Disease 0
or O 0
isolated B-Disease 0
thrombocytopenia I-Disease 0
. O 0

All O 0
19 O 0
patients O 0
had O 0
WASP O 0
mutations O 0
, O 0
each O 0
of O 0
which O 0
localized O 0
to O 0
the O 0
initial O 0
three O 0
or O 0
terminal O 0
three O 0
exons O 0
of O 0
the O 0
gene O 0
, O 0
and O 0
the O 0
majority O 0
of O 0
which O 0
were O 0
unique O 0
in O 0
each O 0
case O 0
. O 0

However O 0
, O 0
a O 0
missense O 0
mutation O 0
which O 0
results O 0
in O 0
substitution O 0
of O 0
the O 0
arginine O 0
at O 0
WAS B-Disease 0
codon O 0
86 O 0
was O 0
identified O 0
in O 0
three O 0
boys O 0
with O 0
severe O 0
WAS B-Disease 0
as O 0
well O 0
as O 0
in O 0
one O 0
boy O 0
presenting O 0
with O 0
thrombocytopenia B-Disease 0
alone O 0
. O 0

While O 0
the O 0
three O 0
mutations O 0
found O 0
in O 0
the O 0
isolated B-Disease 0
thrombocytopenia I-Disease 0
patients O 0
leave O 0
the O 0
reading O 0
frame O 0
intact O 0
, O 0
about O 0
one O 0
- O 0
half O 0
of O 0
the O 0
gene O 0
alterations O 0
detected O 0
in O 0
both O 0
severe O 0
and O 0
attenuated O 0
WAS B-Disease 0
patients O 0
result O 0
in O 0
frameshifted O 0
transcript O 0
and O 0
premature O 0
translation O 0
termination O 0
. O 0

These O 0
findings O 0
therefore O 0
confirm O 0
the O 0
association O 0
of O 0
WAS B-Disease 0
with O 0
WASP O 0
mutation O 0
and O 0
identify O 0
WASP O 0
mutation O 0
as O 0
a O 0
cause O 0
for O 0
isolated O 0
congenital B-Disease 0
thrombocytopenia I-Disease 0
in O 0
males O 0
. O 0

While O 0
the O 0
WASP O 0
gene O 0
defects O 0
responsible O 0
for O 0
isolated B-Disease 0
thrombocytopenia I-Disease 0
and O 0
other O 0
mild O 0
presentations O 0
of O 0
WAS B-Disease 0
do O 0
not O 0
appear O 0
distinct O 0
from O 0
those O 0
resulting O 0
in O 0
severe O 0
WAS B-Disease 0
, O 0
these O 0
data O 0
indicate O 0
that O 0
analysis O 0
of O 0
WASP O 0
gene O 0
mutation O 0
provides O 0
a O 0
valuable O 0
tool O 0
for O 0
distinguishing O 0
the O 0
spectrum O 0
of O 0
WAS B-Disease 0
patients O 0
and O 0
the O 0
subset O 0
of O 0
males O 0
with O 0
isolated B-Disease 0
thrombocytopenia I-Disease 0
who O 0
represent O 0
mild O 0
cases O 0
of O 0
WAS B-Disease 0
. O 0
. O 0

WASP O 0
gene O 0
mutations O 0
in O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
and O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
thrombocytopenia I-Disease 0
. O 0

The O 0
WASP O 0
gene O 0
has O 0
been O 0
recently O 0
cloned O 0
from O 0
Xp11 O 0
. O 0

23 O 0
and O 0
shown O 0
to O 0
be O 0
mutated O 0
in O 0
three O 0
patients O 0
with O 0
the O 0
Wiskott B-Disease 1
- I-Disease 1
Aldrich I-Disease 1
syndrome I-Disease 1
( O 0
WAS B-Disease 0
) O 0
. O 0

We O 0
have O 0
developed O 0
a O 0
screening O 0
protocol O 0
for O 0
identifying O 0
WASP O 0
gene O 0
alterations O 0
in O 0
genomic O 0
DNA O 0
and O 0
have O 0
identified O 0
a O 0
spectrum O 0
of O 0
novel O 0
mutations O 0
in O 0
12 O 0
additional O 0
unrelated O 0
families O 0
. O 0

These O 0
missense O 0
, O 0
nonsense O 0
and O 0
frameshift O 0
mutations O 0
involve O 0
eight O 0
of O 0
the O 0
12 O 0
exons O 0
of O 0
the O 0
gene O 0
. O 0

Two O 0
mutations O 0
creating O 0
premature O 0
termination O 0
codons O 0
were O 0
associated O 0
with O 0
lack O 0
of O 0
detectable O 0
mRNA O 0
on O 0
Northern O 0
blots O 0
. O 0

Four O 0
amino O 0
acid O 0
substitutions O 0
, O 0
Leu27Phe O 0
, O 0
Thr48Ile O 0
, O 0
Val75Met O 0
and O 0
Arg477Lys O 0
, O 0
were O 0
found O 0
in O 0
patients O 0
with O 0
congenital B-Disease 0
thrombocytopenia I-Disease 0
and O 0
no O 0
clinically O 0
evident O 0
immune O 0
defect O 0
indicating O 0
that O 0
the O 0
WASP O 0
gene O 0
is O 0
the O 0
site O 0
for O 0
mutations O 0
in O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
thrombocytopenia I-Disease 0
as O 0
well O 0
as O 0
in O 0
WAS B-Disease 0
. O 0

A O 0
T O 0
- O 0
cell O 0
line O 0
from O 0
a O 0
WAS B-Disease 0
patient O 0
contained O 0
two O 0
independent O 0
DNA O 0
alterations O 0
, O 0
a O 0
constitutional O 0
frameshift O 0
mutation O 0
, O 0
also O 0
present O 0
in O 0
peripheral O 0
blood O 0
leukocytes O 0
from O 0
the O 0
patient O 0
, O 0
and O 0
compensatory O 0
splice O 0
site O 0
mutation O 0
unique O 0
to O 0
the O 0
cell O 0
line O 0
. O 0

The O 0
distribution O 0
of O 0
eight O 0
missense O 0
mutations O 0
provides O 0
valuable O 0
information O 0
on O 0
amino O 0
acids O 0
which O 0
are O 0
essential O 0
for O 0
normal O 0
protein O 0
function O 0
, O 0
and O 0
suggests O 0
that O 0
sites O 0
in O 0
the O 0
first O 0
two O 0
exons O 0
are O 0
hot O 0
- O 0
spots O 0
for O 0
mutation O 0
. O 0

Evidence O 0
for O 0
inter O 0
- O 0
generational O 0
instability O 0
in O 0
the O 0
CAG O 0
repeat O 0
in O 0
the O 0
MJD1 O 0
gene O 0
and O 0
for O 0
conserved O 0
haplotypes O 0
at O 0
flanking O 0
markers O 0
amongst O 0
Japanese O 0
and O 0
Caucasian O 0
subjects O 0
with O 0
Machado B-Disease 0
- I-Disease 0
Joseph I-Disease 0
disease I-Disease 0
. O 0

The O 0
size O 0
of O 0
the O 0
( O 0
CAG O 0
) O 0
n O 0
repeat O 0
array O 0
in O 0
the O 0
3 O 0
' O 0
end O 0
of O 0
the O 0
MJD1 O 0
gene O 0
and O 0
the O 0
haplotype O 0
at O 0
a O 0
series O 0
of O 0
microsatellite O 0
markers O 0
surrounding O 0
the O 0
MJD1 O 0
gene O 0
were O 0
examined O 0
in O 0
a O 0
large O 0
cohort O 0
of O 0
Japanese O 0
and O 0
Caucasian O 0
subjects O 0
affected O 0
with O 0
Machado B-Disease 0
- I-Disease 0
Joseph I-Disease 0
disease I-Disease 0
( O 0
MJD B-Disease 0
) O 0
. O 0

Our O 0
data O 0
provide O 0
five O 0
novel O 0
observations O 0
. O 0

First O 0
, O 0
MJD B-Disease 0
is O 0
associated O 0
with O 0
expansion O 0
fo O 0
the O 0
array O 0
from O 0
the O 0
normal O 0
range O 0
of O 0
14 O 0
- O 0
37 O 0
repeats O 0
to O 0
68 O 0
- O 0
84 O 0
repeats O 0
in O 0
most O 0
Japanese O 0
and O 0
Caucasian O 0
subjects O 0
, O 0
but O 0
no O 0
subjects O 0
were O 0
observed O 0
with O 0
expansions O 0
intermediate O 0
in O 0
size O 0
between O 0
those O 0
of O 0
the O 0
normal O 0
and O 0
MJD B-Disease 0
affected O 0
groups O 0
. O 0

Second O 0
, O 0
the O 0
expanded O 0
allele O 0
associated O 0
with O 0
MJD B-Disease 0
displays O 0
inter O 0
- O 0
generational O 0
instability O 0
, O 0
particularly O 0
in O 0
male O 0
meioses O 0
, O 0
and O 0
this O 0
instability O 0
was O 0
associated O 0
with O 0
the O 0
clinical O 0
phenomenon O 0
of O 0
anticipation O 0
. O 0

Third O 0
, O 0
the O 0
size O 0
of O 0
the O 0
expanded O 0
allele O 0
is O 0
not O 0
only O 0
inversely O 0
correlated O 0
with O 0
the O 0
age O 0
- O 0
of O 0
- O 0
onset O 0
of O 0
MJD B-Disease 0
( O 0
r O 0
= O 0
- O 0
0 O 0
. O 0
738 O 0
, O 0
p O 0
< O 0
0 O 0
. O 0
001 O 0
) O 0
, O 0
but O 0
is O 0
also O 0
correlated O 0
with O 0
the O 0
frequency O 0
of O 0
other O 0
clinical O 0
features O 0
[ O 0
e O 0
. O 0
g O 0
. O 0
pseudoexophthalmos O 0
and O 0
pyramidal O 0
signs O 0
were O 0
more O 0
frequent O 0
in O 0
subjects O 0
with O 0
large O 0
repeats O 0
( O 0
p O 0
< O 0
0 O 0
. O 0
001 O 0
and O 0
p O 0
< O 0
0 O 0
. O 0
05 O 0
respectively O 0
) O 0
] O 0
. O 0

Fourth O 0
, O 0
the O 0
disease O 0
phenotype O 0
is O 0
significantly O 0
more O 0
severe O 0
and O 0
had O 0
an O 0
early O 0
age O 0
of O 0
onset O 0
( O 0
16 O 0
years O 0
) O 0
in O 0
a O 0
subject O 0
homozygous O 0
for O 0
the O 0
expanded O 0
allele O 0
, O 0
which O 0
contrasts O 0
with O 0
Huntington B-Disease 1
disease I-Disease 1
and O 0
suggests O 0
that O 0
the O 0
expanded O 0
allele O 0
in O 0
the O 0
MJD1 O 0
gene O 0
could O 0
exert O 0
its O 0
effect O 0
either O 0
by O 0
a O 0
dominant O 0
negative O 0
effect O 0
( O 0
putatively O 0
excluded O 0
in O 0
HD B-Disease 1
) O 0
or O 0
by O 0
a O 0
gain O 0
of O 0
function O 0
effect O 0
as O 0
proposed O 0
for O 0
HD B-Disease 1
. O 0

Finally O 0
, O 0
Japanese O 0
and O 0
Caucasian O 0
subjects O 0
affected O 0
with O 0
MJD B-Disease 0
share O 0
haplotypes O 0
at O 0
several O 0
markers O 0
surrounding O 0
the O 0
MJD1 O 0
gene O 0
, O 0
which O 0
are O 0
uncommon O 0
in O 0
the O 0
normal O 0
Japanese O 0
and O 0
Caucasian O 0
population O 0
, O 0
and O 0
which O 0
suggests O 0
the O 0
existence O 0
either O 0
of O 0
common O 0
founders O 0
in O 0
these O 0
populations O 0
or O 0
of O 0
chromosomes O 0
susceptible O 0
to O 0
pathologic O 0
expansion O 0
of O 0
the O 0
CAG O 0
repeat O 0
in O 0
the O 0
MJD1 O 0
gene O 0
. O 0

Evidence O 0
for O 0
inter O 0
- O 0
generational O 0
instability O 0
in O 0
the O 0
CAG O 0
repeat O 0
in O 0
the O 0
MJD1 O 0
gene O 0
and O 0
for O 0
conserved O 0
haplotypes O 0
at O 0
flanking O 0
markers O 0
amongst O 0
Japanese O 0
and O 0
Caucasian O 0
subjects O 0
with O 0
Machado B-Disease 0
- I-Disease 0
Joseph I-Disease 0
disease I-Disease 0
. O 0

The O 0
size O 0
of O 0
the O 0
( O 0
CAG O 0
) O 0
n O 0
repeat O 0
array O 0
in O 0
the O 0
3 O 0
' O 0
end O 0
of O 0
the O 0
MJD1 O 0
gene O 0
and O 0
the O 0
haplotype O 0
at O 0
a O 0
series O 0
of O 0
microsatellite O 0
markers O 0
surrounding O 0
the O 0
MJD1 O 0
gene O 0
were O 0
examined O 0
in O 0
a O 0
large O 0
cohort O 0
of O 0
Japanese O 0
and O 0
Caucasian O 0
subjects O 0
affected O 0
with O 0
Machado B-Disease 0
- I-Disease 0
Joseph I-Disease 0
disease I-Disease 0
( O 0
MJD B-Disease 0
) O 0
. O 0

Our O 0
data O 0
provide O 0
five O 0
novel O 0
observations O 0
. O 0

First O 0
, O 0
MJD B-Disease 0
is O 0
associated O 0
with O 0
expansion O 0
fo O 0
the O 0
array O 0
from O 0
the O 0
normal O 0
range O 0
of O 0
14 O 0
- O 0
37 O 0
repeats O 0
to O 0
68 O 0
- O 0
84 O 0
repeats O 0
in O 0
most O 0
Japanese O 0
and O 0
Caucasian O 0
subjects O 0
, O 0
but O 0
no O 0
subjects O 0
were O 0
observed O 0
with O 0
expansions O 0
intermediate O 0
in O 0
size O 0
between O 0
those O 0
of O 0
the O 0
normal O 0
and O 0
MJD B-Disease 0
affected O 0
groups O 0
. O 0

Second O 0
, O 0
the O 0
expanded O 0
allele O 0
associated O 0
with O 0
MJD B-Disease 0
displays O 0
inter O 0
- O 0
generational O 0
instability O 0
, O 0
particularly O 0
in O 0
male O 0
meioses O 0
, O 0
and O 0
this O 0
instability O 0
was O 0
associated O 0
with O 0
the O 0
clinical O 0
phenomenon O 0
of O 0
anticipation O 0
. O 0

Third O 0
, O 0
the O 0
size O 0
of O 0
the O 0
expanded O 0
allele O 0
is O 0
not O 0
only O 0
inversely O 0
correlated O 0
with O 0
the O 0
age O 0
- O 0
of O 0
- O 0
onset O 0
of O 0
MJD B-Disease 0
( O 0
r O 0
= O 0
- O 0
0 O 0
. O 0
738 O 0
, O 0
p O 0
< O 0
0 O 0
. O 0
001 O 0
) O 0
, O 0
but O 0
is O 0
also O 0
correlated O 0
with O 0
the O 0
frequency O 0
of O 0
other O 0
clinical O 0
features O 0
[ O 0
e O 0
. O 0
g O 0
. O 0
pseudoexophthalmos O 0
and O 0
pyramidal O 0
signs O 0
were O 0
more O 0
frequent O 0
in O 0
subjects O 0
with O 0
large O 0
repeats O 0
( O 0
p O 0
< O 0
0 O 0
. O 0
001 O 0
and O 0
p O 0
< O 0
0 O 0
. O 0
05 O 0
respectively O 0
) O 0
] O 0
. O 0

Fourth O 0
, O 0
the O 0
disease O 0
phenotype O 0
is O 0
significantly O 0
more O 0
severe O 0
and O 0
had O 0
an O 0
early O 0
age O 0
of O 0
onset O 0
( O 0
16 O 0
years O 0
) O 0
in O 0
a O 0
subject O 0
homozygous O 0
for O 0
the O 0
expanded O 0
allele O 0
, O 0
which O 0
contrasts O 0
with O 0
Huntington B-Disease 1
disease I-Disease 1
and O 0
suggests O 0
that O 0
the O 0
expanded O 0
allele O 0
in O 0
the O 0
MJD1 O 0
gene O 0
could O 0
exert O 0
its O 0
effect O 0
either O 0
by O 0
a O 0
dominant O 0
negative O 0
effect O 0
( O 0
putatively O 0
excluded O 0
in O 0
HD B-Disease 1
) O 0
or O 0
by O 0
a O 0
gain O 0
of O 0
function O 0
effect O 0
as O 0
proposed O 0
for O 0
HD B-Disease 1
. O 0

Finally O 0
, O 0
Japanese O 0
and O 0
Caucasian O 0
subjects O 0
affected O 0
with O 0
MJD B-Disease 0
share O 0
haplotypes O 0
at O 0
several O 0
markers O 0
surrounding O 0
the O 0
MJD1 O 0
gene O 0
, O 0
which O 0
are O 0
uncommon O 0
in O 0
the O 0
normal O 0
Japanese O 0
and O 0
Caucasian O 0
population O 0
, O 0
and O 0
which O 0
suggests O 0
the O 0
existence O 0
either O 0
of O 0
common O 0
founders O 0
in O 0
these O 0
populations O 0
or O 0
of O 0
chromosomes O 0
susceptible O 0
to O 0
pathologic O 0
expansion O 0
of O 0
the O 0
CAG O 0
repeat O 0
in O 0
the O 0
MJD1 O 0
gene O 0
. O 0

A O 0
4 O 0
- O 0
megabase O 0
YAC O 0
contig O 0
that O 0
spans O 0
the O 0
Langer B-Disease 0
- I-Disease 0
Giedion I-Disease 0
syndrome I-Disease 0
region O 0
on O 0
human O 0
chromosome O 0
8q24 O 0
. O 0
1 O 0
: O 0
use O 0
in O 0
refining O 0
the O 0
location O 0
of O 0
the O 0
trichorhinophalangeal B-Disease 0
syndrome I-Disease 0
and O 0
multiple O 0
exostoses O 0
genes O 0
( O 0
TRPS1 O 0
and O 0
EXT1 O 0
) O 0
. O 0

We O 0
have O 0
constructed O 0
a O 0
physical O 0
map O 0
covering O 0
over O 0
4 O 0
Mb O 0
of O 0
human O 0
chromosome O 0
8q24 O 0
. O 0

1 O 0
and O 0
used O 0
this O 0
map O 0
to O 0
refine O 0
the O 0
locations O 0
of O 0
the O 0
genes O 0
responsible O 0
for O 0
Langer B-Disease 0
- I-Disease 0
Giedion I-Disease 0
syndrome I-Disease 0
. O 0

The O 0
map O 0
is O 0
composed O 0
of O 0
overlapping O 0
YAC O 0
clones O 0
that O 0
were O 0
identified O 0
and O 0
ordered O 0
in O 0
relation O 0
to O 0
sequence O 0
tagged O 0
sites O 0
mapped O 0
to O 0
the O 0
Langer O 0
- O 0
Giedion O 0
chromosomal O 0
region O 0
on O 0
somatic O 0
cell O 0
hybrids O 0
. O 0

The O 0
minimal O 0
region O 0
of O 0
overlap O 0
of O 0
Langer B-Disease 0
- I-Disease 0
Giedion I-Disease 0
syndrome I-Disease 0
deletions O 0
, O 0
previously O 0
identified O 0
by O 0
analysis O 0
of O 0
15 O 0
patients O 0
, O 0
was O 0
placed O 0
on O 0
the O 0
map O 0
by O 0
analysis O 0
of O 0
2 O 0
patients O 0
whose O 0
deletions O 0
define O 0
the O 0
endpoints O 0
. O 0

The O 0
chromosome O 0
8 O 0
breakpoint O 0
of O 0
a O 0
balanced O 0
t O 0
( O 0
8 O 0
; O 0
9 O 0
) O 0
( O 0
q24 O 0
. O 0
11 O 0
; O 0
q33 O 0
. O 0
3 O 0
) O 0
translocation O 0
from O 0
a O 0
patient O 0
with O 0
trichorhinophalangeal B-Disease 0
syndrome I-Disease 0
( O 0
TRPS B-Disease 1
I O 0
) O 0
was O 0
found O 0
to O 0
be O 0
located O 0
just O 0
within O 0
the O 0
proximal O 0
end O 0
of O 0
the O 0
minimal O 0
deletion O 0
region O 0
. O 0

A O 0
deletion O 0
of O 0
8q24 O 0
. O 0

11 O 0
- O 0
q24 O 0
. O 0

3 O 0
in O 0
a O 0
patient O 0
with O 0
multiple O 0
exostoses O 0
was O 0
found O 0
to O 0
overlap O 0
the O 0
distal O 0
end O 0
of O 0
the O 0
LGS B-Disease 1
deletion O 0
region O 0
, O 0
indicating O 0
that O 0
the O 0
EXT1 O 0
gene O 0
is O 0
distal O 0
to O 0
the O 0
TRPS1 O 0
gene O 0
and O 0
supporting O 0
the O 0
hypothesis O 0
that O 0
Langer B-Disease 0
- I-Disease 0
Giedion I-Disease 0
syndrome I-Disease 0
is O 0
due O 0
to O 0
loss O 0
of O 0
functional O 0
copies O 0
of O 0
both O 0
the O 0
TRPS1 O 0
and O 0
the O 0
EXT1 O 0
genes O 0

BRCA1 O 0
mutations O 0
in O 0
a O 0
population O 0
- O 0
based O 0
sample O 0
of O 0
young O 0
women O 0
with O 0
breast B-Disease 0
cancer I-Disease 1
. O 0

BACKGROUND O 0
. O 0

Inherited O 0
mutations O 0
in O 0
the O 0
BRCA1 O 0
gene O 0
are O 0
associated O 0
with O 0
a O 0
high O 0
risk O 0
of O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
in O 0
some O 0
families O 0
. O 0

However O 0
, O 0
little O 0
is O 0
known O 0
about O 0
the O 0
contribution O 0
of O 0
BRCA1 O 0
mutations O 0
to O 0
breast B-Disease 0
cancer I-Disease 1
in O 0
the O 0
general O 0
population O 0
. O 0

We O 0
analyzed O 0
DNA O 0
samples O 0
from O 0
women O 0
enrolled O 0
in O 0
a O 0
population O 0
- O 0
based O 0
study O 0
of O 0
early O 0
- O 0
onset O 0
breast B-Disease 0
cancer I-Disease 1
to O 0
assess O 0
the O 0
spectrum O 0
and O 0
frequency O 0
of O 0
germ O 0
- O 0
line O 0
BRCA1 O 0
mutations O 0
in O 0
young O 0
women O 0
with O 0
breast B-Disease 0
cancer I-Disease 1
. O 0

METHODS O 0
. O 0

We O 0
studied O 0
80 O 0
women O 0
in O 0
whom O 0
breast B-Disease 0
cancer I-Disease 1
was O 0
diagnosed O 0
before O 0
the O 0
age O 0
of O 0
35 O 0
, O 0
and O 0
who O 0
were O 0
not O 0
selected O 0
on O 0
the O 0
basis O 0
of O 0
family O 0
history O 0
. O 0

Genomic O 0
DNA O 0
was O 0
studied O 0
for O 0
BRCA1 O 0
mutations O 0
by O 0
analysis O 0
involving O 0
single O 0
- O 0
strand O 0
conformation O 0
polymorphisms O 0
and O 0
with O 0
allele O 0
- O 0
specific O 0
assays O 0
. O 0

Alterations O 0
were O 0
defined O 0
by O 0
DNA O 0
sequencing O 0
. O 0

RESULTS O 0
. O 0

Germ O 0
- O 0
line O 0
BRCA1 O 0
mutations O 0
were O 0
identified O 0
in O 0
6 O 0
of O 0
the O 0
80 O 0
women O 0
. O 0

Four O 0
additional O 0
rare O 0
sequence O 0
variants O 0
of O 0
unknown O 0
functional O 0
importance O 0
were O 0
also O 0
identified O 0
. O 0

Two O 0
of O 0
the O 0
mutations O 0
and O 0
three O 0
of O 0
the O 0
rare O 0
sequence O 0
variants O 0
were O 0
found O 0
among O 0
the O 0
39 O 0
women O 0
who O 0
reported O 0
no O 0
family O 0
history O 0
of O 0
breast B-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
. O 0

None O 0
of O 0
the O 0
mutations O 0
and O 0
only O 0
one O 0
of O 0
the O 0
rare O 0
variants O 0
was O 0
identified O 0
in O 0
a O 0
reference O 0
population O 0
of O 0
73 O 0
unrelated O 0
subjects O 0
. O 0

CONCLUSIONS O 0
. O 0

Alterations O 0
in O 0
BRCA1 O 0
were O 0
identified O 0
in O 0
approximately O 0
10 O 0
percent O 0
of O 0
this O 0
cohort O 0
of O 0
young O 0
women O 0
with O 0
breast B-Disease 0
cancer I-Disease 1
. O 0

The O 0
risk O 0
of O 0
harboring O 0
a O 0
mutation O 0
was O 0
not O 0
limited O 0
to O 0
women O 0
with O 0
family O 0
histories O 0
of O 0
breast B-Disease 1
or I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
. O 0

These O 0
results O 0
represent O 0
a O 0
minimal O 0
estimate O 0
of O 0
the O 0
frequency O 0
of O 0
BRCA1 O 0
mutations O 0
in O 0
this O 0
population O 0
. O 0

Comprehensive O 0
methods O 0
of O 0
identifying O 0
BRCA1 O 0
mutations O 0
and O 0
understanding O 0
their O 0
importance O 0
will O 0
be O 0
needed O 0
before O 0
testing O 0
of O 0
women O 0
in O 0
the O 0
general O 0
population O 0
can O 0
be O 0
undertaken O 0
. O 0
. O 0

Novel O 0
inherited O 0
mutations O 0
and O 0
variable O 0
expressivity O 0
of O 0
BRCA1 O 0
alleles O 0
, O 0
including O 0
the O 0
founder O 0
mutation O 0
185delAG O 0
in O 0
Ashkenazi O 0
Jewish O 0
families O 0
. O 0

Thirty O 0
- O 0
seven O 0
families O 0
with O 0
four O 0
or O 0
more O 0
cases O 0
of O 0
breast B-Disease 0
cancer I-Disease 1
or O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
were O 0
analyzed O 0
for O 0
mutations O 0
in O 0
BRCA1 O 0
. O 0

Twelve O 0
different O 0
germ O 0
- O 0
line O 0
mutations O 0
, O 0
four O 0
novel O 0
and O 0
eight O 0
previously O 0
observed O 0
, O 0
were O 0
detected O 0
in O 0
16 O 0
families O 0
. O 0

Five O 0
families O 0
of O 0
Ashkenazi O 0
Jewish O 0
descent O 0
carried O 0
the O 0
185delAG O 0
mutation O 0
and O 0
shared O 0
the O 0
same O 0
haplotype O 0
at O 0
eight O 0
polymorphic O 0
markers O 0
spanning O 0
approximately O 0
850 O 0
kb O 0
at O 0
BRCA1 O 0
. O 0

Expressivity O 0
of O 0
185delAG O 0
in O 0
these O 0
families O 0
varied O 0
, O 0
from O 0
early O 0
- O 0
onset O 0
breast B-Disease 0
cancer I-Disease 1
without O 0
ovarian B-Disease 0
cancer I-Disease 1
. O 0

Mutation O 0
4184delTCAA O 0
occurred O 0
independently O 0
in O 0
two O 0
families O 0
. O 0

In O 0
one O 0
family O 0
, O 0
penetrance O 0
was O 0
complete O 0
, O 0
with O 0
females O 0
developing O 0
early O 0
- O 0
onset O 0
breast B-Disease 0
cancer I-Disease 1
or O 0
ovarian B-Disease 0
cancer I-Disease 1
and O 0
the O 0
male O 0
carrier O 0
developing O 0
prostatic B-Disease 0
cancer I-Disease 1
, O 0
whereas O 0
, O 0
in O 0
the O 0
other O 0
family O 0
, O 0
penetrance O 0
was O 0
incomplete O 0
and O 0
only O 0
breast B-Disease 0
cancer I-Disease 1
occurred O 0
, O 0
diagnosed O 0
at O 0
ages O 0
38 O 0
- O 0
81 O 0
years O 0
. O 0

Two O 0
novel O 0
nonsense O 0
mutations O 0
led O 0
to O 0
the O 0
loss O 0
of O 0
mutant O 0
BRCA1 O 0
transcript O 0
in O 0
families O 0
with O 0
10 O 0
and O 0
6 O 0
cases O 0
of O 0
early O 0
- O 0
onset O 0
breast B-Disease 0
cancer I-Disease 1
and O 0
ovarian B-Disease 0
cancer I-Disease 1
. O 0

A O 0
665 O 0
- O 0
nt O 0
segment O 0
of O 0
the O 0
BRCA1 O 0
3 O 0
- O 0
UTR O 0
and O 0
1 O 0
. O 0

3 O 0
kb O 0
of O 0
genomic O 0
sequence O 0
including O 0
the O 0
putative O 0
promoter O 0
region O 0
were O 0
invariant O 0
by O 0
single O 0
- O 0
strand O 0
conformation O 0
analysis O 0
in O 0
13 O 0
families O 0
without O 0
coding O 0
- O 0
sequence O 0
mutations O 0
. O 0

Overall O 0
in O 0
our O 0
series O 0
, O 0
BRCA1 O 0
mutations O 0
have O 0
been O 0
detected O 0
in O 0
26 O 0
families O 0
16 O 0
with O 0
positive O 0
BRCA1 O 0
lod O 0
scores O 0
, O 0
7 O 0
with O 0
negative O 0
lod O 0
scores O 0
( O 0
reflecting O 0
multiple O 0
sporadic O 0
breast B-Disease 0
cancers I-Disease 0
) O 0
, O 0
and O 0
3 O 0
not O 0
tested O 0
for O 0
linkage O 0
. O 0

Three O 0
other O 0
families O 0
have O 0
positive O 0
lod O 0
scores O 0
for O 0
linkage O 0
to O 0
BRCA2 O 0
, O 0
but O 0
13 O 0
families O 0
without O 0
detected O 0
BRCA1 O 0
mutations O 0
have O 0
negative O 0
lod O 0
scores O 0
for O 0
both O 0
BRCA1 O 0
and O 0
BRCA2 O 0
. O 0

A O 0
new O 0
glucose O 0
- O 0
6 O 0
- O 0
phosphate O 0
dehydrogenase O 0
variant O 0
, O 0
G6PD O 0
Orissa O 0
( O 0
44 O 0
Ala O 0
- O 0
- O 0
> O 0
Gly O 0
) O 0
, O 0
is O 0
the O 0
major O 0
polymorphic O 0
variant O 0
in O 0
tribal O 0
populations O 0
in O 0
India O 0
. O 0

Deficiency B-Disease 1
of I-Disease 1
glucose I-Disease 1
- I-Disease 1
6 I-Disease 1
- I-Disease 1
phosphate I-Disease 1
dehydrogenase I-Disease 1
( O 0
G6PD O 0
) O 0
is O 0
usually O 0
found O 0
at O 0
high O 0
frequencies O 0
in O 0
areas O 0
of O 0
the O 0
world O 0
where O 0
malaria B-Disease 1
has O 0
been O 0
endemic O 0
. O 0

The O 0
frequency O 0
and O 0
genetic O 0
basis O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
have O 0
been O 0
studied O 0
in O 0
Africa O 0
, O 0
around O 0
the O 0
Mediterranean O 0
, O 0
and O 0
in O 0
the O 0
Far O 0
East O 0
, O 0
but O 0
little O 0
such O 0
information O 0
is O 0
available O 0
about O 0
the O 0
situation O 0
in O 0
India O 0
. O 0

To O 0
determine O 0
the O 0
extent O 0
of O 0
heterogeneity O 0
of O 0
G6PD O 0
, O 0
we O 0
have O 0
studied O 0
several O 0
different O 0
Indian O 0
populations O 0
by O 0
screening O 0
for O 0
G6PD B-Disease 0
deficiency I-Disease 0
, O 0
followed O 0
by O 0
molecular O 0
analysis O 0
of O 0
deficient O 0
alleles O 0
. O 0

The O 0
frequency O 0
of O 0
G6PD B-Disease 0
deficiency I-Disease 0
varies O 0
between O 0
3 O 0
% O 0
and O 0
15 O 0
% O 0
in O 0
different O 0
tribal O 0
and O 0
urban O 0
groups O 0
. O 0

Remarkably O 0
, O 0
a O 0
previously O 0
unreported O 0
deficient O 0
variant O 0
, O 0
G6PD O 0
Orissa O 0
( O 0
44 O 0
Ala O 0
- O 0
- O 0
> O 0
Gly O 0
) O 0
, O 0
is O 0
responsible O 0
for O 0
most O 0
of O 0
the O 0
G6PD B-Disease 0
deficiency I-Disease 0
in O 0
tribal O 0
Indian O 0
populations O 0
but O 0
is O 0
not O 0
found O 0
in O 0
urban O 0
populations O 0
, O 0
where O 0
most O 0
of O 0
the O 0
G6PD B-Disease 0
deficiency I-Disease 0
is O 0
due O 0
to O 0
the O 0
G6PD O 0
Mediterranean O 0
( O 0
188 O 0
Ser O 0
- O 0
- O 0
> O 0
Phe O 0
) O 0
variant O 0
. O 0

The O 0
KmNADP O 0
of O 0
G6PD O 0
Orissa O 0
is O 0
fivefold O 0
higher O 0
than O 0
that O 0
of O 0
the O 0
normal O 0
enzyme O 0
. O 0

This O 0
may O 0
be O 0
due O 0
to O 0
the O 0
fact O 0
that O 0
the O 0
alanine O 0
residue O 0
that O 0
is O 0
replaced O 0
by O 0
glycine O 0
is O 0
part O 0
of O 0
a O 0
putative O 0
coenzyme O 0
- O 0
binding O 0
site O 0
. O 0
. O 0

Evidence O 0
for O 0
linkage O 0
of O 0
bipolar B-Disease 0
disorder I-Disease 0
to O 0
chromosome O 0
18 O 0
with O 0
a O 0
parent O 0
- O 0
of O 0
- O 0
origin O 0
effect O 0
. O 0

A O 0
susceptibility O 0
gene O 0
on O 0
chromosome O 0
18 O 0
and O 0
a O 0
parent O 0
- O 0
of O 0
- O 0
origin O 0
effect O 0
have O 0
been O 0
suggested O 0
for O 0
bipolar B-Disease 0
affective I-Disease 0
disorder I-Disease 0
( O 0
BPAD B-Disease 0
) O 0
. O 0

We O 0
have O 0
studied O 0
28 O 0
nuclear O 0
families O 0
selected O 0
for O 0
apparent O 0
unilineal O 0
transmission O 0
of O 0
the O 0
BPAD B-Disease 0
phenotype O 0
, O 0
by O 0
using O 0
31 O 0
polymorphic O 0
markers O 0
spanning O 0
chromosome O 0
18 O 0
. O 0

Evidence O 0
for O 0
linkage O 0
was O 0
tested O 0
with O 0
affected O 0
- O 0
sib O 0
- O 0
pair O 0
and O 0
LOD O 0
score O 0
methods O 0
under O 0
two O 0
definitions O 0
of O 0
the O 0
affected O 0
phenotype O 0
. O 0

The O 0
affected O 0
- O 0
sibpair O 0
analyses O 0
indicated O 0
excess O 0
allele O 0
sharing O 0
for O 0
markers O 0
on O 0
18p O 0
within O 0
the O 0
region O 0
reported O 0
previously O 0
. O 0

The O 0
greatest O 0
sharing O 0
was O 0
at O 0
D18S37 O 0
64 O 0
% O 0
in O 0
bipolar O 0
and O 0
recurrent O 0
unipolar O 0
( O 0
RUP O 0
) O 0
sib O 0
pairs O 0
( O 0
P O 0
= O 0
. O 0
0006 O 0
) O 0
. O 0

In O 0
addition O 0
, O 0
excess O 0
sharing O 0
of O 0
the O 0
paternally O 0
, O 0
but O 0
not O 0
maternally O 0
, O 0
transmitted O 0
alleles O 0
was O 0
observed O 0
at O 0
three O 0
markers O 0
on O 0
18q O 0
at O 0
D18S41 O 0
, O 0
51 O 0
bipolar O 0
and O 0
RUP O 0
sib O 0
pairs O 0
were O 0
concordant O 0
for O 0
paternally O 0
transmitted O 0
alleles O 0
, O 0
and O 0
21 O 0
pairs O 0
were O 0
discordant O 0
( O 0
P O 0
= O 0
0004 O 0
) O 0
. O 0

The O 0
evidence O 0
for O 0
linkage O 0
to O 0
loci O 0
on O 0
both O 0
18p O 0
and O 0
18q O 0
was O 0
strongest O 0
in O 0
the O 0
11 O 0
paternal O 0
pedigrees O 0
, O 0
i O 0
. O 0

e O 0
e O 0
. O 0
, O 0
those O 0
in O 0
which O 0
the O 0
father O 0
or O 0
one O 0
of O 0
the O 0
fathers O 0
sibs O 0
is O 0
affected O 0
. O 0

In O 0
these O 0
pedigrees O 0
, O 0
the O 0
greatest O 0
allele O 0
sharing O 0
( O 0
81 O 0
% O 0
; O 0
P O 0
= O 0
. O 0
00002 O 0
) O 0
and O 0
the O 0
highest O 0
LOD O 0
score O 0
( O 0
3 O 0
. O 0
51 O 0
; O 0
phi O 0
= O 0
0 O 0
. O 0
0 O 0
) O 0
were O 0
observed O 0
at O 0
D18S41 O 0
. O 0

Our O 0
results O 0
provide O 0
further O 0
support O 0
for O 0
linkage O 0
of O 0
BPAD B-Disease 0
to O 0
chromosome O 0
18 O 0
and O 0
the O 0
first O 0
molecular O 0
evidence O 0
for O 0
a O 0
parent O 0
- O 0
of O 0
- O 0
origin O 0
effect O 0
operating O 0
in O 0
this O 0
disorder O 0
. O 0

The O 0
number O 0
of O 0
loci O 0
involved O 0
, O 0
and O 0
their O 0
precise O 0
location O 0
, O 0
require O 0
further O 0
study O 0

A O 0
prevalent O 0
mutation O 0
for O 0
galactosemia B-Disease 0
among O 0
black O 0
Americans O 0
. O 0

OBJECTIVE O 0
To O 0
define O 0
the O 0
mutation O 0
causing O 0
galactosemia B-Disease 0
in O 0
patients O 0
of O 0
black O 0
American O 0
origin O 0
who O 0
have O 0
no O 0
galactose O 0
- O 0
1 O 0
- O 0
phosphate O 0
uridyltransferase O 0
( O 0
GALT O 0
) O 0
activity O 0
in O 0
erythrocytes O 0
but O 0
good O 0
clinical O 0
outcome O 0
. O 0

METHODS O 0
We O 0
discovered O 0
a O 0
mutation O 0
caused O 0
by O 0
a O 0
C O 0
- O 0
- O 0
> O 0
T O 0
transition O 0
at O 0
base O 0
- O 0
pair O 0
1158 O 0
of O 0
the O 0
GALT O 0
gene O 0
that O 0
results O 0
in O 0
a O 0
serine O 0
- O 0
to O 0
- O 0
leucine O 0
substitution O 0
at O 0
codon O 0
135 O 0
( O 0
S135L O 0
) O 0
. O 0

We O 0
developed O 0
a O 0
method O 0
with O 0
which O 0
to O 0
screen O 0
populations O 0
for O 0
its O 0
prevalence O 0
. O 0

We O 0
compared O 0
galactose O 0
- O 0
1 O 0
- O 0
phosphate O 0
uridyltransferase O 0
among O 0
erythrocytes O 0
, O 0
leukocytes O 0
, O 0
and O 0
transformed O 0
lymphoblasts O 0
, O 0
as O 0
well O 0
as O 0
total O 0
body O 0
oxidation O 0
of O 0
D O 0
- O 0
( O 0
13C O 0
) O 0
- O 0
galactose O 0
to O 0
13CO2 O 0
among O 0
three O 0
genotypes O 0
for O 0
GALT O 0
( O 0
S135L O 0
/ O 0
S135L O 0
, O 0
Q188R O 0
/ O 0
Q188R O 0
, O 0
and O 0
Normal O 0
/ O 0
Normal O 0
) O 0
. O 0

RESULTS O 0
We O 0
found O 0
a O 0
48 O 0
% O 0
prevalence O 0
of O 0
the O 0
S135L O 0
mutation O 0
among O 0
17 O 0
black O 0
American O 0
patients O 0
with O 0
classic B-Disease 1
galactosemia I-Disease 1
and O 0
a O 0
1 O 0
% O 0
prevalence O 0
in O 0
a O 0
population O 0
of O 0
50 O 0
black O 0
Americans O 0
without O 0
galactosemia B-Disease 0
. O 0

The O 0
S135L O 0
mutation O 0
was O 0
not O 0
found O 0
in O 0
84 O 0
white O 0
patients O 0
with O 0
G O 0
/ O 0
G O 0
galactosemia B-Disease 0
nor O 0
in O 0
87 O 0
white O 0
control O 0
subjects O 0
without O 0
galactosemia B-Disease 0
. O 0

We O 0
found O 0
normal O 0
whole O 0
body O 0
oxidation O 0
of O 0
D O 0
- O 0
( O 0
13C O 0
) O 0
- O 0
galactose O 0
by O 0
the O 0
patient O 0
homozygous O 0
for O 0
S135L O 0
and O 0
various O 0
degrees O 0
of O 0
enzyme O 0
impairment O 0
among O 0
different O 0
tissues O 0
. O 0

CONCLUSIONS O 0
The O 0
S135L O 0
mutation O 0
in O 0
the O 0
GALT O 0
gene O 0
is O 0
a O 0
prevalent O 0
cause O 0
of O 0
galactosemia B-Disease 0
among O 0
black O 0
patients O 0
. O 0

Because O 0
GALT O 0
activity O 0
varies O 0
in O 0
different O 0
tissues O 0
of O 0
patients O 0
homozygous O 0
for O 0
S135L O 0
, O 0
they O 0
may O 0
have O 0
a O 0
better O 0
clinical O 0
outcome O 0
than O 0
patients O 0
who O 0
are O 0
homozygous O 0
for O 0
Q188R O 0
when O 0
both O 0
are O 0
treated O 0
from O 0
infancy O 0
. O 0
. O 0

A O 0
high O 0
incidence O 0
of O 0
BRCA1 O 0
mutations O 0
in O 0
20 O 0
breast B-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
families O 0
. O 0

We O 0
have O 0
analyzed O 0
20 O 0
breast B-Disease 1
- I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
families O 0
, O 0
the O 0
majority O 0
of O 0
which O 0
show O 0
positive O 0
evidence O 0
of O 0
linkage O 0
to O 0
chromosome O 0
17q12 O 0
for O 0
germ O 0
- O 0
line O 0
mutations O 0
in O 0
the O 0
BRCA1 O 0
gene O 0
. O 0

BRCA1 O 0
mutations O 0
cosegregating O 0
with O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
susceptibility O 0
were O 0
identified O 0
in O 0
16 O 0
families O 0
, O 0
including O 0
1 O 0
family O 0
with O 0
a O 0
case O 0
of O 0
male B-Disease 0
breast I-Disease 0
cancer I-Disease 1
. O 0

Nine O 0
of O 0
these O 0
mutations O 0
have O 0
not O 0
been O 0
reported O 0
previously O 0
. O 0

The O 0
majority O 0
of O 0
mutations O 0
were O 0
found O 0
to O 0
generate O 0
a O 0
premature O 0
stop O 0
codon O 0
leading O 0
to O 0
the O 0
formation O 0
of O 0
a O 0
truncated O 0
BRCA1 O 0
protein O 0
of O 0
2 O 0
% O 0
- O 0
88 O 0
% O 0
of O 0
the O 0
expected O 0
normal O 0
length O 0
. O 0

Two O 0
mutations O 0
altered O 0
the O 0
RING O 0
finger O 0
domain O 0
. O 0

Sequencing O 0
of O 0
genomic O 0
DNA O 0
led O 0
to O 0
the O 0
identification O 0
of O 0
a O 0
mutation O 0
in O 0
the O 0
coding O 0
region O 0
of O 0
BRCA1 O 0
in O 0
12 O 0
families O 0
, O 0
and O 0
cDNA O 0
analysis O 0
revealed O 0
an O 0
abnormal O 0
or O 0
missing O 0
BRCA1 O 0
transcript O 0
in O 0
4 O 0
of O 0
the O 0
8 O 0
remaining O 0
families O 0
. O 0

A O 0
total O 0
of O 0
eight O 0
mutations O 0
were O 0
associated O 0
with O 0
a O 0
reduced O 0
quantity O 0
of O 0
BRCA1 O 0
transcript O 0
. O 0

We O 0
were O 0
unable O 0
to O 0
detect O 0
BRCA1 O 0
mutations O 0
in O 0
4 O 0
of O 0
the O 0
20 O 0
families O 0
, O 0
but O 0
only O 0
1 O 0
of O 0
these O 0
was O 0
clearly O 0
linked O 0
to O 0
BRCA1 O 0
. O 0

It O 0
is O 0
expected O 0
that O 0
the O 0
majority O 0
of O 0
clear O 0
examples O 0
of O 0
the O 0
breast B-Disease 1
- I-Disease 1
ovarian I-Disease 1
syndrome I-Disease 1
will O 0
be O 0
associated O 0
with O 0
germ O 0
- O 0
line O 0
mutations O 0
in O 0
the O 0
coding O 0
region O 0
of O 0
BRCA1 O 0
. O 0
. O 0

Brca1 B-Disease 0
deficiency I-Disease 0
results O 0
in O 0
early O 0
embryonic B-Disease 0
lethality I-Disease 0
characterized O 0
by O 0
neuroepithelial B-Disease 0
abnormalities I-Disease 0
. O 0

The O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
susceptibility O 0
gene O 0
, O 0
BRCA1 O 0
, O 0
has O 0
been O 0
cloned O 0
and O 0
shown O 0
to O 0
encode O 0
a O 0
zinc O 0
- O 0
finger O 0
protein O 0
of O 0
unknown O 0
function O 0
. O 0

Mutations O 0
in O 0
BRCA1 O 0
account O 0
for O 0
at O 0
least O 0
80 O 0
% O 0
of O 0
families O 0
with O 0
both O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
, O 0
as O 0
well O 0
as O 0
some O 0
non O 0
- O 0
familial O 0
sporadic O 0
ovarian B-Disease 1
cancers I-Disease 1
. O 0

The O 0
loss O 0
of O 0
wild O 0
- O 0
type O 0
BRCA1 O 0
in O 0
tumours B-Disease 1
of O 0
individuals O 0
carrying O 0
one O 0
nonfunctional O 0
BRCA1 O 0
allele O 0
suggests O 0
that O 0
BRCA1 O 0
encodes O 0
a O 0
tumour B-Disease 1
suppressor O 0
that O 0
may O 0
inhibit O 0
the O 0
proliferation O 0
of O 0
mammary O 0
epithelial O 0
cells O 0
. O 0

To O 0
examine O 0
the O 0
role O 0
of O 0
BRCA1 O 0
in O 0
normal O 0
tissue O 0
growth O 0
and O 0
differentiation O 0
, O 0
and O 0
to O 0
generate O 0
a O 0
potential O 0
model O 0
for O 0
the O 0
cancer B-Disease 1
susceptibility O 0
associated O 0
with O 0
loss O 0
of O 0
BRCA1 O 0
function O 0
, O 0
we O 0
have O 0
created O 0
a O 0
mouse O 0
line O 0
carrying O 0
a O 0
mutation O 0
in O 0
one O 0
Brca1 O 0
allele O 0
. O 0

Analysis O 0
of O 0
mice O 0
homozygous O 0
for O 0
the O 0
mutant O 0
allele O 0
indicate O 0
that O 0
Brca1 O 0
is O 0
critical O 0
for O 0
normal O 0
development O 0
, O 0
as O 0
these O 0
mice O 0
died O 0
in O 0
utero O 0
between O 0
10 O 0
and O 0
13 O 0
days O 0
of O 0
gestation O 0
( O 0
E10 O 0
- O 0
E13 O 0
) O 0
. O 0

Abnormalities O 0
in O 0
Brca1 B-Disease 1
- I-Disease 1
deficient I-Disease 1
embryos O 0
were O 0
most O 0
evident O 0
in O 0
the O 0
neural O 0
tube O 0
, O 0
with O 0
40 O 0
% O 0
of O 0
the O 0
embryos O 0
presenting O 0
with O 0
varying O 0
degrees O 0
of O 0
spina B-Disease 0
bifida I-Disease 0
and O 0
anencephaly B-Disease 1
. O 0

In O 0
addition O 0
, O 0
the O 0
neuroepithelium O 0
in O 0
Brca1 B-Disease 1
- I-Disease 1
deficient I-Disease 1
embryos O 0
appeared O 0
disorganized O 0
, O 0
with O 0
signs O 0
of O 0
both O 0
rapid O 0
proliferation O 0
and O 0
excessive O 0
cell O 0
death O 0
. O 0
. O 0

Identification O 0
of O 0
mutations O 0
in O 0
the O 0
ALD O 0
- O 0
gene O 0
of O 0
20 O 0
families O 0
with O 0
adrenoleukodystrophy B-Disease 1
/ O 0
adrenomyeloneuropathy B-Disease 1
. O 0

Adrenoleukodystrophy B-Disease 0
( O 0
ALD B-Disease 0
) O 0
, O 0
an O 0
X B-Disease 1
- I-Disease 1
linked I-Disease 1
inherited I-Disease 1
metabolic I-Disease 1
disorder I-Disease 1
, O 0
is O 0
the O 0
most O 0
frequent O 0
inborn B-Disease 1
peroxisomal I-Disease 1
disease I-Disease 1
. O 0

It O 0
leads O 0
to O 0
demyelination B-Disease 1
in I-Disease 1
the I-Disease 1
central I-Disease 1
and I-Disease 1
peripheral I-Disease 1
nervous I-Disease 1
system I-Disease 1
. O 0

Defective O 0
beta O 0
- O 0
oxidation O 0
of O 0
saturated O 0
very O 0
long O 0
chain O 0
fatty O 0
acids O 0
( O 0
VLCFAs O 0
; O 0
C22 O 0
0 O 0
- O 0
C26 O 0
0 O 0
) O 0
in O 0
peroxisomes O 0
has O 0
been O 0
shown O 0
to O 0
lead O 0
to O 0
an O 0
accumulation O 0
of O 0
VLCFAs O 0
in O 0
leukoid O 0
areas O 0
of O 0
the O 0
central O 0
nervous O 0
system O 0
, O 0
peripheral O 0
nerves O 0
, O 0
adrenal O 0
gland O 0
, O 0
and O 0
blood O 0
. O 0

The O 0
ALD B-Disease 0
gene O 0
has O 0
been O 0
recently O 0
identified O 0
and O 0
encodes O 0
a O 0
745 O 0
- O 0
amino O 0
- O 0
acid O 0
protein O 0
. O 0

We O 0
screened O 0
patients O 0
with O 0
adrenoleukodystrophy B-Disease 1
/ O 0
adrenomyeloneuropathy B-Disease 1
( O 0
ALD B-Disease 0
/ O 0
AMN B-Disease 0
) O 0
from O 0
20 O 0
kindreds O 0
for O 0
mutations O 0
in O 0
the O 0
ALD B-Disease 0
gene O 0
. O 0

Eleven O 0
missense O 0
and O 0
two O 0
nonsense O 0
mutations O 0
, O 0
five O 0
deletions O 0
, O 0
and O 0
one O 0
insertion O 0
were O 0
detected O 0
by O 0
direct O 0
sequencing O 0
of O 0
eight O 0
reverse O 0
transcribed O 0
fragments O 0
of O 0
the O 0
ALD B-Disease 0
- O 0
gene O 0
mRNA O 0
. O 0

Four O 0
mutations O 0
could O 0
be O 0
shown O 0
to O 0
be O 0
de O 0
novo O 0
. O 0

All O 0
mutations O 0
could O 0
be O 0
confirmed O 0
in O 0
carriers O 0
by O 0
sequencing O 0
genomic O 0
DNA O 0
. O 0

No O 0
correlation O 0
between O 0
the O 0
type O 0
of O 0
mutation O 0
and O 0
the O 0
severity O 0
of O 0
the O 0
phenotype O 0
could O 0
be O 0
observed O 0
. O 0

The O 0
mutations O 0
were O 0
not O 0
detected O 0
in O 0
the O 0
ALD B-Disease 0
gene O 0
of O 0
30 O 0
healthy O 0
persons O 0
. O 0
. O 0

The O 0
murine O 0
homolog O 0
of O 0
the O 0
human O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
susceptibility O 0
gene O 0
Brca1 O 0
maps O 0
to O 0
mouse O 0
chromosome O 0
11D O 0
. O 0

The O 0
recently O 0
cloned O 0
human O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
susceptibility O 0
gene O 0
, O 0
BRCA1 O 0
, O 0
is O 0
located O 0
on O 0
human O 0
chromosome O 0
17q21 O 0
. O 0

We O 0
have O 0
isolated O 0
murine O 0
genomic O 0
clones O 0
containing O 0
Brca1 O 0
as O 0
a O 0
first O 0
step O 0
in O 0
generating O 0
a O 0
mouse O 0
model O 0
for O 0
the O 0
loss O 0
of O 0
BRCA1 O 0
function O 0
. O 0

A O 0
mouse O 0
genomic O 0
library O 0
was O 0
screened O 0
using O 0
probes O 0
corresponding O 0
to O 0
exon O 0
11 O 0
of O 0
the O 0
human O 0
BRCA1 O 0
gene O 0
. O 0

Two O 0
overlapping O 0
mouse O 0
clones O 0
were O 0
identified O 0
that O 0
hybridized O 0
to O 0
human O 0
BRCA1 O 0
exons O 0
9 O 0
- O 0
12 O 0
. O 0

Sequence O 0
analysis O 0
of O 0
1 O 0
. O 0

4 O 0
kb O 0
of O 0
the O 0
region O 0
of O 0
these O 0
clones O 0
corresponding O 0
to O 0
part O 0
of O 0
human O 0
exon O 0
11 O 0
revealed O 0
72 O 0
% O 0
nucleic O 0
acid O 0
identity O 0
but O 0
only O 0
50 O 0
% O 0
amino O 0
acid O 0
identity O 0
with O 0
the O 0
human O 0
gene O 0
. O 0

The O 0
longest O 0
of O 0
the O 0
mouse O 0
Brca1 O 0
genomic O 0
clones O 0
maps O 0
to O 0
chromosome O 0
11D O 0
, O 0
as O 0
determined O 0
by O 0
two O 0
- O 0
color O 0
fluorescence O 0
in O 0
situ O 0
hybridization O 0
. O 0

The O 0
synteny O 0
to O 0
human O 0
chromosome O 0
17 O 0
was O 0
confirmed O 0
by O 0
cohybridization O 0
with O 0
the O 0
mouse O 0
probe O 0
for O 0
the O 0
NF1 O 0
- O 0
gene O 0
. O 0

This O 0
comparative O 0
study O 0
confirms O 0
that O 0
the O 0
relative O 0
location O 0
of O 0
the O 0
BRCA1 O 0
gene O 0
has O 0
been O 0
conserved O 0
between O 0
mice O 0
and O 0
humans O 0
. O 0

Atelosteogenesis B-Disease 0
type I-Disease 0
II I-Disease 0
is O 0
caused O 0
by O 0
mutations O 0
in O 0
the O 0
diastrophic B-Disease 1
dysplasia I-Disease 1
sulfate O 0
- O 0
transporter O 0
gene O 0
( O 0
DTDST O 0
) O 0
: O 0
evidence O 0
for O 0
a O 0
phenotypic O 0
series O 0
involving O 0
three O 0
chondrodysplasias B-Disease 0
. O 0

Atelosteogenesis B-Disease 0
type I-Disease 0
II I-Disease 0
( O 0
AO B-Disease 1
II I-Disease 1
) O 0
is O 0
a O 0
neonatally O 0
lethal O 0
chondrodysplasia B-Disease 1
whose O 0
clinical O 0
and O 0
histological O 0
characteristics O 0
resemble O 0
those O 0
of O 0
another O 0
chondrodysplasia B-Disease 1
, O 0
the O 0
much O 0
less O 0
severe O 0
diastrophic B-Disease 1
dysplasia I-Disease 1
( O 0
DTD B-Disease 1
) O 0
. O 0

The O 0
similarity O 0
suggests O 0
a O 0
shared O 0
pathogenesis O 0
involving O 0
lesions O 0
in O 0
the O 0
same O 0
biochemical O 0
pathway O 0
and O 0
perhaps O 0
the O 0
same O 0
gene O 0
. O 0

DTD B-Disease 1
is O 0
caused O 0
by O 0
mutations O 0
in O 0
the O 0
recently O 0
identified O 0
diastrophic B-Disease 1
dysplasia I-Disease 1
sulfate O 0
- O 0
transporter O 0
gene O 0
( O 0
DTDST O 0
) O 0
. O 0

Here O 0
, O 0
we O 0
report O 0
that O 0
AOII B-Disease 0
patients O 0
also O 0
have O 0
DTDST O 0
mutations O 0
, O 0
which O 0
lead O 0
to O 0
defective O 0
uptake O 0
of O 0
inorganic O 0
sulfate O 0
and O 0
insufficient O 0
sulfation O 0
of O 0
macromolecules O 0
by O 0
patient O 0
mesenchymal O 0
cells O 0
in O 0
vitro O 0
. O 0

Together O 0
with O 0
our O 0
recent O 0
observation O 0
that O 0
a O 0
third O 0
even O 0
more O 0
severe O 0
chondrodysplasia B-Disease 1
, O 0
achondrogenesis O 0
type O 0
IB O 0
, O 0
is O 0
also O 0
caused O 0
by O 0
mutations O 0
in O 0
DTDST O 0
, O 0
these O 0
results O 0
demonstrate O 0
a O 0
phenotypic O 0
series O 0
of O 0
three O 0
chondrodysplasias B-Disease 0
of O 0
increasing O 0
severity O 0
caused O 0
by O 0
lesions O 0
in O 0
a O 0
single O 0
sulfate O 0
- O 0
transporter O 0
gene O 0
. O 0

The O 0
severity O 0
of O 0
the O 0
phenotype O 0
appears O 0
to O 0
be O 0
correlated O 0
with O 0
the O 0
predicted O 0
effect O 0
of O 0
the O 0
mutations O 0
on O 0
the O 0
residual O 0
activity O 0
of O 0
the O 0
DTDST O 0
protein O 0
. O 0
. O 0

Haplotype O 0
and O 0
phenotype O 0
analysis O 0
of O 0
six O 0
recurrent O 0
BRCA1 O 0
mutations O 0
in O 0
61 O 0
families O 0
: O 0
results O 0
of O 0
an O 0
international O 0
study O 0
. O 0

Several O 0
BRCA1 O 0
mutations O 0
have O 0
now O 0
been O 0
found O 0
to O 0
occur O 0
in O 0
geographically O 0
diverse O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
families O 0
. O 0

To O 0
investigate O 0
mutation O 0
origin O 0
and O 0
mutation O 0
- O 0
specific O 0
phenotypes O 0
due O 0
to O 0
BRCA1 O 0
, O 0
we O 0
constructed O 0
a O 0
haplotype O 0
of O 0
nine O 0
polymorphic O 0
markers O 0
within O 0
or O 0
immediately O 0
flanking O 0
the O 0
BRCA1 O 0
locus O 0
in O 0
a O 0
set O 0
of O 0
61 O 0
breast B-Disease 0
/ I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
families O 0
selected O 0
for O 0
having O 0
one O 0
of O 0
six O 0
recurrent O 0
BRCA1 O 0
mutations O 0
. O 0

Tests O 0
of O 0
both O 0
mutations O 0
and O 0
family O 0
- O 0
specific O 0
differences O 0
in O 0
age O 0
at O 0
diagnosis O 0
were O 0
not O 0
significant O 0
. O 0

A O 0
comparison O 0
of O 0
the O 0
six O 0
mutations O 0
in O 0
the O 0
relative O 0
proportions O 0
of O 0
cases O 0
of O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
was O 0
suggestive O 0
of O 0
an O 0
effect O 0
( O 0
P O 0
= O 0
. O 0
069 O 0
) O 0
, O 0
with O 0
57 O 0
% O 0
of O 0
women O 0
presumed O 0
affected O 0
because O 0
of O 0
the O 0
1294 O 0
del O 0
40 O 0
BRCA1 O 0
mutation O 0
having O 0
ovarian B-Disease 0
cancer I-Disease 1
, O 0
compared O 0
with O 0
14 O 0
% O 0
of O 0
affected O 0
women O 0
with O 0
the O 0
splice O 0
- O 0
site O 0
mutation O 0
in O 0
intron O 0
5 O 0
of O 0
BRCA1 O 0
. O 0

For O 0
the O 0
BRCA1 O 0
mutations O 0
studied O 0
here O 0
, O 0
the O 0
individual O 0
mutations O 0
are O 0
estimated O 0
to O 0
have O 0
arisen O 0
9 O 0
- O 0
170 O 0
generations O 0
ago O 0
. O 0

In O 0
general O 0
, O 0
a O 0
high O 0
degree O 0
of O 0
haplotype O 0
conservation O 0
across O 0
the O 0
region O 0
was O 0
observed O 0
, O 0
with O 0
haplotype O 0
differences O 0
most O 0
often O 0
due O 0
to O 0
mutations O 0
in O 0
the O 0
short O 0
- O 0
tandem O 0
- O 0
repeat O 0
markers O 0
, O 0
although O 0
some O 0
likely O 0
instances O 0
of O 0
recombination O 0
also O 0
were O 0
observed O 0
. O 0

For O 0
several O 0
of O 0
the O 0
instances O 0
, O 0
there O 0
was O 0
evidence O 0
for O 0
multiple O 0
, O 0
independent O 0
, O 0
BRCA1 O 0
mutational O 0
events O 0
. O 0

Isolation O 0
of O 0
the O 0
mouse O 0
homologue O 0
of O 0
BRCA1 O 0
and O 0
genetic O 0
mapping O 0
to O 0
mouse O 0
chromosome O 0
11 O 0
. O 0

The O 0
BRCA1 O 0
gene O 0
is O 0
in O 0
large O 0
part O 0
responsible O 0
for O 0
hereditary B-Disease 1
human I-Disease 1
breast I-Disease 1
and I-Disease 1
ovarian I-Disease 1
cancer I-Disease 1
. O 0

Here O 0
we O 0
report O 0
the O 0
isolation O 0
of O 0
the O 0
murine O 0
Brca1 O 0
homologue O 0
cDNA O 0
clones O 0
. O 0

In O 0
addition O 0
, O 0
we O 0
identified O 0
genomic O 0
P1 O 0
clones O 0
that O 0
contain O 0
most O 0
, O 0
if O 0
not O 0
all O 0
, O 0
of O 0
the O 0
mouse O 0
Brca1 O 0
locus O 0
. O 0

DNA O 0
sequence O 0
analysis O 0
revealed O 0
that O 0
the O 0
mouse O 0
and O 0
human O 0
coding O 0
regions O 0
are O 0
75 O 0
% O 0
identical O 0
at O 0
the O 0
nucleotide O 0
level O 0
while O 0
the O 0
predicted O 0
amino O 0
acid O 0
identity O 0
is O 0
only O 0
58 O 0
% O 0
. O 0

A O 0
DNA O 0
sequence O 0
variant O 0
in O 0
the O 0
Brca1 O 0
locus O 0
was O 0
identified O 0
and O 0
used O 0
to O 0
map O 0
this O 0
gene O 0
on O 0
a O 0
( O 0
Mus O 0
m O 0
. O 0
musculus O 0
Czech O 0
II O 0
x O 0
C57BL O 0
/ O 0
KsJ O 0
) O 0
F1 O 0
x O 0
C57BL O 0
/ O 0
KsJ O 0
intersubspecific O 0
backcross O 0
to O 0
distal O 0
mouse O 0
chromosome O 0
11 O 0
. O 0

The O 0
mapping O 0
of O 0
this O 0
gene O 0
to O 0
a O 0
region O 0
highly O 0
syntenic O 0
with O 0
human O 0
chromosome O 0
17 O 0
, O 0
coupled O 0
with O 0
Southern O 0
and O 0
Northern O 0
analyses O 0
, O 0
confirms O 0
that O 0
we O 0
isolated O 0
the O 0
murine O 0
Brca1 O 0
homologue O 0
rather O 0
than O 0
a O 0
related O 0
RING O 0
finger O 0
gene O 0
. O 0

The O 0
isolation O 0
of O 0
the O 0
mouse O 0
Brca1 O 0
homologue O 0
will O 0
facilitate O 0
the O 0
creation O 0
of O 0
mouse O 0
models O 0
for O 0
germline O 0
BRCA1 B-Disease 1
defects I-Disease 1
. O 0
. O 0

Emerin B-Disease 0
deficiency I-Disease 0
at O 0
the O 0
nuclear O 0
membrane O 0
in O 0
patients O 0
with O 0
Emery B-Disease 0
- I-Disease 0
Dreifuss I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
. O 0

Mutations O 0
in O 0
the O 0
STA O 0
gene O 0
at O 0
the O 0
Xq28 O 0
locus O 0
have O 0
been O 0
found O 0
in O 0
patients O 0
with O 0
X B-Disease 0
- I-Disease 0
linked I-Disease 0
Emery I-Disease 0
- I-Disease 0
Dreifuss I-Disease 0
muscular I-Disease 0
dystrophy I-Disease 0
( O 0
EDMD B-Disease 0
) O 0
. O 0

This O 0
gene O 0
encodes O 0
a O 0
hitherto O 0
unknown O 0
protein O 0
named O 0
emerin O 0
. O 0

To O 0
elucidate O 0
the O 0
subcellular O 0
localization O 0
of O 0
emerin O 0
, O 0
we O 0
raised O 0
two O 0
antisera O 0
against O 0
synthetic O 0
peptide O 0
fragments O 0
predicted O 0
from O 0
emerin O 0
cDNA O 0
. O 0

Using O 0
both O 0
antisera O 0
, O 0
we O 0
found O 0
positive O 0
nuclear O 0
membrane O 0
staining O 0
in O 0
skeletal O 0
, O 0
cardiac O 0
and O 0
smooth O 0
muscles O 0
in O 0
the O 0
normal O 0
controls O 0
and O 0
in O 0
patients O 0
with O 0
neuromuscular B-Disease 1
diseases I-Disease 1
other O 0
than O 0
EDMD B-Disease 0
. O 0

In O 0
contrast O 0
, O 0
a O 0
deficiency O 0
in O 0
immunofluorescent O 0
staining O 0
of O 0
skeletal O 0
and O 0
cardiac O 0
muscle O 0
from O 0
EDMD B-Disease 0
patients O 0
was O 0
observed O 0
. O 0

A O 0
34 O 0
kD O 0
protein O 0
is O 0
immunoreactive O 0
with O 0
the O 0
antisera O 0
- O 0
- O 0
the O 0
protein O 0
is O 0
equivalent O 0
to O 0
that O 0
predicted O 0
for O 0
emerin O 0
. O 0

Together O 0
, O 0
our O 0
findings O 0
suggest O 0
the O 0
specific O 0
deficiency B-Disease 0
of I-Disease 0
emerin I-Disease 0
in O 0
the O 0
nuclear O 0
membrane O 0
of O 0
muscle O 0
cells O 0
in O 0
patients O 0
with O 0
EDMD B-Disease 0
. O 0
. O 0

Growth B-Disease 1
retardation I-Disease 1
and O 0
tumour B-Disease 1
inhibition O 0
by O 0
BRCA1 O 0
. O 0

Inherited O 0
mutations O 0
in O 0
BRCA1 O 0
predispose O 0
to O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
, O 0
but O 0
the O 0
role O 0
of O 0
BRCA1 O 0
in O 0
sporadic O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
has O 0
previously O 0
been O 0
elusive O 0
. O 0

Here O 0
, O 0
we O 0
show O 0
that O 0
retroviral O 0
transfer O 0
of O 0
the O 0
wild O 0
- O 0
type O 0
BRCA1 O 0
gene O 0
inhibits O 0
growth O 0
in O 0
vitro O 0
of O 0
all O 0
breast B-Disease 0
and I-Disease 0
ovarian I-Disease 0
cancer I-Disease 1
cell O 0
lines O 0
tested O 0
, O 0
but O 0
not O 0
colon B-Disease 1
or I-Disease 1
lung I-Disease 1
cancer I-Disease 1
cells O 0
or O 0
fibroblasts O 0
. O 0

Mutant O 0
BRCA1 O 0
has O 0
no O 0
effect O 0
on O 0
growth O 0
of O 0
breast B-Disease 0
cancer I-Disease 1
cells O 0
; O 0
ovarian B-Disease 0
cancer I-Disease 1
cell O 0
growth O 0
is O 0
not O 0
affected O 0
by O 0
BRCA1 O 0
mutations O 0
in O 0
the O 0
5 O 0
portion O 0
of O 0
the O 0
gene O 0
, O 0
but O 0
is O 0
inhibited O 0
by O 0
3 O 0
BRCA1 O 0
mutations O 0
. O 0

Development O 0
of O 0
MCF B-Disease 1
- I-Disease 1
7 I-Disease 1
tumours I-Disease 1
in O 0
nude O 0
mice O 0
is O 0
inhibited O 0
when O 0
MCF O 0
- O 0
7 O 0
cells O 0
are O 0
transfected O 0
with O 0
wild O 0
- O 0
type O 0
, O 0
but O 0
not O 0
mutant O 0
, O 0
BRCA1 O 0
. O 0

Most O 0
importantly O 0
, O 0
among O 0
mice O 0
with O 0
established O 0
MCF B-Disease 1
- I-Disease 1
7 I-Disease 1
tumours I-Disease 1
, O 0
peritoneal O 0
treatment O 0
with O 0
a O 0
retroviral O 0
vector O 0
expressing O 0
wild O 0
- O 0
type O 0
BRCA1 O 0
significantly O 0
inhibits O 0
tumour B-Disease 1
growth O 0
and O 0
increased O 0
survival O 0
. O 0
. O 0

